PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wilson, TM; Maric, I; Shukla, J; Brown, M; Santos, C; Simakova, O; Khoury, P; Fay, MP; Kozhich, A; Kolbeck, R; Metcalfe, DD; Klion, AD				Wilson, Todd M.; Maric, Irina; Shukla, Juhi; Brown, Margaret; Santos, Carlo; Simakova, Olga; Khoury, Paneez; Fay, Michael P.; Kozhich, Alexander; Kolbeck, Roland; Metcalfe, Dean D.; Klion, Amy D.			IL-5 receptor alpha levels in patients with marked eosinophilia or mastocytosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hypereosinophilic syndrome; IL-5; mast cell; eosinophil; mastocytosis	HUMAN MAST-CELLS; GM-CSF; DECREASED EXPRESSION; SOLUBLE ISOFORMS; IN-VITRO; INTERLEUKIN-5; MEPOLIZUMAB; CYTOKINES; ASTHMA; CHAIN	Background: IL-5 plays a central role in the development and maintenance of eosinophilia (EO) and eosinophil activation in a wide variety of eosinophilic disorders. Although IL-5, IL-3, and GM-CSF can modulate the expression of IL-5 receptor alpha (IL-5R alpha) on eosinophils in vitro, little is known about soluble and surface IL-5R alpha levels in vivo. Objective: To assess soluble and surface IL-5R alpha levels in patients with EO and/or mastocytosis. Methods: Surface IL-5R alpha expression was assessed by flow cytometry in blood and/or bone marrow from subjects with EO (n = 39) and systemic mastocytosis (n = 8) and from normal volunteers (n = 28). Soluble IL-5R alpha (sIL-5R alpha) level was measured in a cohort of 177 untreated subjects and correlated with EO, eosinophil activation, and serum tryptase and cytokine levels. Results: IL-5R alpha expression on eosinophils inversely correlated with EO (r = 20.48; P < .0001), whereas serum levels of sIL-5R alpha increased with the eosinophil count (r = 0.56; P < .0001) and serum IL-5 (r = 0.40; P < .0001) and IL-13 (r = 0.29; P = .004) levels. Of interest, sIL-5R alpha level was significantly elevated in patients with systemic mastocytosis without EO. Although sIL-5R alpha levels correlated with serum tryptase levels in these patients, eosinophil activation, assessed by CD69 expression on eosinophils and serum eosinophil-derived neurotoxin levels, was increased compared with that in normal subjects. Conclusions: These data are consistent with an in vivo IL-5R alpha regulatory pathway in human eosinophils similar to that described in vitro and involving a balance between soluble and surface receptor levels. This may have implications with respect to the use of novel therapeutic agents targeting IL-5 and its receptor in patients with EO and/or mastocytosis. (J Allergy Clin Immunol 2011;128:1086-92.)	[Shukla, Juhi; Brown, Margaret; Santos, Carlo; Simakova, Olga; Khoury, Paneez; Klion, Amy D.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; [Shukla, Juhi; Brown, Margaret; Santos, Carlo; Simakova, Olga; Khoury, Paneez; Klion, Amy D.] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA; [Kozhich, Alexander; Kolbeck, Roland] MedImmune LLC, Dept Resp Inflammat & Autoimmun, Gaithersburg, MD USA; [Maric, Irina] NIAID, Dept Lab Med, Ctr Clin, NIH, Bethesda, MD 20892 USA; [Wilson, Todd M.; Metcalfe, Dean D.] NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); AstraZeneca; Medimmune; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Klion, AD (corresponding author), NIAID, Parasit Dis Lab, NIH, Bldg 50,Room 6351, Bethesda, MD 20892 USA.	aklion@nih.gov	Khoury, Paneez/ABH-1951-2020; Fay, Michael P/A-2974-2008	Khoury, Paneez/0000-0003-1800-0079; Fay, Michael P/0000-0002-8643-9625; Klion, Amy/0000-0002-4986-5326	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health; MedImmune; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000249, ZIAAI001130] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL080004] Funding Source: NIH RePORTER	Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MedImmune(AstraZenecaMedimmune); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); CLINICAL CENTER	This study was supported in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. MedImmune LLC provided the protocol and reagents for the sIL-5R alpha ELISA.; Disclosure of potential conflict of interest: A. D. Klion has received research support from MedImmune. The rest of the authors have declared that they have no conflict of interest.	Busse WW, 2010, J ALLERGY CLIN IMMUN, V125, P1237, DOI 10.1016/j.jaci.2010.04.005; Bystrom J, 2006, EUR J HAEMATOL, V77, P181, DOI 10.1111/j.1600-0609.2006.00699.x; Dahl C, 2004, ALLERGY, V59, P1087, DOI 10.1111/j.1398-9995.2004.00606.x; Garcia-Montero AC, 2006, BLOOD, V108, P2366, DOI 10.1182/blood-2006-04-015545; Gevaert P, 2003, ALLERGY, V58, P371, DOI 10.1034/j.1398-9995.2003.00110.x; Gevaert P, 2009, ALLERGY, V64, P725, DOI 10.1111/j.1398-9995.2008.01885.x; Gounni AS, 2000, BLOOD, V96, P2163; Gregory B, 2003, J IMMUNOL, V170, P5359, DOI 10.4049/jimmunol.170.11.5359; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hildesheim A, 2002, CANCER EPIDEM BIOMAR, V11, P1477; Jaffe ES, 2008, WHO CLASSIFICATION T; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Klion AD, 2004, BLOOD, V103, P4050, DOI 10.1182/blood-2003-11-3850; Kolbeck R, 2010, J ALLERGY CLIN IMMUN, V125, P1344, DOI 10.1016/j.jaci.2010.04.004; Kulka M, 2005, BLOOD, V105, P592, DOI 10.1182/blood-2004-07-2838; Lei JT, 2008, J LEUKOCYTE BIOL, V84, P499, DOI 10.1189/jlb.1207828; Liu LY, 2002, J IMMUNOL, V169, P6459, DOI 10.4049/jimmunol.169.11.6459; Liu LY, 2002, J IMMUNOL, V169, P6452, DOI 10.4049/jimmunol.169.11.6452; Monahan J, 1997, J IMMUNOL, V159, P4024; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nedoszytko B, 2009, ALLERGY, V64, P287, DOI 10.1111/j.1398-9995.2008.01827.x; Ochi H, 2000, P NATL ACAD SCI USA, V97, P10509, DOI 10.1073/pnas.180318697; Perez C, 2003, BMC BIOTECHNOL, V3, DOI 10.1186/1472-6750-3-17; Rohde G, 2004, INT ARCH ALLERGY IMM, V135, P54, DOI 10.1159/000080043; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Siddiqui Salman, 2009, BMC Pulm Med, V9, P34, DOI 10.1186/1471-2466-9-34; Sperr WR, 2002, INT ARCH ALLERGY IMM, V128, P136, DOI 10.1159/000059404; Tavernier J, 2000, BLOOD, V95, P1600, DOI 10.1182/blood.V95.5.1600.005k22_1600_1607; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Wilson TM, 2011, HAEMATOL-HEMATOL J, V96, P459, DOI 10.3324/haematol.2010.031690; WRIGHT SP, 1992, BIOMETRICS, V48, P1005, DOI 10.2307/2532694	32	42	43	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1086	U263		10.1016/j.jaci.2011.05.032	http://dx.doi.org/10.1016/j.jaci.2011.05.032			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21762978	Green Accepted			2022-12-18	WOS:000296578200023
J	Gagliardo, R; Chanez, P; Profita, M; Bonanno, A; Albano, GD; Montalbano, AM; Pompeo, F; Gagliardo, C; Merendino, AM; Gjomarkaj, M				Gagliardo, Rosalia; Chanez, Pascal; Profita, Mirella; Bonanno, Anna; Albano, Giusy Daniela; Montalbano, Angela Marina; Pompeo, Flora; Gagliardo, Cesare; Merendino, Anna Maria; Gjomarkaj, Mark			I kappa B kinase-driven nuclear factor-kappa B activation in patients with asthma and chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chronic obstructive pulmonary disease; inflammation; I kappa B kinase/nuclear factor kappa B pathway	IKK-ALPHA; CIGARETTE-SMOKE; AIRWAY EPITHELIUM; MUCUS PRODUCTION; GENE-EXPRESSION; BETA; PHOSPHORYLATION; INTERLEUKIN-8; TRANSCRIPTION; PATHWAY	Background: Nuclear factor-kappa B (NF-kappa B) is a transcriptional factor of different inflammatory patterns involved in asthma and chronic obstructive pulmonary disease (COPD) that is tightly controlled by I kappa B kinase (IKK) complex. Objective: We investigated the dysregulation of IKK-driven NF-kappa B activation in patients with asthma and COPD. Methods: We assessed IKK alpha and IKK beta expression and activation, their regulation by glucocorticosteroids, and their involvement in IL-8 synthesis in PBMCs isolated from asthmatic patients, healthy smokers (HSs), patients with COPD, and control subjects. PBMCs from control subjects were stimulated with TNF-alpha and cigarette smoke extract in the presence or absence of fluticasone propionate (FP), L-glutathione reduced, or both, and IKK activation and IL-8 release were evaluated. Results: IKKa activity was higher in patients with COPD and HSs than in asthmatic patients and control subjects. IKK beta activity was higher in asthmatic patients, HSs, and patients with COPD than in control subjects. In vitro FP treatment induced inhibition of both IKK alpha and IKK beta activity in PBMCs from asthmatic patients, patients with COPD, and HSs, although IKK beta activity was more sensitive to FP than that of IKK alpha. FP reduced the IL-8 released from PBMCs of asthmatic patients, patients with COPD, and HSs, although IL-8 inhibition was higher in asthmatic patients than in patients with COPD and HSs. FP reduced IKK alpha and IKK beta activities in TNF-alpha and cigarette smoke extract-treated PBMCs, with higher levels of inhibition for IKK beta than IKK alpha activity. L-glutathione reduced improved the downregulatory effects of FP on IKK alpha and IL-8 levels. Conclusion: Based on differential activation of IKK alpha and IKK beta, our findings suggest a different profile in the upstream regulation of the IKK-driven NF-kappa B system in asthmatic patients and patients with COPD. These differences in the regulation of the inflammatory process may explain, at least in part, the different pharmacologic responses in these patients. (J Allergy Clin Immunol 2011;128:635-45.)	[Gagliardo, Rosalia; Profita, Mirella; Bonanno, Anna; Albano, Giusy Daniela; Montalbano, Angela Marina; Pompeo, Flora; Gjomarkaj, Mark] CNR, Ist Biomed & Immunol Mol, Sez Immunopatol & Farmacol Clin & Sperimentale Ap, Unit Immunopathol & Pharmacol Resp Syst, I-15390146 Palermo, Italy; [Chanez, Pascal] Univ Mediterranee, Dept Malad Resp, Immunol Lab, AP HM, Marseille, France; [Chanez, Pascal] Clin Malad Resp CHU, Inst Natl Sante Rech Med, Montpellier, France; [Pompeo, Flora] Univ Palermo, Dipartimento Biopatol & Metodol Biomed, I-90133 Palermo, Italy; [Gagliardo, Cesare] Univ Palermo, Dipartimento Med Pneumol Fisiol & Nutr Umana, I-90133 Palermo, Italy; [Merendino, Anna Maria] Univ Palermo, Ist Med Sperimentale, Sez Anat Umana, I-90133 Palermo, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; University of Palermo; University of Palermo; University of Palermo	Gagliardo, R (corresponding author), CNR, Ist Biomed & Immunol Mol, Sez Immunopatol & Farmacol Clin & Sperimentale Ap, Unit Immunopathol & Pharmacol Resp Syst, Via Ugo Malfa, I-15390146 Palermo, Italy.	gagliardo@ibim.cnr.it	Bonanno, Anna/AAV-9474-2020; Montalbano, Angela Marina/AAY-3905-2020; Profita, Mirella/AAY-3165-2020; Gagliardo, Rosalia/AAX-7244-2020; Profita, Mirella/AFU-7423-2022; Profita, Mirella/D-8957-2018; bonanno, anna/F-7613-2015; Abano, Giusy Daniela/AAY-3896-2020	Montalbano, Angela Marina/0000-0001-5950-4834; Profita, Mirella/0000-0002-7821-8283; bonanno, anna/0000-0003-3448-283X; Abano, Giusy Daniela/0000-0001-6944-4118; chanez, pascal/0000-0003-4059-0917	Italian National Research Council (CNR); GlaxoSmithKline; Centocor; Schering-Plough; INSERM-CNR; European Respiratory Society	Italian National Research Council (CNR)(Consiglio Nazionale delle Ricerche (CNR)); GlaxoSmithKline(GlaxoSmithKline); Centocor; Schering-Plough(Merck & CompanySchering Plough Corporation); INSERM-CNR; European Respiratory Society	Supported by the Italian National Research Council (CNR), by a GlaxoSmithKline grant for Center of Excellence in COPD, by an INSERM-CNR contract, and by a European Respiratory Society long-term fellowship.; Disclosure of potential conflict of interest: P. Chanez has consulted for Actelion, AstraZeneca, Centocor, Chiesi, GlaxoSmithKline, MSD, Novartis, and Nycomed and has received research support from Centocor and Schering-Plough. The rest of the authors have declared that they have no conflict of interest.	Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Barnes PJ, 2008, J CLIN INVEST, V118, P3546, DOI 10.1172/JCI36130; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404; Broide DH, 2005, P NATL ACAD SCI USA, V102, P17723, DOI 10.1073/pnas.0509235102; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Catley MC, 2005, BRIT J PHARMACOL, V145, P114, DOI 10.1038/sj.bjp.0706170; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Fabbri LM, 2007, LANCET, V370, P797, DOI 10.1016/S0140-6736(07)61383-X; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Gagliardo R, 2003, AM J RESP CRIT CARE, V168, P1190, DOI 10.1164/rccm.200205-479OC; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7, DOI 10.1164/ajrccm.162.1.9911032; Gloire G, 2007, J BIOL CHEM, V282, P21308, DOI 10.1074/jbc.M610728200; Hacker Hans, 2006, Sci STKE, V2006, pre13, DOI 10.1126/stke.3572006re13; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Huber MA, 2002, J BIOL CHEM, V277, P1268, DOI 10.1074/jbc.M109358200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Lora JM, 2005, J BIOL CHEM, V280, P36510, DOI 10.1074/jbc.M507977200; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175, DOI 10.1164/ajrccm.162.3.2001063; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Oltmanns U, 2008, PULM PHARMACOL THER, V21, P292, DOI 10.1016/j.pupt.2007.07.001; Park GY, 2006, J BIOL CHEM, V281, P18684, DOI 10.1074/jbc.M600733200; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Profita M, 2009, J PHARMACOL EXP THER, V329, P753, DOI 10.1124/jpet.108.145888; Rahman I, 1998, THORAX, V53, P601, DOI 10.1136/thx.53.7.601; Rahman Irfan, 2008, Ther Adv Respir Dis, V2, P351, DOI 10.1177/1753465808098224; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Sadikot RT, 2006, J IMMUNOL, V176, P4923, DOI 10.4049/jimmunol.176.8.4923; Shannon J, 2008, CHEST, V133, P420, DOI 10.1378/chest.07-1881; Szulakowski P, 2006, AM J RESP CRIT CARE, V174, P41, DOI 10.1164/rccm.200505-725OC; Vestbo J, 1996, AM J RESP CRIT CARE, V153, P1530, DOI 10.1164/ajrccm.153.5.8630597; WALLAERT B, 1995, J EXP MED, V182, P1897, DOI 10.1084/jem.182.6.1897; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yang SR, 2008, AM J RESP CELL MOL, V38, P689, DOI 10.1165/rcmb.2007-0379OC; Yang SR, 2006, AM J PHYSIOL-LUNG C, V291, pL46, DOI 10.1152/ajplung.00241.2005; 1987, AM REV RESPIR DIS, V136, P225, DOI 10.1164/ajrccm/136.1.225	47	42	44	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					635	U306		10.1016/j.jaci.2011.03.045	http://dx.doi.org/10.1016/j.jaci.2011.03.045			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21571356				2022-12-18	WOS:000294283400024
J	Ito, K; Sjolander, S; Sato, S; Moverare, R; Tanaka, A; Soderstrom, L; Borres, M; Poorafshar, M; Ebisawa, M				Ito, Komei; Sjolander, Sigrid; Sato, Sakura; Moverare, Robert; Tanaka, Akira; Soderstrom, Lars; Borres, Magnus; Poorafshar, Maryam; Ebisawa, Motohiro			IgE to Gly m 5 and Gly m 6 is associated with severe allergic reactions to soybean in Japanese children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FOOD ALLERGY; BETA-CONGLYCININ; SOY; DIAGNOSIS; WHEAT		[Ito, Komei] Aichi Childrens Hlth & Med Ctr, Dept Allergy, Obu, Japan; [Sjolander, Sigrid; Moverare, Robert; Soderstrom, Lars; Borres, Magnus; Poorafshar, Maryam] Phadia AB, Uppsala, Sweden; [Sato, Sakura; Ebisawa, Motohiro] Sagamihara Natl Hosp, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa, Japan; [Moverare, Robert] Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; [Tanaka, Akira] Phadia KK, Tokyo, Japan; [Borres, Magnus] Sahlgrenska Acad Gothenburg Univ, Dept Pediat, Gothenburg, Sweden	Thermo Fisher Scientific; Phadia; Uppsala University; University of Gothenburg	Ito, K (corresponding author), Aichi Childrens Hlth & Med Ctr, Dept Allergy, Obu, Japan.	koumei_itoh@mx.achmc.pref.aichi.jp		Ebisawa, Motohiro/0000-0003-4117-558X; Soderstrom, Lars/0000-0002-6474-6501				Adachi A, 2009, CLIN EXP ALLERGY, V39, P167, DOI 10.1111/j.1365-2222.2008.03148.x; Ballmer-Weber BK, 2008, CURR OPIN ALLERGY CL, V8, P270, DOI 10.1097/ACI.0b013e3282ffb157; Holzhauser T, 2009, J ALLERGY CLIN IMMUN, V123, P452, DOI 10.1016/j.jaci.2008.09.034; Ikematsu Kaori, 2006, Arerugi, V55, P533; Imamura T, 2008, PEDIAT ALLERG IMM-UK, V19, P270, DOI 10.1111/j.1399-3038.2007.00621.x; Ito Komei, 2009, Allergology International, V58, P467, DOI 10.2332/allergolint.09-RAI-0140; Komata Takatsugu, 2009, Allergology International, V58, P599, DOI 10.2332/allergolint.09-OA-0096; Matricardi PM, 2008, CLIN EXP ALLERGY, V38, P493, DOI 10.1111/j.1365-2222.2007.02912.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; THANH VH, 1976, J AGR FOOD CHEM, V24, P1117, DOI 10.1021/jf60208a030	10	42	44	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					673	675		10.1016/j.jaci.2011.04.025	http://dx.doi.org/10.1016/j.jaci.2011.04.025			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	812HS	21555150				2022-12-18	WOS:000294283400032
J	Bouillet, L; Mannic, T; Arboleas, M; Subileau, M; Massot, C; Drouet, C; Huber, P; Vilgrain, I				Bouillet, Laurence; Mannic, Tiphaine; Arboleas, Melanie; Subileau, Mariela; Massot, Christian; Drouet, Christian; Huber, Philippe; Vilgrain, Isabelle			Hereditary angioedema: Key role for kallikrein and bradykinin in vascular endothelial-cadherin cleavage and edema formation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VE-CADHERIN		[Bouillet, Laurence; Mannic, Tiphaine; Arboleas, Melanie; Subileau, Mariela; Huber, Philippe; Vilgrain, Isabelle] CEA, Inst Life Sci Res & Technol, INSERM, U1036, Grenoble, France; [Bouillet, Laurence; Mannic, Tiphaine; Huber, Philippe; Vilgrain, Isabelle] Joseph Fourier Univ, Grenoble, France; [Bouillet, Laurence; Massot, Christian] Grenoble Univ Hosp, Dept Internal Med, Grenoble, France; [Drouet, Christian] Grenoble Univ Hosp, Angioedema Lab, Reference Ctr Angioedema, Grenoble, France; [Drouet, Christian] CNRS, GREPI, TIMC, UMR 5525, Grenoble, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA)	Bouillet, L (corresponding author), CEA, Inst Life Sci Res & Technol, INSERM, U1036, Grenoble, France.	lbouillet@chu-grenoble.fr	Huber, Philippe/C-7971-2019; DROUET, Christian/AAE-5682-2020; Mannic, Tiphaine/L-7394-2013; DROUET, Christian/J-8775-2019	Huber, Philippe/0000-0002-4153-7694; DROUET, Christian/0000-0003-1318-4278; DROUET, Christian/0000-0003-1318-4278; Subileau, Mariela/0000-0002-7759-8376; VILGRAIN, Isabelle/0000-0002-5511-5871				CICARDI M, 2004, J ALLERGY CLIN IMMUN, V114, pS55; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Hermant B, 2003, J BIOL CHEM, V278, P14002, DOI 10.1074/jbc.M300351200; Kaplan AP, 2010, ANN ALLERG ASTHMA IM, V104, P193, DOI 10.1016/j.anai.2010.01.007; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014; Wallez Y, 2006, TRENDS CARDIOVAS MED, V16, P55, DOI 10.1016/j.tcm.2005.11.008	8	42	44	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					232	234		10.1016/j.jaci.2011.02.017	http://dx.doi.org/10.1016/j.jaci.2011.02.017			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	785RE	21439626				2022-12-18	WOS:000292245600038
J	Holm, J; Willumsen, N; Wurtzen, PA; Christensen, LH; Lund, K				Holm, Jens; Willumsen, Nicholas; Wuertzen, Peter A.; Christensen, Lars H.; Lund, Kaare			Facilitated antigen presentation and its inhibition by blocking IgG antibodies depends on IgE repertoire complexity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; allergen; rIgE; rIgG; antibody repertoire; antibody-binding affinity; antibody clonality; blocking IgG; facilitated antigen presentation; T-cell activation	GRASS-POLLEN ALLERGEN; IMMUNOGLOBULIN-E; IN-VITRO; BINDING; CELLS; SERUM; IMMUNOTHERAPY; RESPONSES; ACTIVATION; EPITOPES	Background: The antibody repertoires of allergic subjects are characterized by the presence of allergen-specific IgE antibodies. We have previously shown that the composition of the IgE repertoire is critical for allergen-mediated activation of human effector cells. Activation of CD4(+) T cells in allergic subjects is highly potentiated by the process of facilitated antigen presentation (FAP), in which allergen in complex with IgE is taken up by B cells through the low-affinity IgE receptor CD23 and presented to T cells. Objective: We sought to investigate the influence of IgE repertoire complexity on the formation of IgE/allergen/CD23 complexes on B cells and subsequent T-cell activation. Methods: Using defined allergen-specific recombinant IgE and IgG antibodies, we investigated the influence of individual IgE affinity, IgE clonality, specific IgE concentration, and the ratio between IgE specificities on IgE/allergen/CD23 complex formation in vitro. ResultsAlthough IgE affinity is an important factor, IgE clonality seems to be governing complex formation, especially with medium-and low-affinity IgE antibodies. We demonstrate that differences in allergen-specific IgE affinity correlate with the efficiency of subsequent T-cell activation. In addition, we show that the complexity of an IgE repertoire also affects the ability of allergen-specific IgG antibodies to block FAP. Conclusion: The composition of allergen-specific IgE repertoires in individual patients, especially with respect to IgE clonality, might play an important role in the manifestation of allergic disease not only for the immediate allergic reaction through activation of basophils and mast cells but also for the exacerbation of allergic inflammation through recurring activation of allergen-specific T cells by FAP. (J Allergy Clin Immunol 2011;127:1029-37.)	[Holm, Jens] ALK Abello, Dept Expt Immunol, DK-2970 Horsholm, Denmark	ALK-Abello AS	Holm, J (corresponding author), ALK Abello, Dept Expt Immunol, Boge Alle 6-8, DK-2970 Horsholm, Denmark.	jhodk@alk-abello.com	Willumsen, Nicholas/AAV-5126-2021	Willumsen, Nicholas/0000-0002-5207-5173; Harder Christensen, Lars/0000-0003-4230-7820	ALK-Abello	ALK-Abello	Disclosure of potential conflict of interest: J. Holm is employed by and owns shares in ALK-Abello. P. A. Wurtzen is employed by, owns shares in, and is an employee-elected board member for ALK-Abello. L. H. Christensen is employed by, owns shares in, and receives research support from ALK-Abello. K. Lund is employed by and owns shares in ALK-Abello. N. Willumsen has declared that he has no conflict of interest.	Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BRINGEL H, 1982, CLIN ALLERGY, V12, P37, DOI 10.1111/j.1365-2222.1982.tb03124.x; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; COFFMAN RL, 1986, J IMMUNOL, V136, P949; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Davies JM, 2004, CLIN EXP ALLERGY, V34, P429, DOI 10.1111/j.1365-2222.2004.01900.x; DeLalla C, 1996, MOL IMMUNOL, V33, P1049, DOI 10.1016/S0161-5890(96)00061-2; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; Flinterman AE, 2008, J ALLERGY CLIN IMMUN, V121, P737, DOI 10.1016/j.jaci.2007.11.039; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Janezic A, 1998, J ALLERGY CLIN IMMUN, V101, P391, DOI 10.1016/S0091-6749(98)70253-2; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jogi R, 1998, CLIN EXP ALLERGY, V28, P1072; Jylha S, 2009, J IMMUNOL METHODS, V350, P63, DOI 10.1016/j.jim.2009.07.007; Knol EF, 2006, MOL NUTR FOOD RES, V50, P620, DOI 10.1002/mnfr.200500272; Lee MF, 2008, CLIN EXP IMMUNOL, V152, P464, DOI 10.1111/j.1365-2249.2008.03661.x; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Linneberg A, 2007, CLIN EXP ALLERGY, V37, P1137, DOI 10.1111/j.1365-2222.2007.02760.x; Loveless MH, 1940, J IMMUNOL, V38, P25; Mudde GC, 1996, IMMUNOL CELL BIOL, V74, P167, DOI 10.1038/icb.1996.23; Norderhaug L, 1997, J IMMUNOL METHODS, V204, P77, DOI 10.1016/S0022-1759(97)00034-3; OHNISHI T, 1993, J ALLERGY CLIN IMMUN, V92, P607, DOI 10.1016/0091-6749(93)90085-T; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Petersen AB, 2004, CLIN BIOCHEM, V37, P882, DOI 10.1016/j.clinbiochem.2004.06.010; Pierson-Mullany LK, 2002, CLIN EXP ALLERGY, V32, P107, DOI 10.1046/j.0022-0477.2001.01244.x; Pierson-Mullany LK, 2000, MOL IMMUNOL, V37, P613, DOI 10.1016/S0161-5890(00)00071-7; Poulsen TR, 2007, J IMMUNOL, V179, P3841, DOI 10.4049/jimmunol.179.6.3841; PUNNONEN J, 1994, J IMMUNOL, V152, P1094; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Soussi-Gounni A, 2001, J ALLERGY CLIN IMMUN, V107, P575, DOI 10.1067/mai.2001.114238; Steinberger P, 1996, J BIOL CHEM, V271, P10967, DOI 10.1074/jbc.271.18.10967; URBANEK R, 1986, CLIN ALLERGY, V16, P317, DOI 10.1111/j.1365-2222.1986.tb01963.x; van Neerven RJ, 2006, INT ARCH ALLERGY IMM, V141, P119, DOI 10.1159/000094714; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; van Neerven RJJ, 2001, INT ARCH ALLERGY IMM, V124, P400, DOI 10.1159/000053770; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERHEIJDEN FL, 1995, CLIN EXP IMMUNOL, V99, P289; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737	50	42	42	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2011	127	4					1029	1037		10.1016/j.jaci.2011.01.062	http://dx.doi.org/10.1016/j.jaci.2011.01.062			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	743YL	21377718				2022-12-18	WOS:000289055800026
J	Reece, P; Thanendran, A; Crawford, L; Tulic, MK; Thabane, L; Prescott, SL; Sehmi, R; Denburg, JA				Reece, Pia; Thanendran, Amudhinie; Crawford, Lynn; Tulic, Meri K.; Thabane, Lehana; Prescott, Susan L.; Sehmi, Roma; Denburg, Judah A.			Maternal allergy modulates cord blood hematopoietic progenitor Toll-like receptor expression and function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopy; Toll-like receptors; cytokine receptors; cord blood; CD34; eosinophil-basophil	INNATE IMMUNITY; RISK; CELLS; LIPOPOLYSACCHARIDE; SENSITIZATION; ENVIRONMENT; MONOCYTES; CYTOKINES; ASTHMA; BIRTH	Background: Little is known regarding the prenatal determinants of innate immune responses in relation to infant allergic risk. Environmental exposures, including microbial stimuli, might predispose susceptible subjects to atopy and asthma in early infancy or even in utero. Objective: Because Toll-like receptors (TLRs) recognize microbial products and because cord blood (CB) progenitor alterations have been observed in neonates at risk for atopy, we investigated the expression and function of TLRs on CB hematopoietic progenitors in relation to atopic risk, as defined by maternal allergic sensitization. Methods: Thirty-two (15 with low and 17 with high atopic risk) infant CB samples were assessed for phenotypic and functional alterations in CD34(+) cells by means of flow cytometry and methylcellulose culture, respectively. CD34(+) hematopoietic progenitors were stained for TLR-2, TLR-4, TLR-9, GM-CSF receptor alpha, IL-5 receptor alpha, and IL-3 receptor alpha or cultured in methylcellulose assays for hematopoietic cytokine-stimulated eosinophil-basophil (Eo/B) colony-forming units (CFUs) with or without LPS. Results: High-atopic-risk infants had significantly lower CB CD34(+) cell TLR-2, TLR-4, and TLR-9 expression (P = .009). High-risk infant progenitors gave rise to significantly more Eo/B CFUs (P = .002) with hematopoietic cytokine (IL-3, IL-5, or GM-CSF) stimulation ex vivo. Although LPS costimulation induced Eo/B CFUs from both low-and high-risk infant CB CD34(+) cells, this response was significantly (P = .020) muted in the high-risk CB progenitors. Conclusions: Neonatal CB CD34(+) hematopoietic progenitor cell TLR expression and functional responsiveness are altered in CB from atopic at-risk infants. Maternal allergic sensitization might modulate hematopoietic progenitor TLR expression and function in utero; specifically, Eo/B "lineage priming'' at birth might be circumvented through engagement of TLR pathways in early life. (J Allergy Clin Immunol 2011;127:447-53.)	[Reece, Pia; Thanendran, Amudhinie; Crawford, Lynn; Denburg, Judah A.] McMaster Univ, Div Clin Immunol & Allergy, Hamilton, ON L8S 4L8, Canada; [Sehmi, Roma] McMaster Univ, Asthma Res Grp, Firestone Inst Resp Hlth, Hamilton, ON L8S 4L8, Canada; [Thabane, Lehana] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada; [Tulic, Meri K.; Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Thabane, Lehana] Father Sean OSullivan Res Ctr, Biostat Unit, Hamilton, ON, Canada	McMaster University; McMaster University; McMaster University; University of Western Australia	Denburg, JA (corresponding author), HSC 3V46,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	denburg@mcmaster.ca	Tulic, Meri/P-6613-2016; Prescott, Susan/H-5665-2014; Tulic, Meri K/ABB-5138-2020	Tulic, Meri/0000-0002-2661-2369; Tulic, Meri K/0000-0002-2661-2369	Allergy, Genes, and Environment Network of Centres of Excellence (AllerGen NCE, Inc); Canadian Institutes for Health Research (CIHR); Ontario Graduate Student scholarship award	Allergy, Genes, and Environment Network of Centres of Excellence (AllerGen NCE, Inc); Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Ontario Graduate Student scholarship award	Supported by grants from the Allergy, Genes, and Environment Network of Centres of Excellence (AllerGen NCE, Inc) and the Canadian Institutes for Health Research (CIHR). P. R. is a recipient of an Ontario Graduate Student scholarship award.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Amoudruz P, 2009, CLIN EXP IMMUNOL, V155, P387, DOI 10.1111/j.1365-2249.2008.03792.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; De Luca K, 2009, LEUKEMIA, V23, P2063, DOI 10.1038/leu.2009.155; deMoraesPinto MI, 1997, IMMUNOLOGY, V90, P87, DOI 10.1046/j.1365-2567.1997.00139.x; Denburg JA, 2005, PEDIATR RES, V57, P276, DOI 10.1203/01.PDR.0000148279.72611.1D; Dietert RR, 2008, BIRTH DEFECTS RES B, V83, P547, DOI 10.1002/bdrb.20170; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Fernandes R, 2008, PEDIATR ALLERGY IMMU, V19, P239, DOI 10.1111/j.1399-3038.2007.00615.x; Grzela K, 2007, MED SCI MONITOR, V13, pCR445; Holt PG, 2005, NAT IMMUNOL, V6, P957, DOI 10.1038/ni1005-957; Imanishi T, 2007, J IMMUNOL, V178, P6715, DOI 10.4049/jimmunol.178.11.6715; Kimura A, 2005, P NATL ACAD SCI USA, V102, P17089, DOI 10.1073/pnas.0508517102; Krauss-Etschmann S, 2006, CLIN IMMUNOL, V118, P292, DOI 10.1016/j.clim.2005.10.003; Levy O, 2004, J IMMUNOL, V173, P4627, DOI 10.4049/jimmunol.173.7.4627; Lovegrove Julie A., 1994, Nutrition Research Reviews, V7, P25, DOI 10.1079/NRR19940005; Marks GB, 2006, CLIN EXP PHARMACOL P, V33, P285, DOI 10.1111/j.1440-1681.2006.04360.x; Mueller T, 2006, J IMMUNOL, V176, P5805, DOI 10.4049/jimmunol.176.10.5805; Musikacharoen T, 2003, J BIOL CHEM, V278, P9167, DOI 10.1074/jbc.M211829200; Nagai Y, 2006, IMMUNITY, V24, P801, DOI 10.1016/j.immuni.2006.04.008; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; PERNEGER TV, 2005, J ALLERGY CLIN IMMUN, V115, P1304; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI 10.1016/j.jaci.2008.04.042; Prokesova L, 2008, FOLIA MICROBIOL, V53, P67, DOI 10.1007/s12223-008-0010-5; Saghafian-Hedengren S, 2008, CLIN EXP ALLERGY, V38, P449, DOI 10.1111/j.1365-2222.2007.02917.x; Sandberg M, 2009, PEDIAT ALLERG IMM-UK, V20, P519, DOI 10.1111/j.1399-3038.2008.00794.x; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schroeder JT, 2008, J ALLERGY CLIN IMMUN, V121, P486, DOI 10.1016/j.jaci.2007.09.049; Sioud M, 2006, J MOL BIOL, V364, P945, DOI 10.1016/j.jmb.2006.09.054; Sioud M, 2007, EUR J IMMUNOL, V37, P2834, DOI 10.1002/eji.200737112; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3; Upham JW, 1999, J ALLERGY CLIN IMMUN, V104, P370, DOI 10.1016/S0091-6749(99)70381-7; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211; Zizka J, 2007, FOLIA MICROBIOL, V52, P549, DOI 10.1007/BF02932118	40	42	42	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					447	453		10.1016/j.jaci.2010.11.006	http://dx.doi.org/10.1016/j.jaci.2010.11.006			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21167570				2022-12-18	WOS:000286808000019
J	Gamble, C; Talbott, E; Youk, A; Holguin, F; Pitt, B; Silveira, L; Bleecker, E; Busse, W; Calhoun, W; Castro, M; Chung, KF; Erzurum, S; Israel, E; Wenzel, S				Gamble, Christy; Talbott, Evelyn; Youk, Ada; Holguin, Fernando; Pitt, Bruce; Silveira, Lori; Bleecker, Eugene; Busse, William; Calhoun, William; Castro, Mario; Chung, Kian Fan; Erzurum, Serpil; Israel, Elliot; Wenzel, Sally			Racial differences in biologic predictors of severe asthma: Data from the Severe Asthma Research Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe asthma; race; IgE; allergic sensitization; immunoinflammatory	TO-TREAT ASTHMA; GENETIC ANCESTRY; HEALTH OUTCOMES; ADULT ASTHMA; IGE LEVELS; RESPONSIVENESS; DISPARITIES; PHENOTYPES; ETHNICITY; CHILDREN	Background: Biologic factors are known to contribute to asthma severity. It is unknown whether these factors differentially contribute to asthma severity in black compared with white subjects. Objective: We sought to assess the extent to which racial disparities between black and white subjects with severe asthma are attributable to physiologic, immunoinflammatory, and sociodemographic variables. Methods: Black and white asthmatic adults enrolled in a cross-sectional study focused on severe asthma were evaluated. Severe asthma was identified by using the American Thoracic Society definition. After initial univariable analyses, unconditional logistic regression models were used to estimate the probability of having severe asthma for black and white subjects. Results: Differences in severe asthma in black compared with white subjects were observed. In univariable analysis IgE level was not associated with severe asthma in black or white subjects, whereas in multivariable analysis IgE level was significantly associated with severe asthma for black subjects (P=.014) but not for white subjects. The odds of having severe asthma more than doubled for black subjects with 2 or more family members with asthma (P=.026), whereas the odds of severe asthma for white participants with a strong family history of asthma decreased by almost half (P=.05). Atopy was negatively associated with severe asthma in both races in univariable analysis but remained significant only in black subjects, whereas comorbidities were associated with severe asthma in white subjects. Conclusion: Biologic factors were distinctly associated with severe asthma only in black subjects. Studies that incorporate comprehensive evaluation of biologic factors associated with asthma might lead to the development of therapies that target biologic abnormalities in black subjects. (J Allergy Clin Immunol 2010;126:1149-56.)	[Silveira, Lori] Natl Jewish Hlth, Denver, CO USA; [Gamble, Christy; Talbott, Evelyn; Youk, Ada; Holguin, Fernando; Pitt, Bruce; Wenzel, Sally] Univ Pittsburgh, Pittsburgh, PA USA; [Bleecker, Eugene] Wake Forest Univ, Winston Salem, NC 27109 USA; [Busse, William] Univ Wisconsin, Madison, WI USA; [Busse, William] Univ Texas Galveston, Galveston, TX 77555 USA; [Castro, Mario] Washington Univ, St Louis, MO USA; [Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, London, England; [Erzurum, Serpil] Cleveland Clin, Cleveland, OH 44106 USA; [Israel, Elliot] Brigham & Womens Hosp, Boston, MA 02115 USA	National Jewish Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Medical Branch Galveston; Washington University (WUSTL); Imperial College London; Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital	Gamble, C (corresponding author), 9 NW Montefiore Hosp, 3459 5th Ave, Pittsburgh, PA 15213 USA.	gamble.christy@gmail.com	Chung, Kian Fan/I-8456-2019; Chung, Kian Fan/B-1872-2012	Chung, Kian Fan/0000-0001-7101-1426; Chung, Kian Fan/0000-0001-7101-1426; Talbott, Evelyn/0000-0002-5198-7939; Calhoun, William/0000-0001-7075-712X; Youk, Ada/0000-0001-6912-9759	Clinical and Translational Research Center, National Center for Research Resources [RR024153, HL69116, HL69130, HL69155, HL69167, HL69170, HL69174, HL69349, HL091762, M01 RR02635, M01 RR03186, M01 RR007122-14, 1UL1RR024153, 1UL1RR024989, 1UL1RR024992, 1UL1RR025011]; Aerovance; Amgen; AstraZeneca; Boehringer-Ingelheim; Centocor; Ception; Genentech; GlaxoSmithKline; Novartis; Pfizer; Wyeth; National Institutes of Health (NIH); NIH/National Institute of Allergy and Infectious Diseases (NIAID); NIH/National Heart, Lung, and Blood Institute (NHLBI); MedImmune; Asthmatx; Merck; NIH; Elsevier; MRC UK; Asthma UK; Wellcome Trust; Medical Research Council [G0801056B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005, UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011, M01RR002635, UL1RR024992, M01RR007122, UL1RR024153, M01RR003186, UL1RR024989] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069116, R01HL091762, R01HL069130, R01HL069155, R01HL069349, R01HL069174, R01HL069167, R01HL069170] Funding Source: NIH RePORTER	Clinical and Translational Research Center, National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Aerovance; Amgen(Amgen); AstraZeneca(AstraZeneca); Boehringer-Ingelheim(Boehringer Ingelheim); Centocor; Ception; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); Pfizer(Pfizer); Wyeth(Wyeth); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MedImmune(AstraZenecaMedimmune); Asthmatx; Merck(Merck & Company); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Elsevier; MRC UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by Clinical and Translational Research Center funding: UL1 RR024153 (National Center for Research Resources). Grant support: HL69116, HL69130, HL69155, HL69167, HL69170, HL69174, HL69349, HL091762, M01 RR02635, M01 RR03186, M01 RR007122-14, 1UL1RR024153, 1UL1RR024989, 1UL1RR024992, 1UL1RR025011.; Disclosure of potential conflict of interest: E. Bleecker has served as an advisor/consultant for Aerovance, AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, and Wyeth and has received research support from Aerovance, Amgen, AstraZeneca, Boehringer-Ingelheim, Centocor, Ception, Genentech, GlaxoSmithKline, Novartis, Pfizer, Wyeth, and the National Institutes of Health (NIH). W. Busse is on the advisory board for Altair, Amgen, Centocor, GlaxoSmithKline, Merck, Pfizer, Wyeth, and Johns & Johnson; is a consultant for AstraZeneca, Boehringer-Ingelheim, Novartis, TEVA, and GlaxoSmithKline; is a speaker for Merck; and has received research support from the NIH/National Institute of Allergy and Infectious Diseases (NIAID), the NIH/National Heart, Lung, and Blood Institute (NHLBI), Novartis, AstraZeneca, GlaxoSmithKline, MedImmune, and Ception. M. Castro is a consultant for Electrocore, NKTT, Schering-Plough, Asthmatx, and Cephalon; is on the advisory board for Genentech; is a speaker for AstraZeneca, Boehringer-Ingelheim, Pfizer, Merck, and GlaxoSmithKline; has received research support from Asthmatx, Amgen, Ception, Genentech, MedImmune, Merck, Novartis, the NIH, and GlaxoSmithKline; and has received royalties from Elsevier. K. F. Chung is a consultant for Gilead, is on the advisory board for Merck and GlaxoSmithKline, and has received research support from MRC UK, Asthma UK, and Wellcome Trust. S. Wenzel has served as a consultant for Merck and GlaxoSmithKline and as an advisory board member for Amira. The rest of the authors have declared that they have no conflict of interest.	Alves Roseliane de Souza Araújo, 2008, J. bras. pneumol., V34, P646, DOI 10.1590/S1806-37132008000900003; Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247, DOI 10.1016/S1081-1206(10)61221-5; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Eisner MD, 1998, AM J RESP CRIT CARE, V158, P170, DOI 10.1164/ajrccm.158.1.9801028; El-Ekiaby A, 2006, AM J RESP CRIT CARE, V174, P508, DOI 10.1164/rccm.200603-431OC; GRUNDBACHER FJ, 1985, J ALLERGY CLIN IMMUN, V75, P651, DOI 10.1016/0091-6749(85)90089-2; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Haselkorn T, 2008, ANN ALLERG ASTHMA IM, V101, P256, DOI 10.1016/S1081-1206(10)60490-5; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Kramer JM, 2009, NEW ENGL J MED, V360, P1592, DOI 10.1056/NEJMp0810561; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Lugogo NL, 2006, CLIN CHEST MED, V27, P1, DOI 10.1016/j.ccm.2005.10.006; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Naqvi M, 2007, J ALLERGY CLIN IMMUN, V120, P137, DOI 10.1016/j.jaci.2007.02.045; Ng TP, 2000, BRIT J GEN PRACT, V50, P7; Polosa R, 2008, INTERN MED J, V38, P190, DOI 10.1111/j.1445-5994.2007.01547.x; Shanawani H, 2006, CLIN CHEST MED, V27, P17, DOI 10.1016/j.ccm.2005.11.002; SHERMAN CB, 1993, AM REV RESPIR DIS, V148, P98, DOI 10.1164/ajrccm/148.1.98; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044	26	42	42	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2010	126	6					1149	U133		10.1016/j.jaci.2010.08.049	http://dx.doi.org/10.1016/j.jaci.2010.08.049			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	689RZ	21051082	Green Accepted			2022-12-18	WOS:000284947800010
J	Debley, JS; Stamey, DC; Cochrane, ES; Gama, KL; Redding, GJ				Debley, Jason S.; Stamey, David C.; Cochrane, Elizabeth S.; Gama, Kim L.; Redding, Gregory J.			Exhaled nitric oxide, lung function, and exacerbations in wheezy infants and toddlers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Exhaled nitric oxide; fraction of exhaled nitric oxide; recurrent wheezing; infants; pulmonary function; raised-volume rapid thoracic compression	1ST 6 YEARS; AIRWAY INFLAMMATION; INHALED BUDESONIDE; YOUNG-CHILDREN; INDUCED SPUTUM; SINGLE-BREATH; ASTHMA; MARKERS; RISK; RESPONSIVENESS	Background: There are limited data assessing the relationship between fraction of exhaled nitric oxide and lung function or exacerbations in infants with recurrent wheezing. Objectives: In a longitudinal pilot study of children less than 2 years old, we assessed whether baseline fraction of exhaled nitric oxide was associated with lung function, bronchodilator responsiveness, changes in lung function, or subsequent exacerbations of wheezing. Methods: Forced expiratory flows and volumes using the raised-volume rapid thoracic compression method were measured in 44 infants and toddlers (mean age, 15.7 months) with recurrent wheezing. Single-breath exhaled nitric oxide (SB-eNO) was measured at 50 mL/s. Lung function was again measured 6 months after enrollment. Results: At enrollment, forced expiratory volume in 0.5 seconds (FEV0.5), forced expiratory flow at 25% to 75% of expiration (FEF25-75), and forced expiratory flow at 75% of expiration (FEF75) z scores for the cohort were significantly less than zero. There was no correlation between enrollment SB-eNO levels and enrollment lung function measures. SB-eNO levels were higher in infants with bronchodilator responsiveness (46.1 vs 23.6 ppb, P < .001) and was associated with a decrease in FEV0.5 (r = 0.54, P = .001), FEF25-75 (r = 0.6, P < .001), and FEF75 (r = 0.55, P = .001) over 6 months. A 10-ppb increase in SB-eNO level was associated with a 0.4-point z score decrease in FEV0.5, a 0.4-point z score decrease in FEF25-75, and a 0.42-point z score decrease in FEF75. SB-eNO level was superior to lung function and bronchodilator responsiveness in predicting subsequent wheezing treated with systemic steroids. Conclusions: SB-eNO level might predict changes in lung function and risk of future wheezing and holds promise as a biomarker to predict asthma in wheezy infants and toddlers. (J Allergy Clin Immunol 2010;125:1228-34.)	[Debley, Jason S.; Stamey, David C.; Cochrane, Elizabeth S.; Redding, Gregory J.] Univ Washington, Seattle Childrens Hosp, Dept Pediat, Div Pulm Med, Seattle, WA 98195 USA; [Gama, Kim L.] Univ Washington, Seattle Childrens Hosp, Dept Pharm, Seattle, WA 98195 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; Seattle Children's Hospital; University of Washington; University of Washington Seattle	Debley, JS (corresponding author), Seattle Childrens Hosp, Pulm Div A5937, 4800 Sand Point Way NE, Seattle, WA 98105 USA.	jason.debley@seattlechildrens.org			National Heart, Lung. and Blood Institute [K23HL077626]; CTSA [I ULI RR025014-01]; Seattle Children's Hospital; National Institutes of Health/National Heart, Lung, and Blood Institute; American Lung Association; Merck Co.; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL077626] Funding Source: NIH RePORTER	National Heart, Lung. and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Seattle Children's Hospital; National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Lung Association; Merck Co.(Merck & Company); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Heart, Lung. and Blood Institute K23HL077626; CTSA grant no. I ULI RR025014-01; and Seattle Children's Hospital.; Disclosure of potential conflict of interest: J. S. Debley has received research support from the National Institutes of Health/National Heart, Lung, and Blood Institute, American Lung Association, and Merck & Co. The rest of the authors have declared they have no conflict of interest.	American Thoracic Society, 2005, Am J Respir Crit Care Med, V172, P1463; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], EPR3; Beigelman A, 2009, ANN ALLERG ASTHMA IM, V103, P108, DOI 10.1016/S1081-1206(10)60162-7; BLOOM B, 2009, VITAL HLTH STAT, V239, P1; Borrego LM, 2009, THORAX, V64, P203, DOI 10.1136/thx.2008.099903; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Debley J, 2009, AM J RESP CRIT CARE, V179; Dupont LJ, 2003, CHEST, V123, P751, DOI 10.1378/chest.123.3.751; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894, DOI 10.1164/ajrccm.157.3.9709064; Franklin PJ, 2004, EUR RESPIR J, V23, P369, DOI 10.1183/09031936.04.00084604; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69, DOI 10.1164/ajrccm.159.1.9804134; Gibson PG, 2000, EUR RESPIR J, V16, P1008; Goldstein AB, 2001, AM J RESP CRIT CARE, V164, P447, DOI 10.1164/ajrccm.164.3.2005080; GREENBERG SB, 1993, AM J ROENTGENOL, V161, P639, DOI 10.2214/ajr.161.3.8352124; Grootendorst DC, 1997, CLIN EXP ALLERGY, V27, P769, DOI 10.1111/j.1365-2222.1997.tb01211.x; Jatakanon A, 1999, THORAX, V54, P108, DOI 10.1136/thx.54.2.108; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; Jones M, 2000, AM J RESP CRIT CARE, V161, P353, DOI 10.1164/ajrccm.161.2.9903026; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693, DOI 10.1164/ajrccm.163.7.2009041; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Kissoon N, 2002, PEDIATR PULM, V33, P283, DOI 10.1002/ppul.10023; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; Lum S, 2007, THORAX, V62, P341, DOI 10.1136/thx.2006.068262; Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2002, PEDIATRICS, V109, P362; Martinez T, 2003, J APPL PHYSIOL, V94, P2384, DOI 10.1152/japplphysiol.00758.2002; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800, DOI 10.1164/ajrccm.152.2.7633745; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Nordvall SL, 2005, ALLERGY, V60, P469, DOI 10.1111/j.1398-9995.2005.00735.x; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shin HW, 2001, J APPL PHYSIOL, V90, P777, DOI 10.1152/jappl.2001.90.3.777; Sivan Y, 2009, J PEDIATR-US, V155, P211, DOI 10.1016/j.jpeds.2009.02.034; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Taylor SL, 2006, ARCH ENVIRON OCCUP H, V61, P27, DOI 10.3200/AEOH.61.1.27-32; Warke TJ, 2002, THORAX, V57, P383, DOI 10.1136/thorax.57.5.383; Wildhaber JH, 1999, AM J RESP CRIT CARE, V159, P74, DOI 10.1164/ajrccm.159.1.9805021; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801	44	42	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1228	1234		10.1016/j.jaci.2010.03.023	http://dx.doi.org/10.1016/j.jaci.2010.03.023			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20462633	Bronze, Green Accepted			2022-12-18	WOS:000278831000007
J	Thomas, SY; Chyung, YH; Luster, AD				Thomas, Seddon Y.; Chyung, Yung H.; Luster, Andrew D.			Natural killer T cells are not the predominant T cell in asthma and likely modulate, not cause, asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer T cell; asthma; CD1d; T(H)2 cells; airway hyperresponsiveness	NKT CELLS; AIRWAY HYPERREACTIVITY; ALPHA-GALACTOSYLCERAMIDE; MONOCLONAL-ANTIBODY; DENDRITIC CELLS; ALLERGIC-ASTHMA; INKT-CELLS; TCR ALPHA; ACTIVATION; RECOGNITION	Asthma is a multifactorial disease of the airways characterized by airway inflammation, mucus hypersecretion, and airway hyperresponsiveness. Conventional MHC class II-restricted CD4(+) T cells are considered a key cell in asthma pathogenesis because they have a broad T-cell receptor repertoire, providing specificity and reactivity to diverse protein allergens. This notion was challenged when a study found that invariant Natural Killer (NK) T cells were the predominant T cells in the lung and bronchoalveolar lavage fluid of all asthmatic subjects studied. This finding was provocative because invariant NKT cells have a very limited T-cell receptor repertoire and are specific for a restricted set of lipid antigens that bind to CD1d, a nonpolymorphic MHC-like molecule. However, multiple subsequent studies failed to replicate the initial study and instead found that invariant NKT cells are present as a small fraction of the total T cells in the asthmatic lung. Thus, we believe that although CD1d-restricted NKT cells might play a role in modulating the asthmatic phenotype, they are not the critical drivers of the asthmatic response, a role we believe is still held by conventional MHC class II-restricted CD4(+) T cells. (J Allergy Clin Immunol 2010;125:980-4.)	[Chyung, Yung H.; Luster, Andrew D.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA; [Chyung, Yung H.; Luster, Andrew D.] Harvard Univ, Sch Med, Boston, MA USA; [Thomas, Seddon Y.] Univ Chicago, Dept Pathol, Howard Hughes Med Inst, Comm Immunol, Chicago, IL 60637 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Chicago	Luster, AD (corresponding author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.	aluster@mgh.harvard.edu	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912; Thomas, Seddon/0000-0003-0075-0744	National Institute of Health [R37-AI040618]; American Academy of Allergy, Asthma Immunology; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060548, R37AI040618] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Academy of Allergy, Asthma Immunology; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grant R37-AI040618 from the National Institute of Health to A.D.L.; Disclosure of potential conflict of interest: Y. H. Chyung receives research support from the American Academy of Allergy, Asthma & Immunology. The rest of the authors have declared that they have no conflict of interest.	Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Bratke K, 2007, NEW ENGL J MED, V357, P194; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; Broeckaert F, 2000, ENVIRON HEALTH PERSP, V108, P533, DOI 10.2307/3454615; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Das J, 2006, NAT MED, V12, P1345, DOI 10.1038/nm1206-1345; Exley MA, 2008, EUR J IMMUNOL, V38, P1756, DOI 10.1002/eji.200737389; Fox LM, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000228; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Gern JE, 2000, J ALLERGY CLIN IMMUN, V106, P201, DOI 10.1067/mai.2000.108604; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; Hachem P, 2005, EUR J IMMUNOL, V35, P2793, DOI 10.1002/eji.200535268; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hamzaoui A, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/71214; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497, DOI 10.1164/ajrccm.154.5.8912771; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim JO, 2004, J ALLERGY CLIN IMMUN, V114, P1332, DOI 10.1016/j.jaci.2004.09.004; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Koh YI, 2008, J IMMUNOL, V181, P4560, DOI 10.4049/jimmunol.181.7.4560; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; Lisbonne M, 2003, J IMMUNOL, V171, P1637, DOI 10.4049/jimmunol.171.4.1637; Matangkasombut P, 2009, J ALLERGY CLIN IMMUN, V123, P1181, DOI 10.1016/j.jaci.2009.02.013; Matsuda H, 2005, AM J RESP CELL MOL, V33, P22, DOI 10.1165/rcmb.2004-0010OC; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; Medoff BD, 2008, ANNU REV IMMUNOL, V26, P205, DOI 10.1146/annurev.immunol.26.021607.090312; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Montoya CJ, 2007, IMMUNOLOGY, V122, P1, DOI 10.1111/j.1365-2567.2007.02647.x; Mutalithas K, 2007, J ALLERGY CLIN IMMUN, V119, P1274, DOI 10.1016/j.jaci.2007.02.021; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Nembrini C, 2009, J ALLERGY CLIN IMMUN, V123, P986, DOI 10.1016/j.jaci.2009.03.033; Olivera DS, 2007, INHAL TOXICOL, V19, P13, DOI 10.1080/08958370600985768; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Porcelli S, 1996, HUM IMMUNOL, V48, P63, DOI 10.1016/0198-8859(96)00090-0; Reynolds C, 2009, J ALLERGY CLIN IMMUN, V124, P860, DOI 10.1016/j.jaci.2009.07.022; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Selmi C, 2003, HEPATOLOGY, V38, P1250, DOI 10.1053/jhep.2003.50446; Shannon J, 2008, CHEST, V133, P420, DOI 10.1378/chest.07-1881; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; Thomas SY, 2007, J IMMUNOL, V179, P1901, DOI 10.4049/jimmunol.179.3.1901; Tsuji M, 2006, CELL MOL LIFE SCI, V63, P1889, DOI 10.1007/s00018-006-6073-z; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507	53	42	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					980	984		10.1016/j.jaci.2010.01.032	http://dx.doi.org/10.1016/j.jaci.2010.01.032			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	596LO	20304475	Green Accepted			2022-12-18	WOS:000277686700004
J	Mutschlechner, S; Egger, M; Briza, P; Wallner, M; Lackner, P; Karle, A; Vogt, AB; Fischer, GF; Bohle, B; Ferreira, F				Mutschlechner, Sonja; Egger, Matthias; Briza, Peter; Wallner, Michael; Lackner, Peter; Karle, Anette; Vogt, Anne B.; Fischer, Gottfried F.; Bohle, Barbara; Ferreira, Fatima			Naturally processed T cell-activating peptides of the major birch pollen allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Birch pollen allergy; Bet v 1; antigen processing; antigen presentation; dendritic cells; T cells; T-cell epitopes	BET V 1; DENDRITIC CELLS; ANTIGEN PRESENTATION; IMMUNOGLOBULIN-E; POTENTIAL USE; EPITOPE; REACTIVITY; IMMUNOGENICITY; IDENTIFICATION; INDIVIDUALS	Background: Although antigen processing and presentation of allergens to CD4(+)T lymphocytes are key events in the pathophysiology of allergic disorders, they still remain poorly understood. Objective: To investigate allergen processing and presentation by dendritic cells using the major birch pollen allergen Bet v 1 as a model. Methods: Endolysosomal extracts of dendritic cells derived from patients with birch pollen allergy were used to digest Bet v 1. Dendritic cells were pulsed with Bet v 1, and peptides were eluted from MHC class II molecules. Peptides obtained by either approach were sequenced by tandem mass spectrometry. Bet v 1 specific T-cell cultures were stimulated with HLA-DR-eluted Bet v 1 derived peptides. Bet v 1 specific T-cell lines were generated from each patient and analyzed for epitope recognition. Results: A high proportion of Bet v 1 remained intact for a long period of endolysosomal degradation. The peptides that appeared early in the degradation process contained frequently recognized T-cell epitopes. Bet v 1 derived peptides eluted from MHC class II molecules corresponded to those generated by endolysosomal degradation, matched known T-cell epitopes, and showed T cell activating capacity. The Bet v 1 specific I-cell line of each individual harbored T cells reactive with peptides located within the MHC class II eluted Bet v 1 derived sequences demonstrating their occurrence in vivo. Conclusion: We report for the first time how epitopes of allergens are generated and selected for presentation to T lymphocytes. The limited susceptibility of Bet v 1 to endolysosomal processing might contribute to its high allergenic potential. (J Allergy Clin Immunol 2010;125:711-8.)	[Mutschlechner, Sonja; Bohle, Barbara] Med Univ Vienna, Inst Pathophysiol, Christian Doppler Lab Immunomodulat, Dept Pathophysiol,Ctr Physiol Pathophysiol & Immu, A-1090 Vienna, Austria; [Mutschlechner, Sonja; Egger, Matthias; Briza, Peter; Wallner, Michael; Lackner, Peter; Ferreira, Fatima] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, Dept Mol Biol, A-5020 Salzburg, Austria; [Karle, Anette; Vogt, Anne B.] F Hoffmann La Roche & Co Ltd, Nonclin Safety, CH-4002 Basel, Switzerland; [Fischer, Gottfried F.] Univ Clin Blood Grp Serol & Transfus Med, Clin Dept Blood Grp Serol, Vienna, Austria	Medical University of Vienna; Salzburg University; Roche Holding	Bohle, B (corresponding author), Med Univ Vienna, Inst Pathophysiol, Christian Doppler Lab Immunomodulat, Dept Pathophysiol,Ctr Physiol Pathophysiol & Immu, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at; fatima.ferreira@sbg.ac.at	Briza, Peter/D-7309-2012; Wallner, Michael/L-5437-2015; Ferreira, Fatima/AAB-4321-2019; Lackner, Peter/L-2900-2015; Ferreira, Fatima/E-4889-2011	Briza, Peter/0000-0002-4941-6782; Wallner, Michael/0000-0001-6568-7892; Ferreira, Fatima/0000-0003-0989-2335; Lackner, Peter/0000-0003-4681-6307; Ferreira, Fatima/0000-0003-0989-2335; Bohle, Barbara/0000-0002-5105-7985; Egger, Matthias/0000-0001-7462-5132	Osterreichische Nationalbank [P10150]; Christian Doppler Laboratory for Allergy Diagnosis and Therapy; Christian Doppler Laboratory for Immunomodulation, Austria; Biomay AG; Austrian Science Fund; Christian Doppler Research Association; Austrian National Bank; Christian Doppler Laboratory	Osterreichische Nationalbank; Christian Doppler Laboratory for Allergy Diagnosis and Therapy; Christian Doppler Laboratory for Immunomodulation, Austria; Biomay AG; Austrian Science Fund(Austrian Science Fund (FWF)); Christian Doppler Research Association; Austrian National Bank; Christian Doppler Laboratory	Supported by P10150 of the Osterreichische Nationalbank, the Christian Doppler Laboratory for Allergy Diagnosis and Therapy, and the Christian Doppler Laboratory for Immunomodulation, Austria.; Disclosure of potential conflict of interest: F. Ferreira has received research support from Biomay AG, the Austrian Science Fund, the Christian Doppler Research Association, and the Austrian National Bank and has provided legal consultation services or expert witness testimony relevant to Indoor Biotechnologies and AllergenOnline Database. B. Bohle has received research support from the Austrian Science Fund and the Christian Doppler Laboratory. The rest of the authors have declared that they have no conflict of interest.	Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Bohle B, 2006, CLIN REV ALLERG IMMU, V30, P97, DOI 10.1385/CRIAI:30:2:97; Bohle B, 1998, J IMMUNOL, V160, P2022; Bohle B, 2006, J ALLERGY CLIN IMMUN, V118, P242, DOI 10.1016/j.jaci.2006.03.011; BREITENEDER H, 1995, IMMUNOGENETICS, V42, P53, DOI 10.1007/BF00164987; Carmicle S, 2002, J BIOL CHEM, V277, P155, DOI 10.1074/jbc.M107624200; Carson RT, 1997, IMMUNITY, V7, P387, DOI 10.1016/S1074-7613(00)80360-X; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Delamarre L, 2006, J EXP MED, V203, P2049, DOI 10.1084/jem.20052442; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Friedl-Hajek R, 1999, CLIN EXP ALLERGY, V29, P478, DOI 10.1046/j.1365-2222.1999.00489.x; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Gerstmayr M, 2007, J IMMUNOL, V179, P7270, DOI 10.4049/jimmunol.179.11.7270; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lippolis JD, 2002, J IMMUNOL, V169, P5089, DOI 10.4049/jimmunol.169.9.5089; MALCHEREK G, 1994, J IMMUNOL, V153, P1141; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1998, J IMMUNOL, V161, P2731; Moudgil KD, 1998, IMMUNOL TODAY, V19, P217, DOI 10.1016/S0167-5699(97)01233-4; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6; Rohn TA, 2005, CANCER RES, V65, P10068, DOI 10.1158/0008-5472.CAN-05-1973; Savina A, 2007, IMMUNOL REV, V219, P143, DOI 10.1111/j.1600-065X.2007.00552.x; Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514, DOI 10.4049/jimmunol.180.7.4514; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; Woodfolk JA, 2007, J ALLERGY CLIN IMMUN, V119, P280, DOI 10.1016/j.jaci.2006.11.008	35	42	44	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2010	125	3					711	718		10.1016/j.jaci.2009.10.052	http://dx.doi.org/10.1016/j.jaci.2009.10.052			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	573BK	20132976				2022-12-18	WOS:000275883200030
J	Cortes, JR; Rivas, MD; Molina-Infante, J; Gonzalez-Nunez, MA; Perez, M; Masa, JF; Sanchez, JF; Zamorano, J				Cortes, Jose R.; Rivas, Maria D.; Molina-Infante, Javier; Gonzalez-Nunez, Maria A.; Perez-G, Moises; Masa, Juan F.; Sanchez, Juan F.; Zamorano, Jose			Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EFFICACY		[Cortes, Jose R.; Rivas, Maria D.; Perez-G, Moises; Zamorano, Jose] Hosp San Pedro de Alcantara, Unidad Invest, Caceres, Spain; [Molina-Infante, Javier] Hosp San Pedro de Alcantara, Serv Digest, Caceres, Spain; [Gonzalez-Nunez, Maria A.] Hosp San Pedro de Alcantara, Serv Anat Patol, Caceres, Spain; [Masa, Juan F.] Hosp San Pedro de Alcantara, Serv Neumol, Ctr Invest Biomed Red Enfermedades Resp CiberRes, Caceres, Spain; [Sanchez, Juan F.] Hosp San Pedro de Alcantara, Med Interna Serv, Caceres, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERES	Cortes, JR (corresponding author), Hosp San Pedro de Alcantara, Unidad Invest, Caceres, Spain.	jose.zamorano@ses.juntaextremadura.net	Zamorano, Jose/Q-2514-2017	Zamorano, Jose/0000-0002-4271-3741; Gonzalez Nunez, Maria Angeles/0000-0003-2646-2820				Besancon M, 1997, J BIOL CHEM, V272, P22438, DOI 10.1074/jbc.272.36.22438; Bohm M, 2008, AM J GASTROENTEROL, V103, P2635, DOI 10.1111/j.1572-0241.2008.02116.x; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Hanania NA, 2009, NEW ENGL J MED, V360, P1487, DOI 10.1056/NEJMoa0806290; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694, DOI 10.1164/ajrccm.161.3.9911005; IM WB, 1985, J BIOL CHEM, V260, P9452; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Perez M, 2008, MOL IMMUNOL, V45, P3896, DOI 10.1016/j.molimm.2008.06.026; Sharma B, 2007, WORLD J GASTROENTERO, V13, P1706, DOI 10.3748/wjg.v13.i11.1706	9	42	43	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					607	610		10.1016/j.jaci.2009.06.023	http://dx.doi.org/10.1016/j.jaci.2009.06.023			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	552TG	19665777	Bronze			2022-12-18	WOS:000274315900034
J	Hirahara, K; Yamashita, M; Iwamura, C; Shinoda, K; Hasegawa, A; Yoshizawa, H; Koseki, H; Gejyo, F; Nakayama, T				Hirahara, Kiyoshi; Yamashita, Masakatsu; Iwamura, Chiaki; Shinoda, Kenta; Hasegawa, Akihiro; Yoshizawa, Hirohisa; Koseki, Haruhiko; Gejyo, Fumitake; Nakayama, Toshinori			Repressor of GATA regulates T(H)2-driven allergic airway inflammation and airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						repressor of GATA; POK family; repressor; airway inflammation; airway hyperrsponsiveness; GAT43; T(H)2; allergic asthma	TRANSCRIPTION FACTOR GATA-3; PROTEIN INTERACTION MOTIF; CD4 T-CELLS; GENE LOCUS; HISTONE HYPERACETYLATION; TH2-SPECIFIC EXPRESSION; INTERLEUKIN-5 GENE; CUTTING EDGE; POZ-DOMAIN; TH2 CELLS	Background: Studies of human asthma and of animal models of allergic inflammation/asthma highlight a crucial role for T(H)2 cells in the pathogenesis of allergic asthma. Repressor of GATA (ROG) is a POZ (BTB) domain-containing Kruppel-type zinc finger family (or POK family) repressor. A repressive function to GATA3, a master transcription factor for T(H)2 cell differentiation, is indicated. Objective: The aim of this study was to clarify the regulatory roles of ROG in the pathogenesis of T(H)2-driven allergic diseases, such as allergic asthma. Methods: We examined allergic airway inflammation and airway hyperresponsiveness (AHR) in 3 different mouse models, which use either ROG-deficient (ROG(-/-)) mice, ROG transgenic mice, or adoptive transfer of cells. Results: In ROG(-/-) mice T(H)2 cell differentiation, T(H)2 responses, eosinophilic airway inflammation, and AHR were enhanced. In ROG transgenic mice the levels of eosinophilic airway inflammation and AHR were dramatically reduced. Furthermore, adoptive transfer of T(H)2 cells with increased or decreased levels of ROG expression into the asthmatic mice resulted in reduced or enhanced airway inflammation, respectively. Conclusion: These results indicate that ROG regulates allergic airway inflammation and AHR in a negative manner, and thus ROG might represent another potential therapeutic target for the treatment of asthmatic patients.	[Hirahara, Kiyoshi; Yamashita, Masakatsu; Shinoda, Kenta; Hasegawa, Akihiro; Nakayama, Toshinori] Chiba Univ, Grad Sch Med, Dept Immunol, Chiba 2608670, Japan; [Hirahara, Kiyoshi; Gejyo, Fumitake] Niigata Univ, Grad Sch Med & Dent Sci, Div Resp Med, Dept Homeostat Regulat & Dev, Niigata 95021, Japan; [Yoshizawa, Hirohisa] Niigata Univ Med & Dent Hosp, Biosci Med Res Ctr, Niigata, Japan; [Koseki, Haruhiko] RIKEN Res Ctr Allergy & Immunol, Dev Biol Lab, Yokohama, Kanagawa, Japan	Chiba University; Niigata University; Niigata University; RIKEN	Nakayama, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Immunol H3, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	tnakayama@faculty.chiba-u.jp	Koseki, Haruhiko/I-3825-2014; Nakayama, Toshinori/E-1067-2017; Hirahara, Kiyoshi/E-2460-2017	Koseki, Haruhiko/0000-0001-8424-5854; Nakayama, Toshinori/0000-0002-1434-2007; Hirahara, Kiyoshi/0000-0002-9128-9449	Ministry of Education, Culture, Sports, Science and Technology [17016010, 17390139, 18590466, 19590491, 19591609, 19659121, 18890046]; Promoting Science and Technology	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Promoting Science and Technology	Supported by grants front the Ministry of Education, Culture, Sports, Science and Technology (Japan: Grants-in-Aid for Scientific Research on Priority Areas no. 17016010: Scientific Research [B] no. 17390139: Scientific Research [C] nos. 18590466, 19590491. and 19591609 Exploratory Research no. 19659121. and Young Scientists [Start-up] no. 18890046) and Special Coordination Funds for Promoting Science and Technology.	Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bettelli E, 2007, NAT IMMUNOL, V8, P345, DOI 10.1038/ni0407-345; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Garcia Z, 2007, P NATL ACAD SCI USA, V104, P4553, DOI 10.1073/pnas.0610019104; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Inami M, 2004, J BIOL CHEM, V279, P23123, DOI 10.1074/jbc.M401248200; Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kamata T, 2003, J CLIN INVEST, V111, P109, DOI 10.1172/JCI200315719; Kang BY, 2005, MOL CELL BIOL, V25, P554, DOI 10.1128/MCB.25.2.554-562.2005; Kimura MY, 2005, J EXP MED, V201, P397, DOI 10.1084/jem.20040733; Kiwamoto T, 2006, AM J RESP CRIT CARE, V174, P142, DOI 10.1164/rccm.200601-079OC; Kurata H, 1999, IMMUNITY, V11, P677, DOI 10.1016/S1074-7613(00)80142-9; Lee HJ, 1998, J IMMUNOL, V160, P2343; Lin WC, 1999, BIOCHEM BIOPH RES CO, V264, P789, DOI 10.1006/bbrc.1999.1594; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; Nigo YI, 2006, P NATL ACAD SCI USA, V103, P2286, DOI 10.1073/pnas.0510685103; Omori M, 2003, IMMUNITY, V19, P281, DOI 10.1016/S1074-7613(03)00210-3; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Piazza F, 2004, MOL CELL BIOL, V24, P10456, DOI 10.1128/MCB.24.23.10456-10469.2004; Schwenger GTF, 2001, J BIOL CHEM, V276, P48502, DOI 10.1074/jbc.M107836200; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	47	42	42	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					512	520		10.1016/j.jaci.2008.06.004	http://dx.doi.org/10.1016/j.jaci.2008.06.004			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18620745				2022-12-18	WOS:000259234000011
J	Slatter, MA; Brigham, K; Dickinson, AM; Harvey, HL; Barge, D; Jackson, A; Bown, N; Flood, TJ; Cant, AJ; Abinun, M; Gennery, AR				Slatter, Mary A.; Brigham, Kenneth; Dickinson, Anne M.; Harvey, Helen L.; Barge, Dawn; Jackson, Antony; Bown, Nicholas; Flood, Terence J.; Cant, Andrew J.; Abinun, Mario; Gennery, Andrew R.			Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation	MAR 25-28, 2007	Lyon, FRANCE	European Grp Blood & Marrow Transplantat		severe combined immunodeficiency; hematopoietic stem cell transplantation; T-cell depletion; CD34(+) stem cell selection; immune reconstitution	BONE-MARROW-TRANSPLANTATION; GENE-THERAPY; SINGLE-CENTER; CHIMERISM; DYSFUNCTION; SUBSETS; SCID-X1; INFANTS; DISEASE; BMT	Background: Results of treatment of severe T-lymphocyte immunodeficiencies by means of hematopoietic stem cell (HSC) transplantation have improved. T cell-depleted haploidentical transplantations are successful if there is no HLA-identical donor. Methods to remove T lymphocytes include addition of anti-CD52 antibodies and CD34(+) HSC selection. Objective: Assessment of long-term immune function is important after these treatments. We looked at immune reconstitution in 36 survivors for more than 2 years after HSC transplantation for severe T-lymphocyte immunodeficiencies and compared engraftment quality between the 2 T-lymphocyte depletion methods. Methods: Chimerism, T- and B-lymphocyte subsets, immunoglobulin levels, and specific antibody production at last follow-up were examined. The X(2) (Fisher exact test) and Wilcoxon rank sum analyses were used to compare the groups. Results: Nineteen patients received anti-CD52-treated and 19 anti-CD34-treated HSCs. More anti-CD52-treated patients had full donor myeloid chimerism (P = .025). All patients had full donor T-lymphocyte chimerism. There was no difference in donor B-lymphocyte chimerism, but significantly more anti-CD52-treated patients had class-switched memory B lymphocytes (P = .024), normal IgG levels, and normal responses to tetanus and Haemophilus influenzae type B vaccination. More anti-CD52-treated patients with common gamma chain or Janus-associated kinase 3 severe combined immunodeficiency had donor B lymphocytes. Conclusion: Long-term T-lymphocyte function is good with either treatment method, with a low incidence of graft-versus-host disease. The results imply more incomplete donor chimerism in anti-CD34-treated patients with less B-lymphocyte function.	[Slatter, Mary A.; Harvey, Helen L.; Flood, Terence J.; Cant, Andrew J.; Abinun, Mario; Gennery, Andrew R.] Newcastle Upon Tyne Hosp Fdn Trust, Dept Paediat Immunol, Newcastle Upon Tyne, Tyne & Wear, England; [Brigham, Kenneth; Dickinson, Anne M.] Newcastle Upon Tyne Hosp Fdn Trust, Stem Cell Lab, Newcastle Upon Tyne, Tyne & Wear, England; [Barge, Dawn] Newcastle Upon Tyne Hosp Fdn Trust, Reg Immunol Lab, Newcastle Upon Tyne, Tyne & Wear, England; [Cant, Andrew J.; Abinun, Mario; Gennery, Andrew R.] Univ Newcastle Upon Tyne, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK	Gennery, AR (corresponding author), Newcastle Gen Hosp, Westgate Rd, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	a.r.gennery@ncl.ac.uk						Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Benard A, 2006, EUR J IMMUNOL, V36, P2324, DOI 10.1002/eji.200636434; Berrington JE, 2005, CLIN EXP IMMUNOL, V140, P289, DOI 10.1111/j.1365-2249.2005.02767.x; Borghans JA, 2006, BLOOD, V108, P763, DOI 10.1182/blood-2006-01-009241; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; Chinen J, 2007, BLOOD, V110, P67, DOI 10.1182/blood-2006-11-058933; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Dickinson AM, 1997, BONE MARROW TRANSPL, V19, P323, DOI 10.1038/sj.bmt.1700669; Fischer A, 2005, IMMUNOL REV, V203, P98, DOI 10.1111/j.0105-2896.2005.00223.x; Gennery AR, 2001, CYTOTHERAPY, V3, P221, DOI 10.1080/146532401753174052; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Haddad E, 1998, BLOOD, V91, P3646; Lanfranchi A., 2000, Haematologica, V85, P41; Lang P, 2005, KLIN PADIATR, V217, P334, DOI 10.1055/s-2005-872529; Laurenti L, 2001, TRANSFUSION, V41, P783, DOI 10.1046/j.1537-2995.2001.41060783.x; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; MORIMOTO C, 1993, CLIN EXP RHEUMATOL, V11, P241; Muller SM, 2000, BLOOD, V96, P4344, DOI 10.1182/blood.V96.13.4344.h8004344_4344_4349; Routledge D, 2007, J PEDIAT HEMATOL ONC, V29, P428, DOI 10.1097/MPH.0b013e318064519a; Slatter MA, 2005, BONE MARROW TRANSPL, V35, P683, DOI 10.1038/sj.bmt.1704872; Slatter MA, 2004, BONE MARROW TRANSPL, V33, P949, DOI 10.1038/sj.bmt.1704456; Slatter MA, 2003, BONE MARROW TRANSPL, V32, P225, DOI 10.1038/sj.bmt.1704109; Thrasher AJ, 2005, BLOOD, V105, P4255, DOI 10.1182/blood-2004-12-4837; Ting SS, 2001, BRIT J HAEMATOL, V112, P1004, DOI 10.1046/j.1365-2141.2001.02639.x; White H, 2000, EUR J IMMUNOL, V30, P732	27	42	45	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					361	367		10.1016/j.jaci.2007.10.035	http://dx.doi.org/10.1016/j.jaci.2007.10.035			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	265CX	18086494	Bronze			2022-12-18	WOS:000253337800013
J	Steinke, JW; Rich, SS; Borish, L				Steinke, John W.; Rich, Stephen S.; Borish, Larry			Genetics of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetics; pharmacogenetics; gene-gene; gene-environment; asthma	ASTHMA SUSCEPTIBILITY LOCI; GENOME-WIDE SEARCH; FAMILIAL AGGREGATION; MACULAR DEGENERATION; ASSOCIATION; POPULATION; CHILDHOOD; CHILDREN; LINKAGE; POLYMORPHISM	Genetic variation provides the basis for differences in the host response to a variety of environmental factors that can result in complex genetic diseases, including asthma and atopy. Through our ability to capture genetic variation at the single-nucleotide level and our increasing ability to perform large-scale sequencing of the human genome, including the development of computer algorithms for improved data analysis, our understanding of these complex diseases has increased dramatically in recent years. The genetics of allergy have shifted from characterizing a single polymorphism in a candidate gene as being responsible for the disease to inclusion of a multitude of genetic and nongenetic risk factors. Studies now must consider complex relationships that modify an individual's susceptibility, including possible gene-environment and gene-gene interactions and possible epigenetic modification of the genome. This review will discuss the techniques used for genetic analysis of complex diseases, some of the important genes that have been replicated in multiple asthma studies, and the future of genetic studies in asthma.	[Steinke, John W.; Borish, Larry] Univ Virginia Hlth Syst, Beirne Carter Ctr Immunol Res, Asthma & Allergy Dis Ctr, Charlottesville, VA 22908 USA; [Rich, Stephen S.] Univ Virginia Hlth Syst, Ctr Publ Hlth Genom, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Borish, L (corresponding author), Univ Virginia Hlth Syst, Beirne Carter Ctr Immunol Res, Asthma & Allergy Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	lb4m@virginia.edu		Rich, Stephen/0000-0003-3872-7793				Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; BORISH L, 2004, ALLERGY CLIN IMMUNOL, V16, P20; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; Chan IHS, 2006, J ALLERGY CLIN IMMUN, V117, P127, DOI 10.1016/j.jaci.2005.09.031; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044; Chen Y, 2001, AM J MED GENET, V104, P23, DOI 10.1002/ajmg.10026; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Devereux G, 2007, AM J CLIN NUTR, V85, P853, DOI 10.1093/ajcn/85.3.853; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Hall IP, 2005, THORAX, V60, P357, DOI 10.1136/thx.2005.040790; Hao K, 2005, ANN EPIDEMIOL, V15, P737, DOI 10.1016/j.annepidem.2005.02.002; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Jenkins MA, 1997, GENET EPIDEMIOL, V14, P317, DOI 10.1002/(SICI)1098-2272(1997)14:3<317::AID-GEPI9>3.0.CO;2-1; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim HB, 2006, J HUM GENET, V51, P1055, DOI 10.1007/s10038-006-0061-x; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Marsh DG, 1997, NAT GENET, V15, P389; Mathias RA, 2006, BMC GENET, V7, DOI 10.1186/1471-2156-7-38; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; Morton NE, 1998, P NATL ACAD SCI USA, V95, P11389, DOI 10.1073/pnas.95.19.11389; Niu TH, 2000, AM J RESP CRIT CARE, V162, P1833, DOI 10.1164/ajrccm.162.5.9908127; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer LJ, 2001, EUR RESPIR J, V17, P696, DOI 10.1183/09031936.01.17406960; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Reich DE, 2003, NAT GENET, V33, P457, DOI 10.1038/ng1133; Risch N, 1998, GENOME RES, V8, P1273, DOI 10.1101/gr.8.12.1273; Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505; Steinke JW, 2003, J ALLERGY CLIN IMMUN, V111, P342, DOI 10.1067/mai.2003.67; ZAMBELLIWEINER A, 2005, AM J HUM GENET, V115, P1203	32	42	43	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2		2			S384	S387		10.1016/j.jaci.2007.07.029	http://dx.doi.org/10.1016/j.jaci.2007.07.029			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266IB	18241687				2022-12-18	WOS:000253426600006
J	Frank, MM; Jiang, HX				Frank, Michael M.; Jiang, Haixiang			New therapies for heireditary angioedema: Disease outlook changes dramatically	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hereditary angioedema; angioedema; bradykinin system antagonists; C1 inhibitor	INHIBITOR; EDEMA	Hereditary angioedema (HAE) is an autosomal dominant disease associated with episodic attacks of nonpitting edema that may affect any external or mucosal body surface. Attacks most often affect the extremities, causing local swelling, the GI tract, leading to severe abdominal pain, and the mouth and throat, at times causing asphyxiation. Most patients with HAE have low levels of the plasma serine protease inhibitor C1 inhibitor. The edema in these patients is caused by unregulated generation of bradykinin. Effective chronic therapy of patients with impeded androgens or plasmin inhibitors has been available for decades, but in the United States, we do not have therapy for acute attacks. Five companies have completed or are in the process of conducting phase 3 clinical trials, double-blind, placebo-controlled studies of products designed to terminate acute attacks or to be used in prophylaxis. Two companies, Lev Pharmaceuticals and CSL Behring, have preparations of C1 inhibitor purified from plasma that have been used in Europe for decades (trade names Cinryze and Berinert P, respectively). One company, Pharming, has developed a recombinant C1 inhibitor preparation. One company, Dyax, is testing a kallikrein inhibitor (ecallantide), and one company, Jerini, is completing testing of a bradykinin type 2 receptor antagonist (Icatibant). Although little has been published thus far, all of these products may prove effective. It is likely that HAE treatment will change dramatically within the next few years.	[Frank, Michael M.; Jiang, Haixiang] Duke Univ, Med Ctr, Dept Pediat, Sch Med, Durham, NC 27710 USA	Duke University	Frank, MM (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Sch Med, Box 3352, Durham, NC 27710 USA.	frank007@mc.duke.edu						AGOSTONI A, 1980, NEW ENGL J MED, V9, P526; ALSENZ J, 1987, NEW ENGL J MED, V316, P1360, DOI 10.1056/NEJM198705283162202; Bas M, 2006, ALLERGY, V61, P1490, DOI 10.1111/j.1398-9995.2006.01197.x; BLOHME G, 1972, ACTA MED SCAND, V192, P293; BORK J, 1979, DEUT MED WOCHENSCHR, V11, P405; Bork K, 2006, AM J GASTROENTEROL, V101, P619, DOI 10.1111/j.1572-0241.2006.00492.x; Bork K, 2005, TRANSFUSION, V45, P1774, DOI 10.1111/j.1537-2995.2005.00602.x; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; BORK K, 2002, J HEPATOL, V5; Bork K, 2007, J ALLERGY CLIN IMMUN, V119, P1497, DOI 10.1016/j.jaci.2007.02.012; Caballero T, 2006, J ALLERGY CLIN IMMUN, V117, P476, DOI 10.1016/j.jaci.2005.10.045; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P763, DOI 10.1111/j.1365-2133.1969.tb15938.x; Cicardi M, 2003, TRANSFUS APHER SCI, V29, P221, DOI 10.1016/S1473-0502(03)00164-2; Crampon D, 1998, J HEPATOL, V29, P1035, DOI 10.1016/S0168-8278(98)80140-2; Davis AE, 2005, CLIN IMMUNOL, V114, P3, DOI 10.1016/j.clim.2004.05.007; DAVIS PJ, 1974, JOHNS HOPKINS MED J, V135, P391; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; Farkas H, 2002, PEDIAT ALLERG IMM-UK, V13, P153, DOI 10.1034/j.1399-3038.2002.01014.x; FRANK MM, 1977, NEW ENGL J MED, V296, P1235; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Koles K, 2004, GLYCOBIOLOGY, V14, P51, DOI 10.1093/glycob/cwh010; Lee EDH, 2003, IMMUNOL LETT, V89, P155, DOI 10.1016/S0165-2478(03)00130-5; Levi M, 2006, J ALLERGY CLIN IMMUN, V117, P904, DOI 10.1016/j.jaci.2006.01.002; Levy JH, 2006, EXPERT OPIN INV DRUG, V15, P1077, DOI 10.1517/13543784.15.9.1077; LEVY R, 2007, RESULTS PHASE 3 DOUB, V3; Longhurst HJ, 2007, CLIN EXP IMMUNOL, V147, P11, DOI 10.1111/j.1365-2249.2006.03256.x; LUNDH B, 1968, Clinical and Experimental Immunology, V3, P733; Nilsson I M, 1966, Acta Med Scand Suppl, V448, P1; PICKERING RJ, 1968, J LAB CLIN MED, V72, P298; Reuser AJJ, 2002, EUR J PEDIATR, V161, pS106, DOI 10.1007/s00431-002-1015-8; Rosse W F, 1976, Trans Assoc Am Physicians, V89, P122; Schneider L, 2007, J ALLERGY CLIN IMMUN, V120, P416, DOI 10.1016/j.jaci.2007.04.028; SCHWARTZ RP, 1982, AM J DIS CHILD, V136, P474, DOI 10.1001/archpedi.1982.03970410092029; SHEFFER AL, 1981, J ALLERGY CLIN IMMUN, V68, P181, DOI 10.1016/0091-6749(81)90181-0; SHEFFER AL, 1972, NEW ENGL J MED, V287, P452, DOI 10.1056/NEJM197208312870907; SPAULDING WB, 1960, ANN INTERN MED, V53, P739, DOI 10.7326/0003-4819-53-4-739; van Doorn MBA, 2005, J ALLERGY CLIN IMMUN, V116, P876, DOI 10.1016/j.jaci.2005.05.019; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; Williams A, 2003, TRANSFUS APHER SCI, V29, P255, DOI 10.1016/S1473-0502(03)00170-8; ZIEGENFUSS J, 1973, LANCET, V1, P262; Zuraw BL, 2006, IMMUNOL ALLERGY CLIN, V26, P691, DOI 10.1016/j.iac.2006.09.007; ZURLO JJ, 1990, FERTIL STERIL, V54, P64	45	42	43	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					272	280		10.1016/j.jaci.2007.11.019	http://dx.doi.org/10.1016/j.jaci.2007.11.019			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206518	Bronze			2022-12-18	WOS:000252372000059
J	Badolato, R; Parolini, S				Badolato, Raffaele; Parolini, Silvia			Novel insights from adaptor protein 3 complex deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Hermansky-Pudlak syndrome; NK cells; neutropenia; cytotoxicity; albinism; platelets	HERMANSKY-PUDLAK-SYNDROME; SEVERE CONGENITAL NEUTROPENIA; PIGMENT GRANULE BIOGENESIS; AP-3 ADAPTER; SECRETORY LYSOSOMES; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; BETA-3A SUBUNIT; INTRACELLULAR-TRANSPORT; ANTIGEN PRESENTATION; LYTIC GRANULES	Hermansky-Pudlak type 2 is an autosomal recessive disorder characterized by oculocutaneous albinism, bleeding disorders, recurrent infections, and moderate/severe neutropenia. The disease is caused by mutations in the AP3B1 gene encoding for the beta 3A subunit of the adaptor protein 3 (AP-3) complex. Because the expression of the beta 3A subunit is normally ubiquitous, its deficiency leads to a precise phenotype in cells with a large number of intracellular granules, such as neutrophils, natural killer cells, cytotoxic T lymphocytes, platelets, and melanocytes. Given the AP-3 deficiency, the lysosomal membrane proteins are not appropriately sorted to the granules but are delivered to plasma membrane with subsequent effects on cell development and differentiation. Missorting of proteins (eg, tyrosinase) in melanocytes and platelets accounts for oculocutaneous albinism and bleeding disorders, respectively. Absence of AP-3 leads to low intracellular content of neutrophil elastase and consequently to neutropenia. Abnormal movement of lytic granules and reduced perforin content in cytotoxic T lymphocytes and natural killer cells account for their respective defects in cytolytic activity. It is likely that the investigation of the physiopathology of Hermansky-Pudlak type 2 syndrome will reveal nonredundant functions of this adaptor protein in the intracellular trafficking of membrane proteins.	Univ Brescia, Ist Med Mol Angelo Nocivelli, I-25123 Brescia, Italy; Univ Brescia, Ist Med Mol Angelo Nocivelli, Brescia, Italy; Univ Brescia, Pediat Clin, Brescia, Italy; Univ Brescia, Dipartimento Sci Biomed & Biotecnol, Brescia, Italy	University of Brescia; University of Brescia; University of Brescia; University of Brescia	Badolato, R (corresponding author), Univ Brescia, Ist Med Mol Angelo Nocivelli, C-O Spedali Civili, I-25123 Brescia, Italy.	badolato@med.unibs.it	Badolato, Raffaele/A-8081-2010	Badolato, Raffaele/0000-0001-7375-5410; PAROLINI, Silvia/0000-0003-1968-7765				Beguez-Cesar AB, 1943, B SOC CUBANA PEDIAT, V15, P900; Benson KF, 2003, NAT GENET, V35, P90, DOI 10.1038/ng1224; Berz F, 1996, KLIN PADIATR, V208, P83, DOI 10.1055/s-2008-1044000; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bohn G, 2007, NAT MED, V13, P38, DOI 10.1038/nm1528; Bossi G, 2005, SEMIN IMMUNOL, V17, P87, DOI 10.1016/j.smim.2004.09.007; Caplan S, 2000, IMMUNOL LETT, V72, P113, DOI 10.1016/S0165-2478(00)00176-0; Cernadas M, 2003, J IMMUNOL, V171, P4149, DOI 10.4049/jimmunol.171.8.4149; Clark R, 2003, CURR OPIN IMMUNOL, V15, P516, DOI 10.1016/S0952-7915(03)00113-4; Clark RH, 2003, NAT IMMUNOL, V4, P1111, DOI 10.1038/ni1000; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; DellAngelica EC, 1997, J BIOL CHEM, V272, P15078, DOI 10.1074/jbc.272.24.15078; Donini M, 2007, BLOOD, V109, P4716, DOI 10.1182/blood-2006-09-045427; Elewaut D, 2003, J EXP MED, V198, P1133, DOI 10.1084/jem.20030143; Enders A, 2006, BLOOD, V108, P81, DOI 10.1182/blood-2005-11-4413; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Feng LJ, 2002, BLOOD, V99, P1651, DOI 10.1182/blood.V99.5.1651.h8001651_1651_1658; Filipovich AH, 2006, CURR OPIN ALLERGY CL, V6, P410, DOI 10.1097/01.all.0000246626.57118.d9; Fischer A, 2007, CURR OPIN IMMUNOL, V19, P348, DOI 10.1016/j.coi.2007.04.006; Fontana S, 2006, BLOOD, V107, P4857, DOI 10.1182/blood-2005-11-4398; GRISCELLI C, 1978, AM J MED, V65, P691, DOI 10.1016/0002-9343(78)90858-6; Horwitz M, 2004, TRENDS MOL MED, V10, P163, DOI 10.1016/j.molmed.2004.02.002; Horwitz MS, 2007, BLOOD, V109, P1817, DOI 10.1182/blood-2006-08-019166; Huizing M, 2002, Curr Mol Med, V2, P451, DOI 10.2174/1566524023362357; Huizing M, 2002, PEDIATR RES, V51, P150, DOI 10.1203/00006450-200202000-00006; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; Ihrke G, 2004, TRAFFIC, V5, P946, DOI 10.1111/j.1600-0854.2004.00236.x; Janka GE, 2007, EUR J PEDIATR, V166, P95, DOI 10.1007/s00431-006-0258-1; JONES JB, 1975, J AM VET MED ASSOC, V166, P365; Jung J, 2006, BLOOD, V108, P362, DOI 10.1182/blood-2005-11-4377; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Kretzschmar D, 2000, GENETICS, V155, P213; Li FQ, 2001, J BIOL CHEM, V276, P14230, DOI 10.1074/jbc.M010279200; MORETTA A, 2007, CELL DEATH DIFFER; Mullins C, 1999, MOL GEN GENET, V262, P401, DOI 10.1007/s004380051099; Nakatsu F, 2003, CELL STRUCT FUNCT, V28, P419, DOI 10.1247/csf.28.419; Newell-Litwa K, 2007, J CELL SCI, V120, P531, DOI 10.1242/jcs.03365; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Ooi CE, 1997, EMBO J, V16, P4508; Richmond B, 2005, J INVEST DERMATOL, V124, P420, DOI 10.1111/j.0022-202X.2004.23585.x; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; Seong E, 2005, MOL BIOL CELL, V16, P128, DOI 10.1091/mbc.E04-10-0892; Sevilla LM, 2001, CELL IMMUNOL, V210, P143, DOI 10.1006/cimm.2001.1817; SHANAHAN F, 1988, AM J MED, V85, P823; Shotelersuk V, 2000, AM J MED, V108, P423, DOI 10.1016/S0002-9343(99)00436-2; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Stinchcombe J, 2004, SCIENCE, V305, P55, DOI 10.1126/science.1095291; Sugita M, 2002, IMMUNITY, V16, P697, DOI 10.1016/S1074-7613(02)00311-4; Wei ML, 2006, PIGM CELL RES, V19, P19, DOI 10.1111/j.1600-0749.2005.00289.x; Yang W, 2000, J CELL SCI, V113, P4077; Young LR, 2006, J IMMUNOL, V176, P4361, DOI 10.4049/jimmunol.176.7.4361; Zhen LJ, 1999, BLOOD, V94, P146, DOI 10.1182/blood.V94.1.146.413k39_146_155	57	42	42	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					735	741		10.1016/j.jaci.2007.08.039	http://dx.doi.org/10.1016/j.jaci.2007.08.039			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17931556				2022-12-18	WOS:000250157700003
J	Orihara, K; Narita, M; Tobe, T; Akasawa, A; Ohya, Y; Matsumoto, K; Saito, H				Orihara, Kanami; Narita, Masami; Tobe, Takashi; Akasawa, Akira; Ohya, Yukihiro; Matsumoto, Kenji; Saito, Hirohisa			Circulating Foxp3(+)CD4(+) cell numbers in atopic patients and healthy control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							REGULATORY T-CELLS; FOXP3; EXPRESSION; TRANSCRIPTION		Showa Univ, Natl Res Inst Child Hlth Dev, Dept Allergy & Immunol, Tokyo, Japan; Showa Univ, Natl Ctr Child & Dev, Tokyo, Japan; Showa Univ, Sch Pharmaceut Sci, Tokyo 142, Japan	National Center for Child Health & Development - Japan; Showa University; National Center for Child Health & Development - Japan; Showa University; Showa University	Orihara, K (corresponding author), Showa Univ, Natl Res Inst Child Hlth Dev, Dept Allergy & Immunol, Tokyo, Japan.	hsaito@nch.go.jp	Narita, Masami/AAF-1079-2019	Saito, Hirohisa/0000-0002-6630-8337; Orihara, Kanami/0000-0002-2652-4529				Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Goleva E, 2005, J ALLERGY CLIN IMMUN, V116, P1094, DOI 10.1016/j.jaci.2005.08.051; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Roncador G, 2005, EUR J IMMUNOL, V35, P1681, DOI 10.1002/eji.200526189; Saito Hirohisa, 2003, Allergology International, V52, P65, DOI 10.1046/j.1440-1592.2003.00288.x; Schubert LA, 2001, J BIOL CHEM, V276, P37672, DOI 10.1074/jbc.M104521200; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Wildin RS, 2002, J MED GENET, V39, P537, DOI 10.1136/jmg.39.8.537	10	42	49	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					960	962		10.1016/j.jaci.2007.05.036	http://dx.doi.org/10.1016/j.jaci.2007.05.036			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	220LH	17631953				2022-12-18	WOS:000250157700037
J	Gao, L; Grant, AV; Rafaels, N; Stockton-Porter, M; Watkins, T; Gao, PS; Chi, P; Munoz, M; Watson, H; Dunston, G; Togias, A; Hansel, N; Sevransky, J; Maloney, JP; Moss, M; Shanholtz, C; Brower, R; Garcia, JGN; Grigoryev, DN; Cheadle, C; Beaty, TH; Mathias, RA; Barnes, KC				Gao, Li; Grant, Audrey V.; Rafaels, Nicholas; Stockton-Porter, Maria; Watkins, Tonya; Gao, Peisong; Chi, Peter; Munoz, Melba; Watson, Harold; Dunston, Georgia; Togias, Alkis; Hansel, Nadia; Sevransky, Jonathan; Maloney, James P.; Moss, Marc; Shanholtz, Carl; Brower, Roy; Garcia, Joe G. N.; Grigoryev, Dmitry N.; Cheadle, Christopher; Beaty, Terri H.; Mathias, Rasika A.; Barnes, Kathleen C.			Polymorphisms in the myosin light chain kinase gene that confer risk of severe sepsis are associated with a lower risk of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SNPs; haplotype; MYLK/MLCK; asthma; total IgE; sepsis; ALI	SMOOTH-MUSCLE; PROTEIN; EXPRESSION; MLCK; PHOSPHORYLATION; SUSCEPTIBILITY; POPULATION; MIGRATION; RESPONSES; CLONING	Background: Myosin light chain kinase (MYLK) is a multifunctional protein involved in regulation of airway hyperreactivity and other activities relevant to asthma. Objective: To determine the role of MYLK gene variants in asthma among African Caribbean and African American populations. Methods: We performed association tests between single nucleotide polymorphisms (SNPs) in the MYLK gene and asthma susceptibility and total serum IgE concentrations in 2 independent, family-based populations of African descent. Previously we identified variants/haplotypes in MYLK that confer risk for sepsis and acute lung injury; we compared findings from our asthma populations to findings in the African American sepsis and acute lung injury groups. Results: Significant associations between MYLK SNPs and asthma and total serum IgE concentrations were observed in the African Caribbean families: a promoter SNP (rs936170) in the smooth muscle form gave the strongest association (P = .009). A haplotype including rs936170 corresponding to the actin-binding activity of the nonmuscle and smooth muscle forms was negatively associated with asthma (eg, decreased risk) in both the American (P = .005) and Caribbean families (P = .004), and was the same haplotype that conferred risk for severe sepsis (P = .002). RNA expression studies on PBMCs and rs936170 suggested a significant decrease in MYLK expression among patients with asthma with this variant (P = .025). Conclusion: MYLK polymorphisms may function as a common genetic factor in clinically distinct diseases involving bronchial smooth muscle contraction and inflammation. Clinical implications: Genetic variants in MYLK are significantly associated with both asthma and sepsis in populations of African ancestry.	Johns Hopkins Univ, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21218 USA; Howard Univ, Natl Genome Ctr, Washington, DC 20059 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA; Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA; NHGRI, Inherited Dis Res Branch, NIH, Baltimore, MD USA	Johns Hopkins University; Howard University; University System of Maryland; University of Maryland Baltimore; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; University of Chicago; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute on Aging (NIA)	Barnes, KC (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Room 3A-62, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu	Shanholtz, Carl/P-1190-2019; Garcia, Joe GN/E-8862-2010; maloney, james/K-9428-2015; Grigoryev, Dmitry/C-9422-2015	Shanholtz, Carl/0000-0003-3938-178X; maloney, james/0000-0001-8348-4650; Munoz, Melba/0000-0003-3386-4502; Grigoryev, Dmitry/0000-0002-1849-1763	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072455, U01HL066615, P50HL073994] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [U01 HL72455, HL 73994, U01 HL66615] Funding Source: Medline; NIAID NIH HHS [AI50024-03, HL/AI-49612] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi T, 2003, J ALLERGY CLIN IMMUN, V111, P113, DOI 10.1067/mai.2003.27; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Barnes KC, 2006, J ALLERGY CLIN IMMUN, V118, P70, DOI 10.1016/j.jaci.2006.03.036; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Becker KG, 2004, MED HYPOTHESES, V62, P309, DOI 10.1016/S0306-9877(03)00332-3; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Cetinkaya F, 2007, INT ARCH ALLERGY IMM, V142, P145, DOI 10.1159/000096440; Collins FS, 1997, SCIENCE, V278, P1580, DOI 10.1126/science.278.5343.1580; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Eutamene H, 2005, EUR RESPIR J, V25, P789, DOI 10.1183/09031936.05.00064704; Fallin D, 2001, GENOME RES, V11, P143, DOI 10.1101/gr.148401; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC; Garcia JGN, 1998, J APPL PHYSIOL, V84, P1817, DOI 10.1152/jappl.1998.84.5.1817; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; Graham WV, 2006, J BIOL CHEM, V281, P26205, DOI 10.1074/jbc.M602164200; Grischkan J, 2004, J PEDIATR-US, V144, P321, DOI 10.1016/j.jpeds.2003.11.029; Hayakawa K, 1999, BBA-MOL CELL RES, V1450, P12, DOI 10.1016/S0167-4889(99)00034-8; Herring BP, 2006, AM J PHYSIOL-CELL PH, V291, pC817, DOI 10.1152/ajpcell.00198.2006; Horvath S, 2001, GENET EPIDEMIOL, V21, pS403; JIANG H, 1994, CAN J PHYSIOL PHARM, V72, P1440, DOI 10.1139/y94-208; JIANG H, 1992, AM J RESP CELL MOL, V7, P567, DOI 10.1165/ajrcmb/7.6.567; Joseph CLM, 2006, J ALLERGY CLIN IMMUN, V117, P233, DOI 10.1016/j.jaci.2005.11.004; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kishi H, 1998, ADV EXP MED BIOL, V453, P229; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; LIU XL, 1994, AM J RESP CELL MOL, V11, P676, DOI 10.1165/ajrcmb.11.6.7946396; Ma XF, 2002, AM J PHYSIOL-LUNG C, V283, pL1181, DOI 10.1152/ajplung.00389.2001; Ma XF, 1998, AM J PHYSIOL-CELL PH, V274, pC1206, DOI 10.1152/ajpcell.1998.274.5.C1206; Marsh DG, 1997, NAT GENET, V15, P389; Moss M, 2002, CRIT CARE MED, V30, P1679, DOI 10.1097/00003246-200208000-00001; NAKABAYASHI H, 1991, FEBS LETT, V294, P144, DOI 10.1016/0014-5793(91)81362-C; Petrache I, 2001, AM J PHYSIOL-LUNG C, V280, pL1168, DOI 10.1152/ajplung.2001.280.6.L1168; Pfitzer G, 2001, J APPL PHYSIOL, V91, P497, DOI 10.1152/jappl.2001.91.1.497; POTIER MC, 1995, GENOMICS, V29, P562, DOI 10.1006/geno.1995.9965; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Rakhmanina N, 1997, J ALLERGY CLIN IMMUN, V99, P1760; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; Shen L, 2006, J CELL SCI, V119, P2095, DOI 10.1242/jcs.02915; Smith A, 2003, J CELL SCI, V116, P3123, DOI 10.1242/jcs.00606; SOMIYO AP, 1994, NATURE, V372, P231; Stephens NL, 1998, COMP BIOCHEM PHYS B, V119, P415, DOI 10.1016/S0305-0491(98)00004-2; Sweeney HL, 1998, AM J RESP CRIT CARE, V158, pS95, DOI 10.1164/ajrccm.158.supplement_2.13tac400; Wadgaonkar R, 2005, J CELL BIOCHEM, V95, P849, DOI 10.1002/jcb.20472; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Ye LH, 1997, J BIOL CHEM, V272, P32182, DOI 10.1074/jbc.272.51.32182; Young JH, 2005, PLOS GENET, V1, P730, DOI 10.1371/journal.pgen.0010082; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	52	42	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1111	1118		10.1016/j.jaci.2007.03.019	http://dx.doi.org/10.1016/j.jaci.2007.03.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17472811	Bronze			2022-12-18	WOS:000246427200010
J	Prasse, A; Germann, M; Pechkovsky, DV; Markert, A; Verres, T; Stahl, M; Melchers, I; Luttmann, W; Muller-Quernheim, J; Zissel, G				Prasse, Antje; Germann, Martin; Pechkovsky, Dmitri V.; Markert, Anna; Verres, Tibor; Stahl, Mirjam; Melchers, Inga; Luttmann, Werner; Mueller-Quernheim, Joachim; Zissel, Gernot			IL-10-producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-10; monocytes; atopy; alternative activation; FACS; suppressor of cytokine signaling 3; CCL18; macrophages; flow cytometry; subset	ALVEOLAR MACROPHAGES; T-CELLS; INTERLEUKIN-10 IL-10; DENDRITIC CELLS; TH2 RESPONSES; MESSENGER-RNA; EXPRESSION; ASTHMA; DERMATITIS; OVEREXPRESSION	Background: Recently the immune regulatory role of T cell-derived IL-10 in allergic disease has been extensively studied. In contrast, there is mounting evidence that IL-10 might also have a role in the perpetuation of allergic inflammation and fibrotic remodeling. It has been reported that alternatively (IL-4) activated macrophages (aaM Phi) produce large quantities of IL-10 and lack IL-12 production. Objective: Bearing this in mind, we hypothesized whether functionally different properties of IL-10-producing monocytes could be identified. Methods: Intracellular cytokine expression of IL-10, IL-12, and IL-6 in peripheral blood CD14(+) monocytes was measured in 19 atopic patients and 18 healthy control subjects by means of flow cytometry. In addition, IL-10-secreting monocytes were sorted by means of flow cytometry. Capabilities of these cells regarding further differentiation, accessory cell capacity, and surface molecule expression were analyzed. Results: Our data show a dichotomous expression pattern of either IL-10 or IL-12p40/p70 in peripheral blood monocytes after LPS stimulation. Compared with healthy control subjects, the percentage of IL-10-producing monocytes was significantly increased in atopic patients. IL-10-secreting monocytes were isolated by using an IL-10 secretion assay, and functional analysis of these sorted cells revealed that IL-10-secreting monocytes preferentially differentiate into suppressor of cytokine signaling 3 expressing aaM Phi, which perpetuate T(H)2 immune response. Conclusion: Our study shows the existence of an IL-10-producing monocyte subset, which is increased in atopic disease and which might facilitate allergic inflammation and fibrotic remodeling by differentiation into aaM Phi. Clinical implications: Controlling aaM Phi in T(H)2-driven inflammatory processes might be a novel target for intervention strategies.	Univ Hosp Freiburg, Dept Pneumol, Klin Forschergrp Rheumatol, D-79106 Freiburg, Germany; Univ Hosp Freiburg, Dept Rheumatol, Klin Forschergrp Rheumatol, D-79106 Freiburg, Germany; Univ Hosp Rostock, Dept Pneumol, Rostock, Germany	University of Freiburg; University of Freiburg; University of Rostock	Prasse, A (corresponding author), Univ Hosp Freiburg, Dept Pneumol, Klin Forschergrp Rheumatol, Killianstr 5, D-79106 Freiburg, Germany.	prasse@medizin.ukl.uni-freiburg.de	Prasse, Antje/AAY-6279-2020; Stahl, Mirjam/S-9442-2019; Müller-Quernheim, Joachim/H-1983-2011; Zissel, Gernot/B-1208-2010; Prasse, Antje/AAM-7521-2021	Zissel, Gernot/0000-0001-8021-9798; Prasse, Antje/0000-0002-7336-7458; Pechkovsky, Dmitri/0000-0001-8908-3444				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4; Arakawa S, 2004, CLIN EXP IMMUNOL, V135, P505, DOI 10.1111/j.1365-2249.2004.02405.x; Barbarin V, 2005, AM J PHYSIOL-LUNG C, V288, pL841, DOI 10.1152/ajplung.00329.2004; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; Elenkov IJ, 1998, J IMMUNOL, V161, P2586; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gunther C, 2005, J IMMUNOL, V174, P1723, DOI 10.4049/jimmunol.174.3.1723; Hashimoto S, 1997, BLOOD, V89, P315, DOI 10.1182/blood.V89.1.315.315_315_321; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958, DOI 10.1164/ajrccm.158.6.9804011; Honda K, 2003, J EXP MED, V198, P533, DOI 10.1084/jem.20022218; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; LACHE M, 2003, J ALLERGY CLIN IMMUN, V11, P450; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200; Luttmann W, 1998, EUR J IMMUNOL, V28, P2057, DOI 10.1002/(SICI)1521-4141(199807)28:07<2057::AID-IMMU2057>3.0.CO;2-T; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez JAB, 1997, AM J PHYSIOL-LUNG C, V273, pL676, DOI 10.1152/ajplung.1997.273.3.L676; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; OHMEN JD, 1995, J IMMUNOL, V154, P1956; OHMORI H, 1995, IMMUNOL LETT, V47, P127, DOI 10.1016/0165-2478(95)00084-I; Prasse A, 2000, CLIN EXP IMMUNOL, V122, P241, DOI 10.1046/j.1365-2249.2000.01365.x; Prasse A, 2006, AM J RESP CRIT CARE, V173, P781, DOI 10.1164/rccm.200509-1518OC; Revets H, 2005, J IMMUNOL, V174, P1097, DOI 10.4049/jimmunol.174.2.1097; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113, DOI 10.1165/ajrcmb.14.2.8630259; Seki Y, 2003, NAT MED, V9, P1047, DOI 10.1038/nm896; Steinke JW, 2004, J IMMUNOL, V173, P3215, DOI 10.4049/jimmunol.173.5.3215; Tang CB, 1998, AM J RESP CRIT CARE, V157, P1120, DOI 10.1164/ajrccm.157.4.9706118; Tang CB, 1998, J ALLERGY CLIN IMMUN, V102, P368, DOI 10.1016/S0091-6749(98)70122-8; Tomita K, 2002, CLIN IMMUNOL, V102, P258, DOI 10.1006/clim.2001.5176; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Zou J, 2002, GENOME BIOL, V3	37	42	48	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					464	471		10.1016/j.jaci.2006.09.030	http://dx.doi.org/10.1016/j.jaci.2006.09.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	137YB	17291860				2022-12-18	WOS:000244327900027
J	Rabinovitch, N; Zhang, L; Gelfand, EW				Rabinovitch, Nathan; Zhang, Lening; Gelfand, Erwin W.			Urine leukotriene E-4 levels are associated with decreased pulmonary function in children with persistent airway obstruction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; cysteinyl leukotrienes; pulmonary function; airway obstruction; montelukast	CYSTEINYL LEUKOTRIENES; DOUBLE-BLIND; ASTHMA; MONTELUKAST; ZAFIRLUKAST; INFLAMMATION; FLUTICASONE; RESPONSES	Background: Use of leukotriene receptor antagonists improves disease control in children and adults with asthma. However, the relationship between cysteinyl leukotriene levels and indices of daily asthma control has not been studied directly. Objectives: We sought to assess the relationship between daily variability in urinary leukotriene E-4 (LTE4) levels and daily lung function in children primarily taking inhaled corticosteroids (ICSs) and long-acting beta-agonists (LABAs). Methods: Fifty children primarily with moderate-to-severe asthma were followed with measurements of urinary LTE4, monitoring of FEV1, and albuterol use. Results: Increasing urinary LTE4 levels were associated with significant (P = .006) decreases in percent predicted FEV1 (ppFEV(1)) averaging 4.7% per interquartile range increase in LTE4 and accompanied by increased albuterol use (P = .03). Children with lower FEV1/forced vital capacity ratios demonstrated larger LTE4-related FEV1 decreases (6.4%) compared to those with higher ratios (4.2%, P = .009). This association was blunted in children taking montelukast (1.4% ppFEV(1) decrease) compared with that in children not taking this medication (5.4% ppFEV(1) decrease, P = .05). Children with lower lung function ratios demonstrated greater blunting of the LTE4 effect with montelukast (0.9% ppFEV, decrease) compared to those with higher ratios (3.6% ppFEV(1), P = .0002). Conclusions: Daily variability in LTE4 levels is associated with clinically significant decreases in pulmonary function. In children who demonstrate a response associated with an increase in urinary LTE4 levels, leukotriene receptor antagonists protect against daily FEV1 decreases. This protection might be greatest in those with persistent airway obstruction despite use of ICS and LABA therapy. Clinical implications: Therapies designed to block cysteinyl leukotriene production or function might benefit children receiving ICS and LABA therapy who continue to experience persistent disease.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO 80206 USA	National Jewish Health; National Jewish Health	Rabinovitch, N (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	rabinovitchn@njc.org						Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Becker A, 2004, CURR MED RES OPIN, V20, P1651, DOI 10.1185/030079904X4644; Braccioni F, 2002, J ALLERGY CLIN IMMUN, V110, P96, DOI 10.1067/mai.2002.125000; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962, DOI 10.1164/ajrccm.160.6.9902112; Currie GP, 2003, AM J RESP CRIT CARE, V167, P1232, DOI 10.1164/rccm.200209-1116OC; DOUCET MY, 1990, CAN J PHYSIOL PHARM, V68, P379, DOI 10.1139/y90-053; Ducharme F., 2004, COCHRANE DB SYST REV, V1; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Heaney LG, 2005, LANCET, V365, P974, DOI 10.1016/S0140-6736(05)71087-4; Ilowite J, 2004, ANN ALLERG ASTHMA IM, V92, P641, DOI 10.1016/S1081-1206(10)61430-5; KANWAR S, 1995, CIRC RES, V77, P879, DOI 10.1161/01.RES.77.5.879; Kemp JP, 1999, CHEST, V115, P336, DOI 10.1378/chest.115.2.336; Laitinen A, 2005, J ALLERGY CLIN IMMUN, V115, P259, DOI 10.1016/j.jaci.2004.10.021; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Mondino C, 2004, J ALLERGY CLIN IMMUN, V114, P761, DOI 10.1016/j.jaci.2004.06.054; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; RAM FSF, 2005, COCHRANE DB SYST REV, V1; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Tashkin DP, 1999, J ALLERGY CLIN IMMUN, V103, P246, DOI 10.1016/S0091-6749(99)70498-7; WESTCOTT JY, 1990, J APPL PHYSIOL, V68, P2640, DOI 10.1152/jappl.1990.68.6.2640	24	42	47	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					635	640		10.1016/j.jaci.2006.05.011	http://dx.doi.org/10.1016/j.jaci.2006.05.011			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950282				2022-12-18	WOS:000240649000016
J	Fili, L; Ferri, S; Guarna, F; Sampognaro, S; Manuelli, C; Liotta, F; Cosmi, L; Matucci, A; Vultaggio, A; Annunziato, F; Maggi, E; Guarna, A; Romagnani, S; Parronchi, P				Fili, Lucia; Ferri, Simona; Guarna, Francesco; Sampognaro, Salvatore; Manuelli, Cinzia; Liotta, Francesco; Cosmi, Lorenzo; Matucci, Andrea; Vultaggio, Alessandra; Annunziato, Francesco; Maggi, Enrico; Guarna, Antonio; Romagnani, Sergio; Parronchi, Paola			Redirection of allergen-specific T(H)2 responses by a modified adenine through Toll-like receptor 7 interaction and IL-12/IFN release	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adjuvants; immunotherapy; heterocycles; toll-like receptors; allergy; T(H)1/T(H)2 lymphocytes; GATA-3; T-box expressed in T cells; nuclear factor kappa B	TOLL-LIKE RECEPTORS; IMMUNE-RESPONSES; DENDRITIC CELLS; OLIGODEOXYNUCLEOTIDES; INTERLEUKIN-12; LYMPHOCYTES; DOWNSTREAM; ACTIVATION; MATURATION; ADENOSINE	Background: Natural or synthetic ligands of Toll-like receptors (TLRs), such as CpG-containing oligodeoxynucleotides and imidazoquinolines, affect the functional phenotype of antigen-specific human T lymphocytes by inducing cytokine release by cells of the innate immunity. Objective: In vitro investigation of the ability of substitute adenines (SAs) to affect antigen-presenting cells and shift the functional phenotype of specific human T(H)2 cells was performed. Methods: The functional profile of hapten- and allergen-specific T-cell lines obtained in the absence or presence of modified adenines was assessed by means of quantitative real-time PCR, flow cytometry, and ELISAs. Activation of TLRs was evaluated by means of nucleofection of HEK293 cells. Results: The synthetic heterocycle, chemically related to adenine with substitution in positions 2-, 8-, and 9- (SA-2), but not its related derivative lacking 2- and 8- substitutions, stimulated the production of high amounts of IL-12, IL-10, TNF-alpha, and IL-6 by CD14(+) cells and IFN-alpha and CXCL10 by blood dendritic cell antigen (BDCA)-4(+) plasmacytoid dendritic cells. A nuclear factor kappa B-dependent signaling pathway mediated by SA-2 ligation of TLR7 was responsible for these effects. SA-2 also redirected the in vitro differentiation of either Dermatophagoides pteronyssinus group 1 or amoxicillin-specific TH2 cells toward the T(H)1/T(H)0 phenotype, with parallel downregulation of GATA-3 and upregulation of T-box expressed in T cells transcription factors. Conclusion: Critical substitutions of the adenine backbone confer the ability to activate TLR7, inducing the production of modulatory cytokines able to shift human allergen-specific T(H)2 cells to a T(H)1/T(H)0 phenotype. Clinical implications: Appropriately modified adenines might be used as effective adjuvants for the development of novel immunotherapeutic strategies of allergic disorders.	Univ Florence, Dept Internal Med, Sect Immunoallergol, Ctr Res Transfer & High Educ DENOthe, I-50134 Florence, Italy; Univ Florence, Dept Organ Chem Ugo Schiff, I-50134 Florence, Italy; Univ Florence, Dept Dermatol Sci, I-50134 Florence, Italy	University of Florence; University of Florence; University of Florence	Parronchi, P (corresponding author), Univ Florence, Dept Internal Med, Sect Immunoallergol, Ctr Res Transfer & High Educ DENOthe, Vle Morgagni 85, I-50134 Florence, Italy.	p.parronchi@dmi.unifi.it	Maggi, Enrico/AAA-8045-2019; Annunziato, Francesco/C-1155-2013; Alessandra, Vultaggio/K-3201-2014; Parronchi, Paola/AAE-5422-2022	Maggi, Enrico/0000-0002-1824-3583; Parronchi, Paola/0000-0002-9184-5089; Annunziato, Francesco/0000-0001-8798-7589				Annunziato F, 2001, J ALLERGY CLIN IMMUN, V108, P815; Banerjee B, 2004, INFECT IMMUN, V72, P6087, DOI 10.1128/IAI.72.10.6087-6094.2004; Brugnolo F, 2003, J ALLERGY CLIN IMMUN, V111, P380, DOI 10.1067/mai.2003.102; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; ESTELLE F, 2004, J ALLERGY CLIN IMMUN, V113, P1144; Francis JN, 2004, CURR OPIN ALLERGY CL, V4, P543, DOI 10.1097/00130832-200412000-00012; Gangur V, 1999, INT ARCH ALLERGY IMM, V118, P387, DOI 10.1159/000024144; Hasko G, 2004, TRENDS IMMUNOL, V25, P33, DOI 10.1016/j.it.2003.11.003; Hirota K, 2002, J MED CHEM, V45, P5419, DOI 10.1021/jm0203581; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kandimalla ER, 2005, P NATL ACAD SCI USA, V102, P6925, DOI 10.1073/pnas.0501729102; Kawai T, 2005, CURR OPIN IMMUNOL, V17, P338, DOI 10.1016/j.coi.2005.02.007; Kawai T, 2005, ARTHRITIS RES THER, V7, P12, DOI 10.1186/ar1469; Kurimoto A, 2003, BIOORGAN MED CHEM, V11, P5501, DOI 10.1016/j.bmc.2003.09.032; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; MANETTI R, 1995, EUR J IMMUNOL, V25, P2656, DOI 10.1002/eji.1830250938; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Minguet S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/eji.200425524; Parronchi P, 1999, J IMMUNOL, V163, P5946; Parronchi P, 1999, CURR TOP MICROBIOL, V238, P27; Renard P, 2001, Nucleic Acids Res, V29, pE21, DOI 10.1093/nar/29.4.e21; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; REYTAG LC, 2005, VACCINE, P1804; Romagnani P, 2005, J ALLERGY CLIN IMMUN, V116, P1372, DOI 10.1016/j.jaci.2005.09.035; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Sugiyama T, 2005, J IMMUNOL, V174, P2273, DOI 10.4049/jimmunol.174.4.2273; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Viglianti GA, 2003, IMMUNITY, V19, P837, DOI 10.1016/S1074-7613(03)00323-6	35	42	46	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					511	517		10.1016/j.jaci.2006.05.027	http://dx.doi.org/10.1016/j.jaci.2006.05.027			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	075IH	16890779	Bronze			2022-12-18	WOS:000239877700030
J	Gyllfors, P; Dahlen, SE; Kumlin, M; Larsson, K; Dahlen, B				Gyllfors, Par; Dahlen, Sven-Erik; Kumlin, Maria; Larsson, Kjell; Dahlen, Barbro			Bronchial responsiveness to leukotriene D-4 is resistant to inhaled fluticasone propionate	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ALLERGEN-INDUCED BRONCHOCONSTRICTION; PLACEBO-CONTROLLED TRIAL; RECEPTOR ANTAGONIST; AIRWAY RESPONSIVENESS; MILD ASTHMA; MONTELUKAST; METHACHOLINE; HUMANS; RESPONSES; HYPERRESPONSIVENESS	Background: Inhaled corticosteroids are highly effective in asthma, reducing inflammatory markers and bronchial hyperresponsiveness. Cysteinyl-leukotrienes are major mediators of airway obstruction and display proinflammatory effects. Although the synthesis of leukotrienes is not affected by corticosteroid treatment, the influence of corticosteroids on the leukotriene pathway remains unresolved. Objective: We investigated whether or not bronchial responsiveness to leukotriene (LT) D-4 is reduced by fluticasone propionate in subjects with asthma. Methods: In 13 subjects with mild asthma, inhalation challenges with metbacholine and LTD4 were performed on consecutive days before and after 2 weeks of treatment with inhaled fluticasone 500 mu g, twice daily, in a double-blind, randomized, placebo-controlled study with crossover design and 3 weeks of washout between periods. Exhaled nitric oxide was measured as a marker of corticosteroid responsiveness, and baseline urinary LTE4 concentrations as an index of cysteinyl-leukotriene biosynthesis. Results: Fluticasone produced a significant decrease in methacholine responsiveness, corresponding to 2.6-fold shift in the PD20 FEV1, and a significant reduction in the levels of exhaled nitric oxide. By contrast, bronchial responsiveness to LTD4 in the same subjects was unaffected by fluticasone, as were urinary LTE4 concentrations. Conclusion: These new data indicate that neither the biosynthesis nor the actions of leukotrienes appear to be sensitive to inhaled corticosteroids. Clinical implications: The study provides mechanistic support for the additive therapeutic efficacy of antileukotrienes and inhaled corticosteroids in asthma.	Karolinska Univ, Huddinge Hosp, Div Resp Med & Allergy, Dept Med,Ctr Allergy Res,Karolinska Inst, SE-14186 Stockholm, Sweden; Karolinska Univ Hosp, Dept Med, Div Resp Med, Solna, Sweden; Natl Inst Environm Med, Div Physiol, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Dahlen, B (corresponding author), Karolinska Univ, Huddinge Hosp, Div Resp Med & Allergy, Dept Med,Ctr Allergy Res,Karolinska Inst, SE-14186 Stockholm, Sweden.	Barbro.dablen@ki.se						ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; BEL EH, 1987, AM REV RESPIR DIS, V136, P979, DOI 10.1164/ajrccm/136.4.979; BEL EH, 1989, AM REV RESPIR DIS, V139, P427, DOI 10.1164/ajrccm/139.2.427; Bjermer L, 2003, BMJ-BRIT MED J, V327, P891, DOI 10.1136/bmj.327.7420.891; Dahlen SE, 2006, EUR J PHARMACOL, V533, P40, DOI 10.1016/j.ejphar.2005.12.070; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; Echazarreta AL, 2001, AM J RESP CRIT CARE, V164, P202, DOI 10.1164/ajrccm.164.2.2101105; FROLUND L, 1991, ALLERGY, V46, P355, DOI 10.1111/j.1398-9995.1991.tb00598.x; Gyllfors P, 2005, THORAX, V60, P902, DOI 10.1136/thx.2005.041913; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; HILLS A, 1979, BR J CLIN PHARM, V8, P7; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; Ketchell RI, 2002, THORAX, V57, P575, DOI 10.1136/thorax.57.7.575; KUMLIN M, 1995, CLIN EXP ALLERGY, V25, P467, DOI 10.1111/j.1365-2222.1995.tb01079.x; Kumlin M, 2000, AM J RESP CRIT CARE, V161, pS102, DOI 10.1164/ajrccm.161.supplement_1.ltta-20; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-509OC; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; MANSO G, 1992, EUR RESPIR J, V5, P712; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Sovijarvi ARA, 2003, THORAX, V58, P500, DOI 10.1136/thorax.58.6.500; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; Vachier I, 2003, RESP MED, V97, P1225, DOI 10.1016/S0954-6111(03)00253-1; Van Schoor J, 2005, CLIN EXP ALLERGY, V35, P250, DOI 10.1111/j.1365-2222.2005.02177.x; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578; [No title captured]	33	42	46	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					78	83		10.1016/j.jaci.2006.03.040	http://dx.doi.org/10.1016/j.jaci.2006.03.040			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	065UH	16815141				2022-12-18	WOS:000239184800009
J	Calvert, J; Burney, P				Calvert, J; Burney, P			Effect of body mass on exercise-induced bronchospasm and atopy in African children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epidemiology; nutritional status; asthma; exercise-induced; prevalence comparative study; rural/urban health; South Africa	NONASTHMATIC OBESE; MALNOURISHED MICE; HUMORAL IMMUNITY; ASTHMA; PREVALENCE; ALLERGY; MALNUTRITION; URBAN; INDEX; IGE	Background: Sensitization to allergen is common in rural populations in less affluent countries, but atopic disease is less frequent than in richer countries. Variables explaining this dichotomy may provide insight into underlying mechanisms of atopic diseases like asthma. Objective: To test whether risk of exercise-induced bronchospasm (EIB) in urbanized African populations is increased in association with greater skin sensitivity or increased body mass. Methods: A total of 3322 children were enrolled in a prevalence survey of EIB in urban and rural South Africa. Children responding positively to an exercise challenge and a random sample of children responding negatively were recruited into a case-control study (393 controls, 380 cases). Subjects were investigated by using allergen skin prick testing, anthropometry, and assay of IgE. Stools were analyzed for parasite infestation. Results: The prevalence of EIB was higher in urban (14.9%) than rural (8.9%) areas (P < .0001). The difference in risk of EIB between urban and rural subjects was associated with atopy (odds ratio [OR] for upper tertile of skin wheal diameter, 2.65; 95% CI, 1.43-4.89; P < .0001), increasing weight (OR for upper tertile of body mass index [BMI], 2.17; 95% CI, 1.45-3.26; P = .001), and affluence. Increasing BMI was also associated with a greater strength of association between specific IgE and the corresponding skin test (Dermatophagoides pteronyssinus, OR for a positive skin test result in presence of specific IgE: heavier subjects, OR, 34.6; 95% CI, 0.9-109.3; P < .0001; lighter subjects, OR, 8.05; 95% CI, 2.74-23.6; P < .001). Conclusion: Increases in BMI of rural children in subsistence economies may lead to an increased prevalence of atopic disease. This observation merits further investigation in prospective studies.	Kings Coll London, Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England	University of London; King's College London	Calvert, J (corresponding author), Kings Coll London, Sch Med, Dept Publ Hlth Sci, 5th Floor,Capital House,42 Weston St, London SE1 3QD, England.	jamescalvert@ukonline.co.uk		Burney, Peter/0000-0001-8635-5678	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABBASSY AS, 1974, J TROP MED HYG, V77, P18; ASH RL, 1998, PARASITES GUIDE LAB; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chinn S, 2001, THORAX, V56, P845, DOI 10.1136/thorax.56.11.845; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; Cunha MG, 1997, CLIN EXP ALLERGY, V27, P1212, DOI 10.1111/j.1365-2222.1997.tb01159.x; CUSTOVIC A, 1994, CHEST, V105, P1127, DOI 10.1378/chest.105.4.1127; FALKNER I, 1986, HUMAN GROWTH COMPREH; Faniran AO, 1999, THORAX, V54, P606, DOI 10.1136/thx.54.7.606; Figueroa-Munoz JI, 2001, THORAX, V56, P133, DOI 10.1136/thorax.56.2.133; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; Gokbel H, 1999, J SPORT MED PHYS FIT, V39, P361; HABY MM, 1995, EUR RESPIR J, V8, P729; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323, DOI 10.1046/j.1365-2222.1999.00455.x; Ing R, 2000, P NATL ACAD SCI USA, V97, P7078, DOI 10.1073/pnas.97.13.7078; KAPLAN TA, 1993, CLIN PEDIATR, V32, P220, DOI 10.1177/000992289303200407; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; Klasen S, 1997, SOC INDIC RES, V41, P51, DOI 10.1023/A:1006892216864; Kosunen TU, 2002, CLIN EXP ALLERGY, V32, P373, DOI 10.1046/j.1365-2222.2002.01330.x; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Mai XM, 2003, ACTA PAEDIATR, V92, P1144, DOI 10.1080/08035250310005666; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; Mito N, 2002, METABOLISM, V51, P1241, DOI 10.1053/meta.2002.35196; Ng'ang'a LW, 1998, THORAX, V53, P919, DOI 10.1136/thx.53.11.919; NOHR CW, 1985, SURGERY, V98, P769; NOHR CW, 1986, J SURG RES, V40, P432, DOI 10.1016/0022-4804(86)90211-8; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; Platts-Mills TAE, 2000, ENVIRON HEALTH PERSP, V108, P725, DOI 10.2307/3454409; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RICKARD AL, 1989, AM J CLIN NUTR, V49, P641, DOI 10.1093/ajcn/49.4.641; RIONAVARRO BE, 2003, J INVESTIG ALLERGOL, V13, P118; ROSE AH, 1978, INT ARCH ALLER A IMM, V56, P344, DOI 10.1159/000232040; ROSE AH, 1983, CLIN IMMUNOL IMMUNOP, V28, P371, DOI 10.1016/0090-1229(83)90104-6; RUBINSTEIN I, 1990, ANN INTERN MED, V112, P828, DOI 10.7326/0003-4819-112-11-828; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Sunyer J, 1999, EUR RESPIR J, V14, P885, DOI 10.1034/j.1399-3003.1999.14d26.x; Tantisira KG, 2001, THORAX, V56, P64; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835	39	42	44	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					773	779		10.1016/j.jaci.2005.05.025	http://dx.doi.org/10.1016/j.jaci.2005.05.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210050				2022-12-18	WOS:000235686600010
J	Kazaks, A; Uriu-Adams, JY; Stern, JS; Albertson, TE				Kazaks, A; Uriu-Adams, JY; Stern, JS; Albertson, TE			No significant relationship between exhaled nitric oxide and body mass index in people with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Univ Calif Davis, Dept Internal Med, Div Endocrinol Clin Nutr & Vasc Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kazaks, A (corresponding author), Univ Calif Davis, Dept Nutr, 1 Shields Ave, Davis, CA 95616 USA.				NCCIH NIH HHS [AT00652] Funding Source: Medline; NIDDK NIH HHS [T32 DK 07355] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000652] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007355] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		de Winter-de Groot KM, 2005, J ALLERGY CLIN IMMUN, V115, P419, DOI 10.1016/j.jaci.2004.11.025; Deykin A, 2002, AM J RESP CRIT CARE, V165, P1597, DOI 10.1164/rccm.2201081; Jatakanon A, 1998, THORAX, V53, P91, DOI 10.1136/thx.53.2.91; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Pi-Sunyer FX, 1998, OBES RES, V6, p51S	5	42	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					929	930		10.1016/j.jaci.2005.06.005	http://dx.doi.org/10.1016/j.jaci.2005.06.005			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210074				2022-12-18	WOS:000235686600034
J	Sicherer, SH; Leung, DYM				Sicherer, SH; Leung, DYM			Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dermatology; skin disease; anaphylaxis; allergy; hypersensitivity disorders; food; drug; insect venom	LIPID TRANSFER PROTEIN; ATOPIC-DERMATITIS; DENDRITIC CELLS; COWS MILK; BIRCH POLLEN; MOUSE MODEL; IGE LEVELS; PEANUT; CHILDREN; URTICARIA	This review highlights some of the research advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects that were reported primarily in the Journal in 2004. Clinical observations included that gastrointestinal symptoms during anaphylaxis are associated with an increased risk for hypotension; recurrence of peanut allergy can occur for about 8% of children who pass an oral food challenge and is associated with continued avoidance of the food after the challenge; seafood allergy is reported by 2.3% of the US population; and determination of the time to resolution of childhood egg and milk allergy might be predictable by means of serial determination of food-specific IgE levels. The comorbid effects of atopic dermatitis (AD) on asthma and the role of topical calcineurin inhibitors in the therapy of AD were also addressed. Basic and translational research observations indicate that improved diagnosis and therapy might become possible on the basis of reported identification or characterization of allergens such as: lipid transfer proteins and birch pollen-related cross-reactive allergens in plant foods; proteins in scorpion venom that cross-react with proteins from imported fire ant; mosquito saliva proteins responsible for systemic anaphylaxis; and IgE binding to quinolones detectable with an in vitro immunoassay. In addition, advances in understanding immune regulation associated with abrogation of oral tolerance in food allergy and of dendritic cell function, modulation of regulatory T cells, and chemokine expression in AD have elucidated possible targets for future intervention.	Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Dept Pediat, New York, NY 10029 USA; Univ Colorado, Dept Pediat, Hlth Sci Ctr, Boulder, CO 80309 USA; Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, Denver, CO USA	Icahn School of Medicine at Mount Sinai; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder; National Jewish Health	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu						Apter AJ, 2004, J ALLERGY CLIN IMMUN, V113, P764, DOI 10.1016/j.jaci.2003.11.032; Bagenstose SE, 2004, J ALLERGY CLIN IMMUN, V113, P134, DOI 10.1016/j.jaci.2003.10.002; Boguniewicz Mark, 2003, Journal of Allergy and Clinical Immunology, V112, pS140, DOI 10.1016/j.jaci.2003.09.031; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI [10.1016/j.jaci.2004.01.779, 10.1016/j.jaci.2004.01.079]; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brunetti L, 2004, J ALLERGY CLIN IMMUN, V114, P922, DOI 10.1016/j.jaci.2004.07.042; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; Depta JPH, 2004, J ALLERGY CLIN IMMUN, V113, P519, DOI 10.1016/j.jaci.2003.11.030; Di Lorenzo G, 2004, J ALLERGY CLIN IMMUN, V114, P619, DOI 10.1016/j.jaci.2004.06.018; Echigo T, 2004, J ALLERGY CLIN IMMUN, V113, P940, DOI 10.1016/S0091-6749(04)01061-9; Eichenfield LF, 2003, J ALLERGY CLIN IMMUN, V111, P1154, DOI 10.1067/mai.2003.1492; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Frick OL, 2005, ALLERGY, V60, P243, DOI 10.1111/j.1398-9995.2004.00711.x; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V114, P377, DOI 10.1016/j.jaci.2004.03.040; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V113, P958, DOI 10.1016/j.jaci.2003.12.017; Giustizieri ML, 2004, J ALLERGY CLIN IMMUN, V114, P1176, DOI 10.1016/j.jaci.2004.07.054; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kanda N, 2004, J ALLERGY CLIN IMMUN, V114, P1403, DOI 10.1016/j.jaci.2004.08.041; Kaufmann R, 2004, J ALLERGY CLIN IMMUN, V114, P1183, DOI 10.1016/j.jaci.2004.08.015; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kopper RA, 2004, J ALLERGY CLIN IMMUN, V114, P614, DOI 10.1016/j.jaci.2004.05.012; Liu E, 2004, J ALLERGY CLIN IMMUN, V114, P607, DOI 10.1016/j.jaci.2004.03.052; Man AL, 2004, J ALLERGY CLIN IMMUN, V113, P965, DOI 10.1016/j.jaci.2004.02.038; Manfredi M, 2004, J ALLERGY CLIN IMMUN, V113, P155, DOI 10.1016/j.jaci.2003.09.035; Mastalerz L, 2004, J ALLERGY CLIN IMMUN, V113, P771, DOI 10.1016/j.jaci.2003.12.323; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P215, DOI 10.1067/mai.2003.1590; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, pS128, DOI DOI 10.1016/j.jaci.2003.09.032; Nowak-Wegrzyn A, 2004, J ALLERGY CLIN IMMUN, V113, P558, DOI 10.1016/j.jaci.2003.11.015; Nugent JS, 2004, J ALLERGY CLIN IMMUN, V114, P383, DOI 10.1016/j.jaci.2004.04.016; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Pastorello EA, 2004, J ALLERGY CLIN IMMUN, V114, P908, DOI 10.1016/j.jaci.2004.06.020; Peng ZK, 2004, J ALLERGY CLIN IMMUN, V114, P1189, DOI 10.1016/j.jaci.2004.08.014; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Pons L, 2004, J ALLERGY CLIN IMMUN, V114, P915, DOI 10.1016/j.jaci.2004.06.049; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Scheurer S, 2004, J ALLERGY CLIN IMMUN, V114, P900, DOI 10.1016/j.jaci.2004.06.017; Schocker F, 2004, J ALLERGY CLIN IMMUN, V113, P141, DOI 10.1016/j.jaci.2003.09.013; Schuller E, 2004, J ALLERGY CLIN IMMUN, V114, P137, DOI 10.1016/j.jaci.2004.03.021; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Simon D, 2004, J ALLERGY CLIN IMMUN, V114, P887, DOI 10.1016/j.jaci.2004.05.066; Tiemessen MM, 2004, J ALLERGY CLIN IMMUN, V113, P932, DOI 10.1016/j.jaci.2003.12.016; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Vlieg-Boerstra BJ, 2004, J ALLERGY CLIN IMMUN, V113, P341, DOI 10.1016/j.jaci.2003.10.039; Winningham KM, 2004, J ALLERGY CLIN IMMUN, V114, P928, DOI 10.1016/j.jaci.2004.07.043	63	42	45	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					153	163		10.1016/j.jaci.2005.03.017	http://dx.doi.org/10.1016/j.jaci.2005.03.017			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990789				2022-12-18	WOS:000235686300024
J	Amoudruz, P; Holmlund, U; Malmstrom, V; Trollmo, C; Bremme, K; Scheynius, A; Sverremark-Ekstrom, E				Amoudruz, P; Holmlund, U; Malmstrom, V; Trollmo, C; Bremme, K; Scheynius, A; Sverremark-Ekstrom, E			Neonatal immune responses to microbial stimuli: Is there an influence of maternal allergy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; CD14; cord blood; cytokines; toll-like receptors	GRAM-NEGATIVE BACTERIA; LIPOPOLYSACCHARIDE; DISEASE; ASTHMA; CHILDREN; SIBLINGS; RECEPTOR; CELLS; TLR4; GENE	Background: Environmental factors are believed to play a role in the development of atopic allergy. This is likely to be important very early in life, at the fetal stage. The in utero environment could be affected by maternal allergy and in turn could influence the immune system of the baby. Objective: To investigate how cord blood mononuclear blood cells (CBMCs) from children of women with and without allergy respond to microbial stimuli. Methods: PBMCs from women with (n=9) and without allergy (n=10) and CBMCs from their newborn babies were stimulated in vitro with LPS and peptidoglycan. Cells were analyzed with flow cytometry for expression of CD14, Toll-like receptor (TLR)-2, and TLR4. The release of cytokines and chemokines (IL-1 beta, IL-6, IL-8, IL-10, IL-12p70, TNF-alpha) and soluble CD14 into culture supernatants was measured with Cytometric Bead Array and ELISA, respectively. Results: Cord blood (CB) monocytes from children with mothers with allergy had significantly lower expression of TLR2 and TLR4 compared with maternal monocytes both before and after microbial stimulation, in contrast with CB monocytes from children with mothers without allergy. Further, CBMCs from children with mothers with allergy had a lower (P=.03) IL-6 response after stimulation with peptidoglycan than CBMCs from children with mothers without allergy. Conclusion: Our results imply that CB monocytes and CBMC immune responses are influenced by maternal allergy. On the basis of these findings, we speculate that monocytes from children with mothers with allergy have a reduced capacity to respond to microbial stimuli.	Karolinska Univ, Hosp Solna, Dept Med, Clin Allergy Res Unit L204, SE-17176 Stockholm, Sweden; Karolinska Univ, Hosp Solna, Dept Med, Rheumatol Unit, SE-17176 Stockholm, Sweden; Karolinska Univ, Hosp Solna, Dept Women & Child Hlth, Div Obstet & Gynecol, SE-17176 Stockholm, Sweden; Karolinska Inst, S-10401 Stockholm, Sweden; Univ Stockholm, Wenner Gren Inst, Dept Immunol, S-10691 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Stockholm University	Holmlund, U (corresponding author), Karolinska Univ, Hosp Solna, Dept Med, Clin Allergy Res Unit L204, SE-17176 Stockholm, Sweden.	uholmlund@yahoo.com	Sverremark-Ekström, Eva/A-2305-2016	Sverremark-Ekström, Eva/0000-0001-6271-8681				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BAZIL V, 1991, J IMMUNOL, V147, P1567; Braun-Fahrlander C, 2003, CURR OPIN ALLERGY CL, V3, P325, DOI 10.1097/01.all.0000092600.10871.e0; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Cookson WOC, 2000, HUM MOL GENET, V9, P2359, DOI 10.1093/hmg/9.16.2359; Ding A, 1999, INFECT IMMUN, V67, P4485, DOI 10.1128/IAI.67.9.4485-4489.1999; Dunzendorfer S, 2004, J IMMUNOL, V173, P1166, DOI 10.4049/jimmunol.173.2.1166; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Holmlund U, 2003, CLIN EXP ALLERGY, V33, P455, DOI 10.1046/j.1365-2222.2003.01629.x; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kaiser HB, 2004, ALLERGY ASTHMA PROC, V25, P7; Kitchens RL, 1998, J IMMUNOL, V161, P5534; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Molloy EJ, 2004, AM J OBSTET GYNECOL, V190, P448, DOI 10.1016/j.ajog.2003.08.027; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Poussin C, 1998, J BIOL CHEM, V273, P20285, DOI 10.1074/jbc.273.32.20285; Prescott SL, 1998, J IMMUNOL, V160, P4730; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Schiff DE, 1997, J LEUKOCYTE BIOL, V62, P786, DOI 10.1002/jlb.62.6.786; TRAV, 2004, EMBO REP, V5, P1000; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; Warner JA, 2000, BRIT MED BULL, V56, P883, DOI 10.1258/0007142001903571; Zdolsek HA, 2004, CLIN EXP ALLERGY, V34, P532, DOI 10.1111/j.1365-2222.2004.1921.x	30	42	43	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1304	1310		10.1016/j.jaci.2005.02.036	http://dx.doi.org/10.1016/j.jaci.2005.02.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	935WZ	15940151				2022-12-18	WOS:000229815400031
J	Paul, ME; Mao, C; Charurat, M; Serchuck, L; Foca, M; Hayani, K; Handelsman, EL; Diaz, C; McIntosh, K; Shearer, WT				Paul, ME; Mao, C; Charurat, M; Serchuck, L; Foca, M; Hayani, K; Handelsman, EL; Diaz, C; McIntosh, K; Shearer, WT		Women Infants Transmission Study	Predictors of immunologic long-term nonprogression in HIV-infected children: Implications for initiating therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human immunodeficiency virus; perinatal; immunologic long-term nonprogression; CD8(+) T lymphocyte	IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; DISEASE PROGRESSION; PROGNOSTIC VALUE; VIRAL LOAD; HIV-1-INFECTED CHILDREN; FLOW-CYTOMETRY; LYMPHOCYTE-ACTIVATION; SURVIVING CHILDREN; IMMUNE ACTIVATION	Background: Early markers that predict immunologic long-term nonprogression in infants with perinatally acquired HIV infection might assist in subsequent antiretroviral treatment decisions. Objectives: We sought to identify early markers of immunologic long-term HIV disease nonprogression. Methods: We analyzed immunologic and virologic characteristics at I and 2 months of age in HIV-infected children who were enrolled in the Women and Infants Transmission Study and born before 1995, comparing immunologic long-term nonprogressors (ILTNPs; n = 10) with non-ILTNPs (n = 127). ILTNPs were children who survived to 8 years or older with CD4 percentages of 25% or greater and counts of 500 cells/mm(3) or more without receiving highly active antiretroviral therapy. Non-ILTNPs were defined as all other HIV-infected children. Receiver operating characteristic curve analysis was used to assess combined sensitivity and specificity for each of these characteristics and to determine potential threshold values to discriminate between ILTNPs and non-ILTNPs. Results: Characteristics in the first 2 months of life associated with ILTNP status in univariate analysis included higher CD4 percentages, lower CD8(+) percentages, lower CD8(+)HLA-DR+ percentages, and lower HIV-1 RNA PCR values. In receiver operating characteristic analysis CD8+HLA-DR+ percentage had the best combined sensitivity and specificity for discriminating between ILTNPs and non-ILTNPs. CD8(+)HLA-DR+ percentages of 5% or less predicted ILTNP status with 80% sensitivity and 80% specificity. In multivariate analysis CD8+HLA-DR+ percentage of 5% or less remained a significant predictor of ILTNP status after adjusting for CD3(+) CD4(+) percentage and HIV-1 RNA PCR value (odds ratio, 15.4; 95% CI, 1.9-124.7). Conclusion: CD8(+) HLA-DR+ T-lymphocyte percentage of less than 5% at 1 to 2 months of age might be predictive for ILTNP status but should not be used at this time to make treatment-deferral decisions. Immune activation in HIV-infected infants might herald more disease progression. Further study of the use of this subpopulation in early infancy to predict ILTNP status is warranted.	Baylor Coll Med, Sect Allergy & Immunol, Houston, TX USA; Childrens Hosp, Boston, MA 02115 USA; Univ Maryland, Div Epidemiol & Prevent, Inst Human Virol, Baltimore, MD 21201 USA; Natl Inst Child Hlth & Human Dev, Bethesda, MD USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; Univ Illinois, Dept Pediat, Chicago, IL USA; SUNY Downstate, Brooklyn, NY USA; Univ Puerto Rico, San Juan, PR 00936 USA	Baylor College of Medicine; Harvard University; Boston Children's Hospital; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Columbia University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; University of Puerto Rico	Paul, ME (corresponding author), Texas Childrens Hosp, 6621 Fannin St FC 330-01, Houston, TX 77030 USA.	mepaul@texaschildrens.hospital.org	Paul, Mary/AAA-2722-2021	Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [RR 00645, RR 00188] Funding Source: Medline; NIAID NIH HHS [U01 AI 34841, U01 AI 34858, 1U01 AI 50274-01, N01 AI 85339] Funding Source: Medline; NICHD NIH HHS [U01 HD 41983, HD 36117] Funding Source: Medline; NIDA NIH HHS [U01 DA 15053, 9U01 DA 15054] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD041983, U01HD036117] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI050274, U01AI034841, N01AI085339, U01AI034858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [U01DA015053, U01DA015054] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abrams EJ, 1998, J INFECT DIS, V178, P101, DOI 10.1086/515596; Aldhous MC, 1996, PEDIATR AIDS HIV INF, V7, P20; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; Bakshi SS, 1998, CLIN DIAGN LAB IMMUN, V5, P38, DOI 10.1128/CDLI.5.1.38-40.1998; Buseyne F, 1998, J INFECT DIS, V178, P1019, DOI 10.1086/515660; CALVELLI T, 1993, CYTOMETRY, V14, P702, DOI 10.1002/cyto.990140703; Chen Y, 1997, HUM IMMUNOL, V55, P154, DOI 10.1016/S0198-8859(97)00092-X; DEEKS SG, 2004, BLOOD; Dunn DT, 2003, LANCET, V362, P1605, DOI 10.1016/S0140-6736(03)14793-9; Fahey JL, 1998, AIDS, V12, P1581, DOI 10.1097/00002030-199813000-00004; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Geffin R, 2000, AIDS RES HUM RETROV, V16, P1855, DOI 10.1089/08892220050195810; GELMAN R, 1993, CLIN IMMUNOL IMMUNOP, V66, P150, DOI 10.1006/clin.1993.1019; GIORGI JV, 1994, J INFECT DIS, V170, P775, DOI 10.1093/infdis/170.4.775; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GRUBMAN S, 1995, PEDIATRICS, V95, P657; Kline MW, 1995, PEDIATR AIDS HIV INF, V6, P350; Lederman MM, 2000, JAMA-J AM MED ASSOC, V284, P223, DOI 10.1001/jama.284.2.223; LEVACHER M, 1992, CLIN EXP IMMUNOL, V90, P376; Liu Z, 1998, J ACQ IMMUN DEF SYND, V18, P332, DOI 10.1097/00042560-199808010-00004; Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003; Martin N, 1996, AIDS RES HUM RETROV, V12, P1565, DOI 10.1089/aid.1996.12.1565; McCloskey TW, 1997, CLIN IMMUNOL IMMUNOP, V84, P46, DOI 10.1006/clin.1997.4370; McCloskey TW, 2001, CYTOMETRY, V46, P157, DOI 10.1002/cyto.1100; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Misrahi M, 1998, JAMA-J AM MED ASSOC, V279, P277, DOI 10.1001/jama.279.4.277; Mocroft A, 1997, J ACQ IMMUN DEF SYND, V14, P158, DOI 10.1097/00042560-199702010-00009; Mofenson LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441; Nielsen K, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.4.e4; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; Patarca R, 1996, AIDS RES HUM RETROV, V12, P1063, DOI 10.1089/aid.1996.12.1063; Paul ME, 2001, J ALLERGY CLIN IMMUN, V108, P258, DOI 10.1067/mai.2001.117179; PAXTON H, 1989, CLIN IMMUNOL IMMUNOP, V52, P68, DOI 10.1016/0090-1229(89)90194-3; PLAEGERMARSHALL S, 1994, CLIN IMMUNOL IMMUNOP, V71, P19, DOI 10.1006/clin.1994.1046; Resino S, 2003, J CLIN IMMUNOL, V23, P279, DOI 10.1023/A:1024536816684; Rich KC, 1997, CLIN IMMUNOL IMMUNOP, V85, P273, DOI 10.1006/clin.1997.4439; Romiti ML, 2000, MOL MED, V6, P28, DOI 10.1007/BF03401932; Rousseau CM, 1997, J ACQ IMMUN DEF SYND, V16, P239, DOI 10.1097/00042560-199712010-00003; Salvini F, 2001, AIDS PATIENT CARE ST, V15, P59, DOI 10.1089/108729101300003645; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; SHEARER WT, 2003, MIDDLETONS ALLERGY P, V1, P1; Sherman GG, 2002, PEDIATR RES, V51, P740, DOI 10.1203/01.PDR.0000017478.64723.79; STITES DP, 1989, CLIN IMMUNOL IMMUNOP, V52, P96, DOI 10.1016/0090-1229(89)90196-7; Than S, 1999, J IMMUNOL, V162, P3680; VANDEPERRE P, 1992, AIDS RES HUM RETROV, V8, P435, DOI 10.1089/aid.1992.8.435; [No title captured]	48	42	42	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					848	855		10.1016/j.jaci.2004.11.054	http://dx.doi.org/10.1016/j.jaci.2004.11.054			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	916GM	15806009				2022-12-18	WOS:000228373400028
J	Schuller, E; Oppel, T; Bornhovd, E; Wetzel, S; Wollenberg, A				Schuller, E; Oppel, T; Bornhovd, E; Wetzel, S; Wollenberg, A			Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epidermal dendritic cells; flow cytometry; atopic eczema; topical immunomodulutors; steroid ointment	CYCLOSPORINE-A; FK506; EXPRESSION; SKIN; INHIBITION; ACTIVATION; CD40; CD80; IDEC; B7-1	Background: The topical immunomodulators tacrolimus and pimecrolimus are novel therapeutic options for atopic dermatitis (AD). The inhibition of nuclear factor of activated T cell-dependent proinflammatory cytokine production in cutaneous lymphocytes is an established effect of topical immunomodulators, which additionally influence mast cells, eosinophils, and dendritic cells (DCs). The latter include a reduced expression of the high-affinity IgE receptor FcepsilonRI, a reduced stimulatory capacity of lesional DCs, and a selective depletion of the inflammatory dendritic epidermal cells (IDECs) but not of Langerhans cells (LCs) from the lesional skin. Objective: Because induction of apoptosis in lymphocytes is a reported tacrolimus effect, we asked whether tacrolimus ointment induces apoptosis of LCs or IDECs in AD lesions. Methods: Epidermal single-cell suspensions were prepare from AD lesions of 9 tacrolimus-treated and 5 hydrocortisone butyrate-treated patients with AD before and after 1 week of treatment. Cell numbers, apoptosis rate, and immunophenotype were assessed by using the standardized FACS technique with terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling, Annexin V, and 3-color immunophenotyping. Freshly isolated LCs and monocyte-derived DCs served as in vitro controls. Results: Tacrolimus and steroid ointment induced a selective depletion of IDECs from the epidermis and reduced the expression of the costimulatory molecules CD80 and CD86. Tacrolimus ointment did not increase the rate of apoptotic DCs, whereas steroid ointment did so. The isolation-induced high apoptosis rate of freshly isolated LCs was unaffected by both drugs. Conclusion: Tacrolimus ointment selectively depletes IDECs and alters the immunophenotype of epidermal DCs in AD lesions, but there is no evidence for tacrolimus-induced DC apoptosis in this phenomenon.	Univ Munich, Dept Dermatol, Lab Immunodermatol, D-80337 Munich, Germany	University of Munich	Wollenberg, A (corresponding author), Univ Munich, Dept Dermatol, Lab Immunodermatol, Frauenlobstr 9-11, D-80337 Munich, Germany.	wollenberg@lrz.uni-muenchen.de						Bellinghausen I, 2001, J ALLERGY CLIN IMMUN, V108, P242, DOI 10.1067/mai.2001.117177; Bornhovd E, 2001, J AM ACAD DERMATOL, V45, P736, DOI 10.1067/mjd.2001.117525; Brokaw JJ, 1998, AM J RESP CELL MOL, V19, P598, DOI 10.1165/ajrcmb.19.4.2870; Freeman GJ, 1998, J IMMUNOL, V161, P2708; Hashimoto Y, 2001, CLIN EXP IMMUNOL, V125, P19, DOI 10.1046/j.1365-2249.2001.01586.x; Kalthoff ES, 2003, CLIN EXP IMMUNOL, V133, P350, DOI 10.1046/j.1365-2249.2003.02225.x; Kim KD, 2001, J LEUKOCYTE BIOL, V69, P426; Kochi S, 2000, LIFE SCI, V66, P2255, DOI 10.1016/S0024-3205(00)00554-3; Kraft S, 2002, J INVEST DERMATOL, V118, P830, DOI 10.1046/j.1523-1747.2002.01757.x; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Meingassner JG, 2003, BRIT J DERMATOL, V149, P853, DOI 10.1046/j.1365-2133.2003.05559.x; Panhans-Gross A, 2001, J ALLERGY CLIN IMMUN, V107, P345, DOI 10.1067/mai.2001.112600; Reitamo S, 2002, J ALLERGY CLIN IMMUN, V109, P547, DOI 10.1067/mai.2002.121832; Salgado CG, 1999, J INVEST DERMATOL, V113, P1021, DOI 10.1046/j.1523-1747.1999.00785.x; Schuller E, 2001, ARCH DERMATOL RES, V293, P448, DOI 10.1007/s004030100263; Szabo G, 2001, J INVEST MED, V49, P442, DOI 10.2310/6650.2001.33789; Wollenberg A, 2000, ALLERGY, V55, P205, DOI 10.1034/j.1398-9995.2000.00115.x; Wollenberg A, 1999, CYTOMETRY, V37, P147, DOI 10.1002/(SICI)1097-0320(19991001)37:2<147::AID-CYTO8>3.0.CO;2-Y; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942; WOLLENBERG A, 1998, IMMUNOLOGICAL TECHNI, P20; Yardin C, 1998, NEUROREPORT, V9, P2077, DOI 10.1097/00001756-199806220-00030	23	42	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					137	143		10.1016/j.jaci.2004.03.021	http://dx.doi.org/10.1016/j.jaci.2004.03.021			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	836DA	15241357				2022-12-18	WOS:000222534300021
J	Apter, AJ; Kinman, JL; Bilker, WB; Herlim, M; Margolis, DJ; Lautenbach, E; Hennessy, S; Strom, BL				Apter, AJ; Kinman, JL; Bilker, WB; Herlim, M; Margolis, DJ; Lautenbach, E; Hennessy, S; Strom, BL			Represcription of penicillin after allergic-like events	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						drug allergy; adverse drug reaction; drug hypersensitivity; penicillin; anaphylaxis; urticaria; angioedema; toxic epidermal necrolysis	PRACTICE RESEARCH DATABASE; BETA-LACTAM ANTIBIOTICS; HYPERSENSITIVITY REACTIONS; PREVALENCE; STATINS; DISEASE; RISK	Objective: We sought to determine the frequency of represcription of penicillin to individuals with penicillin allergy and the risk of a second reaction in those who had a previous reaction. Methods: A retrospective cohort study was conducted within the UK General Practice Research Database. All patients who had received a prescription for penicillin were identified. Within that source population, records of patients who had received at least 2 prescriptions for penicillin at least 60 days apart were selected and examined for allergic-like (hypersensitivity) events on the day of or within 30 days after a prescription. Results: At least one prescription for penicillin was given to 3,375,162 patients. Of 6212 (0.18%) patients who experienced an allergic-like event after the initial prescription, 48.5% were given a second prescription compared with 59.8% of those without an initial allergic-like event (risk ratio, 0.81; 95% CI, 0.79-0.83). Two or more prescriptions for penicillin were given to 2,017,957 patients. Three thousand fourteen (0.15%) patients experienced an allergic-like event after the first prescription, and 57 (1.89%) of those had another event after the second prescription. The unadjusted odds ratio of an allergic-like event after the second prescription for those who experienced an allergic-like event after the first prescription, compared with those who had no initial event was 11.2 (95% CI, 8.6-14.6). Adjusting for confounding had no substantive effect on this result. Conclusion: The risk of an allergic-like event after penicillin is markedly increased in those who have had a prior event, although the absolute difference is small (1.72%). Represcription of penicillin to such patients is more frequent than anticipated.	Univ Penn, Div Pulm Allergy & Crit Care Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Div Infect Dis, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Apter, AJ (corresponding author), Hosp Univ Penn, 3600 Spruce St,829 Gates Bldg, Philadelphia, PA 19104 USA.		Bilker, Warren/AAS-3515-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL004337] Funding Source: NIH RePORTER; NHLBI NIH HHS [K23 HL 04337-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adkinson NF, 2002, J ALLERGY CLIN IMMUN, V109, pS461, DOI 10.1067/mai.2002.122214; Apter A J, 1994, Arch Fam Med, V3, P717, DOI 10.1001/archfami.3.8.717; Bashford JNR, 1998, BRIT MED J, V317, P452; Breslow NE., 1987, STAT METHODS CANC RE, P81; *BRIT MED ASS, 2002, BRIT NAT FORM 43; DITTO AM, 2002, PATTERSONS ALLERGIC, P295; *EPIC, 2001, GEN PRACT RES DAT GU; Garcia Rodriguez L A, 2000, PHARMACOEPIDEM DR S, P375; GREEN GR, 1977, J ALLERGY CLIN IMMUN, V60, P339, DOI 10.1016/0091-6749(77)90064-1; GREENBERGER PA, 2002, PATTERSONS ALLERGIC, P335; Gruchalla R, 2000, J ALLERGY CLIN IMMUN, V105, pS637, DOI 10.1067/mai.2000.106156; Hennekens C.H., 1987, EPIDEMIOLOGY MED; Hennessy S, 2001, JAMA-J AM MED ASSOC, V285, P1888, DOI 10.1001/jama.285.14.1888; Huber PJ, 1967, BEHAV MAXIMUM LIKELI; Huovinen P, 1998, BRIT MED J, V317, P613, DOI 10.1136/bmj.317.7159.613; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; Lawson DH, 1998, QJM-MON J ASSOC PHYS, V91, P445, DOI 10.1093/qjmed/91.6.445; LEVINE BB, 1969, J ALLERGY, V43, P231, DOI 10.1016/0021-8707(69)90066-5; Lewis JD, 2002, PHARMACOEPIDEM DR S, V11, P211, DOI 10.1002/pds.698; LIS Y, 1995, J CLIN EPIDEMIOL, V48, P431, DOI 10.1016/0895-4356(94)00137-F; Margolis DJ, 2002, J AM ACAD DERMATOL, V46, P381, DOI 10.1067/mjd.2002.121739; Margolis DJ, 2002, ANN EPIDEMIOL, V12, P321, DOI 10.1016/S1047-2797(01)00255-1; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; Montastruc JL, 2002, FUND CLIN PHARMACOL, V16, P343, DOI 10.1046/j.1472-8206.2002.00100.x; Rothman K., 1998, MODERN EPIDEMIOLOGY; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SHEPHERD GM, 1991, IMMUNOL ALLERGY CLIN, V11, P611; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; van Staa TP, 2001, JAMA-J AM MED ASSOC, V285, P1850, DOI 10.1001/jama.285.14.1850; van Staa TP, 2001, JAMA-J AM MED ASSOC, V286, P669; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; 1996, STAT N GEN PRACTICE	33	42	45	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					764	770		10.1016/j.jaci.2003.11.032	http://dx.doi.org/10.1016/j.jaci.2003.11.032			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100685				2022-12-18	WOS:000220956600027
J	Tangsinmankong, N; Kamchaisatian, W; Lujan-Zilbermann, J; Brown, CL; Sleasman, JW; Emmanuel, PJ				Tangsinmankong, N; Kamchaisatian, W; Lujan-Zilbermann, J; Brown, CL; Sleasman, JW; Emmanuel, PJ			Varicella zoster as a manifestation of immune restoration disease in HIV-infected children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immune restoration disease; HIV-1; highly active anti-retroviral therapy; opportunistic infections; herpes zoster	ACTIVE ANTIRETROVIRAL THERAPY; HERPES-ZOSTER; OPPORTUNISTIC INFECTIONS; PROTEASE INHIBITORS; IMMUNODEFICIENCY; RECONSTITUTION; INITIATION; LYMPHOCYTES; MORTALITY; HAART	Background: Exacerbation of opportunistic infections in HIV-infected patients shortly after initiation of highly active antiretroviral therapy (HAART) has been named immune restoration disease (IRD). Thus far, IRD has not been reported in children. Objective: We describe the clinical and immune characteristics of IRD in HIV-infected children treated with HAART. Methods: A historical cohort study was conducted in a tertiary HIV center in perinatally HIV-infected children who were started on a first stable HAART between January 1996 and July 2002. The incidence of opportunistic infections, newly AIDS-defining events or death after initiation of HAART, and virologic and immunologic information was evaluated at baseline and every 3 months post-HAART. Results: Sixty-one perinatally HIV-infected children were started and maintained on HAART for >6 months. Seven episodes of IRD occurred. All were cutaneous herpes zoster (HZ). Children who developed HZ had significantly lower baseline CD4(+) and CD8(+) T-cell numbers compared with children who did not. HZ occurred only in children (7 of 34 subjects) with virological and immunological success to HAART. In children with a previous history of varicella infection, the risk of developing HZ after HAART was higher in those without a protective level of varicella-specific IgG (50%, or 5 of 10 subjects) compared with those with seroprotection (10%, or 2 of 20). Conclusion: Herpes zoster is a common manifestation of IRD in HIV-infected children after the initiation of HAART. Risks for developing HZ include no protective varicella-specific antibody despite previous varicella infection, severe immunodeficiency at baseline, and vigorous immunologic and virologic responses to HAART.	Univ S Florida, Div Allergy & Immunol, St Petersburg, FL USA; Univ S Florida, All Childrens Hosp, Div Infect Dis, Dept Pediat, St Petersburg, FL USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Tangsinmankong, N (corresponding author), All Childrens Hosp, Dept Pediat, Div Allergy & Immunol, 801 6th St S,Box 9350, St Petersburg, FL 33701 USA.	tangsinn@allkids.org	Lujan-Zilbermann, Jorge/I-4949-2012	Lujan-Zilbermann, Jorge/0000-0002-0099-4063				Arvin Ann M, 2002, Semin Pediatr Infect Dis, V13, P12, DOI 10.1053/spid.2002.29753; Berrey MM, 2001, J INFECT DIS, V183, P1466, DOI 10.1086/320189; Breton G, 1998, CLIN INFECT DIS, V27, P1525, DOI 10.1086/515045; Cooney EL, 2002, CLIN INFECT DIS, V34, P224, DOI 10.1086/323898; Correa R, 2002, AIDS, V16, P1181, DOI 10.1097/00002030-200205240-00013; Dankner WM, 2001, PEDIATR INFECT DIS J, V20, P40, DOI 10.1097/00006454-200101000-00008; Derryck A, 1998, PEDIATR INFECT DIS J, V17, P931, DOI 10.1097/00006454-199810000-00023; DeSimone JA, 2000, ANN INTERN MED, V133, P447, DOI 10.7326/0003-4819-133-6-200009190-00013; Domingo P, 2001, AM J MED, V110, P605, DOI 10.1016/S0002-9343(01)00703-3; Gershon AA, 1997, J INFECT DIS, V176, P1496, DOI 10.1086/514147; Gibb DM, 2000, LANCET, V355, P1331, DOI 10.1016/S0140-6736(00)02117-6; Gonzalez-Castillo J, 2001, MED CLIN-BARCELONA, V117, P81, DOI 10.1016/S0025-7753(01)72024-6; Gortmaker SL, 2001, NEW ENGL J MED, V345, P1522, DOI 10.1056/NEJMoa011157; Hata A, 2002, NEW ENGL J MED, V347, P26, DOI 10.1056/NEJMoa013441; John M, 1998, MED J AUSTRALIA, V169, P473, DOI 10.5694/j.1326-5377.1998.tb123372.x; Johnston AM, 2001, PEDIATR INFECT DIS J, V20, P941, DOI 10.1097/00006454-200110000-00006; Ledergerber B, 1999, JAMA-J AM MED ASSOC, V282, P2220, DOI 10.1001/jama.282.23.2220; Martinez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019; Morlese JF, 2003, AIDS, V17, P1411, DOI 10.1097/00002030-200306130-00025; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Petursson G, 1998, PEDIATR INFECT DIS J, V17, P905, DOI 10.1097/00006454-199810000-00011; PICKERING LK, 2003, RED BOOK 2003 REPORT, P672; Rodriguez-Rosado R, 1998, ANTIVIR THER, V3, P229; Rutschmann OT, 1998, J INFECT DIS, V177, P783, DOI 10.1086/517808; Saag MS, 2001, AIDS, V15, pS4, DOI 10.1097/00002030-200102002-00002; Shearer WT, 2000, J ALLERGY CLIN IMMUN, V106, P559, DOI 10.1067/mai.2000.109433; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Stone S F, 2002, HIV Med, V3, P21, DOI 10.1046/j.1464-2662.2001.00096.x; 1998, PEDIATRICS, V102, P999	29	42	47	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					742	746		10.1016/j.jaci.2004.01.768	http://dx.doi.org/10.1016/j.jaci.2004.01.768			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	814DY	15100682				2022-12-18	WOS:000220956600024
J	Ferrando, RE; Nyengaard, JR; Hays, SR; Fahy, JV; Woodruff, PG				Ferrando, RE; Nyengaard, JR; Hays, SR; Fahy, JV; Woodruff, PG			Applying stereology to measure thickness of the basement membrane zone in bronchial biopsy specimens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CELL		Univ Calif San Francisco, Cardiovasc Res Inst, Div Pulm Med, Dept Med, San Francisco, CA 94143 USA; Univ Aarhus, Stereol Res & Electron Microscopy Lab, Aarhus, Denmark	University of California System; University of California San Francisco; Aarhus University	Ferrando, RE (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Div Pulm Med, Dept Med, Box 0130,505 Parnassus Ave, San Francisco, CA 94143 USA.				NCRR NIH HHS [K23 RR17002] Funding Source: Medline; NHLBI NIH HHS [R01 HL-61662, P50 HL56835] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR017002] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061662] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLENDER RP, 1993, AM J PHYSIOL, V265, pL521, DOI 10.1152/ajplung.1993.265.6.L521; GUNDERSEN HJG, 1978, J MICROSC-OXFORD, V113, P27, DOI 10.1111/j.1365-2818.1978.tb00091.x; Hays SR, 2001, J ALLERGY CLIN IMMUN, V108, P784; JENSEN EB, 1979, J MICROSC-OXFORD, V115, P19, DOI 10.1111/j.1365-2818.1979.tb00149.x; NYENGAARD JR, 1992, J MICROSC-OXFORD, V165, P427, DOI 10.1111/j.1365-2818.1992.tb01497.x; ROCHE WR, 1989, LANCET, V1, P520; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811	7	42	45	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1243	1245		10.1016/j.jaci.2003.09.038	http://dx.doi.org/10.1016/j.jaci.2003.09.038			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	752HC	14657892				2022-12-18	WOS:000187154200035
J	Gelfand, EW				Gelfand, EW			Antibody-directed therapy: Past, present, and future	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CALIFORNIA	Bayer Biol		anti-inflammatory; autoimmunity; monoclonal antibody; polyclonal antibody; hyperimmune Igs; immunomodulation	INTRAVENOUS IMMUNOGLOBULIN TREATMENT; GUILLAIN-BARRE-SYNDROME; NON-HODGKINS-LYMPHOMA; TOXIC SHOCK SYNDROME; IMMUNE GLOBULIN; PLASMA-EXCHANGE; DOUBLE-BLIND; ANTI-GM1 ANTIBODIES; MULTIPLE-SCLEROSIS; RANDOMIZED TRIAL	Antibody-based therapy, which is the administration of polyclonal, hyperimmune, or monoclonal antibodies, has emerged as an important therapeutic approach in a wide variety of diseases. Polyclonal intravenous immunoglobulin became available in the early 1980s and supplanted intramuscular IgG in the treatment of antibody-deficiency diseases. During the last 2 decades, intravenous immunoglobulin has shown potent immunomodulatory and anti-inflammatory effects in many diseases. Whether these effects are mediated through specific antibody or Fc-receptor interactions is unclear. This review examines some of the current and future prospects for antibody-based therapy.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	National Jewish Health	Gelfand, EW (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.							Achiron A, 1999, NEUROLOGY, V52, P214; Atkins JT, 2000, PEDIATR INFECT DIS J, V19, P138, DOI 10.1097/00006454-200002000-00012; AUKRUST P, 1994, BLOOD, V84, P2136; AZULAY JP, 1994, NEUROLOGY, V44, P429, DOI 10.1212/WNL.44.3_Part_1.429; Bain PG, 1996, NEUROLOGY, V47, P678, DOI 10.1212/WNL.47.3.678; BARRY W, 1992, JAMA-J AM MED ASSOC, V267, P3315, DOI 10.1001/jama.267.24.3315; Bendtzen K, 1998, IMMUNOL TODAY, V19, P209, DOI 10.1016/S0167-5699(98)01252-3; Bril V, 1996, NEUROLOGY, V46, P100, DOI 10.1212/WNL.46.1.100; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; Davis TA, 1999, J CLIN ONCOL, V17, P1851, DOI 10.1200/JCO.1999.17.6.1851; Domachowske JB, 1999, CLIN MICROBIOL REV, V12, P298, DOI 10.1128/CMR.12.2.298; DYCK PJ, 1994, ANN NEUROL, V36, P838, DOI 10.1002/ana.410360607; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; Fick R B Jr, 1999, Curr Opin Pulm Med, V5, P76, DOI 10.1097/00063198-199901000-00013; Gajdos P, 1997, ANN NEUROL, V41, P789, DOI 10.1002/ana.410410615; Geisler JP, 1999, GYNECOL ONCOL, V75, P432, DOI 10.1006/gyno.1999.5615; GELFAND EW, 1988, MONOGR ALLERGY, V23, P177; GELFAND EW, 1993, CLIN INFECT DIS   S1, V17, P250; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; Hughes RAC, 1997, LANCET, V349, P225; Hurez V, 1994, Ther Immunol, V1, P269; IMBACH P, 1981, LANCET, V1, P1228; JAYNE DRW, 1993, ADV EXP MED BIOL, V336, P469; Kavanaugh A, 2000, J RHEUMATOL, V27, P841; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; KAZATCHKINE MD, 1994, IMMUNOL REV, V139, P79, DOI 10.1111/j.1600-065X.1994.tb00858.x; Lamothe F, 1995, CLIN INFECT DIS, V21, P1469, DOI 10.1093/clinids/21.6.1469; Landwehr LP, 1998, CHEST, V114, P1349, DOI 10.1378/chest.114.5.1349; Lockwood CM, 1996, CLIN EXP IMMUNOL, V104, P77, DOI 10.1111/cei.1996.104.s1.77; Manyak MJ, 1999, UROLOGY, V54, P1058, DOI 10.1016/S0090-4295(99)00314-3; MARCHALONIS JJ, 1992, P NATL ACAD SCI USA, V89, P3325, DOI 10.1073/pnas.89.8.3325; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; McGuirk JP, 1999, BONE MARROW TRANSPL, V24, P1253, DOI 10.1038/sj.bmt.1702052; Mikula C A, 1999, Gastroenterol Nurs, V22, P245, DOI 10.1097/00001610-199911000-00004; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; MOFENSON LM, 1994, PEDIATR INFECT DIS J, V13, P477, DOI 10.1097/00006454-199406000-00003; MOHIUDDIN AA, 1991, J ALLERGY CLIN IMMUN, V87, P104, DOI 10.1016/0091-6749(91)90219-E; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; Perez CM, 1997, AM J MED, V102, P111, DOI 10.1016/S0002-9343(96)00304-X; Prasad NKA, 1998, J IMMUNOL, V161, P3781; ROIFMAN CM, 1986, AM J MED, V80, P590, DOI 10.1016/0002-9343(86)90812-0; ROIFMAN CM, 1987, LANCET, V1, P1075; ROSSI F, 1989, IMMUNOL REV, V110, P135, DOI 10.1111/j.1600-065X.1989.tb00031.x; Rutgeerts PJ, 1999, ALIMENT PHARM THERAP, V13, P9, DOI 10.1046/j.1365-2036.1999.00025.x; Salmun LM, 1999, J ALLERGY CLIN IMMUN, V103, P810, DOI 10.1016/S0091-6749(99)70424-0; Seitz U, 1999, EUR J NUCL MED, V26, P1265, DOI 10.1007/s002590050582; Sorensen PS, 1997, MULT SCLER, V3, P145, DOI 10.1177/135245859700300216; Spahn JD, 1999, J ALLERGY CLIN IMMUN, V103, P421, DOI 10.1016/S0091-6749(99)70466-5; Svenson M, 1998, BLOOD, V91, P2054, DOI 10.1182/blood.V91.6.2054.2054_2054_2061; vandenBerg LH, 1997, J NEUROL NEUROSUR PS, V63, P674, DOI 10.1136/jnnp.63.5.674; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; WANG EE, 2000, COCHRANE DATABASE SY, V2; Weiner LM, 1999, SEMIN ONCOL, V26, P41; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; YONG JM, 1994, LANCET, V343, P1427, DOI 10.1016/S0140-6736(94)92548-8	56	42	43	4	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S111	S116		10.1067/mai.2001.117824	http://dx.doi.org/10.1067/mai.2001.117824			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	487KL	11586277	Bronze			2022-12-18	WOS:000171874200007
J	Sacher, RA				Sacher, RA		IVIG Advisory Panel	Intravenous immunoglobulin consensus statement	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CA	Bayer Biol		intravenous immune globulin; fetal-neonatal alloimmune thrombocytopenia; fetal-neonatal alloimmune hemolysis; antiphospholipid syndrome; recurrent pregnancy loss; peripheral neuropathy; neuropathy; chronic inflammatory demyelinating; polyneuropathy; Guillain-Barre syndrome; inflammatory neuropathy; neuroimmunology	INFLAMMATORY DEMYELINATING POLYNEUROPATHY; PARVOVIRUS B19 INFECTION; IMMUNE GLOBULIN THERAPY; ALLOIMMUNE THROMBOCYTOPENIA; ANTIPHOSPHOLIPID SYNDROME; KAWASAKI-DISEASE; HUMORAL REJECTION; RANDOMIZED-TRIAL; GAMMA-GLOBULIN; DOUBLE-BLIND	Intravenous immunoglobulin (IVIG) preparations are a mainstay for a number of disorders that include primary immunodeficiency, acute inflammatory conditions, hematological disorders, infections, and neuroimmunological disorders. The range of therapeutic activity is attributed to IVIG's myriad action mechanisms. IVIG can interact and bind onto complement factors, which can prevent complement-mediated tissue damage, modulate T-lymphocytes, alter cytokine profiles, and modulate the immune system. These interactions can act alone or in combination to maintain immune balance while preserving homeostasis. A consensus panel was convened in 2000 to evaluate and define new advances in IVIG therapies.	Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Sacher, RA (corresponding author), Univ Cincinnati, Med Ctr, 3130 Highland Ave,POB 670055, Cincinnati, OH 45267 USA.							*AM COLL OBST GYN, 1998, INT J GYNECOL OBSTET, V61, P193; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; AZULAY JP, 1994, NEUROLOGY, V44, P429, DOI 10.1212/WNL.44.3_Part_1.429; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; BLANCHETTE V, 1994, LANCET, V344, P703, DOI 10.1016/S0140-6736(94)92205-5; BLANCHETTE VS, 1990, BRIT J HAEMATOL, V74, P209, DOI 10.1111/j.1365-2141.1990.tb02567.x; BOUGHTON BJ, 1995, CLIN LAB HAEMATOL, V17, P75; BRANCH DW, 1992, OBSTET GYNECOL, V80, P614; Branch DW, 2000, AM J OBSTET GYNECOL, V182, P122, DOI 10.1016/S0002-9378(00)70500-X; BROWN KE, 1993, SCIENCE, V262, P114, DOI 10.1126/science.8211117; BURD RS, 1992, IMMUNOTHERAPY GRAM N; Burns JC, 1998, PEDIATR INFECT DIS J, V17, P1144, DOI 10.1097/00006454-199812000-00009; Bussel J B, 1990, Transfus Med Rev, V4, P149; BUSSEL JB, 1988, NEW ENGL J MED, V319, P1374, DOI 10.1056/NEJM198811243192103; BUSSEL JB, 1988, PEDIATR RES, V23, P457, DOI 10.1203/00006450-198805000-00003; CALVELLI TA, 1986, PEDIATR INFECT DIS J, V5, pS207; DAFFOS F, 1980, J PEDIAT, V97, P695; DAJANI AS, 1994, CIRCULATION, V89, P916, DOI 10.1161/01.CIR.89.2.916; DAJANI AS, 1993, CIRCULATION, V87, P1776, DOI 10.1161/01.CIR.87.5.1776; Dalakas MC, 1996, ANN NEUROL, V40, P792, DOI 10.1002/ana.410400516; DURONGPISITKUL K, 1995, PEDIATRICS, V96, P1057; Epstein J. L., 1996, NEW SCH NEW COMMUNIT, V12, P5; FALLOON J, 1989, J PEDIATR-US, V114, P1, DOI 10.1016/S0022-3476(89)80596-7; Fazekas F, 1997, LANCET, V349, P589, DOI 10.1016/S0140-6736(96)09377-4; FRICKHOFEN N, 1990, ANN INTERN MED, V113, P926, DOI 10.7326/0003-4819-113-12-926; GOLDSTEIN AR, 1987, ARCH DIS CHILD, V62, P585, DOI 10.1136/adc.62.6.585; Hahn AF, 1996, BRAIN, V119, P1067, DOI 10.1093/brain/119.4.1067; HANSEN MB, 1995, EUR J IMMUNOL, V25, P348, DOI 10.1002/eji.1830250207; HARTUNG HP, 1998, CLIN NEUROIMMUNOLOGY, P294; HERMAN JH, 1986, AM J PEDIAT HEMATOL, V8, P312; Hughes RAC, 1997, LANCET, V349, P225; IMBACH P, 1985, LANCET, V2, P464; Jordan SC, 1998, TRANSPLANTATION, V66, P800, DOI 10.1097/00007890-199809270-00017; KAPLAN C, 1988, BLOOD, V72, P340; Kaveri S, 1996, J CLIN INVEST, V97, P865, DOI 10.1172/JCI118488; KAZATCHKINE MD, 1994, IMMUNOL REV, V139, P79, DOI 10.1111/j.1600-065X.1994.tb00858.x; KNUTSEN AP, 1989, J ALLERGY CLIN IMMUN, V84, P640, DOI 10.1016/0091-6749(89)90203-0; KONDO N, 1994, SCAND J IMMUNOL, V40, P37, DOI 10.1111/j.1365-3083.1994.tb03430.x; Kutteh WH, 1996, AM J OBSTET GYNECOL, V174, P1584, DOI 10.1016/S0002-9378(96)70610-5; LEWIS DE, 1990, SEMIN PEDIATR INFECT, V1, P21; Lockshin MD, 1997, JAMA-J AM MED ASSOC, V277, P1549, DOI 10.1001/jama.277.19.1549; Lutz HU, 1996, BLOOD, V88, P184; Marchand S, 1999, CLIN TRANSPLANT, V13, P17, DOI 10.1034/j.1399-0012.1999.t01-1-130103.x; MCMILLAN R, 1987, BLOOD, V70, P1040; Miyagi F, 1997, J NEUROIMMUNOL, V78, P127, DOI 10.1016/S0165-5728(97)00090-8; MOFENSON LM, 1992, JAMA-J AM MED ASSOC, V268, P483, DOI 10.1001/jama.268.4.483; Montgomery RA, 2000, TRANSPLANTATION, V70, P887, DOI 10.1097/00007890-200009270-00006; Moudgil A, 1997, TRANSPLANTATION, V64, P1847, DOI 10.1097/00007890-199712270-00037; MUELLERECKHARDT C, 1989, LANCET, V1, P363; MURPHY MF, 1990, VOX SANG, V58, P45, DOI 10.1111/j.1423-0410.1990.tb02054.x; NEILD G, 1986, LANCET, V2, P1226; NEWLAND AC, 1984, NEW ENGL J MED, V310, P261; NICOLINI U, 1990, AM J OBSTET GYNECOL, V163, P1144, DOI 10.1016/0002-9378(90)90674-V; OCHS HD, 1987, PEDIATR INFECT DIS J, V6, P509, DOI 10.1097/00006454-198706000-00003; PAHWA S, 1990, CRIT CARE MED, V18, pS138; PILZ G, 1994, CHEST, V105, P76, DOI 10.1378/chest.105.1.76; Portmore AC, 1995, PRINCIPLES PRACTICE, P1439; Rai R, 1997, BRIT MED J, V314, P253, DOI 10.1136/bmj.314.7076.253; Rangel-Frausto MS, 1999, INFECT DIS CLIN N AM, V13, P299, DOI 10.1016/S0891-5520(05)70076-3; REZNIKOFFETIEVANT MF, 1988, VOX SANG, V55, P193, DOI 10.1111/j.1423-0410.1988.tb04697.x; ROSS C, 1995, J CLIN INVEST, V95, P1974, DOI 10.1172/JCI117881; RUBENSTEIN A, 1986, CURR PROBL PEDIATR, V16, P365; Sater RA, 1998, NEUROLOGY, V51, pS9, DOI 10.1212/WNL.51.6_Suppl_5.S9; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; Sherer Y, 2000, RHEUMATOLOGY, V39, P421, DOI 10.1093/rheumatology/39.4.421; Silvestris F, 1996, CLIN EXP IMMUNOL, V104, P91, DOI 10.1111/cei.1996.104.s1.91; SORENSEN RU, 1994, PEDIATR CLIN N AM, V41, P691; Stangel M, 1997, IMMUNOL INVEST, V26, P569, DOI 10.3109/08820139709088541; TANI P, 1989, BLUT, V59, P44, DOI 10.1007/BF00320247; VANDOORN PA, 1988, NEUROLOGY, V38, P1592, DOI 10.1212/WNL.38.10.1592; WENSKE G, 1984, BLUT, V48, P377, DOI 10.1007/BF00319966; WILLIAMS PE, 1988, J HOSP INFECT, V12, P67, DOI 10.1016/0195-6701(88)90032-1; YOUNG N, 1984, J CLIN INVEST, V74, P2024, DOI 10.1172/JCI111625; Yu ZY, 1999, NEW ENGL J MED, V340, P227, DOI 10.1056/NEJM199901213400311; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; 1992, MED LETT DRUGS THER, V34, P116	76	42	44	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S139	S146		10.1067/mai.2001.118640	http://dx.doi.org/10.1067/mai.2001.118640			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	487KL	11586282				2022-12-18	WOS:000171874200012
J	Gordon, S; Fisher, SW; Raymond, RH				Gordon, S; Fisher, SW; Raymond, RH			Elimination of mouse allergens in the working environment: Assessment of individually ventilated cage systems and ventilated cabinets in the containment of mouse allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						laboratory animal allergy; mouse; aeroallergens; ventilated cage; exposure; occupational asthma	LABORATORY-ANIMAL ALLERGY; EXPOSURE-RESPONSE RELATIONSHIPS; UNIVERSITY EMPLOYEES; AIRBORNE ALLERGEN; URINARY PROTEINS; WORKERS; RATS; SENSITIZATION; ATOPY; REDUCTION	Background: Laboratory animal allergy is an important occupational disease that is preventable by reduction of exposure to mammalian allergens. Objective: The purpose of this investigation was to assess the efficacy of safety equipment in containing mouse urinary protein (MUP)-specifically, individually ventilated cage (IVC) systems and class 1-type and class II ventilated cabinets. Methods. Six IVC systems (which are used to house rodents) were operated at positive and negative pressure. Air samples (2 L/min) were collected at the cage front, cage back, air inlet, and air outlet, and the MUP was quantified by immunoassay.. The background MUP of the IVC study room was compared with that of rooms where mice were, housed conventionally or in isolators. Class I-type cabinets (n = 2) were tested during the disposal of soiled litter. Air samples were positioned on and behind the operator and inside the cabinet (n = 2). Personal samples were collected while scientific procedures were performed in a. class Ir cabinet and in the open. Results: All of the IVC systems contained MUP effectively (>250-fold) when operated at negative pressure. At positive pressure, the "unsealed" IVC racks leaked MUP (1- to 25-fold reduction) but the "sealed" IVC system did not. Class 1-type cabinets reduced (10-fold) but did not eliminate exposure during "cleaning out." No MUP was detected when procedures were performed in class II cabinets (protection factor, >10-fold). Conclusion: Safety equipment can substantially reduce exposure to mouse allergen. Allergen exposure in holding rooms will be minimized if mice are housed in IVC systems operated at negative pressure or in "scaled" IVC systems at positive pressure. Respiratory protection should be used whenever "unsealed" IVC systems are operated at positive pressure or during "cleaning out" in class I-type cabinets.	Natl Heart & Lung Inst, ICSM, Dept Occupat & Environm Med, London SW3 6LR, England; Imperial Canc Res Fund, London WC2A 3PX, England	Imperial College London; Cancer Research UK	Gordon, S (corresponding author), Natl Heart & Lung Inst, ICSM, Dept Occupat & Environm Med, 1B Manresa Rd, London SW3 6LR, England.							AOYAMA K, 1992, BRIT J IND MED, V49, P41; BOTHAM PA, 1995, OCCUP ENVIRON MED, V52, P129, DOI 10.1136/oem.52.2.129; Bryant DH, 1995, MED J AUSTRALIA, V163, P415, DOI 10.5694/j.1326-5377.1995.tb124657.x; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; Fisher R, 1998, J OCCUP ENVIRON MED, V40, P609, DOI 10.1097/00043764-199807000-00005; Fuortes LJ, 1996, AM J IND MED, V29, P67, DOI 10.1002/(SICI)1097-0274(199601)29:1<67::AID-AJIM9>3.0.CO;2-W; Fuortes LJ, 1997, AM J IND MED, V32, P665, DOI 10.1002/(SICI)1097-0274(199712)32:6<665::AID-AJIM13>3.0.CO;2-#; Gordon S, 1997, OCCUP ENVIRON MED, V54, P135, DOI 10.1136/oem.54.2.135; GORDON S, 1992, ANN OCCUP HYG, V36, P575, DOI 10.1093/annhyg/36.6.575; GORDON S, 1992, BRIT J IND MED, V49, P416; Gordon S, 1997, CLIN EXP ALLERGY, V27, P744, DOI 10.1046/j.1365-2222.1997.640844.x; Gordon S, 1999, ASTHMA WORKPLACE, P399; Harrison D J, 2001, ILAR J, V42, P17; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; *IND INJ ADV COUNC, 1981, CMND8121; National Institute for Occupational Safety and Health, 1998, NIOSH PUBL; Reeb-Whitaker C, 1999, J ALLERGY CLIN IMMUN, V103, P139, DOI 10.1016/S0091-6749(99)70537-3; Renstrom A, 1997, J ALLERGY CLIN IMMUN, V100, P649, DOI 10.1016/S0091-6749(97)70169-6; SJOSTEDT L, 1993, AM J IND MED, V24, P459, DOI 10.1002/ajim.4700240410; WEISSENBACH T, 1988, SCHWEIZ MED WSCHR, V118, P930; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1; ZIEMANN B, 1992, AM IND HYG ASSOC J, V53, P138, DOI 10.1202/0002-8894(1992)053<0138:TEOTDB>2.0.CO;2	25	42	42	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					288	294		10.1067/mai.2001.117258	http://dx.doi.org/10.1067/mai.2001.117258			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	465HY	11496249				2022-12-18	WOS:000170584600021
J	Fiscus, LC; Van Herpen, J; Steeber, DA; Tedder, TF; Tang, MLK				Fiscus, LC; Van Herpen, J; Steeber, DA; Tedder, TF; Tang, MLK			L-Selectin is required for the development of airway hyperresponsiveness but not airway inflammation in a murine model of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adhesion molecule; asthma; airway hyperresponsiveness; inflammation	BRONCHOALVEOLAR LAVAGE; LYMPHOCYTE MIGRATION; LEUKOCYTE KINETICS; T-LYMPHOCYTES; MAST-CELLS; EOSINOPHILS; EXPRESSION; RESPONSIVENESS; MACROPHAGES; SYMPTOMS	Background: Airway inflammation and airway hyperresponsiveness (AHR) are fundamental features of asthma, h Migration of inflammatory cells from the circulation into the lungs is dependent on adhesion molecule interactions. The cell surface adhesion molecule L-selectin has been demonstrated to mediate leukocyte rolling on inflamed and noninflamed pulmonary endothelium, However, its role in the development of airway inflammation and AHR in asthma has not been examined. Objective: We sought to characterize the role of L-selectin in the recruitment of inflammatory cells to the airway-lung and the development of AHR in a murine model of asthma, Methods: An ovalbumin (OVA)-induced allergic airway disease model of asthma was applied to L-selectin-deficient (LKO) mice and C57BL/6 wild-type (WT) control mice. The development of airway inflammation was assessed by examining leukocyte influx into bronchoalveolar lavage (BAL) fluid and the lung. Total and differential BAL leukocyte counts were determined, and the immunophenotype of BAL lymphocytes was assessed by means of flow cytometry, The development of AHR was assessed by means of whole-body plethysmography, Results: Airway-lung inflammation was equivalent in LKO and WT mice sensitized-challenged with OVA, as measured by total and differential BAL cell counts and histologic analysis of lung tissue. Numbers of eosinophils, neutrophils, lymphocytes, and monocytes in BAL fluid were equivalent in LKO and WT mice. However, phenotypic analysis of BAL lymphocytes demonstrated significantly reduced CD3(+) populations and increased B220(+) populations in LKO compared with WT mice (P < .05). Remarkably, despite a fulminant inflammatory response in the airway-lung in LKO mice sensitized-challenged with OVA, AHR was completely abrogated, Conclusion: L-Selectin plays a crucial role in the development of AHR but not allergic inflammation in an animal model of asthma, L-Selectin represents a potential target for novel asthma therapies specifically aimed at controlling AHR.	Royal Childrens Hosp, Dept Immunol, Parkville, Vic 3052, Australia; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Duke Univ, Med Ctr, Dept Immunol, Durham, NC USA	Royal Children's Hospital Melbourne; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University	Tang, MLK (corresponding author), Royal Childrens Hosp, Dept Immunol, Flemington Rd, Parkville, Vic 3052, Australia.			Tang, Mimi/0000-0002-3839-5293	NIDDK NIH HHS [5T35 DK0386-20] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Asher MI, 1998, EUR RESPIR J, V12, P315; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; Borger P, 1999, CLIN EXP ALLERGY, V29, P772; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150, DOI 10.1164/ajrccm.160.4.9806034; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; FLINT KC, 1985, BRIT MED J, V291, P923, DOI 10.1136/bmj.291.6500.923; GEBB SA, 1995, J APPL PHYSIOL, V79, P493, DOI 10.1152/jappl.1995.79.2.493; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819, DOI 10.1164/ajrccm.155.3.9117011; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; KELLY C, 1988, THORAX, V43, P684, DOI 10.1136/thx.43.9.684; KERAMIDARIS E, IN PRESS J ALLERGY C; KIRBY DA, 1987, CIRC RES, V61, P678, DOI 10.1161/01.RES.61.5.678; Lotvall J, 1998, THORAX, V53, P419, DOI 10.1136/thx.53.5.419; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; Nishio K, 1998, AM J RESP CRIT CARE, V157, P599, DOI 10.1164/ajrccm.157.2.9704102; Pauwels RA, 1997, AM J RESP CRIT CARE, V156, pS78, DOI 10.1164/ajrccm.156.4.12-tac-1; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; SPERTINI O, 1991, J IMMUNOL, V147, P2565; Steeber DA, 1998, J IMMUNOL, V161, P6638; Tang MLK, 1998, J IMMUNOL, V160, P5113; Tang MLK, 1997, J IMMUNOL, V158, P5191; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WOOLLEY KL, 1994, EUR RESPIR J, V7, P1576, DOI 10.1183/09031936.94.07091576; Yamaguchi K, 1997, LAB INVEST, V76, P809	38	42	44	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					1019	1024		10.1067/mai.2001.114703	http://dx.doi.org/10.1067/mai.2001.114703			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	445JR	11398079				2022-12-18	WOS:000169454800013
J	Donahue, JG; Fuhlbrigge, AL; Finkelstein, JA; Fagan, J; Livingston, JM; Lozano, P; Platt, R; Weiss, ST; Weiss, KB				Donahue, JG; Fuhlbrigge, AL; Finkelstein, JA; Fagan, J; Livingston, JM; Lozano, P; Platt, R; Weiss, ST; Weiss, KB		Pediat Asthma Care Patient Outcome	Asthma pharmacotherapy and utilization by children in 3 managed care organizations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; inhaled corticosteroids; cromolyn; bronchodilators; hospitalization; practice guidelines	HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION RATES; UNITED-STATES; MEDICATION USE; MORTALITY; TRENDS; GUIDELINES; PATTERNS; POVERTY; THERAPY	Background: Asthma is the most common chronic disease among children and the most frequent cause of hospitalization, Appropriate pharmacotherapy is a cornerstone of published national guidelines for the care of children with asthma. Objective: The goal was to compare the baseline pharmacotherapy and health care utilization from 1996 to 1997 in children with asthma at managed care organizations (MCOs). Methods: A common protocol was used to extract the study sample from 3 MCOs with automated claims and pharmacy databases. Children mere selected if they were 3 to 15 gears old as of June 1997 with 1 or more encounters (outpatient, emergency department visit, hospitalization) with an asthma diagnosis in the previous year Results: Of the 13,352 children studied, less than 40% were given controllers during the 12-month interval, with ranges of 15% to 77% by level of bronchodilator use, 31% to 44% by age, and 38% to 42% by MCO. Among children given 6 or more bronchodilators, controller dispensing ranged from 73% to 89%, among the 3 MCOs. Variability was most evident for inhaled corticosteroids, for which dispensing ranged from 51% to 70%. Rates of asthma hospitalization and emergency department visits also differed among the MCOs, ranging from 21 to 37 per 1000 person-gears and 37 to 142 per 1000 person-years, respectively, Conclusion: Five years after dissemination of national guidelines for care, the pattern of asthma therapy does not reflect guideline recommendations. Variation among health care organizations with respect to asthma therapy and utilization of health services exists. In addition, controller medications may not be used by all children who could benefit from them.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA; Grp Hlth Cooperat Puget Sound, Seattle, WA USA	Harvard University; Brigham & Women's Hospital; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School; Rush University; Group Health Cooperative	Weiss, KB (corresponding author), Ctr Hlth Serv Res, 1653 W Congress Pkwy, Chicago, IL 60612 USA.		Lozano, Paula Maria/GPP-4090-2022		AHRQ HHS [HS08368-01] Funding Source: Medline; NHLBI NIH HHS [1 K08 HL03919-01] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008368] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003919] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PF, 1995, VITAL HLTH STAT, V10, P83; ADAMS RJ, 2000, IN PRESS PEDIATRICS; Bisgaard H, 1997, PEDIATR PULM, P27; Boushey HA, 1998, J ALLERGY CLIN IMMUN, V102, pS5, DOI 10.1016/S0091-6749(98)70001-6; Buchner DA, 1997, AM J MANAG CARE, V3, P87; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Donahue JG, 1997, J ASTHMA, V34, P273, DOI 10.3109/02770909709067217; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; EVANS R, 1987, CHEST, V91, pS65, DOI 10.1378/chest.91.6_Supplement.65S; Goodman DC, 1999, PEDIATRICS, V104, P187, DOI 10.1542/peds.104.2.187; Goodman DC, 1998, PEDIATRICS, V101, P208, DOI 10.1542/peds.101.2.208; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; GRAVES EJ, 1999, VITAL HLTH STAT, V13, P20; HANRAHAN JP, 1992, POST MARKETING SURVE, V6, P23; Jatulis DE, 1998, ANN ALLERG ASTHMA IM, V81, P82, DOI 10.1016/S1081-1206(10)63113-4; Lozano P, 1997, PEDIATRICS, V99, P757, DOI 10.1542/peds.99.6.757; Lozano P, 1999, J ALLERGY CLIN IMMUN, V104, P957, DOI 10.1016/S0091-6749(99)70075-8; Mannis MJ, 1998, CORNEA, V17, P1; MARTINEZ RD, 1997, PEDIAT PULMONOL, V15, pS9; *NAT ASTHM ED PREV, 1991, NIH NAT HEART LUNG B; *NAT ASTHM ED PREV, 1997, NIH NAT HEART LUNG B; OSBORNE ML, 1992, J CLIN EPIDEMIOL, V45, P403, DOI 10.1016/0895-4356(92)90041-K; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; PERRIN JM, 1994, PEDIATR ANN, V23, P676, DOI 10.3928/0090-4481-19941201-08; Platt R., 1994, PHARMACOEPIDEM DR S, P277; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P456; Simon GE, 1996, J CLIN EPIDEMIOL, V49, P1067, DOI 10.1016/0895-4356(96)00139-4; Stempel DA, 1997, ANN ALLERG ASTHMA IM, V79, P517, DOI 10.1016/S1081-1206(10)63059-1; STEMPEL DA, 1999, ANN ALLERG ASTHMA IM, V76, P153; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; 1995, MMWR MORB MORTAL WKL, V44, P609	35	42	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1108	1114		10.1067/mai.2000.111432	http://dx.doi.org/10.1067/mai.2000.111432			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	384ER	11112894	Bronze			2022-12-18	WOS:000165930300013
J	Laberge, S; Pinsonneault, S; Varga, EM; Till, SJ; Nouri-Aria, K; Jacobson, M; Cruikshank, WW; Center, DM; Hamid, Q; Durham, SR				Laberge, S; Pinsonneault, S; Varga, EM; Till, SJ; Nouri-Aria, K; Jacobson, M; Cruikshank, WW; Center, DM; Hamid, Q; Durham, SR			Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IL-16; segmental challenge; lymphocyte; chemotaxis	LYMPHOCYTE CHEMOATTRACTANT FACTOR; BROWN-NORWAY RATS; CD4(+) T-CELLS; ATOPIC ASTHMA; MESSENGER-RNA; AIRWAY HYPERRESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; HUMAN EOSINOPHILS; MAST-CELLS; CD4+	Background: We have previously shown increased expression of the CD4(+) cell chemoattractant IL-16 in bronchial mucosa of patients with asthma, We investigated the effects of allergen challenge on airway IL-16 expression, Methods: We investigated the expression of IL-16 immunoreactivity in bronchial biopsy samples obtained from atopic asthmatic subjects (n = 19) and normal subjects (n = 6) 24 hours after segmental allergen challenge. Control biopsy samples were obtained either at baseline or after diluent challenge. IL-16 expression was correlated to numbers of CD4(+) cells, CD25(+) cells, and activated eosinophils. IL-16 bioactivity was assessed in bronchoalveolar fluid obtained from patients with asthma. Results: IL-16 expression was higher in control biopsy specimens obtained from subjects with asthma compared with normal subjects (P < .05). In patients with asthma, numbers of IL-16 immunoreactive cells were significantly higher in biopsy specimens obtained after allergen challenge compared with control biopsy specimens (P < .001). Allergen provocation was associated with release of IL-16 in bronchoalveolar fluid in patients with asthma, In normal subjects, there was no difference in the number of IL-16-immunoreactive cells in biopsy specimens obtained after allergen challenge compared with biopsy specimens obtained after diluent challenge. Allergen challenge was associated with an increase in the numbers of EG2(+) eosinophils in patients with asthma but not in normal subjects. IL-16 expression correlated with the numbers of CD4+ cells and CD25+ cells after allergen challenge in asthmatic subjects with a provocative concentration required to decrease the FEV1 by 20% of its baseline value (PC20FEV1) < 4 mg/mL. IL-16-immunoreactive tells were identified mainly as T cells and eosinophils in asthmatic subjects after allergen challenge. Conclusion: Endobronchial allergen provocation in atopic asthmatic patients resulted in increased airway expression of IL-16 and release of bioactive IL-16 in airways. IL-16 may contribute to the immunoregulation of the inflammatory infiltrate in the airways in response to antigen.	Univ Montreal, Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Natl Heart & Lung Inst, Imperial Coll, Sch Med, London, England; Boston Univ, Ctr Pulm, Sch Med, Boston, MA 02215 USA; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada	Universite de Montreal; Imperial College London; Boston University; McGill University	Laberge, S (corresponding author), Univ Montreal, Hop St Justine, Dept Pediat, 3175 Cote St Catherine, Montreal, PQ H3T 1C5, Canada.			Center, David/0000-0002-5879-7978; Till, Stephen/0000-0003-4518-3093				Arima M, 1999, AM J RESP CELL MOL, V21, P684, DOI 10.1165/ajrcmb.21.6.3671; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BERMAN JS, 1990, AM REV RESPIR DIS, V142, P238, DOI 10.1164/ajrccm/142.1.238; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; Cruikshank WW, 1996, J IMMUNOL, V157, P5240; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; CRUIKSHANK WW, 1987, J IMMUNOL, V138, P3817; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587, DOI 10.1165/ajrcmb.10.6.8003337; Haczku A, 1997, IMMUNOLOGY, V91, P176, DOI 10.1046/j.1365-2567.1997.d01-2221.x; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hessel EM, 1998, J IMMUNOL, V160, P2998; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Laberge S, 1999, INT ARCH ALLERGY IMM, V119, P120, DOI 10.1159/000024186; Laberge S, 1998, J ALLERGY CLIN IMMUN, V102, P645, DOI 10.1016/S0091-6749(98)70282-9; Laberge S, 1997, J ALLERGY CLIN IMMUN, V100, P569, DOI 10.1016/S0091-6749(97)70152-0; Laberge S, 1997, AM J RESP CELL MOL, V17, P193, DOI 10.1165/ajrcmb.17.2.2750; Lim KG, 1996, J IMMUNOL, V156, P2566; Mishima H, 1998, AM J RESP CRIT CARE, V158, P1863, DOI 10.1164/ajrccm.158.6.9709123; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Parada NA, 1998, J IMMUNOL, V160, P2115; PAUL WE, 1991, BLOOD, V77, P1859; Rajakulasingam K, 1998, AM J RESP CRIT CARE, V158, P233, DOI 10.1164/ajrccm.158.1.9708106; RAND TH, 1991, J EXP MED, V173, P1521, DOI 10.1084/jem.173.6.1521; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rumsaeng V, 1997, J IMMUNOL, V159, P2904; Theodore AC, 1996, J IMMUNOL, V157, P1958; WATANABE A, 1995, J CLIN INVEST, V96, P1303, DOI 10.1172/JCI118165; Wu D, 1996, AM J RESP CELL MOL B, V153, pA208	32	42	45	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					293	301						9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	343NH	10932073				2022-12-18	WOS:000088708100012
J	Arquint, O; Helbling, A; Crameri, R; Ferreira, F; Breitenbach, M; Pichler, WJ				Arquint, O; Helbling, A; Crameri, R; Ferreira, F; Breitenbach, M; Pichler, WJ			Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						type I allergy; recombinant Bet v 1; recombinant isoforms; skin prick test; intradermal test; conjunctival provocation test	POTENTIAL USE; IMMUNOTHERAPY; BET-V-1; PURIFICATION; ALLERGY; SPECIFICITY; EXPRESSION; REACTIVITY; DIAGNOSIS; IGE	Background: The major allergen of birch pollen, Bet v 1, is present in structurally slightly different isoforms, It has been postulated that certain isoforms show a distinct ability to bind birch pollen-specific IgE, although the T-cell response remains similar. Objective: We verified the hypothesis of a distinct allergenicity but similar T-cell immunogenicity of 2 isoforms in birch pollen-allergic subjects by in vivo tests and an in vitro assay for T-cell stimulation. Methods: Forty-eight birch pollen-allergic, 11 grass pollen-allergic, and 10 nonatopic control individuals n ere tested with 10-fold increasing concentrations (0.01 to 10.0 mu g/mL) of recombinant (r) Bet v la and rBet v Id by skin prick test (SPT), intradermal test (IDT), and conjunctival provocation test (CPT), An allergen-specific proliferation assay was performed on 21 patients with the 2 recombinant and the natural birch pollen allergens. Results: In each test system only birch pollen-allergic subjects but no controls reacted to the recombinant allergens. A positive in vivo response to 10 mu g/mL of rBet v la was observed in 21 of 48 by SPT, in 48 of 38 by IDT, and in 33 of 48 by CPT. In contrast, the IDT response to 10 mu g/mL of rBet v Id was reduced by a factor of 100 because it was equivalent to the response to 0.1 mu g/mL of rBet v la, rBet v Id failed to elicit a positive reaction in SPT and CPT The proliferative response of T cells was similar for both recombinant isoforms because 8 of 21 individuals reacted to rBet v Ia and 6 of 21 to rBet v Id. Only I subject had a positive reaction to rBet v Id alone. Conclusion: The natural isoforms rBet v la and rBet v Id differ in their ability to bind IgE but are similar in their immunogenicity for T cells. Thus rBet v Id might be a promising candidate for use in immunotherapy of birch pollen-allergic individuals.	Univ Bern, Inselspital, Div Allergol, CH-3010 Bern, Switzerland; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Salzburg Univ, Inst Genet & Gen Biol, Salzburg, Austria	University of Bern; University Hospital of Bern; Swiss Institute of Allergy & Asthma Research; Salzburg University	Pichler, WJ (corresponding author), Univ Hosp Bern, Inst Immunol & Allergol, CH-3010 Bern, Switzerland.		Ferreira, Fatima/AAB-4321-2019; Ferreira, Fatima/E-4889-2011	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Pichler, Werner J./0000-0002-8117-359X				ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84, DOI 10.1001/archopht.1990.01070030090035; Boehm M, 1997, BIOL CHEM, V378, P687, DOI 10.1515/bchm.1997.378.7.687; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; DREBORG S, 1984, ALLERGY, V40, P55; Ferreira F, 1997, INT ARCH ALLERGY IMM, V113, P125, DOI 10.1159/000237524; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; GAIJHEDE M, 1996, NAT STRUCT BIOL, V3, P1040; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; Muller U, 1997, CLIN EXP ALLERGY, V27, P915, DOI 10.1111/j.1365-2222.1997.tb01233.x; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175, DOI 10.1111/j.1365-2222.1997.tb00690.x; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607	17	42	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1999	104	6					1239	1243		10.1016/S0091-6749(99)70019-9	http://dx.doi.org/10.1016/S0091-6749(99)70019-9			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	266FD	10589007	Bronze			2022-12-18	WOS:000084289200019
J	Chan-Yeung, M; Ferguson, A; Chan, H; Dimich-Ward, H; Watson, W; Manfreda, J; Becker, A				Chan-Yeung, M; Ferguson, A; Chan, H; Dimich-Ward, H; Watson, W; Manfreda, J; Becker, A			Umbilical cord blood mononuclear cell proliferative response to house dust mite does not predict the development of allergic rhinitis and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cord blood; mononuclear cell proliferation; house dust mite; development of asthma and allergic diseases	INTERFERON-GAMMA PRODUCTION; ENVIRONMENTAL ALLERGENS; INHALANT ALLERGENS; ATOPY; FOOD; SENSITIZATION; REACTIVITY; INFANCY; RISK	Background: Cord blood mononuclear cells (CBMNCs) have been found to proliferate when stimulated with food or inhalant allergens. The significance of this finding is not known. Objectives: We sought to determine the factors associated with proliferation of CBMNCs when stimulated with house dust mite (HDM) allergen and to determine whether proliferation of CBMNCs is associated with subsequent development of HDM sensitization and development of allergic rhinitis and asthma. Methods: Cord blood was taken from infants at high risk for having asthma and allergic diseases who were recruited for a primary prevention study in which infants were randomized into the intervention or the control group. CBMNCs were stimulated with HDM allergen and PAA as a positive control. Infants were assessed at 12 and 24 months for health outcome. Results: When stimulated with HDM allergen, 29.7% of infants had a stimulation index (SI) of 2 or greater. There were no differences in the levels of cord blood IgE and cotinine, maternal smoking, immediate skin test reactivity, maternal IgE, and maternal exposure to HDM allergen between those with an SI of 2 or greater and those with an SI of less than 2. Infants with an SI of less than 2 had a significantly higher proportion of mothers with a history of asthma. No differences in the incidence of "asthma" and rhinitis without cold at 12 months and cumulative prevalence at 24 months were seen between the 2 groups. None of the infants had skin test reactions to ADM allergen. Conclusion: The negative association between HDM allergen-induced proliferation of CBMNCs and maternal mite allergen exposure and health outcomes at 12 and 24 months raises the issue of the significance of CBMNC proliferation.	Univ British Columbia, Dept Med, Occupat & Environm Lung Dis Unit, Vancouver, BC, Canada; Univ British Columbia, Dept Pediat, Div Allergy, Vancouver, BC V6T 1W5, Canada; Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Med & Community Hlth Sci, Winnipeg, MB, Canada	University of British Columbia; University of British Columbia; University of Manitoba; University of Manitoba	Chan-Yeung, M (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam Rd, Hong Kong, Peoples R China.			Ferguson, Alexander C./0000-0002-3143-5619				Burney P, 1996, EUR RESPIR J, V9, P687; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; CHANYEUNG M, 1998, AM J RESP CRIT CARE, V157, pA12; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; KONDO N, 1992, ARCH DIS CHILD, V67, P1003, DOI 10.1136/adc.67.8.1003; LIN H, 1993, J IMMUNOL, V151, P4562; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358, DOI 10.1159/000236692; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; SZEPFALUSI Z, 1995, INT ARCH ALLERGY IMM, V107, P595, DOI 10.1159/000237106; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; VANVUNAKIS H, 1987, ENV CARCINOGENS METH, V9; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D	23	42	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				317	321		10.1016/S0091-6749(99)70373-8	http://dx.doi.org/10.1016/S0091-6749(99)70373-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452751				2022-12-18	WOS:000082364800022
J	Naclerio, R				Naclerio, R			Clinical manifestations of the release of histamine and other inflammatory mediators	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PERENNIAL ALLERGIC RHINITIS; SUBSTANCE-P; TOPICAL CORTICOSTEROIDS; NASAL CHALLENGE; BRADYKININ; ASTHMA; PATHOPHYSIOLOGY; ANTIHISTAMINES; METHACHOLINE; LEUKOTRIENES	This article reviews the symptoms that are characteristic of the early- and late-phase allergic reaction, Each of the cardinal symptoms of seasonal allergic rhinitis (sneezing, pruritus, rhinorrhea, congestion) is discussed, as is the role of various chemical mediators in the expression of these clinical manifestations.	Univ Chicago, Chicago, IL 60637 USA	University of Chicago	Naclerio, R (corresponding author), Univ Chicago, Chicago, IL 60637 USA.							BARANIUK JN, 1990, AM REV RESPIR DIS, V141, P706, DOI 10.1164/ajrccm/141.3.706; BOUSQUET J, 1990, RESP MED, V84, P11, DOI 10.1016/S0954-6111(08)80002-9; COHAN VL, 1989, AM REV RESPIR DIS, V140, P951, DOI 10.1164/ajrccm/140.4.951; Davies RJ, 1996, CLIN EXP ALLERGY, V26, P11, DOI 10.1111/j.1365-2222.1996.tb00653.x; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; Djukanovic R, 1996, CLIN EXP ALLERGY, V26, P44, DOI 10.1111/j.1365-2222.1996.tb00659.x; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734, DOI 10.1164/ajrccm.151.6.7767514; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; DRUCE HM, 1988, JAMA-J AM MED ASSOC, V259, P260, DOI 10.1001/jama.259.2.260; Fajac I, 1995, ALLERGY, V50, P970, DOI 10.1111/j.1398-9995.1995.tb02509.x; GRONBORG H, 1993, ALLERGY, V48, P87, DOI 10.1111/j.1398-9995.1993.tb00691.x; HOLBROOK KA, 1993, ALLERGY PRINCIPLES P, P390; HOWARTH PH, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb02734.x; Howarth PH, 1997, ALLERGY, V52, P12, DOI 10.1111/j.1398-9995.1997.tb04878.x; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; Knapp H R, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P279; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; Levenson T, 1997, ALLERGY ASTHMA PROC, V18, P213, DOI 10.2500/108854197778594016; Meltzer EO, 1997, ALLERGY, V52, P33, DOI 10.1111/j.1398-9995.1997.tb04820.x; Monroe EW, 1997, J ALLERGY CLIN IMMUN, V99, pS798, DOI 10.1016/S0091-6749(97)70128-3; Mygind N, 1996, CLIN EXP ALLERGY, V26, P2, DOI 10.1111/j.1365-2222.1996.tb00652.x; Mygind N, 1996, CLIN EXP ALLERGY, V26, P39, DOI 10.1111/j.1365-2222.1996.tb00658.x; Naclerio R, 1997, JAMA-J AM MED ASSOC, V278, P1842, DOI 10.1001/jama.278.22.1842; Naclerio RM, 1996, J ALLERGY CLIN IMMUN, V98, P721, DOI 10.1016/S0091-6749(96)70118-5; NACLERIO RM, 1991, AM REV RESPIR DIS, V143, pS91, DOI 10.1164/ajrccm/143.5_Pt_2.S91; Naclerio RM, 1997, ALLERGY, V52, P7, DOI 10.1111/j.1398-9995.1997.tb04816.x; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NACLERIO RM, 1993, ALLERGY PRINCIPLES P, P740; NACLERIO RM, 1991, N ENGL J MED, V325, P830; NOMURA Y, 1972, ACTA OTO-LARYNGOL, V73, P493, DOI 10.3109/00016487209138970; OKAMOTO Y, 1993, J IMMUNOL, V151, P4391; OKUDA M, 1988, ANN ALLERGY, V60, P537; PROUD D, 1988, AM REV RESPIR DIS, V137, P613, DOI 10.1164/ajrccm/137.3.613; PROUD D, 1994, BRAZ J MED BIOL RES, V27, P2021; Rachelefsky G, 1997, J PEDIATR-US, V131, P348, DOI 10.1016/S0022-3476(97)80057-1; RAJAKULASINGAM K, 1993, THORAX, V48, P324, DOI 10.1136/thx.48.4.324; RICCIO MM, 1995, AM J RESP CRIT CARE, V152, P1757, DOI 10.1164/ajrccm.152.6.8520734; SCHLEIMER RP, 1982, J IMMUNOL, V129, P1632; SVENSSON C, 1989, THORAX, V44, P13, DOI 10.1136/thx.44.1.13; WAGENMANN M, 1994, J ALLERGY CLIN IMMUN, V93, P594, DOI 10.1016/S0091-6749(94)70071-0; WHITE MV, 1992, J ALLERGY CLIN IMMUN, V90, P699, DOI 10.1016/0091-6749(92)90155-U; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4	42	42	42	1	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1999	103	3	2	S			S382	S385		10.1016/S0091-6749(99)70216-2	http://dx.doi.org/10.1016/S0091-6749(99)70216-2			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	179CL	10069897	Bronze			2022-12-18	WOS:000079305900003
J	Laoprasert, N; Swanson, MC; Jones, RT; Schroeder, DR; Yunginger, JW				Laoprasert, N; Swanson, MC; Jones, RT; Schroeder, DR; Yunginger, JW			Inhalation challenge testing of latex-sensitive health care workers and the effectiveness of laminar flow HEPA-filtered helmets in reducing rhinoconjunctival and asthmatic reactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex allergy; inhalation challenge tests; latex aeroallergens; health care workers	OCCUPATIONAL ASTHMA; GLOVES	Background: There are few data relating latex aeroallergen concentrations to biologic responses in latex-sensitized persons. Objectives: We sought to investigate acceptable latex aeroallergen concentrations below which latex-sensitive health care workers do not experience symptoms and to study the effect of high-efficiency particle arrest (HEPA)-filtered laminar flow helmets in preventing latex-induced symptoms. Methods: Under challenge chamber conditions, latex-sensitive health care workers underwent 7 sequential inhalation challenge tests by donning and discarding either vinyl gloves (challenge 1), low latex-allergen powder-free gloves (challenge 2), or high latex-allergen powdered gloves (challenges 3 to 7) for up to 1 hour. Volunteers wore a laminar flow helmet during all challenges; HEPA biters in the helmet were in place only during challenges 3 and 4. Flow-volume loops, symptom scores, and latex aeroallergen concentrations were measured before and during each test. Results: At 60 minutes, latex aeroallergen concentrations during challenges 3 to 7 (mean, 7600 ng/m(3); range, 93 to 54,000 ng/m3) were significantly higher than during challenges 1 or 2 (mean, 65 ng/m(3); range, nondetectable to 100 ng/m(3)) (P < .001). During challenges 5 and 6, mean maximum percent falls in FEV1 (-16% and -11%, respectively) were significantly greater compared with those measured during challenges 3 and 4 (-3% and -1%, respectively) (P = .03). Mean maximum change from baseline symptom scores during challenges 5 and 6 was significantly higher than that during challenges 3 and 4 (P = .006), During challenges with high latex-allergen gloves, 4 volunteers had reproducible FEV1 falls of 20% or greater at cumulative inhaled latex aeroallergen doses ranging from less than 100 ng to 1500 ng. Conclusion: The laminar flow helmets were effective in reducing latex-induced symptoms. Only 1 volunteer exhibited a fall in FEV1 of 20% or greater after a cumulative inhaled latex aeroallergen dose of less than 100 ng, and no volunteer showed a decline in FEV1 after exposure to powder-free low allergen gloves.	Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Biostat Sect, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Grad Sch Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Yunginger, JW (corresponding author), Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, 406 Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.							[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1987, GUID VAL LIM AM LYS; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; BRUGNAMI G, 1995, J ALLERGY CLIN IMMUN, V96, P457, DOI 10.1016/S0091-6749(95)70287-3; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; MILTON DK, 1995, AM J IND MED, V28, P469, DOI 10.1002/ajim.4700280404; PISATI G, 1994, EUR RESPIR J, V7, P332, DOI 10.1183/09031936.94.07020332; SWANSON MC, 1994, J ALLERGY CLIN IMMUN, V94, P445, DOI 10.1016/0091-6749(94)90199-6; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; Williams P. B., 1997, Journal of Allergy and Clinical Immunology, V99, pS266; WILLIAMS PB, 1997, ANN ALLERG ASTHMA IM, V78, P84	12	42	43	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				998	1004		10.1016/S0091-6749(98)70338-0	http://dx.doi.org/10.1016/S0091-6749(98)70338-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847441				2022-12-18	WOS:000077690700018
J	Menzies, D; Comtois, P; Pasztor, J; Nunes, F; Hanley, JA				Menzies, D; Comtois, P; Pasztor, J; Nunes, F; Hanley, JA			Aeroallergens and work-related respiratory symptoms among office workers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						building-related illness; aeroallergens; respiratory symptoms; house dust mites; Alternaria spp.	SICK-BUILDING SYNDROME; INDOOR AIR-QUALITY; HYPERSENSITIVITY PNEUMONITIS; VENTILATION SYSTEMS; VARYING LEVELS; DUST; EXPOSURE; ASTHMA; BACTERIA	Objective: We sought to determine the association between office workers' respiratory tract symptoms and immediate skin test reactions with exposure to fungal and house dust mite aeroallergens at their work sites. Methods: An initial prevalence survey was conducted among 1102 full-time workers in six mechanically ventilated, air-conditioned, nonindustrial buildings in downtown Montreal. Detailed environmental measures of 214 subjects' work sites were determined, Half of the workers reported frequent work-related respiratory tract symptoms on the initial survey. Participants simultaneously underwent allergy skin prick testing and completed a second self-administered questionnaire. Results: Contaminant levels were low and not associated with symptoms in the great majority of workers. For approximately 17% of workers, symptoms were associated with exposure to total concentrations of house dust mite allergen greater than 1 mu g/gm floor dust (odds ratio [OR], 5.0; 95% confidence interval [CI], 1.3, 19.5]) or to detectable airborne Alternaria allergens in their offices (OR 3.3; 95% CI, 1.2, 9.4) and in the ventilation system supplying their offices (OR, 3.9; 95% CI, 1.6, 9.6). Workers with positive skin test reactions to Alternaria extract were exposed at their work site to airborne Alternaria allergen (OR, 4.4; 95% CI, 1.4, 14.5) and cited significantly more respiratory symptoms on both questionnaires. Detection of airborne Alternaria allergen at work sites was significantly associated with detection in the ventilation system (OR, 4.0; 95% CI, 1.4, 10.9); this was in turn associated with lower efficiency filters. Conclusions: Potentially avoidable exposure to aeroallergens accounted for symptoms in a small subgroup of office workers with frequent work-related respiratory tract symptoms.	McGill Univ, Resp Epidemiol Unit, Montreal, PQ H3A 1A3, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3A 1A3, Canada; Univ Montreal, Dept Geog, Aerobiol Lab, Montreal, PQ H3A 1A3, Canada	McGill University; McGill University; Universite de Montreal	Menzies, D (corresponding author), McGill Univ, Resp Epidemiol Unit, 1110 Pine Ave W, Montreal, PQ H3A 1A3, Canada.							BANASZAK EF, 1970, NEW ENGL J MED, V283, P271, DOI 10.1056/NEJM197008062830601; BERNSTEIN L, 1988, J ALLERGY CLIN IMM S, P488; BERNSTEIN RS, 1983, AM IND HYG ASSOC J, V44, P161, DOI 10.1080/15298668391404581; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; BURR ML, 1988, J R SOC HLTH, V78, P99; DALES RE, 1991, AM REV RESPIR DIS, V143, P505, DOI 10.1164/ajrccm/143.3.505; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; ELIXMANN JH, 1990, INDOOR AIR 90, V1; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GRAVESEN S, 1986, ALLERGY, V41, P520, DOI 10.1111/j.1398-9995.1986.tb00337.x; HODGSON M, 1995, OCCUP MED, V10, P167; HODGSON MJ, 1991, J OCCUP ENVIRON MED, V33, P527; HUGENHOLTZ P, 1992, APPL ENVIRON MICROB, V58, P3914, DOI 10.1128/AEM.58.12.3914-3920.1992; JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755, DOI 10.1093/oxfordjournals.aje.a117498; Mendell MJ, 1996, EPIDEMIOLOGY, V7, P583, DOI 10.1097/00001648-199611000-00004; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; Menzies D, 1996, AM J PUBLIC HEALTH, V86, P1629, DOI 10.2105/AJPH.86.11.1629; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; NEUMEISTER H, 1996, IAQ 96, V1, P125; NORBACK D, 1990, SCAND J WORK ENV HEA, V16, P121, DOI 10.5271/sjweh.1808; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Pasanen P., 1993, INDOOR AIR, V3, P106; ROBERTSON AS, 1985, BRIT MED J, V291, P373, DOI 10.1136/bmj.291.6492.373; ROBY RR, 1979, ANN ALLERGY, V43, P286; Rogers R.R., 1989, SHORT COURSE CLOUD P; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SKOV P, 1989, SCAND J WORK ENV HEA, V15, P286, DOI 10.5271/sjweh.1851; SKOV P, 1990, SCAND J WORK ENV HEA, V16, P363, DOI 10.5271/sjweh.1772; SMORAGIEWICZ W, 1993, INT ARCH OCC ENV HEA, V65, P113, DOI 10.1007/BF00405729; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339; TURIEL I, 1983, ATMOS ENVIRON, V17, P51, DOI 10.1016/0004-6981(83)90007-0; Wallace L. A., 1993, INDOOR AIR, V3, P193, DOI [10.1111/j.1600-0668.1993.t01-1-00005.x, DOI 10.1111/J.1600-0668.1993.T01-1-00005.X]; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOODARD ED, 1988, JAMA-J AM MED ASSOC, V259, P1965, DOI 10.1001/jama.259.13.1965; Zweers T, 1992, INDOOR AIR, V2, P127, DOI DOI 10.1111/J.1600-0668.1992.00001.X; [No title captured]	40	42	43	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1998	101	1	1				38	44		10.1016/S0091-6749(98)70191-5	http://dx.doi.org/10.1016/S0091-6749(98)70191-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YR872	9449499				2022-12-18	WOS:000071539800007
J	Houba, R; vanRun, P; Doekes, G; Heederik, D; Spithoven, J				Houba, R; vanRun, P; Doekes, G; Heederik, D; Spithoven, J			Airborne levels of alpha-amylase allergens in bakeries	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; bakery workers; enzymes; alpha-amylase; allergy; exposure assessment	OCCUPATIONAL ASTHMA; EXPOSURE; FLOUR; HYPERSENSITIVITY; ENZYMES	Background: In the baking industry the use of enzymes has increased throughout the 1980s. Several studies have reported sensitization and respiratory disorders among bakery workers caused by enzymes in dough improvers. Fungal alpha-amylase is the most frequently reported cause of allergy, alpha-Amylase allergen exposure levels in the bakery industry, however, have not yet been reported. Objective: The main objective of this study was to quantify personal alpha-amylase exposure levels of bakery workers. Methods: alpha-Amylase allergens mere measured in 507 personal samples of airborne dust taken in bakeries by using a newly developed sandwich enzyme immunoassay with affinity-purified polyclonal rabbit IgG antibodies. A cascade impactor was used to estimate the size of dust particles carrying alpha-amylase allergens. Results: The rabbit IgG antibodies used in the assay showed, in immunoblotting with commercially available alpha-amylase, a reaction profile very similar to that of IgE from sensitized bakers. The enzyme immunoassay appeared to be highly specific for fungal amylase. Allergen exposure levels varied considerably among bakery workers, depending on the type of bakery and job category (range, 0 to 40 ng/m(3)). In confectioneries no alpha-amylase allergens were detected. In other bakeries alpha-amylase exposure was only found for workers directly involved in dough making. Measurements of the particle size distribution in these bakeries showed that alpha-amylase allergens are most likely to be deposited in the nose and ciliated airways. Conclusion: This study shows that personal monitoring of fungal amylase allergen exposure in bakeries is possible. This permits the identification of high-risk tasks and allergen sources, as well as the study of exposure-response relationships.	WAGENINGEN UNIV AGR,DEPT EPIDEMIOL & PUBL HLTH,NL-6700 AE WAGENINGEN,NETHERLANDS	Wageningen University & Research				Heederik, Dick/0000-0002-4550-1437				*ACGIH, 1986, DOC THRESH LIM VAL B; AGARWAL MK, 1986, AM IND HYG ASSOC J, V47, P138, DOI 10.1080/15298668691389469; BAUR X, 1988, DEUT MED WOCHENSCHR, V113, P1275, DOI 10.1055/s-2008-1067805; BAUR X, 1994, CLIN EXP ALLERGY, V24, P465, DOI 10.1111/j.1365-2222.1994.tb00935.x; BAUR X, 1986, LANCET, V1, P43; BERMEJO N, 1991, REV FR ALLERGOL, V31, P56, DOI 10.1016/S0335-7457(05)80308-9; Bernstein David I., 1993, P373; BIRNBAUM J, 1988, REV MAL RESPIR, V5, P519; BRISMAN J, 1991, BRIT J IND MED, V48, P604; BURDORF A, 1994, ANN OCCUP HYG, V38, P67, DOI 10.1093/annhyg/38.1.67; CARMONA JGB, 1991, ALLERGY, V46, P274, DOI 10.1111/j.1398-9995.1991.tb00585.x; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P579, DOI 10.1136/oem.51.9.579; DEZOTTI R, 1994, OCCUP ENVIRON MED, V51, P548, DOI 10.1136/oem.51.8.548; GRIFFIN P, 1994, CLIN EXP ALLERGY, V24, P177; HELSEL DR, 1990, ENVIRON SCI TECHNOL, V24, P1766, DOI 10.1021/es00082a001; Houba R, 1996, CLIN EXP ALLERGY, V26, P154, DOI 10.1111/j.1365-2222.1996.tb00074.x; Houba R, 1996, AM J RESP CRIT CARE, V154, P130, DOI 10.1164/ajrccm.154.1.8680668; Jauhiainen A, 1993, APPL OCCUP ENV HYG, V8, P721; KUILE WM, 1984, STAUB, V44, P211; LATIL F, 1987, J ALLERGY CLIN IMMUN, V73, P153; LIPPMANN M, 1980, BRIT J IND MED, V37, P337; MONEO I, 1995, OCCUP MED-OXFORD, V45, P151, DOI 10.1093/occmed/45.3.151; QUIRCE S, 1992, J ALLERGY CLIN IMMUN, V90, P970, DOI 10.1016/0091-6749(92)90470-M; SANDER I, 1994, J ALLERGY CLIN IMMUN, V93, P265; SANDIFORD CP, 1994, CLIN EXP ALLERGY, V24, P549, DOI 10.1111/j.1365-2222.1994.tb00952.x; SWANSON MC, 1992, AM IND HYG ASSOC J, V53, P1; TARVAINEN K, 1991, CLIN EXP ALLERGY, V21, P609, DOI 10.1111/j.1365-2222.1991.tb00854.x; WIEWRODT R, 1995, ALLERGY S, V50, P37	29	42	42	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					286	292		10.1016/S0091-6749(97)70044-7	http://dx.doi.org/10.1016/S0091-6749(97)70044-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058682	Bronze			2022-12-18	WOS:A1997WM42200003
J	Jordana, G; Dolovich, J; Briscoe, MP; Day, JH; Douin, MA; Gold, M; Robson, R; Stepner, N; Yang, W				Jordana, G; Dolovich, J; Briscoe, MP; Day, JH; Douin, MA; Gold, M; Robson, R; Stepner, N; Yang, W			Intranasal fluticasone propionate versus loratadine in the treatment of adolescent patients with seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fluticasone propionate; loratadine; intranasal corticosteroid; antihistamine; nasal peak inspiratory flow; seasonal allergic rhinitis		Fluticasone propionate (FP) is a topical corticosteroid with minimal systemic activity. We examined safety and compared the efficacy of FP aqueous nasal spray 200 mu g every day with loratadine tablets, 10 mg by mouth every day in 240 adolescents with ragweed pollen-induced seasonal allergic rhinitis for 4 weeks in a randomized, double-blind, parallel-group study. Nasal and eye symptoms were recorded daily on a 4-point (0 to 3) scale. A higher percentage of symptom-free days was observed for nasal blockage on waking during treatment with FP (p < 0.0001). Significant results were also obtained for all other nasal symptoms when analyzed for both symptom-free days and symptom scores. No differences were found for eye irritation symptoms (p = 0.14). Morning and evening nasal peak inspiratory flow (PIF) was recorded daily by 57 subjects. FP treatment was associated with significantly higher PIF values than loratadine both morning (p = 0.0051) and evening (p = 0.0036). A greater improvement over 4 weeks was observed for PIF morning values in the FP group (p = 0.008) but not for evening values (p = 0.358). Statistically significant correlations were found for nasal blockage and PIF in the morning (r = -0.54, p = 0.0001) and in the evening (r = -0.46, p = 0.008).	MCMASTER UNIV,MED CTR,DEPT PEDIAT,HAMILTON,ON L8N 3Z5,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA; UNIV OTTAWA,DEPT MED,OTTAWA,ON,CANADA; HOSP SICK CHILDREN,TORONTO,ON M5G 1X8,CANADA; GLAXO CANADA INC,MISSISSAUGA,ON,CANADA	McMaster University; Queens University - Canada; University of Ottawa; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); GlaxoSmithKline								BRYSON HM, 1992, DRUGS, V43, P760, DOI 10.2165/00003495-199243050-00009; DARNELL R, 1994, CLIN EXP ALLERGY, V24, P1144, DOI 10.1111/j.1365-2222.1994.tb03320.x; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; KALINER M, 1989, MANAGEMENT OF ALLERGY IN THE 1990S, P5; LOZEWICZ S, 1992, J ALLERGY CLIN IMMUN, V89, P951, DOI 10.1016/0091-6749(92)90217-P; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; SIEGEL SC, 1988, J ALLERGY CLIN IMMUN, V81, P984, DOI 10.1016/0091-6749(88)90166-2; STRICKER WE, 1994, ANN ALLERGY, V72, P86; VANAS A, 1991, ANN ALLERGY, V67, P156; VANBAVEL J, 1994, ARCH INTERN MED, V154, P2699, DOI 10.1001/archinte.1994.00420230086010	11	42	42	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1996	97	2					588	595		10.1016/S0091-6749(96)70303-2	http://dx.doi.org/10.1016/S0091-6749(96)70303-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TW087	8621843	Bronze			2022-12-18	WOS:A1996TW08700003
J	Asahina, A; Hosoi, J; Grabbe, S; Granstein, RD				Asahina, A; Hosoi, J; Grabbe, S; Granstein, RD			Modulation of Langerhans cell function by epidermal nerves	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	New Trends in Immunopharmacology 1994 Conference	JUL 23, 1994	TOKYO, JAPAN	Sandoz Pharm Ltd		calcitonin gene-related peptide; Langerhans cells; antigen presentation; nerve; mouse	GENE-RELATED PEPTIDE; HYPERSENSITIVITY REACTIONS; FIBERS ASSOCIATE; IMMUNE-SYSTEM; SUBSTANCE-P; NEUROPEPTIDES; LYMPHOCYTES; CAPSAICIN; COMPARTMENTS; INNERVATION	Many is not most epidermal Langerhans cells appeared to be closely associated anatomically with calcitonin gene-related peptide (CGRP)-containing nerves as determined by confocal laser scanning microscopy. Furthermore, a small proportion of Langerhans cells had immunoreactive CGRP at or near their cell surfaces, suggesting that nerves are capable of depositing CGRP at or near Langerhans cells. CGRP inhibited Langerhans cell antigen-presenting capability for elicitation of delayed-type hypersensitivity in immunized mice to present alloantigens in the mixed epidermal cell-lymphocyte reaction and to present a protein antigen to a responsive hybridoma. As a whole, these data suggest the possibility that products of nerves within the epidermis might serve to regulate Langerhans cell function. The apparent apposition of epidermal nerves with Langerhans cells suggests a possible locus of interaction between the nervous system and the immune system within the skin.	MASSACHUSETTS GEN HOSP EAST, DEPT DERMATOL, CUTANEOUS BIOL RES CTR, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Grabe, Stephan/AAJ-4578-2021	Grabe, Stephan/0000-0002-6863-8719	NIAMS NIH HHS [AR42329] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BHAN AK, 1981, AM J PATHOL, V102, P20; BIEBER T, 1994, IMMUNOL TODAY, V15, P52, DOI 10.1016/0167-5699(94)90132-5; BOUDARD F, 1991, J NEUROSCI RES, V29, P29, DOI 10.1002/jnr.490290104; BULLOCH K, 1985, NEURAL MODULATION IM, P111; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; FELTEN DL, 1987, J NEUROSCI RES, V18, P28, DOI 10.1002/jnr.490180107; GIANNETTI A, 1992, ACTA DERM-VENEREOL, P90; GIANNETTI A, 1989, BRIT J DERMATOL, V121, P681, DOI 10.1111/j.1365-2133.1989.tb08209.x; GIBBINS IL, 1987, BRAIN RES, V414, P143, DOI 10.1016/0006-8993(87)91335-7; GIROLOMONI G, 1990, J IMMUNOL, V145, P1105; GIROLOMONI G, 1992, ANN NY ACAD SCI, V650, P9; GRABBE S, 1994, CHEM IMMUNOL, V58, P291; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0; KHANSARI DN, 1990, IMMUNOL TODAY, V11, P170, DOI 10.1016/0167-5699(90)90069-L; LORTON D, 1991, BRAIN BEHAV IMMUN, V5, P29, DOI 10.1016/0889-1591(91)90005-U; MCGILLIS JP, 1990, ANN NY ACAD SCI, V594, P85; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; NILSSON G, 1989, INT ARCH ALLER A IMM, V90, P256, DOI 10.1159/000235033; NONG YH, 1989, J IMMUNOL, V143, P45; OLSEN J, 1991, PEPTIDES, V12, P333; RABIN BS, 1989, CRIT REV IMMUNOL, V9, P279; RAYCHAUDHURI SP, 1993, J AM ACAD DERMATOL, V28, P488, DOI 10.1016/S0190-9622(08)81760-4; RHEINS LA, 1989, J INVEST DERMATOL, V93, P511, DOI 10.1111/1523-1747.ep12284064; SINGARAM C, 1991, GASTROENTEROLOGY, V100, P560, DOI 10.1016/0016-5085(91)90231-9; SIRINEK LP, 1991, ACTA ONCOL, V30, P509, DOI 10.3109/02841869109092410; STEAD RH, 1987, IMMUNOL REV, V100, P333, DOI 10.1111/j.1600-065X.1987.tb00538.x; WALKER RF, 1985, J NEUROIMMUNOL, V10, P41, DOI 10.1016/0165-5728(85)90033-5; WALLENGREN J, 1991, CONTACT DERMATITIS, V24, P30, DOI 10.1111/j.1600-0536.1991.tb01626.x; WANG F, 1992, J BIOL CHEM, V267, P21052; WINCHELL SA, 1988, J AM ACAD DERMATOL, V18, P101, DOI 10.1016/S0190-9622(88)70015-8; ZAIDI M, 1990, CRIT REV CL LAB SCI, V28, P109, DOI 10.3109/10408369009105900	32	42	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	2	S			1178	1182		10.1016/S0091-6749(95)70203-2	http://dx.doi.org/10.1016/S0091-6749(95)70203-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	TQ509	8543775	Bronze			2022-12-18	WOS:A1995TQ50900014
J	Tovey, ER; Mahmic, A; McDonald, LG				Tovey, ER; Mahmic, A; McDonald, LG			Clothing - An important source of mite allergen exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							DUST		ROYAL PRINCE ALFRED HOSP, INST RESP MED, SYDNEY, NSW, AUSTRALIA	University of Sydney	Tovey, ER (corresponding author), UNIV SYDNEY, DEPT MED, DO6, SYDNEY, NSW 2006, AUSTRALIA.		Tovey, Euan R/G-8604-2017	Tovey, Euan R/0000-0002-1802-7266				BISCHOFF ERC, 1992, EXP APPL ACAROL, V16, P1, DOI 10.1007/BF01201489; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; MCDONALD LG, 1993, J ALLERGY CLIN IMMUN, V92, P771, DOI 10.1016/0091-6749(93)90022-8; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630	5	42	43	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				999	1001		10.1016/S0091-6749(95)70239-3	http://dx.doi.org/10.1016/S0091-6749(95)70239-3			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543760				2022-12-18	WOS:A1995TN12400019
J	SMOLENSKY, MH; REINBERG, A; LABRECQUE, G				SMOLENSKY, MH; REINBERG, A; LABRECQUE, G			24-HOUR PATTERN IN SYMPTOM INTENSITY OF VIRAL AND ALLERGIC RHINITIS - TREATMENT IMPLICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CIRCADIAN RHYTHMS; COLDS; INFLUENZA; ALLERGIC RHINITIS; RHINORRHEA; CHRONOTHERAPEUTICS	CARRAGEENAN-PAW EDEMA; CIRCADIAN VARIATION; RHYTHM; CHRONOBIOLOGY; BUDESONIDE; FREQUENCY; ASTHMA; RAT	The symptoms of rhinorrhea secondary to influenza and cold virus or seasonal and perennial allergic rhinitis are circadian rhythmic. Cough frequency and handkerchief use by persons suffering from virus-induced rhinorrhea are more prominent during the daytime, especially during the initial hours after awakening from nocturnal sleep. The elevation in sublingual temperature as well as the decrement in mental alertness associated with influenza in particular are more profound at this time. Sneezing, blocked nose, and runny nose secondary to allergic rhinitis are also greater in intensity during the morning in approximately 70% of sufferers. The day-night variation in symptom intensity amounts to approximately 20% of the 24-hour mean level. The treatment of these diseases and their symptoms has traditionally involved equal-interval, equal-dose (homeostatic) medication schedules. The effects of antihistamine and antiinflammatory medicines may be enhanced by timing them to the day-night temporal pattern in symptom manifestation and intensity to achieve an optimization of their beneficial effects with control of toxicity, that is, as a chronotherapy.	FDN ADOLPHE DE ROTHSCHILD, PARIS, FRANCE; UNIV LAVAL, ECOLE PHARM, LAVAL, PQ, CANADA	Laval University	SMOLENSKY, MH (corresponding author), UNIV TEXAS, SCH PUBL HLTH, CTR HERMANN CHRONOBIOL, RM 442, HOUSTON, TX 77025 USA.							BINDER E, 1982, ALLERGY, V37, P389, DOI 10.1111/j.1398-9995.1982.tb02317.x; BRUGUEROLLE B, 1982, BIOL RHYTHMS CLIN LA, P114; BUREAU JP, 1987, PATHOL BIOL, V35, P942; CERESA F, 1969, J CLIN ENDOCR METAB, V29, P1074, DOI 10.1210/jcem-29-8-1074; CZEISLER CA, 1986, SCIENCE, V233, P667, DOI 10.1126/science.3726555; DORE F, 1984, Chronobiology International, V1, P273, DOI 10.3109/07420528409063907; GAULTIER C, 1977, RESP PHYSIOL, V31, P169, DOI 10.1016/0034-5687(77)90100-1; GOSSET P, 1993, J ALLERGY CLIN IMMUN, V92, P878, DOI 10.1016/0091-6749(93)90066-O; HALBERG F, 1967, HUM BIOL, V39, P405; HALBERG F, 1960, COLD SPRING HARB SYM, V25, P289, DOI 10.1101/SQB.1960.025.01.031; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; HAUS E, 1993, AM J ANAT, V168, P457; KUHN JJ, 1982, CHEST, V82, P713, DOI 10.1378/chest.82.6.713; LABERCQUE G, 1992, BIOL RHYTHMS CLIN LA, P483; LABRECQUE G, 1981, LIFE SCI, V28, P1337, DOI 10.1016/0024-3205(81)90406-9; LABRECQUE G, 1984, AGENTS ACTIONS, V14, P719, DOI 10.1007/BF01978914; Labrecque G, 1989, CHRONOPHARMACOLOGY, P545; LABRECQUE G, 1981, P CAN FED BIOL SCI, V24, P803; Lemmer B, 1989, CHRONOPHARMACOLOGY C; LOUBARIS N, 1983, LIFE SCI, V32, P1349, DOI 10.1016/0024-3205(83)90809-3; MARTIN RJ, 1993, NOCTURNAL ASTHMA MEC; MCGOVERN JP, 1977, CHRONOBIOLOGY ALLERG, P79; MOORE JG, 1991, ULCER DIS INVESTIGAT, P55; MULLER JE, 1985, NEW ENGL J MED, V313, P1315, DOI 10.1056/NEJM198511213132103; MUNCH EP, 1983, ALLERGY, V38, P517, DOI 10.1111/j.1398-9995.1983.tb02361.x; NELSON W, 1979, CHRONOBIOLOGIA, V6, P305; Nicholson P A, 1973, Curr Med Res Opin, V1, P395, DOI 10.1185/03007997309111700; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; PEPINE CJ, 1991, JAMA-J AM MED ASSOC, V265, P386, DOI 10.1001/jama.265.3.386; PINCUS DJ, UNPUB J ALLERGY CLIN; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REINBERG A, 1978, EUR J CLIN PHARMACOL, V14, P245, DOI 10.1007/BF00560457; REINBERG A, 1971, CR ACAD SCI D NAT, V272, P1879; REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5; REINBERG A, 1988, J ASTHMA, V25, P219, DOI 10.3109/02770908809071368; REINBERG A, 1982, CLIN PHARMACOKINET, V7, P401, DOI 10.2165/00003088-198207050-00002; REINBERG A, 1985, J ENDOCRINOL, V105, P247, DOI 10.1677/joe.0.1050247; REINBERG A, 1983, J ALLERGY CLIN IMMUN, V71, P425, DOI 10.1016/0091-6749(83)90073-8; REINBERG A, 1977, CHRONOBIOLOGIA, V4, P295; REINBERG A, 1970, ANN ENDOCRINOL-PARIS, V31, P277; REINBERG A, 1989, CHRONOPHARMACOLOGY C, P115; Reinberg A, 1985, ANN REV CHRONOPHARMA, V3, P441; REINBERG A, 1984, ANN REV CHRONOPHARMA, V1, P57; Reinberg A., 1989, CHRONOPHARMACOLOGY C, P137; Reinberg A, 1983, BIOL RHYTHMS MED; RIDKER PM, 1991, CHRONOBIOL INT, V8, P327, DOI 10.3109/07420529109059169; RIETVELD WJ, 1992, BIOL RHYTHMS CLIN LA, P55; SEHGAL A, 1991, ANN NY ACAD SCI, V618, P1, DOI 10.1111/j.1749-6632.1991.tb27233.x; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; SMITH A, 1988, CHRONOBIOL INT, V5, P411, DOI 10.3109/07420528809067786; SMOLENSKY MH, 1976, CHRONOBIOLOGIA, V3, P337; SMOLENSKY MH, 1986, J ASTHMA, V23, P321, DOI 10.3109/02770908609073179; SOLIMAN KFA, 1983, J PHARM PHARMACOL, V35, P388, DOI 10.1111/j.2042-7158.1983.tb02964.x; SOLOMON GD, 1992, CLEV CLIN J MED, V59, P326, DOI 10.3949/ccjm.59.3.326; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; Touitou Y, 1992, BIOL RHYTHMS CLIN LA; Trousseau A, 1865, CLIN MED HOTEL DIEU, V2, P373; VARBANOVA A, 1975, AGRESSOLOGIE, V16, P27; VENER K, 1988, ANN REV CHRONOPHARMA, V4, P257; WASSERFALLEN JB, 1993, J ALLERGY CLIN IMMUN, V91, P1189, DOI 10.1016/0091-6749(93)90322-7; Wever RA., 1979, CIRCADIAN SYSTEM MAN, DOI 10.1007/978-1-4612-6142-1; WIHL JA, 1985, J ALLERGY CLIN IMMUN, V75, P720, DOI 10.1016/0091-6749(85)90100-9; YOUNG MRI, 1995, CHRONOBIOL INT, V12, P19, DOI 10.3109/07420529509064496	64	42	44	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	2				1084	1096		10.1016/S0091-6749(95)70212-1	http://dx.doi.org/10.1016/S0091-6749(95)70212-1			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY918	7751526	Bronze, Green Published			2022-12-18	WOS:A1995QY91800004
J	LI, CS; WAN, GH; HSIEH, KH; CHUA, KY; LIN, RH				LI, CS; WAN, GH; HSIEH, KH; CHUA, KY; LIN, RH			SEASONAL-VARIATION OF HOUSE-DUST MITE ALLERGEN (DER-P-I) IN A SUBTROPICAL CLIMATE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							DERMATOPHAGOIDES; EXPOSURE; ASTHMA		NATL TAIWAN UNIV, COLL MED, GRAD INST MICROBIOL & IMMUNOL, TAIPEI 10764, TAIWAN; NATL TAIWAN UNIV, COLL MED, INST PUBL HLTH, DIV ENVIRONM HLTH SCI, TAIPEI 10764, TAIWAN; NATL TAIWAN UNIV, COLL MED, DEPT PEDIAT, TAIPEI 10764, TAIWAN	National Taiwan University; National Taiwan University; National Taiwan University								CHANG YC, 1989, ANN ALLERGY, V62, P101; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398	5	42	43	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					131	134		10.1016/0091-6749(94)90080-9	http://dx.doi.org/10.1016/0091-6749(94)90080-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027492				2022-12-18	WOS:A1994NX39300017
J	MAKKER, HK; HOLGATE, ST				MAKKER, HK; HOLGATE, ST			THE CONTRIBUTION OF NEUROGENIC REFLEXES TO HYPERTONIC SALINE-INDUCED BRONCHOCONSTRICTION IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; HYPERTONIC CHALLENGE; ATROPINE; IPRATROPIUM BROMIDE; LIDOCAINE	EXERCISE-INDUCED ASTHMA; AIRWAY RESPONSES; COLD AIR; AEROSOLS; LIGNOCAINE; INHIBITION; MECHANISMS; HISTAMINE; LIDOCAINE; ATROPINE	Background: Hypertonic saline induces bronchoconstriction in most patients with asthma; however, the mechanisms involved are not clearly understood. We have investigated the role of neurogenic mechanisms in hypertonic saline-induced bronchoconstriction. Methods: The effect of pretreatment with the anticholinergic drugs atropine and ipratropium bromide and the local anesthetic drug lidocaine on hypertonic saline responsiveness was studied in 11 subjects with asthma. Ultrasonically nebulized hypertonic saline challenge was given in a dose-response manner to determine the provocative dose of hypertonic saline-laden air required to produce a fall in forced expiratory volume in 1 second (FEV1) of 20% or greater (PD20HS). A control PD20HS with no pretreatment was measured before randomization, and on the next three visits PD20HS was determined after pretreatment with each of the following. intramuscularly administered atropine, inhaled ipratropium bromide, and inhaled lidocaine. Results: The baseline mean FEV1 values increased by 3.5% and 4% 30 minutes after administration of atropine and ipratropium bromide, respectively, and decreased by 5.8% at 10 minutes after inhalation of lidocaine. These changes in the baseline FEV1 were not significant and did not have any effect on the PD20HS response. Premedication with atropine, ipratropium bromide, and lidocaine resulted in increases of 2.5, 2.0, and 2.6 times in mean PD20HS, respectively. Conclusions: The protection afforded by the drugs was variable in the individual subjects and not related to age, sex, baseline FEV1, provocative concentration of histamine causing a 20% fall in FEV1 or use of the inhaled corticosteroids. The protection afforded by anticholinergic and local anesthetic drugs suggests the contribution of neurogenic reflexes in the pathogenesis of hypertonic saline-induced bronchoconstriction in asthma.			MAKKER, HK (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,LEVEL D,CTR BLOCK,SOUTHAMPTON S09 4XY,ENGLAND.							ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; BARNES PJ, 1991, LUNG SCI F, P903; BELCHER NG, 1989, EUR RESPIR J, V2, P44; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHEN WY, 1981, CHEST, V79, P651, DOI 10.1378/chest.79.6.651; DAIN DS, 1975, J APPL PHYSIOL, V38, P1045, DOI 10.1152/jappl.1975.38.6.1045; ENRIGHT PL, 1980, AM REV RESPIR DIS, V122, P823; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; FINNERTY JP, 1989, AM REV RESPIR DIS, V140, P593, DOI 10.1164/ajrccm/140.3.593; FREED AN, 1989, J APPL PHYSIOL, V67, P2571, DOI 10.1152/jappl.1989.67.6.2571; GRIFFIN MP, 1982, THORAX, V37, P741, DOI 10.1136/thx.37.10.741; GRIFFIN MP, 1982, J APPL PHYSIOL, V37, P1576; HAHN LH, 1988, AIRWAYS NEURAL CONTG, P241; JANCSO N, 1960, B MILLARD FILLMORE H, V7, P53; MCFADDEN ER, 1977, J APPL PHYSIOL, V42, P746, DOI 10.1152/jappl.1977.42.5.746; MILLER WC, 1975, AM REV RESPIR DIS, V111, P739; NEWMAN SP, 1986, CLIN PHYS PHYSIOL M, V7, P139, DOI 10.1088/0143-0815/7/2/004; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169, DOI 10.1152/jappl.1982.53.1.169; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; SHEPPARD D, 1983, J APPL PHYSIOL, V54, P130, DOI 10.1152/jappl.1983.54.1.130; SMITH CM, 1989, J ALLERGY CLIN IMMUN, V84, P781, DOI 10.1016/0091-6749(89)90309-6; TULLETT WM, 1982, THORAX, V37, P737, DOI 10.1136/thx.37.10.737; TURCOTTE H, 1988, J ALLERGY CLIN IMMUN, V81, P182, DOI 10.1016/0091-6749(88)90293-X; UMENO E, 1990, J CLIN INVEST, V85, P1905, DOI 10.1172/JCI114652; WEISS EB, 1977, CHEST, V72, P429, DOI 10.1378/chest.72.4.429; WILSON NM, 1982, THORAX, V37, P657, DOI 10.1136/thx.37.9.657	26	42	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				82	88		10.1016/0091-6749(93)90041-D	http://dx.doi.org/10.1016/0091-6749(93)90041-D			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335859				2022-12-18	WOS:A1993LQ35300013
J	ARLIAN, LG; RAPP, CM; FERNANDEZCALDAS, E				ARLIAN, LG; RAPP, CM; FERNANDEZCALDAS, E			ALLERGENICITY OF EUROGLYPHUS-MAYNEI AND ITS CROSS-REACTIVITY WITH DERMATOPHAGOIDES SPECIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EUROGLYPHUS-MAYNEI; DERMATOPHAGOIDES SPECIES; ANTIGENICITY; ALLERGENICITY; ALLERGIC DISEASE; HOUSE DUST MITES; CROSS-REACTIVITY; ASTHMA; RHINITIS	HOUSE DUST MITES; PTERONYSSINUS; FARINAE; IDENTIFICATION; CHILDREN; ALLERGY; EXTRACT; ASTHMA; BODY	Background: The house dust mite, Euroglyphus maynei (EM), is common in homes in England, Europe, the southern United States, and other parts of the world. It is often present in densities greater than 100 mites per gram of dust. EM usually occurs with Dermatophagoides farinae (DF) and D. pteronyssinus (DP) and it is frequently more abundant than Dermatophagoides species. Therefore the allergenicity of EM and the cross-reactivity between EM and Dermatophagoides species are important considerations for diagnosis of mite-induced allergy and the use of appropriate immunotherapy. Methods: Crossed immunoelectrophoresis revealed that EM was the source of at least 33 antigens. Crossed radioimmunoelectrophoresis with 32 different sera from patients with RAST results that were positive to EM and skin test results that were positive to both DF and DP identified 15 allergens. Individual sera recognized two to eight EM antigens as allergens. Results: Ninety-one percent of the patients showed serum IgE directed at three or more allergens. Eighty-four percent of the patients had moderate or strong levels of IgE directed at antigen no. 33. All 15 allergens showed moderate or strong IgE binding by one or more sera. EM shared four and six cross-reacting allergens with DF and DP, respectively. Therefore 11 and 9 allergens of EM were species-specific and not shared by DF and DP, respectively. Conclusions: The results of this study clearly indicate that sensitivity to EM should be considered in geographic areas where this mite is abundant in homes.	UNIV S FLORIDA,DIV ALLERGY & CLIN IMMUNOL,TAMPA,FL 33620	State University System of Florida; University of South Florida	ARLIAN, LG (corresponding author), WRIGHT STATE UNIV,DEPT BIOL SCI,DAYTON,OH 45435, USA.							ABEDBENAMARA M, 1983, ACAROLOGIA, V24, P79; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; BLYTHE ME, 1974, CLIN ALLERGY, V4, P25, DOI 10.1111/j.1365-2222.1974.tb01359.x; BLYTHE ME, 1976, BRIT J DIS CHEST, V70, P3, DOI 10.1016/0007-0971(76)90003-6; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; CHARPIN J, 1986, REV FR ALLERGOL, V26, P117, DOI 10.1016/S0335-7457(86)80002-8; COLLOFF MJ, 1991, CLIN EXP ALLERGY, V21, P225, DOI 10.1111/j.1365-2222.1991.tb00834.x; COLLOFF MJ, 1987, MED VET ENTOMOL, V1, P163, DOI 10.1111/j.1365-2915.1987.tb00338.x; COLLOFF MJ, 1991, EXP APPL ACAROL, V11, P177, DOI 10.1007/BF01246090; COLLOFF MJ, 1991, DUST MITE ALLERGENS, P102; DELAHOZ F, 1986, INT ARCH ALLER A IMM, V79, P238, DOI 10.1159/000233979; FERNANDEZCALDAS E, 1990, ALLERGY PROC, V11, P263, DOI 10.2500/108854190778879710; GABRIEL M, 1982, CLIN ALLERGY, V12, P157, DOI 10.1111/j.1365-2222.1982.tb01635.x; GOMEZ MS, 1981, ALLERGOL IMMUNOPATH, V9, P123; HILL MR, 1991, DUST MITE ALLERGENS, P65; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; MUMCUOGLU Y, 1976, J MED ENTOMOL, V13, P361, DOI 10.1093/jmedent/13.3.361; MUMCUOGLU Y, 1977, ACTA ALLERGOL, V32, P339; NOFERI A, 1974, Folia Allergologica et Immunologica Clinica, V21, P466; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V78, P389; Samsinak K., 1978, International Journal of Acarology, V4, P33; SESAY H R, 1972, Acarologia (Paris), V14, P384; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; STENIUS B, 1972, SCAND J RESPIR DIS, V53, P338; Todorov D. A., 1979, Acta Zoologica Bulgarica, V13, P64; VANHAGEHAMSTEN M, 1989, J ALLERGY CLIN IMMUN, V83, P581, DOI 10.1016/0091-6749(89)90069-9; VOORHORST R, 1967, HOUSE DUST ATOPY HOU; WALSHAW MJ, 1987, CLIN ALLERGY, V17, P7, DOI 10.1111/j.1365-2222.1987.tb02314.x	30	42	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1051	1058		10.1016/0091-6749(93)90219-6	http://dx.doi.org/10.1016/0091-6749(93)90219-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491937				2022-12-18	WOS:A1993LC97800013
J	DRUCE, HM				DRUCE, HM			DIAGNOSIS OF SINUSITIS IN ADULTS - HISTORY, PHYSICAL-EXAMINATION, NASAL CYTOLOGY, ECHO, AND RHINOSCOPE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		SINUSITIS; RHINORRHEA; MAXILLARY; ETHMOID; NASAL MUCOSA; SPHENOID CYTOLOGY; A-MODE ULTRASONOGRAPHY; FLEXIBLE AND RIGID ENDOSCOPY	MAXILLARY SINUS; ALLERGY OFFICE; ULTRASOUND; RADIOGRAPHY; RHINOLARYNGOSCOPY	The symptoms of sinusitis are common and overlap other diseases ranging from common colds to perennial rhinitis. When symptoms are prolonged and interfere with daily living, an appropriate set of investigations are indicated. The workup is designed to detect both the presence and extent of any disease in the paranasal sinus cavities. In chronic sinusitis, a constellation of nonspecific symptoms such as facial pressure, headache, nasal obstruction, and drainage may occur. Physical examination is important to exclude anatomic causes of symptoms. A negative physical examination does not rule out the diagnosis. Adjunctive tests in selected cases include nasal cytologic studies, ultrasound studies, and the use of flexible or rigid nasal endoscopes, in addition to imaging tests such as radiology and computed tomography.			DRUCE, HM (corresponding author), ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,1402 S GRAND BLVD,R209,ST LOUIS,MO 63104, USA.							BERG O, 1985, LARYNGOSCOPE, V95, P851; CASTELLANOS J, 1989, J ALLERGY CLIN IMMUN, V83, P91, DOI 10.1016/0091-6749(89)90481-8; CHANDLER JR, 1970, LARYNGOSCOPE, V80, P1414, DOI 10.1288/00005537-197009000-00007; DRUCE HM, 1991, J ALLERGY CLIN IMMUN, V88, P675, DOI 10.1016/0091-6749(91)90161-G; DRUCE HM, 1989, AM J RHINOL, V3, P163; GILL FF, 1989, AM J RHINOL, P13; ISAACSON S, 1978, OTOLARYNG HEAD NECK, V86, P231, DOI 10.1177/019459987808600210; Jannert M, 1982, Acta Otolaryngol Suppl, V389, P1; JENEY EVM, 1990, J ALLERGY CLIN IMMUN, V86, P10, DOI 10.1016/S0091-6749(05)80117-4; KENNEDY DW, 1990, OTOLARYNG HEAD NECK, V103, P884, DOI 10.1177/01945998901030S509; KUHN JP, 1986, J ALLERGY CLIN IMMUN, V77, P6, DOI 10.1016/0091-6749(86)90314-3; LANDMAN MD, 1986, OTOLARYNG HEAD NECK, V94, P157, DOI 10.1177/019459988609400205; MANN W, 1977, ARCH OTO-RHINO-LARYN, V215, P67, DOI 10.1007/BF00463193; NELSON AW, 1986, J ULTRAS MED, V5, P477, DOI 10.7863/jum.1986.5.9.477; PFLEIDERER AG, 1984, CLIN OTOLARYNGOL, V9, P335, DOI 10.1111/j.1365-2273.1984.tb01517.x; Revonta M, 1980, Acta Otolaryngol Suppl, V370, P1; REVONTA M, 1982, INT J PEDIATR OTORHI, V4, P301, DOI 10.1016/0165-5876(82)90042-8; ROHR AS, 1986, J ALLERGY CLIN IMMUN, V78, P58, DOI 10.1016/0091-6749(86)90115-6; SELNER JC, 1985, ANN ALLERGY, V54, P479; SETTIPANE GA, 1990, RHINITIS, P173; SHAPIRO GG, 1986, J ALLERGY CLIN IMMUN, V77, P59, DOI 10.1016/0091-6749(86)90324-6; SLAVIN RG, 1988, ALLERGY PRINCIPLES P, P1291; STAFFORD CT, 1990, OTOLARYNG HEAD NECK, V103, P870, DOI 10.1177/01945998901030S506; TICHENOR WS, 1986, J ALLERGY CLIN IMMUN, V77, P239; WILSON NW, 1988, AM J RHINOL, V2, P55; 1990, NIH901261 DHHS PUBL; [No title captured]	27	42	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			436	441		10.1016/0091-6749(92)90165-X	http://dx.doi.org/10.1016/0091-6749(92)90165-X			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527333				2022-12-18	WOS:A1992JP52100006
J	JENSEN, EJ; PEDERSEN, B; SCHMIDT, E; DAHL, R				JENSEN, EJ; PEDERSEN, B; SCHMIDT, E; DAHL, R			SERUM IGE IN NONATOPIC SMOKERS, NONSMOKERS, AND RECENT EXSMOKERS - RELATION TO LUNG-FUNCTION, AIRWAY SYMPTOMS, AND ATOPIC PREDISPOSITION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SMOKING; SMOKING CESSATION; IGE; LUNG FUNCTION; AIRWAY SYMPTOMS	IMMUNOGLOBULIN-E; CIGARETTE SMOKERS; TOBACCO-SMOKE; ALLERGY; COHORT; AGE	The influence of smoking on serum IgE (s-IgE) was studied in a selected nonatopic population. The variation in s-IgE was followed during 1 year of smoking abstinence. The study included 287 smokers and 137 never smokers. IgE was higher in smokers compared with IgE in never smokers (p < 0.005). Male smokers had higher s-IgE than female smokers (p < 0.01). S-IgE was independent of age and claims of atopy among first-degree relatives. Weighted pack-years consumption was defined for cigarette smokers by modifying pack-years consumption by nicotine content of the brand smoked. Weighted pack-years consumption was associated with level of s-IgE (p < 0.05). S-IgE was higher in smokers with airway symptoms compared with that in smokers without symptoms (p < 0.01). In smokers older than 50 years of age, there tended to be decreased FEV1 residuals (0.05 < p < 0.06), and presence of airway symptoms was (p < 0.03) associated with high levels of s-IgE independent of each other. In 92 quitters, s-IgE increased during the first 26 weeks of abstinence (p < 0.05), and after 1 year, s-IgE had returned to baseline. The increase was only observed in smokers younger than 40 years and had no relation to variations in FEV1 during the 1-year follow-up. The increase in s-IgE after smoking cessation was transient, of minor clinical importance, and probably caused by a relief from an immunosuppressive influence.			JENSEN, EJ (corresponding author), AARHUS UNIV HOSP,DEPT RESP DIS,DK-8000 AARHUS,DENMARK.		Dahl, Ronahl/F-8170-2013					BAHNA SL, 1983, ALLERGY, V38, P57, DOI 10.1111/j.1398-9995.1983.tb00857.x; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BLOOM JW, 1986, CLIN ALLERGY, V16, P25, DOI 10.1111/j.1365-2222.1986.tb01950.x; BURROWS B, 1982, J ALLERGY CLIN IMMUN, V70, P199, DOI 10.1016/0091-6749(82)90042-2; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; GERRARD JW, 1980, ANN ALLERGY, V44, P261; GULSVIK A, 1979, LANCET, V1, P449; HANNEUSE Y, 1978, CLIN ALLERGY, V8, P165, DOI 10.1111/j.1365-2222.1978.tb00461.x; JACOB CV, 1980, IMMUNOLOGY, V40, P621; JARVIS MJ, 1980, BRIT MED J, V281, P484, DOI 10.1136/bmj.281.6238.484; JONES JG, 1980, LANCET, V1, P66; KISHIMOTO S, 1980, J IMMUNOL, V125, P2347; MILLER MR, 1988, THORAX, V43, P265, DOI 10.1136/thx.43.4.265; Orie NGM, 1961, BRONCHITIS INT S; PRIDE N, 1986, CLIN ALLERGY, V16, P3, DOI 10.1111/j.1365-2222.1986.tb01946.x; Quanjer PH, 1983, B EUR PHYSIOPATHO S5, V19, P45; ROMAGNANI S, 1990, ACI NEWS, V2, P192; SEDGWICK JD, 1983, IMMUNOLOGY, V50, P625; TAYLOR RG, 1985, THORAX, V40, P17, DOI 10.1136/thx.40.1.17; TOLLERUD DJ, 1989, AM REV RESPIR DIS, V139, P1446, DOI 10.1164/ajrccm/139.6.1446; VOLLMER WM, 1986, CHEST, V90, P416, DOI 10.1378/chest.90.3.416; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215, DOI 10.1136/bmj.283.6301.1215; [No title captured]	23	42	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					224	229		10.1016/0091-6749(92)90075-D	http://dx.doi.org/10.1016/0091-6749(92)90075-D			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1500626	Bronze			2022-12-18	WOS:A1992JJ42300012
J	LEE, CE; NEULAND, ME; TEAFORD, HG; VILLACIS, BF; DIXON, PS; VALTIER, S; YEH, CH; FOURNIER, DC; CHARLESWORTH, EN				LEE, CE; NEULAND, ME; TEAFORD, HG; VILLACIS, BF; DIXON, PS; VALTIER, S; YEH, CH; FOURNIER, DC; CHARLESWORTH, EN			INTERLEUKIN-6 IS RELEASED IN THE CUTANEOUS RESPONSE TO ALLERGEN CHALLENGE IN ATOPIC INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-6, IL-2; INTERLEUKINS; LATE-PHASE RESPONSE; BLISTER CHAMBER; ALLERGIC CUTANEOUS RESPONSE	PLATELET-ACTIVATING FACTOR; MAST-CELLS; HUMAN EOSINOPHILS; MEDIATOR RELEASE; HISTAMINE; CYTOKINES; IGE; LYMPHOKINES; TRYPTASE; LUNG	The mechanisms responsible for cutaneous response to antigen are complex. Interleukin-1 (IL-1) and interleukin-6 (IL-6) are proinflammatory cytokines that share many properties. Previous studies with a blister-chamber model have demonstrated IL-1 to be produced in the cutaneous response to antigen. Since IL-2 production by activated T cells and IL-6 production by macrophages are both stimulated by IL-1, we hypothesized that IL-2 and IL-6 may be involved in the cutaneous late-phase response (LPR) to antigen. We examined antigen-challenged sites for IL-2 immunoreactivity (ELISA) but found no difference between antigen- and diluent-challenged skin sites (N = 4). Since IL-2 has been demonstrated to be produced in response to IL-1 and IL-1 activity has been demonstrated to be greatest between hours 10 and 12, we speculated that IL-2 might not be detected until after hour 12. We were unable to demonstrate any increase in IL-2 production, even by extending our studies to 24 hours in two subjects. Antigen-challenged, skin blister-chamber fluids from atopic subjects demonstrated the appearance of IL-6 (ELISA) in pooled samples representing hours 1 1/2, 3 1/2, 5 1/2, and 7, but not at diluent control sites (p < 0.05; N = 6). IL-6 reached a median peak of 0.66 ng/ml at 3 1/2 hours. Median levels of IL-6 fell to baseline at 8 hours, followed by a second peak of 0.25 ng/ml at hour 10. Three distinct patterns of IL-6 release were noted: early release of IL-6 followed by a sustained slower rise that peaked at hour 9 before declining to baseline levels at 12 hours, early release of IL-6 followed by a fall to baseline levels at hours 7 to 9 with a second smaller peak at hours 9 to 11, and isolated early release of IL-6. Early IL-6 production correlated with late histamine production (R = 0.801; p = 0.06), and late IL-6 production correlated with eosinophil influx (R = 0.813; p = 0.05). The area of the LPR at skin test sites correlated with early IL-6 peak levels (R = 0.977; p = 0.004) and with total early IL-6 production (R = 0.885; p = 0.05), but not with late IL-6 production. We conclude that IL-6 is released locally in antigen-challenged sites in atopic subjects, that an early monophasic or biphasic release may be observed in individual subjects, and that its degree of early release may play an important role in the pathogenesis of the cutaneous LPR.	WILFORD HALL USAF MED CTR,DEPT MED,ALLERGY IMMUNOL SERV,LACKLAND AFB,TX 78236; WILFORD HALL USAF MED CTR,INVEST DIRECTORATE CLIN,LACKLAND AFB,TX 78236; UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550	United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force; University of Texas System; University of Texas Medical Branch Galveston								ADELMAN DC, 1990, J ALLERGY CLIN IMMUN, V86, P512, DOI 10.1016/S0091-6749(05)80207-6; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BORISH L, 1989, CELL IMMUNOL, V121, P280, DOI 10.1016/0008-8749(89)90026-9; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; COSTA JJ, 1990, FASEB J, V4, pA1943; DEWECK AL, 1989, INT ARCH ALLER A IMM, V90, P17, DOI 10.1159/000235070; DINARELLO CA, 1986, ANNU REV MED, V37, P173; DURUM SK, 1989, FUNDAMENTAL IMMUNOLO, P639; GILLIS S, 1989, FUNDAMENTAL IMMUNOLO, P621; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; HERROD HG, 1989, ANN ALLERGY, V63, P269; HULTNER L, 1989, IMMUNOLOGY, V67, P408; KELLEY J, 1990, AM REV RESPIR DIS, V141, P765, DOI 10.1164/ajrccm/141.3.765; LE JM, 1989, LAB INVEST, V61, P588; Lett-Brown M A, 1989, Year Immunol, V5, P195; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; MENCIAHUERTA JM, 1983, J IMMUNOL, V131, P2958; MICAN J M, 1991, Journal of Allergy and Clinical Immunology, V87, P206, DOI 10.1016/0091-6749(91)91549-9; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; ROLAPLESZCZYNSKI M, 1990, FASEB J, V4, pA1713; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SHALIT M, 1988, J IMMUNOL, V141, P821; SHALIT M, 1990, J ALLERGY CLIN IMMUN, V86, P117, DOI 10.1016/S0091-6749(05)80131-9; TAMURA N, 1987, BIOCHEM BIOPH RES CO, V142, P638, DOI 10.1016/0006-291X(87)91462-8; TANIGUCHI T, 1986, IMMUNOL REV, V92, P121, DOI 10.1111/j.1600-065X.1986.tb01497.x; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WONG GG, 1988, IMMUNOL TODAY, V9, P137, DOI 10.1016/0167-5699(88)91200-5	35	42	42	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1992	89	5					1010	1020		10.1016/0091-6749(92)90224-P	http://dx.doi.org/10.1016/0091-6749(92)90224-P			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HU542	1583243	Bronze			2022-12-18	WOS:A1992HU54200012
J	HAMILOS, DL; CHRISTENSEN, J				HAMILOS, DL; CHRISTENSEN, J			TREATMENT OF CHURG-STRAUSS-SYNDROME WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note											HAMILOS, DL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,1400 JACKSON ST,DENVER,CO 80206, USA.							FURUSHO K, 1987, KAWASAKI DISEASE, P425; GELFAND EW, 1989, CLIN IMMUNOL IMMUNOP, V53, pS1, DOI 10.1016/0090-1229(89)90064-0; LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001; MAZER BD, 1989, CLIN IMMUNOL IMMUNOP, V53, pS156, DOI 10.1016/0090-1229(89)90081-0; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601	5	42	42	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					823	824		10.1016/0091-6749(91)90195-T	http://dx.doi.org/10.1016/0091-6749(91)90195-T			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955642	Bronze			2022-12-18	WOS:A1991GQ45200023
J	KROEGEL, C; CHILVERS, ER; GIEMBYCZ, MA; CHALLISS, RAJ; BARNES, PJ				KROEGEL, C; CHILVERS, ER; GIEMBYCZ, MA; CHALLISS, RAJ; BARNES, PJ			PLATELET-ACTIVATING-FACTOR STIMULATES A RAPID ACCUMULATION OF INOSITOL (1,4,5)TRISPHOSPHATE IN GUINEA-PIG EOSINOPHILS - RELATIONSHIP TO CALCIUM MOBILIZATION AND DEGRANULATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						EOSINOPHIL; PLATELET-ACTIVATING FACTOR; INOSITOL (1,4,5)TRISPHOSPHATE; CALCIUM MOBILIZATION; DEGRANULATION	CYTOSOLIC FREE CALCIUM; PURIFIED HUMAN EOSINOPHILS; 2ND MESSENGER; HL-60 CELLS; RADIORECEPTOR ASSAY; CA-2+ MOBILIZATION; 3-KINASE ACTIVITY; DE-GRANULATION; 1,4,5-TRISPHOSPHATE; TRISPHOSPHATE	The effect of platelet-activating factor (PAF) on inositol (1,4,5)trisphosphate (Ins[1,4,5]P3) mass, calcium mobilization, and the release of granule enzymes was studied on guinea pig peritoneal eosinophils (EOSs). PAF evoked a concentration-dependent accumulation of Ins(1,4,5)P3 with a drug concentration that elicits 50% of the maximum attainable response (EC50) of 10 nmol/L; the production of this second messenger was maximal at 1-mu-mol/L of PAF. Kinetic analysis of PAF (1-mu-mol/L)-induced Ins(1,4,5)P3 accumulation demonstrated it to be transient with a 3.8-fold increase over resting levels observed at 5 seconds. Thereafter, the level of Ins(1,4,5)P3 declined, returning to vehicle-treated levels 60 seconds after PAF challenge. Lyso-PAF, the inactive precursor and metabolite of PAF, was inactive at all concentrations examined. PAF also induced a rapid, concentration-dependent (EC50, 12 nmol/L) rise in the cytosolic-free calcium concentration ([Ca++]i) in fura 2-AM - loaded EOSs that was transient, peaking after the maximum increase in Ins(1,4,5)P3 mass was observed. A highly significant positive correlation was found between the peak increase in Ins(1,4,5)P3 and the peak rise in [Ca++]i. Functionally, PAF evoked a concentration-dependent release of granule constituents from both the small (arylsulfatase B; EC50, 3 nmol/L) and specific (EOS peroxidase; EC50, 2.7 nmol/L) granules that lagged, temporally, behind both Ins(1,4,5)P3 accumulation and the rise in [Ca++]i. Both the biochemical and functional effects of PAF examined in this study were antagonized by WEB 2086 (300 nmol/L), a selective PAF receptor-blocking drug. It is concluded that stimulus (PAF)-response coupling in guinea pig peritoneal EOSs may involve the receptor-mediated formation of Ins(1,4,5)P3 and subsequent release of intracellularly stored Ca++. This sequence of events may link PAF receptor activation to Ca++-dependent cellular responses, such as degranulation.	ROYAL BROMPTON & NATL HEART & LUNG HOSP,NATL HEART & LUNG INST,DEPT THORAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND; UNIV LEICESTER,DEPT PHARMACOL & THERAPEUT,LEICESTER LE1 7RH,ENGLAND	Imperial College London; University of Leicester			Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848; Chilvers, Edwin/0000-0002-4230-9677; Barnes, Peter/0000-0002-5122-4018	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSSON T, 1986, BIOCHEM J, V240, P333, DOI 10.1042/bj2400333; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BEESON PB, 1977, MAJOR PROBLEMS INTER, V14, P17; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD PG, 1986, J BIOL CHEM, V261, P5644; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; BRAQUET P, 1987, PHARMACOL REV, V39, P127; BRUYNZEEL PLB, 1987, PROSTAGLANDINS, V34, P205; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; DOUGHERTY RW, 1984, BIOCHEM J, V222, P307, DOI 10.1042/bj2220307; FINDLAY SR, 1981, AM J PHYSIOL, V241, pC130, DOI 10.1152/ajpcell.1981.241.3.C130; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GARTNER I, 1980, IMMUNOLOGY, V40, P133; GIEMBYCZ MA, 1990, J IMMUNOL, V144, P3489; HALLAM TJ, 1984, BIOCHEM J, V218, P819, DOI 10.1042/bj2180819; HANSEN CA, 1986, J BIOL CHEM, V261, P8100; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; KRAUSE KH, 1985, J CLIN INVEST, V76, P1348, DOI 10.1172/JCI112109; KROEGEL C, 1989, BIOCHEM BIOPH RES CO, V162, P511, DOI 10.1016/0006-291X(89)92027-5; KROEGEL C, 1989, FEBS LETT, V243, P41, DOI 10.1016/0014-5793(89)81214-1; KROEGEL C, 1989, J IMMUNOL, V142, P3518; KROEGEL C, 1988, IMMUNOLOGY, V64, P559; KROEGEL C, 1990, British Journal of Pharmacology, V100, p374P; KROEGEL C, IN PRESS FASEB J; LAMAS AM, 1988, J IMMUNOL, V140, P1500; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948, DOI 10.1164/ajrccm/137.4.948; LEW PD, 1986, J BIOL CHEM, V261, P3121; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; POPPER H, 1989, INFLAMMATION, V13, P147, DOI 10.1007/BF00924786; SPAT A, 1986, NATURE, V319, P514, DOI 10.1038/319514a0; Spitznagel J K, 1984, Contemp Top Immunobiol, V14, P283; SULLIVAN SJ, 1980, J CELL BIOL, V85, P703, DOI 10.1083/jcb.85.3.703; TAMURA N, 1987, BIOCHEM BIOPH RES CO, V142, P638, DOI 10.1016/0006-291X(87)91462-8; TARVER AP, 1987, J BIOL CHEM, V262, P17268; UKENA D, 1989, BIOCHEM PHARMACOL, V38, P1702, DOI 10.1016/0006-2952(89)90322-5; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WOLLHEIM CB, 1986, J BIOL CHEM, V261, P8314; YUKAWA T, 1989, IMMUNOLOGY, V68, P140	44	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1991	88	1					114	124		10.1016/0091-6749(91)90308-B	http://dx.doi.org/10.1016/0091-6749(91)90308-B			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY204	2071775				2022-12-18	WOS:A1991FY20400014
J	PARK, HS; LEE, MK; KIM, BO; LEE, KJ; ROH, JH; MOON, YH; HONG, CS				PARK, HS; LEE, MK; KIM, BO; LEE, KJ; ROH, JH; MOON, YH; HONG, CS			CLINICAL AND IMMUNOLOGICAL EVALUATIONS OF REACTIVE DYE-EXPOSED WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							WESTERN RED CEDAR; HYPERSENSITIVITY; PERMEABILITY; ANTIBODY; ASTHMA	To evaluate type I hypersensitivity to reactive dyes, its prevalence, and its relationship to respiratory dysfunction, we studied clinical and immunologic features, including skin prick tests, RAST, and bronchoprovocation tests, of 309 employees working in a reactive-dye industry. Our survey revealed that 78 (25.2%) employees had work-related lower respiratory symptoms associated with or without nasal, skin, or eye symptoms. Among these employees, 38 (48.7%) had nonspecific bronchial reactivity. Thirteen demonstrated immediate (6), dual (6), or late only (1) asthmatic responses after inhalation of four kinds of reactive-dye solutions. Twenty-five employees demonstrated immediate skin responses to black GR dye, and 21 reacted to orange 3R. Fifty-three employees (17%) had specific serum IgE antibody against black GR and orange 3R-human serum albumin conjugate. Specific IgE was detected more frequently in symptomatic employees (30%) and smokers (100%). No association was found between atopy and specific IgE binding. The RAST-inhibition tests of black GR revealed significant inhibitions by black GR-human serum albumin conjugate and minimal inhibitions by unconjugated black GR. Orange 3R RAST-inhibition tests revealed significant inhibitions by conjugated forms of black GR and orange 3R and some inhibitions by two unconjugated dyes, suggesting an immunologic cross-reactivity between these dyes. These findings suggested that reactive dyes could induce immunologic responses, most likely IgE-mediated.	YONSEI UNIV,COLL MED,DEPT INTERNAL MED,CPO BOX 8044,SEOUL,SOUTH KOREA; YONSEI UNIV,COLL MED,DEPT PREVENT MED & PUBL HLTH,SEOUL,SOUTH KOREA	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System			Park, Hae-Sim/S-7974-2019	Park, Hae-Sim/0000-0003-2614-0303				AKIYAMA K, 1984, J IMMUNOL, V133, P3286; ALANKO K, 1978, CLIN ALLERGY, V8, P25, DOI 10.1111/j.1365-2222.1978.tb00444.x; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BRUGSCH HG, 1963, NEW ENGL J MED, V268, P353, DOI 10.1056/NEJM196302142680705; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHANYEUNG M, 1982, J ALLERGY CLIN IMMUN, V70, P32, DOI 10.1016/0091-6749(82)90198-1; CHANYEUNG M, 1986, AM REV RESPIR DIS, V133, P686; CHEN SE, 1982, J ALLERGY CLIN IMMUN, V70, P382; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; DOCKER A, 1987, BRIT J IND MED, V44, P534; DURLACHER SH, 1947, AM J PATHOL, V23, P679; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HAGGARD W, 1924, J IND HYG, V5, P390; HULBERT WC, 1981, AM REV RESPIR DIS, V123, P320; ISLAM MS, 1972, INT ARCH ARBEITSMED, V29, P221, DOI 10.1007/BF00539250; JONES JG, 1983, THORAX, V38, P129, DOI 10.1136/thx.38.2.129; LAMS S, 1979, J ALLERGY CLIN IMMUN, V63, P28; LEE SJ, 1982, J KOR ALLERGOL SOC, V2, P86; LUCYNSKA CM, 1986, J IMMUNOL METHODS, V95, P177; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; PARK H S, 1989, Yonsei Medical Journal, V30, P298; PARK HS, 1989, ANN ALLERGY, V63, P399; PARK HS, 1989, J KOREAN MED ASSOC, V32, P1197; VENABLES KM, 1985, BRIT MED J, V290, P201, DOI 10.1136/bmj.290.6463.201; 1972, ACTA ALLERGOL, V27, P439; 1966, BRIT MED RES COUNCIL	27	42	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					639	649		10.1016/0091-6749(91)90382-X	http://dx.doi.org/10.1016/0091-6749(91)90382-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005316				2022-12-18	WOS:A1991FB80100006
J	DYKEWICZ, MS; PATTERSON, R; CUGELL, DW; HARRIS, KE; WU, AF				DYKEWICZ, MS; PATTERSON, R; CUGELL, DW; HARRIS, KE; WU, AF			SERUM-IGE AND SERUM-IGG TO FORMALDEHYDE-HUMAN SERUM-ALBUMIN - LACK OF RELATION TO GASEOUS FORMALDEHYDE EXPOSURE AND SYMPTOMS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article								Fifty-five subjects were studied to determine if the presence of IgE or IgG antibodies to formaldehyde (F)-human serum albumin (HSA) was associated with exposure to gaseous F or with respiratory or conjunctival symptoms from such exposure. The study population included cohorts exposed to F in the workplace, smokers, and normal subjects. IgE antibody specific for F-HSA was detected by ELISA in three subjects; immediate-type skin testing was negative in two of these subjects, and not interpretable because of dermatographism in one subject. One of these subjects had a history of respiratory symptoms when the subject was working in a histology laboratory that contained ambient F and xylene; a respiratory challenge with F at concentrations of up to 2 ppm failed to produce respiratory symptoms or significant changes in pulmonary function. Serum from the three subjects with IgE to F-HSA by ELISA failed to passively transfer skin reactivity to F-HSA to rhesus monkey recipients. These three subjects and two other subjects had IgG to F-HSA by ELISA, although this was of generally low titer. We could not define a relationship between the presence of antibodies and (1) a history of F exposure or (2) a history of adverse respiratory or conjunctival symptoms from F. This study is a continuum of 5 years of study in our laboratory attempting to define allergy to gaseous F, and the current study does not support an immunologic basis for respiratory or conjunctival symptoms from gaseous F exposure. Based on the findings of this and our other studies, it is possible that clinical IgE-mediated allergy to gaseous F does not exist, or if it does exist, it is extremely rare.	NORTHWESTERN UNIV, SCH MED,DEPT MED,ALLERGY IMMUNOL SECT, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT MED, PULM MED SECT, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University					NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AYER HE, 1982, AM J PUBLIC HEALTH, V72, P1283, DOI 10.2105/AJPH.72.11.1283; BLEJER HP, 1966, OCCUPATIONAL HLTH RE; BRYSON DD, 1981, LANCET, V1, P1263; CRONIN E, 1982, CONTACT DERMATITIS, P2788; DYKEWICZ MS, 1988, J LAB CLIN MED, V111, P459; FASSBINDER W, 1978, VOX SANG, V35, P41, DOI 10.1111/j.1423-0410.1978.tb02899.x; FRIGAS E, 1984, MAYO CLIN PROC, V59, P295, DOI 10.1016/S0025-6196(12)61423-2; GAMBLE J, 1983, FORMALDEHYDE TOXICIT, P191; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V86, P177, DOI 10.1016/S0091-6749(05)80063-6; HART RW, 1984, US DHHS, V58, P323; HENDRICK DJ, 1977, BRIT J IND MED, V34, P11; HENDRICK DJ, 1983, IMMUNOL ALLERGY PRAC, V5, P21; Horsfall FL, 1934, J IMMUNOL, V27, P569; INFANTE PF, 1981, LANCET, V2, P980; Jacobs JL, 1939, J IMMUNOL, V36, P531; KENSLER CJ, 1963, NEW ENGL J MED, V269, P1161, DOI 10.1056/NEJM196311282692202; KERFOOT EJ, 1975, AM IND HYG ASSOC J, V36, P533, DOI 10.1080/0002889758507286; KRAMPS JA, 1989, CLIN EXP ALLERGY, V19, P509, DOI 10.1111/j.1365-2222.1989.tb02425.x; LANDSTEINE RK, 1917, Z IMMUNITATSFORSCH, V26, P133; LANDSTEINER K, 1914, Z IMMUNITATSFORSCH, V20, P618; LYNEN R, 1983, VOX SANG, V44, P81, DOI 10.1111/j.1423-0410.1983.tb04106.x; Magnusson B., 1970, ALLERGIC CONTACT DER; MAURICE F, 1986, J ALLERGY CLIN IMMUN, V77, P594, DOI 10.1016/0091-6749(86)90351-9; MORGAN WKC, 1981, LANCET, V2, P981; NORDMAN H, 1985, J ALLERGY CLIN IMMUN, V75, P91, DOI 10.1016/0091-6749(85)90018-1; PATTERSON R, 1985, J LAB CLIN MED, V106, P93; PATTERSON R, 1989, J ALLERGY CLIN IMMUN, V84, P359, DOI 10.1016/0091-6749(89)90421-1; PATTERSON R, 1986, INT ARCH ALLER A IMM, V79, P53, DOI 10.1159/000233942; PIRILA V, 1949, Ann Med Intern Fenn, V38, P38; PROSS HF, 1987, J ALLERGY CLIN IMMUN, V79, P797, DOI 10.1016/0091-6749(87)90213-2; ROTH WG, 1969, BERUFS-DERMATOSEN, V17, P263; SALE SR, 1981, J ALLERGY CLIN IMMUN, V68, P188, DOI 10.1016/0091-6749(81)90182-2; SANDLER SG, 1978, ISRAEL J MED SCI, V14, P1177; SCHUCK EA, 1966, ARCH ENVIRON HEALTH, V13, P570, DOI 10.1080/00039896.1966.10664620; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; SIM VM, 1957, JAMA-J AM MED ASSOC, V165, P1908, DOI 10.1001/jama.1957.02980330010003; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; Straus HW, 1937, J IMMUNOL, V32, P251; SWENBERG JA, 1980, CANCER RES, V40, P3398; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WILHELMSSON B, 1987, LANCET, V2, P164; ZEISS CR, 1982, J ALLERGY CLIN IMMUN, V70, P15, DOI 10.1016/0091-6749(82)90195-6; 1981, LANCET, V1, P926; 1979, SMOKING HLTH REPORT; [No title captured]; 1983, J ALLERGY CLIN IMMUN, V72, P515	46	42	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				48	57		10.1016/0091-6749(91)90212-7	http://dx.doi.org/10.1016/0091-6749(91)90212-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991923				2022-12-18	WOS:A1991EX98500007
J	HUSTON, DP; KAVANAUGH, AF; ROHANE, PW; HUSTON, MM				HUSTON, DP; KAVANAUGH, AF; ROHANE, PW; HUSTON, MM			IMMUNOGLOBULIN DEFICIENCY SYNDROMES AND THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PRIMARY IMMUNODEFICIENCY DISEASES; SELECTIVE IGA DEFICIENCY; CONSTANT REGION GENES; T-SUPPRESSOR CELLS; LYMPHOCYTES-B; ANTIBODY DEFICIENCY; CHROMOSOMAL LOCATION; CARRIER DETECTION; BINDING-FACTORS		BAYLOR UNIV,DEPT MED,IMMUNOL SECT,HOUSTON,TX 77030; BAYLOR UNIV,DEPT MICROBIOL & IMMUNOL,IMMUNOL SECT,HOUSTON,TX 77030	Baylor University; Baylor University	HUSTON, DP (corresponding author), METHODIST HOSP,6565 FANNIN,MS F-501,HOUSTON,TX 77030, USA.			Huston, David/0000-0002-2332-0010	PHS HHS [A121289, A124664] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADELMAN D, 1989, J ALLERGY CLIN IMMUN, V83, P299; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; AMBROSINO CM, 1988, J ALLERGY CLIN IMMUN, V81, P1175; AMMANN AJ, 1971, MEDICINE, V50, P223, DOI 10.1097/00005792-197105000-00004; ANKER R, 1989, J EXP MED, V169, P2109, DOI 10.1084/jem.169.6.2109; BJORKANDER J, 1987, J CLIN IMMUNOL, V7, P8, DOI 10.1007/BF00915419; BJORKANDER J, 1985, NEW ENGL J MED, V313, P720, DOI 10.1056/NEJM198509193131203; BRANDTZAEG P, 1968, SCIENCE, V160, P789, DOI 10.1126/science.160.3829.789; BRUTON OC, 1952, PEDIATRICS, V9, P722; BUCKLEY RH, 1986, CLIN IMMUNOL IMMUNOP, V40, P13, DOI 10.1016/0090-1229(86)90065-6; BUCKLEY RH, 1975, J CLIN INVEST, V55, P157, DOI 10.1172/JCI107906; BUCKLEY RH, 1986, ARCH INTERN MED, V146, P377, DOI 10.1001/archinte.146.2.377; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; BURTON DR, 1986, MONOGR ALLERGY, V19, P7; CASSIDY JT, 1969, NEW ENGL J MED, V280, P275; CONLEY ME, 1988, J PEDIATR-US, V112, P688, DOI 10.1016/S0022-3476(88)80683-8; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; COOPER MD, 1972, AM J PATHOL, V699, P513; CROCE CM, 1979, P NATL ACAD SCI USA, V76, P3416, DOI 10.1073/pnas.76.7.3416; CUNNINGHAMRUNDL.C, 1983, PRIMARY IMMUNODEFICI, P201; DELESPESSE G, 1989, IMMUNOL TODAY, V10, P159, DOI 10.1016/0167-5699(89)90173-4; DOSCH HM, 1982, NEW ENGL J MED, V306, P406, DOI 10.1056/NEJM198202183060707; FEARON ER, 1987, NEW ENGL J MED, V316, P427, DOI 10.1056/NEJM198702193160802; FRENCH MAH, 1984, CLIN EXP IMMUNOL, V56, P473; FUJIMURA S, 1985, CHEST, V88, P221, DOI 10.1378/chest.88.2.221; GEHA RS, 1974, NEW ENGL J MED, V291, P1, DOI 10.1056/NEJM197407042910101; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; HALUSKA FG, 1987, P NATL ACAD SCI USA, V84, P6835, DOI 10.1073/pnas.84.19.6835; HAMILTON RG, 1987, CLIN CHEM, V33, P1707; HAMMARSTROM L, 1987, CLIN IMMUNOL IMMUNOP, V45, P461, DOI 10.1016/0090-1229(87)90097-3; HAMMARSTROM L, 1987, J IMMUNOGENET, V4, P197; HANDZEL ZT, 1988, IMUNOL ALLERGY PRACT, V10, P17; HENNEY CS, 1989, IMMUNOL TODAY, V10, P170, DOI 10.1016/0167-5699(89)90175-8; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; INSEL RA, 1986, NEW ENGL J MED, V315, P499, DOI 10.1056/NEJM198608213150807; JANDL RC, 1988, CLIN IMMUNOL IMMUNOP, V46, P115, DOI 10.1016/0090-1229(88)90011-6; JELINEK DF, 1987, ADV IMMUNOL, V40, P1, DOI 10.1016/S0065-2776(08)60237-0; KAWANAUGH AF, 1989, INSIGHTS ALLERGY, V4, P1; KLEMOLA T, 1987, ANN CLIN RES, V19, P248; KORSMEYER SJ, 1987, J CLIN INVEST, V79, P1291, DOI 10.1172/JCI112951; KUHN LC, 1982, TRENDS BIOCHEM SCI, V7, P299, DOI 10.1016/0968-0004(82)90017-2; KURTZMAN G, 1989, NEW ENGL J MED, V321, P519, DOI 10.1056/NEJM198908243210807; KWAN SP, 1986, J CLIN INVEST, V77, P649, DOI 10.1172/JCI112351; LAWTON AR, 1972, J LAB CLIN MED, V80, P26; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; LEE SI, 1986, MONOGR ALLERGY, V19, P108; LEFRANC MP, 1987, FEBS LETT, V213, P231, DOI 10.1016/0014-5793(87)81496-5; LEVITT D, 1983, J CLIN INVEST, V72, P1650, DOI 10.1172/JCI111124; LUKEN MR, 1987, BLOOD, V70, P1316; MANGAN KF, 1986, AM J HEMATOL, V23, P167, DOI 10.1002/ajh.2830230211; MATHESON DS, 1987, J IMMUNOL, V138, P2469; MAX EE, 1984, FUNDAMENTAL IMMUNOLO, P167; MAYER L, 1979, NEW ENGL J MED, V63, P385; MCBRIDE OW, 1982, J EXP MED, V155, P1480, DOI 10.1084/jem.155.5.1480; NAKAGAWA N, 1987, J IMMUNOL, V138, P795; NOLTE MT, 1979, CLIN EXP IMMUNOL, V36, P237; OCHS HD, 1982, J CLIN IMMUNOL, V2, pS22, DOI 10.1007/BF00918363; OCHS HD, 1984, AM J MED, V76, P78, DOI 10.1016/0002-9343(84)90324-3; OHNO T, 1987, CLIN EXP IMMUNOL, V68, P630; Oxelius V A, 1986, Monogr Allergy, V20, P106; OXELIUS VA, 1981, NEW ENGL J MED, V304, P1476, DOI 10.1056/NEJM198106113042408; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PERRI RT, 1985, BLOOD, V66, P345; PIROFSKY B, 1982, J CLIN IMMUNOL, V2, pS7, DOI 10.1007/BF00918361; PIROFSKY B, 1984, AM J MED, V76, P53, DOI 10.1016/0002-9343(84)90320-6; Plebani A, 1986, Monogr Allergy, V20, P171; ROIFMAN CM, 1988, PEDIATR INFECT DIS J, V7, pS92; ROMAN S, 1988, J IMMUNOL, V140, P3622; ROSEN FS, 1986, CLIN IMMUNOL IMMUNOP, V40, P166, DOI 10.1016/0090-1229(86)90082-6; ROSEN FS, 1984, NEW ENGL J MED, V311, P300, DOI 10.1056/NEJM198408023110506; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; SCHUR PH, 1970, NEW ENGL J MED, V283, P631, DOI 10.1056/NEJM197009172831205; SCHWABER J, 1988, J CLIN INVEST, V82, P1471, DOI 10.1172/JCI113754; SCHWABER J, 1988, J CLIN INVEST, V81, P514, DOI 10.1172/JCI113349; SCHWABER J, 1988, J CLIN INVEST, V81, P2004, DOI 10.1172/JCI113550; SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402; SODERSTROM T, 1987, INT ARCH ALLER A IMM, V82, P476, DOI 10.1159/000234258; STIEHM ER, 1987, ANN INTERN MED, V107, P367, DOI 10.7326/0003-4819-107-2-367; STIEHM ER, 1986, CLIN IMMUNOL IMMUNOP, V40, P69, DOI 10.1016/0090-1229(86)90070-X; STROBER W, 1976, NEW ENGL J MED, V294, P351, DOI 10.1056/NEJM197602122940701; TAUSSIG MJ, 1989, IMMUNOL TODAY, V10, P143, DOI 10.1016/0167-5699(89)90163-1; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WALDMAN TA, 1988, IMMUNOLOGICAL DIS, P430; Waldmann T A, 1976, Trans Assoc Am Physicians, V89, P215; WILTON AN, 1985, IMMUNOGENETICS, V21, P333, DOI 10.1007/BF00430799; WRIGHT PF, 1977, J PEDIATR-US, V91, P408, DOI 10.1016/S0022-3476(77)81309-7; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZOLA H, 1987, IMMUNOL TODAY, V8, P308, DOI 10.1016/0167-5699(87)90018-1	92	42	43	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				1	17		10.1016/0091-6749(91)90203-Z	http://dx.doi.org/10.1016/0091-6749(91)90203-Z			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1704022				2022-12-18	WOS:A1991EX98500001
J	LAUSCHADENDORF, S; RUSCHE, AF; WEBER, AK; BUETTNERGOETZ, P; WAHN, U				LAUSCHADENDORF, S; RUSCHE, AF; WEBER, AK; BUETTNERGOETZ, P; WAHN, U			SHORT-TERM EFFECT OF SOLIDIFIED BENZYL BENZOATE ON MITE-ALLERGEN CONCENTRATIONS IN HOUSE DUST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CONTROLLED TRIAL; DERMATOPHAGOIDES-PTERONYSSINUS; AVOIDANCE MEASURES; SENSITIVE ASTHMA; D-FARINAE; ACARICIDE; REDUCTION; CHILDREN	The effect of solidified benzyl benzoate (bb) foam and powder on concentrations of the major allergens of Dermatophagoides pteronyssinus (Der p I) and D. farinae (Der f I) in dust samples from mattresses and carpets in 22 households was investigated in a randomized, double-blind, placebo-controlled trial. All houses had been demonstrated to have significant (greater-than-or-equal-to 2000 ng/gm of dust) mite-allergen concentrations on mattresses. Dust samples were collected from mattresses and carpets before treatment and on days 10, 30, and 60 after the first treatment. There was a second application on day 10. Der p I and Der f I were determined by a sandwich-type ELISA with monoclonal noncross-reacting antibodies to Der p I and polyclonal monospecific antibodies to Der f I. There was a significant reduction of mite allergens in mattresses and carpets within both bb-treated and control groups, but only the results on carpets of the bb-treated group were significantly different from results of the control group on days 30 and 60 (p < 0.05).	INST MED STAT & INFORMAT STEGLITZ,BERLIN,GERMANY		LAUSCHADENDORF, S (corresponding author), FREE UNIV BERLIN,CHILDRENS HOSP,HEUBNERWEG 6,W-1000 BERLIN 19,GERMANY.			Ruggeberg, Anne/0000-0003-2561-0182				BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; BURR ML, 1988, ALLERGY, V43, P299, DOI 10.1111/j.1398-9995.1988.tb00904.x; CARSWELL F, 1982, CLIN ALLERGY, V12, P533, DOI 10.1111/j.1365-2222.1982.tb02552.x; CGREEN WF, 1984, LANCET, V1, P160; COLLOFF MJ, 1986, CLIN ALLERGY, V16, P41, DOI 10.1111/j.1365-2222.1986.tb01952.x; DAUGHTRY C, 1945, JAMA-J AM MED ASSOC, V127, P88; DESTGEORGESGRID.D, 1988, EXP APPL ACAROL, V4, P63; DIETEMANN A, 1989, J ALLERGY CLIN IMMUN, V83, P263; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; ELIXMANN JH, 1988, ALLERGOLOGIE, V11, P274; FASSETT DW, 1963, ESTERS, V2, P1847; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; GREEN WF, 1989, CLIN EXP ALLERGY, V19, P203, DOI 10.1111/j.1365-2222.1989.tb02365.x; GRHAM BE, 1945, J PHARM, V84, P358; HAUSEN BM, 1988, COMMUNICATION; HELLERHAUPT A, 1974, J MED ENTOMOL, V11, P551; HORN N, 1987, INT ARCH ALLER A IMM, V83, P404, DOI 10.1159/000234376; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LEYSEN MT, 1974, ACTA ALLERGOL, V29, P455, DOI 10.1111/j.1398-9995.1974.tb01665.x; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; PENAUD A, 1977, CLIN ALLERGY, V7, P49, DOI 10.1111/j.1365-2222.1977.tb01424.x; PLATTSMILLS TAE, 1985, INT ARCH ALLER A IMM, V77, P163; PLATTSMILLS TAE, 1982, LANCET, V2, P675; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; SCHWARTZ B, 1987, INT ARCH ALLER A IMM, V82, P447, DOI 10.1159/000234250; VANDEMAELE B, 1983, PHARMATHERAPEUTICA, V3, P441; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; WALSHAW MJ, 1986, Q J MED, V58, P199	32	42	46	1	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				41	47		10.1016/0091-6749(91)90211-6	http://dx.doi.org/10.1016/0091-6749(91)90211-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1991922				2022-12-18	WOS:A1991EX98500006
J	LOCKEY, RF; TURKELTAUB, PC; OLIVE, CA; BAIRDWARREN, IA; OLIVE, ES; BUKANTZ, SC				LOCKEY, RF; TURKELTAUB, PC; OLIVE, CA; BAIRDWARREN, IA; OLIVE, ES; BUKANTZ, SC			THE HYMENOPTERA VENOM STUDY .2. SKIN-TEST RESULTS AND SAFETY OF VENOM SKIN TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JAMES A HALEY VET ADM MED CTR,TAMPA,FL 33612; US FDA,CTR DRUGS & BIOL,BETHESDA,MD 20014	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; US Food & Drug Administration (FDA)	LOCKEY, RF (corresponding author), UNIV S FLORIDA,VET ADM HOSP,COLL MED,DEPT MED,DIV ALLERGY & IMMUNOL,VAR 111D,TAMPA,FL 33612, USA.		turkeltaub, paul/U-7729-2019; turkeltaub, paul/AAG-6160-2019	turkeltaub, paul/0000-0002-7350-1469				BOUSQUET J, 1988, ANN ALLERGY, V61, P63; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; GOLDEN D B K, 1982, Journal of Allergy and Clinical Immunology, V69, P124; GOLDEN DBK, 1987, CLIN REV ALLERG, V5, P119; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; GRANT JA, 1983, J ALLERGY CLIN IMMUN, V72, P399, DOI 10.1016/0091-6749(83)90506-7; GREEN AW, 1980, J ALLERGY CLIN IMMUN, V66, P186, DOI 10.1016/0091-6749(80)90037-8; HOFFMAN DR, 1987, CLIN REV ALLERG, V5, P75; KING TP, 1987, CLIN REV ALLERG, V5, P137; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; OST LG, 1984, BEHAV RES THER, V22, P109, DOI 10.1016/0005-7967(84)90099-8; PATRIZZI R, 1979, ALLERGY, V34, P249, DOI 10.1111/j.1398-9995.1979.tb01705.x; RAMIREZ DA, 1981, ANN ALLERGY, V47, P303; RUETZ PP, 1967, MEDICINE, V46, P363, DOI 10.1097/00005792-196709000-00001; SCHUBERTH KC, 1982, J PEDIATR-US, V100, P546, DOI 10.1016/S0022-3476(82)80750-6; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SULLIVAN TJ, 1981, J ALLERGY CLIN IMMUN, V68, P171, DOI 10.1016/0091-6749(81)90180-9; TURKELTAUB PC, 1989, J ALLERGY CLIN IMMUN, V84, P886, DOI 10.1016/0091-6749(89)90384-9	19	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				967	974		10.1016/0091-6749(89)90396-5	http://dx.doi.org/10.1016/0091-6749(89)90396-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2600328				2022-12-18	WOS:A1989CG29300017
J	RESHEF, A; KAGEYSOBOTKA, A; ADKINSON, NF; LICHTENSTEIN, LM; NORMAN, PS				RESHEF, A; KAGEYSOBOTKA, A; ADKINSON, NF; LICHTENSTEIN, LM; NORMAN, PS			THE PATTERN AND KINETICS IN HUMAN-SKIN OF ERYTHEMA AND MEDIATORS DURING THE ACUTE AND LATE-PHASE RESPONSE (LPR)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CLIN IMMUNOL, BALTIMORE, MD 21205 USA	Johns Hopkins University			Reshef, Avner/AAL-3638-2020	Reshef, Avner/0000-0002-3324-7072	NIAID NIH HHS [AI 20136, AI 07290, AI 07056] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI020136, T32AI007056] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1977, J LAB CLIN MED, V90, P1043; ALAM R, 1984, ANN ALLERGY, V53, P66; ATKINS P, 1973, J ALLERGY CLIN IMMUN, V51, P263, DOI 10.1016/0091-6749(73)90128-0; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BOSCHETTO P, 1986, J ALLERGY CLIN IMMUN, V77, P244; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P242; COCKCROFT DW, 1986, J ALLERGY CLIN IMMUN, V77, P122; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; DORSCH W, 1982, J ALLERGY CLIN IMMUN, V70, P236, DOI 10.1016/0091-6749(82)90059-8; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; HAYES EC, 1983, J IMMUNOL, V131, P429; KIISTALA U, 1967, J INVEST DERMATOL, V48, P466, DOI 10.1038/jid.1967.72; MACDONALD SM, IN PRESS CLIN EXP AL; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; ORCHARD MA, 1986, J IMMUNOL, V136, P2240; PETERS SP, 1984, J IMMUNOL, V132, P1972; PETERS SP, 1984, J PHARMACOL EXP THER, V228, P400; PETERS SP, 1985, ALLERGY, P111; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P95, DOI 10.1016/0091-6749(88)90057-7; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; RUZICKA T, 1987, J IMMUNOL, V138, P539; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SCHULMAN ES, 1981, AM REV RESPIR DIS, V124, P402; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SHALIT M, 1988, J IMMUNOL, V141, P821; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; TALBOT SF, 1984, J ALLERGY CLIN IMMUN, V74, P819, DOI 10.1016/0091-6749(84)90185-4; THUESON DO, 1979, J IMMUNOL, V123, P626; WARNER JA, 1986, J IMMUNOL, V136, P2583; WASSERMAN SI, 1983, J ALLERGY CLIN IMMUN, V72, P101, DOI 10.1016/0091-6749(83)90512-2; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0	41	42	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				678	687		10.1016/0091-6749(89)90296-0	http://dx.doi.org/10.1016/0091-6749(89)90296-0			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2478604	Bronze			2022-12-18	WOS:A1989CA31400005
J	RAO, KS; MENON, PK; HILMAN, BC; SEBASTIAN, CS; BAIRNSFATHER, L				RAO, KS; MENON, PK; HILMAN, BC; SEBASTIAN, CS; BAIRNSFATHER, L			DURATION OF THE SUPPRESSIVE EFFECT OF TRICYCLIC ANTIDEPRESSANTS ON HISTAMINE-INDUCED WHEAL-AND-FLARE REACTIONS IN HUMAN-SKIN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									1501 KINGS HIGHWAY, SHREVEPORT, LA 71130 USA; LOUISIANA STATE UNIV, SCH MED, DEPT PEDIAT, PULM ALLERGY SECT, SHREVEPORT, LA 71105 USA; LOUISIANA STATE UNIV, SCH MED, DEPT PSYCHIAT, SHREVEPORT, LA 71105 USA; LOUISIANA STATE UNIV, SCH MED, DEPT BIOMETRY, SHREVEPORT, LA 71105 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport								BAIN WA, 1949, P ROY SOC MED, V42, P615; BAIN WA, 1948, LANCET, V252, P964, DOI 10.1016/S0140-6736(48)91644-4; BAIN WA, 1951, ANALYST, V76, P573, DOI 10.1039/an9517600573; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; FOWLE ASE, 1971, EUR J CLIN PHARMACOL, V3, P215, DOI 10.1007/BF00565009; GALANT SP, 1973, J ALLERGY CLIN IMMUN, V51, P11, DOI 10.1016/0091-6749(73)90003-1; GOLDSOBEL AB, 1986, J ALLERGY CLIN IMMUN, V78, P867, DOI 10.1016/0091-6749(86)90232-0; HARVEY RP, 1980, J ALLERGY CLIN IMMUN, V65, P136, DOI 10.1016/0091-6749(80)90198-0; JOUBERT L, 1969, CLIN PHARMACOL THER, V10, P250; LEE RE, 1977, ANN ALLERGY, V38, P231; LEWIS T, 1927, BLOOD VESSELS HUMAN, P1; RICHELSON E, 1983, MAYO CLIN PROC, V58, P40; RICHELSON E, 1979, MAYO CLIN PROC, V54, P669; RICHELSON E, 1982, J CLIN PSYCHIAT, V43, P4; RICHELSON E, 1978, NATURE, V274, P176, DOI 10.1038/274176a0; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; THOMAS L, 1924, HEART, V11, P109; THOMAS RHM, 1985, J ALLERGY CLIN IMMUN, V76, P864, DOI 10.1016/0091-6749(85)90761-4; 1987, PHYSICIANS DESK REFE	19	42	44	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1988	82	5	1				752	757		10.1016/0091-6749(88)90075-9	http://dx.doi.org/10.1016/0091-6749(88)90075-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R1708	2903876				2022-12-18	WOS:A1988R170800007
J	THORPE, SC; KEMENY, DM; PANZANI, R; LESSOF, MH				THORPE, SC; KEMENY, DM; PANZANI, R; LESSOF, MH			ALLERGY TO CASTOR BEAN .1. ITS RELATIONSHIP TO SENSITIZATION TO COMMON INHALANT ALLERGENS (ATOPY)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									GUYS HOSP,UNITED MED & DENT SCH,DIV MED,ST THOMAS ST,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London								ALILAIRE E, 1914, ANN I PASTEUR, V28, P605; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1021, DOI 10.1016/0019-2791(72)90112-7; Figley KD, 1928, J AMER MED ASSOC, V90, P79, DOI 10.1001/jama.1928.02690290009003; KEMENY DM, 1980, CLIN ALLERGY, V10, P413, DOI 10.1111/j.1365-2222.1980.tb02124.x; KEMENY DM, 1981, CLIN ALLERGY, V11, P463, DOI 10.1111/j.1365-2222.1981.tb01620.x; KEMENY DM, 1981, INT ARCH ALLER A IMM, V66, P96, DOI 10.1159/000232879; LESSOF MH, 1980, CLIN ALLERGY, V10, P115, DOI 10.1111/j.1365-2222.1980.tb02088.x; LUTSKY II, 1975, ANN ALLERGY, V35, P201; ORDMAN D, 1955, INT ARCH ALLER A IMM, V7, P10, DOI 10.1159/000228201; PANZANI R, 1957, INT ARCH ALLER A IMM, V11, P224, DOI 10.1159/000228420; PEPYS J, 1984, CLIN IMMUNOL ALLERGY, V4, P131; Pepys J., 1975, , Clinical aspects of immunology., P877; TAYLOR G, 1976, NATURE, V260, P280, DOI 10.1038/260280a0; THORPE SC, 1987, INT ARCH ALLER A IMM, V82, P456, DOI 10.1159/000234253; THORPE SC, 1988, J ALLERGY CLIN IMMUN, V82, P67, DOI 10.1016/0091-6749(88)90053-X	15	42	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					62	66		10.1016/0091-6749(88)90052-8	http://dx.doi.org/10.1016/0091-6749(88)90052-8			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392371				2022-12-18	WOS:A1988P400400011
J	GRANT, JA; BERNSTEIN, DI; BUCKLEY, CE; CHU, T; FOX, RW; ROCKLIN, RE; SCHOENWETTER, WF; SPECTOR, SL; STAFFORD, CT; STROH, JE; KARPENTER, KM				GRANT, JA; BERNSTEIN, DI; BUCKLEY, CE; CHU, T; FOX, RW; ROCKLIN, RE; SCHOENWETTER, WF; SPECTOR, SL; STAFFORD, CT; STROH, JE; KARPENTER, KM			DOUBLE-BLIND COMPARISON OF TERFENADINE, CHLORPHENIRAMINE, AND PLACEBO IN THE TREATMENT OF CHRONIC IDIOPATHIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI, MED CTR, DIV IMMUNOL, CINCINNATI, OH 45267 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; UNIV S FLORIDA, COLL MED, TAMPA, FL 33612 USA; TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, BOSTON, MA 02111 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90024 USA; ALLERGY & ASTHMA ASSOCIATES SANTA CLARA VALLEY, SAN JOSE, CA USA; PK NICOLLET MED CTR, MINNEAPOLIS, MN USA	University System of Ohio; University of Cincinnati; Duke University; State University System of Florida; University of South Florida; Tufts Medical Center; Tufts University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	GRANT, JA (corresponding author), UNIV TEXAS, MED BRANCH, DEPT MED, CLIN SCI 409, ROUTE G-62, GALVESTON, TX 77550 USA.							BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BOGGS PB, 1987, J RESPIR DIS, V7, P36; CERIO R, 1984, CLIN ALLERGY, V14, P139, DOI 10.1111/j.1365-2222.1984.tb02644.x; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; FERGUSON J, 1985, BRIT J CLIN PHARMACO, V20, P639, DOI 10.1111/j.1365-2125.1985.tb05122.x; FREDRIKSSON T, 1986, CUTIS, V38, P128; GIBSON JP, 1982, ARZNEIM DRUG RES, V22, P1179; GRANT JA, 1986, FASEB J, V45, P2653; GUILL MF, 1986, J ALLERGY CLIN IMMUN, V78, P4, DOI 10.1016/0091-6749(86)90107-7; HARADA S, 1985, ANN ALLERGY, V55, P284; KAPLAN AP, 1978, J ALLERGY CLIN IMMUN, V61, P350, DOI 10.1016/0091-6749(78)90113-6; KEMP JP, 1985, ANN ALLERGY, V54, P502; KRAUSE LB, 1985, ANN ALLERGY, V55, P284; LESSON GA, 1982, ARZNEIMITTEL-FORSCH, V32, P1173; MATHEWS KP, 1983, J ALLERGY CLIN IMMUN, V72, P1, DOI 10.1016/0091-6749(83)90042-8; NATBONY SF, 1983, J ALLERGY CLIN IMMUN, V71, P177, DOI 10.1016/0091-6749(83)90096-9; PATEL KR, 1984, BMJ-BRIT MED J, V288, P1498; QUARANTA J, 1987, J ALLERGY CLIN IMMUN, V79, P182; RAFFERTY P, 1987, AM REV RESPIR DIS, V135, P181; ROSE C, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1171; ROSENSTREICH DL, 1986, J ALLERGY CLIN IMMUN, V78, P1099, DOI 10.1016/0091-6749(86)90256-3; SORKIN EM, 1985, DRUGS, V29, P34, DOI 10.2165/00003495-198529010-00002; WEISCH NL, 1982, ARZNEIM DRUG RES, V22, P1167	23	42	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1988	81	3					563	570		10.1016/0091-6749(88)90197-2	http://dx.doi.org/10.1016/0091-6749(88)90197-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6181	3126220	Bronze			2022-12-18	WOS:A1988M618100013
J	COCKCROFT, DW				COCKCROFT, DW			NONALLERGIC AIRWAY RESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											COCKCROFT, DW (corresponding author), UNIV HOSP SASKATOON,DEPT MED,RESP MED SECT,SASKATOON S7N 0X0,SASKATCHEWAN,CANADA.							ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; AHRENS RC, 1984, AM REV RESPIR DIS, V129, P903; ALTOUNYAN REC, 1970, DISODIUM CROMOGLYCAT, P47; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERTON RC, 1979, J ALLERGY CLIN IMMUN, V63, P315, DOI 10.1016/0091-6749(79)90125-8; AQUILINA AT, 1980, AM REV RESPIR DIS, V122, P3; BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/0007-0971(75)90090-X; BOSCHETTO P, 1986, J ALLERGY CLIN IMMUN, V77, P244; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOULET LP, IN PRESS J ALLERGY C; BOUSHEY HA, 1985, AM REV RESPIR DIS, V131, P312; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; CARTIER A, 1984, CLIN ALLERGY, V14, P193, DOI 10.1111/j.1365-2222.1984.tb02652.x; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHUNG KF, 1985, J APPL PHYSIOL, V58, P1347, DOI 10.1152/jappl.1985.58.4.1347; COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; COCKCROFT DW, 1982, ANN ALLERGY, V48, P93; COCKCROFT DW, 1985, ANN ALLERGY, V55, P527; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, IN PRESS ANN ALLERGY; COCKCROFT DW, 1985, J ALLERGY CLIN IMMUN, V75, pA142; Cockcroft DW, 1985, AIRWAY RESPONSIVENES, P22; COCKCROFT DW, 1984, ANN ALLERGY, V53, P26; COOKSON WOCM, 1986, CLIN ALLERGY, V16, P425, DOI 10.1111/j.1365-2222.1986.tb01977.x; DANNIEL EE, 1985, AIRWAY RESPONSIVENES, P91; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIMEO MJ, 1981, AM REV RESPIR DIS, V124, P245; DOLOVICH J, 1981, THORAX, V36, P641, DOI 10.1136/thx.36.9.614; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GERRARD JW, 1980, AM REV RESPIR DIS, V122, P577; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HALPERIN SA, 1985, AM REV RESPIR DIS, V132, P976; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; HARGREAVE FE, 1985, AIRWAY RESPONSIVENES; HARKONEN H, 1983, AM REV RESPIR DIS, V128, P890; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; INOUE H, 1986, AM REV RESPIR DIS, V133, P367; ISLAM MS, 1972, INT ARCH ARBEITSMED, V29, P221, DOI 10.1007/BF00539250; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; JUNIPER EF, 1982, THORAX, V37, P288, DOI 10.1136/thx.37.4.288; KERREBIJN KF, 1986, EUR J RESPIR DIS, V69, P98; LAM S, 1985, CHEST, V88, P856, DOI 10.1378/chest.88.6.856; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MAPP CE, 1986, EUR J RESPIR DIS, V69, P276; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; MCINTYRE EL, 1982, EUR J RESPIR DIS, V63, P535; MURRAY AB, 1983, PEDIATRICS, V71, P418; MURRAY AB, 1981, J ALLERGY CLIN IMMUN, V68, P119, DOI 10.1016/0091-6749(81)90169-X; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OBYRNE PM, 1986, CHEST, V90, P575, DOI 10.1378/chest.90.4.575; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; RYAN G, 1981, AM REV RESPIR DIS, V123, P195; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SCADDING JG, 1983, ASTHMA, P1; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; SHERTER CB, 1981, CLIN CHEST MED, V2, P67; SLEPIAN IK, 1985, CHEST, V87, P386, DOI 10.1378/chest.87.3.386; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; SPECTOR S, 1976, AM REV RESPIR DIS, V113, P43; STERK P J, 1984, Respiration, V46, P58; STERK PJ, 1986, NOCTURNAL DYSPNOEA I, P73; STERLING GM, 1967, BRIT MED J, V3, P275, DOI 10.1136/bmj.3.5560.275; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P469, DOI 10.1016/0091-6749(84)90380-4; THOMSON NC, 1981, J ALLERGY CLIN IMMUN, V68, P392, DOI 10.1016/0091-6749(81)90138-X; TURCOTTE H, 1987, J ALLERGY CLIN IMMUN, V79, P148; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; ZAMEL N, 1984, J APPL PHYSIOL, V56, P936, DOI 10.1152/jappl.1984.56.4.936	80	42	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1988	81	1					111	119		10.1016/0091-6749(88)90229-1	http://dx.doi.org/10.1016/0091-6749(88)90229-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M0274	3276756				2022-12-18	WOS:A1988M027400018
J	LIVNI, E; HALEVY, S; STAHL, B; JOSHUA, H				LIVNI, E; HALEVY, S; STAHL, B; JOSHUA, H			THE APPEARANCE OF MACROPHAGE MIGRATION-INHIBITION FACTOR IN DRUG-REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BEILINSON MED CTR,CTR DRUG INFORMAT,IL-49100 PETACH TIKVA,ISRAEL; TEL AVIV UNIV,SACKLER SCH MED,TEL AVIV,ISRAEL	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	LIVNI, E (corresponding author), BEILINSON MED CTR,DEPT DERMATOL,CLIN LABS,CLIN LAB,IL-49100 PETACH TIKVA,ISRAEL.							ADERKA D, 1986, ANN ALLERGY, V56, P341; ADKINSON NF, 1984, J ALLERGY CLIN IMMUN, V74, P567, DOI 10.1016/0091-6749(84)90108-8; BARNA BP, 1980, AM J CLIN PATHOL, V73, P172; BENVENISTE J, 1981, CLIN ALLERGY, V11, P1, DOI 10.1111/j.1365-2222.1981.tb01559.x; DARCY PF, 1982, PHARM INT, V3, P389; DAVID M, 1981, J AM ACAD DERMATOL, V5, P702, DOI 10.1016/S0190-9622(81)80125-9; DELPRE G, 1979, AM J MED SCI, V277, P207, DOI 10.1097/00000441-197903000-00010; DELPRE G, 1982, AM J MED SCI, V283, P153, DOI 10.1097/00000441-198205000-00006; DESWARTE RD, 1984, J ALLERGY CLIN IMMUN, V74, P209, DOI 10.1016/0091-6749(84)90246-X; FEUERMAN EJ, 1979, CUTIS, V23, P489; HALEVY S, 1986, ANN ALLERGY, V56, P402; HALEVY S, 1979, CUTIS, V24, P95; KURITZKY A, 1976, J NEUROL SCI, V30, P369, DOI 10.1016/0022-510X(76)90140-4; LIVNI E, 1982, ARCH ANDROLOGY, V8, P69, DOI 10.3109/01485018208987021; MATHEWS KP, 1984, J ALLERGY CLIN IMMUN, V74, P558, DOI 10.1016/0091-6749(84)90107-6; MCEVOY GK, 1986, DRUG INFORMATION AM; MONERETVAUTRIN DA, 1983, THERAPIE, V33, P779; MOTA I, 1956, NATURE, V177, P427, DOI 10.1038/177427a0; NORDLIND K, 1983, INT ARCH ALLER A IMM, V70, P30, DOI 10.1159/000233269; PATTERSON R, 1982, JAMA-J AM MED ASSOC, V248, P2637, DOI 10.1001/jama.248.20.2637; RAJAPAKSE DA, 1970, NATURE, V226, P857, DOI 10.1038/226857a0; RING J, 1981, BEHRING I MITT, V68, P141; ROTMENSCH HH, 1981, ARCH INTERN MED, V14, P1797; RYTTER M, 1982, BRIT J DERMATOL, V106, P161, DOI 10.1111/j.1365-2133.1982.tb00925.x; SARKANY I, 1978, AUSTRALAS J DERMATOL, V19, P45, DOI 10.1111/j.1440-0960.1978.tb00189.x; SARKANY I, 1967, LANCET, V1, P743; SAURAT JH, 1978, ALLERGY, V33, P125, DOI 10.1111/j.1398-9995.1978.tb01521.x; SHELLEY WB, 1961, NATURE, V191, P1056, DOI 10.1038/1911056a0; SIDI Y, 1981, ISRAEL J MED SCI, V17, P1119; SPENGLER H, 1974, P501; TRIPODI D, 1971, TRANSPLANTATION, V11, P487, DOI 10.1097/00007890-197105000-00010; VICKERS MR, 1974, IMMUNOLOGY, V26, P425; WARRINGTON RJ, 1979, CAN MED ASSOC J, V120, P1089; WARRINGTON RJ, 1979, CLIN EXP IMMUNOL, V38, P148; WIDE L, 1971, Clinical Allergy, V1, P171, DOI 10.1111/j.1365-2222.1971.tb03016.x; WOLF R, 1984, ANN ALLERGY, V52, P300	36	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1987	80	6					843	849		10.1016/S0091-6749(87)80275-0	http://dx.doi.org/10.1016/S0091-6749(87)80275-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L5020	3320162				2022-12-18	WOS:A1987L502000012
J	LONGBOTTOM, JL				LONGBOTTOM, JL			ANTIGENS AND ALLERGENS OF ASPERGILLUS-FUMIGATUS .2. THEIR FURTHER IDENTIFICATION AND PARTIAL CHARACTERIZATION OF A MAJOR ALLERGEN (AG-3)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LONGBOTTOM, JL (corresponding author), BROMPTON HOSP,INST CARDIOTHORAC,DEPT ALLERGY & CLIN IMMUNOL,FULHAM RD,LONDON SW3 6HP,ENGLAND.							AUKRUST L, 1984, MOULD ALLERGY WORKSH, P61; CALVANICO NJ, 1981, CLIN EXP IMMUNOL, V45, P662; DREBORG S, 1985, HDB EXPT IMMUNOLOGY; HARBOE NMG, 1983, SCAND J IMMUNOL S10, V17, P107; HEARN VM, 1980, MYKOSEN, V23, P549; KAUFFMANN HF, 1980, INT ARCH ALLER A IMM, V62, P265, DOI 10.1159/000232522; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P132, DOI 10.1016/0091-6749(84)90275-6; KURUP VP, 1983, INFECT IMMUN, V41, P698, DOI 10.1128/IAI.41.2.698-701.1983; LONGBOTTOM JL, 1983, CLIN EXP IMMUNOL, V53, P354; LONGBOTTOM JL, 1983, J ALLERGY CLIN IMMUN, V72, P668, DOI 10.1016/0091-6749(83)90627-9; LONGBOTTOM JL, 1986, J ALLERGY CLIN IMMUN, V78, P9, DOI 10.1016/0091-6749(86)90108-9; LONGBOTTOM JL, 1985, HDB EXPT IMMUNOLOGY; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; SCHONHEYDER H, 1983, INT ARCH ALLER A IMM, V70, P108, DOI 10.1159/000233306; SCHONHEYDER H, 1984, INT ARCH ALLER A IMM, V74, P262, DOI 10.1159/000233555; WALLENBECK I, 1984, INT ARCH ALLER A IMM, V73, P166, DOI 10.1159/000233459	16	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1986	78	1	1				18	24		10.1016/0091-6749(86)90109-0	http://dx.doi.org/10.1016/0091-6749(86)90109-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D2996	3522706				2022-12-18	WOS:A1986D299600004
J	GOLDSTEIN, MF; ATKINS, PC; COGEN, FC; KORNSTEIN, MJ; LEVINE, RS; ZWEIMAN, B				GOLDSTEIN, MF; ATKINS, PC; COGEN, FC; KORNSTEIN, MJ; LEVINE, RS; ZWEIMAN, B			ALLERGIC ASPERGILLUS SINUSITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN, SCH MED, DEPT RADIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania								AXELSSON H, 1978, ACTA OTO-LARYNGOL, V86, P303, DOI 10.3109/00016487809124751; BECKER MH, 1968, RADIOLOGY, V90, P49, DOI 10.1148/90.1.49; BENNETT JE, 1979, PRINCIPLES PRACTICE, P2002; BLITZER A, 1982, OTOLARYNGOLOGY, P48; CENTENO RS, 1981, RADIOLOGY, V140, P383, DOI 10.1148/radiology.140.2.7255714; CHUSID MJ, 1975, ANN INTERN MED, V82, P682, DOI 10.7326/0003-4819-82-5-682; ENGLISH GM, 1983, ALLERGY PRINCIPLES P, P1229; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GERSON SL, 1984, ANN INTERN MED, V100, P345, DOI 10.7326/0003-4819-100-3-345; GONTY AA, 1977, ORAL SURG ORAL MED O, V43, P350, DOI 10.1016/0030-4220(77)90320-6; GREEN WH, 1967, AMER J ROENTGENOL RA, V101, P802, DOI 10.2214/ajr.101.4.802; GREEN WR, 1969, ARCH OPHTHALMOL-CHIC, V82, P302, DOI 10.1001/archopht.1969.00990020304002; GROWTH RG, 1955, AM J CLIN PATHOL, V25, P975; GWALTNEY JM, 1974, PRINCIPLES PRACTICE, P458; HERBERT PA, 1981, CHEST, V80, P220, DOI 10.1378/chest.80.2.220; HESSELINK JR, 1979, RADIOLOGY, V133, P397, DOI 10.1148/133.2.397; HORA JF, 1965, LARYNGOSCOPE, V75, P768, DOI 10.1288/00005537-196505000-00004; JACOBS M, 1982, J COMPUT ASSIST TOMO, V6, P721, DOI 10.1097/00004728-198208000-00010; Jahrsdoerfer R A, 1979, Am J Otolaryngol, V1, P6, DOI 10.1016/S0196-0709(79)80003-4; KATZENSTEIN A, 1982, SURGICAL PATHOLOGY N, P136; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KATZENSTEIN ALA, 1983, AM J SURG PATHOL, V7, P439, DOI 10.1097/00000478-198307000-00006; KERN EB, 1984, J ALLERGY CLIN IMMUN, V73, P25, DOI 10.1016/0091-6749(84)90480-9; KNIGHT A, 1983, ANN ALLERGY, V50, P81; KOGEN SL, 1981, NEW ENGL J MED, V604, P483; LLAMAS R, 1978, CHEST, V73, P871, DOI 10.1378/chest.73.6.871; MARTINSON F D, 1970, Journal of Laryngology and Otology, V84, P857, DOI 10.1017/S0022215100072625; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; MCGILL TJ, 1980, LARYNGOSCOPE, V90, P748; MCGUIRT WF, 1979, LARYNGOSCOPE, V89, P1563, DOI 10.1002/lary.5540891003; MIGLETS AW, 1978, ARCH OTOLARYNGOL, V104, P47; MILOSEY G, 1969, BRIT J SURG, V59, P132; ROBBINS SL, 1976, BASIC PATHOLOGY, P376; ROSAI J, 1981, SURGICAL PATHOLOGY, P205; SAFIRSTEIN B, 1976, CHEST, V70, P6; SLAVIN RG, 1984, J ALLERGY CLIN IMMUN, V74, P17, DOI 10.1016/0091-6749(84)90081-2; SLAVIN RG, 1983, ALLERGY PRINCIPLES P, P1067; STAVETSKY L, 1961, ARCH OTOLARYNGOL, V74, P107; STEVENS MH, 1978, ARCH OTOLARYNGOL, V104, P153; VERESS B, 1973, AM J TROP MED HYG, V22, P765, DOI 10.4269/ajtmh.1973.22.765; WARDER FR, 1975, ARCH OTOLARYNGOL, V101, P683; WILSON M, 1976, RADIOLOGY, V120, P609, DOI 10.1148/120.3.609; YOUNG RC, 1970, MEDICINE, V49, P147, DOI 10.1097/00005792-197003000-00002; Zinneman H H, 1972, Minn Med, V55, P661	45	42	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					515	524		10.1016/0091-6749(85)90737-7	http://dx.doi.org/10.1016/0091-6749(85)90737-7			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	4031323				2022-12-18	WOS:A1985ARC0900017
J	GRAMMER, LC; PATERSON, BF; ROXE, D; DAUGIRDAS, JT; ING, TS; IVANOVICH, PT; BROWN, CB; NICHOLLS, AJ; PATTERSON, R				GRAMMER, LC; PATERSON, BF; ROXE, D; DAUGIRDAS, JT; ING, TS; IVANOVICH, PT; BROWN, CB; NICHOLLS, AJ; PATTERSON, R			IGE AGAINST ETHYLENE OXIDE ALTERED HUMAN-SERUM ALBUMIN IN PATIENTS WITH ANAPHYLACTIC REACTIONS TO DIALYSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,NEPHROL HYPERTENS SECT,CHICAGO,IL 60611; UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,SCH MED,DEPT NEPHROL & TRANSPLANTAT,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; HINES LOYOLA MED CTR,DEPT MED,HINES,IL	Northwestern University; University of Sheffield; Loyola University Chicago	GRAMMER, LC (corresponding author), NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI-11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKIYAMA K, 1984, J IMMUNOL, V133, P3286; CONROY MC, 1977, J IMMUNOL, V118, P1317; CRADDOCK PR, 1977, J CLIN INVEST, V59, P879, DOI 10.1172/JCI108710; DAUGIRDAS JT, 1985, ARCH INTERN MED, V145, P489, DOI 10.1001/archinte.145.3.489; DOLOVICH J, 1978, J ALLERGY CLIN IMMUN, V62, P30, DOI 10.1016/0091-6749(78)90069-6; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V74, P544, DOI 10.1016/0091-6749(84)90392-0; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; MARSHALL C, 1984, Journal of Allergy and Clinical Immunology, V73, P164; NICHOLLS AJ, 1982, BRIT MED J, V285, P1607, DOI 10.1136/bmj.285.6355.1607; PATTERSON R, 1973, Journal of Immunology, V110, P1135; POPLI S, 1982, ARTIF ORGANS, V6, P312; ROBINSON PJ, 1971, BRIT MED J, V1, P528, DOI 10.1136/bmj.1.5748.528; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0; ZEISS CR, 1973, J IMMUNOL, V110, P414	15	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	3					511	514		10.1016/0091-6749(85)90736-5	http://dx.doi.org/10.1016/0091-6749(85)90736-5			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ARC09	4031322				2022-12-18	WOS:A1985ARC0900016
J	VERVLOET, D; ARNAUD, A; SENFT, M; DOR, P; BONGRAND, P; CHARPIN, J; ALAZIA, M				VERVLOET, D; ARNAUD, A; SENFT, M; DOR, P; BONGRAND, P; CHARPIN, J; ALAZIA, M			LEUKOCYTE HISTAMINE-RELEASE TO SUXAMETHONIUM IN PATIENTS WITH ADVERSE REACTIONS TO MUSCLE-RELAXANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP ST MARGUERITE,DEPT IMMUNOL,MARSEILLE,FRANCE; INSERM,F-13258 MARSEILLE 09,FRANCE; CHU TIMONE,DEPT ANESTHESIA & INTENS CARE,F-13385 MARSEILLE 4,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VERVLOET, D (corresponding author), HOP ST MARGUERITE,DEPT CHEST DIS,BP 29,F-13277 MARSEILLE 9,FRANCE.		Bongrand, Pierre/C-4456-2013	Bongrand, Pierre/0000-0001-6185-6572				ASSEM ESK, 1981, ANAESTHESIA, V36, P405, DOI 10.1111/j.1365-2044.1981.tb10248.x; ASSEM ESK, 1983, HDB EXPT PHARM ALLER, V63; BALDO BA, 1983, ANAESTH INTENS CARE, V11, P194, DOI 10.1177/0310057X8301100302; BALDO BA, 1983, NATURE, V306; FISHER M, 1983, MED J AUSTRALIA, V1, P630, DOI 10.5694/j.1326-5377.1983.tb136255.x; FISHER MM, 1980, ANAESTH INTENS CARE, V8, P211, DOI 10.1177/0310057X8000800222; FISHER MM, 1979, ANAESTH INTENS CARE, V7, P58, DOI 10.1177/0310057X7900700110; FISHER MMC, 1980, ANESTHESIOLOGY, V52, P15; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; LICHTENSTEIN LM, 1975, J IMMUNOL, V114, P1962; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MONERETVAUTRIN DA, 1981, CLIN ALLERGY, V11, P175, DOI 10.1111/j.1365-2222.1981.tb01582.x; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SIRAGANIAN RP, 1977, J IMMUNOL, V119, P2078; SIRAGANIAN RP, 1976, J IMMUNOL, V116, P639; VALENTINE RC, 1967, J MOL BIOL, V27, P615, DOI 10.1016/0022-2836(67)90063-0; VERVLOET D, 1983, J ALLERGY CLIN IMMUN, V71, P552, DOI 10.1016/0091-6749(83)90436-0; VERVLOET D, 1979, J ALLERGY CLIN IMMUN, V63, P348, DOI 10.1016/0091-6749(79)90130-1; VERVLOET D, 1983, LANCET, V2, P8360; YOUNGMAN, 1983, LANCET, V2, P597; [No title captured]	21	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					338	342		10.1016/0091-6749(85)90069-7	http://dx.doi.org/10.1016/0091-6749(85)90069-7			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	2579116				2022-12-18	WOS:A1985AEB4600003
J	ROHR, AS; MARSHALL, NA; SAXON, A				ROHR, AS; MARSHALL, NA; SAXON, A			SUCCESSFUL IMMUNOTHERAPY FOR TRIATOMA-PROTRACTA-INDUCED ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NIAID NIH HHS [AI-15332, AI-07126, AI-15251] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015251, P50AI015332, R21AI015251] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		EKKENS DB, 1981, J MED ENTOMOL, V18, P211, DOI 10.1093/jmedent/18.3.211; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Jones JP., 1962, CALIF VECTOR VIEWS, V9, P33; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; LICHTENSTEIN LM, 1979, J ALLERGY CLIN IMMUN, V64, P5, DOI 10.1016/0091-6749(79)90075-7; LINDBERG RE, 1981, J ALLERGY CLIN IMMUN, V67, P25; LYNCH PJ, 1978, CUTIS, V22, P585; MARSHALL NA, 1982, J MED ENTOMOL, V19, P248, DOI 10.1093/jmedent/19.3.248; NICHOLS N, 1963, CALIF MED, V98, P267; RILEY CV, 1894, US DEPT AGR DIV ENTO, V6, P267; RYCKMAN RC, 1979, CALIF VECTOR VIEWS, V26, P3; SHIELDS TL, 1956, ARCH DERMATOL, V74, P14, DOI 10.1001/archderm.1956.01550070016004; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; SWEZEY RL, 1963, ARCH INTERN MED, V112, P977, DOI 10.1001/archinte.1963.03860060189021	16	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	3					369	375		10.1016/0091-6749(84)90410-X	http://dx.doi.org/10.1016/0091-6749(84)90410-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SK155	6366033				2022-12-18	WOS:A1984SK15500011
J	YAMAMOTO, S; YOSHIMOTO, T; FURUKAWA, M; HORIE, T; WATANABEKOHNO, S				YAMAMOTO, S; YOSHIMOTO, T; FURUKAWA, M; HORIE, T; WATANABEKOHNO, S			ARACHIDONATE 5-LIPOXYGENASE AND ITS NEW INHIBITORS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TOKUSHIMA,COLL TECH,DEPT APPL CHEM,TOKUSHIMA 770,JAPAN; KYOTO COLL PHARM,DEPT PHARMACOL,KYOTO 607,JAPAN	Tokushima University; Kyoto Pharmaceutical University	YAMAMOTO, S (corresponding author), UNIV TOKUSHIMA,SCH MED,DEPT BIOCHEM,TOKUSHIMA 770,JAPAN.							ARAI Y, 1983, J MED CHEM, V26, P72, DOI 10.1021/jm00355a015; ASHIDA Y, 1983, PROSTAGLANDINS, V26, P955, DOI 10.1016/0090-6980(83)90157-0; COREY EJ, 1983, TETRAHEDRON LETT, V24, P265, DOI 10.1016/S0040-4039(00)81381-7; COREY EJ, 1982, J AM CHEM SOC, V104, P1752, DOI 10.1021/ja00370a058; EGAN RW, 1983, ADV PROSTAG THROMB L, V11, P151; HOPE WC, 1981, FED PROC, V40, P1022; JAKSCHIK BA, 1980, NATURE, V287, P51, DOI 10.1038/287051a0; KOSHIHARA Y, 1983, FEBS LETT, V158, P41, DOI 10.1016/0014-5793(83)80672-3; KOSHISHARA Y, 1982, FEBS LETT, V143, P13, DOI 10.1016/0014-5793(82)80262-7; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NAGAI H, 1975, JPN J PHARMACOL, V25, P763, DOI 10.1254/jjp.25.763; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; OCHI K, 1983, J BIOL CHEM, V258, P5754; RAIMAN RJ, 1947, SCIENCE, V106, P368, DOI 10.1126/science.106.2755.368; SUN FF, 1983, PROSTAGLANDINS, V26, P211, DOI 10.1016/0090-6980(83)90090-4; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P638; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P470	17	42	47	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					349	352		10.1016/0091-6749(84)90128-3	http://dx.doi.org/10.1016/0091-6749(84)90128-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6432877				2022-12-18	WOS:A1984TQ63300008
J	LONGBOTTOM, JL				LONGBOTTOM, JL			ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS - REACTIVITY OF IGE AND IGG ANTIBODIES WITH ANTIGENIC COMPONENTS OF ASPERGILLUS-FUMIGATUS (IGE IGG ANTIGEN COMPLEXES)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LONGBOTTOM, JL (corresponding author), CARDIOTHORAC INST,DEPT ALLERGY & CLIN IMMUNOL,FULHAM RD,LONDON SW3 6HP,ENGLAND.							AUKRUST L, 1978, INT ARCH ALLER A IMM, V57, P183, DOI 10.1159/000232101; BUSH R K, 1982, Journal of Allergy and Clinical Immunology, V69, P98; CALVANICO NJ, 1981, CLIN EXP IMMUNOL, V45, P662; DESSAINT JP, 1976, CLIN IMMUNOL IMMUNOP, V5, P314, DOI 10.1016/0090-1229(76)90039-8; HASLAM P, 1976, CLIN ALLERGY, V6, P277, DOI 10.1111/j.1365-2222.1976.tb01908.x; JACOBY B, 1977, CLIN ALLERGY, V7, P117, DOI 10.1111/j.1365-2222.1977.tb01432.x; KAUFFMAN HF, 1982, 11 INT C ALL CLIN IM; KAUFFMANN HF, 1980, INT ARCH ALLER A IMM, V62, P265, DOI 10.1159/000232522; KURUP VP, 1978, MICROBIOS, V19, P191; Longbottom J L, 1978, Mykosen Suppl, V1, P207; LONGBOTTOM JL, 1983, CLIN EXP IMMUNOL, V53, P354; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; LONGBOTTOM JL, 1964, THESIS U LONDON; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MALO JL, 1977, THORAX, V32, P269, DOI 10.1136/thx.32.3.269; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; PATTERSON R, 1978, J IMMUNOL, V120, P66; PATTERSON R, 1979, J CLIN LAB IMMUNOL, V2, P199; PEPYS J, 1979, CLIN ALLERGY, V9, P645, DOI 10.1111/j.1365-2222.1979.tb00491.x; PEPYS J, 1977, HDB EXPT IMMUNOLOGY, V3, pCH41; REED C, 1978, J ALLERGY CLIN IMMUN, V61, P277; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SEPULVEDA R, 1979, CLIN ALLERGY, V9, P359, DOI 10.1111/j.1365-2222.1979.tb02494.x; VERVLOET D, 1974, Clinical Allergy, V4, P359, DOI 10.1111/j.1365-2222.1974.tb01397.x	25	42	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	6					668	675		10.1016/0091-6749(83)90627-9	http://dx.doi.org/10.1016/0091-6749(83)90627-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RW048	6605984				2022-12-18	WOS:A1983RW04800006
J	WELLIVER, RC				WELLIVER, RC			UPPER RESPIRATORY-INFECTIONS IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,SCH MED,DEPT PEDIAT,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	WELLIVER, RC (corresponding author), CHILDRENS HOSP,DIV INFECT DIS,BUFFALO,NY 14222, USA.							AQUILINA AT, 1980, AM REV RESPIR DIS, V122, P3; BERMAN SZ, 1975, J ALLERGY CLIN IMMUN, V56, P206, DOI 10.1016/0091-6749(75)90091-3; BROWNSTEIN DG, 1980, AM J PATHOL, V98, P499; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; COLLIER AM, 1978, AM REV RESPIR DIS, V117, P47; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; GURWITZ D, 1980, AM REV RESPIR DIS, V122, P95; GWALTNEY JM, 1978, ANN INTERN MED, V88, P463, DOI 10.7326/0003-4819-88-4-463; HAQUE A, 1980, CLIN EXP IMMUNOL, V40, P487; HEIDBRINK PJ, 1982, AM REV RESPIR DIS, V125, P517, DOI 10.1164/arrd.1982.125.5.517; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; HOLUB M, 1969, IMMUNOLOGY, V17, P207; HORN MEC, 1979, ARCH DIS CHILD, V54, P587, DOI 10.1136/adc.54.8.587; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; JOHNSON KJ, 1979, AM J PATHOL, V95, P795; JURGENSE.PF, 1973, J INFECT DIS, V128, P730, DOI 10.1093/infdis/128.6.730; KALTREIDER HB, 1973, J CLIN INVEST, V52, P2211, DOI 10.1172/JCI107406; KALTREIDER HB, 1976, J IMMUNOL, V116, P423; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; LOUGHLIN GM, 1979, J PEDIATR-US, V94, P365, DOI 10.1016/S0022-3476(79)80572-7; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, J PEDIATR-US, V85, P472, DOI 10.1016/S0022-3476(74)80447-6; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; STEMPEL DA, 1980, J PEDIATR-US, V97, P185, DOI 10.1016/S0022-3476(80)80471-9; TARLO S, 1979, CLIN ALLERGY, V9, P293, DOI 10.1111/j.1365-2222.1979.tb01556.x; WALDMAN RH, 1973, J IMMUNOL, V111, P38; WELLIVER RC, 1980, NEW ENGL J MED, V303, P1198, DOI 10.1056/NEJM198011203032103; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1982, J PEDIATR-US, V101, P889, DOI 10.1016/S0022-3476(82)80005-X; WELLS MA, 1981, J IMMUNOL, V126, P1042; WELLS MA, 1981, J IMMUNOL, V126, P1036	31	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	4					341	346		10.1016/0091-6749(83)90497-9	http://dx.doi.org/10.1016/0091-6749(83)90497-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RN330	6352778				2022-12-18	WOS:A1983RN33000002
J	ATKINS, PC; ROSENBLUM, F; DUNSKY, EH; COFFEY, R; ZWEIMAN, B				ATKINS, PC; ROSENBLUM, F; DUNSKY, EH; COFFEY, R; ZWEIMAN, B			COMPARISON OF PLASMA HISTAMINE AND CYCLIC-NUCLEOTIDES AFTER ANTIGEN AND METHACHOLINE INHALATION IN MAN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SLOAN KETTERING INST CANC RES, DONALD S WALKER LAB, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	ATKINS, PC (corresponding author), UNIV PENN, SCH MED, DEPT MED, ALLERGY & IMMUNOL SECT, PHILADELPHIA, PA 19104 USA.				NCRR NIH HHS [5 MO 4 RR0040] Funding Source: Medline; NIAID NIH HHS [1RO1 AII4332, 5T32 AI07031] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN DH, 1978, J ALLERGY CLIN IMMUN, V61, P140, DOI 10.1016/0091-6749(78)90279-8; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; ATKINS PC, 1979, J ALLERGY CLIN IMMUN, V63, P140; BALL JH, 1972, J CLIN INVEST, V51, P2124, DOI 10.1172/JCI107019; BEAVEN MA, 1971, J PHARMACOL EXP THER, V176, P52; BROADUS AE, 1970, J CLIN INVEST, V49, P2237, DOI 10.1172/JCI106442; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Coffey R G, 1978, Adv Cyclic Nucleotide Res, V9, P661; COFFEY RG, 1977, IMMUNOPHARMACOLOGY, P203; DUNSKY EH, 1978, J ALLERGY CLIN IMMUN, V62, P127, DOI 10.1016/0091-6749(78)90091-X; HENDERSON WR, 1979, NEW ENGL J MED, V300, P642, DOI 10.1056/NEJM197903223001203; KALINER M, 1978, AM REV RESPIR DIS, V118, P1015; KALINER M, 1976, J ALLERGY CLIN IMMUN, V58, P308, DOI 10.1016/0091-6749(76)90136-6; LEVY DA, 1973, J LAB CLIN MED, V81, P291; LINDGREN BR, 1978, SCAND J RESPIR DIS, V59, P333; MARTIN GL, 1979, J ALLERGY CLIN IMMUN, V63, P162; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; NATSUMARA Y, 1976, J ALLERGY CLIN IMMUN, V58, P274; PARKER CD, 1965, ARCH INTERN MED, V115, P452, DOI 10.1001/archinte.1965.03860160078013; POON HC, 1977, INT J CLIN PHARM BI, V15, P432; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; STEINER AL, 1972, ADV CYCL NUCL RES<D>, V2, P51; TOWNLEY RG, 1965, J ALLERGY, V36, P121, DOI 10.1016/0021-8707(65)90161-9; WEHMANN RE, 1974, J CLIN INVEST, V53, P173, DOI 10.1172/JCI107535	24	42	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	6					478	485		10.1016/0091-6749(80)90009-3	http://dx.doi.org/10.1016/0091-6749(80)90009-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KV363	6253543				2022-12-18	WOS:A1980KV36300008
J	PERELMUTTER, L; POTVIN, L; PHIPPS, P				PERELMUTTER, L; POTVIN, L; PHIPPS, P			IMMUNOGLOBULIN-E RESPONSE DURING VIRAL-INFECTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS HOSP EASTERN ONTARIO,VIROL LAB,OTTAWA K1H 8L1,ONTARIO,CANADA	University of Ottawa; Children's Hospital of Eastern Ontario	PERELMUTTER, L (corresponding author), HLTH & WELF CANADA,HLTH PROTECT BRANCH,BUR MED BIOCHEM,DIV IMMUNOL,OTTAWA K1A 0L2,ONTARIO,CANADA.							BAHNA SL, 1978, J ALLERGY CLIN IMMUN, V61, P177, DOI 10.1016/0091-6749(78)90400-1; BAHNA SL, 1978, J ALLERGY CLIN IMMUN, V62, P167, DOI 10.1016/0091-6749(78)90102-1; BERKOVICH S, 1970, ANN ALLERGY, V28, P43; FREEMAN GL, 1962, AM J DIS CHILD, V104, P330, DOI 10.1001/archpedi.1962.02080030332002; FRICK O L, 1977, Annals of Allergy, V38, P449; HEINER DC, 1977, 3RD INT C IMM SYDN; IDA S, 1977, J EXP MED, V145, P892, DOI 10.1084/jem.145.4.892; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; LENNETTE EH, 1977, DIAGNOSTIC PROCEDURE; LEONARDY JG, 1972, ANN ALLERGY, V30, P378; MCINTOSH K, 1973, J PEDIATR-US, V82, P578, DOI 10.1016/S0022-3476(73)80582-7; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MONERETVAUTRIN DA, 1976, SEP S IGE NANC, P91; OUELLETTE JJ, 1965, J ALLERGY, V36, P558, DOI 10.1016/0021-8707(65)90193-0; PERELMUTTER L, 1978, ANN ALLERGY, V41, P158; PERELMUTTER L, 1978, ANN ALLERGY, V40, P319; PERELMUTTER L, UNPUBLISHED; STRANNEGARD O, 1978, IMMUNOL REV, V41, P149, DOI 10.1111/j.1600-065X.1978.tb01463.x; ZETTERSTROM O, UNPUBLISHED	19	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	2					127	130		10.1016/0091-6749(79)90046-0	http://dx.doi.org/10.1016/0091-6749(79)90046-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG426	458056	Green Published, Bronze			2022-12-18	WOS:A1979HG42600006
J	MAKINO, S; IKEMORI, K; KASHIMA, T; FUKUDA, T				MAKINO, S; IKEMORI, K; KASHIMA, T; FUKUDA, T			COMPARISON OF CYCLIC ADENOSINE-MONOPHOSPHATE RESPONSE OF LYMPHOCYTES IN NORMAL AND ASTHMATIC SUBJECTS TO NOREPINEPHRINE AND SALBUTAMOL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									DOKKYO UNIV,SCH MED,DEPT MED,DIV ALLERGY,MIBU,TOCHIGI 321 02,JAPAN	Dokkyo Medical University								ALSTON WC, 1974, BRIT MED J, V1, P90, DOI 10.1136/bmj.1.5898.90; BAXTER JD, 1972, AM J MED, V53, P573, DOI 10.1016/0002-9343(72)90154-4; BENOY CJ, 1975, BRIT J PHARMACOL, V55, P547, DOI 10.1111/j.1476-5381.1975.tb07431.x; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRITTAIN RT, 1968, NATURE, V219, P862, DOI 10.1038/219862a0; BUSSE WW, 1975, CLIN RES, V23, P502; COOKSON DU, 1963, AM REV RESPIR DIS, V88, P636; GEDDES BA, 1974, AM REV RESPIR DIS, V110, P420; GILLESPIE E, 1974, J ALLERGY CLIN IMMUN, V53, P27, DOI 10.1016/0091-6749(74)90096-7; LANDS AM, 1967, NATURE, V214, P597, DOI 10.1038/214597a0; LEFKOWITZ RJ, 1976, NEW ENGL J MED, V295, P323, DOI 10.1056/NEJM197608052950607; LOCKEY SD, 1967, J ALLERGY, V40, P349, DOI 10.1016/0021-8707(67)90024-X; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; LOGSDON PJ, 1973, J ALLERGY CLIN IMMUN, V52, P148, DOI 10.1016/0091-6749(73)90031-6; MAKINO S, 1970, J ALLERGY, V46, P178, DOI 10.1016/0021-8707(70)90096-1; MIDDLETON E, 1968, J ALLERGY, V42, P288, DOI 10.1016/0021-8707(68)90022-1; MUE S, 1975, Japanese Journal of Allergology, V24, P490; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; PARKER CW, 1973, J CLIN INVEST, V52, P48, DOI 10.1172/JCI107173; PARKER CW, 1973, J CLIN INVEST, V52, P1342, DOI 10.1172/JCI107306; REED CE, 1970, J ALLERGY, V46, P90, DOI 10.1016/0021-8707(70)90076-6; REED CE, 1974, J ALLERGY CLIN IMMUN, V53, P34, DOI 10.1016/0091-6749(74)90097-9; RYO UY, 1976, J ALLERGY CLIN IMMUN, V57, P12, DOI 10.1016/0091-6749(76)90074-9; SOKOL WN, 1975, J ALLERGY CLIN IMMUN, V55, P310, DOI 10.1016/0091-6749(75)90003-2; STEINER AL, 1972, J BIOL CHEM, V247, P1114; SUTHERLAND EW, 1971, CYCLIC AMP, P17; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2	27	42	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	5					348	352		10.1016/0091-6749(77)90016-1	http://dx.doi.org/10.1016/0091-6749(77)90016-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DF215	192770				2022-12-18	WOS:A1977DF21500002
J	MCLEAN, JA; MATHEWS, KP; CIARKOWSKI, AA; BRAYTON, PR; SOLOMON, WR				MCLEAN, JA; MATHEWS, KP; CIARKOWSKI, AA; BRAYTON, PR; SOLOMON, WR			EFFECTS OF TOPICAL SALINE AND ISOPROTERENOL ON NASAL AIRWAY-RESISTANCE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH MED,DEPT INTERN MED,ALLERGY SECT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								ANGGARD A, 1974, ACTA OTO-LARYNGOL, V78, P232, DOI 10.3109/00016487409126349; ANGGARD A, 1974, ACTA OTO-LARYNGOL, V77, P131, DOI 10.3109/00016487409124608; BERNSTEI.IL, 1973, J ALLERGY CLIN IMMUN, V51, P22, DOI 10.1016/0091-6749(73)90004-3; COHEN BM, 1969, RESPIRATION, V26, P35, DOI 10.1159/000192591; COHEN BM, 1970, RESPIRATION, V27, P406, DOI 10.1159/000192697; GROBLER NJ, 1966, REACTIVITY NASAL MUC; HALL LJ, 1968, ANN OTO RHINOL LARYN, V77, P1120, DOI 10.1177/000348946807700610; JACKSON RT, 1973, CLIN PEDIATR, V12, P559, DOI 10.1177/000992287301200918; KALINER M, 1973, NEW ENGL J MED, V289, P277, DOI 10.1056/NEJM197308092890601; MALM L, 1974, ACTA OTO-LARYNGOL, V78, P242, DOI 10.3109/00016487409126350; MCLEAN JA, 1976, J ALLERGY CLIN IMMUN, V57, P153, DOI 10.1016/0091-6749(76)90034-8; PELIKAN Z, 1970, ANN ALLERGY, V28, P548; PELIKAN Z, 1974, ACTA ALLERGOL, V29, P337, DOI 10.1111/j.1398-9995.1974.tb01470.x; Sternstein HJ, 1941, ARCHIV OTOLARYNGOL, V34, P523	14	42	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	5					563	574		10.1016/0091-6749(76)90202-5	http://dx.doi.org/10.1016/0091-6749(76)90202-5			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CL088	977863				2022-12-18	WOS:A1976CL08800004
J	CARTER, JB; BARR, GD; LEVIN, AS; BYERS, VS; PONCE, B; FUDENBERG, HH; GERMAN, DF				CARTER, JB; BARR, GD; LEVIN, AS; BYERS, VS; PONCE, B; FUDENBERG, HH; GERMAN, DF			STANDARDIZATION OF TISSUE-CULTURE CONDITIONS FOR SPONTANEOUS THYMIDINE-2-C-14 INCORPORATION BY UNSTIMULATED NORMAL HUMAN PERIPHERAL LYMPHOCYTES - CIRCADIAN-RHYTHM OF DNA-SYNTHESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									KAISER PERMANENTE MED CTR,DEPT ALLERGY,SAN FRANCISCO,CA; UNIV CALIF,MED CTR,DEPT DERMATOL,SAN FRANCISCO,CA; UNIV CALIF,MED CTR,DEPT MED,SAN FRANCISCO,CA	Kaiser Permanente; University of California System; University of California San Francisco; University of California System; University of California San Francisco								BAIN B, 1973, 7 P LEUC CULT C, P29; CONROY RWT, 1970, HUMAN CIRCADIAN RHYT, P72; COULSON AS, 1966, NATURE, V209, P378, DOI 10.1038/209378a0; DENT P, 1970, 5 P LEUK CULT C, P274; DOUGLAS SD, 1969, J IMMUNOL, V103, P1185; ELMADJIAN F, 1946, J CLIN ENDOCR METAB, V6, P287, DOI 10.1210/jcem-6-4-287; GAJLPECZALSKA K, 1969, INT ARCH ALLER A IMM, V36, P546, DOI 10.1159/000230775; GILL FA, 1967, J IMMUNOL, V98, P778; HALBERG F, 1969, ANNU REV PHYSIOL, V31, P675, DOI 10.1146/annurev.ph.31.030169.003331; HALTERMAN RH, 1972, TRANSPLANTATION, V14, P271, DOI 10.1097/00007890-197208000-00022; HERSH EM, 1970, CLIN RES, V18, P425; HOWE ML, 1971, CLIN EXP IMMUNOL, V8, P617; HUGHES D, 1970, INT ARCH ALLER A IMM, V37, P506, DOI 10.1159/000230240; Japha A, 1900, JB KINDERHEILK, V52, P242; MACKINNEY AA, 1965, BLOOD-J HEMATOL, V26, P36, DOI 10.1182/blood.V26.1.36.36; MALEK J, 1962, ANN NY ACAD SCI, V98, P1042, DOI 10.1111/j.1749-6632.1962.tb30617.x; MARTINEZOFERRALL JA, 1968, JOM-J OCCUP MED, V10, P305, DOI 10.1097/00043764-196806000-00005; MAUER AM, 1965, BLOOD-J HEMATOL, V26, P1; MAY CD, 1972, INT ARCH ALLER A IMM, V43, P525, DOI 10.1159/000230867; MCINTYRE OR, 1969, INT ARCH ALLER A IMM, V35, P105; NUGENT CA, 1966, J CLIN ENDOCR METAB, V26, P1116, DOI 10.1210/jcem-26-10-1116; PAGE D, 1971, TRANSPLANTATION, V12, P341; PARKER JW, 1971, 4 P ANN LEUC CULT C, P281; PARKER JW, 1969, 3 P ANN LEUC CULT C, P111; PARKER KL, 1972, TRANSPLANTATION, V14, P135, DOI 10.1097/00007890-197207000-00024; PERPER RJ, 1968, J LAB CLIN MED, V72, P842; QUASTLER H, 1963, ACTIONS CHIMIQUES BI, P147; RUD FINN, 1947, ACTA PSYCHIAT ET NEUROL [COPENHAGEN], V40, P1; Sabin FR, 1925, B JOHNS HOPKINS HOSP, V37, P14; SAMPLE WF, 1971, CLIN EXP IMMUNOL, V9, P419; SHARP GWG, 1960, J ENDOCRINOL, V21, P107, DOI 10.1677/joe.0.0210107; Shaw AFB, 1927, J PATHOL BACTERIOL, V30, P1, DOI 10.1002/path.1700300102; SIMONS MJ, 1969, CELL TISSUE KINET, V2, P1, DOI 10.1111/j.1365-2184.1969.tb00332.x; SORENSEN SF, 1969, ACTA PATHOL MIC SC, V75, P508; TENNENBAUM JI, 1970, 5 P LEUC CULT C NEW, P261; VALENTINE F, 1971, IN VITRO METHODS CEL, P443; WEITZMAN ED, 1971, J CLIN ENDOCR METAB, V33, P14, DOI 10.1210/jcem-33-1-14; WILSON DB, 1966, J EXP ZOOL, V162, P161, DOI 10.1002/jez.1401620203; YACHNIN S, 1972, CLIN EXP IMMUNOL, V11, P109; ZWEIMAN B, 1971, INT ARCH ALLER A IMM, V41, P428, DOI 10.1159/000230536	40	42	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	3					191	205		10.1016/0091-6749(75)90090-1	http://dx.doi.org/10.1016/0091-6749(75)90090-1			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ290	1151013				2022-12-18	WOS:A1975AQ29000004
J	MORRIS, HG; NEUMAN, I; ELLIS, EF				MORRIS, HG; NEUMAN, I; ELLIS, EF			PLASMA STEROID CONCENTRATIONS DURING ALTERNATE-DAY TREATMENT WITH PREDNISONE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NATL JEWISH HOSP,DEPT PEDIAT,3800 E COLFAX AVE,DENVER,CO 80206	National Jewish Health								ACKERMAN GL, 1968, NEW ENGL J MED, V278, P405, DOI 10.1056/NEJM196802222780801; BOSS N, 1971, ACTA ENDOCRINOL-COP, V67, P508, DOI 10.1530/acta.0.0670508; CHAI H, 1973, J ALLERGY CLIN IMMUN, V51, P65, DOI 10.1016/S0091-6749(73)80001-6; FISHER RA, 1954, STATISTICAL METHODS; FLEISHER N, 1970, CLIN RES, V28, P360; GRABER AL, 1965, J CLIN ENDOCR METAB, V25, P11, DOI 10.1210/jcem-25-1-11; HARTER JG, 1963, NEW ENGL J MED, V269, P591, DOI 10.1056/NEJM196309192691201; HOLUB DA, 1959, J CLIN ENDOCR METAB, V19, P1540, DOI 10.1210/jcem-19-12-1540; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; MORRIS HG, 1971, J PEDIATR-US, V79, P480, DOI 10.1016/S0022-3476(71)80163-4; NIELSEN E, 1967, SCAND J CLIN LAB INV, V20, P185, DOI 10.3109/00365516709076942; REIMER LG, TO BE PUBLISHED; RUSSELL SM, 1969, ENDOCRINOLOGY, V85, P512, DOI 10.1210/endo-85-3-512; SIRETT NE, 1969, ENDOCRINOLOGY, V85, P353; SPENCERP.J, 1965, J ENDOCRINOL, V31, P235, DOI 10.1677/joe.0.0310235; TAKEBE K, 1971, ENDOCRINOLOGY, V89, P1014, DOI 10.1210/endo-89-4-1014; van der VIES J., 1961, ACTA ENDOCRINOL, V38, P399; WALSH SD, 1966, BMJ-BRIT MED J, V2, P796, DOI 10.1136/bmj.2.5517.796; WALTON J, 1970, ARCH INTERN MED, V126, P601, DOI 10.1001/archinte.126.4.601; WESTERHOF L, 1970, BMJ-BRIT MED J, V4, P534, DOI 10.1136/bmj.4.5734.534	20	42	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	6					350	358		10.1016/0091-6749(74)90025-6	http://dx.doi.org/10.1016/0091-6749(74)90025-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U9288					2022-12-18	WOS:A1974U928800003
J	KAWAI, T; SALVAGGIO, J; HARRIS, JO; LAKE, W				KAWAI, T; SALVAGGIO, J; HARRIS, JO; LAKE, W			EXPERIMENTAL PRODUCTION OF HYPERSENSITIVITY PNEUMONITIS WITH BAGASSE AND THERMOPHILIC ACTINOMYCETE ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BIGUET J, 1964, ANN I PASTEUR PARIS, V107, P72; DAVID JR, 1964, J IMMUNOL, V93, P264; EISENBERG H W, 1971, Federation Proceedings, V30, P590; FINK JN, 1970, J ALLERGY, V46, P156, DOI 10.1016/0021-8707(70)90094-8; GALINDO B, 1970, J IMMUNOL, V105, P227; GERSTL B, 1949, P SOC EXP BIOL MED, V70, P697, DOI 10.3181/00379727-70-17038; GERY I, 1969, IMMUNOLOGY, V16, P381; GOWANS J, 1958, KINETICS CELLULAR PR; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; HENNEY CS, 1970, SCIENCE, V169, P696, DOI 10.1126/science.169.3946.696; INNES JRM, 1956, AM J PATHOL, V32, P141; JEVITZ MA, 1971, J IMMUNOL, V106, P494; Kendall FE, 1937, J CLIN INVEST, V16, P921, DOI 10.1172/JCI100918; KNIGHT S, 1965, IMMUNOLOGY, V9, P565; LAKE WW, 1971, J IMMUNOL, V107, P1745; LESKOWITZ S, 1960, J IMMUNOL, V84, P58; LING NR, 1967, J CELL SCI, V2, P57; LOEWI G, 1968, IMMUNOLOGY, V14, P257; MILLS JA, 1966, J IMMUNOL, V97, P239; PAUL WE, 1968, J EXP MED, V127, P25, DOI 10.1084/jem.127.1.25; RICHERSON HB, 1971, J ALLERGY, V47, P92; SALVAGGIO J, 1969, AM J MED, V46, P538, DOI 10.1016/0002-9343(69)90073-4; SALVAGGIO JE, 1966, ANN INTERN MED, V64, P748, DOI 10.7326/0003-4819-64-4-748; SEABURY J, 1969, P SOC EXP BIOL MED, V129, P351; SMETANA HF, 1962, LAB INVEST, V11, P868; STULBARG M, 1968, J IMMUNOL, V101, P764; WALDMAN RH, 1971, J EXP MED, V134, P482, DOI 10.1084/jem.134.2.482; WENZEL FJ, 1971, J ALLERGY, V47, P102	28	42	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	5					276	+		10.1016/0091-6749(72)90026-7	http://dx.doi.org/10.1016/0091-6749(72)90026-7			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N9856	4627698				2022-12-18	WOS:A1972N985600003
J	SETTIPANE, GA; SCHOENFELD, E				SETTIPANE, GA; SCHOENFELD, E			ASTHMA AND HYPERTHYROIDISM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; Kasperlik-Zaluska A, 1968, Gruzlica, V36, P581; MASSEY DG, 1967, NEW ENGL J MED, V276, P1104, DOI 10.1056/NEJM196705182762002; MEANS JH, 1963, THYROID ITS DISEASES, P163; PIMSTONE N, 1968, LANCET, V2, P1219; SATOYOSHI E, 1963, NEUROLOGY, V13, P645, DOI 10.1212/WNL.13.8.645; SCHWARTZ HJ, 1966, ANN ALLERGY, V24, P234; STEIN M, 1961, J CLIN INVEST, V40, P348, DOI 10.1172/JCI104262; SUTHERLA.EW, 1966, PHARMACOL REV, V18, P145; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2	11	42	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	6					348	+		10.1016/0091-6749(72)90133-9	http://dx.doi.org/10.1016/0091-6749(72)90133-9			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M6593	4554357	Bronze			2022-12-18	WOS:A1972M659300004
J	STEVENSON, DD; ORGEL, HA; HAMBURGER, RN; REID, RT				STEVENSON, DD; ORGEL, HA; HAMBURGER, RN; REID, RT			DEVELOPMENT OF IGE IN NEWBORN HUMAN INFANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		ALLANSMITH M, 1968, J PEDIATR-US, V72, P276, DOI 10.1016/S0022-3476(68)80324-5; AMMANN AJ, 1969, NEW ENGL J MED, V281, P469, DOI 10.1056/NEJM196908282810904; DAVIS SL, 1970, J ALLERGY, V45, P107; DEES SC, 1959, PEDIATR CLIN N AM, V6, P881; GLEICH GJ, 1970, J ALLERGY, V45, P108; HEINER DC, 1964, JAMA-J AM MED ASSOC, V189, P563; ISHIZAKA K, 1968, J IMMUNOL, V100, P554; ISHIZAKA T, 1969, J IMMUNOL, V102, P884; JOHANSSON SG, 1968, INT ARCH ALLER A IMM, V34, P1; KUHNS WJ, 1965, P SOC EXP BIOL MED, V118, P377, DOI 10.3181/00379727-118-29848; LEVIN S, 1970, ISRAEL J MED SCI, V6, P742; LIDD D, 1963, J ALLERGY, V34, P48, DOI 10.1016/0021-8707(63)90085-6; NEWCOMB RW, 1969, J ALLERGY, V43, P292, DOI 10.1016/0021-8707(69)90150-6; OGAWA M, 1969, NEW ENGL J MED, V281, P1217, DOI 10.1056/NEJM196911272812204; ROTHBERG RM, 1962, CLIN RES, V10, P219; Schloss OM, 1916, AM J DIS CHILD, V11, P342; Sherman WB, 1940, J EXP MED, V72, P611, DOI 10.1084/jem.72.5.611; WALDMANN TA, 1969, NEW ENGL J MED, V281, P1170, DOI 10.1056/NEJM196911202812107	18	42	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1971	48	2					61	+		10.1016/0091-6749(71)90088-1	http://dx.doi.org/10.1016/0091-6749(71)90088-1			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K0446	4104291				2022-12-18	WOS:A1971K044600001
J	Cau, L; Williams, MR; Butcher, AM; Nakatsuji, T; Kavanaugh, JS; Cheng, JYY; Shafiq, F; Higbee, K; Hata, TR; Horswill, AR; Gallo, RL				Cau, Laura; Williams, Michael R.; Butcher, Anna M.; Nakatsuji, Teruaki; Kavanaugh, Jeffrey S.; Cheng, Joyce Y.; Shafiq, Faiza; Higbee, Kyle; Hata, Tissa R.; Horswill, Alexander R.; Gallo, Richard L.			Staphylococcus epidermidis protease EcpA can be a deleterious component of the skin microbiome in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis; microbiome; dysbiosis; Staphylococcus epidermidis; protease; skin; epidermal barrier; inflammation; cytokine	AUREUS; BACTERIAL; BARRIER; BIOFILM; DISEASE; IDENTIFICATION; KERATINOCYTES; INFECTIONS; MECHANISMS; INDUCTION	Background: Staphylococcus aureus and Staphylococcus epidermidis are the most abundant bacteria found on the skin of patients with atopic dermatitis (AD). S aureus is known to exacerbate AD, whereas S epidermidis has been considered a beneficial commensal organism. Objective: In this study, we hypothesized that S epidermidis could promote skin damage in AD by the production of a protease that damages the epidermal barrier. Methods: The protease activity of S epidermidis isolates was compared with that of other staphylococcal species. The capacity of S epidermidis to degrade the barrier and induce inflammation was examined by using human keratinocyte tissue culture and mouse models. Skin swabs from atopic and healthy adult subjects were analyzed for the presence of S epidermidis genomic DNA and mRNA. Results: S epidermidis strains were observed to produce strong cysteine protease activity when grown at high density. The enzyme responsible for this activity was identified as EcpA, a cysteine protease under quorum sensing control. EcpA was shown to degrade desmoglein-1 and LL-37 in vitro, disrupt the physical barrier, and induce skin inflammation in mice. The abundance of S epidermidis and expression of ecpA mRNA were increased on the skin of some patients with AD, and this correlated with disease severity. Another commensal skin bacterial species, Staphylococcus hominis, can inhibit EcpA production by S epidermidis. Conclusion: S epidermidis has commonly been regarded as a beneficial skin microbe, whereas S aureus has been considered deleterious. This study suggests that the overabundance of S epidermidis found on some atopic patients can act similarly to S aureus and damage the skin by expression of a cysteine protease.	[Cau, Laura; Williams, Michael R.; Butcher, Anna M.; Nakatsuji, Teruaki; Cheng, Joyce Y.; Shafiq, Faiza; Higbee, Kyle; Hata, Tissa R.; Gallo, Richard L.] Univ Calif San Diego, Dept Dermatol, 9500 Gilman Dr,0869, La Jolla, CA 92093 USA; [Gallo, Richard L.] Univ Calif San Diego, Ctr Microbiome Innovat, La Jolla, CA 92093 USA; [Cau, Laura] SILAB, R&D Dept, Brive, France; [Kavanaugh, Jeffrey S.; Horswill, Alexander R.] Univ Colorado Anschutz Med Campus, Dept Immunol & Microbiol, Aurora, CO USA; [Horswill, Alexander R.] Dept Vet Affairs Eastern Colorado Hlth Care Syst, Aurora, CO USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus	Gallo, RL (corresponding author), Univ Calif San Diego, Dept Dermatol, 9500 Gilman Dr,0869, La Jolla, CA 92093 USA.	rgallo@ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Cheng, Joyce/0000-0002-7317-7486	National Institutes of Health [R01 AR076082, R37 AI052453, U19 AI117673]; SILAB; US Department of Veteran Affairs [BX002711]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); SILAB; US Department of Veteran Affairs(US Department of Veterans Affairs)	This work was funded by National Institutes of Health grants R01 AR076082, R37 AI052453, and U19 AI117673. Postdoctoral fellowship support for L. Cau was provided by SILAB. A. R. Horswill was supported by a Merit Award (BX002711) from the US Department of Veteran Affairs.	An Q, 2017, CHINESE MED J-PEKING, V130, P1662, DOI 10.4103/0366-6999.209895; Benn CS, 2004, BRIT MED J, V328, P1223, DOI 10.1136/bmj.38069.512245.FE; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Braff MH, 2005, INFECT IMMUN, V73, P6771, DOI 10.1128/IAI.73.10.6771-6781.2005; Byrd AL, 2018, NAT REV MICROBIOL, V16, P143, DOI 10.1038/nrmicro.2017.157; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; Carroll CL, 2005, PEDIATR DERMATOL, V22, P192, DOI 10.1111/j.1525-1470.2005.22303.x; Casagrande BF, 2006, J INVEST DERMATOL, V126, P2414, DOI 10.1038/sj.jid.5700431; Cau L, 2017, J DERMATOL SCI, V86, P106, DOI 10.1016/j.jdermsci.2017.02.280; Cheung GYC, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001133; Cogen AL, 2010, J INVEST DERMATOL, V130, P192, DOI 10.1038/jid.2009.243; Czarnowicki T, 2017, J ALLERGY CLIN IMMUN, V139, P1723, DOI 10.1016/j.jaci.2017.04.004; Dainichi T, 2018, NAT IMMUNOL, V19, P1286, DOI 10.1038/s41590-018-0256-2; Danby Simon G, 2018, Curr Probl Dermatol, V54, P95, DOI 10.1159/000489523; De Benedetto Anna, 2011, J Allergy Clin Immunol, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Dong Y, 2018, VIRULENCE, V9, P621, DOI 10.1080/21505594.2017.1419117; Dubin G, 2004, BIOL CHEM, V385, P543, DOI 10.1515/BC.2004.064; Dubin G, 2001, BIOL CHEM, V382, P1575, DOI 10.1515/BC.2001.192; Flohr C, 2011, CURR PROBL DERMATOL, V41, P1, DOI 10.1159/000323290; Geoghegan JA, 2018, TRENDS MICROBIOL, V26, P484, DOI 10.1016/j.tim.2017.11.008; Glatz M, 2015, J CLIN MED, V4, P1217, DOI 10.3390/jcm4061217; Hon KL, 2016, CLIN EXP DERMATOL, V41, P659, DOI 10.1111/ced.12866; Johansson C, 2002, J INVEST DERMATOL, V118, P1044, DOI 10.1046/j.1523-1747.2002.01758.x; Kanangat S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2086; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Lai YP, 2010, J INVEST DERMATOL, V130, P2211, DOI 10.1038/jid.2010.123; Lai YP, 2009, NAT MED, V15, P1377, DOI 10.1038/nm.2062; LARRICK JW, 1995, IMMUNOTECHNOLOGY, V1, P65, DOI 10.1016/1380-2933(95)00006-2; Le KY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00359; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Liggins MC, 2019, J IMMUNOL, V203, P1589, DOI 10.4049/jimmunol.1900520; Liles WC, 2001, J LEUKOCYTE BIOL, V70, P96; Linehan JL, 2018, CELL, V172, P784, DOI 10.1016/j.cell.2017.12.033; Liu HY, 2017, CELL HOST MICROBE, V22, P653, DOI 10.1016/j.chom.2017.10.006; Mehlin C, 1999, J EXP MED, V189, P907, DOI 10.1084/jem.189.6.907; Mootz JM, 2015, MOL MICROBIOL, V96, P388, DOI 10.1111/mmi.12943; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Naik S, 2015, NATURE, V520, P104, DOI 10.1038/nature14052; Nakagawa S, 2017, CELL HOST MICROBE, V22, P667, DOI 10.1016/j.chom.2017.10.008; Nakamura Y, 2013, NATURE, V503, P397, DOI 10.1038/nature12655; Nakatsuji T, 2019, ANN ALLERG ASTHMA IM, V122, P263, DOI 10.1016/j.anai.2018.12.003; Nakatsuji T, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao4502; Nakatsuji T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah4680; Nakatsuji T, 2016, J INVEST DERMATOL, V136, P2192, DOI 10.1016/j.jid.2016.05.127; Nakatsuji T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2441; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Nutten S, 2015, ANN NUTR METAB, V66, P8, DOI 10.1159/000370220; Oleksy A, 2004, BIOL CHEM, V385, P525, DOI 10.1515/BC.2004.062; Olson ME, 2014, J BACTERIOL, V196, P3482, DOI 10.1128/JB.01882-14; Ong PY, 2016, CLIN REV ALLERG IMMU, V51, P329, DOI 10.1007/s12016-016-8548-5; Otto M, 2001, INFECT IMMUN, V69, P1957, DOI 10.1128/IAI.69.3.1957-1960.2001; Otto Michael, 2010, Expert Rev Dermatol, V5, P183, DOI 10.1586/edm.10.6; Otto M, 2009, NAT REV MICROBIOL, V7, P555, DOI 10.1038/nrmicro2182; Paharik AE, 2017, CELL HOST MICROBE, V22, P746, DOI 10.1016/j.chom.2017.11.001; Paller AS, 2019, J ALLERGY CLIN IMMUN, V143, P26, DOI 10.1016/j.jaci.2018.11.015; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Prohic A, 2016, ACTA DERMATOVENER CR, V24, P274; Ring J, 2001, CURR OPIN IMMUNOL, V13, P701, DOI 10.1016/S0952-7915(01)00282-5; Shaw L, 2004, MICROBIOL-SGM, V150, P217, DOI 10.1099/mic.0.26634-0; Soares J, 2013, J APPL MICROBIOL, V115, P1411, DOI 10.1111/jam.12296; Sonesson A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08046-2; Sparber F, 2019, CELL HOST MICROBE, V25, P389, DOI 10.1016/j.chom.2019.02.002; Stacy A, 2019, SCIENCE, V363, P227, DOI 10.1126/science.aat4326; Syed AK, 2015, INFECT IMMUN, V83, P3428, DOI 10.1128/IAI.00401-15; Uckay I, 2009, ANN MED, V41, P109, DOI 10.1080/07853890802337045; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; Williams MR, 2020, CELL REP, V30, P2923, DOI 10.1016/j.celrep.2020.02.021; Williams MR, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat8329; Williams MR, 2017, J INVEST DERMATOL, V137, P2460, DOI 10.1016/j.jid.2017.09.010; Williams MR, 2017, CELL HOST MICROBE, V22, P579, DOI 10.1016/j.chom.2017.10.015; Williams MR, 2017, J INVEST DERMATOL, V137, P377, DOI 10.1016/j.jid.2016.10.008; Zhang LJ, 2016, IMMUNITY, V45, P119, DOI 10.1016/j.immuni.2016.06.021; Zhang LJ, 2015, SCIENCE, V347, P67, DOI 10.1126/science.1260972; Zhang YQ, 2003, MOL MICROBIOL, V49, P1577, DOI 10.1046/j.1365-2958.2003.03671.x	77	41	42	4	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2021	147	3					955	966		10.1016/j.jaci.2020.06.024	http://dx.doi.org/10.1016/j.jaci.2020.06.024		MAR 2021	12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QS1BR	32634452	Green Accepted			2022-12-18	WOS:000625643100001
J	Rivas, MN; Porritt, RA; Cheng, MH; Bahar, I; Arditi, M				Rivas, Magali Noval; Porritt, Rebecca A.; Cheng, Mary Hongying; Bahar, Ivet; Arditi, Moshe			COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): A novel disease that mimics toxic shock syndrome-the superantigen hypothesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Multisystem inflammatory syndrome in children (MIS-C); Kawasaki disease (KD); toxic shock syndrome (TSS); SARS-CoV-2; COVID-19			[Rivas, Magali Noval; Porritt, Rebecca A.; Arditi, Moshe] Cedars Sinai Med Ctr, Dept Biomed Sci, Div Pediat Infect Dis & Immunol, Infect & Immunol Dis Res Ctr, Los Angeles, CA 90048 USA; [Rivas, Magali Noval; Arditi, Moshe] UCLA, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; [Cheng, Mary Hongying; Bahar, Ivet] Univ Pittsburgh, Sch Med, Dept Computat & Syst Biol, Pittsburgh, PA USA; [Arditi, Moshe] Cedars Sinai Med Ctr, Cedars Sinai Smidt Heart Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Cedars Sinai Medical Center	Arditi, M (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Davis Bldg,Rooms D4024,D4025, Los Angeles, CA 90048 USA.	bahar@pitt.edu; moshe.arditi@cshs.org	Cheng, Mary Hongying/AAU-3768-2021	Cheng, Mary Hongying/0000-0001-5833-8221	National Institutes of Health awards [P41 GM103712, R01 AI072726]	National Institutes of Health awards(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by the National Institutes of Health awards (grant no. P41 GM103712 to I.B. and grant no. R01 AI072726 to M.A.).	Arad G, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001149; Cheng MH, 2020, P NATL ACAD SCI USA, V117, P25254, DOI 10.1073/pnas.2010722117; Cheung EW, 2020, JAMA-J AM MED ASSOC, V324, P294, DOI 10.1001/jama.2020.10374; Consiglio CR, 2020, CELL, V183, P968, DOI 10.1016/j.cell.2020.09.016; Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; MORIO T, 1994, EUR J IMMUNOL, V24, P651, DOI 10.1002/eji.1830240325; Pain CE, 2020, LANCET RHEUMATOL, V2, pE376, DOI 10.1016/S2665-9913(20)30137-5; ROSENE KA, 1982, ANN INTERN MED, V96, P865, DOI 10.7326/0003-4819-96-6-865; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369	10	41	41	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					57	59		10.1016/j.jaci.2020.10.008	http://dx.doi.org/10.1016/j.jaci.2020.10.008		JAN 2021	3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	33075409	Bronze, Green Published			2022-12-18	WOS:000613645900008
J	Ronit, A; Berg, RM; Bay, JT; Haugaard, AK; Ahlstrom, MG; Burgdorf, KS; Ullum, H; Rorvig, SB; Tjelle, K; Foss, NB; Benfield, T; Marquart, HV; Plovsing, RR				Ronit, Andreas; Berg, Ronan Mg; Bay, Jakob T.; Haugaard, Anna K.; Ahlstrom, Magnus G.; Burgdorf, Kristoffer S.; Ullum, Henrik; Rorvig, Sara B.; Tjelle, Klaus; Foss, Nicolai B.; Benfield, Thomas; Marquart, Hanne Vibeke; Plovsing, Ronni R.			Compartmental immunophenotyping in COVID-19 ARDS: A case series	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute respiratory distress syndrome; bronchoalveolar lavage; COVID-19; cytokines; flow cytometry	T-CELLS	Background: Severe immunopathology may drive the deleterious manifestations that are observed in the advanced stages of coronavirus disease 2019 (COVID-19) but are poorly understood. Objective: Our aim was to phenotype leukocyte subpopulations and the cytokine milieu in the lungs and blood of critically ill patients with COVID-19 acute respiratory distress syndrome (ARDS). Methods: We consecutively included patients less than 72 hours after intubation following informed consent from their next of kin. Bronchoalveolar lavage fluid was evaluated by microscopy; bronchoalveolar lavage fluid and blood were assessed by 10-color flow cytometry and a multiplex cytokine panel. Results: Four mechanically ventilated patients (aged 40-75 years) with moderate-to-severe COVID-19 ARDS were included. Immature neutrophils dominated in both blood and lungs, whereas CD4 and CD8 T-cell lymphopenia was observed in the 2 compartments. However, regulatory T cells and TH17 cells were found in higher fractions in the lung. Lung CD4 and CD8 T cells and macrophages expressed an even higher upregulation of activation markers than in blood. A wide range of cytokines were expressed at high levels both in the blood and in the lungs, most notably, IL-1RA, IL-6, IL-8, IP-10, and monocyte chemoattactant protein-1, consistent with hyperinflammation. Conclusion: COVID-19 ARDS exhibits a distinct immunologic profile in the lungs, with a depleted and exhausted CD4 and CD8 T-cell population that resides within a heavily hyperinflammatory milieu.	[Ronit, Andreas; Benfield, Thomas] Hvidovre Univ Hosp, Dept Infect Dis, Hvidovre, Denmark; [Berg, Ronan Mg] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark; [Berg, Ronan Mg] Rigshosp, Dept Clin Physiol Nucl Med & PET, Copenhagen, Denmark; [Berg, Ronan Mg] Rigshosp, Ctr Phys Act Res, Copenhagen, Denmark; [Bay, Jakob T.; Haugaard, Anna K.; Burgdorf, Kristoffer S.; Ullum, Henrik; Marquart, Hanne Vibeke] Rigshosp, Dept Clin Immunol, Copenhagen, Denmark; [Ahlstrom, Magnus G.] Rigshosp, Dept Clin Microbiol, Copenhagen, Denmark; [Rorvig, Sara B.] Rigshosp, Dept Pathol, Copenhagen, Denmark; [Tjelle, Klaus; Foss, Nicolai B.; Plovsing, Ronni R.] Univ Copenhagen, Hvidovre Hosp, Dept Anesthesiol & Intens Care, Hvidovre, Denmark; [Berg, Ronan Mg] Univ South Wales, Fac Life Sci S & Educ, Neurovasc Res Lab, Pontypridd, M Glam, Wales	University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of South Wales	Plovsing, RR (corresponding author), Hvidovre Univ Hosp, Dept Anesthesiol & Nsive Care, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.	ronni.thermann.reitz.plovsing.01@regionh.dk		Ahlstrom, Magnus/0000-0001-5546-3959; Berg, Ronan/0000-0002-5757-9506; Benfield, Thomas/0000-0003-0698-9385; Marquart, Hanne Vibeke/0000-0001-9740-6522; Bay, Jakob Thaning/0000-0003-1159-4003	Lundbeck Foundation [R349-2020-540]	Lundbeck Foundation(Lundbeckfonden)	This study was supported by the Lundbeck Foundation (grant R349-2020-540).	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Aggarwal S, 1999, J IMMUNOL, V162, P2154; ANCOCHEA J, 1993, CHEST, V104, P32, DOI 10.1378/chest.104.1.32; Baughman RP, 2007, SEMIN RESP CRIT CARE, V28, P475, DOI 10.1055/s-2007-991520; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Billard MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017940; Bouhaddou M, 2020, CELL, V182, P685, DOI 10.1016/j.cell.2020.06.034; Carbajosa S, 2017, ONCOTARGET, V8, P17551, DOI 10.18632/oncotarget.14886; Chien JY, 2006, RESPIROLOGY, V11, P715, DOI 10.1111/j.1440-1843.2006.00942.x; European Centre for Disease Prevention and Control, COVID 19 SIT UPD WOR; Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z; Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Heron M, 2012, CLIN EXP IMMUNOL, V167, P523, DOI 10.1111/j.1365-2249.2011.04529.x; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Lindsley AW, 2020, J ALLERGY CLIN IMMUN, V146, P1, DOI 10.1016/j.jaci.2020.04.021; Paats MS, 2013, THORAX, V68, P468, DOI 10.1136/thoraxjnl-2012-202168; Plovsing RR, 2014, CRIT CARE MED, V42, P1658, DOI 10.1097/CCM.0000000000000320; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Statens Serum Institut, TAL OV AGN COVID 19; Torrego A, 2020, AM J RESP CRIT CARE, V202, P284, DOI 10.1164/rccm.202004-0945LE; Venet F, 2004, CRIT CARE MED, V32, P2329, DOI 10.1097/01.CCM.0000145999.42971.4B; Wang CH, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-42; Wang LM, 2012, AM J RESP CRIT CARE, V186, P989, DOI 10.1164/rccm.201202-0261OC; Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE; WHO, NOV COR CHIN; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358; World Health Organization, COR DIS COVID 19 PAN; Wright DJM, 2021, LANCET INFECT DIS, V21, P25, DOI 10.1016/S1473-3099(20)30376-5; Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363; Zhang W, 2019, CANCER CHEMOTH PHARM, V83, P911, DOI 10.1007/s00280-019-03800-x; Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017	39	41	41	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					81	91		10.1016/j.jaci.2020.09.009	http://dx.doi.org/10.1016/j.jaci.2020.09.009		JAN 2021	11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32979342	Green Published, hybrid			2022-12-18	WOS:000613645900011
J	Roufosse, F; Kahn, JE; Rothenberg, ME; Wardlaw, AJ; Klion, AD; Kirby, SY; Gilson, MJ; Bentley, JH; Bradford, ES; Yancey, SW; Steinfeld, J; Gleich, GJ				Roufosse, Florence; Kahn, Jean-Emmanuel; Rothenberg, Marc E.; Wardlaw, Andrew J.; Klion, Amy D.; Kirby, Suyong Yun; Gilson, Martyn J.; Bentley, Jane H.; Bradford, Eric S.; Yancey, Steven W.; Steinfeld, Jonathan; Gleich, Gerald J.		HES Mepolizumab Study Grp	Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hypereosinophilic syndrome; mepolizumab; flare; efficacy; safety	ASTHMA	Background: Anti-IL-5 therapy is a potential treatment for patients with hypereosinophilic syndrome (HES), although its clinical efficacy is unclear. Objective: We sought to investigate the clinical efficacy and safety of mepolizumab versus placebo in patients with HES. Methods: This randomized, multicenter, double-blind, placebo-controlled, phase III trial was conducted across 39 centers in 13 countries. Eligible patients had FIP1L1-PDGFRA-negative HES, experienced 2 or more flares (worsening of HES-related symptoms or blood eosinophil count requiring therapeutic escalation) in the previous 12 months, and had a screening blood eosinophil count greater than or equal to 1000 cells/mL. Patients were randomized (1:1) to subcutaneous mepolizumab (300 mg) or placebo every 4 weeks for 32 weeks, plus existing HES therapy. The primary outcome was the proportion of patients with 1 or more flares (worsening of HES-related symptoms necessitating therapy escalation or >2 courses of blinded rescue oral corticosteroids) during the study; in addition, patients who withdrew early from the study were counted as having a flare. Safety end points were also assessed. Results: The proportion of patients experiencing 1 or more flares/with drawing from the study was 50% lower with mepolizumab versus placebo (15 of 54 [28%] vs 30 of 54 [56%]; P = .002). Logistic regression analysis was consistent with the primary analysis (odds ratio, 0.28; 95% CI, 0.12-0.64; P = .003). Similar proportions of patients in the mepolizumab and placebo groups experienced on-treatment adverse events (48 of 54 [89%] vs 47 of 54 [87%]). Conclusions: Compared with placebo, mepolizumab significantly reduced the occurrence of flares in patients with HES, with no new safety signals identified.	[Roufosse, Florence] Univ Libre Bruxelles, Dept Internal Med, Hop Erasme, Route Lennik 808, B-1070 Brussels, Belgium; [Kahn, Jean-Emmanuel] Univ Versailles St Quentinen Yvelines, Dept Internal Med, Hop Ambroise Pare, Boulogne, France; [Rothenberg, Marc E.] Cincinnati Childrens Hosp Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA; [Rothenberg, Marc E.] Univ Cincinnati, Dept Pediat, Cincinnati, OH USA; [Wardlaw, Andrew J.] Univ Leicester, Inst Lung Hlth, Leicester, Leics, England; [Klion, Amy D.] NIAID, NIH, Bethesda, MD USA; [Kirby, Suyong Yun; Bradford, Eric S.; Yancey, Steven W.] GSK, Resp Therapeut Area, Res Triangle Pk, NC USA; [Gilson, Martyn J.] GSK, Resp Res & Dev, Uxbridge, Middx, England; [Bentley, Jane H.] GSK, Clin Stat, Uxbridge, Middx, England; [Steinfeld, Jonathan] GSK, Resp Res & Dev, Collegeville, PA USA; [Gleich, Gerald J.] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT USA; [Bradford, Eric S.] Aeglea BioTherapeut, Austin, TX USA	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Leicester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Utah System of Higher Education; University of Utah	Roufosse, F (corresponding author), Univ Libre Bruxelles, Dept Internal Med, Hop Erasme, Route Lennik 808, B-1070 Brussels, Belgium.	froufoss@ulb.ac.be			GlaxoSmithKline [200622]	GlaxoSmithKline(GlaxoSmithKline)	This study was funded by GlaxoSmithKline (GSK study ID: 200622; NCT02836496). Editorial support (in the form of writing assistance, including development of the initial draft based on author direction, assembling tables and figures, collating authors' comments, grammatical editing, and referencing) was provided by Laura Gardner, PhD, of Fishawack Indicia Ltd, UK, and was funded by GSK.	[Anonymous], 2019, MEPOLIZUMAB NUCALA S; [Anonymous], 2019, MEPOLIZUMAB NUCALA H; Curtis C, 2016, CLIN REV ALLERG IMMU, V50, P240, DOI 10.1007/s12016-015-8506-7; Duncan EA, 2015, AM J RESP CRIT CARE, V191; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Kahn JE, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00216; Kieser M, 2003, STAT MED, V22, P3571, DOI 10.1002/sim.1585; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Menzella F, 2015, J ASTHMA ALLERGY, V8, P105, DOI 10.2147/JAA.S40244; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Roufosse F, 2010, J ALLERGY CLIN IMMUN, V126, P828, DOI 10.1016/j.jaci.2010.06.049; Roufosse FE, 2013, J ALLERGY CLIN IMMUN, V131, P461, DOI 10.1016/j.jaci.2012.07.055; Shomali W, 2019, AM J HEMATOL, V94, P1149, DOI 10.1002/ajh.25617; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Valent P, 2012, J ALLERGY CLIN IMMUN, V130, P607, DOI 10.1016/j.jaci.2012.02.019; Wechsler ME, 2017, NEW ENGL J MED, V376, P1921, DOI 10.1056/NEJMoa1702079; Whitehouse Michael W., 2011, Inflammopharmacology, V19, P1, DOI 10.1007/s10787-010-0056-2	20	41	42	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2020	146	6					1397	1405		10.1016/j.jaci.2020.08.037	http://dx.doi.org/10.1016/j.jaci.2020.08.037			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PC3XH	32956756	hybrid, Green Published, Green Accepted			2022-12-18	WOS:000596937900021
J	Lehman, HK; Segal, BH				Lehman, Heather K.; Segal, Brahm H.			The role of neutrophils in host defense and disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Neutrophils; neutrophil extracellular traps; granulopoiesis; innate immunity; phagocytosis; degranulation; neutrophil dysfunction	SEVERE CONGENITAL NEUTROPENIA; EXTRACELLULAR DNA TRAPS; DEEP-VEIN THROMBOSIS; NADPH OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES; NETTING NEUTROPHILS; CIRCADIAN VARIATION; GRANULE DEFICIENCY; CANDIDA-ALBICANS; DEIMINASE 4	Neutrophils, the most abundant circulating leukocyte, are critical for host defense. Granulopoiesis is under the control of transcriptional factors and culminates in mature neutrophils with a broad armamentarium of antimicrobial pathways. These pathways include nicotinamide adenine dinucleotide phosphate oxidase, which generates microbicidal reactive oxidants, and nonoxidant pathways that target microbes through several mechanisms. Activated neutrophils can cause or worsen tissue injury, underscoring the need for calibration of activation and resolution of inflammation when infection has been cleared. Acquired neutrophil disorders are typically caused by cytotoxic chemotherapy or immunosuppressive agents. Primary neutrophil disorders typically result from disabling mutations of individual genes that result in impaired neutrophil number or function, and provide insight into basic mechanisms of neutrophil biology. Neutrophils can also be activated by noninfectious causes, including trauma and cellular injury, and can have off-target effects in which pathways that typically defend against infection exacerbate injury and disease. These off-target effects include acute organ injury, autoimmunity, and variable effects on the tumor microenvironment that can limit or worsen tumor progression. A greater understanding of neutrophil plasticity in these conditions is likely to pave the way to new therapeutic approaches.	[Lehman, Heather K.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Pediat, Div Allergy Immunol & Rheumatol, Buffalo, NY 14203 USA; [Segal, Brahm H.] Univ Buffalo, Roswell Park Comprehens Canc Ctr, 665 Elm St, Buffalo, NY 14203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Segal, BH (corresponding author), Univ Buffalo, Roswell Park Comprehens Canc Ctr, 665 Elm St, Buffalo, NY 14203 USA.	brahm.segal@roswellpark.org	Lehman, Heather/AAZ-4560-2021; Segal, Brahm/AAW-2706-2020		National Institutes of Health [R01CA188900]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health grant R01CA188900 (to B.H.S.).	Aarts CEM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02144; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Almyroudis NG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00045; Ancliff PJ, 2006, BLOOD, V108, P2182, DOI 10.1182/blood-2006-01-010249; ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; Atkinson TP, 1997, J PEDIATR-US, V130, P488, DOI 10.1016/S0022-3476(97)70218-X; BAICI A, 1982, RHEUMATOL INT, V2, P11, DOI 10.1007/BF00541264; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; Balabanian K, 2005, BLOOD, V105, P2449, DOI 10.1182/blood-2004-06-2289; Banka S, 2011, EUR J HUM GENET, V19, P18, DOI 10.1038/ejhg.2010.136; BarJoseph G, 1997, J PEDIATR-US, V131, P317, DOI 10.1016/S0022-3476(97)70175-6; Bergin DA, 2013, J INFLAMM RES, V6, P1, DOI 10.2147/JIR.S40081; Boone BA, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4584-2; Brill A, 2012, J THROMB HAEMOST, V10, P136, DOI 10.1111/j.1538-7836.2011.04544.x; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Cassatella MA, 1999, ADV IMMUNOL, V73, P369, DOI 10.1016/S0065-2776(08)60791-9; Chang YC, 1998, J CLIN INVEST, V101, P1843, DOI 10.1172/JCI2301; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; CLARK RA, 1979, J IMMUNOL, V122, P2605; CLARK RA, 1975, J EXP MED, V141, P1442, DOI 10.1084/jem.141.6.1442; Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484; Cowland JB, 2016, IMMUNOL REV, V273, P11, DOI 10.1111/imr.12440; Crow MK, 2014, J IMMUNOL, V192, P5459, DOI 10.4049/jimmunol.1002795; Dale DC, 2002, SEMIN HEMATOL, V39, P89, DOI 10.1053/shem.2002.31917; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; Drewniak A, 2013, BLOOD, V121, P2385, DOI 10.1182/blood-2012-08-450551; Drummond RA, 2019, NAT IMMUNOL, V20, P559, DOI 10.1038/s41590-019-0377-2; Drummond RA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01836; Dworski R, 2011, J ALLERGY CLIN IMMUN, V127, P1260, DOI 10.1016/j.jaci.2010.12.1103; Ella K, 2016, BRAIN BEHAV IMMUN, V57, P209, DOI 10.1016/j.bbi.2016.04.016; Erlewyn-Lajeunesse MDS, 2008, PEDIATR RES, V64, P194, DOI 10.1203/PDR.0b013e318175dd2d; Etulain J, 2015, BLOOD, V126, P242, DOI 10.1182/blood-2015-01-624023; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; FUJISHIMA S, 1993, J CELL PHYSIOL, V154, P478, DOI 10.1002/jcp.1041540305; Furtmuller PG, 1998, BIOCHEMISTRY-US, V37, P17923, DOI 10.1021/bi9818772; GALLIN JI, 1984, BLOOD, V63, P977; Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4; Garcia-Romo GS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001201; Gazendam RP, 2014, BLOOD, V124, P590, DOI 10.1182/blood-2014-01-551473; Gazit Y, 2010, J CLIN IMMUNOL, V30, P308, DOI 10.1007/s10875-009-9354-0; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Gombart AF, 2002, CURR OPIN HEMATOL, V9, P36, DOI 10.1097/00062752-200201000-00007; Grabcanovic-Musija F, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0221-7; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; Hakkim A, 2010, P NATL ACAD SCI USA, V107, P9813, DOI 10.1073/pnas.0909927107; Hitchon CA, 2004, ARTHRITIS RES THER, V6, P265, DOI 10.1186/ar1447; Horwitz MS, 2007, BLOOD, V109, P1817, DOI 10.1182/blood-2006-08-019166; Horwitz MS, 2013, HEMATOL ONCOL CLIN N, V27, P19, DOI 10.1016/j.hoc.2012.10.004; Hosseinzadeh A, 2016, J LEUKOCYTE BIOL, V100, P1105, DOI 10.1189/jlb.3AB0815-379RR; JUNG K, 1993, ACTA DERM-VENEREOL, V73, P433; Kenny EF, 2017, ELIFE, V6, DOI [10.7554/elife.24437, 10.7554/eLife.24437]; Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959; Khandpur R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005580; Knight JS, 2015, ANN RHEUM DIS, V74, P2199, DOI 10.1136/annrheumdis-2014-205365; Kong XN, 2010, J IMMUNOL, V185, P569, DOI 10.4049/jimmunol.0902315; Krishnamoorthy N, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aao4747; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Kuijpers TW, 2009, BLOOD, V113, P4740, DOI 10.1182/blood-2008-10-182154; Lahoz-Beneytez J, 2016, BLOOD, V127, P3431, DOI 10.1182/blood-2016-03-700336; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394, DOI 10.1164/ajrccm.157.2.97-02099; Lande R, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001180; Lanternier F, 2013, NEW ENGL J MED, V369, P1704, DOI 10.1056/NEJMoa1208487; Lanza F, 1998, J MOL MED-JMM, V76, P676, DOI 10.1007/s001090050267; Law SM, 2017, J INFLAMM-LOND, V14, DOI 10.1186/s12950-017-0176-1; Lee WL, 2003, MICROBES INFECT, V5, P1299, DOI 10.1016/j.micinf.2003.09.014; Lee W, 2019, J EXP MED, V216, P176, DOI 10.1084/jem.20181170; Leffler J, 2014, CLIN EXP RHEUMATOL, V32, P66; Leffler J, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4264; Lefrancais E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98178; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/88289; Makaryan V, 2015, CURR OPIN HEMATOL, V22, P3, DOI 10.1097/MOH.0000000000000105; Martinod K, 2016, J THROMB HAEMOST, V14, P551, DOI 10.1111/jth.13239; Martinod K, 2013, P NATL ACAD SCI USA, V110, P8674, DOI 10.1073/pnas.1301059110; Matlung HL, 2018, CELL REP, V23, P3946, DOI 10.1016/j.celrep.2018.05.082; McDermott DH, 2019, NEW ENGL J MED, V380, P163, DOI [10.1056/NEJMoa1808575, 10.1056/nejmoa1808575]; McDermott DH, 2014, BLOOD, V123, P2308, DOI 10.1182/blood-2013-09-527226; MELCHART D, 1992, CHRONOBIOL INT, V9, P35, DOI 10.3109/07420529209064514; Messina CGM, 2002, FEBS LETT, V518, P107, DOI 10.1016/S0014-5793(02)02658-3; Metzler KD, 2014, CELL REP, V8, P883, DOI 10.1016/j.celrep.2014.06.044; Mor-Vaknin N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14252; Mora-Jensen H, 2011, J LEUKOCYTE BIOL, V90, P629, DOI 10.1189/jlb.0311123; Niehaus GD, 2002, CAN J PHYSIOL PHARM, V80, P935, DOI 10.1139/Y02-121; Notarangelo LD, 2009, J LEUKOCYTE BIOL, V85, P335, DOI 10.1189/jlb.0808474; Okada S, 1997, AM J RESP CELL MOL, V17, P519, DOI 10.1165/ajrcmb.17.4.2877; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Pillay J, 2010, BLOOD, V116, P625, DOI 10.1182/blood-2010-01-259028; PILLINGER MH, 1995, RHEUM DIS CLIN N AM, V21, P691; Radic M, 2013, SEMIN IMMUNOPATHOL, V35, P465, DOI 10.1007/s00281-013-0376-6; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150; Rochael NC, 2015, SCI REP-UK, V5, DOI 10.1038/srep18302; Rohrbach AS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00360; Roques G, 2014, PEDIATR BLOOD CANCER, V61, P1041, DOI 10.1002/pbc.24964; Saffarzadeh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032366; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Segal BH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009631; Seger R, 2017, OPEN ACCESS TXB; Sekhar KR, 2003, CANCER RES, V63, P5636; Shaul ME, 2019, NAT REV CLIN ONCOL, V16, P601, DOI 10.1038/s41571-019-0222-4; Shaul ME, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1232221; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503-369OC; Simpson JL, 2016, EUR RESPIR J, V47, P792, DOI 10.1183/13993003.00405-2015; Singel KL, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122311; Singel KL, 2016, IMMUNOL REV, V273, P329, DOI 10.1111/imr.12459; Singel KL, 2016, CLIN SCI, V130, P479, DOI 10.1042/CS20150660; Skokowa J, 2014, BLOOD, V123, P2229, DOI 10.1182/blood-2013-11-538025; Smith CK, 2014, ARTHRITIS RHEUMATOL, V66, P2532, DOI 10.1002/art.38703; Stojkov D, 2017, J CELL BIOL, V216, P4073, DOI 10.1083/jcb.201611168; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; Svensson L, 2009, NAT MED, V15, P306, DOI 10.1038/nm.1931; Szczerba BM, 2019, NATURE, V566, P553, DOI 10.1038/s41586-019-0915-y; Tanaka H, 2000, J ALLERGY CLIN IMMUN, V105, P900, DOI 10.1067/mai.2000.105316; Thomas CJ, 2013, TRENDS IMMUNOL, V34, P317, DOI 10.1016/j.it.2013.02.008; Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183; Treffers LW, 2018, EUR J IMMUNOL, V48, P344, DOI 10.1002/eji.201747215; Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x; Veglia F, 2019, NATURE, V569, P73, DOI 10.1038/s41586-019-1118-2; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Vilboux T, 2013, NEW ENGL J MED, V369, P54, DOI 10.1056/NEJMoa1301296; Villanueva E, 2011, J IMMUNOL, V187, P538, DOI 10.4049/jimmunol.1100450; von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322; Walker MJ, 2007, NAT MED, V13, P981, DOI 10.1038/nm1612; Wengner AM, 2008, BLOOD, V111, P42, DOI 10.1182/blood-2007-07-099648; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Williams DA, 2000, BLOOD, V96, P1646; Willis VC, 2017, CLIN EXP IMMUNOL, V188, P263, DOI 10.1111/cei.12932; Young RP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016476; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96	134	41	41	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2020	145	6					1535	1544		10.1016/j.jaci.2020.02.038	http://dx.doi.org/10.1016/j.jaci.2020.02.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LW4ZZ	32283205	Bronze, Green Accepted			2022-12-18	WOS:000539157800006
J	Bellinghausen, I; Weigmann, B; Zevallos, V; Maxeiner, J; Reissig, S; Waisman, A; Schuppan, D; Saloga, J				Bellinghausen, Iris; Weigmann, Benno; Zevallos, Victor; Maxeiner, Joachim; Reissig, Sonja; Waisman, Ari; Schuppan, Detlef; Saloga, Joachim			Wheat amylase-trypsin inhibitors exacerbate intestinal and airway allergic immune responses in humanized mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Humanized mice; amylase-trypsin inhibitors; allergen; IgE; colon; lung; celiac disease; gluten; wheat sensitivity	GLIADIN PEPTIDES; DENDRITIC CELLS; ANTI-IGE; T-CELLS; INFLAMMATION; ACTIVATION; ASTHMA; PROTEINS; SENSITIVITY; MONOCYTES	Background: Amylase-trypsin inhibitors (ATIs) in wheat and related cereals are potent activators of myeloid innate immune cells via engagement of TLR4. Furthermore, ATIs have been shown to serve as adjuvants in experimental intestinal inflammatory diseases. Objective: The aim of this study was to analyze whether ATIs are also modifiers of allergic inflammation. Methods: Therefore, CD4(+) T cells from donors sensitized to grass or birch pollen were stimulated with autologous allergen-pulsed dendritic cells in the presence or absence of ATIs or the control storage protein zein from corn. To analyze allergen-induced gut and lung inflammation, immunodeficient mice were engrafted with PBMCs from these allergic donors plus the respective allergen, and fed with selected diets. Three weeks later, inflammation was induced by rectal or intranasal allergen challenge and monitored by mini endoscopy or airway hyperreactivity, respectively. Results: Allergen-specific T-cell proliferation and cytokine production was significantly exacerbated by ATIs and not by zein. In vivo, allergen-specific human IgE level was strongly elevated in sera of mice receiving anATI-containing diet compared with mice that were fed gluten-free and thus ATI-free diet. Importantly, allergen-induced IgE-dependent colitis and airway hyperreactivity were also enhanced in ATI-fed mice. Gut inflammation was further increased in mice receiving an additional ATI injection and even detectable in the absence of the aeroallergen, whereas zein had no such effect. Injection of antihuman TLR4 mAbs or the anti-human IgE mAb omalizumab completely abolished ATI-induced allergic inflammation. Conclusions: These results underline that wheat ATIs are important nutritional activators and adjuvants of allergy, which might be exploited for nutritional therapeutic strategies.	[Bellinghausen, Iris; Saloga, Joachim] Johannes Gutenberg Univ Mainz, Dept Dermatol, Mainz, Germany; [Bellinghausen, Iris; Zevallos, Victor; Reissig, Sonja; Waisman, Ari; Schuppan, Detlef; Saloga, Joachim] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy, Mainz, Germany; [Weigmann, Benno] Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Internal Med 1, Erlangen, Germany; [Zevallos, Victor; Schuppan, Detlef] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Translat Immunol, Mainz, Germany; [Maxeiner, Joachim] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Asthma Core Facil, Res Ctr Immunotherapy, Mainz, Germany; [Reissig, Sonja; Waisman, Ari] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Mol Med, Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Erlangen Nuremberg; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Bellinghausen, I (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, Langenbeckstr 1, D-55131 Mainz, Germany.	iris.bellinghausen@unimedizin-mainz.de		Zevallos, Victor F/0000-0003-3135-1359	Deutsche Forschungsgemeinschaft [BE 4504/2-2, 4504/3-1, WE 4656/2-2, SFB1181-B02, Schu 646/17-1, 646/20-1]; Leibniz-Foundation [5480]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Leibniz-Foundation	This work was supported by Deutsche Forschungsgemeinschaft (grant nos. BE 4504/2-2 and 4504/3-1 to I.B., WE 4656/2-2 and SFB1181-B02 to B.W., and Schu 646/17-1 and 646/20-1 to D.S.), and the Leibniz-Foundation (project 5480 to D.S.).	Abadie V, 2014, IMMUNOL REV, V260, P221, DOI 10.1111/imr.12191; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Altenbach Susan B, 2011, BMC Res Notes, V4, P242, DOI 10.1186/1756-0500-4-242; Barone MV, 2014, INT J MOL SCI, V15, P20518, DOI 10.3390/ijms151120518; Becker C, 2006, NAT PROTOC, V1, P2900, DOI 10.1038/nprot.2006.446; Bellinghausen I, 2012, J ALLERGY CLIN IMMUN, V130, P1384, DOI 10.1016/j.jaci.2012.08.039; Bublin M, 2014, J ALLERGY CLIN IMMUN, V134, P521, DOI 10.1016/j.jaci.2014.04.015; Catassi C, 2013, NUTRIENTS, V5, P3839, DOI 10.3390/nu5103839; Cinova J, 2007, J CLIN IMMUNOL, V27, P201, DOI 10.1007/s10875-006-9061-z; Cuccioloni M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13709-1; Eschborn M, 2015, J ALLERGY CLIN IMMUN, V136, P159, DOI 10.1016/j.jaci.2015.04.020; Fasano A, 2015, GASTROENTEROLOGY, V148, P1195, DOI 10.1053/j.gastro.2014.12.049; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; Junker Y, 2012, J EXP MED, V209, P2395, DOI 10.1084/jem.20102660; Kaukinen K, 2014, NAT REV GASTRO HEPAT, V11, P36, DOI 10.1038/nrgastro.2013.141; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lommatzsch M, 2014, THORAX, V69, P94, DOI 10.1136/thoraxjnl-2013-203738; Maiuri L, 2003, LANCET, V362, P30, DOI 10.1016/S0140-6736(03)13803-2; Martin H, 2012, J ALLERGY CLIN IMMUN, V129, P521, DOI 10.1016/j.jaci.2011.09.038; Mauri P, 2014, IMMUNOL LETT, V162, P2, DOI 10.1016/j.imlet.2014.08.010; McClure R, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00386; Michael S, 2015, BEST PRACT RES CL GA, V29, P425, DOI 10.1016/j.bpg.2015.05.001; Nikulina M, 2004, J IMMUNOL, V173, P1925, DOI 10.4049/jimmunol.173.3.1925; Rakhimova M, 2009, J CLIN IMMUNOL, V29, P29, DOI 10.1007/s10875-008-9228-x; Riccio AM, 2012, INT J IMMUNOPATH PH, V25, P475, DOI 10.1177/039463201202500217; Salcedo G, 2011, J INVEST ALLERG CLIN, V21, P81; Samitas K, 2015, EUR RESPIR REV, V24, P594, DOI 10.1183/16000617.00001715; Schuppan D, 2015, BEST PRACT RES CL GA, V29, P469, DOI 10.1016/j.bpg.2015.04.002; Schuppan D, 2015, DIGEST DIS, V33, P260, DOI 10.1159/000371476; Schuppan D, 2013, DTSCH ARZTEBL INT, V110, P835, DOI 10.3238/arztebl.2013.0835; Schuppan D, 2009, GASTROENTEROLOGY, V137, P1912, DOI 10.1053/j.gastro.2009.09.008; Simonato B, 2001, CLIN EXP ALLERGY, V31, P1771, DOI 10.1046/j.1365-2222.2001.01200.x; Tatham AS, 2008, CLIN EXP ALLERGY, V38, P1712, DOI 10.1111/j.1365-2222.2008.03101.x; THEOBALD K, 1986, J ALLERGY CLIN IMMUN, V78, P470, DOI 10.1016/0091-6749(86)90035-7; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Weigmann B, 2012, J ALLERGY CLIN IMMUN, V129, P1126, DOI 10.1016/j.jaci.2011.11.036; Zevallos VF, 2017, GASTROENTEROLOGY, V152, P1100, DOI 10.1053/j.gastro.2016.12.006	38	41	41	0	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					201	+		10.1016/j.jaci.2018.02.041	http://dx.doi.org/10.1016/j.jaci.2018.02.041			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	29574077	Bronze			2022-12-18	WOS:000454918300026
J	Schafer, JR; Salzillo, TC; Chakravarti, N; Kararoudi, MN; Trikha, P; Foltz, JA; Wang, RN; Li, SL; Lee, DA				Schafer, Jolie R.; Salzillo, Travis C.; Chakravarti, Nitin; Kararoudi, Meisam Naeimi; Trikha, Prashant; Foltz, Jennifer A.; Wang, Ruoning; Li, Shulin; Lee, Dean A.			Education-dependent activation of glycolysis promotes the cytolytic potency of licensed human natural killer cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Natural killer cells; licensing; metabolism; glycolysis	TUMOR MICROENVIRONMENT; METABOLIC REQUIREMENTS; INHIBITORY RECEPTORS; GLUCOSE-METABOLISM; PROTEIN-KINASE; NK CELLS; EXPRESSION; SELF; CHECKPOINT; RESPONSES	Background: The mechanism by which natural killer (NK) cell education results in licensed NK cells with heightened effector function against missing self-targets is not known. Objectives: We sought to identify potential mechanisms of enhanced function in licensed human NK cells. Methods: We used expanded human NK cells from killer immunoglobulin-like receptor (KIR)/HLA-genotyped donors sorted for single-KIR+ cells to generate pure populations of licensed and unlicensed NK cells. We performed proteomic and gene expression analysis of these cells before and after receptor cross-linking and performed functional and metabolic analysis before and after interference with selected metabolic pathways. We verified key findings using freshly isolated and sorted NK cells from peripheral blood. Results: We confirmed that licensed human NK cells are greater in number in peripheral blood and proliferate more in vitro than unlicensed NK cells. Using high-throughput protein analysis, we found that unstimulated licensed NK cells have increased expression of the glycolytic enzyme pyruvate kinase muscle isozyme M2 and after KIR cross-linking have increased phosphorylation of the metabolic modulators p38-alpha and 5 ' adenosine monophosphate-activated protein kinase a. After cytokine expansion and activation, unlicensed NK cells depended solely on mitochondrial respiration for cytolytic function, whereas licensed NK cells demonstrated metabolic reprogramming toward glycolysis and mitochondrial-dependent glutaminolysis, leading to accumulation of glycolytic metabolites and depletion of glutamate. As such, blocking both glycolysis and mitochondrial-dependent respiration was required to suppress the cytotoxicity of licensed NK cells. Conclusions: Collectively, our data support an arming model of education in which enhanced glycolysis in licensed NK cells supports proliferative and cytotoxic capacity.	[Schafer, Jolie R.; Salzillo, Travis C.; Li, Shulin] Univ Texas MD Anderson Canc Ctr UT Hlth, Grad Sch Biomed Sci, Houston, TX USA; [Schafer, Jolie R.; Li, Shulin] Univ Texas MD Anderson Canc Ctr, Dept Pediat Res, Houston, TX 77030 USA; [Salzillo, Travis C.] Univ Texas MD Anderson Canc Ctr, Dept Canc Syst Imaging Houston, Houston, TX 77030 USA; [Chakravarti, Nitin; Kararoudi, Meisam Naeimi; Trikha, Prashant; Foltz, Jennifer A.; Wang, Ruoning; Lee, Dean A.] Nationwide Childrens Hosp, Ctr Childhood Canc & Blood Dis, Columbus, OH USA; [Wang, Ruoning; Lee, Dean A.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University	Lee, DA (corresponding author), 700 Childrens Dr,WA4023, Columbus, OH 43110 USA.	dean.lee@nationwidechildrens.org	Li, Shulin/D-6478-2011; Naeimi, Meisam/ABA-1979-2021; Salzillo, Travis/AAA-3476-2022; Chakravarti, Nitin/F-7964-2011	Salzillo, Travis/0000-0001-6271-9879; Chakravarti, Nitin/0000-0002-6619-953X; Foltz, Jennifer/0000-0001-9158-3464	NCI Cancer Center Support Grant [P30CA16672]; Cancer Prevention and Research Institute of Texas (CPRIT); Leukemia & Lymphoma Society; Taylor Trudeau Cycle for Life Foundation; CPRIT Research Training Grant Award [RP170067]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI114581] Funding Source: NIH RePORTER	NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention and Research Institute of Texas (CPRIT); Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Taylor Trudeau Cycle for Life Foundation; CPRIT Research Training Grant Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The flow cytometry core is supported by NCI Cancer Center Support Grant P30CA16672. This work was supported in part by grant support to DAL from the Cancer Prevention and Research Institute of Texas (CPRIT), the Leukemia & Lymphoma Society, and the Taylor Trudeau Cycle for Life Foundation. T.C.S. was supported by CPRIT Research Training Grant Award (RP170067).	Allison KE, 2017, IMMUNOLOGY, V152, P175, DOI 10.1111/imm.12777; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Assmann N, 2017, NAT IMMUNOL, V18, P1197, DOI 10.1038/ni.3838; Bachmann MF, 2012, EUR J IMMUNOL, V42, P819, DOI 10.1002/eji.201242450; Belanger S, 2012, BLOOD, V120, P592, DOI 10.1182/blood-2012-02-408732; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Beziat V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011966; Bjorkstrom NK, 2010, BLOOD, V116, P3853, DOI 10.1182/blood-2010-04-281675; Bolanos Juan P, 2013, Biochem J, V452, pe7, DOI 10.1042/BJ20130560; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Delconte RB, 2016, NAT IMMUNOL, V17, P816, DOI 10.1038/ni.3470; Demanet C, 2004, BLOOD, V103, P3122, DOI 10.1182/blood-2003-07-2500; Denman CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030264; Desideri E, 2014, AUTOPHAGY, V10, P1652, DOI 10.4161/auto.29456; Donnelly RP, 2014, J IMMUNOL, V193, P4477, DOI 10.4049/jimmunol.1401558; Elliott JM, 2011, TRENDS IMMUNOL, V32, P364, DOI 10.1016/j.it.2011.06.001; Fujisaki H, 2009, CANCER RES, V69, P4010, DOI 10.1158/0008-5472.CAN-08-3712; Geng LY, 2007, MOL CELL BIOL, V27, P2625, DOI 10.1128/MCB.02072-06; Hardie DG, 2011, BIOCHEM SOC T, V39, P1, DOI 10.1042/BST0390001; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Jaswal JS, 2007, AM J PHYSIOL-HEART C, V292, pH1978, DOI 10.1152/ajpheart.01121.2006; Kaesler S, 2012, EUR J IMMUNOL, V42, P831, DOI 10.1002/eji.201141690; Kalender A, 2011, CELL RES, V21, P859, DOI 10.1038/cr.2011.65; Kannan GS, 2017, BLOOD REV, V31, P1, DOI 10.1016/j.blre.2016.08.007; Keppel MP, 2015, J IMMUNOL, V194, P1954, DOI 10.4049/jimmunol.1402099; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kouidhi S, 2016, FRONT IMMUNOL, V7, DOI [10.3389/fimmu.2016.0114, 10.3389/fimmu.2016.00114]; Lisovsky I, 2015, J VIROL, V89, P9909, DOI 10.1128/JVI.01546-15; Liu JJ, 2015, CELL PHYSIOL BIOCHEM, V36, P155, DOI 10.1159/000374060; Lombardi G, 2004, BIOCHEM BIOPH RES CO, V318, P496, DOI 10.1016/j.bbrc.2004.04.053; Mah AY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95128; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; Marcais A, 2017, ELIFE, V6, DOI 10.7554/eLife.26423; Marcais A, 2014, CELL CYCLE, V13, P3315, DOI 10.4161/15384101.2014.972919; Martinet L, 2015, CELL REP, V11, P85, DOI 10.1016/j.celrep.2015.03.006; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Muller-Durovic B, 2016, J IMMUNOL, V197, P2891, DOI 10.4049/jimmunol.1600590; NEWSHOLME EA, 1985, BIOSCIENCE REP, V5, P393, DOI 10.1007/BF01116556; Nsiah-Sefaa A, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20150295; Ouyang Q, 2007, ANN NY ACAD SCI, V1106, P240, DOI 10.1196/annals.1392.001; Pacheco R, 2004, J BIOL CHEM, V279, P33352, DOI 10.1074/jbc.M401761200; Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454; Phatarpekar PV, 2016, METHODS MOL BIOL, V1441, P267, DOI 10.1007/978-1-4939-3684-7_22; Romagnani C, 2007, J IMMUNOL, V178, P4947, DOI 10.4049/jimmunol.178.8.4947; Romero-Garcia S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00052; Schaffer SW, 2014, AMINO ACIDS, V46, P47, DOI [10.1007/s00726-012-1414-8, 10.1007/s00726-013-1632-8]; Schmid I, 2004, CURR PROTOC CYTOM; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Somanchi SS, 2011, J VIS EXP; Velasquez SY, 2016, J BIOL CHEM, V291, P12960, DOI 10.1074/jbc.M116.721753; Wang B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073987; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; WARBURG O, 1958, Z NATURFORSCH PT B, V13, P515, DOI 10.1515/znb-1958-0806; Wu SB, 2012, BBA-MOL BASIS DIS, V1822, P233, DOI 10.1016/j.bbadis.2011.09.014; Yawata M, 2008, BLOOD, V112, P2369, DOI 10.1182/blood-2008-03-143727; Yokoyama WM, 2006, IMMUNOL REV, V214, P143, DOI 10.1111/j.1600-065X.2006.00458.x; Yokoyama WM, 2006, IMMUNITY, V24, P249, DOI 10.1016/j.immuni.2006.03.006	60	41	42	1	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2019	143	1					346	+		10.1016/j.jaci.2018.06.047	http://dx.doi.org/10.1016/j.jaci.2018.06.047			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG4BD	30096390	Bronze			2022-12-18	WOS:000454918300038
J	Wallington, JC; Williams, AP; Staples, KJ; Wilkinson, TMA				Wallington, Joshua C.; Williams, Anthony P.; Staples, Karl J.; Wilkinson, Tom M. A.			IL-12 and IL-7 synergize to control mucosal-associated invariant T-cell cytotoxic responses to bacterial infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T cells; mucosal-associated invariant T cells; bacterial infection; cytotoxicity	NONTYPABLE HAEMOPHILUS-INFLUENZAE; OBSTRUCTIVE PULMONARY-DISEASE; CIGARETTE-SMOKE; MAIT CELLS; MICROBIOME; CONTRIBUTE; EXPOSURE; BURDEN	Background: Bacterial respiratory tract infections and exacerbations of chronic lung diseases are commonly caused by nontypeable Haemophilus influenzae (NTHi). Cell-mediated cytotoxicity might be key to controlling infection, but the responses of NTHi-specific T-cell populations are not well understood. Mucosal-associated invariant T (MAIT) cells are a cytotoxicity might be key to controlling infection, but the responses of NTHi-specific T-cell populations are not well understood. Mucosal-associated invariant T (MAIT) cells are a recently discovered, innate-like subset of T cells with cytotoxic function, the role of which in lung immunity is unclear. Objective: The aim of this study was to determine the mechanisms behind conventional T-cell and MAIT cell cytotoxic responses to NTHi. Methods: Human ex vivo lung explants were infected with a clinical strain of NTHi. Monocyte-derived macrophages were also infected with NTHi in vitro and cocultured with autologous T cells. Cytotoxic responses of T-cell subsets were measured by using flow cytometry. Results: We found significant upregulation of the cytotoxic markers CD107a and granzyme B in lung CD4(+), CD8(+), and MAIT cell populations. We show that MAIT cell cytotoxic responses were upregulated by a combination of both time-dependent antigen presentation and a novel mechanism through which IL-12 and IL-7 synergistically control granzyme B through upregulation of the IL-12 receptor. Conclusions: Overall, our data provide evidence for a cytotoxic role of MAIT cells in the lung and highlight important differences in the control of adaptive and innate-like T-cell responses. Understanding these mechanisms might lead to new therapeutic opportunities to modulate the antibacterial response and improve clinical outcome.	[Wallington, Joshua C.; Staples, Karl J.; Wilkinson, Tom M. A.] Univ Southampton, Clin & Expt Sci, Sir Henry Wellcome Labs, Southampton Gen Hosp,Fac Med, Mailpoint 810,Tremona Rd, Southampton SO16 6YD, Hants, England; [Williams, Anthony P.] Univ Southampton, Canc Sci, Sir Henry Wellcome Labs, Southampton Gen Hosp,Fac Med, Southampton, Hants, England; [Wilkinson, Tom M. A.] Southampton Gen Hosp, Southampton NIHR Resp Biomed Res Unit, Southampton, Hants, England; [Williams, Anthony P.; Staples, Karl J.; Wilkinson, Tom M. A.] Univ Southampton, Southampton Gen Hosp, Fac Med, Wessex Invest Sci Hub, Southampton, Hants, England	University of Southampton; University of Southampton; University of Southampton; University of Southampton	Staples, KJ (corresponding author), Univ Southampton, Clin & Expt Sci, Sir Henry Wellcome Labs, Southampton Gen Hosp,Fac Med, Mailpoint 810,Tremona Rd, Southampton SO16 6YD, Hants, England.	k.staples@southampton.ac.uk		Staples, Karl/0000-0003-3844-6457; Wilkinson, Tom/0000-0003-1771-3851	GlaxoSmithKline Biologicals Belgium through a Collaborative Research and Development Agreement (CRADA)	GlaxoSmithKline Biologicals Belgium through a Collaborative Research and Development Agreement (CRADA)	J.C.W. and K.J.S. were funded by GlaxoSmithKline Biologicals Belgium through a Collaborative Research and Development Agreement (CRADA). No restrictions were placed on authors regarding the statements made in the manuscript.	Chua WJ, 2012, INFECT IMMUN, V80, P3256, DOI 10.1128/IAI.00279-12; Cosio MG, 2009, NEW ENGL J MED, V360, P2445, DOI 10.1056/NEJMra0804752; Craig JE, 2001, FEMS MICROBIOL LETT, V203, P55, DOI 10.1016/S0378-1097(01)00328-7; Dias J, 2016, J LEUKOCYTE BIOL, V100, P233, DOI 10.1189/jlb.4TA0815-391RR; Dickson RP, 2016, ANNU REV PHYSIOL, V78, P481, DOI 10.1146/annurev-physiol-021115-105238; Dickson RP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004923; Dickson RP, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-28; Dickson RP, 2013, EXPERT REV RESP MED, V7, P245, DOI [10.1586/ERS.13.24, 10.1586/ers.13.24]; Duell BL, 2016, FEBS LETT, V590, P3840, DOI 10.1002/1873-3468.12351; Dusseaux M, 2011, BLOOD, V117, P1250, DOI 10.1182/blood-2010-08-303339; Fairclough L, 2008, CLIN SCI, V114, P533, DOI 10.1042/CS20070356; Feng Y, 2011, INFECT IMMUN, V79, P229, DOI 10.1128/IAI.00709-10; Gao YF, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00302; Gold MC, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000407; Hernandez CP, 2013, CELL IMMUNOL, V282, P38, DOI 10.1016/j.cellimm.2013.04.005; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Hinks TSC, 2016, AM J RESP CRIT CARE, V194, P1208, DOI 10.1164/rccm.201601-0002OC; Hinks TSC, 2016, IMMUNOLOGY, V148, P1, DOI 10.1111/imm.12582; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Jiang J, 2016, SCI REP-UK, V6, DOI 10.1038/srep32320; Kalathil SG, 2014, AM J RESP CRIT CARE, V190, P40, DOI 10.1164/rccm.201312-2293OC; Kalra R, 2000, J PHARMACOL EXP THER, V293, P166; Kerksiek KM, 1999, CURR OPIN IMMUNOL, V11, P400, DOI 10.1016/S0952-7915(99)80067-3; King PT, 2008, CLIN EXP IMMUNOL, V152, P542, DOI 10.1111/j.1365-2249.2008.03667.x; King PT, 2015, J IMMUNOL RES, V2015, P1; Kirkham Lea-Ann S, 2013, BMC Res Notes, V6, P522, DOI 10.1186/1756-0500-6-522; Kjer-Nielsen L, 2012, NATURE, V14, P773; Kurioka A, 2015, MUCOSAL IMMUNOL, V8, P429, DOI 10.1038/mi.2014.81; Langereis JD, 2015, EMERG INFECT DIS, V21, P1711, DOI 10.3201/eid2110.150004; Le Bourhis L, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003681; Le Bourhis L, 2011, TRENDS IMMUNOL, V32, P212, DOI 10.1016/j.it.2011.02.005; Leeansyah E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005072; Lewinsohn DA, 2011, IMMUNOL REV, V240, P25, DOI 10.1111/j.1600-065X.2010.00997.x; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Loh L, 2016, P NATL ACAD SCI USA, V113, P10133, DOI 10.1073/pnas.1610750113; Lopez AD, 2006, EUR RESPIR J, V27, P397, DOI 10.1183/09031936.06.00025805; Mannino David M, 2006, Int J Chron Obstruct Pulmon Dis, V1, P219; Marina S, 1998, AM J RESP CRIT CARE, V157, P822; Marshall NB, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/954602; McKendry RT, 2016, AM J RESP CRIT CARE, V193, P642, DOI 10.1164/rccm.201504-0782OC; Meierovics A, 2013, P NATL ACAD SCI USA, V110, pE3119, DOI 10.1073/pnas.1302799110; Monasta L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036226; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Salerno-Goncalves R, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00511; Sattler A, 2015, EUR J IMMUNOL, V45, P2286, DOI 10.1002/eji.201445313; Schumacher SK, 2012, PEDIATR INFECT DIS J, V31, P145, DOI 10.1097/INF.0b013e31823aaeb3; Szabo PA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00401; Sze MA, 2014, INT J CHRONIC OBSTR, V9, P229, DOI 10.2147/COPD.S38932; Sze MA, 2012, AM J RESP CRIT CARE, V185, P1073, DOI 10.1164/rccm.201111-2075OC; Turtle CJ, 2011, BLOOD, V118, P2752, DOI 10.1182/blood-2011-02-334698; Ussher JE, 2014, EUR J IMMUNOL, V44, P195, DOI 10.1002/eji.201343509; Van Eldere J, 2014, LANCET INFECT DIS, V3099, P1; van Wilgenburg B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11653; Wang Z, 2016, EUR RESPIR J, V47, P1082, DOI 10.1183/13993003.01406-2015; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612	55	41	41	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2018	141	6					2182	+		10.1016/j.jaci.2017.08.009	http://dx.doi.org/10.1016/j.jaci.2017.08.009			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GI7SD	28870466	Bronze, Green Accepted			2022-12-18	WOS:000434701600023
J	Chipps, BE; Haselkorn, T; Paknis, B; Ortiz, B; Bleecker, ER; Kianifard, F; Foreman, AJ; Szefler, SJ; Zeiger, RS				Chipps, Bradley E.; Haselkorn, Tmirah; Paknis, Brandee; Ortiz, Benjamin; Bleecker, Eugene R.; Kianifard, Farid; Foreman, Aimee J.; Szefler, Stanley J.; Zeiger, Robert S.		Epidemiology Nat Hist Asthma	More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; severe; difficult-to-treat; control; long-term; observational study; follow-up; the Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens; exacerbations	LUNG-FUNCTION; ACTIVITY IMPAIRMENT; REFERENCE VALUES; PHENOTYPES; OBESITY; PRODUCTIVITY; ASSOCIATION; DEFINITION; VALIDATION; ADHERENCE	Background: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR I) study demonstrated high morbidity in patients with severe or difficult-to-treat asthma despite standard-of-care treatment. Objective: We sought to determine the long-term natural history of disease and outcomes in patients in TENOR I after more than a decade. Methods: TENOR I was a multicenter observational study (2001-2004) of 4756 patients with severe or difficult-to-treat asthma. TENOR II was a follow-up study of TENOR I patients using a single cross-sectional visit in 2013/2014. Overall, the sites participating in TENOR II originally enrolled 1230 patients in TENOR I. Clinical and patient-reported outcomes were assessed, including very poorly controlled asthma based on National Heart, Lung, and Blood Institute guidelines. Results: A total of 341 (27.7%) patients were enrolled in TENOR II and were representative of the TENOR I cohort. The most frequent comorbidities were rhinitis (84.0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%). Mean percent predicted prebronchodilator and postbronchodilator FEV1 were 72.7% (SD, 21.4%) and 78.2% (SD, 20.7%), respectively. A total of 231 (72.9%) of 317 patients had positive test responses to 1 or more allergen-specific IgEs. The mean blood eosinophil count was 200/mL (SD, 144/mL). Eighty-eight (25.8%) patients experienced an asthma exacerbation in the prior 3 months requiring hospital attention, oral corticosteroids, or both. More than half (197/339 [58.1%]) had very poorly controlled asthma. Medication use suggested undertreatment. Conclusion: TENOR II provides longitudinal data to characterize disease progression, heterogeneity, and severity in patients with severe or difficult-to-treat asthma. Findings show continued morbidity, including a high degree of comorbid conditions, allergic sensitization, exacerbations, and very poorly controlled asthma, including reduced lung function.	[Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, 5609 J St,Suite C, Sacramento, CA 95819 USA; [Haselkorn, Tmirah] EpiMetrix, Los Altos, CA USA; [Paknis, Brandee; Ortiz, Benjamin; Kianifard, Farid] Novartis Pharmaceut, E Hanover, NJ USA; [Bleecker, Eugene R.] Wake Forest Univ, Ctr Genom & Personalized Med, Sect Pulm & Crit Care Med, Winston Salem, NC 27109 USA; [Foreman, Aimee J.] ICON, San Francisco, CA USA; [Szefler, Stanley J.] Childrens Hosp, Breathing Inst, Aurora, CO USA; [Szefler, Stanley J.] Childrens Hosp, Pulm Med Sect, Aurora, CO USA; [Zeiger, Robert S.] Kaiser Permanente Southern Calif, Dept Allergy, San Diego, CA USA	Novartis; Wake Forest University; ICON plc; Children's Hospital Colorado; Children's Hospital Colorado; Kaiser Permanente	Chipps, BE (corresponding author), Capital Allergy & Resp Dis Ctr, 5609 J St,Suite C, Sacramento, CA 95819 USA.	bchipps@capitalallergy.com		Szefler, Stanley/0000-0002-6911-3199; Zeiger, Robert/0000-0001-5788-5063	Genentech; Novartis; AstraZeneca; Boehringer Ingelheim; Meda; Genentech, Inc; Novartis Pharmaceuticals; National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute; MedImmune; Pfizer; GlaxoSmithKline; Forest; Regeneron; Sanofi; Roche; Aerocrine; Daiichi Sankyo; Boehringer-Ingelheim; Merck; TEVA	Genentech(Roche HoldingGenentech); Novartis(Novartis); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Meda; Genentech, Inc(Roche HoldingGenentech); Novartis Pharmaceuticals(Novartis); National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); MedImmune(AstraZenecaMedimmune); Pfizer(Pfizer); GlaxoSmithKline(GlaxoSmithKline); Forest; Regeneron(Regeneron); Sanofi; Roche(Roche Holding); Aerocrine; Daiichi Sankyo(Daiichi Sankyo Company Limited); Boehringer-Ingelheim(Boehringer Ingelheim); Merck(Merck & Company); TEVA(Teva Pharmaceutical Industries)	B. E. Chipps' institution received consulting fees from Genentech and Novartis for this work and consultancy fees and payment for lectures from AstraZeneca, Boehringer Ingelheim and Meda for other works. T. Haselkorn's institution received consulting fees from Genentech, Inc and Novartis Pharmaceuticals Corporation during this study. F. Kianifard, B. Ortiz, and B. Paknis are employed by and have stock options with Novartis Pharmaceuticals. E. R. Bleecker's institution received a grant from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute for this work and has personally received consultancy fees from AstraZeneca, MedImmune, Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Forest, Novartis, Regeneron, and Sanofi. A.J. Foreman's institution received fee for analytic services from Novartis Pharmaceuticals for this work. S.J. Szefler received consulting fees from Genentech and Novartis and travel expenses from Novartis during this study; his institution has received consultancy fees from Roche, AstraZeneca, Aerocrine, Daiichi Sankyo, Boehringer-Ingelheim and has received grants from GlaxoSmithKline for other works; and he has personally received consultancy fees from Merck for other works. R.S. Zeiger has been paid consultant fees from Genentech for this work; his institution has received grants from Aerocrine, AstraZeneca, Genentech, MedImmune, and Merck for other works; and he has personally received consultant fees from AstraZeneca, Novartis, TEVA, and GlaxoSmithKline for other works.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Altman DG, 1991, PRACTICAL STAT MED R, P36; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Barnes CB, 2015, RESP CARE, V60, P455, DOI 10.4187/respcare.03200; Boulet LP, 2011, EXPERT REV RESP MED, V5, P377, DOI [10.1586/ers.11.34, 10.1586/ERS.11.34]; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Carrier E, 2014, AM J MANAG CARE, V20, P925; Chen H, 2008, VALUE HEALTH, V11, P231, DOI 10.1111/j.1524-4733.2007.00229.x; Chipps BE, 2012, CURR PULMONOL REP, V1, P259, DOI 10.1007/s13665-012-0025-x; Chipps BE, 2012, J ALLERGY CLIN IMMUN, V130, P332, DOI 10.1016/j.jaci.2012.04.014; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Colice GL, 2013, EXPERT REV RESP MED, V7, P307, DOI [10.1586/ERS.13.27, 10.1586/ers.13.27]; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32, DOI 10.1016/S1081-1206(10)61707-3; Hancox RJ, 2016, RESP MED, V111, P54, DOI 10.1016/j.rmed.2015.12.007; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Haselkorn T, 2009, RESP MED, V103, P274, DOI 10.1016/j.rmed.2008.08.010; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P895, DOI 10.1016/j.jaci.2009.07.035; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; HORVITZ DG, 1952, J AM STAT ASSOC, V47, P663, DOI 10.2307/2280784; Jacob C, 2016, EUR J HEALTH ECON, V17, P195, DOI 10.1007/s10198-015-0671-3; Juel CTB, 2013, RESP CARE, V58, P867, DOI 10.4187/respcare.02202; Juel CTB, 2012, J ASTHMA ALLERGY, V5, P21, DOI 10.2147/JAA.S32232; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Kupczyk M, 2014, ALLERGY, V69, P1198, DOI 10.1111/all.12445; Kupczyk M, 2012, J INTERN MED, V272, P121, DOI 10.1111/j.1365-2796.2012.02558.x; Lange P, 2015, NEW ENGL J MED, V373, P111, DOI 10.1056/NEJMoa1411532; Ledford DK, 2014, J ALLER CL IMM-PRACT, V2, P653, DOI 10.1016/j.jaip.2014.09.009; Ledford DK, 2013, CURR OPIN ALLERGY CL, V13, P78, DOI 10.1097/ACI.0b013e32835c16b6; Liang B, 2013, DIS ESOPHAGUS, V26, P794, DOI 10.1111/j.1442-2050.2012.01399.x; Lurie A, 2007, RESP MED, V101, P2145, DOI 10.1016/j.rmed.2007.05.027; Matsunaga K, 2015, J ALLER CL IMM-PRACT, V3, P759, DOI 10.1016/j.jaip.2015.05.005; Matsunaga K, 2014, RESP MED, V108, P976, DOI 10.1016/j.rmed.2014.04.014; Matsunaga K, 2013, RESP MED, V107, P355, DOI 10.1016/j.rmed.2012.11.014; McGeachie MJ, 2016, NEW ENGL J MED, V374, P1842, DOI 10.1056/NEJMoa1513737; McGeachie MJ, 2016, AM J RESP CRIT CARE, V194, P1465, DOI 10.1164/rccm.201602-0250OC; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moore Wendy C, 2013, Ann Am Thorac Soc, V10 Suppl, pS118, DOI 10.1513/AnnalsATS.201309-307AW; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; O'Byrne PM, 2013, CHEST, V143, P511, DOI 10.1378/chest.12-0412; Quanjer PH, 2012, EUR RESPIR J, V40, P1324, DOI 10.1183/09031936.00080312; Reddel HK, 2012, CLIN CHEST MED, V33, P505, DOI 10.1016/j.ccm.2012.06.005; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; REILLY MC, 1993, PHARMACOECONOMICS, V4, P353, DOI 10.2165/00019053-199304050-00006; Schatz M, 2013, J ALLER CL IMM-PRACT, V1, P280, DOI 10.1016/j.jaip.2013.03.001; Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740; Shaw DE, 2015, EUR RESPIR J, V46, P1308, DOI 10.1183/13993003.00779-2015; Sivapalan P, 2015, CURR OPIN PULM MED, V21, P80, DOI 10.1097/MCP.0000000000000119; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Tai A, 2014, J ALLERGY CLIN IMMUN, V133, P1572, DOI 10.1016/j.jaci.2013.12.1033; van den Berge M, 2016, J ASTHMA ALLERGY, V9, P27, DOI 10.2147/JAA.S78900; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Witt CA, 2014, ACAD RADIOL, V21, P986, DOI 10.1016/j.acra.2014.05.001; Worstell M, 2000, CLIN EXP ALLERGY, V30, P11; Zeiger RS, 2016, J ALLER CL IMM-PRACT, V4, P120, DOI 10.1016/j.jaip.2015.08.003	56	41	43	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1590	+		10.1016/j.jaci.2017.07.014	http://dx.doi.org/10.1016/j.jaci.2017.07.014			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	28797732	Bronze			2022-12-18	WOS:000432148200007
J	Walker, MT; Green, JE; Ferrie, RP; Queener, AM; Kaplan, MH; Cook-Mills, JM				Walker, Matthew T.; Green, Jeremy E.; Ferrie, Ryan P.; Queener, Ashley M.; Kaplan, Mark H.; Cook-Mills, Joan M.			Mechanism for initiation of food allergy: Dependence on skin barrier mutations and environmental allergen costimulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sensitization; anaphylaxis; food allergy; peanut; chicken egg ovalbumin; filaggrin; mattrin; Alternaria alternata; house dust mite; skin; ST2	THYMIC STROMAL LYMPHOPOIETIN; OF-FUNCTION MUTATIONS; CELLS IN-UTERO; ATOPIC-DERMATITIS; PEANUT ALLERGY; MATERNAL TRANSMISSION; ASTHMA RISK; DENDRITIC CELLS; ORAL TOLERANCE; HOUSE-DUST	Background: Mechanisms for the development of food allergy in neonates are unknown but clearly linked in patient populations to a genetic predisposition to skin barrier defects. Whether skin barrier defects contribute functionally to development of food allergy is unknown. Objective: The purpose of the study was to determine whether skin barrier mutations, which are primarily heterozygous in patient populations, contribute to the development of food allergy. Methods: Mice heterozygous for the filaggrin (Flg)(ft) and Tmem79(ma) mutations were skin sensitized with environmental and food allergens. After sensitization, mice received oral challenge with food allergen, and then inflammation, inflammatory mediators, and anaphylaxis were measured. Results: We define development of inflammation, inflammatory mediators, and food allergen-induced anaphylaxis in neonatal mice with skin barrier mutations after brief concurrent cutaneous exposure to food and environmental allergens. Moreover, neonates of allergic mothers have increased responses to suboptimal sensitization with food allergens. Importantly, responses to food allergens by these neonatal mice were dependent on genetic defects in skin barrier function and on exposure to environmental allergens. ST2 blockade during skin sensitization inhibited the development of anaphylaxis, antigen-specific IgE, and inflammatory mediators. Neonatal anaphylactic responses and antigen-specific IgE were also inhibited by oral pre-exposure to food allergen, but interestingly, this was blunted by concurrent pre-exposure of the skin to environmental allergen. Conclusion: These studies uncover mechanisms for food allergy sensitization and anaphylaxis in neonatal mice that are consistent with features of human early-life exposures and genetics in patients with clinical food allergy and demonstrate that changes in barrier function drive development of anaphylaxis to food allergen.	[Walker, Matthew T.; Green, Jeremy E.; Ferrie, Ryan P.; Queener, Ashley M.; Cook-Mills, Joan M.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, McGaw M304,240 E Huron, Chicago, IL 60611 USA; [Kaplan, Mark H.] Indiana Univ Sch Med, Dept Pediat, HB Wells Ctr Pediat Res, Indianapolis, IN 46202 USA	Northwestern University; Feinberg School of Medicine; Indiana University System; Indiana University Bloomington	Cook-Mills, JM (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, McGaw M304,240 E Huron, Chicago, IL 60611 USA.	j-cook-mills@northwestern.edu		Kaplan, Mark/0000-0002-2923-8245	National Institutes of Health [R01 HL111624, U01 AI131337, R01 AI095282]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL111624, R01HL124120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI131337, R01AI095282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008061] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health grants R01 HL111624 and U01 AI131337 (to J.M.C.-M.), and R01 AI095282 (to M.H.K.).	Abdala-Valencia H, 2016, AM J PHYSIOL-LUNG C, V310, pL759, DOI 10.1152/ajplung.00301.2015; Abdala-Valencia H, 2014, AM J PHYSIOL-LUNG C, V307, pL482, DOI 10.1152/ajplung.00132.2014; Alduraywish SA, 2016, ALLERGY, V71, P77, DOI 10.1111/all.12784; ALEXANDER G, 1975, BRIT MED BULL, V31, P62, DOI 10.1093/oxfordjournals.bmb.a071243; [Anonymous], 1995, Wkly Epidemiol Rec, V70, P201; Asai Y, 2013, J ALLERGY CLIN IMMUN, V132, P239, DOI 10.1016/j.jaci.2013.03.043; Ashley SE, 2017, ALLERGY, V18, P13143; Baek JO, 2017, ALLERGY, V72, P397, DOI 10.1111/all.12960; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bartnikas LM, 2013, J ALLERGY CLIN IMMUN, V131, P451, DOI 10.1016/j.jaci.2012.11.032; Berdnikovs S, 2013, AM J PHYSIOL-LUNG C, V304, pL240, DOI 10.1152/ajplung.00375.2012; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Bousquet J, 2011, ALLERGY, V66, P596, DOI 10.1111/j.1398-9995.2010.02534.x; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P867, DOI 10.1016/j.jaci.2014.08.011; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Burton OT, 2014, IMMUNITY, V41, P141, DOI 10.1016/j.immuni.2014.05.017; Carlsten C, 2013, ANN ALLERG ASTHMA IM, V110, P24, DOI 10.1016/j.anai.2012.10.005; COPELAND D, 1979, INT J PARASITOL, V9, P205, DOI 10.1016/0020-7519(79)90030-4; DaVeiga SP, 2012, ALLERGY ASTHMA PROC, V33, P227, DOI 10.2500/aap.2012.33.3569; DISCOMBE G, 1946, LANCET, V250, P195; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Ewald DA, 2017, J ALLERGY CLIN IMMUN, V139, P562, DOI 10.1016/j.jaci.2016.08.029; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fedulov AV, 2007, AM J REPROD IMMUNOL, V58, P120, DOI 10.1111/j.1600-0897.2007.00496.x; Fedulov AV, 2011, AM J RESP CELL MOL, V44, P285, DOI 10.1165/rcmb.2009-0400OC; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Friebele E, 1996, ENVIRON HEALTH PERSP, V104, P22, DOI 10.2307/3432754; Frossard CP, 2016, CLIN TRANSL ALLERGY, V6, DOI 10.1186/s13601-016-0090-2; Fukutomi Y, 2015, ALLERGOL INT, V64, P321, DOI 10.1016/j.alit.2015.05.007; Galand C, 2016, J ALLERGY CLIN IMMUN, V138, P1356, DOI 10.1016/j.jaci.2016.03.056; Ganeshan K, 2009, J ALLERGY CLIN IMMUN, V123, P231, DOI 10.1016/j.jaci.2008.10.011; Gerhold K, 2012, ALLERGY, V67, P353, DOI 10.1111/j.1398-9995.2011.02775.x; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; Glatz M, 2015, J CLIN MED, V4, P1217, DOI 10.3390/jcm4061217; Greenhawt M, 2016, ALLERGY, P13100; Greenhawt M, 2016, CURR OPIN ALLERGY CL, V16, P284, DOI 10.1097/ACI.0000000000000271; Hamada K, 2003, J IMMUNOL, V170, P1683, DOI 10.4049/jimmunol.170.4.1683; Hamada K, 2007, J TOXICOL ENV HEAL A, V70, P688, DOI 10.1080/15287390600974692; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Harada K, 2015, J DERMATOL, V42, P250, DOI 10.1111/1346-8138.12700; Hedayati MT, 2009, EUR REV MED PHARMACO, V13, P187; Herz U, 2001, INT ARCH ALLERGY IMM, V124, P193, DOI 10.1159/000053708; Herz U, 2000, AM J RESP CRIT CARE, V162, pS62, DOI 10.1164/ajrccm.162.supplement_2.ras-1; Hubeau C, 2007, J IMMUNOL, V178, P1477, DOI 10.4049/jimmunol.178.3.1477; Hubeau C, 2006, AM J PATHOL, V168, P1931, DOI 10.2353/ajpath.2006.051231; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jarvinen KM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143855; JARRETT E, 1979, NATURE, V280, P145, DOI 10.1038/280145a0; Kelleher MM, 2016, J ALLERGY CLIN IMMUN, V137, P1111, DOI 10.1016/j.jaci.2015.12.1312; Koppelman SJ, 2003, ALLERGY, V58, P1144, DOI 10.1034/j.1398-9995.2003.00259.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Leme AS, 2006, J IMMUNOL, V176, P762, DOI 10.4049/jimmunol.176.2.762; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; Li M, 2014, EUR RESPIR REV, V23, P292, DOI 10.1183/09059180.00004314; Li XM, 1999, J IMMUNOL, V162, P3045; Lim RH, 2009, AM J REPROD IMMUNOL, V61, P1, DOI 10.1111/j.1600-0897.2008.00671.x; Lopez-Exposito I, 2009, J ALLERGY CLIN IMMUN, V124, P1039, DOI 10.1016/j.jaci.2009.08.024; Lunze K, 2012, J PERINATOL, V32, P317, DOI 10.1038/jp.2012.11; Makhija MM, 2016, ANN ALLERG ASTHMA IM, V117, P382, DOI 10.1016/j.anai.2016.07.042; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; Matsuoka S, 1999, PEDIATR INT, V41, P46, DOI 10.1046/j.1442-200x.1999.01011.x; Mittermann I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156077; Monteiro RC, 2010, J CLIN IMMUNOL, V30, P1, DOI 10.1007/s10875-009-9338-0; Muto T, 2014, INT IMMUNOL, V26, P539, DOI 10.1093/intimm/dxu058; Natsume O, 2017, LANCET, V389, P276, DOI 10.1016/S0140-6736(16)31418-0; Noh JY, 2016, EXP DERMATOL, V25, P880, DOI 10.1111/exd.13111; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Peng G, 2018, INFLAMMATION, V41, P154, DOI 10.1007/s10753-017-0673-7; Pohlabeln H, 2010, J INVEST ALLERG CLIN, V20, P195; Rivas MN, 2015, IMMUNITY, V42, P512, DOI 10.1016/j.immuni.2015.02.004; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, P678, DOI 10.1016/j.jaci.2007.12.1164; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Saluja R, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0076-5; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Saunders SP, 2013, J ALLERGY CLIN IMMUN, V132, P1121, DOI 10.1016/j.jaci.2013.08.046; Schmitz R, 2012, PEDIAT ALLERG IMM-UK, V23, P716, DOI 10.1111/j.1399-3038.2012.01342.x; Sehra S, 2016, EUR J IMMUNOL, V46, P2609, DOI 10.1002/eji.201646421; Shaker M, 2014, CURR OPIN PEDIATR, V26, P516, DOI 10.1097/MOP.0000000000000120; Smaldini PL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141116; Smith J, 2013, NEONATAL NETW, V32, P235, DOI [10.1891/0730-0832.32.4.235, 10.1891/0730-0832.32.1.16]; Srivastava KD, 2016, J ALLERGY CLIN IMMUN, V138, P536, DOI 10.1016/j.jaci.2016.01.047; Tan HTT, 2012, J ALLERGY CLIN IMMUN, V130, P1211, DOI 10.1016/j.jaci.2012.07.022; Taracanova A, 2017, P NATL ACAD SCI USA, V114, pE4002, DOI 10.1073/pnas.1524845114; Trendelenburg V, 2013, ALLERGY, V68, P1460, DOI 10.1111/all.12226; van den Oord RAHM, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2433; van Gool CJAW, 2004, ALLERGY, V59, P961, DOI 10.1111/j.1398-9995.2004.00528.x; Van Gramberg JL, 2013, J ALLERGY CAIRO, V2013; van Schayck CP, 2005, EUR RESPIR J, V26, P647, DOI 10.1183/09031936.05.00019805; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079, DOI 10.1164/ajrccm.157.4.9704140; Wang J, 2011, J CLIN INVEST, V121, P827, DOI [10.1172/JCI45434, 10.1186/1710-1492-7-S1-S7]; Wang YJ, 2014, AM J RHINOL ALLERGY, V28, pE193, DOI [10.2500/ajra.2014.2, 10.2500/ajra.2014.28.4095]; Waterhouse J, 2000, CHRONOBIOL INT, V17, P679, DOI 10.1081/CBI-100101074; Wavrin S, 2014, INT ARCH ALLERGY IMM, V164, P189, DOI 10.1159/000363444; Zhang ES, 2011, MICROBIOL IMMUNOL, V55, P625, DOI 10.1111/j.1348-0421.2011.00364.x; ZHANG GH, 1994, J CLIN MICROBIOL, V32, P1537, DOI 10.1128/JCM.32.6.1537-1541.1994; Zheng T., 2014, J CLIN CELLULAR IMMU, V5, P2, DOI [10.4172/2155-9899.1000202, DOI 10.4172/2155-9899.1000202, 4172/2155-9899.1000202]; ZOCK JP, 1995, CLIN EXP ALLERGY, V25, P549, DOI 10.1111/j.1365-2222.1995.tb01093.x	99	41	41	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2018	141	5					1711	+		10.1016/j.jaci.2018.02.003	http://dx.doi.org/10.1016/j.jaci.2018.02.003			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GF7KX	29454836	Bronze, Green Accepted, Green Submitted			2022-12-18	WOS:000432148200018
J	Asai, Y; Eslami, A; van Ginkel, CD; Akhabir, L; Wan, M; Ellis, G; Ben-Shoshan, M; Martino, D; Ferreira, MA; Allen, K; Mazer, B; de Groot, H; de Jong, NW; van Wijk, RNG; Dubois, AEJ; Chin, R; Cheuk, S; Hoffman, J; Jorgensen, E; Witte, JS; Melles, RB; Hong, XM; Wang, XB; Hui, J; Musk, AW; Hunter, M; James, AL; Koppelman, GH; Sandford, AJ; Clarke, AE; Daley, D				Asai, Yuka; Eslami, Aida; van Ginkel, C. Dorien; Akhabir, Loubna; Wan, Ming; Ellis, George; Ben-Shoshan, Moshe; Martino, David; Ferreira, Manuel A.; Allen, Katrina; Mazer, Bruce; de Groot, Hans; de Jong, Nicolette W.; van Wijk, Roy N. Gerth; Dubois, Anthony E. J.; Chin, Rick; Cheuk, Stephen; Hoffman, Joshua; Jorgensen, Eric; Witte, John S.; Melles, Ronald B.; Hong, Xiumei; Wang, Xiaobin; Hui, Jennie; Musk, Arthur W. (Bill); Hunter, Michael; James, Alan L.; Koppelman, Gerard H.; Sandford, Andrew J.; Clarke, Ann E.; Daley, Denise			Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes C11orf30/EMSY as a genetic risk factor for food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; food allergy; genome-wide association study; meta-analysis; EMSY; C11orf30; epigenetics	OF-FUNCTION VARIANTS; ENDOTHELIAL-CELLS; ATOPIC-DERMATITIS; FILAGGRIN GENE; INCREASES SUSCEPTIBILITY; ASTHMA; ANAPHYLAXIS; PREVALENCE; CHILDREN; DISEASES	Background: Peanut allergy (PA) is a complex disease with both environmental and genetic risk factors. Previously, PA loci were identified in filaggrin (FLG) and HLA in candidate gene studies, and loci in HLA were identified in a genome-wide association study and meta-analysis. Objective: We sought to investigate genetic susceptibility to PA. Methods: Eight hundred fifty cases and 926 hyper-control subjects and more than 7.8 million genotyped and imputed single nucleotide polymorphisms (SNPs) were analyzed in a genome-wide association study to identify susceptibility variants for PA in the Canadian population. A meta-analysis of 2 phenotypes (PA and food allergy) was conducted by using 7 studies from the Canadian, American (n = 2), Australian, German, and Dutch (n = 2) populations. Results: An SNP near integrin alpha 6 (ITGA6) reached genome-wide significance with PA (P = 1.80 x 10(-8)), whereas SNPs associated with Src kinase-associated phosphoprotein 1 (SKAP1), matrix metallopeptidase 12 (MMP12)/MMP13, catenin alpha 3 (CTNNA3), rho GTPase-activating protein 24 (ARHGAP24), angiopoietin 4 (ANGPT4), chromosome 11 open reading frame (C11orf30/EMSY), and exocyst complex component 4 (EXOC4) reached a threshold suggestive of association (P <= 1.49 x 10(-6)). In the meta-analysis of PA, loci in or near ITGA6, ANGPT4, MMP12/MMP13, C11orf30, and EXOC4 were significant (P <= 1.49 x 10(-6)). When a phenotype of any food allergy was used for meta-analysis, the C11orf30 locus reached genome-wide significance (P = 7.50 x 10(-11)), whereas SNPs associated with ITGA6, ANGPT4, MMP12/MMP13, and EXOC4 and additional C11orf30 SNPs were suggestive (P <= 1.49 x 10(-6)). Functional annotation indicated that SKAP1 regulates expression of CBX1, which colocalizes with the EMSY protein coded by C11orf30. Conclusion: This study identifies multiple novel loci as risk factors for PA and food allergy and establishes C11orf30 as a risk locus for both PA and food allergy. Multiple genes (C11orf30/EMSY, SKAP1, and CTNNA3) identified by this study are involved in epigenetic regulation of gene expression.	[Asai, Yuka] Queens Univ, Div Dermatol, Dept Med, Kingston, ON, Canada; [Asai, Yuka] McGill Univ, Div Expt Med, Dept Med, Montreal, PQ, Canada; [Eslami, Aida; Akhabir, Loubna; Wan, Ming; Ellis, George; Sandford, Andrew J.; Daley, Denise] Univ British Columbia, Ctr Heart Lung Innovat, Vancouver, BC, Canada; [van Ginkel, C. Dorien; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, Groningen, Netherlands; [van Ginkel, C. Dorien; Koppelman, Gerard H.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Groningen, Netherlands; [Ben-Shoshan, Moshe; Mazer, Bruce] McGill Univ, Montreal Childrens Hosp, Hlth Ctr, Div Allergy & Immunol,Dept Pediat,Res Inst, Montreal, PQ, Canada; [Martino, David; Allen, Katrina; Dubois, Anthony E. J.] Univ Melbourne, Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Ferreira, Manuel A.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [de Groot, Hans] Reinier Graaf Gasthuis, Dept Pediat Allergol, Diaconessenhuis Voorburg, Delft, Netherlands; [de Jong, Nicolette W.; van Wijk, Roy N. Gerth] Erasmus MC, Dept Allergol, Rotterdam, Netherlands; [Chin, Rick; Clarke, Ann E.] Univ Calgary, Cumming Sch Med, Div Rheumatol, Dept Med, Calgary, AB, Canada; [Hoffman, Joshua] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Jorgensen, Eric] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA; [Witte, John S.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Melles, Ronald B.] Kaiser Permanente Northern Calif, Redwood City Med Ctr, Dept Ophthalmol, Oakland, CA USA; [Hong, Xiumei; Wang, Xiaobin] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Early Life Origins Dis, Dept Populat Family & Reprod Hlth, Baltimore, MD USA; [Hui, Jennie] Univ Western Australia, Australia & Pathol & Lab Med, Sch Populat Hlth, Nedlands, WA, Australia; [Musk, Arthur W. (Bill)] Univ Western Australia, Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA, Australia; [Hunter, Michael] Univ Western Australia, Sch Populat Hlth, Perth, WA, Australia; [James, Alan L.] Univ Western Australia, Sir Charles Gairdner Hosp, Dept Pulm Physiol & Sleep Med, Perth, WA, Australia; [James, Alan L.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA, Australia	Queens University - Canada; McGill University; University of British Columbia; University of Groningen; University of Groningen; McGill University; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; QIMR Berghofer Medical Research Institute; Reinier de Graaf Hospital; Erasmus University Rotterdam; Erasmus MC; University of Calgary; University of California System; University of California San Francisco; Kaiser Permanente; University of California System; University of California San Francisco; Kaiser Permanente; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia	Daley, D (corresponding author), St Pauls Hosp, Ctr Heart Lung Innovat, Rm 166,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	denise.daley@hli.ubc.ca	Koppelman, Gerard/AAG-9187-2020; Hunter, Michael L/B-3213-2013; Martino, DJ/X-1753-2019; Allen, Katrina/I-4361-2018; Hui, Jennie/A-9543-2013	Hunter, Michael L/0000-0001-6704-4815; Martino, DJ/0000-0001-6823-4696; Allen, Katrina/0000-0002-1921-4493; Hui, Jennie/0000-0002-1653-2496; Westerlaken - van Ginkel MD PhD, C. Dorien/0000-0002-5247-2697; Melles, Ronald/0000-0003-1027-4083; Koppelman, Gerard/0000-0001-8567-3252; Asai, Yuka/0000-0003-1674-3215	Allergy, Genes, and Environment Network of Centres of Excellence (AllerGen NCE); Canadian Institutes of Health Research; Canadian Research Chairs Program; Natural Sciences and Engineering Research Council; Michael Smith Foundation for Health Research/AllerGen NCE post-doctoral research fellowship awards; Division of Experimental Medicine Entrance Fellowship; Montreal Children's Hospital Foundation; McGill University Health Centre Foundation; Canadian Dermatology Foundation; Canadian Allergy, Asthma and Immunology Foundation; Canadian Society of Allergy and Clinical Immunology; National Institutes of Health [CA112355, RC2 AG036607]; HealthWay; National Health and Medical Research Council (Australia); Australian Research Council; US Department of Defense [W81XWH-10-1-0487]; Nutricia Research Foundation; Dutch Technology Foundation STW, part of the Netherlands Organisation for Scientific Research (NOW); Ministry of Economic Affairs [11868]; Food Allergy Foundation; Siemens Healthcare Diagnostics; HAL Allergy; Intersnack the Netherlands B.V.; ALK-Abello B.V.; Netherlands Anaphylaxis Network; Common Fund of the Office of the Director of the National Institutes of Health; National Cancer Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke	Allergy, Genes, and Environment Network of Centres of Excellence (AllerGen NCE); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Research Chairs Program(Canada Research Chairs); Natural Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Michael Smith Foundation for Health Research/AllerGen NCE post-doctoral research fellowship awards; Division of Experimental Medicine Entrance Fellowship; Montreal Children's Hospital Foundation; McGill University Health Centre Foundation; Canadian Dermatology Foundation; Canadian Allergy, Asthma and Immunology Foundation; Canadian Society of Allergy and Clinical Immunology; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); HealthWay; National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council(Australian Research Council); US Department of Defense(United States Department of Defense); Nutricia Research Foundation(Danone Nutricia); Dutch Technology Foundation STW, part of the Netherlands Organisation for Scientific Research (NOW); Ministry of Economic Affairs; Food Allergy Foundation; Siemens Healthcare Diagnostics; HAL Allergy(HAL Allergy Group); Intersnack the Netherlands B.V.; ALK-Abello B.V.(Bioceros B.V.); Netherlands Anaphylaxis Network; Common Fund of the Office of the Director of the National Institutes of Health; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by the Allergy, Genes, and Environment Network of Centres of Excellence (AllerGen NCE); the Canadian Institutes of Health Research; Canadian Research Chairs Program (salary award to D. Daley); the Natural Sciences and Engineering Research Council; the Michael Smith Foundation for Health Research/AllerGen NCE post-doctoral research fellowship awards (A.E.); the Division of Experimental Medicine Entrance Fellowship (Y.A.); the Montreal Children's Hospital Foundation; the McGill University Health Centre Foundation; the Canadian Dermatology Foundation; the Canadian Allergy, Asthma and Immunology Foundation; the Canadian Society of Allergy and Clinical Immunology; the National Institutes of Health (grant no. CA112355 awarded to J.S.W. and RC2 AG036607 awarded to C.A.S. and N.J.R.); HealthWay; the National Health and Medical Research Council (Australia); the Australian Research Council; and the US Department of Defense (grant no. W81XWH-10-1-0487 to K.A.). C.D.v.G., A.E.J.D., and G.H.K. received an unrestricted grant from the Nutricia Research Foundation to complete the Dutch GENEVA cohort. The Dutch IDEAL cohort of N.W.d.J., H.d.G., R.G.v.W., and A.E.J.D. was supported by the Dutch Technology Foundation STW, which is part of the Netherlands Organisation for Scientific Research (NOW) and partly funded by the Ministry of Economic Affairs (project number 11868) and the Food Allergy Foundation, Siemens Healthcare Diagnostics, HAL Allergy, Intersnack the Netherlands B.V., ALK-Abello B.V., and the Netherlands Anaphylaxis Network. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by the National Cancer Institute; National Human Genome Research Institute; National Heart, Lung, and Blood Institute; National Institute on Drug Abuse; National Institute of Mental Health; and National Institute of Neurological Disorders and Stroke.	Amaral AFS, 2015, ALLERGY, V70, P328, DOI 10.1111/all.12557; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P991, DOI 10.1016/j.jaci.2017.09.015; Asai Y, 2013, J ALLERGY CLIN IMMUN, V132, P239, DOI 10.1016/j.jaci.2013.03.043; Asero R, 2009, INT ARCH ALLERGY IMM, V150, P271, DOI 10.1159/000222679; Barkefors I, 2011, J BIOL CHEM, V286, P24189, DOI 10.1074/jbc.M110.212209; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Boehncke WH, 1998, CLIN EXP ALLERGY, V28, P434, DOI 10.1046/j.1365-2222.1998.00246.x; Brough HA, 2014, J ALLERGY CLIN IMMUN, V134, P1329, DOI 10.1016/j.jaci.2014.06.032; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Conomos MP, 2015, GENET EPIDEMIOL, V39, P276, DOI 10.1002/gepi.21896; Dreskin SC, 2006, ANN ALLERG ASTHMA IM, V96, P766, DOI 10.1016/S1081-1206(10)61337-3; Dreskin SC, 2011, ANN ALLERG ASTHMA IM, V106, P170, DOI 10.1016/j.anai.2010.11.008; Du Toit G, 2016, NEW ENGL J MED, V374, P1435, DOI 10.1056/NEJMoa1514209; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Dubinsky MC, 2013, INFLAMM BOWEL DIS, V19, P1662, DOI 10.1097/MIB.0b013e318281f275; Edwards BJ, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-18; Folmsbee SS, 2016, J ALLERGY CLIN IMMUN, V138, P123, DOI 10.1016/j.jaci.2015.11.037; Greisenegger EK, 2013, EUR J DERMATOL, V23, P142, DOI 10.1684/ejd.2013.1955; Hirosue S, 2014, J IMMUNOL, V192, P5002, DOI 10.4049/jimmunol.1302492; Hoffer V, 2011, PEDIAT ALLERG IMM-UK, V22, P172, DOI 10.1111/j.1399-3038.2010.00990.x; Hoffmann TJ, 2011, GENOMICS, V98, P79, DOI 10.1016/j.ygeno.2011.04.005; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Howell WM, 1998, CLIN EXP ALLERGY, V28, P156, DOI 10.1046/j.1365-2222.1998.00224.x; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; James AL, 2010, EUR RESPIR J, V35, P273, DOI 10.1183/09031936.00194308; Jiang L, 2016, CLIN HEMORHEOL MICRO, V61, P633, DOI 10.3233/CH-151951; Kaustov L, 2011, J BIOL CHEM, V286, P521, DOI 10.1074/jbc.M110.191411; Kesler CT, 2015, FASEB J, V29, P3668, DOI 10.1096/fj.14-268920; Kim M, 2017, J AM ACAD DERMATOL, V76, P40, DOI 10.1016/j.jaad.2016.08.022; L. StataCorp, 2009, STAT STAT SOFTW REL; Li CY, 2016, TRAFFIC, V17, P500, DOI 10.1111/tra.12379; Li J, 2015, J IMMUNOL, V195, P1599, DOI 10.4049/jimmunol.1402310; Li X, 2015, ALLERGY, V70, P1309, DOI 10.1111/all.12683; Li X, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Li XN, 2012, J ALLERGY CLIN IMMUN, V129, P575, DOI 10.1016/j.jaci.2011.09.040; Liem Joel J, 2008, Allergy Asthma Clin Immunol, V4, P144, DOI 10.1186/1710-1492-4-4-144; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; Madore AM, 2013, EUR J HUM GENET, V21, P1181, DOI 10.1038/ejhg.2013.13; Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559; Manz J, 2016, J INVEST DERMATOL, V136, P2380, DOI 10.1016/j.jid.2016.07.009; Maor GL, 2015, TRENDS GENET, V31, P274, DOI 10.1016/j.tig.2015.03.002; Marenholz I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9804; Martino DJ, 2017, CLIN EXP ALLERGY, V47, P217, DOI 10.1111/cea.12863; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Schmitt J, 2016, J ALLERGY CLIN IMMUN, V137, P130, DOI 10.1016/j.jaci.2015.06.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Silva R, 2012, ALLERGOL IMMUNOPATH, V40, P31, DOI 10.1016/j.aller.2010.12.012; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Soller L, 2015, J ALLER CL IMM-PRACT, V3, P291, DOI 10.1016/j.jaip.2014.11.006; Song Y, 2014, J ALLERGY CLIN IMMUN, V134, P1339, DOI 10.1016/j.jaci.2014.08.034; van Ginkel CD, 2015, ALLERGY, V70, P461, DOI 10.1111/all.12569; Varier RA, 2016, J BIOL CHEM, V291, P7313, DOI 10.1074/jbc.M115.701227; Vermeulen M, 2010, CELL, V142, P967, DOI 10.1016/j.cell.2010.08.020; Waterman M, 2011, INFLAMM BOWEL DIS, V17, P1936, DOI 10.1002/ibd.21579; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317; Xu JX, 2013, J BIOL CHEM, V288, P16598, DOI 10.1074/jbc.M112.449306; Yao JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089148	62	41	42	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2018	141	3					991	1001		10.1016/j.jaci.2017.09.015	http://dx.doi.org/10.1016/j.jaci.2017.09.015			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FY6PR	29030101	Green Published, hybrid			2022-12-18	WOS:000426974800019
J	Straka, BT; Ramirez, CE; Byrd, JB; Stone, E; Woodard-Grice, A; Nian, H; Yu, C; Banerji, A; Brown, NJ				Straka, Brittany T.; Ramirez, Claudia E.; Byrd, James B.; Stone, Elizabeth; Woodard-Grice, Alencia; Nian, Hui; Yu, Chang; Banerji, Aleena; Brown, Nancy J.			Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Angioedema; angiotensin-converting enzyme; bradykinin; icatibant; substance P	ANGIOTENSIN-CONVERTING-ENZYME; HEREDITARY ANGIOEDEMA; PLASMA EXTRAVASATION; CONTROLLED-TRIAL; ICATIBANT; ECALLANTIDE; RELEASE; HEART	Background: The B-2 receptor antagonist icatibant is approved for treatment of attacks of hereditary angioedema. Icatibant has been reported to decrease time-to-resolution of angiotensinconverting enzyme (ACE) inhibitor-associated angioedema in 1 study of European patients. Objective: We sought to test the hypothesis that a bradykinin B2 receptor antagonist would shorten time-to-resolution from ACE inhibitor-associated angioedema. Methods: Patients with ACE inhibitor-associated angioedema (defined as swelling of lips, tongue, pharynx, or face during ACE inhibitor use and no swelling in the absence of ACE inhibitor use) were enrolled at Vanderbilt University Medical Center from October 2007 through September 2015 and at Massachusetts General Hospital in 2012. C1 inhibitor deficiency and patients with bowel edema only were excluded. Patients were randomized within 6 hours of presentation to subcutaneous icatibant 30 mg or placebo at 0 and 6 hours later. Patients assessed severity of swelling using a visual analog scale serially following study drug administration or until discharge. Results: Thirty-three patients were randomized and 31 received treatment, with 13 receiving icatibant and 18 receiving placebo. One patient randomized to icatibant did not complete the visual analog scale and was excluded from analyses. Two-thirds of patients were black and two-thirds were women. Time-toresolution of symptoms was similar in placebo and icatibant treatment groups (P =.19 for the primary symptom and P >.16 for individual symptoms of face, lip, tongue, or eyelid swelling). Frequency of administration of H1 and H2 blockers, corticosteroids, and epinephrine was similar in the 2 treatment groups. Time-to-resolution of symptoms was similar in black and white patients. Conclusions: This study does not support clinical efficacy of a bradykinin B2 receptor antagonist in ACE inhibitor-associated angioedema.	[Straka, Brittany T.; Ramirez, Claudia E.; Byrd, James B.; Stone, Elizabeth; Woodard-Grice, Alencia; Brown, Nancy J.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Nian, Hui; Yu, Chang] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Banerji, Aleena] Massachusetts Gen Hosp, Boston, MA 02114 USA	Vanderbilt University; Vanderbilt University; Harvard University; Massachusetts General Hospital	Brown, NJ (corresponding author), Vanderbilt Univ, Sch Med, D-3100 Med Ctr North, Nashville, TN 37232 USA.	Nancy.j.brown@vanderbilt.edu	Banerji, Aleena/ABG-1245-2021; Byrd, James Brian/H-6674-2019	Byrd, James Brian/0000-0002-0509-3520; Ramirez Bustamante, Claudia/0000-0002-1562-6247	National Institutes of Health [UL1 RR024975, R01HL125426, R01HL079184]; Jerini AG/Shire Pharmaceuticals' Investigator-Initiated Research Program; National Institutes of Health grant [T32GM007569]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001436, UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079184, R01HL125426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007569] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jerini AG/Shire Pharmaceuticals' Investigator-Initiated Research Program; National Institutes of Health grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by National Institutes of Health (grants UL1 RR024975, R01HL125426, and R01HL079184) and Jerini AG/Shire Pharmaceuticals' Investigator-Initiated Research Program. B.T.S, J.B.B, and A.W.-G. were funded by National Institutes of Health grant T32GM007569. ClinicalTrials.govgov identifiers: NCT00517582, NCT01574248.	Bas M, 2015, NEW ENGL J MED, V372, P418, DOI 10.1056/NEJMoa1312524; Bernstein JA, 2015, ANN ALLERG ASTHMA IM, V114, P245, DOI 10.1016/j.anai.2014.12.007; Brown NJ, 1997, JAMA-J AM MED ASSOC, V278, P232, DOI 10.1001/jama.278.3.232; Brown NJ, 1996, CLIN PHARMACOL THER, V60, P8, DOI 10.1016/S0009-9236(96)90161-7; Burkhart Greg A., 1996, Pharmacoepidemiology and Drug Safety, V5, P149; Byrd JB, 2010, ALLERGY, V65, P1381, DOI 10.1111/j.1398-9995.2010.02398.x; Byrd JB, 2007, J ALLERGY CLIN IMMUN, V120, P403, DOI 10.1016/j.jaci.2007.04.012; Byrd JB, 2006, IMMUNOL ALLERGY CLIN, V26, P725, DOI 10.1016/j.iac.2006.08.001; Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393; Duerr M, 2010, CLIN J AM SOC NEPHRO, V5, P703, DOI 10.2215/CJN.07371009; Emanueli C, 1998, HYPERTENSION, V31, P1299, DOI 10.1161/01.HYP.31.6.1299; Gainer JV, 1998, NEW ENGL J MED, V339, P1285, DOI 10.1056/NEJM199810293391804; Kostis JB, 2005, ARCH INTERN MED, V165, P1637, DOI 10.1001/archinte.165.14.1637; Lewis LM, 2015, ANN EMERG MED, V65, P204, DOI 10.1016/j.annemergmed.2014.07.014; Loftus PA, 2014, LARYNGOSCOPE, V124, P2502, DOI 10.1002/lary.24777; Lumry WR, 2011, ANN ALLERG ASTHMA IM, V107, P529, DOI 10.1016/j.anai.2011.08.015; Miller DR, 2008, HYPERTENSION, V51, P1624, DOI 10.1161/HYPERTENSIONAHA.108.110270; Pretorius M, 2003, CIRCULATION, V107, P579, DOI 10.1161/01.CIR.0000046268.59922.A4; Seyedi N, 1999, J PHARMACOL EXP THER, V290, P656; Sinert R, 2016, ACAD EMERG MED S1, V23, pS11; Sulpizio AC, 2004, J PHARMACOL EXP THER, V309, P1141, DOI 10.1124/jpet.103.064105; Witherow FN, 2001, CIRCULATION, V104, P2177, DOI 10.1161/hc4301.098252; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977	23	41	44	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					242	+		10.1016/j.jaci.2016.09.051	http://dx.doi.org/10.1016/j.jaci.2016.09.051			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27913306	Bronze, Green Accepted			2022-12-18	WOS:000404542000024
J	Kantor, DB; Stenquist, N; McDonald, MC; Schultz, BJ; Hauptman, M; Smallwood, CD; Nelson, KA; Perzanowski, MS; Matsui, EC; Phipatanakul, W; Hirschhorn, JN				Kantor, David B.; Stenquist, Nicole; McDonald, Molly C.; Schultz, Blake J.; Hauptman, Marissa; Smallwood, Craig D.; Nelson, Kyle A.; Perzanowski, Matthew S.; Matsui, Elizabeth C.; Phipatanakul, Wanda; Hirschhorn, Joel N.			Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Kantor, David B.; Stenquist, Nicole; Schultz, Blake J.; Smallwood, Craig D.] Boston Childrens Hosp, Dept Anesthesiol Perioperat & Pain Med, Div Crit Care Med, Boston, MA USA; [Kantor, David B.] Harvard Med Sch, Dept Anaesthesia, Boston, MA USA; [McDonald, Molly C.] Boston Childrens Hosp, Clin Res Ctr, Boston, MA USA; [Hauptman, Marissa] Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA; [Hauptman, Marissa] Region 1 New England Pediat Environm Hlth Special, Boston, MA USA; [Hauptman, Marissa; Nelson, Kyle A.; Phipatanakul, Wanda] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Nelson, Kyle A.] Boston Childrens Hosp, Div Pediat Emergency Med, Boston, MA USA; [Perzanowski, Matthew S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA; [Matsui, Elizabeth C.] Johns Hopkins Univ, Sch Med, Div Pediat Allergy & Immunol, Baltimore, MD 21205 USA; [Phipatanakul, Wanda] Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA; [Hirschhorn, Joel N.] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA; [Hirschhorn, Joel N.] Broad Inst Harvard, Program Med Populat Genet, Cambridge, MA USA; [Hirschhorn, Joel N.] Harvard Med Sch, Dept Genet, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Columbia University; Johns Hopkins University; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School	Phipatanakul, W (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA USA.; Phipatanakul, W (corresponding author), Boston Childrens Hosp, Div Allergy & Immunol, Boston, MA USA.	wanda.phipatanakul@childrens.harvard.edu; joelh@broadinstitute.org		Hauptman, Marissa/0000-0002-0028-8927; Matsui, Elizabeth/0000-0001-8134-5593	NCATS NIH HHS [UL1 TR001102] Funding Source: Medline; NHLBI NIH HHS [U10 HL098102] Funding Source: Medline; NIAID NIH HHS [U01 AI126614, K24 AI114769, U01 AI083238, U01 AI110397, R01 AI073964, K24 AI106822] Funding Source: Medline; NICHD NIH HHS [T32 HD040128, K12 HD047349] Funding Source: Medline; NIEHS NIH HHS [P30 ES009089, R01 ES023447] Funding Source: Medline; ATSDR CDC HHS [U61 TS000118] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD040128, K12HD047349] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI106822, U01AI083238, U01AI110397, R01AI073964, K24AI114769, U01AI126614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES023447, P30ES009089] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); ATSDR CDC HHS; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Carroll CL, 2005, ANN ALLERG ASTHMA IM, V94, P355, DOI 10.1016/S1081-1206(10)60987-8; Commins SP, 2014, J ALLERGY CLIN IMMUN, V134, P108, DOI 10.1016/j.jaci.2014.01.024; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Ferreira MAR, 2006, ALLERGY, V61, P245, DOI 10.1111/j.1398-9995.2005.00954.x; Forno E, 2012, CURR OPIN PULM MED, V18, P63, DOI 10.1097/MCP.0b013e32834db288; Kennedy JL, 2012, CLIN EXP ALLERGY, V42, P659, DOI 10.1111/j.1365-2222.2011.03944.x; Levin AM, 2013, J ALLERGY CLIN IMMUN, V131, P1176, DOI 10.1016/j.jaci.2012.10.002; Matsui EC, 2010, ALLERGY, V65, P1414, DOI 10.1111/j.1398-9995.2010.02412.x; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x	11	41	45	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1467	+		10.1016/j.jaci.2016.04.044	http://dx.doi.org/10.1016/j.jaci.2016.04.044			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27474123	Green Accepted, Bronze			2022-12-18	WOS:000389542700035
J	Matsushita, T; Huu, DL; Kobayashi, T; Hamaguchi, Y; Hasegawa, M; Naka, K; Hirao, A; Muramatsu, M; Takehara, K; Fujimoto, M				Matsushita, Takashi; Doanh Le Huu; Kobayashi, Tadahiro; Hamaguchi, Yasuhito; Hasegawa, Minoru; Naka, Kazuhito; Hirao, Atsushi; Muramatsu, Masamichi; Takehara, Kazuhiko; Fujimoto, Manabu			A novel splenic B1 regulatory cell subset suppresses allergic disease through phosphatidylinositol 3-kinase-Akt pathway activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rodent; B cells; autoimmunity; IL-10; marginal zone B cell; B1 B cell; phosphatidylinositol 3-kinase; phosphatase and tensin homolog; regulatory B cell	CONTACT HYPERSENSITIVITY REACTIONS; T-CELLS; MARGINAL ZONE; DELAYED-HYPERSENSITIVITY; EXPRESSION; IL-10; PTEN; MICE; INTERLEUKIN-10; LYMPHOCYTES	Background: IL-10-producing regulatory B (B10) cells potently suppress allergic diseases, such as contact hypersensitivity (CHS). Splenic B10 cells share overlapping phenotypic markers with CD5(+) B1 B cells, CD1d(hi) CD21(+) CD23(-) marginal zone (MZ) B cells, and CD1d(hi) CD21(+) CD23(+) T2-MZ precursor B cells but do not exclusively belong to either subset. Objective: In this study we investigated the signaling mechanisms and a novel phenotypic parameter of B10 cells. Method: We performed microarray analysis comparing IL-10(+) and IL-10(+) B cells. B cell-specific phosphatase and tensin homolog (PTEN)-deficient mice, which exhibit aberrant activation of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway in B cells, were examined. Results: Microarray analysis revealed that the PI3K-Akt pathway is important for IL-10 production in B cells. PI3K-Akt pathway inhibitors reducedB10 cell numbers invitro. B10 cellnumberswere significantly increased in B cell-specific PTEN-deficient mice. The CHS response was significantly diminished in PTEN-deficient mice. Unexpectedly, splenic B10 cells in these mice were found within the B1 B-cell subset but not within the MZ B-cell subset. In wild-type mice not only MZ B10 cells but also B1-B10 cells were identified in the spleen. In addition, these 2 B10 cell subsets were predominantly found within the CD9(+) CD80(+) B-cell fraction. Conclusion: A novel splenic B1 regulatory cell subset (B1-B10 cells) was identified. Our findings show that the PI3K-Akt pathway in B cells is critical for B10 cell development and CHS response and that CD9/CD80 coexpression is a novel phenotypic parameter for both MZ-B10 and B1-B10 cells.	[Matsushita, Takashi; Doanh Le Huu; Kobayashi, Tadahiro; Hamaguchi, Yasuhito; Takehara, Kazuhiko] Kanazawa Univ, Grad Sch Med Sci, Dept Dermatol, Kanazawa, Ishikawa 9201192, Japan; [Muramatsu, Masamichi] Kanazawa Univ, Grad Sch Med Sci, Dept Mol Genet, Kanazawa, Ishikawa 9201192, Japan; [Doanh Le Huu] Hanoi Med Univ, Dept Dermatol & Venereol, Hanoi 100803, Vietnam; [Hasegawa, Minoru] Univ Fukui, Dept Dermatol, Fukui, Fukui, Japan; [Naka, Kazuhito] Kanazawa Univ, Exploratory Project Canc Stem Cells, Canc Res Inst, Kanazawa, Ishikawa 9201192, Japan; [Hirao, Atsushi] Kanazawa Univ, Div Mol Genet, Canc Res Inst, Kanazawa, Ishikawa 9201192, Japan; [Fujimoto, Manabu] Univ Tsukuba, Fac Med, Dept Dermatol, Tsukuba, Ibaraki 3058575, Japan	Kanazawa University; Kanazawa University; Hanoi Medical University; University of Fukui; Kanazawa University; Kanazawa University; University of Tsukuba	Fujimoto, M (corresponding author), Univ Tsukuba, Fac Med, Dept Dermatol, Tsukuba, Ibaraki 3058575, Japan.; Matsushita, T (corresponding author), Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Dermatol, Fac Med, Kanazawa, Ishikawa 9208641, Japan.	t-matsushita@med.kanazawa-u.ac.jp; fujimoto-m@umin.ac.jp	Matsushita, Takashi/C-4750-2015; Naka, Kazuhito/X-3756-2019	Matsushita, Takashi/0000-0002-1617-086X; Naka, Kazuhito/0000-0001-6646-6004; Hasegawa, Minoru/0000-0003-3738-2682; Fujimoto, Manabu/0000-0002-3062-4872; Kobayashi, Tadahiro/0000-0003-4367-2336; Le Huu, Doanh/0000-0002-9982-9905	Ministry of Education, Science, and Culture of Japan [23791260]; Ministry of Education, Science, and Culture of Japan; Japanese Government; Grants-in-Aid for Scientific Research [26290038, 15H01509] Funding Source: KAKEN	Ministry of Education, Science, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Science, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Government; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by grants-in-aid from the Ministry of Education, Science, and Culture of Japan (no. 23791260).; Disclosure of potential conflict of interest: T. Matsushita receives research support from the Ministry of Education, Science, and Culture of Japan. M. Fujimoto receives research funding from the Japanese Government. The rest of the authors declare that they have no relevant conflicts of interest.	Anzelon AN, 2003, NAT IMMUNOL, V4, P287, DOI 10.1038/ni892; Baumgarth N, 2011, NAT REV IMMUNOL, V11, P34, DOI 10.1038/nri2901; Bouaziz JD, 2008, IMMUNOL REV, V224, P201, DOI 10.1111/j.1600-065X.2008.00661.x; Brummel R, 2005, J IMMUNOL, V174, P2429, DOI 10.4049/jimmunol.174.4.2429; Calamito M, 2010, BLOOD, V115, P4043, DOI 10.1182/blood-2009-09-241638; Choi Y.K., 2013, EVID-BASED COMPL ALT, V2013, P1, DOI DOI 10.1155/2013/492329><PMID:24324902>; Alves CCD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079565; Huu DL, 2013, BLOOD, V121, P3274, DOI 10.1182/blood-2012-11-465658; Duan W, 2005, INT IMMUNOPHARMACOL, V5, P495, DOI 10.1016/j.intimp.2004.10.015; Evans JG, 2007, J IMMUNOL, V178, P7868, DOI 10.4049/jimmunol.178.12.7868; Fillatreau S, 2002, NAT IMMUNOL, V3, P944, DOI 10.1038/ni833; Fillatreau S, 2008, NAT REV IMMUNOL, V8, P391, DOI 10.1038/nri2315; Ghosh S, 2012, J IMMUNOL, V189, P1322, DOI 10.4049/jimmunol.1200138; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Jin GH, 2013, J ALLERGY CLIN IMMUN, V131, P1674, DOI 10.1016/j.jaci.2013.01.044; KATZ SI, 1974, NATURE, V251, P550, DOI 10.1038/251550a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; Lampropoulou V, 2008, J IMMUNOL, V180, P4763, DOI 10.4049/jimmunol.180.7.4763; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Lee KS, 2008, EUR RESPIR J, V31, P523, DOI 10.1183/09031936.00125007; Lehtimaki S, 2012, J INVEST DERMATOL, V132, P2744, DOI 10.1038/jid.2012.212; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Limon JJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00228; Lund FE, 2008, CURR OPIN IMMUNOL, V20, P332, DOI 10.1016/j.coi.2008.03.003; Martin F, 2001, IMMUNITY, V14, P617, DOI 10.1016/S1074-7613(01)00129-7; Maseda D, 2013, J IMMUNOL, V191, P2780, DOI 10.4049/jimmunol.1300649; Matsumoto M, 2014, IMMUNITY, V41, P1040, DOI 10.1016/j.immuni.2014.10.016; Matsumoto M, 2011, IMMUNITY, V34, P703, DOI 10.1016/j.immuni.2011.03.016; Matsushita T, 2008, J CLIN INVEST, V118, P3420, DOI 10.1172/JCI36030; Matsushita T, 2011, METHODS MOL BIOL, V677, P99, DOI 10.1007/978-1-60761-869-0_7; Matsushita T, 2010, J IMMUNOL, V185, P2240, DOI 10.4049/jimmunol.1001307; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Mauri C, 2008, TRENDS IMMUNOL, V29, P34, DOI 10.1016/j.it.2007.10.004; Miletic AV, 2010, J EXP MED, V207, P2407, DOI 10.1084/jem.20091962; Mizoguchi A, 1997, J EXP MED, V186, P1749, DOI 10.1084/jem.186.10.1749; Mizoguchi A, 2002, IMMUNITY, V16, P219, DOI 10.1016/S1074-7613(02)00274-1; Mizoguchi A, 2006, J IMMUNOL, V176, P705, DOI 10.4049/jimmunol.176.2.705; Nakashima H, 2010, J IMMUNOL, V184, P4637, DOI 10.4049/jimmunol.0901719; NETA R, 1974, J IMMUNOL, V113, P1716; Okkenhaug K, 2002, SCIENCE, V297, P1031; Omori SA, 2006, IMMUNITY, V25, P545, DOI 10.1016/j.immuni.2006.08.015; Ramadani F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001104; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Rieger A, 2008, NAT REV IMMUNOL, V8, P486, DOI 10.1038/nri2315-c1; Ring S, 2006, EUR J IMMUNOL, V36, P2981, DOI 10.1002/eji.200636207; Ring S, 2009, J ALLERGY CLIN IMMUN, V123, P1287, DOI 10.1016/j.jaci.2009.03.022; Serra P, 2006, TRENDS IMMUNOL, V27, P7, DOI 10.1016/j.it.2005.11.003; Spencer NFL, 1997, INT IMMUNOL, V9, P745, DOI 10.1093/intimm/9.5.745; Wang BH, 2000, J IMMUNOL, V165, P6783, DOI 10.4049/jimmunol.165.12.6783; Watanabe R, 2007, AM J PATHOL, V171, P560, DOI 10.2353/ajpath.2007.061279; Wolf SD, 1996, J EXP MED, V184, P2271, DOI 10.1084/jem.184.6.2271; Won WJ, 2002, J IMMUNOL, V168, P5605, DOI 10.4049/jimmunol.168.11.5605; Yanaba K, 2008, IMMUNOL REV, V223, P284, DOI 10.1111/j.1600-065X.2008.00646.x; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yanaba K, 2009, J IMMUNOL, V182, P7459, DOI 10.4049/jimmunol.0900270; ZHOU LJ, 1994, MOL CELL BIOL, V14, P3884, DOI 10.1128/MCB.14.6.3884	57	41	43	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2016	138	4					1170	+		10.1016/j.jaci.2015.12.1319	http://dx.doi.org/10.1016/j.jaci.2015.12.1319			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DZ0AP	26948079	Bronze			2022-12-18	WOS:000385499400023
J	Rawson, R; Yang, T; Newbury, RO; Aquino, M; Doshi, A; Bell, B; Broide, DH; Dohil, R; Kurten, R; Aceves, SS				Rawson, Renee; Yang, Tom; Newbury, Robert O.; Aquino, Melissa; Doshi, Ashmi; Bell, Braxton; Broide, David H.; Dohil, Ranjan; Kurten, Richard; Aceves, Seema S.			TGF-beta 1-induced PAI-1 contributes to a profibrotic network in patients with eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; esophagitis; SerpinE1; remodeling; fibrosis; TGF-beta 1	PLASMINOGEN-ACTIVATOR INHIBITOR-1; ALLERGIC-ASTHMA PATIENTS; GENE-EXPRESSION; LUNG FIBROSIS; CHILDREN; INFLAMMATION; FLUTICASONE; DEPOSITION; INCREASES; DIAGNOSIS	Background: Eosinophilic esophagitis (EoE) is an allergic disease of increasing worldwide incidence. Complications are due to tissue remodeling and involve TGF-beta 1-mediated fibrosis. Plasminogen activator inhibitor 1 (PAI-1/serpinE1) can be induced by TGF-beta 1, but its role in EoE is not known. Objective: We sought to understand the expression and role of PAI-1 in patients with EoE. Methods: We used esophageal biopsy specimens and plasma samples from control subjects and patients with EoE, primary human esophageal epithelial cells, and fibroblasts from patients with EoE in immunohistochemistry, quantitative PCR, and immunoassay experiments to understand the induction of PAI-1 by TGF-beta 1, the relationship between PAI-1 and esophageal fibrosis, and the role of PAI-1 in fibrotic gene expression. Results: PAI-1 expression was significantly increased in epithelial cells of biopsy specimens frompatients with active EoE compared with that seen in biopsy specimens frompatients with inactive EoE or control subjects (P <.001). Treatment of primary esophageal epithelial cells with recombinant TGF-beta 1 increased PAI-1 transcription, intracellular protein expression, and secretion. Esophageal PAI-1 expression correlated with basal zone hyperplasia, fibrosis, and markers of esophageal remodeling, including vimentin, TGF-beta 1, collagen I, fibronectin, and matrix metalloproteases, and plasma PAI-1 levels correlated with plasma TGF-beta 1 levels. PAI-1 inhibition significantly decreased baseline and TGF-beta 1-induced fibrotic gene expression. Conclusions: PAI-1 expression is significantly increased in the epithelium in patients with EoE and reflects fibrosis, and its inhibition decreases TGF-beta 1-induced gene expression. Epithelial PAI-1 might serve as a marker of EoE severity and form part of a TGF-beta 1-induced profibrotic network.	[Rawson, Renee; Yang, Tom; Aquino, Melissa; Doshi, Ashmi; Bell, Braxton; Broide, David H.; Aceves, Seema S.] Univ Calif San Diego, Div Allergy & Immunol, La Jolla, CA 92093 USA; [Rawson, Renee; Yang, Tom; Doshi, Ashmi; Bell, Braxton; Aceves, Seema S.] Univ Calif San Diego, Ctr Infect Immun & Inflammat, La Jolla, CA 92093 USA; [Dohil, Ranjan] Univ Calif San Diego, Div Pediat Gastroenterol & Nutr, La Jolla, CA 92093 USA; [Newbury, Robert O.] Univ Calif San Diego, Dept Pediat, Dept Pediat Pathol, La Jolla, CA 92093 USA; [Newbury, Robert O.] Univ Calif San Diego, Dept Med, Dept Pediat Pathol, La Jolla, CA 92093 USA; [Newbury, Robert O.] Rady Childrens Hosp, San Diego, CA USA; [Kurten, Richard] Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA; [Kurten, Richard] Arkansas Childrens Hosp, Res Inst, 800 Marshall St, Little Rock, AR 72202 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Rady Childrens Hospital San Diego; University of Arkansas System; University of Arkansas Medical Sciences; Arkansas Children's Hospital	Aceves, SS (corresponding author), Ctr Immun Infect & Inflammat, Div Allergy, Immunol, 9500 Gilman Dr,MC-0760, La Jolla, CA 92093 USA.	saceves@ucsd.edu		Broide, David/0000-0001-8405-9090	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI092135]; ART/APFED HOPE Award; Department of Defense [FA100044]; NIH/NIAID [AI107779, AI70535, AI72115]; NIH/National Center for Research Resources (NCRR)/National Center for Advancing Translational Sciences (NCATS) [UL1TR000039]; Hearst Foundation; Office of Rare Diseases Research (ORDR)/NCATS/NIAID/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Consortium of Eosinophilic Gastrointestinal Disease Researchers [U54AI117804]; NIH [UL1TR000100 CTSA]; NIH grant of CTSA [UL1TR000100, UL1TR001442]; NIAID; NIDDK; NCATS; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001442, UL1TR000039, UL1TR000100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072115, R01AI092135, U54AI117804, U19AI070535, R01AI107779] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ART/APFED HOPE Award; Department of Defense(United States Department of Defense); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH/National Center for Research Resources (NCRR)/National Center for Advancing Translational Sciences (NCATS); Hearst Foundation; Office of Rare Diseases Research (ORDR)/NCATS/NIAID/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Consortium of Eosinophilic Gastrointestinal Disease Researchers; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH grant of CTSA; NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) grant AI092135 (to S.S.A.); an ART/APFED HOPE Award (S.S.A.); Department of Defense grant FA100044 (to D.H.B and S.S.A.); NIH/NIAID grants AI107779 (to D.H.B.), AI70535 (to D.H.B.), and AI72115 (to D.H.B.); NIH/National Center for Research Resources (NCRR)/National Center for Advancing Translational Sciences (NCATS) grant UL1TR000039 (to R.K.); the Hearst Foundation (to R.D.); Office of Rare Diseases Research (ORDR)/NCATS/NIAID/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Consortium of Eosinophilic Gastrointestinal Disease Researchers U54AI117804 (to S.S.A.); and NIH grant UL1TR000100 CTSA (to S.S.A.). CEGIR (U54 AI117804) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), the NCATS, and is funded through collaboration between the NIAID, NIDDK, and NCATS. The UCSD/RCHSD database is supported by the NIH grant UL1TR000100 of CTSA funding before August 13, 2015, and grant UL1TR001442 of CTSA funding beginning August 13, 2015, and beyond. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Abonia JP, 2013, J ALLERGY CLIN IMMUN, V132, P378, DOI 10.1016/j.jaci.2013.02.030; Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P1205, DOI 10.1016/j.jaci.2010.10.031; Abu-Sultaneh SMA, 2011, DIGEST DIS SCI, V56, P97, DOI 10.1007/s10620-010-1259-5; Aceves SS, 2010, ALLERGY, V65, P109, DOI 10.1111/j.1398-9995.2009.02142.x; Aceves SS, 2011, J ALLERGY CLIN IMMUN, V128, P1047, DOI 10.1016/j.jaci.2011.09.026; Aceves SS, 2010, J ALLERGY CLIN IMMUN, V126, P1198, DOI 10.1016/j.jaci.2010.08.050; Aceves SS, 2009, ANN ALLERG ASTHMA IM, V103, P401, DOI 10.1016/S1081-1206(10)60359-6; Aceves SS, 2009, IMMUNOL ALLERGY CLIN, V29, P197, DOI 10.1016/j.iac.2008.10.003; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Assa'ad AH, 2011, GASTROENTEROLOGY, V141, P1593, DOI 10.1053/j.gastro.2011.07.044; Beppu L, 2015, J PEDIATR GASTR NUTR, V61, P194, DOI 10.1097/MPG.0000000000000668; Beppu LY, 2014, J ALLERGY CLIN IMMUN, V134, P1100, DOI 10.1016/j.jaci.2014.04.004; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Cho S, 2011, ANN ALLERG ASTHMA IM, V106, P371, DOI 10.1016/j.anai.2010.12.021; Cho SH, 2015, AM J RESP CELL MOL, V52, P88, DOI 10.1165/rcmb.2013-0399OC; Cho SH, 2014, J ALLERGY CLIN IMMUN, V133, P1465, DOI 10.1016/j.jaci.2013.11.009; Cho SH, 2014, J ALLERGY CLIN IMMUN, V133, pe1; Czekay Ralf-Peter, 2011, Int J Cell Biol, V2011, P562481, DOI 10.1155/2011/562481; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; Dellon ES, 2014, GASTROINTEST ENDOSC, V79, P577, DOI 10.1016/j.gie.2013.10.027; Dohil R, 2010, GASTROENTEROLOGY, V139, P418, DOI 10.1053/j.gastro.2010.05.001; Garg N, 2010, J THROMB HAEMOST, V8, P1847, DOI 10.1111/j.1538-7836.2010.03907.x; Ghosh AK, 2012, J CELL PHYSIOL, V227, P493, DOI 10.1002/jcp.22783; Huang WT, 2012, AM J RESP CELL MOL, V46, P87, DOI 10.1165/rcmb.2011-0139OC; Kagalwalla AF, 2012, J ALLERGY CLIN IMMUN, V129, P1387, DOI 10.1016/j.jaci.2012.03.005; Kowal K, 2007, INT ARCH ALLERGY IMM, V144, P240, DOI 10.1159/000103998; Lee SH, 2012, AM J RESP CELL MOL, V46, P842, DOI 10.1165/rcmb.2011-0369OC; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lieberman JA, 2012, ALLERGY, V67, P1299, DOI 10.1111/j.1398-9995.2012.02881.x; Lucendo AJ, 2011, J ALLERGY CLIN IMMUN, V128, P1037, DOI 10.1016/j.jaci.2011.08.007; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Nie W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034385; Oh CK, 2002, BIOCHEM BIOPH RES CO, V294, P1155, DOI 10.1016/S0006-291X(02)00577-6; Pampuch A, 2006, ALLERGY, V61, P234, DOI 10.1111/j.1398-9995.2005.00948.x; Schoepfer AM, 2013, GASTROENTEROLOGY, V145, P1230, DOI 10.1053/j.gastro.2013.08.015; Schuliga M, 2013, CURR OPIN PHARMACOL, V13, P386, DOI 10.1016/j.coph.2013.05.014; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/j.gastro.2003.09.024; Straumann A, 2011, CLIN GASTROENTEROL H, V9, P400, DOI 10.1016/j.cgh.2011.01.017; Wen T, 2013, GASTROENTEROLOGY, V145, P1289, DOI 10.1053/j.gastro.2013.08.046; Zhang YP, 2012, ACTA PHARMACOL SIN, V33, P897, DOI 10.1038/aps.2012.39	40	41	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2016	138	3					791	+		10.1016/j.jaci.2016.02.028	http://dx.doi.org/10.1016/j.jaci.2016.02.028			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DY9ZM	27212082	Bronze, Green Accepted			2022-12-18	WOS:000385496000015
J	Holt, PG; Strickland, D; Bosco, A; Belgrave, D; Hales, B; Simpson, A; Hollams, E; Holt, B; Kusel, M; Ahlstedt, S; Sly, PD; Custovic, A				Holt, Patrick G.; Strickland, Deborah; Bosco, Anthony; Belgrave, Danielle; Hales, Belinda; Simpson, Angela; Hollams, Elysia; Holt, Barbara; Kusel, Merci; Ahlstedt, Staffan; Sly, Peter D.; Custovic, Adnan			Distinguishing benign from pathologic T(H)2 immunity in atopic children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; rhinitis; IgE; IgG1; basophil activation; symptoms; regulatory T cells; IL-10	ALLERGEN IMMUNOTHERAPY; ANTIBODY-RESPONSES; MEMORY RESPONSES; IGG ANTIBODIES; IN-VIVO; ASTHMA; TOLERANCE; SENSITIZATION; MICROARRAYS; MECHANISMS	Although most children with asthma and rhinitis are sensitized to aeroallergens, only a minority of sensitized children are symptomatic, implying the underlying operation of efficient anti-inflammatory control mechanisms. Objective: We sought to identify endogenous control mechanisms that attenuate expression of IgE-associated responsiveness to aeroallergens in sensitized children. Methods: In 3 independent population samples we analyzed relationships between aeroallergen-specific IgE and corresponding allergen-specific IgG (sIgG) and associated immunophenotypes in atopic children and susceptibility to asthma and rhinitis, focusing on responses to house dust mite and grass. Results: Among mite-sensitized children across all populations and at different ages, house dust mite-specific IgG/IgE ratios (but not IgG(4)/IgE ratios) were significantly lower in children with asthma compared with ratios in those without asthma and lowest among the most severely symptomatic. This finding was mirrored by relationships between rhinitis and antibody responses to grass. Depending on age/allergen specificity, 20% to 40% of children with allergen-specific IgE (sIgE) of 0.35 kU/L or greater had negative skin test responses, and these children also expressed the high sIgG/sIgE immunophenotype. sIgG(1) from these children inhibited allergen-induced IgE-dependent basophil activation in a dose-dependent fashion. Profiling of aeroallergen-specific CD4(+) T-H memory responses revealed positive associations between sIgG/sIgE ratios and IL-10-dependent gene signatures and significantly higher IL-10/T(H)2 cytokine (protein) ratios among nonsymptomatic children. Conclusion: In addition to its role in blocking T(H)2 effector activation in the late-phase allergic response, IL-10 is a known IgG(1) switch factor. We posit that its production during allergen-induced memory responses contributes significantly to attenuation of inflammation through promoting IgG(1)-mediated damping of the FceRI-dependent acute-phase reaction. sIgG(1)/sIgE balance might represent a readily accessible therapeutic target for asthma/rhinitis control.	[Holt, Patrick G.; Strickland, Deborah; Bosco, Anthony; Hales, Belinda; Hollams, Elysia; Holt, Barbara; Kusel, Merci] Univ Western Australia, Telethon Kids Inst, Perth, WA 6009, Australia; [Holt, Patrick G.; Sly, Peter D.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Belgrave, Danielle; Simpson, Angela; Custovic, Adnan] Univ Manchester, Inst Inflammat & Repair, Ctr Resp Med & Allergy, Manchester M13 9PL, Lancs, England; [Belgrave, Danielle; Simpson, Angela; Custovic, Adnan] Univ S Manchester Hosp, Manchester, Lancs, England; [Ahlstedt, Staffan] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden	Telethon Kids Institute; University of Western Australia; University of Queensland; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Karolinska Institutet	Holt, PG (corresponding author), Telethon Kids Inst, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	patrick.holt@telethonkids.org	strickland, deborah/K-4597-2019; Strickland, Deborah/AGV-6937-2022; Holt, Patrick G/H-1548-2011; Custovic, Adnan/A-2435-2012; Sly, Peter D/F-1486-2010; Bosco, Anthony/AAC-6900-2022	Strickland, Deborah/0000-0003-0114-4201; Holt, Patrick G/0000-0003-1193-0935; Custovic, Adnan/0000-0001-5218-7071; Sly, Peter D/0000-0001-6305-2201; Hollams, Elysia/0000-0002-3481-6396; Bosco, Anthony/0000-0002-4335-615X; Simpson, Angela/0000-0003-2733-6666; Ahlstedt, Staffan/0000-0003-0545-4661	National Health and Medical Research Council of Australia; UK Medical Research Council (MRC) [G0601361, MR/K002449/1]; JP Moulton Charitable Foundation; MRC [MR/K002449/2, G0601361, MR/M015181/1, MR/K002449/1] Funding Source: UKRI; Medical Research Council [G0601361, MR/M015181/1, MR/K002449/1, MR/K002449/2] Funding Source: researchfish	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); JP Moulton Charitable Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The Australian studies were supported principally by a series of grants from the National Health and Medical Research Council of Australia. The United Kingdom studies were funded by UK Medical Research Council (MRC) grants G0601361 and MR/K002449/1 and the JP Moulton Charitable Foundation.	Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Belgrave DCM, 2013, J ALLERGY CLIN IMMUN, V132, P575, DOI 10.1016/j.jaci.2013.05.041; Bosco A, 2006, J IMMUNOL, V176, P4766, DOI 10.4049/jimmunol.176.8.4766; Bosco A, 2009, J IMMUNOL, V182, P6011, DOI 10.4049/jimmunol.0804125; BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Cady CT, 2010, IMMUNOL LETT, V130, P57, DOI 10.1016/j.imlet.2009.12.001; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; Cassard L, 2012, J IMMUNOL, V189, P2995, DOI 10.4049/jimmunol.1200968; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P1480, DOI 10.1016/j.jaci.2011.03.014; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Flicker S, 2013, IMMUNOBIOLOGY, V218, P884, DOI 10.1016/j.imbio.2012.10.008; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Hales BJ, 2009, CLIN EXP ALLERGY, V39, P1170, DOI 10.1111/j.1365-2222.2009.03252.x; Hales BJ, 2012, THORAX, V67, P321, DOI 10.1136/thoraxjnl-2011-200650; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; Holm J, 2011, J ALLERGY CLIN IMMUN, V127, P1029, DOI 10.1016/j.jaci.2011.01.062; Holt PG, 2014, CHEST, V145, P370, DOI 10.1378/chest.13-1341; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lu J, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr241; MacGlashan D, 2012, INT ARCH ALLERGY IMM, V159, P243, DOI 10.1159/000332150; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Prosperi MCF, 2014, PEDIAT ALLERG IMM-UK, V25, P71, DOI 10.1111/pai.12139; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; Rogers PR, 1999, J IMMUNOL, V163, P1205; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498	39	41	42	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					379	387		10.1016/j.jaci.2015.08.044	http://dx.doi.org/10.1016/j.jaci.2015.08.044			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26518094	Bronze, Green Submitted			2022-12-18	WOS:000369235500005
J	Garne, E; Hansen, AV; Morris, J; Zaupper, L; Addor, MC; Barisic, I; Gatt, M; Lelong, N; Klungsoyr, K; O'Mahony, M; Nelen, V; Neville, AJ; Pierini, A; Tucker, D; de Walle, H; Wiesel, A; Loane, M; Dolk, H				Garne, Ester; Hansen, Anne Vinkel; Morris, Joan; Zaupper, Louise; Addor, Marie-Claude; Barisic, Ingeborg; Gatt, Miriam; Lelong, Nathalie; Klungsoyr, Kari; O'Mahony, Mary; Nelen, Vera; Neville, Amanda J.; Pierini, Anna; Tucker, David; de Walle, Hermien; Wiesel, Awi; Loane, Maria; Dolk, Helen			Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma medication; congenital anomalies; pregnancy; first trimester exposure; inhaled beta(2)-agonists; inhaled corticosteroids	MATERNAL ASTHMA; UNITED-STATES; 1ST TRIMESTER; MALFORMATIONS; OUTCOMES; WOMEN; PREVALENCE	Background: Pregnant women with asthma need to take medication during pregnancy. Objective: We sought to identify whether there is an increased risk of specific congenital anomalies after exposure to antiasthma medication in the first trimester of pregnancy. Methods: We performed a population-based case-malformed control study testing signals identified in a literature review. Odds ratios (ORs) of exposure to the main groups of asthma medication were calculated for each of the 10 signal anomalies compared with registrations with nonchromosomal, nonsignal anomalies as control registrations. In addition, exploratory analyses were done for each nonsignal anomaly. The data set included 76,249 registrations of congenital anomalies from 13 EUROmediCAT registries. Results: Cleft palate (OR, 1.63; 95% CI, 1.05-2.52) and gastroschisis (OR, 1.89; 95% CI, 1.12-3.20) had significantly increased odds of exposure to first-trimester use of inhaled beta(2)-agonists compared with nonchromosomal control registrations. Odds of exposure to salbutamol were similar. Nonsignificant ORs of exposure to inhaled beta(2)-agonists were found for spina bifida, cleft lip, anal atresia, severe congenital heart defects in general, or tetralogy of Fallot. None of the 4 literature signals of exposure to inhaled steroids were confirmed (cleft palate, cleft lip, anal atresia, and hypospadias). Exploratory analyses found an association between renal dysplasia and exposure to the combination of long-acting beta(2)-agonists and inhaled corticosteroids (OR, 3.95; 95% CI, 1.99-7.85). Conclusions: The study confirmed increased odds of first-trimester exposure to inhaled beta(2)-agonists for cleft palate and gastroschisis and found a potential new signal for renal dysplasia associated with combined long-acting beta(2)-agonists and inhaled corticosteroids. Use of inhaled corticosteroids during the first trimester of pregnancy seems to be safe in relation to the risk for a range of specific major congenital anomalies.	[Morris, Joan] Queen Mary Univ, Wolfson Inst Prevent Med, Dept Prevent Med, London, England; [Addor, Marie-Claude] Serv Med Genet, Lausanne, Switzerland; [Barisic, Ingeborg] Univ Zagreb, Sch Med, Childrens Hosp Zagreb, Zagreb 41000, Croatia; [Gatt, Miriam] Directorate Hlth Informat & Res, Valletta, Malta; [Lelong, Nathalie] INSERM, UMR 1153, Obstet Perinatal & Pediat Epidemiol Res Team Epop, Paris, France; [Klungsoyr, Kari] Univ Bergen, Dept Global Publ Hlth & Primary Care, Bergen, Norway; [Klungsoyr, Kari] Norwegian Inst Publ Hlth, Bergen, Norway; [O'Mahony, Mary] Hlth Serv Execut South, Dept Publ Hlth, Hlth Serv, Dublin, Ireland; [Nelen, Vera] Prov Inst Hyg, Antwerp, Belgium; [Pierini, Anna] CNR, Inst Clin Physiol, Natl Res Council, I-56100 Pisa, Italy; [Tucker, David] Publ Hlth Wales, Hlth Intelligence Div, Congenital Anomaly Register & Informat Serv Wales, Swansea, W Glam, Wales; [de Walle, Hermien] Univ Groningen, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands; [Wiesel, Awi] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Paediat, Mainz, Germany; [Loane, Maria; Dolk, Helen] Univ Ulster, Inst Nursing & Hlth Res, Newtownabbey, North Ireland	University of London; Queen Mary University London; University of Zagreb; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Bergen; Norwegian Institute of Public Health (NIPH); Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); University of Groningen; Johannes Gutenberg University of Mainz; Ulster University	Garne, E (corresponding author), Hosp Lillebaelt, Dept Paediat, Skovvangen 2-6, DK-6000 Kolding, Denmark.	Ester.garne@rsyd.dk	Pierini, Anna/A-9622-2013; Barisic, Ingeborg/HDN-8784-2022; Klungsøyr, Kari/ABC-6147-2020; Barisic, Ingeborg/A-7314-2016; Morris, Joan/AAT-9211-2020	Pierini, Anna/0000-0003-3321-9343; Klungsøyr, Kari/0000-0003-2482-1690; Morris, Joan/0000-0002-7164-612X; Hansen, Anne Vinkel/0000-0003-4523-3521; Loane, Maria/0000-0002-1206-3637	European Union [HEALTH-F5-2011-260598]	European Union(European Commission)	Supported by the European Union under the Seventh Framework Programme (grant agreement HEALTH-F5-2011-260598). The funding source had no involvement in the study.	Blais L, 2008, J ALLERGY CLIN IMMUN, V121, P1379, DOI 10.1016/j.jaci.2008.02.038; Blais L, 2010, BIRTH DEFECTS RES A, V88, P216, DOI 10.1002/bdra.20651; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Boyd PA, 2011, BIRTH DEFECTS RES A, V91, pS2, DOI 10.1002/bdra.20780; British Thoracic Society/Scottish Intercollegiate Guidelines Network, 2008, THORAX S4, V63, P12147; Carmichael SL, 2009, J PEDIATR-US, V155, P39, DOI 10.1016/j.jpeds.2009.01.039; Charlton RA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060247; Clark JM, 2007, PAEDIATR PERINAT EP, V21, P154, DOI 10.1111/j.1365-3016.2007.00784.x; Dombrowski Mitchell P, 2008, Obstet Gynecol, V111, P457, DOI 10.1097/AOG.0b013e3181665ff4; Eltonsy S, 2011, BIRTH DEFECTS RES A, V91, P937, DOI 10.1002/bdra.22850; Greenlees R, 2011, BIRTH DEFECTS RES A, V91, pS51, DOI 10.1002/bdra.20775; Hook EB, 2000, TERATOLOGY, V61, P325, DOI 10.1002/(SICI)1096-9926(200005)61:5<325::AID-TERA1>3.0.CO;2-M; Jentink J, 2010, NEW ENGL J MED, V362, P2185, DOI 10.1056/NEJMoa0907328; Kallen, 2014, J PULM RESP MED, V4, P1; Kallen B, 2007, EUR J CLIN PHARMACOL, V63, P383, DOI 10.1007/s00228-006-0259-z; Kwon HL, 2003, ANN EPIDEMIOL, V13, P317, DOI 10.1016/S1047-2797(03)00008-5; Lin S, 2008, AM J EPIDEMIOL, V168, P73, DOI 10.1093/aje/kwn098; Lin S, 2012, PEDIATRICS, V129, pE317, DOI 10.1542/peds.2010-2660; Lin S, 2009, BIRTH DEFECTS RES A, V85, P161, DOI 10.1002/bdra.20523; Munsie JW, 2011, HUM REPROD, V26, P3147, DOI 10.1093/humrep/der315; Murphy VE, 2013, BJOG-INT J OBSTET GY, V120, P812, DOI 10.1111/1471-0528.12224; Murphy VE, 2011, BJOG-INT J OBSTET GY, V118, P1314, DOI 10.1111/j.1471-0528.2011.03055.x; Murphy VE, 2011, CLIN CHEST MED, V32, P93, DOI 10.1016/j.ccm.2010.10.001; Pradat P, 2003, BIRTH DEFECTS RES A, V67, P968, DOI 10.1002/bdra.10134; Rocklin RE, 2011, REPROD TOXICOL, V32, P189, DOI 10.1016/j.reprotox.2011.05.023; Tan TY, 2013, AM J MED GENET C, V163, P295, DOI 10.1002/ajmg.c.31374; Tegethoff M, 2013, PEDIATRICS, V132, P483, DOI 10.1542/peds.2012-3686; Vatti RR, 2012, CLIN REV ALLERG IMMU, V43, P45, DOI 10.1007/s12016-011-8277-8; Zhang XY, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1156	29	41	41	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2015	136	6					1496	U116		10.1016/j.jaci.2015.05.043	http://dx.doi.org/10.1016/j.jaci.2015.05.043			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CX9RZ	26220526	Green Published, hybrid			2022-12-18	WOS:000366044300009
J	Al-Afif, A; Alyazidi, R; Oldford, SA; Huang, YY; King, CA; Marr, N; Haidl, ID; Anderson, R; Marshall, JS				Al-Afif, Ayham; Alyazidi, Raidan; Oldford, Sharon A.; Huang, Yan Y.; King, Christine A.; Marr, Nico; Haidl, Ian D.; Anderson, Robert; Marshall, Jean S.			Respiratory syncytial virus infection of primary human mast cells induces the selective production of type I interferons, CXCL10, and CCL4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mast cells; viral infection; innate immunity; respiratory infection; chemokines; interferons; respiratory syncytial virus	DENDRITIC CELL; INNATE IMMUNITY; T-CELLS; ACTIVATION; INFANTS; BRONCHIOLITIS; CHEMOKINES; EXPRESSION; HISTAMINE; CYTOKINES	Background: Respiratory syncytial virus (RSV) causes severe respiratory tract infections, which might have a role in the development of airway hyperreactivity. Mast cells are important effector cells in allergy, with sentinel cell roles in host defense. However, the role of mast cells in response to RSV infection is unknown. Objective: Human mast cell responses to RSV were investigated with a view to better understanding the role of mast cells in RSV-induced disease. Methods: Human cord blood-derived mast cells and the HMC-1 mast cell line were exposed to RSV or UV-inactivated RSV. Viral gene and protein expression were evaluated by using PCR and flow cytometry. The expression of interferon-stimulated genes and selected mediators were evaluated by using quantitative PCR and ELISA. Results: Human mast cells expressed multiple RSV genes after exposure to RSV, and a small percentage of mast cells supported RSV antigen protein expression. RSV induced mast cells to upregulate production of chemokines, including CCL4, CCL5, and CXCL10, as well as type I interferons, and interferon-stimulated gene expression. However, production of the granulocyte chemoattractants CXCL8 and CCL11 was not induced. Antibody blockade of the type I interferon receptor on human cord blood-derived mast cells reduced the RSV-mediated induction of CXCL10 and CCL4 but not CCL5. Leukotriene C4 production by mast cells was not enhanced by exposure to RSV. Conclusion: Despite low levels of infection, human mast cells produce multiple chemokines in response to RSV through mechanisms that include responses to type I interferons. Such mast cell responses might enhance effector cell recruitment during RSV-induced disease.	[Al-Afif, Ayham; Alyazidi, Raidan; Oldford, Sharon A.; Huang, Yan Y.; King, Christine A.; Haidl, Ian D.; Anderson, Robert; Marshall, Jean S.] Dalhousie Univ, Dept Microbiol & Immunol, Dalhousie Inflammat Grp, Halifax, NS B3H 4R2, Canada; [Marshall, Jean S.] Dalhousie Univ, Dept Pathol, Dalhousie Inflammat Grp, Halifax, NS B3H 4R2, Canada; [Alyazidi, Raidan; Huang, Yan Y.; Anderson, Robert] Dalhousie Univ, Dept Pediat, Dalhousie Inflammat Grp, Halifax, NS B3H 4R2, Canada; [Marr, Nico; Anderson, Robert] Izaak Walter Killam Hlth Ctr, Canadian Ctr Vaccinol, Halifax, NS, Canada; [Alyazidi, Raidan] King Abdulaziz Univ, Fac Med, Dept Pediat, Jeddah 21413, Saudi Arabia	Dalhousie University; Dalhousie University; Dalhousie University; King Abdulaziz University	Marshall, JS (corresponding author), Dalhousie Univ, Dept Microbiol & Immunol, 5850 Coll St, Halifax, NS B3H 4R2, Canada.	robert.anderson@dal.ca; jean.marshall@dal.ca	Marr, Nico/T-7741-2019	Marr, Nico/0000-0002-1927-7072; Oldford, Sharon/0000-0001-8712-0328; Marshall, Jean S./0000-0002-5642-1379	Canadian Institutes of Health Research (CIHR) [MOP10966]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	Supported by the Canadian Institutes of Health Research (CIHR) grant no. MOP10966. The CIHR had no role in the study design; the collection, analysis, and interpretation of data; or the writing and submission process for this manuscript.	Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Amaral MM, 2007, J IMMUNOL, V179, P3425, DOI 10.4049/jimmunol.179.6.3425; Anderson R, 2010, FUTURE MICROBIOL, V5, P585, DOI 10.2217/FMB.10.22; Boukhvalova MS, 2010, CURR PROTOC CELL BIO; Brown MG, 2011, J VIROL, V85, P1145, DOI 10.1128/JVI.01630-10; Burke SM, 2008, BLOOD, V111, P5467, DOI 10.1182/blood-2007-10-118547; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; Chung HL, 2002, ANN ALLERG ASTHMA IM, V88, P463, DOI 10.1016/S1081-1206(10)62383-6; CIRINO NM, 1993, J GEN VIROL, V74, P1527, DOI 10.1099/0022-1317-74-8-1527; Cormier SA, 2010, EXPERT REV ANTI-INFE, V8, P1371, DOI [10.1586/eri.10.125, 10.1586/ERI.10.125]; Dawicki W, 2010, J IMMUNOL, V184, P2116, DOI 10.4049/jimmunol.0803894; Enoksson M, 2011, J IMMUNOL, V186, P2523, DOI 10.4049/jimmunol.1003383; EVERARD ML, 1995, ARCH DIS CHILD, V72, P64, DOI 10.1136/adc.72.1.64; FRANKEULLMANN G, 1995, J IMMUNOL, V154, P268; Galli SJ, 2005, NAT IMMUNOL, V6, P135, DOI 10.1038/ni1158; Garofalo RP, 2001, J INFECT DIS, V184, P393, DOI 10.1086/322788; Guerrero-Plata A, 2009, J IMMUNOL, V182, P3072, DOI 10.4049/jimmunol.0802262; Guhl S, 2010, J GEN VIROL, V91, P1256, DOI 10.1099/vir.0.019505-0; Harrison AM, 1999, AM J RESP CRIT CARE, V159, P1918, DOI 10.1164/ajrccm.159.6.9805083; HEGELE RG, 1994, CHEST, V105, P1848, DOI 10.1378/chest.105.6.1848; Holm CK, 2012, NAT IMMUNOL, V13, P737, DOI 10.1038/ni.2350; Jawdat DM, 2004, J IMMUNOL, V173, P5275, DOI 10.4049/jimmunol.173.8.5275; Jawdat DM, 2006, J IMMUNOL, V177, P1755, DOI 10.4049/jimmunol.177.3.1755; Johnson TR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016458; Jolly S, 2004, VET IMMUNOL IMMUNOP, V97, P125, DOI 10.1016/j.vetimm.2003.08.014; Jones A, 2006, CLIN EXP IMMUNOL, V143, P513, DOI 10.1111/j.1365-2249.2005.03004.x; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kim HH, 2007, J KOREAN MED SCI, V22, P37, DOI 10.3346/jkms.2007.22.1.37; KIMMAN TG, 1989, AM J VET RES, V50, P694; King CA, 2000, J VIROL, V74, P7146, DOI 10.1128/JVI.74.15.7146-7150.2000; King CA, 2002, J VIROL, V76, P8408, DOI 10.1128/JVI.76.16.8408-8419.2002; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Lee N, 2013, CLIN INFECT DIS, V57, P1069, DOI 10.1093/cid/cit471; Lindell DM, 2008, EUR J IMMUNOL, V38, P2168, DOI 10.1002/eji.200838155; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marcet CW, 2013, IMMUNOL RES, V56, P32, DOI 10.1007/s12026-012-8377-4; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Matthews SP, 2005, J VIROL, V79, P2050, DOI 10.1128/JVI.79.4.2050-2057.2005; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; Maurer M, 2004, INT J BIOCHEM CELL B, V36, P1882, DOI 10.1016/j.biocel.2003.10.019; Mazzoni A, 2006, J IMMUNOL, V177, P3577, DOI 10.4049/jimmunol.177.6.3577; McAlpine SM, 2012, FASEB J, V26, P1280, DOI 10.1096/fj.11-188979; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; McKimm-Breschkin JL, 2004, J VIROL METHODS, V120, P113, DOI 10.1016/j.jviromet.2004.02.020; Megjugorac NJ, 2004, J LEUKOCYTE BIOL, V75, P504, DOI 10.1189/jlb.0603291; Menten P, 2002, CYTOKINE GROWTH F R, V13, P455, DOI 10.1016/S1359-6101(02)00045-X; Murata Y, 2009, CLIN LAB MED, V29, P725, DOI 10.1016/j.cll.2009.07.004; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Oymar K, 2006, PEDIAT ALLERG IMM-UK, V17, P37, DOI 10.1111/j.1399-3038.2005.00345.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Radinger Madeleine, 2010, Curr Protoc Immunol, VChapter 7, DOI 10.1002/0471142735.im0737s90; Roe MFE, 2011, PEDIAT ALLERG IMM-UK, V22, P229, DOI 10.1111/j.1399-3038.2010.01032.x; Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314; Saito H, 1996, J IMMUNOL, V157, P343; Shelburne CP, 2009, CELL HOST MICROBE, V6, P331, DOI 10.1016/j.chom.2009.09.004; Shirato K, 2009, VIROLOGY, V386, P88, DOI 10.1016/j.virol.2009.01.011; Stockman LJ, 2012, PEDIATR INFECT DIS J, V31, P5, DOI 10.1097/INF.0b013e31822e68e6; Sundstrom JB, 2007, BLOOD, V109, P5293, DOI 10.1182/blood-2006-11-058438; Suto H, 2006, J IMMUNOL, V176, P4102, DOI 10.4049/jimmunol.176.7.4102; Tsuchida T, 2012, INT ARCH ALLERGY IMM, V157, P21, DOI 10.1159/000324676; VOLLAND H, 1994, J IMMUNOL METHODS, V175, P97, DOI 10.1016/0022-1759(94)90335-2; Wedde-Beer K, 2002, AM J PHYSIOL-LUNG C, V282, pL1143, DOI 10.1152/ajplung.00323.2001; Welliver RC, 2008, CLIN REV ALLERG IMMU, V34, P163, DOI 10.1007/s12016-007-8033-2; Wright M, 2011, PEDIATR PULM, V46, P324, DOI 10.1002/ppul.21377; Yoon JS, 2007, PEDIATR PULM, V42, P277, DOI 10.1002/ppul.20574; Zeng RH, 2011, CYTOKINE, V53, P1, DOI 10.1016/j.cyto.2010.09.011	67	41	44	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2015	136	5					1346	+		10.1016/j.jaci.2015.01.042	http://dx.doi.org/10.1016/j.jaci.2015.01.042			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CW1YE	25819983	hybrid			2022-12-18	WOS:000364787200025
J	Bernard, H; Guillon, B; Drumare, MF; Paty, E; Dreskin, SC; Wal, JM; Adel-Patient, K; Hazebrouck, S				Bernard, Herve; Guillon, Blanche; Drumare, Marie-Francoise; Paty, Evelyne; Dreskin, Stephen C.; Wal, Jean-Michel; Adel-Patient, Karine; Hazebrouck, Stephane			Allergenicity of peanut component Ara h 2: Contribution of conformational versus linear hydroxyproline-containing epitopes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; peanut allergen; posttranslational modifications; hydroxyproline; IgE-binding; conformational and linear epitopes	IGE-BINDING; ATOPIC-DERMATITIS; ALLERGIC PATIENTS; EFFECTOR ACTIVITY; CROSS-REACTIVITY; IDENTIFICATION; ISOFORMS; CHILDREN; ARA-H-2; ALBUMIN	Background: The 2S-albumin Ara h 2 is the most potent peanut allergen and a good predictor of clinical reactivity in allergic children. Posttranslational hydroxylation of proline residues occurs in DPYSP OH S motifs, which are repeated 2 or 3 times in different isoforms. Objectives: We investigated the effect of proline hydroxylation on IgE binding and the relative contributions of linear and conformational epitopes to Ara h 2 allergenicity. Methods: Peptides containing DPYSP OH S motifs were synthesized. A recombinant variant of Ara h 2 without DPYSP OH S motifs was generated by means of deletion mutagenesis. IgE reactivity of 18 French and 5 American patients with peanut allergy toward synthetic peptides and recombinant allergens was assessed by using IgE-binding inhibition assays and degranulation tests of humanized rat basophilic leukemia cells. Results: Hydroxyproline-containing peptides exhibited an IgE-binding activity equivalent to that of the unfolded Ara h 2. In contrast, corresponding peptides without hydroxyprolines displayed a very weak IgE-binding capacity. Despite removal of the DPYSP OH S motifs, the deletion variant still displayed Ara h 2 conformational epitopes. The IgE-binding capacity of Ara h 2 was then recapitulated with an equimolar mixture of a hydroxylated peptide and the deletion variant. Hydroxylated peptides of 15 and 27 amino acid residues were also able to trigger cell degranulation. Conclusions: Sensitization toward linear and conformational epitopes of Ara h 2 is variable among patients with peanut allergy. Optimal IgE binding to linear epitopes of Ara h 2 requires posttranslational hydroxylation of proline residues. The absence of hydroxyprolines could then affect the accuracy of component-resolved diagnostics by using rAra h 2.	[Bernard, Herve; Guillon, Blanche; Drumare, Marie-Francoise; Wal, Jean-Michel; Adel-Patient, Karine; Hazebrouck, Stephane] INRA, UR 496, Unite Immunoallergie Alimentaire, Jouy En Josas, France; [Bernard, Herve; Guillon, Blanche; Drumare, Marie-Francoise; Wal, Jean-Michel; Adel-Patient, Karine; Hazebrouck, Stephane] CEA, iBiTecS Serv Pharmacol & Immunoanal, Gif Sur Yvette, France; [Paty, Evelyne] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Paris, France; [Dreskin, Stephen C.] Univ Colorado Denver, Dept Med, Div Allergy & Clin Immunol, Aurora, CO USA	INRAE; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Hazebrouck, S (corresponding author), CEA Saclay, iBiTec S, Unite Immunoallergie Alimentaire, INRA, SPI Bat 136, F-91191 Gif Sur Yvette, France.	stephane.hazebrouck@cea.fr		HAZEBROUCK, Stephane/0000-0003-4828-7031	AlimH department of INRA; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01-AI099029]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI099029, R01AI052164] Funding Source: NIH RePORTER	AlimH department of INRA; National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by AlimH department of INRA and grant R01-AI099029 from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (to S.C.D.).	Albrecht M, 2009, J ALLERGY CLIN IMMUN, V124, P328, DOI 10.1016/j.jaci.2009.05.031; Apostolovic D, 2013, BBA-PROTEINS PROTEOM, V1834, P2832, DOI 10.1016/j.bbapap.2013.10.004; Bannon GA, 2013, BIOTECHNOL GENET ENG, P68; Bernard H, 2007, J AGR FOOD CHEM, V55, P9663, DOI 10.1021/jf071424g; Bernard H, 2003, ALLERGY, V58, P1285, DOI 10.1046/j.1398-9995.2003.00300.x; Bernard H, 1998, INT ARCH ALLERGY IMM, V115, P235, DOI 10.1159/000023906; Bernard H, 2009, ANAL BIOANAL CHEM, V395, P139, DOI 10.1007/s00216-009-2842-5; Blanc F, 2009, CLIN EXP ALLERGY, V39, P1277, DOI 10.1111/j.1365-2222.2009.03294.x; Bogh KL, 2009, CLIN EXP ALLERGY, V39, P1611, DOI 10.1111/j.1365-2222.2009.03333.x; Bublin M, 2013, J ALLERGY CLIN IMMUN, V132, P118, DOI 10.1016/j.jaci.2013.01.022; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; Chatel JM, 2003, INT ARCH ALLERGY IMM, V131, P14, DOI 10.1159/000070429; Chen XN, 2011, J IMMUNOL METHODS, V372, P65, DOI 10.1016/j.jim.2011.06.031; Clement G, 2005, PROTEIN EXPRES PURIF, V44, P110, DOI 10.1016/j.pep.2005.05.015; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Hales BJ, 2004, INT ARCH ALLERGY IMM, V135, P101, DOI 10.1159/000080652; Hazebrouck S, 2012, MOL NUTR FOOD RES, V56, P548, DOI 10.1002/mnfr.201100614; Jaervinen KM, 2007, ALLERGY, V62, P758, DOI 10.1111/j.1398-9995.2007.01332.x; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; KANE P, 1986, MOL IMMUNOL, V23, P783, DOI 10.1016/0161-5890(86)90090-8; KING TP, 1994, J IMMUNOL, V153, P1124; Klemans RJB, 2014, ALLERGY, V69, P1112, DOI 10.1111/all.12424; Klemans RJB, 2013, J ALLERGY CLIN IMMUN, V131, P157, DOI 10.1016/j.jaci.2012.08.010; Koid AE, 2014, J AGR FOOD CHEM, V62, P206, DOI 10.1021/jf4022509; Koppelman SJ, 2005, CLIN EXP ALLERGY, V35, P490, DOI 10.1111/j.1365-2222.2005.02204.x; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Kulis M, 2012, CLIN EXP ALLERGY, V42, P326, DOI 10.1111/j.1365-2222.2011.03934.x; Lehmann K, 2006, BIOCHEM J, V395, P463, DOI 10.1042/BJ20051728; Li JX, 2010, PROTEIN SCI, V19, P174, DOI 10.1002/pro.295; Lin J, 2012, J ALLERGY CLIN IMMUN, V129, P1321, DOI 10.1016/j.jaci.2012.02.012; Moreno F Javier, 2008, Open Biochem J, V2, P16, DOI 10.2174/1874091X00802010016; Mueller GA, 2011, ALLERGY, V66, P878, DOI 10.1111/j.1398-9995.2010.02532.x; Palmer GW, 2005, CLIN IMMUNOL, V115, P302, DOI 10.1016/j.clim.2005.02.011; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Petersen A, 1998, CLIN EXP ALLERGY, V28, P315; Porterfield HS, 2009, CLIN EXP ALLERGY, V39, P1099, DOI 10.1111/j.1365-2222.2009.03273.x; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Radauer C, 2014, ALLERGY, V69, P413, DOI 10.1111/all.12348; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sen M, 2002, J IMMUNOL, V169, P882, DOI 10.4049/jimmunol.169.2.882; Shi XL, 2013, INT ARCH ALLERGY IMM, V162, P25, DOI 10.1159/000351920; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Starkl P, 2012, CLIN EXP ALLERGY, V42, P1801, DOI 10.1111/cea.12031; Suhr M, 2004, MOL NUTR FOOD RES, V48, P390, DOI 10.1002/mnfr.200400028; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Zhuang YH, 2013, IMMUNOL RES, V55, P125, DOI 10.1007/s12026-012-8355-x	51	41	45	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1267	U684		10.1016/j.jaci.2014.10.025	http://dx.doi.org/10.1016/j.jaci.2014.10.025			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25483599				2022-12-18	WOS:000353980700020
J	Nocerino, R; Leone, L; Cosenza, L; Canani, RB				Nocerino, Rita; Leone, Ludovica; Cosenza, Linda; Canani, Roberto Berni			Increasing rate of hospitalizations for food-induced anaphylaxis in Italian children: An analysis of the Italian Ministry of Health database	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PRESCRIPTIONS; ADMISSIONS		[Nocerino, Rita; Leone, Ludovica; Cosenza, Linda; Canani, Roberto Berni] Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy; [Canani, Roberto Berni] Univ Naples Federico II, European Lab Invest Food Induced Dis, Naples, Italy	University of Naples Federico II; University of Naples Federico II	Nocerino, R (corresponding author), Univ Naples Federico II, Dept Translat Med Sci, Naples, Italy.	berni@unina.it	Nocerino, Rita/ABD-8087-2020; NOCERINO, RITA/AAC-1966-2022; Canani, Roberto Berni/AAC-4810-2022	NOCERINO, RITA/0000-0003-4681-546X; Canani, Roberto Berni/0000-0002-5169-9574; leone, ludovica/0000-0002-4524-0126				Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Canani RB, 2012, CLIN EXP ALLERGY, V42, P1813, DOI 10.1111/cea.12036; Cetinkaya F, 2013, ALLERGY, V68, P128, DOI 10.1111/all.12069; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Marrone G, 2012, EUR J NUTR, V51, P143, DOI 10.1007/s00394-011-0200-9; Mullins RJ, 2009, ANN ALLERG ASTHMA IM, V103, P488, DOI 10.1016/S1081-1206(10)60265-7; Sicherer SH, 2014, J ALLERGY CLIN IMMUN, V133, P291, DOI 10.1016/j.jaci.2013.11.020; Tejedor Alonso MA, 2012, CLIN EXP ALLERGY, V42, P578, DOI 10.1111/j.1365-2222.2012.03930.x	9	41	42	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2015	135	3					833	U399		10.1016/j.jaci.2014.12.1912	http://dx.doi.org/10.1016/j.jaci.2014.12.1912			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CD4PF	25630939				2022-12-18	WOS:000351065000038
J	Fernandez-Boyanapalli, RF; Frasch, SC; Thomas, SM; Malcolm, KC; Nicks, M; Harbeck, RJ; Jakubzick, CV; Nemenoff, R; Henson, PM; Holland, SM; Bratton, DL				Fernandez-Boyanapalli, Ruby F.; Frasch, S. Courtney; Thomas, Stacey M.; Malcolm, Kenneth C.; Nicks, Michael; Harbeck, Ronald J.; Jakubzick, Claudia V.; Nemenoff, Raphael; Henson, Peter M.; Holland, Steven M.; Bratton, Donna L.			Pioglitazone restores phagocyte mitochondrial oxidants and bactericidal capacity in chronic granulomatous disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic granulomatous disease; phagocytes; mitochondria; oxidants; thioglitazones	ACTIVATED-RECEPTOR-GAMMA; REACTIVE OXYGEN; PPAR-GAMMA; NADPH OXIDASE; SUPEROXIDE-PRODUCTION; INSULIN-RESISTANCE; HUMAN NEUTROPHILS; CELL-DEATH; INFLAMMATION; MACROPHAGES	Background: Deficient production of reactive oxygen species (ROS) by the phagocyte nicotinamide adenine dinucleotide (NADPH) oxidase in patients with chronic granulomatous disease (CGD) results in susceptibility to certain pathogens secondary to impaired oxidative killing and mobilization of other phagocyte defenses. Peroxisome proliferator-activated receptor (PPAR) gamma agonists, including pioglitazone, approved for type 2 diabetes therapy alter cellular metabolism and can heighten ROS production. It was hypothesized that pioglitazone treatment of gp91(phox-/-) mice, a murine model of human CGD, would enhance phagocyte oxidant production and killing of Staphylococcus aureus, a significant pathogen in patients with this disorder. Objectives: We sought to determine whether pioglitazone treatment of gp91(phox-/-) mice enhanced phagocyte oxidant production and host defense. Methods: Wild-type and gp91(phox-/-) mice were treated with the PPAR gamma agonist pioglitazone, and phagocyte ROS and killing of Staphylococcus aureus were investigated. Results: As demonstrated by 3 different ROS-sensing probes, short-term treatment of gp91(phox-/-) mice with pioglitazone enhanced stimulated ROS production in neutrophils and monocytes from blood and neutrophils and inflammatory macrophages recruited to tissues. Mitochondria were identified as the source of ROS. Findings were replicated in human monocytes from patients with CGD after ex vivo pioglitazone treatment. Importantly, although mitochondrial (mt) ROS were deficient in gp91(phox-/-) phagocytes, their restoration with treatment significantly enabled killing of Staphylococcus aureus both ex vivo and in vivo. Conclusions: Together, the data support the hypothesis that signaling from the NADPH oxidase under normal circumstances governs phagocyte mtROS production and that such signaling is lacking in the absence of a functioning phagocyte oxidase. PPAR gamma agonism appears to bypass the need for the NADPH oxidase for enhanced mtROS production and partially restores host defense in CGD.	[Fernandez-Boyanapalli, Ruby F.; Frasch, S. Courtney; Thomas, Stacey M.; Nicks, Michael; Harbeck, Ronald J.; Jakubzick, Claudia V.; Henson, Peter M.; Bratton, Donna L.] Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; [Malcolm, Kenneth C.; Harbeck, Ronald J.; Henson, Peter M.] Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; [Harbeck, Ronald J.; Henson, Peter M.] Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO USA; [Nemenoff, Raphael] Univ Denver, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80208 USA; [Holland, Steven M.] NIAID, Labs Clin Infect Dis, NIH, Bethesda, MD 20892 USA	National Jewish Health; National Jewish Health; National Jewish Health; University of Denver; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Bratton, DL (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Rm A540,1400 Jackson St, Denver, CO 80206 USA.	brattond@njhealth.org		Thomas, Stacey/0000-0002-5666-4311	National Institutes of Health [AI058228, AI110408, HL34303]; Chronic Granulomatous Disorder Society (United Kingdom) [J4G/10/03]; NATIONAL CANCER INSTITUTE [P50CA058187, R01CA108610] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL114381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058228, R01AI110408, R56AI058228] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chronic Granulomatous Disorder Society (United Kingdom); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This investigation was entirely funded by National Institutes of Health grants AI058228, AI110408, and HL34303 and the Chronic Granulomatous Disorder Society (United Kingdom, J4G/10/03).	Ahmed KA, 2012, BIOCHEM J, V441, P719, DOI 10.1042/BJ20111130; Aronoff DM, 2007, PPAR RES, V2007, DOI 10.1155/2007/52546; Bassoe CF, 2003, CYTOM PART B-CLIN CY, V51B, P21, DOI 10.1002/cyto.b.10003; Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010; Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003; Brown JR, 2003, J LEUKOCYTE BIOL, V73, P591, DOI 10.1189/jlb.1202599; Burlak C, 2006, MOL CELL PROTEOMICS, V5, P620, DOI 10.1074/mcp.M500336-MCP200; Campbell AM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004801; Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163; Consoli A, 2005, LUPUS, V14, P794, DOI 10.1191/0961203305lu2223oa; Coste A, 2003, IMMUNITY, V19, P329, DOI 10.1016/S1074-7613(03)00229-2; Coste A, 2008, J IMMUNOL, V180, P4939, DOI 10.4049/jimmunol.180.7.4939; Daiber A, 2010, BBA-BIOENERGETICS, V1797, P897, DOI 10.1016/j.bbabio.2010.01.032; Decleva E, 2006, J LEUKOCYTE BIOL, V79, P87, DOI 10.1189/jlb.0605338; Feinstein DL, 2005, BIOCHEM PHARMACOL, V70, P177, DOI 10.1016/j.bcp.2005.03.033; Fernandez-Boyanapalli R, 2010, BLOOD, V116, P4512, DOI 10.1182/blood-2010-02-272005; Frasch SC, 2013, J BIOL CHEM, V288, P4583, DOI 10.1074/jbc.M112.438507; Frasch SC, 2008, J BIOL CHEM, V283, P33736, DOI 10.1074/jbc.M807047200; Garcia-Ruiz I, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-88; Gautier EL, 2012, J IMMUNOL, V189, P2614, DOI 10.4049/jimmunol.1200495; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002; Hampton MB, 1996, FEBS LETT, V399, P277, DOI 10.1016/S0014-5793(96)01341-5; HASLETT C, 1985, AM J PATHOL, V119, P101; HOIDAL JR, 1979, AM REV RESPIR DIS, V120, P613; Holland SM, 2010, CLIN REV ALLERG IMMU, V38, P3, DOI 10.1007/s12016-009-8136-z; Huang J, 2009, AUTOPHAGY, V5, P887, DOI 10.4161/auto.9125; Huang J, 2009, P NATL ACAD SCI USA, V106, P6226, DOI 10.1073/pnas.0811045106; Ingersoll MA, 2010, BLOOD, V116, P857; Inoue I, 2001, METABOLISM, V50, P3, DOI 10.1053/meta.2001.19415; Jacob CO, 2012, P NATL ACAD SCI USA, V109, pE59, DOI 10.1073/pnas.1113251108; JOHNSTON RB, 1975, J CLIN INVEST, V55, P1357, DOI 10.1172/JCI108055; Kalyanaraman B, 2011, BIOCHEM SOC T, V39, P1221, DOI 10.1042/BST0391221; Kielian T, 2008, J IMMUNOL, V180, P5004, DOI 10.4049/jimmunol.180.7.5004; Kim KY, 2007, MOL PHARMACOL, V72, P674, DOI 10.1124/mol.107.035584; Kuhns DB, 2010, NEW ENGL J MED, V363, P2600, DOI 10.1056/NEJMoa1007097; Kyrmizi I, 2013, J IMMUNOL, V191, P1287, DOI 10.4049/jimmunol.1300132; Lefevre L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012828; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Lopes F, 2011, ARTHRITIS RHEUM-US, V63, P2651, DOI 10.1002/art.30448; Maianski NA, 2004, CELL DEATH DIFFER, V11, P143, DOI 10.1038/sj.cdd.4401320; Manzanillo PS, 2013, NATURE, V501, P512, DOI 10.1038/nature12566; Martinet W, 2009, FEBS J, V276, P2227, DOI 10.1111/j.1742-4658.2009.06951.x; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846; Omar HA, 2013, BIOL CHEM, V394, P865, DOI 10.1515/hsz-2013-0139; OREN R, 1963, J CELL BIOL, V17, P487, DOI 10.1083/jcb.17.3.487; Perez-Ortiz JM, 2007, MOL PHARMACOL, V72, P407, DOI 10.1124/mol.106.032458; Pizzolla A, 2011, EUR J IMMUNOL, V41, P403, DOI 10.1002/eji.201040598; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Remijsen Q, 2011, CELL RES, V21, P290, DOI 10.1038/cr.2010.150; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; Sanmun D, 2009, AM J PHYSIOL-CELL PH, V297, pC621, DOI 10.1152/ajpcell.00651.2008; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Shah P, 2010, EXPERT OPIN DRUG SAF, V9, P347, DOI 10.1517/14740331003623218; Shiloh MU, 1997, INFECT IMMUN, V65, P3193, DOI 10.1128/IAI.65.8.3193-3198.1997; Shiomi T, 2002, CIRCULATION, V106, P3126, DOI 10.1161/01.CIR.0000039346.31538.2C; Straus DS, 2007, TRENDS IMMUNOL, V28, P551, DOI 10.1016/j.it.2007.09.003; Van Raam BJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002013; Violi F, 2009, CIRCULATION, V120, P1616, DOI 10.1161/CIRCULATIONAHA.109.877191; Voltan S, 2008, GASTROENTEROLOGY, V135, P1216, DOI 10.1053/j.gastro.2008.07.007; Wang SP, 2014, ENDOCRINOLOGY, V155, P3047, DOI 10.1210/en.2014-1031; Wei L, 2013, BRIT J CLIN PHARMACO, V75, P254, DOI 10.1111/j.1365-2125.2012.04325.x; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhao WP, 2009, J IMMUNOL, V183, P2729, DOI 10.4049/jimmunol.0804341	69	41	42	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					517	U323		10.1016/j.jaci.2014.10.034	http://dx.doi.org/10.1016/j.jaci.2014.10.034			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25498313	Green Accepted			2022-12-18	WOS:000349372300026
J	Stinson, SE; Amrani, Y; Brightling, CE				Stinson, Sally E.; Amrani, Yassine; Brightling, Christopher E.			D prostanoid receptor 2 (chemoattractant receptor-homologous molecule expressed on T(H)2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Expression; asthma; immunohistochemistry; prostaglandin D-2; biopsy	BRONCHOALVEOLAR LAVAGE FLUID; CRTH2 ANTAGONIST OC000459; EPIDERMAL-GROWTH-FACTOR; INNATE LYMPHOID-CELLS; PROSTAGLANDIN D-2; MEDIATOR CONCENTRATIONS; DOUBLE-BLIND; EOSINOPHILS; ACTIVATION; EFFICACY	Background: The D prostanoid receptor 2 (DP2; also known as chemoattractant receptor-homologous molecule expressed on T(H)2 cells) is implicated in the pathogenesis of asthma, but its expression within bronchial biopsy specimens is unknown. Objectives: We sought to investigate the bronchial submucosal DP2 expression in asthmatic patients and healthy control subjects and to explore its functional role in epithelial cells. Methods: DP2 protein expression was assessed in bronchial biopsy specimens from asthmatic patients (n = 22) and healthy control subjects (n = 10) by using immunohistochemistry and in primary epithelial cells by using flow cytometry, immunofluorescence, and quantitative RT-PCR. The effects of the selective DP2 agonist 13, 14-dihydro-15-keto prostaglandin D-2 on epithelial cell migration and differentiation were determined. Results: Numbers of submucosal DP2(+) cells were increased in asthmatic patients compared with those in healthy control subjects (mean [SEM]: 78 [5] vs 22 [3]/mm(2) submucosa, P < .001). The bronchial epithelium expressed DP2, but its expression was decreased in asthmatic patients compared with that seen in healthy control subjects (mean [SEM]: 21 [3] vs 72 [11]/10 mm(2) epithelial area, P = .001), with similar differences observed in vitro by primary epithelial cells. Squamous metaplasia of the bronchial epithelium was increased in asthmatic patients and related to decreased DP2 expression (r(s) = 0.69, P < .001). 13, 14-Dihydro-15-keto prostaglandin D-2 promoted epithelial cell migration and at air-liquid interface cultures increased the number of MUC5AC(+) and involucrin-positive cells, which were blocked with the DP2-selective antagonist AZD6430. Conclusions: DP2 is expressed by the bronchial epithelium, and its activation drives epithelial differentiation, suggesting that in addition to its well-characterized role in inflammatory cell migration, DP2 might contribute to airway remodeling in asthmatic patients.	[Stinson, Sally E.; Amrani, Yassine; Brightling, Christopher E.] Univ Leicester, Inst Lung Hlth, Dept Infect Inflammat & Immun, Leicester LE1 7RH, Leics, England	University of Leicester	Brightling, CE (corresponding author), Univ Hosp, Inst Lung Hlth, Leicester LE3 9QP, Leics, England.	ceb17@le.ac.uk	Amrani, Yassine/A-1826-2013; Amrani, Yassine/Q-6323-2019	Amrani, Yassine/0000-0002-7042-6926; brightling, chris/0000-0002-9345-4903	AstraZeneca; European Regional Development Fund [ERDF 05567]; National Institute for Health Research Leicester Respiratory Biomedical Research Unit; AirPROM [FP7-270194]; National Institute for Health Research [NF-SI-0512-10018] Funding Source: researchfish	AstraZeneca(AstraZeneca); European Regional Development Fund(European Commission); National Institute for Health Research Leicester Respiratory Biomedical Research Unit; AirPROM; National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by AstraZeneca. C.E.B. is a Wellcome Trust Senior Clinical Fellow. The research was performed in laboratories funded in part by the European Regional Development Fund (ERDF 05567). This study was also supported in part by the National Institute for Health Research Leicester Respiratory Biomedical Research Unit and AirPROM (FP7-270194). The views expressed are those of the author(s) and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health. The European Regional Development Fund had no involvement in the design of the study, data collection, analysis and interpretation of the data, in the writing of the manuscript, or in the decision to submit the manuscript.	Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; [Anonymous], 1993, BMJ, V306, P776; Araya J, 2007, J CLIN INVEST, V117, P3551, DOI 10.1172/JCI32526; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Barnes N, 2012, CLIN EXP ALLERGY, V42, P38, DOI 10.1111/j.1365-2222.2011.03813.x; Birring SS, 2004, AM J RESP CRIT CARE, V169, P15, DOI 10.1164/rccm.200308-1092OC; Boehme SA, 2009, INT IMMUNOL, V21, P1, DOI 10.1093/intimm/dxn118; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Busse WW, 2013, J ALLERGY CLIN IMMUN, V131, P339, DOI 10.1016/j.jaci.2012.10.013; Chiba T, 2007, INT ARCH ALLERGY IMM, V143, P23, DOI 10.1159/000101400; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; CREA AEG, 1992, EUR RESPIR J, V5, P190; Davies Donna E, 2009, Proc Am Thorac Soc, V6, P678, DOI 10.1513/pats.200907-067DP; Erjefalt JS, 1997, THORAX, V52, P213, DOI 10.1136/thx.52.3.213; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; Gallant MA, 2005, J BONE MINER RES, V20, P672, DOI 10.1359/JBMR.041211; Gazi L, 2005, PROSTAG OTH LIPID M, V75, P153, DOI 10.1016/j.prostaglandins.2004.11.003; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Heinemann A, 2003, J IMMUNOL, V170, P4752, DOI 10.4049/jimmunol.170.9.4752; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Horak F, 2012, ALLERGY, V67, P1572, DOI 10.1111/all.12042; Kicic A, 2006, AM J RESP CRIT CARE, V174, P1110, DOI 10.1164/rccm.200603-392OC; Krug N, 2014, J ALLERGY CLIN IMMUN, V133, P414, DOI 10.1016/j.jaci.2013.10.013; Kuesap J, 2008, BIOCHEM BIOPH RES CO, V367, P413, DOI 10.1016/j.bbrc.2007.12.148; Lachowicz-Scroggins ME, 2010, AM J RESP CELL MOL, V43, P652, DOI 10.1165/rcmb.2009-0244OC; LEUBE RE, 1991, VIRCHOWS ARCH B, V61, P227; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Lukacs NW, 2008, AM J PHYSIOL-LUNG C, V295, pL767, DOI 10.1152/ajplung.90351.2008; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Mutalithas K, 2010, CLIN EXP IMMUNOL, V161, P34, DOI 10.1111/j.1365-2249.2010.04161.x; Nagata K, 2003, PROSTAG LEUKOTR ESS, V69, P169, DOI 10.1016/S0952-3278(03)00078-4; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Park KS, 2006, AM J RESP CELL MOL, V34, P151, DOI 10.1165/rcmb.2005-0332OC; Parker JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061023; Pettipher R, 2008, BRIT J PHARMACOL, V153, pS191, DOI 10.1038/sj.bjp.0707488; Puchelle Edith, 2006, Proc Am Thorac Soc, V3, P726, DOI 10.1513/pats.200605-126SF; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Sargent C, 2009, BRIT J PHARMACOL, V7; Shirasaki H, 2009, ANN ALLERG ASTHMA IM, V102, P110, DOI 10.1016/S1081-1206(10)60239-6; Singh D, 2013, EUR RESPIR J, V41, P46, DOI 10.1183/09031936.00092111; Snell N, 2013, RESP MED, V107, P1722, DOI 10.1016/j.rmed.2013.06.006; St-Laurent J, 2008, CLIN EXP ALLERGY, V38, P1582, DOI 10.1111/j.1365-2222.2008.03032.x; Stebbins KJ, 2010, EUR J PHARMACOL, V638, P142, DOI 10.1016/j.ejphar.2010.04.031; Tanabe T, 2012, CHEST, V142, P1274, DOI 10.1378/chest.11-1710; Tanaka K, 2004, BIOCHEM BIOPH RES CO, V316, P1009, DOI 10.1016/j.bbrc.2004.02.151; Wright CD, 2012, CELL SIGNAL, V24, P794, DOI 10.1016/j.cellsig.2011.11.014; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Xue LZ, 2009, J IMMUNOL, V182, P7580, DOI 10.4049/jimmunol.0804090; Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531	53	41	42	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					395	U536		10.1016/j.jaci.2014.08.027	http://dx.doi.org/10.1016/j.jaci.2014.08.027			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25312757	Green Published, hybrid			2022-12-18	WOS:000349372300011
J	Samuelov, L; Sprecher, E				Samuelov, Liat; Sprecher, Eli			Peeling off the genetics of atopic dermatitis-like congenital disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Netherton syndrome; peeling skin syndrome type-B; skin dermatitis; multiple severe allergies; metabolic wasting syndrome; lymphoepithelial Kazal-type related inhibitor type 5; desmoglein 1; corneodesmosin	PROTEINASE-ACTIVATED RECEPTOR-2; GENERALIZED EXFOLIATIVE ERYTHRODERMA; HUMAN TISSUE KALLIKREINS; LAMELLAR BODY SECRETION; NETHERTON-SYNDROME; STRATUM-CORNEUM; EPIDERMAL BARRIER; SKIN-SYNDROME; BETA-CATENIN; ICHTHYOSIFORM ERYTHRODERMA	The epidermis forms during the course of a complex differentiation process known as cornification, which culminates with the formation of the epidermal barrier. The epidermal barrier serves as a vital line of defense against the environment and mainly consists of 3 elements: intracellular keratin filaments, intercellular lipids, and the cornified cell envelope. Adequate epidermal barrier function is also critically dependent on normal shedding of terminally differentiated keratinocytes, a process termed desquamation, which requires the dissolution of cell-cell junctions in the upper granular layers. Although much has been learned about epidermal differentiation through the deciphering of the molecular basis of various cornification disorders, less is currently known about the mechanisms regulating epidermal desquamation and disorders resulting from disruption of this process. Netherton syndrome, peeling skin syndrome type B, and skin dermatitis-multiple severe allergies-metabolic wasting syndrome are 3 autosomal recessive conditions resulting from aberrant regulation of epidermal desquamation. The deciphering of their pathogenesis has not only broadened our understanding of this process but has also shed new light on clinical and mechanistic links between allergic reactions and abnormal desquamation, substantiating the notion that allergic manifestations might, under some circumstances, be the sole consequence of a primary epidermal defect.	[Samuelov, Liat; Sprecher, Eli] Tel Aviv Sourasky Med Ctr, Dept Dermatol, IL-64239 Tel Aviv, Israel; [Sprecher, Eli] Tel Aviv Univ, Sackler Fac Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Sprecher, E (corresponding author), Tel Aviv Sourasky Med Ctr, Dept Dermatol, 6 Weizmann St, IL-64239 Tel Aviv, Israel.	elisp@tlvmc.gov.il			Ram family; Tel Aviv Sourasky Medical Center	Ram family; Tel Aviv Sourasky Medical Center	Supported by a generous donation of the Ram family (to E. S.). L. S. is recipient of an Excellence Award from the Tel Aviv Sourasky Medical Center.	Alpigiani MG, 2012, PEDIATR DERMATOL, V29, P521, DOI 10.1111/j.1525-1470.2011.01525.x; Bitoun E, 2003, HUM MOL GENET, V12, P2417, DOI 10.1093/hmg/ddg247; Bonnart C, 2010, M S-MED SCI, V26, P681, DOI 10.1051/medsci/2010268-9681; Bonnart C, 2010, J CLIN INVEST, V120, P871, DOI 10.1172/JCI41440; Brennan D, 2007, J CELL SCI, V120, P758, DOI 10.1242/jcs.03392; Briot A, 2010, J INVEST DERMATOL, V130, P2736, DOI 10.1038/jid.2010.233; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Buddenkotte J, 2005, J INVEST DERMATOL, V124, P38, DOI 10.1111/j.0022-202X.2004.23539.x; Burk C, 2008, PEDIATR DERMATOL, V25, P287, DOI 10.1111/j.1525-1470.2008.00663.x; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Caubet C, 2004, J INVEST DERMATOL, V122, P747, DOI 10.1111/j.0022-202X.2004.22331.x; Chao SC, 2005, BRIT J DERMATOL, V152, P159, DOI 10.1111/J.1365-2133.2005.06337.X; Charvet C, 2003, ONCOGENE, V22, P4557, DOI 10.1038/sj.onc.1206778; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Deraison C, 2007, MOL BIOL CELL, V18, P3607, DOI 10.1091/mbc.E07-02-0124; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Descargues P, 2006, J INVEST DERMATOL, V126, P1622, DOI 10.1038/sj.jid.5700284; Egelrud T, 2005, BRIT J DERMATOL, V153, P1200, DOI 10.1111/j.1365-2133.2005.06834.x; El Shabrawi-Caelen L, 2004, ARCH DERMATOL, V140, P1275, DOI 10.1001/archderm.140.10.1275-a; Elias PM, 2014, J ALLERGY CLIN IMMUN, V134, P781, DOI 10.1016/j.jaci.2014.05.048; Fartasch M, 1999, ARCH DERMATOL, V135, P823, DOI 10.1001/archderm.135.7.823; Fischer J, 2014, J INVEST DERMATOL, V134, P1305, DOI 10.1038/jid.2013.502; Folster-Holst R, 1999, BRIT J DERMATOL, V140, P1139; Fong K, 2011, CLIN EXP DERMATOL, V36, P412, DOI 10.1111/j.1365-2230.2010.03976.x; Fortugno P, 2012, HUM MOL GENET, V21, P4187, DOI 10.1093/hmg/dds243; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Furio L, 2014, BIOL CHEM, V395, P945, DOI 10.1515/hsz-2014-0137; Furio L, 2014, J EXP MED, V211, P499, DOI 10.1084/jem.20131797; Garrod D, 2008, BBA-BIOMEMBRANES, V1778, P572, DOI 10.1016/j.bbamem.2007.07.014; Garty BZ, 2008, PEDIATR DERMATOL, V25, P134, DOI 10.1111/j.1525-1470.2007.00608.x; Getsios S, 2009, J CELL BIOL, V185, P1243, DOI 10.1083/jcb.200809044; Green KJ, 2007, J INVEST DERMATOL, V127, P2499, DOI 10.1038/sj.jid.5701015; Gschwandtner M, 2013, ALLERGY, V68, P37, DOI 10.1111/all.12051; Gu LH, 2007, CURR OPIN CELL BIOL, V19, P13, DOI 10.1016/j.ceb.2006.12.007; Haliasos EC, 2013, PEDIATR DERMATOL, V30, P163, DOI 10.1111/pde.12097; HANIFIN JM, 1985, J INVEST DERMATOL, V85, pS161, DOI 10.1111/1523-1747.ep12276359; Hardman MJ, 2005, MOL CELL BIOL, V25, P969, DOI 10.1128/MCB.25.3.969-978.2005; Harmon RM, 2013, CELL COMMUN ADHES, V20, P171, DOI 10.3109/15419061.2013.855204; Harmon RM, 2013, J CLIN INVEST, V123, P1556, DOI 10.1172/JCI65220; Hatano Y, 2005, J INVEST DERMATOL, V124, P786, DOI 10.1111/j.0022-202X.2005.23651.x; Hausser I, 1996, PEDIATR DERMATOL, V13, P183, DOI 10.1111/j.1442-200X.1996.tb02615.x; Hobbs RP, 2012, J INVEST DERMATOL, V132, P482, DOI 10.1038/jid.2011.318; Holthofer B, 2007, INT REV CYTOL, V264, P65, DOI 10.1016/S0074-7696(07)64003-0; Houben E, 2007, SKIN PHARMACOL PHYS, V20, P122, DOI 10.1159/000098163; Hovnanian A, 2013, CELL TISSUE RES, V351, P289, DOI 10.1007/s00441-013-1558-1; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Igarashi S, 2004, BRIT J DERMATOL, V151, P355, DOI 10.1111/j.1365-2133.2004.06061.x; Incorvaia C, 2008, CLIN EXP IMMUNOL, V153, P27, DOI 10.1111/j.1365-2249.2008.03718.x; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Ishida-Yamamoto A, 2014, EXP DERMATOL, V23, P60, DOI 10.1111/exd.12292; Ishida-Yamamoto A, 2011, J DERMATOL, V38, P645, DOI 10.1111/j.1346-8138.2011.01227.x; Israeli S, 2014, DERMATOLOGY, V228, P183, DOI 10.1159/000357560; Israeli S, 2011, J INVEST DERMATOL, V131, P779, DOI 10.1038/jid.2010.363; Jayakumar A, 2004, PROTEIN EXPRES PURIF, V35, P93, DOI 10.1016/j.pep.2003.12.004; Jonca N, 2002, J BIOL CHEM, V277, P5024, DOI 10.1074/jbc.M108438200; Kim BE, 2011, J INVEST DERMATOL, V131, P1272, DOI 10.1038/jid.2011.24; Komatsu N, 2005, J INVEST DERMATOL, V125, P1182, DOI 10.1111/j.0022-202X.2005.23933.x; Komatsu N, 2006, J INVEST DERMATOL, V126, P925, DOI 10.1038/sj.jid.5700146; Komatsu N, 2006, J INVEST DERMATOL, V126, P2338, DOI 10.1038/sj.jid.5700379; Koster MI, 2007, P NATL ACAD SCI USA, V104, P3255, DOI 10.1073/pnas.0611376104; Krasagakis K, 2003, DERMATOLOGY, V207, P182, DOI 10.1159/000071791; Kubo A, 2012, J CLIN INVEST, V122, P440, DOI 10.1172/JCI57416; Lacroix M, 2012, J INVEST DERMATOL, V132, P575, DOI 10.1038/jid.2011.366; Lai YH, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-50; Leclerc EA, 2009, J CELL SCI, V122, P2699, DOI 10.1242/jcs.050302; Leyva-Castillo JM, 2013, J INVEST DERMATOL, V133, P154, DOI 10.1038/jid.2012.239; Li ALK, 2011, J PLAST RECONSTR AES, V64, P1533, DOI 10.1016/j.bjps.2011.03.013; LUNDSTROM A, 1994, ARCH DERMATOL RES, V286, P369, DOI 10.1007/BF00371795; Macfarlane SR, 2005, BRIT J PHARMACOL, V145, P535, DOI 10.1038/sj.bjp.0706204; Macknet CA, 2008, PEDIATR DERMATOL, V25, P368, DOI 10.1111/j.1525-1470.2008.00685.x; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; Magert HJ, 2002, INT J BIOCHEM CELL B, V34, P573, DOI 10.1016/S1357-2725(01)00179-0; Mahoney MG, 2006, EXP DERMATOL, V15, P101, DOI 10.1111/j.1600-0625.2006.00391.x; Mallet A, 2013, BRIT J DERMATOL, V169, P1322, DOI 10.1111/bjd.12593; Matsumoto M, 2008, P NATL ACAD SCI USA, V105, P6720, DOI 10.1073/pnas.0709345105; Menon GK, 2012, INT J PHARMACEUT, V435, P3, DOI 10.1016/j.ijpharm.2012.06.005; Merritt AJ, 2002, MOL CELL BIOL, V22, P5846, DOI 10.1128/MCB.22.16.5846-5858.2002; Mitsudo K, 2003, BIOCHEMISTRY-US, V42, P3874, DOI 10.1021/bi027029v; Miyai M, 2014, J INVEST DERMATOL, V134, P1665, DOI 10.1038/jid.2014.3; Mizuno O, 2014, J EUR ACAD DERMATOL; Mizuno Y, 2006, CLIN EXP DERMATOL, V31, P677, DOI 10.1111/j.1365-2230.2006.02207.x; Mizuno Y, 2005, BRIT J DERMATOL, V153, P661, DOI 10.1111/j.1365-2133.2005.06770.x; Montezin M, 1997, EXP CELL RES, V231, P132, DOI 10.1006/excr.1996.3452; Neuber S, 2010, DERMAT RES PRACT, V2010, DOI 10.1155/2010/101452; Nie ZX, 2011, J BIOL CHEM, V286, P2143, DOI 10.1074/jbc.M110.192245; North AJ, 1996, P NATL ACAD SCI USA, V93, P7701, DOI 10.1073/pnas.93.15.7701; Oji V, 2010, AM J HUM GENET, V87, P274, DOI 10.1016/j.ajhg.2010.07.005; Ong C, 2004, BRIT J DERMATOL, V151, P1253, DOI 10.1111/j.1365-2133.2004.06180.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pohl M, 1998, EUR J PEDIATR, V157, P157, DOI 10.1007/s004310050789; Raghunath M, 2004, J INVEST DERMATOL, V123, P474, DOI 10.1111/j.0022-202X.2004.23220.x; Rakowska A, 2009, PEDIATR DERMATOL, V26, P320, DOI 10.1111/j.1525-1470.2008.00778.x; Roan F, 2012, J LEUKOCYTE BIOL, V91, P877, DOI 10.1189/jlb.1211622; Sales KU, 2010, NAT GENET, V42, P676, DOI 10.1038/ng.629; Samuelov L, 2013, NAT GENET, V45, P1244, DOI 10.1038/ng.2739; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Segre JA, 2006, J CLIN INVEST, V116, P1150, DOI 10.1172/JCI28521; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; Shimomura Y, 2005, BRIT J DERMATOL, V153, P1026, DOI 10.1111/j.1365-2133.2005.06900.x; Simon M, 2001, J BIOL CHEM, V276, P20292, DOI 10.1074/jbc.M100201200; Simpson CL, 2011, NAT REV MOL CELL BIO, V12, P565, DOI 10.1038/nrm3175; Sobolik-Delmaire T, 2010, J INVEST DERMATOL, V130, P2638, DOI 10.1038/jid.2010.191; Soreide K, 2005, J PEDIATR SURG, V40, DOI 10.1016/j.jpedsurg.2005.07.058; Sprecher E, 2004, CLIN EXP DERMATOL, V29, P513, DOI 10.1111/j.1365-2230.2004.01589.x; Sprecher E, 2001, J INVEST DERMATOL, V117, P179, DOI 10.1046/j.1523-1747.2001.01389.x; Stefansson K, 2008, J INVEST DERMATOL, V128, P18, DOI 10.1038/sj.jid.5700965; Sun JD, 2006, INT J DERMATOL, V45, P693, DOI 10.1111/j.1365-4632.2005.02637.x; Suzuki Y, 1996, BRIT J DERMATOL, V134, P460, DOI 10.1046/j.1365-2133.1996.31794.x; Tan X, 2013, EUR J MED CHEM, V70, P661, DOI 10.1016/j.ejmech.2013.10.040; Tan X, 2013, BIOORG MED CHEM LETT, V23, P4547, DOI 10.1016/j.bmcl.2013.06.039; Teixeira TSP, 2011, BIOORG MED CHEM LETT, V21, P6112, DOI 10.1016/j.bmcl.2011.08.044; Telem DF, 2012, ARCH DERMATOL RES, V304, P251, DOI 10.1007/s00403-011-1195-z; Vasileiou Z, 2010, BIOPOLYMERS, V94, P339, DOI 10.1002/bip.21376; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Yamasaki K, 2007, NAT MED, V13, P975, DOI 10.1038/nm1616; Yousef GM, 2005, ADV CLIN CHEM, V39, P11, DOI 10.1016/S0065-2423(04)39002-5; Zhurinsky J, 2000, J CELL SCI, V113, P3127; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	121	41	45	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2014	134	4					808	815		10.1016/j.jaci.2014.07.061	http://dx.doi.org/10.1016/j.jaci.2014.07.061			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AQ9GC	25282561				2022-12-18	WOS:000343155700005
J	Maglione, PJ; Ko, HBM; Beasley, MB; Strauchen, JA; Cunningham-Rundles, C				Maglione, Paul J.; Ko, Huaibin M.; Beasley, Mary B.; Strauchen, James A.; Cunningham-Rundles, Charlotte			Tertiary lymphoid neogenesis is a component of pulmonary lymphoid hyperplasia in patients with common variable immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Common variable immunodeficiency; lymphoid neogenesis; chronic lung disease; pulmonary hyperplasia; germinal center; ectopic follicle	INTERSTITIAL LUNG-DISEASE; GERMINAL CENTER; SJOGRENS-SYNDROME; B-CELLS; MULTIPLE-SCLEROSIS; IMMUNE-DEFICIENCY; DISORDERS; RITUXIMAB; PNEUMONIA; THERAPY	Background: Despite reducing pneumonia and other infections, antibody replacement does not appear to treat pulmonary lymphoid hyperplasia (PLH) in patients with common variable immunodeficiency (CVID). The pathogenesis and optimal treatments remain to be clarified. Objective: We aimed to better understand the pathology of CVID-associated lung disease. Tertiary lymphoneogenesis, although a component of interstitial lung disease associated with autoimmune diseases, has not previously been explored in patients with CVID. Methods: We examined the clinical characteristics and pathologic findings of 6 patients with CVID with nodular/infiltrative lung disease who had biopsy specimens demonstrating PLH. Results: In these subjects regions of PLH contained distinct Band T-cell zones, with B-cell predominance in 1 patient and T-cell predominance in the others. Colocalization of Ki67, Bcl6, and CD23 within this ectopic lymphoid architecture demonstrated tertiary lymphoneogenesis with active centers of cellular proliferation. One patient received rituximab with improved pulmonary radiologic findings. Conclusion: Ectopic lymphoid tissue forming germinal centers suggest tertiary lymphoneogenesis inCVID-associated lung disease. B cell-targeted therapy might disrupt CVID-associated lymphoid hyperplasia.	[Maglione, Paul J.; Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Inst Immunol, New York, NY 10029 USA; [Maglione, Paul J.; Beasley, Mary B.; Strauchen, James A.; Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; [Ko, Huaibin M.; Beasley, Mary B.; Strauchen, James A.] Mt Sinai Sch Med, Dept Pathol, New York, NY 10029 USA; [Cunningham-Rundles, Charlotte] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Cunningham-Rundles, C (corresponding author), Mt Sinai Sch Med, Dept Med, Inst Immunol, 1425 Madison Ave, New York, NY 10029 USA.	Charlotte.Cunningham-Rundles@mssm.edu	Ko, Huai-Bin/AAO-2767-2020	Ko, Huai-Bin/0000-0003-1062-2383; Maglione, Paul J./0000-0001-6805-7271	Thrasher Research Fund Early Career Award; National Institutes of Health [AI 048693, AI 061093]; Jeffrey Modell Foundation; David S. Gottesman Immunology Chair; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI061093, R18AI048693] Funding Source: NIH RePORTER	Thrasher Research Fund Early Career Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jeffrey Modell Foundation; David S. Gottesman Immunology Chair; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Thrasher Research Fund Early Career Award, National Institutes of Health grants AI 048693 and AI 061093, the Jeffrey Modell Foundation, and the David S. Gottesman Immunology Chair.	Aghamohammadi A, 2010, RESPIROLOGY, V15, P289, DOI 10.1111/j.1440-1843.2009.01679.x; Ardeniz O, 2009, CLIN IMMUNOL, V133, P198, DOI 10.1016/j.clim.2009.05.001; Arish N, 2006, THORAX, V61, P1096, DOI 10.1136/thx.2004.029819; Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8; Bates CA, 2004, J ALLERGY CLIN IMMUN, V114, P415, DOI 10.1016/j.jaci.2004.05.057; Bondioni MP, 2010, J COMPUT ASSIST TOMO, V34, P395, DOI 10.1097/RCT.0b013e3181cad9da; Boursiquot JN, 2013, J CLIN IMMUNOL, V33, P84, DOI 10.1007/s10875-012-9778-9; Bouvry D, 2013, EUR RESPIR J, V41, P115, DOI 10.1183/09031936.00189011; Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, P1001, DOI 10.1067/mai.2002.124999; Chan AC, 2010, NAT REV IMMUNOL, V10, P301, DOI 10.1038/nri2761; Chapel H, 2008, BLOOD, V112, P277, DOI 10.1182/blood-2007-11-124545; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Chase NM, 2013, J CLIN IMMUNOL, V33, P30, DOI 10.1007/s10875-012-9755-3; da Silva SP, 2011, J CLIN IMMUNOL, V31, P784, DOI 10.1007/s10875-011-9565-z; Davies CWH, 2000, THORAX, V55, P88, DOI 10.1136/thorax.55.1.88; de Gracia J, 2004, INT IMMUNOPHARMACOL, V4, P745, DOI 10.1016/j.intimp.2004.02.011; Detkova D, 2007, CHEST, V131, P1883, DOI 10.1378/chest.06-2994; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534; Garcia MAM, 2001, RESP MED, V95, P191, DOI 10.1053/rmed.2000.1020; Glace B, 2012, ANN RHEUM DIS, V71, P1429, DOI 10.1136/annrheumdis-2011-200915; Gregersen S, 2010, ANN ALLERG ASTHMA IM, V104, P503, DOI 10.1016/j.anai.2010.04.015; Guinee DG, 2010, ARCH PATHOL LAB MED, V134, P691, DOI 10.1043/1543-2165-134.5.691; Hampson FA, 2012, CLIN RADIOL, V67, P587, DOI 10.1016/j.crad.2011.10.028; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; Keir GJ, 2012, EUR RESPIR J, V40, P641, DOI 10.1183/09031936.00163911; KOHLER PF, 1982, J ALLERGY CLIN IMMUN, V70, P299, DOI 10.1016/0091-6749(82)90066-5; KOSS MN, 1987, PATHOLOGY, V19, P178, DOI 10.3109/00313028709077131; Krautler NJ, 2012, CELL, V150, P194, DOI 10.1016/j.cell.2012.05.032; Lin JH, 2006, J ALLERGY CLIN IMMUN, V117, P878, DOI 10.1016/j.jaci.2006.01.034; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Malbran A, 2010, CLIN IMMUNOL, V134, P359, DOI 10.1016/j.clim.2009.11.014; Marie I, 2012, RESP MED, V106, P581, DOI 10.1016/j.rmed.2012.01.001; Okada T, 2012, IMMUNOL REV, V247, P120, DOI 10.1111/j.1600-065X.2012.01120.x; Orange JS, 2010, CLIN IMMUNOL, V137, P21, DOI 10.1016/j.clim.2010.06.012; Park CS, 2005, IMMUNOLOGY, V114, P2, DOI 10.1111/j.1365-2567.2004.02075.x; Park JH, 2010, CLIN IMMUNOL, V134, P97, DOI 10.1016/j.clim.2009.10.002; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Perez ERF, 2012, IMMUNOL ALLERGY CLIN, V32, P621, DOI 10.1016/j.iac.2012.08.003; Pijpe J, 2005, ARTHRITIS RHEUM-US, V52, P2740, DOI 10.1002/art.21260; POPA V, 1988, ANN ALLERGY, V60, P203; Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1; Randall TD, 2010, ADV IMMUNOL, V107, P187, DOI [10.1016/S0065-2776(10)07002-1, 10.1016/B978-0-12-381300-8.00007-1]; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Salomonsson S, 2003, ARTHRITIS RHEUM-US, V48, P3187, DOI 10.1002/art.11311; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Serafini B, 2004, BRAIN PATHOL, V14, P164, DOI 10.1111/j.1750-3639.2004.tb00049.x; Swartz MA, 2011, JCR-J CLIN RHEUMATOL, V17, P454, DOI 10.1097/RHU.0b013e31823ac199; Swigris JJ, 2002, CHEST, V122, P2150, DOI 10.1378/chest.122.6.2150; Takemura S, 2001, J IMMUNOL, V167, P1072, DOI 10.4049/jimmunol.167.2.1072; Tian XL, 2012, SEMIN RESP CRIT CARE, V33, P450, DOI 10.1055/s-0032-1325156; Touw CML, 2010, PEDIAT ALLERG IMM-UK, V21, P793, DOI 10.1111/j.1399-3038.2009.00963.x; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; WATTS WJ, 1986, AM REV RESPIR DIS, V134, P699; Yong PFK, 2011, ADV IMMUNOL, V111, P47, DOI 10.1016/B978-0-12-385991-4.00002-7	55	41	44	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					535	542		10.1016/j.jaci.2013.08.022	http://dx.doi.org/10.1016/j.jaci.2013.08.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24131823	Green Accepted			2022-12-18	WOS:000332397100030
J	Martins, TB; Bandhauer, ME; Bunker, AM; Roberts, WL; Hill, HR				Martins, Thomas B.; Bandhauer, Michael E.; Bunker, Ashley M.; Roberts, William L.; Hill, Harry R.			New childhood and adult reference intervals for total IgE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SERUM IGE; REFERENCE VALUES; POPULATION; ASSOCIATION; CHILDREN; ALLERGY; ASTHMA; ONSET; PRIST; ATOPY		[Martins, Thomas B.; Bandhauer, Michael E.; Bunker, Ashley M.; Roberts, William L.; Hill, Harry R.] Univ Utah, ARUP Inst Clin & Expt Pathol, Salt Lake City, UT 84112 USA; [Roberts, William L.] Univ Utah, Dept Pathol, Salt Lake City, UT USA; [Hill, Harry R.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA; [Hill, Harry R.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA; [Hill, Harry R.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; ARUP Laboratories; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Martins, TB (corresponding author), Univ Utah, ARUP Inst Clin & Expt Pathol, Salt Lake City, UT 84112 USA.	martintb@aruplab.com						BHALLA RB, 1982, ADV INTERPRETATION C, P295; Carsin AE, 2013, INT ARCH ALLERGY IMM, V160, P387, DOI 10.1159/000342464; Clinical and Laboratory Standards Institute, 2008, C28A3 CLSI; DATI F, 1982, CLIN CHEM, V28, P1556; Ezeamuzie CI, 1999, CLIN EXP ALLERGY, V29, P375; Harrop J, 2007, CLIN EXP ALLERGY, V37, P526, DOI 10.1111/j.1365-2222.2007.02679.x; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; Levin AM, 2013, J ALLERGY CLIN IMMUN, V131, P1176, DOI 10.1016/j.jaci.2012.10.002; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x	12	41	43	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					589	591		10.1016/j.jaci.2013.08.037	http://dx.doi.org/10.1016/j.jaci.2013.08.037			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC3EF	24139495				2022-12-18	WOS:000332397100041
J	Yao, TC; Du, GX; Han, LD; Sun, Y; Hu, DL; Yang, JJ; Mathias, R; Roth, LA; Rafaels, N; Thompson, EE; Loisel, DA; Anderson, R; Eng, C; Orbegozo, MA; Young, M; Klocksieben, JM; Anderson, E; Shanovich, K; Lester, LA; Williams, LK; Barnes, KC; Burchard, EG; Nicolae, DL; Abney, M; Ober, C				Yao, Tsung-Chieh; Du, Gaixin; Han, Lide; Sun, Ying; Hu, Donglei; Yang, James J.; Mathias, Rasika; Roth, Lindsey A.; Rafaels, Nicholas; Thompson, Emma E.; Loisel, Dagan A.; Anderson, Rebecca; Eng, Celeste; Orbegozo, Maitane Arruabarrena; Young, Melody; Klocksieben, James M.; Anderson, Elizabeth; Shanovich, Kathleen; Lester, Lucille A.; Williams, L. Keoki; Barnes, Kathleen C.; Burchard, Esteban G.; Nicolae, Dan L.; Abney, Mark; Ober, Carole			Genome-wide association study of lung function phenotypes in a founder population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						FEV1/FVC; FEV1; FVC; GWAS; LASSO regression; GRAIL	PULMONARY-FUNCTION; MISSING HERITABILITY; QUANTITATIVE TRAITS; CYSTIC-FIBROSIS; COMPLEX TRAITS; HUMAN HEIGHT; FAMILIAL AGGREGATION; GENERAL-POPULATION; ASTHMA; SAMPLE	Background: Lung function is a long-term predictor of mortality and morbidity. Objective: We sought to identify single nucleotide polymorphisms (SNPs) associated with lung function. Methods: We performed a genome-wide association study (GWAS) of FEV1, forced vital capacity (FVC), and FEV1/FVC in 1144 Hutterites aged 6 to 89 years, who are members of a founder population of European descent. We performed least absolute shrinkage and selection operation regression to select the minimum set of SNPs that best predict FEV1/FVC in the Hutterites and used the GRAIL algorithm to mine the Gene Ontology database for evidence of functional connections between genes near the predictive SNPs. Results: Our GWAS identified significant associations between FEV1/FVC and SNPs at the THSD4-UACA-TLE3 locus on chromosome 15q23 (P = 5.7 x 10(-8) to 3.4 x 10(-9)). Nine SNPs at or near 4 additional loci had P < 10(-5) with FEV1/FVC. Only 2 SNPs were found with P < 10(5)(-) for FEV1 or FVC. We found nominal levels of significance with SNPs at 9 of the 27 previously reported loci associated with lung function measures. Among a predictive set of 80 SNPs, 6 loci were identified that had a significant degree of functional connectivity (GRAIL P < .05), including 3 clusters of beta-defensin genes, 2 chemokine genes (CCL18 and CXCL12), and TNFRSF13B. Conclusion: This study identifies genome-wide significant associations and replicates results of previous GWASs. Multimarker modeling implicated for the first time common variation in genes involved in antimicrobial immunity in airway mucosa that influences lung function.	[Yao, Tsung-Chieh; Du, Gaixin; Han, Lide; Sun, Ying; Thompson, Emma E.; Loisel, Dagan A.; Anderson, Rebecca; Orbegozo, Maitane Arruabarrena; Nicolae, Dan L.; Abney, Mark; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Yao, Tsung-Chieh] Chang Gung Mem Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Tao Yuan 333, Taiwan; [Yao, Tsung-Chieh] Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; [Hu, Donglei; Roth, Lindsey A.; Eng, Celeste; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Yang, James J.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Mathias, Rasika; Rafaels, Nicholas; Barnes, Kathleen C.] Johns Hopkins Univ, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD USA; [Young, Melody; Lester, Lucille A.; Nicolae, Dan L.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Klocksieben, James M.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Anderson, Elizabeth; Shanovich, Kathleen] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Nicolae, Dan L.] Univ Chicago, Dept Stat, Chicago, IL 60637 USA	University of Chicago; Chang Gung Memorial Hospital; Chang Gung University; University of California System; University of California San Francisco; Henry Ford Health System; Henry Ford Hospital; Johns Hopkins University; University of Chicago; University of Chicago; University of Wisconsin System; University of Wisconsin Madison; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University of California System; University of California San Francisco; University of Chicago	Yao, TC (corresponding author), Chang Gung Mem Hosp, Dept Pediat, 5 Fu Hsin St, Tao Yuan 333, Taiwan.	yao@adm.cgmh.org.tw; c-ober@genetics.uchicago.edu	Du, Gaixin/M-9901-2014	Du, Gaixin/0000-0002-4616-7725; Ober, Carole/0000-0003-4626-9809; Nicolae, Dan/0000-0002-0918-4630	National Institutes of Health [R01 HL085197, R01 HG002899]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085197] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002899] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Supported by the National Institutes of Health grant R01 HL085197 (C.O.) and grant R01 HG002899 (M.A.).	Abney M, 2002, AM J HUM GENET, V70, P920, DOI 10.1086/339705; Abney M, 2001, AM J HUM GENET, V68, P1302, DOI 10.1086/320112; Andresen E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021898; ASTEMBORSKI JA, 1985, AM J MED GENET, V21, P741, DOI 10.1002/ajmg.1320210417; BEATY TH, 1987, GENET EPIDEMIOL, V4, P211, DOI 10.1002/gepi.1370040306; Bourgain C, 2004, GENETICS, V168, P2349, DOI 10.1534/genetics.104.031617; Bremer LA, 2008, HUM MOL GENET, V17, P2228, DOI 10.1093/hmg/ddn123; Burney PGJ, 2011, THORAX, V66, P49, DOI 10.1136/thx.2010.147041; Chang Y, 2010, FASEB J, V24, P5063, DOI 10.1096/fj.10-162560; Chen Y, 1996, GENET EPIDEMIOL, V13, P35, DOI 10.1002/(SICI)1098-2272(1996)13:1<35::AID-GEPI4>3.0.CO;2-5; COTCH MF, 1990, AM REV RESPIR DIS, V142, P1337, DOI 10.1164/ajrccm/142.6_Pt_1.1337; COULTAS DB, 1991, AM REV RESPIR DIS, V144, P770, DOI 10.1164/ajrccm/144.4.770; Crovella S, 2011, CLIN CHEM LAB MED, V49, P49, DOI 10.1515/CCLM.2011.023; Cusanovich DA, 2012, HUM MOL GENET, V21, P2111, DOI 10.1093/hmg/dds021; de los Campos G, 2010, NAT REV GENET, V11, P880, DOI 10.1038/nrg2898; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Dickens JA, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-146; Drumm ML, 2005, NEW ENGL J MED, V353, P1443, DOI 10.1056/NEJMoa051469; Eichler EE, 2010, NAT REV GENET, V11, P446, DOI 10.1038/nrg2809; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; GHIO AJ, 1989, CHEST, V96, P743, DOI 10.1378/chest.96.4.743; GIBSON JB, 1983, ANN HUM BIOL, V10, P547, DOI 10.1080/03014468300006771; Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284; Gudbjartsson DF, 2008, NAT GENET, V40, P609, DOI 10.1038/ng.122; Guo Wei, 2011, BMC Proc, V5 Suppl 9, pS12, DOI 10.1186/1753-6561-5-S9-S12; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Hieshima K, 1997, J IMMUNOL, V159, P1140; Hirschhorn JN, 2009, NEW ENGL J MED, V360, P1699, DOI 10.1056/NEJMp0808934; Hostetler J, 1974, HUTTERITE SOC; HUBERT HB, 1982, AM REV RESPIR DIS, V125, P409; Janzi M, 2012, GENES IMMUN, V13, P59, DOI 10.1038/gene.2011.55; Kochanek Kenneth D, 2011, Natl Vital Stat Rep, V59, P1; Kraft P, 2009, NEW ENGL J MED, V360, P1701, DOI 10.1056/NEJMp0810107; Kutalik Z, 2011, GENET EPIDEMIOL, V35, P341, DOI 10.1002/gepi.20582; Lee SH, 2011, AM J HUM GENET, V88, P294, DOI 10.1016/j.ajhg.2011.02.002; Lettre G, 2008, NAT GENET, V40, P584, DOI 10.1038/ng.125; Levy H, 2005, J ALLERGY CLIN IMMUN, V115, P252, DOI 10.1016/j.jaci.2004.11.013; LEWITTER FI, 1984, AM J EPIDEMIOL, V120, P518, DOI 10.1093/oxfordjournals.aje.a113912; Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a; Makowsky R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002051; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; MCCLEARN GE, 1994, J GERONTOL, V49, pM264, DOI 10.1093/geronj/49.6.M264; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Myint PK, 2005, EUR RESPIR J, V26, P494, DOI 10.1183/09031936.05.00023605; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1998, CLIN EXP ALLERGY, V28, P101; Ober C, 2001, AM J HUM GENET, V69, P1068, DOI 10.1086/324025; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Ober C, 2009, J LIPID RES, V50, P798, DOI 10.1194/jlr.M800515-JLR200; Palmer LJ, 2001, EUR RESPIR J, V17, P696, DOI 10.1183/09031936.01.17406960; Palmer LJ, 2000, EUR J HUM GENET, V8, P853, DOI 10.1038/sj.ejhg.5200551; Polverino F, 2010, AM J RESP CRIT CARE, V182, P1011, DOI 10.1164/rccm.200911-1700OC; Raychaudhuri S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000534; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Schunemann HJ, 2000, CHEST, V118, P656, DOI 10.1378/chest.118.3.656; Soler Artigas M, 2011, NAT GENET, V43, P1082, DOI 10.1038/ng.941; STEINBERG ARTHUR G., 1967, P267; Tecle T, 2010, INNATE IMMUN-LONDON, V16, P151, DOI 10.1177/1753425910365734; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Visscher PM, 2008, NAT GENET, V40, P489, DOI 10.1038/ng0508-489; Weedon MN, 2008, NAT GENET, V40, P575, DOI 10.1038/ng.121; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726; WEISS ST, 1995, AM J EPIDEMIOL, V142, P493, DOI 10.1093/oxfordjournals.aje.a117665; Wilk JB, 2000, GENET EPIDEMIOL, V19, P81, DOI 10.1002/1098-2272(200007)19:1<81::AID-GEPI6>3.0.CO;2-8; Wu TT, 2009, BIOINFORMATICS, V25, P714, DOI 10.1093/bioinformatics/btp041; Xu JG, 2007, AM J RESP CELL MOL, V37, P291, DOI 10.1165/rcmb.2006-0187OC; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608; Young RP, 2007, EUR RESPIR J, V30, P616, DOI 10.1183/09031936.00021707	69	41	41	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					248	+		10.1016/j.jaci.2013.06.018	http://dx.doi.org/10.1016/j.jaci.2013.06.018			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23932459	Green Accepted			2022-12-18	WOS:000329105700033
J	Leung, J; Hundal, NV; Katz, AJ; Shreffler, WG; Yuan, Q; Butterworth, CA; Hesterberg, PE				Leung, John; Hundal, Navneet Virk; Katz, Aubrey J.; Shreffler, Wayne G.; Yuan, Qian; Butterworth, Carolyn A.; Hesterberg, Paul E.			Tolerance of baked milk in patients with cow's milk-mediated eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ELIMINATION DIET; CHILDREN; ALLERGY		[Leung, John; Shreffler, Wayne G.; Hesterberg, Paul E.] Massachusetts Gen Hosp, Dept Allergy & Immunol, Boston, MA 02114 USA; [Hundal, Navneet Virk; Katz, Aubrey J.; Yuan, Qian; Butterworth, Carolyn A.] Massachusetts Gen Hosp, Dept Pediat Gastroenterol & Nutr, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Leung, J (corresponding author), Massachusetts Gen Hosp, Dept Allergy & Immunol, Boston, MA 02114 USA.	phesterberg@partners.org			NIAID NIH HHS [U19 AI095261] Funding Source: Medline; NIDDK NIH HHS [P30 DK040561] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cummings AJ, 2010, ALLERGY, V65, P933, DOI 10.1111/j.1398-9995.2010.02342.x; Kagalwalla AF, 2012, J PEDIATR GASTR NUTR, V55, P711, DOI 10.1097/MPG.0b013e318268da40; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lucendo AJ, 2013, J ALLERGY CLIN IMMUN, V131, P797, DOI 10.1016/j.jaci.2012.12.664; Medeiros Lilian C. S., 2004, J. Pediatr. (Rio J.), V80, P363, DOI 10.1590/S0021-75572004000600006; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P234, DOI 10.1097/ACI.0b013e32832b88e7; Vicario M, 2010, GUT, V59, P12, DOI 10.1136/gut.2009.178020	9	41	42	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1215	1216		10.1016/j.jaci.2013.08.017	http://dx.doi.org/10.1016/j.jaci.2013.08.017			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24084076	Green Accepted			2022-12-18	WOS:000326235600024
J	Shamji, MH; Francis, JN; Wurtzen, PA; Lund, K; Durham, SR; Till, SJ				Shamji, Mohamed H.; Francis, James N.; Wuertzen, Peter A.; Lund, Kaare; Durham, Stephen R.; Till, Stephen J.			Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: Inhibition by blocking antibody responses after immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							GRASS-POLLEN IMMUNOTHERAPY; BINDING		[Shamji, Mohamed H.; Francis, James N.; Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol, Natl Heart & Lung Inst, Fac Med, London, England; [Wuertzen, Peter A.; Lund, Kaare] ALK Abello, Horsholm, Denmark; [Till, Stephen J.] Kings Coll London, Div Asthma Allergy & Lung Biol, Sch Med, Guys Hosp, London, England; [Shamji, Mohamed H.; Francis, James N.; Durham, Stephen R.; Till, Stephen J.] MRC, London, England; [Shamji, Mohamed H.; Francis, James N.; Durham, Stephen R.; Till, Stephen J.] Asthma UK Ctr Allerg Mech Asthma, London, England	Imperial College London; ALK-Abello AS; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London	Shamji, MH (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol, Natl Heart & Lung Inst, Fac Med, London, England.	stephen.till@kcl.ac.uk	Shamji, Mohamed/AAU-8811-2020; Shamji, Mohamed/AAD-1788-2019	Shamji, Mohamed/0000-0003-3425-3463; Till, Stephen/0000-0003-4518-3093	MRC [G0601303, G0200485] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council Funding Source: Medline; Medical Research Council [G0601303, G0200485, G1000758] Funding Source: Medline; Medical Research Council [G1000758B] Funding Source: researchfish; Asthma UK [MRC-AsthmaUKCentre] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK		Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Hibbert RG, 2005, J EXP MED, V202, P751, DOI 10.1084/jem.20050811; Holm J, 2011, J ALLERGY CLIN IMMUN, V127, P1029, DOI 10.1016/j.jaci.2011.01.062; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Willumsen N, 2012, CLIN EXP ALLERGY, V42, P1227, DOI 10.1111/j.1365-2222.2012.04009.x	9	41	41	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2013	132	4					1003	+		10.1016/j.jaci.2013.05.025	http://dx.doi.org/10.1016/j.jaci.2013.05.025			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	227FR	23827773				2022-12-18	WOS:000325096500039
J	Krause, K; Mahamed, A; Weller, K; Metz, M; Zuberbier, T; Maurer, M				Krause, Karoline; Mahamed, Aos; Weller, Karsten; Metz, Martin; Zuberbier, Torsten; Maurer, Marcus			Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PERIODIC SYNDROMES; ANTAGONIST; DISEASE; PATIENT		[Krause, Karoline; Mahamed, Aos; Weller, Karsten; Metz, Martin; Zuberbier, Torsten; Maurer, Marcus] Charite, Allergie Ctr Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Krause, Karoline; Zuberbier, Torsten; Maurer, Marcus] Charite, Autoinflammat Reference Ctr Charite, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Krause, K (corresponding author), Charite, Allergie Ctr Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany.	marcus.maurer@charite.de	Metz, Martin/M-5237-2013; Maurer, Marcus/ABG-2174-2020; Krause, Karoline/G-5218-2018; Metz, Martin/B-8799-2009	Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Krause, Karoline/0000-0001-9711-9654; Metz, Martin/0000-0002-4070-9976; Weller, Karsten/0000-0003-4437-0313				Besbas N, 1997, SCAND J RHEUMATOL, V26, P456, DOI 10.3109/03009749709065719; Botsios C, 2007, SCAND J RHEUMATOL, V36, P236, DOI 10.1080/03009740600938647; Direskeneli H, 2006, RHEUMATOLOGY, V45, P1461, DOI 10.1093/rheumatology/kel329; Hoffman HM, 2008, CURR MED RES OPIN, V24, P2531, DOI [10.1185/03007990802297495, 10.1185/03007990802297495 ]; Lachmann HJ, 2009, J EXP MED, V206, P1029, DOI 10.1084/jem.20082481; Lewis V, 2004, J INVEST DERM SYMP P, V9, P169, DOI 10.1111/j.1087-0024.2004.09113.x; Makol A, 2012, JCR-J CLIN RHEUMATOL, V18, P92, DOI 10.1097/RHU.0b013e31823ecd73; Shikiar Richard, 2005, Health Qual Life Outcomes, V3, P36, DOI 10.1186/1477-7525-3-36; Venzor J, 2002, CLIN REV ALLERG IMMU, V23, P201, DOI 10.1385/CRIAI:23:2:201	9	41	41	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					751	754		10.1016/j.jaci.2013.04.008	http://dx.doi.org/10.1016/j.jaci.2013.04.008			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23711544				2022-12-18	WOS:000323612000033
J	Sugawara, K; Zakany, N; Hundt, T; Emelianov, V; Tsuruta, D; Schafer, C; Kloepper, JE; Biro, T; Paus, R				Sugawara, Koji; Zakany, Nora; Hundt, Torsten; Emelianov, Vladimir; Tsuruta, Daisuke; Schaefer, Christian; Kloepper, Jennifer E.; Biro, Tamas; Paus, Ralf			Cannabinoid receptor 1 controls human mucosal-type mast cell degranulation and maturation in situ	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Nasal polyp; mucosa; organ culture; endocannabinoid; cannabinoid receptor; mast cell; stem cell factor; c-Kit; tryptase; chymase	HUMAN HAIR FOLLICLE; HUMAN NASAL-MUCOSA; ALLERGIC RHINITIS; BRONCHIAL-MUCOSA; SUBSTANCE-P; CHRONIC RHINOSINUSITIS; AIRWAY INFLAMMATION; HUMAN SKIN; ASTHMA; EXPRESSION	Background: Because many chronic inflammatory and allergic disorders are intimately linked to excessive mast cell (MC) numbers and activation, it is clinically important to understand the physiologic mechanisms preventing excess MC accumulation/degranulation in normal human tissues. Objective: Because endocannabinoids are increasingly recognized as neuroendocrine regulators of MC biology, we investigated how cannabinoid receptor (CB) 1 signaling affects human mucosal-type mast cells (hMMCs). Methods: Using organ-cultured nasal polyps as a surrogate tissue for human bronchial mucosa, we investigated how CB1 stimulation, inhibition, or knockdown affects hMMC biology using quantitative (immuno) histomorphometry and electron microscopy. Results: Kit 1 hMMCs express functional CB1 in situ. Blockade of CB1 signaling (with the specific CB1 antagonist N-(piperidin1- yl)-1-(2,4-dichlorophenyl)-5-(4-chlorophenyl)-4-methyl-1Hpyrazole- 3-carboxamide [AM251] or CB1 gene knockdown) enhanced hMMC degranulation and increased total numbers without affecting their proliferation in situ. This suggests that inhibiting CB1 signaling induces hMMC maturation from resident progenitor cells within human mucosal stroma. hMMC maturation was induced at least in part through upregulating stem cell factor production. Both the prototypic endocannabinoid anandamide and the CB1-selective agonist arachidonyl-2-chloroethylamide effectively counteracted secretagogue-triggered excessive hMMC degranulation. Conclusions: The current serum-free nasal polyp organ culture model allows physiologically and clinically relevant insights into the biology and pharmacologic responses of primary hMMCs in situ. In human airway mucosa hMMC activation and maturation are subject to a potent inhibitory endocannabinoid tone through CB1 stimulation. This invites one to target the endocannabinoid system in human airway mucosa as a novel strategy in the future management of allergic diseases.	[Sugawara, Koji; Zakany, Nora; Hundt, Torsten; Emelianov, Vladimir; Kloepper, Jennifer E.; Paus, Ralf] Univ Lubeck, Dept Dermatol, Lubeck, Germany; [Sugawara, Koji; Tsuruta, Daisuke] Osaka City Univ, Grad Sch Med, Dept Dermatol, Osaka 5458585, Japan; [Zakany, Nora; Biro, Tamas] Univ Debrecen, DE MTA Lendulet Cellular Physiol Res Grp, Dept Physiol, RCMM,MHSC, Debrecen, Hungary; [Schaefer, Christian] Schuesselbuden, ENT Clin Lubeck, Lubeck, Germany; [Paus, Ralf] Univ Manchester, Salford Royal NHS Fdn Trust, Inst Inflammat & Repair, Dermatol Ctr, Manchester M13 9PL, Lancs, England	University of Lubeck; Osaka Metropolitan University; University of Debrecen; Salford Royal NHS Foundation Trust; University of Manchester	Sugawara, K (corresponding author), Osaka City Univ, Grad Sch Med, Dept Dermatol, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	kojilaminin@yahoo.co.jp	Kloepper, Jennifer E/B-7403-2015; Hundt, Jennifer/AAU-4504-2020; Paus, Ralf/B-5279-2015	Paus, Ralf/0000-0002-3492-9358; Sugawara, Koji/0000-0003-1662-3272	Deutsche Forschungsgemeinschaft (DFG) [GRK 1722]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	Supported in part by a grant from Deutsche Forschungsgemeinschaft (DFG, GRK 1722; to R.P.).	Abramson J, 2007, IMMUNOL REV, V217, P231, DOI 10.1111/j.1600-065X.2007.00518.x; Akimoto S, 1998, BRIT J DERMATOL, V138, P399; Arck P, 2010, EXP DERMATOL, V19, P401, DOI 10.1111/j.1600-0625.2009.01060.x; Barnes PJ, 2011, IMMUNOL REV, V242, P31, DOI 10.1111/j.1600-065X.2011.01020.x; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Biro T, 2009, TRENDS PHARMACOL SCI, V30, P411, DOI 10.1016/j.tips.2009.05.004; Braunstahl GJ, 2001, AM J RESP CRIT CARE, V164, P858, DOI 10.1164/ajrccm.164.5.2006082; Cantarella G, 2011, BIOCHEM PHARMACOL, V82, P380, DOI 10.1016/j.bcp.2011.05.004; Cerrato S, 2010, VET IMMUNOL IMMUNOP, V133, P9, DOI 10.1016/j.vetimm.2009.06.011; De Filippis D, 2008, J NEUROENDOCRINOL, V20, P20, DOI 10.1111/j.1365-2826.2008.01674.x; DeMarcantonio MA, 2011, OTOLARYNG CLIN N AM, V44, P685, DOI 10.1016/j.otc.2011.03.005; Di Marzo V, 2011, HANDB EXP PHARMACOL, V203, P75, DOI 10.1007/978-3-642-17214-4_4; Dinh Q T, 2011, Pneumologie, V65, P283, DOI 10.1055/s-0030-1256123; Dobrosi N, 2008, FASEB J, V22, P3685, DOI 10.1096/fj.07-104877; DVORAK AM, 1991, BLOOD, V77, P569; Elishmereni M, 2011, ALLERGY, V66, P376, DOI 10.1111/j.1398-9995.2010.02494.x; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Galli SJ, 2010, EUR J IMMUNOL, V40, P1843, DOI 10.1002/eji.201040559; Giannini L, 2008, J CELL MOL MED, V12, P2381, DOI 10.1111/j.1582-4934.2008.00258.x; Gibbs BF, 2001, METH MOLEC MED, V56, P161, DOI 10.1385/1-59259-151-5:161; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; Hellings PW, 2001, CLIN EXP ALLERGY, V31, P782, DOI 10.1046/j.1365-2222.2001.01081.x; Hennino A, 2006, CLIN REV ALLERG IMMU, V30, P3, DOI 10.1385/CRIAI:30:1:003; Howl J, 2003, CHEMBIOCHEM, V4, P1312, DOI 10.1002/cbic.200300694; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Ito N, 2010, J INVEST DERMATOL, V130, P995, DOI 10.1038/jid.2009.387; Jogie-Brahim S, 2004, J ALLERGY CLIN IMMUN, V113, P1086, DOI 10.1016/j.jaci.2004.02.032; JOOS GF, 1989, CLIN EXP ALLERGY, V19, P9; Koh YI, 2002, INT ARCH ALLERGY IMM, V129, P341, DOI 10.1159/000067593; Lamb JP, 2002, AM J RESP CRIT CARE, V166, P1269, DOI 10.1164/rccm.2112018; Liu CX, 2010, MOL BIOL REP, V37, P1993, DOI 10.1007/s11033-009-9650-z; Liu J, 2008, NEUROPHARMACOLOGY, V54, P1, DOI 10.1016/j.neuropharm.2007.05.020; Lu ZF, 2007, EXP DERMATOL, V16, P37, DOI 10.1111/j.1600-0625.2006.00510.x; Martinez-Suastegui L, 2011, ANN BIOMED ENG, V39, P636, DOI 10.1007/s10439-010-0186-0; Moon TC, 2010, MUCOSAL IMMUNOL, V3, P111, DOI 10.1038/mi.2009.136; Nascimento NG, 2010, TOXICON, V55, P343, DOI 10.1016/j.toxicon.2009.08.009; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Ohnmacht C, 2009, BLOOD, V113, P2816, DOI 10.1182/blood-2008-05-154773; Okayama Y, 2007, CURR OPIN IMMUNOL, V19, P687, DOI 10.1016/j.coi.2007.07.018; Okuda M, 1999, ALLERGY, V54, P50, DOI 10.1111/j.1398-9995.1999.tb04406.x; OTSUKA H, 1995, J ALLERGY CLIN IMMUN, V96, P528, DOI 10.1016/S0091-6749(95)70297-0; Otsuka H, 1998, J ALLERGY CLIN IMMUN, V102, P757, DOI 10.1016/S0091-6749(98)70015-6; Patou J, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-11; Pawankar R, 2003, CURR OPIN ALLERGY CL, V3, P1, DOI 10.1097/01.all.0000053260.61007.d6; Pertwee RG, 2010, PHARMACOL REV, V62, P588, DOI 10.1124/pr.110.003004; Peters EMJ, 2007, AM J PATHOL, V171, P1872, DOI 10.2353/ajpath.2007.061206; Qi JC, 2003, J HISTOCHEM CYTOCHEM, V51, P643, DOI 10.1177/002215540305100510; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; SCHIERHORN K, 1995, INT ARCH ALLERGY IMM, V107, P109, DOI 10.1159/000236946; SCHIERHORN K, 1995, IN VITRO CELL DEV-AN, V31, P215; Solinas M, 2008, BRIT J PHARMACOL, V154, P369, DOI 10.1038/bjp.2008.130; Soundararajan A, 2011, RADIOLOGY, V261, P813, DOI 10.1148/radiol.11110361; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Sugawara K, 2012, J ALLERGY CLIN IMMUN, V129, P726, DOI 10.1016/j.jaci.2011.11.009; Sugawara K, 2007, J HISTOCHEM CYTOCHEM, V55, P43, DOI 10.1369/jhc.6A6920.2006; Takabayashi T, 2012, J ALLERGY CLIN IMMUN, V130, P410, DOI 10.1016/j.jaci.2012.02.046; Tan BK, 2011, INT FORUM ALLERGY RH, V1, P88, DOI 10.1002/alr.20025; Telek A, 2007, FASEB J, V21, P3534, DOI 10.1096/fj.06-7689com; Theoharides TC, 2012, ANN ALLERG ASTHMA IM, V109, P14, DOI 10.1016/j.anai.2012.03.003; Verbruggen K, 2009, INT ARCH ALLERGY IMM, V148, P87, DOI 10.1159/000155739; WEISENTHAL LM, 1983, CANCER RES, V43, P749; Welker P, 2000, J INVEST DERMATOL, V114, P44, DOI 10.1046/j.1523-1747.2000.00827.x; Xing W, 2011, P NATL ACAD SCI USA, V108, P14210, DOI 10.1073/pnas.1111048108; Zhang GM, 2012, ANAT REC, V295, P758, DOI 10.1002/ar.22430	64	41	42	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2013	132	1					182	U307		10.1016/j.jaci.2013.01.002	http://dx.doi.org/10.1016/j.jaci.2013.01.002			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	173BF	23453134	Bronze			2022-12-18	WOS:000321052300023
J	Li, JN; Wang, Y; Tang, LH; de Villiers, WJS; Cohen, D; Woodward, J; Finkelman, FD; Eckhardt, ERM				Li, Jianing; Wang, Yu; Tang, Lihua; de Villiers, Willem J. S.; Cohen, Donald; Woodward, Jerold; Finkelman, Fred D.; Eckhardt, Erik R. M.			Dietary medium-chain triglycerides promote oral allergic sensitization and orally induced anaphylaxis to peanut protein in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; triglycerides; thymic stromal lymphopoietin; adjuvant; chylomicrons; intestinal epithelium; T(H)2 responses	THYMIC STROMAL LYMPHOPOIETIN; FOOD ALLERGY; T-CELLS; IN-VIVO; TOLERANCE; ANTIGEN; ACID; PREVALENCE; RAT; MACROPHAGES	Background: The prevalence of peanut allergies is increasing. Peanuts and many other allergen sources contain significant amounts of triglycerides, which affect absorption of antigens but have unknown effects on sensitization and anaphylaxis. We recently reported that dietary medium-chain triglycerides (MCTs), which bypass mesenteric lymph and directly enter portal blood, reduce intestinal antigen absorption into blood compared with long-chain triglycerides (LCTs), which stimulate mesenteric lymph flow and are absorbed in chylomicrons through mesenteric lymph. Objective: We sought to test how dietary MCTs affect food allergy. Methods: C3H/HeJ mice were fed peanut butter protein in MCT, LCT (peanut oil), or LCT plus an inhibitor of chylomicron formation (Pluronic L81). Peanut-specific antibodies in plasma, responses of the mice to antigen challenges, and intestinal epithelial cytokine expression were subsequently measured. Results: MCT suppressed antigen absorption into blood but stimulated absorption into Peyer patches. A single gavage of peanut protein with MCT, as well as prolonged feeding in MCT-based diets, caused spontaneous allergic sensitization. MCT-sensitized mice experienced IgG-dependent anaphylaxis on systemic challenge and IgE-dependent anaphylaxis on oral challenge. MCT feeding stimulated jejunal-epithelial thymic stromal lymphopoietin, Il25, and Il33 expression compared with that seen after LCT feeding and promoted T(H)2 cytokine responses in splenocytes. Moreover, oral challenges of sensitized mice with antigen in MCT significantly aggravated anaphylaxis compared with challenges with the LCT. Importantly, the effects of MCTs could be mimicked by adding Pluronic L81 to LCTs, and in vitro assays indicated that chylomicrons prevent basophil activation. Conclusion: Dietary MCTs promote allergic sensitization and anaphylaxis by affecting antigen absorption and availability and by stimulating T(H)2 responses. (J Allergy Clin Immunol 2013;131:442-50.)	[Li, Jianing; Wang, Yu; Tang, Lihua; de Villiers, Willem J. S.; Eckhardt, Erik R. M.] Univ Kentucky, Div Digest Dis & Nutr, Grad Ctr Nutr Sci, Lexington, KY USA; [Li, Jianing; Wang, Yu; Tang, Lihua; de Villiers, Willem J. S.; Eckhardt, Erik R. M.] Univ Kentucky, Div Digest Dis & Nutr, Dept Internal Med, Lexington, KY USA; [Cohen, Donald; Woodward, Jerold; Eckhardt, Erik R. M.] Univ Kentucky, Dept Immunol Microbiol & Mol Genet, Lexington, KY USA; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Dept Med, Cincinnati, OH 45221 USA; [Finkelman, Fred D.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH USA	University of Kentucky; University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Eckhardt, ERM (corresponding author), Grad Ctr Nutr Sci, 588 Charles T Wethington Bldg,900 S Limestone, Lexington, KY 40536 USA.	erikeckhardt@live.com		Eckhardt, Erik/0000-0002-3015-5180	National Institutes of Health [5R21AI088605-02, 5P20RR021954-03]; US Department of Veterans Affairs; National Institutes of Health (NIH); NIH; Abbott; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR021954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI088605, R21AI103816] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Abbott(Abbott Laboratories); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants 5R21AI088605-02 and 5P20RR021954-03 (to E. R. M. E.) and a Merit Award from the US Department of Veterans Affairs (to F.D.F.).; J. Li has received research support and travel support from the National Institutes of Health (NIH). J. Woodward and E. R. M. Eckhardt have received research support from the NIH. F. D. Finkelman has received consultancy fees from Abbott and has a preliminary patent from the University of Cincinnati. The rest of the authors declare that they have no relevant conflicts of interest.	BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Blazquez AB, 2010, GASTROENTEROLOGY, V139, P1301, DOI 10.1053/j.gastro.2010.06.055; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; BRYAN H, 1976, PEDIATRICS, V58, P787; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; De Pascale C, 2009, FEBS J, V276, P5689, DOI 10.1111/j.1742-4658.2009.07260.x; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Elias KM, 2008, BLOOD, V111, P1013, DOI 10.1182/blood-2007-06-096438; Finkelman FD, 2010, CURR OPIN IMMUNOL, V22, P783, DOI 10.1016/j.coi.2010.10.005; Fujihashi K, 2001, P NATL ACAD SCI USA, V98, P3310, DOI 10.1073/pnas.061412598; Ghoshal S, 2009, J LIPID RES, V50, P90, DOI 10.1194/jlr.M800156-JLR200; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Harrison EH, 2001, J NUTR, V131, P1405, DOI 10.1093/jn/131.5.1405; Heyman M, 2005, EUR J GASTROEN HEPAT, V17, P1279, DOI 10.1097/00042737-200512000-00003; Hoshimoto A, 2002, BRIT J PHARMACOL, V136, P280, DOI 10.1038/sj.bjp.0704719; Humphreys NE, 2008, J IMMUNOL, V180, P2443, DOI 10.4049/jimmunol.180.4.2443; Khodoun M, 2009, J ALLERGY CLIN IMMUN, V123, P342, DOI 10.1016/j.jaci.2008.11.004; KVIETYS PR, 1991, AM J PHYSIOL, V261, pG384, DOI 10.1152/ajpgi.1991.261.3.G384; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Okumura T, 2006, J ATHEROSCLER THROMB, V13, P38, DOI 10.5551/jat.13.38; Proust B, 2008, INT ARCH ALLERGY IMM, V146, P212, DOI 10.1159/000115889; Qualls JE, 2006, J LEUKOCYTE BIOL, V80, P802, DOI 10.1189/jlb.1205734; ROBINSON SF, 1979, LIPIDS, V14, P343, DOI 10.1007/BF02533417; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Suzuki H, 2008, GASTROENTEROLOGY, V135, P917, DOI 10.1053/j.gastro.2008.05.037; Taylor BC, 2009, J EXP MED, V206, P655, DOI 10.1084/jem.20081499; TSO P, 1981, AM J PHYSIOL, V241, pG487, DOI 10.1152/ajpgi.1981.241.6.G487; Vickery BP, 2009, CURR OPIN ALLERGY CL, V9, P364, DOI 10.1097/ACI.0b013e32832d9add; Wang YH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008442; Yoshida H, 2001, J NUTR, V131, P2943, DOI 10.1093/jn/131.11.2943; Zhao AP, 2010, J IMMUNOL, V185, P6921, DOI 10.4049/jimmunol.1000450; Ziegler SF, 2010, CURR OPIN IMMUNOL, V22, P795, DOI 10.1016/j.coi.2010.10.020	37	41	42	0	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					442	450		10.1016/j.jaci.2012.10.011	http://dx.doi.org/10.1016/j.jaci.2012.10.011			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	23182172	Green Accepted			2022-12-18	WOS:000314661500023
J	Sturm, GJ; Bilo, MB; Bonadonna, P; Hemmer, W; Caruso, B; Bokanovic, D; Aberer, W				Sturm, Gunter J.; Bilo, Maria Beatrice; Bonadonna, Patrizia; Hemmer, Wolfgang; Caruso, Beatrice; Bokanovic, Danijela; Aberer, Werner			Ves v 5 can establish the diagnosis in patients without detectable specific IgE to wasp venom and a possible north-south difference in Api m 1 sensitization in Europe	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							DISTINGUISH BEE; VESPULA VENOM; ALLERGY; SENSITIVITY; SUFFICIENT		[Sturm, Gunter J.; Bokanovic, Danijela; Aberer, Werner] Med Univ Graz, Div Environm Dermatol & Venerol, Dept Dermatol, Graz, Austria; [Bilo, Maria Beatrice] Univ Hosp Osped Riuniti Ancona, Dept Allergy Immunol & Resp Dis, Ancona, Italy; [Bonadonna, Patrizia] Azienda Osped Univ Integrata, Allergy Unit, Verona, Italy; [Hemmer, Wolfgang] Floridsdorf Allergy Ctr, Vienna, Austria; [Caruso, Beatrice] Azienda Osped Univ Integrata, Dept Clin Chem & Haematol, Verona, Italy	Medical University of Graz; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Sturm, GJ (corresponding author), Med Univ Graz, Div Environm Dermatol & Venerol, Dept Dermatol, Graz, Austria.	gunter.sturm@medunigraz.at	Caruso, Beatrice/C-7528-2017	Caruso, Beatrice/0000-0003-2291-4025				Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V128, P248, DOI 10.1016/j.jaci.2011.02.020; Hofmann SC, 2011, J ALLERGY CLIN IMMUN, V127, P265, DOI 10.1016/j.jaci.2010.06.042; Korosec P, 2012, J ALLERGY CLIN IMMUN, V129, P1406, DOI 10.1016/j.jaci.2011.12.975; Korosec P, 2011, J ALLERGY CLIN IMMUN, V128, P671, DOI 10.1016/j.jaci.2011.03.012; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Sturm GJ, 2011, J ALLERGY CLIN IMMUN, V128, P247, DOI 10.1016/j.jaci.2011.02.021	6	41	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					817	817		10.1016/j.jaci.2012.05.047	http://dx.doi.org/10.1016/j.jaci.2012.05.047			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22795371				2022-12-18	WOS:000308463500037
J	Spycher, BD; Henderson, J; Granell, R; Evans, DM; Smith, GD; Timpson, NJ; Sterne, JAC				Spycher, Ben D.; Henderson, John; Granell, Raquel; Evans, David M.; Smith, George Davey; Timpson, Nicholas J.; Sterne, Jonathan A. C.			Genome-wide prediction of childhood asthma and related phenotypes in a longitudinal birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory sounds; hypersensitivity; respiratory function tests; genome-wide association study; forecasting	1ST 6 YEARS; GENETIC-ANALYSIS; LUNG-FUNCTION; ASSOCIATION; CHILDREN; VARIANTS; 17Q21; ATOPY; HERITABILITY; DISEASE	Background: Childhood wheezing and asthma vary greatly in clinical presentation and time course. The extent to which phenotypic variation reflects heterogeneity in disease pathways is unclear. Objective: We sought to assess the extent to which single nucleotide polymorphisms (SNPs) associated with childhood asthma in a genome-wide association study are predictive of asthma-related phenotypes. Methods: In 8365 children from a population-based birth cohort, the Avon Longitudinal Study of Parents and Children, allelic scores were derived based on between 10 and 215,443 SNPs ranked according to the inverse of the P value for their association with physician-diagnosed asthma in an independent genome-wide association study (6176 cases and 7111 control subjects). We assessed the predictive value of allelic scores for asthma-related outcomes at age 7 to 9 years (physician's diagnosis, longitudinal wheezing phenotypes, and measurements of pulmonary function, bronchial responsiveness, and atopy). Results: Scores based on the 46 highest-ranked SNPs were associated with the symptom-based phenotypes early onset persistent wheeze (P < 10(-11); area under the receiver operating characteristic curve [AUC], 0.59) and intermediate-onset wheeze (P < 10(-3); AUC, 0.58). Among lower-ranked SNPs (ranks, 21,545-46,416), there was evidence for associations with diagnosed asthma ( P < 10(-4); AUC, 0.54) and atopy ( P < 10(-5); AUC, 0.55). We found little evidence of associations with transient early wheezing, reduced pulmonary function, or nonasthma phenotypes. Conclusion: The genetic origins of asthma are diverse, and some pathways are specific to wheezing syndromes, whereas others are shared with atopy and bronchial hyperresponsiveness. Our study also provides evidence of etiologic differences among wheezing syndromes. (J Allergy Clin Immunol 2012; 130:503-9.)	[Spycher, Ben D.; Henderson, John; Granell, Raquel; Evans, David M.; Smith, George Davey; Timpson, Nicholas J.; Sterne, Jonathan A. C.] Univ Bristol, Sch Social & Community Med, Bristol BS8 2PS, Avon, England; [Spycher, Ben D.] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland	University of Bristol; University of Bern	Sterne, JAC (corresponding author), Univ Bristol, Sch Social & Community Med, Canynge Hall,39 Whatley Rd, Bristol BS8 2PS, Avon, England.	jonathan.sterne@bristol.ac.uk	Fox, Laura J/C-6249-2016; Sterne, Jonathan/Z-3106-2019; Granell, Raquel/AAB-5256-2022; Attrill, Lauren/V-1688-2018; Spycher, Ben D/B-3308-2008; Timpson, Nicholas John/O-7548-2015; Evans, David M/H-6325-2013; Granell, Raquel/AAY-4846-2020; Davey Smith, George/A-7407-2013	Sterne, Jonathan/0000-0001-8496-6053; Granell, Raquel/0000-0002-4890-4012; Spycher, Ben D/0000-0002-1430-5695; Timpson, Nicholas John/0000-0002-7141-9189; Evans, David M/0000-0003-0663-4621; Davey Smith, George/0000-0002-1407-8314; s, hema/0000-0002-3440-9475; Venkatasubramanian, Siddharth/0000-0002-5860-0768	UK Medical Research Council; Wellcome Trust [092731, WT084703MA]; European Respiratory Society/Marie Curie Joint Research Fellowship [MC 1614-2010]; European Respiratory Society; European Community [PCOFUND-GA-2008-229571]; UK Medical Research Council [0401540]; European Commission [018996]; French Ministry of Research; Asthma UK; Medical Research Council; MRC [G0600705, G0401540, G0800582, G0902125] Funding Source: UKRI; Medical Research Council [G0800582, G0600705, G9815508, G0401540, G0902125] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10168] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); European Respiratory Society/Marie Curie Joint Research Fellowship; European Respiratory Society; European Community(European Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Commission(European CommissionEuropean Commission Joint Research Centre); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Asthma UK; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	The UK Medical Research Council and the Wellcome Trust (grant reference 092731) and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children. B.D.S. is the recipient of a European Respiratory Society/Marie Curie Joint Research Fellowship (no. MC 1614-2010). The research leading to these results has received funding from the European Respiratory Society and the European Community's Seventh Framework Programme FP7/2007-2013-Marie Curie Actions under grant agreement RESPIRE, PCOFUND-GA-2008-229571. R.G. was supported by the UK Medical Research Council (grant no. 0401540). The GABRIEL project was supported by a contract from the European Commission (018996) and grants from the French Ministry of Research, the Wellcome Trust (WT084703MA), and Asthma UK. Disclosure of potential conflict of interest: J. Henderson, G. D. Smith, and J. A. C. Sterne receive research support from the Medical Research Council and the Wellcome Trust. R. Granell receives research support from the Medical Research Council. The rest of the authors declare that they have no relevant conflicts of interest.	[Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Binia A, 2011, J HUM GENET, V56, P97, DOI 10.1038/jhg.2010.134; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Bureau A, 2005, GENET EPIDEMIOL, V28, P171, DOI 10.1002/gepi.20041; CHINN S, 1992, THORAX, V47, P707, DOI 10.1136/thx.47.9.707; de los Campos G, 2010, NAT REV GENET, V11, P880, DOI 10.1038/nrg2898; Duffy DL, 1998, AM J RESP CRIT CARE, V157, P840, DOI 10.1164/ajrccm.157.3.9702070; Evans DM, 2009, HUM MOL GENET, V18, P3525, DOI 10.1093/hmg/ddp295; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Ferreira MAR, 2006, ALLERGY, V61, P245, DOI 10.1111/j.1398-9995.2005.00954.x; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Hancock DB, 2010, NAT GENET, V42, P45, DOI 10.1038/ng.500; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Henderson J, 2009, ARCH DIS CHILD, V94, P333, DOI 10.1136/adc.2008.143636; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Jones RW, 2000, EUR J HUM GENET, V8, P653, DOI 10.1038/sj.ejhg.5200502; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Noguchi E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002170; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; Repapi E, 2010, NAT GENET, V42, P36, DOI 10.1038/ng.501; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schultz A, 2011, PAEDIATR RESPIR REV, V12, P160, DOI 10.1016/j.prrv.2011.01.008; Silverman M, 2002, RESP INFECT ALLERGY, P427; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Spycher BD, 2008, EUR RESPIR J, V31, P974, DOI 10.1183/09031936.00153507; Spycher BD, 2010, CLIN EXP ALLERGY, V40, P1130, DOI 10.1111/j.1365-2222.2010.03541.x; Steyerberg E., 2008, CLIN PREDICTION MODE; Thomsen SF, 2006, CLIN EXP ALLERGY, V36, P1382, DOI 10.1111/j.1365-2222.2006.02512.x; Thomsen SF, 2009, ALLERGY, V64, P427, DOI 10.1111/j.1398-9995.2008.01850.x; Thomsen SF, 2008, TWIN RES HUM GENET, V11, P112, DOI 10.1375/twin.11.2.112; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Wechsler D, 1992, WISC 3UK WECHSLER IN; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132; Williams SM, 2011, ANN HUM GENET, V75, P348, DOI 10.1111/j.1469-1809.2011.00640.x; Wray NR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000864; Wu T, 2010, EUR RESPIR J, V36, P261, DOI 10.1183/09031936.00123909; Xu MS, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-90; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608	47	41	41	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					503	+		10.1016/j.jaci.2012.06.002	http://dx.doi.org/10.1016/j.jaci.2012.06.002			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22846752	Green Accepted			2022-12-18	WOS:000307002200034
J	Gentinetta, T; Pecaric-Petkovic, T; Wan, D; Falcone, FH; Dahinden, CA; Pichler, WJ; Hausmann, OV				Gentinetta, Thomas; Pecaric-Petkovic, Tatjana; Wan, Daniel; Falcone, Franco H.; Dahinden, Clemens A.; Pichler, Werner J.; Hausmann, Oliver V.			Individual IL-3 priming is crucial for consistent in vitro activation of donor basophils in patients with chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoantibodies; autologous serum skin test; basophil activation test; CD203c; CD63; chronic urticaria; flow cytometry; IgE receptor; IL-3	HUMAN BLOOD BASOPHILS; SERUM SKIN-TEST; HISTAMINE-RELEASE; CD63 EXPRESSION; FLOW-CYTOMETRY; UP-REGULATION; DIAGNOSIS; AUTOANTIBODIES; ALPHA; ASSAY	Background: The in vivo autologous serum skin test (ASST) is the diagnostic gold standard to detect autoantibodies against Fc epsilon RI or IgE itself, as well as other autoreactive serum components, in patients with chronic spontaneous urticaria (CU). Coincubation of patient sera with donor basophils and measuring their degranulation in vitro could be a safe alternative but has shown inconsistent results. Objective: Optimization of the basophil activation test to detect autoreactive serum components in patients with CU. Methods: The ability of patient sera to induce CD63 and CD203c in donor basophils (n = 15) was measured by means of flow cytometry. Sera of 20 patients with CU (10 with positive ASST results), 15 patients with cold urticaria, and 27 healthy control subjects were included to optimize test conditions with donor basophils and a basophil cell line (RBL703/21) followed by testing of 110 consecutive patients from clinical routine. Results: We demonstrate that individual IL-3 priming normalized the initially inconsistent basophil reactivity and led to reproducible and comparable test results irrespective of the basophil donors used. CD203c as an activation marker and the use of a basophil cell line were less suitable for this purpose. Conclusion: The basophil activation test with individualized IL-3 priming for each basophil donor is a reproducible and reliable alternative to the ASST. There are several advantages over the ASST: no risk of accidental infection, no influence of antihistamines on the test result, quantifiable results, and a potential in providing treatment monitoring. The exact nature of the degranulating factor or factors in patient sera remains an open question. (J Allergy Clin Immunol 2011;128:1227-34.)	[Gentinetta, Thomas; Pecaric-Petkovic, Tatjana; Pichler, Werner J.; Hausmann, Oliver V.] Univ Bern, Inselspital, Dept Rheumatol Clin Immunol & Allergol, CH-3010 Bern, Switzerland; [Gentinetta, Thomas; Pecaric-Petkovic, Tatjana; Pichler, Werner J.] ADR AC GmbH, Bern, Switzerland; [Wan, Daniel; Falcone, Franco H.] Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England; [Dahinden, Clemens A.] Univ Bern, Inselspital, Inst Immunol, CH-3010 Bern, Switzerland	University of Bern; University Hospital of Bern; University of Nottingham; University of Bern; University Hospital of Bern	Hausmann, OV (corresponding author), Dept Rheumatol Clin Immunol & Allergol, Freiburgstr 10, CH-3010 Bern, Switzerland.	oliver.hausmann@insel.ch	Falcone, Franco H/F-9210-2013; Falcone, Franco/AAE-8026-2021	Falcone, Franco H/0000-0002-1732-9932; Falcone, Franco/0000-0002-1732-9932; Pichler, Werner J./0000-0002-8117-359X	Biotechnology and Biological Sciences Research Council [967514] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Asero R, 2006, J ALLERGY CLIN IMMUN, V117, P1113, DOI 10.1016/j.jaci.2005.12.1343; Asero R, 2007, J ALLERGY CLIN IMMUN, V119, P705, DOI 10.1016/j.jaci.2006.08.043; De Swerdt A, 2005, J ALLERGY CLIN IMMUN, V116, P662, DOI 10.1016/j.jaci.2005.04.042; Ebo DG, 2008, CYTOM PART B-CLIN CY, V74B, P201, DOI 10.1002/cyto.b.20419; Ferrer M, 1998, J ALLERGY CLIN IMMUN, V101, P672, DOI 10.1016/S0091-6749(98)70176-9; Ferrer M, 2003, ALLERGY, V58, P802, DOI 10.1034/j.1398-9995.2003.00195.x; Frezzolini A, 2006, ALLERGY, V61, P1071, DOI 10.1111/j.1398-9995.2006.01033.x; Grattan CEH, 2000, BRIT J DERMATOL, V143, P365, DOI 10.1046/j.1365-2133.2000.03664.x; Greaves MW, 2007, CLIN REV ALLERG IMMU, V33, P134, DOI 10.1007/s12016-007-0038-3; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; Gyimesi E, 2004, BRIT J DERMATOL, V151, P388, DOI 10.1111/j.1365-2133.2004.06042.x; Hausmann OV, 2011, ALLERGY, V66, P85, DOI 10.1111/j.1398-9995.2010.02431.x; Hauswirth AW, 2007, INT J IMMUNOPATH PH, V20, P267, DOI 10.1177/039463200702000207; Hermes B, 1999, J ALLERGY CLIN IMMUN, V103, P307, DOI 10.1016/S0091-6749(99)70506-3; Ishmael S, 2009, J LEUKOCYTE BIOL, V86, P313, DOI 10.1189/jlb.1208724; Isik SR, 2011, INT ARCH ALLERGY IMM, V154, P63, DOI 10.1159/000319210; Jorgensen HG, 2003, LEUKEMIA, V17, P1430, DOI 10.1038/sj.leu.2402967; Kaplan AP, 2009, CLIN EXP ALLERGY, V39, P777, DOI 10.1111/j.1365-2222.2009.03256.x; Kaplan AP, 2007, J ALLERGY CLIN IMMUN, V120, P729, DOI 10.1016/j.jaci.2007.05.008; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; Kikuchi Y, 2001, J ALLERGY CLIN IMMUN, V107, P1056, DOI 10.1067/mai.2001.115484; KNOL EF, 1993, J IMMUNOL, V151, P4926; Konstantinou GN, 2009, ALLERGY, V64, P1256, DOI 10.1111/j.1398-9995.2009.02132.x; Ladics GS, 2008, REGUL TOXICOL PHARM, V51, P288, DOI 10.1016/j.yrtph.2008.04.012; Metz M, 2009, J ALLERGY CLIN IMMUN, V123, P705, DOI 10.1016/j.jaci.2008.11.040; Miadonna A, 1996, ALLERGY, V51, P525; Miescher Sylvia M., 2001, Human Antibodies, V10, P119; Najib U, 2010, J ALLERGY CLIN IMMUN, V125, pAB95, DOI 10.1016/j.jaci.2009.12.374; Najib U, 2009, ALLERGY ASTHMA PROC, V30, P1, DOI 10.2500/aap.2009.30.3191; Nakamura R, 2010, ALLERGY, V65, P1266, DOI 10.1111/j.1398-9995.2010.02363.x; Niimi N, 1996, J INVEST DERMATOL, V106, P1001, DOI 10.1111/1523-1747.ep12338544; Ochensberger B, 1996, BLOOD, V88, P3028, DOI 10.1182/blood.V88.8.3028.bloodjournal8883028; Ocmant A, 2007, J IMMUNOL METHODS, V320, P40, DOI 10.1016/j.jim.2006.12.002; ODonnell BF, 1997, BRIT J DERMATOL, V136, P197; Pachlopnik JM, 2004, J AUTOIMMUN, V22, P43, DOI 10.1016/j.jaut.2003.09.007; Platzer MH, 2005, ALLERGY, V60, P1152, DOI 10.1111/j.1398-9995.2005.00841.x; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Schroeder JT, 2009, J IMMUNOL, V182, P2432, DOI 10.4049/jimmunol.0801782; Siebenhaar F, 2007, CLIN EXP DERMATOL, V32, P241, DOI 10.1111/j.1365-2230.2007.02376.x; Smith KB, 1999, J IMMUNOL METHODS, V228, P29, DOI 10.1016/S0022-1759(99)00087-3; Takagi K, 2003, BIOL PHARM BULL, V26, P252, DOI 10.1248/bpb.26.252; Tong LJ, 1997, J ALLERGY CLIN IMMUN, V99, P461, DOI 10.1016/S0091-6749(97)70071-X; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Vonakis BM, 2008, CURR OPIN IMMUNOL, V20, P709, DOI 10.1016/j.coi.2008.09.005; Wang F, 2009, J ALLERGY CLIN IMMUN, V123, P972, DOI 10.1016/j.jaci.2009.01.039; Wedi B, 2000, J ALLERGY CLIN IMMUN, V105, P552, DOI 10.1067/mai.2000.104939; Yasnowsky KM, 2006, J ALLERGY CLIN IMMUN, V117, P1430, DOI 10.1016/j.jaci.2006.02.016; Zuberbier T, 2009, ALLERGY, V64, P1417, DOI 10.1111/j.1398-9995.2009.02179.x	48	41	42	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1227	U561		10.1016/j.jaci.2011.07.021	http://dx.doi.org/10.1016/j.jaci.2011.07.021			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	865WX	21855127				2022-12-18	WOS:000298342700011
J	Chen, Y; Stirling, RG; Paul, E; Hore-Lacy, F; Thompson, BR; Douglass, JA				Chen, Yan; Stirling, Rob G.; Paul, Eldho; Hore-Lacy, Fiona; Thompson, Bruce R.; Douglass, Jo A.			Longitudinal decline in lung function in patients with primary immunoglobulin deficiencies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PRIMARY-IMMUNODEFICIENCY; BRONCHIECTASIS		[Chen, Yan; Stirling, Rob G.; Hore-Lacy, Fiona; Thompson, Bruce R.; Douglass, Jo A.] Alfred Hosp, Dept Allergy Immunol & Resp Med AIRmed, Melbourne, Vic, Australia; [Stirling, Rob G.; Thompson, Bruce R.; Douglass, Jo A.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Paul, Eldho] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Monash University	Chen, Y (corresponding author), Alfred Hosp, Dept Allergy Immunol & Resp Med AIRmed, Melbourne, Vic, Australia.	j.douglass@alfred.org.au	stirling, rob/AAY-7125-2020	stirling, rob/0000-0001-9877-5450; Douglass, Jo/0000-0002-1200-8048; Thompson, Bruce/0000-0002-5885-0652; Paul, Eldho/0000-0003-1263-7255; Hore-Lacy, Fiona/0000-0003-0744-2170				Gathmann B, 2009, CLIN EXP IMMUNOL, V157, P3, DOI 10.1111/j.1365-2249.2009.03954.x; Haidopoulou K, 2009, PEDIATR PULM, V44, P669, DOI 10.1002/ppul.21036; Kerstjens HAM, 1997, THORAX, V52, P820, DOI 10.1136/thx.52.9.820; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Kohansal R, 2009, AM J RESP CRIT CARE, V180, P3, DOI 10.1164/rccm.200901-0047OC; Loebinger MR, 2009, EUR RESPIR J, V34, P843, DOI 10.1183/09031936.00003709; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Senn S, 2000, STAT MED, V19, P861, DOI 10.1002/(SICI)1097-0258(20000330)19:6<861::AID-SIM407>3.0.CO;2-F; VANPELT W, 1994, AM J RESP CRIT CARE, V149, P1218, DOI 10.1164/ajrccm.149.5.8173762	10	41	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1414	1417		10.1016/j.jaci.2011.03.041	http://dx.doi.org/10.1016/j.jaci.2011.03.041			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21546068	Bronze			2022-12-18	WOS:000291048500015
J	Nahum, A; Dadi, H; Bates, A; Roifman, CM				Nahum, Amit; Dadi, Harjit; Bates, Andrea; Roifman, Chaim M.			The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							POLYMORPHISMS; DEFICIENCY; INFECTION		[Nahum, Amit] Hosp Sick Children, Dept Pediat, Canadian Ctr Primary Immunodeficiency, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Nahum, A (corresponding author), Hosp Sick Children, Dept Pediat, Canadian Ctr Primary Immunodeficiency, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada.	chaim.roifman@sickkids.ca						Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nahum A, 2008, J ALLERGY CLIN IMMUN, V122, P1220, DOI 10.1016/j.jaci.2008.10.027; Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P17696, DOI 10.1074/jbc.M700209200; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Touil T, 2006, J IMMUNOL, V177, P7505, DOI 10.4049/jimmunol.177.11.7505; Van der Graaf CAA, 2006, EUR CYTOKINE NETW, V17, P29; Wochrle T, 2008, CYTOKINE, V41, P322, DOI 10.1016/j.cyto.2007.12.006; Zhang SY, 2007, SCIENCE, V317, P1522, DOI 10.1126/science.1139522	9	41	45	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2011	127	2					528	531		10.1016/j.jaci.2010.09.031	http://dx.doi.org/10.1016/j.jaci.2010.09.031			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	714KH	21093032				2022-12-18	WOS:000286808000032
J	Thorp, WA; Goldner, W; Meza, J; Poole, JA				Thorp, Warren Ancheta; Goldner, Whitney; Meza, Jane; Poole, Jill A.			Reduced vitamin D levels in adult subjects with chronic urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Thorp, Warren Ancheta; Poole, Jill A.] Univ Nebraska, Med Ctr, Div Pulm Crit Care Sleep & Allergy, Omaha, NE 68198 USA; [Goldner, Whitney] Univ Nebraska, Med Ctr, Dept Internal Med, Div Diabet Endocrine & Metab, Omaha, NE USA; [Meza, Jane] Univ Nebraska, Med Ctr, Coll Publ Hlth, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Thorp, WA (corresponding author), Univ Nebraska, Med Ctr, Div Pulm Crit Care Sleep & Allergy, Omaha, NE 68198 USA.	japoole@unmc.edu		goldner, whitney/0000-0002-9724-7987				Hata TR, 2008, J ALLERGY CLIN IMMUN, V122, P829, DOI 10.1016/j.jaci.2008.08.020; Khan DA, 2008, ALLERGY ASTHMA PROC, V29, P439, DOI 10.2500/aap.2008.29.3151; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Stechschulte SA, 2009, AM J MED, V122, P793, DOI 10.1016/j.amjmed.2009.02.029; Wjst M, 2007, ALLERGY, V62, P1085, DOI 10.1111/j.1398-9995.2007.01437.x	5	41	43	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2								10.1016/j.jaci.2010.04.040	http://dx.doi.org/10.1016/j.jaci.2010.04.040			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20621341				2022-12-18	WOS:000281203800039
J	Conus, S; Straumann, A; Bettler, E; Simon, HU				Conus, Sebastien; Straumann, Alex; Bettler, Eva; Simon, Hans-Uwe			Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXPRESSION		[Conus, Sebastien; Bettler, Eva; Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, CH-3012 Bern, Switzerland; [Straumann, Alex] Kantonsspital, Dept Gastroenterol, Olten, Switzerland	University of Bern; Kantonsspital Aarau AG (KSA); Kantonsspital Olten	Conus, S (corresponding author), Univ Bern, Inst Pharmacol, CH-3012 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-7410-2020	Simon, Hans-Uwe/0000-0002-9404-7736				Conus S, 2009, J ALLERGY CLIN IMMUN, V123, P269, DOI 10.1016/j.jaci.2008.09.031; Gevaert P, 2009, ALLERGY, V64, P725, DOI 10.1111/j.1398-9995.2008.01885.x; Izcue A, 2009, ANNU REV IMMUNOL, V27, P313, DOI 10.1146/annurev.immunol.021908.132657; Kato M, 1998, ANAT REC, V252, P418, DOI 10.1002/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Penissi AB, 2003, BIOCELL, V27, P163; Straumann A, 2005, INFLAMM BOWEL DIS, V11, P720, DOI 10.1097/01.MIB.0000172557.39767.53; Straumann A, 2010, GUT, V59, P21, DOI 10.1136/gut.2009.178558; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855	9	41	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					175	177		10.1016/j.jaci.2010.04.029	http://dx.doi.org/10.1016/j.jaci.2010.04.029			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	627SE	20542323				2022-12-18	WOS:000280061800035
J	Amirav, I; Newhouse, MT; Minocchieri, S; Castro-Rodriguez, JA; Schuepp, KG				Amirav, Israel; Newhouse, Michael T.; Minocchieri, Stefan; Castro-Rodriguez, Jose A.; Schueepp, Karen G.			Factors that affect the efficacy of inhaled corticosteroids for infants and young children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Small-particle aerosols; asthma; infants; nebulizers; inhalers; corticosteroids; aerosol delivery devices; adherence	METERED-DOSE INHALER; VALVED-HOLDING CHAMBERS; UPPER AIRWAY MODEL; AEROSOL DEPOSITION; CYSTIC-FIBROSIS; LUNG DEPOSITION; PARTICLE-SIZE; BECLOMETHASONE DIPROPIONATE; INHALATION-THERAPY; PRESCHOOL-CHILDREN	Infants (0-1 years of age) and young children (1-3 years of age) are a unique subpopulation with regard to inhaled therapies. There are various anatomic, physiological, and emotional factors peculiar to this age group that present significant difficulties and challenges for aerosol delivery. Most studies of therapeutic aerosols that have been performed with patients of this age group, particularly recent studies with inhaled corticosteroids (ICSs), administered aerosols with relatively large particles (ie, >3 mu m in mass median aerodynamic diameter). These drugs were designed for use in adults and older children and were administered with masks, which are frequently rejected by patients. Based on these studies, it was recently suggested that ICSs might not be as therapeutically effective in infants and young children as in adults. We review the reasons that large-particle corticosteroid aerosols are not likely to be effective in infants and young children. This patient population differs from adults in airway anatomy and physiology, as well as in behavior and adherence to therapy. We suggest that the benefit of ICSs in this age group requires further evaluation to determine whether better therapeutic outcomes might be achieved with smaller particles. (J Allergy Clin Immunol 2010;125:1206-11.)	[Amirav, Israel] Technion Israel Inst Technol, Ziv Med Ctr, Dept Pediat, Fac Med, IL-12000 Haifa, Israel; [Newhouse, Michael T.] McMaster Univ, St Josephs Hosp, Firestone Inst Resp Hlth, Hamilton, ON L8S 4L8, Canada; [Minocchieri, Stefan] Univ Western Australia, Princess Margaret Hosp Children, Sch Paediat & Child Hlth, Subiaco, WA, Australia; [Castro-Rodriguez, Jose A.] Pontificia Univ Catolica Chile, Sch Med, Santiago, Chile; [Schueepp, Karen G.] Univ Childrens Hosp, Dept Resp Med, Swiss Paediat Resp Res Grp, Bern, Switzerland	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Ziv Medical Center; McGill University; McMaster University; University of Western Australia; Pontificia Universidad Catolica de Chile; University of Bern; University Hospital of Bern	Amirav, I (corresponding author), Technion Israel Inst Technol, Ziv Med Ctr, Dept Pediat, Fac Med, IL-12000 Haifa, Israel.	amirav@012.net.il	Castro-Rodriguez, Jose A./ABA-2760-2021; Castro-Rodriguez, Jose A./ABA-6591-2021; Amirav, Israel/I-9286-2019	Castro-Rodriguez, Jose A./0000-0002-0708-4281; Amirav, Israel/0000-0002-6917-5285	Swiss National Science Research Foundation [PBZHP3-123293]	Swiss National Science Research Foundation(Swiss National Science Foundation (SNSF))	S. Minocchieri has been supported by a personal grant (PBZHP3-123293) from Swiss National Science Research Foundation.	Agertoft L, 2003, PEDIATR PULM, V35, P192, DOI 10.1002/ppul.10238; Amirav I, 2003, ARCH DIS CHILD, V88, P719, DOI 10.1136/adc.88.8.719; Amirav I, 2002, J NUCL MED, V43, P487; Amirav I, 2001, PEDIATRICS, V108, P389, DOI 10.1542/peds.108.2.389; Amirav I, 2008, PEDIATR PULM, V43, P268, DOI 10.1002/ppul.20767; BECQUEMIN MH, 1991, EUR RESPIR J, V4, P694; CHUA HL, 1994, EUR RESPIR J, V7, P2185, DOI 10.1183/09031936.94.07122185; Clark AR, 2007, J AEROSOL MED, V20, P75, DOI 10.1089/jam.2006.0557; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P921; Devadason SG, 2003, EUR RESPIR J, V21, P1007, DOI 10.1183/09031936.03.00087803; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Everard ML, 2000, ARCH DIS CHILD, V82, P428; EVERARD ML, 1992, ARCH DIS CHILD, V67, P586, DOI 10.1136/adc.67.5.586; Fok TF, 1996, PEDIATR PULM, V21, P301, DOI 10.1002/(SICI)1099-0496(199605)21:5<301::AID-PPUL5>3.0.CO;2-P; Geller DE, 1998, PEDIATR PULM, V25, P83, DOI 10.1002/(SICI)1099-0496(199802)25:2<83::AID-PPUL2>3.3.CO;2-H; Gold DR, 2006, NEW ENGL J MED, V354, P2058, DOI 10.1056/NEJMe068058; HISLOP A, 1972, THORAX, V27, P265, DOI 10.1136/thx.27.3.265; Howarth PH, 2001, J AEROSOL MED, V14, pS27, DOI 10.1089/08942680150506312; Iles R, 1999, ARCH DIS CHILD, V81, P163, DOI 10.1136/adc.81.2.163; Janssens HM, 2004, J AEROSOL MED, V17, P51, DOI 10.1089/089426804322994460; Janssens HM, 2003, CHEST, V123, P2083, DOI 10.1378/chest.123.6.2083; Kohler E, 2008, ARCH DIS CHILD-FETAL, V93, pF275, DOI 10.1136/adc.2007.121285; Lasserson TJ, 2006, COCHRANE DB SYST REV, V2; Mallol J, 1996, PEDIATR PULM, V21, P276, DOI 10.1002/(SICI)1099-0496(199605)21:5<276::AID-PPUL2>3.0.CO;2-L; Marguet C, 2001, PEDIATR ALLERGY IMMU, V12, P224, DOI 10.1034/j.1399-3038.2001.012004224.x; MURAKAMI G, 1990, ANN ALLERGY, V64, P383; Pedersen S, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.6.e92; Roller CM, 2007, EUR RESPIR J, V29, P299, DOI 10.1183/09031936.00051106; Sangwan S, 2004, PEDIATR PULM, V37, P447, DOI 10.1002/ppul.10454; Schueepp KG, 2009, RESP MED, V103, P1738, DOI 10.1016/j.rmed.2009.04.029; Schuepp KG, 2005, J AEROSOL MED, V18, P225, DOI 10.1089/jam.2005.18.225; Schuepp KG, 2004, SWISS MED WKLY, V134, P198; Skoner DP, 2008, PEDIATRICS, V121, pE1, DOI 10.1542/peds.2006-2206; Tal A, 1996, J PEDIATR-US, V128, P479, DOI 10.1016/S0022-3476(96)70357-8; Wildhaber JH, 1999, J PEDIATR-US, V135, P28, DOI 10.1016/S0022-3476(99)70323-9	35	41	44	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1206	1211		10.1016/j.jaci.2010.01.034	http://dx.doi.org/10.1016/j.jaci.2010.01.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20338620				2022-12-18	WOS:000278831000004
J	Juhn, YJ; Qin, R; Urm, S; Katusic, S; Vargas-Chanes, D				Juhn, Young J.; Qin, Rui; Urm, Sanghwa; Katusic, Slavica; Vargas-Chanes, Delfino			The influence of neighborhood environment on the incidence of childhood asthma: A propensity score approach	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Neighborhood; epidemiology; socioeconomic status; pediatric asthma; propensity score	MULTILEVEL ANALYSIS; PARENTAL SMOKING; BIRTH COHORT; CHILDREN; HEALTH; BIAS; EPIDEMIOLOGY; PREVALENCE; SYMPTOMS; ILLNESS	Background: The propensity score method has been underused in research concerning asthma epidemiology, which is useful for addressing covariate imbalance in observational studies. Objective: To examine the impact of neighborhood environment on asthma incidence by applying the propensity score method. Methods: The study was designed as a retrospective cohort study. Study subjects were all children born in Rochester, Minn, between 1976 and 1979. Asthma status was previously determined by applying predetermined criteria. We applied the propensity score method to match children who lived in census tracts facing or not facing intersections with major highways or railroads. The propensity score of children living in a census tract facing intersections was formulated from a logistic regression model with 16 variables that may not be balanced between comparison groups. The Cox proportional hazard models were used in the matched samples to estimate hazard ratios of neighborhood environment and some other variables of interest and their corresponding 95% CIs. Results: After matching with propensity scores, we found that children who lived in census tracts facing intersections with major highways or railroads had a higher risk of asthma (hazard ratios, 1.385-1.669 depending on the matching methods) compared with the matched counterparts who lived in census tracts not facing intersections with major highways or railroads. Conclusion: Neighborhood environment may be an important risk factor in understanding the development of pediatric asthma. The propensity score method is a useful tool in addressing covariate imbalance and exploring for causal effect in studying asthma epidemiology. (J Allergy Clin Immunol 2010;125:838-43.)	[Juhn, Young J.] Mayo Clin, Div Community Pediat & Adolescent Med, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; [Qin, Rui; Katusic, Slavica] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; [Urm, Sanghwa] Inje Univ, Dept Prevent Med, Pusan, South Korea; [Vargas-Chanes, Delfino] Colegio Mexico, Ctr Sociol Studies, Mexico City 10740, DF, Mexico	Mayo Clinic; Mayo Clinic; Inje University; Colegio de Mexico	Juhn, YJ (corresponding author), Mayo Clin, Div Community Pediat & Adolescent Med, Dept Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	juhn.young@mayo.edu	Qin, Rui/H-5638-2012	Vargas, Delfino/0000-0002-6046-3643	Mayo Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01-AR30582]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	Mayo Foundation; National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by the Scholarly Clinician Award from the Mayo Foundation and made possible by the Rochester Epidemiology Project (R01-AR30582) front the National Institute of Arthritis and Musculoskeletal and Skin Diseases.	Austin PC, 2008, J CLIN EPIDEMIOL, V61, P537, DOI 10.1016/j.jclinepi.2007.07.011; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; CERNELC D, 1975, ACTA ALLERGOL, V30, P423, DOI 10.1111/j.1398-9995.1975.tb01676.x; Cook DG, 1997, THORAX, V52, P1081, DOI 10.1136/thx.52.12.1081; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DiezRoux AV, 1997, AM J EPIDEMIOL, V146, P48, DOI 10.1093/oxfordjournals.aje.a009191; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; *I MED, 2001, CLEARN AIR ASTHM IND; Juhn YJ, 2005, J ALLERGY CLIN IMMUN, V116, P510, DOI 10.1016/j.jaci.2005.05.043; Juhn YJ, 2005, SOC SCI MED, V60, P2453, DOI 10.1016/j.socscimed.2004.11.034; Katusic SK, 1996, AM J MENT RETARD, V100, P335; Katusic SK, 1998, MAYO CLIN PROC, V73, P1053, DOI 10.4065/73.11.1053; Kinney PL, 2000, ENVIRON HEALTH PERSP, V108, P213, DOI 10.2307/3454436; Meng Y, 2000, J AIR WASTE MANAGE, V50, P252, DOI 10.1080/10473289.2000.10464005; Montnemery P, 2003, RESP MED, V97, P970, DOI 10.1016/S0954-6111(03)00126-4; Nelson DA, 1997, ANN ALLERG ASTHMA IM, V78, P21, DOI 10.1016/S1081-1206(10)63365-0; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103a; OCampo P, 1997, AM J PUBLIC HEALTH, V87, P1113, DOI 10.2105/AJPH.87.7.1113; ROSENBAUM PR, 1985, BIOMETRICS, V41, P103, DOI 10.2307/2530647; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Sawicki DS, 1996, J AM PLANN ASSOC, V62, P165, DOI 10.1080/01944369608975683; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555, DOI 10.1164/ajrccm/142.3.555; Seeger JD, 2003, AM J CARDIOL, V92, P1447, DOI 10.1016/j.amjcard.2003.08.057; Seeger JD, 2007, MED CARE, V45, pS143, DOI 10.1097/MLR.0b013e318074ce79; Stafford M, 2003, INT J EPIDEMIOL, V32, P357, DOI 10.1093/ije/dyg084; Strachan DP, 1997, THORAX, V52, P905, DOI 10.1136/thx.52.10.905; Sturmer T, 2006, J CLIN EPIDEMIOL, V59, P437, DOI 10.1016/j.jclinepi.2005.07.004; Subramanian SV, 2006, AM J EPIDEMIOL, V164, P823, DOI 10.1093/aje/kwj313; U.S. Census Bureau - Geography Division, 2000, CENS TRACTS BLOCK NU; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/ajrccm.164.12.2106126; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; Yang HH, 2004, CHEMOSPHERE, V54, P369, DOI 10.1016/S0045-6535(03)00655-6; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888	33	41	41	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					838	843		10.1016/j.jaci.2009.12.998	http://dx.doi.org/10.1016/j.jaci.2009.12.998			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	584XP	20236695	Green Accepted			2022-12-18	WOS:000276787900008
J	Waibel, KH; Reese, DA; Hamilton, RG; Devillez, RL				Waibel, Kirk H.; Reese, Drew A.; Hamilton, Robert G.; Devillez, Richard L.			Partial improvement of solar urticaria after omalizumab	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTI-IGE; THERAPY		[Waibel, Kirk H.; Reese, Drew A.; Devillez, Richard L.] Brooke Army Med Ctr, Allergy Clin, Ft Sam Houston, TX 78234 USA; [Waibel, Kirk H.; Reese, Drew A.; Devillez, Richard L.] Brooke Army Med Ctr, Dermatol Clin, Ft Sam Houston, TX 78234 USA; [Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA	San Antonio Military Medical Center; United States Department of Defense; United States Army; San Antonio Military Medical Center; United States Department of Defense; United States Army; Johns Hopkins University	Waibel, KH (corresponding author), Brooke Army Med Ctr, Allergy Clin, Ft Sam Houston, TX 78234 USA.	kirk.waibel@amedd.army.mil						Botto NC, 2008, J AM ACAD DERMATOL, V59, P909, DOI 10.1016/j.jaad.2008.08.020; Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Guzelbey O, 2008, ALLERGY, V63, P1563, DOI 10.1111/j.1398-9995.2008.01879.x; Hamilton RG, 2006, J ALLERGY CLIN IMMUN, V117, P759, DOI 10.1016/j.jaci.2006.01.012; Hamilton RG, 2005, J IMMUNOL METHODS, V303, P81, DOI 10.1016/j.jim.2005.06.008; HARBER LC, 1963, J INVEST DERMATOL, V41, P439, DOI 10.1038/jid.1963.138; LEENUTAPHONG V, 1989, J AM ACAD DERMATOL, V21, P237, DOI 10.1016/S0190-9622(89)70167-5; MacGlashan D, 2009, J ALLERGY CLIN IMMUN, V123, P114, DOI 10.1016/j.jaci.2008.10.053; Monfrecola G, 2000, Am J Contact Dermat, V11, P89, DOI 10.1053/AC.2000.6347; Otto HF, 2009, ALLERGY ASTHMA PROC, V30, P333, DOI 10.2500/aap.2009.30.3237	10	41	41	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					490	491		10.1016/j.jaci.2009.11.007	http://dx.doi.org/10.1016/j.jaci.2009.11.007			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20159260	Bronze			2022-12-18	WOS:000274764000030
J	Bauermeister, K; Ballmer-Weber, BK; Bublin, M; Fritsche, P; Hanschmann, KMO; Hoffmann-Sommergruber, K; Lidholm, J; Oberhuber, C; Randow, S; Holzhauser, T; Vieths, S				Bauermeister, Kerstin; Ballmer-Weber, Barbara K.; Bublin, Merima; Fritsche, Philipp; Hanschmann, Kay-Martin O.; Hoffmann-Sommergruber, Karin; Lidholm, Jonas; Oberhuber, Christina; Randow, Stefanie; Holzhauser, Thomas; Vieths, Stefan			Assessment of component-resolved in vitro diagnosis of celeriac allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Component-resolved diagnosis; celeriac allergy; ImmunoCAP; recombinant allergens; cross-reactive carbohydrate determinants; pollen-related food allergy; cross-reactivity	CROSS-REACTIVITY; BIRCH POLLEN; MOLECULAR CHARACTERIZATION; CARBOHYDRATE EPITOPES; APIUM-GRAVEOLENS; DOUBLE-BLIND; MUGWORT; API-G-1; IGE; SENSITIVITY	Background: Previous studies have demonstrated insufficient sensitivity of commercially available celeriac extract reagents in the diagnosis of celeriac allergy. Objective: We sought to assess the diagnostic performance of specific IgE determination based on recombinant and purified natural celeriac allergens in comparison with an extract-based assay and to investigate interference by IgE to cross-reactive carbohydrate determinants and its biologic activity. Methods: Twenty-four subjects with a positive double-blind, placebo-controlled food challenge result to celeriac; 20 atopic control subjects with birch pollen allergy who tolerated celeriac; and 20 nonatopic subjects were enrolled. IgE binding was investigated for celeriac allergens (rApi g 1.01, rApi g 4, and nApi g 5), extract reagents (celeriac, birch, mugwort, and timothy grass pollen), birch pollen allergens (rBet v 1 and rBet v 2), and cross-reactive carbohydrate determinants by means of ImmunoCAP analysis. Biologic activity of allergens was determined based on basophil mediator release. Results: Component-resolved ImmunoCAP analysis considerably increased the sensitivity to detect celeriac-specific IgE by 20%. Sensitization to carbohydrate structures was detected in 38% of patients with celeriac allergy, and there was an excellent correlation between sensitization to the glycoprotein Api g 5 and isolated glycan. Positive results among atopic control subjects were mainly caused by protein allergens, whereas the effect of carbohydrate epitopes was marginal. The ability of allergens to induce mediator release decreased in the order Bet v 1 > Api g 1 > Api g 5, confirming the low biologic activity of IgE to carbohydrate epitopes. Conclusion: Component-resolved diagnosis allowed an increase in diagnostic sensitivity from 67% to 88% compared with extract-based diagnosis. Sensitization to Api g 5 was attributable to its glycan moieties but did not interfere with diagnostic specificity. (J Allergy Clin Immunol 2009; 124:1273-81.)	[Bauermeister, Kerstin; Hanschmann, Kay-Martin O.; Randow, Stefanie; Holzhauser, Thomas; Vieths, Stefan] Paul Ehrlich Inst, D-63225 Langen, Germany; [Ballmer-Weber, Barbara K.; Fritsche, Philipp] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; [Bublin, Merima; Hoffmann-Sommergruber, Karin] Med Univ Vienna, Dept Pathophysiol, Vienna, Austria; [Lidholm, Jonas] Phadia AB, Uppsala, Sweden; [Oberhuber, Christina] Biomay AG, Vienna, Austria	Paul Ehrlich Institute; University of Zurich; University Zurich Hospital; Medical University of Vienna; Thermo Fisher Scientific; Phadia	Vieths, S (corresponding author), Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.	viest@pei.de	Holzhauser, Thomas/ABD-5038-2020	Lidholm, Jonas/0000-0002-7779-3411; Bublin, Merima/0000-0002-7191-9431; Holzhauser, Thomas/0000-0002-7818-7261; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X	European Commission [514000]; Austrian Science Fund [SFB F01802]	European Commission(European CommissionEuropean Commission Joint Research Centre); Austrian Science Fund(Austrian Science Fund (FWF))	K. B. was supported by the European Commission, EuroPrevall "The Prevalence, Cost and Basis of Food Allergy across Europe," contract no. 514000. M. B. was supported in part by the Austrian Science Fund, grant SFB F01802.	Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; ANDRE F, 1994, TOXICOLOGY, V93, P77, DOI 10.1016/0300-483X(94)90198-8; AXEN RE, 1988, NEW ENG REG ALLERGY, V9, P503; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Bublin M, 2003, FASEB J, V17, P1697, DOI 10.1096/fj.02-0872fje; Bublin M, 2008, MOL NUTR FOOD RES, V52, pS241, DOI 10.1002/mnfr.200700270; DeWitt AM, 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Ganglberger E, 2000, CLIN EXP ALLERGY, V30, P566, DOI 10.1046/j.1365-2222.2000.00773.x; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P115, DOI 10.1159/000024367; Jankiewicz A, 1997, J SCI FOOD AGR, V75, P359, DOI 10.1002/(SICI)1097-0010(199711)75:3&lt;359::AID-JSFA889&gt;3.0.CO;2-Y; JANKIEWICZ A, 1998, ALLERGO J, V7, P87; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; Mittag D, 2004, J ALLERGY CLIN IMMUN, V113, P148, DOI 10.1016/j.jaci.2003.09.030; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; PAULI G, 1988, ANN ALLERGY, V60, P243; Reuter A, 2006, CLIN EXP ALLERGY, V36, P815, DOI 10.1111/j.1365-2222.2006.2492.x; Scheurer S, 2000, CLIN EXP ALLERGY, V30, P962, DOI 10.1046/j.1365-2222.2000.00821.x; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Schimek EM, 2005, J ALLERGY CLIN IMMUN, V116, P1327, DOI 10.1016/j.jaci.2005.09.007; Schirmer T, 2005, J MOL BIOL, V351, P1101, DOI 10.1016/j.jmb.2005.06.054; VALLIER P, 1992, CLIN EXP ALLERGY, V22, P774, DOI 10.1111/j.1365-2222.1992.tb02818.x; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; van Ree R, 2004, CURR OPIN ALLERGY CL, V4, P235, DOI [10.1097/00130832-200406000-00017, 10.1097/01.all.0000129457.27092.8f]; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Wangorsch A, 2007, MOL IMMUNOL, V44, P2518, DOI 10.1016/j.molimm.2006.12.023; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	32	41	41	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1273	1281		10.1016/j.jaci.2009.07.033	http://dx.doi.org/10.1016/j.jaci.2009.07.033			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VH	19800675	Bronze			2022-12-18	WOS:000273071500020
J	Broccardo, CJ; Mahaffey, SB; Strand, M; Reisdorph, NA; Leung, DYM				Broccardo, Carolyn J.; Mahaffey, Spencer B.; Strand, Matthew; Reisdorph, Nichole A.; Leung, Donald Y. M.			Peeling off the layers: Skin taping and a novel proteomics approach to study atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							PROTEINS		[Broccardo, Carolyn J.; Mahaffey, Spencer B.; Reisdorph, Nichole A.] Natl Jewish Hlth, Dept Immunol, Denver, CO USA; [Strand, Matthew] Natl Jewish Hlth, Dept Biostat & Bioinformat, Denver, CO USA; [Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Strand, Matthew] Colorado Sch Publ Hlth, Dept Biostat, Denver, CO USA; [Reisdorph, Nichole A.] Univ Colorado, Dept Immunol, Denver, CO 80202 USA; [Leung, Donald Y. M.] Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	National Jewish Health; National Jewish Health; National Jewish Health; Colorado School of Public Health; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Broccardo, CJ (corresponding author), Natl Jewish Hlth, Dept Immunol, Denver, CO USA.	Leungd@njhealth.org	Mahaffey, Spencer/AAC-8712-2021; Reisdorph, Nichole/AAX-8774-2020; Strand, Matt/AAU-3762-2021	Reisdorph, Nichole/0000-0002-0425-8012; Strand, Matt/0000-0002-9083-5989	NCRR NIH HHS [S10 RR023703, UL1 RR025780, S10RR023703] Funding Source: Medline; NIAID NIH HHS [N01AI40029, U01 AI147462, #N01-AI-40029] Funding Source: Medline; NIAMS NIH HHS [R01 AR41256, R01 AR041256] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780, S10RR023703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CARR SA, 2008, CURRENT PROTOCOLS PR; Eichenfield Lawrence F, 2003, J Am Acad Dermatol, V49, P1088, DOI 10.1016/S0190-9622(03)02539-8; El-Rachkidy RG, 2008, J INVEST DERMATOL, V128, P2219, DOI 10.1038/jid.2008.71; Makowski L, 2004, J NUTR, V134, p2464S, DOI 10.1093/jn/134.9.2464S; Mitsuishi K, 2005, CLIN EXP ALLERGY, V35, P1327, DOI 10.1111/j.1365-2222.2005.02353.x; Oymar K, 2005, ALLERGY, V60, P86, DOI 10.1111/j.1398-9995.2005.00658.x; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; Yamane Y, 2009, INT ARCH ALLERGY IMM, V150, P89, DOI 10.1159/000210385; Zimmer JSD, 2004, J BIOL CHEM, V279, P7420, DOI 10.1074/jbc.M311404200	10	41	43	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1113	1115		10.1016/j.jaci.2009.07.057	http://dx.doi.org/10.1016/j.jaci.2009.07.057			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19748658	Green Accepted, Bronze			2022-12-18	WOS:000272108000038
J	Sverrild, A; Porsbjerg, C; Thomsen, SF; Backer, V				Sverrild, Asger; Porsbjerg, Celeste; Thomsen, Simon Francis; Backer, Vibeke			Diagnostic properties of inhaled mannitol in the diagnosis of asthma: A population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchial hyperresponsiveness; asthma; mannitol; bronchial provocation test; epidemiology	METHACHOLINE; CHALLENGE; SENSITIVITY; EXERCISE; CHILDREN; RESPONSIVENESS; SPECIFICITY; ADENOSINE; SAMPLE; LIFE	Background: A new indirect bronchial provocation test measuring airway responsiveness by using inhaled mannitol was recently introduced. Objective: The aim of this study was to examine the diagnostic properties of airway responsiveness to inhaled mannitol in the assessment of asthma in an unselected sample of young adults. Methods: Two hundred thirty-eight young adults randomly drawn from the nationwide civil registration list were challenged with inhaled, dry-powder mannitol. A respiratory specialist, blind to the test results, classified all 238 subjects with respect to the presence of asthma. The classification was based on respiratory symptoms, spirometric results, atopy, and fraction of exhaled nitric oxide values and response to inhaled beta(2)-agonists. On this basis, sensitivity, specificity, and predictive values were assessed to different cutoff values of the test. A receiver operating characteristic curve was constructed, and the accuracy of the test, defined as the area under the curve, was computed. Results: Fifty-one (21.4%) subjects had current asthma. Of 33 subjects with airway hyperresponsiveness to mannitol, 30 had current asthma. The specificity and sensitivity were 98.4% (95% CI, 96.2% to 99.4%) and 58.8% (95% CI, 50.7% to 62.6%), respectively. The positive predictive value (PPV) and negative predictive value (NPV) were 90.9% (95% CI, 78.4% to 96.8%) and 89.8 (95% CI, 87.7% to 90.7%), respectively. The area under the receiver operating characteristic curve was 0.89 (95% C1, 0.83-0.95). Conclusions: In an unselected sample of young adults, bronchial provocation with inhaled dry-powder mannitol had a high diagnostic specificity for the diagnosis of asthma. (J Allergy Clin Immunol 2009;124:928-32.)	[Sverrild, Asger; Porsbjerg, Celeste; Thomsen, Simon Francis; Backer, Vibeke] Bispebjerg Hosp, Dept Resp Med L, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital	Sverrild, A (corresponding author), Bispebjerg Hosp, Dept Resp Med L, DK-2400 Copenhagen NV, Denmark.	asgersverrild@stud.ku.dk	Sverrild, Asger/GPC-7753-2022; Backer, Vibeke/AAQ-9379-2021; Backer, Vibeke/I-9573-2014	Backer, Vibeke/0000-0002-7806-7219; Sverrild, Asger/0000-0003-0625-6405; Porsbjerg, Celeste/0000-0003-4825-9436	Danish Agency for Science, Technology and Innovation, an institution under the Danish Ministry of Science, Technology and Innovation	Danish Agency for Science, Technology and Innovation, an institution under the Danish Ministry of Science, Technology and Innovation	The Danish Agency for Science, Technology and Innovation, an institution under the Danish Ministry of Science, Technology and Innovation, granted a 1-year scholarship. Pharmaxis provided the research team with an unrestricted grant, with which one of the research assistants was employed. Moreover, parts of the Mannitol kits were delivered at no cost by Pharmaxis.	Alberg AJ, 2004, J GEN INTERN MED, V19, P460, DOI 10.1111/j.1525-1497.2004.30091.x; Anderson SD, 2008, CURR OPIN PULM MED, V14, P39, DOI 10.1097/MCP.0b013e3282f197f6; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758, DOI 10.1164/ajrccm.156.3.9701113; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; BACKER V, 1992, CLIN EXP ALLERGY, V22, P741, DOI 10.1111/j.1365-2222.1992.tb02813.x; BACKER V, 1991, EUR RESPIR J, V4, P1093; Brannan JD, 2002, RESPIROLOGY, V7, P37, DOI 10.1046/j.1440-1843.2002.00357.x; Brannan JD, 2007, CLIN RESPIR J, V1, P3, DOI 10.1111/j.1752-699X.2007.00004.x; Brusasco V, 2001, ALLERGY, V56, P1114, DOI 10.1034/j.1398-9995.2001.00148.x; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; de Meer G, 2004, CLIN EXP ALLERGY, V34, P9, DOI 10.1111/j.1365-2222.2004.01830.x; Fowler SJ, 2000, AM J RESP CRIT CARE, V162, P1318, DOI 10.1164/ajrccm.162.4.9912103; Global Initiative for Asthma, 2007, GLOB STRAT ASTHM MAN; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; Kornaar BGM, 1997, EUR RESPIR J, V10, P44; Leuppi JD, 2002, SWISS MED WKLY, V132, P151; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172, DOI 10.1016/S1081-1206(10)60692-8; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nolte F, 2006, RESP MED, V100, P354, DOI 10.1016/j.rmed.2005.05.012; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Porsbjerg C, 2008, CLIN EXP ALLERGY, V38, P43, DOI 10.1111/j.1365-2222.2007.02878.x; Schoor J. Van, 2005, Clinical and Experimental Allergy, V35, P250; Thomsen SF, 2004, ANN ALLERG ASTHMA IM, V92, P506, DOI 10.1016/S1081-1206(10)61757-7; Winder JA, 2000, ANN ALLERG ASTHMA IM, V85, P467, DOI 10.1016/S1081-1206(10)62573-2	26	41	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					928	932		10.1016/j.jaci.2009.06.028	http://dx.doi.org/10.1016/j.jaci.2009.06.028			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19665779	Bronze			2022-12-18	WOS:000272108000008
J	Hijnen, D; Haeck, I; van Kraats, AA; Nijhuis, E; de Bruin-Weller, MS; Bruijnzeel-Koomen, CAFM; Knol, EF				Hijnen, DirkJan; Haeck, Inge; van Kraats, Annemieke A.; Nijhuis, Evert; de Bruin-Weller, Marjolein S.; Bruijnzeel-Koomen, Carla A. F. M.; Knol, Edward F.			Cyclosporin A reduces CD4(+)CD25(+) regulatory T-cell numbers in patients with atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RHEUMATOID-ARTHRITIS; INDUCTION		[Hijnen, DirkJan; Haeck, Inge; van Kraats, Annemieke A.; Nijhuis, Evert; de Bruin-Weller, Marjolein S.; Bruijnzeel-Koomen, Carla A. F. M.; Knol, Edward F.] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Hijnen, D (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands.	D.J.Hijnen@umcutrecht.nl	Hijnen, DirkJan/L-1387-2015	Hijnen, DirkJan/0000-0003-3379-3425; Knol, Edward/0000-0001-7368-9820				Baan CC, 2005, TRANSPLANTATION, V80, P110, DOI 10.1097/01.TP.0000164142.98167.4B; Brandt C, 2009, ALLERGY; Han GM, 2008, CELL IMMUNOL, V253, P92, DOI 10.1016/j.cellimm.2008.05.007; Mantel PY, 2006, J IMMUNOL, V176, P3593, DOI 10.4049/jimmunol.176.6.3593; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; SAN SD, 2007, TRANSPL P, V39, P2290; van Amelsfort JMR, 2007, ARTHRITIS RHEUM, V56, P732, DOI 10.1002/art.22414; Zeiser R, 2006, BLOOD, V108, P390, DOI 10.1182/blood-2006-01-0329	8	41	42	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					856	858		10.1016/j.jaci.2009.07.056	http://dx.doi.org/10.1016/j.jaci.2009.07.056			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19767068				2022-12-18	WOS:000270802800039
J	Sheehan, WJ; Graham, D; Ma, L; Baxi, S; Phipatanakul, W				Sheehan, William J.; Graham, Dionne; Ma, Lin; Baxi, Sachin; Phipatanakul, Wanda			Higher incidence of pediatric anaphylaxis in northern areas of the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VITAMIN-D; EPIDEMIOLOGY; POPULATION		[Sheehan, William J.; Baxi, Sachin; Phipatanakul, Wanda] Childrens Hosp, Div Immunol, Boston, MA 02115 USA; [Graham, Dionne] Childrens Hosp, Clin Res Program, Boston, MA 02115 USA; [Ma, Lin] Childrens Hosp, Program Patient Safety & Qual, Boston, MA 02115 USA; [Sheehan, William J.; Graham, Dionne; Baxi, Sachin; Phipatanakul, Wanda] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Sheehan, WJ (corresponding author), Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	William.Sheehan@childrens.harvard.edu		Graham, Dionne/0000-0002-1526-547X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073964, T32AI007512, K23AI054972] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI007512-13, K23 AI054972, K-23 AI-054972, R01 AI073964-02, T32-AI-007512, R01 AI073964, R-01 AI-073964, T32 AI007512] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Camargo CA, 2007, AM J CLIN NUTR, V85, P788, DOI 10.1093/ajcn/85.3.788; de Silva IL, 2008, ALLERGY, V63, P1071, DOI 10.1111/j.1398-9995.2008.01719.x; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596, DOI 10.1016/S1081-1206(10)61086-1; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Simons FER, 2008, J ALLERGY CLIN IMMUN, V122, P1166, DOI 10.1016/j.jaci.2008.10.019; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	9	41	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					850	852		10.1016/j.jaci.2009.06.044	http://dx.doi.org/10.1016/j.jaci.2009.06.044			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19703706	Green Accepted			2022-12-18	WOS:000270802800036
J	Suttner, K; Rosenstiel, P; Depner, M; Schedel, M; Pinto, LA; Ruether, A; Adamski, J; Klopp, N; Illig, T; Vogelberg, C; Schreiber, S; von Mutius, E; Kabesch, M				Suttner, Kathrin; Rosenstiel, Philip; Depner, Martin; Schedel, Michaela; Pinto, Leonardo A.; Ruether, Andreas; Adamski, Jerzy; Klopp, Norman; Illig, Thomas; Vogelberg, Christian; Schreiber, Stefan; von Mutius, Erika; Kabesch, Michael			TBX21 gene variants increase childhood asthma risk in combination with HLX1 variants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TBX21; HLX1; asthma; association study; genetic analysis; functional promoter analysis; risk score model	T-BET; TRANSCRIPTION FACTOR; RECEPTOR POLYMORPHISMS; PREVALENCE; HAPLOTYPE; CHILDREN; CELL; EXPRESSION; GERMANY; GATA-3	Background: The T cell-specific T-box transcription factor (TBX21) plays a crucial role in the regulation of the immune system because this factor induces the differentiation of T(H)1 and blocks T(H)2 commitment together with the homeobox transcription factor HLX1. Objective: The role of genetic variants in TBX21 alone and in combination with HLX1 polymorphisms was investigated in the development of T(H)2-associated atopy and asthma. Methods: The TBX21 gene was resequenced in 37 adult volunteers. Polymorphisms identified were genotyped in a cross-sectional (N = 3099) and nested asthma case-control population (N = 1872) using mainly matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Effects of promoter polymorphisms on TBX21 gene expression were studied by reporter gene assays. Furthermore, the impact of combinations of TBX21 and HLX1 polymorphisms on the development of asthma was assessed by using a risk score model. Statistical analyses were performed by using SAS/Genetics. Results: Forty-three polymorphisms were identified in the TBX21 gene. Considering a minor allele frequency of at least 10%, single nucleotide polymorphisms were assigned to 7 linkage disequilibrium blocks. Three tagging single nucleotide polymorphisms increased childhood asthma risk significantly (odds ratio [OR], 2.60, 95% CI, 1.34-5.03, P = .003; OR, 1.39, 95% CI, 1.02-1.90, P = .039; and OR, 1.97,95% CI, 1.18-3.30, P = .009). TBX21 promoter polymorphisms contained in 2 blocks significantly influenced TBX21 promoter activity. In a risk score model, the combination of TBX21 and HLX1 polymorphisms increased the asthma risk by more than 3-fold. Conclusions: These data suggest that TBX21 polymorphisms contribute to the development of asthma, potentially by altering TBX21 promoter activity. A risk score model indicates that TBX21 and HLX1 polymorphisms may have synergistic effects on asthma risk. (J Allergy Clin Immunol 2009;123:1062-8.)	[Kabesch, Michael] Hannover Med Sch, Ctr Paediat, Clin Paediat Pneumol & Neonatol, D-30625 Hannover, Germany; [Rosenstiel, Philip; Ruether, Andreas; Schreiber, Stefan] Univ Hosp Schleswig Holstein, Inst Clin Mol Biol, Campus Kiel, Germany; [Depner, Martin; Pinto, Leonardo A.; von Mutius, Erika] Univ Munich, Univ Childrens Hosp, Munich, Germany; [Adamski, Jerzy] Helmholtz Zentrum Munich, Inst Expt Genet, Neuherberg, Germany; [Klopp, Norman; Illig, Thomas] Helmholtz Zentrum Munich, Inst Epidemiol, Neuherberg, Germany; [Vogelberg, Christian] Univ Childrens Hosp Dresden, Dresden, Germany	Hannover Medical School; University of Kiel; Schleswig Holstein University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technische Universitat Dresden	Kabesch, M (corresponding author), Hannover Med Sch, Ctr Paediat, Clin Paediat Pneumol & Neonatol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	Kabesch.Michael@mh-hannover.de	Kabesch, Michael/AAB-5701-2020; Rosenstiel, Philip/A-5137-2009; Pinto, Leonardo A./C-6866-2008; Schedel, Michaela/B-3065-2019; Kabesch, Michael/GZM-1583-2022; Pinto, Leonardo A./AAG-2800-2020	Rosenstiel, Philip/0000-0002-9692-8828; Pinto, Leonardo A./0000-0002-3906-5456; Schedel, Michaela/0000-0001-8465-2986; Pinto, Leonardo A./0000-0002-3906-5456; Adamski, Jerzy/0000-0001-9259-0199; von Mutius, Erika/0000-0002-8893-4515	German Research Foundation; Allergic Immune Responses of the Lung [A 15, Z3]; National Genome Research Network [NGFN 01GS 0429, NUW-S23T16]; Applied Biosystems; German Research Council; German Ministry of Science; European Union Commission; European Union; Bundesministerium fur Gesundheit; Deutsche Forschungsgemeinschaft	German Research Foundation(German Research Foundation (DFG)); Allergic Immune Responses of the Lung; National Genome Research Network; Applied Biosystems; German Research Council(German Research Foundation (DFG)); German Ministry of Science; European Union Commission(European Commission); European Union(European Commission); Bundesministerium fur Gesundheit; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	Supported by the German Research Foundation as part of trans-regional collaborative research program TR22, Allergic Immune Responses of the Lung, grants A 15 and Z3, and National Genome Research Network research grants NGFN 01GS 0429 to M.K and NUW-S23T16 to P.R. Genotyping was performed in the Genome Analysis Center of the Helmholtz Zentrum Munich.; Disclosure of potential conflict of interest: P. Rosenstiel is a consultant for UCB S.A. Inc and receives grant support from Applied Biosystems. S. Schreiber receives grant support from the German Research Council. the German Ministry of Science, and the European Union Commission. M. Kabesch receives grant support from the European Union, Bundesministerium fur Gesundheit, and Deutsche Forschungsgemeinschaft. The rest of the authors have declared that they have no conflict of interest.	Akahoshi M, 2005, HUM GENET, V117, P16, DOI 10.1007/s00439-005-1285-0; Asher MI, 1998, EUR RESPIR J, V12, P315; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633; Chung Hun Taek, 2003, Hum Mutat, V22, P257, DOI 10.1002/humu.9169; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Ding CM, 2003, P NATL ACAD SCI USA, V100, P3059, DOI 10.1073/pnas.0630494100; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Haas SL, 2007, SCAND J IMMUNOL, V65, P166, DOI 10.1111/j.1365-3083.2006.01876.x; Kiwamoto T, 2006, AM J RESP CRIT CARE, V174, P142, DOI 10.1164/rccm.200601-079OC; Kormann MSD, 2008, J ALLERGY CLIN IMMUN, V122, P86, DOI 10.1016/j.jaci.2008.04.039; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807; Munthe-Kaas MC, 2008, J ALLERGY CLIN IMMUN, V121, P51, DOI 10.1016/j.jaci.2007.07.068; Raby BA, 2006, AM J RESP CRIT CARE, V173, P64, DOI 10.1164/rccm.200503-505OC; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Suttner K, 2009, J ALLERGY CLIN IMMUN, V123, P82, DOI 10.1016/j.jaci.2008.09.047; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tantisira KG, 2004, P NATL ACAD SCI USA, V101, P18099, DOI 10.1073/pnas.0408532102; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Ylikoski E, 2004, CLIN EXP ALLERGY, V34, P1049, DOI 10.1111/j.1365-2222.2004.01995.x; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	25	41	43	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1062	1068		10.1016/j.jaci.2009.02.025	http://dx.doi.org/10.1016/j.jaci.2009.02.025			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	449CW	19362357	Bronze			2022-12-18	WOS:000266309400012
J	Kuehn, A; Hilger, C; Hentges, F				Kuehn, Annette; Hilger, Christiane; Hentges, Francois			Anaphylaxis provoked by ingestion of marshmallows containing fish gelatin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGY		[Hentges, Francois] Ctr Hosp Luxembourg, Unit Immunol & Allergol, Luxembourg, Luxembourg	Luxembourg Hospital Center		annette.kuehn@crp-sante.lu		Hilger, Christiane/0000-0001-9455-5442; Kuehn, Annette/0000-0003-0474-2135				Andre F, 2003, INT ARCH ALLERGY IMM, V130, P17, DOI 10.1159/000068370; Hamada Yuki, 2003, Allergology International, V52, P139, DOI 10.1046/j.1440-1592.2003.00293.x; Hansen TK, 2004, FOOD CHEM TOXICOL, V42, P2037, DOI 10.1016/j.fct.2004.08.008; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; Sakaguchi M, 2000, J ALLERGY CLIN IMMUN, V106, P579, DOI 10.1067/mai.2000.108499; Sakaguchi M, 1996, J ALLERGY CLIN IMMUN, V98, P1058, DOI 10.1016/S0091-6749(96)80191-6; Taylor SL, 2006, CURR OPIN ALLERGY CL, V6, P186, DOI 10.1097/01.all.0000225158.75521.ad; Taylor SL, 2004, J FOOD SCI, V69, pR175, DOI 10.1111/j.1750-3841.2004.tb18022.x; Wang J, 2005, ANN ALLERG ASTHMA IM, V94, P530, DOI 10.1016/S1081-1206(10)61128-3	9	41	41	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					708	709		10.1016/j.jaci.2008.12.012	http://dx.doi.org/10.1016/j.jaci.2008.12.012			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	426TQ	19178936				2022-12-18	WOS:000264731200038
J	Tepper, RS; Llapur, CJ; Jones, MH; Tiller, C; Coates, C; Kimmel, R; Kisling, J; Katz, B; Ding, Y; Swigonski, N				Tepper, Robert S.; Llapur, Conrado J.; Jones, Marcus H.; Tiller, Christina; Coates, Cathy; Kimmel, Risa; Kisling, Jeffrey; Katz, Barry; Ding, Yan; Swigonski, Nancy			Expired nitric oxide and airway reactivity in infants at risk for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; eczema; airway reactivity	AGE 7 YEARS; RESPIRATORY SYMPTOMS; ATOPIC-DERMATITIS; LUNG-FUNCTION; ALLERGIC SENSITIZATION; PARENTAL SMOKING; FAMILY-HISTORY; YOUNG-CHILDREN; NATURAL COURSE; EXHALED NO	Background: Family histories of atopy, as well as histories of atopic dermatitis and food allergy, are important risk factors for an infant to have asthma. Although atopic sensitization appears to contribute to the development of asthma, it is unclear when the airways become involved with the atopic process and whether airway function relates to the atopic characteristics of the infant. Objective: We sought to evaluate whether atopic infants without prior episodes of wheezing have increased expired nitric oxide (eNO) levels and heightened airway reactivity. Methods: Infants with eczema were recruited, and atopic status was defined by specific IgE levels to foods or aeroallergens and total IgE levels. eNO, forced expiratory flow at 75% exhaled volume (FEF(75)), and airway reactivity to inhaled methacholine were measured in sedated infants. Airway reactivity was quantified by using the provocative concentration to decrease FEF75 by 30%. Results: Median age for the 114 infants evaluated was 10.7 months (range, 2.6-19.1 months). Infants sensitized to egg or milk compared with infants sensitized to neither egg nor milk had lower flows (FEF75: 336 vs 285 mL/s, P < .003) and lower InPC(30) (mg/mL) provocative concentrations to decrease FEF75 by 30% (-0.6 vs -1.2, P < .02) but no difference in eNO levels. Infants with total serum IgE levels of greater than 20 IU/mL had higher eNO levels compared with infants with IgE levels of 20 IU/mL or less (14.6 vs 11.2 ppb, P < .023) but no difference in forced flows or airway reactivity. Conclusions: Our findings suggest that atopic characteristics of the infant might be important determinants of the airway physiology of forced expiratory flows, airway reactivity, and eNO.	[Tepper, Robert S.; Tiller, Christina; Coates, Cathy; Kimmel, Risa; Kisling, Jeffrey; Swigonski, Nancy] Indiana Univ, Med Ctr, James Whitcomb Riley Hosp Children, Dept Pediat,Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; [Llapur, Conrado J.] Univ Nacl Tucuman, Fac Med, Hosp Nino Jesus, Dept Pediat,Catedra Metodol Invest, San Miguel De Tucuman, Argentina; [Jones, Marcus H.] Pontificia Univ Catolica Rio de Janeiro, Dept Pediat, Porto Alegre, Brazil; [Katz, Barry; Ding, Yan] Indiana Univ, Med Ctr, Dept Biostat, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Universidad Nacional de Tucuman; Indiana University System; Indiana University-Purdue University Indianapolis	Tepper, RS (corresponding author), Indiana Univ, Med Ctr, James Whitcomb Riley Hosp Children, Dept Pediat,Wells Ctr Pediat Res, 702 Barnhill Dr,ROC 4270, Indianapolis, IN 46202 USA.	rtepper@iupui.edu	Jones, Marcus Herbert/A-3580-2011	Jones, Marcus Herbert/0000-0002-8263-1265	National Institutes of Health [HL54062]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080071, R01HL054062] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Institutes of Health grant no. HL54062.	Barnes Kathleen C, 2007, Proc Am Thorac Soc, V4, P58, DOI 10.1513/pats.200607-146JG; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Bohme M, 2003, CLIN EXP ALLERGY, V33, P1226, DOI 10.1046/j.1365-2222.2003.01749.x; Brusasco V, 1998, THORAX, V53, P992, DOI 10.1136/thx.53.11.992; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Depalo A, 2008, J INTERN MED, V263, P70, DOI 10.1111/j.1365-2796.2007.01875.x; Franklin PJ, 2006, EUR RESPIR J, V28, P730, DOI 10.1183/09031936.06.00007206; Franklin PJ, 2004, CHEST, V126, P1540, DOI 10.1378/chest.126.5.1540; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Frey U, 2004, AM J RESP CRIT CARE, V170, P260, DOI 10.1164/rccm.200307-1002OC; Hall GL, 2002, J APPL PHYSIOL, V92, P59, DOI 10.1152/jappl.2002.92.1.59; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129, DOI 10.1164/ajrccm/145.5.1129; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Jones M, 2000, AM J RESP CRIT CARE, V161, P353, DOI 10.1164/ajrccm.161.2.9903026; Kusel MMH, 2005, J ALLERGY CLIN IMMUN, V116, P1067, DOI 10.1016/j.jaci.2005.06.038; Latzin P, 2006, AM J RESP CRIT CARE, V174, P1292, DOI 10.1164/rccm.200606-782OC; Leuppi JD, 2002, THORAX, V57, P518, DOI 10.1136/thorax.57.6.518; Lopez N, 2002, EUR RESPIR J, V20, P640, DOI 10.1183/09031936.02.00219302; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; MARTINEZ T, 2002, AM J RESP CRIT CARE, V165, pA486; Moeller A, 2008, J ALLERGY CLIN IMMUN, V121, P705, DOI 10.1016/j.jaci.2007.11.008; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37, DOI 10.1164/ajrccm.163.1.2005013; Pucci N, 2005, ALLERGY, V60, P113, DOI 10.1111/j.1398-9995.2004.00622.x; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Ricciardolo FLM, 2004, J ALLERGY CLIN IMMUN, V113, P610, DOI 10.1016/j.jaci.2003.12.034; Saito J, 2004, J ALLERGY CLIN IMMUN, V114, P512, DOI 10.1016/j.jaci.2004.05.033; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45, DOI 10.1164/ajrccm.160.1.9809091; Steerenberg PA, 2003, THORAX, V58, P242, DOI 10.1136/thorax.58.3.242; Stevenson MD, 2007, J PEDIATR-US, V151, P187, DOI 10.1016/j.jpeds.2007.03.001; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1016/j.jaci.2003.08.014; Tepper RS, 2005, AM J RESP CRIT CARE, V171, P78, DOI 10.1164/rccm.200406-711OC; Wang IJ, 2004, ANN ALLERG ASTHMA IM, V93, P334, DOI 10.1016/S1081-1206(10)61391-9; Wildhaber JH, 1999, AM J RESP CRIT CARE, V159, P74, DOI 10.1164/ajrccm.159.1.9805021; Wuthrich B, 2002, ALLERGY, V57, P267, DOI 10.1034/j.1398-9995.2002.1n3572.x; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	42	41	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					760	765		10.1016/j.jaci.2008.07.022	http://dx.doi.org/10.1016/j.jaci.2008.07.022			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	359LU	18760452	Green Accepted, Green Published			2022-12-18	WOS:000259989000021
J	Brandt, EB; Mingler, MK; Stevenson, MD; Wang, N; Hershey, GKK; Whitsett, JA; Rothenberg, ME				Brandt, Eric B.; Mingler, Melissa K.; Stevenson, Michelle D.; Wang, Ning; Hershey, Gurjit K. Khurana; Whitsett, Jeffrey A.; Rothenberg, Marc E.			Surfactant protein D alters allergic lung responses in mice and human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; lung; surfactant protein D; polymorphism; eosinophil; IL-13; Aspergillus; endotoxin	ASPERGILLUS-FUMIGATUS; D GENE; SP-A; HYGIENE HYPOTHESIS; DEFICIENT MICE; SFTPD GENE; ASTHMA; INFLAMMATION; EMPHYSEMA; POLYMORPHISM	Background: Surfactant protein (SP) D has been proposed to be protective in allergic airway responses. Objective: We aimed to determine the effect of SP-D deficiency on murine and human airway allergy. Methods: Immunologic responses of SP-D gene-deficient mice (Sftpd(-/-)) at baseline and after 4 intranasal Aspergillus fumigatus exposures were assessed. In addition, the significance of a single nucleotide polymorphism (Met(11)Thr) in the human SP-D gene (known to decrease SP-D function) was investigated. Results: Macrophage and neutrophil bronchoalveolar lavage fluid levels and large airway mucus production were increased in naive Sftpd(-/-) mice in association with increased lung CCL17 levels and CD4(+) T cell numbers. T(H)2-associated antibody levels (IgG1 and IgE) were significantly lower in 4- to 5-week-old Sftpd(-/-) mice (P <.05). Accordingly, naive Sftpd(-/-) splenocytes released significantly less IL-4 and IL-13 on anti-CD3/CD28 stimulation (P <.01). After intranasal allergen exposures, a modest decrease in bronchoalveolar lavage fluid eosinophilia and IL-13 levels was observed in Sftpd(-/-) mice compared with values seen in wild-type mice in association with decreased airway resistance (P <.01). A single nucleotide polymorphism in the SFTPD gene, affecting SP-D levels and pathogen binding, was associated with decreased atopy in black subjects and potentially lower asthma susceptibility in white subjects. Conclusion: Sftpd(-/-) mice have an impaired systemic T(H)2 response at baseline and reduced inflammation and airway responses after allergen exposure. Translational studies revealed that a polymorphism in the SFTPD gene was associated with lower atopy and possibly asthma susceptibility. Taken together, these results support the hypothesis that SP-D-dependent innate immunity influences atopy and asthma.	[Brandt, Eric B.; Mingler, Melissa K.; Wang, Ning; Hershey, Gurjit K. Khurana; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Div Allergy & Immunol, Dept Pediat,Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Whitsett, Jeffrey A.] Univ Cincinnati, Coll Med, Div Neonatol & Pulm Biol, Dept Pediat,Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Stevenson, Michelle D.] Akron Childrens Hosp, Div Emergency Med, Akron, OH USA; [Stevenson, Michelle D.] Northeastern Ohio Univ Coll Med & Pharm, Akron, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Akron Children's Hospital; Northeast Ohio Medical University (NEOMED)	Rothenberg, ME (corresponding author), Univ Cincinnati, Coll Med, Div Allergy & Immunol, Dept Pediat,Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Rothenberg@cchmc.org		Khurana Hershey, Gurjit/0000-0001-6663-977X; Brandt, Eric/0000-0003-0617-4100; Stevenson, Michelle/0000-0002-3583-4481	NHLBI NIH HHS [P01 HL076383, HL-63329, R01 HL063329, HL-076383] Funding Source: Medline; NIAID NIH HHS [R01 AI42242, AI057803, R01 AI042242, R01 AI057803] Funding Source: Medline; NIAMS NIH HHS [R01 AR042242] Funding Source: Medline; NICHD NIH HHS [T32 HD043005, T32 HD43005-01] Funding Source: Medline; NIEHS NIH HHS [T32 ES010957, T32 ES10957-03] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD043005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063329, P01HL076383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042242, R01AI057803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042242] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES010957] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allen MJ, 1999, INFECT IMMUN, V67, P4563, DOI 10.1128/IAI.67.9.4563-4569.1999; Brandt EB, 2006, CLIN EXP ALLERGY, V36, P543, DOI 10.1111/j.1365-2222.2006.02456.x; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Erpenbeck VJ, 2006, ALLERGY, V61, P598, DOI 10.1111/j.1398-9995.2006.01062.x; Erpenbeck VJ, 2005, AM J PHYSIOL-LUNG C, V288, pL692, DOI 10.1152/ajplung.00362.2004; Fisher JH, 2002, AM J RESP CELL MOL, V27, P24, DOI 10.1165/ajrcmb.27.1.4563; Floros J, 2000, J INFECT DIS, V182, P1473, DOI 10.1086/315866; Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299; Haczku A, 2006, PHARMACOL THERAPEUT, V110, P14, DOI 10.1016/j.pharmthera.2005.08.008; Haczku A, 2006, J IMMUNOL, V176, P3557, DOI 10.4049/jimmunol.176.6.3557; Heidinger K, 2005, IMMUNOGENETICS, V57, P1, DOI 10.1007/s00251-005-0775-5; Hohlfeld JM, 2002, PATHOBIOLOGY, V70, P287, DOI 10.1159/000070744; Jain D, 2007, AM J PHYSIOL-LUNG C, V292, pL861, DOI 10.1152/ajplung.00145.2006; Kishore U, 2005, ARCH IMMUNOL THER EX, V53, P399; Koopmans JG, 2004, CLIN EXP ALLERGY, V34, P1827, DOI 10.1111/j.1365-2222.2004.02083.x; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Krueger M, 2006, PEDIAT ALLERG IMM-UK, V17, P77, DOI 10.1111/j.1399-3038.2005.00353.x; Lahti M, 2002, PEDIATR RES, V51, P696, DOI [10.1203/00006450-200206000-00006, 10.1023/01.PDR.0000015911.65104.93]; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Leth-Larsen R, 2005, J IMMUNOL, V174, P1532, DOI 10.4049/jimmunol.174.3.1532; Lieberam I, 1999, EUR J IMMUNOL, V29, P2684, DOI 10.1002/(SICI)1521-4141(199909)29:09<2684::AID-IMMU2684>3.3.CO;2-P; Liu CF, 2005, CLIN EXP ALLERGY, V35, P515, DOI 10.1111/j.1365-2222.2005.02205.x; Liu WL, 2003, BMC GENET, V4, DOI 10.1186/1471-2156-4-13; Madan T, 1997, CLIN EXP IMMUNOL, V110, P241; Madan T, 2005, J IMMUNOL, V174, P6943, DOI 10.4049/jimmunol.174.11.6943; Madan T, 2001, J CLIN INVEST, V107, P467, DOI 10.1172/JCI10124; Malherbe DC, 2005, AM J PHYSIOL-LUNG C, V289, pL856, DOI 10.1152/ajplung.00009.2005; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; Schaub B, 2004, CLIN EXP ALLERGY, V34, P1819, DOI 10.1111/j.1365-2222.2004.02068.x; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Senft AP, 2005, J IMMUNOL, V174, P4953, DOI 10.4049/jimmunol.174.8.4953; Takeda K, 2003, AM J RESP CRIT CARE, V168, P783, DOI 10.1164/rccm.200304-548OC; Vercelli D, 2006, CURR OPIN IMMUNOL, V18, P733, DOI 10.1016/j.coi.2006.09.002; Wang JY, 1996, CLIN EXP IMMUNOL, V106, P367, DOI 10.1046/j.1365-2249.1996.d01-838.x; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Wert S, 2000, CHEST, V117, p248S, DOI 10.1378/chest.117.5_suppl_1.248S; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Zhang XC, 2006, J CLIN INVEST, V116, P3050, DOI 10.1172/JCI28139	40	41	41	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1140	1147		10.1016/j.jaci.2008.02.011	http://dx.doi.org/10.1016/j.jaci.2008.02.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18355911	Green Accepted			2022-12-18	WOS:000255961700010
J	Heinecke, L; Proud, D; Sanders, S; Schleimer, RP; Kim, J				Heinecke, Lowella; Proud, David; Sanders, Scherer; Schleimer, Robert P.; Kim, Jean			Induction of B7-H1 and B7-DC expression on airway epithelial cells by the Toll-like receptor 3 agonist double-stranded RNA and human rhinovirus infection: In vivo and in vitro studies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B7 homologs; costimulatory ligands; cell-surface molecules; human airway epithelial cells; rhinovirus infection; double-stranded RNA	THYMIC STROMAL LYMPHOPOIETIN; COLONY-STIMULATING FACTOR; NITRIC-OXIDE; T-CELLS; NASAL POLYPS; KAPPA-B; ASTHMA; ACTIVATION; LINE; GLUCOCORTICOIDS	Background: T-cell infiltration of the epithelium is a key feature of chronic rhinosinusitis and asthma. Viral infections are an important cause of disease exacerbations. We have found virus-induced expression of T cell-interacting ligands, B7 homolog costimulatory molecules, on airway epithelium. Objective: We tested the ability of human rhinovirus (HRV) 16 and double-stranded RNA (dsRNA) to alter the expression of B7 homologs on human airway epithelial cells. Methods: BEAS2B and primary human airway epithelial cells were exposed in vitro to dsRNA (25 mu g/mL) or HRV-16, and then expression of cell-surface protein and mRNA for B7 homologs was assessed by means of flow cytometry and real-time PCR, respectively. Additionally, human subjects were infected with HRV-16 in vivo, and mRNA for B7 homologs was assessed by means of real-time PCR in fresh nasal epithelial cell scrapings obtained before and daily up to 4 days after infection. Results: dsRNA exposure of BEAS2B and human primary bronchial epithelial cells resulted in increased levels of cell-surface and mRNA expression of B7-H1 and B7-DC but not B7-H2 or B7-H3. Exposure of primary cells to HRV-16 resulted in induction of cell-surface expression of B7-H1 and B7-DC. Pretreatment with fluticasone propionate failed to suppress the induction of B7-H1 and B7-DC. Nasal scrapings taken at the time of peak symptom scores (3 days) after infection of 6 human subjects with HRV-16 displayed selective induction of levels of mRNA for B7-H1 and B7-DC. Conclusion: These data show that HRV-16 infection or exposure to dsRNA induces epithelial B7-H1 and B7-DC.	[Heinecke, Lowella; Sanders, Scherer; Kim, Jean] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Sanders, Scherer] Johns Hopkins Univ, Sch Med, Dept Pulm Med, Baltimore, MD USA; [Kim, Jean] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD USA; [Proud, David] Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 1N4, Canada; [Schleimer, Robert P.] Northwestern Univ, Feinberg Sch Med, Allergy Immunol Div, Chicago, IL 60611 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Calgary; Northwestern University; Feinberg School of Medicine	Kim, J (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle,Rm 3B65A, Baltimore, MD 21224 USA.	jeankim@jhmi.edu			NCRR NIH HHS [M01 RR002719, M01-RR-02719] Funding Source: Medline; NHLBI NIH HHS [HL078860, HL068546, R01 HL068546, R01 HL078860-02, R01 HL078860, R37 HL068546] Funding Source: Medline; NIAID NIH HHS [AI57400, K23 AI057400] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL068546, R01HL078860, R01HL068546] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI057400] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adkins KK, 1998, AM J PHYSIOL-LUNG C, V275, pL372, DOI 10.1152/ajplung.1998.275.2.L372; Atsuta J, 1999, AM J RESP CELL MOL, V20, P643, DOI 10.1165/ajrcmb.20.4.3265; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; CHURCHILL L, 1992, IMMUNOLOGY, V75, P189; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Deppong C, 2006, J IMMUNOL, V176, P3909, DOI 10.4049/jimmunol.176.7.3909; Garrett J, 1998, ARCH DIS CHILD, V79, P12, DOI 10.1136/adc.79.1.12; Gern JE, 2000, J ALLERGY CLIN IMMUN, V106, P201, DOI 10.1067/mai.2000.108604; Gern JE, 1996, J IMMUNOL, V157, P1605; Gern JE, 1996, J IMMUNOL, V156, P621; GWALTNEY JM, 1992, PROG MED VIROL, V39, P256; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Jahnsen FL, 1998, AM J RESP CELL MOL, V18, P392, DOI 10.1165/ajrcmb.18.3.2995; Kalb TH, 1997, AM J RESP CELL MOL, V17, P561, DOI 10.1165/ajrcmb.17.5.2512; KALB TH, 1991, AM J RESP CELL MOL, V4, P320, DOI 10.1165/ajrcmb/4.4.320; Kato A, 2007, J IMMUNOL, V179, P1080, DOI 10.4049/jimmunol.179.2.1080; KENNEDY DW, 1995, ANN OTO RHINOL LARYN, V104, P22; Kim HK, 2006, J LEUKOCYTE BIOL, V79, P686, DOI 10.1189/jlb.0805436; Kim J, 2005, AM J RESP CELL MOL, V33, P280, DOI 10.1165/rcmb.2004-0129OC; KNIGHT V, 1964, PROG MED VIROL, V6, P1; Kurosawa S, 2003, AM J RESP CELL MOL, V28, P563, DOI 10.1165/rcmb.2002-0199OC; Lee JH, 2001, AM J RESP CELL MOL, V25, P474, DOI 10.1165/ajrcmb.25.4.4522; MILLER CH, 1994, OTOLARYNG HEAD NECK, V111, P51, DOI 10.1177/019459989411100111; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 2000, J ALLERGY CLIN IMMUN, V105, P318, DOI 10.1016/S0091-6749(00)90082-4; Pitkaranta A, 1997, J CLIN MICROBIOL, V35, P1791; PROUD D, 1993, MIDDLETONS ALLERGY P, P373; Radhakrishnan S, 2005, J ALLERGY CLIN IMMUN, V116, P668, DOI 10.1016/j.jaci.2005.04.038; Radhakrishnan S, 2004, J IMMUNOL, V173, P1360, DOI 10.4049/jimmunol.173.2.1360; REDDEL RR, 1988, CANCER RES, V48, P1904; Salik E, 1999, AM J RESP CELL MOL, V21, P365, DOI 10.1165/ajrcmb.21.3.3529; Sanchez-Segura A, 1998, J ALLERGY CLIN IMMUN, V102, P953, DOI 10.1016/S0091-6749(98)70333-1; Sanders SP, 1998, J VIROL, V72, P934, DOI 10.1128/JVI.72.2.934-942.1998; Sanders SP, 2004, J ALLERGY CLIN IMMUN, V113, P697, DOI 10.1016/j.jaci.2004.01.755; Sanders SP, 2001, J ALLERGY CLIN IMMUN, V107, P235, DOI 10.1067/mai.2001.112028; Sanders SP, 2001, AM J RESP CELL MOL, V24, P317, DOI 10.1165/ajrcmb.24.3.4131; Schuh S, 2000, NEW ENGL J MED, V343, P689, DOI 10.1056/NEJM200009073431003; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; STELLATO C, 1995, J IMMUNOL, V155, P410; Stellato C, 2007, J ALLERGY CLIN IMMUN, V120, P1247, DOI 10.1016/j.jaci.2007.10.041; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Suzuki T, 2000, AM J PHYSIOL-LUNG C, V278, pL560, DOI 10.1152/ajplung.2000.278.3.L560; SVEDMYR J, 1995, ACTA PAEDIATR, V84, P884; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Zheng T, 2003, J ALLERGY CLIN IMMUN, V111, P720, DOI 10.1067/mai.2003.1383	48	41	43	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1155	1160		10.1016/j.jaci.2008.02.009	http://dx.doi.org/10.1016/j.jaci.2008.02.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	302IJ	18378285	Green Accepted			2022-12-18	WOS:000255961700012
J	Spahn, JD; Covar, R				Spahn, Joseph D.; Covar, Ronina			Clinical assessment of asthma progression in children and adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma progression; natural history of asthma; lung function decline; remission; relapse; birth cohort studies; early intervention	RESPIRATORY-SYNCYTIAL-VIRUS; LUNG-FUNCTION DECLINE; AIR-FLOW OBSTRUCTION; INHALED CORTICOSTEROID BUDESONIDE; PROSPECTIVE FOLLOW-UP; LONG-TERM TREATMENT; CHILDHOOD ASTHMA; NATURAL-HISTORY; RISK-FACTORS; BRONCHIAL RESPONSIVENESS	Asthma is a heterogeneous disorder with a variable course, characterized by episodes of cough, wheezing and shortness of breath, reversible airflow limitation, and bronchial hyperresponsiveness. It begins early in life in many subjects with intermittent symptoms occurring with viral respiratory tract infections. Over time, and in genetically susceptible children (those with an atopic predisposition), the disease becomes more persistent with symptoms occurring in the absence of respiratory tract infections. Children with persistent wheezing are eventually diagnosed with asthma, with those at greatest risk having developed allergic sensitization early in life. Among children with asthma, some will have lifelong asthma with active symptoms and progressive loss of lung function over time, whereas other children will undergo asthma remission in adolescence. Once in remission, the disease may remain quiescent, or it may relapse in midadult life. This review focuses on studies that have enhanced our understanding of the progression of asthma from infancy to adulthood. Studies evaluating progressive loss of lung function, the best-studied measure of asthma progression, are also reviewed, followed by a brief discussion of whether asthma progression can be modified by inhaled glucocorticoid therapy.	[Spahn, Joseph D.] Natl Jewish Med & Res Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Div Clin Pharmacol, Dept Pediat, Denver, CO 80206 USA; [Spahn, Joseph D.; Covar, Ronina] Natl Jewish Med & Res Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Div Allergy Clin Immunol, Dept Pediat, Denver, CO 80206 USA; [Spahn, Joseph D.; Covar, Ronina] Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Boulder	Spahn, JD (corresponding author), Natl Jewish Med & Res Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Div Clin Pharmacol, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	spahnj@njc.org						[Anonymous], 2007, MORBIDITY MORTALITY, V56; Apostol GG, 2002, AM J RESP CRIT CARE, V166, P166, DOI 10.1164/rccm.2007035; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BROOKE AM, 1995, AM J RESP CRIT CARE, V152, P1872, DOI 10.1164/ajrccm.152.6.8520749; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214, DOI 10.1001/archpedi.1966.02090120082007; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910, DOI 10.1164/ajrccm.153.3.8630572; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Clough JB, 1999, AM J RESP CRIT CARE, V160, P1473, DOI 10.1164/ajrccm.160.5.9807019; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; Delacourt C, 2001, AM J RESP CRIT CARE, V164, P1382, DOI 10.1164/ajrccm.164.8.2007066; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GODDEN DJ, 1994, AM J RESP CRIT CARE, V149, P106, DOI 10.1164/ajrccm.149.1.8111567; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Gustafsson PM, 2000, RESP MED, V94, P466, DOI 10.1053/rmed.1999.0763; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; JENKINS MA, 1994, BRIT MED J, V309, P90, DOI 10.1136/bmj.309.6947.90; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26, DOI 10.1164/ajrccm/138.1.26; KOKKONEN J, 1993, EUR RESPIR J, V6, P657; Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058; Kupczyk M, 2004, RESPIRATION, V71, P233, DOI 10.1159/000077420; Lange P, 2006, THORAX, V61, P100, DOI 10.1136/thx.2004.037978; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Morais-Almeida M, 2007, ALLERGY ASTHMA PROC, V28, P183, DOI 10.2500/aap.2007.28.2953; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Paul EF, 2002, SOCIETY, V39, P7, DOI 10.1007/s12115-002-1000-x; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Porsbjerg C, 2006, CHEST, V129, P309, DOI 10.1378/chest.129.2.309; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; RACKEMANN FM, 1952, NEW ENGL J MED, V246, P815, DOI 10.1056/NEJM195205222462104; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176, DOI 10.1164/ajrccm.165.2.2104032; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; RYSSING E, 1963, ACTA PAEDIATR, V52, P97, DOI 10.1111/j.1651-2227.1963.tb04083.x; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-1404OC; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Taniguchi H, 2002, J ASTHMA, V39, P217, DOI 10.1081/JAS-120002471; Tantisira KG, 2006, J ALLERGY CLIN IMMUN, V117, P1264, DOI 10.1016/j.jaci.2006.01.050; Toelle BG, 2004, EUR RESPIR J, V23, P66, DOI 10.1183/09031936.03.00046903; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107, DOI 10.1164/ajrccm.164.11.2006165; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953, DOI 10.1164/ajrccm.162.3.9909033; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352, DOI 10.1164/ajrccm.158.2.9705079; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	77	41	42	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					548	557		10.1016/j.jaci.2008.01.012	http://dx.doi.org/10.1016/j.jaci.2008.01.012			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	273GR	18328886				2022-12-18	WOS:000253918900001
J	Yamanaka, KI; Dimitroff, CJ; Fuhlbrigge, RC; Kakeda, M; Kurokawa, I; Mizutani, H; Kupper, TS				Yamanaka, Kei-ichi; Dimitroff, Charles J.; Fuhlbrigge, Robert C.; Kakeda, Masato; Kurokawa, Ichiro; Mizutani, Hitoshi; Kupper, Thomas S.			Vitamins A and D are potent inhibitors of cutaneous lymphocyte-associated antigen expression	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						1,25-dihydroxyvitamin D(3); retinoic acid; cutaneous lytnphocyte-associated antigen; chemokine receptor	T-CELLS; E-SELECTIN; SKIN; DIFFERENTIATION; SPECIFICITY; MECHANISMS; MIGRATION; BLOOD; VII	Background: Cutaneous lymphocyte-associated antigen (CLA) is a surface glycoprotein expressed by skin-homing T cells. This carbohydrate moiety expressed on mucin-like surface glycoproteins, including P-selectin glycoprotein ligand 1 and CD43, confers binding activity to dermal endothelial E-selectin and is critical for T-cell recruitment to the skin. Vitamin A (retinoic acid [RA]) and the active form of vitamin D3 (1,25 dihydroxyvitamin D3 [1,251)(3)]) have been used to treat certain T cell-mediated inflammatory skin diseases, as well as cutaneous T-cell lymphomas; however, their effect on CLA expression has not been studied. Objective: We analyzed the effects of RA and 1,25D(3) on expression of CLA and other lymphocyte-homing receptors on human T cells. Methods: We cultured human T cells with 1,25D(3) and RA and analyzed the expression of CLA and other homing receptors. We also pretreated mice with either vitamin and then induced an antigen-dependent contact hypersensitivity response. Results: Both RA and 1,25D(3) downregulated expression of the CLA and, in parallel, functional E-selectin ligand. Whereas RA increased expression of the gut-homing receptor alpha 4 beta 7 and reduced L-selectin expression, 1,251)(3) had no effect on other homing receptors. In an in vivo assay treatment with RA or 1,251)(3) downregulated the skin infiltration of effector CD4(+) T cells. Conclusion: These findings suggest that 1,251)(3) can selectively downregulate CLA expression without influencing lymphocyte migration patterns to other tissues.	[Yamanaka, Kei-ichi; Dimitroff, Charles J.; Fuhlbrigge, Robert C.; Kupper, Thomas S.] Harvard Univ, Harvard Skin Dis Res Ctr, Inst Med, Boston, MA 02115 USA; [Yamanaka, Kei-ichi; Kakeda, Masato; Kurokawa, Ichiro; Mizutani, Hitoshi] Mie Univ, Grad Sch Med, Mie, Japan	Harvard University; Harvard Medical School; Mie University	Kupper, TS (corresponding author), Harvard Univ, Harvard Skin Dis Res Ctr, Inst Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	tskLipper@rics.bwh.harvard.edu	Kupper, Thomas/O-4962-2019	Kakeda, Masato/0000-0001-9011-3655	NATIONAL CANCER INSTITUTE [R01CA118124] Funding Source: NIH RePORTER; NCI NIH HHS [CA118124, R01 CA118124-01A2, R01 CA118124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; Armerding D, 1999, INT ARCH ALLERGY IMM, V119, P212, DOI 10.1159/000024197; Cantorna MT, 2000, J NUTR, V130, P2648, DOI 10.1093/jn/130.11.2648; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S, DOI 10.1093/ajcn/80.6.1717S; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dimitroff CJ, 2003, J CLIN INVEST, V112, P1008, DOI 10.1172/JCI200319220; Dimitroff CJ, 2003, BLOOD, V101, P602, DOI 10.1182/blood-2002-06-1736; Ferenczi K, 2002, J INVEST DERMATOL, V119, P1405, DOI 10.1046/j.1523-1747.2002.19610.x; Fuhlbrigge RC, 2006, BLOOD, V107, P1421, DOI 10.1182/blood-2005-05-2112; Fuhlbrigge RC, 2002, J IMMUNOL, V168, P5645, DOI 10.4049/jimmunol.168.11.5645; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Kitagaki H, 1997, J IMMUNOL, V159, P2484; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Mahon BD, 2003, J CELL BIOCHEM, V89, P922, DOI 10.1002/jcb.10580; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nakayama F, 2000, J INVEST DERMATOL, V115, P299, DOI 10.1046/j.1523-1747.2000.00032.x; Piemonti L, 2000, J IMMUNOL, V164, P4443, DOI 10.4049/jimmunol.164.9.4443; Robert C, 1999, NEW ENGL J MED, V341, P1817, DOI 10.1056/NEJM199912093412407; SANTAMARIA LF, 1995, INT ARCH ALLERGY IMM, V107, P359, DOI 10.1159/000237032; Sigmundsdottir H, 2001, CLIN EXP IMMUNOL, V126, P365, DOI 10.1046/j.1365-2249.2001.01688.x; Sigmundsdottir H, 2007, NAT IMMUNOL, V8, P285, DOI 10.1038/ni1433; Wagers AJ, 1996, BLOOD, V88, P2125, DOI 10.1182/blood.V88.6.2125.bloodjournal8862125	24	41	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					148	157		10.1016/j.jaci.2007.08.014	http://dx.doi.org/10.1016/j.jaci.2007.08.014			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	17910894	Bronze, Green Accepted			2022-12-18	WOS:000252372000022
J	Fawaz, LM; Sharif-Askari, E; Hajoui, O; Soussi-Gounni, A; Hamid, O; Mazer, BD				Fawaz, Lama M.; Sharif-Askari, Ehssan; Hajoui, Oumnia; Soussi-Gounni, Abdelilah; Hamid, Outayba; Mazer, Bruce D.			Expression of IL-9 receptor alpha chain on human germinal center B cells modulates IgE secretion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						germinal center B cells; B-cell maturation; IL-9; IgE	AIRWAY SMOOTH-MUSCLE; TRANSGENIC MICE; INTERLEUKIN 9; DIFFERENTIATION; LYMPHOCYTES; ACTIVATION; ASTHMA; GROWTH; STAT5; HYPERRESPONSIVENESS	Background: IL-9 has been shown to affect the differentiation pathway of different cell types. However, its potential role in the maturation pathway of antigen-driven B-cell differentiation and its functional effects remain unknown. Objective: To characterize IL-9 receptor alpha chain (IL-9R alpha) expression on human tonsillar B cells at different maturational stages, and to assess its effect on IgE production. Methods: Freshly purified human tonsillar B cells were fractionated into 3 populations: low-density (LD), medium-density, and high-density cells. Expression levels of IL-9R alpha were determined by using inummohistochemistry and flow cytometry. IL-9R alpha(high) -expressing cells were stimulated with IL-9 in the presence or absence of IL-4, and IgE release was measured by ELISA. Results: IL-9R alpha was expressed on human LD tonsillar B cells, with an ability to transduce signals through activation of signal transducer and activator of transcription 3 and 5. Although IL-9 was unable to induce IgE secretion by itself, it potentiated IL-4-mediated IgE production from LD cells. Moreover, increased IgE was paralleled by an upregulation of IL-9R alpha and CD27, with the latter a memory B-cell marker implicated in increased IgE secretion. Conclusion: These results highlight a crucial role for IL-9 in modulating T-cell-dependent B-cell differentiation and establish a new paradigm for understanding the synergistic role of T(H)2 cytokines and their modulatory effect on B-cell maturation and IgE production.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Div Expt Med, Dept Med, Montreal, PQ, Canada; McGill Univ, Montreal Childrens Hosp, Res Inst, Div Allergy & Immunol, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Manitoba, Dept Immunol, Winnipeg, MB R3T 2N2, Canada	McGill University; McGill University; McGill University; Universite de Montreal; University of Manitoba	Mazer, BD (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	bruce.mazer@mcgill.ca	Gounni, Abdelilah Soussi/AAH-3456-2020	Soussi Gounni, Abdelilah/0000-0002-7282-0388; Gounni, Abdelilah/0000-0003-1265-6560				Baraldo S, 2003, AM J PHYSIOL-LUNG C, V284, pL1093, DOI 10.1152/ajplung.00300.2002; Bastien Y, 1999, J IMMUNOL, V162, P5498; Busslinger M, 2004, ANNU REV IMMUNOL, V22, P55, DOI 10.1146/annurev.immunol.22.012703.104807; Chow S, 2001, CYTOMETRY, V46, P72, DOI 10.1002/cyto.1067; Chung JB, 2003, TRENDS IMMUNOL, V24, P343, DOI 10.1016/S1471-4906(03)00119-4; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Demoulin JB, 1999, J BIOL CHEM, V274, P25855, DOI 10.1074/jbc.274.36.25855; Demoulin JB, 2000, CANCER RES, V60, P3971; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Demoulin JB, 2001, CELL GROWTH DIFFER, V12, P169; Dong Q, 1999, EUR J IMMUNOL, V29, P2130, DOI 10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO;2-S; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Fornek JL, 2006, BLOOD, V107, P1085, DOI 10.1182/blood-2005-07-2871; Gounni AS, 2000, BLOOD, V96, P2163; Gounni AS, 2004, J IMMUNOL, V173, P2771, DOI 10.4049/jimmunol.173.4.2771; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; Hajoui O, 2004, J ALLERGY CLIN IMMUN, V114, P657, DOI 10.1016/j.jaci.2004.05.034; HAJOUI O, 2007, J ALLERGY CLIN IMMUN; Hendriks RW, 2004, TRENDS IMMUNOL, V25, P249, DOI 10.1016/j.it.2004.02.011; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; Liu YJ, 1997, IMMUNOL REV, V156, P111, DOI 10.1111/j.1600-065X.1997.tb00963.x; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Louahed J, 2000, AM J RESP CELL MOL, V22, P649, DOI 10.1165/ajrcmb.22.6.3927; Louahed J, 2001, BLOOD, V97, P1035, DOI 10.1182/blood.V97.4.1035; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; RENAULD JC, 1994, ONCOGENE, V9, P1327; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Steiniger B, 2005, IMMUNOLOGY, V116, P429, DOI 10.1111/j.1365-2567.2005.02242.x; SUZUKI N, 1988, J CLIN INVEST, V81, P261, DOI 10.1172/JCI113304; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307	34	41	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1208	1215		10.1016/j.jaci.2007.08.022	http://dx.doi.org/10.1016/j.jaci.2007.08.022			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	231TZ	17919707				2022-12-18	WOS:000250973400034
J	Lay, JC; Alexis, NE; Kleeberger, SR; Roubey, RAS; Harris, BD; Bromberg, PA; Hazucha, MJ; Devlin, RB; Peden, DB				Lay, John C.; Alexis, Neil E.; Kleeberger, Steven R.; Roubey, Robert A. S.; Harris, Bradfrd D.; Bromberg, Philip A.; Hazucha, Milan J.; Devlin, Robert B.; Peden, David B.			Ozone enhances markers of innate immunity and antigen presentation on airway monocytes in healthy individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							IN-VIVO; EXPOSURE; ASTHMA; VOLUNTEERS		Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27515 USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA; Natl Inst Environm Hlth, Lab Res Biol, Res Triangle Pk, NC USA; US EPA, Natl Hlth Environm Effects Res Lab, Human Studies Div, Clin Res Branch, Res Triangle Pk, NC 27711 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); United States Environmental Protection Agency	Lay, JC (corresponding author), Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27515 USA.	jcl@med.unc.edu	Lay, John/A-6380-2012; Kleeberger, Steven R/F-1807-2019	Kleeberger, Steven R/0000-0003-2948-8452; Peden, David/0000-0003-4526-4627	NCRR NIH HHS [M01 RR000046-461441, M01 RR000046] Funding Source: Medline; NIEHS NIH HHS [R01 ES012706, R01 ES012706-03] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012706, Z01ES100512] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1396, DOI 10.1016/j.jaci.2006.02.030; Alexis NE, 2005, J ALLERGY CLIN IMMUN, V115, P345, DOI 10.1016/j.jaci.2004.11.040; Alexis NE, 2004, CLIN IMMUNOL, V111, P126, DOI 10.1016/j.clim.2003.12.002; Boehlecke B, 2003, J ALLERGY CLIN IMMUN, V112, P1241, DOI 10.1016/j.jaci.2003.08.052; Eisenbarth SC, 2003, CURR OPIN IMMUNOL, V15, P620, DOI 10.1016/j.coi.2003.09.003; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198, DOI 10.1016/S0091-6749(99)70013-8; Koike E, 2004, TOXICOLOGY, V197, P37, DOI 10.1016/j.tox.2003.12.007; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Vagaggini B, 1999, EUR RESPIR J, V13, P274, DOI 10.1034/j.1399-3003.1999.13b09.x	9	41	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					719	722		10.1016/j.jaci.2007.05.005	http://dx.doi.org/10.1016/j.jaci.2007.05.005			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17586033				2022-12-18	WOS:000249505400037
J	Marks, GB; Bush, RK				Marks, Guy B.; Bush, Robert K.			It's blowing in the wind: New insights into thunderstorm-related asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material							ALTERNARIA; EPIDEMICS; AUSTRALIA; OUTBREAKS; ALLERGENS; EXPOSURE; POLLEN; MOLDS; DUST; RISK		Woolcock Inst Med Res, Sydney, NSW, Australia; Univ Wisconsin, Madison, WI USA; Wm S Middleton VA Hosp, Madison, WI USA	University of Sydney; Woolcock Institute of Medical Research; University of Wisconsin System; University of Wisconsin Madison	Bush, RK (corresponding author), 2500 Overlook Terrace, Madison, WI 53705 USA.	Robert.bush@va.gov	Marks, Guy B./F-5058-2013	Marks, Guy B./0000-0002-8976-8053				Ackroyd J F, 1983, Clin Allergy, V13, P287, DOI 10.1111/j.1365-2222.1983.tb02600.x; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Atkinson RW, 2006, OCCUP ENVIRON MED, V63, P580, DOI 10.1136/oem.2005.024448; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Codina R, 1998, J ALLERGY CLIN IMMUN, V102, P318, DOI 10.1016/S0091-6749(98)70102-2; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455, DOI 10.1164/ajrccm.164.3.2008042; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Green BJ, 2005, CLIN DIAGN LAB IMMUN, V12, P1114, DOI 10.1128/CDLI.12.9.1114-1116.2005; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; MENDES E, 1954, J ALLERGY, V25, P253, DOI 10.1016/0021-8707(54)90183-5; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PACKE GE, 1985, LANCET, V2, P199; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PICCOLO MC, 1988, ANN ALLERGY, V60, P107; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; Pulimood TB, 2007, J ALLERGY CLIN IMMUN, V120, P610, DOI 10.1016/j.jaci.2007.04.045; REDFEARN P L, 1953, Med Bull US, V1, P108; SALVAGGIO JE, 1967, J ALLERGY, V39, P227, DOI 10.1016/0021-8707(67)90015-9; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	23	41	42	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					530	532		10.1016/j.jaci.2007.07.012	http://dx.doi.org/10.1016/j.jaci.2007.07.012			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17765752				2022-12-18	WOS:000249505400006
J	Yamada, J; Hamuro, J; Hatanaka, H; Hamabata, K; Kinoshita, S				Yamada, Jun; Hamuro, Junji; Hatanaka, Hiroki; Hamabata, Kuniko; Kinoshita, Shigeru			Alleviation of seasonal allergic symptoms with superfine beta-1-glucan: A randomized study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alergic conjunctivitis; beta-1,3-glucan; immunoregulation; macrophages	ANTIGEN-PRESENTING CELLS; INDUCED AIRWAY HYPERRESPONSIVENESS; DISTINCTIVE CYTOKINE PRODUCTION; HEAT-KILLED LISTERIA; HYGIENE HYPOTHESIS; T-CELLS; ALTERNATIVE ACTIVATION; LUNG MACROPHAGES; IFN-GAMMA; 2 PARTS	Background: The incidence of allergic symptoms to cedar pollen has reached epidemic proportions in Japan. Intravenous injection of beta-1,3-glucan in human subjects is known to induce a TO response, whereas oral uptake does not. Objective: It was examined whether orally ingested, superfine dispersed beta-1,3-glucan (SDG), easily absorbed by intestinal mucosa, would alleviate allergic symptoms. Methods: Allergic patients were orally administrated either SDG (n = 30) or nondispersed beta-1,3-glucan (n = 30), and allergic symptoms were assessed clinically in a double-blind, placebo-controlled randomized study. Results: SDG alleviated ongoing symptoms of Japanese cedar pollen-induced rhinorrhea, sneezing, nasal congestion, and itchy watery eyes, and its oral uptake before symptom onset exhibited preventive effects. Alleviation of allergic symptoms was evident not only for seasonal allergy to cedar pollen but also for perennial allergy. Oral ingestion of beta-1,3-glucan in individuals with allergic tropism could reduce the spontaneous increase in both allergen-specific and total IgE titers. The clinical responses to treatment were well correlated with the capacity of monocytes to bind to beta-1,3-glucan. Although SDG reduced allergic symptoms, the oral uptake of nondispersed beta-1,3-glucan produced no clinical effects, despite the identical amount of beta-1,3-glucan in both preparations. Conclusion: We postulate that orally taken beta-1.3-glucan prepared in a form easily absorbed by intestinal mucosa is able to alleviate cedar pollen-induced allergic symptoms. Clinical implications: Orally effective SDG might greatly contribute to the resolution of epidemic medical problems of seasonal cedar pollen-induced allergy.	Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan; Meiji Univ Oriental Med, Dept Ophthalmol, Kyoto, Japan	Kyoto Prefectural University of Medicine	Yamada, J (corresponding author), Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan.	jyamada@ophth.kpu-m.ac.jp						Brusselle GG, 1997, AM J RESP CELL MOL, V17, P767, DOI 10.1165/ajrcmb.17.6.2820; Bufford JD, 2005, IMMUNOL ALLERGY CLIN, V25, P247, DOI 10.1016/j.iac.2005.03.005; CHIHARA G, 1969, Nature (London), V222, P687; CHIHARA G, 1970, CANCER RES, V30, P2776; DAVIES P, 1976, AGENTS ACTIONS, V6, P60, DOI 10.1007/BF01972187; Desmedt M, 1998, J IMMUNOL, V160, P5300; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Fireman P, 1997, AM J RHINOL, V11, P95, DOI 10.2500/105065897782537142; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gentile DA, 2000, IMMUNOL ALLERGY CLIN, V20, P355, DOI 10.1016/S0889-8561(05)70152-1; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; HAMURO J, 1985, RETICULOENDOTHELIAL, V8; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J IMMUNOL, V164, P223, DOI 10.4049/jimmunol.164.1.223; Holgate ST, 1999, NATURE, V402, pB2, DOI 10.1038/35037000; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535, DOI 10.1164/ajrccm.153.2.8564093; Kreutner W, 2000, ARZNEIMITTEL-FORSCH, V50, pE345; Laskin DL, 2001, J LEUKOCYTE BIOL, V70, P163; Liu AH, 2006, J ALLERGY CLIN IMMUN, V117, P1063, DOI 10.1016/j.jaci.2006.03.027; Marcucci F, 2003, ALLERGY, V58, P657, DOI 10.1034/j.1398-9995.2003.00193.x; Mills CD, 2000, J IMMUNOL, V164, P6166, DOI 10.4049/jimmunol.164.12.6166; Munder M, 1998, J IMMUNOL, V160, P5347; Murata Y, 2002, INT IMMUNOPHARMACOL, V2, P673, DOI 10.1016/S1567-5769(01)00212-0; Murata Y, 2002, INT IMMUNOL, V14, P201, DOI 10.1093/intimm/14.2.201; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Spector S, 1999, J ALLERGY CLIN IMMUN, V103, pS386, DOI 10.1016/S0091-6749(99)70217-4; Suga Y., 2005, BIOTHERAPY, V19, P273; TAGUCHI T, 1985, RATIONALE BIOL RESPO, P151; Takeuchi M, 1998, J IMMUNOL, V160, P1589; Tang CB, 1998, J ALLERGY CLIN IMMUN, V102, P368, DOI 10.1016/S0091-6749(98)70122-8; Tang CB, 2001, J IMMUNOL, V166, P1471, DOI 10.4049/jimmunol.166.3.1471; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; Underhill DM, 2004, CURR OPIN IMMUNOL, V16, P483, DOI 10.1016/j.coi.2004.05.012; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Utsugi M, 2003, J IMMUNOL, V171, P628, DOI 10.4049/jimmunol.171.2.628; Yeung VP, 1998, J IMMUNOL, V161, P4146	44	41	46	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1119	1126		10.1016/j.jaci.2007.02.005	http://dx.doi.org/10.1016/j.jaci.2007.02.005			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17379290				2022-12-18	WOS:000246427200011
J	Jeon, SG; Lee, CG; Oh, MH; Chun, EY; Gho, YS; Cho, SH; Kim, JH; Min, KU; Kim, YY; Kim, YK; Elias, JA				Jeon, Seong Gyu; Lee, Chun Geun; Oh, Min-Hee; Chun, Eun-Young; Gho, Yong Song; Cho, Sang-Heon; Kim, Jong-Hoon; Min, Kyung-Up; Kim, You-Young; Kim, Yoon-Keun; Elias, Jack A.			Recombinant basic fibroblast growth factor inhibits the airway hyperresponsiveness, mucus production, and lung inflammation induced by an allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway hyperresponsiveness; FGF2; mucus production	ASTHMA; RESPONSES; FIBROSIS; OVEREXPRESSION; INTERLEUKIN-13; MYOFIBROBLAST; APOPTOSIS	Background: IL-13 is believed to be a central mediator of asthma. and TGF-beta 1 is a key downstream mediator in the development of IL-13-mediated asthma phenotypes. Objective: To evaluate the biological roles of basic fibroblast growth factor (FGF2) in phenotype expression in transgenic (TG) mice overexpressing lung-specific TGF-beta 1, and the therapeutic effects of recombinant FGF2 in the development of asthma phenotypes. Methods: To evaluate the roles of FGF2 in airway hyperresponsiveness (AHR) expression induced by high levels of TGF-beta 1. TGF-beta 1 TG (+) mice were bred with FGF2-deficient mice. To evaluate the therapeutic effects of recombinant FGF2 (rFGF2) in the development of asthma, mice were given 10 mu g of rFGF2 subcutaneously once a day, I hour before the allergen challenge in an asthma mouse model. AHR was evaluated using noninvasive whole-body plethysmography, mucus production by diastase-resistant periodic acid Schiff (DPAS) staining, and lung inflammation using bronchoalveolar lavage (BAL) cellularity and lung histology. Results; AHR decreased in TGF-beta 1 TG (+) mice and was accompanied by the upregulation of FGF2 mRNA expression in lung tissues, when compared with littermate wild-type control mice. Interestingly, AHR was enhanced markedly in TGF-beta 1 mice with homozygous FGF2 gene disruption. In an asthma mouse model, AHR, mucus production, and lung inflammation were inhibited markedly by rFGF2 treatment. This inhibition was accompanied by downregulation of the allergen-induced proliferation of T cells from regional lymph nodes. Conclusion: FGF2 seems to be a key inhibitor in the development of AHR, and rFGF2 treatment constrains the development of asthma phenotypes.	Pohang Univ Sci & Technol, Dept Life Sci, Postech Biotech Ctr, Pohang 790784, South Korea; Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT USA; Seoul Natl Univ, Dept Internal Med, Inst Allergy & Clin Immunol, Coll Med, Seoul 151, South Korea; Korea Univ, Coll Life Sci & Biotechnol, Div Biotechnol, Seoul, South Korea	Pohang University of Science & Technology (POSTECH); Yale University; Seoul National University (SNU); Korea University	Kim, YK (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Postech Biotech Ctr, San 31, Pohang 790784, South Korea.	juinea@postech.ac.kr	Min, Kyung-Up/J-5468-2012; Cho, Sang Heon/J-2793-2012; Kim, Jong-Hoon/H-1476-2015; Kim, Jong-Hoon/F-2504-2013; Lee, Chun Geun/AAC-2838-2021	Kim, Jong-Hoon/0000-0003-3419-0538; Oh, Min-Hee/0000-0003-1581-4288; Lee, Chun Geun/0000-0002-9514-3658				Bhandari V, 2006, P NATL ACAD SCI USA, V103, P11021, DOI 10.1073/pnas.0601057103; Bosse Y, 2006, AM J RESP CELL MOL, V34, P746, DOI 10.1165/rcmb.2005-0309OC; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate ST, 2002, MOL BIOTECHNOL, V22, P179, DOI 10.1385/MB:22:2:179; Hoshino A, 2004, INT IMMUNOL, V16, P1497, DOI 10.1093/intimm/dxh151; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee CG, 2002, J BIOL CHEM, V277, P35466, DOI 10.1074/jbc.M206395200; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee Chun Geun, 2006, Proc Am Thorac Soc, V3, P418, DOI 10.1513/pats.200602-017AW; Maltseva O, 2001, INVEST OPHTH VIS SCI, V42, P2490; Morishima Y, 2001, AM J RESP CELL MOL, V24, P1; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Park Y, 2001, J ALLERGY CLIN IMMUN, V108, P570; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Vicencio AG, 2004, AM J RESP CELL MOL, V31, P650, DOI 10.1165/rcmb.2004-0092OC; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	25	41	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					831	837		10.1016/j.jaci.2006.12.653	http://dx.doi.org/10.1016/j.jaci.2006.12.653			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17289133				2022-12-18	WOS:000245729500010
J	Pajno, GB				Pajno, Giovanni B.			Sublingual immunotherapy: The optimism and the issues	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sublingual immunotherapy; asthma; rhinitis; food allergy; early intervention	HOUSE-DUST MITE; DOUBLE-BLIND; ALLERGIC RHINITIS; FOLLOW-UP; INHALED CORTICOSTEROIDS; SWALLOW IMMUNOTHERAPY; ATOPIC-DERMATITIS; CLINICAL-EFFICACY; FOOD ALLERGY; CHILDREN	The acceptability of sublingual immunotherapy (SLIT) in guidelines or statements has recently increased. SLIT is currently used in Europe, Asia, and Australia for the treatment of allergic respiratory diseases. Four meta-analyses have shown that SLIT is an effective tool for the treatment of patients with asthma and/or rhinitis, and only conflicting results were reported for children with allergic rhinitis. Moreover, it offers logistic advantages and is safe. However, some unmet needs are to be faced, such as the difficulty of manufacturers to achieve the homogeneity of standardized vaccines, the magnitude of their clinical efficacy, and the pivotal question of an early intervention with SLIT in young children with IgE-mediated disorders. Altogether, SLIT has already given convincing results in respiratory diseases both in adults and children. In the future, this route of administration of allergic vaccines may improve even the treatment of patients with IgE-mediated food allergy. These patients indeed deserve better than allergen avoidance. The immunomodulatory treatment of allergic diseases probably has found a new tool; however, a more balanced understanding of this form of allergen immunotherapy is needed. This aim could be achieved through: (1) the improvement of products standardization quality; (2) an attempt to modify in children the natural course of allergic diseases; and (3) new research on mechanisms of action.	Univ Messina, Dept Pediat, Allergy Unit, I-98125 Messina, Italy	University of Messina	Pajno, GB (corresponding author), Univ Messina, Dept Pediat, Allergy Unit, Via Consolare Valeria, I-98125 Messina, Italy.	Giovanni.Pajno@unime.it						AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; BOCK SA, 1987, PEDIATRICS, V79, P683; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1398-9995.2006.01205.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Chapman JA, 2006, ANN ALLERG ASTHMA IM, V96, pS1, DOI 10.1016/S1081-1206(10)60926-X; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254, DOI 10.1016/S1081-1206(10)61222-7; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Grier TJ, 2002, ALLERGY ASTHMA PROC, V23, P125; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hasseus B, 2004, CLIN EXP IMMUNOL, V136, P483, DOI 10.1111/j.1365-2249.2004.02469.x; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kinet JP, 2005, NEW ENGL J MED, V353, P310, DOI 10.1056/NEJMcibr051440; Kowalski ML, 2006, ALLERGY, V61, P791, DOI 10.1111/j.1398-9995.2006.01187.x; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li JT, 2003, ANN ALLERG ASTHMA IM, V90, P1, DOI 10.1016/S1081-1206(10)63600-9; Lowenstein H, 2001, Curr Allergy Asthma Rep, V1, P474, DOI 10.1007/s11882-001-0036-0; MALLING HJ, 1993, ALLERGY, V48, P9; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Mistrello G, 1996, ALLERGY, V51, P8, DOI 10.1111/j.1398-9995.1996.tb04543.x; Moingeon P, 2006, ALLERGY, V61, P15, DOI 10.1111/j.1398-9995.2006.01157.x; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Niggemann B, 2006, ALLERGY, V61, P808, DOI 10.1111/j.1398-9995.2006.01066.x; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; OSTERGAARD PA, 1986, ALLERGY, V41, P588; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2006, J ALLERGY CLIN IMMUN, V117, pS233, DOI 10.1016/j.jaci.2005.12.921; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Patriarca G, 2003, ALIMENT PHARM THER, V17, P459, DOI 10.1046/j.1365-2036.2003.01468.x; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141, DOI 10.1016/S1081-1206(10)60004-X; Potter PC, 2006, ANN ALLERG ASTHMA IM, V96, pS22, DOI 10.1016/S1081-1206(10)60898-8; Ree R, 2004, ALLERGY, V59, P571, DOI 10.1111/j.1398-9995.2004.00499.x; Saarinen KM, 2005, J ALLERGY CLIN IMMUN, V116, P869, DOI 10.1016/j.jaci.2005.06.018; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Taams LS, 1999, J IMMUNOL, V162, P1974; VANREE R, 2005, PHARMEUROPA BIO, P27; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Wuthrich B, 1996, MONOGR ALLERGY, V32, P236	64	41	46	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					796	801		10.1016/j.jaci.2007.01.009	http://dx.doi.org/10.1016/j.jaci.2007.01.009			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17306355				2022-12-18	WOS:000245729500004
J	Semic-Jusufagic, A; Bachert, C; Gevaert, P; Holtappels, G; Lowe, L; Woodcock, A; Simpson, A; Custovic, A				Semic-Jusufagic, Aida; Bachert, Claus; Gevaert, Philippe; Holtappels, Gabriele; Lowe, Lesley; Woodcock, Ashley; Simpson, Angela; Custovic, Adrian			Staphylococcus aureus sensitization and allergic disease in early childhood: Population-based birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Staphylococcus aureus; superantigens; early life; wheeze; eczema	ENTEROTOXIN-B; ATOPIC-DERMATITIS; AIRWAY-RESISTANCE; NASAL CARRIAGE; ASTHMA; INFLAMMATION; CHILDREN; RHINITIS; SKIN; SUPERANTIGENS	Background: Staphylococcus aureus-secreted enterotoxins (SEs) may be involved in the pathophysiology of atopic diseases. Objective: We investigated the role of SEs in allergic diseases during early childhood (using the mixture of SE-specific IgEs [SE-mix] as a marker). Methods: Children (N = 510) were followed from birth to age 5 years (repeated questionnaires, IgE to inhalant and food allergens, lung function [spirometry, plethysmography], airway reactivity [dry air challenge]). We measured SE-mix specific IgE (SE-A, SE-C, toxic shock syndrome toxin 1) by using fluorescence immunoassay. Results: We found no association between rhinitis and SE-mix sensitization. Children with eczema were more frequently SE-mix-sensitized than children without (17.4% vs 8.3%; P =.02). SE-mix sensitization rate increased significantly with increasing eczema severity (no eczema, mild, moderate/severe: 8.3%, 14.8%, 42.9%; P =.003) and remained independently associated with eczema in a multivariate model adjusting for total IgE (adjusted odds ratio, 2.19; 95% CI, 1.05-4.56; P =.04). SE-mix sensitization was associated with current wheeze in the univariate but not the multivariate model. Among wheeze phenotypes, persistent wheezers were most commonly sensitized to SE-mix (never, transient, late-onset, persistent: 8.5%, 3.8%, 7.7%, 17.6%; P =.05). Among wheezers, those SE-mix-sensitized had significantly higher airway reactivity compared with those nonsensitized (mean FEV1 change, mL [95% CI]: -59 [-121, 31 vs 19 [-10.2, 48.9]; P =.04), with little difference after adjusting for atopy. Conclusion: We found differences in SE-mix IgE antibodies between healthy 5-year-old children and children with eczema and wheeze. The proportion of patients sensitized to SE-mix increases with increasing disease severity. Clinical implications: Staphylococcal enterotoxins are potential modifiers of childhood wheeze and eczema.	Univ Manchester, Manchester M13 9PL, Lancs, England; Univ Ghent, Ghent, Belgium	University of Manchester; Ghent University	Semic-Jusufagic, A (corresponding author), Univ Manchester, NW Lung Ctr, Wythenshawe Hosp, Manchester M23 9LT, Lancs, England.	aidajusufagic@yahoo.com	Custovic, Adnan/A-2435-2012; Bachert, Claus/J-8825-2012; Gevaert, Philippe/AAP-1892-2020; Gevaert, Philippe/ABA-4588-2021	Custovic, Adnan/0000-0001-5218-7071; Gevaert, Philippe/0000-0002-1629-8468; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666				Akiyama H, 1996, ARCH DERMATOL RES, V288, P418, DOI 10.1007/BF02507115; Bachert C, 2003, J ALLERGY CLIN IMMUN, V111, P1131, DOI 10.1016/S0091-6749(03)70044-X; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Breuer K, 2001, ALLERGY, V56, P1034, DOI 10.1034/j.1398-9995.2001.00146.x; Breuer K, 2000, ALLERGY, V55, P551, DOI 10.1034/j.1398-9995.2000.00432.x; Cardona ID, 2006, J ALLERGY CLIN IMMUN, V117, P688, DOI 10.1016/j.jaci.2005.11.037; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; DAB I, 1976, PEDIATR RES, V10, P996, DOI 10.1203/00006450-197612000-00009; Hauk PJ, 1999, J ALLERGY CLIN IMMUN, V104, P37, DOI 10.1016/S0091-6749(99)70111-9; Heaton T, 2003, ALLERGY, V58, P252, DOI 10.1034/j.1398-9995.2003.00088.x; Hellings PW, 2006, CLIN EXP ALLERGY, V36, P1063, DOI 10.1111/j.1365-2222.2006.02527.x; Herz U, 1999, EUR J IMMUNOL, V29, P1021, DOI 10.1002/(SICI)1521-4141(199903)29:03<1021::AID-IMMU1021>3.0.CO;2-3; Klug B, 1997, EUR RESPIR J, V10, P1599, DOI 10.1183/09031936.97.10071599; Laouini D, 2003, J ALLERGY CLIN IMMUN, V112, P981, DOI 10.1016/j.jaci.2003.07.007; Lee JH, 2005, INT ARCH ALLERGY IMM, V138, P305, DOI 10.1159/000088868; Lehmann HS, 2004, INT ARCH ALLERGY IMM, V135, P306, DOI 10.1159/000082324; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P215, DOI 10.1067/mai.2003.1590; Okano M, 2001, AM J RHINOL, V15, P417, DOI 10.1177/194589240101500611; PEARCE N, 1993, EUR RESPIR J, V6, P1455; Perez-Novo CA, 2006, AM J RHINOL, V20, P456, DOI 10.2500/ajr.2006.20.2873; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; Riechelmann H, 2005, ALLERGY, V60, P1418, DOI 10.1111/j.1398-9995.2005.00902.x; Rohde G, 2004, RESP MED, V98, P858, DOI 10.1016/j.rmed.2004.02.012; Shiomori T, 2000, J ALLERGY CLIN IMMUN, V105, P449, DOI 10.1067/mai.2000.104256; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Zhang N, 2005, RHINOLOGY, V43, P162	29	41	42	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					930	936		10.1016/j.jaci.2006.12.639	http://dx.doi.org/10.1016/j.jaci.2006.12.639			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	157OK	17292957				2022-12-18	WOS:000245729500023
J	de Diego, RP; Lopez-Granados, E; Pozo, M; Rodriguez, C; Sabina, P; Ferreira, A; Fontan, G; Garcia-Rodriguez, MC; Alemany, S				de Diego, Rebeca Perez; Lopez-Granados, Eduardo; Pozo, Maite; Rodriguez, Cristina; Sabina, Prado; Ferreira, Antonio; Fontan, Gurnersindo; Garcia-Rodriguez, Maria Cruz; Alemany, Susana			Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						X-linked agammaglobulinemia; Bruton's tyrosine kinase; LPS signaling; mitogen-activated protein kinases; tumor necrosis factor alpha; IL-6; oxidative burst activity; monocytes	X-LINKED AGAMMAGLOBULINEMIA; DEFICIENT EXPRESSION; RECEPTOR; FAMILY; BTK	Background: X-linked agammaglobulinemia (XLA) is characterized by impaired B-cell differentiation caused by mutations in the Bruton's tyrosine kinase (Btk) gene. The natural disease model, the X-linked immunodeficiency mouse, shows a less severe phenotype, indicating a different requirement of Btk in human and mouse B cells. Btk is also expressed in the myeloid line and participates in LPS signaling. Deficient oxidative burst and myeloid differentiation have been reported in the X-linked immunodeficiency mouse, but the precise mechanism and relevance of Btk activity in human monocytes is poorly understood. Objective: The apparent absence in XLA of clinical manifestations of myeloid deficiency prompted us to explore the relevance of complete Btk absence in human myeloid cells. Methods: Seven patients with XLA with BTK mutations conditioning a null protein expression were included in the study. Monocyte LPS-induced mitogen-activated protein kinase activation, TNF-alpha and IL-6 production in monocytes, and oxidative burst in monocytes and granulocytes were analyzed by means of flow cytometry. Results: We show that in response to LPS, Btk-null monocytes from patients with XLA induce early mitogen-activated protein kinase activation and intracellular TNF-a and IL-6 production with the same intensity as cells from age- and sex-matched control subjects. In addition, the oxidative burst in response to LPS and other stimulants was completely normal in Btk-null monocytes and neutrophils. Conclusion: Our results indicate that Btk is not essential for early LPS signaling in human monocytes and that different Btk dependency might exist between human and mouse myeloid cells. Clinical implications: These findings provide a better understanding of XLA, and they show the differences between human XLA and murine Xid models.	Univ Hosp La Paz, Immunol Unit, Madrid 28046, Spain; Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Fac Med, Madrid, Spain	Hospital Universitario La Paz; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	de Diego, RP (corresponding author), Univ Hosp La Paz, Immunol Unit, PoCastellana,261, Madrid 28046, Spain.	rperez.hulp@salud.madrid.org; mcruzgarcia.hulp@salud.madrid.org	Alemany, Susana/J-6307-2014	Alemany, Susana/0000-0002-4089-7620; Perez de Diego, Rebeca/0000-0001-8426-8765				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Caivano M, 2003, J BIOL CHEM, V278, P52124, DOI 10.1074/jbc.M306583200; Cham B, 2002, SEMIN HEMATOL, V39, P107, DOI 10.1053/shem.2002.31916; Conley ME, 1999, CLIN IMMUNOL, V93, P189, DOI 10.1006/clim.1999.4798; Futatani T, 1998, BLOOD, V91, P595; Gagliardi MC, 2003, CLIN EXP IMMUNOL, V133, P115, DOI 10.1046/j.1365-2249.2003.t01-1-02178.x; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Jefferies CA, 2004, IMMUNOL LETT, V92, P15, DOI 10.1016/j.imlet.2003.11.017; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Johnston RB, 2001, CURR OPIN HEMATOL, V8, P17, DOI 10.1097/00062752-200101000-00004; Kollias G, 1999, ANN RHEUM DIS, V58, P32, DOI 10.1136/ard.58.2008.i32; LEDERMAN HM, 1985, MEDICINE, V64, P145, DOI 10.1097/00005792-198505000-00001; Mangla A, 2004, BLOOD, V104, P1191, DOI 10.1182/blood-2004-01-0207; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MCKINNEY RE, 1987, REV INFECT DIS, V9, P334; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Rodriguez M C, 2001, Hum Mutat, V18, P84, DOI 10.1002/humu.1155; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Sawyer D W, 1989, Rev Infect Dis, V11 Suppl 7, pS1532; Schmidt U, 2004, J EXP MED, V199, P785, DOI 10.1084/jem.20031109; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wangwijit T, 2002, POLYM ADVAN TECHNOL, V13, P25, DOI 10.1002/pat.149; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2	29	41	42	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1462	1469		10.1016/j.jaci.2006.01.037	http://dx.doi.org/10.1016/j.jaci.2006.01.037			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751014				2022-12-18	WOS:000238332300040
J	Limb, SL; Brown, KC; Wood, RA; Wise, RA; Eggleston, PA; Tonascia, J; Adkinson, NF				Limb, SL; Brown, KC; Wood, RA; Wise, RA; Eggleston, PA; Tonascia, J; Adkinson, NF			Irreversible lung function deficits in young adults with a history of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood asthma; pulmonary function test; spirometry; methacholine sensitivity	RISK-FACTORS; CHILDREN; POPULATION; GROWTH; AGE	Background: Asthma, traditionally characterized as reversible airway obstruction, might lead to structural changes and permanent impairment. Objective: We sought to study the frequency, severity, and reversibility of pulmonary deficits in adults with a history of moderate-to-severe childhood allergic asthma. Methods: Subjects (n = 121) previously enrolled in a randomized trial of immunotherapy for childhood asthma were recalled. Eighty-four young adults (age, 17-30 years; 78% male) were reevaluated by means of spirometry. Subjects with a postbronchodilator FEV1, forced vital capacity, or FEV1/forced vital capacity ratio less than or equal to the 5th percentile or 2 or more indices less than or equal to the 10th percentile (National Health and Nutrition Examination Survey III normative data) were invited to undergo complete pulmonary function testing, physical examination, and chest radiography after 1 week of 1 mg/kg daily prednisone. Results: Of 84 subjects reevaluated, 40 (48%) bad one or more spirometric indices less than or equal to the 5th and 10th percentiles (P < .0001). Twenty-eight of the 40 subjects were reassessed after prednisone treatment, of whom 21 (75%) did not improve. Adult and childhood (age 5-12 years) spirometric results were positively correlated (r = 0.49-0.72, P < .001). Abnormal adult spirometric results were associated with a longer duration of asthma at enrollment in the original trial (4.6 vs 6 years, P = .02), increased childhood methacholine sensitivity (PC20, 0.11 vs 0.18 mg/mL; P = .01), and birth prematurity (adjusted odds ratio, 10.7; 95% CI, 1.4-84.5). Immunotherapy status was unrelated to adult lung function. Conclusions: Many adults with a history of moderate-to-severe allergic asthma in childhood have irreversible lung function deficits. Childhood spirometry, duration of asthma, methacholine sensitivity, and birth prematurity might identify such individuals at a young age.	Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Adkinson, NF (corresponding author), Rm 2A62,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	fadkinso@jhmi.edu		Wise, Robert/0000-0002-8353-2349	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002719] Funding Source: NIH RePORTER; NCRR NIH HHS [5M01RR02719] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Bacharier LB, 2003, PEDIATRICS, V112, pE85, DOI 10.1542/peds.112.2.e85; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830, DOI 10.1164/ajrccm.160.6.9812100; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Jenkins HA, 2003, CHEST, V124, P32, DOI 10.1378/chest.124.1.32; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Raby BA, 2004, PEDIATRICS, V114, pE327, DOI 10.1542/peds.2003-0838-L; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50, DOI 10.1164/ajrccm.162.1.9811005	22	41	42	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1213	1219		10.1016/j.jaci.2005.09.024	http://dx.doi.org/10.1016/j.jaci.2005.09.024			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IJ	16337448				2022-12-18	WOS:000235687000007
J	Eggleston, PA				Eggleston, PA			Improving indoor environments: Reducing allergen exposures	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						environment; aeroallergen; allergen exposure; allergen; dust mites; pets; cockroach	HOUSE-DUST-MITE; FEL-D-I; COCKROACH ALLERGENS; MOUSE ALLERGEN; BEDDING ENCASEMENT; CHEMICAL TREATMENT; AVOIDANCE MEASURES; ASTHMATIC-PATIENTS; CONTROLLED-TRIAL; AIR FILTRATION	Homes cannot be made allergen free, but exposure to the major indoor allergens can be reduced. All reduction recommendations are based on the principle of reducing or isolating the source, and certain recommendations can be made on the basis of published evidence. House dust mite avoidance measures include fitting allergen-proof mattress and pillow encasings, washing bedding regularly, and reducing humidity. Furred pet avoidance requires removal of the pet form the home, followed by thorough and repeated cleaning; room air cleaners, washing the pet, and isolating the pet from a bedroom are ineffective alternatives. Cockroach allergen avoidance begins with effective pest control, followed by thorough and repeated cleaning; 1 to 2 months are required to eliminate roaches, and an additional 4 to 6 months are required to remove residual allergen. Once allergen levels have been reduced, continued efforts are necessary to maintain the home free of allergen sources.	Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA	Johns Hopkins University	Eggleston, PA (corresponding author), Johns Hopkins Univ Hosp, Dept Pediat, CMSC 1102,600 N Wolfe St, Baltimore, MD USA.	pegglest@jhmi.edu			NHLBI NIH HHS [HL058942] Funding Source: Medline; NIEHS NIH HHS [ES09606] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL058942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009606] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V113, P109, DOI 10.1016/j.jaci.2003.10.042; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, P99, DOI 10.1067/mai.2001.112119; Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; CORN M, 1983, J ALLERGY CLIN IMMUN, V72, P231, DOI 10.1016/0091-6749(83)90026-X; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53, DOI 10.1046/j.1365-2222.1998.00183.x; CUSTOVIC A, 1995, CLIN EXP ALLERGY, V25, P312, DOI 10.1111/j.1365-2222.1995.tb01048.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94, DOI 10.1164/ajrccm.155.1.9001295; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; De Lucca SD, 1999, J ALLERGY CLIN IMMUN, V104, P672, DOI 10.1016/S0091-6749(99)70341-6; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842, DOI 10.1016/S0091-6749(99)70296-4; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V107, pS422, DOI 10.1067/mai.2001.113671; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V107, pS403, DOI 10.1067/mai.2001.113673; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Francis H, 2003, CLIN EXP ALLERGY, V33, P101, DOI 10.1046/j.1365-2222.2003.01570.x; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gore RB, 2003, CLIN EXP ALLERGY, V33, P765, DOI 10.1046/j.1365-2222.2003.01678.x; Green R, 1999, ALLERGY, V54, P484, DOI 10.1034/j.1398-9995.1999.00029.x; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; Institute of Medicine (US) Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Luczynska C, 2003, CLIN EXP ALLERGY, V33, P1648, DOI 10.1111/j.1365-2222.2003.01729.x; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; Miller J. D., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81180-8; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Munir A K, 1993, Pediatr Allergy Immunol, V4, P136, DOI 10.1111/j.1399-3038.1993.tb00082.x; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; Niven RM, 1999, J ALLERGY CLIN IMMUN, V103, P756, DOI 10.1016/S0091-6749(99)70416-1; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Paul K, 1998, EUR J PEDIATR, V157, P109, DOI 10.1007/s004310050780; Phipatanakul W, 2004, ANN ALLERG ASTHMA IM, V92, P420, DOI 10.1016/S1081-1206(10)61777-2; Rijssenbeek-Nouwens LHM, 2002, THORAX, V57, P784, DOI 10.1136/thorax.57.9.784; Sporik R, 1998, J ALLERGY CLIN IMMUN, V101, P451, DOI 10.1016/S0091-6749(98)70352-5; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; VANDENHOVE T, 1993, ALLERGY, V48, P264, DOI 10.1111/j.1398-9995.1993.tb00726.x; VANDERBREMPT X, 1991, J ALLERGY CLIN IMMUN, V87, P595, DOI 10.1016/0091-6749(91)90020-O; vanderHeide S, 1997, ALLERGY, V52, P921, DOI 10.1111/j.1398-9995.1997.tb01252.x; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; Vojta PJ, 2001, ENVIRON HEALTH PERSP, V109, P815, DOI 10.2307/3454824; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358, DOI 10.1164/ajrccm/137.2.358; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115, DOI 10.1164/ajrccm.158.1.9712110; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; WOODFOLK JA, 1994, J ALLERGY CLIN IMMUN, V94, P19, DOI 10.1016/0091-6749(94)90066-3	50	41	45	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					122	126		10.1016/j.jaci.2005.04.012	http://dx.doi.org/10.1016/j.jaci.2005.04.012			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990784				2022-12-18	WOS:000235686300019
J	Kawai, K; Tsuno, NH; Matsuhashi, M; Kitayama, J; Osada, T; Yamada, J; Tsuchiya, T; Yoneyama, S; Watanabe, T; Takahashi, K; Nagawa, H				Kawai, K; Tsuno, NH; Matsuhashi, M; Kitayama, J; Osada, T; Yamada, J; Tsuchiya, T; Yoneyama, S; Watanabe, T; Takahashi, K; Nagawa, H			CD11b-mediaited migratory property of peripheral blood B cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						B cell; peripheral blood; CD11b; migration	SPLENIC MARGINAL ZONE; EPIGALLOCATECHIN GALLATE; LYMPHOID-TISSUES; MATRIX PROTEINS; HUMAN-MEMORY; L-SELECTIN; IN-VITRO; T-CELLS; ADHESION; EXPRESSION	Background: CD11b belongs to the integrin family and is expressed on neutrophils, monocytes, natural killer cells, and a subset of lymphocytes. Although CD11b expressed on neutrophils and monocytes has been extensively investigated and has been reported to play an important role in the migration of these subsets of leukocytes, the function of CD11b expressed on a subset of B cells has not yet been clarified. Objective: To elucidate the functional activity of CD11b expressed on B cells, we characterized the CD11b-expressing cells among the B-cell population and investigated their migratory ability. Methods: Isolated peripheral blood CD19(+) B cells were analyzed by flow cytometry. The migratory ability of B cells was evaluated by the transwell assay, and the contribution of CD11b to this ability was investigated by using an anti-CD11b blocking mAb. Results: The majority of CD27(-)IgD(+) naive B cells were CD11b(-), whereas most CD27(+) memory cells were CD11b(+). Among the CD27(+) memory cells, expression of CD11b was stronger on the IgD(-) cells than on the IgD(+) cells. In the transwell assay, the migrating cells were predominantly CD27(+)IgD(-) cells, most of which expressed CD11b. The addition of an anti-CD11b blocking mAb resulted in the significant reduction of the number of migrating B cells. Conclusion: Memory B cells express CD11b and, in contrast with naive B cells, have high migratory ability. CD11b plays an essential role in the homing process of memory cells.	Univ Tokyo, Dept Surg Oncol, Fac Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Transfus Med, Fac Med, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo	Kawai, K (corresponding author), Univ Tokyo, Dept Surg Oncol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kz-kawai@mvd.biglobe.ne.jp	Kawai, Kazushige/AAF-4334-2020	Kawai, Kazushige/0000-0002-5881-0036				Agematsu K, 2000, IMMUNOL TODAY, V21, P204, DOI 10.1016/S0167-5699(00)01605-4; ARNOLD LW, 1994, J EXP MED, V179, P1585, DOI 10.1084/jem.179.5.1585; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BOHNSACK JF, 1990, J EXP MED, V171, P1221, DOI 10.1084/jem.171.4.1221; BUTCHER EC, 1986, CURR TOP MICROBIOL, V128, P85; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Carsetti R, 2004, IMMUNOL REV, V197, P179, DOI 10.1111/j.0105-2896.2004.0109.x; Csencsits KL, 2001, J IMMUNOL, V167, P2441, DOI 10.4049/jimmunol.167.5.2441; Ding ZM, 1999, J IMMUNOL, V163, P5029; Elphick GF, 2003, J APPL PHYSIOL, V95, P199, DOI 10.1152/japplphysiol.01054.2002; KASAIAN MT, 1992, J IMMUNOL, V148, P2690; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI 10.1016/S0091-6749(03)02007-4; Kawai K, 2004, J ALLERGY CLIN IMMUN, V113, P1211, DOI 10.1016/j.jaci.2004.02.044; Lo CG, 2003, J EXP MED, V197, P353, DOI 10.1084/jem.20021569; Lu TT, 2002, SCIENCE, V297, P409, DOI 10.1126/science.1071632; LUNDGRENAKERLUND E, 1993, SCAND J IMMUNOL, V37, P569, DOI 10.1111/j.1365-3083.1993.tb02573.x; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MAURER D, 1992, J IMMUNOL, V148, P3700; NIELSEN HV, 1994, J IMMUNOL, V153, P2021; Ottonello L, 1999, J IMMUNOL, V162, P6510; PICKER LJ, 1994, CURR OPIN IMMUNOL, V6, P394, DOI 10.1016/0952-7915(94)90118-X; POSTIGO AA, 1991, J EXP MED, V174, P1313, DOI 10.1084/jem.174.6.1313; Rott LS, 2000, J LEUKOCYTE BIOL, V68, P807; Roy MP, 2002, J IMMUNOL, V169, P1676, DOI 10.4049/jimmunol.169.4.1676; Shi YH, 2003, CLIN IMMUNOL, V108, P128, DOI 10.1016/S1521-6616(03)00092-5; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; THOMPSON HL, 1992, CLIN EXP IMMUNOL, V90, P280; Weller S, 2004, BLOOD, V104, P3647, DOI 10.1182/blood-2004-01-0346; Yoshino T, 1999, CELL IMMUNOL, V197, P39, DOI 10.1006/cimm.1999.1552	30	41	44	1	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					192	197		10.1016/j.jaci.2005.03.021	http://dx.doi.org/10.1016/j.jaci.2005.03.021			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990794				2022-12-18	WOS:000235686300029
J	Sanak, M; Szczeklik, W; Szczeklik, A				Sanak, M; Szczeklik, W; Szczeklik, A			Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CYCLOOXYGENASE-2 GENE; POLYMORPHISM		Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Krakow, Poland	Jagiellonian University	Sanak, M (corresponding author), Jagiellonian Univ, Sch Med, Dept Med, Ul Skawinska 8, PL-31066 Krakow, Poland.		Sanak, Marek/A-2115-2008; Szczeklik, Wojciech/N-8096-2014; Sanak, Marek/AAV-1628-2021	Szczeklik, Wojciech/0000-0002-1349-1123; Sanak, Marek/0000-0001-7635-8103				Ahmadi KR, 2005, NAT GENET, V37, P84, DOI 10.1038/ng1488; Campa D, 2004, CARCINOGENESIS, V25, P229, DOI 10.1093/carcin/bgh008; Papafili A, 2002, ARTERIOSCL THROM VAS, V22, P1631, DOI 10.1161/01.ATV.0000030340.80207.C5; SCHNEIDER S, ARLEQUIN VER 2 00 SO; Shi J, 2004, CLIN EXP ALLERGY, V34, P1714, DOI 10.1111/j.1365-2222.2004.02094.x; Szczeklik W, 2004, J ALLERGY CLIN IMMUN, V114, P248, DOI 10.1016/j.jaci.2004.05.030	6	41	42	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					221	223		10.1016/j.jaci.2005.03.010	http://dx.doi.org/10.1016/j.jaci.2005.03.010			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IC	15990799	Green Submitted			2022-12-18	WOS:000235686300034
J	Luijk, B; Lindemans, CA; Kanters, D; van der Heijde, R; Bertics, P; Lammers, JWJ; Bates, ME; Koenderman, L				Luijk, B; Lindemans, CA; Kanters, D; van der Heijde, R; Bertics, P; Lammers, JWJ; Bates, ME; Koenderman, L			Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						priming; allergen challenge; eosinophils; allergic asthma; peripheral blood	ANTIGEN CHALLENGE; BONE-MARROW; ASTHMA; INFLAMMATION; EXPRESSION; RESPONSIVENESS; MOBILIZATION; INDIVIDUALS; ACTIVATION; DISEASE	Background: Eosinophils isolated from the blood of patients with allergic asthma exhibit enhanced responsiveness to multiple stimuli compared with cells from normal controls, a phenomenon generally referred to as priming. This priming response is essential for optimal activation with augmented responses including chemotaxis, cytotoxicity, respiratory burst, and the release of proinflammatory lipid mediators. Objective: To monitor the kinetics of priming of eosinophils in the peripheral blood and in the bronchoalveolar lavage fluid of patients with allergic asthma before and after allergen challenge. Methods: Priming of blood eosinophils obtained from patients with allergy and donors without allergy was measured by labeling with monoclonal phage antibodies A17 and A27 recognizing priming-associated epitopes on phagocytes. In addition, blood and bronchoalveolar lavage fluid eosinophils from subjects with allergy after segmental and whole lung allergen challenge were similarly analyzed. Results: A dose-dependent cytokine-induced upregulation of priming-associated epitopes on blood eosinophils was found. Patients with allergic asthma exhibited an in vivo partially primed eosinophil phenotype, which is further primed in vitro after cytokine or chemokine incubation. Priming was increased in peripheral blood 6 hours after whole lung challenge as well as after segmental allergen challenge. Interestingly, eosinophils obtained from the bronchoalveolar lavage fluid 48 hours after segmental allergen challenge exhibited a higher primed phenotype. Conclusion: These data are consistent with a model in which local allergic inflammatory reactions induce partial systemic eosinophil priming in the peripheral blood. Eosinophils found in the airway are highly primed, consistent with the markedly upregulated inflammatory capacity observed in these cells.	Univ Utrecht, Med Ctr, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	Utrecht University; University of Wisconsin System; University of Wisconsin Madison	Koenderman, L (corresponding author), Univ Utrecht, Med Ctr, Dept Pulm Dis, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	L.Koenderman@hli.azu.nl	Koenderman, Leo/AAE-7870-2020	Koenderman, Leo/0000-0002-5636-6453	NCRR NIH HHS [MO RR03186] Funding Source: Medline; NHLBI NIH HHS [HL56396 P50] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465, DOI 10.1164/ajrccm/147.6_Pt_1.1465; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Cyr MM, 2001, CURR OPIN IMMUNOL, V13, P727, DOI 10.1016/S0952-7915(01)00286-2; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; Grutters JC, 1999, EUR RESPIR J, V14, P915, DOI 10.1034/j.1399-3003.1999.14d31.x; HARGREAVE FE, 1993, ALLERGY, V48, P81, DOI 10.1111/j.1398-9995.1993.tb04705.x; Horvath I, 1998, AM J RESP CRIT CARE, V158, P1042, DOI 10.1164/ajrccm.158.4.9710091; Jarjour NN, 1997, AM J RESP CRIT CARE, V155, P1515, DOI 10.1164/ajrccm.155.5.9154851; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; KOBAYASHI T, 1994, CLIN EXP IMMUNOL, V96, P110; Koenderman L, 2000, J LEUKOCYTE BIOL, V68, P58; Koenderman L, 1996, Eur Respir J Suppl, V22, p119s; Koenderman L, 2001, ALLERGY, V56, P204, DOI 10.1034/j.1398-9995.2001.056003204.x; KUIJPERS TW, 1991, BLOOD, V78, P1105; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; MENGELERS HJ, 1994, AM J RESP CRIT CARE, V149, P345, DOI 10.1164/ajrccm.149.2.8306028; MOSER R, 1992, J IMMUNOL, V149, P1432; *NAT HEART LUNG BL, 2002, PUBL NAT HEART LUNG; Pignatti P, 2002, ALLERGY, V57, P411, DOI 10.1034/j.1398-9995.2002.23454.x; Pizzichini MMM, 1996, EUR RESPIR J, V9, P449, DOI 10.1183/09031936.96.09030449; Saracli T, 1967, J Asthma Res, V4, P219; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SEHMI R, 1992, BLOOD, V79, P2952; Sehmi R, 2003, IMMUNOLOGY, V109, P536, DOI 10.1046/j.1365-2567.2003.01686.x; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Stirling RG, 2001, AM J RESP CRIT CARE, V164, P1403, DOI 10.1164/ajrccm.164.8.2010002; van der Bruggen T, 1998, J ALLERGY CLIN IMMUN, V101, P103, DOI 10.1016/S0091-6749(98)70200-3; Venge P, 1999, CLIN EXP ALLERGY, V29, P1172; WARRINGA RAJ, 1992, BLOOD, V79, P1836	32	41	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					997	1003		10.1016/j.jaci.2005.02.002	http://dx.doi.org/10.1016/j.jaci.2005.02.002			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	925LR	15867857				2022-12-18	WOS:000229055100015
J	Kaufmann, R; Folster-Holst, R; Hoger, P; Thaci, D; Loffler, H; Staab, D; Brautigam, M				Kaufmann, R; Folster-Holst, R; Hoger, P; Thaci, D; Loffler, H; Staab, D; Brautigam, M		CASM981CDE04-Study Grp	Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						piniecrolimus; infants; atopic eczema; dermatitis	LONG-TERM MANAGEMENT; SDZ ASM 981; ANTIINFLAMMATORY DRUG; SEVERITY INDEX; SKIN DISEASES; MAST-CELLS; DERMATITIS; EFFICACY; ASM-981; SAFETY	Background: Data on the efficacy of pimecrolimus cream 1% within the first days of treatment are scarce, as in previous studies, the first postbaseline assessment was performed only after 1 week. Objective: We sought to investigate the onset of action of pimecrolimus cream 1% in infants with mild to very severe atopic eczema. Methods: We used pimecrolimus cream 1% (n = 129) or vehicle cream (n = 66) administered in a double-blind manner for 4 weeks and then open-label pimecrolimus cream 1% for 12 weeks, with a 4-week follow-up period. Results: Pimecrolimus cream 1% reduced the mean Eczema Area and Severity Index at 4 weeks by 71.5% compared with an increase of 19.4% with vehicle (P < .001). The reduction in the Eczema Area and Severity Index with pimecrolimus cream 1% was significant at day 4 (38.5% vs 17.6% increase with vehicle). Significant improvements in caregivers' assessments of pruritus and sleep loss were observed with pimecrolimus cream 1% by day 2 (P < .03) and day 3 (P = .002), respectively, compared with vehicle. Responses to pimecrolimus cream 1% were sustained during the open-label phase, and pimecrolimus cream 1% was well tolerated. Symptoms of atopic eczema returned gradually after discontinuation. Conclusion: Pimecrolimus cream 1% was well tolerated and effective in patients with mild to very severe atopic eczema, with rapid onset of action and no disease rebound after discontinuation.	Johann Wolfgang Goethe Univ Hosp, Dept Dermatol & Venerol, Hautklin, D-60590 Frankfurt, Germany; Univ Kiel, Hautklin, Kiel, Germany; Univ Hamburg, Dept Dermatol, Div Paediat Dermatol, Hamburg, Germany; Novartis Pharma GmbH, Clin Res, Nurnberg, Germany; Charite Virchow Klinikum, Kinderklin & Poliklin, Berlin, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Kiel; University of Hamburg; Novartis; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kaufmann, R (corresponding author), Johann Wolfgang Goethe Univ Hosp, Dept Dermatol & Venerol, Hautklin, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	kaufmann@em.uni-frankfurt.de	Hoeger, Peter/G-2269-2017; Thaci, Prof. Dr Diamant/K-5455-2012; Thaci, Diamant/AAE-7310-2022; Fölster-Holst, Regina/A-9560-2010	Hoeger, Peter/0000-0003-3268-7479; Braeutigam, Matthias/0000-0002-1961-6396; Thaci, Diamant/0000-0001-8513-550X				*ADM UFAD, 1997, FED REGISTER, V62, P25691; Barbier N, 2004, BRIT J DERMATOL, V150, P96, DOI 10.1111/j.1365-2133.2004.05696.x; BODE HH, 1980, JAMA-J AM MED ASSOC, V244, P813, DOI 10.1001/jama.244.8.813; Boguniewicz Mark, 2003, Journal of Allergy and Clinical Immunology, V112, pS140, DOI 10.1016/j.jaci.2003.09.031; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Grassberger M, 1999, BRIT J DERMATOL, V141, P264; Gunther S, 1976, Z Hautkr, V51, P569; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; HILL CJH, 1978, CUTIS, V21, P624; Ho VC, 2003, J PEDIATR-US, V142, P155, DOI 10.1067/mpd.2003.65; Hultsch T, 1998, ARCH DERMATOL RES, V290, P501, DOI 10.1007/s004030050343; Kapp A, 2002, J ALLERGY CLIN IMMUN, V110, P277, DOI 10.1067/mai.2002.126500; KAY J, 1994, J AM ACAD DERMATOL, V30, P35, DOI 10.1016/S0190-9622(94)70004-4; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; LARSEN FS, 1993, MONOGR ALLERGY, V31, P9; MCLEAN CJ, 1995, LANCET, V345, P330, DOI 10.1016/S0140-6736(95)90324-0; Meingassner JG, 1997, BRIT J DERMATOL, V137, P568, DOI 10.1111/j.1365-2133.1997.tb03788.x; Meurer M, 2002, DERMATOLOGY, V205, P271, DOI 10.1159/000065863; Queille C, 1984, Pediatr Dermatol, V1, P246, DOI 10.1111/j.1525-1470.1984.tb01124.x; Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x; Raimer SS, 2000, CLIN PEDIATR, V39, P1, DOI 10.1177/000992280003900101; REID P, 1995, CLIN EXP DERMATOL, V20, P38, DOI 10.1111/j.1365-2230.1995.tb01280.x; RUIZMALDONADO R, 1982, AM J DIS CHILD, V136, P274, DOI 10.1001/archpedi.1982.03970390088024; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; STALDER JF, 1993, DERMATOLOGY, V186, P23, DOI 10.1159/000247298; Wadonda N, 2000, BR J DERMATOL S57, V143, P33; Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2; Zuberbier T, 2001, J ALLERGY CLIN IMMUN, V108, P275, DOI 10.1067/mai.2001.116865	29	41	52	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1183	1188		10.1016/j.jaci.2004.08.015	http://dx.doi.org/10.1016/j.jaci.2004.08.015			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536429				2022-12-18	WOS:000225047800029
J	Karlsson, AS; Andersson, B; Renstrom, A; Svedmyr, J; Larsson, K; Borres, MP				Karlsson, AS; Andersson, B; Renstrom, A; Svedmyr, J; Larsson, K; Borres, MP			Airborne cat allergen reduction in classrooms that use special school clothing or ban pet ownership	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cat allergen; allergen sampling; airborne; Fel d 1; intervention; school; petri dish; allergen avoidance; pump	EXPOSURE; ASTHMA; CHILDREN; DUST; DOG; SENSITIZATION; HOMES; SITE; MITE	Background: Allergens from furred animals are brought to school mainly via clothing of pet owners. Asthmatic children allergic to cat have more symptoms when attending a class with many cat owners, and some schools allocate specific resources to allergen avoidance measures. Objective: The aim of the current study was to evaluate the effect of school clothing or pet owner-free classes compared with control classes on airborne cat allergen levels and to investigate attitudes and allergic symptoms among the children. Methods; Allergen measurements were performed prospectively in 2 classes with school clothing, 1 class of children who were not pet owners, and 3 control classes during a 6-week period in 2 consecutive years. Portable pumps and petri dishes were used for collection of airborne cat allergen, and a roller was used for sampling on children's clothes. Cat allergen (Fel d 1) was analyzed with enzyme-linked immunoassay and immunostaining. Both years, questionnaires were administered to the children. Results: We found 4-fold to 6-fold lower airborne cat allergen levels in intervention classes compared with control classes. Levels of cat allergen were 3-fold higher on clothing of cat owners than of children without cats in control classes. Pet ownership ban seemed less accepted than school clothing as an intervention measure. Conclusion: For the first time, it has been shown that levels of airborne cat allergen can be reduced by allergen avoidance measures at school by using school clothing or pet ownership ban, and that both measures are equally efficient. The clinical effect of these interventions remains to be evaluated.	Pharmacia Diagnost AB, S-75182 Uppsala, Sweden; Falun Cent Hosp, Paediat Clin, Falun, Sweden; Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden	Pfizer; Pharmacia Corporation; Falun Hospital; Karolinska Institutet	Karlsson, AS (corresponding author), Karolinska Inst, Inst Environm Med, Box 287, S-17177 Stockholm, Sweden.	Anne-Sophie.Karlsson@imm.ki.se	Tuluc, Petronel/C-2527-2011					Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Borres MP, 2002, ALLERGY, V57, P454, DOI 10.1034/j.1398-9995.2002.13650.x; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164, DOI 10.1111/j.1365-2222.1994.tb03323.x; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; ENBERG RN, 1993, ANN ALLERGY, V70, P471; Heissenhuber A, 2003, ALLERGY, V58, P154, DOI 10.1034/j.1398-9995.2003.00037.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Karlsson AS, 2002, CLIN EXP ALLERGY, V32, P1776, DOI 10.1046/j.1365-2222.2002.01553.x; Karlsson AS, 2002, ALLERGY, V57, P164, DOI 10.1034/j.1398-9995.2002.1s3297.x; KARLSSON AS, IN PRESS ALLERGY; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; OLIVER J, 1995, INT ARCH ALLERGY IMM, V107, P452, DOI 10.1159/000237078; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Reisman RE, 2001, ANN ALLERG ASTHMA IM, V87, P41, DOI 10.1016/S1081-1206(10)62339-3; Ritz BR, 2002, ALLERGY, V57, P357, DOI 10.1034/j.1398-9995.2002.1s3404.x; Wickman M, 1999, CLIN EXP ALLERGY, V29, P626	20	41	41	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1172	1177		10.1016/j.jaci.2003.12.590	http://dx.doi.org/10.1016/j.jaci.2003.12.590			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	829ZI	15208601				2022-12-18	WOS:000222091000025
J	de Meer, G; Toelle, BG; Ng, K; Tovey, E; Marks, GB				de Meer, G; Toelle, BG; Ng, K; Tovey, E; Marks, GB			Presence and timing of cat ownership by age 18 and the effect on atopy and asthma at age 28	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						childhood cat ownership; asthma; AHR; atopy; wheeze	HOUSE-DUST ENDOTOXIN; ALLERGEN SENSITIZATION; BRONCHIAL HYPERRESPONSIVENESS; CHILDHOOD ASTHMA; INDOOR ALLERGENS; COMMON ALLERGENS; PET OWNERSHIP; RISK-FACTORS; EXPOSURE; CHILDREN	Background: Asthma and allergic sensitization to cats frequently coexist, although recent studies show less atopic disease among people who had pets in infancy. However, no long-term evaluations have been performed thus far. Objective: We sought to evaluate the relationship between cat ownership at different age periods (< 18, > 18, and both periods and atopic disease at age 28. Methods: Australian school children aged 8 to 10 years were recruited in 1982 and participated in follow-up surveys until 2002. Cat ownership was defined by surveys in 1992 and 2002 as having a cat before age 18 only, after age 18 only, or in both periods of life. Health outcomes were defined at a mean age of 28.5 years. Results: Complete data were available for 224 subjects, 50 of whom had a cat before 18 years of age only, 14 after age 18 only, and 70 in both periods. Compared with 90 subjects that never had a cat, having a cat before age 18 protected against atopy to outdoor allergens, airway hyperresponsiveness (AHR) to histamine, current wheeze, and current asthma (P < .05). In contrast, subjects who acquired their first cat after age 18 showed a trend toward higher prevalence rates for asthma symptoms and AHR (P > .10). Conclusions: Having had a cat before 18 years of age protects against adult asthma and atopy.	Univ Utrecht, Inst Risk Assessment Sci Environm & Occupat Hlth, NL-3508 TD Utrecht, Netherlands; Woolcock Inst Med Res, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia	Utrecht University; University of Sydney; Woolcock Institute of Medical Research; University of Sydney	de Meer, G (corresponding author), Univ Utrecht, Inst Risk Assessment Sci Environm & Occupat Hlth, POB 80176, NL-3508 TD Utrecht, Netherlands.		Tovey, Euan R/G-8604-2017; Marks, Guy B./F-5058-2013; Toelle, Brett G/B-1531-2008	Tovey, Euan R/0000-0002-1802-7266; Marks, Guy B./0000-0002-8976-8053; Toelle, Brett G/0000-0002-7375-0019				Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; Arshad SH, 2001, J INVEST ALLERG CLIN, V11, P94; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1111/j.1365-2222.1997.tb00672.x; Chan-Yeung M, 1999, CLIN EXP ALLERGY, V29, P762; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805, DOI 10.1164/ajrccm.152.6.8520740; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; DELACOURT C, 1994, ALLERGY, V49, P843, DOI 10.1111/j.1398-9995.1994.tb00785.x; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356, DOI 10.1164/ajrccm.155.4.9105079; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; LIN RY, 1993, ANN ALLERGY, V71, P33; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775, DOI 10.1016/S0091-6749(99)70287-3; Noertjojo K, 1999, J ALLERGY CLIN IMMUN, V103, P60, DOI 10.1016/S0091-6749(99)70526-9; NORRMAN E, 1994, ALLERGY, V49, P808, DOI 10.1111/j.1398-9995.1994.tb00779.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Parameswaran K, 1999, J ASTHMA, V36, P613, DOI 10.3109/02770909909087299; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Ritz BR, 2002, ALLERGY, V57, P357, DOI 10.1034/j.1398-9995.2002.1s3404.x; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Sporik R, 1999, THORAX, V54, P675, DOI 10.1136/thx.54.8.675; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	39	41	43	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					433	438		10.1016/j.jaci.2003.10.008	http://dx.doi.org/10.1016/j.jaci.2003.10.008			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007342				2022-12-18	WOS:000220144200013
J	Hohlfeld, JM; Schmiedl, A; Erpenbeck, VJ; Venge, P; Krug, N				Hohlfeld, JM; Schmiedl, A; Erpenbeck, VJ; Venge, P; Krug, N			Eosinophil cationic protein alters pulmonary surfactant structure and function in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; airway obstruction; eosinophils; surfactant function; surfactant ultrastructure	SEGMENTAL ALLERGEN CHALLENGE; BRONCHOALVEOLAR LAVAGE; NARROW TUBE; INFLAMMATION; SPUTUM; DYSFUNCTION; AIRWAYS; DISEASE; LUNG; RAT	Background: Impaired surfactant function has been demonstrated in patients with asthma. Inhibitory proteins originating from plasma or inflammatory mediators are good candidates to contribute to this dysfunction. Eosinophils are potent effector cells in asthma, which, on activation, release inflammatory mediators, especially reactive granula proteins such as eosinophil cationic protein (ECP). Objective: Because the potential role of ECP in the inhibition of surfactant function is not known, we tested the hypothesis of whether ECP levels in bronchoalveolar lavage fluid (BALF) of patients with asthma after segmental allergen provocation correlate to surfactant dysfunction. Furthermore, we tested the effect of purified ECP on surfactant function and structure in vitro. Methods: Surfactant isolated from BALF of asthmatic patients was assessed for biophysical function with the Pulsating Bubble Surfactometer and the Capillary Surfactometer and correlated to ECP levels. Purified ECP and plasma proteins at various concentrations were incubated with natural surfactant. Surfactant function was studied with the Capillary Surfactometer, and surfactant structure was determined by electron microscopy. Results: ECP is elevated in BALF from patients with asthma after allergen challenge compared with baseline. ECP levels after allergen challenge correlate well to surfactant dysfunction. In vitro, ECP induces a concentration-dependent inhibition of surfactant function that can be inhibited by antibodies against ECP. ECP is more potent compared with albumin or fibrinogen. Finally, ECP induces severe ultrastructural changes to surfactant vesicles that are more pronounced than changes induced by either fibrinogen or albumin. Conclusions: ECP contributes to surfactant dysfunction in asthma, which in turn could lead to airway obstruction.	Hannover Med Sch, Dept Resp Med, D-30625 Hannover, Germany; Hannover Med Sch, Dept Anat, D-30625 Hannover, Germany; Fraunhofer Inst Toxicol & Expt Med, Dept Immunol Allergol & Clin Inhalat, Hannover, Germany; Univ Uppsala Hosp, Dept Clin Chem, S-75185 Uppsala, Sweden	Hannover Medical School; Hannover Medical School; Fraunhofer Gesellschaft; Uppsala University; Uppsala University Hospital	Hohlfeld, JM (corresponding author), Hannover Med Sch, Dept Resp Med, Carl Neuberg Str 1, D-30625 Hannover, Germany.			Hohlfeld, Jens/0000-0003-2646-6186				COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; ENHORNING G, 1995, AM J RESP CRIT CARE, V151, P554, DOI 10.1164/ajrccm.151.2.7842219; ENHORNING G, 1993, J APPL PHYSIOL, V74, P2922, DOI 10.1152/jappl.1993.74.6.2922; ENHORNING G, 1996, CAN RESPIR J, V3, P21; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; Fujimoto K, 1997, CHEST, V112, P1241, DOI 10.1378/chest.112.5.1241; Heeley EL, 2000, AM J PHYSIOL-LUNG C, V278, pL305, DOI 10.1152/ajplung.2000.278.2.L305; Hohlfeld J, 1997, EUR RESPIR J, V10, P482, DOI 10.1183/09031936.97.10020482; Hohlfeld JM, 2001, RESPIR RES, V3, DOI 10.1186/rr176; Hohlfeld JM, 1999, AM J RESP CRIT CARE, V159, P1803, DOI 10.1164/ajrccm.159.6.9806145; Jarjour NN, 1999, AM J RESP CRIT CARE, V160, P336, DOI 10.1164/ajrccm.160.1.9806155; Krug N, 2001, AM J RESP CELL MOL, V25, P125, DOI 10.1165/ajrcmb.25.1.4194; Kurashima K, 1997, AM J RESP CRIT CARE, V155, P1254, DOI 10.1164/ajrccm.155.4.9105063; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Lee LY, 2001, J APPL PHYSIOL, V91, P1318, DOI 10.1152/jappl.2001.91.3.1318; LIU MY, 1991, J APPL PHYSIOL, V71, P742, DOI 10.1152/jappl.1991.71.2.742; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Peebles RS, 1998, J ALLERGY CLIN IMMUN, V101, P265, DOI 10.1016/S0091-6749(98)70392-6; Rosner B, 2011, FUNDAMENTALS BIOSTAT; SCHMEKEL B, 1991, EUR RESPIR J, V4, P517; SEEGER W, 1993, EUR RESPIR J, V6, P971; SEEGER W, 1985, J APPL PHYSIOL, V58, P326, DOI 10.1152/jappl.1985.58.2.326; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442, DOI 10.1164/ajrccm.155.2.9032176; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; VENGE P, 1990, AGENTS ACTIONS, V29, P122, DOI 10.1007/BF01964739; WEIBEL ER, 1973, AM REV RESPIR DIS, V107, P579, DOI 10.1164/arrd.1973.107.4.579; WOOLLEY KL, 1995, AM J RESP CRIT CARE, V151, P1915, DOI 10.1164/ajrccm.151.6.7767540; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0	28	41	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					496	502		10.1016/j.jaci.2003.12.008	http://dx.doi.org/10.1016/j.jaci.2003.12.008			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007353				2022-12-18	WOS:000220144200023
J	Nettis, E; Pannofino, A; Cavallo, E; Ferrannini, A; Tursi, A				Nettis, E; Pannofino, A; Cavallo, E; Ferrannini, A; Tursi, A			Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHRONIC IDIOPATHIC URTICARIA; LEUKOTRIENE-E4; RESPONSES; HISTAMINE; RELEASE; ASTHMA; TRIAL		Univ Bari, Padigl Chini Policlin, Cattedra Allergol & Immunol Clin, I-70121 Bari, Italy	Universita degli Studi di Bari Aldo Moro	Nettis, E (corresponding author), Univ Bari, Padigl Chini Policlin, Cattedra Allergol & Immunol Clin, I-70121 Bari, Italy.		Nettis, Eustachio/P-8554-2016	Nettis, Eustachio/0000-0003-1383-105X				Amsellem C, 1998, PULM PHARMACOL THER, V11, P245, DOI 10.1006/pupt.1998.0151; CHYREKBOROWSKA S, 1995, J INVEST ALLERG CLIN, V5, P103; CZARNETZKI BM, 1984, BRIT J DERMATOL, V111, P315, DOI 10.1111/j.1365-2133.1984.tb04729.x; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; FRIEDMAN PS, 2001, CLIN EXP ALLERGY, V31, P1607; MALTBY NH, 1989, CLIN EXP ALLERGY, V19, P33, DOI 10.1111/j.1365-2222.1989.tb02340.x; MAXWELL DL, 1990, J ALLERGY CLIN IMMUN, V86, P759, DOI 10.1016/S0091-6749(05)80180-0; Nettis E, 2001, ARCH DERMATOL, V137, P99; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Sansom JE, 1997, BRIT J DERMATOL, V136, P790, DOI 10.1111/j.1365-2133.1997.tb03674.x; Vena GA, 1998, ACTA DERM-VENEREOL, V78, P304	12	41	41	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					212	213		10.1067/mai.2003.1559	http://dx.doi.org/10.1067/mai.2003.1559			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847504				2022-12-18	WOS:000184010600035
J	Schmid-Grendelmeier, P; Holzmann, D; Himly, M; Weichel, M; Tresch, S; Ruckert, B; Menz, G; Ferreira, F; Blaser, K; Wuthrich, B; Crameri, R				Schmid-Grendelmeier, P; Holzmann, D; Himly, M; Weichel, M; Tresch, S; Ruckert, B; Menz, G; Ferreira, F; Blaser, K; Wuthrich, B; Crameri, R			Native Art v 1 and recombinant Art v 1 are able to induce humoral and T cell-mediated in vitro and in vivo responses in mugwort allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; Art v 1; hay fever; lgE; nasal provocation test; mugwort pollen; recombinant allergens; skin prick test; T cell	IGE-BINDING; ASPERGILLUS-FUMIGATUS; CROSS-REACTIVITY; MAJOR ALLERGEN; SKIN PRICK; POLLEN; EXPRESSION; CELERY; PHOSPHOLIPASE-A2; IDENTIFICATION	Background: Mugwort pollen is an important allergen source in hay fever and pollen-related food allergy. Little is known about the clinical relevance of the major mugwort allergen Art v 1 and its importance in allergy. Objective: In this study we aimed to investigate the allergenicity of mugwort extract compared with the allergenicity of native (n)Art v 1 and recombinant (r)Art v 1, one major allergen of mugwort, in vivo and in vitro. Methods: Thirty-two patients allergic to mugwort and 10 control subjects were investigated by means of skin prick and nasal provocation testing with different concentrations of mugwort extract, nArt v 1, and rArt v 1. nArt v 1 was purified from aqueous mugwort extract, and rArt v 1 was cloned, expressed in Escherichia coli, and then purified. The in vitro allergenicity was measured by means of ImmunoCAP, ELISA, ELISA-inhibition experiments, and T-cell proliferation assays. Results: nArt v 1 and rArt v 1 were able to elicit positive in vivo and in vitro reactions. The IgE-binding capacity, as determined by means of ELISA, was slightly higher for nArt v 1 than for rArt v 1, and both allergens were able to induce T-cell proliferation in sensitized patients. However, rArt v 1 elicited a reduced response in skin and nasal provocation tests compared with nArt v 1. Compared with mugwort extract, both nArt v 1 and rArt v 1 showed lower sensitivity in patients with mugwort allergy in vivo. Conclusions: Art v 1, either in its native or recombinant form, is able to induce allergic reactions in patients with mugwort allergy. rArt v 1 induced comparable Immoral and cell-mediated responses in vitro but showed reduced in vivo allergenicity compared with biochemically purified nArt v 1. (J Allergy Clin Immunol 2003;111:1328-36.).	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; SIAF, Swiss Inst Allergy & Asthma Res, Davos, Switzerland; Univ Zurich Hosp, Ear Nose & Throat Unit, CH-8091 Zurich, Switzerland; Salzburg Univ, Inst Genet & Gen Biol, A-5020 Salzburg, Austria; Zurcher Hochgebirgsklin, Davos, Switzerland	University of Zurich; University Zurich Hospital; Swiss Institute of Allergy & Asthma Research; University of Zurich; University Zurich Hospital; Salzburg University	Schmid-Grendelmeier, P (corresponding author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.		Holzmann, David/ABC-7620-2020; Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019; Himly, Martin/D-1568-2015	Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Himly, Martin/0000-0001-5416-085X; Holzmann, David/0000-0002-8176-8358				Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; de Jong NW, 1998, ALLERGY, V53, P204, DOI 10.1111/j.1398-9995.1998.tb03872.x; DEMOLY P, 1991, J ALLERGY CLIN IMMUN, V88, P758, DOI 10.1016/0091-6749(91)90183-O; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; DREBORG S, 1987, ALLERGY, V42, P109, DOI 10.1111/j.1398-9995.1987.tb02368.x; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; FERNANDEZ C, 1993, J ALLERGY CLIN IMMUN, V92, P660, DOI 10.1016/0091-6749(93)90008-4; GRAMMER LC, 1985, J ALLERGY CLIN IMMUN, V76, P123, DOI 10.1016/0091-6749(85)90815-2; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956, DOI 10.1164/ajrccm.156.6.9702087; Himly M, 2002, FASEB J, V16, P106, DOI 10.1096/fj.02-0472fje; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196, DOI 10.1016/S0091-6749(98)70384-7; Iacovacci P, 2001, CLIN EXP ALLERGY, V31, P458, DOI 10.1046/j.1365-2222.2001.01019.x; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Melillo G, 1997, ALLERGY, V52, P5, DOI 10.1111/j.1398-9995.1997.tb04814.x; MOSER M, 1992, J IMMUNOL, V149, P454; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; Muller U, 1997, CLIN EXP ALLERGY, V27, P915, DOI 10.1111/j.1365-2222.1997.tb01233.x; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; NILSEN BM, 1990, MOL IMMUNOL, V27, P1047, DOI 10.1016/0161-5890(90)90128-M; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; vanderVeen MJ, 1996, J ALLERGY CLIN IMMUN, V98, P1028, DOI 10.1016/S0091-6749(96)80187-4; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x	29	41	44	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1328	1336		10.1067/mai.2003.1495	http://dx.doi.org/10.1067/mai.2003.1495			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789236				2022-12-18	WOS:000183424700024
J	Solomon, WR				Solomon, WR			Airborne pollen: A brief life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						pollen; tapetum; anthesis; pollen transport; pollen-stigma interactions; pollen allergens; paucimicronic; submicronic	DIESEL EXHAUST PARTICLES; GRASS-POLLEN; RAGWEED-POLLEN; SELF-INCOMPATIBILITY; ATMOSPHERIC AEROSOL; STIGMA INTERACTION; ALLERGEN CARRIAGE; ASTHMA; IDENTIFICATION; PURIFICATION	The transfer of pollen, whether it is transported by insects or carried by the wind, from floral anther to recipient stigma is the critical reproductive event among higher plants. In this scenario, the pollen grain functions as a fully constituted life-cycle stage, capable of growth (albeit limited) and delivery of gametes. Pollen is prepared for this role by an intricate developmental process with dual sources of structural elements and chemical constituents, including allergens. The resulting complexity relates, at least in part, to the requirements of an unforgiving recognition process at stigmatic surfaces and of active growth before the achievement of gametic union. Recently, the basic participants in pollen-stigma interactions have been defined, and they provide a striking counterpoint to human histocompatibility concerns. Pollen development offers a useful tableau in terms of which to reexamine forces affecting pollen prevalence and their interactions. Development also provides clues to the sources and significance of more minute bioaerosols now known to carry pollen allergens.	Univ Michigan, Sch Med, Dept Internal Med, Div Allergy, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Solomon, WR (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Allergy, Ann Arbor, MI 48109 USA.							Baatout S, 1996, EUR J CLIN CHEM CLIN, V34, P575; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; Cadot P, 2000, J ALLERGY CLIN IMMUN, V105, P286, DOI 10.1016/S0091-6749(00)90078-2; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; Dickinson H, 1999, SCIENCE, V286, P1690, DOI 10.1126/science.286.5445.1690; Dickinson HG, 2000, TRENDS GENET, V16, P373, DOI 10.1016/S0168-9525(00)02083-7; Fahlbusch B, 2000, CLIN EXP ALLERGY, V30, P1645, DOI 10.1046/j.1365-2222.2000.00926.x; FRANKLAND AW, 1973, NATURE, V245, P336, DOI 10.1038/245336a0; Frei T, 1997, GRANA, V36, P34, DOI 10.1080/00173139709362587; Gregory P.H., 1973, MICROBIOLOGY ATMOSPH, V2nd; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; Heslop-Harrison Y, 2000, ANN BOT-LONDON, V85, P5, DOI 10.1006/anbo.1999.1063; HESLOPHARRISON J, 1982, SCIENCE, V215, P1358, DOI 10.1126/science.215.4538.1358; HUSSAIN R, 1981, J ALLERGY CLIN IMMUN, V67, P217, DOI 10.1016/0091-6749(81)90064-6; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; LEE YS, 1979, J ALLERGY CLIN IMMUN, V63, P336, DOI 10.1016/0091-6749(79)90128-3; Newson R, 1997, THORAX, V52, P680, DOI 10.1136/thx.52.8.680; RANTIOLEHTIMAKI A, 1994, CLIN EXP ALLERGY, V24, P23, DOI 10.1111/j.1365-2222.1994.tb00912.x; Raven P. H., 1999, BIOL PLANTS, V6th; ROWE MS, 1986, J ALLERGY CLIN IMMUN, V77, P714, DOI 10.1016/0091-6749(86)90416-1; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633, DOI 10.1046/j.1365-2222.1999.00567.x; Schappi GF, 1997, SEX PLANT REPROD, V10, P315, DOI 10.1007/s004970050105; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; Spieksma FTM, 1999, ALLERGY, V54, P235, DOI 10.1034/j.1398-9995.1999.00817.x; Stanley RG., 1974, POLLEN, DOI [10.1007/978-3-642-65905-8, DOI 10.1007/978-3-642-65905-8]; Stone SL, 1999, SCIENCE, V286, P1729, DOI 10.1126/science.286.5445.1729; Suphioglu C, 1998, INT ARCH ALLERGY IMM, V116, P253, DOI 10.1159/000023953; Takasaki T, 2000, NATURE, V403, P913, DOI 10.1038/35002628; Taylor PE, 2002, J ALLERGY CLIN IMMUN, V109, P51, DOI 10.1067/mai.2002.120759; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; Vinckier S, 2001, ALLERGY, V56, P1129, DOI 10.1034/j.1398-9995.2001.00172.x; Zinkl GM, 1999, DEVELOPMENT, V126, P5431	32	41	43	2	17	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					895	900		10.1067/mai.2002.125556	http://dx.doi.org/10.1067/mai.2002.125556			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	566RU	12063515				2022-12-18	WOS:000176442700001
J	Brockow, K; Akin, C; Huber, M; Scott, LM; Schwartz, LB; Metcalfe, DD				Brockow, K; Akin, C; Huber, M; Scott, LM; Schwartz, LB; Metcalfe, DD			Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: Correlation with dermal mast-cell numbers and mast-cell tryptase	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mastocytosis; atopic dermatitis; mast cells; tryptase; stem-cell factor; IL-6	BLOOD MONONUCLEAR-CELLS; C-KIT; INTERLEUKIN-6; IDENTIFICATION; HYPERPLASIA; MUTATION; DENSITY; LIGAND	Background: Mast-cell accumulation has been observed in the skin and other organs of patients with systemic indolent mastocytosis (SM). The basis for this pathologic increase is not fully understood. Objective: We sought to determine levels of mast-cell growth factors in the skin and plasma of patients with SM, patients with atopic dermatitis (AD), and healthy individuals and to correlate these levels to dermal mast-cell numbers and levels of mast-cell tryptase. Methods: Skin suction blister fluid and plasma levels of stem-cell factor, IL-3, IL-4, IL-6, vascular endothelial growth factor, and total mast-cell tryptase were analyzed by means of ELISA. The number of mast cells wag determined in a biopsy section taken from adjacent skin. Results. Mast-cell numbers in the dermis were higher in patients with SM compared with numbers in patients with AD (P <.001) or in healthy control subjects (P <.0001) and. correlated with tryptase levels in both skin blister fluid (P <.0001) and plasma (P <.0001). Stem-cell factor and vascular endothelial growth factor levels in the skin blister fluid and plasma of patients with SM were not significantly different from those in patients with AD or healthy control subjects. IL-3 and IL-4 levels were below the limit of detection. IL-6 levels were significantly increased in the plasma of patients with SM compared with in plasma of patients with AD (P <.002) and healthy control subjects (P <.0001) and correlated with plasma tryptase levels (P <.05) and dermal mast-cell numbers (P <.02). Conclusion: Because elevated levels of IL-6 could contribute to the fever, fatigue, and osteoporosis observed in patients with SM and because IL-6 is antiapoptotic for mast cells, IL-6 could potentiate the biologic consequences of this disease.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIH, Ctr Clin, Dept Nursing, Bethesda, MD 20892 USA; Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, Richmond, VA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Virginia Commonwealth University	Metcalfe, DD (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Room 11C205,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.			Akin, Cem/0000-0001-6301-4520	NIAID NIH HHS [AI20487] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020487, Z01AI000249, R37AI020487, R21AI020487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Awadhi A, 1999, J RHEUMATOL, V26, P1250; Buttner C, 1998, J INVEST DERMATOL, V111, P1227, DOI 10.1046/j.1523-1747.1998.00414.x; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; Damsgaard TE, 1997, ARCH DERMATOL RES, V289, P256, DOI 10.1007/s004030050189; DELEURAN B, 1991, BRIT J DERMATOL, V125, P14, DOI 10.1111/j.1365-2133.1991.tb06031.x; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; EADY RAJ, 1979, BRIT J DERMATOL, V100, P623, DOI 10.1111/j.1365-2133.1979.tb08065.x; GARRIGA MM, 1988, J ALLERGY CLIN IMMUN, V82, P425, DOI 10.1016/0091-6749(88)90015-2; Grisius MM, 1997, J RHEUMATOL, V24, P1089; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; GROTH S, 1984, SCAND J CLIN LAB INV, V44, P311, DOI 10.3109/00365518409083813; GRUBER BL, 1995, BLOOD, V86, P2488; Grutzkau A, 1998, MOL BIOL CELL, V9, P875, DOI 10.1091/mbc.9.4.875; HAGER K, 1994, NEUROBIOL AGING, V15, P771, DOI 10.1016/0197-4580(94)90066-3; HAMANN K, 1995, BRIT J DERMATOL, V133, P203, DOI 10.1111/j.1365-2133.1995.tb02616.x; Henz BM, 1998, J INVEST DERMATOL, V110, P186; HORAN RF, 1991, J INVEST DERMATOL, V96, pS5, DOI 10.1111/1523-1747.ep12468899; Kambe M, 2001, CLIN EXP ALLERGY, V31, P1077, DOI 10.1046/j.1365-2222.2001.01126.x; KIRSHENBAUM AS, 1989, J IMMUNOL, V142, P2424; Krober SM, 1997, J CLIN PATHOL, V50, P525, DOI 10.1136/jcp.50.6.525; Lacki JK, 1997, CLIN RHEUMATOL, V16, P275, DOI 10.1007/BF02238963; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; LONGLEY J, 1994, ANN MED, V26, P115, DOI 10.3109/07853899409147338; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; MULLER U, 1990, ALLERGY, V45, P597, DOI 10.1111/j.1398-9995.1990.tb00945.x; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003-4819-128-2-199801150-00009; SEHGAL PB, 1990, J INVEST DERMATOL, V94, pS2, DOI 10.1111/1523-1747.ep12874963; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; Valent P, 2001, WHO CLASSIFICATION T, P293; WEISS RR, 1995, J INVEST DERMATOL, V104, P101, DOI 10.1111/1523-1747.ep12613587; Worobec AS, 1998, CANCER, V83, P2120, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C; WUTHRICH B, 1992, ARCH DERMATOL RES, V284, P339, DOI 10.1007/BF00372036	33	41	42	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					82	88		10.1067/mai.2002.120524	http://dx.doi.org/10.1067/mai.2002.120524			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799370				2022-12-18	WOS:000173739300013
J	Lilly, CM; Churg, A; Lazarovich, M; Pauwels, R; Hendeles, L; Rosenwasser, LJ; Ledford, D; Wechsler, ME				Lilly, CM; Churg, A; Lazarovich, M; Pauwels, R; Hendeles, L; Rosenwasser, LJ; Ledford, D; Wechsler, ME			Asthma therapies and Churg-Strauss Syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Churg-Strauss syndrome; vasculitis; asthma; asthma therapy; leukotriene modifiers; beta-agonist; corticosteroids; forme fruste	CORTICOSTEROID WITHDRAWAL; SYSTEMIC VASCULITIS; HYPEREOSINOPHILIC SYNDROME; ALLERGIC GRANULOMATOSIS; LEUKOTRIENE MODIFIERS; INTERFERON-ALPHA; EOSINOPHILIA; MONTELUKAST; ZAFIRLUKAST; ANGIITIS	The pulmonary vasculitides are a group of rare but serious disorders that require early recognition, accurate diagnosis, and effective therapy. Churg-Strauss syndrome (CSS) is classified as small vessel vasculitis. Four different definitions for the diagnosis of CSS have been developed: (1) the pathologic criteria put forth by Churg and Strauss, (2) the criteria based on clinical grounds from Lanham and colleagues, (3) the criteria based on clinical grounds from the American College of Rheumatology, and (4) the criteria from the Chapel Hill Consensus Conference, which closely concur with the Churg and Strauss definition. It is apparent that cessation, diminution, or even a switch from low-dose systemic to inhaled corticosteroid therapy can precipitate the appearance of CSS. The term forme fruste has been used to indicate that the signs and symptoms of CSS were (inadvertently) suppressed by corticosteroids. The clinical risk factors for CSS are moderately severe or severe asthma, chronic sinusitis, or reductions in systemic corticosteroid therapy. Differential diagnosis, treatment, and ongoing monitoring of CSS therapeutic responses are reviewed. The introduction of leukotriene modifiers and high-potency inhaled corticosteroids have allowed control of asthma symptoms, which results in avoidance or reduction in oral corticosteroid use. The advent of these agents has been associated with reports of CSS appearing in patients with asthma. The available data regarding the association of CSS and antiasthma agents are most consistent with the unmasking of a previously contained pathologic condition (forme-fruste CSS) or disease that progresses because systemic corticosteroids were avoided. Early recognition and immunosuppressive therapy are the keystones of successful treatment of this rare disorder .	Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Univ British Columbia, Dept Pathol, Vancouver, BC, Canada; Allergy & Asthma Ctr Vermont, Montpelier, VT USA; Ghent Univ Hosp, Dept Resp Dis, Ghent, Belgium; Univ Florida, Coll Pharm, Gainesville, FL USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Univ S Florida, Tampa, FL USA	Harvard University; Brigham & Women's Hospital; University of British Columbia; Ghent University; Ghent University Hospital; State University System of Florida; University of Florida; National Jewish Health; State University System of Florida; University of South Florida	Lilly, CM (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, 75 Francis St, Boston, MA 02115 USA.		Wechsler, Michael/B-3979-2013; Wechsler, Michael/AAC-5506-2019	Wechsler, Michael/0000-0003-3505-2946; Lazarovich, Mark/0000-0002-9338-9355				ADKINSON NF, 1998, ALLERGY PRINCIPLES P, P1214; Bili A, 1999, J ALLERGY CLIN IMMUN, V104, P1060, DOI 10.1016/S0091-6749(99)70089-8; BLANCA M, 1994, CLIN EXP ALLERGY, V24, P407, DOI 10.1111/j.1365-2222.1994.tb00928.x; CHUMBLEY LC, 1977, MAYO CLIN PROC, V52, P477; CHURG A, 1995, CHEST, V108, P320, DOI 10.1378/chest.108.2.320; CHURG J, 1951, AM J PATHOL, V27, P277; COOPER S, 2001, UNPUB ARTHRITIS RHEU; Cottin V, 1999, ALLERGY, V54, P535, DOI 10.1034/j.1398-9995.1999.t01-1-00091.x; Derom E, 1999, AM J RESP CRIT CARE, V160, P157, DOI 10.1164/ajrccm.160.1.9805106; FAUCI AS, 1982, ANN INTERN MED, V97, P78, DOI 10.7326/0003-4819-97-1-78; Franco J, 1999, THORAX, V54, P558, DOI 10.1136/thx.54.6.558; GODMAN GC, 1954, AMA ARCH PATHOL, V58, P533; Green RL, 1999, LANCET, V353, P725, DOI 10.1016/S0140-6736(99)00565-6; Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; HART B, 1998, EUR RESPIR REV, V8, P1056; HOFFMAN BB, 1996, GOODMAN GILMANS PHAR, P200; Hubner C, 1997, LANCET, V350, P563, DOI 10.1016/S0140-6736(05)63139-X; IMAI H, 1989, NEPHRON, V51, P405, DOI 10.1159/000185332; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; Katz RS, 1998, JAMA-J AM MED ASSOC, V279, P1949, DOI 10.1001/jama.279.24.1949; Kinoshita M, 1999, J ALLERGY CLIN IMMUN, V103, P534, DOI 10.1016/S0091-6749(99)70483-5; KLASSEN CD, 1996, GOODMAN GILMANS PHAR, P68; Knoell DL, 1998, CHEST, V114, P332, DOI 10.1378/chest.114.1.332; KURLAND TC, 1984, EPIDEMIOLOGY RHEUMAT, P196; Kussmaul A, 1866, DTSCH ARCH KLIN MED, P484; LANHAM JG, 1984, MEDICINE, V63, P65, DOI 10.1097/00005792-198403000-00001; LANHAM JG, 1991, SYSTEMIC VASCULITIDE, P101; Le Gall C, 2000, EUR RESPIR J, V15, P978, DOI 10.1034/j.1399-3003.2000.15e29.x; Martin RM, 1999, PHARMACOEPIDEM DR S, V8, P179, DOI 10.1002/(SICI)1099-1557(199905/06)8:3<179::AID-PDS414>3.3.CO;2-B; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; Orriols R, 1996, EUR RESPIR J, V9, P175, DOI 10.1183/09031936.96.09010175; Peen E, 2000, ARTHRITIS RHEUM, V43, P1897, DOI 10.1002/1529-0131(200008)43:8<1897::AID-ANR29>3.0.CO;2-I; Reid AJC, 1998, QJM-MON J ASSOC PHYS, V91, P219, DOI 10.1093/qjmed/91.3.219; Rosenwasser LJ, 1999, J ALLERGY CLIN IMMUN, V103, P374, DOI 10.1016/S0091-6749(99)70459-8; SAXON A, 1988, J ALLERGY CLIN IMMUN, V82, P213, DOI 10.1016/0091-6749(88)91001-9; Simms RW, 1998, NEW ENGL J MED, V339, P755, DOI 10.1056/NEJM199809103391108; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Tatsis E, 1998, ANN INTERN MED, V129, P370, DOI 10.7326/0003-4819-129-5-199809010-00004; THOMPSON JW, 1993, DRUG SAFETY, V9, P132, DOI 10.2165/00002018-199309020-00005; Tuggey JM, 2000, THORAX, V55, P805, DOI 10.1136/thorax.55.9.805; Villena V, 2000, EUR RESPIR J, V15, P626, DOI 10.1034/j.1399-3003.2000.15.33.x; WATTS RA, 1995, SEMIN ARTHRITIS RHEU, V25, P28, DOI 10.1016/S0049-0172(95)80015-8; Watts RA, 2000, ARTHRITIS RHEUM, V43, P414, DOI 10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0; Wechsler ME, 1999, DRUG SAFETY, V21, P241, DOI 10.2165/00002018-199921040-00001; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; Wechsler ME, 2000, CHEST, V117, P708, DOI 10.1378/chest.117.3.708; WECHSLER ME, 1999, AM J RESP CRIT CARE, V103, P374; Wegener F, 1939, BEITR PATHOL ANAT AL, V102, P36; ZIELINSKI RM, 1990, ANN INTERN MED, V113, P716, DOI 10.7326/0003-4819-113-9-716	51	41	43	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					S1	S19		10.1067/mai.2002.120854	http://dx.doi.org/10.1067/mai.2002.120854			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	519RM	11799357				2022-12-18	WOS:000173739300035
J	Cho, JY; Miller, M; Baek, KJ; Castaneda, D; Nayar, J; Roman, M; Raz, E; Broide, DH				Cho, JY; Miller, M; Baek, KJ; Castaneda, D; Nayar, J; Roman, M; Raz, E; Broide, DH			Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunostimulatory DNA sequence; respiratory syncytial virus; IFN-gamma; asthma	INTERFERON-GAMMA; BACTERIAL-DNA; SENSITIZED MICE; CPG MOTIFS; VIRUS; HYPERRESPONSIVENESS; ALLERGEN; MURINE; ASTHMA	Background: Immunostimulatory DNA sequences (ISS) activate the innate immune system to generate antiviral cytokines, such as IFN-gamma. Objective: This study investigated whether ISS could reduce viral load, mucus secretion, airway inflammation, and airway hyperreactivity to methacholine in a mouse model of respiratory syncytial virus (RSV) infection. Methods: Mice were pretreated with ISS 6 days before RSV infection, and lung indices of RSV viral load (viral titer and PCR), bronchoalveolar lavage fluid cytokines (IFN-gamma), airway inflammation (peribronchial inflammation and periodic acid-Schiff-positive mucus cells), and airway hyperreactivity (methacholine responsiveness) were assessed 4 to 6 days after RSV infection. Results: ISS induced the expression of the antiviral cytokine IFN-gamma in the lung, and this was associated with significantly reduced RSV viral titers, mucus secretion, and peribronchial inflammation. ISS reduced, but did not significantly inhibit, RSV-induced airway hyperreactivity to methacholine. Conclusion: Because ISS induced significant levels of lung IFN-gamma, an immunization strategy based solely on the administration of IFN-gamma may be insufficient to inhibit RSV-induced airway hyperreactivity to methacholine, an endpoint important in the subset of RSV-infected subjects with asthma.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Broide, DH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Broide, David/0000-0001-8405-9090	NIAID NIH HHS [AI 38425, AI 40682, AI 33977] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033977, R37AI038425, P01AI040682, R01AI038425] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ballas ZK, 1996, J IMMUNOL, V157, P1840; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P419, DOI 10.1016/S0952-7915(00)00111-4; Brandenburg AH, 2001, VACCINE, V19, P2769, DOI 10.1016/S0264-410X(00)00536-3; Broide D, 1998, J IMMUNOL, V161, P7054; Bukreyev A, 1999, P NATL ACAD SCI USA, V96, P2367, DOI 10.1073/pnas.96.5.2367; Chace JH, 1997, CLIN IMMUNOL IMMUNOP, V84, P185, DOI 10.1006/clin.1997.4380; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708, DOI 10.1164/ajrccm.157.6.9707163; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; HALL CB, 1994, SCIENCE, V265, P1393, DOI 10.1126/science.7915433; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766, DOI 10.1164/ajrccm.156.3.9606031; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Kumar M, 1999, VACCINE, V18, P558, DOI 10.1016/S0264-410X(99)00185-1; Matsuse H, 2000, J IMMUNOL, V164, P6583, DOI 10.4049/jimmunol.164.12.6583; MURPHY BR, 1989, VACCINE, V7, P533, DOI 10.1016/0264-410X(89)90278-8; Peebles RS, 1999, J MED VIROL, V57, P186, DOI 10.1002/(SICI)1096-9071(199902)57:2<186::AID-JMV17>3.0.CO;2-Q; Peebles RS, 2001, J MED VIROL, V63, P178, DOI 10.1002/1096-9071(20000201)63:2<178::AID-JMV1013>3.3.CO;2-F; Rohwedder A, 1998, J MED VIROL, V54, P320, DOI 10.1002/(SICI)1096-9071(199804)54:4&lt;320::AID-JMV13&gt;3.0.CO;2-J; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076; Tekkanat KK, 2001, J IMMUNOL, V166, P3542, DOI 10.4049/jimmunol.166.5.3542; vandenBroek MF, 1995, IMMUNOL REV, V148, P5; Will A, 1996, J IMMUNOL, V157, P4576; YAMAMOTO S, 1988, JPN J CANCER RES, V79, P866, DOI 10.1111/j.1349-7006.1988.tb00049.x	25	41	48	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					697	702		10.1067/mai.2001.119918	http://dx.doi.org/10.1067/mai.2001.119918			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692091				2022-12-18	WOS:000172523800006
J	Mohanty, JG; Raible, DG; McDermott, LJ; Pelleg, A; Schulman, ES				Mohanty, JG; Raible, DG; McDermott, LJ; Pelleg, A; Schulman, ES			Effects of purine and pyrimidine nucleotides on intracellular Ca2+ in human eosinophils: Activation of purinergic P2Y receptors	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN PERIPHERAL EOSINOPHILS; HUMAN-LUNG; INTERFERON-GAMMA; IFN-GAMMA; ASTHMATIC REACTIONS; RESPIRATORY BURST; EXTRACELLULAR ATP; MESSENGER-RNA; MAST-CELLS; HISTAMINE	Background: Extracellular adenosine 5 ' -triphosphate (ATP) increases human eosinophil intracellular Ca2+ concentration; the mechanism of action is not fully known, ATP, a physiologic regulator, acts through 2 purinergic receptor types: cation channels (P2X) and G protein-coupled receptors (P2Y). Objective: This study is aimed at identifying the functional purinergic receptors in human eosinophils, Methods: The relative potency of ATP, uridine (UTP), cytidine (CTP), and inosine (ITP) 5 ' -triphosphates (P2Y agonists); 2-methylthio-ATP (P2Y(1) agonist); and 2 P2X agonists, alpha,beta -methylene-ATP and beta,gamma -methylene-ATP on intracellular Ca2+ concentration was examined in Ca2+-sensitive Fura-2-labeled human eosinophils, For comparison, ATP effects were similarly studied in human neutrophils. P2X/P2Y mRNA expression in cells was examined by reverse transcription and PCR. Results: The nucleotide potency order was UTP greater than or equal to ATP > ITP > > > 2-methylthio-ATP > alpha,beta -methylene-ATP = beta,gamma -methylene-ATP = CTP = 0 in eosinophils, Pertussis toxin (500 ng/mL) pretreatment abolished the effect of lower (10(-6) mol/L) but not higher (10(-5) mol/L) concentrations of ATP in eosinophils, whereas it attenuated the effects of 10(-4) mol/L ATP in neutrophils, The phospholipase C inhibitor U73122 (2 mu mol/L) partially inhibited the effect of ATP in eosinophils but totally blocked it in neutrophils, Both cells constitutively express mRNA for P2X(1), P2X(4), P2X(5), P2Y(1), and P2Y(2), but not P2X(7), with much weaker expressions of P2X(4) and P2X(5) in neutrophils, Eosinophils cultured with the T(H)1 cytokine, IFN-gamma, expressed mRNA for PZX(7), a receptor linked to apoptosis, Conclusions: These results suggest that the P2 purinergic receptor signal transduction pathways in eosinophils and neutrophils are different and are mediated by more than 1 subtype of functional P2Y receptors.	MCPHU, Div Pulm Crit Care, Philadelphia, PA 19102 USA; MCPHU, Dept Cardiol, Philadelphia, PA 19102 USA; MCPHU, Dept Med Cardiol, Philadelphia, PA 19102 USA; MCPHU, Dept Pharmacol, Philadelphia, PA 19102 USA	Drexel University; Drexel University; Drexel University; Drexel University	Mohanty, JG (corresponding author), MCPHU, Div Pulm & Crit Care Med, Mail Stop 107,245 N 15th St, Philadelphia, PA 19102 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R23AI020634, R29AI033941, R01AI020634] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20634, AI-33941] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKSOY MO, 1995, AM J RESP CELL MOL, V13, P410, DOI 10.1165/ajrcmb.13.4.7546770; BOGUNIEWICZ M, 1995, J ALLERGY CLIN IMMUN, V95, P133, DOI 10.1016/S0091-6749(95)70162-1; BOUSQUET J, 1994, AM J RESP CRIT CARE, V150, P533; BURGERS JA, 1993, BLOOD, V81, P49; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Clarke LL, 1999, AM J PHYSIOL-CELL PH, V276, pC777, DOI 10.1152/ajpcell.1999.276.4.C777; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; Dichmann S, 2000, BLOOD, V95, P973, DOI 10.1182/blood.V95.3.973.003k47_973_978; DiVirgilio F, 1996, CIBA F SYMP, V198, P290; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; ELSNER J, 1995, J INVEST DERMATOL, V105, P231, DOI 10.1111/1523-1747.ep12317519; Elsner J, 1996, EUR J IMMUNOL, V26, P1919, DOI 10.1002/eji.1830260837; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; FORESTA C, 1995, BIOCHEM J, V311, P269, DOI 10.1042/bj3110269; GLAUM MC, 1995, CLIN IMMUNOL IMMUNOP, V75, P171, DOI 10.1006/clin.1995.1068; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; HICKMAN SE, 1994, BLOOD, V84, P2452; Ishihara C, 1997, CLIN EXP IMMUNOL, V110, P524, DOI 10.1046/j.1365-2249.1997.4511469.x; Jaffe JS, 1996, AM J RESP CELL MOL, V15, P473, DOI 10.1165/ajrcmb.15.4.8879181; Janssens R, 1996, BIOCHEM BIOPH RES CO, V221, P588, DOI 10.1006/bbrc.1996.0640; Jumblatt JE, 1998, EXP EYE RES, V67, P341, DOI 10.1006/exer.1998.0520; Katchanov C, 1998, DRUG DEVELOP RES, V45, P342; Kennedy C, 2000, MOL PHARMACOL, V57, P926; King BF, 1998, TRENDS PHARMACOL SCI, V19, P506, DOI 10.1016/S0165-6147(98)01271-1; Leonard C, 1997, AM J RESP CELL MOL, V17, P368, DOI 10.1165/ajrcmb.17.3.2797; Li XM, 1996, J IMMUNOL, V157, P3216; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; Muto Y, 1997, J PHARMACOL EXP THER, V282, P1379; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; Ochiai K, 1999, CLIN EXP IMMUNOL, V118, P340; Parronchi P, 2000, INT ARCH ALLERGY IMM, V121, P2, DOI 10.1159/000024291; Pavord ID, 1997, THORAX, V52, P498, DOI 10.1136/thx.52.6.498; PELLEG A, 2001, IN PRESS DRUG DEV RE; Pellegrino R, 1996, J APPL PHYSIOL, V81, P964, DOI 10.1152/jappl.1996.81.2.964; Raible DG, 1999, AM J RESP CRIT CARE, V159, pA466; RAIBLE DG, 1994, AM J RESP CRIT CARE, V149, P1506, DOI 10.1164/ajrccm.149.6.8004306; RAIBLE DG, 1992, J IMMUNOL, V148, P3536; SAITO H, 1991, INT ARCH ALLER A IMM, V94, P68, DOI 10.1159/000235327; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; Schulman ES, 1999, AM J RESP CELL MOL, V20, P530, DOI 10.1165/ajrcmb.20.3.3387; Schulze-Lohoff E, 1998, AM J PHYSIOL-RENAL, V275, pF962, DOI 10.1152/ajprenal.1998.275.6.F962; Sikora A, 1999, J IMMUNOL, V163, P558; Walker BAM, 1997, AM J RESP CELL MOL, V16, P531, DOI 10.1165/ajrcmb.16.5.9160835; Wiebe SH, 1999, CELL PHYSIOL BIOCHEM, V9, P323, DOI 10.1159/000016326; Wiley JS, 1998, AM J PHYSIOL-CELL PH, V275, pC1224, DOI 10.1152/ajpcell.1998.275.5.C1224	51	41	45	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					849	855		10.1067/mai.2001.114658	http://dx.doi.org/10.1067/mai.2001.114658			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344352				2022-12-18	WOS:000168812300013
J	Simons, FER; Silver, NA; Gu, XC; Simons, KJ				Simons, FER; Silver, NA; Gu, XC; Simons, KJ			Skin concentrations of H-1-receptor antagonists	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						H-1-receptor antagonist; antihistamine; fexofenadine; diphenhydramine; skin punch biopsy; wheat; flare; histamine blockade; adults; urticaria	CHRONIC IDIOPATHIC URTICARIA; CONTROLLED TRIAL; DOUBLE-BLIND; FEXOFENADINE; HISTAMINE; DIPHENHYDRAMINE; MANAGEMENT	Background: H-1-receptor antagonists are widely used in the treatment of allergic skin disorders. Objective: We sought to evaluate the extent of fexofenadine and diphenhydramine distribution into the skin concomitantly with their peripheral H-1-receptor antagonist activity. Methods: In a prospective, randomized, double-blind, parallel-group study, 7 men received 120 mg of fexofenadine, and 7 received 50 mg of diphenhydramine. Before dosing; at 1, 3, 6, 9, and 24 hours after the first dose; and at 168 hours (steady-state), 12 hours after the seventh and last daily dose, blood samples and skin punch biopsy specimens were obtained, and epicutaneous tests with histamine phosphate, 1 mg/mL, were performed. Results: Fexofenadine penetrated the skin to a significantly greater extent than diphenhydramine at 6, 9, 24, and 168 hours (P less than or equal to .05). Maximum skin/plasma ratios of both the H-1-antagonists (41.3 +/- 7.8 for fexofenadine and 8.1 +/- 4.4 for diphenhydramine) were obtained at 24 hours. Fexofenadine also produced significantly greater suppression of wheals at 3, 6, and 9 hours and of flares at 3, 6, 9, and 168 hours compared with diphenhydramine (P less than or equal to .05). Conclusion: In disorders in which the presence and the effects of H-1-receptor antagonists in the skin are clinically relevant, our results support the use of fexofenadine and indicate the need to re-examine the role of diphenhydramine.	Univ Manitoba, Fac Pharm, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Simons, KJ (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.							[Anonymous], 2000, PHYS DESK REF; Church MK, 1999, CLIN EXP ALLERGY, V29, P39, DOI 10.1046/j.1365-2222.1999.00011.x; Finn AF, 1999, J ALLERGY CLIN IMMUN, V104, P1071, DOI 10.1016/S0091-6749(99)70091-6; GREAVES MW, 1995, NEW ENGL J MED, V332, P1767, DOI 10.1056/NEJM199506293322608; GREENE SL, 1985, J AM ACAD DERMATOL, V12, P669, DOI 10.1016/S0190-9622(85)70092-8; HOLFORD NHG, 1981, CLIN PHARMACOKINET, V6, P429, DOI 10.2165/00003088-198106060-00002; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Nelson HS, 2000, ANN ALLERG ASTHMA IM, V84, P517, DOI 10.1016/S1081-1206(10)62515-X; NETER J, 1993, APPL LINEAR STAT MOD, P517; Paul E, 1998, J DERMATOL TREAT, V9, P143, DOI 10.3109/09546639809160545; Petersen LJ, 1999, ALLERGY, V54, P607, DOI 10.1034/j.1398-9995.1999.00038.x; Petersen LJ, 1997, CLIN EXP ALLERGY, V27, P284; PONTASCH MJ, 1993, ANN PHARMACOTHER, V27, P730, DOI 10.1177/106002809302700612; Schmelz M, 1997, J NEUROSCI, V17, P8003; SCHWINGHAMMER TL, 1988, J CLIN PHARMACOL, V28, P388, DOI 10.1002/j.1552-4604.1988.tb05745.x; Simons FER, 1999, CLIN PHARMACOKINET, V36, P329, DOI 10.2165/00003088-199936050-00003; SIMONS FER, 1995, J ALLERGY CLIN IMMUN, V95, P759, DOI 10.1016/S0091-6749(95)70183-4; Simons FER, 1997, ANN ALLERG ASTHMA IM, V79, P530, DOI 10.1016/S1081-1206(10)63061-X; SIMONS FER, 2000, ALLERGIC SKIN DIS, P477; SIMONS KJ, 1990, J CLIN PHARMACOL, V30, P665, DOI 10.1002/j.1552-4604.1990.tb01871.x; Simpson K, 2000, DRUGS, V59, P301, DOI 10.2165/00003495-200059020-00020; SUSSMAN G, 1991, ANN ALLERGY, V67, P433	22	41	42	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					526	530		10.1067/mai.2001.113080	http://dx.doi.org/10.1067/mai.2001.113080			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	416RE	11240955				2022-12-18	WOS:000167793300016
J	Kurz, T; Strauch, K; Heinzmann, A; Braun, S; Jung, M; Ruschendorf, F; Moffatt, MF; Cookson, WOCM; Inacio, F; Ruffilli, A; Nordskov-Hansen, G; Peltre, G; Forster, J; Kuehr, J; Reis, A; Wienker, TF; Deichmann, KA				Kurz, T; Strauch, K; Heinzmann, A; Braun, S; Jung, M; Ruschendorf, F; Moffatt, MF; Cookson, WOCM; Inacio, F; Ruffilli, A; Nordskov-Hansen, G; Peltre, G; Forster, J; Kuehr, J; Reis, A; Wienker, TF; Deichmann, KA			A European study on the genetics of mite sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mite sensitization; atopy; asthma; linkage analysis; imprinting; inflammation	HOUSE-DUST-MITE; MULTIPOINT LINKAGE ANALYSIS; GENOME-WIDE SEARCH; DER-P-II; BRONCHIAL HYPERRESPONSIVENESS; IGE RESPONSIVENESS; CHROMOSOME 5Q; ATOPY LOCUS; ASTHMA; ALLERGY	Background: Sensitization to mite allergens represents a prominent feature of atopy and an important predictor of bronchial asthma. Objective: It was the intention of this study to define genetic loci linked to mite sensitization because these could represent the genetic basis of the important atopic component of asthma. Methods: We studied a multiethnic white population of 99 families, including 224 sib pairs sensitized to Dermatophagoides pteronyssinus. A genome-wide candidate-region search was performed that covered potential asthma and atopy regions. Results: As for nonparametric linkage (NPL) analysis, 14 of the candidate regions showed evidence for linkage (NPL > 2.0), and 4 of them showed prominent linkage (NPL > 3.0). However, there were substantial ethnic differences. Maximizing the LOD score analysis identified candidate regions with suspected dominant and recessive mode of inheritance. Furthermore, genetic imprinting models provided significant evidence for linkage in the 8p23 region and revealed potential maternal imprinting. The regions found are distinct to those in asthma searches that have been found to be linked to asthma, as well to other inflammatory diseases. In addition, we could not Find linkage to the HLA region. By different cutoff points of the phenotype definition, the IL cluster showed evidence of being linked to the degree of sensitization rather than to sensitization per se. Conclusion: The results indicate that the genetic basis of the atopic component of asthma is different from that of the inflammatory component. Furthermore, it seems reasonable to assume that specific sensitizations are influenced by distinct genetic variants leading to their initiation versus those leading to their enhancement.	Univ Freiburg, Childrens Hosp, D-79106 Freiburg, Germany; Univ Bonn, Inst Med Biometry Informat & Epidemiol, D-5300 Bonn, Germany; Ingenium Pharmaceut AG, Martinsried, Germany; Max Delbruck Ctr Mol Med, Mikrosatellitenzentrum, Berlin, Germany; Univ Oxford, Wellcome Trust Ctr Human Genet Dis, Oxford, England; Hosp Setubal, Immunol Lab, Setubal, Portugal; CNR, Ist Int Genet & Biofis, I-80125 Naples, Italy; ALK ABELLO, Horsholm, Denmark; Inst Pasteur, Paris, France	University of Freiburg; University of Bonn; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Oxford; Wellcome Centre for Human Genetics; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); ALK-Abello AS; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Deichmann, KA (corresponding author), Univ Freiburg, Childrens Hosp, Mathildenstr 1, D-79106 Freiburg, Germany.		Reis, André/D-2309-2009; Cookson, William/HHC-1790-2022	Reis, André/0000-0002-6301-6363; 				Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Barnes KC, 1998, IMMUNOL TODAY, V19, P325, DOI 10.1016/S0167-5699(97)01241-3; Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; CLERGETDARPOUX F, 1990, GENET EPIDEMIOL, V7, P245, DOI 10.1002/gepi.1370070403; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; FORD SA, 1990, CLIN EXP ALLERGY, V20, P27, DOI 10.1111/j.1365-2222.1990.tb02771.x; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P449, DOI 10.1016/S0091-6749(98)70134-4; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P443, DOI 10.1016/S0091-6749(98)70133-2; Hodge SE, 1997, AM J HUM GENET, V60, P217; Howard TD, 1999, CLIN EXP ALLERGY, V29, P86; Kruglyak L, 1998, J COMPUT BIOL, V5, P1, DOI 10.1089/cmb.1998.5.1; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Lara-Marquez ML, 1999, CLIN EXP ALLERGY, V29, P60, DOI 10.1046/j.1365-2222.1999.00461.x; LeSouef P, 1997, PEDIATR PULM, P3; Mansur AH, 1998, CLIN EXP ALLERGY, V28, P141; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Moffatt MF, 1999, THORAX, V54, P757, DOI 10.1136/thx.54.9.757; Moffatt MF, 1996, MONOGR ALLERGY, V33, P71; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Noguchi E, 1998, GENOMICS, V47, P121, DOI 10.1006/geno.1997.5054; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; OBRIEN RM, 1994, CLIN EXP ALLERGY, V24, P737, DOI 10.1111/j.1365-2222.1994.tb00984.x; Palmer LJ, 1998, AM J RESP CRIT CARE, V158, P1825, DOI 10.1164/ajrccm.158.6.9804037; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; PLATTSMILLS TAE, 1982, LANCET, V2, P675; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; SANDFORD AJ, 1995, EUR J HUM GENET, V3, P188; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Strauch K, 1999, GENET EPIDEMIOL, V17, pS331; Strauch K, 2000, AM J HUM GENET, V66, P1945, DOI 10.1086/302911; Symula DJ, 1999, NAT GENET, V23, P241, DOI 10.1038/13880; THOMPSON SJ, 1988, IMMUNOLOGY, V64, P311; VERVLOET D, 1991, ALLERGY, V46, P554, DOI 10.1111/j.1398-9995.1991.tb00620.x; WEEKS DE, 1990, GENET EPIDEMIOL, V7, P237, DOI 10.1002/gepi.1370070402; Wiltshire S, 1998, HUM MOL GENET, V7, P27, DOI 10.1093/hmg/7.1.27; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Wjst M, 1998, BIOINFORMATICS, V14, P827, DOI 10.1093/bioinformatics/14.9.827	46	41	41	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					925	932		10.1067/mai.2000.110557	http://dx.doi.org/10.1067/mai.2000.110557			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080716	Bronze			2022-12-18	WOS:000167865200018
J	Lima, JO; Zhang, LM; Atkinson, TP; Philips, J; Dasanayake, AP; Schroeder, HW				Lima, JO; Zhang, LM; Atkinson, TP; Philips, J; Dasanayake, AP; Schroeder, HW			Early expression of I epsilon, CD23 (Fc epsilon RII), IL-4R alpha, and IgE in the human fetus	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; immunoglobulin variable region; CD23; IL-4 receptor; receptors Fc; spleen; liver; cord blood; gut; mesentery; fetus; human	HUMAN B-CELLS; INTERLEUKIN-4 RECEPTOR; BLOOD-LYMPHOCYTES; HUMAN-FETAL; TRANSCRIPTS; GENE; ASTHMA; FC-EPSILON-RII/CD23; DIVERSITY; SEGMENTS	Background: A major predictor of childhood atopy is the concentration of IgE in the cord blood, but whether the source of cord blood IgE is maternal or fetal remains unclear. Objective: We sought to determine the pattern of in situ IgE production during ontogeny. Methods: Ninety-seven fetal, 142 natal, and 96 childhood samples were analyzed by using reverse transcription PCR for transcription of VDJC epsilon, I epsilon, and CD23. Thirty-eight fetal liver samples were analyzed for tile IL4RA genotype. Results: IL-4R alpha, CD23a, CD23b, and sterile I epsilon transcripts were present as early as 8 weeks' gestation. VDJC epsilon transcripts were found in second-trimester fetal liver and third-trimester cord blood, although they were rare. VDJCe transcripts were more common in the blood of children 9 months and older. Sequence analysis suggested that fetal VDJC epsilon was the product of selection. All fetal livers actively transcribing I epsilon, VDJC epsilon, and IL-4R alpha contained at least one copy of the atopy-associated IL4RA*A1902G polymorphism. Conclusion: The human fetus contains B cells that are primed to undergo IgE class switching from the earliest stages of ontogeny and can produce endogenous IgE by 20 weeks' gestation. However, IgE-producing cells are rare until 9 months after birth.	Univ Alabama, Div Dev & Clin Immunol, Wallace Tumor Inst 378, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Specialized Ctr Caries Res, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Schroeder, HW (corresponding author), Univ Alabama, Div Dev & Clin Immunol, Wallace Tumor Inst 378, 1530 3rd Ave S, Birmingham, AL 35294 USA.			Schroeder, Harry/0000-0002-3767-6878; Lima, Jose/0000-0002-3666-1439	NIAID NIH HHS [AI34568] Funding Source: Medline; NICHD NIH HHS [HD36292] Funding Source: Medline; NIDCR NIH HHS [DE11147] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI034568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE011147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abdelilah SG, 1998, INT IMMUNOL, V10, P395, DOI 10.1093/intimm/10.4.395; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; BOFILL M, 1985, J IMMUNOL, V134, P1531; Corbett SJ, 1997, J MOL BIOL, V270, P587, DOI 10.1006/jmbi.1997.1141; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; EFREMOV DG, 1993, J IMMUNOL, V151, P2195; FLANAGAN JG, 1982, EMBO J, V1, P655, DOI 10.1002/j.1460-2075.1982.tb01223.x; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Holgate ST, 1999, J ALLERGY CLIN IMMUN, V104, P1139, DOI 10.1016/S0091-6749(99)70005-9; Iciek LA, 1997, J IMMUNOL, V158, P4769; Janezic A, 1998, J ALLERGY CLIN IMMUN, V101, P391, DOI 10.1016/S0091-6749(98)70253-2; Jones CA, 1999, CLIN EXP ALLERGY, V29, P865; Jones CA, 1998, LANCET, V351, P1859, DOI 10.1016/S0140-6736(05)78805-X; KANOWITHKLEIN S, 1988, CLIN IMMUNOL IMMUNOP, V48, P214, DOI 10.1016/0090-1229(88)90085-2; KOHLER PF, 1966, NATURE, V210, P1070, DOI 10.1038/2101070a0; Kruse S, 1999, IMMUNOLOGY, V96, P365; Lamers MC, 1995, IMMUNOL REV, V148, P71, DOI 10.1111/j.1600-065X.1995.tb00094.x; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; NISHIDA Y, 1982, P NATL ACAD SCI-BIOL, V79, P3833, DOI 10.1073/pnas.79.12.3833; PLAYFAIR JH, 1963, BRIT J HAEMATOL, V9, P336, DOI 10.1111/j.1365-2141.1963.tb06558.x; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; ROTHMAN P, 1990, INT IMMUNOL, V2, P621, DOI 10.1093/intimm/2.7.621; RUSSELL GJ, 1990, PEDIATR RES, V27, P239, DOI 10.1203/00006450-199003000-00007; Sambrook J, 1989, MOL CLONING LAB MANU; Schroeder HW, 1995, ANN NY ACAD SCI, V764, P242; SENO M, 1983, NUCLEIC ACIDS RES, V11, P719, DOI 10.1093/nar/11.3.719; Shiokawa S, 1999, J IMMUNOL, V162, P6060; Snow RE, 1998, EUR J IMMUNOL, V28, P3354, DOI 10.1002/(SICI)1521-4141(199810)28:10<3354::AID-IMMU3354>3.0.CO;2-Z; Snow RE, 1997, EUR J IMMUNOL, V27, P162, DOI 10.1002/eji.1830270124; Steinberger P, 1997, INT ARCH ALLERGY IMM, V113, P258, DOI 10.1159/000237564; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TIMENS W, 1987, IMMUNOLOGY, V60, P603; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	37	41	41	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					911	917		10.1067/mai.2000.110228	http://dx.doi.org/10.1067/mai.2000.110228			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080714	Bronze			2022-12-18	WOS:000167865200016
J	Zitouni, N; Errahali, Y; Metche, M; Kanny, G; Moneret-Vautrin, DA; Nicolas, JP; Fremont, S				Zitouni, N; Errahali, Y; Metche, M; Kanny, G; Moneret-Vautrin, DA; Nicolas, JP; Fremont, S			Influence of refining steps on trace allergenic protein content in sunflower oil	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; sunflower oil; crude oil; refined oil; food processing; Western blot	FOOD ALLERGY; PEANUT OIL; DOUBLE-BLIND; SEED; POLLEN; QUANTITATION; CHALLENGE; BINDING; NUT	Background: Although allergy to sunflower seed and oil is a relatively rare occurrence, several cases of sunflower seed allergy have been observed, and me have already described one case of anaphylaxis after eating sunflower oil and margarine. Objective: The aim of our study was to determine and characterize the allergens from sunflower oil at the different steps of the refining process: crude pressed oil (step A), acidification and neutralization (step B), pregumming by centrifugation (step C), washing (step D), bleaching (step E), gumming by filtration (step F), and deodorization (step G). Methods: A sample of oil from each step of the process (steps A to G) was heat extracted with PBS, The protein concentration of each extract was evaluated by using the micro-Bradford assay. Samples mere run on SDS-PACE, The immunoblot was performed with the serum of a patient sensitized to sunflower seed and oil. Results: The extracts obtained after each step reveal a decrease in total protein concentration from 13.6 mug/mL to 0.22 mug/mL. The result of SDS-PAGE shows 5 bands, from 67 kd to 145 kd, with the most abundant being the 67-kd protein, The amount of this protein decreases after each step of the process, It is, however, still present in trace amounts in the refined oil. The 67-kd protein, which is mainly present in the crude oil and slightly in the refined oil, has been shown to be allergenic. Conclusion: Because of the presence of allergenic proteins, refined sunflower oil may pose a threat to people highly sensitized to sunflower seeds.	Fac Med Vandoeuvre Nancy, Lab Biochim Med & Pediat, U308, F-54505 Vandoeuvre Nancy, France; CHU Nancy, Serv Immunol Clin & Allergol, Nancy, France	Universite de Lorraine; CHU de Nancy	Fremont, S (corresponding author), Fac Med Vandoeuvre Nancy, Lab Biochim Med & Pediat, U308, BP 184, F-54505 Vandoeuvre Nancy, France.		Kanny, Gisèle/AHA-8910-2022					AXELSSON IGK, 1994, ALLERGY, V49, P517, DOI 10.1111/j.1398-9995.1994.tb01122.x; BOBROW MN, 1991, J IMMUNOL METHODS, V137, P103, DOI 10.1016/0022-1759(91)90399-Z; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Davis PJ, 1998, ALLERGY, V53, P102, DOI 10.1111/j.1398-9995.1998.tb04975.x; GHEYASUDDIN S, 1970, J FOOD SCI, V35, P453, DOI 10.1111/j.1365-2621.1970.tb00955.x; HALSEY AB, 1986, J ALLERGY CLIN IMMUN, V78, P408, DOI 10.1016/0091-6749(86)90025-4; HOFFMAN DR, 1994, J ALLERGY CLIN IMMUN, V93, P801, DOI 10.1016/0091-6749(94)90262-3; Hourihane JO, 1997, BRIT MED J, V314, P1084, DOI 10.1136/bmj.314.7087.1084; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Kanny G, 1996, ALLERGY, V51, P952; KANNY G, 1994, ALLERGY, V49, P561, DOI 10.1111/j.1398-9995.1994.tb01129.x; Kelly JD, 2000, INT ARCH ALLERGY IMM, V121, P19, DOI 10.1159/000024293; KLURFELD DM, 1987, LIPIDS, V22, P667, DOI 10.1007/BF02533947; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPANJE S, 1978, PROTEIN DENATURATION; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Malanin K, 1995, ALLERGY, V50, P988, DOI 10.1111/j.1398-9995.1995.tb02513.x; Moneret-Vautrin DA, 1998, CLIN EXP ALLERGY, V28, P1113, DOI 10.1046/j.1365-2222.1998.00370.x; MONERETVAUTRIN DA, 1991, LANCET, V338, P1149, DOI 10.1016/0140-6736(91)92008-P; MoneretVautrin DA, 1996, REV MED INTERNE, V17, P551, DOI 10.1016/0248-8663(96)83091-8; Olszewski A, 1998, CLIN EXP ALLERGY, V28, P850, DOI 10.1046/j.1365-2222.1998.00325.x; ONADERRA M, 1994, EUR J BIOCHEM, V225, P609, DOI 10.1111/j.1432-1033.1994.00609.x; Ortiz JCG, 1996, ALLERGY, V51, P927, DOI 10.1111/j.1398-9995.1996.tb04495.x; SIEHERER H, 1999, J ALLERGY CLIN IMMUN, V104, P114; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; Teuber SS, 1997, J ALLERGY CLIN IMMUN, V99, P502, DOI 10.1016/S0091-6749(97)70077-0; VENKTESH A, 1993, J AGR FOOD CHEM, V41, P18, DOI 10.1021/jf00025a005; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x; Voitenko V, 1997, ALLERGY, V52, P136, DOI 10.1111/j.1398-9995.1997.tb00967.x	29	41	43	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					962	967		10.1067/mai.2000.110229	http://dx.doi.org/10.1067/mai.2000.110229			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080721	Bronze			2022-12-18	WOS:000167865200023
J	Yarbrough, JA; Armstrong, JL; Blumberg, MZ; Phillips, AE; McGahee, E; Dolen, WK				Yarbrough, JA; Armstrong, JL; Blumberg, MZ; Phillips, AE; McGahee, E; Dolen, WK			Allergic rhinoconjunctivitis caused by Harmonia axyridis (Asian lady beetle, Japanese lady beetle, or lady bug)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									Med Coll Georgia, AllergyImmunol Sect, Augusta, GA 30912 USA; Allergy Clin NE Georgia, Gainesville, FL USA; Asthma Clin NE Georgia, Gainesville, FL USA; Virginia Allergy & Pulm Associates, Richmond, VA USA	University System of Georgia; Augusta University	Dolen, WK (corresponding author), Med Coll Georgia, AllergyImmunol Sect, CK-170, Augusta, GA 30912 USA.							ERIKSSON NE, 1989, ALLERGY, V44, P305, DOI 10.1111/j.1398-9995.1989.tb00451.x; SIRACUSA A, 1994, J ALLERGY CLIN IMMUN, V93, P424, DOI 10.1016/0091-6749(94)90350-6; SOPARKAR GR, 1993, J ALLERGY CLIN IMMUN, V92, P61, DOI 10.1016/0091-6749(93)90038-H; Wahl R, 1997, ALLERGY, V52, P236, DOI 10.1111/j.1398-9995.1997.tb00987.x	4	41	46	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				704	705		10.1016/S0091-6749(99)70347-7	http://dx.doi.org/10.1016/S0091-6749(99)70347-7			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482851				2022-12-18	WOS:000082870000040
J	Szefler, SJ; Boushey, HA; Pearlman, DS; Togias, A; Liddle, R; Furlong, A; Shah, T; Knobil, K				Szefler, SJ; Boushey, HA; Pearlman, DS; Togias, A; Liddle, R; Furlong, A; Shah, T; Knobil, K			Time to onset of effect of fluticasone propionate in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fluticasone propionate; asthma; glucocorticoid; onset; peak expiratory flow; FEV1	TO-MODERATE ASTHMA; EFFICACY; AEROSOL; ADULTS	Background: The effectiveness of inhaled glucocorticoids in the treatment of asthma is well documented; however, times to onset and maximal treatment effects of these agents have been poorly described, Objective: We sought to determine the time to onset of effect and the time to the best observed effect of inhaled fluticasone propionate (FP) in patients with asthma, Methods: Data from 8 randomized; double-blind, placebo-controlled clinical trials of at least 8 weeks' duration were analyzed. Corticosteroid-naive patients (n = 1461) were treated with either FP (25 mu g to 500 mu g) or placebo twice daily. Efficacy evaluations included morning peak expiratory flow (PEF), asthma symptom scores, supplemental albuterol use, and FEV1, Results: Statistically significant improvements in PEF, asthma symptom scores, and supplemental albuterol use were observed beginning on day 1 of treatment in the FP group versus the placebo group (P < .001); significant increases in FEV1 were observed at the first measurement at week 1 (P < .001). The best observed effect occurred within 3 weeks of the start of FP treatment for PEF (+36 L/min) and FEV1 (+0.52 L) and within 2 weeks for reduction in supplemental albuterol use and asthma symptom scores. Patients with the most severe airflow obstruction had the greatest change in PEF (+56 L/min) and fastest time to 50% of best observed effect (3 days) compared with patients with-mild or moderate airflow obstruction; however, time to best observed effect was similar in the 3 groups (20 to 27 days). Conclusion: In patients with asthma, the onset of significant benefit of FP on PEF, symptoms, and rescue albuterol use occurred within 1 day of the start of therapy FEV1 improved within 1 week of the start; of therapy (the first measurement after randomization), There was no effect of sex, age, or dose of FP on the time to response. The best observed response in PEF varies with the degree of baseline airflow obstruction; however, the degree of airflow obstruction has no effect on the time to best observed response.	Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Calif San Francisco, Asthma Clin Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Allergy & Immunol, San Francisco, CA 94143 USA; Colorado Allergy & Asthma Ctr, PC, Denver, CO USA; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Glaxo Wellcome Inc, US Med Affairs, Res Triangle Pk, NC 27709 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Medicine; GlaxoSmithKline	Knobil, K (corresponding author), Glaxo Wellcome Inc, US Med Affairs, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.							[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; ARKY R, 1997, PHYSICIANS DESK REFE, P1004; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Esmailpour N, 1997, EUR RESPIR J, V10, P1496, DOI 10.1183/09031936.97.10071496; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; HOLLIDAY SM, 1994, DRUGS, V47, P318, DOI 10.2165/00003495-199447020-00007; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; KAMADA AK, 1992, J ALLERGY CLIN IMMUN, V90, P685, DOI 10.1016/0091-6749(92)90144-Q; LAWRENCE M, 1995, J ALLERGY CLIN IMMUN, V95, P311; *NAT HEART LUNG BL, 1997, EXP PAN REP 2 GUID D; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; PHILLIPPS GH, 1990, RESP MED, V84, P19, DOI 10.1016/S0954-6111(08)80003-0; Polgar G, 1971, PULMONARY FUNCTION T; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; Wasserman SI, 1996, J ASTHMA, V33, P265, DOI 10.3109/02770909609055367	19	41	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				780	788		10.1016/S0091-6749(99)70420-3	http://dx.doi.org/10.1016/S0091-6749(99)70420-3			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329810				2022-12-18	WOS:000080470200011
J	Klimek, L; Wolf, H; Mewes, T; Dormann, D; Reske-Kunz, A; Schnitker, J; Mann, W				Klimek, L; Wolf, H; Mewes, T; Dormann, D; Reske-Kunz, A; Schnitker, J; Mann, W			The effect of short-term immunotherapy with molecular standardized grass and rye allergens on eosinophil cationic protein and tryptase in nasal secretions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						short-term immunotherapy; specific immunotherapy; allergic rhinitis; grass pollen; rye pollen; eosinophil cationic protein; tryptase	HUMAN MAST-CELLS; DOUBLE-BLIND; HAY-FEVER; POLLEN IMMUNOTHERAPY; CHEMOTACTIC ACTIVITY; RAGWEED POLLEN; LAVAGE FLUID; RHINITIS; ASTHMA; CHALLENGE	Background: Activation of mast cells and eosinophils under pollen exposure can be inhibited by specific immunotherapy. Objective: The effect of short-term immunotherapy with 7 preseasonal injections of molecular standardized allergens from grass and rye pollen on eosinophil cationic protein (ECP) and tryptase levels in nasal secretions has been compared with symptomatic drug treatment in an open, randomized study with 48 patients. Methods: Nasal reactivity and mediator levels in nasal secretions were measured at baseline, before season, in season, and after season. Results: Symptom scores in the immunotherapy group were 134.5 (95% CI, 65 to 336) versus 386.0 (95% CI, 185 to 563), significantly lower as in the drug-treated group. ECP and tryptase levels increased significantly during natural allergen exposition. The seasonal levels in the immunotherapy group were significantly lower than in the drug-treated group with 272.1 ng/mL (252.0 to 293.9 ng/mL; immunotherapy) versus 470.4 ng/mL (SEM, 435.6 to 508.0 ng/mL; drugs) for ECP and with 8.73 ng/mL (SEM, 8.20 to 9.29 ng/mL) versus 17.47 ng/mL (16.42 to 18.60 ng/mL) for tryptase (all, P < .001). The ECP level induced by nasal provocation was 105.6 ng/mL (99.0 to 112.6 ng/mL) versus 180.1 ng/mL (169.2 to 192.4 ng/mL), significantly lower (P < .001) in the immunotherapy group, as was the tryptase level with 12.12 ng/mL (11.53 to 12.75 ng/mL) versus 8.19 ng/mL (7.79 to 8.62 ng/mL; P < .001) at the after-season visit. Conclusion: Short-term immunotherapy is able to reduce tryptase and ECP in nasal secretions more effectively than drug treatment in patients with allergic rhinitis.	Johannes Gutenberg Univ Mainz, Klin Hals Nasen & Ohrenheilkunde, D-55101 Mainz, Germany; ALK SCHERAX Arzneimittel GmbH, Klin Forsch, Hamburg, Germany; Johannes Gutenberg Univ Mainz, Klin Forsch Grp Allergie, D-6500 Mainz, Germany; Inst Angew Stat GmbH, Bielefeld, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Klimek, L (corresponding author), Johannes Gutenberg Univ Mainz, Klin Hals Nasen & Ohrenheilkunde, Langenbeckstr 1, D-55101 Mainz, Germany.							AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; ABUGHAZALEH RI, 1992, J LEUKOCYTE BIOL, V52, P611, DOI 10.1002/jlb.52.6.611; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P76, DOI 10.1016/S0091-6749(05)80043-0; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; CRAIG SS, 1989, IMMUNOL RES, V8, P130, DOI 10.1007/BF02919075; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; DURHAM SR, 1995, EUR ARCH OTO-RHINO-L, V252, pS64, DOI 10.1007/BF02484438; *EUR EC COMM, 1990, PHARMACOL TOXICOL, V67, P361; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; GLENNER GG, 1960, NATURE, V185, P846, DOI 10.1038/185846a0; GRIFFIN E, 1991, J ALLERGY CLIN IMMUN, V87, P548, DOI 10.1016/0091-6749(91)90014-F; ITIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V85, P606, DOI 10.1016/0091-6749(90)90100-I; Klimek L, 1996, AM J RHINOL, V10, P319, DOI 10.2500/105065896782159738; KLIMEK L, 1996, FOLGEN ALLERGIE RHIN, P52; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; MALLING HJ, 1993, ALLERGY, V48, P9; NORMAN PS, 1988, J ALLERGY CLIN IMMUN, V81, P992, DOI 10.1016/0091-6749(88)90167-4; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; *PHARM, 1992, ECP RIA DIR US; *PHARM, 1992, TRYPT RIA DIR US; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; RASP G, 1994, CLIN EXP ALLERGY, V24, P1151, DOI 10.1111/j.1365-2222.1994.tb03321.x; RASP G, 1993, ALLERGY, V48, P72, DOI 10.1111/j.1398-9995.1993.tb00688.x; RIECHELMANN H, 1995, ALLERGOLOGIE, V18, P126; SCHWARTZ LB, 1987, ANN ALLERGY, V58, P226; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SHALIT M, 1990, J ALLERGY CLIN IMMUN, V86, P117, DOI 10.1016/S0091-6749(05)80131-9; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; VENGE P, 1991, J ALLERGY CLIN IMMUN, V88, P699, DOI 10.1016/0091-6749(91)90175-N; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; WENZEL S, 1986, J IMMUNOL METHODS, V86, P139, DOI 10.1016/0022-1759(86)90277-2; World Medical Association, 1989, DECL HELS; Zenner HP, 1997, J ALLERGY CLIN IMMUN, V100, P23, DOI 10.1016/S0091-6749(97)70190-8	46	41	45	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				47	53		10.1016/S0091-6749(99)70524-5	http://dx.doi.org/10.1016/S0091-6749(99)70524-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893184				2022-12-18	WOS:000078112300008
J	Reeb-Whitaker, C; Harrison, DJ; Jones, RB; Kacergis, JB; Myers, DD; Paigen, B				Reeb-Whitaker, C; Harrison, DJ; Jones, RB; Kacergis, JB; Myers, DD; Paigen, B			Control strategies for aeroallergens in an animal facility	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						laboratory animal allergy; aeroallergen; animal facility; breathing zone exposure; ventilated cages; cage tops; room ventilation; cage changing; mice	DISPLACEMENT VENTILATION; AIRBORNE ALLERGENS; MOUSE ALLERGEN; AIR-QUALITY; RATS; REDUCTION; SYSTEM; MICE; ROOM; CHALLENGE	Background: Prevalence of the occupational disease laboratory animal allergy could be reduced if aeroallergen reduction strategies are identified, Objective: To reduce worker exposure to Mus m 1, an allergen from laboratory mice, the effect of filter cage tops, increased room ventilation, negatively pressurized ventilated cages, and ventilated cage-changing tables were evaluated. Methods: Aeroallergen was collected in the ambient air and in the breathing zone and quantified by using a competitive immunoassay. Results: When mice were housed in unventilated cages, ambient allergen was reduced from 5.1 ng/m(3) with no cage top to 13 ng/m(3) with a simple filter-sheet top and 0.8 ng/m(3) with a fitted filter-bonnet top (P < .05), Room ventilation was increased from 6 to 10, 15, and 20 air changes per hour and had little effect on aeroallergen levels and no impact on airborne particulate matter. When mice were housed in ventilated cages, ambient allergen was significantly reduced from 1.1 ng/m(3) at positive cage pressure to 0.3 ng/m(3) at negative cage pressure (P < .05), Negative cage pressure combined with handling animals under a ventilated table reduced breathing zone allergen from 28 ng/m(3) with neither control strategy in place to 9 ng/m(3) (P < .05). Use of a ventilated table controlled bacterial contamination, measured as colony forming units, found in negatively pressurized cages. Conclusion: Three aeroallergen control strategies are use of filter cage tops, operation of negatively pressurized cages, and use of ventilated changing tables.	Jackson Lab, Bar Harbor, ME 04609 USA	Jackson Laboratory	Paigen, B (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Whitaker, Carolyn/AAW-2505-2020					BREUM NO, 1992, BUILD ENVIRON, V27, P447, DOI 10.1016/0360-1323(92)90043-O; CLOUGH G, 1995, LAB ANIM, V29, P139, DOI 10.1258/002367795780740221; CUNLIFFEBEAMER TL, 1983, LAB ANIM SCI, V33, P495; EDWARDS RG, 1983, LAB ANIM, V17, P235, DOI 10.1258/002367783781070696; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; EGGLESTON PA, 1990, J ALLERGY CLIN IMMUN, V86, P63, DOI 10.1016/S0091-6749(05)80124-1; EGGLESTON PA, 1989, J ALLERGY CLIN IMMUN, V84, P347, DOI 10.1016/0091-6749(89)90419-3; EGGLESTON PA, 1992, ALLERGY PROC, V13, P289, DOI 10.2500/108854192778816942; FLOOD JF, 1995, PHYSIOL BEHAV, V57, P669, DOI 10.1016/0031-9384(94)00318-1; GORDON S, 1992, BRIT J IND MED, V49, P416; Gordon S, 1997, CLIN EXP ALLERGY, V27, P744, DOI 10.1046/j.1365-2222.1997.640844.x; Gressel MG., 1988, APPL IND HYG, V3, P316, DOI [10.1080/08828032.1988.10389864, DOI 10.1080/08828032.1989.10388570]; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562, DOI 10.1164/ajrccm.155.2.9032195; Hughes H., 1996, PHARM ENG, V16, P44; HUNSKAAR S, 1990, LAB ANIM, V24, P358, DOI 10.1258/002367790780865877; JONES RB, 1995, AM IND HYG ASSOC J, V56, P398, DOI 10.1202/0002-8894(1995)056<0398:TEORHO>2.0.CO;2; Kacergis JB, 1996, AM IND HYG ASSOC J, V57, P634, DOI 10.1202/0002-8894(1996)057<0634:AQIAAF>2.0.CO;2; KRISTENSSON JA, 1993, ASHRAE TRAN, V99, P992; Lindqvist C, 1996, SCAND J LAB ANIM SCI, V23, P135; *NAT RES COUNC, 1996, GUID CAR US LAB; NEWILL CA, 1986, J OCCUP ENVIRON MED, V28, P1158; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PRICE JA, 1988, CLIN ALLERGY, V18, P95, DOI 10.1111/j.1365-2222.1988.tb02848.x; Reeb CK, 1997, CONTEMP TOP LAB ANIM, V36, P74; Reeb CK, 1998, CONTEMP TOP LAB ANIM, V37, P43; Renstrom A, 1997, J ALLERGY CLIN IMMUN, V100, P649, DOI 10.1016/S0091-6749(97)70169-6; RENSTROM A, 1997, ARBETE OCH HALSA, V26; SAKAGUCHI M, 1990, LAB ANIM SCI, V40, P613; SCHUMACHER MJ, 1987, NEW ENGL REG ALLERGY, V8, P225; TURNER WA, 1993, ASHRAE T, V98, P262; TWIGGS JT, 1982, J ALLERGY CLIN IMMUN, V69, P522, DOI 10.1016/0091-6749(82)90177-4; YAMAUCHI C, 1989, LAB ANIM, V23, P7, DOI 10.1258/002367789780886849; ZIEMANN B, 1992, AM IND HYG ASSOC J, V53, P138, DOI 10.1202/0002-8894(1992)053<0138:TEOTDB>2.0.CO;2	34	41	42	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				139	146		10.1016/S0091-6749(99)70537-3	http://dx.doi.org/10.1016/S0091-6749(99)70537-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893197				2022-12-18	WOS:000078112300021
J	Zeibecoglou, K; Ying, S; Yamada, T; North, J; Burman, J; Bungre, J; Meng, Q; Kay, AB; Robinson, DS				Zeibecoglou, K; Ying, S; Yamada, T; North, J; Burman, J; Bungre, J; Meng, Q; Kay, AB; Robinson, DS			Increased mature and immature CCR3 messenger RNA+ eosinophils in bone marrow from patients with atopic asthma compared with atopic and nonatopic control subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; eosinophil; progenitor cell; bone marrow	COLONY-STIMULATING FACTOR; EOTAXIN RECEPTOR; T-CELL; BRONCHIAL BIOPSIES; MOLECULAR-CLONING; CD34(+) CELLS; EXPRESSION; INTERLEUKIN-5; PROGENITOR; CHEMOKINE	Background: Eosinophil infiltration of the bronchial mucosa is characteristic of asthma. Eosinophils differentiate from CD34(+) progenitors. Animal models suggest cooperation between IL-5 and eotaxin to allow rapid mobilization of a pool of bone marrow eosinophils followed by recruitment to the airway mucosa. Objective: The purpose of this study was to enumerate CD34+ cell numbers in blood and bone marrow from atopic asthmatics and control subjects and to test the hypothesis that there is an increased bone marrow pool of CCR3(+) eosinophils in patients with atopic asthma, as compared with control subjects. Methods: Bone marrow aspirates and peripheral blood were obtained from volunteers with asthma and control volunteers. CD34(+) cell numbers were evaluated by flow cytometry, and eosinophil colony-forming activity was evaluated by methylcellulose cultures. Mature eosinophils, eosinophil myelocytes, metamyelocytes, and band forms (immature eosinophils) were enumerated by morphologic findings and immunocytochemistry for eosinophil cationic protein. CCR3 and eotaxin mRNA expression was examined by in situ hybridization, and protein expression was examined by immunocytochemistry. CCR3+ cells were further identified with Chromotrope 2R staining. Results: CD34(+) cell numbers in bone marrow were increased in atopic subjects. Numbers of eosinophil colony-forming units in blood and bone marrow did not differ between groups. Percentages of bath mature and immature eosinophils were increased in bone marrow from patients with atopic asthma, but not atopic patients with no asthma or normal control subjects. CCR3 was expressed by immature and mature bone marrow eosinophils. Eotaxin was expressed by bone marrow cells from all 3 groups, but there was no increase in subjects with asthma. Conclusion: These findings suggest that in humans there is an increased bone marrow pool of CCR3(+) mature and immature eosinophils available for rapid mobilization in subjects with asthma but not in atopic subjects with no asthma.	Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Allergy & Clin Immunol, London SW3 6LY, England; Royal Brompton Hosp NHS Trust, Dept Hematol, London, England	Imperial College London; Royal Brompton Hospital	Robinson, DS (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Allergy & Clin Immunol, Dovehouse St, London SW3 6LY, England.							ANDREWS RG, 1990, J EXP MED, V172, P355, DOI 10.1084/jem.172.1.355; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35, DOI 10.1165/ajrcmb/8.1.35; BERENSON RJ, 1991, BLOOD, V77, P1717; BUSSE WW, 1993, AM REV RESPIR DIS, V147, pS20, DOI 10.1164/ajrccm/147.6_Pt_2.S20; CLUTTERBUCK EJ, 1990, BLOOD, V75, P1774; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DENBURG JA, 1985, BLOOD, V66, P312; Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404, DOI 10.1165/ajrcmb.17.4.2691; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; GOLDMAN JM, 1989, POSTGRADUATE HEMATOL, P234; Gratama JW, 1997, CYTOMETRY, V30, P109, DOI 10.1002/(SICI)1097-0320(19970615)30:3<109::AID-CYTO1>3.0.CO;2-G; GREAVES MF, 1992, LEUKEMIA, V6, P31; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Palframan RT, 1998, BLOOD, V91, P2240, DOI 10.1182/blood.V91.7.2240.2240_2240_2248; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274, DOI 10.1164/ajrccm/144.6.1274; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645, DOI 10.1165/ajrcmb.15.5.8918371; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Shalit M, 1996, J ALLERGY CLIN IMMUN, V98, P344, DOI 10.1016/S0091-6749(96)70159-8; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Tiffany HL, 1998, J IMMUNOL, V160, P1385; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; WALKER C, 1991, J IMMUNOL, V146, P1829; WOOLLEY MJ, 1994, AM J RESP CELL MOL, V11, P600, DOI 10.1165/ajrcmb.11.5.7946389; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; ZEPEDA EAG, 1996, NAT MED, V2, P449	36	41	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1999	103	1	1				99	106		10.1016/S0091-6749(99)70532-4	http://dx.doi.org/10.1016/S0091-6749(99)70532-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	158JM	9893192				2022-12-18	WOS:000078112300016
J	Le Mao, J; Mayer, CE; Peltre, G; Desvaux, FX; David, B; Weyer, A; Senechal, H				Le Mao, J; Mayer, CE; Peltre, G; Desvaux, FX; David, B; Weyer, A; Senechal, H			Mapping of Dermatophagoides farinae mite allergens by two-dimensional immunoblotting	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mire allergy; Dermatophagoides farinae; isoallergens; two-dimensional electrophoresis; IgE-immunoblotting; protein microsequencing	HOUSE-DUST MITE; MAJOR ALLERGEN; SEQUENCE POLYMORPHISMS; MONOCLONAL-ANTIBODIES; HUMAN IGE; EXTRACTS; PTERONYSSINUS; RECOMBINANT; BINDING; REACTIVITY	Background: Allergens from the house dust mite Dermatophagoides farinae are responsible for frequent respiratory allergic disorders, but only 3 groups of these allergens are well characterized. Objective: This study was performed to complete the repertoire of D farinae allergens using two-dimensional (2-D) electrophoresis, Methods: D farinae mite allergens, extracted from whole cultures in the presence of a mild detergent, were separated by 2-D electrophoresis with subsequent immunoblotting. IgE-binding proteins were detected with individual mite-sensitive patient sera and the anti-D pteronyssinus human serum pool. Allergens were identified by an inhibition immunoblot test, by means of specific mAbs, or by biochemical characterization. The internal peptides of 2 allergens were microsequenced. Results: 2-D immunoblotting with individual patient sera showed a marked heterogeneity in the isoelectric point of the allergens, as well as differences in the individual IgE-binding patterns. In addition to identification of allergens Der f 1, Der f 2, and Der f 3, new allergens have been characterized as Der f 4, Der f 5, and 2 high molecular mass allergens. Microsequencing of peptides from the latter allergens revealed significant homologies with allergen Mag 3 from D farinae and with a chitinase from prawn Penaeus japonicus. Conclusion: 2-D electrophoresis with subsequent immunoblotting and protein microsequencing allowed characterization of a more complete repertoire of D farinae allergens and their multiple isoforms, and identification of six new allergens.	Inst Pasteur, Unite Immuno Allergie, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Le Mao, J (corresponding author), Inst Pasteur, Unite Immuno Allergie, 25-28 Rue Du Dr Roux, F-75724 Paris 15, France.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baldo B.A., 1989, Advances in the Biosciences, V74, P13; BATARD T, 1993, INT ARCH ALLERGY IMM, V100, P68, DOI 10.1159/000236390; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; CHUA KY, 1993, INT ARCH ALLERGY IMM, V101, P364, DOI 10.1159/000236478; Chua KY, 1996, CLIN EXP ALLERGY, V26, P829, DOI 10.1111/j.1365-2222.1996.tb00615.x; DANDEU JP, 1982, IMMUNOLOGY, V46, P679; DAUSSANT J, 1987, J CEREAL SCI, V5, P13, DOI 10.1016/S0733-5210(87)80004-8; DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; DESVAUX FX, 1990, ELECTROPHORESIS, V11, P37, DOI 10.1002/elps.1150110109; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; Fujikawa A, 1996, MOL IMMUNOL, V33, P311, DOI 10.1016/0161-5890(95)00127-1; GORG A, 1980, J BIOCHEM BIOPH METH, V3, P273, DOI 10.1016/0165-022X(80)90008-1; HILL MR, 1993, CLIN EXP ALLERGY, V23, P110, DOI 10.1111/j.1365-2222.1993.tb00305.x; HONG C-S, 1991, Yonsei Medical Journal, V32, P24; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; LEMAO J, 1992, MOL IMMUNOL, V29, P205, DOI 10.1016/0161-5890(92)90101-3; LEMAO J, 1980, J ALLERGY CLIN IMMUN, V65, P381, DOI 10.1016/0091-6749(80)90217-1; LEMAO J, 1992, INDOOR ENVIRON, V1, P212; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62, DOI 10.1159/000236804; OLSSON S, 1994, ALLERGY, V49, P620, DOI 10.1111/j.1398-9995.1994.tb00129.x; RABILLOUD T, 1990, ANAL BIOCHEM, V185, P94, DOI 10.1016/0003-2697(90)90261-7; Shen HD, 1997, CLIN EXP ALLERGY, V27, P824, DOI 10.1046/j.1365-2222.1997.650890.x; Smith WA, 1996, INT ARCH ALLERGY IMM, V109, P133, DOI 10.1159/000237212; Smith WA, 1996, CLIN EXP ALLERGY, V26, P571, DOI 10.1111/j.1365-2222.1996.tb00578.x; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; Watanabe T, 1997, ZOOL SCI, V14, P65, DOI 10.2108/zsj.14.65	29	41	44	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1998	102	4	1				631	636		10.1016/S0091-6749(98)70280-5	http://dx.doi.org/10.1016/S0091-6749(98)70280-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	131XK	9802372				2022-12-18	WOS:000076600400014
J	Gruchalla, RS; Pesenko, RD; Do, TT; Skiest, DJ				Gruchalla, RS; Pesenko, RD; Do, TT; Skiest, DJ			Sulfonamide-induced reactions in desensitized patients with AIDS - The role of covalent protein haptenation by sulfamethoxazole	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sulfamethoxazole; AIDS; prophylaxis; desensitization; haptenation	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HIV-INFECTED PATIENTS; PNEUMOCYSTIS-CARINII PNEUMONIA; HALOTHANE-ASSOCIATED HEPATITIS; TRIMETHOPRIM-SULFAMETHOXAZOLE; HYPERSENSITIVITY REACTIONS; DRUG HYPERSENSITIVITY; ADVERSE REACTIONS; CUTANEOUS HYPERSENSITIVITY; HYDROXYLAMINE METABOLITES	Background: Adverse reactions to sulfonamides cause significant morbidity in patients with AIDS. We have demonstrated previously a similar or equal to 40 kd sulfamethoxazole (SMX)-substituted protein in the serum of some individuals treated with SMX. Objective: The purpose of this study was to examine patients with AIDS who had undergone SMX desensitization because of a prior history of SMX allergy for the presence of SMX-haptenated serum proteins and to determine whether these proteins, SMX-specific Ige antibodies, or both predict the development of subsequent clinical reactivity. Methods: Four patients with no history of allergy and in whom SMX prophylaxis was initiated and eight patients with AIDS who had undergone SMX desensitization because of prior allergy were evaluated. SMX-conjugated serum proteins mere identified with an immunoblotting assay, and SMX-specific IgG antibodies were identified by ELISA inhibition. Results: One of the four patients receiving SMX prophylactic treatment demonstrated SMX-protein haptenation, none had detectable SMX-specific IgG antibodies, and none developed an SMX-associated reaction during the time in which they were followed. Of the eight patients who underwent SMX desensitization, six (75%) demonstrated SMX-protein haptenation, and three of these six (50%) subsequently developed SMX-induced cutaneous reactions. Only one of these six patients had detectable SMX-specific IgG antibodies. The two individuals who did not demonstrate SMX-protein haptenation have not developed a clinical reaction. Conclusion: These preliminary data suggest that SMX haptenation, but not SMX-specific antibodies, mag be important in the development of clinical sensitivity in patients with AIDS who have undergone SMX desensitization.	Univ Texas, SW Med Ctr, Dept Internal Med, Div Allergy & Immunol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Div Infect Dis, Dallas, TX USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gruchalla, RS (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Div Allergy & Immunol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI033711] Funding Source: NIH RePORTER; NIAID NIH HHS [1-R29-AI33711-05] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABSAR N, 1994, J ALLERGY CLIN IMMUN, V93, P1001, DOI 10.1016/S0091-6749(94)70048-6; ARNOLD PA, 1982, DRUG INTELLIGENCE CL, V22, P43; BATTEGAY M, 1989, LANCET, V2, P1100; BAYARD PJ, 1992, J ACQ IMMUN DEF SYND, V5, P1237; BEAUNE P, 1987, P NATL ACAD SCI USA, V84, P551, DOI 10.1073/pnas.84.2.551; CARR A, 1994, CLIN EXP IMMUNOL, V97, P260, DOI 10.1111/j.1365-2249.1994.tb06078.x; CARR A, 1993, CLIN EXP IMMUNOL, V94, P21; CARR A, 1993, J INFECT DIS, V167, P180, DOI 10.1093/infdis/167.1.180; CARR A, 1993, AIDS, V7, P65, DOI 10.1097/00002030-199301000-00010; CARR A, 1994, AIDS, V8, P333, DOI 10.1097/00002030-199403000-00006; CARR A, 1991, J CLIN IMMUNOL, V11, P55, DOI 10.1007/BF00917741; CARRINGTON DM, 1987, J ALLERGY CLIN IMMUN, V79, P442, DOI 10.1016/0091-6749(87)90361-7; Coeshott Claire, 1996, Journal of Allergy and Clinical Immunology, V97, P346, DOI 10.1016/S0091-6749(96)80874-8; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; CRIBB AE, 1990, DRUG METAB DISPOS, V18, P784; DAFTARIAN MP, 1995, CLIN DIAGN LAB IMMUN, V2, P199, DOI 10.1128/CDLI.2.2.199-204.1995; DROGE W, 1993, PHARMACOLOGY, V46, P61, DOI 10.1159/000139029; EPSTEIN M, 1989, J ALLERGY CLIN IMMUN, V86, P416; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V79, P484, DOI 10.1016/0091-6749(87)90366-6; GRUCHALLA RS, 1991, J ALLERGY CLIN IMMUN, V88, P784, DOI 10.1016/0091-6749(91)90186-R; GRUCHALLA RS, 1990, J ALLERGY CLIN IMMUN, V35, P157; HARLE DG, 1988, MOL IMMUNOL, V25, P1347, DOI 10.1016/0161-5890(88)90050-8; HENNESSY S, 1995, J GEN INTERN MED, V10, P380, DOI 10.1007/BF02599836; KALISH RS, 1994, J ALLERGY CLIN IMMUN, V94, P465, DOI 10.1016/0091-6749(94)90202-X; KENNA JG, 1988, J PHARMACOL EXP THER, V245, P1103; KENNA JG, 1988, HEPATOLOGY, V8, P1635, DOI 10.1002/hep.1840080627; KENNA JG, 1987, J PHARMACOL EXP THER, V242, P733; KENNA JG, 1990, BIOCHEM SOC T, V19, P191; KIEFEL V, 1987, TRANSFUSION, V27, P262, DOI 10.1046/j.1537-2995.1987.27387235635.x; KOOPMANS PP, 1995, AIDS, V9, P217, DOI 10.1097/00002030-199509030-00001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCTOT KL, 1994, J CLIN PHARMACOL, V34, P1228, DOI 10.1002/j.1552-4604.1994.tb04736.x; LEE BL, 1994, CLIN PHARMACOL THER, V56, P184, DOI 10.1038/clpt.1994.122; LEE BL, 1993, CLIN PHARMACOL THER, V53, P529, DOI 10.1038/clpt.1993.66; LEE BL, 1992, CLIN INFECT DIS, V14, P773, DOI 10.1093/clinids/14.3.773-a; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MARTIN JL, 1993, HEPATOLOGY, V18, P858, DOI 10.1002/hep.1840180417; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; MEEKINS CV, 1994, J ALLERGY CLIN IMMUN, V94, P1017, DOI 10.1016/0091-6749(94)90120-1; ONEIL CE, 1991, INT ARCH ALLER A IMM, V94, P246, DOI 10.1159/000235372; RIEDER MJ, 1988, J PHARMACOL EXP THER, V244, P724; RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13, DOI 10.1038/clpt.1991.3; RIEDER MJ, 1989, ANN INTERN MED, V110, P286, DOI 10.7326/0003-4819-110-4-286; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; SATOH H, 1985, MOL PHARMACOL, V28, P468; SATOH H, 1985, J PHARMACOL EXP THER, V233, P857; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SHEAR NH, 1985, CAN J PHYSIOL PHARM, V63, P1370, DOI 10.1139/y85-225; SHEAR NH, 1986, ANN INTERN MED, V105, P179, DOI 10.7326/0003-4819-105-2-179; VANDERVEN AJM, 1994, J ANTIMICROB CHEMOTH, V34, P1, DOI 10.1093/jac/34.1.1; VERGANI D, 1980, NEW ENGL J MED, V303, P66, DOI 10.1056/NEJM198007103030202; WARRINGTON RJ, 1983, CLIN ALLERGY, V13, P235, DOI 10.1111/j.1365-2222.1983.tb02593.x; WRIGHT DN, 1990, J ALLERGY CLIN IMMUN, V85, P445, DOI 10.1016/0091-6749(90)90154-V	54	41	43	1	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1998	101	3					371	378		10.1016/S0091-6749(98)70250-7	http://dx.doi.org/10.1016/S0091-6749(98)70250-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZC570	9525454	Bronze			2022-12-18	WOS:000072593900015
J	Peebles, RS; Liu, MC; Adkinson, NF; Lichtenstein, LM; Hamilton, RG				Peebles, RS; Liu, MC; Adkinson, NF; Lichtenstein, LM; Hamilton, RG			Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; IgE; IgA; bronchoalveolar lavage; lung; eosinophil; ragweed	RECOMBINANT HUMAN INTERLEUKIN-5; MAJOR BASIC-PROTEIN; ALLERGIC ASTHMATICS; TRACHEAL EPITHELIUM; SECRETORY COMPONENT; ACCUMULATION; RECEPTORS; CELLS	Background: Migration of eosinophils and release of eosinophil degranulation products into bronchoalveolar lavage fluid is a consistent finding in studies of late responses to allergen challenge in the lung. However, the mechanism of eosinophil activation and release of eosinophil products in vivo is unclear. Objective: We investigated the hypothesis that antigen-specific IgG, IgA, secretory IgA, or IgE is responsible for the eosinophil activation observed in the late-phase pulmonary reaction. Methods: Ragweed-specific IgE, IgA, secretory IgA, and IgG were measured by monoclonal antibody-based immunoassays in bronchoalveolar lavage (BAL) fluid and in serum from 19 asthmatic subjects allergic to ragweed and six healthy nonallergic control subjects before and 20 hours after segmental lung challenge with ragweed extract. Eosinophil cationic protein (ECP) was also measured in BAL fluid as a marker of eosinophil activation. Results: Most allergic asthmatic subjects had detectable levels of ragweed-specific IgE, IgA, and IgG in their serum and BAL fluid, whereas normal subjects had ragweed-specific IgA with no ragweed-specific IgE and little ragweed-specific IgG. IgA was the dominant ragweed-specific antibody isotype in BAL fluids. Ragweed-specific sIgA (r(s) = 0.52, p = 0.02) and IgA (r(s) = 0.50, p = 0.03) in BAL fluid after segmental lung challenge were significantly correlated with ECP. Ragweed-specific IgE and IgA in serum also correlated with ECP (r(s) = 0.74, p < 0.001 and r(s) = 0.48, p = 0.04, respectively). Conclusions: The correlation of allergen-specific IgA and IgE antibody levels with ECP as a marker of eosinophil degranulation suggests an important role for IgE antibodies in allergic pulmonary inflammation and a potential role for antigen-specific IgA in eosinophil degranulation in the lung after antigen challenge.	Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy Clin Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Pulm Crit Care Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Peebles, RS (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Lung Res, T-1217 MCN, Nashville, TN 37232 USA.							ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; BRADDING P, 1993, J IMMUNOL, V151, P3852; Butler JE, 1991, IMMUNOCHEMISTRY SOLI, P173; CAPRON M, 1985, J IMMUNOL, V134, P3013; CAPRON M, 1984, J IMMUNOL, V132, P462; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COLLINS DS, 1993, AM REV RESPIR DIS, V147, P677, DOI 10.1164/ajrccm/147.3.677; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; FRIGAS E, 1980, LAB INVEST, V42, P35; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HAMILTON RG, 1992, MANUAL CLIN IMMUNOLO, P689; KANEKO M, 1995, J ALLERGY CLIN IMMUN, V95, P339; KITA H, 1995, J ALLERGY CLIN IMMUN, V95, P339; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; LAMKHIOUED B, 1995, EUR J IMMUNOL, V25, P117, DOI 10.1002/eji.1830250121; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Mestecky J, 1996, J IMMUNOL METHODS, V193, P103, DOI 10.1016/0022-1759(95)00289-8; MONTEIRO RC, 1993, J CLIN INVEST, V92, P1681, DOI 10.1172/JCI116754; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801, DOI 10.1164/ajrccm/139.3.801; PEEBLES RS, 1995, J IMMUNOL METHODS, V179, P77; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; SCHWARTZ L, 1993, ALLERGY PRINCIPLES P, P135; TERADA N, 1992, J ALLERGY CLIN IMMUN, V90, P160, DOI 10.1016/0091-6749(92)90067-C; VENGE P, 1993, CLIN EXP ALLERGY, V23, P3, DOI 10.1111/j.1365-2222.1993.tb00372.x; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112	30	41	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				265	273		10.1016/S0091-6749(98)70392-6	http://dx.doi.org/10.1016/S0091-6749(98)70392-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500761	hybrid			2022-12-18	WOS:000072244800017
J	Leone, C; Teodoro, C; Pelucchi, A; Mastropasqua, B; Cavigioli, G; Marazzini, L; Foresi, A				Leone, C; Teodoro, C; Pelucchi, A; Mastropasqua, B; Cavigioli, G; Marazzini, L; Foresi, A			Bronchial responsiveness and airway inflammation in patients with nonallergic rhinitis with eosinophilia syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nonallergic rhinitis with eosinophilia syndrome; bronchial; responsiveness; nasal lavage; induced sputum	NON-ALLERGIC RHINITIS; BRONCHOALVEOLAR LAVAGE; NASAL SYMPTOMS; POLLEN SEASON; MAST-CELLS; ASTHMA; HYPERRESPONSIVENESS; HYPERREACTIVITY; EXPOSURE; CHALLENGE	Background: Nonallergic rhinitis with eosinophilia syndrome (NARES) is characterized by persistent nasal symptoms without allergy and by a marked eosinophil recruitment in the nasal cavities. Objective: We studied whether patients with NARES had bronchial responsiveness to methacholine and airway inflammation and examined the relationship between these factors. Methods: We selected a group of 39 patients referred to our allergy clinic for symptoms of perennial rhinitis. Atopic status was excluded by skin prick tests and RASTs. None of the patients had a history of respiratory symptoms. We preliminarily performed nasal lavage in all patients, and the diagnosis of NARES was made on the basis of the presence of at least 10% eosinophils in nasal lavage fluid. A methacholine challenge and sputum induction were also done on two different days. Results: Eosinophils in nasal lavage fluid ranged between 10% and 86%. Serum IgE levels were within normal range. Total circulating eosinophils ranged between 40 and 890/mm(3). Methacholine PD20 values were measurable in only 18 patients (range, 0.32 to 22.56 mu mol; group 1). In the remaining 21 patients, methacholine PD20 values were greater than 24 mu mol (group 2). We found that differential cell counts in nasal lavage fluid in group 1 were not different from those in group 2. Methacholine PD20 values were not significantly related to any cell count in the nasal lavage fluid. Induced sputum was accomplished only in 22 patients. Eosinophils in induced sputum ranged between 0% and 56.5%. Numbers of total cells, macrophages, lymphocytes, neutrophils, and epithelial cells in the two subgroups were not different. The number of metachromatic cells tended to be higher in group 1 compared with group 2 (0.31% vs 0.05%), but the difference was not significant. The eosinophil count in the induced sputum was significantly higher in group 1 compared with group 2 (16.8% vs 3.1%; p < 0.05). In the entire population, methacholine PD20 values were significantly correlated with the number of eosinophils in sputum (r = -0.63; p < 0.001). Conclusion: We showed that 46% of patients with NARES but without histories of respiratory symptoms had a measurable bronchial responsiveness. The presence of bronchial responsiveness was associated with an increased number of eosinophils in induced sputum but not with the inflammatory process in the nose.	Osped Sesto San Giovanni, Serv Fisiopatol Resp Modulo Allergol & Immunopato, I-20099 Sesto San Giovanni, Italy		Foresi, A (corresponding author), Osped Sesto San Giovanni, Serv Fisiopatol Resp Modulo Allergol & Immunopato, Viale Matteotti 83, I-20099 Sesto San Giovanni, Italy.							BOULET LP, 1990, J ALLERGY CLIN IMMUN, V86, P19, DOI 10.1016/S0091-6749(05)80118-6; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Djukanovic R, 1996, THORAX, V51, P575, DOI 10.1136/thx.51.6.575; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126, DOI 10.1164/ajrccm/147.5.1126; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58, DOI 10.1016/S0091-6749(97)70195-7; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; IRVIN CG, 1992, J ALLERGY CLIN IMMUN, V90, P521, DOI 10.1016/0091-6749(92)90179-6; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; Jankowski R, 1992, Ann Otolaryngol Chir Cervicofac, V109, P39; Jankowski R, 1992, Ann Otolaryngol Chir Cervicofac, V109, P47; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KOHLER C, 1992, Bulletin de l'Association des Anatomistes, V76, P43; Moneret-Vautrin D A, 1989, Ann Otolaryngol Chir Cervicofac, V106, P47; Moneret-Vautrin Denise Anne, 1992, Rhinology (Utrecht), V30, P161; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MULLARKEY MF, 1988, J ALLERGY CLIN IMMUN, V82, P941, DOI 10.1016/0091-6749(88)90037-1; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; Rouvier P, 1992, Ann Otolaryngol Chir Cervicofac, V109, P264; VERDIANI P, 1990, J ALLERGY CLIN IMMUN, V86, P576, DOI 10.1016/S0091-6749(05)80215-5; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315, DOI 10.1164/ajrccm.151.2.7842184; WOOLCOCK AJ, 1991, AM REV RESPIR DIS, V143, P1438, DOI 10.1164/ajrccm/143.6.1438; ZHONG NS, 1992, CHEST, V102, P1104, DOI 10.1378/chest.102.4.1104	30	41	44	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				775	780		10.1016/S0091-6749(97)70273-2	http://dx.doi.org/10.1016/S0091-6749(97)70273-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438486				2022-12-18	WOS:000071353600010
J	van Halteren, HK; van der Linden, PWG; Burgers, JA; Bartelink, AKM				van Halteren, HK; van der Linden, PWG; Burgers, JA; Bartelink, AKM			Discontinuation of yellow jacket venom immunotherapy: Follow-up of 75 patients by means of deliberate sting challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; immunotherapy; Hymenoptera; desensitization; yellow jacket; sting challenge	NATURAL-HISTORY; WASP VENOM; INSECT; ALLERGY; ANAPHYLAXIS; SEVERITY; CHILDREN; SYMPTOMS	Background: Venom immunotherapy is effective in preventing systemic reactions in patients with a history of an anaphylactic reaction to Hymenoptera stings. It is uncertain how long venom immunotherapy should be continued. Objective: We evaluated whether the duration of venom immunotherapy given to yellow jacket-sensitive patients related to the risk of an anaphylactic reaction to a later sting. Methods: Seventy-five yellow jacket-sensitive patients (29 male and 46 female) received a median number of three in-hospital sting challenges from a live insect in 3 subsequent years after discontinuation of venom immunotherapy. An anaphylactic reaction to one or more of the sting challenges was considered a relapse. We analyzed whether patients with and patients without a relapse differed in terms of gender, age, preimmunotherapy skin test data, preimmunotherapy level of venom-specific IgE, severity of the field-sting reaction that preceded immunotherapy, severity of the reaction to the sting challenge that preceded immunotherapy, adverse reactions to immunotherapy, changes in IgE and IgG(4) levels during immunotherapy, duration of immunotherapy, and presence of venom-specific IgE after cessation of therapy. Results: Venom immunotherapy was given for a median duration of 40 months (range, 7 to 120 months). Relapses were observed in six patients. In two of them, a rather severe anaphylactic reaction was observed after the second sting challenge. No relation was found between duration of venom immunotherapy and relapse risk. The relapse rate was higher among patients with high levels of specific IgE before and after immunotherapy. During therapy, the mean level of specific IgE decreased. This decline persisted in the 3 following years. No relapses of sting reactions were observed among patients without detectable specific IgE. Conclusion: Discontinuation of venom immunotherapy appears safe for patients with pretreatment IgE antibodies if these antibodies can no longer be detected during immunotherapy. For the remaining patients, a treatment period of 3 years may suffice. After discontinuation of immunotherapy, a clinical sting challenge can be considered to estimate the patient's current grade of hypersensitivity.	Eemland Hosp, Dept Internal Med, NL-3818 ES Amersfoort, Netherlands; Kennemer Gasthuis, Dept Internal Med, Haarlem, Netherlands; Acad Hosp, Dept Pulmonol, Utrecht, Netherlands	Spaarne Hospital	Bartelink, AKM (corresponding author), Eemland Hosp, Dept Internal Med, Utrechtseweg 160, NL-3818 ES Amersfoort, Netherlands.							Aalberse R C, 1979, Monogr Allergy, V14, P29; AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; BERNSTEIN DI, 1989, J ALLERGY CLIN IMMUN, V84, P951, DOI 10.1016/0091-6749(89)90394-1; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; CHIPPS BE, 1980, J PEDIATR-US, V97, P177, DOI 10.1016/S0022-3476(80)80470-7; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; KAMPELMACHER MJ, 1987, CLIN ALLERGY, V17, P317, DOI 10.1111/j.1365-2222.1987.tb02021.x; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; MOSBECH H, 1986, ALLERGY, V41, P95, DOI 10.1111/j.1398-9995.1986.tb00284.x; Mueller H L, 1966, J Asthma Res, V3, P331; MULLER U, 1993, ALLERGY, V48, P37; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; NATAF P, 1984, CLIN ALLERGY, V14, P269, DOI 10.1111/j.1365-2222.1984.tb02206.x; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V90, P335, DOI 10.1016/S0091-6749(05)80012-0; REISMAN RE, 1993, J ALLERGY CLIN IMMUN, V92, P831, DOI 10.1016/0091-6749(93)90060-S; REISMAN RE, 1985, J ALLERGY CLIN IMMUN, V75, P731, DOI 10.1016/0091-6749(85)90103-4; REISMAN RE, 1981, J ALLERGY CLIN IMMUN, V68, P406, DOI 10.1016/0091-6749(81)90140-8; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1053/ai.1994.v94.a54889; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; vanHalteren HK, 1996, J ALLERGY CLIN IMMUN, V97, P1058, DOI 10.1016/S0091-6749(96)70258-0	25	41	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1997	100	6	1				767	770		10.1016/S0091-6749(97)70271-9	http://dx.doi.org/10.1016/S0091-6749(97)70271-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YQ151	9438484				2022-12-18	WOS:000071353600008
J	Laberge, S; Durham, SR; Ghaffar, O; Rak, S; Center, DM; Jacobson, M; Hamid, Q				Laberge, S; Durham, SR; Ghaffar, O; Rak, S; Center, DM; Jacobson, M; Hamid, Q			Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticosteroid treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin; late nasal response; messenger RNA; inflammation; immunoreactivity	LYMPHOCYTE CHEMOATTRACTANT FACTOR; CYTOKINE MESSENGER-RNA; INDUCED RHINITIS; T-LYMPHOCYTES; CELLS; MUCOSA; EOSINOPHILS; IDENTIFICATION; INTERLEUKIN-16	Allergen-induced late nasal responses (LNRs) are associated with a cellular infiltrate in which CD4(+) cells are prominent. These cells have been shown to be the major cellular source of Th2-type cytokines. Mechanisms responsible for the local accumulation of CD4(+) cells in the nasal mucosa after allergen exposure are unclear. IL-16 is a potent chemoattractant for CD4(+) cells in vitro and may play a significant role in recruiting CD4(+) cells in LNRs. We investigated the expression of IL-16 messenger RNA and immunoreactivity in nasal biopsy specimens from 17 subjects with allergic rhinitis. A biopsy specimen of the nasal inferior turbinate was obtained before and 24 hours after local nasal provocation with grass pollen extract after 6 weeks of treatment with either topical fluticasone propionate (n = 9) or placebo (n = 8) nasal spray twice daily. IL-16 mRNA-positive cells and IL-16-immunoreactive cells were identified in both the epithelium and the subepithelial tissue at baseline. Within the placebo-treated group, the numbers of epithelial and subepithelial IL-16 mRNA-positive cells and IL-16-immunoreactive cells were significantly increased 24 hours after challenge compared with baseline (p < 0.001). Topical glucocorticoid therapy resulted in a decrease in allergen-induced epithelial immunoreactive cells and subepithelial IL-16 mRNA-positive cells. The numbers of CD4(+) cells increased after antigen challenge compared with baseline (p < 0.05), and this increase was inhibited by glucocorticoid treatment. There were significant correlations between epithelial and subepithelial IL-16 immunoreactivity and CD4(+) cell infiltration after antigen challenge. The upregulation of IL-16 expression in allergic nasal mucosa after antigen challenge may have critical implications in the accumulation of CD4(+) cells in response to antigen exposure. Steroid-mediated inhibition of IL-16 may be partly responsible for the decrease in local CD4(+) cells after topical glucocorticoid therapy.	MCGILL UNIV,ROYAL VICTORIA HOSP,MEAKINS CHRISTIE LABS,MONTREAL,PQ H3A 1A1,CANADA; UNIV MONTREAL,ST JUSTINE HOSP,MONTREAL,PQ,CANADA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,NATL HEART & LUNG INST,LONDON,ENGLAND; GOTHENBURG UNIV,SAHLGRENS HOSP,S-41345 GOTHENBURG,SWEDEN; BOSTON UNIV,SCH MED,CTR PULM,BOSTON,MA 02118	McGill University; Royal Victoria Hospital; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Imperial College London; Sahlgrenska University Hospital; University of Gothenburg; Boston University				Center, David/0000-0002-5879-7978	NIAID NIH HHS [AI 35680] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035680, R21AI035680] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Arima M, 1996, J ALLERGY CLIN IMMUN, V97, P443; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738, DOI 10.1165/ajrcmb.13.6.7576712; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ghaffar O., 1996, Journal of Allergy and Clinical Immunology, V97, P194, DOI 10.1016/S0091-6749(96)80264-8; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; LABERGE S, 1995, J IMMUNOL, V155, P2902; LABERGE S, 1997, IN PRESS AM J RESP C; Lim KG, 1996, J IMMUNOL, V156, P2566; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170, DOI 10.1164/ajrccm/146.1.170; Wu D, 1996, AM J RESP CELL MOL B, V153, pA208; YING S, 1994, IMMUNOLOGY, V82, P200; YING S, 1993, AM J RESP CELL MOL, V9, P356, DOI 10.1165/ajrcmb/9.4.356	17	41	44	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1997	100	4					569	574		10.1016/S0091-6749(97)70152-0	http://dx.doi.org/10.1016/S0091-6749(97)70152-0			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YA529	9338554				2022-12-18	WOS:A1997YA52900023
J	Petersen, LJ; Church, MK; Skov, PS				Petersen, LJ; Church, MK; Skov, PS			Platelet-activating factor Induces histamine release from human skin mast cells in vivo, which is reduced by local nerve blockade	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						platelet-activating factor; histamine release; skin; human; microdialysis	FACTOR PAF-ACETHER; INFLAMMATORY RESPONSES; INVIVO; MICRODIALYSIS; ANTIGEN; CETIRIZINE; CAPSAICIN	Background: Intradermal injection of platelet-activating factor (PM) causes wheal and flare reactions, which are inhibited by antihistamines, However, PAF does not release histamine from human dispersed skin mast cells in vitro. The purpose of this study was to investigate the extent and possible mechanisms of PAF-induced histamine release in human skin in vivo with the use of dermal microdialysis. Methods: Hollow dialysis fibers were inserted into the upper dermis in forearm skin and each fiber was perfused with Krebs-Ringer bicarbonate solution at a rate of 3.0 mu l/min. PAF (4.5 to 36 mu mol/L), lyso-PAF (36 mu mol/L), vehicle (negative control), and codeine 750 or 250 mu mol/L (positive control) were injected intradermally above separate fibers. Dialysate was collected in 2-minute fractions for 20 minutes and histamine analyzed spectrofluorometrically. Results: PAF, but not lyso-PAF, caused statistically significant dose-related histamine release and wheal and Rare reactions. Intradermal mepivacaine administration significantly abrogated flare reactions by PAF and codeine and inhibited histamine release and wheal reactions by PAI; but not by codeine. Long-term topical capsaicin administration inhibited histamine release and wheal reactions by PAF hut not by codeine. It inhibited dare reactions induced by both compounds. PAF did not release histamine from blood basophils. Conclusions: These data suggest that PAP induced histamine release from mast cells in intact human skin indirectly via neurogenic activation. Further, on the intradermal injection of PAI; histamine release and the skin responses, the wheal and the hare, are differentially regulated by neurogenic components.	REFERENCE LAB, COPENHAGEN, DENMARK; SOUTHAMPTON GEN HOSP, IMMUNOPHARMACOL GRP, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of Southampton	Petersen, LJ (corresponding author), UNIV COPENHAGEN, BISPEBJERG HOSP, DEPT DERMATOL, DK-2400 COPENHAGEN NV, DENMARK.							ARCHER CB, 1985, BRIT J PHARMACOL, V85, P109, DOI 10.1111/j.1476-5381.1985.tb08836.x; BARR RM, 1993, BRIT J CLIN PHARMACO, V35, P637, DOI 10.1111/j.1365-2125.1993.tb04194.x; BASRAN G S, 1983, European Journal of Pharmacology, V86, P143; BEWLEY AP, 1995, SKIN PHARMACOL, V9, P143; BLENNERHASSETT MG, 1992, AM J RESP CELL MOL, V6, P504, DOI 10.1165/ajrcmb/6.5.504; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; CHUNG KF, 1988, J ALLERGY CLIN IMMUN, V81, P1192, DOI 10.1016/0091-6749(88)90890-1; COLUMBO M, 1990, J IMMUNOL, V145, P3855; COLUMBO M, 1995, J ALLERGY CLIN IMMUN, V95, P565, DOI 10.1016/S0091-6749(95)70319-5; FADEL R, 1990, J ALLERGY CLIN IMMUN, V86, P314, DOI 10.1016/S0091-6749(05)80093-4; FJELLNER B, 1985, ACTA DERM-VENEREOL, V65, P409; FOREMAN J, 1983, AGENTS ACTIONS, V13, P105, DOI 10.1007/BF01967311; HENOCQ E, 1988, J ALLERGY CLIN IMMUN, V81, P691, DOI 10.1016/0091-6749(88)91040-8; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; Kornecki E, 1987, Adv Exp Med Biol, V221, P477; LOWMAN MA, 1988, BRIT J PHARMACOL, V95, P121, DOI 10.1111/j.1476-5381.1988.tb16555.x; LYNN B, 1988, Skin Pharmacology, V1, P217; MCCUSKER MT, 1989, J ALLERGY CLIN IMMUN, V83, P1118, DOI 10.1016/0091-6749(89)90455-7; MENCIAHUERTA JM, 1989, CLIN EXP ALLERGY, V19, P125, DOI 10.1111/j.1365-2222.1989.tb02356.x; MICHEL L, 1987, J INVEST DERMATOL, V88, P675, DOI 10.1111/1523-1747.ep12470331; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; OKUDA Y, 1988, INT ARCH ALLER A IMM, V85, P341, DOI 10.1159/000234529; PERETTI F, 1993, AM REV RESPIR DIS, V148, P927; PETERSEN LJ, 1995, CLIN EXP ALLERGY, V25, P1045, DOI 10.1111/j.1365-2222.1995.tb03250.x; PETERSEN LJ, 1992, J INVEST DERMATOL, V99, P357, DOI 10.1111/1523-1747.ep12616676; Petersen LJ, 1996, J ALLERGY CLIN IMMUN, V98, P790, DOI 10.1016/S0091-6749(96)70128-8; PETERSEN LJ, 1994, J ALLERGY CLIN IMMUN, V94, P773, DOI 10.1016/0091-6749(94)90186-4; SCIBERRAS DG, 1991, BRIT J CLIN PHARMACO, V32, P85, DOI 10.1111/j.1365-2125.1991.tb05617.x; SHALIT M, 1989, J ALLERGY CLIN IMMUN, V83, P691, DOI 10.1016/0091-6749(89)90084-5; SHIGENOBU K, 1989, CAN J PHYSIOL PHARM, V67, P669, DOI 10.1139/y89-107; SPINA D, 1991, BRIT J PHARMACOL, V103, P1268, DOI 10.1111/j.1476-5381.1991.tb12335.x; STOLL LL, 1989, CELL REGUL, V15, P137; TAINSH KR, 1992, IMMUNOPHARMACOLOGY, V24, P171, DOI 10.1016/0162-3109(92)90073-L; THOMAS G, 1990, CLIN EXP ALLERGY, V20, P377, DOI 10.1111/j.1365-2222.1990.tb02797.x; TOMEO AC, 1991, FASEB J, V5, P2850, DOI 10.1096/fasebj.5.13.1655549; WILLARD AL, 1992, ANN NY ACAD SCI, V664, P284, DOI 10.1111/j.1749-6632.1992.tb39768.x	37	41	42	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1997	99	5					640	647		10.1016/S0091-6749(97)70026-5	http://dx.doi.org/10.1016/S0091-6749(97)70026-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WY600	9155831	Bronze			2022-12-18	WOS:A1997WY60000012
J	Ball, BA; Folinsbee, LJ; Peden, DB; Kehrl, HR				Ball, BA; Folinsbee, LJ; Peden, DB; Kehrl, HR			Allergen bronchoprovocation of patients with mild allergic asthma after ozone exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen; bronchial provocation; allergen challenge; ozone	AIRWAY INFLAMMATION; PULMONARY-FUNCTION; BRONCHIAL RESPONSIVENESS; MODERATE EXERCISE; 0.12 PPM; RESPONSES; REACTIVITY; POLLUTION; HISTAMINE	Background: Clinical and epidemiologic studies suggest that ambient ozone exposure may increase the response of patients with asthma to inhaled allergen. Objectives: The study was designed to evaluate whether a resting 1-hour exposure to 0.12 ppm ozone increases the sensitivity of patients with atopic asthma to inhaled allergen. Methods: Outside of their allergen season, 15 patients with mild atopic asthma (5 women and 10 men) were exposed, on separate occasions for 1 hour at rest to clean air and 0.12 ppm ozone. Exposures were separated by a minimum of 4 weeks in a counterbalanced, double-blind design. After exposure, subjects underwent inhalation challenge with doubling doses of aerosolized allergen (0.05 to a maximum of 1600 protein nitrogen units/ml) until we elicited a 20% FEV(1) decrement (PC20). Results: Baseline symptoms spirometry, and histamine bronchoreactivity were similar for the two exposures. Neither spirometry results nor symptoms were significantly changed after either exposure. The mean difference in response to allergen challenge on the air and ozone days, for the 12 subjects who attained a PC20, was not significant (p = 0.124). Three subjects required the same allergen dose to reach PC20 for both exposures, five required less allergen after ozone exposure, and four required more. There was no order effect for the acute response to allergen challenges (p = 0.325). However 20 hours after allergen challenge, histamine bronchoreactivity was increased (p < 0.05) to a similar degree for both air and ozone. Conclusions: A testing exposure for 1 hour to 0.12 ppm ozone did not potentiate an immediate bronchoconstrictive response to grass allergen in this group of patients with mild atopic asthma.	US EPA,NATL HLTH & ENVIRONM EFFECTS RES LAB,DIV HUMAN STUDIES,CLIN RES BRANCH,RES TRIANGLE PK,NC 27711	United States Environmental Protection Agency	Ball, BA (corresponding author), UNIV N CAROLINA,CTR ENVIRONM MED & LUNG BIOL,CB NO 7310,104 MASON FARM RD,CHAPEL HILL,NC 27599, USA.			Peden, David/0000-0003-4526-4627	NCRR NIH HHS [RR00046] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*AM LUNG ASS, 1987, STAT COMP AD LUNG DI, P65; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363, DOI 10.1164/ajrccm/148.5.1363; BASCOM R, 1990, AM REV RESPIR DIS, V142, P594, DOI 10.1164/ajrccm/142.3.594; BATES DV, 1983, CAN J PUBLIC HEALTH, V74, P117; CHEN LL, 1995, AM J RESP CRIT CARE, V151, pA27; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; CROPP GJA, 1980, AM THOR SOC NEWS, V6, P9; DOHLMAN AW, 1993, AM REV RESPIR DIS, V148, P955, DOI 10.1164/ajrccm/148.4_Pt_1.955; DRECHSLERPARKS DM, 1987, EXP GERONTOL, V22, P91, DOI 10.1016/0531-5565(87)90044-1; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FOLINSBEE LJ, 1988, JAPCA J AIR WASTE MA, V38, P28, DOI 10.1080/08940630.1988.10466349; FOLINSBEE LJ, 1978, ENV STRESS INDIVIDUA, P111; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HORSTMAN DH, 1990, AM REV RESPIR DIS, V142, P1158, DOI 10.1164/ajrccm/142.5.1158; JORRES R, 1993, AM J RESP CRIT CARE, V153, P56; KEHRL HR, 1987, AM REV RESPIR DIS, V135, P1124; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407, DOI 10.1164/ajrccm/139.2.407; KREIT JW, 1989, J APPL PHYSIOL, V66, P217, DOI 10.1152/jappl.1989.66.1.217; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336, DOI 10.1164/ajrccm.151.5.7735583; ROMBOUT PJA, 1986, JAPCA J AIR WASTE MA, V36, P913, DOI 10.1080/00022470.1986.10466130; SCHOETTLIN CE, 1961, PUBLIC HEALTH REP, V76, P545, DOI 10.2307/4591201; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; STRONG AA, 1978, EPA PUBLICATION; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687	29	41	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1996	98	3					563	572		10.1016/S0091-6749(96)70090-8	http://dx.doi.org/10.1016/S0091-6749(96)70090-8			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VJ428	8828534	Bronze			2022-12-18	WOS:A1996VJ42800013
J	Sperr, WR; Agis, H; Czerwenka, K; Virgolini, I; Bankl, HC; Muller, MR; Zsebo, K; Lechner, K; Valent, P				Sperr, WR; Agis, H; Czerwenka, K; Virgolini, I; Bankl, HC; Muller, MR; Zsebo, K; Lechner, K; Valent, P			Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; histamine; c-kit; stem cell factor; IgE; tryptase	KIT PROTOONCOGENE PRODUCT; CYTOSOLIC BINDING-PROTEIN; PEPTIDYL-PROLYL ISOMERASE; CIS-TRANS ISOMERASE; FETAL LIVER-CELLS; C-KIT; MEDIATOR RELEASE; RECOMBINANT HUMAN; HUMAN BASOPHILS; IMMUNOSUPPRESSANT FK506	Stem cell factor (SCF) is a key regulator of human mast cells (MCs) and a potential mediator of allergy. In this study the effects of cyclosporin A (CSA) and FK-506, two potent immunosuppressive drugs, on SCF-dependent histamine release and growth of human MCs were analyzed. Preincubation of tissue MCs with CSA (3 mu g/ml) resulted in inhibition of histamine release provoked by either recombinant human (rh) SCF (70.3% +/- 20.6% inhibition, p<0.001) or anti-IgE (76.7%+/-21.9%, p<0.001) or by rhSCF+ anti-IgE (77.4%+/-13.9%, p<0.001). Almost the same inhibition was produced by FK-506 (rhSCF: 82.0%+/-18.9% inhibition, p<0.001; anti-IgE: 71.5%+/-16.7%, p<0.001; rhSCF+ anti-IgE: 70.0%+/-7.3%, p<0.001). The effects of CSA and FK-506 on SCF-dependent release of histamine were dose-dependent (IC50: CSA, 1 to 10 ng/ml; FK-506, 0.3 to 3 ng/ml. IC50 values about three to 10 times higher were found for MCs preincubated with rhSCF before anti-IgE activation, compared with anti-IgE or SCF alone. SCF-dependent differentiation of human MCs was analyzed in a long-term suspension culture system (n=6). Unexpectedly, CSA and FK-506 were unable to suppress, but even enhanced SCF-dependent growth of MCs and formation of MC tryptase in long-term culture. Together, CSA and FK-506 inhibit SCF-dependent release of histamine from human MCs and even augment SCF-dependent growth of human MCs in long-term culture.	UNIV VIENNA,AKH,DEPT INTERNAL MED 1,DIV HEMATOL & HEMOSTASEOL,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT GYNECOL 1,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT NUCL MED,A-1090 VIENNA,AUSTRIA; UNIV VIENNA,DEPT SURG 2,A-1090 VIENNA,AUSTRIA; AMGEN RES CTR,THOUSAND OAKS,CA	University of Vienna; University of Vienna; University of Vienna; University of Vienna			Gamperl, Susi/V-2715-2019; Sperr, Mast/V-4767-2019; Test, Test/Y-7921-2019; Test, PV/U-9451-2019; Valent, Peter/B-8533-2016	Gamperl, Susi/0000-0003-0456-5095; Sperr, Mast/0000-0002-7778-5219; Valent, Peter/0000-0003-0456-5095; Sperr, Wolfgang/0000-0003-3288-8027				ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; ASHMAN LK, 1991, BLOOD, V78, P30; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; CALNE RY, 1978, LANCET, V2, P1323; CASOLARO V, 1993, J IMMUNOL, V151, P5563; CIRILLO R, 1990, J IMMUNOL, V144, P3891; COLEMAN JW, 1993, J IMMUNOL, V150, P556; COLUMBO M, 1992, J IMMUNOL, V149, P599; DEPAULIS A, 1991, J IMMUNOL, V146, P2374; DEPAULIS A, 1991, J IMMUNOL, V147, P4278; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GALLI SJ, 1990, LAB INVEST, V62, P5; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HESS AD, 1983, J IMMUNOL, V130, P717; HIRAI K, 1988, J IMMUNOL, V141, P3958; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IRANI AA, 1995, IMMUNOLOGY, V84, P72; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; KAUFMANN Y, 1984, TRANSPLANTATION, V38, P148, DOI 10.1097/00007890-198408000-00011; KINO T, 1987, J ANTIBIOT, V40, P1256, DOI 10.7164/antibiotics.40.1256; KITAMURA Y, 1981, NATURE, V291, P159, DOI 10.1038/291159a0; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; KURIMOTO Y, 1989, J EXP MED, V170, P467, DOI 10.1084/jem.170.2.467; LERNER NB, 1991, BLOOD, V77, P1876; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARONE G, 1988, RES CLIN LAB, V18, P53, DOI 10.1007/BF02918819; MASSEY WA, 1991, J IMMUNOL, V147, P1621; MAYRHOFER G, 1987, IMMUNOL CELL BIOL, V65, P241, DOI 10.1038/icb.1987.27; MITSUI H, 1993, P NATL ACAD SCI USA, V90, P735, DOI 10.1073/pnas.90.2.735; NILSSON G, 1994, BLOOD, V84, P1519; SAWADA S, 1987, J IMMUNOL, V139, P1797; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHULMAN ES, 1982, J IMMUNOL, V129, P2662; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; SERAFIN WE, 1987, NEW ENGL J MED, V317, P30, DOI 10.1056/NEJM198707023170106; SHEVACH EM, 1985, ANNU REV IMMUNOL, V3, P397; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SILLABER C, 1994, INT ARCH ALLERGY IMM, V105, P264, DOI 10.1159/000236767; SILLABER C, 1991, J IMMUNOL, V147, P4224; SPERR WR, 1993, INT ARCH ALLERGY IMM, V102, P170, DOI 10.1159/000236568; STARZL TE, 1989, LANCET, V2, P1000; STELLATO C, 1992, J INVEST DERMATOL, V98, P800, DOI 10.1111/1523-1747.ep12499960; STILLER CR, 1984, SCIENCE, V223, P1362, DOI 10.1126/science.6367043; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; TINDALL RSA, 1987, NEW ENGL J MED, V316, P719, DOI 10.1056/NEJM198703193161205; TRIGGANI M, 1989, INT ARCH APPL IMMUNO, V88, P235; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENT P, 1992, BLOOD, V80, P2237; VALENT P, 1989, BLOOD, V73, P1778; VALENT P, 1990, J IMMUNOL, V145, P3432; VIRGOLINI I, 1992, J BIOL CHEM, V267, P12700; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	58	41	41	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1996	98	2					389	399		10.1016/S0091-6749(96)70163-X	http://dx.doi.org/10.1016/S0091-6749(96)70163-X			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VC995	8757216				2022-12-18	WOS:A1996VC99500018
J	deJong, EC; Spanhaak, S; Martens, BPM; Kapsenberg, ML; Penninks, AH; Wierenga, EA				deJong, EC; Spanhaak, S; Martens, BPM; Kapsenberg, ML; Penninks, AH; Wierenga, EA			Food allergen (peanut)-specific T-h2 clones generated from the peripheral blood of a patient with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; peanut; T-cell clones; cytokines; phenotype	T-CELL RESPONSES; ARA H-II; ATOPIC-DERMATITIS; IGE SYNTHESIS; INTERFERON-GAMMA; HUMAN INTERLEUKIN-5; LYMPHOCYTE-RESPONSES; SERUM LEVELS; PROTEIN; ASTHMA	Background: Increasing evidence indicates a prominent role of allergen-specific T-H2 cells, with high IL-4 and IL-5 production and low interferon-gamma production, in the regulation of IgE and eosinophil production in allergic disorders. However, most studies have concentrated on T cells reactive with inhalation allergens, whereas little is known about the properties of food allergen-reactive T cells. Objective: In this study we therefore characterized peanut-specific T cells, cloned from a patient with severe peanut allergy. Methods: Peripheral blood mononuclear cells from patients with peanut allergy and nonallergic individuals were stimulated with crude peanut exb act (CPE) to compare the proliferative responses and to select a suitable patient for the cloning of CPE-specific T cells. The resultant panel of CPE-reactive T-lymphocyte clones was serologically phenotyped by flow cytometry and analyzed for cytokine secretion by ELISA. Results: The patients' peripheral blood mononuclear cells showed a dose-dependent proliferative response to CPE, which was significantly higher (p < 0.05) than in peripheral blood mononuclear cells of nonallergic donors. The CPE-specific T-lymphocyte clones generated from the selected patient were all CD4(+)/CDB- T helper cells with a T-H2 cytokine profile, secreting high amounts of IL-4 and IL-5, but little or no interferon-gamma. Conclusions: This study demonstrates that peanut-specific T cells do occur in the peripheral blood of patients with peanut allergy and suggests an increased frequency of these T cells in patients compared with nonallergic control subjects. The CD4(+) phenotype and the T-H2 cytokine profile of the CPE-specific T-lymphocyte clones suggest a functional role of allergen-specific T-H2 cells in the pathophysiology of food allergy, similar to the function of inhalation allergen-specific T-H2 cells.	TNO, NUTR & FOOD RES INST, NETHERLANDS ORG APPL SCI RES, NL-3700 AJ ZEIST, NETHERLANDS; UTRECHT TOXICOL CTR, UTRECHT, NETHERLANDS; ALLERGY CTR, UTRECHT, NETHERLANDS; UNIV AMSTERDAM, DEPT CELL BIOL & HISTOL, AMSTERDAM, NETHERLANDS	Netherlands Organization Applied Science Research; University of Amsterdam								BARNETT D, 1983, J ALLERGY CLIN IMMUN, V72, P61, DOI 10.1016/0091-6749(83)90053-2; BELLANTI JA, 1991, IMMUNOL ALLERGY CLIN, V11, P885; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P9; BURASTERO SE, 1993, J ALLERGY CLIN IMMUN, V91, P1075, DOI 10.1016/0091-6749(93)90222-2; BURKS AW, 1989, ALLERGY PROC, V10, P265, DOI 10.2500/108854189778960045; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BUSH RK, 1989, ALLERGY PROC, V10, P261, DOI 10.2500/108854189778959975; Businco L, 1993, Pediatr Allergy Immunol, V4, P33; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; COFFMAN RL, 1986, J IMMUNOL, V136, P949; DELPRETE G, 1992, ALLERGY, V47, P450; DELPRETE G, 1988, J IMMUNOL, V140, P4193; DORION BJ, 1994, J ALLERGY CLIN IMMUN, V93, P93, DOI 10.1016/0091-6749(94)90237-2; EBNER C, 1993, J IMMUNOL, V150, P1047; ENBERG RN, 1991, IMMUNOL ALLERGY CLIN, V11, P767; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; HEUSSER CH, 1991, INT ARCH ALLER A IMM, V94, P87, DOI 10.1159/000235333; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; JAFFE JS, 1993, ANN ALLERGY, V71, P362; KAJOSAARI M, 1982, ACTA PAEDIATR SCAND, V71, P815, DOI 10.1111/j.1651-2227.1982.tb09525.x; KONDO N, 1990, J ALLERGY CLIN IMMUN, V86, P253, DOI 10.1016/S0091-6749(05)80073-9; LEBEDIN YS, 1991, INT ARCH ALLER A IMM, V96, P92, DOI 10.1159/000235540; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; May C D, 1972, Clin Allergy, V2, P335, DOI 10.1111/j.1365-2222.1972.tb01298.x; MCNAMEE LA, 1991, J IMMUNOL METHODS, V141, P81, DOI 10.1016/0022-1759(91)90212-X; METCALFE DD, 1991, CURR OPIN IMMUNOL, V3, P881, DOI 10.1016/S0952-7915(05)80007-X; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NAGI AM, 1989, VET IMMUNOL IMMUNOP, V22, P67, DOI 10.1016/0165-2427(89)90164-5; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; RAMBLINDHAUER C, 1991, ARCH DERMATOL RES, V283, P71, DOI 10.1007/BF00371611; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, pS13, DOI 10.1016/0090-1229(89)90110-4; SAMPSON HA, 1992, JAMA-J AM MED ASSOC, V268, P2840, DOI 10.1001/jama.268.20.2840; SCHEINMANN P, 1976, CLIN ALLERGY, V6, P515, DOI 10.1111/j.1365-2222.1976.tb01936.x; SCHREIBER RA, 1989, MAYO CLIN PROC, V64, P1381, DOI 10.1016/S0025-6196(12)65380-4; SCHULTZ CL, 1991, CURR OPIN IMMUNOL, V3, P350, DOI 10.1016/0952-7915(91)90037-2; SHINODA S, 1993, CLIN EXP ALLERGY, V23, P689, DOI 10.1111/j.1365-2222.1993.tb01795.x; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915, DOI 10.1016/0016-5085(85)90019-8; VERCELLI D, 1991, J ALLERGY CLIN IMMUN, V88, P285, DOI 10.1016/0091-6749(91)90087-5; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; YUNGINGER JW, 1989, ALLERGY PROC, V10, P249, DOI 10.2500/108854189778959993	50	41	43	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1996	98	1					73	81		10.1016/S0091-6749(96)70228-2	http://dx.doi.org/10.1016/S0091-6749(96)70228-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VA692	8765820				2022-12-18	WOS:A1996VA69200009
J	SCHWARTZ, HJ				SCHWARTZ, HJ			LATEX - A POTENTIAL HIDDEN FOOD ALLERGEN IN FAST-FOOD RESTAURANTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									CASE WESTERN RESERVE UNIV,CLEVELAND,OH	Case Western Reserve University	SCHWARTZ, HJ (corresponding author), UNIV CLEVELAND HOSP,AIRWAYS DIS CTR,DEPT MED,CLEVELAND,OH, USA.							CHARPIN D, 1993, CLIN REV ALLERG, V11, P385; HAMANN CP, 1994, ALLERGY PROC, V15, P17, DOI 10.2500/108854194778816643; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; PECQUET C, 1993, CLIN REV ALLERG, V11, P381; SCHWARTZ HJ, 1994, MAYO CLIN PROC, V69, P93, DOI 10.1016/S0025-6196(12)61622-X; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16, DOI 10.1016/S0025-6196(12)61606-1	6	41	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1995	95	1	1				139	140		10.1016/S0091-6749(95)70165-6	http://dx.doi.org/10.1016/S0091-6749(95)70165-6			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QC312	7822658	Bronze			2022-12-18	WOS:A1995QC31200021
J	DENBURG, JA; WOOLLEY, M; LEBER, B; LINDEN, M; OBYRNE, P				DENBURG, JA; WOOLLEY, M; LEBER, B; LINDEN, M; OBYRNE, P			BASOPHIL AND EOSINOPHIL DIFFERENTIATION IN ALLERGIC REACTIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							NERVE GROWTH-FACTOR; COLONY-STIMULATING FACTOR; HUMAN PERIPHERAL-BLOOD; NASAL METACHROMATIC CELLS; HUMAN MAST-CELLS; HEMATOPOIETIC PROGENITORS; CIRCULATING EOSINOPHILS; MARROW-CELLS; HL-60 CELLS; HUMAN IL-3		ASTRO DRACO AB,DEPT PHARMACOL 1,LUND,SWEDEN		DENBURG, JA (corresponding author), MCMASTER UNIV,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,1200 MAIN ST W,HAMILTON,ON L8N 3Z5,CANADA.			Leber, Brian/0000-0001-5502-1480; O'Byrne, Paul/0000-0003-0979-281X				AGOSTI JM, 1988, NEW ENGL J MED, V319, P1623, DOI 10.1056/NEJM198812223192502; BOCHNER BS, 1991, J EXP MED, V173, P1553, DOI 10.1084/jem.173.6.1553; DENBURG J, 1992, HIGHLIGHTS IN ALLERGY AND CLINICAL IMMUNOLOGY, P95; DENBURG J, 1992, INT ARCH ALLERGY IMM, V99, P330, DOI 10.1159/000236276; DENBURG JA, 1985, BLOOD, V66, P312; DENBURG JA, 1992, BLOOD, V79, P846; DENBURG JA, 1983, BLOOD, V61, P775; DENBURG JA, 1980, BRIT J HAEMATOL, V45, P13, DOI 10.1111/j.1365-2141.1980.tb03806.x; DENBURG JA, 1989, CLIN EXP ALLERGY, V19, P249, DOI 10.1111/j.1365-2222.1989.tb02379.x; DENBURG JA, 1991, BLOOD, V77, P1462; DENBURG JA, 1990, SPRINGER SEMIN IMMUN, V12, P401; DENBURG JA, 1985, EXP HEMATOL, V13, P185; DENBURG JA, 1994, J ALLERGY CLIN IMMUN, V93, P194; DENBURG JA, 1984, CLIN RES, V32, pA145; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; DENBURG JA, 1986, MAST CELL DIFFERENTI, P379; DONAHUE RE, 1988, SCIENCE, V241, P1820, DOI 10.1126/science.3051378; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331, DOI 10.1164/ajrccm/143.2.331; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; HOWARD M, 1992, J CLIN IMMUNOL, V12, P239, DOI 10.1007/BF00918147; IHLE JN, 1983, J IMMUNOL, V131, P282; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LEARY AG, 1984, BLOOD, V64, P78; LEBER BF, 1992, BLOOD SI, V80, pA401; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MATSUDA H, 1988, INT ARCH ALLER A IMM, V86, P453, DOI 10.1159/000234634; MATSUDA H, 1988, P NATL ACAD SCI USA, V85, P6508, DOI 10.1073/pnas.85.17.6508; MAYER P, 1989, BLOOD, V74, P613; MCCLANAHAN T, 1993, BLOOD, V81, P2903; METCALF D, 1993, BLOOD, V82, P3515; OGAWA M, 1983, P NATL ACAD SCI-BIOL, V80, P4494, DOI 10.1073/pnas.80.14.4494; OHNO I, 1991, AM J RESP CELL MOL, V5, P505, DOI 10.1165/ajrcmb/5.6.505; OTSUKA H, 1986, AM REV RESPIR DIS, V133, P757; OTSUKA H, 1986, J ALLERGY CLIN IMMUN, V78, P365, DOI 10.1016/S0091-6749(86)80091-4; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SANDERSON CJ, 1985, J EXP MED, V162, P60, DOI 10.1084/jem.162.1.60; SILLABER C, 1992, BLOOD, V80, P634; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; TANNO Y, 1987, EXP HEMATOL, V15, P24; TSAI S, 1992, GENE DEV, V6, P2258, DOI 10.1101/gad.6.12a.2258; TSUDA T, 1991, BLOOD, V77, P971; TSUDA T, 1990, INT ARCH ALLER A IMM, V91, P15, DOI 10.1159/000235083; VALENT P, 1990, INT ARCH ALLER A IMM, V91, P198, DOI 10.1159/000235115; VALENT P, 1989, BLOOD, V73, P1763; VALENT P, 1991, P NATL ACAD SCI USA, V88, P3339, DOI 10.1073/pnas.88.8.3339; VALENT P, 1989, BLOOD, V73, P1778; VALENT P, 1990, J IMMUNOL, V145, P3432; WICH TR, 1990, EXP HEMATOL, V18, P311; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WONG D A, 1990, Journal of Allergy and Clinical Immunology, V85, P173; ZON LI, 1993, BLOOD, V81, P3234	54	41	42	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1135	1141		10.1016/0091-6749(94)90321-2	http://dx.doi.org/10.1016/0091-6749(94)90321-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7528232				2022-12-18	WOS:A1994QA02000002
J	HUSS, RW; HUSS, K; SQUIRE, EN; CARPENTER, GB; SMITH, LJ; SALATA, K; HERSHEY, J				HUSS, RW; HUSS, K; SQUIRE, EN; CARPENTER, GB; SMITH, LJ; SALATA, K; HERSHEY, J			MITE ALLERGEN CONTROL WITH ACARICIDE FAILS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ACARICIDE; MITE ALLERGY; ASTHMA; ALLERGEN; HOME VISITS; AVOIDANCE; RESPIRATORY STATUS	DUST MITE; HOUSE DUST; BENZYL BENZOATE; ASTHMA; MANAGEMENT; AVOIDANCE; CHILDREN; TRIAL	Background: We compared the effects of an acaricide, benzyl benzoate, with the effects of baking soda control applied to bedroom and living room carpets on house dust mite allergen levels, lung function, and medication use in 12 adult patients with asthma for it months. Methods: This was a randomized, double-blind placebo-controlled study. Patients were enrolled from the allergy clinic of a large tertiary care center in a metropolitan area. All patients had positive dust mite puncture test results. Sir patients used benzyl benzoate, and sir used baking soda. Other aggressive mite control measures were implemented uniformly in each group. Subjects were to make two carpet applications, at baseline and at 6 months according to the manufacturer's recommendations. Dust samples were collected in bedroom and living room carpets at 0 3, 6, 9, and 12 months; and quantities of Der p I and Der f I allergens were determined Spirometry was done every 3 months, and peak flow rates were recorded for to days after each dust sampling. Results: There were no significant differences in mean allergen levels between the two groups over time at either site. There were no significant changes in lung function or medication use for either group. Conclusions: Benzyl benzoate powder applications may not be effective when done according to manufacturer's instructions. Further studies are necessary to test effectiveness when applied more frequently and for longer periods.	WALTER REED ARMY MED CTR,ALLERGY IMMUNOL SERV,WASHINGTON,DC 20307; JOHNS HOPKINS UNIV,CTR NURSING RES,BALTIMORE,MD	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Johns Hopkins University								BISCHOFF E, 1990, J CLIN THER, V12, P213; BROWN HM, 1991, ANN ALLERGY, V67, P25; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; HUSS K, 1992, J ALLERGY CLIN IMMUN, V89, P836, DOI 10.1016/0091-6749(92)90439-9; KERSTEN W, 1988, ALLERGOLOGIE, V11, P371; LAUSCHADENDORF S, 1991, J ALLERGY CLIN IMMUN, V87, P41, DOI 10.1016/0091-6749(91)90211-6; MURRAY AB, 1983, PEDIATRICS, V71, P418; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P812; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; PLATTSMILLS TAE, 1991, IMMUNOL ALLERY PRAC, V13, P156; SARSFIELD JK, 1974, ARCH DIS CHILD, V49, P716, DOI 10.1136/adc.49.9.716; VANBRONSWIJK JEMH, 1990, CLIN THER, V12, P221; WALSHAW MJ, 1986, Q J MED, V58, P199	16	41	42	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1994	94	1					27	32		10.1016/0091-6749(94)90067-1	http://dx.doi.org/10.1016/0091-6749(94)90067-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	NX393	8027495				2022-12-18	WOS:A1994NX39300004
J	NISH, WA; CHARLESWORTH, EN; DAVIS, TL; WHISMAN, BA; VALTIER, S; CHARLESWORTH, MG; LEIFERMAN, KM				NISH, WA; CHARLESWORTH, EN; DAVIS, TL; WHISMAN, BA; VALTIER, S; CHARLESWORTH, MG; LEIFERMAN, KM			THE EFFECT OF IMMUNOTHERAPY ON THE CUTANEOUS LATE-PHASE RESPONSE TO ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; LATE-PHASE RESPONSE; SKIN CHAMBER; ALLERGIC RHINITIS	RAGWEED-POLLEN; INFLAMMATORY MEDIATORS; ALLERGIC RHINITIS; NASAL CHALLENGE; SKIN REACTIONS; FACTOR HRF; HAY-FEVER; HISTAMINE; EOSINOPHIL; ASTHMA	Background: This study used the skin chamber model to evaluate prospectively the effect of immunotherapy (IT) on the cutaneous early and late phase response (LPR) to epicutaneous antigen challenge. Methods: Nine subjects with allergic rhinitis were studied at three time points: before starting IT, after 3 months of IT, and after 6 months of IT. Skin chamber histamine content was measured hourly for it hours, and cell counts performed hourly during hours 6 to 12. An intradermal skin test was placed, and the reaction was measured hourly for 12 hours. Skin biopsy specimens were obtained 8 hours after intradermal placement and evaluated for cellular infiltrate and major basic protein deposition. Serum antigen-specific IgG and IgE levels were measured at each time point to confirm physiologic effect of IT. Results: Six months of IT significantly (p < 0.05) decreased both early and LPR shin test reactivity and skin chamber histamine for hours 1 to 3, 4 to 6, and 9 to 12. Skin chamber LPR cellular influx decreased significantly (p < 0.05) for neutrophils only. Decrease in LPR histamine after 6 months of IT was significantly correlated with both decrease in mononuclear cells (R(2) = 0.817, p = 0.002) and decrease in neutrophils (R(2) = 0.813, p = 0.009). Also significantly correlated were decrease in LPR skin test reactivity, with percent change in skin chamber mononuclear cells (R(2) = 0.800, p = 0.009) and decrease in early skin test reactivity (R(2) = 0.675, p = 0.01). Biopsy specimens showed no consistent change in either dermal cellular infiltrate or deposition of major basic protein. Conclusion: IT significantly attenuates cutaneous histamine release and skin test reactivity and is accompanied by a decrease in skin chamber LPR neutrophil influx without significantly altering the dermal infiltrate at 8 hours.	WILFORD HALL USAF MED CTR,DEPT ALLERGY IMMUNOL,LACKLAND AFB,TX; WILFORD HALL USAF MED CTR,DEPT DERMATOL,LACKLAND AFB,TX; MAYO CLIN & MAYO FDN,DEPT DERMATOL,ROCHESTER,MN 55905	United States Department of Defense; United States Air Force; United States Department of Defense; United States Air Force; Mayo Clinic					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036008, R23AR036008] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36008] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BOCHNER BS, 1990, J ALLERGY CLIN IMMUN, V86, P830, DOI 10.1016/S0091-6749(05)80143-5; BROWN MJ, 1982, J ALLERGY CLIN IMMUN, V69, P20, DOI 10.1016/0091-6749(82)90082-3; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P87, DOI 10.1016/S0091-6749(05)80044-2; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CHARLESWORTH EN, 1989, INT ARCH ALLERGY IMM, V83, P50; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; DESHAZO RD, 1979, J IMMUNOL, V122, P692; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; Durham S R, 1991, Clin Exp Allergy, V21 Suppl 1, P206, DOI 10.1111/j.1365-2222.1991.tb01729.x; FEIN BT, 1962, J ALLERGY, V33, P141; FLING JA, 1989, J ALLERGY CLIN IMMUN, V83, P101, DOI 10.1016/0091-6749(89)90483-1; FREW AJ, 1988, J IMMUNOL, V141, P4158; FREW AJ, 1989, INT ARCH ALLER A IMM, V88, P63, DOI 10.1159/000234750; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GRANT JA, 1991, J ALLERGY CLIN IMMUN, V88, P683, DOI 10.1016/0091-6749(91)90170-S; HEDLIN G, 1989, J ALLERGY CLIN IMMUN, V84, P390, DOI 10.1016/0091-6749(89)90426-0; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; JORDANWAGNER DL, 1992, J ALLERGY CLIN IMMUN, V89, P306; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LEE CE, 1992, J ALLERGY CLIN IMMUN, V89, P1010, DOI 10.1016/0091-6749(92)90224-P; LEIFERMAN KM, 1990, LAB INVEST, V62, P579; LIAO TN, 1990, J ALLERGY CLIN IMMUN, V86, P894, DOI 10.1016/S0091-6749(05)80152-6; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; PARKER WA, 1989, J ALLERGY CLIN IMMUN, V84, P667, DOI 10.1016/0091-6749(89)90294-7; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; TALBOT SF, 1985, J CLIN INVEST, V76, P650, DOI 10.1172/JCI112018; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; WANG JY, 1989, ASIAN PAC J ALLERGY, V7, P199; WARNER JA, 1986, J IMMUNOL, V136, P2583	34	41	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					484	493		10.1016/0091-6749(94)90358-1	http://dx.doi.org/10.1016/0091-6749(94)90358-1			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	8120276				2022-12-18	WOS:A1994MY58100010
J	LYMPANY, PA; WELSH, KI; CHRISTIE, PE; SCHMITZSCHUMANN, M; KEMENY, DM; LEE, TH				LYMPANY, PA; WELSH, KI; CHRISTIE, PE; SCHMITZSCHUMANN, M; KEMENY, DM; LEE, TH			AN ANALYSIS WITH SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBES OF THE ASSOCIATION BETWEEN ASPIRIN-INDUCED ASTHMA AND ANTIGENS OF THE HLA SYSTEM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASPIRIN; ASTHMA; HLA; PCR	SENSITIVE ASTHMA; IMMUNE-RESPONSE; BEE VENOM; ALLERGIC-ASTHMA; NONRESPONSIVENESS; CHALLENGE; PROVOCATION; ANALGESICS; ANTIBODIES; DIAGNOSIS	Background: Previous work has suggested that in addition to environmental influences, there is a genetic predisposition for the development of both asthma and atopy. A subset of asthmatic subjects who are intolerant to aspirin has been identified. A previous study has suggested that there is an association between aspirin sensitivity and HLA-DQw2. Methods: To further assess this association, we studied two populations of aspirin-sensitive subjects and aspirin-tolerant subjects with asthma. Genomic DNA was amplified by polymerase chain reaction and hybridized with radiolabeled oligonucleotide probes specific to the second exon of the DRB1, DQA1, DQB1, and DPB1 chains. Results: Using polymerase chain reaction amplification of genomic DNA and sequence-specific oligonucleotide probes, we have been unable to confirm a significant association between aspirin sensitivity and HLA-DQw2. Conclusion: We have shown, however, that there is a significant decrease in the incidence of DPB1*0401 in both aspirin-tolerant and aspirin-intolerant subjects with asthma in both populations studied.	UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, GUYS HOSP, DEPT ALLERGY & ALL RESP DISORDERS, LONDON SE1 9RT, ENGLAND; CHURCHILL HOSP, TISSUE TYPING LAB, OXFORD OX3 7LJ, ENGLAND; SCHWEIZER INST ALLERGIE & ASTHMAFORSCH, DAVOS, SWITZERLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Oxford			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				ANSARI AA, 1991, IMMUNOGENETICS, V33, P24; ASAD SI, 1987, ANN ALLERGY, V59, P219; BLUMENTHAL MN, 1974, SCIENCE, V184, P1301, DOI 10.1126/science.184.4143.1301; BLUMENTHAL MN, 1981, AM J MED GENET, V10, P219, DOI 10.1002/ajmg.1320100304; Bodmer W F, 1973, Natl Cancer Inst Monogr, V36, P127; CARABALLO L, 1992, J ALLERGY CLIN IMMUN, V89, P234; CARABALLO LR, 1990, TISSUE ANTIGENS, V35, P182, DOI 10.1111/j.1399-0039.1990.tb01777.x; Cooke RA, 1916, J IMMUNOL, V1, P201; DAHLEN B, 1990, EUR RESPIR J, V3, P527; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; DOHERTY DG, 1992, HUM IMMUNOL, V34, P53, DOI 10.1016/0198-8859(92)90085-2; GERRARD JW, 1976, ANN ALLERGY, V36, P10; HIRAYAMA K, 1987, NATURE, V327, P426, DOI 10.1038/327426a0; JONES DH, 1984, ANN ALLERGY, V52, P87; KEMENY DM, 1980, CLIN ALLERGY, V10, P413, DOI 10.1111/j.1365-2222.1980.tb02124.x; KEMENY DM, 1983, J ALLERGY CLIN IMMUN, V71, P505, DOI 10.1016/0091-6749(83)90469-4; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; LEVITT RC, 1988, FASEB J, V2, P2605, DOI 10.1096/fasebj.2.10.3384240; LYMPANY P, 1990, J ALLERGY CLIN IMMUN, V86, P160, DOI 10.1016/S0091-6749(05)80061-2; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; MARSH DG, 1981, INT ARCH ALLER A IMM, V66, P48, DOI 10.1159/000232866; MATSUSHITA S, 1987, J IMMUNOL, V138, P109; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MULLARKEY MF, 1986, AM REV RESPIR DIS, V133, P261; NEPOM GT, 1986, LANCET, V2, P1002; PHILLIPS GD, 1989, J ALLERGY CLIN IMMUN, V84, P232, DOI 10.1016/0091-6749(89)90330-8; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; REID MJ, 1992, J ALLERGY CLIN IMMUN, V89, P593, DOI 10.1016/0091-6749(92)90327-X; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1973, HOSP PRACT, V8, P85; SASAZUKI T, 1983, IMMUNOL REV, V70, P51, DOI 10.1111/j.1600-065X.1983.tb00709.x; SCHMITZSCHUMANN M, 1982, PRAX KLIN PNEUMOL, V36, P17; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; SMITH AP, 1971, BRIT MED J, V2, P494, DOI 10.1136/bmj.2.5760.494; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; SZCZEKLIK A, 1975, BRIT MED J, V1, P67, DOI 10.1136/bmj.1.5949.67; SZCZEKLIK A, 1977, RESPIRATION, V34, P79; TSUJI K, 1991, 15TH P HIST WORKSH K, V2; TSUJI K, 1991, 15TH P HIST WORKSH K, V1; TURTON CWG, 1979, THORAX, V34, P670, DOI 10.1136/thx.34.5.670; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; VAUGHAN RW, 1990, TISSUE ANTIGENS, V36, P149, DOI 10.1111/j.1399-0039.1990.tb01821.x	46	41	44	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1993	92	1	1				114	123		10.1016/0091-6749(93)90045-H	http://dx.doi.org/10.1016/0091-6749(93)90045-H			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LQ353	8335847	Bronze			2022-12-18	WOS:A1993LQ35300017
J	BURASTERO, SE; FENOGLIO, D; CRIMI, E; BRUSASCO, V; ROSSI, GA				BURASTERO, SE; FENOGLIO, D; CRIMI, E; BRUSASCO, V; ROSSI, GA			FREQUENCY OF ALLERGEN-SPECIFIC T-LYMPHOCYTES IN BLOOD AND BRONCHIAL RESPONSE TO ALLERGEN IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AIRWAY RESPONSIVENESS; METHACHOLINE CHALLENGE; ALLERGEN CHALLENGE; HOUSE-DUST MITE; T-LYMPHOCYTES	DERMATOPHAGOIDES-PTERONYSSINUS; CELLS; RESPONSIVENESS; IGE	Background: This study was designed to investigate whether the bronchial response to the sensitizing allergen in asthma is correlated with the frequency of allergen-specific T lymphocytes. Methods: Twenty-three asthmatic patients sensitized to Dermatophagoides pteryonyssinus who had never received hyposensitizing therapy and 11 healthy control subjects were studied. Allergen-specific T lymphocytes were enumerated in peripheral blood with limiting dilution cultures. Bronchial challenge with methacholine was performed in all subjects; patients with asthma also underwent an allergen bronchial challenge. Correlations between allergen-specific T cell frequencies and nonspecific bronchial hyperresponsiveness to methacholine as independent variables and early and late bronchial responsiveness to allergen challenge as dependent variables were investigated by means of stepwise-multiple regression analysis. Results: We found that the frequency of allergen-specific T lymphocytes was higher than in control subjects in both patients with asthma with (p < 0.001) and those without (p < 0.05) late-phase asthmatic response to allergen. Moreover, the provocative does of allergen necessary to produce an early 15% fall of forced expiratory volume in 1 second could be predicted in part (59%) by an equation that incorporates methacholine sensitivity and allergen-specific T cell frequency. Conclusions: We conclude that allergen-specific T lymphocytes, which have an established influence on immunoglobulin E production, play an additional role in the induction of the bronchospastic response to inhaled allergen.	UNIV GENOA,CATTEDRA FISIOPATOL RESP,DIPARTIMENTO SCI MOTORIE,I-16126 GENOA,ITALY; UNIV GENOA,CATTEDRA IMMUNOL,I-16126 GENOA,ITALY; IST GIANNINA GASLINI,DIV PNEUMOL,I-16148 GENOA,ITALY	University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini	BURASTERO, SE (corresponding author), HOSP SAN RAFFAELE,DIBIT,DEPT BIOTECHNOL,60 VIA OLGETTINA,I-16132 MILAN,ITALY.		Fenoglio, Daniela/I-7220-2018; , Burastero/AAN-2425-2020	Fenoglio, Daniela/0000-0001-9532-6473; , Burastero/0000-0001-7302-6381				BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209, DOI 10.1152/jappl.1990.69.6.2209; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CRIMI E, 1986, J ALLERGY CLIN IMMUN, V78, P908, DOI 10.1016/0091-6749(86)90239-3; CRIMI E, 1992, MAY AM THOR SOC INT; DESTGROTH SF, 1982, J IMMUNOL METHODS, V49, pR11, DOI 10.1016/0022-1759(82)90269-1; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; GERBLICH AA, 1991, AM REV RESPIR DIS, V143, P533, DOI 10.1164/ajrccm/143.3.533; GERMAN RD, 1990, J ALLERGY CLIN IMMUN, V85, P200; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600, DOI 10.1164/ajrccm/136.3.600; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZAVECCHIA A, 1983, CLIN EXP IMMUNOL, V52, P21; MARAGUCHI A, 1988, J EXP MED, V67, P332; MARTINEZMAZA O, 1986, CLIN IMMUNOL IMMUNOP, V39, P405, DOI 10.1016/0090-1229(86)90168-6; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67, DOI 10.1146/annurev.iy.09.040191.000435; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; RAWLE FC, 1984, J IMMUNOL, V133, P195; SALTINI C, 1991, LUNG SCI F, P459; VERCELLI D, 1990, J IMMUNOL, V144, P570; 1962, AM REV RESPIR DIS, V84, P762	22	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1075	1081		10.1016/0091-6749(93)90222-2	http://dx.doi.org/10.1016/0091-6749(93)90222-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491940	Bronze			2022-12-18	WOS:A1993LC97800016
J	VERBERNE, AAPH; HOP, WCJ; BOS, AB; KERREBIJN, KF				VERBERNE, AAPH; HOP, WCJ; BOS, AB; KERREBIJN, KF			EFFECT OF A SINGLE DOSE OF INHALED SALMETEROL ON BASE-LINE AIRWAY CALIBER AND METHACHOLINE-INDUCED AIRWAY-OBSTRUCTION IN ASTHMATIC-CHILDREN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SALMETEROL; BRONCHODILATION; AIRWAY RESPONSIVENESS; ASTHMA; CHILDREN	BRONCHIAL RESPONSIVENESS; LUNG-FUNCTION; AGONIST; HYPERRESPONSIVENESS; DISEASE; AGENTS	Background: Salmeterol is a new inhaled selelctive beta2-adrenergic receptor agonist with a long duration of action. We studied the duration of the bronchodilation and the protective effect against methacholine-induced airway obstruction of a single dose of salmeterol in a double-blind, randomized, placebo-controlled, crossover design. Methods: Seventeen boys and three girls with mild-to-moderate asthma participated in the study. On two separate days either 50 mug salmeterol or placebo was inhaled. FEV1 and PD20 methacholine were determined before and 1, 4, 8, 12, and 24 hours after inhalation. Results: Salmeterol resulted in a significant bronchodilation compared with placebo, up to 12 hours (p = 0.0001). At 24 hours there was a residual effect that approached significance; mean FEV1 being 8.3% +/- 2.4% above baseline (p = 0.06). Significant protection against airway sensitivity to methacholine after salmeterol inhalation was found at all time points (p < 0.005). Twenty-four hours after administration mean PD20 was still 1.22 +/- 0.29 doubling dose above baseline. No important adverse effects were noted. Conclusion: We conclude that a single dose of 50 mug salmeterol in children with asthma gives a long-lasting bronchodilation, exceeding 12 hours, which is comparable to the results in adult studies. The duration of the protection against airway sensitivity to methacholine exceeds 24 hours.	ERASMUS UNIV,DEPT PEDIAT,SUBDIV PEDIAT RESP MED,3000 DR ROTTERDAM,NETHERLANDS; ERASMUS UNIV,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam	VERBERNE, AAPH (corresponding author), UNIV ROTTERDAM,SOPHIA CHILDRENS HOSP,DEPT PEDIAT,SUBDIV PEDIAT RESP MED,POB 70029,3000 LL ROTTERDAM,NETHERLANDS.							BALL DI, 1991, BRIT J PHARMACOL, V104, P665, DOI 10.1111/j.1476-5381.1991.tb12486.x; BEL EH, 1991, THORAX, V46, P9, DOI 10.1136/thx.46.1.9; BIRNIE D, 1990, THORAX, V45, P199, DOI 10.1136/thx.45.3.199; BUTCHERS PR, 1991, BRIT J PHARMACOL, V104, P672, DOI 10.1111/j.1476-5381.1991.tb12487.x; DEBAETS FM, 1990, AM REV RESPIR DIS, V142, P581, DOI 10.1164/ajrccm/142.3.581; DEROM EY, 1992, J ALLERGY CLIN IMMUN, V89, P811, DOI 10.1016/0091-6749(92)90435-5; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P770; DUIVERMAN EJ, 1987, PEDIATR PULM, V3, P38, DOI 10.1002/ppul.1950030111; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325, DOI 10.1164/ajrccm/140.5.1325; GLEESON JGA, 1988, BRIT J DIS CHEST, V82, P172, DOI 10.1016/0007-0971(88)90039-3; GONGORA HC, 1991, AM REV RESPIR DIS, V144, P626, DOI 10.1164/ajrccm/144.3_Pt_1.626; GUSTAFSSON B, 1991, THORAX, V46, P360, DOI 10.1136/thx.46.5.360; JOSEPHS LK, 1990, EUR RESPIR J, V3, P220; KERREBIJN KF, 1991, ASTHMA ITS PATHOLOGY, V49, P523; KOCH GG, 1972, BIOMETRICS, V28, P577, DOI 10.2307/2556170; MACONOCHIE JG, 1988, BRIT J CLIN PHARMACO, V25, pP115; MALO JL, 1992, J ALLERGY CLIN IMMUN, V89, P567, DOI 10.1016/0091-6749(92)90324-U; NEIJENS HJ, 1979, J ALLERGY CLIN IMMUN, V64, P507, DOI 10.1016/0091-6749(79)90060-5; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; STERK PJ, 1989, EUR RESPIR J, V2, P267; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; ULLMAN A, 1988, THORAX, V43, P674, DOI 10.1136/thx.43.9.674; VANESSENZANDVLIET EEM, 1990, IMMUNOL ALLERGY CLIN, V10, P483; VERBERNE A, 1991, American Review of Respiratory Disease, V143, pA20; WEISS ST, 1984, CHEST, V86, P3, DOI 10.1378/chest.86.1.3; 1987, AM REV RESPIR DIS, V136, P225	27	41	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1993	91	1	1				127	134		10.1016/0091-6749(93)90305-Y	http://dx.doi.org/10.1016/0091-6749(93)90305-Y			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KK044	8093705	Bronze			2022-12-18	WOS:A1993KK04400012
J	WINDOM, HH; MCGUIRE, WP; HAMILTON, RG; ADKINSON, NF				WINDOM, HH; MCGUIRE, WP; HAMILTON, RG; ADKINSON, NF			ANAPHYLAXIS TO CARBOPLATIN - A NEW PLATINUM CHEMOTHERAPEUTIC AGENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									JOHNS HOPKINS ASTHMA & ALLERGY CTR,5501 HOPKINS BAYVIEW CIRCLE,BALTIMORE,MD 21224	Johns Hopkins University; Johns Hopkins Medicine								CROMWELL O, 1979, CLIN ALLERGY, V9, P109, DOI 10.1111/j.1365-2222.1979.tb01529.x; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P540, DOI 10.1016/0091-6749(84)90391-9; KHAN A, 1975, CANCER RES, V35, P2766; NACLERIO R, 1983, J ALLERGY CLIN IMMUN, V71, P294, DOI 10.1016/0091-6749(83)90083-0; Pepys J, 1972, Clin Allergy, V2, P391, DOI 10.1111/j.1365-2222.1972.tb01303.x; WIESENFELD M, 1979, CANCER TREAT REP, V63, P219	6	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1992	90	4	1				681	683		10.1016/0091-6749(92)90142-O	http://dx.doi.org/10.1016/0091-6749(92)90142-O			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT995	1401647				2022-12-18	WOS:A1992JT99500015
J	SPECTOR, SL				SPECTOR, SL			THE ROLE OF ALLERGY IN SINUSITIS IN ADULTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	SYMP ON MECHANISMS, DIAGNOSIS, AND TREATMENT OF SINUSITIS IN CHILDREN AND ADULTS	JAN 24-25, 1992	SCOTTSDALE, AZ	ALLEN & HANBURYS		SINUSITIS; ALLERGY	MAXILLARY SINUSITIS	Allergic sinus disease in adults has not been definitively established. On the other hand, sinusitis is more common in allergic individuals than control subjects. Nasal provocation studies with allergens produce clinical findings and radiographic evidence suggestive of allergic sinusitis. Studies that use single-photon emission computerized tomography do not confirm direct entry of pollens into the sinuses. Fungal sinusitis typically occurs in patients with allergic rhinitis and nasal obstruction for many years. Patients often have an elevated specific IgE and total IgE with positive skin tests to the fungus involved. The diagnosis is confirmed by computed tomographic scan or magnetic resonance imaging of the sinuses. There is no direct fungal invasion. Many patients who have chronic severe sinusitis, asthma, and frequently aspirin idiosyncrasy appear to have immunologic reactions in the sinuses (and bronchial tissue). Histologic findings of the sinus mucosa show infiltration with plasma cells and eosinophils. Immunoflourescent stains show IgE dispersed throughout the tissue possibly in plasma cells. An intense linear stain for IgD is found along the epithelial side of the basement membrane.	UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								BORTS MR, 1989, J ALLERGY CLIN IMMUN, V83, P302; GOURLEY DS, 1990, J ALLERGY CLIN IMMUN, V85, P583, DOI 10.1016/0091-6749(90)90097-N; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; SAVOLAINEN S, 1989, ALLERGY, V44, P116, DOI 10.1111/j.1398-9995.1989.tb02234.x; SCHLENTER WW, 1981, ADV SINUSITIS MICROB; SCULLY RE, 1991, NEW ENGL J MED, V324, P1423; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P284, DOI 10.1016/0091-6749(88)90700-2; SPECTOR SL, 1989, PROVOCATIVE CHALLENG; SPECTOR SL, 1983, ALLERGY PRINCIPLES P, P1249; VAN DISHOECK H A, 1957, Pract Otorhinolaryngol (Basel), V19, P502; VANDISHOECK HAE, 1961, ADV OTORHINOLARYNGOL, V10, P1	13	41	41	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1992	90	3	2	S			518	520		10.1016/0091-6749(92)90178-5	http://dx.doi.org/10.1016/0091-6749(92)90178-5			3	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JP521	1527344	Bronze			2022-12-18	WOS:A1992JP52100019
J	KYANAUNG, U; HALLSWORTH, M; HASKARD, D; DEVOS, C; LEE, TH				KYANAUNG, U; HALLSWORTH, M; HASKARD, D; DEVOS, C; LEE, TH			THE EFFECTS OF CETIRIZINE ON THE ADHESION OF HUMAN EOSINOPHILS AND NEUTROPHILS TO CULTURED HUMAN UMBILICAL VEIN ENDOTHELIAL-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							MOLECULE-1; ADHERENCE; INVITRO; INVIVO		UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT ALLERGY,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT RHEUMATOL,LONDON SE1 9RT,ENGLAND; UNIV CLIN BRUSSELS,PHARMACEUT SECTOR,B-1470 BRAINE LALLEUD,BELGIUM	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London			Lee, Tak/AAA-9526-2020	Lee, Tak/0000-0002-7554-4059				BOCHNER BS, 1988, J CLIN INVEST, V81, P1355, DOI 10.1172/JCI113463; FADEL R, 1990, J ALLERGY CLIN IMMUN, V86, P314, DOI 10.1016/S0091-6749(05)80093-4; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HENOCQ E, 1990, CLIN EXP ALLERGY, V20, P269, DOI 10.1111/j.1365-2222.1990.tb02682.x; KYANAUNG U, 1991, J IMMUNOL, V146, P521; KYANAUNG U, 1991, AM J RESP CELL MOL, V5, P445, DOI 10.1165/ajrcmb/5.5.445; WALSH GM, 1991, J IMMUNOL, V146, P3419	7	41	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1992	90	2					270	272		10.1016/0091-6749(92)90083-E	http://dx.doi.org/10.1016/0091-6749(92)90083-E			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JJ423	1354226				2022-12-18	WOS:A1992JJ42300020
J	POLLA, BS; EZEKOWITZ, RA; LEUNG, DYM				POLLA, BS; EZEKOWITZ, RA; LEUNG, DYM			MONOCYTES FROM PATIENTS WITH ATOPIC-DERMATITIS ARE PRIMED FOR SUPEROXIDE PRODUCTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; SUPEROXIDE; MONOCYTES	ALVEOLAR MACROPHAGES; POLYMORPHONUCLEAR LEUKOCYTES; INTERFERON-GAMMA; IMMUNOGLOBULIN-E; CELLS; NEUTROPHILS; STIMULATION; GENERATION; DISEASE; ASTHMA	To determine the potential role of monocytes (peripheral blood monocytes, PBMs) in the pathogenesis of atopic dermatitis (AD), we investigated whether PBMs from patients with severe AD are primed to generate toxic oxygen metabolites. To induce in vitro superoxide anion (O2-) production, we used either particulate (e.g., opsonized bacteria or zymosan) or soluble (e.g., phorbol esters) stimuli, which allowed us to test two distinct pathways for reduced nicotinamide-adenine dinucleotide phosphate activation. In addition, PBMs from the same patients were also examined for their levels of expression of the low-affinity receptor for IgE, FC(epsilon) receptor 2 (CD23). We found that PBMs, but not peripheral blood neutrophils, from patients with AD were primed for O2- production as compared to PBMs from either normal control subjects or patients with allergic rhinitis. These cells also expressed increased levels of CD23, and there was a significant correlation between these two parameters. Since the monocytes infiltrating into the AD lesions bear CD23, our data suggest that in vivo priming of PBMs and increased O2- production may participate in the pathogenesis of this skin disease.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,BOSTON,MA 02115; UNIV GENEVA,HOP CANTONAL,DIV IMMUNOL & ALLERGY,ALLERGY UNIT,CH-1211 GENEVA 4,SWITZERLAND	National Jewish Health; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Geneva								BORISH L, 1991, J IMMUNOL, V146, P63; CALHOUN WJ, 1990, J ALLERGY CLIN IMMUN, V86, P306, DOI 10.1016/S0091-6749(05)80092-2; EZEKOWITZ RAB, 1985, J CLIN INVEST, V76, P2368, DOI 10.1172/JCI112249; FANTONE JC, 1982, AM J PATHOL, V107, P397; FRANK L, 1983, TRENDS PHARMACOL SCI, V4, P124, DOI 10.1016/0165-6147(83)90327-9; FULLER RW, 1986, CLIN EXP IMMUNOL, V65, P416; HALLIWELL B, 1987, FASEB J, V1, P358, DOI 10.1096/fasebj.1.5.2824268; HANIFIN JM, 1982, J AM ACAD DERMATOL, V6, P1, DOI 10.1016/S0190-9622(82)70001-5; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; JUJO K, 1991, Journal of Allergy and Clinical Immunology, V87, P235, DOI 10.1016/0091-6749(91)91664-F; KLEBANOFF SJ, 1986, J IMMUNOL, V136, P4220; KOOMENBRUYNZEEL C, 1986, ARCH DERMATOL RES, V278, P199; LEUNG DYM, 1987, CLIN IMMUNOL IMMUNOP, V42, P328, DOI 10.1016/0090-1229(87)90021-3; LEUNG DYM, IN PRESS CLIN RES; LEUNG DYM, 1986, DERMATOLOGY GENERAL, P1385; MARIDONNEAUPARINI I, 1989, J CLIN INVEST, V83, P1936, DOI 10.1172/JCI114101; MARIDONNEAUPARINI I, 1986, J IMMUNOL, V137, P2925; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MELTZER S, 1989, J ALLERGY CLIN IMMUN, V83, P960, DOI 10.1016/0091-6749(89)90112-7; POLLA BS, 1989, J LEUKOCYTE BIOL, V45, P381, DOI 10.1002/jlb.45.5.381; POLLA BS, 1986, J CLIN INVEST, V77, P1332, DOI 10.1172/JCI112438; POLLA BS, 1989, AM REV RESPIR DIS, V139, P274; RANKIN JA, 1982, NATURE, V297, P329, DOI 10.1038/297329a0; ROUXLOMBARD P, 1986, CELL IMMUNOL, V97, P286, DOI 10.1016/0008-8749(86)90399-0; SECHLER JMG, 1988, P NATL ACAD SCI USA, V85, P4874, DOI 10.1073/pnas.85.13.4874; TAUBER AI, 1979, BIOCHEMISTRY-US, V18, P5576, DOI 10.1021/bi00592a009; VERCELLI D, 1988, J EXP MED, V167, P1406, DOI 10.1084/jem.167.4.1406; VOLLENWEIDER S, 1991, J ALLERGY CLIN IMMUN, V87, P1088, DOI 10.1016/0091-6749(91)92154-S; WHITE MI, 1986, CLIN EXP DERMATOL, V11, P34, DOI 10.1111/j.1365-2230.1986.tb00421.x	30	41	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1992	89	2					545	551		10.1016/0091-6749(92)90321-R	http://dx.doi.org/10.1016/0091-6749(92)90321-R			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD753	1311007				2022-12-18	WOS:A1992HD75300006
J	JAFFER, AM				JAFFER, AM			SULFASALAZINE IN THE TREATMENT OF CORTICOSTEROID-DEPENDENT CHRONIC IDIOPATHIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note									UNIV CALIF SAN DIEGO,SCH MED,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARRETT KE, 1985, EUR J PHARMACOL, V107, P279, DOI 10.1016/0014-2999(85)90071-8; BESTEL EP, 1988, J ALLERGY CLIN IMMUN, V82, P265; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; PEPPERCORN M, 1988, ANN INTERN MED, V17, P246; PINALS RS, 1988, SEMIN ARTHRITIS RHEU, V17, P246, DOI 10.1016/0049-0172(88)90010-8	5	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1991	88	6					964	965		10.1016/0091-6749(91)90255-M	http://dx.doi.org/10.1016/0091-6749(91)90255-M			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GW262	1683883				2022-12-18	WOS:A1991GW26200019
J	RITTER, C; BATTIG, M; KRAEMER, R; STADLER, BM				RITTER, C; BATTIG, M; KRAEMER, R; STADLER, BM			IGE HIDDEN IN IMMUNE-COMPLEXES WITH ANTI-IGE AUTOANTIBODIES IN CHILDREN WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANTI-IGE; ASTHMA; AUTOANTIBODY; CHILD; IGE; IGE-DETERMINATION; IMMUNE COMPLEX	OCCURRING HUMAN ANTIGLOBULINS; SERUM IGE; IMMUNOGLOBULIN-E; MONOCLONAL-ANTIBODIES; ATOPIC-DERMATITIS; SPECIFICITY; PREVALENCE; ALLERGY; INVITRO; GAMMAE	Serum levels of IgE, anti-IgE autoantibodies (Abs), and IgE/IgE anti-IgE immune complexes (ICs) were measured in 110 children with asthma and 90 healthy control children. Significantly enhanced levels of IgE/anti-IgE IC were detected in children with asthma. However, only a weak correlation was found between anti-IgE auto-Ab serum levels and the degree of lung function abnormalities in children with asthma. However, children with asthma with low serum IgE levels had elevated IC serum levels of IgE/anti-IgE auto-Abs, suggesting that IgE might be hidden within these ICs and is therefore not measurable in vitro. The significant elevation of IgE/anti-IgE IC serum levels raises the question whether IgE within ICs is neutralized or might still be involved in immunologic mechanisms responsible for clinical symptoms of bronchial asthma.	UNIV BERN, INSELSPITAL, INST CLIN IMMUNOL, CH-3010 BERN, SWITZERLAND; UNIV BERN, INSELSPITAL, DEPT PEDIAT, CH-3010 BERN, SWITZERLAND	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern								AALBERSE RC, 1974, J LAB CLIN MED, V83, P831; BELLANTI JA, 1975, BRONCHIAL ASTHMA MEC, P105; BENNICH H, 1975, BRONCHIAL ASTHMA MEC, P171; CANO PO, 1977, CLIN ALLERGY, V7, P167, DOI 10.1111/j.1365-2222.1977.tb01438.x; CARINI C, 1988, ANN ALLERGY, V60, P48; CARINI C, 1983, ANN ALLERGY, V51, P251; DORRINGTON KJ, 1973, J BIOL CHEM, V248, P8378; ELLIS E, 1988, ALLERGY PRINCIPLES P, V2, P1037; FELDMEIER H, 1983, INT ARCH ALLER A IMM, V72, P211, DOI 10.1159/000234870; Fujimoto T, 1987, Prog Clin Biol Res, V250, P209; GRASSI J, 1986, J ALLERGY CLIN IMMUN, V77, P808, DOI 10.1016/0091-6749(86)90378-7; GRUBER BL, 1988, J INVEST DERMATOL, V90, P213, DOI 10.1111/1523-1747.ep12462239; HONG CS, 1986, J IMMUNOL METHODS, V95, P195; IGANAS M, 1981, INT ARCH ALLER A IMM, V65, P51; JOHANSSON SGO, 1986, J ALLERGY CLIN IMMUN, V77, P555, DOI 10.1016/0091-6749(86)90344-1; JOHANSSON SGO, 1986, 12 P INT C ALL CLIN, P193; JOHANSSON SGO, 1978, MONOGR ALLERGY, V26, P198; KERREBIJN KF, 1989, ROLE INFLAMMATORY PR, P1; KNUTTIMULLER JM, 1986, ALLERGY, V41, P457, DOI 10.1111/j.1398-9995.1986.tb00327.x; KOIKE T, 1989, MONOGR ALLERGY, V26, P165; KOIKE T, 1987, ALLERGY TODAY, V2, P4; KUSAKAWA S, 1976, PEDIATR RES, V10, P108, DOI 10.1203/00006450-197602000-00007; LOIDOLT D, 1990, LARYNGO RHINO OTOL, V69, P255, DOI 10.1055/s-2007-998185; MAGNUSSON CGM, 1986, INT ARCH ALLER A IMM, V79, P149, DOI 10.1159/000233963; MIYAMOTO T, 1974, J ALLERGY CLIN IMMUN, V53, P9, DOI 10.1016/0091-6749(74)90094-3; MORELL A, 1986, EUR J PEDIATR, V145, P199, DOI 10.1007/BF00446065; NAKAJIMA K, UNPUB EFFECT NATURAL; NAWATA Y, 1984, CLIN EXP IMMUNOL, V58, P348; NAWATA Y, 1985, J IMMUNOL, V135, P478; NICKELSEN JA, 1988, J ALLERGY CLIN IMMUN, V83, P486; PAGANELLI R, 1988, J CLIN LAB IMMUNOL, V26, P153; PAGANELLI R, 1986, CLIN ALLERGY, V16, P513, DOI 10.1111/j.1365-2222.1986.tb01989.x; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; PRZYBILLA B, 1986, HAUTARZT, V37, P77; QIU G, 1989, CHIN J IMMUNOL, V5, P354; QUINTI I, 1986, J ALLERGY CLIN IMMUN, V77, P586, DOI 10.1016/0091-6749(86)90350-7; SHIBASAKI M, 1988, J ALLERGY CLIN IMMUN, V82, P86, DOI 10.1016/0091-6749(88)90056-5; SMITH JM, 1988, ALLERGY PRINCIPLES P, V2, P891; STADLER BM, 1989, CYTOKINES REGULATING, V2, P37; STEVENS WJ, 1984, J ALLERGY CLIN IMMUN, V73, P276, DOI 10.1016/S0091-6749(84)80020-2; STEVENS WJ, 1983, CLIN EXP IMMUNOL, V52, P144; STEVENS WJ, 1980, PROG RESPIR RES, V14, P51; SWAINSON JA, 1985, INT ARCH ALLER A IMM, V76, P237, DOI 10.1159/000233698; TSUDA M, 1984, ALLERGY, V33, P59; TSUTSUMI A, 1988, IMMUNOL ALLERGY PRAC, V10, P149; VASSELLA CC, 1990, CLIN EXP ALLERGY, V20, P295, DOI 10.1111/j.1365-2222.1990.tb02687.x; VASSELLA CC, 1990, INT ARCH ALLER A IMM, V92, P272, DOI 10.1159/000235189; WILLIAMS RC, 1972, J CLIN INVEST, V51, P955, DOI 10.1172/JCI106890; YOKOGAWA M, 1976, AM J TROP MED HYG, V25, P581, DOI 10.4269/ajtmh.1976.25.581; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	50	41	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1991	88	5					793	801		10.1016/0091-6749(91)90187-S	http://dx.doi.org/10.1016/0091-6749(91)90187-S			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GQ452	1955638				2022-12-18	WOS:A1991GQ45200015
J	TADOKORO, K; OHTOSHI, T; TAKAFUJI, S; NAKAJIMA, K; SUZUKI, S; YAMAMOTO, K; ITO, K; MIYAMOTO, T; MURANAKA, M				TADOKORO, K; OHTOSHI, T; TAKAFUJI, S; NAKAJIMA, K; SUZUKI, S; YAMAMOTO, K; ITO, K; MIYAMOTO, T; MURANAKA, M			TOPICAL THROMBIN-INDUCED IGE-MEDIATED ANAPHYLAXIS - RAST ANALYSIS AND SKIN-TEST STUDIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						TOPICAL THROMBIN; SHOCK; ANAPHYLAXIS; IGE ANTIBODY; RAST; BOVINE; SKIN TEST; INTRAVASCULAR COAGULATION; IMMUNOGENICITY; PREDICTION		Bovine topical thrombin (BTT) is a heterologous plasma thrombin concentrate that has been frequently used for the hemostasis since the 1940s. Recently, three patients in Japan went into shock after the topical application of BTT at lesion sites, and two of these patients had received BTT repeatedly. The clinical symptoms and the increased anti-BTT percent RAST counts suggest that these reactions were shock mediated by anti-BTT IgE antibodies. The RAST-inhibition analysis suggested that the antigenic substance(s) were bovine-specific moiety(ies) mainly involved in the contaminant rather than bovine thrombin itself. The skin tests were studied to predict such allergic reactions. The intracutaneous test provoked nonspecific reactions even at the low concentrations of BTT. The prospective study on the predictive value of the prick test with 1000 U / ml (1 mg / ml) of BTT in 192 patients suggested that it is useful to detect highly sensitive patients. In addition, the increased levels of anti-BTT IgE antibodies in patients 1 month after the single administration of BTT suggested the immunogenicity of the topical application of BTT.	YUGAWARA KOUSEINENKIN HOSP,KANAGAWA,JAPAN		TADOKORO, K (corresponding author), UNIV TOKYO,FAC MED,DEPT MED & PHYS THERAPY,HONGO 7-3-1,BUNKYO KU,TOKYO 113,JAPAN.		Yamamoto, Kazuhiko/N-5096-2015					BIELORY L, 1988, JAMA-J AM MED ASSOC, V21, P3164; BLIN LGA, 1977, CLIN ALLERGY, V7, P55; ENZMANN H, 1982, LARYNG RHINOL OTOL V, V61, P302, DOI 10.1055/s-2007-1008579; GRUBBS FE, 1972, TECHNOMETRICS, V14, P847, DOI 10.2307/1267134; GUNTHER R, 1976, DEUT MED WOCHENSCHR, V101, P1491; HOFFMANN RG, 1963, JAMA-J AM MED ASSOC, V185, P864, DOI 10.1001/jama.1963.03060110068020; ISHIZAKI T, 1969, J JPN MED ASS, V62, P761; JASANI B, 1977, LANCET, V2, P332; JASTRZEBSKI J, 1975, BRIT J ANAESTH, V47, P654, DOI 10.1093/bja/47.6.654; LUNDERQUIST A, 1974, NEW ENGL J MED, V291, P646, DOI 10.1056/NEJM197409262911303; NELSON HS, 1983, ANN ALLERGY, V51, P411; Tidrick RT, 1943, SURGERY, V14, P191; USUDA T, 1986, JAP J BURN INJURIES, V12, P55; WATANABE T, 1970, Acta Medica et Biologica, V18, P49	14	41	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1991	88	4					620	629		10.1016/0091-6749(91)90156-I	http://dx.doi.org/10.1016/0091-6749(91)90156-I			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GL049	1918728				2022-12-18	WOS:A1991GL04900011
J	CHIU, JT; HAYDIK, IB				CHIU, JT; HAYDIK, IB			SESAME SEED OIL ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							PEANUT		ALLERGY IMMUNO TECHNOL INC,NEWPORT BEACH,CA; UNIV CALIF IRVINE,DIV ALLERGY IMMUNOL,ORANGE,CA 92668	University of California System; University of California Irvine								MALANIN G, 1988, J ALLERGY CLIN IMMUN, V82, P261, DOI 10.1016/0091-6749(88)91009-3; MALISH D, 1981, J ALLERGY CLIN IMMUN, V67, P35, DOI 10.1016/0091-6749(81)90042-7; SACHS MI, 1981, J ALLERGY CLIN IMMUN, V67, P27, DOI 10.1016/0091-6749(81)90041-5; SHIBASAKI M, 1980, INT ARCH ALLER A IMM, V61, P448; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4	5	41	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				414	415		10.1016/0091-6749(91)90106-X	http://dx.doi.org/10.1016/0091-6749(91)90106-X			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1716274	Bronze			2022-12-18	WOS:A1991GG12600038
J	KANG, BC; WILSON, M; PRICE, KH; KAMBARA, T				KANG, BC; WILSON, M; PRICE, KH; KAMBARA, T			COCKROACH-ALLERGEN STUDY - ALLERGEN PATTERNS OF 3 COMMON COCKROACH SPECIES PROBED BY ALLERGIC SERA COLLECTED IN 2 CITIES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BRONCHIAL-ASTHMA; PURIFICATION; IGE	Antigens/allergens of three common cockroach extracts, crude whole body extract of the American cockroach (CRa-A), crude whole body extract of the German cockroach (CRa-G), and crude whole body extract of the Oriental cockroach (CRa-O), were studied with crossed immunoelectrophoresis, crossed radioimmunoelectrophoresis, and Western blot analysis. Sera of cockroach-allergic patients with asthma, 10 from Chicago, Ill. (C group) and six patients from Lexington, Ky. (L group), were used; results were then compared with sera of control subjects with asthma. Qualitative differences in protein bands were noted among CRa-A, CRa-G, and CRa-O by crossed immunoelectrophoresis and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Allergen bands on Western blot were analyzed for distribution by molecular weight (MW) with relative intensity scores. Results were compared by species and by geography. Two to 12 allergenic bands of variable MW (14 kd to > 116 kd) were identified by 13 of 16 individual sera from cockroach-allergic patients from all three extracts. CRa-A demonstrated 55 bands with an intensity score of 125; CRa-G, 58 bands with an intensity score of 100; and CRa-O, 51 bands with an intensity score of 108. Allergenic bands of CRa-A were identified by six sera of the C group and one sera of the L group, whereas bands of both CRa-G and CRa-O were noted by nine sera of the C group and four sera of the L group. All three species had an allergen band in MW range of 40 to 45 kd that reacted to most sera from cockroach-allergic patients with asthma.			KANG, BC (corresponding author), UNIV KENTUCKY, DEPT MED, 800 ROSE ST, LEXINGTON, KY 40536 USA.							BALDO BA, 1988, INT ARCH ALLER A IMM, V85, P278, DOI 10.1159/000234518; BERNTON HS, 1967, SOUTH MED J, V60, P852, DOI 10.1097/00007611-196708000-00012; BERNTON HS, 1969, SOUTHERN MED J, V62, P1207, DOI 10.1097/00007611-196910000-00013; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; HELM RM, 1988, INT ARCH ALLER A IMM, V87, P230, DOI 10.1159/000234678; JONES GS, 1986, CLIN RES, V34, pA888; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG B, 1989, ANN ALLERGY, V62, P30; KANG BC, 1988, J ASTHMA, V25, P205, DOI 10.3109/02770908809071367; KANG BC, UNPUB ANN ALLERGY; RALOFF O, 1986, SCI NEWS, V129, P378; ROTH LM, 1951, MISCELLANEOUS SMITHS, V134, P4; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; THOMS EM, 1986, J ECON ENTOMOL, V79, P431, DOI 10.1093/jee/79.2.431; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; YUN D K, 1990, Journal of Allergy and Clinical Immunology, V85, P181	18	41	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1073	1080		10.1016/0091-6749(91)92152-Q	http://dx.doi.org/10.1016/0091-6749(91)92152-Q			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045612	Bronze			2022-12-18	WOS:A1991FR06600006
J	ORYSZCZYN, MP; GODIN, J; ANNESI, I; HELLIER, G; KAUFFMANN, F				ORYSZCZYN, MP; GODIN, J; ANNESI, I; HELLIER, G; KAUFFMANN, F			INUTERO EXPOSURE TO PARENTAL SMOKING, COTININE MEASUREMENTS, AND CORD BLOOD IGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							SERUM IGE; IMMUNOGLOBULIN-E; BRONCHIAL RESPONSIVENESS; ATOPIC DISEASE; FAMILY HISTORY; CHILDREN; NICOTINE; INFANCY; ALLERGY; PREDICTOR	The relationship between parental smoking and cord blood IgE has been studied in a survey conducted in 99 unselected newborn infants with a sensitive test for IgE and cotinine as a biologic marker to validate smoking data. For both cord blood cotinine and maternal urine cotinine creatinine ratio (CCR), significantly higher levels were observed for smokers compared to nonsmokers. Furthermore, among nonsmokers, passive smokers had significantly higher cotinine levels than true nonsmokers, which demonstrates that cord blood may be used to assess active as well as passive maternal smoking. No association was observed in this study between cord blood IgE and maternal smoking assessed by questionnaire (geometric means of cord blood IgE levels were 0.11 IU/ml for newborn infants of smoking mothers and 0.12 IU/ml for newborn infants of nonsmoking mothers). The same observations were drawn from the analysis of cord blood IgE and cotinine levels, with correlation coefficients of -0.005 for cord blood CCR and 0.003 for maternal CCR. Additional studies are needed to determine whether maternal smoking is casually related to cord blood IgE and by which mechanisms.			ORYSZCZYN, MP (corresponding author), INSERM,U169,16 AVE PAUL VAILLANT COUTURIER,F-94807 VILLEJUIF,FRANCE.							BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BIBER A, 1987, TOXICOL LETT, V35, P45, DOI 10.1016/0378-4274(87)90084-1; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CHERVIN B S, 1988, American Review of Respiratory Disease, V137, P253; CRONER S, 1982, ARCH DIS CHILD, V57, P364, DOI 10.1136/adc.57.5.364; FREIDHOFF LR, 1986, INT ARCH ALLER A IMM, V79, P188, DOI 10.1159/000233969; GERRARD JW, 1980, ANN ALLERGY, V44, P261; HUEL G, 1989, ENVIRON RES, V50, P173, DOI 10.1016/S0013-9351(89)80056-8; JOHNSON C, 1989, J ALLERGY CLIN IMMUN, V83, P266; KAUFFMANN F, 1989, BRONCHITIS, V4, P57; KJELLMAN NIM, 1981, LANCET, V1, P993; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; LUCK W, 1985, J PEDIATR-US, V107, P816, DOI 10.1016/S0022-3476(85)80427-3; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MAGNUSSON CGM, 1985, J ALLERGY CLIN IMMUN, V75, P513, DOI 10.1016/S0091-6749(85)80026-9; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518, DOI 10.1164/ajrccm/138.3.518; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; OSAKA F, 1985, Japanese Journal of Hygiene, V40, P789; OWNBY D, 1989, J ALLERGY CLIN IMMUN, V83, P249; OWNBY DR, 1988, J ALLERGY CLIN IMMUN, V82, P634, DOI 10.1016/0091-6749(88)90976-1; Snedecor G.W., 1980, STAT METHODS, V7; SORSA M, 1988, METHODS DETECTING DN, P129; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573, DOI 10.1164/arrd.1985.131.4.573	24	41	43	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1991	87	6					1169	1174		10.1016/0091-6749(91)92163-U	http://dx.doi.org/10.1016/0091-6749(91)92163-U			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FR066	2045619				2022-12-18	WOS:A1991FR06600017
J	SCHATA, M; JORDE, W; RICHARZBARTHAUER, U				SCHATA, M; JORDE, W; RICHARZBARTHAUER, U			LEVOCABASTINE NASAL SPRAY BETTER THAN SODIUM CROMOGLYCATE AND PLACEBO IN THE TOPICAL TREATMENT OF SEASONAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ANTAGONIST; H-1	The efficacy and safety of the nasal administration (twice in each nostril, four times a day) of levocabastine (0.5 mg/ml) were compared with those of sodium cromoglycate (20 mg/ml) and placebo in a 2-week, parallel, double-blind trial in patients with seasonal allergic rhinitis. At the end of treatment, 89% of patients in the levocabastine-treated group rated their treatment as globally good or excellent as compared with 32% (p = 0.003) of sodium cromoglycate-treated and 35% (p = 0.002) of placebo-treated patients. According to the investigators' ratings, the severest nasal symptom and ocular complaints responded better to levocabastine than to cromoglycate (p = 0.05 and p = 0.03) or placebo treatment (p = 0.001). Visual analogue scale ratings in patients' diaries indicated that at the end of therapy, nasal symptoms were less severe in the levocabastine-treated group than in the sodium cromoglycate-treated (p = 0.03) or placebo-treated group (p = 0.001). Total symptom severity as a percentage of the theoretical maximum symptom severity during the treatment period was lower for levocabastine than for sodium cromoglycate (p = 0.06) or placebo (p = 0.004) for the severest nasal symptom (35% versus 47% and 76%), sneezing (the most frequent symptom) (27% versus 42% and 67%), and itchy nose (18% versus 37% and 67%). The percentage of days at which nasal symptoms were entirely absent was markedly higher in the levocabastine-treated (33%) than in the sodium cromoglycate-treated (9%; p = 0.006) or placebo-treated (3%; p = 0.001) group. Adverse effects in the levocabastine-treated and sodium cromoglycate-treated group, and, in particular, daytime fatigue, did not occur more frequently than with placebo treatment. It is concluded that levocabastine is an efficacious and well-tolerated drug in the treatment of seasonal allergic rhinitis.	ASTHMA KRANKENHAUS KAMILLIANER,DEPT INTERNAL MED,MONCHENGLADBACH,GERMANY; JANSSEN RES FDN,DEPT CLIN RES,NEUSS,GERMANY	Johnson & Johnson								BENDE M, 1987, ALLERGY, V42, P512, DOI 10.1111/j.1398-9995.1987.tb00374.x; BERNAOLA G, 1987, REV ESP ALERGOL INMU, V2, P278; DELAFUENTE JC, 1989, CLIN PHARMACY, V8, P474; KOLLY M, 1986, BRIT J CLIN PHARMACO, V22, P389, DOI 10.1111/j.1365-2125.1986.tb02907.x; PALMACARLOS AG, 1988, INT J CLIN PHARM RES, V8, P25; PALMACARLOS AG, 1987, REV ESP ALERGOL IMMU, V2, P279; SECHER C, 1982, J ALLERGY CLIN IMMUN, V70, P211, DOI 10.1016/0091-6749(82)90044-6; TOGIAS AG, 1986, JAMA-J AM MED ASSOC, V255, P225, DOI 10.1001/jama.255.2.225; VANWAUWE JP, 1989, RHINOCONJUNCTIVITIS, P27; WELSH PW, 1987, MAYO CLIN PROC, V62, P125, DOI 10.1016/S0025-6196(12)61882-5	10	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					873	878		10.1016/0091-6749(91)90136-C	http://dx.doi.org/10.1016/0091-6749(91)90136-C			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	1672878				2022-12-18	WOS:A1991FG05900018
J	VANDERBREMPT, X; CHARPIN, D; HADDI, E; DAMATA, P; VERVLOET, D				VANDERBREMPT, X; CHARPIN, D; HADDI, E; DAMATA, P; VERVLOET, D			CAT REMOVAL AND FEL D I LEVELS IN MATTRESSES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Note							ALLERGEN CONTENT; DUST		HOP ST MARGUERITE,DEPT MALAD RESP,SERV PNEUMOL,BP 29,F-13277 MARSEILLE 9,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			VAN DER BREMPT, Xavier/GLT-1646-2022					CHAPMAN MD, 1988, J IMMUNOL, V140, P812; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; OHMAN JL, 1987, J ALLERGY CLIN IMMUN, V79, P955, DOI 10.1016/0091-6749(87)90246-6; SWANSON MC, 1989, J ALLERGY CLIN IMMUN, V83, P776, DOI 10.1016/0091-6749(89)90014-6; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7	5	41	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1991	87	2					595	596		10.1016/0091-6749(91)90020-O	http://dx.doi.org/10.1016/0091-6749(91)90020-O			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX987	1993818				2022-12-18	WOS:A1991EX98700019
J	ARZUBIAGA, C; MORROW, J; ROBERTS, LJ; BIAGGIONI, I				ARZUBIAGA, C; MORROW, J; ROBERTS, LJ; BIAGGIONI, I			NEUROPEPTIDE-Y, A PUTATIVE COTRANSMITTER IN NORADRENERGIC NEURONS, INDUCES MAST-CELL DEGRANULATION BUT NOT PROSTAGLANDIN-D2 RELEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HISTAMINE-RELEASE; SUBSTANCE-P; RAT; SKIN; VASODILATATION; STIMULATION	Recent evidence suggests that neural transmitters, including neuropeptides, may modulate the release of mast cell mediators. Because neuropeptide Y (NPY) has recently been recognized as a putative cotransmitter in noradrenergic neurons, we studied the effect of NPY on purified rat peritoneal mast cells. NPY induced mast cell degranulation, as assessed by a dose-dependent increase in net release of beta-hexosaminidase. The concentration that produced 50% of the maximal effect, approximately 10-mu-ml/L, evoked a 40% +/- 3% release. As previously reported for other neuropeptides, release was fast with maximal release already achieved at 60 seconds. Release was at 4-degrees-C. In contrast to its effects on mast cell degranulation, NPY had no effect on the generation of prostaglandin D2, the major mast cell cyclooxygenase product. By comparison, the calcium ionophore A23187, at doses (4-mu-mol/L) that evoked comparable release of beta-hexosaminidase, stimulated a net release of 37 +/- 9 ng of PGD2 per 10(6) mast cells. These results raise the possibility that NPY may act as a modulator between the autonomic nervous system and mast cells. The results also imply that with neuropeptide stimulation, the release of preformed and newly formed mast cell mediators are mediated through independent pathways.	VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DIV CLIN PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,DIV DERMATOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University					NCRR NIH HHS [2S07-RR05424-27] Funding Source: Medline; NIGMS NIH HHS [GM15431] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM015431, P01GM015431] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; BANISACCHI T, 1986, J PHYSIOL-LONDON, V371, P29, DOI 10.1113/jphysiol.1986.sp015960; BERNSTEIN JE, 1981, J INVEST DERMATOL, V76, P394, DOI 10.1111/1523-1747.ep12520912; CHRONWALL BM, 1984, NEUROSCI LETT, V52, P213, DOI 10.1016/0304-3940(84)90164-2; CHURCH MK, 1989, INT ARCH ALLER A IMM, V88, P70, DOI 10.1159/000234752; FEWTRELL CMS, 1982, J PHYSIOL-LONDON, V330, P393, DOI 10.1113/jphysiol.1982.sp014347; FOREMAN JC, 1987, INT ARCH ALLER A IMM, V82, P366, DOI 10.1159/000234229; FRIED G, 1985, ACTA PHYSIOL SCAND, V125, P145, DOI 10.1111/j.1748-1716.1985.tb07701.x; FRIF G, 1985, J NEUROSCI, V5, P450; GOETZL EJ, 1983, J EXP MED, V158, P731, DOI 10.1084/jem.158.3.731; IRANI AMA, 1989, CLIN EXP ALLERGY, V19, P143, DOI 10.1111/j.1365-2222.1989.tb02357.x; ISHIZAKA T, 1980, P NATL ACAD SCI-BIOL, V77, P1903, DOI 10.1073/pnas.77.4.1903; KASSESSINOFF TA, 1988, AGENTS ACTIONS, V23, P211, DOI 10.1007/BF02142543; KIERNAN JA, 1972, Q J EXP PHYSIOL CMS, V57, P311, DOI 10.1113/expphysiol.1972.sp002164; KOWALSKI ML, 1988, J IMMUNOL, V140, P3905; LEVISCHAFFER F, 1989, INT ARCH ALLER A IMM, V90, P352, DOI 10.1159/000235052; LOWMAN MA, 1988, BRIT J PHARMACOL, V95, P121, DOI 10.1111/j.1476-5381.1988.tb16555.x; LUNDBERG JM, 1985, REGUL PEPTIDES, V13, P41, DOI 10.1016/0167-0115(85)90085-0; LUNDBERG JM, 1986, NEUROSCI LETT, V63, P96, DOI 10.1016/0304-3940(86)90020-0; NEUSON B, 1983, NEUROSCIENCE, V10, P565; PARSONS WG, 1988, J IMMUNOL, V141, P2413; ROBERTS LJ, 1984, ANAL BIOCHEM, V136, P258, DOI 10.1016/0003-2697(84)90333-6; ROBERTS LJ, 1979, BIOCHIM BIOPHYS ACTA, V575, P185, DOI 10.1016/0005-2760(79)90020-1; SCHWARTZ LB, 1979, J IMMUNOL, V330, P393; SYDBOM A, 1988, AGENTS ACTIONS, V23, P204, DOI 10.1007/BF02142541; TSENG CJ, 1988, AM J MED SCI, V296, P11, DOI 10.1097/00000441-198807000-00003; TSENG CJ, 1988, CIRC RES, V64, P55	27	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1991	87	1	1				88	93		10.1016/0091-6749(91)90216-B	http://dx.doi.org/10.1016/0091-6749(91)90216-B			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EX985	1825102				2022-12-18	WOS:A1991EX98500011
J	STEVENSON, DD; HOUGHAM, AJ; SCHRANK, PJ; GOLDLUST, MB; WILSON, RR				STEVENSON, DD; HOUGHAM, AJ; SCHRANK, PJ; GOLDLUST, MB; WILSON, RR			SALSATE CROSS-SENSITIVITY IN ASPIRIN-SENSITIVE PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									THREE M PHARMACEUT,ST PAUL,MN		STEVENSON, DD (corresponding author), SCRIPPS CLIN & RES FDN,DEPT MOLEC & EXPTL MED,DIV ALLERGY & IMMUNOL,LA JOLLA,CA 92037, USA.				NCRR NIH HHS [M01RR00833] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		CHUDWIN DS, 1986, ANN ALLERGY, V57, P133; DROMGOOLE SH, 1983, CLIN PHARMACOL THER, V34, P539, DOI 10.1038/clpt.1983.211; ESTES D, 1980, ARTHRITIS RHEUM-US, V23, P1303, DOI 10.1002/art.1780231113; FERRERI NR, 1988, AM REV RESPIR DIS, V137, P847, DOI 10.1164/ajrccm/137.4.847; HARRISON LI, 1981, J CLIN PHARMACOL, V21, P401, DOI 10.1002/j.1552-4604.1981.tb01740.x; KOCSIS JJ, 1973, PROSTAG OTH LIPID M, V3, P141, DOI 10.1016/0090-6980(73)90081-6; LEWIS RA, 1984, J CLIN INVEST, V73, P889, DOI 10.1172/JCI111312; MORRIS HG, 1983, CLIN PHARMACOL THER, V33, P197; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; SETTIPANE RA, 1989, J ALLERGY CLIN IMMUN, V84, P26, DOI 10.1016/0091-6749(89)90174-7; SHERMAN NA, 1983, J ALLERGY CLIN IMMUN, V71, P153, DOI 10.1016/0091-6749(83)90382-2; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P617, DOI 10.1016/0091-6749(84)90115-5; STEVENSON DD, 1987, J ALLERGY CLIN IMMUN, V80, P788, DOI 10.1016/S0091-6749(87)80266-X; STEVENSON DD, 1986, NEW ENGL REG ALLERGY, V7, P101; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; VAN JR, 1979, ANTIINFLAMMATORY DRU, P12; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; 1989, J RHEUMATOL, V16, P321	20	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					749	758		10.1016/S0091-6749(05)80179-4	http://dx.doi.org/10.1016/S0091-6749(05)80179-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229840				2022-12-18	WOS:A1990EJ63100007
J	VANBEVER, HP; STEVENS, WJ				VANBEVER, HP; STEVENS, WJ			EVOLUTION OF THE LATE ASTHMATIC REACTION DURING IMMUNOTHERAPY AND AFTER STOPPING IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV INSTELLING ANTWERP,DEPT IMMUNOL,UNIV SPLEIN 1,B-2610 WILRIJK,BELGIUM; UNIV INSTELLING ANTWERP,DEPT PEDIAT,B-2610 WILRIJK,BELGIUM	University of Antwerp; University of Antwerp								BEHRENS BL, 1984, AM REV RESPIR DIS, V130, P1134; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; FLING JA, 1989, J ALLERGY CLIN IMMUN, V83, P101, DOI 10.1016/0091-6749(89)90483-1; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; METZGER WJ, 1983, J ALLERGY CLIN IMMUN, V71, P119, DOI 10.1016/0091-6749(83)90245-2; PEPYS J, 1974, CLIN ALLERGY, V4, P13, DOI 10.1111/j.1365-2222.1974.tb01358.x; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; RAK S, 1987, INT ARCH ALLER A IMM, V82, P249; ROCKLIN RE, 1983, J ALLERGY CLIN IMMUN, V72, P323, DOI 10.1016/0091-6749(83)90492-X; STEVENS WJ, 1985, ALLERGY, V40, P447, DOI 10.1111/j.1398-9995.1985.tb02684.x; TAMIR R, 1987, J ALLERGY CLIN IMMUN, V79, P591, DOI 10.1016/S0091-6749(87)80154-9; VANBEVER HP, 1988, ALLERGY, V43, P378, DOI 10.1111/j.1398-9995.1988.tb00432.x; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399, DOI 10.1111/j.1365-2222.1989.tb02405.x; WARNER JO, 1978, LANCET, V2, P912; WARNER JO, 1976, ARCH DIS CHILD, V51, P905, DOI 10.1136/adc.51.12.905; WOOLCOCK AJ, 1988, CLIN ALLERGY, V18, P165, DOI 10.1111/j.1365-2222.1988.tb02856.x	17	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1990	86	2					141	146		10.1016/S0091-6749(05)80058-2	http://dx.doi.org/10.1016/S0091-6749(05)80058-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DV316	2384645				2022-12-18	WOS:A1990DV31600001
J	DAUL, CB; MORGAN, JE; LEHRER, SB				DAUL, CB; MORGAN, JE; LEHRER, SB			THE NATURAL-HISTORY OF SHRIMP HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALTON OCHSNER MED INST,DEPT MED,ALLERGY & CLIN IMMUNOL SECT,NEW ORLEANS,LA; ALTON OCHSNER MED INST,DEPT PEDIAT,NEW ORLEANS,LA; TULANE UNIV,MED CTR,NEW ORLEANS,LA 70118	Ochsner Health System; Ochsner Health System; Tulane University					NIAID NIH HHS [AI-19266] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019266] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BLOCH KJ, 1981, J ALLERGY CLIN IMMUN, V67, P312, DOI 10.1016/0091-6749(81)90027-0; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BROSTOFF J, 1979, LANCET, V1, P1268; CARINI C, 1987, ANN ALLERGY, V59, P110; CASTRO A, 1977, RES COMMUN CHEM PATH, V16, P199; CUNNINGHAMRUNDLES C, 1978, P NATL ACAD SCI USA, V75, P3387, DOI 10.1073/pnas.75.7.3387; DANNAEUS A, 1979, CLIN ALLERGY, V9, P263, DOI 10.1111/j.1365-2222.1979.tb01552.x; DANNAEUS A, 1977, ACTA PAEDIATR SCAND, V66, P31, DOI 10.1111/j.1651-2227.1977.tb07803.x; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; DAUL CB, 1987, J ALLERGY CLIN IMMUN, V80, P716, DOI 10.1016/0091-6749(87)90293-4; DAUL CB, 1988, J ALLERGY CLIN IMMUN, V81, P1180, DOI 10.1016/0091-6749(88)90888-3; FIRER MA, 1987, INT ARCH ALLER A IMM, V84, P173, DOI 10.1159/000234419; GOODWIN BFJ, 1982, CLIN ALLERGY, V12, P55, DOI 10.1111/j.1365-2222.1982.tb03126.x; GRUSKAY FL, 1955, PEDIATRICS, V16, P763; HALPERN GM, 1986, J ALLERGY CLIN IMMUN, V77, P124; HALPERN GM, 1987, ANN ALLERGY, V58, P14; HUSBY S, 1985, INT ARCH ALLER A IMM, V77, P416, DOI 10.1159/000233819; KARR RM, 1978, J ALLERGY CLIN IMMUN, V62, P143, DOI 10.1016/0091-6749(78)90098-2; MAY CD, 1982, ACTA PAEDIATR SCAND, V71, P43, DOI 10.1111/j.1651-2227.1982.tb09370.x; MAY CD, 1977, CLIN ALLERGY, V7, P583, DOI 10.1111/j.1365-2222.1977.tb01489.x; MORGAN JE, 1989, J ALLERGY CLIN IMMUN, V83, P1112, DOI 10.1016/0091-6749(89)90454-5; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; WARING NP, 1985, J ALLERGY CLIN IMMUN, V76, P440, DOI 10.1016/0091-6749(85)90724-9	24	41	43	1	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1990	86	1					88	93		10.1016/S0091-6749(05)80127-7	http://dx.doi.org/10.1016/S0091-6749(05)80127-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DQ688	2370391				2022-12-18	WOS:A1990DQ68800013
J	WADEE, AA; BOTING, LA; RABSON, AR				WADEE, AA; BOTING, LA; RABSON, AR			FRUIT ALLERGY - DEMONSTRATION OF IGE ANTIBODIES TO A 30 KD PROTEIN PRESENT IN SEVERAL FRUITS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WITWATERSRAND,JOHANNESBURG 2001,SOUTH AFRICA	University of Witwatersrand	WADEE, AA (corresponding author), S AFRICAN INST MED RES,SCH PATHOL,DEPT IMMUNOL,POB 1038,JOHANNESBURG 2000,SOUTH AFRICA.							AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; ARTO L, 1980, ALLERGY, V35, P297; BAHNA SL, 1980, ANN ALLERGY, V44, P146; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; ERIKSSON NE, 1978, ALLERGY, V33, P189, DOI 10.1111/j.1398-9995.1978.tb01533.x; EZEOKE A C J, 1985, African Journal of Medicine and Medical Sciences, V14, P121; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235, DOI 10.1159/000233550; HANNUKSELA M, 1977, CONTACT DERMATITIS, V3, P79, DOI 10.1111/j.1600-0536.1977.tb03603.x; KAJOSAARI M, 1982, ACTA PAEDIATR SCAND, V71, P815, DOI 10.1111/j.1651-2227.1982.tb09525.x; KING TP, 1979, J ALLERGY CLIN IMMUN, V64, P159, DOI 10.1016/0091-6749(79)90090-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHTI A, 1978, ALLERGY, V33, P143, DOI 10.1111/j.1398-9995.1978.tb01524.x; OWHASHI M, 1983, AM J TROP MED HYG, V32, P359, DOI 10.4269/ajtmh.1983.32.359; PIGATTO PD, 1983, CONTACT DERMATITIS, V9, P511, DOI 10.1111/j.1600-0536.1983.tb04475.x; RADCLIFFE MJ, 1982, CLIN IMMUNOL ALLERGY, V2, P205	18	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					801	807		10.1016/0091-6749(90)90202-F	http://dx.doi.org/10.1016/0091-6749(90)90202-F			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2324418	Bronze			2022-12-18	WOS:A1990DA43700019
J	ANDO, M; SAKATA, T; YOSHIDA, K; YAMASAKI, H; ARAKI, S; ONOUE, K; SHINODA, T				ANDO, M; SAKATA, T; YOSHIDA, K; YAMASAKI, H; ARAKI, S; ONOUE, K; SHINODA, T			SEROTYPE-RELATED ANTIGEN OF TRICHOSPORON-CUTANEUM IN THE INDUCTION OF SUMMER-TYPE HYPERSENSITIVITY PNEUMONITIS - CORRELATION BETWEEN SEROTYPE OF INHALATION CHALLENGE POSITIVE ANTIGEN AND THAT OF THE ISOLATES FROM PATIENTS HOMES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MEIJI COLL PHARM,DEPT MICROBIOL,KUMAMOTO,JAPAN; KUMAMOTO UNIV,SCH MED,INST MED IMMUNOL,DEPT BIOCHEM,KUMAMOTO 860,JAPAN	Meiji Pharmaceutical University; Kumamoto University	ANDO, M (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 1,1-1-1 HONJO,KUMAMOTO 860,JAPAN.							ANDO M, 1984, THORAX, V39, P850, DOI 10.1136/thx.39.11.850; ANDO M, 1986, AM REV RESPIR DIS, V134, P177; CORMIER Y, 1984, AM REV RESPIR DIS, V130, P1046; COSTABEL U, 1985, AM REV RESPIR DIS, V131, P337; EDWARDS JH, 1981, J ALLERGY CLIN IMMUN, V68, P58, DOI 10.1016/0091-6749(81)90124-X; EDWARDS JH, 1972, J LAB CLIN MED, V79, P683; FINK JN, 1984, J ALLERGY CLIN IMMUN, V74, P1, DOI 10.1016/0091-6749(84)90077-0; GERBER JD, 1973, AM REV RESPIR DIS, V108, P1124; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; IKEDA R, 1982, J CLIN MICROBIOL, V16, P22, DOI 10.1128/JCM.16.1.22-29.1982; KAWAI T, 1984, CHEST, V85, P311, DOI 10.1378/chest.85.3.311; KELLER RH, 1984, AM REV RESPIR DIS, V130, P766; LEATHERMAN JW, 1984, ANN INTERN MED, V100, P390, DOI 10.7326/0003-4819-100-3-390; MIYAKAWA T, 1978, CLIN ALLERGY, V8, P9; MOORE VL, 1980, J ALLERGY CLIN IMMUN, V65, P365, DOI 10.1016/0091-6749(80)90214-6; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; REINHERZ EL, 1980, NEW ENGL J MED, V303, P370, DOI 10.1056/NEJM198008143030704; SALVAGGIO JE, 1987, J ALLERGY CLIN IMMUN, V79, P558, DOI 10.1016/S0091-6749(87)80149-5; SCHLUETER DP, 1974, AM J MED, V57, P476, DOI 10.1016/0002-9343(74)90141-7; SEELIGER H. P. R., 1963, Sabouraudia, V2, P248; SHIMAZU K, 1984, AM REV RESPIR DIS, V130, P407; SODA K, 1988, CHEST, V93, P76, DOI 10.1378/chest.93.1.76; SODA K, 1986, AM REV RESPIR DIS, V133, P83, DOI 10.1164/arrd.1986.133.1.83; SOLALCELIGNY P, 1982, AM REV RESPIR DIS, V126, P964; WILLIAMS J. V., 1963, THORAX, V18, P182, DOI 10.1136/thx.18.2.182; YOSHIDA K, 1988, J ALLERGY CLIN IMMUN, V81, P475, DOI 10.1016/0091-6749(88)90920-7	26	41	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1990	85	1	1				36	44		10.1016/0091-6749(90)90218-S	http://dx.doi.org/10.1016/0091-6749(90)90218-S			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CM378	2299104				2022-12-18	WOS:A1990CM37800006
J	MOIRA, CY; CHAN, H; TSE, KS; SALARI, H; LAM, S				MOIRA, CY; CHAN, H; TSE, KS; SALARI, H; LAM, S			HISTAMINE AND LEUKOTRIENES RELEASE IN BRONCHOALVEOLAR FLUID DURING PLICATIC ACID-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ICHILOV HOSP, DEPT RHEUMATOL, IL-64239 TEL AVIV, ISRAEL; ICHILOV HOSP, DEPT HEMATOL, IL-64239 TEL AVIV, ISRAEL; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; BIOL INST, NESS ZIONA, ISRAEL; ASAFF HAROFEH MED CTR, ZERIFIN, ISRAEL; HEBREW UNIV JERUSALEM, HADASSAH MED CTR, LAUTENBERG CTR GEN & TUMOR IMMUNOL, JERUSALEM, ISRAEL	Tel Aviv University; Tel Aviv University; Weizmann Institute of Science; Hebrew University of Jerusalem; Hadassah University Medical Center								CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1973, AM REV RESPIR DIS, V108, P1103; FICK RB, 1987, J APPL PHYSIOL, V63, P1147, DOI 10.1152/jappl.1987.63.3.1147; FORESI A, 1986, J ALLERGY CLIN IMMUN, V78, P1130, DOI 10.1016/0091-6749(86)90262-9; GRAVELYN TR, 1988, AM REV RESPIR DIS, V137, P641, DOI 10.1164/ajrccm/137.3.641; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; GUERZON GM, 1979, AM REV RESPIR DIS, V119, P59; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; HOLGATE ST, 1986, EUR J RESPIR DIS, V68, P34; HOLROYDE MC, 1981, LANCET, V2, P17; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KALINER M, 1987, CHEST, V91, pS171, DOI 10.1378/chest.91.6.171S; LAM S, 1985, CHEST, V88, P856, DOI 10.1378/chest.88.6.856; LAM S, 1979, J ALLERGY CLIN IMMUN, V63, P28, DOI 10.1016/0091-6749(79)90158-1; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; SALARI H, 1985, J EXP MED, V162, P1904, DOI 10.1084/jem.162.6.1904; SALARI H, 1986, IMMUNOLOGY, V58, P473; VERBURG KM, 1983, LIFE SCI, V32, P2855, DOI 10.1016/0024-3205(83)90322-3; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P2814, DOI 10.1001/jama.249.20.2814; ZEHR B, 1988, AM REV RESPIR DIS, V137, pA211	26	41	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				762	768		10.1016/0091-6749(89)90306-0	http://dx.doi.org/10.1016/0091-6749(89)90306-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2478608				2022-12-18	WOS:A1989CA31400015
J	CRIMI, N; PALERMO, F; POLOSA, R; OLIVERI, R; MACCARRONE, C; PALERMO, B; MISTRETTA, A				CRIMI, N; PALERMO, F; POLOSA, R; OLIVERI, R; MACCARRONE, C; PALERMO, B; MISTRETTA, A			EFFECT OF INDOMETHACIN ON ADENOSINE-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CRIMI, N (corresponding author), UNIV CATANIA,INST MALATTIE APPARATO RESP & TISIOL,VIA PASSO GRAVINA 187,I-95125 CATANIA,ITALY.		Crimi, Nunzio/AAL-2994-2020	Crimi, Nunzio/0000-0002-8591-4535				ADVENIER C, 1982, BRIT J PHARMACOL, V77, P39, DOI 10.1111/j.1476-5381.1982.tb09266.x; AIZAWA H, 1985, J APPL PHYSIOL, V59, P1918, DOI 10.1152/jappl.1985.59.6.1918; Burka J F, 1980, Adv Prostaglandin Thromboxane Res, V8, P1755; CHRISTIE J, 1980, BRIT J PHARMACOL, V70, P512, DOI 10.1111/j.1476-5381.1980.tb09768.x; CHURCH MK, 1983, BRIT J PHARMACOL, V80, P719, DOI 10.1111/j.1476-5381.1983.tb10063.x; COLEMAN RA, 1974, BRIT J PHARMACOL, V52, P167, DOI 10.1111/j.1476-5381.1974.tb09697.x; COLEMAN RA, 1976, BRIT J PHARMACOL, V57, P51, DOI 10.1111/j.1476-5381.1976.tb07655.x; CRIMI N, 1986, EUR J RESPIR DIS, V69, P258; CUSHLEY HJ, 1983, THORAX, V38, P705; Cushley M J, 1983, Agents Actions Suppl, V13, P109; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; CUSHLEY MJ, 1985, J ALLERGY CLIN IMMUN, V75, P272, DOI 10.1016/0091-6749(85)90057-0; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; FARMER JB, 1976, J PHARM PHARMACOL, V28, P748, DOI 10.1111/j.2042-7158.1976.tb04040.x; FERREIRA SH, 1971, NATURE-NEW BIOL, V231, P237, DOI 10.1038/newbio231237a0; FLORES AGA, 1972, AM J PHYSIOL, V223, P1392, DOI 10.1152/ajplegacy.1972.223.6.1392; HIGGS GA, 1976, ADV PROSTAG THROMB R, V1, P105; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; JOUBERT JR, 1985, ALLERGY, V40, P202, DOI 10.1111/j.1398-9995.1985.tb00217.x; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; MORLEY J, 1982, BRONCHIAL HYPERREACT, P219; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P220; OBYRNE PM, 1984, PROSTAGLANDINS, V28, P537, DOI 10.1016/0090-6980(84)90242-9; PETERS SP, 1985, AM REV RESPIR DIS, V132, P367; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; RINNEY MJB, 1985, BRIT J PHARMACOL, V5, P29; SHEPHARD EG, 1985, BRIT J CLIN PHARMACO, V19, P459, DOI 10.1111/j.1365-2125.1985.tb02671.x; WALTERS E, 1981, THORAX, V36, P5721	30	41	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1989	83	5					921	925		10.1016/0091-6749(89)90106-1	http://dx.doi.org/10.1016/0091-6749(89)90106-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U7161	2715550				2022-12-18	WOS:A1989U716100012
J	DAXUN, Z; RAFFERTY, P; RICHARDS, R; SUMMERELL, S; HOLGATE, ST				DAXUN, Z; RAFFERTY, P; RICHARDS, R; SUMMERELL, S; HOLGATE, ST			AIRWAY REFRACTORINESS TO ADENOSINE 5'-MONOPHOSPHATE AFTER REPEATED INHALATION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SOUTHAMPTON GEN HOSP,IMMUNOPHARMACOL GRP,TREMONA RD,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	University of Southampton								ALTOUNYAN REC, 1986, EUR J RESPIR DIS, V69, P277; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; BARYISHAY E, 1983, AM REV RESPIR DIS, V127, P572, DOI 10.1164/arrd.1983.127.5.572; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822, DOI 10.1164/arrd.1987.135.4.822; CHURCH MK, 1983, BRIT J PHARMACOL, V80, P719, DOI 10.1111/j.1476-5381.1983.tb10063.x; CUSHLEY HJ, 1983, THORAX, V38, P705; Cushley M J, 1983, Agents Actions Suppl, V13, P109; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; CUSHLEY MJ, 1985, J ALLERGY CLIN IMMUN, V75, P272, DOI 10.1016/0091-6749(85)90057-0; HAHN AG, 1984, THORAX, V39, P919, DOI 10.1136/thx.39.12.919; HOWARTH PH, 1987, J ALLERGY CLIN IMMUN, V80, P703, DOI 10.1016/0091-6749(87)90291-0; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; LEWIS RA, 1984, DRUGS LUNG; MANN JS, 1984, THORAX, V39, P230; MANN JS, 1986, CLIN SCI, V70, P461, DOI 10.1042/cs0700461; MANN JS, 1983, CLIN SCI, V65, P22; MANNING PJ, 1987, THORAX, V42, P748; MARQUARDT DL, 1987, J ALLERGY CLIN IMMUN, V79, P162; MARQUARDT DL, 1978, J IMMUNOL, V120, P871; MARQUARDT DL, 1984, J IMMUNOL, V133, P932; MARQUARDT DL, 1984, P NATL ACAD SCI-BIOL, V81, P6192, DOI 10.1073/pnas.81.19.6192; MCNEILL RS, 1966, Q J MED, V35, P55; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PAUWELS R, 1986, ARCH INT PHARMACOD T, V280, P229; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369, DOI 10.1164/ajrccm/136.2.369; SCHOEFFEL RE, 1980, THORAX, V35, P164, DOI 10.1136/thx.35.3.164; Soto M E, 1985, Pediatr Pulmonol, V1, P80, DOI 10.1002/ppul.1950010205; THOMSON NC, 1986, EUR J RESPIR DIS, V69, P297	28	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					152	158		10.1016/0091-6749(89)90490-9	http://dx.doi.org/10.1016/0091-6749(89)90490-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2913134				2022-12-18	WOS:A1989T041900021
J	SIMONS, FER; WATSON, WTA; SIMONS, KJ				SIMONS, FER; WATSON, WTA; SIMONS, KJ			LACK OF SUBSENSITIVITY TO TERFENADINE DURING LONG-TERM TERFENADINE TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,FAC PHARM,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba	SIMONS, FER (corresponding author), UNIV MANITOBA,FAC MED,HLTH SCI CLIN RES CTR,840 SHERBROOK ST,WINNIPEG R3A 1S1,MANITOBA,CANADA.							[Anonymous], 1980, PRINCIPLES PROCEDURE; BANTZ EW, 1987, ANN ALLERGY, V59, P341; BANTZ EW, 1987, J ALLERGY CLIN IMMUN, V80, P99, DOI 10.1016/S0091-6749(87)80198-7; BATEMAN DN, 1983, EUR J CLIN PHARMACOL, V25, P547, DOI 10.1007/BF00542126; BURNS JJ, 1963, ANN NY ACAD SCI, V104, P881, DOI 10.1111/j.1749-6632.1963.tb57090.x; BYE CE, 1977, EUR J CLIN PHARMACOL, V12, P181, DOI 10.1007/BF00609857; CONNEY AH, 1961, J PHARMACOL EXP THER, V132, P202; DANNENBERG TB, 1951, J ALLERGY, V22, P330, DOI 10.1016/0021-8707(51)90033-0; GARTEIZ DA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1185; GENDREAUREID L, 1986, J ALLERGY CLIN IMMUN, V77, P335, DOI 10.1016/S0091-6749(86)80114-2; Gibaldi M, 1982, PHARMACOKINETICS; HUTHER KJ, 1977, EUR J CLIN PHARMACOL, V12, P195, DOI 10.1007/BF00609860; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; MONASH S, 1950, J INVEST DERMATOL, V15, P1, DOI 10.1038/jid.1950.61; PANG KS, 1985, J PHARMACOKINET BIOP, V13, P633, DOI 10.1007/BF01058905; REINBERG A, 1978, EUR J CLIN PHARMACOL, V14, P245, DOI 10.1007/BF00560457; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; ROMAN IJ, 1986, ANN ALLERGY, V57, P253; SHUMAKER RC, 1986, DRUG METAB REV, V17, P331, DOI 10.3109/03602538608998295; SIMONS FER, 1987, J ALLERGY CLIN IMMUN, V80, P884; SIMONS KJ, 1987, J ALLERGY CLIN IMMUN, V79, P928, DOI 10.1016/0091-6749(87)90242-9; TAYLOR RJ, 1985, J ALLERGY CLIN IMMUN, V76, P103, DOI 10.1016/0091-6749(85)90811-5	22	41	44	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1988	82	6					1068	1075						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	R6311	2904930				2022-12-18	WOS:A1988R631100016
J	BOULET, LP; LEGRIS, C; TURCOTTE, H; HEBERT, J				BOULET, LP; LEGRIS, C; TURCOTTE, H; HEBERT, J			PREVALENCE AND CHARACTERISTICS OF LATE ASTHMATIC RESPONSES TO EXERCISE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHU LAVAL,UNITE RECH IMMUNOL & RHUMATOL,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University	BOULET, LP (corresponding author), HOP LAVAL,CTR PNEUMOL,2725 CHEMIN STE FOY,STE FOY G1V 4G5,QUEBEC,CANADA.							ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BIERMAN CW, 1980, J ALLERGY CLIN IMMUN, V65, P206; BIERMAN CW, 1984, J ALLERGY CLIN IMMUN, V74, P701, DOI 10.1016/0091-6749(84)90233-1; BIERMAN WC, 1984, J ALLERGY CLIN IMMUN, V73, P654; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1979, AM REV RESPIR DIS, V119, P505; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CROPP GJA, 1979, J ALLERGY CLIN IMMUN, V64, P627, DOI 10.1016/0091-6749(79)90026-5; FELDMAN CH, 1982, AM REV RESPIR DIS, V125, P195; GALLIN JI, 1973, J IMMUNOL, V110, P233; HARGREAVE FE, 1983, SEMIN RESPIR MED, V4, P224, DOI 10.1055/s-2007-1012487; HORN CR, 1984, CLIN ALLERGY, V14, P307, DOI 10.1111/j.1365-2222.1984.tb02210.x; IIKURA Y, 1985, J ALLERGY CLIN IMMUN, V75, P285, DOI 10.1016/0091-6749(85)90059-4; JONES NL, 1982, CLIN EXERCISE TESTIN, P83; LEE TH, 1984, J ALLERGY CLIN IMMUN, V73, P634, DOI 10.1016/0091-6749(84)90296-3; LEE TH, 1983, NEW ENGL J MED, V308, P1502, DOI 10.1056/NEJM198306233082504; MACINTYRE D, 1984, CLIN ALLERGY, V14, P311, DOI 10.1111/j.1365-2222.1984.tb02211.x; MELLIS CM, 1978, AM REV RESPIR DIS, V117, P911; NADEL JA, 1984, J ALLERGY CLIN IMMUN, V73, P651, DOI 10.1016/0091-6749(84)90299-9; NAGAKURA T, 1983, THORAX, V38, P233; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; RACHIELE A, 1983, B EUR PHYSIOPATH RES, V19, P465; SUZUKI S, 1985, ANN ALLERGY, V54, P136; ZAR JH, 1984, BIOSTAT ANAL, P121	27	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1987	80	5					655	662		10.1016/0091-6749(87)90284-3	http://dx.doi.org/10.1016/0091-6749(87)90284-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K9930	3316344				2022-12-18	WOS:A1987K993000004
J	WILSONPESSANO, SR; MELLINS, RB				WILSONPESSANO, SR; MELLINS, RB			WORKSHOP ON ASTHMA SELF-MANAGEMENT - SUMMARY OF WORKSHOP DISCUSSION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material																		CLARK NM, 1980, HEALTH EDUC QUART, V7, P278, DOI 10.1177/109019818000700403; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1986, PATIENT EDUC COUNS, V8, P27, DOI 10.1016/0738-3991(86)90024-8; CREER TL, IN PRESS PRACTICE BE; EVANS D, 1987, HEALTH EDUC QUART, V14, P267, DOI 10.1177/109019818701400302; HINDIALEXANDER MC, 1984, J ALLERGY CLIN IMMUN, V74, P505, DOI 10.1016/0091-6749(84)90386-5; LEWIS CE, 1984, PEDIATRICS, V74, P478; MCNABB WL, 1985, AM J PUBLIC HEALTH, V75, P1219, DOI 10.2105/AJPH.75.10.1219; MCNABB WL, 1986, J PEDIATR PSYCHOL, V11, P103, DOI 10.1093/jpepsy/11.1.103; Parcel G S, 1980, J Dev Behav Pediatr, V1, P128; RAKOS RF, 1985, J PSYCHOSOM RES, V29, P101, DOI 10.1016/0022-3999(85)90014-5; WHITMAN N, 1985, HEALTH EDUC QUART, V12, P333, DOI 10.1177/109019818501200312; WILSONPESSANO SR, 1985, PREV MED, V14, P670, DOI 10.1016/0091-7435(85)90066-0	13	41	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	2	S			487	490		10.1016/0091-6749(87)90081-9	http://dx.doi.org/10.1016/0091-6749(87)90081-9			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1037					2022-12-18	WOS:A1987K103700029
J	ARLIAN, LG; BERNSTEIN, IL; VYSZENSKIMOHER, DL; GALLAGHER, JS				ARLIAN, LG; BERNSTEIN, IL; VYSZENSKIMOHER, DL; GALLAGHER, JS			INVESTIGATIONS OF CULTURE MEDIUM-FREE HOUSE DUST MITES .4. CROSS ANTIGENICITY AND ALLERGENICITY BETWEEN THE HOUSE DUST MITES, DERMATOPHAGOIDES-FARINAE AND DERMATOPHAGOIDES-PTERONYSSINUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WRIGHT STATE UNIV,COLL SCI & ENGN,DEPT PHYSIOL,DAYTON,OH 45435; WRIGHT STATE UNIV,SCH MED,DAYTON,OH 45435; UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,CINCINNATI,OH 45267	Wright State University Dayton; Wright State University Dayton; University of Cincinnati	ARLIAN, LG (corresponding author), WRIGHT STATE UNIV,COLL SCI & ENGN,DEPT BIOL SCI,DAYTON,OH 45435, USA.				NIAID NIH HHS [R01 AI 13702] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLIAN L G, 1984, Journal of Allergy and Clinical Immunology, V73, P119; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, 1987, J MED ENTOMOL, V24; BILIOTTI G, 1972, Clinical Allergy, V2, P109, DOI 10.1111/j.1365-2222.1972.tb01275.x; BILIOTTI G, 1975, CLIN ALLERGY, V1, P69; DAILEY F, 1982, Journal of Allergy and Clinical Immunology, V69, P127; DASGUPTA A, 1970, CLIN EXP IMMUNOL, V6, P891; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P142, DOI 10.1016/0091-6749(84)90277-X; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P132, DOI 10.1016/0091-6749(84)90275-6; LEMAO J, 1983, J ALLERGY CLIN IMMUN, V71, P588, DOI 10.1016/0091-6749(83)90441-4; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; MAUNSELL K, 1968, LANCET, V1, P1267; SARSFIELD JK, 1979, ARCH DIS CHILD, V49, P711; STEWART GA, 1986, J ALLERGY CLIN IMMUN, V77, P14, DOI 10.1016/0091-6749(86)90316-7; TOVEY ER, 1985, INT ARCH ALLER A IMM, V76, P82, DOI 10.1159/000233667; WRAITH DG, 1979, CLIN ALLERGY, V9, P545, DOI 10.1111/j.1365-2222.1979.tb00478.x	19	41	42	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1987	79	3					467	476		10.1016/0091-6749(87)90364-2	http://dx.doi.org/10.1016/0091-6749(87)90364-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	G4795	2434550				2022-12-18	WOS:A1987G479500009
J	JOAD, JP; AHRENS, RC; LINDGREN, SD; WEINBERGER, MM				JOAD, JP; AHRENS, RC; LINDGREN, SD; WEINBERGER, MM			EXTRAPULMONARY EFFECTS OF MAINTENANCE THERAPY WITH THEOPHYLLINE AND INHALED ALBUTEROL IN PATIENTS WITH CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV IOWA,DEPT PEDIAT,JCP,IOWA CITY,IA 52242	University of Iowa					NCRR NIH HHS [RR-59] Funding Source: Medline; NIAID NIH HHS [AI 16151] Funding Source: Medline; NIGMS NIH HHS [GM 7442-07] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNMAN K, 1975, ACTA MED SCAND, V197, P271; BARCLAY J, 1981, LANCET, V2, P369; Benton A., 1983, CONTRIBUTIONS NEUROP; Benton A.L., 1974, REVISED VISUAL RETEN; Benton AL, 1976, MULTILINGUAL APHASIA; BOWSER EN, 1975, P SOC EXP BIOL MED, V148, P344; COLIN AA, 1984, MINER ELECTROL METAB, V10, P359; DANZIGER Y, 1985, CLIN PHARMACOL THER, V37, P469, DOI 10.1038/clpt.1985.73; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; DUSDIEKER L, 1982, J PEDIATR-US, V101, P281; EKWO E, 1978, J ALLERGY CLIN IMMUN, V61, P240, DOI 10.1016/0091-6749(78)90198-7; ELKINS RN, 1981, AM J PSYCHIAT, V138, P178; ENSINCK JW, 1970, J CLIN ENDOCR METAB, V31, P153, DOI 10.1210/jcem-31-2-153; FURUKAWA CT, 1984, LANCET, V1, P621; FURUKAWA CT, 1984, PEDIATRICS, V74, P453; Golden C.J., 1978, STROOP COLOR WORD TE; GRANT IWB, 1981, LANCET, V2, P36; HAMBLETON G, 1977, LANCET, V1, P381; IMON MA, 1981, J PHYSIOL-LONDON, V321, P343, DOI 10.1113/jphysiol.1981.sp013988; KELLY HW, 1985, ANN ALLERGY, V54, P405; KEMP JP, 1984, J ALLERGY CLIN IMMUN, V73, P32, DOI 10.1016/0091-6749(84)90481-0; LARSSON S, 1977, AM REV RESPIR DIS, V116, P861; LINDGREN SD, 1984, PEDIATRIC ASSESSMENT; MCLOUGHLIN J, 1983, ANN ALLERGY, V51, P506; MORITA Y, 1984, J ALLERGY CLIN IMMUN, V74, P707, DOI 10.1016/0091-6749(84)90234-3; MUDGE GH, 1980, PHARMACOL BASIS THER, P892; MURPHY MB, 1980, BRIT MED J, V281, P1322, DOI 10.1136/bmj.281.6251.1322; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; Rall T. W., 1980, PHARMACOL BASIS THER, P592; RAPOPORT JL, 1984, ARCH GEN PSYCHIAT, V41, P1073; REA H H, 1985, American Review of Respiratory Disease, V131, pA51; Reitan RM, 1974, CLIN NEUROPSYCHOLOGY; RIEGELMAN S, 1981, ASSESSMENT THEOPHYLL; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SMITH JA, 1980, CHEST, V78, P816, DOI 10.1378/chest.78.6.816; SPRINGER C, 1985, J ALLERGY CLIN IMMUN, V76, P64, DOI 10.1016/0091-6749(85)90806-1; SUTHERLAND DC, 1981, LANCET, V2, P988; TAYLOR DR, 1985, AM REV RESPIR DIS, V131, P747; VANDEWALKER ML, 1985, ANN ALLERGY, V54, P338; Wechsler D, 1981, WECHSLER ADULT INTEL; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1975, CLIN PHARMACOL THER, V17, P585; WEINBERGER M, 1983, NEW ENGL J MED, V308, P760, DOI 10.1056/NEJM198303313081306; WEINBERGER M, 1981, LANCET, V2, P370; WHITEHURST VE, 1983, J AM COLL TOXICOL, V2, P147, DOI 10.3109/10915818309140676; Wilcoxon F, 1964, SOME RAPID APPROXIMA; WILSON JD, 1981, LANCET, V1, P1235; 1980, DIAGNOSTIC STATISTIC	48	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1147	1153		10.1016/0091-6749(86)90264-2	http://dx.doi.org/10.1016/0091-6749(86)90264-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3537092				2022-12-18	WOS:A1986F302600010
J	ZURAW, BL; SUGIMOTO, S; CURD, JG				ZURAW, BL; SUGIMOTO, S; CURD, JG			THE VALUE OF ROCKET IMMUNOELECTROPHORESIS FOR C-4 ACTIVATION IN THE EVALUATION OF PATIENTS WITH ANGIOEDEMA OR C1-INHIBITOR DEFICIENCY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ZURAW, BL (corresponding author), SCRIPPS CLIN & RES FDN,CTR AUTOIMMUNE DIS,DEPT BASIC & CLIN RES,10666 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Zuraw, Bruce/0000-0003-0640-6768	NCRR NIH HHS [RR 00833] Funding Source: Medline; NIAID NIH HHS [AI 10386] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI010386] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGOSTONI A, 1980, J ALLERGY CLIN IMMUN, V65, P75, DOI 10.1016/0091-6749(80)90181-5; AUSTEN KF, 1965, NEW ENGL J MED, V272, P649, DOI 10.1056/NEJM196504012721301; DONALDSON VH, 1966, PEDIATRICS, V37, P1017; DONALDSON VH, 1964, J CLIN INVEST, V43, P2204, DOI 10.1172/JCI105094; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; GIGLI I, 1968, J IMMUNOL, V100, P1154; KAHLER PF, 1967, J IMMUNOL, V99, P1211; LAURELL AB, 1979, ACTA PATH MICRO IM C, V87, P79; MATHISON DA, 1977, ANN INTERN MED, V86, P534, DOI 10.7326/0003-4819-86-5-534; MILGROM H, 1980, J IMMUNOL, V124, P2780; NITSCHE JF, 1981, AM J CLIN PATHOL, V76, P679; PITTS JS, 1978, J LAB CLIN MED, V92, P501; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; SHEFFER AL, 1981, J ALLERGY CLIN IMMUN, V68, P181, DOI 10.1016/0091-6749(81)90181-0; YELVINGTON M, 1983, AM J CLIN PATHOL, V80, P309, DOI 10.1093/ajcp/80.3.309; ZICCARDI RJ, 1982, J IMMUNOL, V128, P2505; ZICCARDI RJ, 1980, CLIN IMMUNOL IMMUNOP, V15, P465, DOI 10.1016/0090-1229(80)90058-6	19	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1986	78	6					1115	1120		10.1016/0091-6749(86)90259-9	http://dx.doi.org/10.1016/0091-6749(86)90259-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	F3026	3782676				2022-12-18	WOS:A1986F302600005
J	JONKMAN, JHG				JONKMAN, JHG			THERAPEUTIC CONSEQUENCES OF DRUG-INTERACTIONS WITH THEOPHYLLINE PHARMACOKINETICS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									STATE UNIV GRONINGEN,DEPT PHARMACEUT & ANALYT CHEM,9700 AB GRONINGEN,NETHERLANDS	University of Groningen								ALBIN H, 1983, THERAPIE, V38, P333; ANDERSON JL, 1984, CLIN PHARMACY, V3, P187; ARNOLD LA, 1979, AM J HOSP PHARM, V36, P1059, DOI 10.1093/ajhp/36.8.1059; BOYCE EG, 1985, CLIN PHARMACOL THER, V37, P183; BRAZIER JL, 1980, THERAPIE, V35, P545; BREEN KJ, 1982, CLIN PHARMACOL THER, V31, P297, DOI 10.1038/clpt.1982.36; BRITTON L, 1982, CAN MED ASSOC J, V126, P1375; BUCHANAN N, 1979, S AFR MED J, V57, P1147; BUKOWSKYJ M, 1984, AM REV RESPIR DIS, V129, P672, DOI 10.1164/arrd.1984.129.5.672; CHANG KC, 1978, LANCET, V1, P1132; COHEN IA, 1984, GASTROENTEROLOGY, V86, P1050; CONRAD KA, 1980, CLIN PHARMACOL THER, V28, P463, DOI 10.1038/clpt.1980.189; CONRAD KA, 1981, BRIT J CLIN PHARMACO, V12, P756, DOI 10.1111/j.1365-2125.1981.tb01303.x; CUSACK BJ, 1985, CLIN PHARMACOL THER, V37, P330, DOI 10.1038/clpt.1985.48; CUSACK BJ, 1984, CLIN RES, V32, pA240; DALNEGRO R, 1984, INT J CLIN PHARM TH, V22, P221; DANZIGER Y, 1985, CLIN PHARMACOL THER, V37, P469, DOI 10.1038/clpt.1985.73; DARZENTAS LJ, 1983, DRUG INTEL CLIN PHAR, V17, P555, DOI 10.1177/106002808301700717; DEANGELIS C, 1983, CLIN PHARMACY, V2, P563; FENJE PC, 1982, CAN MED ASSOC J, V126, P1178; FERNANDEZ E, 1984, ANN INTERN MED, V100, P279; FISCHER RG, 1982, CAN MED ASSOC J, V126, P1312; GARDNER ME, 1985, ANN INTERN MED, V102, P559, DOI 10.7326/0003-4819-102-4-559_1; GARDNER MJ, 1984, USE SUSTAINED RELEAS, P98; GIBSON GA, 1985, THER DRUG MONIT, V7, P181, DOI 10.1097/00007691-198506000-00007; GODARD P, 1981, REV FRANC ALLERG IMM, V21, P3; GOLDSTEIN RS, 1982, CAN MED ASSOC J, V126, P470; GOMOLIN IH, 1985, J AM GERIATR SOC, V33, P269, DOI 10.1111/j.1532-5415.1985.tb07115.x; GREEN AW, 1984, AM J MED, V77, P1115, DOI 10.1016/0002-9343(84)90199-2; GRYGIEL JJ, 1984, EUR J CLIN PHARMACOL, V26, P335, DOI 10.1007/BF00548764; GRYGIEL JJ, 1979, CLIN PHARMACOL THER, V26, P660; HAUSER AR, 1983, CLIN PHARMACOL THER, V33, P254; HEMSTREET MP, 1982, J ALLERGY CLIN IMMUN, V69, P360, DOI 10.1016/0091-6749(82)90146-4; ILIOPOULOU A, 1982, BRIT J CLIN PHARMACO, V14, P495, DOI 10.1111/j.1365-2125.1982.tb02018.x; JACKSON J E, 1980, Pharmacologist, V22, P231; JACKSON JE, 1981, AM REV RESPIR DIS, V123, P615; JACKSON JE, 1981, DRUG INTEL CLIN PHAR, V15, P809, DOI 10.1177/106002808101501019; JOAQUIN VHS, 1982, CLIN PEDIATR, V21, P724; JONKMAN JHG, 1983, CHEST, V84, P309, DOI 10.1378/chest.84.3.309; JONKMAN JHG, 1985, THER DRUG MONIT, V7, P92, DOI 10.1097/00007691-198503000-00016; JONKMAN JHG, 1985, BRIT J CLIN PHARMACO, V19, P99, DOI 10.1111/j.1365-2125.1985.tb02620.x; JONKMAN JHG, 1985, EUR J RESPIR DIS, V66, P47; JONKMAN JHG, 1985, J PHARM SCI, V74, P1103, DOI 10.1002/jps.2600741019; JONKMAN JHG, 1984, USE SUSTAINED RELEAS, P98; JONKMAN JHG, STEADY STATE THEOPHY; JONKMAN JHG, NO CHANGE THEOPHYLLI; JUSKO WJ, 1979, J PHARM SCI, V68, P1358, DOI 10.1002/jps.2600681106; KELLY J F, 1982, Clinical Pharmacology and Therapeutics, V31, P238; KELLY SJ, 1981, CLIN RES, V29, pA796; KRAEMER MJ, 1982, PEDIATRICS, V69, P476; LAFORCE CF, 1981, J PEDIATR-US, V99, P153, DOI 10.1016/S0022-3476(81)80983-3; LAFORCE CF, 1983, J ALLERGY CLIN IMMUN, V71, P131; LAFORCE CF, 1981, J ALLERGY CLIN IMMUN, V67, P40; LALONDE RL, 1983, CHEST, V83, P221, DOI 10.1378/chest.83.2.221; LANDAY RA, 1978, J ALLERGY CLIN IMMUN, V62, P27, DOI 10.1016/0091-6749(78)90068-4; LAVARENNE J, 1981, THERAPIE, V36, P451; LEAVENGOOD DC, 1983, ANN ALLERGY, V50, P249; MACLEOD S, 1985, CLIN PHARMACOL THER, V37, P209; MADDUX MS, 1982, CHEST, V81, P563, DOI 10.1378/chest.81.5.563; MANFREDI RL, 1981, CLIN PHARMACOL THER, V29, P224, DOI 10.1038/clpt.1981.36; MARQUIS JF, 1982, NEW ENGL J MED, V307, P1189, DOI 10.1056/NEJM198211043071906; MATHIS J W, 1982, Clinical Pharmacy, V1, P446; MAY DC, 1982, J CLIN PHARMACOL, V22, P125, DOI 10.1002/j.1552-4604.1982.tb02659.x; MELETHIL S, 1982, RES COMMUN CHEM PATH, V35, P341; MILLER M, 1984, CLIN PHARMACOL THER, V35, P666, DOI 10.1038/clpt.1984.92; MINERS JO, 1981, CLIN EXP PHARMACOL P, V8, P633; MONKS TJ, 1979, CLIN PHARMACOL THER, V26, P513, DOI 10.1002/cpt1979264513; MONKS TJ, 1981, BIOPHARM DRUG DISPOS, V2, P31, DOI 10.1002/bdd.2510020104; MULKEY PM, 1983, CLIN PHARMACY, V2, P439; MYHRE KI, 1983, BRIT J CLIN PHARMACO, V15, P683, DOI 10.1111/j.1365-2125.1983.tb01550.x; OROURKE PP, 1984, CRIT CARE MED, V12, P373, DOI 10.1097/00003246-198404000-00007; PALADINO JA, 1983, THER DRUG MONIT, V5, P135, DOI 10.1097/00007691-198303000-00016; PFEIFER HJ, 1979, CLIN PHARMACOL THER, V26, P36; PIASKY KM, 1977, CLIN PHARM THER, V22, P1495; POWELL JR, 1984, ARCH INTERN MED, V144, P484, DOI 10.1001/archinte.144.3.484; POWELLJACKSON PR, 1984, THORAX, V39, P692; PRINCE RA, 1981, J ALLERGY CLIN IMMUN, V68, P427, DOI 10.1016/0091-6749(81)90196-2; REED RC, 1984, J PHARMACOKINET BIOP, V12, P315, DOI 10.1007/BF01061723; REED RC, 1983, NEW ENGL J MED, V308, P724; REISZ G, 1983, AM REV RESPIR DIS, V127, P584; REITBERG DP, 1981, ANN INTERN MED, V95, P582, DOI 10.7326/0003-4819-95-5-582; RENTON KW, 1980, CAN MED ASSOC J, V123, P288; RENTON KW, 1981, CLIN PHARMACOL THER, V30, P422, DOI 10.1038/clpt.1981.182; ROBERTS RK, 1984, MED J AUSTRALIA, V140, P279, DOI 10.5694/j.1326-5377.1984.tb104037.x; ROBERTS RK, 1983, J LAB CLIN MED, V101, P821; ROBERTS RK, 1981, GASTROENTEROLOGY, V81, P19; ROBSON RA, 1984, BRIT J CLIN PHARMACO, V18, P445, DOI 10.1111/j.1365-2125.1984.tb02487.x; RUFF F, 1982, NOUV PRESSE MED, V11, P3512; SEGGEV JS, 1985, ANN ALLERGY, V54, P367; SHARGEL L, 1981, J PHARM SCI, V70, P599, DOI 10.1002/jps.2600700606; SKLAR SJ, 1985, DRUG INTEL CLIN PHAR, V19, P34, DOI 10.1177/106002808501900109; STRAUGHN AB, 1984, THER DRUG MONIT, V6, P153, DOI 10.1097/00007691-198406000-00004; STULTS BM, 1983, WESTERN J MED, V139, P651; STULTS BM, 1983, SOUTHERN MED J, V76, P714, DOI 10.1097/00007611-198306000-00008; TORNATORE KM, 1982, EUR J CLIN PHARMACOL, V23, P129, DOI 10.1007/BF00545966; VESTAL RE, 1983, BRIT J CLIN PHARMACO, V15, P411, DOI 10.1111/j.1365-2125.1983.tb01523.x; VOZEH S, 1980, CLIN PHARMACOL THER, V27, P194, DOI 10.1038/clpt.1980.30; WALKER S, 1981, CAN MED ASSOC J, V125, P243; WEINBERGER M, 1977, J ALLERGY CLIN IMMUN, V59, P228, DOI 10.1016/0091-6749(77)90154-3; ZAROWITZ BJM, 1981, CLIN PHARMACOL THER, V29, P601, DOI 10.1038/clpt.1981.84	100	41	41	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				736	742		10.1016/0091-6749(86)90054-0	http://dx.doi.org/10.1016/0091-6749(86)90054-0			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	2877015				2022-12-18	WOS:A1986E568400012
J	OGASAWARA, H; FUJITANI, T; DRZEWIECKI, G; MIDDLETON, E				OGASAWARA, H; FUJITANI, T; DRZEWIECKI, G; MIDDLETON, E			THE ROLE OF HYDROGEN-PEROXIDE IN BASOPHIL HISTAMINE-RELEASE AND THE EFFECT OF SELECTED FLAVONOIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SUNY BUFFALO,DEPT MED,BUFFALO,NY 14260; SUNY BUFFALO,DEPT PEDIAT,BUFFALO,NY 14260	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ALLEN RC, 1972, BIOCHEM BIOPH RES CO, V47, P679, DOI 10.1016/0006-291X(72)90545-1; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BENNETT JP, 1981, ARZNEIMITTEL-FORSCH, V31-1, P433; BORS W, 1979, EUR J BIOCHEM, V95, P621, DOI 10.1111/j.1432-1033.1979.tb13003.x; BUSSE WW, 1984, J ALLERGY CLIN IMMUN, V73, P801, DOI 10.1016/0091-6749(84)90450-0; CHAKRAVARTY NK, 1979, MAST CELL ITS ROLE H, P38; CURNUTTE JT, 1974, J CLIN INVEST, V53, P1662, DOI 10.1172/JCI107717; DECHATELET LR, 1975, ANTIMICROB AGENTS CH, V8, P146, DOI 10.1128/AAC.8.2.146; DVORAK AM, 1981, J IMMUNOL, V126, P523; FEWTRELL CMS, 1977, NATURE, V265, P635, DOI 10.1038/265635a0; FEWTRELL CMS, 1977, BIOCHIM BIOPHYS ACTA, V469, P52, DOI 10.1016/0005-2736(77)90325-X; GARTNER I, 1980, IMMUNOLOGY, V40, P133; GOETZL EJ, 1974, J CLIN INVEST, V53, P591, DOI 10.1172/JCI107594; HELD AM, 1978, BIOCHEM BIOPH RES CO, V81, P878, DOI 10.1016/0006-291X(78)91433-X; HENDERSON WR, 1978, J CLIN INVEST, V61, P187, DOI 10.1172/JCI108917; KAZURA JW, 1981, J CLIN INVEST, V67, P93, DOI 10.1172/JCI110037; LAMPERT MB, 1983, BLOOD, V62, P645; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MIDDLETON E, 1982, BIOCHEM PHARMACOL, V31, P1449, DOI 10.1016/0006-2952(82)90044-2; MIDDLETON E, 1981, J IMMUNOL, V127, P546; MIDDLETON E, 1984, BIOCHEM PHARMACOL, V33, P333; NATHAN CF, 1979, J EXP MED, V149, P100, DOI 10.1084/jem.149.1.100; OHMORI H, 1979, BIOCHEM PHARMACOL, V28, P333, DOI 10.1016/0006-2952(79)90524-0; OHMORI H, 1980, BIOCHEM PHARMACOL, V29, P741, DOI 10.1016/0006-2952(80)90550-X; OYANAGUI Y, 1976, BIOCHEM PHARMACOL, V25, P1473; ROOT RK, 1977, J CLIN INVEST, V60, P1266, DOI 10.1172/JCI108886; ROSEN H, 1977, J BIOL CHEM, V252, P4803; SAGONE AL, 1976, J CLIN INVEST, V57, P1352, DOI 10.1172/JCI108403; WEISS SJ, 1978, J EXP MED, V147, P316, DOI 10.1084/jem.147.2.316	29	41	43	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1986	78	2					321	328		10.1016/S0091-6749(86)80083-5	http://dx.doi.org/10.1016/S0091-6749(86)80083-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	D7261	2426322				2022-12-18	WOS:A1986D726100013
J	ELLIS, EF				ELLIS, EF			THEOPHYLLINE TOXICITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											ELLIS, EF (corresponding author), STATE UNIV NEW YORK BUFFALO, CHILDRENS HOSP, DIV ALLERGY IMMUNOL, 219 BRYANT ST, BUFFALO, NY 14222 USA.							ARANDA JV, 1976, J PEDIATR-US, V89, P833, DOI 10.1016/S0022-3476(76)80819-0; ARMAND J, 1973, LYON MED, V229, P485; BERLINGER WG, 1983, CLIN PHARMACOL THER, V33, P351, DOI 10.1038/clpt.1983.44; BRESNICK E, 1948, JAMA-J AM MED ASSOC, V136, P397, DOI 10.1001/jama.1948.72890230007008; DENENBERG VH, 1982, J PHARMACOL EXP THER, V221, P604; DOBMEYER DJ, 1983, NEW ENGL J MED, V308, P814, DOI 10.1056/NEJM198304073081405; DUNWIDDIE TV, 1981, N-S ARCH PHARMACOL, V316, P326, DOI 10.1007/BF00501365; EHLERS SM, 1978, JAMA-J AM MED ASSOC, V240, P474, DOI 10.1001/jama.240.5.474; ELLIS EF, 1978, ALLERGY PRINCIPLES P; GAUDREAULT P, 1983, J PEDIATR-US, V102, P474, DOI 10.1016/S0022-3476(83)80682-9; Gottstein U, 1972, STROKE, V3, P560, DOI 10.1161/01.STR.3.5.560; HENDELES L, 1977, DRUG INTEL CLIN PHAR, V11, P12, DOI 10.1177/106002807701100101; LUBBE WF, 1978, J CLIN INVEST, V61, P1260, DOI 10.1172/JCI109042; MAITRE M, 1974, BIOCHEM PHARMACOL, V23, P2807, DOI 10.1016/0006-2952(74)90054-9; MAKEN TH, 1961, CLIN RES, V9, P57; MATTHAY RA, 1976, THORAX, V31, P470, DOI 10.1136/thx.31.4.470; Merrill George Adams, 1943, JOUR AMER MED ASSOC, V123, P1115; NOBEL PA, 1977, J PEDIATR-US, V90, P825, DOI 10.1016/S0022-3476(77)81262-6; OGILVIE RI, 1977, EUR J CLIN PHARMACOL, V12, P409, DOI 10.1007/BF00561059; OWENS GR, 1981, ANN INTERN MED, V94, P212, DOI 10.7326/0003-4819-94-2-212; ROSENKRANTZ TS, 1984, AM J DIS CHILD, V138, P489, DOI 10.1001/archpedi.1984.02140430065017; RUSSO ME, 1979, NEW ENGL J MED, V300, P24, DOI 10.1056/NEJM197901043000107; SAHNEY S, 1983, PEDIATRICS, V71, P615; SNODGRASS W, 1980, DRUG INTEL CLIN PHAR, V14, P783, DOI 10.1177/106002808001401107; WECHSLER RL, 1950, J CLIN INVEST, V29, P28, DOI 10.1172/JCI102230; WEINBERGER M, 1980, DEV PHARMACOL THERAP, V1, P26, DOI 10.1159/000455518	26	41	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					297	301		10.1016/0091-6749(85)90645-1	http://dx.doi.org/10.1016/0091-6749(85)90645-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	4019958				2022-12-18	WOS:A1985APE8900009
J	STUCKEY, MS; WITT, CS; SCHMITT, LH; WARLOW, R; LATTIMORE, M; DAWKINS, RL				STUCKEY, MS; WITT, CS; SCHMITT, LH; WARLOW, R; LATTIMORE, M; DAWKINS, RL			HISTAMINE SENSITIVITY INFLUENCES REACTIVITY TO ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WESTERN AUSTRALIA,DEPT ANAT & HUMAN BIOL,NEDLANDS,WA 6009,AUSTRALIA	University of Western Australia								BAKER RJ, 1978, GLIM MANUAL RELEASE; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; BAZARAL M, 1974, J ALLERGY CLIN IMMUN, V54, P283; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; GERRARD JW, 1978, AM J HUM GENET, V30, P46; ISHAZAKA K, 1976, ADV IMMUNOL, V23, P1; JOHANSSON SGO, 1972, PROG CLIN IMMUNOL, V1, P1; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; Pepys J, 1975, CLIN ASPECTS IMMUNOL, P55; STASZAK C, 1980, J IMMUNOL, V125, P181	10	41	41	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	3					373	376		10.1016/0091-6749(85)90074-0	http://dx.doi.org/10.1016/0091-6749(85)90074-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AEB46	3973311				2022-12-18	WOS:A1985AEB4600008
J	BACH, MK; BRASHLER, JR; PECK, RE; MORTON, DR				BACH, MK; BRASHLER, JR; PECK, RE; MORTON, DR			LEUKOTRIENE-C SYNTHETASE, A SPECIAL GLUTATHIONE S-TRANSFERASE - PROPERTIES OF THE ENZYME AND INHIBITOR STUDIES WITH SPECIAL REFERENCE TO THE MODE OF ACTION OF U-60,257, A SELECTIVE INHIBITOR OF LEUKOTRIENE SYNTHESIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UPJOHN CO,DEPT EXPTL SCI 1,KALAMAZOO,MI 49001	Pfizer	BACH, MK (corresponding author), UPJOHN CO,DEPT HYPERSENSIT DIS RES,KALAMAZOO,MI 49001, USA.							BACH MK, 1982, ADV PROSTAG THROMB L, V9, P103; BACH MK, 1982, PROSTAGLANDINS, V23, P759; FITZPATRICK FA, 1982, J BIOL CHEM, V257, P4680; JAKOBY WB, 1976, GLUTATHIONE METABOLI, P213; JAKSCHIK BA, 1983, ADV PROSTAG THROMB L, V11, P141; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; SUN FF, 1983, PROSTAGLANDINS, V26, P211, DOI 10.1016/0090-6980(83)90090-4	7	41	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	74	3					353	357		10.1016/0091-6749(84)90129-5	http://dx.doi.org/10.1016/0091-6749(84)90129-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TQ633	6381574				2022-12-18	WOS:A1984TQ63300009
J	BARSELA, S; TEICHTAHL, H; LUTSKY, I				BARSELA, S; TEICHTAHL, H; LUTSKY, I			OCCUPATIONAL ASTHMA IN POULTRY WORKERS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT COMPARAT MED,IL-91010 JERUSALEM,ISRAEL; HADASSAH MED CTR,DEPT MED A,ALLERGY UNIT,JERUSALEM,ISRAEL; CHAIM SHEBA MED CTR,PULM UNIT,IL-52621 TEL HASHOMER,ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; Chaim Sheba Medical Center								BOYER RS, 1974, AM REV RESPIR DIS, V109, P630; BROOKS SM, 1982, J ALLERGY CLIN IMMUN, V70, P56, DOI 10.1016/0091-6749(82)90202-0; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P274; ELMAN AJ, 1968, ARCH ENVIRON HEALTH, V17, P98, DOI 10.1080/00039896.1968.10665196; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; Korn D S, 1968, JAMA, V205, P114, DOI 10.1001/jama.205.1.114; LUTSKY I, 1982, LANCET, V2, P874; LUTSKY II, 1975, ANN ALLERGY, V35, P201; PEPYS J, 1964, CLIN ASPECTS IMMUNOL, P55; PETRO W, 1978, INT ARCH OCC ENV HEA, V42, P119, DOI 10.1007/BF01297550; Salter HH., 1864, ASTHMA ITS PATHOLOGY; STAHULJAKBERITIC D, 1977, INT ARCH OCC ENV HEA, V40, P131, DOI 10.1007/BF00575157; VYSKOCIL J, 1975, KLIN NEM POV LEK FAK, V27, P240; WARREN CPW, 1974, AM REV RESPIR DIS, V109, P672; WEAVER HK, 1973, J OCCUP MED, V15, P156; 1981, CMND8121, P21	16	41	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	2					271	275		10.1016/S0091-6749(84)80019-6	http://dx.doi.org/10.1016/S0091-6749(84)80019-6			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SF020	6699310				2022-12-18	WOS:A1984SF02000009
J	GORDON, EH; KROUSE, HA; KINNEY, JL; STIEHM, ER; KLAUSTERMEYER, WB				GORDON, EH; KROUSE, HA; KINNEY, JL; STIEHM, ER; KLAUSTERMEYER, WB			DELAYED CUTANEOUS HYPERSENSITIVITY IN NORMALS - CHOICE OF ANTIGENS AND COMPARISON TO INVITRO ASSAYS OF CELL-MEDIATED-IMMUNITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									VET ADM WADSWORTH MED CTR,DEPT MED,ALLERGY & IMMUNOL SECT 691-111R,LOS ANGELES,CA 90073; VET ADM WADSWORTH MED CTR,DEPT RES,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,SCH MED,DIV PEDIAT IMMUNOL & ALLERGY,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NIAID NIH HHS [AI-15332] Funding Source: Medline; NICHD NIH HHS [HD-09800] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R22HD009800, R01HD009800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI015332] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BICE DE, 1974, INT ARCH ALLER A IMM, V47, P54; BORUT TC, 1980, J PEDIATR-US, V97, P567, DOI 10.1016/S0022-3476(80)80010-2; CHAPARAS SD, 1970, AM REV RESPIR DIS, V101, P67; CUTLER JE, 1974, P SOC EXP BIOL MED, V147, P471; FAIRSHTER RD, 1980, J ALLERGY CLIN IMMUN, V66, P452, DOI 10.1016/0091-6749(80)90005-6; FAKTOR MA, 1973, J ALLERGY CLIN IMMUN, V52, P1; FERGUSON AC, 1976, AM J CLIN PATHOL, V68, P499; FRANZ ML, 1976, J PEDIATR-US, V88, P975, DOI 10.1016/S0022-3476(76)81053-0; GALANT SP, 1977, J ALLERGY CLIN IMMUN, V60, P247, DOI 10.1016/0091-6749(77)90139-7; GROSS L, 1965, CANCER, V18, P201, DOI 10.1002/1097-0142(196502)18:2<201::AID-CNCR2820180211>3.0.CO;2-V; GROSSMAN J, 1975, J ALLERGY CLIN IMMUN, V55, P268, DOI 10.1016/0091-6749(75)90146-3; HEFTON JM, 1980, J IMMUNOL, V125, P1007; KANTOR FS, 1975, NEW ENGL J MED, V292, P629; KAUFMAN DB, 1980, AM J DIS CHILD, V134, P479, DOI 10.1001/archpedi.1980.02130170029011; KNIKER WT, 1979, ANN ALLERGY, V43, P73; LEVINE L, 1960, J PEDIATR-US, V57, P836, DOI 10.1016/S0022-3476(60)80134-5; MUNOZ AI, 1977, J PEDIATR-US, V91, P565, DOI 10.1016/S0022-3476(77)80503-9; NELSON RD, 1975, J IMMUNOL, V115, P1650; NILSSON BS, 1971, SCAND J RESPIR DIS, V52, P39; PALMER DL, 1974, J INFECT DIS, V130, P132, DOI 10.1093/infdis/130.2.132; SHANNON DC, 1966, NEW ENGL J MED, V275, P690, DOI 10.1056/NEJM196609292751302; SNEDECOR CW, 1967, STATISTICAL METHODS, P115; STEELE RW, 1976, AM J DIS CHILD, V130, P1218, DOI 10.1001/archpedi.1976.02120120052008; STIEHM ER, 1979, PEDIATRICS, V64, P814; STIMPSON PG, 1976, SOUTHERN MED J, V69, P424, DOI 10.1097/00007611-197604000-00013; TAYLOR FB, 1971, J ALLERGY CLIN IMMUN, V48, P23, DOI 10.1016/0091-6749(71)90051-0; Waldorf D, 1968, JAMA-J AM MED ASSOC, V203, P111; WILSON WR, 1977, MAYO CLIN PROC, V52, P196	28	41	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	72	5					487	494		10.1016/0091-6749(83)90586-9	http://dx.doi.org/10.1016/0091-6749(83)90586-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RR916	6355249				2022-12-18	WOS:A1983RR91600010
J	MCINTYRE, E; FITZGIBBON, B; OTTO, H; MINSON, R; ALPERS, J; RUFFIN, R				MCINTYRE, E; FITZGIBBON, B; OTTO, H; MINSON, R; ALPERS, J; RUFFIN, R			INHALED VERAPAMIL IN HISTAMINE-INDUCED BRONCHOCONSTRICTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT MED,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia			McIntyre, Ellen/E-5264-2015	McIntyre, Ellen/0000-0002-2230-1619				AUSTEN KF, 1975, AM REV RESPIR DIS, V112, P423; CERRINA J, 1981, AM REV RESPIR DIS, V123, P156; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CROPP GJA, 1980, AM THORACIC SOC NEWS, V6, P11; EBASHI S, 1977, EXCITATION CONTRACTI, P325; FARLEY JM, 1978, J PHARMACOL EXP THER, V207, P340; HENRY PD, 1980, AM J CARDIOL, V46, P1047, DOI 10.1016/0002-9149(80)90366-5; HIMORI N, 1980, BRIT J PHARMACOL, V68, P595, DOI 10.1111/j.1476-5381.1980.tb10848.x; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Kirkpatrick CT, 1981, SMOOTH MUSCLE ASSESS, P385; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; Nayler W G, 1980, Eur Heart J, V1, P225; NIE NH, 1975, SPSS STATISTICAL PAC; PATEL KR, 1981, BRIT MED J, V282, P932, DOI 10.1136/bmj.282.6268.932; PATEL KR, 1981, CLIN ALLERGY, V11, P441, DOI 10.1111/j.1365-2222.1981.tb01617.x; RUFFIN RE, 1981, J ALLERGY CLIN IMMUN, V67, P285, DOI 10.1016/0091-6749(81)90023-3; RUFFIN RE, 1981, AUST NZ J MED, V11, P98; Sokal R R, 1981, BIOMETRY, P232; SOMLYO AV, 1968, J PHARMACOL EXP THER, V159, P129; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P691; WILLIAMS DO, 1981, BRIT MED J, V283, P348, DOI 10.1136/bmj.283.6287.348	22	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	4					375	381		10.1016/0091-6749(83)90065-9	http://dx.doi.org/10.1016/0091-6749(83)90065-9			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QL121	6833677				2022-12-18	WOS:A1983QL12100004
J	BERNSTEIN, IL				BERNSTEIN, IL			CROMOLYN SODIUM IN THE TREATMENT OF ASTHMA - CHANGING CONCEPTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											BERNSTEIN, IL (corresponding author), UNIV CINCINNATI, MED CTR, DEPT INTERNAL MED, DIV IMMUNOL, CINCINNATI, OH 45267 USA.							ALTOUNYAN RE, 1967, ACTA ALLERGOL, V22, P487; ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; ALTOUNYAN REC, 1974, CLIN PEDIATR, V13, P435; ATKINS PC, 1978, J ALLERGY CLIN IMMUN, V62, P149, DOI 10.1016/0091-6749(78)90099-4; ATKINS PC, 1977, ANN INTERN MED, V86, P415, DOI 10.7326/0003-4819-86-4-415; BASOMBA A, 1976, CLIN ALLERGY, V6, P269, DOI 10.1111/j.1365-2222.1976.tb01907.x; BERNSTEIN IL, 1972, J ALLERGY CLIN IMMUN, V50, P235, DOI 10.1016/0091-6749(72)90017-6; BERNSTEIN IL, 1978, ANN INTERN MED, V89, P228, DOI 10.7326/0003-4819-89-2-228; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRESLIN FJ, 1980, AM REV RESPIR DIS, V122, P11; BROOKS SM, 1980, AM REV RESPIR DIS, V121, P117; BUCKLEY JM, 1980, OCT P AM AC PED ANN; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; CADE JF, 1971, LANCET, V2, P186; CAIRNS H, 1979, MAST CELL ITS ROLE H, P172; CHURCH MK, 1978, MED ACT DRUGS TODAY, V14, P281; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Cox J S, 1970, Adv Drug Res, V5, P115; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; COX JSG, 1976, BRONCHIAL ASTHMA MEC, P805; DAHL R, 1979, SCAND J RESPIR DIS, V60, P51; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DELANEY JC, 1976, CLIN ALLERGY, V6, P365, DOI 10.1111/j.1365-2222.1976.tb01917.x; DEVRIES K, 1962, INT ARCH ALLER A IMM, V20, P93, DOI 10.1159/000229248; DICKSON W, 1979, MAST CELL ITS ROLE H, P343; DIXON M, 1980, BRIT J PHARMACOL, V70, P11, DOI 10.1111/j.1476-5381.1980.tb10898.x; EDMUNDS AT, 1980, BRIT MED J, V281, P842, DOI 10.1136/bmj.281.6244.842; ENGSTROM I, 1977, SCAND J RESPIR DIS, P49; FOREMAN JC, 1975, BIOCHEM PHARMACOL, V24, P538, DOI 10.1016/0006-2952(75)90142-2; GODFREY S, 1975, J PEDIATR-US, V87, P465, DOI 10.1016/S0022-3476(75)80663-9; GODFREY S, 1975, PEDIATRICS, V56, P930; GOODMAN DH, 1972, ANN ALLERGY, V30, P258; GRIECO MH, 1972, CHEST, V61, P432, DOI 10.1378/chest.61.5.432; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; HAMBLETON G, 1977, LANCET, V1, P381; HARRIES MG, 1981, LANCET, V1, P5; HETZEL MR, 1977, BMJ-BRIT MED J, V1, P808, DOI 10.1136/bmj.1.6064.808; JOHNSON HG, 1978, IMMUNOL SER, V7, P533; KERR JW, 1972, J ALLERGY CLIN IMMUN, V49, P128; KINGSLEY PJ, 1978, ALLERGY PRINCIPLES P, V1, P481; KONIG P, 1979, ANN ALLERGY, V43, P293; LAVIN N, 1976, J ALLERGY CLIN IMMUN, V57, P80, DOI 10.1016/0091-6749(76)90081-6; MACDONALD TH, 1979, J INT MED RES, V7, P87; MARKS MB, 1979, ANN ALLERGY, V43, P19; MAZUREK N, 1980, NATURE, V286, P722, DOI 10.1038/286722a0; MUNROFORD R, 1971, ANN ALLERGY, V29, P8; NARASBHAT K, 1976, J ALLERGY CLIN IMMUN, V58, P647, DOI 10.1016/0091-6749(76)90176-7; NEWMANTAYLOR AJ, 1979, CLIN ALLERGY, V9, P213; ORR TSC, 1969, NATURE, V223, P197, DOI 10.1038/223197b0; PEPYS J, 1968, LANCET, V2, P134; ROY AC, 1974, BIOCHEM PHARMACOL, V23, P917, DOI 10.1016/0006-2952(74)90223-8; RYO UY, 1976, JAMA-J AM MED ASSOC, V236, P927; SETTIPANE GA, 1979, JAMA-J AM MED ASSOC, V241, P811, DOI 10.1001/jama.241.8.811; SHEFFER AL, 1975, NEW ENGL J MED, V293, P1220, DOI 10.1056/NEJM197512112932402; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; THEOHARIDES TC, 1980, SCIENCE, V207, P80, DOI 10.1126/science.6153130; THOMSON NC, 1978, THORAX, V33, P694, DOI 10.1136/thx.33.6.694; WANNER A, 1979, AM J MED, V67, P477, DOI 10.1016/0002-9343(79)90797-6; WEILERRAVELL D, 1981, J ALLERGY CLIN IMMUN, V67, P391, DOI 10.1016/0091-6749(81)90085-3; WESTERMAN DE, 1979, AM J MED, V66, P565, DOI 10.1016/0002-9343(79)91165-3; WOENNE R, 1979, AM REV RESPIR DIS, V119, P927	61	41	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	4					247	253						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML525	6169751				2022-12-18	WOS:A1981ML52500001
J	JOSEPHS, SH; ROTHMAN, SJ; BUCKLEY, RH				JOSEPHS, SH; ROTHMAN, SJ; BUCKLEY, RH			PHENYTOIN HYPERSENSITIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Discussion									DUKE UNIV,MED CTR,SCH MED,DEPT PEDIAT,DURHAM,NC 27710; DUKE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27706	Duke University; Duke University			Buckley, Rebecca/AAB-1578-2019					AARLI JA, 1976, ACTA NEUROL SCAND, V54, P423, DOI 10.1111/j.1600-0404.1976.tb04374.x; AGARWAL BN, 1977, NEPHRON, V18, P249, DOI 10.1159/000180836; ANTHONY JJ, 1970, ARCH NEUROL-CHICAGO, V22, P450, DOI 10.1001/archneur.1970.00480230068008; BRAVERMANN JM, 1963, AM J MED, V35, P418; CHARLESWORTH EN, 1977, ARCH DERMATOL, V113, P477, DOI 10.1001/archderm.113.4.477; FONTANA A, 1976, LANCET, V2, P228; GAMS RA, 1968, ANN INTERN MED, V69, P557, DOI 10.7326/0003-4819-69-3-557; GROB PJ, 1972, BRIT MED J, V2, P561, DOI 10.1136/bmj.2.5813.561; GROPPER AL, 1956, N ENGL J MED, V254, P552; HARINASUTA U, 1968, J AMER MED ASSOC, V203, P1015; HEPTINSTALL RH, 1974, PATHOLOGY KIDNEY, P826; HJALMARSSON O, 1977, BRIT MED J, V1, P614; HOLLAND P, 1965, J PEDIATR-US, V66, P322, DOI 10.1016/S0022-3476(65)80189-5; HYMAN LR, 1978, J PEDIATR-US, V92, P915, DOI 10.1016/S0022-3476(78)80360-6; JOSKE RA, 1976, MED J AUSTRALIA, V2, P555, DOI 10.5694/j.1326-5377.1976.tb130385.x; JOUBERT PH, 1977, S AFR MED J, V52, P642; KLECKNER HB, 1975, ANN INTERN MED, V83, P522, DOI 10.7326/0003-4819-83-4-522; LEE TJ, 1976, GASTROENTEROLOGY, V70, P422; MACKINNEY AA, 1972, ARCH INTERN MED, V129, P988, DOI 10.1001/archinte.129.6.988; Mandelbaum H, 1941, ARCH NEURO PSYCHIATR, V45, P769, DOI 10.1001/archneurpsyc.1941.02280170047003; MCGEACHY TE, 1953, AM J MED, V14, P600, DOI 10.1016/0002-9343(53)90376-3; Merritt HH, 1939, ARCH NEURO PSYCHIATR, V42, P1053, DOI 10.1001/archneurpsyc.1939.02270240091005; MICHAEL, 1976, J AM MED A, V236, P2773; OOI BS, 1974, LANCET, V1, P1254; PARKER WA, 1979, NEUROLOGY, V29, P175, DOI 10.1212/WNL.29.2.175; PEZZIMENTI JF, 1970, ARCH INTERN MED, V125, P118, DOI 10.1001/archinte.125.1.118; RALLISON ML, 1961, AM J DIS CHILD, V101, P75; Ritchie EB, 1942, ARCH DERMATOL SYPH, V46, P856, DOI 10.1001/archderm.1942.01500180078012; ROBINSON HM, 1970, ARCH DERMATOL, V101, P462, DOI 10.1001/archderm.101.4.462; SALTZSTEIN SL, 1959, CANCER-AM CANCER SOC, V12, P164, DOI 10.1002/1097-0142(195901/02)12:1<164::AID-CNCR2820120122>3.0.CO;2-Y; SEAGER J, 1975, LANCET, V2, P632; Sexton DL, 1941, J AMER MED ASSOC, V116, P700, DOI 10.1001/jama.1941.62820080001009; SHETH KJ, 1977, J PEDIATR-US, V91, P438, DOI 10.1016/S0022-3476(77)81318-8; SIEGAL S, 1961, J ALLERGY, V32, P447, DOI 10.1016/0021-8707(61)90022-3; SORRELL TC, 1971, LANCET, V2, P1233; SPARBERG M, 1963, ANN INTERN MED, V59, P914, DOI 10.7326/0003-4819-59-6-914; STANWORTH DR, 1977, LANCET, V1, P1001; VANEPPS E, 1976, CLIN EXP IMMUNOL, V23, P444; VANWYK JJ, 1948, ARCH INTERN MED, V81, P605, DOI 10.1001/archinte.1948.00220230003001; WATTS JC, 1962, PEDIATRICS, V30, P592; WOODBURY DM, 1972, ANTIEPILEPTIC DRUGS	41	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	2					166	172		10.1016/0091-6749(80)90065-2	http://dx.doi.org/10.1016/0091-6749(80)90065-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD119	7400479				2022-12-18	WOS:A1980KD11900012
J	MCFADDEN, ER; SOTER, NA; INGRAM, RH				MCFADDEN, ER; SOTER, NA; INGRAM, RH			MAGNITUDE AND SITE OF AIRWAY RESPONSE TO EXERCISE IN ASTHMATICS IN RELATION TO ARTERIAL HISTAMINE LEVELS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ROBERT B BRIGHAM HOSP,DEPT MED,DIV DERMATOL,BOSTON,MA 02120		MCFADDEN, ER (corresponding author), PETER BENT BRIGHAM HOSP,DEPT MED,DIV DERMATOL,BOSTON,MA 02115, USA.			Soter, Nicholas/0000-0003-3518-3209	NHLBI NIH HHS [HL-17873+, HL-00013] Funding Source: Medline; NIAID NIH HHS [AI-14292] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; BOUCHER RC, 1977, J ALLERGY CLIN IMMUN, V60, P134, DOI 10.1016/0091-6749(77)90039-2; BOUCHER RC, 1978, J APPL PHYSIOL, V45, P939, DOI 10.1152/jappl.1978.45.6.939; BRESLIN FJ, 1980, J APPL PHYSIOL, V48, P619, DOI 10.1152/jappl.1980.48.4.619; BRISCOE WA, 1958, J CLIN INVEST, V37, P1279, DOI 10.1172/JCI103715; BRUCE C, 1976, THORAX, V31, P724, DOI 10.1136/thx.31.6.724; CHARLES TJ, 1979, CLIN SCI, V57, P39, DOI 10.1042/cs0570039; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEAL EC, 1979, J APPL PHYSIOL, V46, P484, DOI 10.1152/jappl.1979.46.3.484; DEAL EC, 1978, J APPL PHYSIOL, V45, P238, DOI 10.1152/jappl.1978.45.2.238; DEAL EC, 1979, J APPL PHYSIOL, V46, P467, DOI 10.1152/jappl.1979.46.3.467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; DEAL EC, 1980, J CLIN INVEST, V65, P659, DOI 10.1172/JCI109711; DESPAS PJ, 1972, J CLIN INVEST, V51, P3235, DOI 10.1172/JCI107150; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; HAYNES RL, 1976, AM REV RESPIR DIS, V114, P739; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; LEITH DE, 1974, PROCEDURES STANDARDI; MAKINO S, 1966, J ALLERGY, V38, P127, DOI 10.1016/0021-8707(66)90036-0; MCFADDEN ER, 1977, J APPL PHYSIOL, V42, P746, DOI 10.1152/jappl.1977.42.5.746; MCFADDEN ER, 1977, ASTHMA PHYSL IMMUNOP, P351; PORTER JF, 1970, CLIN SCI, V38, P135, DOI 10.1042/cs0380135; SIMON RA, 1977, J ALLERGY CLIN IMMUN, V60, P312, DOI 10.1016/0091-6749(77)90111-7; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; SYKES TW, 1977, AM REV RESPIR DIS, V115, P581; THOMSON NC, 1978, THORAX, V33, P694, DOI 10.1136/thx.33.6.694; TOWLEY RG, 1975, J ALLERGY CLIN IMMUN, V56, P429; 1962, AM REV RESPIR DIS, V85, P762	30	41	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	6					472	477		10.1016/0091-6749(80)90008-1	http://dx.doi.org/10.1016/0091-6749(80)90008-1			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KV363	7430505	Bronze			2022-12-18	WOS:A1980KV36300007
J	YOCUM, MW; HELLER, AM; ABELS, RI				YOCUM, MW; HELLER, AM; ABELS, RI			EFFICACY OF INTRAVENOUS PRETESTING AND ANTIHISTAMINE PROPHYLAXIS IN RADIOCONTRAST MEDIA-SENSITIVE PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HENRY FORD HOSP,DEPT INTERNAL MED,DIV ALLERGY & IMMUNOL,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital								ANDREWS EJ, 1976, RADIOLOGY, V121, P1; ANSELL G, 1970, INVEST RADIOL, V5, P374, DOI 10.1097/00004424-197011000-00002; ARROYAVE CM, 1976, J IMMUNOL, V117, P1866; DAVIES P, 1975, BMJ-BRIT MED J, V2, P434, DOI 10.1136/bmj.2.5968.434; Fischer H W, 1976, Curr Probl Diagn Radiol, V6, P1; FISCHER HW, 1972, RADIOLOGY, V103, P497, DOI 10.1148/103.3.497; LANG EK, 1965, RADIOLOGY, V85, P666, DOI 10.1148/85.4.666; MILLER WL, 1975, J ALLERGY CLIN IMMUN, V56, P291, DOI 10.1016/0091-6749(75)90103-7; OCHSNER SF, 1971, SOUTHERN MED J, V64, P907, DOI 10.1097/00007611-197108000-00002; PETERS GA, 1966, J ALLERGY, V38, P74, DOI 10.1016/0021-8707(66)90046-3; ROCKOFF SD, 1972, INVEST RADIOL, V7, P403, DOI 10.1097/00004424-197209000-00008; SCHATZ M, 1975, J ALLERGY CLIN IMMUN, V55, P358, DOI 10.1016/0091-6749(75)90007-X; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145, DOI 10.2214/ajr.124.1.145; STANLEY RJ, 1976, RADIOLOGY, V121, P5, DOI 10.1148/121.1.5; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832, DOI 10.2214/ajr.119.4.832; WITTEN DM, 1975, JAMA-J AM MED ASSOC, V231, P974; ZWEIMAN B, 1975, ANN INTERN MED, V83, P159, DOI 10.7326/0003-4819-83-2-159	17	41	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	5					309	313		10.1016/0091-6749(78)90163-X	http://dx.doi.org/10.1016/0091-6749(78)90163-X			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FW432	29919				2022-12-18	WOS:A1978FW43200009
J	DAVID, MF				DAVID, MF			PREVENTION OF HOMOCYTOTROPIC ANTIBODY-FORMATION AND ANAPHYLACTIC SENSITIZATION BY PREFEEDING ANTIGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MANITOBA,WINNIPEG CLIN,WINNIPEG R3T 2N2,MANITOBA,CANADA; UNIV MANITOBA,DEPT PAEDIAT,WINNIPEG R3T 2N2,MANITOBA,CANADA	University of Manitoba; University of Manitoba								ADA GL, 1968, P NATL ACAD SCI USA, V61, P556, DOI 10.1073/pnas.61.2.556; BARTH EEE, 1966, IMMUNOLOGY, V10, P459; BAZIN H, 1976, IMMUNOLOGY, V30, P679; CANTOR HM, 1967, NATURE, V215, P744, DOI 10.1038/215744a0; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; CLARK SL, 1959, J BIOPHYS BIOCHEM CY, V5, P41, DOI 10.1083/jcb.5.1.41; CRABBE PA, 1969, J EXP MED, V130, P723, DOI 10.1084/jem.130.4.723; FELDMANN M, 1972, TRANSPLANT REV, V13, P3; FELDMANN M, 1970, J EXP MED, V131, P247, DOI 10.1084/jem.131.2.247; GERSHON RK, 1972, J IMMUNOL, V108, P586; GRUSKAY FL, 1955, PEDIATRICS, V16, P763; HALLIDAY R, 1955, PROC R SOC SER B-BIO, V143, P408, DOI 10.1098/rspb.1955.0020; HEREMANS JF, 1971, METHODS IMMUNOLOGY I, V3, P213; INCHLEY CJ, 1969, CLIN EXP IMMUNOL, V5, P173; JARRETT EEE, 1976, IMMUNOLOGY, V30, P671; KRAEHENBUHL JP, 1969, J CELL BIOL, V42, P345, DOI 10.1083/jcb.42.2.345; LEVINE BB, 1970, INT ARCH ALLER A IMM, V39, P156, DOI 10.1159/000230343; MALKIEL S, 1952, P SOC EXP BIOL MED, V81, P689, DOI 10.3181/00379727-81-19988; MURGITA RA, 1975, J EXP MED, V141, P269, DOI 10.1084/jem.141.2.269; OGILVIE BM, 1974, TRANSPLANT REV, V19, P147; OGRA PL, 1968, NEW ENGL J MED, V279, P893, DOI 10.1056/NEJM196810242791701; OGRA PL, 1969, J IMMUNOL, V102, P1423; ROTHBERG RM, 1969, SECRETORY IMMUNOLOGI, P293; SOUHAMI RL, 1972, IMMUNOLOGY, V22, P685; TADA T, 1973, J IMMUNOL, V111, P952; THOMAS HC, 1976, GASTROENTEROLOGY, V71, P114; THOMAS HC, 1974, IMMUNOLOGY, V27, P631; THOMAS HC, 1973, LANCET, V1, P1288; TRIGER DR, 1972, LANCET, V1, P665; WALKER WA, 1974, AM J CLIN NUTR, V27, P1434, DOI 10.1093/ajcn/27.12.1434; WALKER WA, 1972, J CELL BIOL, V54, P195, DOI 10.1083/jcb.54.2.195; WALKER WA, 1975, J IMMUNOL, V115, P854; WELLS HG, 1911, J INFECT DIS, V8, P77; YACHNIN S, 1975, J EXP MED, V141, P242, DOI 10.1084/jem.141.1.242	34	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	3					180	187		10.1016/0091-6749(77)90122-1	http://dx.doi.org/10.1016/0091-6749(77)90122-1			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DU852	893876				2022-12-18	WOS:A1977DU85200006
J	IRONS, JS; PRUZANSKY, JJ; PATTERSON, R; ZEISS, CR				IRONS, JS; PRUZANSKY, JJ; PATTERSON, R; ZEISS, CR			STUDIES OF PERENNIAL RAGWEED IMMUNOTHERAPY - ASSOCIATED CHANGES IN CELLULAR RESPONSIVENESS, TOTAL SERUM ANTIGEN-BINDING CAPACITY, AND SPECIFIC IGE ANTIBODY CONCENTRATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,MED CTR,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University								ARBESMAN CE, 1960, J ALLERGY, V31, P342, DOI 10.1016/0021-8707(60)90070-8; ARBESMAN CE, 1967, J ALLERGY, V39, P124; BOOTH BH, 1972, ALLERGIC DISEASES DI, P63; Brown A, 1927, J IMMUNOL, V13, P273; CONNELL JT, 1963, J IMMUNOL, V91, P197; EVANS R, 1972, J ALLERGY CLIN IMMUN, V49, P285, DOI 10.1016/0091-6749(72)90096-6; GUTMAN AA, 1972, ALLERGIC DISEASES DI, P88; Harley D, 1933, LANCET, V2, P1469; IRONS JS, 1974, J ALLERGY CLIN IMMUN, V53, P113; IRONS JS, 1975, J ALLERGY CLIN IMMUN, V56, P64, DOI 10.1016/0091-6749(75)90035-4; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; JOHNSTONE DE, 1957, AM J DIS CHILD, V44, P1; LEVY DA, 1967, J IMMUNOL, V99, P1068; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN LM, 1968, J ALLERGY, V41, P49, DOI 10.1016/0021-8707(68)90007-5; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663, DOI 10.7326/0003-4819-75-5-663; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1969, J ALLERGY, V43, P180; LICHTENSTEIN LM, 1966, J IMMUNOL, V96, P169; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; Loveless MH, 1943, J IMMUNOL, V47, P165; LOWELL FC, 1963, J ALLERGY, V34, P165, DOI 10.1016/0021-8707(63)90069-8; MEACOCK SCR, 1965, J ALLERGY, V36, P1, DOI 10.1016/0021-8707(65)90027-4; MELAM H, 1970, J ALLERGY, V45, P43, DOI 10.1016/0021-8707(70)90015-8; MELAM H, 1971, J ALLERGY, V47, P262, DOI 10.1016/S0091-6749(71)80004-0; MELAM HL, 1970, J ALLERGY, V46, P292, DOI 10.1016/0021-8707(70)90069-9; Noon L, 1911, LANCET, V1, P1572; PRUZANSK.JJ, 1965, J ALLERGY, V36, P196; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; PRUZANSKY JJ, 1968, J AMER MED ASSOC, V203, P805, DOI 10.1001/jama.203.9.805; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; Sherman WB, 1941, J IMMUNOL, V40, P289; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; STARR MS, 1970, INT ARCH ALLER A IMM, V38, P514, DOI 10.1159/000230304; Steel RGD, 1960, PRINCIPLES PROCEDURE, P481; TADA T, 1971, J IMMUNOL, V106, P1002; VANARSDE.PP, 1965, FED PROC, V24, P632; VANARSDEL P, 1961, J ALLERGY, V32, P348, DOI 10.1016/0021-8707(61)90103-4; VANMETRE TE, 1969, J ALLERGY, V43, P180; Vaughan WT, 1931, J AMER MED ASSOC, V97, P0090, DOI 10.1001/jama.1931.02730020018005; WEINSTOCK M, 1970, INT ARCH ALLER A IMM, V37, P385, DOI 10.1159/000230801; ZEISS CR, 1973, J IMMUNOL, V110, P414	43	41	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	59	3					190	199		10.1016/0091-6749(77)90149-X	http://dx.doi.org/10.1016/0091-6749(77)90149-X			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CZ249	65371				2022-12-18	WOS:A1977CZ24900002
J	OKAZAKI, T; IIEA, VS; ROSARIO, NA; REISMAN, RE; ARBESMAN, CE; LEE, JB; MIDDLETON, E				OKAZAKI, T; IIEA, VS; ROSARIO, NA; REISMAN, RE; ARBESMAN, CE; LEE, JB; MIDDLETON, E			REGULATORY ROLE OF PROSTAGLANDIN-E IN ALLERGIC HISTAMINE-RELEASE WITH OBSERVATIONS ON RESPONSIVENESS OF BASOPHIL LEUKOCYTES AND EFFECT OF ACETYLSALICYLIC-ACID	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP, ALLERGY RES LAB, BUFFALO, NY 14203 USA; SUNY BUFFALO, DEPT MED, BUFFALO, NY 14214 USA; SUNY BUFFALO, DEPT MICROBIOL, BUFFALO, NY 14214 USA	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			rosario, nelson/K-7205-2012	rosario, nelson/0000-0002-8550-8051				ANDERSEN NH, 1969, J LIPID RES, V10, P320; ARBESMAN CE, 1974, J ALLERGY CLIN IMMUN, V53, P81; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; EVANS R, 1972, J ALLERGY CLIN IMMUN, V49, P285, DOI 10.1016/0091-6749(72)90096-6; HUBSCHER T, 1975, J IMMUNOL, V114, P1389; ISHIZAKA T, 1973, J IMMUNOL, V111, P500; IZHIZAKA T, 1972, J IMMUNOL, V108, P1000; JARRETT EEE, 1971, CLIN EXP IMMUNOL, V9, P585; LEE JB, 1974, TXB ENDOCRINOLOGY, P854; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1970, IMMUNOLOGY, V19, P831; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1972, PROSTAGLANDINS CELLU, P293; LICHTENSTEIN LM, 1971, BIOCH ACUTE ALLERGIC, P161; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; OKAZAKI T, 1976, J ALLERGY CLIN IMMUN, V57, P124, DOI 10.1016/0091-6749(76)90031-2; OKAZAKI T, 1976, J ALLERGY CLIN IMMUN, V57, P454, DOI 10.1016/0091-6749(76)90061-0; OKAZAKI T, 1976, J ALLERGY CLIN IMMUN, V57, P192; OKAZAKI T, 1975, J ALLERGY CLIN IMMUN, V56, P27, DOI 10.1016/0091-6749(75)90031-7; OKAZAKI T, 1975, FED PROC, V34, P1045; OKAZAKI T, 1975, AM REV RESPIR DIS, V111, P916; OKAZAKI T, UNPUBLISHED OBSERVAT; Osler A G, 1968, Adv Immunol, V8, P183, DOI 10.1016/S0065-2776(08)60467-8; SZCZEKLIK A, 1976, LANCET, V1, P488; UVNAS B, 1971, BIOCHEMISTRY ACUTE A, P204; Zurier R B, 1975, Inflammation, V1, P93, DOI 10.1007/BF00918062; ZUSMAN RM, 1972, PROSTAGL, V2, P41, DOI 10.1016/0090-6980(72)90028-7	28	41	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	6					360	366		10.1016/0091-6749(77)90067-7	http://dx.doi.org/10.1016/0091-6749(77)90067-7			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ED834	72766				2022-12-18	WOS:A1977ED83400005
J	KRELL, RD; CHAKRIN, LW; WARDELL, JR				KRELL, RD; CHAKRIN, LW; WARDELL, JR			EFFECT OF CHOLINERGIC AGENTS ON A CANINE MODEL OF ALLERGIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SK&F LABS,DEPT BIOL RES,RESP DIS SECT,PHILADELPHIA,PA 19101	GlaxoSmithKline								CHICK TW, 1975, CLIN RES, V23, pA137; CHIESA A, 1975, AM REV RESPIR DIS, V111, P148; CROPP GJ, 1975, J ALLERGY CLIN IMMUN, V55, P98; DRAZEN JM, 1974, J CLIN INVEST, V53, P1679, DOI 10.1172/JCI107719; GILES RE, 1971, ARCH INT PHARMACOD T, V194, P213; GOLD W M, 1973, P169; GOLD WM, 1972, J APPL PHYSIOL, V33, P719, DOI 10.1152/jappl.1972.33.6.719; HOGARTHS.RS, 1967, IMMUNOLOGY, V13, P535; ITKIN IH, 1970, J ALLERGY, V45, P178, DOI 10.1016/0021-8707(70)90126-7; KESSLER GF, 1973, J APPL PHYSIOL, V35, P703, DOI 10.1152/jappl.1973.35.5.703; KESSLER GF, 1974, INT ARCH ALLER A IMM, V47, P313, DOI 10.1159/000231225; KRELL RD, 1974, PHARMACOLOGIST, V16, P594; KRELL RD, IMMUNOPHARMACOLOGY, P125; MILLS JE, 1969, J PHYSIOL-LONDON, V203, P337, DOI 10.1113/jphysiol.1969.sp008867; MILLS JE, 1970, BRIT J PHARMACOL, V39, P724, DOI 10.1111/j.1476-5381.1970.tb09898.x; PATTERSON R, 1974, CHEST, V65, P488, DOI 10.1378/chest.65.5.488; ROSENTHA.RR, 1974, J ALLERGY CLIN IMMUN, V53, P73; ROSENTHAL RR, 1974, CHEST, V65, P598; YU DYC, 1972, J APPL PHYSIOL, V32, P823, DOI 10.1152/jappl.1972.32.6.823	19	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	1					19	30		10.1016/0091-6749(76)90103-2	http://dx.doi.org/10.1016/0091-6749(76)90103-2			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	BX742	947975				2022-12-18	WOS:A1976BX74200003
J	NEVA, FA; KAPLAN, AP; PACHECO, G; GRAY, L; DANARAJ, TJ				NEVA, FA; KAPLAN, AP; PACHECO, G; GRAY, L; DANARAJ, TJ			TROPICAL EOSINOPHILIA - HUMAN MODEL OF PARASITIC IMMUNOPATHOLOGY, WITH OBSERVATIONS ON SERUM IGE LEVELS BEFORE AND AFTER TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,LAB PARASITIC DIS,BLDG 5,ROOM 114,BETHESDA,MD 20014; NIAID,LAB CLIN INVEST,BETHESDA,MD	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BEAVER PAUL C., 1956, EXPTL PARASITOL, V5, P587, DOI 10.1016/0014-4894(56)90032-7; BEAVER PC, 1970, AM J TROP MED HYG, V19, P181, DOI 10.4269/ajtmh.1970.19.181; BUCKLEY J. J. C., 1958, East African Medical Journal, V35, P493; DANARAJ T. J., 1956, Proceedings of the Alumni Association of Malaya, V9, P172; DANARAJ TJ, 1958, Q J MED, V27, P243; DANARAJ TJ, 1966, AM J TROP MED HYG, V15, P183, DOI 10.4269/ajtmh.1966.15.183; DANARAJ TJ, 1959, AM J TROP MED HYG, V8, P151, DOI 10.4269/ajtmh.1959.8.151; DONOHUGH DL, 1963, NEW ENGL J MED, V269, P1357, DOI 10.1056/NEJM196312192692507; EZOKE A, 1973, CLIN ALLERGY, V3, P33; Frimodt-Moller C, 1940, Ind Med Gaz, V75, P607; GALLIARD H, 1957, Bull World Health Organ, V16, P601; GANATRA RD, 1955, INDIAN J MED SCI, V9, P672; HARTZ PH, 1948, AM J CLIN PATHOL, V18, P637; HIRST W. R., 1945, Naval Medical Bulletin, V44, P1277; IRWIN JW, 1946, ANN INTERN MED, V25, P329, DOI 10.7326/0003-4819-25-2-329; JARRETT EEE, 1973, VET REC, V93, P480, DOI 10.1136/vr.93.18.480; JOHANSSON SG, 1968, LANCET, V1, P1118; LEVIN JJ, 1956, ANN INTERN MED, V44, P1264, DOI 10.7326/0003-4819-44-6-1264; LIEKIAN J, 1962, AM J TROP MED HYG, V11, P646; MEYERS F. M., 1939, GENEESK TIJDSCHR NEDERLAND INDIE, V79, P853; PACHECO G, 1966, AM J TROP MED HYG, V15, P355, DOI 10.4269/ajtmh.1966.15.355; PATTERSON R, 1974, J ALLERGY CLIN IMMUN, V53, P245, DOI 10.1016/0091-6749(74)90088-8; PRAKASH N, 1974, J ALLERGY CLIN IMMUN, V53, P189, DOI 10.1016/0091-6749(74)90007-4; RADERMECKER M, 1974, INT ARCH ALLER A IMM, V47, P285, DOI 10.1159/000231221; ROSEN L, 1962, JAMA-J AM MED ASSOC, V179, P620, DOI 10.1001/jama.1962.03050080032007; ROSENBERG EB, 1970, NEW ENGL J MED, V283, P1148, DOI 10.1056/NEJM197011192832107; SPITZ E, 1972, J ALLERGY CLIN IMMUN, V49, P337, DOI 10.1016/0091-6749(72)90132-7; WEBB JKG, 1960, LANCET, V1, P835; Weingarten RJ, 1943, LANCET, V1, P103; WILDERVANCK A, 1953, Doc Med Geogr Trop, V5, P67; WONG MM, 1964, AM J TROP MED HYG, V13, P66, DOI 10.4269/ajtmh.1964.13.66; WONG MM, 1973, AM VET MED ASSOC, V163, P133	32	41	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	6					422	429		10.1016/0091-6749(75)90081-0	http://dx.doi.org/10.1016/0091-6749(75)90081-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AE593	1138016				2022-12-18	WOS:A1975AE59300009
J	JENNE, JW; CHICK, TW; MILLER, BA; DEESTRIC.R				JENNE, JW; CHICK, TW; MILLER, BA; DEESTRIC.R			EFFECT OF CONGESTIVE HEART-FAILURE ON ELIMINATION OF THEOPHYLLINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Meeting Abstract																			0	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	2					80	80						1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S0380					2022-12-18	WOS:A1974S038000038
J	ORGEL, HA; LENOIR, MA; BAZARAL, M				ORGEL, HA; LENOIR, MA; BAZARAL, M			SERUM IGG, IGA, IGM, AND IGE LEVELS AND ALLERGY IN FILIPINO CHILDREN IN UNITED-STATES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									LETTERMAN GEN HOSP,PEDIAT DEPT,SAN FRANCISCO,CA; UNIV CALIF,SAN DIEGO,SCH MED,PEDIAT IMMUNOL & ALLERGY DIV,LA JOLLA,CA 42037	University of California System; University of California San Diego								ALLANSMITH M, 1969, J IMMUNOL, V102, P1504; ARBESMAN CE, 1972, J ALLERGY CLIN IMMUN, V49, P72, DOI 10.1016/0091-6749(72)90058-9; BAZARAL M, 1971, J IMMUNOL, V107, P794; BAZARAL M, 1973, CLIN EXP IMMUNOL, V14, P117; BAZARAL M, 1972, Clinical Research, V20, P258; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; BERG T, 1969, INT ARCH ALLER A IMM, V36, P219, DOI 10.1159/000230745; BUCKLEY CE, 1970, J IMMUNOL, V105, P964; BUCKLEY RH, 1968, PEDIATRICS, V41, P600; Cooke RA, 1916, J IMMUNOL, V1, P201; DAVIS LR, 1961, BRIT J DERMATOL, V73, P410, DOI 10.1111/j.1365-2133.1961.tb14988.x; FAUST E. C., 1938, American Journal of Tropical Medicine, V18, P169; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; HAMBURGER RN, 1973, CONTROL MECHANISMS R; HOGARTHSCOTT RS, 1969, CLIN EXP IMMUNOL, V5, P619; Hunter G. W. III, 1948, Bulletin of the United States Army Medical Department, V8, P128; ITO K, 1972, JPN J EXP MED, V42, P115; JOHANSSON SG, 1968, LANCET, V1, P1118; KALFF MW, 1969, CLIN EXP IMMUNOL, V5, P469; KOHLER PF, 1967, J ALLERGY, V39, P311, DOI 10.1016/0021-8707(67)90095-0; LICHTMAN MA, 1967, ARTHRITIS RHEUM, V10, P204, DOI 10.1002/art.1780100306; LICHTMAN MA, 1965, AM J CLIN NUTR, V16, P492, DOI 10.1093/ajcn/16.6.492; OGILVIE BM, 1967, IMMUNOLOGY, V12, P113; PHILLS JA, 1972, NEW ENGL J MED, V286, P965, DOI 10.1056/NEJM197205042861802; ROSENBERG EB, 1970, NEW ENGL J MED, V283, P1148, DOI 10.1056/NEJM197011192832107; ROWE D S, 1970, Bulletin of the World Health Organization, V43, P609; SEDLIS E, 1965, J PEDIATR, V66, P154; STIEHM ER, 1966, PEDIATRICS, V37, P715; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; WALKER RB, 1956, BRIT J DERMATOL, V68, P182, DOI 10.1111/j.1365-2133.1956.tb12805.x; WEINER AS, 1936, ANN EUGEN, V7, P141; Worth RM, 1962, HAWAII MED J, V22, P31; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	33	41	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	53	4					213	222		10.1016/0091-6749(74)90083-9	http://dx.doi.org/10.1016/0091-6749(74)90083-9			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	S6732	4209102				2022-12-18	WOS:A1974S673200004
J	STEINBERG, P; ISHIZAKA, K; NORMAN, PS				STEINBERG, P; ISHIZAKA, K; NORMAN, PS			POSSIBLE ROLE OF IGE-MEDIATED REACTION IN IMMUNITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP, SCH MED, DEPT MED, BALTIMORE, MD USA	Johns Hopkins University								AVRAMEAS S, 1969, IMMUNOCHEMISTRY, V6, P53, DOI 10.1016/0019-2791(69)90178-5; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; CHANOCK RM, 1970, SECRETORY IMMUNOLOGI, P83; FRASER D. T., 1931, TRANS ROY SOC CANADA SECT 5 BIOL SCI, V25, P175; FRIEDEMANN U, 1947, BACTERIOL REV, V11, P275, DOI 10.1128/MMBR.11.4.275-302.1947; HENSON PM, 1971, J EXP MED, V133, P554, DOI 10.1084/jem.133.3.554; ISHIZAKA K, 1967, J ALLERGY, V39, P254, DOI 10.1016/0021-8707(67)90019-6; ISHIZAKA K, 1957, Jpn J Med Sci Biol, V10, P343; ISHIZAKA K, 1968, J IMMUNOL, V100, P554; ISHIZAKA K, 1968, J ALLERGY, V42, P330, DOI 10.1016/0021-8707(68)90095-6; ISHIZAKA K, 1970, IMMUNOCHEMISTRY, V7, P687, DOI 10.1016/0019-2791(70)90175-8; ISHIZAKA T, 1970, J IMMUNOL, V104, P854; KAY AB, 1971, J IMMUNOL, V107, P899; POLMAR SH, 1972, J CLIN INVEST, V51, P326, DOI 10.1172/JCI106817; TADA T, 1970, Journal of Immunology, V104, P377; TOMASI TB, 1968, ADV IMMUNOL, V9, P2; TOMIOKA H, 1971, J IMMUNOL, V107, P971	17	41	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1974	54	6					359	366		10.1016/0091-6749(74)90026-8	http://dx.doi.org/10.1016/0091-6749(74)90026-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U9288					2022-12-18	WOS:A1974U928800004
J	JOHNSON, RA; KHURANA, RG; KIRKPATRICK, CH; BAER, H; DAWSON, CR				JOHNSON, RA; KHURANA, RG; KIRKPATRICK, CH; BAER, H; DAWSON, CR			COMPARISON OF CONTACT ALLERGENICITY OF 4 PENTADECYLCATECHOLS DERIVED FROM POISON IVY URUSHIOL IN HUMAN SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		AUERBACH R, 1964, J ALLERGY, V35, P201, DOI 10.1016/0021-8707(64)90002-4; BAER H, 1967, J IMMUNOL, V99, P365; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; DAWSON CHARLES R., 1956, TRANS NEW YORK ACAD SCI, V18, P427; Keil H, 1944, J EXP MED, V80, P275, DOI 10.1084/jem.80.4.275; KLIGMAN AM, 1958, ARCH DERMATOL, V77, P149, DOI 10.1001/archderm.1958.01560020001001; KLIGMAN AM, 1958, ARCH DERMATOL, V78, P47, DOI 10.1001/archderm.1958.01560070051008; MARKIEWITZ KH, 1965, J ORG CHEM, V30, P1610, DOI 10.1021/jo01016a067; Siegel S., 1956, NONPARAMETRIC STAT B; SPAIN WC, 1934, J ALLERGY, V5, P571; SYMES WF, 1954, J AM CHEM SOC, V76, P2959, DOI 10.1021/ja01640a030	11	41	42	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	1					27	+		10.1016/0091-6749(72)90120-0	http://dx.doi.org/10.1016/0091-6749(72)90120-0			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	L3388	4257103				2022-12-18	WOS:A1972L338800004
J	SIEGEL, I; SHERMAN, WB				SIEGEL, I; SHERMAN, WB			INTERACTION OF LYMPHOCYTES WITH AUTOLOGOUS RED-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article																		BACH JF, 1969, TRANSPLANTATION, V8, P265, DOI 10.1097/00007890-196909000-00008; BESSIS M, 1956, CYTOLOGY BLOOD BLOOD; BRAIN P, 1970, CLIN EXP IMMUNOL, V6, P61; BURNET M, 1969, CELLULAR IMMUNOLOGY; GRANGER GA, 1969, MEDIATORS CELLULAR I, P324; MARTIN S P, 1958, Methods Med Res, V7, P136; MCFARLAN.W, 1965, NATURE, V205, P887, DOI 10.1038/205887a0; MOSCONA AA, 1965, CELLS TISSUE CULT, V1, P489; SAINTEMARIE G, 1964, THYMUS IMMUNOBIOLOGY, P207; SIEGEL I, 1970, J CELL BIOL, V47, pA191; SIEGEL I, 1970, J ALLERGY, V46, P190, DOI 10.1016/0021-8707(70)90097-3; SIEGEL I, 1970, J IMMUNOL, V105, P879; Wybran J, 1971, Trans Assoc Am Physicians, V84, P239	13	41	41	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	50	2					65	&		10.1016/0091-6749(72)90001-2	http://dx.doi.org/10.1016/0091-6749(72)90001-2			0	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N1795	4114294				2022-12-18	WOS:A1972N179500001
J	Troelnikov, A; Perkins, G; Yuson, C; Ahamdie, A; Balouch, S; Hurtado, PR; Hissaria, P				Troelnikov, Alexander; Perkins, Griffith; Yuson, Chino; Ahamdie, Aida; Balouch, Summaya; Hurtado, Plinio R.; Hissaria, Pravin			Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						COVID-19; vaccine allergy; SARS-CoV-2; polyethylene glycol and polysorbate allergy; lipid nanoparticles; liposomes; Pfizer BNT162b2; basophil activation testing; skin testing		Background: The mechanisms underpinning allergic reactions to the BNT162b2 (Pfizer) COVID-19 vaccine remain unknown, with polyethylene glycol (PEG) contained in the lipid nanoparticle suspected as being the cause. Objective: Our aim was to evaluate the performance of skin testing and basophil activation testing to PEG, polysorbate 80, and the BNT162b2 (Pfizer) and AZD1222 (AstraZeneca) COVID-19 vaccines in patients with a history of PEG allergy. Methods: Three known individuals with PEG allergy and 3 healthy controls were recruited and evaluated for hypersensitivity to the BNT162b2 and AZD1222 vaccines, and to related compounds by skin testing and basophil activation, as measured by CD63 upregulation using flow cytometry. Results: We found that the BNT162b2 vaccine induced positive skin test results in patients with PEG allergy, whereas the result of traditional PEG skin testing was negative in 2 of 3 patients. One patient was found to be cosensitized to both the BNT162b2 and AZD1222 vaccines because of cross-reactive PEG and polysorbate allergy. The BNT162b2 vaccine, but not PEG alone, induced dose-dependent activation of all patients' basophils ex vivo. Similar basophil activation could be induced by PEGylated liposomal doxorubicin, suggesting that PEGylated lipids within nanoparticles, but not PEG in its native state, are able to efficiently induce degranulation. Conclusions: Our findings implicate PEG, as covalently modified and arranged on the vaccine lipid nanoparticle, as a potential trigger of anaphylaxis in response to BNT162b2, and highlight shortcomings of current skin testing protocols for allergy to PEGylated liposomal drugs. (J Allergy Clin Immunol 2021;148:91-5.)	[Troelnikov, Alexander; Perkins, Griffith; Hissaria, Pravin] SA Pathol, Adelaide, SA, Australia; [Perkins, Griffith] Univ Adelaide, Sch Biol Sci, Adelaide, SA, Australia; [Hurtado, Plinio R.] Univ Adelaide, Sch Med, Adelaide, SA, Australia; [Yuson, Chino; Ahamdie, Aida; Balouch, Summaya; Hissaria, Pravin] Royal Adelaide Hosp, Dept Immunol, Adelaide, SA, Australia; [Hurtado, Plinio R.] Royal Adelaide Hosp, Dept Renal Med, Adelaide, SA, Australia	SA Pathology; University of Adelaide; University of Adelaide; Royal Adelaide Hospital; Royal Adelaide Hospital	Hissaria, P (corresponding author), Royal Adelaide Hosp, Allergy & Immunol Dept, 9G 370,1 Port Rd, Adelaide, SA 5000, Australia.	pravin.hissaria@sa.gov.au		Perkins, Griffith/0000-0001-8559-5872; Troelnikov, Alexander/0000-0002-7239-3814; Hurtado, Plinio Reinaldo/0000-0002-0913-7797	Hospital Services Charitable Gifts Board of South Australia	Hospital Services Charitable Gifts Board of South Australia	This work was supported by the Hospital Services Charitable Gifts Board of South Australia.	Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Blumenthal KG, 2021, JAMA-J AM MED ASSOC, V325, P1562, DOI 10.1001/jama.2021.3976; Bruusgaard-Mouritsen MA, 2021, CLIN EXP ALLERGY, V51, P463, DOI 10.1111/cea.13822; CAELYX, 2018, PEG LIP DOX HYDR INJ; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Ebo DG, 2021, J ALLERGY CLIN IMMUN, V147, P1143, DOI 10.1016/j.jaci.2020.10.027; Klimek L, 2021, ALLERGY, V76, P3307, DOI 10.1111/all.14794; Klimek L, 2021, ALLERGY, V76, P1624, DOI [10.1111/all.14726, 10.1007/s40629-021-00165-7]; Kozma GT, 2019, ACS NANO, V13, P9315, DOI 10.1021/acsnano.9b03942; LEADRIANA TT, 2020, J ALLERGY CLIN IMMUN, V8, P1757; Li PH, 2018, J ALLER CL IMM-PRACT, V6, P1655, DOI 10.1016/j.jaip.2018.01.007; Sanchez-Borges M, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-017-0148-1; Schellekens H, 2013, PHARM RES-DORDR, V30, P1729, DOI 10.1007/s11095-013-1067-7; Sellaturay P, 2021, CLIN EXP ALLERGY, V51, P861, DOI 10.1111/cea.13874; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Stone CA, 2019, J ALLER CL IMM-PRACT, V7, P1533, DOI 10.1016/j.jaip.2018.12.003; Strasser J, 2019, NANO LETT, V19, P4787, DOI 10.1021/acs.nanolett.9b02220; Su JR, 2019, J ALLERGY CLIN IMMUN, V143, P1465, DOI 10.1016/j.jaci.2018.12.1003; Zhou ZH, 2021, J ALLER CL IMM-PRACT, V9, P1731, DOI 10.1016/j.jaip.2020.11.011	19	40	40	5	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2021	148	1					91	95		10.1016/j.jaci.2021.04.032	http://dx.doi.org/10.1016/j.jaci.2021.04.032		JUL 2021	5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TE3IE	33991580				2022-12-18	WOS:000669906700016
J	Pontali, E; Volpi, S; Signori, A; Antonucci, G; Castellaneta, M; Buzzi, D; Montale, A; Bustaffa, M; Angelelli, A; Caorsi, R; Giambruno, E; Bobbio, N; Feasi, M; Gueli, I; Tricerri, F; Calautti, F; Castagnola, E; Moscatelli, A; Rollandi, GA; Ravelli, A; Cassola, G; Sormani, MP; Gattorno, M				Pontali, Emanuele; Volpi, Stefano; Signori, Alessio; Antonucci, Giancarlo; Castellaneta, Marco; Buzzi, Davide; Montale, Amedeo; Bustaffa, Marta; Angelelli, Alessia; Caorsi, Roberta; Giambruno, Elisa; Bobbio, Nicoletta; Feasi, Marcello; Gueli, Ilaria; Tricerri, Francesca; Calautti, Francesca; Castagnola, Elio; Moscatelli, Andrea; Rollandi, Gian Andrea; Ravelli, Angelo; Cassola, Giovanni; Sormani, Maria Pia; Gattorno, Marco			Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-1; anakinra; glucocorticoid; early treatment; COVID-19 pneumonia	RECEPTOR BLOCKADE; INTERLEUKIN-1; CELLS; MORTALITY	Background: IL-1 plays a pivotal role in the inflammatory response during cytokine storm syndromes. Objective: Our aim was to analyze the efficacy and safety of early anti-inflammatory treatment (AIT) with intravenous anakinra with or without glucocorticoids in coronavirus disease 2019 (COVID-19) pneumonia. Methods: We performed a retrospective single-center cohort study of patients admitted for COVID-19 pneumonia from February 26 to April 29, 2020, to assess the efficacy of early AIT with intravenous anakinra (100 mg every 8 hours for 3 days, with tapering) alone or in combination with a glucocorticoid (intravenous methylprednisolone, 1-2 mg/kg daily, with tapering). The standard of care (SOC) treatment was hydroxychloroquine and/or azithromycin with or without antivirals and anticoagulants. Late rescue AIT with anakinra or tocilizumab was also evaluated. Treatment effect on overall survival was assessed by a propensity score-adjusted Cox model. Results: A total of 128 patients were analyzed; 63 patients received early AIT (30 received anakinra alone and 33 received anakinra plus a glucocorticoid) at admission, and 65 patients did not receive early AIT and were used as controls; of the latter 65 patients, 44 received the SOC treatment alone and 21 received the SOC treatment plus late rescue AIT. After adjustment for all the unbalanced baseline covariates, early AIT reduced the hazard of mortality by 74% (adjusted hazard ratio [HR] = 0.26; P < .001). The effect was similar in patients receiving anakinra alone (adjusted HR = 0.28; P = .04) and anakinra plus a glucocorticoid (adjusted HR = 0.33; P = .07). Late rescue treatment did not show a significant advantage over SOC treatment alone (adjusted HR = 0.82; P = .70). Conclusions: This study suggests, on a larger series of patients with COVID-19 pneumonia, the potential efficacy and safety of the early use of high doses of intravenous anakinra with or without glucocorticoids.	[Pontali, Emanuele; Antonucci, Giancarlo; Castellaneta, Marco; Buzzi, Davide; Montale, Amedeo; Giambruno, Elisa; Bobbio, Nicoletta; Feasi, Marcello; Tricerri, Francesca; Calautti, Francesca; Rollandi, Gian Andrea; Cassola, Giovanni] Ente Osped Osped Galliera, Genoa, Italy; [Volpi, Stefano; Bustaffa, Marta; Angelelli, Alessia; Caorsi, Roberta; Gueli, Ilaria; Castagnola, Elio; Moscatelli, Andrea; Ravelli, Angelo; Gattorno, Marco] IRCCS G Gaslini, Genoa, Italy; [Signori, Alessio; Sormani, Maria Pia] Univ Genoa, Sect Biostat, Dept Hlth Sci, Genoa, Italy; [Sormani, Maria Pia] Osped Policlin San Martino IRCCS, Genoa, Italy	Ente Ospedaliero Ospedali Galliera; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa	Gattorno, M (corresponding author), IRCCS G Gaslini, Ctr Autoinflammatory Dis & Immunodeficiencies, I-16145 Genoa, Italy.	marcogattorno@gaslini.org	Bustaffa, Marta/AAU-1790-2021; Signori, Alessio/L-3081-2016	Signori, Alessio/0000-0001-6289-9144; Bustaffa, Marta/0000-0003-2384-0179				Ahn M, 2019, NAT MICROBIOL, V4, P789, DOI 10.1038/s41564-019-0371-3; Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Bozzi G, 2021, J ALLERGY CLIN IMMUN, V147, P561, DOI 10.1016/j.jaci.2020.11.006; Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009; Cauchois R, 2020, P NATL ACAD SCI USA, V117, P18951, DOI 10.1073/pnas.2009017117; Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2; Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695; Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; Eloseily EM, 2020, ARTHRITIS RHEUMATOL, V72, P326, DOI 10.1002/art.41103; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Kooistra EJ, 2020, LANCET RHEUMATOL, V2, pE523, DOI 10.1016/S2665-9913(20)30235-6; Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904; Langer-Gould A, 2020, INT J INFECT DIS, V99, P291, DOI 10.1016/j.ijid.2020.07.081; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Mann ER, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6197; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Navarro-Millan I, 2020, ARTHRITIS RHEUMATOL, V72, P1990, DOI 10.1002/art.41422; Ong EZY, 2020, CELL HOST MICROBE, V27, P879, DOI 10.1016/j.chom.2020.03.021; Pontali E, 2020, J ALLERGY CLIN IMMUN, V146, P213, DOI 10.1016/j.jaci.2020.05.002; Ravelli A, 2015, HEMATOL ONCOL CLIN N, V29, P927, DOI 10.1016/j.hoc.2015.06.010; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Shah S, 2016, NEURON, V92, P342, DOI 10.1016/j.neuron.2016.10.001; Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402; Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5; Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R; Stuart EA, 2013, J CLIN EPIDEMIOL, V66, pS84, DOI 10.1016/j.jclinepi.2013.01.013; Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568; van de Veerdonk FL, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03166-0; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	38	40	44	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2021	147	4					1217	1225		10.1016/j.jaci.2021.01.024	http://dx.doi.org/10.1016/j.jaci.2021.01.024		APR 2021	9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RJ1NP	33556464	Bronze, Green Published			2022-12-18	WOS:000637368900012
J	Dicker, AJ; Huang, JTJ; Lonergan, M; Keir, HR; Fong, CJ; Tan, B; Cassidy, AJ; Finch, S; Mullerova, H; Miller, BE; Tal-Singer, R; Chalmers, JD				Dicker, Alison J.; Huang, Jeffrey T. J.; Lonergan, Mike; Keir, Holly R.; Fong, Christopher J.; Tan, Brandon; Cassidy, Andrew J.; Finch, Simon; Mullerova, Hana; Miller, Bruce E.; Tal-Singer, Ruth; Chalmers, James D.			The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbiome; COPD; eosinophil; phenotype; Haemophilus	LUNG MICROBIOME; ACUTE EXACERBATIONS; COPD; SEVERITY; FIBROSIS; TRAPS	Background: The sputum microbiome has a potential role in disease phenotyping and risk stratification in chronic obstructive pulmonary disease (COPD), but few large longitudinal cohort studies exist. Objective: Our aim was to investigate the COPD sputum microbiome and its association with inflammatory phenotypes and mortality. Methods: 16S ribosomal RNA gene sequencing was performed on sputum from 253 clinically stable COPD patients (4-year median follow-up). Samples were classified as Proteobacteria or Firmicutes (phylum level) and Haemophilus or Streptococcus (genus level) dominant. Alpha diversity was measured by using Shannon-Wiener diversity and Berger-Parker dominance indices. Survival was modeled by using Cox proportional hazards regression. A subset of 78 patients had label-free liquid chromatography with tandem mass spectrometry performed, with partial least square discriminant analysis integrating clinical, microbiome, and proteomics data. Results: Proteobacteria dominance and lower diversity was associated with more severe COPD according to the Global Initiative for Chronic Obstructive Lung Disease classification system (P = .0015), more frequent exacerbations (P = .0042), blood eosinophil level less than or equal to 100 cells/ILL (P < .0001), and lower FEV1 (P = .026). Blood eosinophil counts showed a positive relationship with percent of Firmicutes and Streptococcus and a negative association with percent Proteobacteria and Haemophilus. Proteobacteria dominance was associated with increased mortality compared with Firmicutes-dominated or balanced microbiome profiles (hazard ratio = 2.58; 95% CI = 1.43-4.66; P = .0017 and hazard ratio = 7.47; 95% CI = 1.02-54.86; P = .048, respectively). Integrated omics analysis showed significant associations between Proteobacteria dominance and the neutrophil activation pathway in sputum. Conclusion: The sputum microbiome is associated with clinical and inflammatory phenotypes in COPD. Reduced microbiome diversity, associated with Proteobacteria (predominantly Haemophilus) dominance, is associated with neutrophilassociated protein profiles and an increased risk of mortality.	[Dicker, Alison J.; Huang, Jeffrey T. J.; Lonergan, Mike; Keir, Holly R.; Fong, Christopher J.; Tan, Brandon; Cassidy, Andrew J.; Finch, Simon; Chalmers, James D.] Univ Dundee, Scottish Ctr Resp Res, Dundee, Scotland; [Mullerova, Hana; Miller, Bruce E.; Tal-Singer, Ruth] GlaxoSmithKline Res & Dev Ltd, Med Innovat, Collegeville, PA USA	University of Dundee; GlaxoSmithKline	Chalmers, JD (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee DD1 9SY, Scotland.	jchalmers@dundee.ac.uk	Tal-Singer, Ruth/AAQ-2925-2021	Tal-Singer, Ruth/0000-0002-5275-8062; Huang, Jeffrey/0000-0001-9982-2298; Chalmers, James/0000-0001-5514-7868; Dicker, Alison/0000-0002-4791-3259	GlaxoSmithKline; British Lung Foundation through the GSK-BLF Chair of Respiratory Research	GlaxoSmithKline(GlaxoSmithKline); British Lung Foundation through the GSK-BLF Chair of Respiratory Research	This study was funded by GlaxoSmithKline and by the British Lung Foundation through the GSK-BLF Chair of Respiratory Research to J.D.C.	Agusti A, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01655-2017; Agusti A, 2016, EUR RESPIR J, V47, P410, DOI 10.1183/13993003.01359-2015; Alotaibi NM, 2019, INT J CHRONIC OBSTR, V14, P311, DOI 10.2147/COPD.S188186; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bafadhel M, 2015, INT J CHRONIC OBSTR, V10, P1075, DOI 10.2147/COPD.S80091; Bafadhel M, 2011, AM J RESP CRIT CARE, V184, P662, DOI 10.1164/rccm.201104-0597OC; Brusselle G, 2018, RESP MED, V138, P21, DOI 10.1016/j.rmed.2018.03.016; Cantoli M, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.00451-2017; Chalmers JD, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0040-z; Dicker AJ, 2018, THORAX, V73, P510, DOI 10.1136/thoraxjnl-2016-209931; Dicker AJ, 2018, J ALLERGY CLIN IMMUN, V141, P117, DOI 10.1016/j.jaci.2017.04.022; Fabbri LM, 2009, LANCET, V374, P695, DOI 10.1016/S0140-6736(09)61252-6; Faner R, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02086-2016; Flynn RWV, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0960-3; Garcha DS, 2012, THORAX, V67, P1075, DOI 10.1136/thoraxjnl-2012-201924; Garcia-Vidal C, 2009, EUR RESPIR J, V34, P1072, DOI 10.1183/09031936.00003309; Gevaert E, 2017, J ALLERGY CLIN IMMUN, V139, P1849, DOI 10.1016/j.jaci.2017.01.019; Ghebre MA, 2018, J ALLERGY CLIN IMMUN, V141, P2027, DOI 10.1016/j.jaci.2018.04.013; Han MK, 2014, LANCET RESP MED, V2, P548, DOI 10.1016/S2213-2600(14)70069-4; Han MK, 2010, AM J RESP CRIT CARE, V182, P598, DOI 10.1164/rccm.200912-1843CC; Hill AT, 2000, AM J MED, V109, P288, DOI 10.1016/S0002-9343(00)00507-6; Hutchison D C, 1987, Eur J Respir Dis Suppl, V153, P78; Leitao FS, 2019, AM J RESP CRIT CARE, V199, P1205, DOI 10.1164/rccm.201806-1135OC; Lipson DA, 2018, NEW ENGL J MED, V378, P1671, DOI 10.1056/NEJMoa1713901; Mayhew D, 2018, THORAX, V73, P422, DOI 10.1136/thoraxjnl-2017-210408; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Pavord ID, 2016, LANCET RESP MED, V4, P731, DOI 10.1016/S2213-2600(16)30148-5; Rogers GB, 2014, LANCET RESP MED, V2, P988, DOI 10.1016/S2213-2600(14)70213-9; Singanayagam Aran, 2013, Ann Am Thorac Soc, V10, P81, DOI 10.1513/AnnalsATS.201208-043OC; Singh D, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00164-2019; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Vogelmeier CF, 2017, EUR RESPIR J, V49, DOI [10.1164/rccm.201701-0218PP, 10.1183/13993003.00214-2017, 10.1111/resp.13012, 10.1016/j.arbres.2017.02.001]; Wang Z, 2018, THORAX, V73, P331, DOI 10.1136/thoraxjnl-2017-210741; Wang Z, 2016, EUR RESPIR J, V47, P1082, DOI 10.1183/13993003.01406-2015	34	40	41	7	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2021	147	1					158	167		10.1016/j.jaci.2020.02.040	http://dx.doi.org/10.1016/j.jaci.2020.02.040		JAN 2021	10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA7UA	32353489	Green Published			2022-12-18	WOS:000613645900020
J	Wang, LQ; Foer, D; Bates, DW; Boyce, JA; Zhou, L				Wang, Liqin; Foer, Dinah; Bates, David W.; Boyce, Joshua A.; Zhou, Li			Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									[Wang, Liqin; Bates, David W.; Zhou, Li] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA; [Foer, Dinah; Boyce, Joshua A.] Brigham & Womens Hosp, Dept Med, Div Allergy & Clin Immunol, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Wang, LQ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA.	lwang@bwh.harvard.edu			National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID) [R01AI150295]; Agency for Healthcare Research and Quality [R01HS025375]; NIH [T32AI007306]; NIH-NIAID [R01AI078908, R01AI136041, R37AI052353, U19AI095219]; NIH-National Heart, Lung, and Blood Institute [R01HL117945]	National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH-NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIH-National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	L.W., D.W.B., and L.Z. are supported by the National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID) (grant no. R01AI150295) and the Agency for Healthcare Research and Quality (grant no. R01HS025375). D.F. is supported by the NIH (grant no. T32AI007306). J.A.B. is supported by the NIH-NIAID (grant nos. R01AI078908, R01AI136041, R37AI052353, and U19AI095219) and the NIH-National Heart, Lung, and Blood Institute (grant no. R01HL117945).	Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2; Du RH, 2020, ANN AM THORAC SOC, V17, P839, DOI 10.1513/AnnalsATS.202003-225OC; Feng Y, 2020, AM J RESP CRIT CARE, V201, P1380, DOI 10.1164/rccm.202002-0445OC; Halpin DMG, 2020, LANCET RESP MED, V8, P436, DOI 10.1016/S2213-2600(20)30167-3; Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202; Ravanetti L, 2019, J ALLERGY CLIN IMMUN, V143, P1355, DOI 10.1016/j.jaci.2018.08.051; Richardson Safiya, 2020, JAMA, V323, P2052, DOI 10.1001/jama.2020.6775; Satia I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228544; Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE	9	40	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2020	146	4					808	812		10.1016/j.jaci.2020.07.018	http://dx.doi.org/10.1016/j.jaci.2020.07.018			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	OH2JO	32735807	Bronze, Green Published			2022-12-18	WOS:000582395800011
J	Storni, F; Zeltins, A; Balke, I; Heath, MD; Kramer, MF; Skinner, MA; Zha, L; Roesti, E; Engeroff, P; Muri, L; von Werdt, D; Gruber, T; Cragg, M; Mlynarczyk, M; Kundig, TM; Vogel, M; Bachmann, MF				Storni, Federico; Zeltins, Andris; Balke, Ina; Heath, Matthew D.; Kramer, Matthias F.; Skinner, Murray A.; Zha, Lisha; Roesti, Elisa; Engeroff, Paul; Muri, Lukas; von Werdt, Diego; Gruber, Thomas; Cragg, Mark; Mlynarczyk, Malgorzata; Kundig, Thomas M.; Vogel, Monique; Bachmann, Martin F.			Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; novel therapy; virus-like particles	ARA H 1; CROSS-REACTIVITY; FOOD ALLERGY; IMMUNOTHERAPY; RESPONSES; CHILDREN; IL-10	Background: Peanut allergy is a severe and increasingly frequent disease with high medical, psychosocial, and economic burden for affected patients and wider society. A causal, safe, and effective therapy is not yet available. Objective: We sought to develop an immunogenic, protective, and nonreactogenic vaccine candidate against peanut allergy based on virus-like particles (VLPs) coupled to single peanut allergens. Methods: To generate vaccine candidates, extracts of roasted peanut (Ara R) or the single allergens Ara h 1 or Ara h 2 were coupled to immunologically optimized Cucumber Mosaic Virus-derived VLPs (CuMVtt). BALB/c mice were sensitized intraperitoneally with peanut extract absorbed to alum. Immunotherapy consisted of a single subcutaneous injection of CuMVtt coupled to Ara R, Ara h 1, or Ara h 2. Results: The vaccines CuMVtt-Ara R, CuMVtt-Ara h 1, and CuMVtt-Ara h 2 protected peanut-sensitized mice against anaphylaxis after intravenous challenge with the whole peanut extract. Vaccines did not cause allergic reactions in sensitized mice. CuMVtt-Ara h 1 was able to induce specific IgG antibodies, diminished local reactions after skin prick tests, and reduced the infiltration of the gastrointestinal tract by eosinophils and mast cells after oral challenge with peanut. The ability of CuMVtt-Ara h 1 to protect against challenge with the whole extract was mediated by IgG, as shown via passive IgG transfer. FcgRIIb was required for protection, indicating that immune complexes with single allergens were able to block the allergic response against the whole extract, consisting of a complex allergen mixture. Conclusions: Our data suggest that vaccination using single peanut allergens displayed on CuMVtt may represent a novel therapy against peanut allergy with a favorable safety profile.	[Storni, Federico; Roesti, Elisa; Engeroff, Paul; Vogel, Monique; Bachmann, Martin F.] Univ Hosp Bern, Dept Rheumatol Immunol & Allergol, Bern, Switzerland; [Storni, Federico] Univ Bern, Dept BioMed Res, Bern, Switzerland; [Storni, Federico] Univ Bern, Bern Univ Hosp, Inselspital, Dept Visceral Surg & Med, Bern, Switzerland; [Zeltins, Andris; Balke, Ina] Latvian Biomed Res & Study Ctr, Riga, Latvia; [Heath, Matthew D.; Kramer, Matthias F.; Skinner, Murray A.] Allergy Therapeut UK Ltd, Worthing, England; [Zha, Lisha] Anhui Agr Ctr, Int Immunol Ctr, Hefei, Anhui, Peoples R China; [Muri, Lukas] Univ Bern, Inst Infect Dis, Neuroinfect Lab, Bern, Switzerland; [von Werdt, Diego; Gruber, Thomas] Univ Bern, Inst Pathol, Bern, Switzerland; [Cragg, Mark] Univ Southampton, Gen Hosp, Antibody & Vaccine Grp, Ctr Canc Immunol,Canc Sci Unit,Fac Med, Southampton, Hants, England; [Mlynarczyk, Malgorzata] IZZ, Zurich, Switzerland; [Kundig, Thomas M.] Univ Hosp Zurich, Dermatol, Zurich, Switzerland; [Bachmann, Martin F.] Univ Oxford, Jenner Inst, Ctr Cellular & Mol Physiol, Nuffield Dept Med, Oxford, England	University of Bern; University Hospital of Bern; University of Bern; University of Bern; University Hospital of Bern; Latvian Biomedical Research & Study Centre; University of Bern; University of Bern; University of Southampton; University of Zurich; University Zurich Hospital; University of Oxford; Jenner Institute	Storni, F; Bachmann, MF (corresponding author), Univ Bern, Inselspital, RIA, Immunol, Sahlihaus 1-2, CH-3010 Bern, Switzerland.	federico.storni@insel.ch; martin.bachmann@me.com	Storni, Federico/CAH-3483-2022; Zeltins, Andris/AAI-1017-2021; Cragg, Mark S/E-5965-2010; Engeroff, Paul/AGS-3183-2022; Kramer, Matthias F./AAK-9279-2021; Balke, Ina/AAG-6618-2020	Cragg, Mark S/0000-0003-2077-089X; Engeroff, Paul/0000-0002-3409-512X; Kramer, Matthias F./0000-0002-3740-4733; Muri, Lukas/0000-0001-8630-4272; Heath, Matthew/0000-0002-6095-4098; Roesti, Elisa Simona/0000-0002-3599-4960; Balke, Ina/0000-0002-5171-7744; von Werdt, Diego/0000-0002-4669-4760	Swiss National Science Foundation (SNSF) [310030-185114]; Saiba GmbH (Switzerland); SNSF [310030_170084]; Allergy Therapeutics Ltd (United Kingdom)	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF)); Saiba GmbH (Switzerland); SNSF(Swiss National Science Foundation (SNSF)); Allergy Therapeutics Ltd (United Kingdom)	This study was funded by the Swiss National Science Foundation (SNSF grant no. 310030-185114 to M.F.B.), Saiba GmbH (Switzerland), and Allergy Therapeutics Ltd (United Kingdom). Experiments related to intestinal analysis were funded by SNSF (grant no. 310030_170084).	Anagnostou K, 2014, LANCET, V383, P1297, DOI 10.1016/S0140-6736(13)62301-6; Bachmann MF, 2017, ALLERGY, V72, P13, DOI 10.1111/all.12890; Bublin M, 2013, J ALLERGY CLIN IMMUN, V132, P118, DOI 10.1016/j.jaci.2013.01.022; Burks AW, 2015, J ALLERGY CLIN IMMUN, V135, P1240, DOI 10.1016/j.jaci.2014.12.1917; Cummings AJ, 2010, ALLERGY, V65, P933, DOI 10.1111/j.1398-9995.2010.02342.x; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Durham SR, 2012, J ALLERGY CLIN IMMUN, V129, P717, DOI 10.1016/j.jaci.2011.12.973; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Eckl-Dorna J, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03131; Engeroff P, 2018, ALLERGY, V73, P341, DOI 10.1111/all.13268; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Koppelman SJ, 2016, FOOD CHEM TOXICOL, V91, P82, DOI 10.1016/j.fct.2016.02.016; Lanser BJ, 2015, PEDIATR CLIN N AM, V62, P1531, DOI 10.1016/j.pcl.2015.07.015; Levy AM, 2001, AM J GASTROENTEROL, V96, P1522; Liu Y, 2013, J ALLERGY CLIN IMMUN, V131; Malbec O, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aag1401; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Mueller GA, 2014, CURR ALLERGY ASTHM R, V14, DOI 10.1007/s11882-014-0429-5; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Nwaru BI, 2014, ALLERGY, V69, P62, DOI 10.1111/all.12305; O'Konek JJ, 2018, J ALLERGY CLIN IMMUN, V141, P2121, DOI 10.1016/j.jaci.2018.01.042; Orengo JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03636-8; Pali-Scholl I, 2016, CURR OPIN IMMUNOL, V42, P113, DOI 10.1016/j.coi.2016.08.004; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Sampson HA, 2015, J ALLERGY CLIN IMMUN, V135, pAB390, DOI 10.1016/j.jaci.2014.12.1901; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Schmitz N, 2009, J EXP MED, V206, P1941, DOI 10.1084/jem.20090199; Smit JJ, 2015, CLIN TRANSL ALLERGY, V5, DOI 10.1186/s13601-015-0056-9; Stassen M, 2000, J IMMUNOL, V164, P5549, DOI 10.4049/jimmunol.164.11.5549; Tran MM, 2017, PEDIAT ALLERG IMM-UK, V28, P471, DOI 10.1111/pai.12739; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Vickery BP, 2018, NEW ENGL J MED, V379, P1991, DOI 10.1056/NEJMoa1812856; Vickery BP, 2013, J ALLERGY CLIN IMMUN, V131, P128, DOI 10.1016/j.jaci.2012.10.048; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Winther L, 2006, CLIN EXP ALLERGY, V36, P254, DOI 10.1111/j.1365-2222.2006.02340.x; Wood RA, 2016, J ALLERGY CLIN IMMUN, V137, P973, DOI 10.1016/j.jaci.2016.01.001; Zellweger F, 2017, ALLERGY, V72, P1174, DOI 10.1111/all.13109; Zeltins A, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0030-8; Zha LS, 2018, J ALLERGY CLIN IMMUN, V142, P1529, DOI 10.1016/j.jaci.2017.09.054	40	40	40	3	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1240	+		10.1016/j.jaci.2019.12.007	http://dx.doi.org/10.1016/j.jaci.2019.12.007			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	31866435	Green Accepted, hybrid, Green Published			2022-12-18	WOS:000523633400020
J	Dumas, O; Hasegawa, K; Mansbach, JM; Sullivan, AF; Piedra, PA; Camargo, CA				Dumas, Orianne; Hasegawa, Kohei; Mansbach, Jonathan M.; Sullivan, Ashley F.; Piedra, Pedro A.; Camargo, Carlos A., Jr.			Severe bronchiolitis profiles and risk of recurrent wheeze by age 3 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Respiratory tract infections; cluster analysis; respiratory syncytial virus; rhinovirus; asthma	RESPIRATORY SYNCYTIAL VIRUS; BACTERIAL-COLONIZATION; ATOPY PHENOTYPES; VIRAL-INFECTIONS; LUNG-FUNCTION; EARLY-LIFE; ASTHMA; CHILDHOOD; ASSOCIATION; MANAGEMENT	Background: A better understanding of bronchiolitis heterogeneity might help clarify its relationship with the development of recurrent wheezing and asthma. Objectives: We sought to identify severe bronchiolitis profiles using a clustering approach and to investigate for the first time their association with allergy/inflammatory biomarkers, nasopharyngeal microbiota, and development of recurrent wheezing by age 3 years. Methods: We analyzed data from a prospective, 17-center US cohort study of 921 infants (age < 1 year) hospitalized with bronchiolitis (2011-2014 winters) with posthospitalization follow-up. Severe bronchiolitis profiles at baseline (hospitalization) were determined by using latent class analysis based on clinical factors and viral etiology. Blood biomarkers and nasopharyngeal microbiota profiles were determined by using samples collected within 24 hours of hospitalization. Recurrent wheezing by age 3 years was defined based on parental report of breathing problem episodes after discharge. Results: Three severe bronchiolitis profiles were identified: profile A (15%), which was characterized by a history of breathing problems/eczema during infancy and non-respiratory syncytial virus (mostly rhinovirus) infection; profile B (49%), which has the largest probability of respiratory syncytial virus infection and resembled classic respiratory syncytial virus-induced bronchiolitis; and profile C (36%), which was composed of the most severely ill group. Profile A infants had higher eosinophil counts, higher cathelicidin levels, and increased proportions of Haemophilus-dominant or Moraxella-dominant microbiota profiles. Compared with profile B, we observed significantly increased risk of recurrent wheezing in children with profile A (hazard ratio, 2.64; 95% CI, 1.90-3.68) and, to a lesser extent, with profile C (hazard ratio, 1.51; 95% CI, 1.14-2.01). Conclusion: Although longer follow-up is needed, our results might help identify, among children hospitalized for bronchiolitis, subgroups with particularly increased risk of asthma.	[Dumas, Orianne] INSERM, U1168, VIMA Aging & Chron Dis Epidemiol & Publ Hlth Appr, F-94807 Villejuif, France; [Dumas, Orianne] Univ Versailles St Quentin En Yvelines, UMR S 1168, F-78180 Montigny El Bretonneux, France; [Hasegawa, Kohei; Sullivan, Ashley F.; Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Mansbach, Jonathan M.] Harvard Med Sch, Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol, Houston, TX 77030 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Microbiol & Pediat, Houston, TX 77030 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine	Dumas, O (corresponding author), INSERM, UMRS 1168, VIMA Aging & Chron Dis Epidemiol & Publ Hlth Appr, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	orianne.dumas@inserm.fr	Dumas, Orianne/R-8636-2016; Camargo, Carlos A./C-2145-2008	Dumas, Orianne/0000-0001-8423-2826; Camargo, Carlos A./0000-0002-5071-7654	National Institutes of Health [U01 AI-087881, R01 AI-114552, R01 AI-108588, R21 HL-129909, UG3 OD-023253, R01 AI-127507]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL129909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI114552, R01AI127507, R01AI108588, U01AI087881] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [UG3OD023253] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by National Institutes of Health grants U01 AI-087881, R01 AI-114552, R01 AI-108588, R21 HL-129909, UG3 OD-023253, and R01 AI-127507. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P91, DOI 10.1016/j.jaci.2012.02.010; Backman K, 2015, PEDIAT ALLERG IMM-UK, V26, P668, DOI 10.1111/pai.12448; Belgrave DCM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001748; Bergroth E, 2015, PEDIATR INFECT DIS J, V35, P1; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024; Burbank AJ, 2017, CURR OPIN ALLERGY CL, V17, P146, DOI 10.1097/ACI.0000000000000341; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Cangiano G, 2016, PEDIATR PULM, V51, P1330, DOI 10.1002/ppul.23476; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Depner M, 2017, J ALLERGY CLIN IMMUN, V139, P826, DOI 10.1016/j.jaci.2016.05.050; Ducharme FM, 2014, LANCET, V383, P1593, DOI 10.1016/S0140-6736(14)60615-2; Dumas O, 2016, THORAX, V71, P712, DOI 10.1136/thoraxjnl-2016-208535; Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Feldman AS, 2015, AM J RESP CRIT CARE, V191, P34, DOI 10.1164/rccm.201405-0901PP; Florin TA, 2017, LANCET, V389, P211, DOI 10.1016/S0140-6736(16)30951-5; Genuneit J, 2013, J ALLERGY CLIN IMMUN, V132, P1237, DOI 10.1016/j.jaci.2013.06.044; Gern JE, 2016, AM J RESP CRIT CARE, V194, P1044, DOI 10.1164/rccm.201605-1018ED; Hasegawa K, 2017, J ALLERGY CLIN IMMUN, V139, P1383, DOI 10.1016/j.jaci.2016.09.037; Hasegawa K, 2016, EUR RESPIR J, V48, P1329, DOI 10.1183/13993003.00152-2016; Hasegawa K, 2016, EXPERT REV RESP MED, V10, P891, DOI 10.1080/17476348.2016.1190647; Hasegawa K, 2013, PEDIATRICS, V132, P28, DOI 10.1542/peds.2012-3877; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Herr M, 2012, J ALLERGY CLIN IMMUN, V130, P389, DOI 10.1016/j.jaci.2012.05.054; Hose AJ, 2017, J ALLERGY CLIN IMMUN, V139, P1935, DOI 10.1016/j.jaci.2016.08.046; Jackson DJ, 2017, J ALLERGY CLIN IMMUN, V139, P379, DOI 10.1016/j.jaci.2016.12.941; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jartti T, 2017, J ALLERGY CLIN IMMUN, V140, P895, DOI 10.1016/j.jaci.2017.08.003; Karakoc F, 2002, CLIN EXP ALLERGY, V32, P51, DOI 10.1046/j.0022-0477.2001.01273.x; Lazic N, 2013, ALLERGY, V68, P764, DOI 10.1111/all.12134; Mansbach JM, 2017, CLIN INFECT DIS, V65, P967, DOI 10.1093/cid/cix483; Mansbach JM, 2016, J ALLERGY CLIN IMMUN, V137, P1909, DOI 10.1016/j.jaci.2016.01.036; Mansbach JM, 2016, J PEDIATR-US, V172, P202, DOI 10.1016/j.jpeds.2016.01.041; Mansbach JM, 2012, J ALLERGY CLIN IMMUN, V130, P1007, DOI 10.1016/j.jaci.2012.07.044; Mansbach JM, 2012, ARCH PEDIAT ADOL MED, V166, P700, DOI 10.1001/archpediatrics.2011.1669; Midulla F, 2014, ACTA PAEDIATR, V103, P1094, DOI 10.1111/apa.12720; Mikalsen IB, 2014, ACTA PAEDIATR, V103, P86, DOI 10.1111/apa.12432; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Piters WAAD, 2016, AM J RESP CRIT CARE, V194, P1104, DOI 10.1164/rccm.201602-0220OC; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Rubner FJ, 2016, J ALLERGY CLIN IMMUN, V139, P1; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schoos AMM, 2016, J ALLERGY CLIN IMMUN, V137, P844, DOI 10.1016/j.jaci.2015.10.004; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Szefler S, 2012, J ALLERGY CLIN IMMUN, V129, P1; Telcian AG, 2017, ANTIVIR RES, V137, P93, DOI 10.1016/j.antiviral.2016.11.004; Turunen R, 2014, PEDIAT ALLERG IMM-UK, V25, P796, DOI 10.1111/pai.12318; Vandamme D, 2012, CELL IMMUNOL, V280, P22, DOI 10.1016/j.cellimm.2012.11.009; Vissing NH, 2013, AM J RESP CRIT CARE, V188, P1246, DOI 10.1164/rccm.201302-0215OC; Yoo JK, 2013, J ALLERGY CLIN IMMUN, V132, P1263, DOI 10.1016/j.jaci.2013.06.006	52	40	42	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1371	+		10.1016/j.jaci.2018.08.043	http://dx.doi.org/10.1016/j.jaci.2018.08.043			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30240701	Green Accepted, Green Published, Bronze			2022-12-18	WOS:000463348900014
J	Serezal, IG; Hoffer, E; Ignatov, B; Martini, E; Zitti, B; Ehrstrom, M; Eidsmo, L				Serezal, Irene Gallais; Hoffer, Elena; Ignatov, Borislav; Martini, Elisa; Zitti, Beatrice; Ehrstrom, Marcus; Eidsmo, Liv			A skewed pool of resident T cells triggers psoriasis-associated tissue responses in never-lesional skin from patients with psoriasis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Skin; psoriasis; resident T cells; chemokine; CCL20; IFN-alpha; CCR6	INDUCED PROTEIN IP-10; GENE-EXPRESSION; CHEMOKINE PRODUCTION; GAMMA; INNATE; KERATINOCYTES; INJECTION; DEFENSINS; BIOMARKER; IMMUNITY	Background: Resident T cells are implicated in the maintenance and recurrence of psoriatic lesions. Whether skin that has not yet experienced psoriasis in patients with established disease harbors pathogenic T cells is less investigated. Objective: We sought to analyze the composition of resident T cells and T cell-driven tissue responses in skin never affected by psoriasis from patients with mild disease. Methods: Never-lesional skin from patients with psoriasis (NLP) was collected from those with mild disease. T-cell profiles were assessed by using confocal imaging and flow cytometry. Tissue responses to T-cell stimulation were measured by using multiplex and NanoString technology. Results: T-cell activation ex vivo triggered psoriasiform and type I interferon tissue responses in NLP psoriasis. Accordingly, keratinocytes from NLP responded to IFN-gamma stimulation with myxovirus 1 (MX1) expression and IFN-alpha release. Additionally, CCR6-expressing resident T cells poised to produce IFN-gamma and IL-17 were enriched in epidermis from NLP, whereas dermal tissue responses and T-cell compositions were similar to those in healthy skin. Finally, keratinocytes from NLP exposed to IL-17 and skin explants exposed to common fungal antigens responded with upregulation of the CCR6 ligand CCL20. Conclusion: Epidermal resident T cells capable of triggering psoriasiform tissue responses accumulate in epidermis from NLP. Our global analysis of NLP reveals that microbial interplay with genetically predisposed keratinocytes might shape the local pool of resident T cells.	[Serezal, Irene Gallais; Hoffer, Elena; Ignatov, Borislav; Martini, Elisa; Eidsmo, Liv] Karolinska Inst, Dept Med Solna, Stockholm, Sweden; [Serezal, Irene Gallais; Hoffer, Elena; Ignatov, Borislav; Martini, Elisa; Eidsmo, Liv] New Karolinska Hosp, Dermatol, Stockholm, Sweden; [Zitti, Beatrice] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Ctr Haematol & Regenerat Med, Stockholm, Sweden; [Ehrstrom, Marcus] Karolinska Univ Hosp Solna, Dept Reconstruct Plast Surg, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Eidsmo, L (corresponding author), Karolinska Inst, Dermatol & Venereol Unit, Dept Med, CMM L8 02, S-17177 Solna, Sweden.	liv.eidsmo@ki.se		Gallais Serezal, Irene/0000-0002-7301-9699	Swedish Research Council; Ragnar Soderbergs stiftelse; Psoriasisfonden; Gosta Karlssons stiftelse; Marcus and MarianneWallenbergs Stiftelse; Karolinska Institutet (KID); Societe Francaise de Dermatologie	Swedish Research Council(Swedish Research CouncilEuropean Commission); Ragnar Soderbergs stiftelse; Psoriasisfonden; Gosta Karlssons stiftelse; Marcus and MarianneWallenbergs Stiftelse; Karolinska Institutet (KID); Societe Francaise de Dermatologie	Supported by grants from the Swedish Research Council, Ragnar Soderbergs stiftelse, Psoriasisfonden and Gosta Karlssons stiftelse, and Marcus and MarianneWallenbergs Stiftelse. I. G. S. received funding from the Karolinska Institutet (KID funding) and the Societe Francaise de Dermatologie.	Abji F, 2016, ARTHRITIS RHEUMATOL, V68, P2911, DOI 10.1002/art.39800; BAKER BS, 1988, SCAND J IMMUNOL, V28, P735, DOI 10.1111/j.1365-3083.1988.tb01507.x; BAKER BS, 1986, LANCET, V2, P342; BATACSORGO Z, 1995, J CLIN INVEST, V95, P317, DOI 10.1172/JCI117659; Bond E, 2012, J INVEST DERMATOL, V132, P114, DOI 10.1038/jid.2011.246; Boyman O, 2004, J EXP MED, V199, P731, DOI 10.1084/jem.20031482; BRINKMANN V, 1993, J EXP MED, V178, P1655, DOI 10.1084/jem.178.5.1655; Cheuk S, 2017, EXP DERMATOL, V26, P824, DOI 10.1111/exd.13284; Cheuk S, 2017, IMMUNITY, V46, P287, DOI 10.1016/j.immuni.2017.01.009; Cheuk S, 2014, J IMMUNOL, V192, P3111, DOI 10.4049/jimmunol.1302313; Chiricozzia Suarez-Farinas M, 2015, BRIT J DERMATOL, V174, P136; Clark RA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010641; Di Meglio P, 2016, J ALLERGY CLIN IMMUN, V138, P274, DOI 10.1016/j.jaci.2015.10.046; FIERLBECK G, 1990, ARCH DERMATOL, V126, P351, DOI 10.1001/archderm.126.3.351; FUNK J, 1991, BRIT J DERMATOL, V125, P463, DOI 10.1111/j.1365-2133.1991.tb14774.x; Garzorz-Stark N, 2018, J ALLERGY CLIN IMMUN, V141, P1320, DOI 10.1016/j.jaci.2017.07.045; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Gottlieb AB, 2005, J IMMUNOL, V175, P2721, DOI 10.4049/jimmunol.175.4.2721; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; Gudjonsson JE, 2009, J INVEST DERMATOL, V129, P2795, DOI 10.1038/jid.2009.173; Haller O, 2015, TRENDS MICROBIOL, V23, P154, DOI 10.1016/j.tim.2014.12.003; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Hu D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01571-8; Jackson M, 1999, FASEB J, V13, P495, DOI 10.1096/fasebj.13.3.495; Jo JH, 2017, VIRULENCE, V8, P324, DOI 10.1080/21505594.2016.1249093; Jo JH, 2016, J INVEST DERMATOL, V136, P2356, DOI 10.1016/j.jid.2016.05.130; Johnson-Huang LM, 2012, J INVEST DERMATOL, V132, P1177, DOI 10.1038/jid.2011.458; Jordan CT, 2012, AM J HUM GENET, V90, P796, DOI 10.1016/j.ajhg.2012.03.013; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; Keijsers RRMC, 2013, BRIT J DERMATOL, V168, P1294, DOI 10.1111/bjd.12236; Kim TG, 2014, J INVEST DERMATOL, V134, P1462, DOI 10.1038/jid.2013.534; Kolbinger F, 2017, J ALLERGY CLIN IMMUN, V139, P923, DOI 10.1016/j.jaci.2016.06.038; Lee AYS, 2015, CYTOKINE, V72, P97, DOI 10.1016/j.cyto.2014.11.029; Machado LR, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00115; Maerki C, 2009, J IMMUNOL, V182, P507, DOI 10.4049/jimmunol.182.1.507; Matos TR, 2017, J CLIN INVEST, V127, P4031, DOI 10.1172/JCI93396; Nestle FO, 2005, J EXP MED, V202, P135, DOI 10.1084/jem.20050500; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Nickoloff BJ, 1999, AM J PATHOL, V155, P145, DOI 10.1016/S0002-9440(10)65109-7; Nograles KE, 2008, BRIT J DERMATOL, V159, P1092, DOI 10.1111/j.1365-2133.2008.08769.x; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; QUESADA JR, 1986, LANCET, V1, P1466; Schlums H, 2017, BLOOD, V129, P1927, DOI 10.1182/blood-2016-08-734236; Serezal IG, 2018, J INVEST DERMATOL, V138, P1754, DOI 10.1016/j.jid.2018.02.030; Sharma H, 2015, PLOS ONE, V10, P1; Suarez-Farinas M, 2011, J INVEST DERMATOL, V131, P391, DOI 10.1038/jid.2010.280; Swindell W. R., 2017, SCI REP-UK, V7, P1; Swindell WR, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-527; Takemoto A, 2014, J DERMATOL, V41, P1; WATANABE R, 2015, SCI TRANSL MED, V7; Wickham H, 2011, J STAT SOFTW, V40, P1, DOI 10.18637/jss.v040.i01; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yin XJ, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00112	53	40	41	2	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2019	143	4					1444	1454		10.1016/j.jaci.2018.08.048	http://dx.doi.org/10.1016/j.jaci.2018.08.048			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HR7QE	30268387	hybrid			2022-12-18	WOS:000463348900020
J	Moghaddas, F; Zeng, P; Zhang, YX; Schutzle, H; Brenner, S; Hofmann, SR; Berner, R; Zhao, YB; Lu, BT; Chen, XY; Zhang, L; Cheng, SY; Winkler, S; Lehmberg, K; Canna, SW; Czabotar, PE; Wicks, IP; De Nardo, D; Hedrich, CM; Zeng, HS; Masters, SL				Moghaddas, Fiona; Zeng, Ping; Zhang, Yuxia; Schuetzle, Heike; Brenner, Sebastian; Hofmann, Sigrun R.; Berner, Reinhard; Zhao, Yuanbo; Lu, Bingtai; Chen, Xiaoyun; Zhang, Li; Cheng, Suyun; Winkler, Stefan; Lehmberg, Kai; Canna, Scott W.; Czabotar, Peter E.; Wicks, Ian P.; De Nardo, Dominic; Hedrich, Christian M.; Zeng, Huasong; Masters, Seth L.			Autoinflammatory mutation in NLRC4 reveals a leucine-rich repeat (LRR)-LRR oligomerization interface	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autoinflammatory disease; periodic fever syndrome; NLRC4; macrophage activation syndrome; inflammasome; Nod-like receptor; IPAF; IL-18	INNATE IMMUNE DETECTION; SPHINGOMONAS-PAUCIMOBILIS; CASPASE-1 ACTIVATION; NLRP3 INFLAMMASOME; BACTERIAL LIGANDS; PROTEIN; RECRUITMENT; IPAF; ASC; IDENTIFICATION	Background: Monogenic autoinflammatory disorders are characterized by dysregulation of the innate immune system, for example by gain-of-function mutations in inflammasome-forming proteins, such as NOD-like receptor family CARD-containing 4 protein (NLRC4). Objective: Here we investigate the mechanism by which a novel mutation in the leucine-rich repeat (LRR) domain of NLRC4 (c.G1965C, p.W655C) contributes to autoinflammatory disease. Methods: We studied 2 unrelated patients with early-onset macrophage activation syndrome harboring the same de novo mutation in NLRC4. In vitro inflammasome complex formation was quantified by using flow cytometric analysis of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) specks. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 techniques and lentiviral transduction were used to generate THP-1 cells with either wild-type or mutant NLRC4 cDNA. Cell death and release of IL-1 beta/IL-18 were quantified by using flow cytometry and ELISA, respectively. Results: The p.W655C NLRC4 mutation caused increased ASC speck formation, caspase-1-dependent cell death, and IL-1 beta/IL-18 production. ASC contributed to p.W655C NLRC4-mediated cytokine release but not cell death. Mutation of p.W655 activated the NLRC4 inflammasome complex by engaging with 2 interfaces on the opposing LRR domain of the oligomer. One key set of residues (p.D1010, p.D1011, p.L1012, and p.I1015) participated in LRR-LRR oligomerization when triggered by mutant NLRC4 or type 3 secretion system effector (PrgI) stimulation of the NLRC4 inflammasome complex. Conclusion: This is the first report of a mutation in the LRR domain of NLRC4 causing autoinflammatory disease. c.G1965C/p. W655C NLRC4 increased inflammasome activation in vitro. Data generated from various NLRC4 mutations provides evidence that the LRR-LRR interface has an important and previously unrecognized role in oligomerization of the NLRC4 inflammasome complex.	[Moghaddas, Fiona; Wicks, Ian P.; De Nardo, Dominic; Masters, Seth L.] Walter & Eliza Hall Inst Med Res, Inflammat Div, Parkville, Vic, Australia; [Czabotar, Peter E.] Walter & Eliza Hall Inst Med Res, Struct Biol Div, Parkville, Vic, Australia; [Moghaddas, Fiona; Czabotar, Peter E.; Wicks, Ian P.; De Nardo, Dominic; Masters, Seth L.] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Zeng, Ping; Cheng, Suyun; Zeng, Huasong] Guangzhou Women & Childrens Med Ctr, Dept Rheumatol, Guangzhou, Guangdong, Peoples R China; [Zhang, Yuxia; Zhao, Yuanbo; Lu, Bingtai; Chen, Xiaoyun; Zhang, Li; Masters, Seth L.] Guangzhou Inst Paediat, Immunol Lab, Guangzhou, Guangdong, Peoples R China; [Schuetzle, Heike; Brenner, Sebastian; Hofmann, Sigrun R.; Berner, Reinhard; Winkler, Stefan; Hedrich, Christian M.] Tech Univ Dresden, Univ Hosp, Dept Pediat, Dresden, Germany; [Schuetzle, Heike; Brenner, Sebastian; Hofmann, Sigrun R.; Berner, Reinhard; Winkler, Stefan; Hedrich, Christian M.] Tech Univ Dresden, Fac Med Carl Gustav Carus, Dept Pediat, Dresden, Germany; [Zhao, Yuanbo] Guizhou Med Univ, Dept Biol Chem, Guiyang, Guizhou, Peoples R China; [Lehmberg, Kai] Univ Med Ctr Hamburg Eppendorf, Div Pediat Stem Cell Transplantat & Immunol, Hamburg, Germany; [Canna, Scott W.] UPMC, Childrens Hosp Pittsburgh, RK Mellon Inst, Pediat Rheumatol, Pittsburgh, PA USA; [Wicks, Ian P.] Royal Melbourne Hosp, Dept Rheumatol, Parkville, Vic, Australia; [Hedrich, Christian M.] Univ Liverpool, Dept Womens & Childrens Hlth, Inst Translat Med, Liverpool, Merseyside, England; [Hedrich, Christian M.] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Paediat Rheumatol, Liverpool, Merseyside, England	Walter & Eliza Hall Institute; Walter & Eliza Hall Institute; University of Melbourne; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Guizhou Medical University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Royal Melbourne Hospital; University of Liverpool; Alder Hey Children's NHS Foundation Trust	Masters, SL (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3052, Australia.	masters@wehi.edu.au	Berner, Reinhard/P-7351-2017; Masters, Seth L/N-2886-2013; Hedrich, Christian/AAD-6855-2019; Zeng, Huasong/GOV-4872-2022; Hedrich, Christian/AAW-3958-2020	Berner, Reinhard/0000-0002-6216-9173; Masters, Seth L/0000-0003-4763-576X; Czabotar, Peter/0000-0002-2594-496X; Moghaddas, Fiona/0000-0002-0406-6408; De Nardo, Dominic/0000-0002-7045-4695	Australian National Health and Medical Research Council Program (NHMRC) [1113577]; NHMRC [1099262, 1081299]; Viertel Fellowship; Howard Hughes Medical Institute; National Natural Science Foundation of China [31770978]; Children's Medical Centre Startup Fund [5001-3001032]; GlaxoSmithKline; intramural MeDDrive program of TU Dresden; Fritz-Thyssen Foundation; Paediatric Institute of Guangzu; Guangzhou Women and Children's Medical Centre project [0160001]; German Research Foundation [KF0249, HO4510/1-2]	Australian National Health and Medical Research Council Program (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Viertel Fellowship; Howard Hughes Medical Institute(Howard Hughes Medical Institute); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Children's Medical Centre Startup Fund; GlaxoSmithKline(GlaxoSmithKline); intramural MeDDrive program of TU Dresden; Fritz-Thyssen Foundation; Paediatric Institute of Guangzu; Guangzhou Women and Children's Medical Centre project; German Research Foundation(German Research Foundation (DFG))	Funding for this work was provided by a Australian National Health and Medical Research Council Program (NHMRC) project grant (1113577; to I.P.W.); NHMRC projects grants (1099262 and 1081299), a Viertel Fellowship, the Howard Hughes Medical Institute, and GlaxoSmithKline (to S.L.M.); the National Natural Science Foundation of China (31770978) and Children's Medical Centre Startup Fund (5001-3001032; to Y.Z.); the intramural MeDDrive program of TU Dresden and the Fritz-Thyssen Foundation (to C.M.H.); internal funding of the Paediatric Institute of Guangzu and a Guangzhou Women and Children's Medical Centre project grant (0160001; to P.Z.); and the German Research Foundation (KF0249, HO4510/1-2; to S.R.H.).	Abdelaziz DHA, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00018; Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Aubrey BJ, 2015, CELL REP, V10, P1422, DOI 10.1016/j.celrep.2015.02.002; Baker PJ, 2015, EUR J IMMUNOL, V45, P2918, DOI 10.1002/eji.201545655; Canna SW, 2017, J ALLERGY CLIN IMMUN, V139, P1698, DOI 10.1016/j.jaci.2016.10.022; Canna SW, 2014, NAT GENET, V46, P1140, DOI 10.1038/ng.3089; Case CL, 2009, INFECT IMMUN, V77, P1981, DOI 10.1128/IAI.01382-08; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Franchi L, 2007, EUR J IMMUNOL, V37, P3030, DOI 10.1002/eji.200737532; Gloria YC, 2018, METHODS MOL BIOL, V1714, P97, DOI 10.1007/978-1-4939-7519-8_7; Hsueh PR, 1998, CLIN INFECT DIS, V26, P676, DOI 10.1086/514595; Hu ZH, 2015, SCIENCE, V350, P399, DOI 10.1126/science.aac5489; Hu ZH, 2013, SCIENCE, V341, P172, DOI 10.1126/science.1236381; Kawasaki Y, 2017, ARTHRITIS RHEUMATOL, V69, P447, DOI 10.1002/art.39960; Kitamura A, 2014, J EXP MED, V211, P2385, DOI 10.1084/jem.20141091; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057; Li W, 2016, CELL MOL IMMUNOL, V13, P514, DOI 10.1038/cmi.2015.33; Liang JC, 2017, PEDIATR DEVEL PATHOL, V20, P498, DOI 10.1177/1093526616686890; Lugito NPH, 2016, CASE REP INFECT DIS, V2016, DOI 10.1155/2016/3294639; Man SM, 2014, P NATL ACAD SCI USA, V111, P7403, DOI 10.1073/pnas.1402911111; Man SM, 2013, J IMMUNOL, V191, P5239, DOI 10.4049/jimmunol.1301581; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Masters SL, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1471; Miao EA, 2010, P NATL ACAD SCI USA, V107, P3076, DOI 10.1073/pnas.0913087107; Moghaddas F, 2017, ANN RHEUM DIS, V76, P2085, DOI 10.1136/annrheumdis-2017-211473; Mutlu M, 2011, INDIAN PEDIATR, V48, P723, DOI 10.1007/s13312-011-0114-x; Novick D, 2017, J ALLERGY CLIN IMMUN, V140, P316, DOI 10.1016/j.jaci.2017.02.037; Qu Y, 2016, J EXP MED, V213, P877, DOI 10.1084/jem.20132234; Raghawan AK, 2017, J BIOL CHEM, V292, P1218, DOI 10.1074/jbc.M116.763979; Romberg N, 2014, NAT GENET, V46, P1135, DOI 10.1038/ng.3066; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Sester DP, 2015, J IMMUNOL, V194, P455, DOI 10.4049/jimmunol.1401110; Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111; Tanzer MC, 2017, CELL DEATH DIFFER, V24, P481, DOI 10.1038/cdd.2016.147; Tenthorey JL, 2017, SCIENCE, V358, P888, DOI 10.1126/science.aao1140; Tenthorey JL, 2014, MOL CELL, V54, P17, DOI 10.1016/j.molcel.2014.02.018; Volker-Touw CML, 2017, BRIT J DERMATOL, V176, P244, DOI 10.1111/bjd.14757; Yang JL, 2013, P NATL ACAD SCI USA, V110, P14408, DOI 10.1073/pnas.1306376110; Zhang LM, 2015, SCIENCE, V350, P404, DOI 10.1126/science.aac5789; Zhao Y, 2016, J EXP MED, V213, P647, DOI 10.1084/jem.20160006; Zhao Y, 2015, IMMUNOL REV, V265, P85, DOI 10.1111/imr.12293; Zhong FL, 2016, CELL, V167, P187, DOI 10.1016/j.cell.2016.09.001	43	40	41	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2018	142	6					1956	+		10.1016/j.jaci.2018.04.033	http://dx.doi.org/10.1016/j.jaci.2018.04.033			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HD2BJ	29778503	Green Published, hybrid			2022-12-18	WOS:000452315800028
J	Ta, LDH; Yap, GC; Tay, CJX; Lim, ASM; Huang, CH; Chu, CW; De Sessions, PF; Shek, LP; Goh, A; Van Bever, HPS; Teoh, OH; Soh, JY; Thomas, B; Ramamurthy, MB; Goh, DYT; Lay, C; Soh, SE; Chan, YH; Saw, SM; Kwek, K; Chong, YS; Godfrey, KM; Hibberd, ML; Lee, BW				Le Duc Huy Ta; Yap, Gaik Chin; Tay, Carina Jing Xuan; Lim, Alicia Shi Min; Huang, Chiung-Hui; Chu, Collins Wenhan; De Sessions, Paola Florez; Shek, Lynette P.; Goh, Anne; Van Bever, Hugo P. S.; Teoh, Oon Hoe; Soh, Jian Yi; Thomas, Biju; Ramamurthy, Mahesh Babu; Goh, Daniel Y. T.; Lay, Christophe; Soh, Shu-E; Chan, Yiong Huak; Saw, Seang-Mei; Kwek, Kenneth; Chong, Yap-Seng; Godfrey, Keith M.; Hibberd, Martin Lloyd; Lee, Bee Wah			Establishment of the nasal microbiota in the first 18 months of life: Correlation with early-onset rhinitis and wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis; wheeze; eczema; infant; cesarean section; nasal microbiota; 16S rRNA gene; Aerococcaceae; Corynebacteriaceae; Oxalobacteraceae; Staphylococcaceae; Moraxellaceae	RESPIRATORY SYNCYTIAL VIRUS; ALLOIOCOCCUS-OTITIDIS; SEX-DIFFERENCES; NASOPHARYNGEAL MICROBIOTA; BACTERIAL-COLONIZATION; ASTHMA; CHILDREN; ALLERGY; AIRWAY; RISK	Background: Dynamic establishment of the nasal microbiota in early life influences local mucosal immune responses and susceptibility to childhood respiratory disorders. Objective: The aim of this case-control study was to monitor, evaluate, and compare development of the nasal microbiota of infants with rhinitis and wheeze in the first 18 months of life with those of healthy control subjects. Methods: Anterior nasal swabs of 122 subjects belonging to the Growing Up in Singapore Towards Healthy Outcomes (GUSTO) birth cohort were collected longitudinally over 7 time points in the first 18 months of life. Nasal microbiota signatures were analyzed by using 16S rRNA multiplexed pair-end sequencing from 3 clinical groups: (1) patients with rhinitis alone (n = 28), (2) patients with rhinitis with concomitant wheeze (n = 34), and (3) healthy control subjects (n = 60). Results: Maturation of the nasal microbiome followed distinctive patterns in infants from both rhinitis groups compared with control subjects. Bacterial diversity increased over the period of 18 months of life in control infants, whereas infants with rhinitis showed a decreasing trend (P < .05). An increase in abundance of the Oxalobacteraceae family (Proteobacteria phylum) and Aerococcaceae family (Firmicutes phylum) was associated with rhinitis and concomitant wheeze (adjusted P < .01), whereas the Corynebacteriaceae family (Actinobacteria phylum) and early colonization with the Staphylococcaceae family (Firmicutes phylum; 3 weeks until 9 months) were associated with control subjects (adjusted P < .05). The only difference between the rhinitis and control groups was a reduced abundance of the Corynebacteriaceae family (adjusted P < .05). Determinants of nasal microbiota succession included sex, mode of delivery, presence of siblings, and infant care attendance. Conclusion: Our results support the hypothesis that the nasal microbiome is involved in development of early-onset rhinitis and wheeze in infants.	[Le Duc Huy Ta; Yap, Gaik Chin; Tay, Carina Jing Xuan; Lim, Alicia Shi Min; Huang, Chiung-Hui; Shek, Lynette P.; Van Bever, Hugo P. S.; Soh, Jian Yi; Ramamurthy, Mahesh Babu; Goh, Daniel Y. T.; Lay, Christophe; Soh, Shu-E; Lee, Bee Wah] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Paediat, Singapore, Singapore; [Chan, Yiong Huak] Natl Univ Singapore, Yong Loo Lin Sch Med, Biostat Unit, Singapore, Singapore; [Saw, Seang-Mei] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Chong, Yap-Seng] Natl Univ Singapore, Dept Obstet & Gynaecol, Singapore, Singapore; [Chu, Collins Wenhan; De Sessions, Paola Florez; Hibberd, Martin Lloyd] Agcy Sci Technol & Res Singapore, Genome Inst Singapore, Singapore, Singapore; [Shek, Lynette P.; Van Bever, Hugo P. S.; Soh, Jian Yi; Ramamurthy, Mahesh Babu; Goh, Daniel Y. T.] Natl Univ Hlth Syst, Khoo Teck Puat Natl Univ Childrens Med Inst, Singapore, Singapore; [Goh, Anne; Teoh, Oon Hoe; Thomas, Biju] KK Womens & Childrens Hosp, Dept Paediat, Singapore, Singapore; [Kwek, Kenneth] KK Womens & Childrens Hosp, Dept Maternal Fetal Med, Singapore, Singapore; [Lay, Christophe] Danone Nutricia Res, Singapore, Singapore; [Chong, Yap-Seng] Agcy Sci Technol & Res Singapore, Singapore Inst Clin Sci, Singapore, Singapore; [Godfrey, Keith M.] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England; [Godfrey, Keith M.] Univ Southampton, NIHR Southampton Biomed Res Ctr, Southampton, Hants, England; [Godfrey, Keith M.] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; KK Women's & Children's Hospital; KK Women's & Children's Hospital; Danone Nutricia; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS); University of Southampton; University of Southampton; University of Southampton; University Hospital Southampton NHS Foundation Trust	Lee, BW (corresponding author), Natl Univ Singapore, Dept Paediat, Tahir Fdn Bldg MD1,Level 15,12 Sci Dr 2, Singapore 117549, Singapore.	paeleebw@nus.edu.sg		Hibberd, Martin/0000-0001-8587-1849; Ta, Le Duc Huy/0000-0001-8579-0125; Chong, Yap Seng/0000-0002-7232-8473; SOH, SHU E/0000-0002-0790-4200; Godfrey, Keith/0000-0002-4643-0618; Shek, Lynette/0000-0001-9064-8983	Singapore National Research Foundation under its Translational and Clinical Research (TCR) Flagship Programme; Singapore Ministry of Health's National Medical Research Council (NMRC) [NMRC/TCR/004-NUS/2008, NMRC/CSA/022/2010, NMRC/CIRG/1344/2012]; NRF CREATE Programme [NRF370062-HUJ-NUS-PROJECT 10]; NUHS cross-department; National Institute for Health Research through the NIHR Southampton Biomedical Research Centre; British Heart Foundation [RG/15/17/31749] Funding Source: researchfish; Medical Research Council [MC_UP_A620_1017, MC_UU_12011/4] Funding Source: researchfish; National Institute for Health Research [NF-SI-0515-10042] Funding Source: researchfish; MRC [MC_UU_12011/4, MC_UP_A620_1017] Funding Source: UKRI	Singapore National Research Foundation under its Translational and Clinical Research (TCR) Flagship Programme; Singapore Ministry of Health's National Medical Research Council (NMRC); NRF CREATE Programme; NUHS cross-department; National Institute for Health Research through the NIHR Southampton Biomedical Research Centre; British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Singapore National Research Foundation under its Translational and Clinical Research (TCR) Flagship Programme and administered by the Singapore Ministry of Health's National Medical Research Council (NMRC), Singapore-NMRC/TCR/004-NUS/2008, NMRC/CSA/022/2010, and NMRC/CIRG/1344/2012. Additional funding is provided by the NRF CREATE Programme (NRF370062-HUJ-NUS-PROJECT 10) and NUHS cross-department grant 2011. K.M.G. is supported by the National Institute for Health Research through the NIHR Southampton Biomedical Research Centre.	Akmatov MK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01212-6; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Becklake MR, 1999, THORAX, V54, P1119, DOI 10.1136/thx.54.12.1119; Beigelman A, 2016, CURR OPIN ALLERGY CL, V16, P172, DOI 10.1097/ACI.0000000000000244; Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P1283, DOI 10.1164/rccm.201407-1240OC; Biesbroek G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032942; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bogaert D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017035; Bomar L, 2016, MBIO, V7, DOI 10.1128/mBio.01725-15; Bosch AATM, 2017, AM J RESP CRIT CARE, V196, P1582, DOI 10.1164/rccm.201703-0554OC; Chiu CY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02067-7; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; del Rosal T, 2016, ALLERGOL IMMUNOPATH, V44, P410, DOI 10.1016/j.aller.2015.07.004; DOERSHUK CF, 1974, AM REV RESPIR DIS, V109, P452; Durmaz R, 2002, MICROBIOLOGICA, V25, P265; Faust Karoline, 2016, F1000Res, V5, P1519; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; FLEISHER B, 1985, OBSTET GYNECOL, V66, P327; Grabenhenrich LB, 2015, J ALLERGY CLIN IMMUN, V136, P932, DOI 10.1016/j.jaci.2015.03.040; Han S, 2015, ANN AM THORAC SOC, V12, P765, DOI 10.1513/AnnalsATS.201411-507FR; Hannigan GD, 2015, MBIO, V6, DOI 10.1128/mBio.01578-15; Hardjojo A, 2015, PEDIAT ALLERG IMM-UK, V26, P25, DOI 10.1111/pai.12330; Harimaya A, 2005, FEMS IMMUNOL MED MIC, V43, P385, DOI 10.1016/j.femsim.2004.10.014; Harimaya A, 2007, FEMS IMMUNOL MED MIC, V49, P41, DOI 10.1111/j.1574-695X.2006.00166.x; Harimaya A, 2006, INT J PEDIATR OTORHI, V70, P1009, DOI 10.1016/j.ijporl.2005.10.012; Hasegawa K, 2017, PEDIATR INT, V59, P473, DOI 10.1111/ped.13168; Hilty M, 2012, J INFECT DIS, V205, P1048, DOI 10.1093/infdis/jis024; Hohlfeld JM, 2001, RESPIR RES, V3, DOI 10.1186/rr176; Hyde ER, 2014, J ALLERGY CLIN IMMUN, V133, P1220, DOI 10.1016/j.jaci.2013.10.049; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Kurukulaaratchy RJ, 2011, CLIN EXP ALLERGY, V41, P851, DOI 10.1111/j.1365-2222.2011.03765.x; Lee JH, 2016, ALLERGY ASTHMA IMMUN, V8, P181, DOI 10.4168/aair.2016.8.3.181; Lemon KP, 2010, MBIO, V1, DOI 10.1128/mBio.00129-10; Lu S, 2016, PEDIATR PULM, V51, P1382, DOI 10.1002/ppul.23461; Lukkarinen M, 2017, J ALLERGY CLIN IMMUN, V140, P988, DOI 10.1016/j.jaci.2016.12.991; Lynch JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00156; Mansbach JM, 2016, J ALLERGY CLIN IMMUN, V137, P1909, DOI 10.1016/j.jaci.2016.01.036; Miller CS, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-r44; Muenchhoff M, 2014, J INFECT DIS, V209, pS120, DOI 10.1093/infdis/jiu232; NIELSEN HC, 1992, P SOC EXP BIOL MED, V199, P446; NIELSEN HC, 1985, J CLIN INVEST, V76, P177, DOI 10.1172/JCI111943; Nkadi PO, 2009, MOL GENET METAB, V97, P95, DOI 10.1016/j.ymgme.2009.01.015; Ong SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060811; Pettigrew MM, 2012, APPL ENVIRON MICROB, V78, P6262, DOI 10.1128/AEM.01051-12; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sakwinska O, 2014, J CLIN MICROBIOL, V52, P1590, DOI 10.1128/JCM.03280-13; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Soh SE, 2014, INT J EPIDEMIOL, V43, P1401, DOI 10.1093/ije/dyt125; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Sun HQ, 2016, BRAZ J INFECT DIS, V20, P179, DOI 10.1016/j.bjid.2015.12.005; Tan TN, 2006, ASIAN PAC J ALLERGY, V24, P175; Tan TN, 2005, PEDIAT ALLERG IMM-UK, V16, P151, DOI 10.1111/j.1399-3038.2005.00242.x; Tano K, 2008, APMIS, V116, P785, DOI 10.1111/j.1600-0463.2008.01003.x; Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008; Vissing NH, 2013, AM J RESP CRIT CARE, V188, P1246, DOI 10.1164/rccm.201302-0215OC; Yi FC, 1999, ASIAN PAC J ALLERGY, V17, P189	57	40	40	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					86	95		10.1016/j.jaci.2018.01.032	http://dx.doi.org/10.1016/j.jaci.2018.01.032			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29452199	Green Accepted, Bronze			2022-12-18	WOS:000437837500013
J	McCleary, N; Nwaru, BI; Nurmatov, UB; Critchley, H; Sheikh, A				McCleary, Nicola; Nwaru, Bright I.; Nurmatov, Ulugbek B.; Critchley, Hilary; Sheikh, Aziz			Endogenous and exogenous sex steroid hormones in asthma and allergy in females: A systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							BODY-MASS INDEX; ADULT-ONSET ASTHMA; REPLACEMENT THERAPY; EARLY MENARCHE; LUNG-FUNCTION; PULMONARY-FUNCTION; BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY SYMPTOMS; PERIMENOPAUSAL WOMEN; REPRODUCTIVE HISTORY		[McCleary, Nicola; Nwaru, Bright I.; Nurmatov, Ulugbek B.; Sheikh, Aziz] Univ Edinburgh, Asthma UK Ctr Appl Res, Ctr Med Informat, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [McCleary, Nicola] Ottawa Hosp, Clin Epidemiol Program, Res Inst, Ottawa, ON, Canada; [Nwaru, Bright I.] Univ Gothenburg, Inst Med, Krefting Res Ctr, Gothenburg, Sweden; [Nwaru, Bright I.] Univ Gothenburg, Inst Med, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden; [Nurmatov, Ulugbek B.] Cardiff Univ, Div Populat Med, Sch Med, Cardiff, S Glam, Wales; [Critchley, Hilary] Univ Edinburgh, Queens Med Res Inst, Med Res Council, Ctr Reprod Hlth, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Ottawa; Ottawa Hospital Research Institute; University of Gothenburg; University of Gothenburg; Cardiff University; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Edinburgh	McCleary, N (corresponding author), Univ Edinburgh, Asthma UK Ctr Appl Res, Ctr Med Informat, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland.; McCleary, N (corresponding author), Ottawa Hosp, Clin Epidemiol Program, Res Inst, Ottawa, ON, Canada.	nmccleary@ohri.ca	CRITCHLEY, HILARY OD/C-7575-2013	McCleary, Nicola/0000-0002-4394-703X; Sheikh, Aziz/0000-0001-7022-3056	Chief Scientist Office, Scotland [CZH/4/1083]; Asthma UK Centre for Applied Research; Farr Institute; Knut and Alice Wallenberg Foundation; Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg; Medical Research Council [MR/M501633/2, G1000758, G1000758B, MR/K007017/1, MC_PC_13040, MR/M501633/1] Funding Source: researchfish; Asthma UK [AUK-IG-2016-346, MRC-AsthmaUKCentre, AUK-AC-2012-01, MRC-Asthma UK Centre] Funding Source: researchfish; Chief Scientist Office [CZH/4/1083] Funding Source: researchfish; MRC [MR/K007017/1, MR/M501633/2] Funding Source: UKRI	Chief Scientist Office, Scotland; Asthma UK Centre for Applied Research; Farr Institute; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK; Chief Scientist Office; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Chief Scientist Office, Scotland (grant no. CZH/4/1083). A.S. is also supported by the Asthma UK Centre for Applied Research and the Farr Institute. The funder had no role in the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the article for publication. B.I.N. acknowledges the support of Knut and Alice Wallenberg Foundation and the Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg.	Al-Sahab B, 2011, AM J EPIDEMIOL, V173, P64, DOI 10.1093/aje/kwq324; Baibergenova A, 2006, ANN ALLERG ASTHMA IM, V96, P666, DOI 10.1016/S1081-1206(10)61063-0; Balzano G, 2007, Monaldi Arch Chest Dis, V67, P135; Barbaro MPF, 2010, ALLERGY, V65, P1306, DOI 10.1111/j.1398-9995.2009.02314.x; Barr RG, 2004, ARCH INTERN MED, V164, P379, DOI 10.1001/archinte.164.4.379; Bjornerem A, 2004, J CLIN ENDOCR METAB, V89, P6039, DOI 10.1210/jc.2004-0735; Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V135, P813, DOI 10.1016/j.jaci.2014.11.019; Burgess JA, 2007, EUR RESPIR J, V29, P668, DOI 10.1183/09031936.00080906; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Carlson CL, 2001, AM J RESP CRIT CARE, V163, P423, DOI 10.1164/ajrccm.163.2.2003040; Cevrioglu AS, 2004, MATURITAS, V49, P221, DOI 10.1016/j.maturitas.2004.01.009; Day FR, 2015, SCI REP-UK, V5, DOI 10.1038/srep11208; Dratva J, 2010, J ALLERGY CLIN IMMUN, V125, P823, DOI 10.1016/j.jaci.2009.12.938; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Erkocoglu M, 2013, ALLERGOL IMMUNOPATH, V41, P169, DOI 10.1016/j.aller.2012.03.003; Ernst P, 2002, EUR RESPIR J, V20, P635, DOI 10.1183/09031936.02.00962002; Fida N, 2012, AM J EPIDEMIOL, V175, pS136; Forbes L, 1999, EUR RESPIR J, V14, P1028, DOI 10.1183/09031936.99.14510289; Fu Liang, 2014, Ann Am Thorac Soc, V11, P939, DOI 10.1513/AnnalsATS.201402-084OC; Galobardes B, 2012, AM J EPIDEMIOL, V176, P733, DOI 10.1093/aje/kws161; Gnatiuc L, 2013, J ASTHMA, V50, P751, DOI 10.3109/02770903.2013.799686; Grantham JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099776; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Herrera-Trujillo M, 2005, J ASTHMA, V42, P705, DOI 10.1080/02770900500265306; Hong CC, 2014, PEDIAT ALLERG IMM-UK, V25, P773, DOI 10.1111/pai.12307; Jarvis D, 2008, ALLERGY, V63, P95, DOI 10.1111/j.1398-9995.2007.01530.x; Jenkins MA, 2006, CLIN EXP ALLERGY, V36, P609, DOI 10.1111/j.1365-2222.2006.02475.x; Jeon YH, 2009, J KOREAN MED SCI, V24, P20, DOI 10.3346/jkms.2009.24.1.20; Khatibi A, 2004, MATURITAS, V48, P438, DOI 10.1016/j.maturitas.2003.10.001; Khatibi A, 2009, MENOPAUSE, V16, P315, DOI 10.1097/gme.0b013e31818c0456; Koksal Nurhan, 2004, Tuberk Toraks, V52, P237; Kos-Kudla B, 2001, GYNECOL ENDOCRINOL, V15, P304, DOI 10.1080/713602889; Kumar Pradeep, 2011, Indian J Med Sci, V65, P64; Kynyk JA, 2011, CURR OPIN PULM MED, V17, P6, DOI 10.1097/MCP.0b013e3283410038; Lange P, 2001, THORAX, V56, P613, DOI 10.1136/thorax.56.8.613; Lieberoth S, 2015, RESP MED, V109, P565, DOI 10.1016/j.rmed.2015.03.007; Lieberoth S, 2014, J ASTHMA, V51, P559, DOI 10.3109/02770903.2014.903966; Macsali F, 2011, AM J RESP CRIT CARE, V183, P8, DOI 10.1164/rccm.200912-1886OC; Macsali F, 2009, J ALLERGY CLIN IMMUN, V123, P391, DOI 10.1016/j.jaci.2008.10.041; Mandhane PJ, 2009, CHEST, V136, P1301, DOI 10.1378/chest.09-0604; MANTEL N, 1959, J NATL CANCER I, V22, P719; Marin-Martinez F, 2010, EDUC PSYCHOL MEAS, V70, P56, DOI 10.1177/0013164409344534; Matheson M.C., 2015, ERJ OPEN RES, V1, P00026, DOI 10.1183/23120541.00026-2015; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Mueller JE, 2003, RESP MED, V97, P990, DOI 10.1016/S0954-6111(03)00128-8; Munro MG, 2011, INT J GYNECOL OBSTET, V113, P3, DOI 10.1016/j.ijgo.2010.11.011; Murphy VE, 2008, J ASTHMA, V45, P696, DOI 10.1080/02770900802207279; Nicolai T, 2001, PEDIATR ALLERGY IMMU, V12, P142, DOI 10.1034/j.1399-3038.2001.0007.x; Nwaru BI, 2016, NPJ PRIM CARE RESP M, V26, DOI 10.1038/npjpcrm.2015.78; Nwaru BI, 2015, J ROY SOC MED, V108, P358, DOI 10.1177/0141076815588320; Paleev N P, 1999, Klin Med (Mosk), V77, P17; Paleev N. R., 2002, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk, P16; Pamukcu A, 2013, TURK THORAC J, V14, P24, DOI 10.5152/ttd.2013.05; Pata O, 2003, MATURITAS, V46, P213, DOI 10.1016/S0378-5122(03)00191-9; Protudjer JLP, 2015, TWIN RES HUM GENET, V18, P142, DOI 10.1017/thg.2015.11; Protudjer JLP, 2014, ANN ALLERG ASTHMA IM, V112, P78, DOI 10.1016/j.anai.2013.10.015; Real FG, 2006, THORAX, V61, P34, DOI 10.1136/thx.2005.040881; Real FG, 2008, J ALLERGY CLIN IMMUN, V121, P72, DOI 10.1016/j.jaci.2007.08.057; Real FG, 2007, J ALLERGY CLIN IMMUN, V120, P557, DOI 10.1016/j.jaci.2007.04.041; Resmi S. S., 2002, Indian Journal of Physiology and Pharmacology, V46, P361; Romieu I, 2010, THORAX, V65, P292, DOI 10.1136/thx.2009.116079; Salam MT, 2006, J ALLERGY CLIN IMMUN, V117, P1001, DOI 10.1016/j.jaci.2006.02.004; Scott HA, 2016, ALLERGY, V71, P1037, DOI 10.1111/all.12891; Sim J, 2005, PHYS THER, V85, P257; Siroux V, 2004, J ALLERGY CLIN IMMUN, V114, P491, DOI 10.1016/j.jaci.2004.05.027; Songur N, 2010, J WOMENS HEALTH, V19, P1145, DOI 10.1089/jwh.2009.1715; Stipic I, 2012, REJUV RES, V15, P596, DOI 10.1089/rej.2012.1337; Svanes C, 2005, THORAX, V60, P445, DOI 10.1136/thx.2004.032615; Tansavatdi K, 2004, Minerva Ginecol, V56, P105; The Cochrane Collaboration, 2011, COCHRANE HDB SYSTEMA; Trabelsi Y, 2007, ANN HUM BIOL, V34, P195, DOI 10.1080/03014460601116779; Trabelsi Y, 2010, ARCH PEDIATRIE, V17, P243, DOI 10.1016/j.arcped.2009.11.025; Triebner K, 2016, J ALLERGY CLIN IMMUN, V137, P50, DOI 10.1016/j.jaci.2015.08.019; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Vink NM, 2010, J ALLERGY CLIN IMMUN, V126, P498, DOI 10.1016/j.jaci.2010.06.018; Viswanathan M, 2012, J CLIN EPIDEMIOL, V65, P163, DOI 10.1016/j.jclinepi.2011.05.008; Wei JX, 2015, ANN ALLERG ASTHMA IM, V115, P21, DOI 10.1016/j.anai.2015.04.019; Westergaard T, 2003, CLIN EXP ALLERGY, V33, P301, DOI 10.1046/j.1365-2222.2003.01441.x; Zemp E, 2012, MATURITAS, V73, P212, DOI 10.1016/j.maturitas.2012.08.010	80	40	40	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2018	141	4					1510	+		10.1016/j.jaci.2017.11.034	http://dx.doi.org/10.1016/j.jaci.2017.11.034			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GB6QV	29305316	Green Accepted, hybrid, Green Published			2022-12-18	WOS:000429197800044
J	Bonilla, FA				Bonilla, Francisco A.			Update: Vaccines in primary immunodeficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunology; primary immunodeficiency; vaccines	COMMON VARIABLE IMMUNODEFICIENCY; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; 22Q11.2 DELETION SYNDROME; LIVE VIRAL VACCINES; HUMAN-PAPILLOMAVIRUS; ANTIBODY-RESPONSES; IMMUNE-DEFICIENCY; DIGEORGE-SYNDROME; RECEIVING IMMUNOGLOBULIN; CONJUGATE VACCINE	Vaccines were originally developed to prevent or ameliorate infectious disease. As knowledge of immune function and appreciation of immunodeficiency has developed, researchers have used vaccine responses as a tool to characterize the phenotypes of patients exhibiting various syndromes. Thus it has become possible for a clinician to evaluate individual responses to vaccines to interrogate the immunocompetence of their patients. Although there have been many advances in these areas, we still have much to learn about the quantity and quality of humoral and cellular vaccine responses in healthy and immunodeficient subjects and how that knowledge can then be extrapolated to diagnostic purposes. Adverse effects of vaccines have been recognized for many years, especially the occurrence of infections caused by viable vaccine organisms in immunodeficient hosts. Nevertheless, vaccines are essential for disease prevention in immunodeficient patients, just as they are for healthy subjects. Clinicians must understand the appropriate and safe use of vaccines in patients with immunodeficiency. This review highlights some recent advances and ongoing challenges in application of vaccines for the diagnosis and treatment of immunodeficiencies.	[Bonilla, Francisco A.] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Bonilla, Francisco A.] Harvard Med Sch, Dept Pediat, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Bonilla, FA (corresponding author), Boston Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	Francisco.bonilla@childrens.harvard.edu			Shire, Inc; Albany Medical College; Drexel University	Shire, Inc; Albany Medical College; Drexel University	F. A. Bonilla has a board membership with the Louis August Jonas Foundation; has consultant arrangements with Grand Rounds Health, the Immune Deficiency Foundation, Charles River Associates International, Green Cross, Parexel, Sarepta Inc, Cowen Group, Gerson-Lehrman Group, Grifols, and Huron Consulting Group; has received a grant from Shire, Inc; has received payment for lectures from Albany Medical College and Drexel University; and has received royalties from UpToDate.	Abghari PF, 2017, GLOB PEDIAT HLTH, V4; Adam E, 2015, J CLIN IMMUNOL, V35, P213, DOI 10.1007/s10875-015-0131-y; Al-Sukaiti N, 2010, J ALLERGY CLIN IMMUN, V126, P868, DOI 10.1016/j.jaci.2010.07.018; Alleman MM, 2016, VACCINE, V34, P6502, DOI 10.1016/j.vaccine.2016.10.059; Azzari C, 2005, VACCINE, V23, P1668, DOI 10.1016/j.vaccine.2004.10.005; Bakare N, 2010, VACCINE, V28, P6609, DOI 10.1016/j.vaccine.2010.07.039; Ballow M, 2013, ANN ALLERG ASTHMA IM, V111, P163, DOI 10.1016/j.anai.2013.05.033; Bausch-Jurken MT, 2017, J CLIN IMMUNOL, V37, P427, DOI 10.1007/s10875-017-0406-6; Bayer DK, 2014, CLIN EXP IMMUNOL, V178, P459, DOI 10.1111/cei.12421; Bernatowska EA, 2007, EMERG INFECT DIS, V13, P799, DOI 10.3201/eid1305.060865; Bester JC, 2016, JAMA PEDIATR, V170, P1209, DOI 10.1001/jamapediatrics.2016.1787; Bitnun A, 1999, CLIN INFECT DIS, V29, P855, DOI 10.1086/520449; Bodemer C, 2014, CLIN MICROBIOL INFEC, V20, pO656, DOI 10.1111/1469-0691.12573; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Bossuyt X, 2011, J ALLERGY CLIN IMMUN, V127, P1079, DOI 10.1016/j.jaci.2010.12.1109; Boudjemaa S, 2017, PEDIATR DEVEL PATHOL, V20, P255, DOI 10.1177/1093526616686255; Carpenter PA, 2016, BLOOD, V127, P2824, DOI 10.1182/blood-2015-12-550475; Cavaliere FM, 2013, J CLIN IMMUNOL, V33, P838, DOI 10.1007/s10875-012-9856-z; Centers for Disease Control and Prevention, 2016, PNEUM VACC REC; Clark Michael, 2006, BMC Pediatr, V6, P5, DOI 10.1186/1471-2431-6-5; Sarmiento JD, 2016, VACCINE, V34, P1611, DOI 10.1016/j.vaccine.2016.01.047; Dorn JM, 2017, J ALLER CL IMM-PRACT, V5, P1149, DOI 10.1016/j.jaip.2017.02.010; Fried AJ, 2013, J CLIN IMMUNOL, V33, P847, DOI 10.1007/s10875-013-9870-9; Goldacker S, 2007, CLIN IMMUNOL, V124, P294, DOI 10.1016/j.clim.2007.04.011; Guo J, 2015, VACCINE, V33, P1235, DOI 10.1016/j.vaccine.2015.01.018; HARA M, 1981, MICROBIOL IMMUNOL, V25, P905, DOI 10.1111/j.1348-0421.1981.tb00095.x; Hofstetter AM, 2014, PEDIATRICS, V133, pE946, DOI 10.1542/peds.2013-0831; Ingels H, 2012, VACCINE, V30, P3944, DOI 10.1016/j.vaccine.2012.03.060; Janssen WJM, 2014, J CLIN IMMUNOL, V34, P3, DOI 10.1007/s10875-013-9925-y; Jorba J, 2016, MMWR-MORBID MORTAL W, V65, P763, DOI 10.15585/mmwr.mm6530a3; Junker AK, 2004, CLIN IMMUNOL, V112, P219, DOI 10.1016/j.clim.2004.03.013; Kaplon J, 2015, PEDIATR INFECT DIS J, V34, P326, DOI 10.1097/INF.0000000000000560; Kreuter A, 2010, ARCH DERMATOL, V146, P1196, DOI 10.1001/archdermatol.2010.290; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Ladhani S, 2011, VACCINE, V29, P9137, DOI 10.1016/j.vaccine.2011.09.107; Leiding JW, 2012, J ALLERGY CLIN IMMUN, V130, P1030, DOI 10.1016/j.jaci.2012.07.049; Leung J, 2014, HUM VACC IMMUNOTHER, V10, P146, DOI 10.4161/hv.26200; Li L, 2014, J INFECT DIS, V210, pS368, DOI 10.1093/infdis/jiu065; Licciardi PV, 2012, J ALLERGY CLIN IMMUN, V129, P794, DOI 10.1016/j.jaci.2011.11.043; Lopez A, 2017, J AUTOIMMUN, V80, P10, DOI 10.1016/j.jaut.2017.03.011; MacIntyre CR, 2016, VACCINE, V34, P4343, DOI 10.1016/j.vaccine.2016.06.049; Marciano BE, 2014, J ALLERGY CLIN IMMUN, V133, P1134, DOI 10.1016/j.jaci.2014.02.028; Maurer DM, 2003, AM FAM PHYSICIAN, V68, P889; McCusker C, 1997, ANN ALLERG ASTHMA IM, V79, P145, DOI 10.1016/S1081-1206(10)63101-8; Miller PDE, 2017, BONE MARROW TRANSPL, V52, P1082, DOI 10.1038/bmt.2017.87; Moens L, 2017, J CLIN IMMUNOL, V37, P277, DOI 10.1007/s10875-017-0380-z; Moinho R, 2014, BMJ CASE REP, V2014; Moschese V, 2016, J ALLERGY CLIN IMMUN, V137, P617, DOI 10.1016/j.jaci.2015.06.014; Neven B, 2017, CLIN INFECT DIS, V64, P83, DOI 10.1093/cid/ciw675; Nobre FA, 2014, BMC IMMUNOL, V15, DOI 10.1186/1471-2172-15-26; Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002; Paradiso P, 2009, VACCINE, V27, pC15, DOI 10.1016/j.vaccine.2009.06.008; Paris K, 2007, ANN ALLERG ASTHMA IM, V99, P462, DOI 10.1016/S1081-1206(10)60572-8; Patel NC, 2010, NEW ENGL J MED, V362, P314, DOI 10.1056/NEJMoa0904485; Patel RR, 2015, THER CLIN RISK MANAG, V11, P217, DOI 10.2147/TCRM.S52008; Perez EE, 2003, PEDIATRICS, V112, pE325, DOI 10.1542/peds.112.4.e325; Rezaei N, 2010, CLIN VACCINE IMMUNOL, V17, P524, DOI 10.1128/CVI.00389-09; Romero-Steiner S, 2006, CLIN VACCINE IMMUNOL, V13, P165, DOI 10.1128/CVI.13.2.165-169.2006; Roxo P, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-54; Salinas JL, 2016, MMWR-MORBID MORTAL W, V65, P273, DOI 10.15585/mmwr.mm6511a2; Sanchez-Ramon S, 2016, CLIN IMMUNOL, V169, P80, DOI 10.1016/j.clim.2016.05.006; Santos A, 2010, J MICROBIOL IMMUNOL, V43, P530, DOI 10.1016/S1684-1182(10)60082-5; Schaballie H, 2016, CLIN EXP IMMUNOL, V185, P180, DOI 10.1111/cei.12784; Schaballie H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00546; Schutz K, 2013, J CLIN IMMUNOL, V33, P288, DOI 10.1007/s10875-012-9792-y; Schuil J, 1998, INT OPHTHALMOL, V22, P345, DOI 10.1023/A:1006396906378; Seidel MG, 2010, VACCINE, V28, P6621, DOI 10.1016/j.vaccine.2010.07.027; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P961, DOI 10.1016/j.jaci.2013.11.043; Slotved HC, 2016, VACCINE, V34, P769, DOI 10.1016/j.vaccine.2015.12.056; Smith LL, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00410; Smith SP, 2017, CLIN EXP DERMATOL, V42, P306, DOI 10.1111/ced.13038; Sobh A, 2016, J ALLER CL IMM-PRACT, V4, P1066, DOI 10.1016/j.jaip.2016.09.012; Sorensen RU, 2014, J CLIN IMMUNOL, V34, P127, DOI 10.1007/s10875-013-9977-z; Stewart AJ, 2006, J INFECTION, V52, P329, DOI 10.1016/j.jinf.2005.07.021; Sullivan K, 2004, IMMUNOLOGIC DISORDER, V5, P523; Tuerlinckx D, 2007, CLIN EXP IMMUNOL, V149, P295, DOI 10.1111/j.1365-2249.2007.03409.x; Tuerlinckx D, 2014, PEDIATRICS, V133, pE154, DOI 10.1542/peds.2013-1155; Valenzise M, 2014, VACCINE, V32, P5552, DOI 10.1016/j.vaccine.2014.08.047; van Assen S, 2011, CLIN IMMUNOL, V141, P161, DOI 10.1016/j.clim.2011.07.004; van Assen S, 2010, CLIN IMMUNOL, V136, P228, DOI 10.1016/j.clim.2010.03.430; van der Spek J, 2015, J CLIN IMMUNOL, V35, P416, DOI 10.1007/s10875-015-0152-6; van Zelm MC, 2006, NEW ENGL J MED, V354, P1901, DOI 10.1056/NEJMoa051568; Varada S, 2014, CURR PROBL DERMATOL, V45, P197, DOI 10.1159/000357187; Waters V, 2007, ARCH DIS CHILD, V92, P519, DOI 10.1136/adc.2006.097493; Whaley MJ, 2010, CLIN VACCINE IMMUNOL, V17, P862, DOI 10.1128/CVI.00022-10	85	40	40	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2018	141	2					474	481		10.1016/j.jaci.2017.12.980	http://dx.doi.org/10.1016/j.jaci.2017.12.980			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FV2PQ	29288077	Bronze			2022-12-18	WOS:000424410800002
J	Radonjic-Hoesli, S; Wang, XL; de Graauw, E; Stoeckle, C; Styp-Rekowska, B; Hlushchuk, R; Simon, D; Spaeth, PJ; Yousefi, S; Simon, HU				Radonjic-Hoesli, Susanne; Wang, Xiaoliang; de Graauw, Elisabeth; Stoeckle, Christina; Styp-Rekowska, Beata; Hlushchuk, Ruslan; Simon, Dagmar; Spaeth, Peter J.; Yousefi, Shida; Simon, Hans-Uwe			Adhesion-induced eosinophil cytolysis requires the receptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signaling pathway, which is counterregulated by autophagy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Autophagy; eosinophil cytolysis; eosinophilic disease; necrosis; necroptosis; non-apoptotic cell death; mixed lineage kinase-like; RIP kinase; reactive oxygen species	EXTRACELLULAR DNA TRAPS; CELL-DEATH; PROGRAMMED NECROSIS; PIECEMEAL DEGRANULATION; NECROTIC DEATH; DOMAIN-LIKE; IN-VIVO; ACTIVATION; RELEASE; RIP3	Background: Eosinophils are a subset of granulocytes that can be involved in the pathogenesis of different diseases, including allergy. Their effector functions are closely linked to their cytotoxic granule proteins. Release takes place through several different mechanisms, one of which is cytolysis, which is associated with release of intact granules, so-called clusters of free eosinophil granules. The mechanism underlying this activation-induced form of cell death in eosinophils has remained unclear. Objective: We aimed to elucidate the molecular mechanism of eosinophil cytolysis. Methods: Isolated blood eosinophils were incubated on glass coverslips coated with intravenous immunoglobulin and inactive complement component 3b. A morphologic characterization of the distinct stages of the proposed cascade was addressed by means of time-lapse automated fluorescence microscopy, electron microscopy, and immunohistochemistry. Experiments with pharmacologic inhibitors were performed to elucidate the sequence of events within the cascade. Tissue samples of patients with eosinophilic skin diseases or eosinophilic esophagitis were used for in vivo analyses. Results: After eosinophil adhesion, we observed reactive oxygen species production, early degranulation, and granule fusion processes, leading to a distinct morphology exhibiting cytoplasmic vacuolization and, finally, cytolysis. Using a pharmacologic approach, we demonstrate the presence of a receptor-interacting protein kinase 3 (RIPK3)-mixed lineage kinase-like (MLKL) signaling pathway in eosinophils, which, after its activation, leads to the production of high levels of reactive oxygen species in a p38 mitogen-activated protein kinase and phosphatidylinositol 39-kinase-dependent manner. All these steps are required for cytoplasmic vacuolization and subsequent cytolysis to occur. Interestingly, triggering cytolysis is associated with an induction of autophagy in eosinophils, and additional stimulation of autophagy by means of pharmacologic inhibition of the mechanistic target of rapamycin counterregulates cell death. Moreover, MLKL phosphorylation, cytoplasmic vacuolization, and cytolysis were observed in eosinophils under in vivo inflammatory conditions. Conclusion: We report that adhesion-induced eosinophil cytolysis takes place through RIPK3-MLKL-dependent necroptosis, which can be counterregulated by autophagy.	[Radonjic-Hoesli, Susanne; Wang, Xiaoliang; de Graauw, Elisabeth; Stoeckle, Christina; Spaeth, Peter J.; Yousefi, Shida; Simon, Hans-Uwe] Bern Univ Hosp, Inst Pharmacol, Inselspital, Bern, Switzerland; [Radonjic-Hoesli, Susanne; Simon, Dagmar] Bern Univ Hosp, Dept Dermatol, Inselspital, Bern, Switzerland; [Styp-Rekowska, Beata; Hlushchuk, Ruslan] Univ Bern, Inst Anat, Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern; University of Bern	Simon, HU (corresponding author), Univ Bern, Inselspital, Inst Pharmacol, INO F, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Yousefi, Shida/L-9689-2016; Hlushchuk, Ruslan/AAE-7872-2022; Stoeckle, Christina/B-8261-2012; Simon, Hans-Uwe/AAU-5079-2020; Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-7410-2020	Yousefi, Shida/0000-0002-9855-4305; Stoeckle, Christina/0000-0001-8424-3365; Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736; Hlushchuk, Ruslan/0000-0002-6722-8996	Swiss National Science Foundation [310030_146181, 310030_166473, 310030_146215]; Foundation Allergiestiftung Ulrich Muller-Gierok, Bern; Swiss National Science Foundation	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Foundation Allergiestiftung Ulrich Muller-Gierok, Bern; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	Supported by the Swiss National Science Foundation (grant nos. 310030_146181 and 310030_166473, both to H.-U. S., and grant no. 310030_146215 to S. Y.) and the Foundation Allergiestiftung Ulrich Muller-Gierok, Bern (to S. R.-H. and H.-U. S.). S. R.H. participated in an MD/PhD program funded by the Swiss National Science Foundation.	Basit F, 2013, CELL DEATH DIFFER, V20, P1161, DOI 10.1038/cdd.2013.45; Bray K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041831; BUTTERWORTH AE, 1979, J EXP MED, V150, P1456, DOI 10.1084/jem.150.6.1456; Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883; Chihara J, 2000, J ALLERGY CLIN IMMUN, V106, pS99, DOI 10.1067/mai.2000.106884; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; DVORAK AM, 1991, AM J PATHOL, V138, P69; EBISAWA M, 1992, J IMMUNOL, V149, P4021; Erjefalt JS, 1998, J ALLERGY CLIN IMMUN, V102, P286, DOI 10.1016/S0091-6749(98)70098-3; Erjefalt JS, 1999, AM J RESP CRIT CARE, V160, P304, DOI 10.1164/ajrccm.160.1.9809048; Erjefalt JS, 1997, CLIN EXP ALLERGY, V27, P1344; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; FUKUDA T, 1985, J IMMUNOL, V135, P1349; Geering B, 2011, BLOOD, V117, P5953, DOI 10.1182/blood-2010-11-322206; Goundiam O, 2010, CELL BIOL INT, V34, P385, DOI [10.1042/CBI20990147, 10.1042/CBI20090147]; He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; HENDERSON WR, 1985, J CELL SCI, V73, P33; Hildebrand JM, 2014, P NATL ACAD SCI USA, V111, P15072, DOI 10.1073/pnas.1408987111; Johansson MW, 2008, J IMMUNOL, V180, P7622, DOI 10.4049/jimmunol.180.11.7622; Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341; Kano G, 2017, IMMUNOBIOLOGY, V222, P343, DOI 10.1016/j.imbio.2016.09.006; Kano G, 2013, J ALLERGY CLIN IMMUN, V132, P437, DOI 10.1016/j.jaci.2013.03.024; KAY AB, 1985, CLIN EXP IMMUNOL, V62, P1; Kim SK, 2015, J INVEST DERMATOL, V135, P2021, DOI 10.1038/jid.2015.90; Lawlor KE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7282; Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019; Mandal P, 2014, MOL CELL, V56, P481, DOI 10.1016/j.molcel.2014.10.021; Melo RCN, 2009, LAB INVEST, V89, P769, DOI 10.1038/labinvest.2009.40; Mihalache CC, 2011, J IMMUNOL, V186, P6532, DOI 10.4049/jimmunol.1004055; Morshed M, 2014, J IMMUNOL, V192, P5314, DOI 10.4049/jimmunol.1303418; Munafo DB, 2001, J CELL SCI, V114, P3619; Muniz-Junqueira MI, 2013, ALLERGY, V68, P911, DOI 10.1111/all.12176; Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191; Persson CGA, 1997, THORAX, V52, P569, DOI 10.1136/thx.52.6.569; Radonjic-Hoesli S, 2015, ANNU REV PHARMACOL, V55, P633, DOI 10.1146/annurev-pharmtox-010814-124407; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saffari H, 2014, J ALLERGY CLIN IMMUN, V133, P1728, DOI 10.1016/j.jaci.2013.11.024; Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010; Simon D, 2011, J ALLERGY CLIN IMMUN, V127, P194, DOI 10.1016/j.jaci.2010.11.002; Simon HU, 2010, J ALLERGY CLIN IMMUN, V126, P45, DOI 10.1016/j.jaci.2010.03.042; Ueki S, 2016, J ALLERGY CLIN IMMUN, V137, P258, DOI 10.1016/j.jaci.2015.04.041; Ueki S, 2013, BLOOD, V121, P2074, DOI 10.1182/blood-2012-05-432088; Upton JW, 2012, CELL HOST MICROBE, V11, P290, DOI [10.1016/j.chom.2019.09.004, 10.1016/j.chom.2012.01.016]; Valent P, 2012, J ALLERGY CLIN IMMUN, V130, P607, DOI 10.1016/j.jaci.2012.02.019; Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003; Wang XL, 2016, J IMMUNOL, V197, P4090, DOI 10.4049/jimmunol.1600051; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109	50	40	41	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1632	1642		10.1016/j.jaci.2017.01.044	http://dx.doi.org/10.1016/j.jaci.2017.01.044			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28412393	Bronze			2022-12-18	WOS:000417206000018
J	Han, Y; Chen, YX; Liu, XC; Zhang, JX; Su, HC; Wen, H; Li, W; Yao, X				Han, Yue; Chen, Yuxin; Liu, Xiaochun; Zhang, Jingxi; Su, Huichun; Wen, He; Li, Wei; Yao, Xu			Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MODERATE; PLACEBO		[Han, Yue; Liu, Xiaochun; Zhang, Jingxi; Su, Huichun; Wen, He; Yao, Xu] Chinese Acad Med Sci, Inst Dermatol, Nanjing, Jiangsu, Peoples R China; [Han, Yue; Liu, Xiaochun; Zhang, Jingxi; Su, Huichun; Wen, He; Yao, Xu] Peking Union Med Coll, Nanjing, Jiangsu, Peoples R China; [Chen, Yuxin] Nanjing Univ, Med Sch, Nanjing Drum Tower Hosp, Dept Lab Med, Nanjing, Jiangsu, Peoples R China; [Li, Wei] Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Dermatology - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Nanjing University; Fudan University	Li, W (corresponding author), Fudan Univ, Huashan Hosp, Dept Dermatol, Shanghai, Peoples R China.	liweiderma@163.com; dryao_xu@126.com	Chen, Yuxin/AFR-3812-2022	Chen, Yuxin/0000-0001-5955-687X	National Natural Science Foundation of China [81371735, 81573045, 81573038, 81600201]; Natural Science Foundation of Jiangsu province [BK20151066]; Jiangsu provincial Key Laboratory of Molecular Biology for Skin Diseases and STIs [2015KF14]; Milstein Medical Asian American Partnership Foundation	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu province(Natural Science Foundation of Jiangsu Province); Jiangsu provincial Key Laboratory of Molecular Biology for Skin Diseases and STIs; Milstein Medical Asian American Partnership Foundation	This work was supported by the National Natural Science Foundation of China (grant nos. 81371735, 81573045, 81573038, and 81600201), the Natural Science Foundation of Jiangsu province (grant no. BK20151066), Open Grant of the Jiangsu provincial Key Laboratory of Molecular Biology for Skin Diseases and STIs (grant no. 2015KF14), and the Milstein Medical Asian American Partnership Foundation.	Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Hamilton JD, 2014, J ALLERGY CLIN IMMUN, V134, P1293, DOI 10.1016/j.jaci.2014.10.013; Kaesler S, 2014, J ALLERGY CLIN IMMUN, V134, P92, DOI 10.1016/j.jaci.2014.02.017; Roekevisch E, 2014, J ALLERGY CLIN IMMUN, V133, P429, DOI 10.1016/j.jaci.2013.07.049; Simpson EL, 2016, NEW ENGL J MED, V375, P2335, DOI 10.1056/NEJMoa1610020; Simpson EL, 2016, J AM ACAD DERMATOL, V75, P506, DOI 10.1016/j.jaad.2016.04.054; Suarez-Farinas M, 2013, J ALLERGY CLIN IMMUN, V132, P361, DOI 10.1016/j.jaci.2013.04.046; Thaci D, 2016, LANCET, V387, P40, DOI 10.1016/S0140-6736(15)00388-8; Wenzel S, 2016, LANCET, V388, P31, DOI 10.1016/S0140-6736(16)30307-5	9	40	44	3	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					888	+		10.1016/j.jaci.2017.04.015	http://dx.doi.org/10.1016/j.jaci.2017.04.015			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28479326	Bronze			2022-12-18	WOS:000409241500037
J	Harris, JM; Cabanski, CR; Scheerens, H; Samineni, D; Bradley, MS; Cochran, C; Staubach, P; Metz, M; Sussman, G; Maurer, M				Harris, Jeffrey M.; Cabanski, Christopher R.; Scheerens, Heleen; Samineni, Divya; Bradley, Mary S.; Cochran, Colette; Staubach, Petra; Metz, Martin; Sussman, Gordon; Maurer, Marcus			A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							OMALIZUMAB		[Harris, Jeffrey M.; Cabanski, Christopher R.; Scheerens, Heleen; Samineni, Divya; Bradley, Mary S.; Cochran, Colette] Genentech Inc, San Francisco, CA 94080 USA; [Staubach, Petra] Univ Med Ctr Mainz, Dept Dermatol, Mainz, Germany; [Metz, Martin; Maurer, Marcus] Charite Univ Med Berlin, Allergie Ctr Charite, Dept Dermatol & Allergy, Berlin, Germany; [Sussman, Gordon] Univ Toronto, Dept Med, Div Clin Immunol & Allergy, Toronto, ON, Canada	Roche Holding; Genentech; Johannes Gutenberg University of Mainz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Toronto	Harris, JM (corresponding author), Genentech Inc, San Francisco, CA 94080 USA.	harris.jeffrey@gene.com	Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X				Altrichter S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014794; Brightbill D., 2014, CLIN ANTIINFLAMM ANT, V1, P24, DOI [10.2174/22127038114019990003, DOI 10.2174/22127038114019990003, DOI 10.3389/fimmu.2018.00460]; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Gauvreau GM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008961; O'Donnell BF, 2014, IMMUNOL ALLERGY CLIN, V34, P89, DOI 10.1016/j.iac.2013.09.011; Saini SS, 2014, IMMUNOL ALLERGY CLIN, V34, P33, DOI 10.1016/j.iac.2013.09.012; Scheerens H., 2012, AM J RESP CRIT CARE, V185, pA6791; Zhao ZT, 2016, J ALLERGY CLIN IMMUN, V137, P1742, DOI 10.1016/j.jaci.2015.12.1342; Zuberbier T, 2014, ALLERGY, V69, P868, DOI 10.1111/all.12313	9	40	42	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1730	1732		10.1016/j.jaci.2016.06.023	http://dx.doi.org/10.1016/j.jaci.2016.06.023			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27567329				2022-12-18	WOS:000390019300036
J	Lagresle-Peyrou, C; Luce, S; Ouchani, F; Soheili, TS; Sadek, H; Chouteau, M; Durand, A; Pic, I; Majewski, J; Brouzes, C; Lambert, N; Bohineust, A; Verhoeyen, E; Cosset, FL; Magerus-Chatinet, A; Rieux-Laucat, F; Gandemer, V; Monnier, D; Heijmans, C; van Gijn, M; Dalm, VA; Mahlaoui, N; Stephan, JL; Picard, C; Durandy, A; Kracker, S; Hivroz, C; Jabado, N; de Saint Basile, G; Fischer, A; Cavazzana, M; Andre-Schmutz, I				Lagresle-Peyrou, Chantal; Luce, Sonia; Ouchani, Farid; Soheili, Tayebeh Shabi; Sadek, Hanem; Chouteau, Myriam; Durand, Amandine; Pic, Isabelle; Majewski, Jacek; Brouzes, Chantal; Lambert, Nathalie; Bohineust, Armelle; Verhoeyen, Els; Cosset, Francois-Loic; Magerus-Chatinet, Aude; Rieux-Laucat, Frederic; Gandemer, Virginie; Monnier, Delphine; Heijmans, Catherine; van Gijn, Marielle; Dalm, Virgil A.; Mahlaoui, Nizar; Stephan, Jean-Louis; Picard, Capucine; Durandy, Anne; Kracker, Sven; Hivroz, Claire; Jabado, Nada; de Saint Basile, Genevieve; Fischer, Alain; Cavazzana, Marina; Andre-Schmutz, Isabelle			X-linked primary immunodeficiency associated with hemizygous mutations in the moesin (MSN) gene	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Leukopenia; primary immunodeficiency; moesin; ezrinradixin-moesin protein; adhesion; migration	ERM PROTEINS; EZRIN; PHOSPHORYLATION; LYMPHOCYTES; CD43; MICE; CLASSIFICATION; MICROVILLI; RADIXIN; SYNAPSE	Background: We investigated 7 male patients (from 5 different families) presenting with profound lymphopenia, hypogammaglobulinemia, fluctuating monocytopenia and neutropenia, a poor immune response to vaccine antigens, and increased susceptibility to bacterial and varicella zoster virus infections. Objective: We sought to characterize the genetic defect involved in a new form of X-linked immunodeficiency. Methods: We performed genetic analyses and an exhaustive phenotypic and functional characterization of the lymphocyte compartment. Results: We observed hemizygous mutations in the moesin (MSN) gene (located on the X chromosome and coding for MSN) in all 7 patients. Six of the latter had the same missense mutation, which led to an amino acid substitution (R171W) in the MSN four-point-one, ezrin, radixin, moesin domain. The seventh patient had a nonsense mutation leading to a premature stop codon mutation (R533X). The naive T-cell counts were particularly low for age, and most CD8(+) T cells expressed the senescence marker CD57. This phenotype was associated with impaired T-cell proliferation, which was rescued by expression of wild-type MSN. MSN-deficient T cells also displayed poor chemokine receptor expression, increased adhesion molecule expression, and altered migration and adhesion capacities. Conclusion: Our observations establish a causal link between an ezrin-radixin-moesin protein mutation and a primary immunodeficiency that could be referred to as X-linked moesin-associated immunodeficiency.	[Lagresle-Peyrou, Chantal; Luce, Sonia; Ouchani, Farid; Soheili, Tayebeh Shabi; Sadek, Hanem; Chouteau, Myriam; Durand, Amandine; Pic, Isabelle; Durandy, Anne; Kracker, Sven; Cavazzana, Marina; Andre-Schmutz, Isabelle] INSERM, UMR 1163, Lab Human Lymphohematopoiesis, Paris, France; [Lagresle-Peyrou, Chantal; Luce, Sonia; Ouchani, Farid; Soheili, Tayebeh Shabi; Sadek, Hanem; Chouteau, Myriam; Durand, Amandine; Pic, Isabelle; Magerus-Chatinet, Aude; Rieux-Laucat, Frederic; Mahlaoui, Nizar; Picard, Capucine; Durandy, Anne; Kracker, Sven; de Saint Basile, Genevieve; Fischer, Alain; Cavazzana, Marina; Andre-Schmutz, Isabelle] Paris Descartes Sorbonne Paris Cite Univ, Imagine Inst, Paris, France; [Cavazzana, Marina; Andre-Schmutz, Isabelle] Necker Childrens Hosp, AP HP, Biotherapy Clin Invest Ctr, Paris, France; [Brouzes, Chantal] Necker Childrens Hosp, AP HP, Lab Oncohematol, Paris, France; [Picard, Capucine; Fischer, Alain] Necker Childrens Hosp, AP HP, French Natl Reference Ctr Primary Immune Deficien, Paris, France; [Picard, Capucine; Fischer, Alain] Necker Childrens Hosp, AP HP, Pediat Immunol Haematol & Rheumatol Unit, Paris, France; [Majewski, Jacek; Jabado, Nada] McGill Univ, Montreal, PQ, Canada; [Majewski, Jacek; Jabado, Nada] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Lambert, Nathalie; Picard, Capucine; de Saint Basile, Genevieve] Hop Necker Enfants Malad, AP HP, Study Ctr Primary Immunodeficiencies, Paris, France; [Bohineust, Armelle; Hivroz, Claire] Inst Curie, Ctr Rech, Pavillon Pasteur, Paris, France; [Bohineust, Armelle; Hivroz, Claire] INSERM, Unite 932, Immunite & Canc, Paris, France; [Verhoeyen, Els; Cosset, Francois-Loic] Univ Lyon 1, CIRI, Int Ctr Infectiol Res, EVIR Grp,INSERM,U1111,CNRS, Lyon, France; [Verhoeyen, Els] C3M, INSERM, U1065, Equipe Controle Metab Morts Cellulaires, Nice, France; [Magerus-Chatinet, Aude; Rieux-Laucat, Frederic] Necker Childrens Hosp, INSERM, UMR 1163, Lab Immunogenet Pediat Autoimmun, Paris, France; [Gandemer, Virginie] Univ Rennes 1, CNRS, UMR 6290, Unite Hematooncol & Greffes Moelle,CHU Rennes, Rennes, France; [Monnier, Delphine] CHU Rennes, Serv Immunol Therapie Cellulaire & Hematopoiese, Rennes, France; [Heijmans, Catherine] Ctr Hosp Jolimont, La Louviere, Belgium; [Heijmans, Catherine] Hop Univ Enfants Reine Fabiola, Brussels, Belgium; [van Gijn, Marielle] Univ Med Ctr Utrecht, Dept Med Genet, Utrecht, Netherlands; [Dalm, Virgil A.] Erasmus MC, Dept Internal Med & Immunol, Rotterdam, Netherlands; [Mahlaoui, Nizar; Picard, Capucine] Necker Childrens Hosp, AP HP, INSERM, U1163,Lab Human Genet Infect Dis,Necker Branch, Paris, France; [Stephan, Jean-Louis] CHU Nord, Serv Pediat, St Etienne, France; [Jabado, Nada] McGill Univ, Ctr Hlth, Dept Pediat, Montreal, PQ, Canada; [de Saint Basile, Genevieve] Hop Necker Enfants Malad, INSERM, Unite U1163, Normal & Pathol Homeostasis Immune Syst, Paris, France; [Fischer, Alain] Hop Necker Enfants Malad, INSERM, Unite U1163, Paris, France; [Fischer, Alain] Coll France, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Rennes; Universite de Rennes; CHU Rennes; Groupe Jolimont; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam; Erasmus MC; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU de St Etienne; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; College de France	Andre-Schmutz, I (corresponding author), Inst Imagine, INSERM, U1163, 24 Blvd Montparnasse, F-75015 Paris, France.	isabelle.andre-schmutz@inserm.fr	Peyrou, Chantal Lagresle/AAK-9689-2020; Jabado, Nada/AAN-4026-2020; Magerus-Chatinet, Aude/I-6245-2017; Rieux-Laucat, Frédéric/A-7916-2017; Soheili, Tayebeh/H-3089-2017; MAHLAOUI, Nizar/AAH-6103-2020; Cosset, François-Loïc/M-5862-2019; Sadek, Hanem/H-7888-2017; Verhoeyen, Els/AAW-4853-2021; Verhoeyen, Els/H-6360-2016; Hivroz, Claire/H-2711-2014; Kracker, Sven/H-3681-2017; Durand, Amandine/H-8199-2017; Andre, Isabelle/F-6263-2013; Durandy, Anne/H-7475-2017; Peyrou, Chantal Lagresle/H-2911-2017; Mahlaoui, Nizar/J-7928-2017; de Saint Basile, Genevieve/G-9731-2017	Peyrou, Chantal Lagresle/0000-0002-2216-6453; Magerus-Chatinet, Aude/0000-0001-7365-699X; Rieux-Laucat, Frédéric/0000-0001-7858-7866; Soheili, Tayebeh/0000-0002-0506-8077; MAHLAOUI, Nizar/0000-0002-0030-8094; Cosset, François-Loïc/0000-0001-8842-3726; Sadek, Hanem/0000-0003-0756-0193; Verhoeyen, Els/0000-0001-9224-5491; Hivroz, Claire/0000-0002-6794-2890; Kracker, Sven/0000-0003-4543-8236; Durand, Amandine/0000-0002-4354-365X; Andre, Isabelle/0000-0002-3905-9910; Durandy, Anne/0000-0001-7706-8466; Peyrou, Chantal Lagresle/0000-0002-2216-6453; Mahlaoui, Nizar/0000-0002-0030-8094; Cavazzana, Marina/0000-0002-0264-0891; de Saint Basile, Genevieve/0000-0002-1913-5269; Bohineust, Armelle/0000-0002-9734-0049	French National Institute of Health and Medical Research (INSERM); French National Research Agency ("Investments for the Future'' program) [ANR-01-A0-IAHU]; European Research Council [PIDIMMUN 249816]; La Ligue contre le Cancer; La Fondation ARC pour la Recherche sur le Cancer [DOC20120604712]	French National Institute of Health and Medical Research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); French National Research Agency ("Investments for the Future'' program)(French National Research Agency (ANR)); European Research Council(European Research Council (ERC)European Commission); La Ligue contre le Cancer(Ligue nationale contre le cancer); La Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer)	This research has received state funding from the French National Institute of Health and Medical Research (INSERM), the French National Research Agency (as part of the "Investments for the Future'' program, reference: ANR-01-A0-IAHU), and the European Research Council (reference: PIDIMMUN 249816). A.B. was funded by La Ligue contre le Cancer and La Fondation ARC pour la Recherche sur le Cancer (DOC20120604712).	Allenspach EJ, 2001, IMMUNITY, V15, P739, DOI 10.1016/S1074-7613(01)00224-2; Belkina NV, 2009, P NATL ACAD SCI USA, V106, P4707, DOI 10.1073/pnas.0805963106; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Bousfiha A, 2015, J CLIN IMMUNOL, V35, P727, DOI 10.1007/s10875-015-0198-5; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brown MJ, 2003, BLOOD, V102, P3890, DOI 10.1182/blood-2002-12-3807; de Saint Basile G, 1999, EUR J IMMUNOL, V29, P367, DOI 10.1002/(SICI)1521-4141(199901)29:01<367::AID-IMMU367>3.0.CO;2-4; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; Dobbs K, 2015, NEW ENGL J MED, V372, P2409, DOI 10.1056/NEJMoa1413462; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Hashimoto S, 2008, AM J PHYSIOL-LUNG C, V295, pL566, DOI 10.1152/ajplung.90250.2008; Hirata T, 2012, INT IMMUNOL, V24, P705, DOI 10.1093/intimm/dxs077; Ilani T, 2007, J CELL BIOL, V179, P733, DOI 10.1083/jcb.200707199; Ivetic A, 2004, IMMUNOLOGY, V112, P165, DOI 10.1111/j.1365-2567.2004.01882.x; Lee JH, 2009, EXP DERMATOL, V18, P997, DOI 10.1111/j.1600-0625.2009.00898.x; Moulding DA, 2013, IMMUNOL REV, V256, P282, DOI 10.1111/imr.12114; Niggli V, 2014, INT REV CEL MOL BIO, V312, P201, DOI 10.1016/B978-0-12-800178-3.00007-5; Parameswaran N, 2013, IMMUNOL REV, V256, P63, DOI 10.1111/imr.12104; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104; Picard C, 2015, J CLIN IMMUNOL, V35, P696, DOI 10.1007/s10875-015-0201-1; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Pore D, 2015, CRIT REV IMMUNOL, V35, P15, DOI 10.1615/CritRevImmunol.2015012327; Puck JM, 1998, NEW ENGL J MED, V338, P325, DOI 10.1056/NEJM199801293380611; Saotome I, 2004, DEV CELL, V6, P855, DOI 10.1016/j.devcel.2004.05.007; Shaffer MH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012404; Shaffer MH, 2009, J IMMUNOL, V182, P1021, DOI 10.4049/jimmunol.182.2.1021; Shcherbina A, 1999, FEBS LETT, V443, P31, DOI 10.1016/S0014-5793(98)01674-3; Simons PC, 1998, BIOCHEM BIOPH RES CO, V253, P561, DOI 10.1006/bbrc.1998.9823	30	40	46	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2016	138	6					1681	+		10.1016/j.jaci.2016.04.032	http://dx.doi.org/10.1016/j.jaci.2016.04.032			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EF0MK	27405666	Bronze			2022-12-18	WOS:000390019300024
J	Venturelli, N; Lexmond, WS; Ohsaki, A; Nurko, S; Karasuyama, H; Fiebiger, E; Oyoshi, AK				Venturelli, Nicholas; Lexmond, Willem S.; Ohsaki, Asa; Nurko, Samuel; Karasuyama, Hajime; Fiebiger, Edda; Oyoshi, Michiko K.			Allergic skin sensitization promotes eosinophilic esophagitis through the IL-33-basophil axis in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Basophils; eosinophilic esophagitis; filaggrin; skin barrier; IL-33; ST2	THYMIC STROMAL LYMPHOPOIETIN; GENOME-WIDE ASSOCIATION; BASOPHIL-DERIVED INTERLEUKIN-4; ATOPIC-DERMATITIS; EPICUTANEOUS SENSITIZATION; PROTEIN ANTIGEN; FLAKY TAIL; T-CELLS; IL-33; INFLAMMATION	Background: Eosinophilic esophagitis (EoE) is an allergic inflammatory disorder characterized by accumulation of eosinophils in the esophagus. EoE often coexists with atopic dermatitis, a chronic inflammatory skin disease. The impaired skin barrier in patients with atopic dermatitis has been suggested as an entry point for allergic sensitization that triggers development of EoE. Objective: We sought to define the mechanisms whereby epicutaneous sensitization through a disrupted skin barrier induces development of EoE. Methods: To elicit experimental EoE, mice were epicutaneously sensitized with ovalbumin (OVA), followed by intranasal OVA challenge. Levels of esophageal mRNA for T(H)2 cytokines and the IL-33 receptor Il1rl1 (St2) were measured by using quantitative PCR. Esophageal eosinophil accumulation was assessed by using flow cytometry and hematoxylin and eosin staining. In vivo basophil depletion was achieved with diphtheria toxin treatment of Mcpt8(DTR) mice, and animals were repopulated with bone marrow basophils. mRNA analysis of esophageal biopsy specimens from patients with EoE was used to validate our findings in human subjects. Results: Epicutaneous sensitization and intranasal challenge of wild-type mice resulted in accumulation of eosinophils and upregulation of T(H)2 cytokines and St2 in the esophagus. Disruption of the IL-33-ST2 axis or depletion of basophils reduced these features. Expression of ST2 on basophils was required to accumulate in the esophagus and transfer experimental EoE. Expression of IL1RL1/ST2 mRNA was increased in esophageal biopsy specimens from patients with EoE. Topical OVA application on unstripped skin induced experimental EoE in filaggrin-deficient flaky tail (ft/ft) mice but not in wild-type control or ft/ft.St2(-/-) mice. Conclusion: Epicutaneous allergic sensitization promotes EoE, and this is critically mediated through the IL-33-ST2-basophil axis.	[Venturelli, Nicholas; Ohsaki, Asa; Oyoshi, Michiko K.] Boston Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA; [Lexmond, Willem S.; Nurko, Samuel; Fiebiger, Edda] Boston Childrens Hosp, Div Gastroenterol & Nutr, Boston, MA USA; [Nurko, Samuel] Boston Childrens Hosp, Ctr Motil & Funct Gastrointestinal Disorders, Boston, MA USA; [Nurko, Samuel] Boston Childrens Hosp, Eosinophil Gastrointestinal Dis Ctr, Boston, MA USA; [Nurko, Samuel; Fiebiger, Edda; Oyoshi, Michiko K.] Harvard Med Sch, Dept Pediat, Boston, MA USA; [Karasuyama, Hajime] Tokyo Med & Dent Univ, Grad Sch, Dept Immune Regulat, Tokyo, Japan	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Tokyo Medical & Dental University (TMDU)	Oyoshi, AK (corresponding author), Boston Childrens Hosp, Div Immunol, 300 Longwood Ave, Boston, MA 02115 USA.	michiko.oyoshi@childrens.harvard.edu	Karasuyama, Hajime/A-7966-2011	Karasuyama, Hajime/0000-0003-0689-0836; Nurko, Samuel/0000-0003-0936-4807	Food Allergy Research Education; HOPE APFED/ARTrust Pilot Grant; William F. Milton Fund; Boston Children's Hospital Pediatric Associates Award; Gerber Foundation; National Institutes of Health [R01AI075037, K24DK82792-1]; Research Council, Boston Children's Hospital; Royal Netherlands Academy of Arts and Sciences; Banning de Jong Fund in The Netherlands; Harvard Digestive Diseases Center [P30 DK034854]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI075037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [15H05786] Funding Source: KAKEN	Food Allergy Research Education; HOPE APFED/ARTrust Pilot Grant; William F. Milton Fund; Boston Children's Hospital Pediatric Associates Award; Gerber Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Council, Boston Children's Hospital; Royal Netherlands Academy of Arts and Sciences; Banning de Jong Fund in The Netherlands(Netherlands Government); Harvard Digestive Diseases Center; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by Food Allergy Research & Education, the HOPE APFED/ARTrust Pilot Grant, the William F. Milton Fund, and the Boston Children's Hospital Pediatric Associates Award (to M.K.O.); the Gerber Foundation (to S.N. and E.F.), National Institutes of Health grants R01AI075037 (to E.F.) and K24DK82792-1 (to S.N.); the Research Council, Boston Children's Hospital (pilot study, to S.N. and E.F.); and the Ter Meulen Fund of the Royal Netherlands Academy of Arts and Sciences and the Banning de Jong Fund in The Netherlands (to W.S.L.). This work was also supported by the Harvard Digestive Diseases Center (grant P30 DK034854).	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Cianferoni A, 2014, IMMUNOTHERAPY-UK, V6, P321, DOI 10.2217/imt.14.3; Dickel H, 2010, CONTACT DERMATITIS, V63, P215, DOI 10.1111/j.1600-0536.2010.01769.x; Divekar R, 2015, CURR OPIN ALLERGY CL, V15, P98, DOI 10.1097/ACI.0000000000000133; Doherty TA, 2015, J ALLERGY CLIN IMMUN, V136, P792, DOI 10.1016/j.jaci.2015.05.048; Egawa M, 2013, IMMUNITY, V38, P570, DOI 10.1016/j.immuni.2012.11.014; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Furuta GT, 2015, NEW ENGL J MED, V373, P1640, DOI 10.1056/NEJMra1502863; Giacomin PR, 2012, J IMMUNOL, V189, P4371, DOI 10.4049/jimmunol.1200691; Greenhawt M, 2013, J ALLER CL IMM-PRACT, V1, P332, DOI 10.1016/j.jaip.2013.05.009; Han HW, 2014, J CLIN INVEST, V124, P5442, DOI 10.1172/JCI77798; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Hinds DA, 2013, NAT GENET, V45, P907, DOI 10.1038/ng.2686; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jin HL, 2009, J CLIN INVEST, V119, P47, DOI 10.1172/JCI32310; Judd LM, 2016, AM J PHYSIOL-GASTR L, V310, pG13, DOI 10.1152/ajpgi.00290.2015; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim BS, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005374; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; LANE PW, 1972, J HERED, V63, P135, DOI 10.1093/oxfordjournals.jhered.a108252; Leung DYM, 2013, ALLERGOL INT, V62, P151, DOI 10.2332/allergolint.13-RAI-0564; Lexmond WS, 2014, AM J GASTROENTEROL, V109, P646, DOI 10.1038/ajg.2014.12; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; MOLOFSKY AB, 2015, IMMUNITY, V42, P1005, DOI [DOI 10.1016/j.immuni.2015.06.006, DOI 10.1016/J.IMMUNI.2015.06.006]; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Morita H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134226; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Mulder DJ, 2011, MUCOSAL IMMUNOL, V4, P139, DOI 10.1038/mi.2010.88; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129, P1048, DOI 10.1016/j.jaci.2012.01.063; Nakashima C, 2014, J ALLERGY CLIN IMMUN, V134, P100, DOI 10.1016/j.jaci.2014.02.026; Niranjan R, 2013, IMMUNOL CELL BIOL, V91, P408, DOI 10.1038/icb.2013.21; Niranjan R, 2013, AM J PHYSIOL-GASTR L, V304, pG1087, DOI 10.1152/ajpgi.00070.2013; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Oyoshi MK, 2015, CURR OPIN PEDIATR, V27, P741, DOI 10.1097/MOP.0000000000000284; Oyoshi MK, 2015, J ALLERGY CLIN IMMUN, V135, P1511, DOI 10.1016/j.jaci.2014.12.1923; Oyoshi MK, 2014, J ALLERGY CLIN IMMUN, V133, P309, DOI 10.1016/j.jaci.2013.12.1045; Oyoshi MK, 2011, J CLIN INVEST, V121, P2210, DOI 10.1172/JCI43586; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Ram G, 2015, ANN ALLERG ASTHMA IM, V115, P224, DOI 10.1016/j.anai.2015.07.004; Rothenberg ME, 2015, GASTROENTEROLOGY, V148, P1143, DOI 10.1053/j.gastro.2015.02.002; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Savinko T, 2012, J INVEST DERMATOL, V132, P1392, DOI 10.1038/jid.2011.446; Scharschmidt TC, 2009, ALLERGY CLIN IMMUNOL, V124, P496; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schneider E, 2009, J IMMUNOL, V183, P3591, DOI 10.4049/jimmunol.0900328; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Simon D, 2015, ALLERGY, V70, P443, DOI 10.1111/all.12570; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Suzukawa M, 2008, J IMMUNOL, V181, P5981, DOI 10.4049/jimmunol.181.9.5981; Tamagawa-Mineoka R, 2014, J AM ACAD DERMATOL, V70, P882, DOI 10.1016/j.jaad.2014.01.867; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Tordesillas L, 2014, J CLIN INVEST, V124, P4965, DOI 10.1172/JCI75660; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Ziegler SF, 2012, J ALLERGY CLIN IMMUN, V130, P845, DOI 10.1016/j.jaci.2012.07.010	75	40	40	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1367	+		10.1016/j.jaci.2016.02.034	http://dx.doi.org/10.1016/j.jaci.2016.02.034			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27233150	Bronze			2022-12-18	WOS:000389542700016
J	Sordillo, JE; Kelly, R; Bunyavanich, S; McGeachie, M; Qiu, WL; Croteau-Chonka, DC; Soto-Quiros, M; Avila, L; Celedon, JC; Brehm, JM; Weiss, ST; Gold, DR; Litonjua, AA				Sordillo, Joanne E.; Kelly, Roxanne; Bunyavanich, Supinda; McGeachie, Michael; Qiu, Weiliang; Croteau-Chonka, Damien C.; Soto-Quiros, Manuel; Avila, Lydiana; Celedon, Juan C.; Brehm, John M.; Weiss, Scott T.; Gold, Diane R.; Litonjua, Augusto A.			Genome-wide expression profiles identify potential targets for gene-environment interactions in asthma severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Dust mite allergen; asthma exacerbation; asthma severity; IL-9; gene expression	HOUSE-DUST MITE; DER-P-I; LUNG-FUNCTION; ALLERGEN EXPOSURE; SENSITIZATION; CHILDREN; IL-9; CHILDHOOD; POLYMORPHISMS; COCKROACH	Background: Gene-environment interaction studies using genome-wide association study data are often underpowered after adjustment for multiple comparisons. Differential gene expression in response to the exposure of interest can capture the most biologically relevant genes at the genome-wide level. Objective: We used differential genome-wide expression profiles from the Epidemiology of Home Allergens and Asthma birth cohort in response to Der f 1 allergen (sensitized vs nonsensitized) to inform a gene-environment study of dust mite exposure and asthma severity. Methods: Polymorphisms in differentially expressed genes were identified in genome-wide association study data from the Childhood Asthma Management Program, a clinical trial in childhood asthmatic patients. Home dust mite allergen levels (<10 or >= 10 mu g/g dust) were assessed at baseline, and (>= 1) severe asthma exacerbation (emergency department visit or hospitalization for asthma in the first trial year) served as the disease severity outcome. The Genetics of Asthma in Costa Rica Study and a Puerto Rico/Connecticut asthma cohort were used for replication. Results: IL9, IL5, and proteoglycan 2 expression (PRG2) was upregulated in Der f 1-stimulated PBMCs from dust mite-sensitized patients (adjusted P < .04). IL9 polymorphisms (rs11741137, rs2069885, and rs1859430) showed evidence for interaction with dust mite in the Childhood Asthma Management Program (P = .02 to .03), with replication in the Genetics of Asthma in Costa Rica Study (P = .04). Subjects with the dominant genotype for these IL9 polymorphisms were more likely to report a severe asthma exacerbation if exposed to increased dust mite levels. Conclusions: Genome-wide differential gene expression in response to dust mite allergen identified IL9, a biologically plausible gene target that might interact with environmental dust mite to increase severe asthma exacerbations in children.	[Sordillo, Joanne E.; Kelly, Roxanne; McGeachie, Michael; Qiu, Weiliang; Croteau-Chonka, Damien C.; Weiss, Scott T.; Gold, Diane R.; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Sordillo, Joanne E.; Kelly, Roxanne; McGeachie, Michael; Qiu, Weiliang; Croteau-Chonka, Damien C.; Weiss, Scott T.; Gold, Diane R.; Litonjua, Augusto A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Pediat, Dept Genet & Genom Sci, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA; [Soto-Quiros, Manuel; Avila, Lydiana; Celedon, Juan C.] Hosp Nacl Ninos Dr Carlos Saenz Herrera, Div Pediat Pulmonol, San Jose, Costa Rica; [Brehm, John M.] UPMC, Childrens Hosp Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sordillo, JE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA.	rejoa@channing.harvard.edu	Avila, Lydiana/D-5638-2015	Avila, Lydiana/0000-0002-9579-1591	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL117191, R00HL109162, K01HL004370, K04HL001079, P01HL083069, K99HL109162, R37HL066289, U01HL065899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI035786, R01AI118833, R01AI056230, R01AI035786] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NHLBI NIH HHS [P01-HL83069, R37HL066289, R00HL109162, HL1079, R37 HL066289, HL04370, U01-HL065899, K99 HL109162, HL117191, R00 HL109162] Funding Source: Medline; NIAID NIH HHS [AI035786, R01 AI118833, R01-AI056230] Funding Source: Medline	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahluwalia SK, 2013, J ALLERGY CLIN IMMUN, V132, P830, DOI 10.1016/j.jaci.2013.05.005; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1999, Control Clin Trials, V20, P91; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Aschard H, 2009, GENES IMMUN, V10, P559, DOI 10.1038/gene.2009.46; Brehm JM, 2012, AM J RESP CRIT CARE, V186, P140, DOI 10.1164/rccm.201203-0431OC; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Bunyavanich S, 2012, CLIN EXP ALLERGY, V42, P229, DOI 10.1111/j.1365-2222.2011.03874.x; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chruszcz M, 2012, J BIOL CHEM, V287, P7388, DOI 10.1074/jbc.M111.311159; Custovic A, 2012, J INVEST ALLERG CLIN, V22, P393; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Forno E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040383; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Gounni AS, 2004, J IMMUNOL, V173, P2771, DOI 10.4049/jimmunol.173.4.2771; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; Horka H, 2012, J IMMUNOL, V188, P2669, DOI 10.4049/jimmunol.1100529; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Kanchongkittiphon W, 2015, ENVIRON HEALTH PERSP, V123, P6, DOI [10.1289/ehp.1307922, 10.1289/ehp.123-A6]; Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC; Lalani T, 1999, ANN ALLERG ASTHMA IM, V82, P317, DOI 10.1016/S1081-1206(10)63281-4; Melen E, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.023135; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Noelle RJ, 2010, NAT REV IMMUNOL, V10, P683, DOI 10.1038/nri2848; Parker JM, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-14; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Schuurhof A, 2010, PEDIATR PULM, V45, P608, DOI 10.1002/ppul.21229; Sharma S, 2009, AM J RESP CRIT CARE, V179, P356, DOI 10.1164/rccm.200808-1268OC; Sordillo JE, 2011, J ALLERGY CLIN IMMUN, V127, P1165, DOI 10.1016/j.jaci.2011.01.066; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wang TN, 2006, INT J IMMUNOGENET, V33, P105, DOI 10.1111/j.1744-313X.2006.00578.x	33	40	41	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2015	136	4					885	+		10.1016/j.jaci.2015.02.035	http://dx.doi.org/10.1016/j.jaci.2015.02.035			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CT7EJ	25913104	Green Accepted, Green Submitted			2022-12-18	WOS:000362976300007
J	Herro, R; Antunes, RD; Aguilera, AR; Tamada, K; Croft, M				Herro, Rana; Antunes, Ricardo Da Silva; Aguilera, Amelia Roman; Tamada, Koji; Croft, Michael			Tumor necrosis factor superfamily 14 (LIGHT) controls thymic stromal lymphopoietin to drive pulmonary fibrosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pulmonary fibrosis; asthma; IPF; bronchial epithelial cell; TNFSF14; LIGHT; TSLP; HVEM	ATOPIC-DERMATITIS; MECHANISMS; PATHOGENESIS; CHEMOKINES; EXPRESSION; TSLP; TNF	Background: Pulmonary fibrosis is characterized by excessive accumulation of collagen and a-smooth muscle actin in the lung. The key molecules that promote these phenotypes are of clinical interest. Objectives: Thymic stromal lymphopoietin (TSLP) has been found at high levels in patients with asthma and idiopathic pulmonary fibrosis, and TSLP has been proposed as a primary driver of lung fibrotic disease. We asked whether tumor necrosis factor superfamily protein 14 (TNFSF14) (aka LIGHT) controls TSLP production to initiate fibrosis. Methods: Expression of TSLP and initiation of pulmonary fibrosis induced by bleomycin were assessed in mice deficient in LIGHT. The ability of recombinant LIGHT, given intratracheally to naive mice, to promote TSLP and fibrosis was also determined. Results: Genetic deletion of LIGHT abolished lung TSLP expression driven by bleomycin, accompanied by near-complete absence of accumulation of lung collagen and alpha-smooth muscle actin. Furthermore, recombinant LIGHT administered in vivo induced lung expression of TSLP in the absence of other inflammatory stimuli, and strikingly reproduced the primary features of bleomycin-driven disease in a TSLP-dependent manner. Blockade of LIGHT binding to either of its receptors, herpes virus entry mediator and lymphotoxin beta receptor, inhibited clinical symptoms of pulmonary fibrosis, and correspondingly both receptors were found on human bronchial epithelial cells, a primary source of TSLP. Moreover, LIGHT induced TSLP directly in human bronchial epithelial cells and synergized with IL-13 and TGF-beta in vivo to promote TSLP in the lungs and drive fibrosis. Conclusions: These results show that LIGHT is a profibrogenic cytokine that may be a key driver of TSLP production during the initiation and development of lung fibrotic disease.	[Herro, Rana; Antunes, Ricardo Da Silva; Aguilera, Amelia Roman; Croft, Michael] La Jolla Inst Allergy & Immunol, Div Immune Regulat, La Jolla, CA 92037 USA; [Tamada, Koji] Yamaguchi Univ, Sch Med, Dept Immunol, Yamaguchi, Japan	La Jolla Institute for Immunology; Yamaguchi University	Croft, M (corresponding author), La Jolla Inst Allergy & Immunol, Div Immune Regulat, 9420 Athena Circle, La Jolla, CA 92037 USA.	mick@lji.org		da Silva Antunes, Ricardo/0000-0001-9785-5272	National Institutes of Health [AI070535, AI100905]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI100905, U19AI070535] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institutes of Health (grant nos. AI070535 and AI100905 to M.C.).	Anand S, 2006, J CLIN INVEST, V116, P1045, DOI 10.1172/JCI27083; Boin F, 2009, NAT REV RHEUMATOL, V5, P357, DOI 10.1038/nrrheum.2009.108; Carpino N, 2004, MOL CELL BIOL, V24, P2584, DOI 10.1128/MCB.24.6.2584-2592.2004; Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051268; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Comeau MR, 2010, MUCOSAL IMMUNOL, V3, P138, DOI 10.1038/mi.2009.134; Croft M, 2013, NAT REV DRUG DISCOV, V12, P147, DOI 10.1038/nrd3930; Datta A, 2013, J IMMUNOL, V191, P4867, DOI 10.4049/jimmunol.1300588; Doherty TA, 2011, NAT MED, V17, P596, DOI 10.1038/nm.2356; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Huaux F, 2003, J IMMUNOL, V171, P5470, DOI 10.4049/jimmunol.171.10.5470; Izuhara K, 2014, ALLERGOL INT, V63, P143, DOI 10.2332/allergolint.13-RAI-0663; Kirstein F, 2010, J ALLERGY CLIN IMMUN, V126, P347, DOI 10.1016/j.jaci.2010.04.028; Miyata M, 2009, EUR J IMMUNOL, V39, P3078, DOI 10.1002/eji.200939302; Moeller A, 2008, INT J BIOCHEM CELL B, V40, P362, DOI 10.1016/j.biocel.2007.08.011; Oh MH, 2011, J IMMUNOL, V186, P7232, DOI 10.4049/jimmunol.1100504; Rosenbloom J, 2010, ANN INTERN MED, V152, P159, DOI 10.7326/0003-4819-152-3-201002020-00007; Scheu S, 2002, J EXP MED, V195, P1613, DOI 10.1084/jem.20020215; Thannickal VJ, 2004, ANNU REV MED, V55, P395, DOI 10.1146/annurev.med.55.091902.103810; Wang Y, 2005, J CLIN INVEST, V115, P711, DOI 10.1172/JCI200522982; Wilson MS, 2009, MUCOSAL IMMUNOL, V2, P103, DOI 10.1038/mi.2008.85; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhu Z, 2011, SCI REP-UK, V1, DOI 10.1038/srep00023	28	40	42	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					757	768		10.1016/j.jaci.2014.12.1936	http://dx.doi.org/10.1016/j.jaci.2014.12.1936			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25680454	Green Accepted			2022-12-18	WOS:000360913300028
J	Laidlaw, TM; Boyce, JA				Laidlaw, Tanya M.; Boyce, Joshua A.			Platelets in patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Platelet; samter triad; aspirin-exacerbated respiratory disease; asthma; nasal polyp; leukotriene; thromboxane; prostaglandin; eosinophil	ACTIVATING-FACTOR; P-SELECTIN; INDUCED BRONCHOCONSTRICTION; ALLERGIC INFLAMMATION; ENDOTHELIAL-CELLS; EOSINOPHIL MIGRATION; ASTHMATIC SUBJECTS; ATOPIC-DERMATITIS; MEMBRANE-PROTEIN; BRONCHIAL-ASTHMA	Aspirin-exacerbated respiratory disease (AERD) is a chronic inflammatory disease characterized clinically by the triad of asthma, nasal polyposis, and pathognomonic respiratory reactions after ingestion of aspirin. It is a distinct syndrome associated with eosinophilic infiltration of respiratory tissues and excessive production of cysteinyl leukotrienes. Despite the consistent clinical phenotype of the respiratory disease, the underlying pathogenesis of the disease remains unclear. In addition to their role in hemostasis, platelets have the capacity to influence the activation state and function of other immune cells during inflammation and to facilitate granulocyte recruitment into the tissues. Platelets also possess a repertoire of potent preformed mediators of inflammation that are released on activation and are a rich source of newly synthesized lipid mediators that alter vascular permeability and smooth muscle tone. Accordingly, platelet activity has been linked to diverse inflammatory diseases, including asthma. Both human and animal studies strongly suggest that platelet activity is uniquely associated with the pathophysiology of AERD. This article summarizes the evidence supporting an effector role for platelets in asthmatic patients in general and in patients with AERD in particular and considers the potential therapeutic implications.	[Laidlaw, Tanya M.; Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; [Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; [Boyce, Joshua A.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard University; Brigham & Women's Hospital	Laidlaw, TM (corresponding author), Brigham & Womens Hosp, 1 Jimmy Fund Way,Smith Bldg, Boston, MA 02115 USA.	tlaidlaw@partners.org			NHLBI NIH HHS [K23 HL111113] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL111113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMEISEN JC, 1985, INT ARCH ALLER A IMM, V78, P438, DOI 10.1159/000233927; AVERILL FJ, 1992, AM REV RESPIR DIS, V145, P571, DOI 10.1164/ajrccm/145.3.571; Borchers MT, 2002, J LEUKOCYTE BIOL, V71, P1033; BRUIJNZEEL PLB, 1993, J INVEST DERMATOL, V100, P137, DOI 10.1111/1523-1747.ep12462781; Cheng K, 2006, P NATL ACAD SCI USA, V103, P6682, DOI 10.1073/pnas.0601574103; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025, DOI 10.1164/ajrccm/143.5_Pt_1.1025; CHUNG KF, 1991, LIPIDS, V26, P1277, DOI 10.1007/BF02536547; CROVELLO CS, 1993, J BIOL CHEM, V268, P14590; Cummings HE, 2013, J IMMUNOL, V191, P5807, DOI 10.4049/jimmunol.1302187; Evangelista V, 1999, THROMB HAEMOSTASIS, V81, P442; Fujisawa T, 2002, J ALLERGY CLIN IMMUN, V110, P139, DOI 10.1067/mai.2002.126079; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; Hasegawa S, 2010, PLATELETS, V21, P253, DOI 10.3109/09537101003615394; HAYASHI N, 1994, INT ARCH ALLERGY IMM, V104, P57, DOI 10.1159/000236754; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Ishizuka T, 1996, EUR J PHARMACOL, V312, P367, DOI 10.1016/0014-2999(96)00478-5; JANKALA E O, 1961, J Physiol, V159, P381; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Johansson MW, 2012, AM J RESP CRIT CARE, V185, P498, DOI 10.1164/rccm.201109-1712OC; JOHNSON CE, 1986, THORAX, V41, P290, DOI 10.1136/thx.41.4.290; JOHNSTON GI, 1989, J BIOL CHEM, V264, P1816; JOHNSTON SL, 1995, EUR RESPIR J, V8, P411, DOI 10.1183/09031936.95.08030411; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KELLY MT, 1971, J CLIN INVEST, V50, P1044, DOI 10.1172/JCI106575; Klinkhardt U, 2003, CLIN PHARMACOL THER, V73, P232, DOI 10.1067/mcp.2003.13; KNAUER KA, 1981, NEW ENGL J MED, V304, P1404, DOI 10.1056/NEJM198106043042307; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kowal K, 2006, CLIN EXP ALLERGY, V36, P426, DOI 10.1111/j.1365-2222.2006.02446.x; Kupczyk M, 2010, RESP MED, V104, P1404, DOI 10.1016/j.rmed.2010.04.017; Laidlaw TM, 2014, J ALLERGY CLIN IMMUN, V133, P1692, DOI 10.1016/j.jaci.2013.12.1034; Laidlaw TM, 2012, BLOOD, V119, P3790, DOI 10.1182/blood-2011-10-384826; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; Liu T, 2013, P NATL ACAD SCI USA, V110, P16987, DOI 10.1073/pnas.1313185110; Lussana F, 2015, J THROMB HAEMOST, V13, P136, DOI 10.1111/jth.12779; MACLOUF J, 1994, ANN NY ACAD SCI, V714, P143, DOI 10.1111/j.1749-6632.1994.tb12038.x; MARASINI B, 1985, RES CLIN LAB, V15, P247; MAUGERI N, 1994, THROMB HAEMOSTASIS, V72, P450; Meessen NEL, 1996, THORAX, V51, P1192, DOI 10.1136/thx.51.12.1192; MEYERS KM, 1982, AM J PHYSIOL, V243, pR454, DOI 10.1152/ajpregu.1982.243.3.R454; Morimoto R, 2014, J BIOL CHEM, V289, P15566, DOI 10.1074/jbc.M114.558874; Moritani C, 1998, CHEST, V113, P452, DOI 10.1378/chest.113.2.452; MORIYAMA T, 1994, BIOSCI BIOTECH BIOCH, V58, P93, DOI 10.1271/bbb.58.93; MORRISON JFJ, 1991, THORAX, V46, P197, DOI 10.1136/thx.46.3.197; NAJEAN Y, 1969, ANNU REV MED, V20, P47, DOI 10.1146/annurev.me.20.020169.000403; Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Pitchford SC, 2005, BLOOD, V105, P2074, DOI 10.1182/blood-2004-06-2282; Pitchford SC, 2004, BLOOD, V103, P639, DOI 10.1182/blood-2003-05-1707; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; Pitchford SC, 2008, AM J RESP CRIT CARE, V177, P604, DOI 10.1164/rccm.200702-214OC; Raiden S, 2003, LAB INVEST, V83, P589, DOI 10.1097/01.LAB.0000062851.71286.47; Rajan JP, 2015, J ALLERGY CLIN IMMUN, V135, P676, DOI 10.1016/j.jaci.2014.08.020; REID GK, 1990, J BIOL CHEM, V265, P19818; Rendu F, 2001, PLATELETS, V12, P261, DOI 10.1080/09537100120068170; Schatz M, 2014, J ALLERGY CLIN IMMUN, V133, P1549, DOI 10.1016/j.jaci.2013.10.006; SMITH LJ, 1988, AM REV RESPIR DIS, V137, P1015, DOI 10.1164/ajrccm/137.5.1015; Song WL, 2012, J CLIN INVEST, V122, P1459, DOI 10.1172/JCI59262; Soulet C, 2005, J THROMB HAEMOST, V3, P2296, DOI 10.1111/j.1538-7836.2005.01588.x; Takami M, 1998, PHARMACOL RES, V38, P133, DOI 10.1006/phrs.1998.0345; Tornhamre S., 2002, Clinical and Experimental Allergy, V32, P1566, DOI 10.1046/j.1365-2222.2002.01531.x; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WHITTLE BJR, 1978, PROSTAG OTH LIPID M, V16, P373, DOI 10.1016/0090-6980(78)90216-2; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; YASUBA H, 1991, J LIPID MEDIATOR, V4, P5	65	40	42	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1407	1415		10.1016/j.jaci.2015.02.005	http://dx.doi.org/10.1016/j.jaci.2015.02.005			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	26051947	Green Accepted			2022-12-18	WOS:000355933400001
J	Xue, LZ; Fergusson, J; Salimi, M; Panse, I; Ussher, JE; Hegazy, AN; Vinall, SL; Jackson, DG; Hunter, MG; Pettipher, R; Ogg, G; Klenerman, P				Xue, Luzheng; Fergusson, Joannah; Salimi, Maryam; Panse, Isabel; Ussher, James E.; Hegazy, Ahmed N.; Vinall, Shan L.; Jackson, David G.; Hunter, Michael G.; Pettipher, Roy; Ogg, Graham; Klenerman, Paul			Prostaglandin D-2 and leukotriene E-4 synergize to stimulate diverse T(H)2 functions and T(H)2 cell/neutrophil crosstalk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prostaglandin D-2; leukotriene E-4; chemoattractant receptor-homologous molecule expressed on T(H)2 cells; T(H)2 cells; neutrophils	INNATE LYMPHOID-CELLS; HUMAN TH2 CELLS; CYSTEINYL LEUKOTRIENES; CYTOKINE PRODUCTION; RECEPTOR; ASTHMA; CRTH2; IDENTIFICATION; INFLAMMATION; EXPRESSION	Background: Prostaglandin D-2 (PGD(2)) and cysteinyl leukotrienes (cysLTs) are lipid mediators derived from mast cells, which activate T(H)2 cells. The combination of PGD(2) and cysLTs (notably cysteinyl leukotriene E-4 [LTE4]) enhances T(H)2 cytokine production. However, the synergistic interaction of cysLTs with PGD(2) in promoting T(H)2 cell activation is still poorly understood. The receptors for these mediators are drug targets in the treatment of allergic diseases, and hence understanding their interaction is likely to have clinical implications. Objective: We aimed to comprehensively define the roles of PGD(2), LTE4, and their combination in activating human T(H)2 cells and how such activation might allow the T(H)2 cells to engage downstream effectors, such as neutrophils, which contribute to the pathology of allergic responses. Methods: The effects of PGD(2), LTE4, and their combination on human T(H)2 cell gene expression were defined by using a microarray, and changes in specific inflammatory pathways were confirmed by means of PCR array, quantitative RT-PCR, ELISA, Luminex, flow cytometry, and functional assays, including analysis of downstream neutrophil activation. Blockade of PGD(2) and LTE4 was tested by using TM30089, an antagonist of chemoattractant receptor-homologous molecule expressed on T(H)2 cells, and montelukast, an antagonist of cysteinyl leukotriene receptor 1. Results: PGD(2) and LTE4 altered the transcription of a wide range of genes and induced diverse functional responses in T(H)2 cells, including cell adhesion, migration, and survival and cytokine production. The combination of these lipids synergistically or additively enhanced T(H)2 responses and, strikingly, induced marked production of diverse nonclassical T(H)2 inflammatory mediators, including IL-22, IL-8, and GMCSF, at concentrations sufficient to affect neutrophil activation. Conclusions: PGD(2) and LTE4 activate T(H)2 cells through different pathways but act synergistically to promote multiple downstream effector functions, including neutrophil migration and survival. Combined inhibition of both PGD(2) and LTE4 pathways might provide an effective therapeutic strategy for allergic responses, particularly those involving interaction between T(H)2 cells and neutrophils, such as in patients with severe asthma.	[Xue, Luzheng; Salimi, Maryam; Panse, Isabel; Ogg, Graham; Klenerman, Paul] Univ Oxford, John Radcliffe Hosp, Oxford NIHR Biomed Res Ctr, Nuffield Dept Med,Translat Immunol Lab, Oxford OX3 9DU, England; [Xue, Luzheng] Univ Oxford, Nuffield Dept Med, Resp Med Unit, Oxford OX3 9DU, England; [Fergusson, Joannah; Ussher, James E.; Klenerman, Paul] Univ Oxford, Nuffield Dept Med, Peter Medawar Bldg Pathogen Res, Oxford OX3 9DU, England; [Salimi, Maryam; Jackson, David G.; Ogg, Graham] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DU, England; [Hegazy, Ahmed N.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Translat Gastroenterol Unit, Oxford OX3 9DU, England; [Vinall, Shan L.; Hunter, Michael G.; Pettipher, Roy] Atopix Therapeut Ltd, Abingdon, Oxon, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford	Xue, LZ (corresponding author), Univ Oxford, John Radcliffe Hosp, Oxford NIHR Biomed Res Ctr, Nuffield Dept Med,Translat Immunol Lab, Oxford OX3 9DU, England.	luzheng.xue@ndm.ox.ac.uk	Ussher, James/O-4493-2019	Ussher, James/0000-0001-9222-7680; klenerman, paul/0000-0003-4307-9161; Ogg, Graham/0000-0002-3097-045X; Fergusson, Joannah/0000-0001-9223-1209; , david/0000-0002-4133-9364; Hegazy, Ahmed N./0000-0002-2946-8251	Wellcome Trust [WT091663MA, 092871/Z/10/Z]; Medical Research Council [CFRXNC00/CF00.G1]; NIHR; Oxford Martin School; British Medical Association; Oxfordshire Health Services Research Committee Research Grant [1075]; Oxford Dominions Trust; European Molecular Biology Organization long-term fellowship [ALTF1161-2012]; Marie Curie Fellowship [330621]; National Institutes of Health [U19AI082630]; National Institute for Health Research Senior Investigator [WT 091663]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI082630] Funding Source: NIH RePORTER; Medical Research Council [MC_UU_12010/5, MC_U137884182, MC_UU_12010/2, G1100134] Funding Source: researchfish; National Institute for Health Research [NF-SI-0510-10204] Funding Source: researchfish; MRC [MC_UU_12010/5, G1100134, MC_UU_12010/2, MC_U137884182] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR(National Institute for Health Research (NIHR)); Oxford Martin School; British Medical Association; Oxfordshire Health Services Research Committee Research Grant; Oxford Dominions Trust; European Molecular Biology Organization long-term fellowship(European Molecular Biology Organization (EMBO)); Marie Curie Fellowship(European Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute for Health Research Senior Investigator; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Wellcome Trust (WT091663MA to P.K. and 092871/Z/10/Z to J.F.), the Medical Research Council (CFRXNC00/CF00.G1 to G.O. and D.G.J.), the NIHR (Biomedical Research Centre Programme to L.X., G.O., and M.S.), the Oxford Martin School (to P.K.), the British Medical Association (James Trust 2011; to G.O., P.K., and L.X.), the Oxfordshire Health Services Research Committee Research Grant (1075 to L.X.), the Oxford Dominions Trust (to J.E.U.), the European Molecular Biology Organization long-term fellowship (ALTF1161-2012 to A.N.H.), the Marie Curie Fellowship (330621 to A.N.H.), and the National Institutes of Health (U19AI082630 to L.X. and P.K.). P.K. is a National Institute for Health Research Senior Investigator and is funded by WT 091663 MA.	DRANSFIELD I, 1994, J IMMUNOL, V153, P1254; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; FORD PM, 1977, INT ARCH ALLER A IMM, V53, P56, DOI 10.1159/000231731; Fujitani Y, 2002, J IMMUNOL, V168, P443, DOI 10.4049/jimmunol.168.1.443; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Himmel ME, 2011, EUR J IMMUNOL, V41, P306, DOI 10.1002/eji.201040459; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Jones TR, 2009, P NATL ACAD SCI USA, V106, P1826, DOI 10.1073/pnas.0808843106; Kanaoka Y, 2013, J BIOL CHEM, V288, P10967, DOI 10.1074/jbc.C113.453704; Kikuchi S, 2005, INT ARCH ALLERGY IMM, V137, P7, DOI 10.1159/000085425; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Mamedova L, 2005, BIOCHEM PHARMACOL, V71, P115, DOI 10.1016/j.bcp.2005.10.003; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moore WC, 2014, J ALLERGY CLIN IMMUN, V133, P1557, DOI 10.1016/j.jaci.2013.10.011; Nagata K, 2003, PROSTAG LEUKOTR ESS, V69, P169, DOI 10.1016/S0952-3278(03)00078-4; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Parmentier CN, 2012, J ALLERGY CLIN IMMUN, V129, P1136, DOI 10.1016/j.jaci.2012.01.057; Paruchuri S, 2008, J BIOL CHEM, V283, P16477, DOI 10.1074/jbc.M705822200; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; PHILLIPS GD, 1989, J APPL PHYSIOL, V66, P304, DOI 10.1152/jappl.1989.66.1.304; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Robinson DS, 2000, BRIT MED BULL, V56, P956, DOI 10.1258/0007142001903625; Sampson SE, 1997, THORAX, V52, P513, DOI 10.1136/thx.52.6.513; Sarra Massimiliano, 2012, Inflammation & Allergy Drug Targets, V11, P313; SCHLEIMER RP, 1985, J ALLERGY CLIN IMMUN, V76, P369, DOI 10.1016/0091-6749(85)90656-6; SMITH WB, 1995, BLOOD, V86, P3938, DOI 10.1182/blood.V86.10.3938.bloodjournal86103938; Takeshita K, 2004, INT IMMUNOL, V16, P947, DOI 10.1093/intimm/dxh096; Tanaka K, 2004, BIOCHEM BIOPH RES CO, V316, P1009, DOI 10.1016/j.bbrc.2004.02.151; TAYLOR GW, 1989, LANCET, V1, P584; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wood LG, 2012, CHEST, V142, P86, DOI 10.1378/chest.11-1838; Xue LZ, 2007, BIOCHEM PHARMACOL, V73, P843, DOI 10.1016/j.bcp.2006.11.021; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Xue LZ, 2012, J IMMUNOL, V188, P694, DOI 10.4049/jimmunol.1102474; Xue LZ, 2009, J IMMUNOL, V182, P7580, DOI 10.4049/jimmunol.0804090; Xue LZ, 2005, J IMMUNOL, V175, P6531, DOI 10.4049/jimmunol.175.10.6531; Yamashita N, 2002, CELL IMMUNOL, V219, P92, DOI 10.1016/S0008-8749(02)00565-8; Zhao Y, 2010, INT ARCH ALLERGY IMM, V151, P297, DOI 10.1159/000250438	42	40	42	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2015	135	5					1358	U419		10.1016/j.jaci.2014.09.006	http://dx.doi.org/10.1016/j.jaci.2014.09.006			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH4DA	25441644	Green Published, hybrid			2022-12-18	WOS:000353980700030
J	Silverberg, JI; Braunstein, M; Lee-Wong, M				Silverberg, Jonathan I.; Braunstein, Marc; Lee-Wong, Mary			Association between climate factors, pollen counts, and childhood hay fever prevalence in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hay fever prevalence; rhinoconjunctivitis; relative humidity; indoor heating; ultraviolet index; stratospheric ozone levels; air temperature; Palmer drought index; precipitation; rain pollen count; pediatric; children	ALLERGIC RHINITIS; ASTHMA; SYMPTOMS; LATITUDE; CHILDREN; DISEASE; ECZEMA; AIR	Background: Climate factors and pollen counts may play a role in hay fever. Objective: We sought to determine the impact of specific climate factors and pollen counts on the US prevalence of hay fever and statewide variation in prevalence. Methods: We used a merged analysis of the 2007 National Survey of Children's Health from a representative sample of 91,642 children aged 0 to 17 years and the 2006-2007 National Climate Data Center and Weather Service measurements of relative humidity (%), indoor heating degree days, precipitation, Palmer Hydrological Drought Index, clear sky and issued ultraviolet indices, stratospheric ozone levels, and outdoor air temperature and National Allergy Bureau total pollen counts. Multivariate survey logistic regression models controlled for sex, race/ethnicity, age, household income, and birthplace. Results: The US prevalence of hay fever in childhood was 18.0% (95% CI, 17.7% to 18.2%), with the highest prevalence in southeastern and southern states. Hay fever prevalence was significantly lower with second and third quartile mean annual relative humidity (logistic regression, P <= .01 for both), fourth quartile mean annual Palmer Hydrological Drought Index (P = .02), third and fourth quartile mean annual heating degree days (P < .0001 for both), and third and fourth quartile mean annual stratospheric ozone levels but increased with second, third, and fourth quartile mean annual temperature (P <= .02 for both), fourth quartile mean annual precipitation (P = .0007), mean total pollen counts (P = .01), and second, third, and fourth quartile issued ultraviolet index (P <= .0001 for all). Principal-component analysis was also used to determine the combined effects of correlated climate variables and pollen counts. Conclusions: This study provides evidence of the influence of climate on the US prevalence of childhood hay fever.	[Silverberg, Jonathan I.] Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA; St Lukes Roosevelt Hosp, New York, NY USA	Northwestern University; Mount Sinai St. Luke's; Mount Sinai West	Silverberg, JI (corresponding author), Northwestern Univ, Dept Dermatol, Ste 1400,680 Lakeshore Dr, Chicago, IL 60611 USA.	JonathanISilverberg@Gmail.com	silverberg, jonathan/ABH-2765-2021	silverberg, jonathan/0000-0003-3686-7805				Aronne G, 2006, PROTOPLASMA, V228, P127, DOI 10.1007/s00709-006-0173-3; Baroody FM, 2000, ARCH OTOLARYNGOL, V126, P749, DOI 10.1001/archotol.126.6.749; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehmer D, 2010, EXPERT REV MED DEVIC, V7, P21, DOI 10.1586/ERD.09.56; Cingi Cemal, 2010, Ther Adv Respir Dis, V4, P209, DOI 10.1177/1753465810374610; D'Amato G, 2007, ALLERGY, V62, P11, DOI 10.1111/j.1398-9995.2006.01271.x; Erbas B, 2007, INT J ENVIRON HEAL R, V17, P361, DOI 10.1080/09603120701628693; Hoppin JA, 2011, AM J EPIDEMIOL, V173, P544, DOI 10.1093/aje/kwq392; Hughes AM, 2011, PEDIAT ALLERG IMM-UK, V22, P327, DOI 10.1111/j.1399-3038.2010.01099.x; Jones AM, 2004, SCI TOTAL ENVIRON, V326, P151, DOI 10.1016/j.scitotenv.2003.11.021; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; KARL TR, 1986, J CLIM APPL METEOROL, V25, P145, DOI 10.1175/1520-0450(1986)025<0145:AMTETT>2.0.CO;2; Leong SC, 2011, RHINOLOGY, V49, P499, DOI 10.4193/Rhino11.118; Mullins RJ, 2011, PEDIAT ALLERG IMM-UK, V22, P583, DOI 10.1111/j.1399-3038.2011.01151.x; Oktaria V, 2013, ANN ALLERG ASTHMA IM, V110, P80, DOI 10.1016/j.anai.2012.11.005; OPHIR D, 1988, ANN ALLERGY, V60, P239; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Sheffield PE, 2011, MT SINAI J MED, V78, P78, DOI 10.1002/msj.20232; Silverberg JI, 2013, J INVEST DERMATOL, V133, P1752, DOI 10.1038/jid.2013.19; Silverberg JI, 2013, JAMA PEDIATR, V167, P554, DOI 10.1001/jamapediatrics.2013.1319; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Williams CG, 2013, AM J BOT, V100, P1184, DOI 10.3732/ajb.1300085; Wjst Matthias, 2009, Allergy Asthma Clin Immunol, V5, P8, DOI 10.1186/1710-1492-5-8	25	40	40	1	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2015	135	2					463	U624		10.1016/j.jaci.2014.08.003	http://dx.doi.org/10.1016/j.jaci.2014.08.003			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CB1FL	25304658				2022-12-18	WOS:000349372300019
J	Sharma, S; Zhou, XB; Thibault, DM; Himes, BE; Liu, A; Szefler, SJ; Strunk, R; Castro, M; Hansel, NN; Diette, GB; Vonakis, BM; Adkinson, NF; Avila, L; Soto-Quiros, M; Barraza-Villareal, A; Lemanske, RF; Solway, J; Krishnan, J; White, SR; Cheadle, C; Berger, AE; Fan, JS; Boorgula, MP; Nicolae, D; Gilliland, F; Barnes, K; London, SJ; Martinez, F; Ober, C; Celedon, JC; Carey, VJ; Weiss, ST; Raby, BA				Sharma, Sunita; Zhou, Xiaobo; Thibault, Derek M.; Himes, Blanca E.; Liu, Andy; Szefler, Stanley J.; Strunk, Robert; Castro, Mario; Hansel, Nadia N.; Diette, Gregory B.; Vonakis, Becky M.; Adkinson, N. Franklin, Jr.; Avila, Lydiana; Soto-Quiros, Manuel; Barraza-Villareal, Albino; Lemanske, Robert F., Jr.; Solway, Julian; Krishnan, Jerry; White, Steven R.; Cheadle, Chris; Berger, Alan E.; Fan, Jinshui; Boorgula, Meher Preethi; Nicolae, Dan; Gilliland, Frank; Barnes, Kathleen; London, Stephanie J.; Martinez, Fernando; Ober, Carole; Celedon, Juan C.; Carey, Vincent J.; Weiss, Scott T.; Raby, Benjamin A.			A genome-wide survey of CD4(+) lymphocyte regulatory genetic variants identifies novel asthma genes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; CD4(+) lymphocytes; regulatory variants; expression quantitative trait locus; haplotype; integrative genomics	ASSOCIATION; CELLS; POLYMORPHISMS; INFLAMMATION; CLUSTER; OBESITY; ACID	Background: Genome-wide association studies have yet to identify the majority of genetic variants involved in asthma. We hypothesized that expression quantitative trait locus (eQTL) mapping can identify novel asthma genes by enabling prioritization of putative functional variants for association testing. Objective: We evaluated 6706 cis-acting expression-associated variants (eSNPs) identified through a genome-wide eQTL survey of CD4(+) lymphocytes for association with asthma. Methods: eSNPs were tested for association with asthma in 359 asthmatic patients and 846 control subjects from the Childhood Asthma Management Program, with verification by using family-based testing. Significant associations were tested for replication in 579 parent-child trios with asthma from Costa Rica. Further functional validation was performed by using formaldehyde-assisted isolation of regulatory elements (FAIRE) quantitative PCR and chromatin immunoprecipitation PCR in lung-derived epithelial cell lines (Beas-2B and A549) and Jurkat cells, a leukemia cell line derived from T lymphocytes. Results: Cis-acting eSNPs demonstrated associations with asthma in both cohorts. We confirmed the previously reported association of ORMDL3/GSDMB variants with asthma (combined P = 2.9 x 10(-8)). Reproducible associations were also observed for eSNPs in 3 additional genes: fatty acid desaturase 2 (FADS2; P = .002), N-acetyl-alpha-D-galactosaminidase (NAGA; P = .0002), and Factor XIII, A1 (F13A1; P = .0001). Subsequently, we demonstrated that FADS2 mRNA is increased in CD4(+) lymphocytes in asthmatic patients and that the associated eSNPs reside within DNA segments with histone modifications that denote open chromatin status and confer enhancer activity. Conclusions: Our results demonstrate the utility of eQTL mapping in the identification of novel asthma genes and provide evidence for the importance of FADS2, NAGA, and F13A1 in the pathogenesis of asthma.	[Sharma, Sunita; Zhou, Xiaobo; Thibault, Derek M.; Himes, Blanca E.; Carey, Vincent J.; Weiss, Scott T.; Raby, Benjamin A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Sharma, Sunita; Zhou, Xiaobo; Thibault, Derek M.; Himes, Blanca E.; Carey, Vincent J.; Weiss, Scott T.; Raby, Benjamin A.] Harvard Univ, Sch Med, Boston, MA USA; [Sharma, Sunita; Zhou, Xiaobo; Raby, Benjamin A.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Liu, Andy; Szefler, Stanley J.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Strunk, Robert; Castro, Mario] Washington Univ, Sch Med, Dept Pediat, Div Allergy Immunol & Pulm Med, St Louis, MO USA; [Hansel, Nadia N.; Diette, Gregory B.; Vonakis, Becky M.; Adkinson, N. Franklin, Jr.; Cheadle, Chris; Berger, Alan E.; Fan, Jinshui; Boorgula, Meher Preethi; Barnes, Kathleen] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Avila, Lydiana; Soto-Quiros, Manuel] Hosp Nacl Ninos Dr Carlos Saenz Herrera, San Jose, Costa Rica; [Barraza-Villareal, Albino] Hosp Infantil Mexico Dr Federico Gomez, Natl Inst Publ Hlth Mexico, Mexico City, DF, Mexico; [Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Med, Div Allergy & Immunol, Madison, WI USA; [Solway, Julian; White, Steven R.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; [Nicolae, Dan; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Krishnan, Jerry] Univ Illinois Hosp & Hlth Sci Syst, Dept Med, Chicago, IL USA; [Gilliland, Frank] Univ So Calif, Dept Med, Div Environm & Occupat Hlth, Los Angeles, CA USA; [London, Stephanie J.] NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; [Martinez, Fernando] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Celedon, Juan C.] Univ Pittsburgh, Childrens Hosp Pittsburgh UPMC, Dept Pediat, Div Pulm Med Allergy & Immunol, Pittsburgh, PA 15260 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; National Jewish Health; Washington University (WUSTL); Johns Hopkins University; Hospital Infantil de Mexico Federico Gomez; Instituto Nacional de Salud Publica; University of Wisconsin System; University of Wisconsin Madison; University of Chicago; University of Chicago; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sharma, S (corresponding author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA.	sunita.sharma@channing.harvard.edu	London, Stephanie/C-3734-2019; Boorgula, Meher Preethi/AAC-6252-2022; Avila, Lydiana/D-5638-2015; Raby, Benjamin/AAK-3866-2021	London, Stephanie/0000-0003-4911-5290; Avila, Lydiana/0000-0002-9579-1591; Zhou, Xiaobo/0000-0002-7127-2869; Szefler, Stanley/0000-0002-6911-3199; Vonakis, Becky/0000-0003-4174-6514; Nicolae, Dan/0000-0002-0918-4630; Ober, Carole/0000-0003-4626-9809	National Heart, Lung, and Blood Institute/ National Institutes of Health (NIH/NHLBI) [R01 HL086601, RC2 HL101543]; NIH and National Center for Research Resources [1 UL1 RR025780]; NIH [K99 HL105663, P01ES011627]; NIH/NHLBI [K08 HL096833]; Division of Intramural Research, National Institute of Environmental Health Sciences, NIH;  [R37 HL066289];  [U01 HL075419];  [U01 HL65899];  [P01 HL083069]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430, UL1TR001082] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL086601, R00HL105663, K08HL096833, U01HL065899, RC2HL101543, R37HL066289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K24ES021098, P01ES011627, ZIAES049019] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute/ National Institutes of Health (NIH/NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH and National Center for Research Resources; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Division of Intramural Research, National Institute of Environmental Health Sciences, NIH; ; ; ; ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by R01 HL086601, RC2 HL101543, R37 HL066289, and K08 HL096833. All work on data collected from the CAMP Genetic Ancillary Study was conducted at the Channing Laboratory of the Brigham andWomen's Hospital under appropriate CAMP policies and human subject protections. This work is supported by grants R01 HL086601 and RC2 HL101543 from the National Heart, Lung, and Blood Institute/ National Institutes of Health (NIH/NHLBI). The CAMP Genetics Ancillary Study is supported by U01 HL075419, U01 HL65899, and P01 HL083069 and through the Colorado CTSA grant 1 UL1 RR025780 from the NIH and National Center for Research Resources. B. E. H. was supported by NIH K99 HL105663. S. S. receives additional support from K08 HL096833 from NIH/NHLBI. Additional support was provided by NIH P01ES011627 (PI: F. Gilliland). Supported in part by the Division of Intramural Research, National Institute of Environmental Health Sciences, NIH.	Busse M, 2012, J IMMUNOL, V189, P1975, DOI 10.4049/jimmunol.1103581; Calder PC, 2008, MOL NUTR FOOD RES, V52, P885, DOI 10.1002/mnfr.200700289; Chambers JC, 2011, NAT GENET, V43, P1131, DOI 10.1038/ng.970; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Fisher RA., 1948, AM STAT, V2, P30, DOI DOI 10.2307/2681650; Fukuda T, 1995, J ALLERGY CLIN IMMUN, V96, P1076, DOI 10.1016/S0091-6749(95)70193-1; Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506; Gu W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047288; Hao K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003029; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Lattka E, 2010, J LIPID RES, V51, P182, DOI 10.1194/jlr.M900289-JLR200; LEW DB, 1990, LUNG, V168, P273, DOI 10.1007/BF02719704; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Loo LWM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030477; Luca D, 2008, AM J HUM GENET, V82, P453, DOI 10.1016/j.ajhg.2007.11.003; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Marioni RE, 2010, GENES BRAIN BEHAV, V9, P348, DOI 10.1111/j.1601-183X.2010.00565.x; Martinelli N, 2008, AM J CLIN NUTR, V88, P941, DOI 10.1093/ajcn/88.4.941; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Murphy A, 2010, HUM MOL GENET, V19, P4745, DOI 10.1093/hmg/ddq392; Naukkarinen J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000976; Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888; OKAYAMA Y, 1995, CHEM IMMUNOL, V61, P114; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Qiu W., 2012, AM THOR SOC INT C PH, pA2521; Rzehak P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013261; Sanderson P, 1997, J LEUKOCYTE BIOL, V62, P771, DOI 10.1002/jlb.62.6.771; Sanmugalingam D, 2000, J LEUKOCYTE BIOL, V68, P38; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Schaeffer L, 2006, HUM MOL GENET, V15, P1745, DOI 10.1093/hmg/ddl117; Schmid CD, 2007, CELL, V131, P831, DOI 10.1016/j.cell.2007.11.017; Sharma SMA, 2010, EQTL MAPPING PERIPHE; SIBBALD B, 1980, ARCH DIS CHILD, V55, P354, DOI 10.1136/adc.55.5.354; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Standl M, 2012, ALLERGY, V67, P83, DOI 10.1111/j.1398-9995.2011.02708.x; Stranger BE, 2012, PLOS GENET, V8, P272, DOI 10.1371/journal.pgen.1002639; Tanaka T, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000338; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Verlaan DJ, 2009, AM J HUM GENET, V85, P377, DOI 10.1016/j.ajhg.2009.08.007; Ward LD, 2012, NAT BIOTECHNOL, V30, P1095, DOI 10.1038/nbt.2422	44	40	40	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2014	134	5					1153	1162		10.1016/j.jaci.2014.04.011	http://dx.doi.org/10.1016/j.jaci.2014.04.011			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AT4UN	24934276	Green Accepted, Green Published			2022-12-18	WOS:000344938900021
J	Pai, SY; de Boer, H; Massaad, MJ; Chatila, TA; Keles, S; Jabara, HH; Janssen, E; Lehmann, LE; Hanna-Wakim, R; Dbaibo, G; McDonald, DR; Al-Herz, W; Geha, RS				Pai, Sung-Yun; de Boer, Helen; Massaad, Michel J.; Chatila, Talal A.; Keles, Sevgi; Jabara, Haifa H.; Janssen, Erin; Lehmann, Leslie E.; Hanna-Wakim, Rima; Dbaibo, Ghassan; McDonald, Douglas R.; Al-Herz, Waleed; Geha, Raif S.			Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Pai, Sung-Yun; de Boer, Helen; Lehmann, Leslie E.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; [Pai, Sung-Yun; Lehmann, Leslie E.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Massaad, Michel J.; Chatila, Talal A.; Keles, Sevgi; Jabara, Haifa H.; Janssen, Erin; McDonald, Douglas R.; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA USA; [Hanna-Wakim, Rima; Dbaibo, Ghassan] Amer Univ Beirut, Div Pediat Infect Dis, Beirut, Lebanon; [Al-Herz, Waleed] Kuwait Univ, Dept Pediat, Fac Med, Kuwait, Kuwait	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; American University of Beirut; Kuwait University	Pai, SY (corresponding author), Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.	sung-yun.pai@childrens.harvard.edu	Pai, Sung-Yun/AAH-7762-2019; Dbaibo, Ghassan S./X-2978-2019	Pai, Sung-Yun/0000-0002-0158-8147; Chatila, Talal/0000-0001-7439-2762; Janssen, Erin/0000-0002-0687-2550	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065617, R01AI100315, R21AI087627] Funding Source: NIH RePORTER; NIAID NIH HHS [5R01AI065617, R01 AI100315, R01 AI065617, 1R01AI100315, 1R21AI087627, R21 AI087627] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Mousa H, 2013, J ALLERGY CLIN IMMUN, V131, P1244, DOI 10.1016/j.jaci.2012.12.663; [Anonymous], 2009, NEW ENGL J MED, V361, P2046; Bittner TC, 2010, KLIN PADIATR, V222, P351, DOI 10.1055/s-0030-1265135; Engelhardt KR, 2009, J ALLERGY CLIN IMMUN, V124, P1289, DOI 10.1016/j.jaci.2009.10.038; Gatz SA, 2011, BONE MARROW TRANSPL, V46, P552, DOI 10.1038/bmt.2010.169; Jabara HH, 2012, NAT IMMUNOL, V13, P612, DOI 10.1038/ni.2305; Mizesko MC, 2013, J ALLERGY CLIN IMMUN, V131, P840, DOI 10.1016/j.jaci.2012.12.1568; Randall KL, 2011, J EXP MED, V208, P2305, DOI 10.1084/jem.20110345; Randall KL, 2009, NAT IMMUNOL, V10, P1283, DOI 10.1038/ni.1820	9	40	42	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2014	134	1					221	223		10.1016/j.jaci.2014.02.023	http://dx.doi.org/10.1016/j.jaci.2014.02.023			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AL2BH	24698323	Green Accepted			2022-12-18	WOS:000338930300029
J	van Til, NP; Sarwari, R; Visser, TP; Hauer, J; Lagresle-Peyrou, C; van der Velden, G; Malshetty, V; Cortes, P; Jollet, A; Danos, O; Cassani, B; Zhang, F; Thrasher, AJ; Fontana, E; Poliani, PL; Cavazzana, M; Verstegen, MMA; Villa, A; Wagemaker, G				van Til, Niek P.; Sarwari, Roya; Visser, Trudi P.; Hauer, Julia; Lagresle-Peyrou, Chantal; van der Velden, Guus; Malshetty, Vidyasagar; Cortes, Patricia; Jollet, Arnaud; Danos, Olivier; Cassani, Barbara; Zhang, Fang; Thrasher, Adrian J.; Fontana, Elena; Poliani, Pietro L.; Cavazzana, Marina; Verstegen, Monique M. A.; Villa, Anna; Wagemaker, Gerard			Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; lentiviral gene therapy; autoimmune reactions	T-CELL-DEVELOPMENT; RAG-1-DEFICIENT MICE; V(D)J RECOMBINATION; IN-VIVO; VECTOR; EXPRESSION; RAG1; LYMPHOCYTES; NUCLEASES; DELIVERY	Background: Recombination-activating gene 1 (RAG1) deficiency results in severe combined immunodeficiency (SCID) caused by a complete lack of T and B lymphocytes. If untreated, patients succumb to recurrent infections. Objectives: We sought to develop lentiviral gene therapy for RAG1-induced SCID and to test its safety. Methods: Constructs containing the viral spleen-focus-forming virus (SF), ubiquitous promoters, or cell type-restricted promoters driving sequence-optimized RAG1 were compared for efficacy and safety in sublethally preconditioned Rag1(-/-) mice undergoing transplantation with transduced bone marrow progenitors. Results: Peripheral blood CD3(+) T-cell reconstitution was achieved with SF, ubiquitous promoters, and cell type-restricted promoters but 3- to 18-fold lower than that seen in wild-type mice, and with a compromised CD4(+)/CD8(+) ratio. Mitogen-mediated T-cell responses and T cell-dependent and T cell-independent B-cell responses were not restored, and T-cell receptor patterns were skewed. Reconstitution of mature peripheral blood B cells was approximately 20-fold less for the SF vector than in wild-type mice and often not detectable with the other promoters, and plasma immunoglobulin levels were abnormal. Two months after transplantation, gene therapy-treated mice had rashes with cellular tissue infiltrates, activated peripheral blood CD44(+) CD69(+) T cells, high plasma IgE levels, antibodies against double-stranded DNA, and increased B cell-activating factor levels. Only rather high SF vector copy numbers could boost T-and B-cell reconstitution, but mRNA expression levels during T-and B-cell progenitor stages consistently remained less than wild-type levels. Conclusions: These results underline that further development is required for improved expression to successfully treat patients with RAG1-induced SCID while maintaining low vector copy numbers and minimizing potential risks, including autoimmune reactions resembling Omenn syndrome.	[van Til, Niek P.; Sarwari, Roya; Visser, Trudi P.; van der Velden, Guus; Verstegen, Monique M. A.; Wagemaker, Gerard] Erasmus Univ, Med Ctr, Dept Hematol, NL-3015 GE Rotterdam, Netherlands; [Hauer, Julia; Lagresle-Peyrou, Chantal; Cavazzana, Marina] Univ Paris 05, INSERM U768, Paris, France; [Hauer, Julia; Lagresle-Peyrou, Chantal; Cavazzana, Marina] Hop Necker Enfants Malad, Paris, France; [Hauer, Julia] Univ Dusseldorf, Dept Pediat Oncol Hematol & Clin Immunol, Ctr Child & Adolescent Hlth, Dusseldorf, Germany; [Malshetty, Vidyasagar; Cortes, Patricia] Mt Sinai Sch Med, Inst Immunol, Dept Med, New York, NY USA; [Jollet, Arnaud; Danos, Olivier] Hop Necker Enfants Malad, INSERM, U781, Lab Transfert Genes, Paris, France; [Cassani, Barbara; Villa, Anna] CNR IRGB, Milan Unit, Milan, Italy; [Cassani, Barbara] Humanitas Clin & Res Ctr, Milan, Italy; [Zhang, Fang; Thrasher, Adrian J.] UCL, Mol Immunol Unit, Ctr Immunodeficiency, Inst Child Hlth, London WC1E 6BT, England; [Fontana, Elena; Poliani, Pietro L.] Univ Brescia, Dept Pathol, I-25121 Brescia, Italy; [Cavazzana, Marina] Univ Paris 05, Dept Biotherapy, Hop Necker Enfants Malad, AP HP, Paris, France; [Cavazzana, Marina] Grp Hosp Univ Ouest, INSERM, Ctr Invest Clin Integre Biotherapies, AP HP, Paris, France; [Villa, Anna] Telethon Inst Gene Therapy H San Raffaele, Milan, Italy	Erasmus University Rotterdam; Erasmus MC; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Heinrich Heine University Dusseldorf; Icahn School of Medicine at Mount Sinai; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); University of London; University College London; University of Brescia; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante et de la Recherche Medicale (Inserm); Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget)	Wagemaker, G (corresponding author), Erasmus Univ, Med Ctr, Room Na 202k,Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	g.wagemaker@genetherapy.nl	Peyrou, Chantal Lagresle/AAK-9689-2020; Fontana, Elena/K-3845-2016; Peyrou, Chantal Lagresle/H-2911-2017; Cassani, Barbara/K-3871-2016; POLIANI, Pietro Luigi/E-8145-2010	Peyrou, Chantal Lagresle/0000-0002-2216-6453; Fontana, Elena/0000-0001-8853-3335; Peyrou, Chantal Lagresle/0000-0002-2216-6453; Cassani, Barbara/0000-0002-4115-8109; POLIANI, Pietro Luigi/0000-0002-5662-8978; van Til, Niek/0000-0002-9515-4103; Thrasher, Adrian/0000-0002-6097-6115; Verstegen, Monique/0000-0001-9908-6673; Villa, Anna/0000-0003-4428-9013; Cavazzana, Marina/0000-0002-0264-0891	European Commission [QLK3-CT-2001-00427-INHERINET, LSHB-CT-2004-005242-CONSERT, 222878-PERSIST, 261387-CELL-PID, RF-2009-148589]; Netherlands Organization for Health Research ZonMw [43100016]; National Institutes of Health; Association Francaise contre les Myopathies; Wellcome Trust; Fondazione Telethon Funding Source: Custom	European Commission(European CommissionEuropean Commission Joint Research Centre); Netherlands Organization for Health Research ZonMw(Netherlands Organization for Health Research and Development); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); Wellcome Trust(Wellcome TrustEuropean Commission); Fondazione Telethon(Fondazione Telethon)	Supported by the European Commission's 5th, 6th and 7th Framework Programs, contracts QLK3-CT-2001-00427-INHERINET, LSHB-CT-2004-005242-CONSERT, 222878-PERSIST, 261387-CELL-PID, and RF-2009-148589 to A. V., as well as by The Netherlands Organization for Health Research ZonMw, program grant 43100016.; N. P. van Til, R. Sarwari, T. P. Visser, and G. Wagemaker have received research support and travel support from The Netherlands Organization for Health Research ZonMw and the European Commission. G. van der Velden has received research support from The Netherlands Organization for Health Research ZonMw and the European Commission. V. Malshetty has received research support from the National Institutes of Health. P. Cortes has received research support, travel support, and fees for participation in review activities from the National Institutes of Health. O. Danos has received research support from the Association Francaise contre les Myopathies. A. J. Thrasher has received research support from the Wellcome Trust and is a panel member for the Hong Kong Research Grants Council. The rest of the authors declare that they have no relevant conflicts of interest.	Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126/science.1233151; Barreto V, 2001, EUR J IMMUNOL, V31, P3763, DOI 10.1002/1521-4141(200112)31:12<3763::AID-IMMU3763>3.0.CO;2-Y; Biffi A, 2013, SCIENCE, V341, P864, DOI 10.1126/science.1233158; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Cartier N, 2009, SCIENCE, V326, P818, DOI 10.1126/science.1171242; Cavazzana-Calvo M, 2012, CURR OPIN IMMUNOL, V24, P580, DOI 10.1016/j.coi.2012.08.008; Cavazzana-Calvo M, 2010, NATURE, V467, P318, DOI 10.1038/nature09328; Cesana D, 2012, J CLIN INVEST, V122, P1667, DOI 10.1172/JCI62189; Chou J, 2012, J ALLERGY CLIN IMMUN, V130, P1414, DOI 10.1016/j.jaci.2012.06.012; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Giblin W, 2009, BLOOD, V113, P2965, DOI 10.1182/blood-2008-07-165167; Hsu LY, 2003, IMMUNITY, V19, P105, DOI 10.1016/S1074-7613(03)00181-X; Huston MW, 2011, MOL THER, V19, P1867, DOI 10.1038/mt.2011.127; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; Kerns HM, 2010, BLOOD, V115, P2146, DOI 10.1182/blood-2009-09-241869; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Lagresle-Peyrou C, 2006, BLOOD, V107, P63, DOI 10.1182/blood-2005-05-2032; Lagresle-Peyrou C, 2008, MOL THER, V16, P396, DOI 10.1038/sj.mt.6300353; Lombardo A, 2007, NAT BIOTECHNOL, V25, P1298, DOI 10.1038/nbt1353; Marrella V, 2007, J CLIN INVEST, V117, P1260, DOI 10.1172/JCI30928; Marrella V, 2012, BLOOD, V120, P1005, DOI 10.1182/blood-2012-01-406827; Marrella V, 2011, CURR OPIN ALLERGY CL, V11, P525, DOI 10.1097/ACI.0b013e32834c311a; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morgan ME, 2005, HUM IMMUNOL, V66, P13, DOI 10.1016/j.humimm.2004.05.016; Mussolino C, 2012, CURR OPIN BIOTECH, V23, P644, DOI 10.1016/j.copbio.2012.01.013; Pike-Overzet K, 2011, LEUKEMIA, V25, P1471, DOI 10.1038/leu.2011.106; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Sather BD, 2011, MOL THER, V19, P515, DOI 10.1038/mt.2010.259; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; van der Loo JCM, 2012, GENE THER, V19, P872, DOI 10.1038/gt.2012.37; van Til NP, 2012, MOL THER, V20, P1968, DOI 10.1038/mt.2012.110; van Til NP, 2010, BLOOD, V115, P5329, DOI 10.1182/blood-2009-11-252874; van Til NP, 2005, MOL THER, V11, P26, DOI 10.1016/j.ymthe.2004.09.012; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Walter JE, 2010, J EXP MED, V207, P1541, DOI 10.1084/jem.20091927; WAYNE J, 1994, IMMUNITY, V1, P95, DOI 10.1016/1074-7613(94)90103-1; WAYNE J, 1994, J IMMUNOL, V153, P5491; Yannoutsos N, 2004, NAT IMMUNOL, V5, P443, DOI 10.1038/ni1053; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287; Yu W, 1999, SCIENCE, V285, P1080, DOI 10.1126/science.285.5430.1080; Zufferey R, 1998, J VIROL, V72, P9873, DOI 10.1128/JVI.72.12.9873-9880.1998	41	40	41	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1116	1123		10.1016/j.jaci.2013.10.009	http://dx.doi.org/10.1016/j.jaci.2013.10.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24332219	Bronze			2022-12-18	WOS:000333531700023
J	Chana, KK; Fenwick, PS; Nicholson, AG; Barnes, PJ; Donnelly, LE				Chana, Kirandeep K.; Fenwick, Peter S.; Nicholson, Andrew G.; Barnes, Peter J.; Donnelly, Louise E.			Identification of a distinct glucocorticosteroid-insensitive pulmonary macrophage phenotype in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Matrix metalloproteinase 9; flow cytometry; CD163; CD206	TUMOR-ASSOCIATED MACROPHAGES; BONE-MARROW-TRANSPLANTATION; ALVEOLAR MACROPHAGES; INDUCED SPUTUM; BRONCHOALVEOLAR LAVAGE; FUNCTIONAL-HETEROGENEITY; ALTERNATIVE ACTIVATION; CYTOKINE RELEASE; GUINEA-PIG; LUNG	Background: In patients with chronic obstructive pulmonary disease (COPD), pulmonary macrophages increase in number, release increased levels of inflammatory mediators, and respond poorly to glucocorticosteroids. Whether this is due to a change in macrophage phenotype or localized activation is unknown. Objective: We sought to investigate whether macrophages from patients with COPD are a distinct phenotype. Methods: Macrophage populations were isolated from human lung tissue from nonsmokers, smokers, and patients with COPD by using Percoll density gradients. Five macrophage populations were isolated on the basis of density (1.011-1.023, 1.023-1.036, 1.036-1.048, 1.048-1.061, and 1.061-1.073 g/mL), and cell-surface expression of CD14, CD16, CD163, CD40, and CD206 was assessed by using flow cytometry. Release of active matrix metalloproteinase 9, TNF-alpha, CXCL8, and IL-10 was measured by using ELISA. Results: The 2 least dense fractions were more than 90% apoptotic/necrotic, with the remaining fractions greater than 70% viable. Macrophages from nonsmokers and smokers were CD163(+), CD206(+), CD14(+), and CD40(-), whereas macrophages from patients with COPD were less defined, showing significantly lower expression of all receptors. There were no differences in receptor expression associated with density. Macrophages from patients with COPD of a density of 1.036 to 1.048 g/mL released higher levels of active matrix metalloproteinase 9 compared with cells from nonsmokers, with no difference between the remaining fractions. This population of macrophages from patients with COPD was less responsive to budesonide compared with those from nonsmokers and smokers when stimulated with LPS. Glucocorticosteroid insensitivity was selective for proinflammatory cytokines because budesonide inhibition of LPS-stimulated IL-10 release was similar for all macrophages. Conclusions: This study identifies a specific macrophage phenotype in the lungs of patients with COPD who are glucocorticosteroid insensitive with a density of 1.036 to 1.048 g/mL but do not correspond to the current concept of macrophage phenotypes.	[Chana, Kirandeep K.; Fenwick, Peter S.; Nicholson, Andrew G.; Barnes, Peter J.; Donnelly, Louise E.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; [Nicholson, Andrew G.] Royal Brompton & Harefield NHS Fdn Trust, Dept Histopathol, London, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust	Donnelly, LE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	l.donnelly@imperial.ac.uk		Barnes, Peter/0000-0002-5122-4018; Donnelly, Louise/0000-0002-0753-5425	BBSRC, United Kingdom; National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton Hospital and Harefield Foundation NHS Trust and Imperial College London; National Institute for Health Research [NF-SI-0611-10148] Funding Source: researchfish	BBSRC, United Kingdom(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton Hospital and Harefield Foundation NHS Trust and Imperial College London; National Institute for Health Research(National Institute for Health Research (NIHR))	Supported by a studentship from the BBSRC, United Kingdom. Also supported by the National Institute of Health Research Respiratory Disease Biomedical Research Unit at the Royal Brompton Hospital and Harefield Foundation NHS Trust and Imperial College London.	Barnes PJ, 2004, J COPD, V1, P50; Berenson CS, 2006, J INFECT DIS, V194, P1375, DOI 10.1086/508428; Buhling F, 2000, IMMUNOL LETT, V71, P185, DOI 10.1016/S0165-2478(00)00164-4; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; Culpitt SV, 2005, RESP MED, V99, P703, DOI 10.1016/j.rmed.2004.10.022; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635, DOI 10.1164/ajrccm.160.5.9811058; Culpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC; DAUBER JH, 1983, J RETICULOENDOTH SOC, V33, P119; Finney-Hayward TK, 2010, AM J RESP CELL MOL, V43, P296, DOI 10.1165/rcmb.2008-0373OC; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Hahn I, 2011, AM J RESP CELL MOL, V45, P534, DOI 10.1165/rcmb.2010-0279OC; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; HOLIAN A, 1983, J RETICULOENDOTH SOC, V33, P157; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K., 2001, FASEB Journal, V15, P1110; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542, DOI 10.1164/ajrccm.155.2.9032192; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kunz LIZ, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-34; KUO HP, 1993, CHEST, V104, P1773, DOI 10.1378/chest.104.6.1773; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Marques LJ, 1997, AM J RESP CRIT CARE, V156, P1700, DOI 10.1164/ajrccm.156.5.9611052; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Matute-Bello G, 2004, J IMMUNOL METHODS, V292, P25, DOI 10.1016/j.jim.2004.05.010; MOKOENA T, 1985, J CLIN INVEST, V75, P624, DOI 10.1172/JCI111740; MURPHY MA, 1984, J LEUKOCYTE BIOL, V35, P39, DOI 10.1002/jlb.35.1.39; NAKSTAD B, 1989, ULTRASTRUCT PATHOL, V13, P1; OGHISO Y, 1987, J LEUKOCYTE BIOL, V42, P188, DOI 10.1002/jlb.42.3.188; Ratcliffe MJ, 2012, BMC PHARMACOL TOXICO, V13, DOI 10.1186/2050-6511-13-15; Rogler G, 1998, CLIN EXP IMMUNOL, V112, P205; Russell REK, 2002, AM J RESP CELL MOL, V26, P602, DOI 10.1165/ajrcmb.26.5.4685; Saetta M, 1997, AM J RESP CRIT CARE, V156, P1633, DOI 10.1164/ajrccm.156.5.9701081; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; Shapiro SD, 2002, BIOCHEM SOC T, V30, P98, DOI 10.1042/BST0300098; Shaykhiev R, 2009, J IMMUNOL, V183, P2867, DOI 10.4049/jimmunol.0900473; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; SKOLD CM, 1992, CHEST, V101, P989, DOI 10.1378/chest.101.4.989; Smith SJ, 2006, BRIT J PHARMACOL, V149, P393, DOI 10.1038/sj.bjp.0706885; St-Laurent J, 2009, J ASTHMA, V46, P1, DOI 10.1080/02770900802444211; Taut K, 2008, AM J RESP CELL MOL, V38, P105, DOI 10.1165/rcmb.2007-0132OC; Taylor AE, 2010, EUR RESPIR J, V35, P1039, DOI 10.1183/09031936.00036709; Taylor ML, 2000, CLIN IMMUNOL, V94, P33, DOI 10.1006/clim.1999.4803; THOMPSON B, 1985, EXP LUNG RES, V9, P237, DOI 10.3109/01902148509057526; Tudhope SJ, 2008, J PHARMACOL EXP THER, V324, P306, DOI 10.1124/jpet.107.127670; Van Ginderachter JA, 2006, IMMUNOBIOLOGY, V211, P487, DOI 10.1016/j.imbio.2006.06.002; Verreck FAW, 2006, J LEUKOCYTE BIOL, V79, P285, DOI 10.1189/jlb.0105015; WALKER WS, 1974, IMMUNOLOGY, V26, P1025	51	40	44	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					207	+		10.1016/j.jaci.2013.08.044	http://dx.doi.org/10.1016/j.jaci.2013.08.044			21	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24176116				2022-12-18	WOS:000329105700028
J	Loureiro, CC; Duarte, IF; Gomes, J; Carrola, J; Barros, AS; Gil, AM; Bousquet, J; Bom, AT; Rocha, SM				Loureiro, Claudia Chaves; Duarte, Iola F.; Gomes, Joana; Carrola, Joana; Barros, Antonio S.; Gil, Ana M.; Bousquet, Jean; Bom, Ana Todo; Rocha, Silvia M.			Urinary metabolomic changes as a predictive biomarker of asthma exacerbation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Loureiro, Claudia Chaves] Hosp Univ Coimbra, Serv Pneumol, Coimbra, Portugal; [Loureiro, Claudia Chaves; Bom, Ana Todo] Univ Coimbra, Fac Med, Ctr Pneumol, Coimbra, Portugal; [Duarte, Iola F.; Carrola, Joana; Gil, Ana M.] Univ Aveiro, Dept Quim, CICECO, P-3800 Aveiro, Portugal; [Gomes, Joana; Barros, Antonio S.; Rocha, Silvia M.] Univ Aveiro, Dept Quim, QOPNA, P-3800 Aveiro, Portugal; [Bousquet, Jean] Univ Hosp, Hop Arnaud de Villeneuve, Montpellier, France; [Bousquet, Jean] INSERM, CESP Ctr Res Epidemiol & Populat Hlth, U1018, Resp & Environm Epidemiol Team, Villejuif, France	Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade de Aveiro; Universidade de Aveiro; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Loureiro, CC (corresponding author), Hosp Univ Coimbra, Serv Pneumol, Coimbra, Portugal.	cl_loureiro@hotmail.com	Loureiro, Claudia Chaves/AAW-3420-2021; Todo Bom, Ana/AHD-3630-2022; Duarte, Iola F/H-5505-2013; Gil, Ana M/B-5440-2013; Barros, António S./B-5847-2009; Gil, Ana/O-3871-2019; Bousquet, Jean/O-4221-2019; Carrola, Joana/N-9674-2015	Loureiro, Claudia Chaves/0000-0003-0438-6126; Duarte, Iola F/0000-0003-4289-9256; Gil, Ana M/0000-0003-3766-4364; Barros, António S./0000-0002-9103-5852; Gil, Ana/0000-0003-3766-4364; Carrola, Joana/0000-0003-1155-8539; Todo-Bom, Ana/0000-0002-1850-6689; Rocha, Silvia/0000-0002-0396-3019				Caldeira M, 2011, J CHROMATOGR A, V1218, P3771, DOI 10.1016/j.chroma.2011.04.026; Carrola J, 2011, J PROTEOME RES, V10, P221, DOI 10.1021/pr100899x; Rocha SM, 2012, J CHROMATOGR A, V1252, P155, DOI 10.1016/j.chroma.2012.06.067; Saude EJ, 2011, J ALLERGY CLIN IMMUN, V127, P757, DOI 10.1016/j.jaci.2010.12.1077; Zuo L, 2013, MOL IMMUNOL, V56, P57, DOI 10.1016/j.molimm.2013.04.002	5	40	43	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					261	263		10.1016/j.jaci.2013.11.004	http://dx.doi.org/10.1016/j.jaci.2013.11.004			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24369803	Green Submitted			2022-12-18	WOS:000329105700036
J	Garn, H; Neves, JF; Blumberg, RS; Renz, H				Garn, Holger; Neves, Joana F.; Blumberg, Richard S.; Renz, Harald			Effect of barrier microbes on organ-based inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic inflammation; allergy; asthma; inflammatory bowel disease; hygiene hypothesis; microbiota hypothesis; biodiversity; dysbiosis; microbiome	GENOME-WIDE ASSOCIATION; ALLERGIC AIRWAY INFLAMMATION; TOLL-LIKE RECEPTORS; COWS MILK ALLERGY; GUT MICROBIOTA; INTESTINAL MICROBIOTA; FECAL MICROBIOTA; EARLY-LIFE; ULCERATIVE-COLITIS; IMMUNE-RESPONSES	The prevalence and incidence of chronic inflammatory disorders, including allergies and asthma, as well as inflammatory bowel disease, remain on the increase. Microbes are among the environmental factors that play an important role in shaping normal and pathologic immune responses. Several concepts have been put forward to explain the effect of microbes on the development of these conditions, including the hygiene hypothesis and the microbiota hypothesis. Recently, the dynamics of the development of (intestinal) microbial colonization, its effect on innate and adaptive immune responses (homeostasis), and the role of environmental factors, such as nutrition and others, have been extensively investigated. Furthermore, there is now increasing evidence that a qualitative and quantitative disturbance in colonization (dysbiosis) is associated with dysfunction of immune responses and development of various chronic inflammatory disorders. In this article the recent epidemiologic, clinical, and experimental evidence for this interaction is discussed.	[Garn, Holger; Renz, Harald] Univ Marburg, Inst Lab Med, D-35043 Marburg, Germany; [Neves, Joana F.; Blumberg, Richard S.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Gastroenterol & Hepatol,Sch Med, Boston, MA 02115 USA	Philipps University Marburg; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Renz, H (corresponding author), Univ Marburg, Inst Lab Med, Baldinger Str, D-35043 Marburg, Germany.	renzh@med.uni-marburg.de	Neves, Joana F/J-9406-2014	Neves, Joana F/0000-0001-5842-4162; Garn, Holger/0000-0002-5178-4023	Deutsche Forschungsgemeinschaft (DFG) [SFB/TR22]; German Lung Centre (DZL); LOEWE Centre "Universities Giessen and Marburg Lung Centre" (UGMLC); National Institutes of Health [DK044319, DK051362, DK053056, DK088199]; Harvard Digestive Diseases Center [DK0034854]; DFG; BMBF; Hessen; BMWI; Behring/Rontgen Stiftung; Mead Johnson Nutrition; European Union; Land Hessen; Stiftung Pathobiochemie; Ernst-Wendt-Stiftung; DAAD; ALK-Abello; Allergopharma; Novartis; Abbott; Med-Update; cmeAkademiee; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053056, R01DK044319, R01DK051362, P30DK034854, R01DK088199, R37DK044319, R01DK053056] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Lung Centre (DZL); LOEWE Centre "Universities Giessen and Marburg Lung Centre" (UGMLC); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Digestive Diseases Center; DFG(German Research Foundation (DFG)); BMBF(Federal Ministry of Education & Research (BMBF)); Hessen; BMWI(Federal Ministry for Economic Affairs and Energy (BMWi)); Behring/Rontgen Stiftung; Mead Johnson Nutrition; European Union(European Commission); Land Hessen; Stiftung Pathobiochemie; Ernst-Wendt-Stiftung; DAAD(Deutscher Akademischer Austausch Dienst (DAAD)); ALK-Abello; Allergopharma; Novartis(Novartis); Abbott(Abbott Laboratories); Med-Update; cmeAkademiee; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	H.G. and H. R. are supported by the Deutsche Forschungsgemeinschaft (DFG; SFB/TR22), the German Lung Centre (DZL), and the LOEWE Centre "Universities Giessen and Marburg Lung Centre" (UGMLC). R. S. B. is supported by National Institutes of Health grants DK044319, DK051362, DK053056, and DK088199 and the Harvard Digestive Diseases Center (DK0034854).; Disclosure of potential conflict of interest: H. Garn has consultant arrangements with, is employed by, and has stock/stock options with Sterna Biologicals; has received grants from DFG, BMBF, Hessen, BMWI, and Behring/Rontgen Stiftung; and has received payment for lectures from Mead Johnson Nutrition. H. Renz is President of DGAKI and is on the Seminar Committee for the American Academy of Allergy, Asthma & Immunology; has consultant arrangements with Allergopharma, ALK-Abello, Bencard, Sterna Biologicals, Novartis, and Boehringer Ingelheim; receives grants from DFG, BMBF, the European Union, Land Hessen, Stiftung Pathobiochemie, Ernst-Wendt-Stiftung, DAAD, and ALK-Abello; and has received payment for lectures from Allergopharma, Novartis, Abbott, Med-Update, and cmeAkademiee. The rest of the authors declare that they have no relevant conflicts of interest.	Abraham C, 2011, GASTROENTEROLOGY, V140, P1729, DOI 10.1053/j.gastro.2011.02.012; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Abubucker S, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002358; Adlerberth I, 2009, ACTA PAEDIATR, V98, P229, DOI 10.1111/j.1651-2227.2008.01060.x; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Barrett JC, 2009, NAT GENET, V41, P1330, DOI 10.1038/ng.483; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342, DOI 10.1046/j.1365-2222.1999.00560.x; Blaschitz C, 2010, J CLIN IMMUNOL, V30, P196, DOI 10.1007/s10875-010-9368-7; Blaser MJ, 2009, NAT REV MICROBIOL, V7, P887, DOI 10.1038/nrmicro2245; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; Brand S, 2012, J ALLERGY CLIN IMMUN, V129, P1602, DOI 10.1016/j.jaci.2011.12.963; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009; Caicedo RA, 2005, PEDIATR RES, V58, P625, DOI 10.1203/01.PDR.0000180533.09295.84; Cario E, 2007, GASTROENTEROLOGY, V132, P1359, DOI 10.1053/j.gastro.2007.02.056; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Chung HC, 2012, CELL, V149, P1578, DOI 10.1016/j.cell.2012.04.037; Clarke TB, 2010, NAT MED, V16, P228, DOI 10.1038/nm.2087; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Cox MJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0011044, 10.1371/journal.pone.0008745]; Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061; Davidson R, 2010, BMC PULM MED, V10, DOI 10.1186/1471-2466-10-14; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Dethlefsen L, 2011, P NATL ACAD SCI USA, V108, P4554, DOI 10.1073/pnas.1000087107; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Dobber R, 1992, Dev Immunol, V2, P141, DOI 10.1155/1992/57057; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Duta F, 2006, HISTOCHEM CELL BIOL, V126, P495, DOI 10.1007/s00418-006-0188-z; Ege MJ, 2012, ALLERGY, V67, P1565, DOI 10.1111/all.12028; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Francavilla R, 2012, PEDIAT ALLERG IMM-UK, V23, P420, DOI 10.1111/j.1399-3038.2012.01286.x; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Franke A, 2010, NAT GENET, V42, P292, DOI 10.1038/ng.553; Ganal SC, 2012, IMMUNITY, V37, P171, DOI 10.1016/j.immuni.2012.05.020; Gerhold K, 2003, J ALLERGY CLIN IMMUN, V112, P389, DOI 10.1067/mai.2003.1646; Geuking MB, 2011, IMMUNITY, V34, P794, DOI 10.1016/j.immuni.2011.03.021; Goksor E, 2011, ACTA PAEDIATR, V100, P1561, DOI 10.1111/j.1651-2227.2011.02411.x; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Gronlund MM, 2000, ARCH DIS CHILD-FETAL, V83, pF186, DOI 10.1136/fn.83.3.F186; Hagner S, 2013, ALLERGY, V68, P322, DOI 10.1111/all.12094; Hall JA, 2008, IMMUNITY, V29, P637, DOI 10.1016/j.immuni.2008.08.009; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hill DA, 2012, NAT MED, V18, P538, DOI 10.1038/nm.2657; Hormannsperger G, 2012, J ALLERGY CLIN IMMUN, V129, P1452, DOI 10.1016/j.jaci.2011.12.993; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Hong PY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009964; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Iliev ID, 2012, SCIENCE, V336, P1314, DOI 10.1126/science.1221789; Ismail IH, 2012, PEDIAT ALLERG IMM-UK, V23, P674, DOI 10.1111/j.1399-3038.2012.01328.x; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Johansson MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023031; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Julia A, 2013, GUT; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Karpa KD, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-87; Kaser A, 2010, ANNU REV IMMUNOL, V28, P573, DOI 10.1146/annurev-immunol-030409-101225; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Kim YS, 2004, IMMUNOLOGY, V112, P624, DOI 10.1111/j.1365-2567.2004.01880.x; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Koplin JJ, 2012, ALLERGY, V67, P1415, DOI 10.1111/all.12015; Kronman MP, 2012, PEDIATRICS, V130, pE794, DOI 10.1542/peds.2011-3886; Lange NE, 2012, CLIN EXP ALLERGY, V42, P901, DOI 10.1111/j.1365-2222.2011.03950.x; Lepage P, 2011, GASTROENTEROLOGY, V141, P227, DOI 10.1053/j.gastro.2011.04.011; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058; Lindner C, 2012, J EXP MED, V209, P365, DOI 10.1084/jem.20111980; Lupp C, 2007, CELL HOST MICROBE, V2, P119, DOI 10.1016/j.chom.2007.06.010; Lyons A, 2010, CLIN EXP ALLERGY, V40, P811, DOI 10.1111/j.1365-2222.2009.03437.x; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Magnus MC, 2011, AM J EPIDEMIOL, V174, P1275, DOI 10.1093/aje/kwr242; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Marra F, 2009, PEDIATRICS, V123, P1003, DOI 10.1542/peds.2008-1146; Marsland BJ, 2012, THORAX, V67, P93, DOI 10.1136/thoraxjnl-2011-200750; Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Mei L, 2007, GASTROENTEROLOGY, V132, pA444; Menezes AMB, 2011, CLIN EXP ALLERGY, V41, P218, DOI 10.1111/j.1365-2222.2010.03611.x; Metsala J, 2010, AM J EPIDEMIOL, V171, P1310, DOI 10.1093/aje/kwq074; Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001; Morin S, 2012, MOL NUTR FOOD RES, V56, P1838, DOI 10.1002/mnfr.201200412; Murray CS, 2005, CLIN EXP ALLERGY, V35, P741, DOI 10.1111/j.1365-2222.2005.02259.x; Nagalingam NA, 2012, INFLAMM BOWEL DIS, V18, P968, DOI 10.1002/ibd.21866; Nakayama J, 2011, FEMS IMMUNOL MED MIC, V63, P397, DOI 10.1111/j.1574-695X.2011.00872.x; Nell S, 2010, NAT REV MICROBIOL, V8, P564, DOI 10.1038/nrmicro2403; Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Ouwehand AC, 2001, J ALLERGY CLIN IMMUN, V108, P144, DOI 10.1067/mai.2001.115754; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Papadakis KA, 2007, GASTROENTEROLOGY, V132, pA74; Pasare C, 2004, IMMUNITY, V21, P733, DOI 10.1016/j.immuni.2004.10.006; Patel M, 2005, J IMMUNOL, V174, P7558, DOI 10.4049/jimmunol.174.12.7558; Penders J, 2007, ALLERGY, V62, P1223, DOI 10.1111/j.1398-9995.2007.01462.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Raelson JV, 2007, P NATL ACAD SCI USA, V104, P14747, DOI 10.1073/pnas.0706645104; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2006, IMMUNITY, V25, P319, DOI 10.1016/j.immuni.2006.06.010; Ravel J, 2011, P NATL ACAD SCI USA, V108, P4680, DOI 10.1073/pnas.1002611107; Renz H, 2011, J ALLERGY CLIN IMMUN, V128, pS27, DOI 10.1016/j.jaci.2011.09.039; Renz H, 2011, NAT IMMUNOL, V12, P273, DOI 10.1038/ni0411-273; Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952; Rodriguez B, 2012, FEMS MICROBIOL ECOL, V79, P192, DOI 10.1111/j.1574-6941.2011.01207.x; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; RUMP JA, 1990, IMMUNOBIOLOGY, V181, P406, DOI 10.1016/S0171-2985(11)80509-7; Russell SL, 2012, CURR OPIN GASTROEN, V28, P563, DOI 10.1097/MOG.0b013e3283573017; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P202, DOI 10.1016/S0091-6749(05)80067-3; Scupham AJ, 2006, APPL ENVIRON MICROB, V72, P793, DOI 10.1128/AEM.72.1.793-801.2006; Sel S, 2007, J IMMUNOL, V178, P7805, DOI 10.4049/jimmunol.178.12.7805; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaw MH, 2012, J EXP MED, V209, P251, DOI 10.1084/jem.20111703; Shaw SY, 2010, AM J GASTROENTEROL, V105, P2687, DOI 10.1038/ajg.2010.398; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Standaert-Vitse A, 2006, GASTROENTEROLOGY, V130, P1764, DOI 10.1053/j.gastro.2006.02.009; STARK PL, 1982, J MED MICROBIOL, V15, P189, DOI 10.1099/00222615-15-2-189; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Sudo N, 1997, J IMMUNOL, V159, P1739; Thompson-Chagoyan OC, 2011, INT ARCH ALLERGY IMM, V156, P325, DOI 10.1159/000323893; TLASKALOVAHOGENOVA H, 1983, ANN NY ACAD SCI, V409, P96, DOI 10.1111/j.1749-6632.1983.tb26862.x; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; UMESAKI Y, 1993, IMMUNOLOGY, V79, P32; Vael C, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-68; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Vogel K, 2008, J ALLERGY CLIN IMMUN, V122, P307, DOI 10.1016/j.jaci.2008.05.016; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Wang Q, 2006, J EXP MED, V203, P2853, DOI 10.1084/jem.20062008; Willing B, 2009, INFLAMM BOWEL DIS, V15, P653, DOI 10.1002/ibd.20783; Willing BP, 2010, GASTROENTEROLOGY, V139, P1844, DOI 10.1053/j.gastro.2010.08.049; World Health Organisation (WHO), 2013, GLOB ACT PLAN PREV C; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zaph C, 2008, J EXP MED, V205, P2191, DOI 10.1084/jem.20080720	152	40	43	0	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1465	1478		10.1016/j.jaci.2013.04.031	http://dx.doi.org/10.1016/j.jaci.2013.04.031			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23726530	Green Accepted			2022-12-18	WOS:000320532800002
J	Nicodemus-Johnson, J; Laxman, B; Stern, RK; Sudi, J; Tierney, CN; Norwick, L; Hogarth, DK; McConville, JF; Naureckas, ET; Sperling, AI; Solway, J; Krishnan, JA; Nicolae, DL; White, SR; Ober, C				Nicodemus-Johnson, Jessie; Laxman, Bharathi; Stern, Randi K.; Sudi, Jyotsna; Tierney, Courtney N.; Norwick, Lourdes; Hogarth, Douglas K.; McConville, John F.; Naureckas, Edward T.; Sperling, Anne I.; Solway, Julian; Krishnan, Jerry A.; Nicolae, Dan L.; White, Steven R.; Ober, Carole			Maternal asthma and microRNA regulation of soluble HLA-G in the airway	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; maternal asthma; microRNA; human leukocyte antigen	LEUKOCYTE ANTIGEN-G; INTERLEUKIN-10 LEVELS; EXPRESSION; CYTOKINE; PLASMA; GENE; ASSOCIATION; CANDIDATE; CHILDREN; RHINITIS	Background: We previously reported an interaction between maternal asthma and the child's HLA-G genotype on the child's subsequent risk for asthma. The implicated single nucleotide polymorphism at +3142 disrupted a target site for the microRNA (miR)-152 family. We hypothesized that the interaction effect might be mediated by these miRs. Objective: The objective of this study was to test this hypothesis in adults with asthma who are a subset of the same subjects who participated in our earlier family-based studies. Methods: We measured soluble HLA-G (sHLA-G) concentrations in bronchoalveolar lavage fluid (n = 36) and plasma (n = 57) from adult asthmatic subjects with and without a mother with asthma, and HLA-G and miR-152 family (miR-148a, miR-148b, and miR-152) transcript levels in airway epithelial cells from the same subjects. Results: miR-148b levels were significantly increased in airway epithelial cells from asthmatic subjects with an asthmatic mother compared with those seen in asthmatic subjects without an asthmatic mother, and +3142 genotypes were associated with sHLA-G concentrations in bronchoalveolar lavage fluid among asthmatic subjects with an asthmatic mother but not among those with a nonasthmatic mother. Neither effect was observed in the plasma (sHLA-G) or white blood cells (miRNA). Conclusion: These combined results are consistent with +3142 allele-specific targeting of HLA-G by the miR-152 family and support our hypothesis that miRNA regulation of sHLA-G in the airway is influenced by both the asthma status of the subject's mother and the subject's genotype. Moreover, we demonstrate that the effects of maternal asthma on the gene regulatory landscape in the airways of the mother's children persist into adulthood.	[Nicodemus-Johnson, Jessie; Nicolae, Dan L.; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Laxman, Bharathi; Stern, Randi K.; Sudi, Jyotsna; Tierney, Courtney N.; Norwick, Lourdes; Hogarth, Douglas K.; McConville, John F.; Naureckas, Edward T.; Sperling, Anne I.; Solway, Julian; Krishnan, Jerry A.; Nicolae, Dan L.; White, Steven R.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Nicolae, Dan L.] Univ Chicago, Dept Stat, Chicago, IL 60637 USA; [Ober, Carole] Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Ober, C (corresponding author), Univ Chicago, Dept Human Genet, 920 E 58th St,Rm 425, Chicago, IL 60637 USA.	jnicodem@bsd.uchicago.edu; c-ober@bsd.uchicago.edu	Sperling, Anne/ACZ-2351-2022	Ober, Carole/0000-0003-4626-9809; Sperling, Anne I./0000-0002-4265-9212; Nicolae, Dan/0000-0002-0918-4630	National Institutes of Health [RC2 HL101543, U19 AI095320]; AstraZeneca; Cytokinetics; Novartis; Eisai; Boehringer Ingelheim;  [T32 HL07605]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI095230, R00AI095320, K99AI095320] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AstraZeneca(AstraZeneca); Cytokinetics; Novartis(Novartis); Eisai(Eisai Co Ltd); Boehringer Ingelheim(Boehringer Ingelheim); ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by National Institutes of Health grants RC2 HL101543 (to C.O.) and U19 AI095320 (to S. R. W. and C.O.). J.N.-J. is supported by T32 HL07605.; Disclosure of potential conflict of interest: E. T. Naureckas, A. I. Sperling, J. Solway, J. A. Krishnan, D. L. Nicolae, S. R. White, and C. Ober have received grants from the National Institutes of Health. J. Solway has received grants from AstraZeneca; has received consulting fees or honoraria from Cytokinetics, Novartis, and Eisai; and has received royalties on patents from Boston Scientific. S. R. White has received payment for service on the speakers' bureaus from Boehringer Ingelheim and has received royalties from Marcel-Dekker. The rest of the authors declare that they have no relevant conflicts of interest.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Barker DJP, 2004, ACTA PAEDIATR, V93, P26, DOI 10.1080/08035320410022730; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Borghi A, 2008, ARCH DERMATOL RES, V300, P551, DOI 10.1007/s00403-008-0886-6; Chibana K, 2008, CLIN EXP ALLERGY, V38, P936, DOI 10.1111/j.1365-2222.2008.02969.x; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crestani E, 2004, J ALLERGY CLIN IMMUN, V113, P284, DOI 10.1016/j.jaci.2003.11.009; Eggleston PA, 2009, PEDIATRICS, V123, pS160, DOI 10.1542/peds.2008-2233F; Fainardi E, 2003, J NEUROIMMUNOL, V142, P149, DOI 10.1016/S0165-5728(03)00266-2; Galan I, 2010, THORAX, V65, P398, DOI 10.1136/thx.2009.118992; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; Glas J, 2007, INT IMMUNOL, V19, P621, DOI 10.1093/intimm/dxm027; Hunt JS, 2005, FASEB J, V19, P681, DOI 10.1096/fj.04-2078rev; Ishitani A, 2003, J IMMUNOL, V171, P1376, DOI 10.4049/jimmunol.171.3.1376; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28, DOI 10.1164/ajrccm.164.supplement_2.2106061; KAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P345, DOI 10.1016/0091-6749(83)90090-8; Lemanske RF, 2002, PEDIAT ALLERG IMM-UK, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Li CL, 2009, P NATL ACAD SCI USA, V106, P5767, DOI 10.1073/pnas.0901173106; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176, DOI 10.1164/ajrccm.158.1.9710014; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loisel D, 2012, MOL HUM REPROD; Marsh DG, 1997, NAT GENET, V15, P389; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Melen E, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-86; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Ongaro A, 2010, HUM IMMUNOL, V71, P342, DOI 10.1016/j.humimm.2010.01.015; Osei-Kumah A, 2006, PLACENTA, V27, P847, DOI 10.1016/j.placenta.2005.08.007; Osei-Kumah A, 2008, CYTOKINE, V43, P187, DOI 10.1016/j.cyto.2008.05.008; Osei-Kumah A, 2010, INFLAMM RES, V59, P349, DOI 10.1007/s00011-009-0102-y; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Pike KC, 2008, BJOG-INT J OBSTET GY, V115, P149, DOI 10.1111/j.1471-0528.2007.01603.x; Rajagopalan S, 2006, PLOS BIOL, V4, P70, DOI 10.1371/journal.pbio.0040009; Scott NM, 2011, PLACENTA, V32, P454, DOI 10.1016/j.placenta.2011.03.004; Scott NM, 2009, J IMMUNOL, V182, P1411, DOI 10.4049/jimmunol.182.3.1411; Soto-Quiros ME, 2002, PEDIATR PULM, V33, P237, DOI 10.1002/ppul.10070; Tan Z, 2005, HUM MOL GENET, V14, P3619, DOI 10.1093/hmg/ddi389; Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200; van der Meer A, 2007, MOL HUM REPROD, V13, P123, DOI 10.1093/molehr/gal100; Verbruggen LA, 2006, HUM IMMUNOL, V67, P561, DOI 10.1016/j.humimm.2006.03.023; White SR, 2010, EUR RESPIR J, V35, P925, DOI 10.1183/09031936.00164809; Zheng XQ, 2010, HUM IMMUNOL, V71, P982, DOI 10.1016/j.humimm.2010.06.018; Zhu XM, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.03.002	44	40	44	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2013	131	6					1496	+		10.1016/j.jaci.2013.01.037	http://dx.doi.org/10.1016/j.jaci.2013.01.037			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	166CT	23534973	Green Accepted			2022-12-18	WOS:000320532800005
J	Gelfand, EW; Ochs, HD; Shearer, WT				Gelfand, Erwin W.; Ochs, Hans D.; Shearer, William T.			Controversies in IgG replacement therapy in patients with antibody deficiency diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antibody deficiency; immunoglobulin replacement; common variable immunodeficiency; primary immunodeficiency; pneumococcal antibody concentration; specific antibody deficiency	COMMON VARIABLE IMMUNODEFICIENCY; PNEUMOCOCCAL CONJUGATE VACCINE; ACADEMY-OF-ALLERGY; INTRAVENOUS IMMUNOGLOBULIN; AMERICAN-ACADEMY; GENE-THERAPY; CHILDREN; POLYSACCHARIDE; ASTHMA; ASSAY	This Current perspectives article will review and highlight the importance of accurate diagnosis of patients who have failed to produce specific antibodies to naturally encountered foreign proteins or polysaccharides or after vaccination and the appropriate institution of immunoglobulin replacement therapy. The field of primary immunodeficiency disease (PIDD) has expanded remarkably since the early descriptions 6 decades ago. With greater recognition and advanced cellular and molecular diagnostic technology, new entities and single-gene defects in patients with PIDD are rapidly being defined. This, combined with treatment advances and newborn screening for severe combined immunodeficiency, has resulted in improved outcomes and survival and even permanent cures. Awareness of PIDD has also increased, but the guidelines for recognition remain to be validated. The zeal for registering and enrolling patients has potentially created a large body of "patients'' treated with immunoglobulin replacement unnecessarily. The complexity, diversity, and availability of laboratory testing have brought awareness of PIDD to the forefront, but because of an absence of standardization of certain assays, concerns about the correct diagnosis and appropriate treatment have increased. We hope to refocus the discussion on identifying clear laboratory and clinical guidelines for the establishment of an accurate diagnosis of antibody deficiency, its rationale, and, where indicated, institution of safe treatment. (J Allergy Clin Immunol 2013; 131:1001-5.)	[Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Div Cell Biol, Denver, CO USA; [Ochs, Hans D.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Ochs, Hans D.] Seattle Childrens Res Inst, Seattle, WA USA; [Shearer, William T.] Baylor Coll Med, Dept Pediat, Sect Immunol Allergy & Rheumatol, Houston, TX 77030 USA	National Jewish Health; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Baylor College of Medicine	Shearer, WT (corresponding author), Texas Childrens Hosp, Baylor Coll Med, 1102 Bates St,Suite 330, Houston, TX 77030 USA.	wtsheare@TexasChildrensHospital.org		Shearer, William/0000-0002-2483-2130	AI grant [082976]; David Fund, Texas Children's Hospital; Jeffrey Modell Foundation; CSL Behring	AI grant; David Fund, Texas Children's Hospital; Jeffrey Modell Foundation; CSL Behring	Supported in part by AI grant 082976 and the David Fund, Texas Children's Hospital, and the Jeffrey Modell Foundation.; Disclosure of potential conflict of interest: E. W. Gelfand has consultant arrangements with Biotest. H. D. Ochs serves on advisory boards for CSL Behring, Baxter, and Grifols and has received a grant from CSL Behring. W. T. Shearer declares that he has no relevant conflicts of interest.	Abraham R.S., 2012, CLIN IMMUNOLOGY PRIN, P1145; Abraham RS, 2012, J ALLERGY CLIN IMMUN, V130, P558, DOI 10.1016/j.jaci.2012.06.013; Abraham Roshini S, 2011, Clin Mol Allergy, V9, P6, DOI 10.1186/1476-7961-9-6; Aiuti A, 2012, CURR OPIN IMMUNOL, V24, P585, DOI 10.1016/j.coi.2012.07.012; Al-Herz W, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00054; Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Ballow M, 2013, CLIN IMMUNOLOGY PRIN, P1041; Blessing JJH, 2013, CLIN IMMUNOLOGY PRIN, P1160; Bonagura VR, 2008, J ALLERGY CLIN IMMUN, V122, P210, DOI 10.1016/j.jaci.2008.04.044; Bonilla FA, 2010, PEDIAT ALLERGY PRINC, P88; Bossuyt X, 2007, CLIN CHEM, V53, P124, DOI 10.1373/clinchem.2007.075861; Buckley Rebecca H, 2002, Curr Allergy Asthma Rep, V2, P356, DOI 10.1007/s11882-002-0067-1; Buckley RH, 2012, J ALLERGY CLIN IMMUN, V129, P597, DOI 10.1016/j.jaci.2011.12.964; Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06; Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, P1001, DOI 10.1067/mai.2002.124999; Cavazzana-Calvo M, 2012, CURR OPIN IMMUNOL, V24, P580, DOI 10.1016/j.coi.2012.08.008; Chapel H, 2009, BRIT J HAEMATOL, V145, P709, DOI 10.1111/j.1365-2141.2009.07669.x; Chinen J, 2013, CLIN IMMUNOLOGY PRIN, P381; Chua I, 2011, J ALLERGY CLIN IMMUN, V127, P1410, DOI 10.1016/j.jaci.2011.01.035; Conley ME, 2009, ANNU REV IMMUNOL, V27, P199, DOI 10.1146/annurev.immunol.021908.132649; Cunningham-Rundles C, 2012, HEMATOL-AM SOC HEMAT, P301, DOI 10.1182/asheducation-2012.1.301; de Roux A, 2008, CLIN INFECT DIS, V46, P1015, DOI 10.1086/529142; Fleisher TA, 2013, CLIN IMMUNOLOGY PRIN, P1162; Gelfand EW, 2012, NEW ENGL J MED, V367, P2015, DOI 10.1056/NEJMra1009433; GELFAND EW, 1988, MONOGR ALLERGY, V23, P177; Hare ND, 2009, J ALLERGY CLIN IMMUN, V123, P195, DOI 10.1016/j.jaci.2008.09.021; Hernandez-Trujillo HS, 2012, CLIN EXP IMMUNOL, V169, P57, DOI 10.1111/j.1365-2249.2012.04588.x; Hu BT, 2005, CLIN DIAGN LAB IMMUN, V12, P287, DOI 10.1128/CDLI.12.2.287-295.2005; Janzi M, 2009, CLIN IMMUNOL, V133, P78, DOI 10.1016/j.clim.2009.05.014; Jeurissen A, 2007, CLIN CHEM, V53, P505, DOI 10.1373/clinchem.2006.080051; Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348; Kamchaisatian W, 2006, J ALLERGY CLIN IMMUN, V118, P1336, DOI 10.1016/j.jaci.2006.09.036; Lack G, 1996, J PEDIATR-US, V129, P898, DOI 10.1016/S0022-3476(96)70035-5; LEFRANC MP, 1982, NATURE, V300, P760, DOI 10.1038/300760a0; Lucas M, 2010, J ALLERGY CLIN IMMUN, V125, P1354, DOI 10.1016/j.jaci.2010.02.040; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Oliveira JB, 2010, J ALLERGY CLIN IMMUN, V125, pS297, DOI 10.1016/j.jaci.2009.08.043; Orange JS, 2012, CLIN EXP IMMUNOL, V169, P172, DOI 10.1111/j.1365-2249.2012.04594.x; Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002; Orange JS, 2006, J ALLERGY CLIN IMMUN, V117, pS525, DOI 10.1016/j.jaci.2006.01.015; Ozen A, 2010, CLIN IMMUNOL, V137, P374, DOI 10.1016/j.clim.2010.08.010; Park MA, 2008, LANCET, V372, P489, DOI 10.1016/S0140-6736(08)61199-X; Parvaneh N, 2013, J ALLERGY CLIN IMMUN, V131, P314, DOI 10.1016/j.jaci.2012.11.051; Puck JM, 2012, J ALLERGY CLIN IMMUN, V129, P607, DOI 10.1016/j.jaci.2012.01.032; Quartier P, 1999, J PEDIATR-US, V134, P589, DOI 10.1016/S0022-3476(99)70246-5; Romero-Steiner S, 2006, CLIN VACCINE IMMUNOL, V13, P165, DOI 10.1128/CVI.13.2.165-169.2006; Rose MA, 2005, CLIN DIAGN LAB IMMUN, V12, P1216, DOI 10.1128/CDLI.12.10.1216-1222.2005; Salzer U, 2009, BLOOD, V113, P1967, DOI 10.1182/blood-2008-02-141937; Schuerman L, 2011, CLIN VACCINE IMMUNOL, V18, P2161, DOI 10.1128/CVI.05313-11; SIBER GR, 1980, NEW ENGL J MED, V303, P178, DOI 10.1056/NEJM198007243030402; Skoda-Smith S, 2010, THER CLIN RISK MANAG, V6, P1; Stiehm E Richard, 2010, Adv Pediatr, V57, P185, DOI 10.1016/j.yapd.2010.08.005; Subbarayan A, 2011, PEDIATRICS, V127, P810, DOI 10.1542/peds.2010-3680; Uddin S, 2006, VACCINE, V24, P5637, DOI 10.1016/j.vaccine.2006.03.088; Vale AM, 2010, J ALLERGY CLIN IMMUN, V125, P778, DOI 10.1016/j.jaci.2010.02.018; Verbsky J, 2012, J ALLERGY CLIN IMMUN, V129, P622, DOI 10.1016/j.jaci.2011.12.004; Wehr C, 2008, BLOOD, V111, P77, DOI 10.1182/blood-2007-06-091744; Yong PFK, 2009, IMMUNOL REV, V229, P101, DOI 10.1111/j.1600-065X.2009.00764.x	58	40	40	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1001	1005		10.1016/j.jaci.2013.02.028	http://dx.doi.org/10.1016/j.jaci.2013.02.028			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23540617				2022-12-18	WOS:000317187200006
J	Levin, AM; Mathias, RA; Huang, LL; Roth, LA; Daley, D; Myers, RA; Himes, BE; Romieu, I; Yang, M; Eng, C; Park, JE; Zoratti, K; Gignoux, CR; Torgerson, DG; Galanter, JM; Huntsman, S; Nguyen, EA; Becker, AB; Chan-Yeung, M; Kozyrskyj, AL; Kwok, PY; Gilliland, FD; Gauderman, WJ; Bleecker, ER; Raby, BA; Meyers, DA; London, SJ; Martinez, FD; Weiss, ST; Burchard, EG; Nicolae, DL; Ober, C; Barnes, KC; Williams, LK				Levin, Albert M.; Mathias, Rasika A.; Huang, Lili; Roth, Lindsey A.; Daley, Denise; Myers, Rachel A.; Himes, Blanca E.; Romieu, Isabelle; Yang, Mao; Eng, Celeste; Park, Julie E.; Zoratti, Karla; Gignoux, Christopher R.; Torgerson, Dara G.; Galanter, Joshua M.; Huntsman, Scott; Nguyen, Elizabeth A.; Becker, Allan B.; Chan-Yeung, Moira; Kozyrskyj, Anita L.; Kwok, Pui-Yan; Gilliland, Frank D.; Gauderman, W. James; Bleecker, Eugene R.; Raby, Benjamin A.; Meyers, Deborah A.; London, Stephanie J.; Martinez, Fernando D.; Weiss, Scott T.; Burchard, Esteban G.; Nicolae, Dan L.; Ober, Carole; Barnes, Kathleen C.; Williams, L. Keoki			A meta-analysis of genome-wide association studies for serum total IgE in diverse study populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Meta-analysis; genome-wide association study; total IgE; race-ethnicity; continental population groups	CHILDHOOD ASTHMA; AFRICAN-AMERICAN; AIRWAY RESPONSIVENESS; COMPONENTS-ANALYSIS; LATINO POPULATIONS; GENETIC ANCESTRY; IMMUNOGLOBULIN-E; LUNG-FUNCTION; CHILDREN; DISEASE	Background: IgE is both a marker and mediator of allergic inflammation. Despite reported differences in serum total IgE levels by race-ethnicity, African American and Latino subjects have not been well represented in genetic studies of total IgE. Objective: We sought to identify the genetic predictors of serum total IgE levels. Methods: We used genome-wide association data from 4292 subjects (2469 African Americans, 1564 European Americans, and 259 Latinos) in the EVE Asthma Genetics Consortium. Tests for association were performed within each cohort by race-ethnic group (ie, African American, Latino, and European American) and asthma status. The resulting P values were meta-analyzed, accounting for sample size and direction of effect. Top single nucleotide polymorphism associations from the meta-analysis were reassessed in 6 additional cohorts comprising 5767 subjects. Results: We identified 10 unique regions in which the combined association statistic was associated with total serum IgE levels (P < 5.0 x 10(-6)) and the minor allele frequency was 5% or greater in 2 or more population groups. Variant rs9469220, corresponding to HLA-DQB1, was the single nucleotide polymorphism most significantly associated with serum total IgE levels when assessed in both the replication cohorts and the discovery and replication sets combined (P = .007 and 2.45 x 10(-7), respectively). In addition, findings from earlier genome-wide association studies were also validated in the current meta-analysis. Conclusion: This meta-analysis independently identified a variant near HLA-DQB1 as a predictor of total serum IgE levels in multiple race-ethnic groups. This study also extends and confirms the findings of earlier genome-wide association analyses in African American and Latino subjects. (J Allergy Clin Immunol 2013;131:1176-84.)	[Levin, Albert M.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Mathias, Rasika A.] Johns Hopkins Univ, Dept Med, Div Gen Internal Med, Baltimore, MD USA; [Mathias, Rasika A.; Huang, Lili; Barnes, Kathleen C.] Johns Hopkins Univ, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Roth, Lindsey A.; Eng, Celeste; Gignoux, Christopher R.; Torgerson, Dara G.; Galanter, Joshua M.; Huntsman, Scott; Nguyen, Elizabeth A.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Daley, Denise] Univ British Columbia, James Hogg Res Ctr, Inst Heart & Lung Hlth, Vancouver, BC V5Z 1M9, Canada; [Myers, Rachel A.; Nicolae, Dan L.; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Himes, Blanca E.; Raby, Benjamin A.; Weiss, Scott T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA; [Romieu, Isabelle] WHO, Int Agcy Res Canc, Lyon, France; [Yang, Mao; Zoratti, Karla; Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA; [Park, Julie E.] Univ British Columbia, Providence Hlth Care Res Inst, Vancouver, BC V5Z 1M9, Canada; [Becker, Allan B.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Becker, Allan B.] Univ Manitoba, Manitoba Inst Child Hlth, Winnipeg, MB, Canada; [Chan-Yeung, Moira] Univ British Columbia, Occupat & Environm Lung Dis Unit, Vancouver, BC V5Z 1M9, Canada; [Kozyrskyj, Anita L.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Kozyrskyj, Anita L.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada; [Kwok, Pui-Yan] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Kwok, Pui-Yan] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Gilliland, Frank D.; Gauderman, W. James] Univ So Calif, Keck Sch Med, Dept Preventat Med, Los Angeles, CA 90033 USA; [Bleecker, Eugene R.; Meyers, Deborah A.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA; [London, Stephanie J.] NIEHS, NIH, US Dept HHS, Res Triangle Pk, NC 27709 USA; [Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Martinez, Fernando D.] Univ Arizona, Inst BIO5, Tucson, AZ USA; [Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Nicolae, Dan L.] Univ Chicago, Dept Stat, Chicago, IL 60637 USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA	Henry Ford Health System; Henry Ford Hospital; Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Francisco; University of British Columbia; University of Chicago; Harvard University; Brigham & Women's Hospital; Harvard Medical School; World Health Organization; International Agency for Research on Cancer (IARC); Henry Ford Health System; Henry Ford Hospital; University of British Columbia; University of Manitoba; University of Manitoba; University of British Columbia; University of Alberta; University of Manitoba; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Southern California; Wake Forest University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Arizona; University of Arizona; University of California System; University of California San Francisco; University of Chicago; Henry Ford Health System; Henry Ford Hospital	Williams, LK (corresponding author), Henry Ford Hlth Syst, Ctr Hlth Serv Res, 1 Ford Pl,3A, Detroit, MI USA.	kbarnes@jhmi.edu; kwillia5@hfhs.org	London, Stephanie/C-3734-2019; Kwok, Pui-Yan/F-7725-2014; Raby, Benjamin/AAK-3866-2021	London, Stephanie/0000-0003-4911-5290; Kwok, Pui-Yan/0000-0002-5087-3059; Ober, Carole/0000-0003-4626-9809; Nicolae, Dan/0000-0002-0918-4630; Nguyen, Elizabeth/0000-0002-8070-6382; Galanter, Joshua/0000-0002-2561-6384	National Heart, Lung, and Blood Institute [HL085197, HL087665, HL072414, HL49596, HL064307, HL064313, HL075419, HL65899, HL083069, HL066289, HL101543, HL101651, HL079055, HL087699, HL049612, HL075417, HL04266, HL072433, HL061768, HL076647, HL087680, HL078885, HL088133, HL069167]; National Institutes of Allergy and Infectious Disease [AI070503, AI079139, AI061774, AI050024, AI044840, AI041040, AI077439]; National Institute of Diabetes and Digestive and Kidney Diseases [DK064695]; National Institutes of Environmental Health Sciences [ES09606, ES018176, ES015903, ES007048, ES009581, R826708, RD831861, ES011627, ES015794]; National Institutes of Environmental Health Sciences, Division of Intramural Research [Z01 ES049019]; National Center for Research Resources [RR03048]; Environmental Protection Agency [83213901, R-826724]; American Asthma Foundation; Fund for Henry Ford Hospital; Mary Beryl Patch Turnbull Scholar Program; National Council of Science and Technology (Mexico) [26206-M]; Centers for Disease Control, US; Flight Attendant Medical Research Institute (FAMRI); RWJF Amos Medical Faculty Development Award; Sandler Foundation; AllerGen NCE (the Allergy, Genes and Environment Network); Canadian Institutes for Health Research; Tier II Canadian Research Chair; Michael Smith Foundation for Health Research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD049480] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072433, U10HL064307, U01HL049612, R01HL078885, R01HL061768, P01HL083069, R01HL085197, R01HL072414, U01HL075417, R01HL079055, R01HL066289, R01HL076647, RC2HL101543, U01HL075419, R01HL087699, RC2HL101651, P01HL070831, U10HL064313, R01HL087680, K23HL004266, R37HL066289, R01HL069167, R01HL088133, R01HL087665, U01HL065899, K23HL111636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070503, R01AI079139, R01AI041040, R01AI061774, R01AI044840, U19AI077439, R18AI044840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009581, P50ES018176, ZIAES049019, P50ES015903, P01ES011627, R01ES015794, R21ES011672, P30ES007048, P01ES009606, P01ES018176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institutes of Environmental Health Sciences, Division of Intramural Research; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Environmental Protection Agency(United States Environmental Protection Agency); American Asthma Foundation; Fund for Henry Ford Hospital; Mary Beryl Patch Turnbull Scholar Program; National Council of Science and Technology (Mexico)(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Centers for Disease Control, US(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Flight Attendant Medical Research Institute (FAMRI); RWJF Amos Medical Faculty Development Award; Sandler Foundation; AllerGen NCE (the Allergy, Genes and Environment Network); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Tier II Canadian Research Chair; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the National Heart, Lung, and Blood Institute (HL101651 to C.O. and D.L.N.; HL087665 to D.L.N.; HL085197, HL087665, HL072414, and HL49596 to C.O.; HL064307 and HL064313 to F. D. M.; HL075419, HL65899, HL083069, HL066289, HL087680, HL101543, and HL101651 to S. T. W.; HL079055 to L. K. W.; HL087699, HL049612, HL075417, HL04266, and HL072433 to K. C. B.; HL061768, HL076647, to F. D. G.; HL087680 to W.J.G.; HL078885 and HL088133 to E. G. B.; HL087665 to D. A. M.; and HL069167 to E. R. B), the National Institutes of Allergy and Infectious Disease (AI070503 to C.O.; AI079139 and AI061774 to L. K. W.; AI050024, AI044840, and AI041040 to K. C. B.; and AI077439 to E. G. B.), the National Institute of Diabetes and Digestive and Kidney Diseases to L. K. W. (DK064695); the National Institutes of Environmental Health Sciences (ES09606, ES018176, and ES015903 to K. C. B.; ES007048, ES009581, R826708, RD831861, and ES011627 to F. D. G.; ES015794 to E. G. B.; and the Division of Intramural Research, Z01 ES049019, to S.J.L.); the National Center for Research Resources (RR03048 to K. C. B.), the Environmental Protection Agency (83213901 and R-826724 to K. C. B.), the American Asthma Foundation and the Fund for Henry Ford Hospital (to L. K. W.), Mary Beryl Patch Turnbull Scholar Program (to K. C. B.), the National Council of Science and Technology (Mexico; 26206-M to I. R.), the Centers for Disease Control, US (to I. R.); and the Flight Attendant Medical Research Institute (FAMRI), RWJF Amos Medical Faculty Development Award, the American Asthma Foundation, and the Sandler Foundation (to E. G. B.). The Canadian studies (SAGE and CAPPS) were supported by AllerGen NCE (the Allergy, Genes and Environment Network, which is a member of the Networks of Centres of Excellence) and by a grant from the Canadian Institutes for Health Research. D. D. is supported by a Tier II Canadian Research Chair and a scholar award from the Michael Smith Foundation for Health Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341; [Anonymous], 2007, NATURE, V447, P661; Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Begin P, 2007, AM J RESP CRIT CARE, V175, P1109, DOI 10.1164/rccm.200607-1012OC; Brand S, 2009, GUT, V58, P1152, DOI 10.1136/gut.2008.163667; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Chan A, 2006, GENES IMMUN, V7, P169, DOI 10.1038/sj.gene.6364287; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; Galanter JM, 2011, J ALLERGY CLIN IMMUN, V128, P37, DOI 10.1016/j.jaci.2011.03.050; Gamazon ER, 2010, BIOINFORMATICS, V26, P259, DOI 10.1093/bioinformatics/btp644; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; Granada M, 2012, J ALLERGY CLIN IMMUN, V129, P840, DOI 10.1016/j.jaci.2011.09.029; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; HANSON B, 1991, AM J HUM GENET, V48, P873; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Holzer U, 2003, J IMMUNOL, V170, P1218, DOI 10.4049/jimmunol.170.3.1218; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; Jin Y, 2010, J ALLERGY CLIN IMMUN, V126, P618, DOI 10.1016/j.jaci.2010.06.007; Kozyrskyj AL, 2009, ALLERGY, V64, P1185, DOI 10.1111/j.1398-9995.2009.02033.x; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Li XN, 2012, J ALLERGY CLIN IMMUN, V129, P575, DOI 10.1016/j.jaci.2011.09.040; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Lourenco VM, 2011, BIOINFORMATICS, V27, P815, DOI 10.1093/bioinformatics/btr006; Mathias RA, 2001, GENET EPIDEMIOL, V20, P340, DOI 10.1002/gepi.5; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Oryszczyn MP, 2000, AM J RESP CRIT CARE, V161, P1241, DOI 10.1164/ajrccm.161.4.9905027; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Rothers J, 2011, J ALLERGY CLIN IMMUN, V128, P397, DOI 10.1016/j.jaci.2011.04.044; SALKIE ML, 1984, CLIN BIOCHEM, V17, P362, DOI 10.1016/S0009-9120(84)90734-3; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Smith MW, 2001, AM J HUM GENET, V69, P1080, DOI 10.1086/323922; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Stolerman ES, 2008, DIABETES, V57, P1971, DOI 10.2337/db08-0266; Strunk RC, 2008, J ALLERGY CLIN IMMUN, V122, P1138, DOI 10.1016/j.jaci.2008.09.028; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P622, DOI 10.1016/j.jaci.2012.03.045; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tsai HJ, 2006, HUM GENET, V119, P547, DOI 10.1007/s00439-006-0169-2; Vergara C, 2008, AM J RESP CRIT CARE, V178, P1017, DOI 10.1164/rccm.200801-182OC; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Woszczek G, 2002, EUR RESPIR J, V20, P79, DOI 10.1183/09031936.02.01002001; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044; YUNGINGER JW, 1973, J ALLERGY CLIN IMMUN, V51, P174, DOI 10.1016/0091-6749(73)90022-5	61	40	41	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1176	1184		10.1016/j.jaci.2012.10.002	http://dx.doi.org/10.1016/j.jaci.2012.10.002			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	120QT	23146381	Green Accepted, Green Published			2022-12-18	WOS:000317187200028
J	Price, D; Popov, TA; Bjermer, L; Lu, S; Petrovic, R; Vandormael, K; Mehta, A; Strus, JD; Polos, PG; Philip, G				Price, David; Popov, Todor A.; Bjermer, Leif; Lu, Susan; Petrovic, Romana; Vandormael, Kristel; Mehta, Anish; Strus, Jolanta D.; Polos, Peter G.; Philip, George			Effect of montelukast for treatment of asthma in cigarette smokers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Montelukast; smoking; fluticasone propionate; leukotriene receptor antagonist; asthma control; corticosteroids	LOCALLY WEIGHTED REGRESSION; THERAPEUTIC RESPONSE; ORAL MONTELUKAST; LUNG-FUNCTION; SMOKING; CORTICOSTEROIDS; BECLOMETHASONE; ANTAGONISTS; DISEASE; PLACEBO	Many asthmatic patients are unable to quit cigarettes; therefore information is needed on treatment options for smokers. This study evaluates 10 mg/d montelukast and 250 mu g of fluticasone propionate twice daily, each compared with placebo, in patients with self-reported active smoking (unable to quit) and asthma. Methods: Patients (ages 18-55 years, with asthma [>= 1 year], FEV1 of 60% to 90% of predicted value, airway reversibility [>= 12%], and self-reported active smoking [>= 0.5 to <= 2 packs per day]) were randomized (after a 3-week, single-blind, placebo, run-in period) to 1 of 3 parallel, 6-month, double-blind treatment arms. The primary efficacy end point was the percentage of days with asthma control during treatment. Adverse experiences (AEs) were also evaluated. Results: There were 347, 336, and 336 patients randomized to montelukast, fluticasone, and placebo, respectively. The mean percentage of days with asthma control over 6 months of treatment was 45% (montelukast, P < .05 vs placebo), 49% (fluticasone, P < .001 vs placebo), and 39% (placebo); the difference between montelukast and fluticasone was not significant (P = .14). Patients with a smoking history of <= 11 pack years (the median value) tended to show more benefit with fluticasone, whereas those with a smoking history of >11 pack years tended to show more benefit with montelukast. AEs occurred in similar proportions among treatment groups. Conclusions: In a population of asthmatic patients actively smoking cigarettes, both 10 mg/d montelukast and 250 mu g of fluticasone propionate twice daily significantly increased the mean percentage of days with asthma control compared with placebo. (J Allergy Clin Immunol 2013;131:763-71.)	[Price, David] Univ Aberdeen, Ctr Acad Primary Care, Aberdeen AB25 2AY, Scotland; [Popov, Todor A.] Alexanders Univ Hosp, Clin Allergy & Asthma, Sofia, Bulgaria; [Bjermer, Leif] Skane Univ Hosp, Dept Resp Med & Allergol, Lund, Sweden; [Lu, Susan; Petrovic, Romana; Vandormael, Kristel; Mehta, Anish; Strus, Jolanta D.; Polos, Peter G.; Philip, George] Merck Sharp & Dohme Ltd, Whitehouse Stn, NJ USA	University of Aberdeen; Medical University Sofia; Lund University; Skane University Hospital; Merck & Company	Price, D (corresponding author), Univ Aberdeen, Ctr Acad Primary Care, Foresterhill Hlth Ctr, Westburn Rd, Aberdeen AB25 2AY, Scotland.	david@respiratoryresearch.org	Price, David/H-2837-2019; Popov, Todor/Q-9928-2016; Bjermer, Leif H/I-4899-2014	Price, David/0000-0002-9728-9992; Popov, Todor/0000-0001-5052-5866; Bjermer, Leif H/0000-0002-3441-8099	Merck Sharp & Dohme Corp, Whitehouse Station, NJ; Boehringer Ingelheim; GlaxoSmithKline; Mundipharma; Novartis; Teva; UK National Health Service; Aerocrine; AstraZeneca; Pfizer; Chiesi; Merck; Almirall; Nigard; Nycomed-Takeda	Merck Sharp & Dohme Corp, Whitehouse Station, NJ; Boehringer Ingelheim(Boehringer Ingelheim); GlaxoSmithKline(GlaxoSmithKline); Mundipharma; Novartis(Novartis); Teva(Teva Pharmaceutical Industries); UK National Health Service; Aerocrine; AstraZeneca(AstraZeneca); Pfizer(Pfizer); Chiesi(Chiesi Pharmaceuticals Inc); Merck(Merck & Company); Almirall(Almirall); Nigard; Nycomed-Takeda	Supported by Merck Sharp & Dohme Corp, Whitehouse Station, NJ.; Disclosure of potential conflict of interest: D. Price has received consulting fees and travel support from Merck; has received consultancy fees from Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, Novartis, and Teva; has received research support from the UK National Health Service, Aerocrine, AstraZeneca, Mundipharma, Novartis, Pfizer, Teva, Chiesi, and Boehringer Ingelheim; has received lecture fees from Teva, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, and Pfizer; has a patent with and has stock/stock options in AKL Ltd; has received payment for the development of educational presentations from Teva and AstraZeneca; has received travel support from Teva, Novartis, Boehringer Ingelheim, and Mundipharma; and is Owner of Research in Real Life Ltd. L. Bjermer is on the AstraZeneca, Almirall, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma, Merck, Novartis, and Nycomed-Takeda boards and has received lecture fees from AstraZeneca, Almirall, GlaxoSmithKline, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma, Merck, Nigard, Novartis, and Nycomed-Takeda. S. Lu, K. Vandormael, A. Mehta, J. D. Strus, and G. Philip are employed by and have stock/stock options in Merck. R. Petrovic was employed by Merck until 2010. P. G. Polos was employed by Merck at the time of the study. T. A. Popov declares that he has no relevant conflicts of interest.	Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; British Thoracic Society Scottish Intercollegiate Guidelines Network, 2008, Thorax, V63 Suppl 4, piv1, DOI 10.1136/thx.2008.097741; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Baumgartner RA, 2003, EUR RESPIR J, V21, P123, DOI 10.1183/09031936.03.00028803; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chaudhuri R, 2008, ALLERGY, V63, P132, DOI 10.1111/j.1398-9995.2007.01538.x; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; Clatworthy Jane, 2009, Prim Care Respir J, V18, P300, DOI 10.4104/pcrj.2009.00037; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CLEVELAND WS, 1981, AM STAT, V35, P54, DOI 10.2307/2683591; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Fauler J, 1997, EUR J CLIN INVEST, V27, P43, DOI 10.1046/j.1365-2362.1997.650619.x; Floreani A A, 1999, Curr Opin Pulm Med, V5, P38, DOI 10.1097/00063198-199901000-00007; Gaki E, 2007, RESP MED, V101, P826, DOI 10.1016/j.rmed.2006.06.031; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; Ito K., 2001, FASEB Journal, V15, P1110; KENNEDY SM, 1984, AM REV RESPIR DIS, V129, P143; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; McCoy K, 2006, J ALLERGY CLIN IMMUN, V118, P1226, DOI 10.1016/j.jaci.2006.09.006; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Pedersen B, 1996, AM J RESP CRIT CARE, V153, P1519, DOI 10.1164/ajrccm.153.5.8630596; Price D, 2011, NEW ENGL J MED, V364, P1695, DOI 10.1056/NEJMoa1010846; Rabinovitch N, 2011, J ALLERGY CLIN IMMUN, V128, P323, DOI 10.1016/j.jaci.2011.05.035; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Santanello NC, 1997, EUR RESPIR J, V10, P646; Schatz M, 2006, J ALLERGY CLIN IMMUN, V118, P1048, DOI 10.1016/j.jaci.2006.07.057; Schwartz J, 2011, THORAX, V66, P841, DOI 10.1136/thx.2010.154195; Silverman RA, 2003, CHEST, V123, P1472, DOI 10.1378/chest.123.5.1472; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Stine RA, 2001, STAT MED, V20, P215, DOI 10.1002/1097-0258(20010130)20:2<215::AID-SIM642>3.0.CO;2-X; Storms W, 2007, EXPERT OPIN PHARMACO, V8, P2173, DOI 10.1517/14656566.8.13.2173; Strine TW, 2007, J ASTHMA, V44, P651, DOI 10.1080/02770900701554896; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Yanbaeva DG, 2007, CHEST, V131, P1557, DOI 10.1378/chest.06-2179	38	40	43	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					763	+		10.1016/j.jaci.2012.12.673	http://dx.doi.org/10.1016/j.jaci.2012.12.673			15	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23380218				2022-12-18	WOS:000315587800018
J	Konya, V; Ullen, A; Kampitsch, N; Theiler, A; Philipose, S; Parzmair, GP; Marsche, G; Peskar, BA; Schuligoi, R; Settler, W; Heinemann, A				Konya, Viktoria; Ullen, Andreas; Kampitsch, Nora; Theiler, Anna; Philipose, Sonia; Parzmair, Gerald P.; Marsche, Gunther; Peskar, Bernhard A.; Schuligoi, Rufina; Settler, Wolfgang; Heinemann, Akos			Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic obstructive pulmonary disease; acute lung injury; endothelial barrier; prostaglandins; vascular leakage; neutrophil trafficking	CELL-MIGRATION; FACTOR-I; EP4; ACTIVATION; EXPRESSION; PROSTAGLANDINS; ANGIOGENESIS; ENHANCEMENT	Background: Increased vascular permeability is a fundamental characteristic of inflammation. Substances that are released during inflammation, such as prostaglandin (PG) E-2, can counteract vascular leakage, thereby hampering tissue damage. Objective: In this study we investigated the role of PGE(2) and its receptors in the barrier function of human pulmonary microvascular endothelial cells and in neutrophil trafficking. Methods: Endothelial barrier function was determined based on electrical impedance measurements. Neutrophil recruitment was assessed based on adhesion and transendothelial migration. Morphologic alterations are shown by using immunofluorescence microscopy. Results: We observed that activation of E-type prostanoid (EP) 4 receptor by PGE(2) or an EP4-selective agonist (ONO AE1-329) enhanced the barrier function of human microvascular lung endothelial cells. EP4 receptor activation prompted similar responses in pulmonary artery and coronary artery endothelial cells. These effects were reversed by an EP4 antagonist (ONO AE3-208), as well as by blocking actin polymerization with cytochalasin B. The EP4 receptor-induced increase in barrier function was independent of the classical cyclic AMP/protein kinase A signaling machinery, endothelial nitric oxide synthase, and Rac1. Most importantly, EP4 receptor stimulation showed potent anti-inflammatory activities by (1) facilitating wound healing of pulmonary microvascular endothelial monolayers, (2) preventing junctional and cytoskeletal reorganization of activated endothelial cells, and (3) impairing neutrophil adhesion to endothelial cells and transendothelial migration. The latter effects could be partially attributed to reduced E-selectin expression after EP4 receptor stimulation. Conclusion: These data indicate that EP4 agonists as anti-inflammatory agents represent a potential therapy for diseases with increased vascular permeability and neutrophil extravasation. (J Allergy Clin Immunol 2013;131:532-40.)	[Konya, Viktoria; Kampitsch, Nora; Theiler, Anna; Philipose, Sonia; Parzmair, Gerald P.; Marsche, Gunther; Peskar, Bernhard A.; Schuligoi, Rufina; Heinemann, Akos] Med Univ Graz, Inst Expt & Clin Pharmacol, A-8010 Graz, Austria; [Ullen, Andreas; Settler, Wolfgang] Med Univ Graz, Inst Mol Biol & Biochem, A-8010 Graz, Austria	Medical University of Graz; Medical University of Graz	Heinemann, A (corresponding author), Med Univ Graz, Inst Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemann@medunigraz.at		Marsche, Gunther/0000-0002-2422-5381; Heinemann, Akos/0000-0002-8554-2372; Konya, Viktoria/0000-0002-7999-9093; Parzmair, Gerald/0000-0002-7915-6758	PhD Program Molecular Medicine of the Medical University of Graz; Medical University of Graz [ASO109000101]; Austrian Science Fund FWF [P22521, P21004]; SFB Lipotox project [3007]; Jubilaumsfonds of the Austrian National Bank [14263, 13487]; AstraZeneca AB (Sweden); Alimrall SA (Spain); Austrian Science Fund (FWF) [P 22976, P 22521, P 21004, F 3007] Funding Source: researchfish	PhD Program Molecular Medicine of the Medical University of Graz; Medical University of Graz; Austrian Science Fund FWF(Austrian Science Fund (FWF)); SFB Lipotox project; Jubilaumsfonds of the Austrian National Bank; AstraZeneca AB (Sweden)(AstraZeneca); Alimrall SA (Spain); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	V.K., A.U., and S.P. were funded by the PhD Program Molecular Medicine of the Medical University of Graz. This work was supported by the Start Funding Program of the Medical University of Graz (ASO109000101 to V. K.), the Austrian Science Fund FWF (grants P22521 to A. H., P21004 to G. M., and SFB Lipotox project 3007 to W. S.), and Jubilaumsfonds of the Austrian National Bank (14263 to A. H. and 13487 to R.S.).; A. Heinemann has received one or more payments for lecturing from AstraZeneca AB (Sweden), is a Principal Investigator for the Austria Science Funds (FWF) and for Jubilaumfonds of the Austrian National Bank (OeNB), and has received research funding from AstraZeneca AB (Sweden) and from Alimrall SA (Spain). The rest of the authors declare that they have no relevant conflicts of interest.	Alfranca A, 2006, CARDIOVASC RES, V70, P446, DOI 10.1016/j.cardiores.2005.12.020; Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036; Bogatcheva NV, 2008, MICROVASC RES, V76, P202, DOI 10.1016/j.mvr.2008.06.003; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; DELVECCHIO PJ, 1992, IN VITRO CELL DEV-AN, V28A, P711; deMoraes VLG, 1996, BRIT J PHARMACOL, V117, P1792; Demyanets S, 2011, ARTERIOSCL THROM VAS, V31, P2080, DOI 10.1161/ATVBAHA.111.231431; El-Gamal D, 2012, ANTIOXID REDOX SIGN, V16, P129, DOI 10.1089/ars.2011.4090; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gordon SR, 2005, CELL MOTIL CYTOSKEL, V62, P244, DOI 10.1002/cm.20099; Grinnell KL, 2012, MICROVASC RES, V83, P12, DOI 10.1016/j.mvr.2011.04.005; Hartnell A, 2004, J IMMUNOL, V173, P6448, DOI 10.4049/jimmunol.173.10.6448; Hristovska AM, 2007, HYPERTENSION, V50, P525, DOI 10.1161/HYPERTENSIONAHA.107.088948; Jacobson JR, 2007, CURR DRUG TARGETS, V8, P509, DOI 10.2174/138945007780362719; Keese CR, 2004, P NATL ACAD SCI USA, V101, P1554, DOI 10.1073/pnas.0307588100; Konya V, 2011, EUR J IMMUNOL, V41, P2379, DOI 10.1002/eji.201141460; Konya V, 2010, J ALLERGY CLIN IMMUN, V125, P1105, DOI 10.1016/j.jaci.2009.12.002; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Liang XB, 2011, J CLIN INVEST, V121, P4362, DOI 10.1172/JCI46279; Luschnig-Schratl P, 2011, CELL MOL LIFE SCI, V68, P3573, DOI 10.1007/s00018-011-0642-5; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Norel X, 2007, THESCIENTIFICWORLDJO, V7, P1359, DOI 10.1100/tsw.2007.184; Park GY, 2006, AM J PHYSIOL-LUNG C, V290, pL797, DOI 10.1152/ajplung.00513.2005; Rao R, 2007, J BIOL CHEM, V282, P16959, DOI 10.1074/jbc.M701214200; Sedej M, 2012, J ALLERGY CLIN IMMUN, V129, P492, DOI 10.1016/j.jaci.2011.08.015; Sehrawat S, 2011, BLOOD, V117, P708, DOI 10.1182/blood-2010-02-268870; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Stehbens SJ, 2009, FRONT BIOSCI-LANDMRK, V14, P3159, DOI 10.2741/3442; Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Zhang YS, 2011, BLOOD, V118, P5355, DOI 10.1182/blood-2011-04-350587	33	40	45	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					532	+		10.1016/j.jaci.2012.05.008	http://dx.doi.org/10.1016/j.jaci.2012.05.008			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086CT	22704539				2022-12-18	WOS:000314661500033
J	Daley, D; Park, JE; He, JQ; Yan, J; Akhabir, L; Stefanowicz, D; Becker, AB; Chan-Yeung, M; Bosse, Y; Kozyrskyj, AL; James, AL; Musk, AW; Laprise, C; Hegele, RG; Pare, PD; Sandford, AJ				Daley, Denise; Park, Julie E.; He, Jian-Qing; Yan, Jin; Akhabir, Loubna; Stefanowicz, Dorota; Becker, Allan B.; Chan-Yeung, Moira; Bosse, Yohan; Kozyrskyj, Anita L.; James, Alan L.; Musk, Arthur W.; Laprise, Catherine; Hegele, Richard G.; Pare, Peter D.; Sandford, Andrew J.			Associations and interactions of genetic polymorphisms in innate immunity genes with early viral infections and susceptibility to asthma and asthma-related phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; atopic asthma; airway hyperresponsiveness; genetics; association; gene-environment interactions; viral exposures	SINGLE-NUCLEOTIDE POLYMORPHISMS; LINKAGE DISEQUILIBRIUM; PRIMARY PREVENTION; CHILDHOOD ASTHMA; EARLY-LIFE; HIGH-RISK; BINDING-PROTEIN; RECEPTOR; CHILDREN; ATOPY	Background: The innate immune system is essential for host survival because of its ability to recognize invading pathogens and mount defensive responses. Objectives: We sought to identify genetic associations of innate immunity genes with atopy and asthma and interactions with early viral infections (first 12 months of life) in a high-risk birth cohort. Methods: Three Canadian family-based studies and 1 Australian population-based case-control study (n = 5565) were used to investigate associations of 321 single nucleotide polymorphisms (SNPs) in 26 innate immunity genes with atopy, asthma, atopic asthma, and airway hyperresponsiveness. Interactions between innate immunity genes and early viral exposure to 3 common viruses (parainfluenza, respiratory syncytial virus, and picornavirus) were examined in the Canadian Asthma Primary Prevention Study by using both an affected-only family-based transmission disequilibrium test and case-control methods. Results: In a joint analysis of all 4 cohorts, IL-1 receptor 2 (IL1R2) and Toll-like receptor 1 (TLR1) SNPs were associated with atopy after correction for multiple comparisons. In addition, an NFKBIA SNP was associated with atopic asthma. Six SNPs (rs1519309 [TLR3], rs740044 [ILIR2], rs4543123 [TLR1], rs5741812 [LBP], rs917998 [IL18RAP], and rs3136641 [NFKBIB]) were significant (P < .05, confirmed with 30,000 permutations) in both the combined analysis of main genetic effects and SNP-virus interaction analyses in both case-control and family-based methods. The TLR1 variant (rs4543123) was associated with both multiple viruses (respiratory syncytial virus and parainfluenza virus) and multiple phenotypes. Conclusion: We have identified novel susceptibility genes for asthma and related traits and interactions between these genes and early-life viral infections. (J Allergy Clin Immunol 2012;130:1284-93.)	[Daley, Denise; Park, Julie E.; He, Jian-Qing; Yan, Jin; Akhabir, Loubna; Stefanowicz, Dorota; Pare, Peter D.; Sandford, Andrew J.] Univ British Columbia, James Hogg Res Ctr, Inst Heart & Lung Hlth, Vancouver, BC V6Z 1Y6, Canada; [Becker, Allan B.] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Becker, Allan B.] Univ Manitoba, Manitoba Inst Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Chan-Yeung, Moira] Univ British Columbia, Occupat & Environm Lung Dis Unit, Vancouver, BC V6Z 1Y6, Canada; [Bosse, Yohan] Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Bosse, Yohan] Univ Laval, Dept Mol Med, Ste Foy, PQ G1K 7P4, Canada; [Kozyrskyj, Anita L.] Univ Alberta, Dept Pediat, Fac Med & Dent, Edmonton, AB, Canada; [Kozyrskyj, Anita L.] Univ Manitoba, Dept Pediat & Child Hlth, Fac Med, Winnipeg, MB R3T 2N2, Canada; [James, Alan L.] Sir Charles Gairdner Hosp, Dept Pulm Physiol & Sleep Med, Perth, WA, Australia; [Musk, Arthur W.] Sir Charles Gairdner Hosp, Dept Resp Med, Perth, WA, Australia; [Laprise, Catherine] Univ Quebec Chicoutimi, Dept Sci Fondamentales, Saguenay, PQ, Canada; [Laprise, Catherine] Univ Montreal, Chicoutimi Hosp, Community Genom Med Ctr, Saguenay, PQ, Canada; [Hegele, Richard G.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Pare, Peter D.; Sandford, Andrew J.] Univ British Columbia, Dept Med, Div Resp Med, Vancouver, BC V6Z 1Y6, Canada	University of British Columbia; University of Manitoba; University of Manitoba; University of British Columbia; Laval University; University of Alberta; University of Manitoba; University of Western Australia; University of Quebec; University of Quebec Chicoutimi; Universite de Montreal; University of Toronto; University of British Columbia	Daley, D (corresponding author), Univ British Columbia, James Hogg Res Ctr, St Pauls Hosp, Room 166,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	denise.daley@hli.ubc.ca	Pare, Peter D/C-7425-2011; He, Jian-Qing/AAA-6269-2021	Hegele, Richard/0000-0003-1073-8044; He, Jian-Qing/0000-0002-0966-1302; Laprise, Catherine/0000-0001-5526-9945	AllerGen, a Network of Centres of Excellence (Canada); Canadian Institutes of Health Research (CIHR); Institute of Gender and Health (CIHR); BC Lung Association; Genome Quebec; Respiratory Health Network of the Fonds de la Recherche en Sante du Quebec (FRSQ); Healthway, Western Australia; National Health and Medical Research Council of Australia [303145, 458513]; Child Health Research Foundation of Western Australia; Asthma Foundation of Western Australia; Michael Smith Foundation for Health Research Doctoral Award; Izaak Walton Killam Memorial Scholarship Award; National Health and Medical Research Council of Australia Practitioner Fellowship; CIHR; Michael Smith Foundation for Health Research (MSFHR) Scholar Award; AllerGen; Canadian Institute for Health Research; Canada Research Chair	AllerGen, a Network of Centres of Excellence (Canada); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Institute of Gender and Health (CIHR)(Canadian Institutes of Health Research (CIHR)); BC Lung Association; Genome Quebec; Respiratory Health Network of the Fonds de la Recherche en Sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); Healthway, Western Australia; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Child Health Research Foundation of Western Australia; Asthma Foundation of Western Australia; Michael Smith Foundation for Health Research Doctoral Award(Michael Smith Foundation for Health Research); Izaak Walton Killam Memorial Scholarship Award; National Health and Medical Research Council of Australia Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); CIHR(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research (MSFHR) Scholar Award(Michael Smith Foundation for Health Research); AllerGen; Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	Supported by AllerGen, a Network of Centres of Excellence (Canada); the Canadian Institutes of Health Research (CIHR); the Institute of Gender and Health (CIHR); the BC Lung Association; Genome Quebec; and the Respiratory Health Network of the Fonds de la Recherche en Sante du Quebec (FRSQ). The 1994 Busselton follow-up study was funded by Healthway, Western Australia. This work was also supported by the National Health and Medical Research Council of Australia (303145, 458513), the Child Health Research Foundation of Western Australia, and the Asthma Foundation of Western Australia. J.-Q.H. is the recipient of a Michael Smith Foundation for Health Research Doctoral Award and an Izaak Walton Killam Memorial Scholarship Award. A.L.J. is a recipient of a National Health and Medical Research Council of Australia Practitioner Fellowship. Y.B. is a research scholar from the Heart and Stroke Foundation of Canada. Y.B. and D. D. were recipients of fellowship awards (CIHR), and A. L. K. is a recipient of a New Investigator Award (CIHR). D. D. is the recipient of a Michael Smith Foundation for Health Research (MSFHR) Scholar Award. A.J.S. is the recipient of a MSFHR Senior Scholar Award. D. D., C. L., and A.J.S. hold Canadian Research Chair appointments.; D. Daley has received grants and travel support from AllerGen and the Canadian Institute for Health Research. A. B. Becker has received grants from the Canadian Institute for Health Research. A. W. Musk has received grants and travel support from AllerGen and the Canadian Institute for Health Research. C. Laprise has received grants from the Canada Research Chair and AllerGen and is employed by the Universite du Quebec a Chicoutimi. P. D. Pare has received grants from AllerGen and the Canadian Institute for Health Research. The rest of the authors declare that they have no relevant conflicts of interest.	Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Begin P, 2007, AM J RESP CRIT CARE, V175, P1109, DOI 10.1164/rccm.200607-1012OC; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657, DOI 10.1001/archpedi.154.7.657; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; Cordell HJ, 2009, GENOMICS, V93, P5, DOI 10.1016/j.ygeno.2008.05.002; Daley D, 2009, HUM GENET, V125, P445, DOI 10.1007/s00439-009-0643-8; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; GAZZANOSANTORO H, 1992, INFECT IMMUN, V60, P4754, DOI 10.1128/IAI.60.11.4754-4761.1992; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823, DOI 10.1164/ajrccm/146.4.823; Gern JE, 2010, J VIROL, V84, P7418, DOI 10.1128/JVI.02290-09; Gilbert LL, 1996, J CLIN MICROBIOL, V34, P140, DOI 10.1128/JCM.34.1.140-143.1996; Godfrey S, 2000, Paediatr Respir Rev, V1, P148, DOI 10.1053/prrv.2000.0042; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; Guan Y, 2010, J IMMUNOL, V184, P5094, DOI 10.4049/jimmunol.0901888; Guerra S, 2008, ANNU REV MED, V59, P327, DOI 10.1146/annurev.med.59.060406.213232; Gupta K, 1999, J ALLERGY CLIN IMMUN, V103, P1100, DOI 10.1016/S0091-6749(99)70185-5; He JQ, 2009, J ALLERGY CLIN IMMUN, V124, P222, DOI 10.1016/j.jaci.2009.04.018; Hegele RG, 2001, J PEDIATR-US, V138, P831, DOI 10.1067/mpd.2001.114479; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; James Alan L, 2005, Med J Aust, V183, pS17; Kormann MSD, 2008, J ALLERGY CLIN IMMUN, V122, P86, DOI 10.1016/j.jaci.2008.04.039; Kormann MS, 2008, J ALLERGY CLIN IMMUN, V122, pe1; Kozyrskyj AL, 2009, ALLERGY, V64, P1185, DOI 10.1111/j.1398-9995.2009.02033.x; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; Kuribayashi K, 2002, CLIN EXP ALLERGY, V32, P641, DOI 10.1046/j.0954-7894.2002.01346.x; Lazarus R, 2003, GENOMICS, V81, P85, DOI 10.1016/S0888-7543(02)00022-8; Le Souef PN, 2009, CURR OPIN ALLERGY CL, V9, P123, DOI 10.1097/ACI.0b013e3283292283; Lee KK, 2007, PEDIATR PULM, V42, P290, DOI 10.1002/ppul.20578; Lyon H, 2004, GENET EPIDEMIOL, V26, P155, DOI 10.1002/gepi.10298; Mai XM, 2007, J ALLERGY CLIN IMMUN, V120, P551, DOI 10.1016/j.jaci.2007.05.004; Martinez Fernando D, 2009, Proc Am Thorac Soc, V6, P272, DOI 10.1513/pats.200808-092RM; Message SD, 2001, EUR RESPIR J, V18, P1013, DOI 10.1183/09031936.01.00228701; Miller EK, 2011, J ALLERGY CLIN IMMUN, V127, P883, DOI 10.1016/j.jaci.2010.11.041; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Noguchi E, 2004, CLIN EXP ALLERGY, V34, P177, DOI 10.1111/j.1365-2222.2004.01839.x; Phipps S, 2007, IMMUNOL CELL BIOL, V85, P463, DOI 10.1038/sj.icb.7100104; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Sekigawa T, 2009, CLIN EXP ALLERGY, V39, P972, DOI 10.1111/j.1365-2222.2009.03229.x; Sly PD, 2011, CURR OPIN ALLERGY CL, V11, P24, DOI 10.1097/ACI.0b013e328342309d; Spielman RS, 1996, AM J HUM GENET, V59, P983; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Tantisira K, 2004, GENES IMMUN, V5, P343, DOI 10.1038/sj.gene.6364096; Watanabe M, 2002, J ALLERGY CLIN IMMUN, V109, P669, DOI 10.1067/mai.2002.122158; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	55	40	42	4	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1284	1293		10.1016/j.jaci.2012.07.051	http://dx.doi.org/10.1016/j.jaci.2012.07.051			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23063165	Bronze			2022-12-18	WOS:000311641100006
J	Rumpel, JA; Ahmedani, BK; Peterson, EL; Wells, KE; Yang, M; Levin, AM; Yang, JJ; Kumar, R; Burchard, EG; Williams, LK				Rumpel, Jennifer A.; Ahmedani, Brian K.; Peterson, Edward L.; Wells, Karen E.; Yang, Mao; Levin, Albert M.; Yang, James J.; Kumar, Rajesh; Burchard, Esteban Gonzalez; Williams, L. Keoki			Genetic ancestry and its association with asthma exacerbations among African American subjects with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; continental population groups; African continental ancestry group; genetic association study; health status disparities; minority health	SYSTEMIC-LUPUS-ERYTHEMATOSUS; INHALED CORTICOSTEROIDS; POPULATION-STRUCTURE; MULTIPLE-SCLEROSIS; ETHNIC-DIFFERENCES; UNITED-STATES; SKIN COLOR; ADMIXTURE; ADHERENCE; RACE	Background: There are large and persisting disparities in severe asthma exacerbations by race-ethnicity, and African American subjects are among those at greatest risk. It is unclear whether this increased risk solely represents differences in environmental exposures and health care or whether there is a predisposing genetic component. Objective: We sought to assess the relationship between genetic ancestry and severe exacerbations among African American subjects with asthma. Methods: Participants were part of the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE). These subjects were 12 to 56 years of age, received care from a single large health system, and had a physician's diagnosis of asthma. Genetic ancestry was estimated by using a set of validated ancestry informative markers. Severe exacerbations (ie, asthma-related emergency department visits, hospitalizations, and burst oral steroid use) were prospectively identified from health care claims. Results: We assessed genetic ancestry in 392 African American subjects with asthma. The average proportion of African ancestry was 76.1%. A significant interaction was identified between ancestry and sex on severe exacerbations, such that the risk was significantly higher with increasing African ancestry among male but not female subjects. The association among male subjects persisted after adjusting for potential confounders (relative rate, 4.30 for every 20% increase in African ancestry; P = .029). Conclusions: African ancestry was significantly and positively associated with severe exacerbations among male African American subjects. These findings suggest that a portion of the risk of asthma exacerbations in this high-risk group is attributable to a genetic risk factor that partitions with ancestry. (J Allergy Clin Immunol 2012;130:1302-6.)	[Rumpel, Jennifer A.; Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Ahmedani, Brian K.; Yang, Mao; Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA; [Peterson, Edward L.; Wells, Karen E.; Levin, Albert M.; Yang, James J.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Kumar, Rajesh] Northwestern Univ, Dept Pediat, Childrens Mem Hosp, Feinberg Sch Med, Chicago, IL 60611 USA; [Burchard, Esteban Gonzalez] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA USA; [Burchard, Esteban Gonzalez] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Williams, LK (corresponding author), Henry Ford Hosp, Ctr Hlth Policy & Hlth Serv Res, 1 Ford Pl,3A CHSR, Detroit, MI 48202 USA.	kwillia5@hfhs.org		Kumar, Rajesh/0000-0002-1962-7108	American Asthma Foundation; Flight Attendant Medical Research Institute; Fund for Henry Ford Hospital; Robert Wood Johnson Foundation Amos Medical Faculty Development Program; Sandler Foundation; National Institutes of Health: National Institute of Allergy and Infectious Diseases [AI079139, AI061774, AI077439]; National Institutes of Health: National Heart, Lung, and Blood Institute [K23HL093023, HL078885, HL088133, 5RC2HL101651, HL079055]; National Institutes of Health: National Institute of Environmental Health Sciences [ES015794]; National Institutes of Health: National Institute of Diabetes and Digestive and Kidney Diseases [DK064695]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088133, K23HL093023, R01HL078885, R01HL079055, RC2HL101651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077439, R01AI061774, R01AI079139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER	American Asthma Foundation; Flight Attendant Medical Research Institute; Fund for Henry Ford Hospital; Robert Wood Johnson Foundation Amos Medical Faculty Development Program(Robert Wood Johnson Foundation (RWJF)); Sandler Foundation; National Institutes of Health: National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health: National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health: National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institutes of Health: National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the American Asthma Foundation (E.G.B. and L.K.W.), the Flight Attendant Medical Research Institute (E. G. B.), the Fund for Henry Ford Hospital (L. K. W.), the Robert Wood Johnson Foundation Amos Medical Faculty Development Program (E. G. B.), the Sandler Foundation (E. G. B.), and the following institutes of the National Institutes of Health: National Institute of Allergy and Infectious Diseases (AI079139 and AI061774 to L. K. W. and AI077439 to E. G. B.); the National Heart, Lung, and Blood Institute (K23HL093023 to R. K.; HL078885, HL088133, and 5RC2HL101651 to E. G. B.; and HL079055 and 5RC2HL101651 to L. K. W.); the National Institute of Environmental Health Sciences (ES015794 to E. G. B.); and the National Institute of Diabetes and Digestive and Kidney Diseases (DK064695 to L.K.W.).	ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Bae SC, 1998, ARTHRITIS RHEUM-US, V41, P2091, DOI 10.1002/1529-0131(199812)41:12<2091::AID-ART2>3.3.CO;2-4; Bryc K, 2010, P NATL ACAD SCI USA, V107, P786, DOI 10.1073/pnas.0909559107; Carroll ML, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-184; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P381; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P350; Flores C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0026807; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Fuhlbrigge A, 2012, J ALLERGY CLIN IMMUN, V129, pS34, DOI 10.1016/j.jaci.2011.12.983; Gould W, 2010, J ALLERGY CLIN IMMUN, V126, P1131, DOI 10.1016/j.jaci.2010.08.002; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; HIBBERT M, 1995, PEDIATR PULM, V19, P129, DOI 10.1002/ppul.1950190208; Hoggart CJ, 2003, AM J HUM GENET, V72, P1492, DOI 10.1086/375613; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kamble S, 2009, J ASTHMA, V46, P73, DOI 10.1080/02770900802503107; Krieger N, 1998, AM J PUBLIC HEALTH, V88, P1308, DOI 10.2105/AJPH.88.9.1308; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Mannino David M, 2002, MMWR Surveill Summ, V51, P1; McKeigue PM, 2005, AM J HUM GENET, V76, P1, DOI 10.1086/426949; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Molokhia M, 2003, HUM GENET, V112, P310, DOI 10.1007/s00439-002-0883-3; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Parra EJ, 2004, NAT GENET, V36, pS54, DOI 10.1038/ng1440; Parra EJ, 1998, AM J HUM GENET, V63, P1839, DOI 10.1086/302148; Price AL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000519; Pritchard JK, 2000, GENETICS, V155, P945; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reich D, 2005, NAT GENET, V37, P1113, DOI 10.1038/ng1646; SAS Institute Inc, 2008, STAT AN SYST SAS STA; Shriver MD, 2003, HUM GENET, V112, P387, DOI 10.1007/s00439-002-0896-y; Simonoff J.S., 2003, ANAL CATEGORICAL DAT; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183, DOI 10.1164/ajrccm.152.4.7551368; Tsai HJ, 2006, HUM GENET, V118, P626, DOI 10.1007/s00439-005-0080-2; Venn A, 1998, BRIT MED J, V316, P1945, DOI 10.1136/bmj.316.7149.1945; Wallin MT, 2004, ANN NEUROL, V55, P65, DOI 10.1002/ana.10788; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Wells K, 2008, AM J RESP CRIT CARE, V178, P1194, DOI 10.1164/rccm.200808-1233OC; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2007, J ALLERGY CLIN IMMUN, V119, P168, DOI 10.1016/j.jaci.2006.09.029; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Williams LK, 2010, J ALLERGY CLIN IMMUN, V126, P225, DOI 10.1016/j.jaci.2010.03.034; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Yaeger R, 2008, CANCER EPIDEM BIOMAR, V17, P1329, DOI 10.1158/1055-9965.EPI-07-2505; Zhang Y, 2011, AM J RESP CRIT CARE, V183, P596, DOI 10.1164/rccm.200912-1863OC	49	40	40	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2012	130	6					1302	1306		10.1016/j.jaci.2012.09.001	http://dx.doi.org/10.1016/j.jaci.2012.09.001			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	044RP	23069492	Green Accepted			2022-12-18	WOS:000311641100008
J	Bochner, BS; Book, W; Busse, WW; Butterfield, J; Furuta, GT; Gleich, GJ; Klion, AD; Lee, JJ; Leiferman, KM; Minnicozzi, M; Moqbel, R; Rothenberg, ME; Schwartz, LB; Simon, HU; Wechsler, ME; Weller, PF				Bochner, Bruce S.; Book, Wendy; Busse, William W.; Butterfield, Joseph; Furuta, Glenn T.; Gleich, Gerald J.; Klion, Amy D.; Lee, James J.; Leiferman, Kristin M.; Minnicozzi, Michael; Moqbel, Redwan; Rothenberg, Marc E.; Schwartz, Lawrence B.; Simon, Hans-Uwe; Wechsler, Michael E.; Weller, Peter F.			Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophil; apoptosis; therapeutics; research; discovery; fusion oncoproteins; hypereosinophilic syndromes; Churg-Strauss syndrome; coagulopathy	CHURG-STRAUSS-SYNDROME; HYPEREOSINOPHILIC SYNDROME; EPISODIC ANGIOEDEMA; CONSENSUS RECOMMENDATIONS; ESOPHAGEAL EOSINOPHILIA; TREATMENT OPTION; THE-LITERATURE; PATHOGENESIS; CELL; MEPOLIZUMAB	Background: Eosinophils are blood cells that are often found in high numbers in the tissues of allergic conditions and helminthic parasite infections. The pathophysiologic roles that eosinophils may serve in other human "eosinophil-associated" diseases remain obscure. Objective: National Institutes of Health (NIH) Institutes and the Office of Disease Prevention assembled an international taskforce of clinical and basic scientists with the charge to propose and prioritize unmet research needs in eosinophil-associated diseases. Methods: The taskforce used an organ system approach to identify the different and common themes of eosinophil cell involvement in these diseases. In early 2012, a draft document was circulated for review. The document was amended and the prioritizations were set at a NIH-organized workshop in June 2012. Results: The taskforce identified significant research needs. These needs cross disease entities but some are disease specific. There are substantial shortcomings to the various preclinical animal models, as well as significant gaps in our epidemiologic, pathophysiologic, diagnostic, prognostic, and therapeutic knowledge. The taskforce recognized that recent efforts by patient advocacy groups have played instrumental roles in improving the identification and characterization of these disorders. However, communications among the eosinophil-interested communities, for example, governmental funding and regulatory agencies, and industry and clinician scientists need to be more comprehensive. Conclusions: Significant efforts are required to address our knowledge gaps to improve the outcomes of eosinophil-associated diseases. NIH Institutes, other federal agencies, lay organizations, and the pharmaceutical industry should consider the taskforce's recommendations in their future research activities. (J Allergy Clin Immunol 2012;130:587-96.)	[Bochner, Bruce S.] Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol, Dept Med, Baltimore, MD 21224 USA; [Book, Wendy] Amer Partnership Eosinophil Disorders, Atlanta, GA USA; [Busse, William W.] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Div Clin Immunol & Allergy, Madison, WI USA; [Butterfield, Joseph] Mayo Clin, Dept Med, Div Allerg Dis, Rochester, MN USA; [Furuta, Glenn T.] Univ Colorado, Sch Med,Sect Pediat Gastroenterol Hepatol & Nutr, Dept Pediat,Gastrointestinal Eosinophil Dis Progr, Childrens Hosp,Digest Hlth Inst,Natl Jewish Hlth, Aurora, CO USA; [Gleich, Gerald J.; Leiferman, Kristin M.] Univ Utah, Hlth Sci Ctr, Dept Dermatol, Salt Lake City, UT USA; [Klion, Amy D.] NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; [Lee, James J.] Mayo Clin Arizona, Div Pulm Med, Dept Biochem & Mol Biol, Scottsdale, AZ USA; [Moqbel, Redwan] Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; [Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Pediat, Div Allergy & Immunol,Cincinnati Childrens Hosp M, Cincinnati, OH USA; [Schwartz, Lawrence B.] Virginia Commonwealth Univ, Dept Internal Med, Div Rheumatol Allergy & Immunol, Richmond, VA 23284 USA; [Simon, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Wechsler, Michael E.] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care, Boston, MA 02115 USA; [Wechsler, Michael E.] Harvard Univ, Sch Med, Boston, MA USA; [Weller, Peter F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Allergy & Inflammat,Div Infect Dis, Boston, MA 02215 USA	Johns Hopkins University; Johns Hopkins Medicine; University of Wisconsin System; University of Wisconsin Madison; Mayo Clinic; Children's Hospital Colorado; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Mayo Clinic; Mayo Clinic Phoenix; University of Manitoba; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Virginia Commonwealth University; University of Bern; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Bochner, BS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Allergy & Clin Immunol, Dept Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	bbochner@jhmi.edu	Wechsler, Michael/B-3979-2013; Simon, Hans-Uwe/AAU-7410-2020; Wechsler, Michael/AAC-5506-2019	Wechsler, Michael/0000-0003-3505-2946; Simon, Hans-Uwe/0000-0002-9404-7736; Klion, Amy/0000-0002-4986-5326	National Institute of Allergy and Infectious Diseases; Office of Disease Prevention; National Institute of Allergy and Infectious Diseases (NIAID); National Heart, Lung, and Blood Institute; UpToDate; Elsevier; Abbott Nutrition; Nutricia; National Institutes of Health (NIH)/NIAID; Mayo Clinic; TRIA Bioscience Corp; ImmViz; Teva; National Institutes of Health; Mayo Foundation for Medical Education and Research; CIHR (Canada); MHRC; MICH; NIH; GlaxoSmithKline; Genentech; Carolus; NeilMed; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001130, R37AI045898, R01AI072265, R37AI020241, R56AI072265] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Office of Disease Prevention(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); UpToDate; Elsevier; Abbott Nutrition(Abbott Laboratories); Nutricia(Danone Nutricia); National Institutes of Health (NIH)/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Mayo Clinic; TRIA Bioscience Corp; ImmViz; Teva(Teva Pharmaceutical Industries); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mayo Foundation for Medical Education and Research; CIHR (Canada)(Canadian Institutes of Health Research (CIHR)); MHRC; MICH; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GlaxoSmithKline(GlaxoSmithKline); Genentech(Roche HoldingGenentech); Carolus; NeilMed; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the National Institute of Allergy and Infectious Diseases and the Office of Disease Prevention.; B. S. Bochner has received grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Heart, Lung, and Blood Institute; has consultant arrangements with Sanofi-Aventis, Genentech, Merck, Roche, GlaxoSmithKline, TEVA, GlycoFi, and Medicis; is on scientific advisory boards for Merck and Allakos; is a co-inventor on existing and pending Siglec-8 related patents; may be entitled to a share of royalties on the potential sales of Siglec-8-related products; receives royalties from UpToDate and Elsevier; is a co-founder of and has purchased stock in Allakos, Inc; and holds stock options for Glycomimetics, Inc. W. M. Book has received public education grants on behalf of the American Partnership for Eosinophilic Disorders from Abbott Nutrition and Nutricia. W. W. Busse has received grants from the National Institutes of Health (NIH)/NIAID; has served on an advisory board for Merck; has consulted for Amgen, AstraZeneca, Novartis, GlaxoSmithKline, MedImmune, and Genentech; and has received royalties from Elsevier. J. Butterfield has received royalty payments for licensing of technology from the Mayo Clinic. G. J. Gleich is on the board of the American Partnership for Eosinophilic Disorders; has consulted for GlaxoSmithKline; has received grants from TRIA Bioscience Corp and ImmViz; has patent agreements with ImmViz; has received royalties from Teva; and has stock or stock options in Immune Design Corp. J. J. Lee has received grants from the National Institutes of Health and royalties from the Mayo Foundation for Medical Education and Research. K. M. Leiferman is co-director for the Immunodermatology Laboratory, Department of Dermatology; has received payment for lectures from the American Academy of Allergy, Asthma, & Immunology/American College of Allergy, Asthma, & Immunology Joint Board Review Course 2012; has a patent with ImmViz; and is the spouse of co-author Gerald Gleich. R. Moqbel has consulted for GlaxoSmithKline Canada; has received grants from CIHR (Canada), MHRC, and MICH; and holds a patent on diagnosing respiratory diseases with urine metabolites identified by nuclear magnetic resonance. M. E. Rothenberg is Chief Scientific Officer of Immune Pharmaceuticals; has consultant arrangements with TEVA Pharmaceuticals; has received grants from the NIH; is the inventor of patents owned by Cincinnati Children's Hospital Medical Center; and has stock/stock options in IMMUNE Pharmaceuticals. L. Schwartz has received grants from GlaxoSmithKline, Genentech, Carolus, and NeilMed; has received support for travel from the NIH; is president of the Clinical Immunology Society; is a board member of the Asthma & Allergy Foundation of America; has consultant arrangements with Genentech, Marshall Edwards Inc, and Sanofi-Aventis; and receives royalties from ThermoFisher, Hycult & BioLegend, and Millpore. H.-U. Simon has consultant arrangements with Pfizer. M. Wechsler has received grants from the NIH; has consultant arrangements with GlaxoSmithKline, Cephalon, Novartis, Sepracor/Sunovion, Schering Plough, NKT Therapeutics, Asthmatx/BSCI, Genzyme, Map-Pharma, Genentech, and Boehringer Ingelheim; and has received honoraria from Merck. P. Weller has consultant arrangements with GlaxoSmithKline. The rest of the authors declare that they have no relevant conflicts of interest.	Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Ackerman SJ, 2007, IMMUNOL ALLERGY CLIN, V27, P357, DOI 10.1016/j.iac.2007.07.004; Akuthota P, 2008, CLIN EXP ALLERGY, V38, P1254, DOI 10.1111/j.1365-2222.2008.03037.x; Antic M, 2006, DERMATOLOGY, V213, P93, DOI 10.1159/000093847; Bischoff L, 2008, INT J DERMATOL, V47, P29, DOI 10.1111/j.1365-4632.2007.03544.x; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Bochner BS, 2010, J ALLERGY CLIN IMMUN, V126, P16, DOI 10.1016/j.jaci.2010.02.026; BUTTERFIELD JH, 1992, BLOOD, V79, P688; Butterfield JH, 2009, LEUKEMIA RES, V33, P1127, DOI 10.1016/j.leukres.2008.12.001; Chen H, 2004, AM J SURG PATHOL, V28, P505, DOI 10.1097/00000478-200404000-00010; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; DeBrosse CW, 2011, J ALLERGY CLIN IMMUN, V128, P132, DOI 10.1016/j.jaci.2011.05.006; DeBrosse CW, 2010, J ALLERGY CLIN IMMUN, V126, P112, DOI 10.1016/j.jaci.2010.05.027; Effat KG, 2006, J LARYNGOL OTOL, V120, P411, DOI 10.1017/S0022215106001009; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Gevaert P, 2011, J ALLERGY CLIN IMMUN, V128, P989, DOI 10.1016/j.jaci.2011.07.056; GLEICH GJ, 1984, NEW ENGL J MED, V310, P1621, DOI 10.1056/NEJM198406213102501; Goldman M, 2001, TRENDS IMMUNOL, V22, P247, DOI 10.1016/S1471-4906(01)01893-2; Gonsalves N, 2012, GASTROENTEROLOGY, V142, P1451, DOI 10.1053/j.gastro.2012.03.001; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Hellmich B, 2003, CLIN EXP RHEUMATOL, V21, pS69; HERTZMAN PA, 1990, NEW ENGL J MED, V322, P869, DOI 10.1056/NEJM199003293221301; Hogan SP, 2002, CURR OPIN ALLERGY CL, V2, P239, DOI 10.1097/00130832-200206000-00014; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Kim S, 2010, J ALLERGY CLIN IMMUN, V125, P1336, DOI 10.1016/j.jaci.2010.03.028; Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005; LAKHANPAL S, 1988, SEMIN ARTHRITIS RHEU, V17, P221, DOI 10.1016/0049-0172(88)90008-X; Lee JJ, 2010, CLIN EXP ALLERGY, V40, P563, DOI 10.1111/j.1365-2222.2010.03484.x; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Leiferman KM, 2006, ARCH DERMATOL, V142, P1215, DOI 10.1001/archderm.142.9.1215; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lierman E, 2009, EXPERT REV ANTICANC, V9, P1295, DOI [10.1586/era.09.82, 10.1586/ERA.09.82]; Makepeace BL, 2012, CURR MED CHEM, V19, P1567; Marchand E, 2006, SEMIN RESP CRIT CARE, V27, P134, DOI 10.1055/s-2006-939516; Masterson JC, 2011, CURR OPIN GASTROEN, V27, P515, DOI 10.1097/MOG.0b013e32834b314c; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Noel RJ, 2005, CURR OPIN PEDIATR, V17, P690, DOI 10.1097/01.mop.0000184291.34654.be; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909, DOI 10.4049/jimmunol.173.10.5909; Ogbogu PU, 2009, J ALLERGY CLIN IMMUN, V124, P1319, DOI 10.1016/j.jaci.2009.09.022; Perez ERF, 2011, MED CLIN N AM, V95, P1163, DOI 10.1016/j.mcna.2011.08.006; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Simon HU, 2010, J ALLERGY CLIN IMMUN, V126, P45, DOI 10.1016/j.jaci.2010.03.042; Simson L, 2007, J IMMUNOL, V178, P4222, DOI 10.4049/jimmunol.178.7.4222; Straumann A, 2012, ALLERGY, V67, P477, DOI 10.1111/j.1398-9995.2012.02787.x; Tulic MK, 2012, J ALLERGY CLIN IMMUN, V129, P199, DOI 10.1016/j.jaci.2011.10.016; Tulic MK, 2009, AM J PATHOL, V175, P2043, DOI 10.2353/ajpath.2009.090015; Valent P, 2012, EXPERT REV HEMATOL, V5, P157, DOI [10.1586/EHM.11.81, 10.1586/ehm.11.81]; Van TC, 2011, NAT IMMUNOL, V12, P151, DOI 10.1038/ni.1981; Weaver J, 2010, AM J DERMATOPATH, V32, P31, DOI 10.1097/DAD.0b013e3181a85293; Wechsler ME, 2007, IMMUNOL ALLERGY CLIN, V27, P477, DOI 10.1016/j.iac.2007.07.005; Wehling-Henricks M, 2008, HUM MOL GENET, V17, P2280, DOI 10.1093/hmg/ddn129; WOLF C, 1989, J AM ACAD DERMATOL, V20, P21, DOI 10.1016/S0190-9622(89)70003-7; Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475	55	40	40	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					587	596		10.1016/j.jaci.2012.07.024	http://dx.doi.org/10.1016/j.jaci.2012.07.024			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22935587	Green Accepted, Bronze, Green Published			2022-12-18	WOS:000308463500003
J	Norton, SK; Wijesinghe, DS; Dellinger, A; Sturgill, J; Zhou, ZG; Barbour, S; Chalfant, C; Conrad, DH; Kepley, CL				Norton, Sarah K.; Wijesinghe, Dayanjan S.; Dellinger, Anthony; Sturgill, Jamie; Zhou, Zhiguo; Barbour, Suzanne; Chalfant, Charles; Conrad, Daniel H.; Kepley, Christopher L.			Epoxyeicosatrienoic acids are involved in the C-70 fullerene derivative-induced control of allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Fullerene derivative; eicosanoids; asthma; airway inflammation; bronchoconstriction; allergy	ARACHIDONIC-ACID; MAST-CELLS; PATHOGENESIS; INFLAMMATION; METABOLISM; MECHANISMS; MODEL; MICE	Background: Fullerenes are molecules being investigated for a wide range of therapeutic applications. We have shown previously that certain fullerene derivatives (FDs) inhibit mast cell (MC) function in vitro, and here we examine their in vivo therapeutic effect on asthma, a disease in which MCs play a predominant role. Objective: We sought to determine whether an efficient MC-stabilizing FD (C-70-tetraglycolate [TGA]) can inhibit asthma pathogenesis in vivo and to examine its in vivo mechanism of action. Methods: Asthma was induced in mice, and animals were treated intranasally with TGA either simultaneously with treatment or after induction of pathogenesis. The efficacy of TGA was determined through the measurement of airway inflammation, bronchoconstriction, serum IgE levels, and bronchoalveolar lavage fluid cytokine and eicosanoid levels. Results: We found that TGA-treated mice have significantly reduced airway inflammation, eosinophilia, and bronchoconstriction. The TGA treatments are effective, even when given after disease is established. Moreover, we report a novel inhibitory mechanism because TGA stimulates the production of an anti-inflammatory P-450 eicosanoid metabolites (cis-epoxyeicosatrienoic acids [EETs]) in the lung. Inhibitors of these anti-inflammatory EETs reversed TGA inhibition. In human lung MCs incubated with TGA, there was a significant upregulation of CYP1B gene expression, and TGA also reduced IgE production from B cells. Lastly, MCs incubated with EET and challenged through Fc epsilon RI had a significant blunting of mediator release compared with nontreated cells. Conclusion: The inhibitory capabilities of TGA reported here suggest that FDs might be used a platform for developing treatments for asthma. (J Allergy Clin Immunol 2012;130:761-9.)	[Norton, Sarah K.; Sturgill, Jamie; Conrad, Daniel H.] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23284 USA; [Wijesinghe, Dayanjan S.; Barbour, Suzanne; Chalfant, Charles] Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23284 USA; [Dellinger, Anthony; Zhou, Zhiguo; Kepley, Christopher L.] Luna Innovat Inc, Danville, PA USA; [Dellinger, Anthony; Kepley, Christopher L.] Joint Sch Nanomed & Nanoengn, Greensboro, NC USA	Virginia Commonwealth University; Virginia Commonwealth University	Kepley, CL (corresponding author), Joint Sch Nanosci & Nanoengn, 2901 E Lee St,Suite 2200, Greensboro, NC 27401 USA.	clkepley@uncg.edu		Sturgill, Jamie/0000-0001-8856-3227	American Heart Association [10PRE4170025]; National Institutes of Health/National Institute of Neurological Disorders and Stroke center [5P3ONS047463]; National Institutes of Health (NIH);  [1R01GM083274-01C];  [R21 ESO15696-01A1];  [1U19AI077435-project 2]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072925] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES015696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083274] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [S10OD010641] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Institutes of Health/National Institute of Neurological Disorders and Stroke center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by grants 1R01GM083274-01C and R21 ESO15696-01A1 to C. L. K., grant 1U19AI077435-project 2 to D. H. C., and American Heart Association predoctoral award no. 10PRE4170025 to S.K.N. Microscopy was performed at the VCU Department of Neurobiology and Anatomy microscopy facility, which is supported in part with funding from a National Institutes of Health/National Institute of Neurological Disorders and Stroke center core grant 5P3ONS047463.; S. K. Norton has received research support from the National Institutes of Health (NIH) and the American Heart Association. A. Dellinger, S. Barbour, D. H. Conrad, and C. L. Kepley have received research support from the NIH. The rest of the authors declare that they have no relevant conflicts of interest.	Bachelet Ido, 2005, Expert Rev Clin Immunol, V1, P63, DOI 10.1586/1744666X.1.1.63; Basso AS, 2008, J CLIN INVEST, V118, P1532, DOI 10.1172/JCI33464; Boyce JA, 2012, J ALLERGY CLIN IMMUN, V129, P335, DOI 10.1016/j.jaci.2011.12.968; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; CASALE TB, 1987, J CLIN INVEST, V80, P1507, DOI 10.1172/JCI113234; Caven TH, 2005, CELL IMMUNOL, V238, P123, DOI 10.1016/j.cellimm.2006.03.001; Choudhary D, 2004, DRUG METAB DISPOS, V32, P840, DOI 10.1124/dmd.32.8.840; Djordjevic A, 2006, J BUON, V11, P391; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Dumoulin M, 1998, AM J PHYSIOL-LUNG C, V275, pL423, DOI 10.1152/ajplung.1998.275.3.L423; Gauthier KM, 2002, CIRC RES, V90, P1028, DOI 10.1161/01.RES.0000018162.87285.F8; Giboney PT, 2005, AM FAM PHYSICIAN, V71, P1105; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Jensen AW, 1996, BIOORGAN MED CHEM, V4, P767, DOI 10.1016/0968-0896(96)00081-8; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; Kolosnjaj J, 2007, ADV EXP MED BIOL, V620, P168; MacFarland DK, 2008, J MED CHEM, V51, P3681, DOI 10.1021/jm800521j; Mathews JA, 2011, ALLERGY, V66, P1193, DOI 10.1111/j.1398-9995.2011.02614.x; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Norton SK, 2010, CTS-CLIN TRANSL SCI, V3, P158, DOI 10.1111/j.1752-8062.2010.00212.x; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Ogawa Y, 2006, J ALLERGY CLIN IMMUN, V118, P789, DOI 10.1016/j.jaci.2006.08.009; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; REITMAN S, 1957, AM J CLIN PATHOL, V28, P56, DOI 10.1093/ajcp/28.1.56; Ryan JJ, 2007, J IMMUNOL, V179, P665, DOI 10.4049/jimmunol.179.1.665; STEINITZ K, 1947, Harefuah, V32, P174; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Wilson SR, 2002, PERSPECTIVES OF FULLERENE NANOTECHNOLOGY, P155, DOI 10.1007/0-306-47621-5_14; ZELDIN DC, 1995, J CLIN INVEST, V95, P2150, DOI 10.1172/JCI117904	31	40	41	1	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					761	+		10.1016/j.jaci.2012.04.023	http://dx.doi.org/10.1016/j.jaci.2012.04.023			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22664166	Green Accepted, Green Submitted			2022-12-18	WOS:000308463500027
J	Kamemura, N; Tada, H; Shimojo, N; Morita, Y; Kohno, Y; Ichioka, T; Suzuki, K; Kubota, K; Hiyoshi, M; Kido, H				Kamemura, Norio; Tada, Hitomi; Shimojo, Naoki; Morita, Yoshinori; Kohno, Yoichi; Ichioka, Takao; Suzuki, Koichi; Kubota, Kenji; Hiyoshi, Mineyoshi; Kido, Hiroshi			Intrauterine sensitization of allergen-specific IgE analyzed by a highly sensitive new allergen microarray	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Prenatal; allergen-specific IgE; IgA; IgG; and IgG(4); sensitization; cord blood; allergen chip	DUST-MITE ALLERGEN; CORD-BLOOD; IMMUNOGLOBULIN-E; PRENATAL EXPOSURE; RISK; ANTIBODIES; TRANSPORT; ASTHMA; FETUS; ATOPY	Background: To design a rational allergy prevention program, it is important to determine whether allergic sensitization starts in utero under the maternal immune system. Objective: To investigate the origin of allergen-specific IgE antibodies in cord blood (CB) and maternofetal transfer of immunoglobulins. Methods: The levels of food and inhalant allergen-specific IgE, IgA, IgG, and IgG4 antibodies in CB and maternal blood (MB) from 92 paired neonates and mothers were measured by using a novel allergen microarray of diamond-like-carbon-coated chip, with high-sensitivity detection of allergen-specific antibodies and allergen profiles. Results: The levels of allergen-specific IgE antibodies against food and inhalant allergens and allergen profiles were identical in CB and newborn blood, but the levels and profiles, specifically against inhalant allergens, were different from those in MB. The level of allergen-specific IgA antibodies was below the detection levels in CB despite clear detection in MB. Therefore, contamination with MBin CB was excluded on the basis of extremely low levels of IgA antibodies in CB and the obvious mismatch of the allergenspecific IgE and IgA profiles between CB and MB. However, the levels of allergen-specific IgG and IgG4 antibodies and their allergen profiles were almost identical in both MB and CB. Conclusion: Allergen-specific levels of IgE and IgA antibodies and their allergen profiles analyzed by the diamond-like-carbon allergen chip indicate that IgE antibodies in CB are of fetal origin. Food-allergen specific IgE antibodies were detected more often than inhalant-allergen specific IgE antibodies in CB, the reason of which remains unclarified. (J Allergy Clin Immunol 2012;130:113-21.)	[Kamemura, Norio; Tada, Hitomi; Suzuki, Koichi; Kubota, Kenji; Hiyoshi, Mineyoshi; Kido, Hiroshi] Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Tokushima 7708503, Japan; [Shimojo, Naoki; Morita, Yoshinori; Kohno, Yoichi] Chiba Univ, Grad Sch Med, Dept Pediat, Chiba, Japan; [Ichioka, Takao] Hlth Insurance Naruto Hosp, Naruto, Japan	Tokushima University; Chiba University	Kido, H (corresponding author), Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Kuramoto Cho 3-18-15, Tokushima 7708503, Japan.	kido@ier.tokushima-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology [18659293, 21659245, 19659253]; Ministry of Health, Labor and Welfare [21200501]; Japan Science and Technology Agency of Japan	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Japan Science and Technology Agency of Japan	Supported in part by Grants-in-Aid 18659293, 21659245, and 19659253 from the Ministry of Education, Culture, Sports, Science, and Technology; by Health and Labor Sciences Research Grants of the Research on Allergic Diseases and Immunology (grant no. 21200501) from the Ministry of Health, Labor and Welfare; and by the supporting program for creating university ventures from Japan Science and Technology Agency of Japan.	AVRECH OM, 1994, INT ARCH ALLERGY IMM, V103, P160, DOI 10.1159/000236622; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; Bonnelykke K, 2010, J ALLERGY CLIN IMMUN, V126, P657, DOI 10.1016/j.jaci.2010.06.027; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; Eysink PED, 1999, CLIN EXP ALLERGY, V29, P604, DOI 10.1046/j.1365-2222.1999.00554.x; Hagendorens MM, 2004, PEDIAT ALLERG IMM-UK, V15, P308, DOI 10.1111/j.1399-3038.2004.00169.x; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Jenmalm MC, 2000, CLIN EXP ALLERGY, V30, P34, DOI 10.1046/j.1365-2222.2000.00771.x; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; LILJA G, 1988, CLIN ALLERGY, V18, P131, DOI 10.1111/j.1365-2222.1988.tb02852.x; Lima JO, 2000, J ALLERGY CLIN IMMUN, V106, P911, DOI 10.1067/mai.2000.110228; Loibichler C, 2001, CLIN EXP ALLERGY, V32, P1546; Malek A, 1996, AM J REPROD IMMUNOL, V36, P248; MILLER DL, 1973, J ALLERGY CLIN IMMUN, V52, P182, DOI 10.1016/0091-6749(73)90035-3; Nambu M, 2003, BIOL NEONATE, V83, P102, DOI 10.1159/000067961; Ownby DR, 1996, PEDIATR ALLERGY IMMU, V7, P125, DOI 10.1111/j.1399-3038.1996.tb00119.x; Peters JL, 2009, J ALLERGY CLIN IMMUN, V123, P1041, DOI 10.1016/j.jaci.2009.02.027; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358, DOI 10.1159/000236692; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Sadeghnejad A, 2004, THORAX, V59, P936, DOI 10.1136/thx.2004.024224; Saji F, 1999, REV REPROD, V4, P81, DOI 10.1530/revreprod/4.2.81; Scirica CV, 2007, J ALLERGY CLIN IMMUN, V119, P81, DOI 10.1016/j.jaci.2006.09.002; Simister NE, 2003, VACCINE, V21, P3365, DOI 10.1016/S0264-410X(03)00334-7; Suzuki K, 2011, ANAL CHIM ACTA, V706, P321, DOI 10.1016/j.aca.2011.08.034; Szepfalusi Z, 2006, CLIN EXP ALLERGY, V36, P1130, DOI 10.1111/j.1365-2222.2006.02559.x; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x	31	40	42	1	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					113	+		10.1016/j.jaci.2012.02.023	http://dx.doi.org/10.1016/j.jaci.2012.02.023			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22464644				2022-12-18	WOS:000306644800016
J	Corrigan, CJ; Napoli, RL; Meng, Q; Fang, CL; Wu, HF; Tochiki, K; Reay, V; Lee, TH; Ying, S				Corrigan, Chris J.; Napoli, Rahilya L.; Meng, Qiu; Fang, Cailong; Wu, Huifen; Tochiki, Keri; Reay, Victoria; Lee, Tak H.; Ying, Sun			Reduced expression of the prostaglandin E-2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aspirin; prostaglandin E-2; E-prostanoid receptor; asthma	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NEAR-FATAL ASTHMA; INTOLERANT ASTHMA; INFLAMMATORY CELLS; MAST-CELLS; MECHANICAL VENTILATION; RESPIRATORY-DISEASE; RHINOSINUSITIS; PGE(2); LUNG	Background: Prostaglandin E-2 (PGE(2)) is thought to play a role in the pathogenesis of aspirin-sensitive asthma (ASA). Objective: We sought to extend our previous observations implicating impaired inflammatory cell responsiveness to PGE(2) as a pathogenetic mechanism in patients with aspirin-sensitive rhinosinusitis to the bronchial mucosa in patients with ASA. Methods: Immunohistochemistry was used to enumerate inflammatory cells and their expression of cysteinyl leukotriene receptors 1 and 2 (CysLT(1) and CysLT(2)) and the PGE(2) receptors E-prostanoid 1 to 4 (EP1-EP4) in bronchial biopsy specimens from patients with ASA, patients with aspirin-tolerant asthma, and control subjects (n = 15 in each group). Concentrations of PGE(2) in bronchoalveolar lavage fluid were measured by using ELISA. The effects of PGE(2) and EP receptor agonists on CD3/CD28-stimulated cytokine production by PBMCs were measured by using ELISA. Airways responsiveness to LTD4 in vivo was measured in asthmatic patients by means of bronchial challenge. Results: Compared with patients with aspirin-tolerant asthma, patients with ASA had increased bronchial mucosal neutrophil and eosinophil numbers but reduced percentages of T cells, macrophages, mast cells, and neutrophils expressing EP2. Both groups showed increased bronchial sensitivity to inhaled LTD4, but this did not correlate with mucosal expression of CysLT(1) or CysLT(2). Bronchoalveolar lavage fluid PGE(2) concentrations were comparable in all groups. In vitro PGE(2) inhibited cytokine production by PBMCs through EP2 but not other PGE(2) receptors. Conclusion: Our data are consistent with the hypothesis that impaired inhibition of inflammatory leukocytes by PGE(2) acting through the EP2 receptor has a role in the pathogenesis of ASA. (J Allergy Clin Immunol 2012;129:1636-46.)	[Ying, Sun] Kings Coll London, MRC, Div Asthma Allergy & Lung Biol, London SE1 9RT, England; [Ying, Sun] Guys Hosp, Asthma UK Ctr Allerg Mech Asthma, London SE1 9RT, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Ying, S (corresponding author), Kings Coll London, MRC, Div Asthma Allergy & Lung Biol, 5th Floor,Tower Wing, London SE1 9RT, England.	ying.sun@kcl.ac.uk	Lee, Tak/AAA-9526-2020; Reay, Victoria/T-1403-2017	Lee, Tak/0000-0002-7554-4059; Reay, Victoria/0000-0002-8794-3479; Corrigan, Chris/0000-0002-0706-6534	Medical Research Council; Asthma UK; Department of Health through a National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre; Medical Research Council [G1000758, G1000758B, G0400897] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212, ACF-2009-17-002] Funding Source: researchfish; MRC [G0400897] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Department of Health through a National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Medical Research Council and Asthma UK and the Department of Health through a National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.	Bochenek G, 1996, ALLERGY, V51, P16, DOI 10.1111/j.1398-9995.1996.tb00004.x; Celik G, 2001, CLIN EXP ALLERGY, V31, P1615, DOI 10.1046/j.1365-2222.2001.01074.x; Chowdhury F, 2009, J IMMUNOL METHODS, V340, P55, DOI 10.1016/j.jim.2008.10.002; Corrigan C, 2005, J ALLERGY CLIN IMMUN, V115, P316, DOI 10.1016/j.jaci.2004.10.051; Corrigan CJ, 2011, P NATL ACAD SCI USA, V108, P1579, DOI 10.1073/pnas.1014241108; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Duffy SM, 2008, EUR J IMMUNOL, V38, P2548, DOI 10.1002/eji.200738106; Farooque SP, 2009, ANNU REV PHYSIOL, V71, P465, DOI 10.1146/annurev.physiol.010908.163114; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453; Jinnai N, 2004, HUM MOL GENET, V13, P3203, DOI 10.1093/hmg/ddh332; Kay LJ, 2006, BRIT J PHARMACOL, V147, P707, DOI 10.1038/sj.bjp.0706664; Kolodsick JE, 2003, AM J RESP CELL MOL, V29, P537, DOI 10.1165/rcmb.2002-0243OC; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391, DOI 10.1164/ajrccm.161.2.9902034; Lee TH, 2009, J ALLERGY CLIN IMMUN, V124, P417, DOI 10.1016/j.jaci.2009.04.020; MARQUETTE CH, 1992, AM REV RESPIR DIS, V146, P76, DOI 10.1164/ajrccm/146.1.76; Martins JO, 2010, CELL PHYSIOL BIOCHEM, V26, P739, DOI 10.1159/000322341; Mastalerz L, 2008, THORAX, V63, P27, DOI 10.1136/thx.2007.080903; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nasser S, 1996, THORAX, V51, P64, DOI 10.1136/thx.51.1.64; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90, DOI 10.1164/ajrccm.153.1.8542168; Okano M, 2006, IMMUNOLOGY, V118, P343, DOI 10.1111/j.1365-2567.2006.02376.x; PICADO C, 1989, EUR RESPIR J, V2, P127; Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491; Quiralte J, 1996, J ALLERGY CLIN IMMUN, V98, P678, DOI 10.1016/S0091-6749(96)70102-1; Roca-Ferrer J, 2011, J ALLERGY CLIN IMMUN, V128, P66, DOI 10.1016/j.jaci.2011.01.065; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; Sanak M, 2011, J ALLERGY CLIN IMMUN, V127, P1141, DOI 10.1016/j.jaci.2010.12.1108; Schmidt LM, 2011, J IMMUNOL, V186, P2095, DOI 10.4049/jimmunol.1002414; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Staples KJ, 2001, J IMMUNOL, V167, P2074, DOI 10.4049/jimmunol.167.4.2074; Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608, DOI 10.1164/ajrccm.154.6.8970343; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Takafuji V, 2000, PROSTAG LEUKOTR ESS, V63, P223, DOI 10.1054/plef.2000.0144; Takahashi HK, 2009, J PHARMACOL EXP THER, V331, P656, DOI 10.1124/jpet.109.157594; Vancheri C, 2004, TRENDS IMMUNOL, V25, P40, DOI 10.1016/j.it.2003.11.001; Wang XS, 2007, ALLERGY, V62, P620, DOI 10.1111/j.1398-9995.2007.01364.x; Widal M, 1922, PRESSE MED, V30, P189; Ying S, 2006, J ALLERGY CLIN IMMUN, V117, P312, DOI 10.1016/j.jaci.2005.10.037; Ying S, 2008, J IMMUNOL, V181, P2790, DOI 10.4049/jimmunol.181.4.2790; Yoshimine F, 2005, RESPIROLOGY, V10, P477, DOI 10.1111/j.1440-1843.2005.00740.x	44	40	42	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1636	1646		10.1016/j.jaci.2012.02.007	http://dx.doi.org/10.1016/j.jaci.2012.02.007			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	952BL	22418066	Bronze			2022-12-18	WOS:000304764600026
J	Liang, GQ; Barker, T; Xie, ZH; Charles, N; Rivera, J; Druey, KM				Liang, Genqing; Barker, Tolga; Xie, Zhihui; Charles, Nicolas; Rivera, Juan; Druey, Kirk M.			Naive T cells sense the cysteine protease allergen papain through protease-activated receptor 2 and propel T(H)2 immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chemokines; basophils; chemotaxis; T(H)2; allergens	HELPER TYPE-2 RESPONSE; DENDRITIC CELLS; IN-VIVO; IL-4 PRODUCTION; BASOPHILS; DIFFERENTIATION; EXPRESSION; COMPLEXES; CYTOKINES; CCL17	Background: Sensitization to protease allergens, such as papain, or helminth infection is associated with basophil recruitment to draining lymph nodes (LNs). Basophils have the capacity to present antigen to naive T cells and promote T(H)2 differentiation directly or indirectly through IL-4 production. Objective: We studied how papain induces basophil migration to LNs and the contribution of various leukocytes to papain-induced immune responses. Methods: We immunized mice in the footpad with papain and studied leukocyte recruitment and inflammatory cytokine and chemokine production in the draining popliteal LNs. Results: Papain directly activated naive T cells through protease-activated receptor (PAR) 2 to initiate a chemokine/cytokine program that includes CCL17, CCL22, and IL-4. Papain-triggered innate immune responses were dependent on both CD4 T cells and PAR2 and were strongly reduced in the absence of CCR4, the primary receptor for CCL17/CCL22. Conclusion: These results elucidate a novel innate allergen-recognition pathway mediated by naive T cells through PAR2, which provide an immediate source of chemokines and IL-4 upstream of basophils and antigen-restricted T(H)2 differentiation. PAR2 antagonism might thus hold promise for the treatment of allergic disease. (J Allergy Clin Immunol 2012;129:1377-86.)	[Liang, Genqing; Barker, Tolga; Xie, Zhihui; Druey, Kirk M.] NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; [Charles, Nicolas; Rivera, Juan] NIAMSD, Immunogenet Mol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Druey, KM (corresponding author), NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, 10 Ctr Dr,Rm 11N242, Bethesda, MD 20892 USA.	kdruey@niaid.nih.gov	CHARLES, Nicolas/S-2214-2019; CHARLES, Nicolas/P-5430-2014	CHARLES, Nicolas/0000-0002-5416-5834; CHARLES, Nicolas/0000-0002-5416-5834	National Institutes of Health, National Institute of Allergy and Infectious Diseases; National Institute of Arthritis and Musculoskeletal and Skin Diseases [AI000939]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000939, ZIAAI000746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041155] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Arthritis and Musculoskeletal and Skin Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported in part by the Intramural Research Programs of the National Institutes of Health, National Institute of Allergy and Infectious Diseases, and National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant no. AI000939 LAD to K. M. D.).	Alferink J, 2003, J EXP MED, V197, P585, DOI 10.1084/jem.20021859; Alkan SS, 1996, ANN NY ACAD SCI, V796, P82, DOI 10.1111/j.1749-6632.1996.tb32569.x; Chambers L, 1998, BIOCHEM BIOPH RES CO, V253, P837, DOI 10.1006/bbrc.1998.9862; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Charles N, 2009, IMMUNITY, V30, P533, DOI 10.1016/j.immuni.2009.02.008; Dogan RNE, 2011, J LEUKOCYTE BIOL, V89, P93, DOI 10.1189/jlb.0810442; Falcone FH, 2005, INFLAMM RES, V54, pS13, DOI 10.1007/s00011-004-0405-y; FINKELMAN FD, 1992, PARASITOL TODAY, V8, P311, DOI 10.1016/0169-4758(92)90105-B; Heath WR, 2009, NAT IMMUNOL, V10, P1237, DOI 10.1038/ni.1822; Henri S, 2010, IMMUNOL CELL BIOL, V88, P366, DOI 10.1038/icb.2010.34; Hirata H, 2003, J CLIN IMMUNOL, V23, P34, DOI 10.1023/A:1021948214742; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; KUMAGAI K, 1979, J IMMUNOL METHODS, V29, P17, DOI 10.1016/0022-1759(79)90121-2; Lee JH, 2011, J ALLERGY CLIN IMMUN, V128, P1326, DOI 10.1016/j.jaci.2011.06.036; Mekala DJ, 2003, J IMMUNOL, V171, P4089, DOI 10.4049/jimmunol.171.8.4089; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; Nakagawa Y, 2011, J IMMUNOL, V186, P2881, DOI 10.4049/jimmunol.1003485; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Paul WE, 2010, IMMUNOL CELL BIOL, V88, P236, DOI 10.1038/icb.2010.2; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Pulendran B, 2010, NAT IMMUNOL, V11, P647, DOI 10.1038/ni.1894; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Shichijo Michitaka, 2006, Allergol Int, V55, P271, DOI 10.2332/allergolint.55.271; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Stack C, 2011, ADV EXP MED BIOL, V712, P116, DOI 10.1007/978-1-4419-8414-2_8; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Stutte S, 2010, P NATL ACAD SCI USA, V107, P8736, DOI 10.1073/pnas.0906126107; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138; Wirnsberger G, 2006, EUR J IMMUNOL, V36, P1882, DOI 10.1002/eji.200635972; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; Zhu Wei, 2005, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V21, P519	37	40	40	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1377	U282		10.1016/j.jaci.2012.02.035	http://dx.doi.org/10.1016/j.jaci.2012.02.035			23	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22460072	Green Accepted			2022-12-18	WOS:000303418000029
J	Parmentier, CN; Fuerst, E; McDonald, J; Bowen, H; Lee, TH; Pease, JE; Woszczek, G; Cousins, DJ				Parmentier, Celine N.; Fuerst, Elisabeth; McDonald, Joanne; Bowen, Holly; Lee, Tak H.; Pease, James E.; Woszczek, Grzegorz; Cousins, David J.			Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human; T(H)1; T(H)2; cysteinyl leukotrienes; chemotaxis; CYSLTR1; cysteinyl leukotriene receptor 1 protein; LTD4	ASTHMA; INFLAMMATION; CHEMOTAXIS; MECHANISMS; DISEASE; GAMMA	Background: Allergic asthma is characterized by reversible airway obstruction and bronchial hyperresponsiveness associated with T(H)2 cell-mediated inflammation. Cysteinyl leukotrienes (CysLTs) are potent lipid mediators involved in bronchoconstriction, mucus secretion, and cell trafficking in asthmatic patients. Recent data have implicated CysLTs in the establishment and amplification of T(H)2 responses in murine models, although the precise mechanisms are unresolved. Objectives: Preliminary microarray studies suggested that human T(H)2 cells might selectively express cysteinyl leukotriene receptor 1 (CYSLTR1) mRNA. We sought to establish whether human T(H)2 cells are indeed a CysLT target cell type. Methods: We examined the expression of CYSLTR1 using real-time PCR in human T(H)1 and T(H)2 cells. We functionally assessed cysteinyl leukotriene receptor 1 protein (CysLT(1)) expression using calcium flux, cyclic AMP, and chemotaxis assays. Results: We show that human TH2 cells selectively express CYSLTR1 mRNA at high levels compared with T(H)1 cells after in vitro differentiation from naive precursors. Human T(H)2 cells are selectively responsive to CysLTs in a calcium flux assay when compared with T(H)1 cells with a rank order of potency similar to that described for CysLT(1) (leukotriene [LT] D-4 > LTC4 > LTE4). We also show that LTD4-induced signaling in T(H)2 cells is mediated through CysLT(1) coupled to G(alpha)q and G(alpha)i proteins, and both pathways can be completely inhibited by selective CysLT(1) antagonists. LTD4 is also found to possess potent chemotactic activity for T(H)2 cells at low nanomolar concentrations. Conclusions: These findings suggest a novel mechanism of action for CysLTs in the pathogenesis of asthma and provide a potential explanation for the anti-inflammatory effects of CysLT(1) antagonists. (J Allergy Clin Immunol 2012; 129:1136-42.)	[Parmentier, Celine N.; Fuerst, Elisabeth; McDonald, Joanne; Bowen, Holly; Lee, Tak H.; Pease, James E.; Woszczek, Grzegorz; Cousins, David J.] Kings Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, London SE1 9RT, England; [Parmentier, Celine N.; Fuerst, Elisabeth; McDonald, Joanne; Bowen, Holly; Lee, Tak H.; Woszczek, Grzegorz; Cousins, David J.] Kings Coll London, Div Asthma Allergy & Lung Biol, London SE1 9RT, England; [Pease, James E.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London, England	University of London; King's College London; University of London; King's College London; Imperial College London	Cousins, DJ (corresponding author), Kings Coll London, MRC & Asthma UK Ctr Allerg Mech Asthma, Div Asthma Allergy & Lung Biol, Guys Hosp, 5th Floor Tower Wing, London SE1 9RT, England.	david.cousins@kcl.ac.uk	Lee, Tak/AAA-9526-2020; Woszczek, Grzegorz/H-5792-2012; Pease, James/X-4521-2018	Lee, Tak/0000-0002-7554-4059; Pease, James/0000-0003-3749-0341; Cousins, David/0000-0003-3821-9596	Medical Research Council [G0400503, G9536930, G0900536]; Asthma UK [09/020, 10/062, 09/024]; Guy's & St Thomas' Charity; Friends of Guy's Hospital; Department of Health through the National Institute for Health Research's (NIHR) comprehensive Biomedical Research Centre; King's College London and King's College Hospital NHS Foundation Trust; MRC [G9536930, G0400503, G0900536] Funding Source: UKRI; Medical Research Council [G1000758, G1000758B] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Asthma UK; Guy's & St Thomas' Charity; Friends of Guy's Hospital; Department of Health through the National Institute for Health Research's (NIHR) comprehensive Biomedical Research Centre; King's College London and King's College Hospital NHS Foundation Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); Asthma UK	D.J.C. has received grant support from the Medical Research Council (G0400503), Asthma UK (09/020 and 10/062), Guy's & St Thomas' Charity, and the Friends of Guy's Hospital. C.N.P. and J.M. were supported by Medical Research Council PhD studentships. T.H.L. has received grant support from the Medical Research Council (G9536930 and G0400503). J.E.P. has received grant support from Asthma UK (09/024). G.W. has received grant support from the Medical Research Council (G0900536). The authors also acknowledge financial support from the Department of Health through the National Institute for Health Research's (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Austen KF, 2008, NAT IMMUNOL, V9, P113, DOI 10.1038/ni0208-113; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2003, CURR OPIN PHARMACOL, V3, P257, DOI 10.1016/S1471-4892(03)00036-5; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Bautz F, 2001, BLOOD, V97, P3433, DOI 10.1182/blood.V97.11.3433; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cousins DJ, 2002, J IMMUNOL, V169, P2498, DOI 10.4049/jimmunol.169.5.2498; De Nadai P, 2006, J IMMUNOL, V176, P6286, DOI 10.4049/jimmunol.176.10.6286; Early SB, 2007, AM J RESP CELL MOL, V36, P715, DOI 10.1165/rcmb.2006-0252OC; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Lynch KR, 1999, NATURE, V399, P789; Machida I, 2004, J IMMUNOL, V172, P1833, DOI 10.4049/jimmunol.172.3.1833; Maekawa A, 2009, P NATL ACAD SCI USA, V106, P11685, DOI 10.1073/pnas.0905364106; Okunishi K, 2004, J IMMUNOL, V173, P6393, DOI 10.4049/jimmunol.173.10.6393; Paruchuri S, 2009, J EXP MED, V206, P2543, DOI 10.1084/jem.20091240; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Prinz I, 2005, J IMMUNOL, V175, P713, DOI 10.4049/jimmunol.175.2.713; Rabinovitch N, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Rabinovitch N, 2010, J ALLERGY CLIN IMMUN, V126, P545, DOI 10.1016/j.jaci.2010.07.008; Robinson DS, 2010, J ALLERGY CLIN IMMUN, V126, P1081, DOI 10.1016/j.jaci.2010.06.025; Sallusto F, 1999, EUR J IMMUNOL, V29, P2037, DOI 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V; Sandig H, 2007, P NATL ACAD SCI USA, V104, P12440, DOI 10.1073/pnas.0705457104; Sandig H, 2009, J ALLERGY CLIN IMMUN, V124, P528, DOI 10.1016/j.jaci.2009.04.036; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sharma R, 2011, J IMMUNOL, V186, P1268, DOI 10.4049/jimmunol.1002677; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Woszczek G, 2008, J ALLERGY CLIN IMMUN, V121, P215, DOI 10.1016/j.jaci.2007.09.013	35	40	41	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2012	129	4					1136	1142		10.1016/j.jaci.2012.01.057	http://dx.doi.org/10.1016/j.jaci.2012.01.057			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	917AP	22391114	Bronze			2022-12-18	WOS:000302144600030
J	O'Byrne, PM				O'Byrne, Paul M.			Therapeutic strategies to reduce asthma exacerbations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; treatment; inhaled corticosteroids; leukotriene antagonist; long-acting beta(2)-agonists; anti-IgE	BUDESONIDE/FORMOTEROL COMBINATION THERAPY; ALLERGEN-INDUCED BRONCHOCONSTRICTION; LEUKOTRIENE RECEPTOR ANTAGONIST; DOUBLE-BLIND; BRONCHIAL THERMOPLASTY; CLINICAL ASTHMA; AIRWAY HYPERRESPONSIVENESS; INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; SEPTEMBER EPIDEMIC	Asthma exacerbations can occur in patients with all degrees of asthma severity. They generally develop over 5 to 7 days and are most often initiated by an upper respiratory tract infection (usually with human rhinovirus) or by environmental allergen exposure in atopic subjects. Inhaled corticosteroids (ICSs) taken on a regular basis are very effective in reducing the risk of asthma exacerbations, and the combination of ICSs and long-acting inhaled beta(2)-agonists further reduces this risk. In addition, use of the combination of the ICS budesonide and the long-acting inhaled beta(2)-agonist formoterol, both as maintenance asthma treatment and also as rescue treatment (instead of a short-acting inhaled beta(2)-agonist), has a significant further beneficial effect on asthma exacerbation risk. Other therapies that have been demonstrated to reduce severe asthma exacerbations are leukotriene receptor antagonists, which have been demonstrated to be effective most consistently in this regard in children, and anti-IgE mAbs, which are effective in subjects with difficult-to-treat allergic asthma. Approximately 50% of severe asthma exacerbations are eosinophilic in nature, whereas many of the remaining are neutrophilic. Several studies have demonstrated that making asthma treatment decisions based on minimizing airway eosinophil numbers (measured in induced sputum) can reduce the risks of severe exacerbations. In addition, treatment of patients with severe asthma with an anti-IL-5 mAb also reduces the number of severe asthma exacerbations, demonstrating a central role of eosinophils in many exacerbations. (J Allergy Clin Immunol 2011;128:257-63.)	[O'Byrne, Paul M.] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [O'Byrne, Paul M.] St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada	McMaster University; McMaster University	O'Byrne, PM (corresponding author), McMaster Univ, Dept Med, HSC 3W10,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X	AstraZeneca; GlaxoSmithKline; Merck; Wyeth; Schering-Plough; Alexion	AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Wyeth(Wyeth); Schering-Plough(Merck & CompanySchering Plough Corporation); Alexion	P. M. O'Byrne is on the advisory boards for and has received speakers honoraria from AstraZeneca and GlaxoSmithKline; is on the advisory boards for Topigen, Wyeth, and Schering-Plough; and has received research support from AstraZeneca, GlaxoSmithKline, Merck, Wyeth, Schering-Plough, and Alexion.	Balanag VM, 2006, PULM PHARMACOL THER, V19, P139, DOI 10.1016/j.pupt.2005.04.009; Barnett SBL, 2011, J ALLERGY CLIN IMMUN, V127, P145, DOI 10.1016/j.jaci.2010.10.020; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 1997, PEDIATR PULM, P27; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Bjermer L, 2003, BMJ-BRIT MED J, V327, P891, DOI 10.1136/bmj.327.7420.891; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; Brightling Christopher E, 2005, Treat Respir Med, V4, P309, DOI 10.2165/00151829-200504050-00002; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse WW, 2007, CURR MED RES OPIN, V23, P2379, DOI 10.1185/030079907X226258; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; COX G, 1995, J IMMUNOL, V154, P4719; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Cox PG, 2004, EUR RESPIR J, V24, P659, DOI 10.1183/09031936.04.00054604; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738, DOI 10.1164/ajrccm.156.6.96-08042; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640, DOI 10.1164/ajrccm.160.2.9809130; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473, DOI 10.1164/ajrccm.161.5.9908090; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Gibson PG, 2000, J ALLERGY CLIN IMMUN, V105, P752, DOI 10.1067/mai.2000.105319; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RM, 2002, BMJ-BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hamilton AL, 1997, THORAX, V52, P348, DOI 10.1136/thx.52.4.348; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; JUNIPER EF, 1990, EUR RESPIR J, V3, P1122; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; Kelly MM, 2010, J ALLERGY CLIN IMMUN, V125, P349, DOI 10.1016/j.jaci.2009.09.011; Lin RY, 2009, ANN ALLERG ASTHMA IM, V103, P442, DOI 10.1016/S1081-1206(10)60366-3; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; Miller JD, 2005, CHEST, V127, P1999, DOI 10.1378/chest.127.6.1999; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; O'Byrne PM, 2006, LANCET, V368, P794, DOI 10.1016/S0140-6736(06)69289-1; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; OBYRNE PM, 1988, J ALLERGY CLIN IMMUN, V81, P119, DOI 10.1016/0091-6749(88)90230-8; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740, DOI 10.1164/ajrccm/136.3.740; OByrne PM, 1997, ANN INTERN MED, V127, P472, DOI 10.7326/0003-4819-127-6-199709150-00009; Palmqvist M, 1997, EUR RESPIR J, V10, P2484, DOI 10.1183/09031936.97.10112489; Palmqvist M, 1999, AM J RESP CRIT CARE, V160, P244, DOI 10.1164/ajrccm.160.1.9901063; Papi A, 2007, EUR RESPIR J, V29, P682, DOI 10.1183/09031936.00095906; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Ramsay CF, 2011, THORAX, V66, P7, DOI 10.1136/thx.2010.135038; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; ROBERTSON CF, 1990, MED J AUSTRALIA, V152, P511, DOI 10.5694/j.1326-5377.1990.tb125350.x; Scottish Intercollegiate Guidelines Network Healthcare Improvement Scotland, 2013, MAN SCH NAT CLIN GUI; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Stanford RH, 2008, CURR MED RES OPIN, V24, P3141, DOI [10.1185/03007990802462990, 10.1185/03007990802462990 ]; Strunk RC, 2009, J PEDIATR-US, V154, P682, DOI 10.1016/j.jpeds.2008.11.036; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594, DOI 10.1164/ajrccm.160.2.9811100; Tattersfield AE, 2001, LANCET, V357, P257, DOI 10.1016/S0140-6736(00)03611-4; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V; TURNER MO, 1995, THORAX, V50, P1057, DOI 10.1136/thx.50.10.1057; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	80	40	42	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					257	265		10.1016/j.jaci.2011.03.035	http://dx.doi.org/10.1016/j.jaci.2011.03.035			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21531015				2022-12-18	WOS:000293280800001
J	Rabinovitch, N; Reisdorph, N; Silveira, L; Gelfand, EW				Rabinovitch, Nathan; Reisdorph, Nichole; Silveira, Lori; Gelfand, Erwin W.			Urinary leukotriene E-4 levels identify children with tobacco smoke exposure at risk for asthma exacerbation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; biomarker; exacerbation; leukotriene E-4; secondhand smoke	EXHALED NITRIC-OXIDE; CYSTEINYL LEUKOTRIENES; PASSIVE SMOKING; TRIAL; METHACHOLINE; EOSINOPHIL; RESPONSES; HEALTH; IMPACT	Background: Children with asthma exposed to secondhand smoke (SHS) might be at higher risk for severe exacerbations, but biomarkers of susceptibility to SHS exposure have not been previously reported. Objectives: We sought to assess the usefulness of urinary leukotriene E-4 (uLTE(4)) levels in the prediction of increased risk of severe asthma exacerbations requiring emergency department (ED) or urgent care (UC) visits. Methods: Forty-four schoolchildren with moderate-to-severe asthma receiving inhaled corticosteroids were followed for 5 months with repeated measurements of uLTE(4) and monitoring of ED and UC visits. SHS exposure status was determined by using prestudy questionnaires and repeated measurements of urinary cotinine during the study. Results: Nine (45%) of 20 children with SHS exposure experienced a severe exacerbation requiring an ED or UC visit compared with 3 (12.5%) of 24 children without significant SHS exposure (relative risk, 3.6; 95% CI, 1.1-11.5; P = .02). The uLTE(4) level was a significant predictor of exacerbation risk in children exposed to SHS (area under the curve, 0.85; P = .003). Other predictors, such as nighttime symptom frequency, prebronchodilator and postbronchodilator lung function, and exhaled nitric oxide levels, were not related to exacerbations in this group. uLTE(4) levels at or greater than 106 pg/mg achieved 67% (6/9) sensitivity and 100% (11/11) specificity for predicting children with SHS exposure who required an ED or UC visit. Conclusions: Children exposed to SHS are at increased risk for severe asthma exacerbations, despite use of inhaled corticosteroids. uLTE(4) levels identify children exposed to SHS at high risk for asthma exacerbations. (J Allergy Clin Immunol 2011;128:323-7.)	[Rabinovitch, Nathan; Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Reisdorph, Nichole] Natl Jewish Hlth, Dept Immunol, Denver, CO USA; [Silveira, Lori] Natl Jewish Hlth, Div Biostat, Denver, CO USA	National Jewish Health; National Jewish Health; National Jewish Health	Rabinovitch, N (corresponding author), Natl Jewish Med Hlth, 1400 Jackson St, Denver, CO 80206 USA.	rabinovitchn@njhealth.org	Reisdorph, Nichole/AAX-8774-2020	Reisdorph, Nichole/0000-0002-0425-8012	National Institutes of Health/National Institutes of Environmental Health Sciences [ES015510-01]; Alere; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES015510] Funding Source: NIH RePORTER	National Institutes of Health/National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Alere; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health/National Institutes of Environmental Health Sciences K23 grant no. ES015510-01.; N. Reisdorph receives research support from Alere. The rest of the authors have declared that they have no conflict of interest.	Adenuga D, 2009, AM J RESP CELL MOL, V40, P464, DOI 10.1165/rcmb.2008-0255OC; Armstrong M, 2009, J CHROMATOGR B, V877, P3169, DOI 10.1016/j.jchromb.2009.08.011; Austen KF, 2009, J ALLERGY CLIN IMMUN, V124, P406, DOI 10.1016/j.jaci.2009.05.046; Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Cohen RT, 2010, J ALLERGY CLIN IMMUN, V126, P491, DOI 10.1016/j.jaci.2010.06.016; Cornelius MD, 2003, NICOTINE TOB RES, V5, P333, DOI 10.1080/1462220031000094141; COURIEL JM, 1994, THORAX, V49, P731, DOI 10.1136/thx.49.8.731; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; DOUCET MY, 1990, CAN J PHYSIOL PHARM, V68, P379, DOI 10.1139/y90-053; Fauler J, 1997, EUR J CLIN INVEST, V27, P43, DOI 10.1046/j.1365-2362.1997.650619.x; FORASTIERE F, 1992, INT J EPIDEMIOL, V21, P66, DOI 10.1093/ije/21.1.66; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Goldstein MF, 2001, CHEST, V119, P1001, DOI 10.1378/chest.119.4.1001; Gyllfors P, 2005, THORAX, V60, P902, DOI 10.1136/thx.2005.041913; Invernizzi G, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-48; Kumlin M, 2000, AM J RESP CRIT CARE, V161, pS102, DOI 10.1164/ajrccm.161.supplement_1.ltta-20; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lee TH, 2009, J ALLERGY CLIN IMMUN, V124, P417, DOI 10.1016/j.jaci.2009.04.020; Muscat JE, 2005, CANCER-AM CANCER SOC, V103, P1420, DOI 10.1002/cncr.20953; Pedersen B, 1996, AM J RESP CRIT CARE, V153, P1519, DOI 10.1164/ajrccm.153.5.8630596; Petsky HL, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006340.pub2; Rabinovitch N, 2008, J ALLERGY CLIN IMMUN, V121, P1365, DOI 10.1016/j.jaci.2008.03.016; Rabinovitch N, 2006, J ALLERGY CLIN IMMUN, V118, P635, DOI 10.1016/j.jaci.2006.05.011; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; SMITH CM, 1992, EUR RESPIR J, V5, P693; STODDARD JJ, 1995, AM J EPIDEMIOL, V141, P96, DOI 10.1093/oxfordjournals.aje.a117418; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8	31	40	41	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					323	327		10.1016/j.jaci.2011.05.035	http://dx.doi.org/10.1016/j.jaci.2011.05.035			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	799IQ	21807251	Green Accepted			2022-12-18	WOS:000293280800011
J	Bousquet, PJ; Calderon, MA; Demoly, P; Larenas, D; Passalacqua, G; Bachert, C; Brozek, J; Canonica, GW; Casale, T; Fonseca, J; Dahl, R; Durham, SR; Merk, H; Worm, M; Wahn, U; Zuberbier, T; Schunemann, HJ; Bousquet, J				Bousquet, Philippe J.; Calderon, Moises A.; Demoly, Pascal; Larenas, Desiree; Passalacqua, Giovanni; Bachert, Claus; Brozek, Jan; Canonica, G. Walter; Casale, Thomas; Fonseca, Joao; Dahl, Ronald; Durham, Stephen R.; Merk, Hans; Worm, Margitta; Wahn, Ulrich; Zuberbier, Torsten; Schuenemann, Holger J.; Bousquet, Jean			The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA(2)LEN) article	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Subcutaneous immunotherapy; sublingual immunotherapy; allergen; CONSORT; randomized clinical trial	SUBLINGUAL-SWALLOW IMMUNOTHERAPY; HOUSE-DUST-MITE; PLACEBO-CONTROLLED EVALUATION; RANDOMIZED CONTROLLED-TRIAL; ENZYME-POTENTIATED DESENSITIZATION; PARIETARIA-JUDAICA EXTRACT; GRASS-POLLEN IMMUNOTHERAPY; SHORT-TERM IMMUNOTHERAPY; DOUBLE-BLIND; CLINICAL-EFFICACY	Background: Randomized trials provide evidence to inform treatment decisions. The Consolidated Standards of Reporting Trials (CONSORT) Statement is a set of recommendations for the reporting of trials. Objective: We sought to assess the quality of reporting allergen-specific immunotherapy trials according to CONSORT criteria. Methods: The reporting of the procedure, randomization, dropouts, strict conduct of intention-to-treat (ITT) analysis, and sample size calculation according to CONSORT were assessed in the 46 subcutaneous and 48 sublingual immunotherapy (SLIT) blind, placebo-controlled randomized trials published between 1996 and 2009 in English. Results: One subcutaneous immunotherapy (2.2%) and 3 SLIT (6.6%) trials met CONSORT Statement criteria. These were used for the registration of sublingual tablets to the European Medicines Agency. In subcutaneous immunotherapy, 16 (35%) studies reported a CONSORT flow chart, and 12 (26%) provided a description of dropouts. Adequate randomization was reported in 9 (35%) studies, and incomplete randomization was reported in 15 (33%). Power analysis was reported in 15 (33%) studies. In SLIT, 20 (42%) studies reported a CONSORT flow chart, and 16 (32%) a description of dropouts. ITT analysis was carried out in 1 (2.2%) SLIT study, and a modified ITT analysis was used in 1 (2.2%) subcutaneous immunotherapy study and 2 (4.4%) SLIT studies. Adequate randomization was reported in 6 (12%) studies, and incomplete randomization was reported in 16 (32%). Power analysis was reported in 15 (27%) studies. Conclusion: As in other areas of medicine, the quality of reporting of most immunotherapy trials is low, and only 4.2% of SLIT randomized controlled trials met all of the criteria of the CONSORT Statement. Use of the CONSORT criteria should be encouraged. (J Allergy Clin Immunol 2011;127:49-56.)	[Bousquet, Philippe J.; Demoly, Pascal; Bousquet, Jean] Univ Hosp Montpellier, Dept Resp Dis, Montpellier, France; [Calderon, Moises A.; Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London SW7 2AZ, England; [Larenas, Desiree] Hosp Med Sur, Dept Allergy, Mexico City, DF, Mexico; [Bousquet, Jean] Hop Arnaud Villeneuve, Serv Malad Resp, Inserm U657, F-34295 Montpellier, France; [Passalacqua, Giovanni; Canonica, G. Walter] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy; [Bachert, Claus] Ghent Univ Hosp, Upper Airways Res Lab URL, B-9000 Ghent, Belgium; [Brozek, Jan; Schuenemann, Holger J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Brozek, Jan; Schuenemann, Holger J.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Casale, Thomas] Creighton Univ, Dept Med, Div Allergy & Immunol, Omaha, NE 68178 USA; [Fonseca, Joao] Univ Porto, Biostat & Med Informat Dept, P-4100 Oporto, Portugal; [Fonseca, Joao] Univ Porto, Div Allergy, P-4100 Oporto, Portugal; [Dahl, Ronald] Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark; [Merk, Hans] Univ Aachen, Dept Dermatol, D-5100 Aachen, Germany; [Fonseca, Joao] Univ Porto, CINTESIS, P-4100 Oporto, Portugal; [Worm, Margitta; Zuberbier, Torsten] Charite, Dept Dermatol, Allergy Ctr Charite, D-13353 Berlin, Germany; [Wahn, Ulrich] Charite Hosp, Dept Pediat, Berlin, Germany; [Bousquet, Jean] Inserm 1018, CESP, Villejuif, France	Universite de Montpellier; CHU de Montpellier; Imperial College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; University of Genoa; Ghent University; Ghent University Hospital; McMaster University; McMaster University; Creighton University; Universidade do Porto; Universidade do Porto; Aarhus University; RWTH Aachen University; Universidade do Porto; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bousquet, J (corresponding author), Hop Arnaud Villeneuve, Serv Malad Resp, Inserm U657, F-34295 Montpellier, France.	jean.bousquet@inserm.fr	Dahl, Ronahl/F-8170-2013; Demoly, Pascal/Y-9938-2019; canonica, giorgio walter/ABF-2037-2020; Fonseca, João A./B-7562-2008; Bachert, Claus/J-8825-2012; Bousquet, Philippe Jean/AAW-8608-2021; Bousquet, Jean/O-4221-2019; , CINTESIS/C-6631-2014	Demoly, Pascal/0000-0001-7827-7964; canonica, giorgio walter/0000-0001-8467-2557; Fonseca, João A./0000-0002-0887-8796; Bousquet, Philippe Jean/0000-0002-0217-5483; Schunemann, Holger/0000-0003-3211-8479; Larenas Linnemann, Desiree/0000-0002-5713-5331; Worm, Margitta/0000-0002-3449-1245; , CINTESIS/0000-0001-7248-2086	EU [FOOD-CT-2004-506378]; Global Allergy and Asthma European Network; ALK-Abello; Stallergenes; Chiesi and CoPharma; Allergy Therapeutics; Schering-Plough; Bial-Aristegui; Pfizer; Boehringer-Ingelheim; AstraZeneca; Novartis; Horsholm Denmark; GlaxoSmithKline; Medical Research Council [G1000758B, G1000758] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	EU(European Commission); Global Allergy and Asthma European Network; ALK-Abello; Stallergenes; Chiesi and CoPharma(Chiesi Pharmaceuticals Inc); Allergy Therapeutics; Schering-Plough(Merck & CompanySchering Plough Corporation); Bial-Aristegui(Bial Group); Pfizer(Pfizer); Boehringer-Ingelheim(Boehringer Ingelheim); AstraZeneca(AstraZeneca); Novartis(Novartis); Horsholm Denmark; GlaxoSmithKline(GlaxoSmithKline); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was exclusively funded by the Global Allergy and Asthma European Network, supported by the European Union Framework program for research, contract no. FOOD-CT-2004-506378) and was initiated during a GA<SUP>2</SUP>LEN workshop held in Rome on July 12, 2009.; P. Demoly has received honoraria from ALK-Abello and Stallergenes. D. Larenas has received research support from ALK-Abello, Stallergenes, and Alerquim; is the Chair of the Immunotherapy Committee of the Colegio Mexicano de Alergia and the American Academy of Allergy, Asthma & Immunology; and is Secretary of the Immunotherapy Dosing Task Force of the European Academy of Allergy and Clinical Immunology. G. W. Canonica is a consultant for MSD, Nycomed, Stallergenes, ALK-Abello, and HAL and has received research support from Chiesi and CoPharma. T. Casale has received research support from Allergy Therapeutics, Schering-Plough, and Stallergenes. J. Fonseca has received research support from Bial-Aristegui. R. Dahl has lectured for or is on the advisory board of Boehringer-Ingelheim, AstraZeneca, GlaxoSmithKline, Almirall, UCB, ALK-Abello , Airsonett, MSD, and Novartis; and has received research support from ALK-Abello, Stallergenes, Pfizer, Boehringer-Ingelheim, AstraZeneca, Novartis, and Almirall; is Chairman of the Danish Respiratory Society and Interasma; and is Vice-Chair of the Global Alliance against chronic respiratory diseases. S. R. Durham has received lecture and consultancy fees from ALK-Abello, Horsholm Denmark, and GlaxoSmithKline; is a consultant for Merck, Greer Laboratories, and Ono Pharma (United Kingdom); and has received research support from ALK-Abello, Horsholm Denmark, and GlaxoSmithKline. H. Merk is a consultant for Stallergenes and ALK-Abello . M. Worm has received honoraria from Stallergenes, Actelion, Basilea, Beta Pharma, Essex Pharma, ALK-Abello, and AllergoPharma. T. Zuberbier is a consultant for Schering-Plough, Novartis, Leri, Stallergenes, Bayer Schering, Ansell Kryolan, UCB, MSD, DST, Sanofi-Aventis, and Procter & Gamble; is on the Editorial Board of the Journal of Allergy; is on the Scientific Advisory Board of the German Federal Ministry of Consumer Protection; is Chairman of the European Academy of Allergology and Clinical Immunology (EAACI) Dermatology Section; is Head of European Centre for Allergy Research Foundation (ECARF); is a committee member of the WHO-Initiative Allergy Rhinitis and its Impact on Asthma (ARIA); is a member of the World Allergy Organization Communications Council; and is Secretary General of the Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN). J. Bousquet has received honoraria from Stallergenes, Actelion, Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Merck, MSD, Novartis, OM Pharma, Sanofi-Aventis, Schering-Plough, TEVA, and Uriach. The rest of the authors have declared that they have no conflict of interest.	Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Altintas D, 1999, Allergol Immunopathol (Madr), V27, P309; Alvarez-Cuesta E, 2005, CLIN EXP ALLERGY, V35, P572, DOI 10.1111/j.1365-2222.2005.02245.x; Ameal A, 2005, ALLERGY, V60, P1178, DOI 10.1111/j.1398-9995.2005.00862.x; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Ariano R, 1997, Allergol Immunopathol (Madr), V25, P23; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; Arvidsson MB, 2002, J ALLERGY CLIN IMMUN, V109, P777, DOI 10.1067/mai.2002.123868; Astarita C, 1996, J INVEST ALLERG CLIN, V6, P248; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Balda BR, 1998, ALLERGY, V53, P740; Basomba A, 2002, J ALLERGY CLIN IMMUN, V109, P943, DOI 10.1067/mai.2002.124465; Bausch B, 2009, EUR RESPIR J, V34, P1060, DOI 10.1183/09031936.00159108; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Blumberga G, 2006, ALLERGY, V61, P843, DOI 10.1111/j.1398-9995.2006.01088.x; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet PJ, 2009, ALLERGY, V64, P1737, DOI 10.1111/j.1398-9995.2009.02232.x; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425, DOI 10.1016/S1081-1206(10)61408-1; Brozek JL, 2008, ALLERGY, V63, P38, DOI 10.1111/j.1398-9995.2007.01560.x; Brozek JL, 2009, ALLERGY, V64, P669, DOI 10.1111/j.1398-9995.2009.01973.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calderon MA, 2011, J ALLERGY CLIN IMMUN, V127, P30, DOI 10.1016/j.jaci.2010.08.024; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Chakraborty P, 2006, J INVEST ALLERG CLIN, V16, P377; Charpin D, 2007, INT ARCH ALLERGY IMM, V143, P83, DOI 10.1159/000098656; Clark HD, 1999, CONTROL CLIN TRIALS, V20, P448, DOI 10.1016/S0197-2456(99)00026-4; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Colas C, 2006, J ALLERGY CLIN IMMUN, V117, P810, DOI 10.1016/j.jaci.2005.11.039; Committee for Medicinal Products for Human Use, 2008, CHMPEWP185042006 EUR; Committee for medicinal products for human use (CPMP), 2008, EMEACHMPBWP304831200; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Crimi Nunzio, 2004, Ann Ital Med Int, V19, P98; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; De Blay F, 2007, ANN ALLERG ASTHMA IM, V99, P453, DOI 10.1016/S1081-1206(10)60571-6; de Queirs MGJ, 2008, J INVEST ALLERG CLIN, V18, P84; Devereaux PJ, 2004, J CLIN EPIDEMIOL, V57, P1232, DOI 10.1016/j.jclinepi.2004.03.017; Di Stanislao C, 1997, Allerg Immunol (Paris), V29, P39; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dokic D, 2005, Prilozi, V26, P113; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Ethgen M, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-24; Ferrer M, 2005, J INVEST ALLERG CLIN, V15, P283; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Garcia-Robaina JC, 2006, J ALLERGY CLIN IMMUN, V118, P1026, DOI 10.1016/j.jaci.2006.07.043; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jadad AR, 1996, LANCET, V347, P274, DOI 10.1016/S0140-6736(96)90456-0; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lewith GT, 2002, BMJ-BRIT MED J, V324, P520, DOI 10.1136/bmj.324.7336.520; Leynadier F, 2001, CLIN EXP ALLERGY, V31, P988, DOI 10.1046/j.1365-2222.2001.01145.x; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Lue KH, 2006, PEDIAT ALLERG IMM-UK, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Mirone C, 2004, CLIN EXP ALLERGY, V34, P1408, DOI 10.1111/j.1365-2222.2004.02056.x; Mosges R, 2007, ACTA DERMATOVEN ALP, V16, P143; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; Montori VM, 2001, CAN MED ASSOC J, V165, P1339; Moreno-Ancillo A, 2007, J INVEST ALLERG CLIN, V17, P399; Mortemousque B, 2003, CLIN EXP ALLERGY, V33, P464, DOI 10.1046/j.1365-2222.2003.01622.x; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Okubo Kimihiro, 2008, Allergol Int, V57, P265, DOI 10.2332/allergolint.O-07-514; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2008.01875.x, 10.1111/j.1398-9995.2009.02194.x]; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Palma-Carlos A G, 2006, Allergol Immunopathol (Madr), V34, P194, DOI 10.1157/13094026; Panzner P, 2008, RESP MED, V102, P1296, DOI 10.1016/j.rmed.2008.03.024; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1398-9995.2006.01095.x; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pfaar O, 2008, ANN ALLERG ASTHMA IM, V100, P256, DOI 10.1016/S1081-1206(10)60451-6; Pham-Thi N, 2007, PEDIAT ALLERG IMM-UK, V18, P47, DOI 10.1111/j.1399-3038.2006.00475.x; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Radcliffe MJ, 2003, BMJ-BRIT MED J, V327, P251, DOI 10.1136/bmj.327.7409.251; Roberts G, 2006, J ALLERGY CLIN IMMUN, V117, P263, DOI 10.1016/j.jaci.2005.09.054; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Sackett D., 2000, EVIDENCE BASED MED P, DOI DOI 10.1136/BMJ.H3089; Schulz KF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000251; Schulz KF, 2002, JAMA-J AM MED ASSOC, V288, P2406, DOI 10.1001/jama.288.19.2406; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Stelmach I, 2009, CLIN EXP ALLERGY, V39, P401, DOI 10.1111/j.1365-2222.2008.03159.x; Tabar AI, 2008, PEDIAT ALLERG IMM-UK, V19, P67, DOI 10.1111/j.1399-3038.2007.00589.x; Tari MG, 1997, ALLERGY, V52, P65, DOI 10.1111/j.1398-9995.1997.tb02547.x; Toerien M, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-52; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Valovirta E, 2006, ALLERGY, V61, P1177, DOI 10.1111/j.1398-9995.2006.01190.x; Varney VA, 2003, CLIN EXP ALLERGY, V33, P1076, DOI 10.1046/j.1365-2222.2003.01735.x; Vervloet D, 2007, INT ARCH ALLERGY IMM, V142, P239, DOI 10.1159/000097026; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wang H, 2006, ALLERGY, V61, P191, DOI 10.1111/j.1398-9995.2005.00913.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; Worm M, 2006, Eur Ann Allergy Clin Immunol, V38, P355; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145; Zenner HP, 1997, J ALLERGY CLIN IMMUN, V100, P23, DOI 10.1016/S0091-6749(97)70190-8	124	40	41	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					49	U511		10.1016/j.jaci.2010.09.017	http://dx.doi.org/10.1016/j.jaci.2010.09.017			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21112079				2022-12-18	WOS:000285917300008
J	Kasperkiewicz, M; Schmidt, E; Frambach, Y; Rose, C; Meier, M; Nitschke, M; Falk, TM; Reich, K; Ludwig, RJ; Zillikens, D				Kasperkiewicz, Michael; Schmidt, Enno; Frambach, Yvonne; Rose, Christian; Meier, Markus; Nitschke, Martin; Falk, Thomas M.; Reich, Kristian; Ludwig, Ralf J.; Zillikens, Detlef			Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ANTI-IGE THERAPY; OMALIZUMAB; EFFICACY; ECZEMA		[Kasperkiewicz, Michael; Schmidt, Enno; Frambach, Yvonne; Rose, Christian; Ludwig, Ralf J.; Zillikens, Detlef] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany; [Meier, Markus; Nitschke, Martin] Med Univ Lubeck, Dept Internal Med, D-23538 Lubeck, Germany; [Falk, Thomas M.; Reich, Kristian] Dermatologikum, Hamburg, Germany	University of Lubeck; University of Lubeck; Dermatologikum Hamburg	Kasperkiewicz, M (corresponding author), Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany.	Michael.Kasperkiewicz@uk-sh.de	Kasperkiewicz, Michael/G-4829-2014; Nitschke, Martin/ABA-9388-2021; Schmidt, Enno/C-4008-2009; Ludwig, Ralf J/A-2629-2008; Ludwig, Ralf/F-3996-2018; Zillikens, Detlef/C-8572-2011	Nitschke, Martin/0000-0002-2716-7527; Schmidt, Enno/0000-0002-1206-8913; Ludwig, Ralf J/0000-0002-1394-1737; Ludwig, Ralf/0000-0002-1394-1737; 				Belloni B, 2007, J ALLERGY CLIN IMMUN, V120, P1223, DOI 10.1016/j.jaci.2007.08.060; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Schmidt E, 2010, ARCH DERMATOL RES, V302, P241, DOI 10.1007/s00403-009-1024-9; Sheinkopf LE, 2008, ALLERGY ASTHMA PROC, V29, P530, DOI 10.2500/aap.2008.29.3160; Vigo PG, 2006, J AM ACAD DERMATOL, V55, P168, DOI 10.1016/j.jaad.2005.12.045	9	40	40	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					267	270		10.1016/j.jaci.2010.07.042	http://dx.doi.org/10.1016/j.jaci.2010.07.042			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	20970174				2022-12-18	WOS:000285917300040
J	Wadsworth, SJ; Atsuta, R; McIntyre, JO; Hackett, TL; Singhera, GK; Dorscheid, DR				Wadsworth, Samuel J.; Atsuta, Ryo; McIntyre, J. Oliver; Hackett, Tillie-Louise; Singhera, Gurpreet K.; Dorscheid, Delbert R.			IL-13 and T(H)2 cytokine exposure triggers matrix metalloproteinase 7-mediated Fas ligand cleavage from bronchial epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; airway epithelial cells; immune barrier; T(H)2 cytokines; Fas ligand; matrix metalloproteinase 3; matrix metalloproteinase 7; inflammation	AIRWAY EPITHELIUM; MATRILYSIN EXPRESSION; APOPTOSIS; ACTIVATION; ASTHMA; INTERLEUKIN-13; REGENERATION; ISOFORMS; RECEPTOR	Background: Bronchial epithelial damage and activation likely contribute to the inflammatory and airway-remodeling events characteristic of severe asthma. Interaction of Fas receptor (CD95) with its ligand (FasL; CD95L) is an important mechanism of cell-mediated apoptosis. Bronchial epithelial FasL expression provides immune barrier protection from immune cell-mediated damage. Objectives: Membrane FasL (mFasL) is a cleavage target of matrix metalloproteinases (MMPs). We investigated whether the asthmatic T(H)2 environment might influence disease processes by increasing airway epithelial MMP-mediated cleavage of mFasL into proinflammatory soluble FasL. Methods: We used human airway epithelial cell lines and primary cells to model the human airway epithelium in vitro. Airway tissue from healthy subjects and patients with severe asthma was used to investigate MMP expression patterns in diseased airways. Results: We demonstrate that active MMP-7 is present in the ciliated epithelial cells of normal human airways. In patients with severe asthma, MMP-7 levels are increased in basal epithelial cells. Airway epithelial cell lines (1HAEo(-) and 16HBE14o(-)) in vitro express constitutively high levels of MMP-2 and MMP-9 but relatively low levels of MMP-7. TH2 cytokine (IL-4, IL-9, and IL-13) treatment of 1HAEo(-) cells increased MMP-7 mRNA and activity, triggered colocalization of intracellular MMP-7 with FasL, and caused mFasL cleavage with soluble FasL release. Small interfering RNA knockdown shows that cytokine-induced mFasL cleavage is dependent on MMP-7 activity. Conclusions: MMPs serve multiple beneficial roles in the lung. However, chronic disordered epithelial expression of MMP-7 in patients with asthma might increase mFasL cleavage and contribute to airway epithelial damage and inflammation. (J Allergy Clin Immunol 2010;126:366-74.)	[Wadsworth, Samuel J.; Hackett, Tillie-Louise; Singhera, Gurpreet K.; Dorscheid, Delbert R.] Univ British Columbia, UBC James Hogg Res Labs, Providence Heart & Lung Inst, Vancouver, BC V5Z 1M9, Canada; [Atsuta, Ryo] Juntendo Univ, Sch Med, Dept Resp Med, Tokyo 113, Japan; [McIntyre, J. Oliver] Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN USA; [McIntyre, J. Oliver] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA	University of British Columbia; Juntendo University; Vanderbilt University; Vanderbilt University	Wadsworth, SJ (corresponding author), St Pauls Hosp, UBC James Hogg Res Labs, Providence Heart Lung Inst, Room 166,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	samuel.wadsworth@hli.ubc.ca			Canadian Institutes of Health Research; Canadian/British Columbia Lung Associations; Allergen NCE; BC-Lung Association; Michael Smith Foundation for Health Research; Susan G. Komen Foundation; National Institutes of Health (NCI)	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian/British Columbia Lung Associations; Allergen NCE; BC-Lung Association; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); National Institutes of Health (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by operating grants from the Canadian Institutes of Health Research, the Canadian/British Columbia Lung Associations, and Allergen NCE and personal support awards from the BC-Lung Association (S. J. W.), the Michael Smith Foundation for Health Research (D. R. D.), and the Canadian Institutes of Health Research (D. R. D.).; J. O. McIntyre has received research support from the Susan G. Komen Foundation and the National Institutes of Health (NCI). The rest of the authors have declared that they have no conflict of interest.	BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Bhathena PR, 2000, LUNG, V178, P149, DOI 10.1007/s004080000018; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Cho WJ, 2006, HISTOCHEM CELL BIOL, V126, P9, DOI 10.1007/s00418-005-0128-3; Ciechomska I, 2003, ONCOGENE, V22, P7617, DOI 10.1038/sj.onc.1207137; Coraux C, 2005, J PATHOL, V206, P160, DOI 10.1002/path.1757; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; COZENS AL, 1991, ADV EXP MED BIOL, V290, P187; Danahay H, 2002, AM J PHYSIOL-LUNG C, V282, pL226, DOI 10.1152/ajplung.00311.2001; Dorscheid DR, 1999, HISTOCHEM J, V31, P145, DOI 10.1023/A:1003599916558; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747, DOI 10.1165/ajrcmb.19.5.3166; Dunsmore SE, 1998, J CLIN INVEST, V102, P1321, DOI 10.1172/JCI1516; Durieu I, 1999, THORAX, V54, P1093, DOI 10.1136/thx.54.12.1093; Ferguson TA, 2006, IMMUNOL REV, V213, P228, DOI 10.1111/j.1600-065X.2006.00430.x; Forbes B, 2003, INT J PHARM, V257, P161, DOI 10.1016/S0378-5173(03)00129-7; Goswami S, 2008, FASEB J, V22; Grehan JF, 2005, J IMMUNOL, V175, P1903, DOI 10.4049/jimmunol.175.3.1903; Hamann KJ, 1998, AM J RESP CELL MOL, V19, P537, DOI 10.1165/ajrcmb.19.4.3100; Holgate ST, 2000, CHEM IMMUNOL, V78, P62; KEENAN KP, 1983, VIRCHOWS ARCH B, V43, P213, DOI 10.1007/BF02932958; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14, DOI 10.1165/ajrcmb.16.1.8998074; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; Lopez-Boado YS, 2001, J BIOL CHEM, V276, P41417, DOI 10.1074/jbc.M107121200; Matsuno H, 2001, J RHEUMATOL, V28, P22; McGuire JK, 2003, AM J PATHOL, V162, P1831, DOI 10.1016/S0002-9440(10)64318-0; McIntyre JO, 2004, BIOCHEM J, V377, P617, DOI 10.1042/BJ20030582; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Ottonello L, 1999, J IMMUNOL, V162, P3601; Patchell BJ, 2007, AM J PHYSIOL-LUNG C, V293, pL354, DOI 10.1152/ajplung.00412.2006; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rosas IO, 2008, PLOS MED, V5, P623, DOI 10.1371/journal.pmed.0050093; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Seino K, 1998, J IMMUNOL, V161, P4484; SMITH DL, 1993, AM REV RESPIR DIS, V148, P523, DOI 10.1164/ajrccm/148.2.523; Swee M, 2008, J LEUKOCYTE BIOL, V83, P1404, DOI 10.1189/jlb.0108016; Tanaka M, 1996, NAT MED, V2, P317, DOI 10.1038/nm0396-317; Vargo-Gogola T, 2002, ARCH BIOCHEM BIOPHYS, V408, P155, DOI 10.1016/S0003-9861(02)00525-8; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403, DOI 10.1164/ajrccm.157.2.96-08040; Wang ML, 2008, AM J PHYSIOL-GASTR L, V295, pG1122, DOI 10.1152/ajpgi.90430.2008; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	45	40	41	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					366	U73		10.1016/j.jaci.2010.05.015	http://dx.doi.org/10.1016/j.jaci.2010.05.015			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20624652				2022-12-18	WOS:000281203800023
J	Buckley, RH				Buckley, Rebecca H.			B-cell function in severe combined immunodeficiency after stem cell or gene therapy: A review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Severe combined immunodeficiency; adenosine deaminase deficiency; Janus kinase 3 deficiency; recombinase activating genes 1 and 2 deficiencies; IL-7 receptor alpha chain deficiency; DNA protein kinase catalytic subunit; graft-versus-host disease; hematopoietic stem cell transplantation; immunoglobulin therapy; matched unrelated donor	BONE-MARROW-TRANSPLANTATION; IMMUNE RECONSTITUTION; IMMUNOLOGICAL RECONSTITUTION; THYMIC OUTPUT; SINGLE-CENTER; DEFICIENCY; DISEASE; MUTATIONS; ENGRAFTMENT; CHIMERISM	Although bone marrow transplantation has resulted in life-saving T-cell reconstitution in infants with severe combined immunodeficiency (SCID), correction of B-cell function has been more problematic. This review examines B-cell reconstitution results presented in 19 reports from the United States and Europe on posttransplantation immune reconstitution in patients with SCID over the past 2 decades. The analysis considered whether pretransplantation conditioning regimens were used, the overall survival rate, the percentage with donor B-cell chimerism, the percentage with B-cell function, and the percentage of survivors requiring immunoglobulin replacement. The survival rates were higher at those centers that did not use pretransplantation conditioning or posttransplantation graft-versus-host disease prophylaxis. The percentage of survivors with B-cell chimerism, function, or both was higher and the percentage requiring immunoglobulin replacement was lower at those centers that used pretransplantation conditioning. However, there were substantial numbers of patients requiring immunoglobulin replacement at all centers. Thus pretransplantation conditioning does not guarantee that B-cell function will develop. Because most infants with SCID either present with serious infections or are given diagnoses as newborns, one must decide whether there is justification for using agents that compromise innate immunity and have intrinsic toxicities to gain B-cell immune reconstitution. (J Allergy Clin Immunol 2010;125:790-7.)	[Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Buckley, Rebecca H.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University; Duke University	Buckley, RH (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Box 2898, Durham, NC 27710 USA.	buckL003@mc.duke.edu	Buckley, Rebecca/AAB-1578-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042951, R01AI047605] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI042951-10, R01 AI047605-09A1, R01 AI042951, R01 AI047605] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056/NEJMoa0805817; Antoine C, 2003, LANCET, V361, P553, DOI 10.1016/S0140-6736(03)12513-5; Bartolome J, 2002, BONE MARROW TRANSPL, V29, P625, DOI 10.1038/sj.bmt.1703410; Bertrand Y, 1999, J PEDIATR-US, V134, P740, DOI 10.1016/S0022-3476(99)70291-X; Borghans JA, 2006, BLOOD, V108, P763, DOI 10.1182/blood-2006-01-009241; Buck D, 2006, EUR J IMMUNOL, V36, P224, DOI 10.1002/eji.200535401; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; BUCKLEY RH, 1986, J IMMUNOL, V136, P2398; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Cavazzana-Calvo M, 2007, BLOOD, V109, P4575, DOI 10.1182/blood-2006-07-029090; ClementDeBoers A, 1996, J PEDIATR-US, V129, P544; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; de Saint Basile G, 2004, J CLIN INVEST, V114, P1512, DOI 10.1172/JCI200422588; DROR Y, 1993, BLOOD, V81, P2021; Dvorak CC, 2008, BIOL BLOOD MARROW TR, V14, P1125, DOI 10.1016/j.bbmt.2008.07.008; Friedrich W, 2007, IMMUNOL RES, V38, P165, DOI 10.1007/s12026-007-0030-2; Gaspar HB, 2006, MOL THER, V14, P505, DOI 10.1016/j.ymthe.2006.06.007; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; GATTI RA, 1968, LANCET, V2, P1366; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056/NEJMoa012616; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI 10.1172/JCI35700; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Hirschhorn R, 1999, PRIMARY IMMUNODEFICIENCY DISEASES, P121; Kung C, 2000, NAT MED, V6, P343; Mazzolari E, 2007, J ALLERGY CLIN IMMUN, V120, P892, DOI 10.1016/j.jaci.2007.08.007; MOEN RC, 1987, BLOOD, V70, P664; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Myers LA, 2002, BLOOD, V99, P872, DOI 10.1182/blood.V99.3.872; Neven B, 2009, BLOOD, V113, P4114, DOI 10.1182/blood-2008-09-177923; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; O'Marcaigh AS, 2001, BONE MARROW TRANSPL, V27, P703, DOI 10.1038/sj.bmt.1702831; Patel NC, 2009, J ALLERGY CLIN IMMUN, V124, P1062, DOI 10.1016/j.jaci.2009.08.041; Patel NC, 2008, J ALLERGY CLIN IMMUN, V122, P1185, DOI 10.1016/j.jaci.2008.10.030; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Railey MD, 2009, J PEDIATR-US, V155, P834, DOI 10.1016/j.jpeds.2009.07.049; Roberts JL, 2004, BLOOD, V103, P2009, DOI 10.1182/blood-2003-06-2104; Roberts JL, 2007, BLOOD, V109, P3198, DOI 10.1182/blood-2006-08-043166; Sarzotti-Kelsoe M, 2009, BLOOD, V114, P1445, DOI 10.1182/blood-2009-01-199323; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Slatter MA, 2008, J ALLERGY CLIN IMMUN, V121, P361, DOI 10.1016/j.jaci.2007.10.035; Smogorzewska Elzbieta M., 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P111; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; Throm RE, 2009, BLOOD, V113, P5104, DOI 10.1182/blood-2008-11-191049; van der Burg M, 2009, J CLIN INVEST, V119, P91, DOI 10.1172/JCI37141; VANLEEUWEN JEM, 1994, BLOOD, V84, P3936, DOI 10.1182/blood.V84.11.3936.bloodjournal84113936; WIJNAENDTS L, 1989, BLOOD, V74, P2212	47	40	41	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2010	125	4					790	797		10.1016/j.jaci.2010.02.012	http://dx.doi.org/10.1016/j.jaci.2010.02.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	584XP	20371393	Green Accepted			2022-12-18	WOS:000276787900002
J	Szefler, SJ; Martin, RJ				Szefler, Stanley J.; Martin, Richard J.			Lessons learned from variation in response to therapy in clinical trials	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; treatment response; inhaled corticosteroids; leukotriene receptor antagonists; leukotriene modifiers; beta-adrenergic agonists	PERSISTENT CHILDHOOD ASTHMA; INHALED CORTICOSTEROIDS; PEDIATRIC ASTHMA; MONTELUKAST; FLUTICASONE	In the past, we viewed lack of response to asthma medications as a rare event. Based on recent studies, we now expect significant variation in treatment response for all asthma medications. However, little information is available about methods to predict favorable treatment response. Research conducted in the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network verified this variability in response to several long-term control medications, specifically inhaled corticosteroids and leukotriene receptor antagonists, in adults and children with mild-to-moderate persistent asthma. The networks also identified potential methods to use patients' characteristics, such as age and allergic status, and biomarkers, such as bronchodilator response, exhaled nitric oxide, and urinary leukotrienes, to help predict response to inhaled corticosteroids and leukotriene receptor antagonists and to determine which of the 2 treatments might be more effective in individual patients. This information now, assist's the clinician in personalizing asthma treatment at the time of initiating long-term control therapy. (J Allergy Clin Immunol 2010;125:285-92.)	[Szefler, Stanley J.] Natl Jewish Hlth, Div Pediat Clin Pharmacol, Dept Pediat, Denver, CO 80206 USA; [Szefler, Stanley J.] Natl Jewish Hlth, Div Allergy & Immunol, Dept Pediat, Denver, CO 80206 USA; [Martin, Richard J.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA	National Jewish Health; National Jewish Health; National Jewish Health	Szefler, SJ (corresponding author), Natl Jewish Hlth, Div Pediat Clin Pharmacol, Dept Pediat, 1400 Jackson St,Room J304 Molly Blank Bldg, Denver, CO 80206 USA.	szeflers@njhealth.org			Public Health Services [HR-16048, HL64288, HL 51834, AI-25496, HL081335, HL075416, HL087811]; National Institutes of Health and National Center for Research Resources [1 UL1 RR025780]; Colorado Cancer, Cardiovascular, and Pulmonary Disease Program; DIVISION OF LUNG DISEASES [N01HR016048] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL075416, U10HL051834, U10HL064288, U01HL081335, R21HL087811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI025496] Funding Source: NIH RePORTER	Public Health Services(United States Department of Health & Human ServicesUnited States Public Health Service); National Institutes of Health and National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Colorado Cancer, Cardiovascular, and Pulmonary Disease Program; DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported in part by Public Health Services research grants HR-16048, HL64288, HL 51834, AI-25496, HL081335. HL075416, and HL087811; the Colorado CTSA grant 1 UL1 RR025780 from the National Institutes of Health and National Center for Research Resources; and the Colorado Cancer, Cardiovascular, and Pulmonary Disease Program.	[Anonymous], 2007, J ALLERGY CLIN IMM S, V120, pS94; Bacharier LB, 2009, J ALLERGY CLIN IMMUN, V123, P1077, DOI 10.1016/j.jaci.2008.12.1120; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Knuffman JE, 2009, J ALLERGY CLIN IMMUN, V123, P411, DOI 10.1016/j.jaci.2008.11.016; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; *NIH NAT ASTHM ED, 2007, 3 NIH NAT ASTHM ED P; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	13	40	41	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					285	292		10.1016/j.jaci.2009.10.026	http://dx.doi.org/10.1016/j.jaci.2009.10.026			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	558RU	20074785	Green Accepted			2022-12-18	WOS:000274764000001
J	Gelfand, EW; Kraft, M				Gelfand, Erwin W.; Kraft, Monica			The importance and features of the distal airways in children and adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; small airways; distal airways; adult; children; clinical; therapeutic	LUNG-FUNCTION; INHALED CORTICOSTEROIDS; CHILDHOOD ASTHMA; ALVEOLAR TISSUE; INFLAMMATION; OBSTRUCTION; SYMPTOMS; LIFE; SENSITIZATION; SEVERITY	Asthma remains a major problem worldwide, even with new categories of medications that have been brought into the therapeutic armamentarium. One area of disease pathology and physiology that is involved in the pathobiology of asthma is the distal (small) airways. Better understanding of this area in both the pediatric and adult asthmatic populations will lead to improved targeted therapy for all asthmatic patients. This article discusses the importance of the distal airways for both children and adults with asthma. (J Allergy Clin Immunol 2009;124:S84-7.)	[Gelfand, Erwin W.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Kraft, Monica] Duke Univ, Dept Med, Durham, NC 27706 USA	National Jewish Health; Duke University	Gelfand, EW (corresponding author), Care of Martin RJ, Natl Jewish Hlth, 1400 Jackson St, Denver, CO 80206 USA.				Teva Respiratory, LLC	Teva Respiratory, LLC	Supported by an unrestricted grant from Teva Respiratory, LLC	Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; [Anonymous], 2006, LANCET, V368, P705; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-1174OC; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778, DOI 10.1164/ajrccm.162.5.2001037; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Irvin CG, 2000, AM J RESP CRIT CARE, V161, P50, DOI 10.1164/ajrccm.161.1.9804053; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998, DOI 10.1164/ajrccm.158.3.9711092; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1219, DOI 10.1164/ajrccm.163.5.2002058; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228, DOI 10.1164/ajrccm.159.1.9804033; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551, DOI 10.1164/ajrccm.163.7.2008013; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kraft M, 2006, CHEST, V130, P1726, DOI 10.1378/chest.130.6.1726; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; Martin RJ, 2002, J ALLERGY CLIN IMMUN, V109, pS447, DOI 10.1067/mai.2002.121409; Minshall EM, 1998, J ALLERGY CLIN IMMUN, V101, P386, DOI 10.1016/S0091-6749(98)70252-0; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Paul EF, 2002, SOCIETY, V39, P7, DOI 10.1007/s12115-002-1000-x; Slade DJ, 2006, CLIN CHEST MED, V27, P71, DOI 10.1016/j.ccm.2005.11.001; Spahn JD, 2006, ANN ALLERG ASTHMA IM, V96, P541, DOI 10.1016/S1081-1206(10)63548-X; Spahn JD, 2004, AM J RESP CRIT CARE, V169, P784, DOI 10.1164/rccm.200309-1234OE; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Tulic MK, 2006, CLIN CHEST MED, V27, P41, DOI 10.1016/j.ccm.2005.10.007; Tulic MK, 2002, SEMIN RESP CRIT CARE, V23, P347, DOI 10.1055/s-2002-34330; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447, DOI 10.1164/ajrccm.157.2.9611043; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; YANAI M, 1992, J APPL PHYSIOL, V72, P1016, DOI 10.1152/jappl.1992.72.3.1016	40	40	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6		S			S84	S87		10.1016/j.jaci.2009.07.062	http://dx.doi.org/10.1016/j.jaci.2009.07.062			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	536VJ	19962041	Bronze			2022-12-18	WOS:000273071700004
J	Yamanaka, K; Yuta, A; Kakeda, M; Sasaki, R; Kitagawa, H; Gabazza, EC; Okubo, K; Kurokawa, I; Mizutani, H				Yamanaka, Kei-ichi; Yuta, Atsushi; Kakeda, Masato; Sasaki, Ryogen; Kitagawa, Hiroshi; Gabazza, Esteban C.; Okubo, Kimihiro; Kurokawa, Ichiro; Mizutani, Hitoshi			Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							SUBLINGUAL IMMUNOTHERAPY; MECHANISMS; LYMPHOMA		[Yamanaka, Kei-ichi; Kakeda, Masato; Kitagawa, Hiroshi; Kurokawa, Ichiro; Mizutani, Hitoshi] Mie Univ, Grad Sch Med, Dept Dermatol, Kawasaki, Kanagawa, Japan; [Yuta, Atsushi] Mie Univ, Grad Sch Med, Dept Otorhinolaryngol, Kawasaki, Kanagawa, Japan; [Sasaki, Ryogen] Mie Univ, Grad Sch Med, Dept Neurol, Kawasaki, Kanagawa, Japan; [Gabazza, Esteban C.] Mie Univ, Grad Sch Med, Dept Immunol, Kawasaki, Kanagawa, Japan; [Okubo, Kimihiro] Nippon Med Sch, Dept Otorhinolaryngol, Kawasaki, Kanagawa, Japan	Mie University; Mie University; Mie University; Mie University; Nippon Medical School	Yamanaka, K (corresponding author), Mie Univ, Grad Sch Med, Dept Dermatol, Kawasaki, Kanagawa, Japan.	yamake@clin.medic.mie-u.ac.jp		Kakeda, Masato/0000-0001-9011-3655; Gabazza, Esteban/0000-0001-5748-1499				Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Frew AJ, 2008, NEW ENGL J MED, V358, P2259, DOI 10.1056/NEJMct0708337; Horiguchi S, 2008, INT ARCH ALLERGY IMM, V146, P76, DOI 10.1159/000112506; Orihara K, 2007, J ALLERGY CLIN IMMUN, V120, P960, DOI 10.1016/j.jaci.2007.05.036; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Wu K, 2007, CELL MOL IMMUNOL, V4, P269; Yamanaka K, 2005, CLIN CANCER RES, V11, P5748, DOI 10.1158/1078-0432.CCR-04-2514; Yawalkar N, 2003, BLOOD, V102, P4059, DOI 10.1182/blood-2003-04-1044	8	40	45	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					842	845		10.1016/j.jaci.2009.06.020	http://dx.doi.org/10.1016/j.jaci.2009.06.020			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	506UV	19703707				2022-12-18	WOS:000270802800033
J	Tsurikisawa, N; Saito, H; Tsuburai, T; Oshikata, C; Ono, E; Mitomi, H; Akiyama, K				Tsurikisawa, Naomi; Saito, Hiroshi; Tsuburai, Takahiro; Oshikata, Chiyako; Ono, Emiko; Mitomi, Hiroyuki; Akiyama, Kazuo			Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Churg-Strauss syndrome; regulatory T cells; chronic eosinophilic pneumonia; CD4(+)CD25(+) T cells; IL-10; TGF-beta; IL-2	BRONCHOALVEOLAR LAVAGE FLUID; SYSTEMIC-LUPUS-ERYTHEMATOSUS; GROWTH-FACTOR-BETA; ALLERGIC GRANULOMATOSIS; RHEUMATOID-ARTHRITIS; MULTIPLE-SCLEROSIS; INDUCTION; TOLERANCE; LYMPHOCYTES; VASCULITIS	Background: Chronic eosinophilic pneumonia (CEP) with asthma precedes the onset of Churg-Strauss syndrome (CSS) in half of all patients with CSS. It is not known what determines whether patients with CEP after asthma will have CSS. Objective: We examined whether activation of regulatory T cells in patients with CEP inhibits CSS development and is otherwise involved in the mechanism of CSS disease. Methods: In patients with CSS (n = 38), CEP with asthma (n = 20), and general adult asthma (n = 108), we examined the number of CD4(+)CD25(+) T cells in peripheral blood, as well as levels of expression of the cytokines IL-2, IL-5, IL-10, and TGF-beta by CD4(+)CD25(+) T cells, CD4(+)CD25(-) T cells, or both. Results: At disease onset, patients with CSS, unlike patients with CEP, had significantly fewer CD4(+)CD25(+) T cells than patients with any step of asthma. CD4(+)CD25(+) T cells producing IL-10 were rarely detected in patients with CSS at disease onset or relapse, whereas the numbers of IL-10-producing T cells in patients with CEP were high at disease onset. There were fewer CD4(+)CD25(-) T cells producing IL-2 in patients with CSS before treatment than in patients with CEP at disease onset. The proportions of CD4(+)CD25(+) T cells producing IL-10 and CD4(+)CD25(-) T cells producing IL-2 in patients with CSS increased at remission. Conclusions: Maintenance of the numbers of regulatory T cells in patients with CEP with asthma might inhibit CSS development through the action of cytokines, such as IL-10 and IL-2, produced by CD4(+)CD25(+) or CD4(+)CD25(-) T cells. This might be part of a mechanism that influences progression and prognosis in these diseases.	[Tsurikisawa, Naomi; Saito, Hiroshi; Tsuburai, Takahiro; Oshikata, Chiyako; Ono, Emiko; Mitomi, Hiroyuki; Akiyama, Kazuo] Sagamihara Natl Hosp, Natl Hosp Org, Clin Res Ctr Allergy & Rheumatol, Kanagawa 2288522, Japan		Tsurikisawa, N (corresponding author), Sagamihara Natl Hosp, Natl Hosp Org, Clin Res Ctr Allergy & Rheumatol, 18-1 Sakuradai, Kanagawa 2288522, Japan.	n-tsurikisawa@sugamihara-hosp.gr.jp						ALBERA C, 1995, EUR RESPIR J, V8, P1281, DOI 10.1183/09031936.95.08081281; Alvarado-Sanchez B, 2006, J AUTOIMMUN, V27, P110, DOI 10.1016/j.jaut.2006.06.005; Astier AL, 2006, J CLIN INVEST, V116, P3252, DOI 10.1172/JCI29251; Behrens F, 2007, ANN RHEUM DIS, V66, P1151, DOI 10.1136/ard.2006.068320; CHUMBLEY LC, 1977, MAYO CLIN PROC, V52, P477; Churg A, 2001, MODERN PATHOL, V14, P1284, DOI 10.1038/modpathol.3880475; CHURG J, 1951, AM J PATHOL, V27, P277; Cottin V, 2005, ALLERGY, V60, P841, DOI 10.1111/j.1398-9995.2005.00812.x; ELSON LH, 1995, J IMMUNOL, V154, P4294; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Hallermann C, 2007, EUR J HAEMATOL, V78, P260, DOI 10.1111/j.1600-0609.2006.00809.x; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Katoh S, 2000, J ALLERGY CLIN IMMUN, V106, P730, DOI 10.1067/mai.2000.109827; Katoh S, 2004, ALLERGY, V59, P850, DOI 10.1111/j.1398-9995.2004.00492.x; Keever-Taylor CA, 2007, CYTOTHERAPY, V9, P144, DOI 10.1080/14653240601145223; Kiene A, 2001, ARTHRITIS RHEUM-US, V44, P469, DOI 10.1002/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0; Kinter AL, 2007, AIDS RES HUM RETROV, V23, P438, DOI 10.1089/aid.2006.0162; Kurashima K, 1997, LAB INVEST, V76, P67; LANDAY AL, 1989, CLIN IMMUNOL IMMUNOP, V52, P48, DOI 10.1016/0090-1229(89)90192-X; Lee JH, 2007, CLIN EXP IMMUNOL, V148, P53, DOI 10.1111/j.1365-2249.2007.03329.x; LHOTE F, 1995, RHEUM DIS CLIN N AM, V21, P911; Li H, 2007, J CLIN IMMUNOL, V27, P317, DOI 10.1007/s10875-007-9076-0; Marchand E, 2006, SEMIN RESP CRIT CARE, V27, P134, DOI 10.1055/s-2006-939516; Martin RM, 1999, PHARMACOEPIDEM DR S, V8, P179, DOI 10.1002/(SICI)1099-1557(199905/06)8:3<179::AID-PDS414>3.3.CO;2-B; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; Miyazaki E, 2002, AM J RESP CRIT CARE, V165, P1125, DOI 10.1164/ajrccm.165.8.2106110; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; *NIH, 2002, NIH PUBL, P67; Nummer D, 2007, J NATL CANCER I, V99, P1188, DOI 10.1093/jnci/djm064; Pavone L, 2006, J RHEUMATOL, V33, P1299; Pritchard J, 2007, J NEUROIMMUNOL, V183, P232, DOI 10.1016/j.jneuroim.2006.12.002; Roncarolo MG, 2007, NAT REV IMMUNOL, V7, P585, DOI 10.1038/nri2138; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Shi HZ, 2004, CLIN IMMUNOL, V113, P172, DOI 10.1016/j.clim.2004.06.009; STEINFELD S, 1994, EUR RESPIR J, V7, P2098; Tsurikisawa N, 2004, ANN ALLERG ASTHMA IM, V92, P80, DOI 10.1016/S1081-1206(10)61714-0; Tsurikisawa N, 2007, ALLERGY ASTHMA PROC, V28, P336, DOI 10.2500/aap.2007.28.2997; Tsurikisawa N, 2007, CHEST, V131, P592, DOI 10.1378/chest.06-1208; Valencia X, 2007, J IMMUNOL, V178, P2579, DOI 10.4049/jimmunol.178.4.2579; van Amelsfort JMR, 2007, ARTHRITIS RHEUM, V56, P732, DOI 10.1002/art.22414; WATTS RA, 1995, SEMIN ARTHRITIS RHEU, V25, P28, DOI 10.1016/S0049-0172(95)80015-8; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Zheng SG, 2007, J IMMUNOL, V178, P2018, DOI 10.4049/jimmunol.178.4.2018	48	40	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					610	616		10.1016/j.jaci.2008.05.040	http://dx.doi.org/10.1016/j.jaci.2008.05.040			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	348TW	18586318				2022-12-18	WOS:000259234000026
J	Vercelli, D				Vercelli, Donata			Advances in asthma and allergy genetics in 2007	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; genetics; single nucleotide polymorphisms; association studies	OF-FUNCTION MUTATIONS; CHAIN KINASE GENE; ATOPIC-DERMATITIS; ICHTHYOSIS VULGARIS; CONFER RISK; POLYMORPHISMS; FILAGGRIN; CHILDREN; ASSOCIATION; EXPRESSION	This review discusses the main advances in the genetics of asthma and allergy published in the Journal in 2007. The association studies discussed herein addressed 3 main topics: the effect of the environment and gene-environment interactions on asthma/allergy susceptibility, the contribution of T(H)2 immunity gene variants to allergic inflammation, and the role of filaggrin mutations in atopic dermatitis and associated phenotypes. Other articles revealed novel, potentially important candidate genes or confirmed known ones. Collectively, the works published in 2007 reiterate that allergy and asthma are typical complex diseases; that is, they are disorders in which intricate interactions among environmental and genetic factors modify disease susceptibility by altering the fundamental structural and functional properties of target organs at critical developmental windows.	[Vercelli, Donata] Univ Arizona, Dept Cell Biol, Tucson, AZ 85721 USA	University of Arizona	Vercelli, D (corresponding author), BIO5 Inst, Thomas W Keating Biores Bldg,Room 321,1657 E Hele, Tucson, AZ 85719 USA.	donata@arc.arizona.edu						Acevedo N, 2007, J ALLERGY CLIN IMMUN, V119, P505, DOI 10.1016/j.jaci.2006.10.002; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Andrews AL, 2007, J ALLERGY CLIN IMMUN, V120, P91, DOI 10.1016/j.jaci.2007.04.026; Bae JS, 2007, J ALLERGY CLIN IMMUN, V119, P449, DOI 10.1016/j.jaci.2006.10.006; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Baynam G, 2007, J ALLERGY CLIN IMMUN, V119, P366, DOI 10.1016/j.jaci.2006.09.018; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Cameron L, 2006, J IMMUNOL, V177, P8633, DOI 10.4049/jimmunol.177.12.8633; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Dhiman N, 2007, J ALLERGY CLIN IMMUN, V120, P666, DOI 10.1016/j.jaci.2007.04.036; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ermers MJJ, 2007, J ALLERGY CLIN IMMUN, V119, P1086, DOI 10.1016/j.jaci.2006.12.655; Gao L, 2006, AM J RESP CELL MOL, V34, P487, DOI 10.1165/rcmb.2005-0404OC; Gao L, 2007, CURR OPIN ALLERGY CL, V7, P459, DOI 10.1097/ACI.0b013e3282f1fb9a; Gao L, 2007, J ALLERGY CLIN IMMUN, V119, P1111, DOI 10.1016/j.jaci.2007.03.019; Hong SJ, 2007, J ALLERGY CLIN IMMUN, V119, P398, DOI 10.1016/j.jaci.2006.10.031; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V120, P84, DOI 10.1016/j.jaci.2007.04.032; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Koehm S, 2007, J ALLERGY CLIN IMMUN, V120, P570, DOI 10.1016/j.jaci.2007.04.037; Lee JH, 2007, J ALLERGY CLIN IMMUN, V120, P1110, DOI 10.1016/j.jaci.2007.08.041; Loza MJ, 2007, J ALLERGY CLIN IMMUN, V120, P578, DOI 10.1016/j.jaci.2007.05.019; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Raby BA, 2007, J ALLERGY CLIN IMMUN, V120, P351, DOI 10.1016/j.jaci.2007.05.029; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rogers AJ, 2007, J ALLERGY CLIN IMMUN, V120, P1332, DOI 10.1016/j.jaci.2007.09.037; Schulz F, 2007, J ALLERGY CLIN IMMUN, V120, P1097, DOI 10.1016/j.jaci.2007.07.065; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Tantisira KG, 2007, J ALLERGY CLIN IMMUN, V120, P1285, DOI 10.1016/j.jaci.2007.09.005; Thompson EE, 2007, J ALLERGY CLIN IMMUN, V119, P1423, DOI 10.1016/j.jaci.2007.03.029; Ueta M, 2007, J ALLERGY CLIN IMMUN, V120, P1457, DOI 10.1016/j.jaci.2007.07.048; Ungvavi I, 2007, J ALLERGY CLIN IMMUN, V119, P1545, DOI 10.1016/j.jaci.2007.02.038; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van den Biggelaar AHJ, 2007, J ALLERGY CLIN IMMUN, V120, P973, DOI 10.1016/j.jaci.2007.06.044; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; Wu H, 2007, J ALLERGY CLIN IMMUN, V120, P322, DOI 10.1016/j.jaci.2007.04.022; Yang KD, 2007, J ALLERGY CLIN IMMUN, V120, P842, DOI 10.1016/j.jaci.2007.07.009; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030	43	40	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					267	271		10.1016/j.jaci.2008.06.008	http://dx.doi.org/10.1016/j.jaci.2008.06.008			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	337HO	18619666				2022-12-18	WOS:000258426300008
J	Rabinovitch, N; Strand, M; Stuhlman, K; Gelfand, EW				Rabinovitch, Nathan; Strand, Matthew; Stuhlman, Kate; Gelfand, Erwin W.			Exposure to tobacco smoke increases leukotriene E-4-related albuterol usage and response to montelukast	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; cysteinyl leukotrienes; LTE4; FENO; montelukast	EXHALED NITRIC-OXIDE; CIGARETTE-SMOKING; HEALTHY-SUBJECTS; SEVERE ASTHMA; DOUBLE-BLIND; E-4 LEVELS; FLUTICASONE; MILD; CHILDREN; INFLAMMATION	Background: Cysteinyl leukotrienes (CysLTs) are important mediators of asthma in children. Predictors of susceptibility to CysLT effects have not been developed. Objectives: To identify susceptibility markers to CysLT effects and montelukast response. Methods: Twenty-seven schoolchildren were followed for 5 months with measurements of urinary leukotriene E4 (LTE4), cotinine, fractional exhaled nitric oxide (FENO), and monitoring of albuterol use. After a baseline run-in, children were randomized to receive daily montelukast or placebo without change in their current controller medications. Results: At baseline, a significant (P=.003) positive association was observed between LTE4 levels and albuterol use 2 days later. LTE4-related albuterol usage (ie, change per interquartile increase in LTE4) declined significantly after montelukast treatment (12% decline; P=.0005 for relative difference between intervals) but not placebo (2% increase; P=.80). Declines in LTE4-related albuterol usage between intervals tended to be greater in girls (P=.01 for girls; P=.21 for boys; P=.07 for interaction) and were greater among children with higher cotinine levels (P=.01 for high cotinine group; P=.17 for low cotinine group; P=.04 for interaction). Children with high LTE4 levels relative to FENO demonstrated significant (P=.05) declines in LTE4-related albuterol usage between intervals (P=.89 for low ratio group; P=.25 for interaction). Conclusion: Increased individual CysLT levels are associated with subsequent albuterol usage. CysLT-related albuterol usage and montelukast responsiveness are increased in children exposed to tobacco smoke and tend to be greater in girls than boys. Measurement of LTE4 to FENO ratios may help predict susceptibility to montelukast.	[Rabinovitch, Nathan; Stuhlman, Kate] Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; [Strand, Matthew] Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO 80206 USA	National Jewish Health; National Jewish Health	Rabinovitch, N (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	rabinovitchn@njc.org	Strand, Matt/AAU-3762-2021	Strand, Matt/0000-0002-9083-5989	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K23ES015510] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR00051] Funding Source: Medline; NIEHS NIH HHS [K23 ES015510-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barnes N, 2005, J ALLERGY CLIN IMMUN, V115, P47, DOI 10.1016/j.jaci.2004.10.011; Becker A, 2004, CURR MED RES OPIN, V20, P1651, DOI 10.1185/030079904X4644; Bellia V, 1996, J ALLERGY CLIN IMMUN, V97, P735, DOI 10.1016/S0091-6749(96)80149-7; Bjermer L, 2003, BMJ-BRIT MED J, V327, P891, DOI 10.1136/bmj.327.7420.891; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Cai C, 2007, LUNG, V185, P105, DOI 10.1007/s00408-006-0001-8; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9, DOI 10.1164/ajrccm.165.1.2010080; Delfino RJ, 2006, AM J RESP CRIT CARE, V173, P1054, DOI 10.1164/rccm.2603001; Dobson A., 2001, INTRO GEN LINEAR MOD, DOI 10.1201/9781420057683; DOUCET MY, 1990, CAN J PHYSIOL PHARM, V68, P379, DOI 10.1139/y90-053; Ducharme F., 2004, COCHRANE DB SYST REV, V1; Early SB, 2007, AM J RESP CELL MOL, V36, P715, DOI 10.1165/rcmb.2006-0252OC; Fauler J, 1997, EUR J CLIN INVEST, V27, P43, DOI 10.1046/j.1365-2362.1997.650619.x; Gyllfors P, 2005, THORAX, V60, P902, DOI 10.1136/thx.2005.041913; Heaney LG, 2005, LANCET, V365, P974, DOI 10.1016/S0140-6736(05)71087-4; Ilowite J, 2004, ANN ALLERG ASTHMA IM, V92, P641, DOI 10.1016/S1081-1206(10)61430-5; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; KANWAR S, 1995, CIRC RES, V77, P879, DOI 10.1161/01.RES.77.5.879; Kauermann G, 2001, J AM STAT ASSOC, V96, P1387, DOI 10.1198/016214501753382309; Kurokawa K, 2001, CHEST, V120, P1822, DOI 10.1378/chest.120.6.1822; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-1746OC; Lu B, 2007, BIOMETRICS, V63, P935, DOI 10.1111/j.1541-0420.2007.00764.x; MANSO G, 1992, EUR RESPIR J, V5, P712; Misso NLA, 2004, CLIN EXP ALLERGY, V34, P624, DOI 10.1111/j.1365-2222.2004.1912.x; Nordvall SL, 2005, ALLERGY, V60, P469, DOI 10.1111/j.1398-9995.2005.00735.x; NORTH LM, 1993, ANN NY ACAD SCI, V694, P332, DOI 10.1111/j.1749-6632.1993.tb18381.x; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; Rabinovitch N, 2006, J ALLERGY CLIN IMMUN, V118, P635, DOI 10.1016/j.jaci.2006.05.011; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; RAM FSF, 2005, COCHRANE DB SYST REV, V1; Reid DW, 2003, RESPIROLOGY, V8, P479, DOI 10.1046/j.1440-1843.2003.00495.x; SMITH CM, 1992, EUR RESPIR J, V5, P693; Strunk RC, 2004, J ALLERGY CLIN IMMUN, V113, P790, DOI 10.1016/j.jaci.2004.01.569; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Warke TJ, 2003, ARCH ENVIRON HEALTH, V58, P613, DOI 10.3200/AEOH.58.10.613-616; Westcott JY, 1998, PROSTAG OTH LIPID M, V55, P301, DOI 10.1016/S0090-6980(98)00027-6; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	40	40	44	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1365	1371		10.1016/j.jaci.2008.03.016	http://dx.doi.org/10.1016/j.jaci.2008.03.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	313WW	18439662				2022-12-18	WOS:000256771700010
J	Roifman, CM; Zhang, J; Atkinson, A; Grunebaunt, E; Mandel, K				Roifman, Chaim M.; Zhang, Junyan; Atkinson, Adelle; Grunebaunt, Eyal; Mandel, Karen			Adenosine deaminase deficiency can present with features of Omenn syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COMBINED IMMUNODEFICIENCY; MUTATIONS; POPULATION; DISEASE		[Roifman, Chaim M.; Zhang, Junyan; Atkinson, Adelle; Grunebaunt, Eyal] Hosp Sick Children, Div Immunol & Allergy, Toronto, ON M5G 1X8, Canada; [Roifman, Chaim M.; Zhang, Junyan; Atkinson, Adelle; Grunebaunt, Eyal] Univ Toronto, Toronto, ON, Canada; [Mandel, Karen] Childrens Hosp Eastern Ontario, Div Hematol Oncol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Ottawa; Children's Hospital of Eastern Ontario	Roifman, CM (corresponding author), Hosp Sick Children, Div Immunol & Allergy, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; MELAMED I, 1994, CLIN EXP IMMUNOL, V95, P14; OMENN GS, 1965, NEW ENGL J MED, V273, P427, DOI 10.1056/NEJM196508192730806; Roifman CM, 2006, J ALLERGY CLIN IMMUN, V117, P897, DOI 10.1016/j.jaci.2006.01.003; SANTISTEBAN I, 1995, HUM MOL GENET, V4, P2081, DOI 10.1093/hmg/4.11.2081; SANTISTEBAN I, 1993, J CLIN INVEST, V92, P2291, DOI 10.1172/JCI116833; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; WIRT DP, 1989, NEW ENGL J MED, V321, P370, DOI 10.1056/NEJM198908103210606; Zhang JY, 2005, PEDIATRICS, V116, pE445, DOI 10.1542/peds.2005-0369	9	40	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1056	1058		10.1016/j.jaci.2007.12.1148	http://dx.doi.org/10.1016/j.jaci.2007.12.1148			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18243287	Bronze			2022-12-18	WOS:000254884000038
J	Simon, D; Salemi, S; Yousefi, S; Sinion, HU				Simon, Dagmar; Salemi, Souzan; Yousefi, Shida; Sinion, Hans-Uwe			Primary resistance to imatinib in Fip1-like1-platelet-derived growth factor receptor alpha - positive eosinophilic leukemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							HYPEREOSINOPHILIC SYNDROME; ANTI-INTERLEUKIN-5 ANTIBODY; BCR-ABL; MECHANISMS; FUSION		[Simon, Dagmar] Univ Bern, Inselspital, Dept Dermatol, CH-3010 Bern, Switzerland; [Salemi, Souzan; Yousefi, Shida; Sinion, Hans-Uwe] Univ Bern, Inst Pharmacol, Bern, Switzerland	University of Bern; University Hospital of Bern; University of Bern	Simon, D (corresponding author), Univ Bern, Inselspital, Dept Dermatol, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-5079-2020; Simon, Hans-Uwe/AAU-7410-2020; Yousefi, Shida/AAU-7986-2020	Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736; Yousefi, Shida/0000-0002-9855-4305; Salemi, Souzan/0000-0002-9777-3717				Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Gleich GJ, 2002, LANCET, V359, P1577, DOI 10.1016/S0140-6736(02)08505-7; Klion AD, 2004, BLOOD, V103, P2939, DOI 10.1182/blood-2003-10-3620; Klion AD, 2004, BLOOD, V103, P473, DOI 10.1182/blood-2003-08-2798; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Plotz S, 2003, NEW ENGL J MED, V349, P2334, DOI 10.1056/NEJMoa031261; Simon HU, 1999, NEW ENGL J MED, V341, P1112, DOI 10.1056/NEJM199910073411503; Simon HU, 2003, EUR J IMMUNOL, V33, P834, DOI 10.1002/eji.200323727; Yamada Y, 2006, BLOOD, V107, P4071, DOI 10.1182/blood-2005-08-3153	10	40	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					1054	1056		10.1016/j.jaci.2007.11.027	http://dx.doi.org/10.1016/j.jaci.2007.11.027			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	286YY	18234315				2022-12-18	WOS:000254884000037
J	Levan, TD; Michel, O; Dentener, M; Thorn, J; Vertongen, F; Beiier, L; Martinez, FD				Levan, Tricia D.; Michel, Olivier; Dentener, Mieke; Thorn, Jrgen; Vertongen, Francoise; Beiier, Lena; Martinez, Fernando D.			Association between CD14 polymorphisms and serum soluble CD14 levels: Effect of atopy and endotoxin inhalation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cD14 antigen; endotoxin; single nucleotide polymorphism; inflammation; innate immunity; atopy; lipopolysaccharide; exposure	SINGLE-NUCLEOTIDE POLYMORPHISMS; HELICOBACTER-PYLORI INFECTION; PROMOTER POLYMORPHISMS; INHALED ENDOTOXIN; RECEPTOR GENE; LIPOPOLYSACCHARIDE; BINDING; PROTEIN; LPS; RECOGNITION	Background: A prerequisite for activation of the innate immune response by endotoxin is its binding to CD14. Objective: The aim of this study was to evaluate the role of CD14 polymorphisms, atopy, and inhaled endotoxin in modulating serum CD14 levels. Methods: Healthy volunteers (n = 88) were genotyped for CD14 polymorphisms at the -1619, -1359, and -159 loci, relative to the transcription start site. Subjects inhaled 20 mu g of endotoxin, and white blood cell, C-reactive protein, LPS-binding protein, and soluble CD14 (sCD14) levels were measured before and after exposure. Results: Homozygotes for the -1619G, -1359G, and -159T alleles had higher baseline levels of sCD14 than carriers of the CD14/-1619AA (P = .015), -1359GT/TT (P = .015), or -159CC (P = 0.017) genotypes. sCD14 levels increased within 24 hours of endotoxin inhalation (P < .0001 for all biomarkers); however, the association between CD14 polymorphisms and sCD14 levels was no longer present after exposure. The atopic status of an individual did not alter these associations. CD14 polymorphisms were not associated with levels of white blood cells, C-reactive protein, and LPS-binding protein before or after endotoxin challenge. Conclusion: These data suggest that CD14 promoter polymorphisms and inhaled endotoxin modulate sCD14 levels.	[Levan, Tricia D.] Univ Nebraska, Med Ctr, Dept Internal Med Pulm & Critical Care, Omaha, NE 68198 USA; [Levan, Tricia D.; Martinez, Fernando D.] Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ USA; [Michel, Olivier] Free Univ Brussels, CHU St Pierre, Clin Allergyol & Resp Dis, B-1050 Brussels, Belgium; [Vertongen, Francoise] Free Univ Brussels, CHU St Pierre, Dept Chem, B-1050 Brussels, Belgium; [Dentener, Mieke] Univ Gotenburg, Dept Resp Med, Gothenburg, Sweden; [Thorn, Jrgen; Beiier, Lena] Univ Gotenburg, Dept Environm Med, Gothenburg, Sweden	University of Nebraska System; University of Nebraska Medical Center; University of Arizona; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Levan, TD (corresponding author), Univ Nebraska, Med Ctr, Dept Internal Med Pulm & Critical Care, 985300 Nebraska Med Ctr, Omaha, NE 68198 USA.	tievan@unmc.edu	michel, olivier/G-5016-2010	michel, olivier/0000-0002-1528-1277	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K01ES000386] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61892] Funding Source: Medline; NIEHS NIH HHS [ES-00386] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alexis NE, 2004, J ALLERGY CLIN IMMUN, V114, P1325, DOI 10.1016/j.jaci.2004.09.002; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Bas S, 2004, J IMMUNOL, V172, P4470, DOI 10.4049/jimmunol.172.7.4470; BAZIL V, 1991, J IMMUNOL, V147, P1567; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; CLAYTON D, 2001, HDB STAT GENETICS, P519; Eng HL, 2003, J INFECT DIS, V188, P90, DOI 10.1086/375744; FROON AHM, 1995, J INFECT DIS, V171, P1250, DOI 10.1093/infdis/171.5.1250; Gibot S, 2002, CRIT CARE MED, V30, P969, DOI 10.1097/00003246-200205000-00003; Gioannini TL, 2005, J ENDOTOXIN RES, V11, P117, DOI 10.1179/096805105X35198; Guerra S, 2004, AM J REPROD IMMUNOL, V52, P204, DOI 10.1111/j.1600-0897.2004.00207.x; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Holla LI, 2002, J MED GENET, V39, P844, DOI 10.1136/jmg.39.11.844; Hubacek JA, 1999, CIRCULATION, V99, P3218, DOI 10.1161/01.CIR.99.25.3218; Jackola DR, 2006, INT ARCH ALLERGY IMM, V139, P217, DOI 10.1159/000091167; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Karhukorpi J, 2002, CLIN EXP IMMUNOL, V128, P326, DOI 10.1046/j.1365-2249.2002.01837.x; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297, DOI 10.1164/ajrccm.160.1.9808144; KOTLOFF RM, 1990, AM J RESP CELL MOL, V3, P497, DOI 10.1165/ajrcmb/3.5.497; Landmann R, 1996, INFECT IMMUN, V64, P1762, DOI 10.1128/IAI.64.5.1762-1769.1996; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Leung TF, 2003, PEDIAT ALLERG IMM-UK, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; LeVan TT, 2006, GENES IMMUN, V7, P77, DOI 10.1038/sj.gene.6364276; Liang XH, 2006, PHARMACOGENET GENOM, V16, P229; MARTINEZ F, INNATE IMMUNITY PGA; Martinez FD, 2005, IMMUNOL ALLERGY CLIN, V25, P709, DOI 10.1016/j.iac.2005.09.001; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; MICHEL O, 1995, CLIN EXP ALLERGY, V25, P73, DOI 10.1111/j.1365-2222.1995.tb01005.x; Nightingale JA, 1998, THORAX, V53, P563, DOI 10.1136/thx.53.7.563; Obana N, 2002, SCAND J GASTROENTERO, V37, P699, DOI 10.1080/00365520212504; Palmer SM, 2007, AM J TRANSPLANT, V7, P693, DOI 10.1111/j.1600-6143.2007.01669.x; Pan Z, 2000, J BIOL CHEM, V275, P36430, DOI 10.1074/jbc.M003192200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Rylander R, 2002, J ENDOTOXIN RES, V8, P241, DOI 10.1179/096805102125000452; Schumann RR, 1996, MOL CELL BIOL, V16, P3490; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Tan CY, 2006, J HUM GENET, V51, P59, DOI 10.1007/s10038-005-0323-z; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Zdolsek HA, 2004, CLIN EXP ALLERGY, V34, P532, DOI 10.1111/j.1365-2222.2004.1921.x; Zhao D, 2007, CLIN CANCER RES, V13, P2362, DOI 10.1158/1078-0432.CCR-06-2612	47	40	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					434	440		10.1016/j.jaci.2007.08.050	http://dx.doi.org/10.1016/j.jaci.2007.08.050			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	17949800				2022-12-18	WOS:000253337800024
J	Schroeder, JT; Chichester, KL; Bienernan, AP				Schroeder, John T.; Chichester, Kristin L.; Bienernan, Ania P.			Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-alpha	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						toll-like receptor; IgE receptor dendritic cells; cytokine; IgE; allergy	EPSILON-F-RI; INTERFERON; EXPRESSION; OMALIZUMAB; RELEASE; OSTEOPONTIN; SUBSETS; ASTHMA; TLR9	Background: Functional significance for the alpha gamma(2) variant of the high-affinity IgE receptor (Fc epsilon RI) reportedly expressed on human dendritic cell subtypes remains poorly understood. Studies show that immature plasmacytoid dendritic cells (pDCs) secrete large quantities of TNF-alpha and IL-6 when directly stimulated with anti-IgE antibody. This mode of activation, however, reduces Toll-like receptor 9 (TLR9) expression in pDCs and their ability to mount an IFN-alpha response when subsequently activated with oligodeoxynucleotide containing CpG. Objective: To investigate the mechanisms underlying this IgE-dependent suppression of TLR9 and innate immune responsiveness in pDCs by focusing on autocrine cytokine responses. Methods: pDCs were isolated from blood by using blood dendritic cell antigen 4 selection. Cytokine responses to anti-IgE antibody-dependent and/or CpG-dependent stimulation were measured by using ELISA. TLR9 expression was determined by using quantitative RT-PCR and Western blotting. Results: The time required for downregulating TLR9 expression in pDCs after anti-IgE stimulation correlated with the induction and duration of TNF-alpha secreted by these cells. Pretreatment of pDCs with recombinant TNF-alpha (but not IL-6 or IL-10) markedly suppressed TLR9 expression. Functional response to CpG (ie, IFN-alpha induction) was also inhibited with TNF-alpha pretreatment (inhibitory concentration(50) = similar to 200 pg/mL). Finally, an antibody that neutralizes TNF-alpha activity completely restored TLR9 expression during anti-IgE stimulation and significantly improved IFN-a secretion on subsequent activation with CpG. Conclusion: Autocrine TNF-a secretion resulting from IgE/Fc epsilon RI-dependent activation plays a critical role in suppressing TLR9-dependent responses in pDCs that normally promote T(H)1 activity.	[Schroeder, John T.; Chichester, Kristin L.; Bienernan, Ania P.] Johns Hopkins Univ, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21218 USA	Johns Hopkins University	Schroeder, JT (corresponding author), Johns Hopkins Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	schray@jhmi.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI070345] Funding Source: NIH RePORTER; NIAID NIH HHS [AI070345-01] Funding Source: Medline; PHS HHS [R01A42221] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Banchereau J, 2006, IMMUNITY, V25, P383, DOI 10.1016/j.immuni.2006.08.010; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bourke E, 2003, BLOOD, V102, P956, DOI 10.1182/blood-2002-11-3355; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Cao W, 2007, CURR OPIN IMMUNOL, V19, P24, DOI 10.1016/j.coi.2006.11.004; Cao W, 2006, J EXP MED, V203, P1399, DOI 10.1084/jem.20052454; Chen YH, 2003, J ALLERGY CLIN IMMUN, V112, P944, DOI 10.1016/j.jaci.2003.08.027; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Duramad O, 2003, BLOOD, V102, P4487, DOI 10.1182/blood-2003-07-2465; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Le TV, 2007, J ALLERGY CLIN IMMUN, V119, pS258, DOI 10.1016/j.jaci.2006.12.379; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; MacGlashan D, 2005, ANN NY ACAD SCI, V1050, P73, DOI 10.1196/annals.1313.009; Marshall JD, 2007, J LEUKOCYTE BIOL, V82, P497, DOI 10.1189/jlb.0906575; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Popovic PJ, 2006, J IMMUNOL, V177, P8701, DOI 10.4049/jimmunol.177.12.8701; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724; Shinohara ML, 2006, NAT IMMUNOL, V7, P498, DOI 10.1038/ni1327; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580	23	40	44	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2008	121	2					486	491		10.1016/j.jaci.2007.09.049	http://dx.doi.org/10.1016/j.jaci.2007.09.049			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	265CX	18036648				2022-12-18	WOS:000253337800031
J	Ruppert, AA; Averous, G; Stanciu, D; Deroide, N; Rielun, S; Poindron, V; Pauli, G; Debn, C; De Blay, F				Ruppert, Anne-Alarie; Averous, Gerlinde; Stanciu, Daniela; Deroide, Nicolas; Rielun, Sophie; Poindron, Vincent; Pauli, Gabrielle; Debn, Christian; De Blay, Frederic			Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Ruppert, Anne-Alarie; Stanciu, Daniela; Deroide, Nicolas; Pauli, Gabrielle; De Blay, Frederic] Hop Univ, Dept Chest Dis, Strasbourg, France; [Averous, Gerlinde] Hop Univ, Dept Anatomopathol, Strasbourg, France; [Poindron, Vincent] Hop Univ, Clin Immunol, Strasbourg, France; [Debn, Christian] Hop Univ, Dept Otolaryngol, Strasbourg, France	CHU Strasbourg; CHU Strasbourg; CHU Strasbourg; CHU Strasbourg	Ruppert, AA (corresponding author), Hop Univ, Dept Chest Dis, Strasbourg, France.	frederic.deblay@chru-strasbour.fr						Churg A, 2001, MODERN PATHOL, V14, P1284, DOI 10.1038/modpathol.3880475; CHURG A, 1995, CHEST, V108, P320, DOI 10.1378/chest.108.2.320; Giavina-Bianchi P, 2007, J ALLERGY CLIN IMMUN, V119, P1279, DOI 10.1016/j.jaci.2007.01.041; Le Gall C, 2000, EUR RESPIR J, V15, P978, DOI 10.1034/j.1399-3003.2000.15e29.x; Noth I, 2003, LANCET, V361, P587, DOI 10.1016/S0140-6736(03)12518-4; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Wechsler ME, 2000, CHEST, V117, P708, DOI 10.1378/chest.117.3.708; Winchester DE, 2006, NEW ENGL J MED, V355, P1281	8	40	41	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					253	254		10.1016/j.jaci.2007.10.040	http://dx.doi.org/10.1016/j.jaci.2007.10.040			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18206510				2022-12-18	WOS:000252372000039
J	Loza, MJ; Chang, BL				Loza, Matthew J.; Chang, Bao-Li			Association between Q551R IL4R genetic variants and atopic asthma risk demonstrated by meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; asthma; IL4R; IL-4; meta-analysis; genetic analyses; case-control	INTERLEUKIN-4 RECEPTOR-ALPHA; SERUM IGE LEVELS; IL-4 RECEPTOR; ALLERGIC-ASTHMA; ILE50VAL VARIANT; POLYMORPHISMS; POPULATION; SEVERITY; CHAIN; SUSCEPTIBILITY	Background: IL4R, the gene encoding the a chain of the IL-4 and IL-13 receptors, has received extensive attention as a candidate gene for asthma risk. However, the results from studies testing for associations of the 150V and Q551R IL4R genetic variants are conflicting. Objective: We sought to determine the average risk of asthma associated with the 150V and Q551R IL4R variants based on the results of case-control studies reported in the literature. Methods: Meta-analyses were performed with data from case-control association studies that met specified inclusion criteria (9 and 8 studies for 150V and Q551R, respectively). Random-effects models were used to calculate combined odds ratios (ORs) and significance of associations. Analyses were performed for asthma in general and for subgroups based on the atopy status of the asthma population. Results: The R551 IL4R variant was significantly associated with increased risk of asthma, most notably atopic asthma (combined OR, 1.6; P =.004). Exclusion of the outlier study reporting an OR of less than I greatly increased the significance of association (OR, 1.8; P = 3 X 10(-9)). 150V variants were not significantly associated with asthma. Conclusions: A meta-analysis of results from case-control studies strongly supports the conclusion that the R551 IL4R variant imparts a modest yet significant risk for atopic asthma. Clinical implications: Knowledge that the R551 IL4R variant is associated with increased asthma risk should provide a basis for understanding the heterogeneity of asthma pathogenesis and for pharmacogenetic approaches to treat individuals carrying this variant.	Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Pediat Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University	Loza, MJ (corresponding author), Wake Forest Univ, Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	mloza@wfubmc.edu		Loza, Matthew/0000-0002-8609-118X	NATIONAL CANCER INSTITUTE [R01CA119069, U01CA089600] Funding Source: NIH RePORTER; NCI NIH HHS [1U01 CA89600, 1R01 CA119069] Funding Source: Medline; WHI NIH HHS [NHLBI-WH-06-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); WHI NIH HHS		Aoki Takeshi, 2006, J Hum Genet, V51, P677, DOI 10.1007/s10038-006-0007-3; Beghe B, 2003, CLIN EXP ALLERGY, V33, P1111, DOI 10.1046/j.1365-2222.2003.01731.x; Blakey J, 2005, THORAX, V60, P274, DOI 10.1136/thx.2004.027227; Bottini N, 2002, CLIN GENET, V61, P288, DOI 10.1034/j.1399-0004.2002.610408.x; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Chan IHS, 2006, J ALLERGY CLIN IMMUN, V117, P127, DOI 10.1016/j.jaci.2005.09.031; Chatila TA, 2004, TRENDS MOL MED, V10, P493, DOI 10.1016/j.molmed.2004.08.004; Colavita AM, 2000, CLIN CHEST MED, V21, P263, DOI 10.1016/S0272-5231(05)70265-3; Cui TP, 2003, CLIN CHEM LAB MED, V41, P888, DOI 10.1515/CCLM.2003.134; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Hytonen AM, 2004, CLIN EXP ALLERGY, V34, P1570, DOI 10.1111/j.1365-2222.2004.02069.x; Isidoro-Garcia Maria, 2005, Clin Mol Allergy, V3, P15, DOI 10.1186/1476-7961-3-15; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1016/j.jaci.2003.08.033; Kauppi P, 2001, GENOMICS, V77, P35, DOI 10.1006/geno.2001.6613; Kedda MA, 2005, THORAX, V60, P211, DOI 10.1136/thx.2004.028449; Kruse S, 1999, IMMUNOLOGY, V96, P365; Lee SG, 2004, CLIN EXP ALLERGY, V34, P1202, DOI 10.1111/j.1365-2222.2004.02015.x; Liu X, 2003, J ALLERGY CLIN IMMUN, V112, P382, DOI 10.1067/mai.2003.1635; Migliaccio C, 2003, EUR J IMMUNOGENET, V30, P349, DOI 10.1046/j.1365-2370.2003.00415.x; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Mujica-Lopez KI, 2002, EUR J IMMUNOGENET, V29, P375, DOI 10.1046/j.1365-2370.2002.00331.x; Nishimura Fumichika, 2006, Allergol Int, V55, P55, DOI 10.2332/allergolint.55.55; Noguchi E, 1999, AM J RESP CRIT CARE, V160, P342, DOI 10.1164/ajrccm.160.1.9807130; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Risma KA, 2002, J IMMUNOL, V169, P1604, DOI 10.4049/jimmunol.169.3.1604; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008, DOI 10.1016/S0091-6749(99)70082-5; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135, DOI 10.1067/mai.2000.107926; SUTTON AJ, 2000, RANDOM EFFECTS MODEL, P73; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wjst M, 2002, EUR J IMMUNOGENET, V29, P263, DOI 10.1046/j.1365-2370.2002.00300.x	37	40	43	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					578	585		10.1016/j.jaci.2007.05.019	http://dx.doi.org/10.1016/j.jaci.2007.05.019			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17586032				2022-12-18	WOS:000249505400016
J	Siebenhaar, F; Kuhn, W; Zuberbier, T; Maurer, M				Siebenhaar, Frank; Kuehn, Wolfgang; Zuberbier, Torsten; Maurer, Marcus			Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MAST-CELL; CLASSIFICATION; OMALIZUMAB		Charite Univ Med Berlin, Allergie Centrum Charite, Dept Dermatol & Allergy, Berlin, Germany; Praxis Otolaryngol & Allergy, Stassfurt, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Siebenhaar, F (corresponding author), Charite Univ Med Berlin, Allergie Centrum Charite, Dept Dermatol & Allergy, Berlin, Germany.	marcus.maurer@charite.de	Maurer, Marcus/ABG-2174-2020	Maurer, Marcus/0000-0002-4121-481X; Siebenhaar, Frank/0000-0003-4532-1644				[Anonymous], 1995, OTOLARYNGOL HEAD NEC, V113, P181; Babu KS, 2001, EXPERT OPIN BIOL TH, V1, P1049, DOI 10.1517/14712598.1.6.1049; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Chang TW, 2006, J ALLERGY CLIN IMMUN, V117, P1203, DOI 10.1016/j.jaci.2006.04.005; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Maurer M, 2005, EXP DERMATOL, V14, P923, DOI 10.1111/j.1600-0625.2005.00369.x; Ruckenstein MJ, 1999, AM J OTOLARYNG, V20, P161, DOI 10.1016/S0196-0709(99)90064-9; Saeed SR, 1998, BRIT MED J, V316, P368, DOI 10.1136/bmj.316.7128.368; Valent P, 2005, LEUKEMIA LYMPHOMA, V46, P35, DOI 10.1080/10428190400010775; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Valent P, 2006, IMMUNOL ALLERGY CLIN, V26, P515, DOI 10.1016/j.iac.2006.05.002	11	40	40	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					213	215		10.1016/j.jaci.2007.05.011	http://dx.doi.org/10.1016/j.jaci.2007.05.011			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17544095	Bronze			2022-12-18	WOS:000248066400033
J	Ermers, MJJ; Hoebee, B; Hodemaekers, HM; Kimman, TG; Kimpen, JLL; Bont, L				Ermers, Marieke J. J.; Hoebee, Barbara; Hodemaekers, Hennie M.; Kimman, Tjeerd G.; Kimpen, Jan L. L.; Bont, Louis			IL-13 genetic polymorphism identifies children with late wheezing after respiratory syncytial virus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; bronchiolitis; children; genetics; IL-4; IL-13; infant; postbronchiolitis wheezing; respiratory syncytial virus	SERUM IGE LEVELS; TRACT INFECTION; BRONCHIAL-ASTHMA; AGE 13; BRONCHIOLITIS; ASSOCIATION; ALLERGY; INTERLEUKIN-4; VARIANTS; DISEASE	Background: The nature of wheezing after respiratory syncytial virus lower respiratory tract infection (RSV LRTI) is usually transient. However, some children will develop persistent or late wheezing. Objective: We hypothesized that early and late postbronchiolitis wheezing are determined by distinct clinical, immunologic, and genetic variables. Methods: A cohort of 101 children hospitalized for RSV LRTI was prospectively followed for 6 years. During RSV LRTI, cytokine studies were performed and genetic polymorphisms were determined. Parents performed daily log registration of respiratory symptoms during the first 3 years of follow-up and again at age 6 years during the winter season. Results: Distinctive associations for early and late postbronchiolitis wheezing were found. We previously showed that airflow limitation during RSV LRTI as well as convalescent monocyte IL-10 production are associated with early wheezing. These variables were not associated with late wheezing. On the other hand, atopic family history was not associated with early wheezing, but it was associated with late wheezing. Most importantly, the IL-13 Gln allele was associated with late wheezing (odds ratio 3.27, 95% confidence interval 1.32-8.06), but it was not associated with early wheezing. Conclusion: This study revealed distinct clinical, immunologic, and genetic determinants of early and late wheezing after RSV LRTI, indicating distinct pathophysiological mechanisms. We conclude that late wheezing at age 6 years, but not early postbronchiolitis wheezing, is an asthmatic phenomenon and genetically related to a functional IL-13 polymorphism.	Univ Utrecht, Med Ctr, Wilhelmina Childrens Hosp, Dept Paediat Infect Dis, NL-3508 AB Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, Lab Toxicol Pathol & Genet, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Lab Vaccine Preventable Dis, NL-3720 BA Bilthoven, Netherlands	Utrecht University; Wilhelmina Kinderziekenhuis; Netherlands National Institute for Public Health & the Environment; Netherlands National Institute for Public Health & the Environment	Bont, L (corresponding author), Univ Utrecht, Med Ctr, Wilhelmina Childrens Hosp, Dept Paediat Infect Dis, POB 85090, NL-3508 AB Utrecht, Netherlands.	l.bont@umcutrecht.nl						Arima K, 2002, J ALLERGY CLIN IMMUN, V109, P980, DOI 10.1067/mai.2002.124656; Bancroft AJ, 1998, J IMMUNOL, V160, P3453; Bont L, 2000, AM J RESP CRIT CARE, V161, P1518, DOI 10.1164/ajrccm.161.5.9904078; Bont L, 2004, THORAX, V59, P512, DOI 10.1136/thx.2003.013391; Bont L, 2004, PEDIATR INFECT DIS J, V23, P414, DOI 10.1097/01.inf.0000122604.32137.29; Bont L, 2000, Paediatr Respir Rev, V1, P221, DOI 10.1053/prrv.2000.0052; Bont L, 2001, PEDIATR INFECT DIS J, V20, P277, DOI 10.1097/00006454-200103000-00012; Bont L, 2001, J INFECT DIS, V184, P355, DOI 10.1086/322035; Choi EH, 2002, J INFECT DIS, V186, P1207, DOI 10.1086/344310; Goetghebuer T, 2004, CLIN EXP ALLERGY, V34, P801, DOI 10.1111/j.1365-2222.2004.1947.x; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Heinzmann A, 2004, J ALLERGY CLIN IMMUN, V114, P671, DOI 10.1016/j.jaci.2004.06.038; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hoebee B, 2004, J INFECT DIS, V189, P239, DOI 10.1086/380908; Hoebee B, 2003, J INFECT DIS, V187, P2, DOI 10.1086/345859; Howard TD, 2001, AM J RESP CELL MOL, V25, P377, DOI 10.1165/ajrcmb.25.3.4483; Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Pattemore PK, 2004, PEDIATR PULM, V37, P433, DOI 10.1002/ppul.10449; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; van Woensel JBM, 2000, PEDIATR PULM, V30, P92; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	25	40	41	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1086	1091		10.1016/j.jaci.2006.12.655	http://dx.doi.org/10.1016/j.jaci.2006.12.655			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	167CB	17313976				2022-12-18	WOS:000246427200006
J	Maloney, JM; Chapman, MD; Sicherer, SH				Maloney, Jennifer M.; Chapman, Martin D.; Sicherer, Scott H.			Peanut allergen exposure through saliva: Assessment and interventions to reduce exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; kissing; anaphylaxis; saliva; Ara h 1	TREE NUT ALLERGY; KISS; CHILDREN; ARA-H-1; FOODS	Background: Exposure to food allergens through saliva (kissing, utensils) can cause local and systemic allergic reactions. Objective: To determine the time course of peanut allergen (Ara h 1) persistence in saliva after ingestion of peanut butter and to evaluate mouth cleansing interventions to reduce salivary peanut allergen. Methods: Thirty-eight individuals ingested 2 tablespoons of peanut butter, and saliva was collected at various time points. At another time, samples were collected after 5 interventions (brushing teeth, brushing and rinsing, rinsing, waiting then brushing, waiting then chewing gum). Detection of Ara h 1 was performed by a monoclonal-based ELISA (detection limit, 15-20 ng/mL). Results: Salivary Ara h 1 varied considerably immediately after ingestion, but included levels expected to invoke reactions (as much as 40 mu g/mL). Most (87%) subjects with detectable peanut after a meat had undetectable levels by 1 hour with no interventions. None had detectable levels several hours later after a peanut-free lunch. This result indicates (95% confidence) that 90% would have undetectable Ara h I in saliva under these circumstances. All of the interventions reduced salivary Ara h 1, in some cases by > 95%, but Ara h 1 remained detectable in similar to 40% of samples (though typically below thresholds reported to induce reactions). Conclusion: Patients with peanut allergy require counseling regarding risks of kissing or sharing utensils, even if partners have brushed teeth or chewed gum. Advice to reduce risks, though not as ideal as total avoidance, includes waiting a few hours plus eating a peanut-free meal. Clinical implications: Waiting several hours and ingesting a peanut-free meal were more effective at reducing salivary peanut protein concentration than simple, immediate interventions.	Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, Dept Pediat, New York, NY USA; INDOOR Biotechnol Inc, Charlottesville, VA USA	Icahn School of Medicine at Mount Sinai; INDOOR Biotechnologies	Maloney, JM (corresponding author), CUNY Mt Sinai Sch Med, Div Pediat Allergy & Immunol, 1 Gustave L Levy Pl,Box 1198, New York, NY 10029 USA.	jennifer.maloney@mssm.edu		Chapman, Martin/0000-0002-0845-3632				Bindslev-Jensen C, 2002, ALLERGY, V57, P741, DOI 10.1034/j.1398-9995.2002.23797.x; Eriksson NE, 2003, J INVEST ALLERG CLIN, V13, P149; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; Hallett R, 2002, NEW ENGL J MED, V346, P1833, DOI 10.1056/NEJM200206063462320; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Koppelman SJ, 2001, ALLERGY, V56, P132, DOI 10.1034/j.1398-9995.2001.056002132.x; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Maleki SJ, 2006, J ALLERGY CLIN IMMUN, V117, pS49, DOI 10.1016/j.jaci.2005.12.199; Maleki SJ, 2000, J IMMUNOL, V164, P5844, DOI 10.4049/jimmunol.164.11.5844; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Pomes A, 2004, J FOOD PROTECT, V67, P793, DOI 10.4315/0362-028X-67.4.793; Pomes A, 2003, J ALLERGY CLIN IMMUN, V111, P640, DOI 10.1067/mai.2003.118; SAMPSON HA, 1991, J PEDIATR-US, V118, P520, DOI 10.1016/S0022-3476(05)90001-2; Scurlock AM, 2004, ANN ALLERG ASTHMA IM, V93, pS12, DOI 10.1016/S1081-1206(10)61727-9; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Steensma DP, 2003, MAYO CLIN PROC, V78, P221, DOI 10.4065/78.2.221; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Wuthrich B, 1997, ALLERGY, V52, P235, DOI 10.1111/j.1398-9995.1997.tb00986.x; Wuthrich B, 2001, ALLERGY, V56, P913, DOI 10.1034/j.1398-9995.2001.00302.x	23	40	41	1	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					719	724		10.1016/j.jaci.2006.05.017	http://dx.doi.org/10.1016/j.jaci.2006.05.017			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	086BV	16950293	Bronze			2022-12-18	WOS:000240649000027
J	Graif, Y; Romano-Zelekha, O; Livne, I; Green, MS; Shohat, T				Graif, Yael; Romano-Zelekha, Orly; Livne, Irit; Green, Manfred S.; Shohat, Tamy			Allergic reactions to insect stings: Results from a national survey of 10,000 junior high school children in Israel	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						schoolchildren; insect stings; large local reaction; mild systemic reaction; moderate-to-severe systemic reaction; hospital attendance	VENOM ALLERGY; IMMUNOLOGICAL SURVEYS; HYMENOPTERA STINGS; PREVALENCE; BEE; ANAPHYLAXIS; POPULATION; EPIDEMIOLOGY; SCHOOLCHILDREN; SYMPTOMS	Background: Insect sting allergy is a medical condition the magnitude of which has not been fully estimated in children. Objectives: We sought to evaluate the prevalence of insect stings among schoolchildren in Israel, the rate of allergic reactions, and hospital attendance. Methods: A self-report questionnaire of the International Study of Asthma and Allergies in Childhood was administered to a national sample of schoolchildren aged 13 to 14 years across Israel. Questions regarding insect stings, allergic reactions, and hospital attendance were added. Results: Ten thousand twenty-one questionnaires were available for analysis. Most (56.3%) had been stung at least once in their lifetime. Of these, 20.5% had a large local reaction (LLR), 11.6% had a mild (cutaneous) systemic reaction (MSR), and 4.4% had a moderate-to-severe systemic reaction (SSR); 11.5%, 6.5%, and 2.5% of the study group, respectively. Arabs had significantly more allergic reactions of all 3 types than Jews (P < .0001). On multivariate analysis, LLR was associated with SSR (odds ratio, 6.25; 95% CI, 4.66-8.41) and MSR (odds ratio, 5.15; 95% CI, 4.24-6.25). More than 10% of the children with an LLR only attended a hospital compared with 7.5% of those with an MSR only and 14.5% with an SSR only. Conclusions: The frequency of reported allergic sting reactions in children might be higher than previously estimated. Arab children reported significantly more allergic reactions than Jews. Hospital attendance does not correlate with the severity of the allergic reaction, and only a minority of children with SSRs are treated in hospital. Clinical implications: The improper care of severe reactions highlights the need for better public and physician education.	Tel Aviv Univ, Sackler Fac Med, Allergy & Immunol Clin, Pulm Inst,Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel; Israel Minist Hlth, Israel Ctr Dis Control, Tel Hashomer, Israel; Israel Minist Educ, Jerusalem, Israel; Tel Aviv Univ, Dept Epidemiol & Prevent Med, Fac Med, IL-69978 Tel Aviv, Israel; Israel Minist Hlth, Tel Aviv Dist Hlth Off, Tel Aviv, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University	Graif, Y (corresponding author), Tel Aviv Univ, Sackler Fac Med, Allergy & Immunol Clin, Pulm Inst,Rabin Med Ctr, Beilinson Campus, IL-49100 Petah Tiqwa, Israel.	graif@post.tau.ac.il		Green, Manfred S./0000-0002-9753-5612				ABRISHAMI MA, 1971, ACTA ALLERGOL, V26, P117; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BJORNSSON E, 1995, ALLERGY, V50, P800, DOI 10.1111/j.1398-9995.1995.tb05052.x; BOUSQUET J, 1982, CLIN ALLERGY, V12, P331, DOI 10.1111/j.1365-2222.1982.tb02537.x; CHARPIN D, 1992, J ALLERGY CLIN IMMUN, V90, P331, DOI 10.1016/S0091-6749(05)80011-9; Clark S, 2005, J ALLERGY CLIN IMMUN, V116, P643, DOI 10.1016/j.jaci.2005.06.026; Eich-Wanger C, 1998, CLIN EXP ALLERGY, V28, P1292, DOI 10.1046/j.1365-2222.1998.00411.x; FERBANDEZ J, 2005, CLIN EXP ALLERGY, V35, P179; Fernandez J, 1999, CLIN EXP ALLERGY, V29, P1069, DOI 10.1046/j.1365-2222.1999.00614.x; Goldberg A, 2001, J ALLERGY CLIN IMMUN, V107, P902, DOI 10.1067/mai.2001.114986; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 2003, AM FAM PHYSICIAN, V67, P2541; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GRAFT DF, 1984, J PEDIATR-US, V104, P664, DOI 10.1016/S0022-3476(84)80940-3; Graif Y, 2004, ANN ALLERG ASTHMA IM, V92, P245, DOI 10.1016/S1081-1206(10)61555-4; Grigoreas C, 1997, ALLERGY, V52, P51, DOI 10.1111/j.1398-9995.1997.tb02545.x; Helbling A, 2004, CLIN EXP ALLERGY, V34, P285, DOI 10.1111/j.1365-2222.2004.01882.x; Kalyoncu AF, 1997, ANN ALLERG ASTHMA IM, V78, P408, DOI 10.1016/S1081-1206(10)63203-6; LOCKEY RF, 1988, J ALLERGY CLIN IMMUN, V82, P370, DOI 10.1016/0091-6749(88)90008-5; MULLER U, 1991, CLIN EXP ALLERGY, V21, P281, DOI 10.1111/j.1365-2222.1991.tb01659.x; Navarro LA, 2004, J INVEST ALLERG CLIN, V14, P134; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; Novembre E, 1998, CLIN EXP ALLERGY, V28, P834, DOI 10.1046/j.1365-2222.1998.00313.x; Peng MM, 2004, ARCH INTERN MED, V164, P317, DOI 10.1001/archinte.164.3.317; Reisman RE, 2001, J ALLERGY CLIN IMMUN, V107, P781, DOI 10.1067/mai.2001.115042; Riley AW, 2004, AMBUL PEDIATR, V4, P371, DOI 10.1367/A03-178R.1; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SHIMIZU T, 1995, ANN ALLERG ASTHMA IM, V74, P495; Shohat T, 2000, EUR RESPIR J, V15, P725, DOI 10.1034/j.1399-3003.2000.15d16.x; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; Yu ITS, 2004, ARCH DIS CHILD, V89, P544, DOI 10.1136/adc.2003.033688	32	40	40	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1435	1439		10.1016/j.jaci.2006.03.004	http://dx.doi.org/10.1016/j.jaci.2006.03.004			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	053UX	16751010				2022-12-18	WOS:000238332300036
J	Kelly, MM; Leigh, R; Jayaram, L; Goldsmith, CH; Parameswaran, K; Hargreave, FE				Kelly, Margaret M.; Leigh, Richard; Jayaram, Lata; Goldsmith, Charlie H.; Parameswaran, Krishnan; Hargreave, Frederick E.			Eosinophilic bronchitis in asthma: A model for establishing dose-response and relative potency of inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inhaled corticosteroids; fluticasone propionate; relative potency; sputum eosinophils	EXHALED NITRIC-OXIDE; SHORT-TERM TREATMENT; FLUTICASONE PROPIONATE; AIRWAY INFLAMMATION; INDUCED SPUTUM; BECLOMETHASONE DIPROPIONATE; PERSISTENT ASTHMA; THERAPEUTIC INDEX; DOUBLE-BLIND; BUDESONIDE	Background: Newer generations and formulations of inhaled corticosteroids have necessitated the development or a clinically relevant model to compare their clinical potency. Objective: We evaluated whether sputum eosinophil counts could demonstrate a dose-response to inhaled corticosteroids, and compared the response with other inflammatory markers. Methods: Fourteen steroid-naive patients with asthma with an initial sputum eosinophilia of >= 2.5% entered a 6-week sequential, placebo-controlled, patient-blinded, cumulative dose-response study. After 7 days of placebo, they received incremental doses of fluticasone propionate (FP), 50, 100, 200, and 400 mu g/d, each for 7 days. Measurements were made of sputum and blood eosinophils, exhaled nitric oxide, spirometry, airway responsiveness to methacholine (methacholine PC20), and symptom scores before and after each dose. Results: Sputum eosinophils and exhaled nitric oxide were extremely sensitive to the effects of FP, and exhibited significant dose-dependent reductions of 99.4% and 99.8 parts per billion, respectively, where each variable was expressed per 100 mu g/d FP. This compared with a 0.5 doubling dose increase of airway responsiveness to methacholine and a 0.3 decrease in symptom scores. Airway responsiveness to methacholine was the only variable that increased throughout the study.	McMaster Univ, St Josephs Healthcare, Ctr Evaluat Med, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; McMaster Univ, St Josephs Healthcare, Airways Res Grp, Firestone Inst Resp Hlth, Hamilton, ON, Canada	McMaster University; McMaster University	Kelly, MM (corresponding author), Univ Calgary, Immunol Res Grp, Inst Infect Immun & Inflammat, Room HSC 1863,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	mmkelly@ucalgary.ca	Kelly, Margaret M/G-4128-2012	Kelly, Margaret M/0000-0002-1629-3210				Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1, DOI 10.1164/ajrccm.157.3.157315; Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; BOOTH H, 1995, AM J RESP CRIT CARE, V152, P45, DOI 10.1164/ajrccm.152.1.7599861; Boulet LP, 1998, EUR RESPIR J, V11, P1194, DOI 10.1183/09031936.98.11051194; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215, DOI 10.1016/S0091-6749(99)70016-3; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, P457, DOI 10.1016/S0091-6749(98)70353-7; CLAMAN DM, 1994, J ALLERGY CLIN IMMUN, V94, P861, DOI 10.1016/0091-6749(94)90154-6; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; FINNEY DJ, 1976, STAT METHOD BIOL ASS; Gershman NH, 2000, EUR RESPIR J, V15, P11, DOI 10.1183/09031936.00.15101100; Giannini D, 2003, RESP MED, V97, P463, DOI 10.1053/rmed.2002.1458; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Holt S, 2001, BRIT MED J, V323, P253, DOI 10.1136/bmj.323.7307.253; Inman MD, 2001, AM J RESP CRIT CARE, V164, P569, DOI 10.1164/ajrccm.164.4.2007063; Inoue H, 1999, LUNG, V177, P53, DOI 10.1007/PL00007627; Jatakanon A, 1998, EUR RESPIR J, V12, P1084, DOI 10.1183/09031936.98.12051084; Jayaram L, 2006, EUR RESPIR J, V27, P483, DOI 10.1183/09031936.06.00137704; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Kelly HW, 1998, J ALLERGY CLIN IMMUN, V102, pS36, DOI 10.1016/S0091-6749(98)70004-1; Kelly HW, 2003, ANN ALLERG ASTHMA IM, V91, P326, DOI 10.1016/S1081-1206(10)61677-8; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lemiere Catherine, 2004, Can Respir J, V11 Suppl A, p9A; Lim S, 1999, AM J RESP CRIT CARE, V159, P22, DOI 10.1164/ajrccm.159.1.9706006; Masoli M, 2004, EUR RESPIR J, V23, P552, DOI 10.1183/09031936.04.00076604; Masoli M, 2004, THORAX, V59, P16; Nathan RA, 2001, AM J MED, V111, P195, DOI 10.1016/S0002-9343(01)00800-2; Noonan MJ, 1998, J ASTHMA, V35, P153, DOI 10.3109/02770909809068203; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864, DOI 10.1164/ajrccm.155.6.9196087; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pavord ID, 2002, EUR RESPIR J, V20, p40S, DOI 10.1183/09031936.02.00004002; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043, DOI 10.1164/ajrccm.159.4.9806052; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Turner M O, 1998, Can Respir J, V5, P261; Wales D, 1999, CHEST, V115, P1278, DOI 10.1378/chest.115.5.1278; Wilson AM, 2000, AM J MED, V108, P269, DOI 10.1016/S0002-9343(99)00435-0; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V102, P751, DOI 10.1016/S0091-6749(98)70014-4; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590	44	40	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					989	994		10.1016/j.jaci.2006.01.045	http://dx.doi.org/10.1016/j.jaci.2006.01.045			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	041EM	16675323				2022-12-18	WOS:000237436300003
J	Pasternack, R; Huhtala, H; Karjalainen, J				Pasternack, R; Huhtala, H; Karjalainen, J			Chlamydophila (Chlamydia) pneumoniae serology and asthma in adults: A longitudinal analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; Chlamydophila pneumoniae; Chlamydia pneumoniae infection; lung function; population-based; remodeling; risk; serology	ONSET ASTHMA; RESPIRATORY-DISEASE; INCREASED FREQUENCY; STRAIN TWAR; INFECTION; ANTIBODIES; EXACERBATIONS; ASSOCIATION; TRACHOMATIS; BRONCHITIS	Background: Many cross-sectional studies have found an association between Chlamydophila pneumoniae infection and asthma, and a possible causative role of C pneumoniae infection in asthma pathogenesis has been proposed. No longitudinal studies have been undertaken to estimate the effect on asthma incidence or previous or chronic infection. Objective: We evaluated whether serological findings suggestive for recent or chronic C pneumoniae infection affect asthma risk or lung function during follow-up. Methods: We followed a population-based adult cohort for 15 years and made a clinical evaluation of persons with new persistent asthma (n = 83) and matched controls (n = 162). Serological testing was performed by microinimunofluo-rescence and enzyme immunoassay front both baseline and follow-up samples. Results: Subjects with serologically diagnosed recent or chronic C pneumoniae infection did not run a higher risk of new asthma. An increased risk was found in subjects with allergic rhinitis, low lung function, history of smoking, and positive family background of asthma or allergy. However, chronic C pneumoniae infection was round to accelerate the loss of lung function significantly in subjects who contracted new nonatopic asthma (median change in FEV1, 89.6 vs 55.9 mL/y; P =.032). Conclusion: Chronic C pneumoniae infection promotes the development or airflow limitation in adults with nonatopic asthma. However, our results indicate that at the population level, any possible effect or C pneumoniae infection on asthma incidence is or minor significance.	Univ Tampere, Sch Publ Hlth, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Dermatol & Venerol, Tampere, Finland; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital	Karjalainen, J (corresponding author), Univ Tampere, Sch Med, FIN-33014 Tampere, Finland.	jussi.karjalainen@uta.fi		Pasternack, Rafael/0000-0003-4899-1504				ALLEGRA L, 1994, EUR RESPIR J, V7, P2165, DOI 10.1183/09031936.94.07122165; Black PN, 2001, AM J RESP CRIT CARE, V164, P536, DOI 10.1164/ajrccm.164.4.2011040; Black PN, 2000, EUR RESPIR J, V15, P254, DOI 10.1034/j.1399-3003.2000.15b06.x; Blasi F, 2002, THORAX, V57, P672, DOI 10.1136/thorax.57.8.672; BRETT MM, 1990, ARCH DIS CHILD, V65, P259, DOI 10.1136/adc.65.3.259; BUCK GE, 1986, J INFECT DIS, V153, P664, DOI 10.1093/infdis/153.4.664; Cook PJ, 1998, THORAX, V53, P254, DOI 10.1136/thx.53.4.254; DODGE R, 1994, J ALLERGY CLIN IMMUN, V94, P831, DOI 10.1016/0091-6749(94)90150-3; EKMAN MR, 1993, CLIN INFECT DIS, V17, P420, DOI 10.1093/clinids/17.3.420; Gencay M, 2001, AM J RESP CRIT CARE, V163, P1097, DOI 10.1164/ajrccm.163.5.2003162; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; Hahn DL, 2000, ANN ALLERG ASTHMA IM, V84, P227, DOI 10.1016/S1081-1206(10)62760-3; Hahn DL, 1998, ANN ALLERG ASTHMA IM, V80, P45, DOI 10.1016/S1081-1206(10)62938-9; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; HAHN DL, 1992, LANCET, V339, P1173, DOI 10.1016/0140-6736(92)90775-X; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565, DOI 10.1164/ajrccm.164.4.2012146; KARVONEN M, 1994, INT J EPIDEMIOL, V23, P1315, DOI 10.1093/ije/23.6.1315; MABEY DCW, 1987, LANCET, V2, P1491; MARRIE TJ, 1993, THORAX, V48, P1, DOI 10.1136/thx.48.1.1; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; MCINTOSH JC, 1992, INFECT IMMUN, V60, P2936, DOI 10.1128/IAI.60.7.2936-2942.1992; Miyashita N, 1998, ANN ALLERG ASTHMA IM, V80, P405, DOI 10.1016/S1081-1206(10)62992-4; MOORE DE, 1982, LANCET, V2, P574; Nagy A, 2003, J ALLERGY CLIN IMMUN, V112, P729, DOI 10.1016/S0091-6749(03)02010-4; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Rodel J, 2000, INFECT IMMUN, V68, P3635, DOI 10.1128/IAI.68.6.3635-3641.2000; Routes JM, 2000, J ALLERGY CLIN IMMUN, V105, P391, DOI 10.1016/S0091-6749(00)90093-9; SAIKKU P, 1992, J INFECTION, V25, P27, DOI 10.1016/0163-4453(92)91913-V; Strachan DP, 2000, AM J RESP CRIT CARE, V161, P493, DOI 10.1164/ajrccm.161.2.9904055; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5; von Hertzen L, 1999, CLIN EXP ALLERGY, V29, P522; von Hertzen L, 1998, J MED MICROBIOL, V47, P441, DOI 10.1099/00222615-47-5-441; von Hertzen L, 2000, RESP MED, V94, P356, DOI 10.1053/rmed.1999.0715; von Hertzen LC, 2002, EUR RESPIR J, V19, P546, DOI 10.1183/09031936.02.00254402	35	40	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1123	1128		10.1016/j.jaci.2005.08.030	http://dx.doi.org/10.1016/j.jaci.2005.08.030			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275386	Bronze			2022-12-18	WOS:000235686700027
J	Seroogy, CM; Gern, JE				Seroogy, CM; Gern, JE			The role of T regulatory cells in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; T regulatory cells; inflammation; CD25; Foxp3; tolerance	FOXP3 EXPRESSION; IN-VIVO; SUPPRESSION; INDUCTION; TOLERANCE; MICE; SELF	As a chronic inflammatory disease, much of the research related to asthma has been focused on proinflammatory mechanisms. Recently, advances have been made in defining mechanisms that control inflammation and induce immune tolerance to specific antigens. Subsets of CD4(+) cells known as T regulatory cells play an important role in directing these processes, and recent experiments have begun to define crucial molecular and signaling pathways. There is a growing body of evidence describing the function of T regulatory cells in the development, disease activity, and treatment responses related to asthma and other atopic diseases. Collectively, this new information suggests that a greater understanding of these pathways might lead to new therapeutic targets for asthma and other diseases of chronic airway inflammation.	Univ Wisconsin, Dept Pediat, Div Rheumatol Allergy & Immunol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Seroogy, CM (corresponding author), Univ Wisconsin, Dept Pediat, Div Rheumatol Allergy & Immunol, H4-474 CSC,600 Highland Ave, Madison, WI 53792 USA.	cmseroogy@wisc.edu						Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102; Cobbold SP, 2004, J IMMUNOL, V172, P6003, DOI 10.4049/jimmunol.172.10.6003; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Fahlen L, 2005, J EXP MED, V201, P737, DOI 10.1084/jem.20040685; Fantini MC, 2004, J IMMUNOL, V172, P5149, DOI 10.4049/jimmunol.172.9.5149; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Holtzman MJ, 2003, J ALLERGY CLIN IMMUN, V111, P244, DOI 10.1067/mai.2003.141; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hsieh CS, 2004, IMMUNITY, V21, P267, DOI 10.1016/j.immuni.2004.07.009; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; SAKAGUCHI S, 1985, J EXP MED, V161, P72, DOI 10.1084/jem.161.1.72; Thorstenson KM, 2001, J IMMUNOL, V167, P188, DOI 10.4049/jimmunol.167.1.188; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180	19	40	46	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					996	999		10.1016/j.jaci.2005.07.015	http://dx.doi.org/10.1016/j.jaci.2005.07.015			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275366				2022-12-18	WOS:000235686700007
J	Kroczek, R; Hamelmann, E				Kroczek, R; Hamelmann, E			T-cell costimulatory molecules: Optimal targets for the treatment of allergic airway disease with monoclonal antibodies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic airway disease; monoclonal antibodies; deplenon therapy; T cells; costimulatory molecules; inducible costinudator; OX40	OX40; EXPRESSION; ASTHMA; CD30; ICOS; IGE	Current treatment for chronic allergic airway disease with anti-inflammatory agents is effective but not specific, and is symptomatic rather than curative. The present review article outlines the involvement of T cells by dissecting the various steps in which naive CD4(+) T cells differentiate to allergen-specific, activated T cells of the T(H)2 type, which play a pivotal role in the pathogenesis of chronic allergic airway disease. Aiming at a concept for a highly specific therapy of this disease, various T cell costimulatory molecules (CD28, CD27, HVAM, BTLA, ICOS, OX40, CD30, 4-IBB, SLAM, CTLA-4, and PD-1) and the non-costimulatory molecule CD40L, all of them expressed on activated TH2 effector T cells, are discussed as potential targets for an antibody-based therapy. Considering various criteria, including T-cell specific expression and expression characteristics on resting versus activated T cells, reasons are given why ICOS and OX40 can be regarded as optimal targets for such an immunotherapy. Furthermore, arguments are put forward that strongly favor an immunodepletion strategy as compared to an immunoblockade approach, when heading for a specific, long-lasting therapy of chronic allergic airway disease.	Robert Koch Inst, D-13353 Berlin, Germany; Charite Univ Med, Dept Pediat Pneumol & Immunol, Berlin, Germany	Robert Koch Institute; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Kroczek, R (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.	kroczek@rki.de						Beier KC, 2004, J ALLERGY CLIN IMMUN, V114, P775, DOI 10.1016/j.jaci.2004.06.024; Croft M, 2003, CYTOKINE GROWTH F R, V14, P265, DOI 10.1016/S1359-6101(03)00025-X; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; Hamelmann E, 2003, J ALLERGY CLIN IMMUN, V111, P248, DOI 10.1067/mai.2003.156; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; KALLINICH T, 2005, IN PRESS CLIN EXP AL; Kawai T, 2000, NAT MED, V6, P114, DOI 10.1038/72162; Kim MY, 2003, IMMUNITY, V18, P643, DOI 10.1016/S1074-7613(03)00110-9; Kroczek RA, 2004, CURR OPIN IMMUNOL, V16, P321, DOI 10.1016/j.coi.2004.03.002; Lane P, 2000, J EXP MED, V191, P201, DOI 10.1084/jem.191.2.201; Leckie Maggie J, 2003, Am J Respir Med, V2, P245; Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632; Ngoc LP, 2005, CURR OPIN ALLERGY CL, V5, P161, DOI 10.1097/01.all.0000162309.97480.45; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Tarkowski M, 2003, CURR OPIN HEMATOL, V10, P267, DOI 10.1097/00062752-200307000-00003; Veillette A, 2003, CURR OPIN IMMUNOL, V15, P277, DOI 10.1016/S0952-7915(03)00041-4; Wahn Ulrich, 2004, Clin Allergy Immunol, V18, P625	17	40	49	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					906	909		10.1016/j.jaci.2005.07.005	http://dx.doi.org/10.1016/j.jaci.2005.07.005			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IF	16210068				2022-12-18	WOS:000235686600028
J	Mehandru, S; Tenner-Racz, K; Racz, P; Markowitz, M				Mehandru, S; Tenner-Racz, K; Racz, P; Markowitz, M			The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						acute HIV-1; gastrointestinal tract; CD4(+) T cells	T-CELL DEPLETION; IMMUNODEFICIENCY-VIRUS TYPE-1; LAMINA PROPRIA; SIV INFECTION; LYMPHOCYTES; REPLICATION; ANTIGENS; TISSUE	It has become evident that the gastrointestinal tract is preferentially and profoundly depleted of CD4(+) T cells during acute HIV-1 infection. The enhanced susceptibility of gastrointestinal lymphoid tissue to HIV-1 is in part due to the large complement of CCR5(+) memory CD4(+) T cells resident at this site. Here we summarize the recent findings demonstrating that the gastrointestinal tract plays a critical role in the pathogenesis of acute HIV-1 and simian immunodeficiency virus infections. Ongoing work in this field is likely to have a significant effect on HIV research in the near future.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Bernhard Nocht Inst Trop Med, Hamburg, Germany	Rockefeller University; Bernhard Nocht Institut fur Tropenmedizin	Mehandru, S (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave,7th Floor, New York, NY 10016 USA.	smehandr@adarc.org						Anton PA, 2000, AIDS, V14, P1761, DOI 10.1097/00002030-200008180-00011; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; *DEP HLTH HUM SERV, 2005, GUID US ANT AG HIV I; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; LIM SG, 1993, CLIN EXP IMMUNOL, V92, P448, DOI 10.1111/j.1365-2249.1993.tb03419.x; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; SCHIEFERDECKER HL, 1992, J IMMUNOL, V149, P2816; SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524; Smit-McBride Z, 1998, J VIROL, V72, P6646, DOI 10.1128/JVI.72.8.6646-6656.1998; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427	14	40	41	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					419	422		10.1016/j.jaci.2005.05.040	http://dx.doi.org/10.1016/j.jaci.2005.05.040			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017ID	16083799				2022-12-18	WOS:000235686400027
J	Cabana, MD; Slish, KK; Lewis, TC; Brown, RW; Nan, B; Lin, XH; Clark, NM				Cabana, MD; Slish, KK; Lewis, TC; Brown, RW; Nan, B; Lin, XH; Clark, NM			Parental management of asthma triggers within a child's environment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	60th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR 18-23, 2004	San Francisco, CA	Amer Acad Allergy, Asthma & Immunol		children; asthma; parents; self-management; adherence; environmental control	EXPOSURES	Background: Control of environmental precipitants of asthma is an important component of self-management. Objective: To assess the type and frequency of attempts by families to control environmental precipitants of symptoms and their degree of consistency with current guidelines. Methods: We analyzed data from a nationwide sample of 896 children (2-12 years) with asthma. We collected data on insurance, race, sex, income, asthma education exposure, and severity. Parents were asked open-ended questions about their child's asthma triggers and what, if any, actions they took to control these triggers. Results: We completed interviews with the parents of 896 of 1077 (83%) eligible patients. Patients had a mean age of 7.2 years, 65% were boys, 13% had Medicaid insurance, 12% were African American, and 31% had persistent asthma. Eighty percent (717/896) of parents could identify at least 1 asthma trigger (mean, 2.2; range, 0-9). Eighty-two percent (582/717) of these parents had attempted an environmental control measure. Of 1788 actions initiated, 916 (51%) were unlikely to be beneficial on the basis of current guidelines. No specific demographic characteristic predicted which parents were more or less likely to institute environmental controls. Conclusion: In our sample, more than half (51%) of the environmental actions initiated were not specifically endorsed by current guidelines. Improving awareness about recognized methods to address triggers may help families use more effective measures. Clinicians should not assume that they can predict which families will be more or less likely to attempt environmental control, but should provide education regarding effective environmental measures for all families with potentially modifiable asthma triggers.	Univ Michigan, Hlth Syst, Dept Pediat, Div Gen Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Publ Hlth, Dept Hlth Behav, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Publ Hlth, Dept Hlth Educ & Biostat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Cabana, MD (corresponding author), Univ Michigan, Hlth Syst, Dept Pediat, Div Gen Pediat, 6-D-19 NIB,Box 0456,300 N Ingalls St, Ann Arbor, MI 48109 USA.	mcabana@med.umich.edu						Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P1219, DOI 10.1067/mai.2003.1479; Finkelstein JA, 2002, ARCH PEDIAT ADOL MED, V156, P258, DOI 10.1001/archpedi.156.3.258; Flores G, 2003, PEDIATRICS, V112, P1021, DOI 10.1542/peds.112.5.1021; Lanphear BP, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e98; *NAT HLEART BLOOD, 1997, 2 NAT HEART BLOOD LU; Robinson AR, 2004, ARCH INTERN MED, V164, P427, DOI 10.1001/archinte.164.4.427; Sherman J, 2000, J PEDIATR-US, V136, P532, DOI 10.1016/S0022-3476(00)90019-2; *US DEP HHS, 2004, PRIOR HHS POV GUID F; VanGanse E, 1997, J ASTHMA, V34, P203, DOI 10.3109/02770909709068190; Weiss ST, 2001, J ALLERGY CLIN IMMUN, V107, P634, DOI 10.1067/mai.2001.113869	10	40	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					352	357		10.1016/j.jaci.2004.04.047	http://dx.doi.org/10.1016/j.jaci.2004.04.047			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	847OU	15316515				2022-12-18	WOS:000223405600022
J	Novak, N; Allam, JP; Bieber, T				Novak, N; Allam, JP; Bieber, T			Allergic hyperreactivity to microbial components: A trigger factor of "intrinsic" atopic dermatitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXOTOXINS; SKIN		Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany	University of Bonn	Novak, N (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.							Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x	5	40	42	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					215	216		10.1067/mai.2003.1590	http://dx.doi.org/10.1067/mai.2003.1590			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	698QQ	12847506				2022-12-18	WOS:000184010600037
J	Simons, FER; Silas, P; Portnoy, JM; Catuogno, J; Chapman, D; Olufade, AO				Simons, FER; Silas, P; Portnoy, JM; Catuogno, J; Chapman, D; Olufade, AO			Safety of cetirizine in infants 6 to 11 months of age: A randomized, doubleblind, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						H-I-antihistamine; cetirizine; somnolence; electrocardiogram; infant; early treatment of the atopic child	ATOPIC-DERMATITIS; ALLERGIC RHINITIS; YOUNG-CHILDREN; ANTAGONIST CETIRIZINE; PRESCHOOL-CHILDREN; CONTROLLED TRIAL; DOUBLE-BLIND; PHARMACOKINETICS; MULTICENTER; TOXICITY	Background: H-1-antihistamines are widely used for symptom relief in allergic disorders in infants and children; however, there are few prospective, randomized, double-blind, controlled studies of these medications in young children, and to date, no such studies have been conducted in infants. Objective: This prospective, randomized, parallel-group, double-blind, placebo-controlled study was designed to evaluate the safety of the H-1-antihistamine cetirizine, particularly with regard to central nervous system and cardiac effects, in infants age 6 to 11 months, inclusive. Methods: Infants who met the entry criteria for age and had a history of treatment with an H-1-antihistamine for an allergic or other disorder were randomized to receive 0.25 mg/kg cetirizine orally or matching placebo twice daily orally for 1 week. Results: The mean daily dose in cetirizine-treated infants was 4.5 +/- 0.7 mg (SD). No differences in all-cause or treatment-related adverse events were observed between the cetirizineand placebo-treated groups. A trend was observed toward fewer adverse events and sleep-related disturbances in the cetirizine group compared with the placebo group. No prolongation in the linear corrected QT interval was observed in cetirizine-treated infants compared with either baseline values or with values in placebo-treated infants. Conclusions: We have documented the safety of cetirizine in this short-term investigation, the first randomized, double-blind, placebo-controlled study of any H-1-antihistamine in infants. Additional prospective, randomized, double-blind, placebo-controlled, long-term studies of cetirizine and other HI-antihistamines are needed in this population.	Univ Manitoba, FRCPC, Fac Med, Dept Pediat & Child Hlth,Sect Allergy & Clin Immu, Winnipeg, MB R3A IR9, Canada; Wee Care Pediat, Layton, UT USA; Childrens Mercy Hosp & Clin, Sect Allergy Asthma & Immunol, Kansas City, KS USA; US Pharmaceut Pfizer Inc, New York, NY USA	University of Manitoba; Children's Mercy Hospital; Pfizer	Simons, FER (corresponding author), Univ Manitoba, FRCPC, Fac Med, Dept Pediat & Child Hlth,Sect Allergy & Clin Immu, 820 Sherbrook St, Winnipeg, MB R3A IR9, Canada.							Allegra L, 1993, Pediatr Allergy Immunol, V4, P157, DOI 10.1111/j.1399-3038.1993.tb00085.x; BAELDE Y, 1992, DRUG INVEST, V4, P466, DOI 10.1007/BF03259210; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856, DOI 10.1001/archpedi.1995.02170210030005; DAUD LR, 1993, ARCH DIS CHILD, V69, P670, DOI 10.1136/adc.69.6.670; de Longueville M, 1998, J ALLERGY CLIN IMMUN, V101, pS198; DeBenedictis FM, 1997, PEDIATR ASTHMA ALLER, V11, P119, DOI 10.1089/pai.1997.11.119; Diepgen TL, 2002, PEDIAT ALLERG IMM-UK, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Emerson RM, 2001, BRIT J DERMATOL, V144, P514, DOI 10.1046/j.1365-2133.2001.04077.x; Estelle F, 2001, J ALLERGY CLIN IMMUN, V107, P703, DOI 10.1067/mai.2001.113866; Garza MB, 2000, PEDIATR EMERG CARE, V16, P97, DOI 10.1097/00006565-200004000-00008; GROSWASSER J, 1995, PEDIAT ALLERGY IMM S, V6, P96; Gunn VL, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e52; HICKSON GB, 1990, PEDIATRICS, V86, P221; Jumbelic MI, 1997, AM J FOREN MED PATH, V18, P65, DOI 10.1097/00000433-199703000-00012; KAHN A, 1982, PEDIATRICS, V70, P75; LINDSAY CA, 1995, CRIT CARE MED, V23, P777, DOI 10.1097/00003246-199504000-00031; MAGERA BE, 1981, PEDIATRICS, V67, P280; Ponsonby AL, 1997, J PAEDIATR CHILD H, V33, P317, DOI 10.1111/j.1440-1754.1997.tb01608.x; Reuveni H, 1999, ARCH PEDIAT ADOL MED, V153, P249; Ridout SM, 1997, J ALLERGY CLIN IMMUN, V99, P860, DOI 10.1016/S0091-6749(97)80028-0; SAGIE A, 1992, AM J CARDIOL, V70, P797, DOI 10.1016/0002-9149(92)90562-D; Salmun LM, 2000, CLIN THER, V22, P613, DOI 10.1016/S0149-2918(00)80048-X; Simons FER, 1996, ALLERGY ASTHMA PROC, V17, P185, DOI 10.2500/108854196778996895; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; SIMONS FER, 2002, HISTAMINE H1 ANTIHIS, P437; Skoner DP, 2000, J ALLERGY CLIN IMMUN, V105, pS605, DOI 10.1067/mai.2000.106150; Spencer C M, 1999, Paediatr Drugs, V1, P51, DOI 10.2165/00128072-199901010-00005; Spicak V, 1997, CLIN PHARMACOL THER, V61, P325; Stevenson J, 2002, PEDIATR RES, V52, DOI 10.1203/01.PDR.0000024060.49308.89; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; WYNGAARDEN JB, 1951, JAMA-J AM MED ASSOC, V145, P277, DOI 10.1001/jama.1951.02920230001001; Yasuhara A, 1998, NEUROPEDIATRICS, V29, P320, DOI 10.1055/s-2007-973585; YOKOYAMA H, 1993, METHOD FIND EXP CLIN, V15, P183	33	40	46	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1244	1248		10.1067/mai.2003.1496	http://dx.doi.org/10.1067/mai.2003.1496			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	688FZ	12789224				2022-12-18	WOS:000183424700012
J	Platts-Mills, TAE; Erwin, EA; Allison, AB; Blumenthal, K; Barr, M; Sredl, D; Burge, H; Gold, D				Platts-Mills, TAE; Erwin, EA; Allison, AB; Blumenthal, K; Barr, M; Sredl, D; Burge, H; Gold, D			The relevance of maternal immune responses to inhalant allergens to maternal symptoms, passive transfer to the infant, and development of antibodies in the first 2 years of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cord blood; IgG antibody; IgG4 antibody; eczema; cat; dust mile; maternal inheritance	HOUSE-DUST MITE; IGG4 ANTIBODIES; BIRTH COHORT; RISK-FACTORS; P-I; ASTHMA; SENSITIZATION; CHILDREN; IGE; EXPOSURE	Background: Asthma and other atopic diseases are strongly hereditary. Although the mother might play a special role, the mechanisms for such an effect are not clear. Objective: We sought to investigate the influence of maternal immune responses to cat and mite allergens on (1) maternal symptoms, (2) the development of immune responses in the infant, and (3) the development of allergic disease during the first 3 years of life. Methods: In sera from 465 mothers and 424 infants (cord blood), as well as in sera from 230 of the children at age to years, total IgE and IgE antibodies were measured by using CAP testing; IgG and IgG4 antibodies for the cat allergen Fell d I were measured by means of radioimmunoprecipitation. Results: In both mothers and children, approximately 15% of sera contained IgG antibodies to Fel d l without IgE antibodies to cat. The strongest predictor of the maternal IgG antibody response was exposure to greater than 8 mug of Fel d l/g of dust. Thus approximately 70% of children living in a house with a cat had received IgG antibodies from their mothers. In many cases the infant received IgG and IgG4 antibodies to Fel d l from a nonallergic mother. Maternal IgE antibodies were consistently associated with asthma; by contrast, the IgG antibody was not independently related to asthma but was related to rhinitis in the mothers (odds ratio, 2.6; 95% CI, 1.1-6.2) and to eczema in children. At age 3 years, 13 of 230 sera contained IgE antibodies to mite, but only 5 had IgE antibodies to cat. Conclusions: A significant proportion (approximately 15%) of mothers and children exposed to high concentrations of cat (but not mite) allergens have serum IgG antibodies without IgE antibodies. This IgG antibody is freely transferred to the infant and might influence IgG antibody production in the child. The results indicate the importance of understanding the mechanisms of tolerance to cats and raise questions about the independent role of the mother in the inheritance of allergy.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA	University of Virginia; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Platts-Mills, TAE (corresponding author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.			Platts-Mills, Thomas/0000-0002-1263-329X; Allison, Anne/0000-0002-6941-3159	NIAID NIH HHS [AI20565, AI/EHS POI 50989, AI/EHS35786] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020565, P01AI050989, R37AI020565, R01AI035786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1983, J IMMUNOL, V130, P722; Agresti A, 1999, INT ARCH ALLERGY IMM, V118, P279, DOI 10.1159/000024099; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Bollinger ME, 1998, J ALLERGY CLIN IMMUN, V101, P124, DOI 10.1016/S0091-6749(98)70203-9; Crater DD, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e97; Doekes G., 1997, J AGROMEDICINE, V4, P79; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Ellinger I, 2001, EXP CELL RES, V269, P322, DOI 10.1006/excr.2001.5330; Firan M, 2001, INT IMMUNOL, V13, P993, DOI 10.1093/intimm/13.8.993; HAY FC, 1971, CLIN EXP IMMUNOL, V9, P355; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; KELSO JM, 1991, ANN ALLERGY, V67, P511; Lannero E, 2002, PEDIAT ALLERG IMM-UK, V13, P182, DOI 10.1034/j.1399-3038.2002.01055.x; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615, DOI 10.1067/mai.2001.113523; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361, DOI 10.1164/ajrccm/141.2.361; MARIANI F, 1992, CLIN EXP ALLERGY, V22, P29, DOI 10.1111/j.1365-2222.1992.tb00111.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; PITCHERWILMOTT RW, 1980, CLIN EXP IMMUNOL, V41, P303; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; PROUVOSTDANON A, 1977, EUR J IMMUNOL, V7, P342, DOI 10.1002/eji.1830070604; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Ronmark E, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e37; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760, DOI 10.1164/ajrccm.156.6.9704026; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang XB, 1997, INT J EPIDEMIOL, V26, P978, DOI 10.1093/ije/26.5.978; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; Williams PB, 2000, J ALLERGY CLIN IMMUN, V105, P1221, DOI 10.1067/mai.2000.105219; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; WRIGHT AL, 1991, J PEDIATR-US, V118, P207, DOI 10.1016/S0022-3476(05)80484-6; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888, DOI 10.1164/ajrccm/146.4.888; ZHANG K, 1994, J IMMUNOL, V152, P3427	44	40	41	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					123	130		10.1067/mai.2003.10	http://dx.doi.org/10.1067/mai.2003.10			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	636PR	12532107				2022-12-18	WOS:000180465500019
J	Diaz-Perales, A; Tabar, AI; Sanchez-Monge, R; Garcia, BE; Gomez, B; Barber, D; Salcedo, G				Diaz-Perales, A; Tabar, AI; Sanchez-Monge, R; Garcia, BE; Gomez, B; Barber, D; Salcedo, G			Characterization of asparagus allergens: A relevant role of lipid transfer proteins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asparagus allergy; lipid transfer protein; profilin; cross-reacting carbohydrate determinant; Pru p 3	MAJOR ALLERGEN; LINKED GLYCANS; CROSS-REACTIVITY; IGE-BINDING; POLLEN; GLYCOPROTEINS; URTICARIA; FAMILY; PLANTS	Background: No asparagus allergen has been characterized to date. Lipid transfer proteins (LTPs) have an ubiquitous distribution in plant foods and have been identified as relevant allergens in some fruits, seeds, and pollens. Objective: We sought to identify asparagus allergens and to evaluate the potential involvement of the panallergen UP family in asparagus allergy. Methods: Eighteen patients with asthma, anaphylaxis, and/or contact urticaria after asparagus ingestion or exposure and positive skin prick test (SPT) responses and serum-specific IgE levels to asparagus were selected. Two LTPs were isolated from crude asparagus extract by using chromatographic methods and characterized by means of N-terminal amino acid sequencing. Both isolated proteins were tested by means of immunodetection, CAP inhibition assays, and SPTs. Additional asparagus allergens were located by using immunodetection with a pool of sera from patients allergic to asparagus and with rabbit polyclonal antibodies to sunflower pollen profilin and anti-complex asparagine-linked glycans antibodies. Results: The purified LTPs showed an N-terminal amino acid sequence similar to that of Pro p 3 and a strong reaction to anti-Pru p 3 antibodies. Each isolated protein reached inhibition values of up to 60% in CAP inhibition assays against asparagus extracts and elicited positive SPT responses in 9 of 18 patients with asparagus allergy. Immunodetection assays allowed us to identify profilin and cross-reacting carbohydrate determinants as asparagus IgE-binding components. Conclusion: Asparagus LTPs are relevant allergens. In addition, profilin and glycoproteins harboring complex asparagine-linked glycans can also be involved in asparagus allergy.	ETS Ingenieros Agron, Dept Biotecnol, Unidad Bioquim, Madrid 28040, Spain; Serv Navarro Salud, Secc Alergol, Pamplona, Spain; ALK Abello, Dept I&D, Madrid, Spain	Servicio Navarro de Salud - Osasunbidea; ALK-Abello AS	Salcedo, G (corresponding author), ETS Ingenieros Agron, Dept Biotecnol, Unidad Bioquim, Ciudad Univ, Madrid 28040, Spain.		Barber, Domingo/Y-9516-2019; Díaz-Perales, Araceli/D-8433-2016	Barber, Domingo/0000-0002-5488-5700; Díaz-Perales, Araceli/0000-0002-1093-3627				Asero R, 2001, J ALLERGY CLIN IMMUN, V108, P309, DOI 10.1067/mai.2001.116983; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Asturias JA, 1998, MOL IMMUNOL, V35, P469, DOI 10.1016/S0161-5890(98)00036-4; Bonura A, 2001, INT ARCH ALLERGY IMM, V126, P32, DOI 10.1159/000049492; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Brenna O, 2000, J AGR FOOD CHEM, V48, P493, DOI 10.1021/jf9906681; Diaz-Perales A, 1999, J ALLERGY CLIN IMMUN, V104, P681, DOI 10.1016/S0091-6749(99)70342-8; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; Eng PA, 1996, CLIN EXP ALLERGY, V26, P330, DOI 10.1046/j.1365-2222.1996.d01-315.x; Escribano MM, 1998, ALLERGY, V53, P622, DOI 10.1111/j.1398-9995.1998.tb03942.x; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; Garcia-Selles FJ, 2002, INT ARCH ALLERGY IMM, V128, P115, DOI 10.1159/000059401; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIERE M, 1989, PLANT PHYSIOL, V90, P1182, DOI 10.1104/pp.90.3.1182; Lopez-Rubio A, 1998, ALLERGY, V53, P1216, DOI 10.1111/j.1398-9995.1998.tb03845.x; Malling HJ., 2003, ALLERGY, V48, P55; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V105, P371, DOI 10.1016/S0091-6749(00)90090-3; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Rodriguez R, 2001, INT ARCH ALLERGY IMM, V125, P185, DOI 10.1159/000053815; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V82, P718, DOI 10.1016/0091-6749(88)90070-X; Sanchez MC, 1997, CONTACT DERMATITIS, V37, P181, DOI 10.1111/j.1600-0536.1997.tb00194.x; Sanchez-Hernandez MC, 2000, ALLERGY, V55, P297, DOI 10.1034/j.1398-9995.2000.00460.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VALENTA R, 1992, J EXP MED, V175, P77; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451	31	40	43	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					790	796		10.1067/mai.2002.128242	http://dx.doi.org/10.1067/mai.2002.128242			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	612NN	12417890				2022-12-18	WOS:000179082500016
J	Karjalainen, J; Hulkkonen, J; Pessi, T; Huhtala, H; Nieminen, MM; Aromaa, A; Klaukka, T; Hurme, M				Karjalainen, J; Hulkkonen, J; Pessi, T; Huhtala, H; Nieminen, MM; Aromaa, A; Klaukka, T; Hurme, M			The IL1A genotype associates with atopy in nonasthmatic adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; IgE; IL-1 alpha; adult; polymorphisin; genetics	SKIN-TEST REACTIVITY; COMMON AEROALLERGENS; RESPIRATORY SYMPTOMS; GENETIC ASSOCIATION; POPULATION-SAMPLE; MESSENGER-RNA; HUMAN-DISEASE; ASTHMA; POLYMORPHISM; INTERLEUKIN-1	Background: The skin prick test is used to examine specific IgE-mediated allergic responses. Generally, results accord well with anamnestic information on atopy. Several genetic factors probably affect the strength of allergen-mediated skin test reactions. Objective: We sought to investigate skin test findings in a population-based sample of adult asthmatic patients and control subjects and to establish whether the IL1A genotype affects allergy testing. Methods: We analyzed the single G-to-T base exchange polymorphism in exon 5 at +4845 of the gene encoding IL-1alpha (IL1A) in adult asthmatic patients (n = 245) and nonasthmatic control subjects (n = 405). The data were assessed for correlation with data on the skin test responses of these subjects to common allergens. Results: The IL1A genotype distribution and allele frequencies proved similar in patients and control subjects. Surprisingly, the IL1A genotype distribution was markedly different in control subjects with positive (ie, A positive reaction) and negative skin test responses (P=.006). This difference was caused by an increase in the frequency of the rarer allele 2 in control subjects with negative skin test responses (P=.004). Conclusion: Our study demonstrates that the IL1 gene complex is involved in the regulation of IgE-mediated atopic reactions. The results suggest that skin test responses to specific allergens are differently regulated in nonasthmatic and asthmatic subjects. Because of the potential role of the IL1A genotype as a confounding factor in skin prick testing, these results, require special attention and should be further evaluated in other clinical settings.	Univ Tampere, Sch Med, Dept Microbiol & Immunol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland; Tampere Univ Hosp, Ctr Lab Med, Tampere, Finland; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Social Insurance Inst, Helsinki, Finland	Tampere University; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital; Tampere University; Finland National Institute for Health & Welfare	Karjalainen, J (corresponding author), Univ Tampere, Sch Med, Dept Microbiol & Immunol, FIN-33014 Tampere, Finland.			Hurme, Mikko/0000-0002-8614-1044				Baldacci S, 1996, ALLERGY, V51, P149, DOI 10.1111/j.1398-9995.1996.tb00055.x; Baldacci S, 2001, EUR RESPIR J, V17, P773, DOI 10.1183/09031936.01.17407730; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P15, DOI 10.1016/0091-6749(81)90117-2; Bidwell J, 1999, GENES IMMUN, V1, P3, DOI 10.1038/sj.gene.6363645; BURROWS B, 1976, ANN INTERN MED, V84, P134, DOI 10.7326/0003-4819-84-2-134; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; Cox A, 1998, AM J HUM GENET, V62, P1180, DOI 10.1086/301817; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Excoffier L, 2000, SOFTWARE POPULATION; GILCHREST BA, 1982, J INVEST DERMATOL, V79, P11, DOI 10.1111/1523-1747.ep12510417; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V153, P561, DOI 10.1164/ajrccm.153.2.8564098; Jouvenne P, 1999, EUR CYTOKINE NETW, V10, P33; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565, DOI 10.1164/ajrccm.164.4.2012146; Karjalainen J, 2002, J ALLERGY CLIN IMMUN, V109, P514, DOI 10.1067/mai.2002.121948; Kermani F, 2000, TOXICOL APPL PHARM, V169, P231, DOI 10.1006/taap.2000.9085; La EH, 2001, J IMMUNOL, V166, P6149, DOI 10.4049/jimmunol.166.10.6149; MCDOWELL TL, 1995, ARTHRITIS RHEUM, V38, P221, DOI 10.1002/art.1780380210; *NAT AG MED KEL, 1998, FINN STAT MED; Pichowski JS, 2001, J APPL TOXICOL, V21, P115, DOI 10.1002/jat.742; Reilly DM, 2000, ACTA DERM-VENEREOL, V80, P171; Remes ST, 1996, ACTA PAEDIATR, V85, P965, DOI 10.1111/j.1651-2227.1996.tb14195.x; Rosenwasser LJ, 1998, J ALLERGY CLIN IMMUN, V102, P344; Simola M, 1999, ANN ALLERG ASTHMA IM, V82, P152, DOI 10.1016/S1081-1206(10)62589-6; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TIMONEN KL, 1995, EUR RESPIR J, V8, P1155, DOI 10.1183/09031936.95.08071155; VANDERVELDEN PA, 1993, HUM MOL GENET, V2, P1753; Willis CM, 2001, BRIT J DERMATOL, V145, P258, DOI 10.1046/j.1365-2133.2001.04343.x	28	40	42	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					429	434		10.1067/mai.2002.126784	http://dx.doi.org/10.1067/mai.2002.126784			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	592KM	12209090	Bronze			2022-12-18	WOS:000177936900013
J	Turjanmaa, K; Kanto, M; Kautiainen, H; Reunala, T; Palosuo, T				Turjanmaa, K; Kanto, M; Kautiainen, H; Reunala, T; Palosuo, T			Long-term outcome of 160 adult patients with natural rubber latex allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CALIFORNIA	Malaysian Rubber Res Inst		latex allergy; occupational; hand eczema; skin prick test; challenge tests	CONTACT URTICARIA; GLOVES; WORKERS	Allergy to natural rubber latex is a major occupational problem in the health care sector and a problem even in other occupations in which protective gloves are used. There is little information available about the long-term outcome at work in large patient populations. To study the occupational outcome when all gloves in the working environment were changed either to low-allergen latex or non-latex gloves, in 1995 to 1996 we re-examined 160 of 174 adult subjects who were diagnosed with natural rubber latex allergy between 1982 and 1994 after a median of 3 years (range, 0.5 to 24 years) after the diagnosis. The outcome in daily work or as a patient in health care was investigated with the use of a questionnaire. Special attention was paid to the assessment of the occurrence of hand eczema. Glove selection policy as an intervention in the treatment of natural rubber latex allergy is described. Of 71 health care workers and 89 non-health care workers, 72% and 83% were atopic; 54% and 65% had hand eczema at the time of diagnosis, and 89% and 19% had work-related allergy to natural rubber latex, respectively. On re-examination, none of the health care workers had changed work because of natural rubber latex allergy, and only 38% had hand eczema (significant decrease). Ninety-eight percent of the non-health care workers, of which 58% had hand eczema, continued with their previous jobs. The use of low-allergen latex or non-latex gloves throughout the health care sector seems to be an adequate step for health care workers who have natural rubber latex allergy; non-health care workers get along with personal avoidance of latex gloves if they are not working directly with natural rubber latex-containing materials in production.	Tampere Univ Hosp, Dept Dermatol, FIN-33521 Tampere, Finland; Tampere Univ, FIN-33101 Tampere, Finland; Rheumatol Fdn Hosp, Heinola, Finland; Natl Inst Publ Hlth, Helsinki, Finland	Tampere University; Tampere University Hospital; Tampere University; Rheumatism Foundation Hospital	Turjanmaa, K (corresponding author), Tampere Univ Hosp, Dept Dermatol, POB 2000, FIN-33521 Tampere, Finland.							Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; Hamilton RG, 2000, J ALLERGY CLIN IMMUN, V105, P839, DOI 10.1067/mai.2000.105224; Jolanki R, 1999, CONTACT DERMATITIS, V40, P329, DOI 10.1111/j.1600-0536.1999.tb06088.x; Levy DA, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988; MAIBACH HI, 1975, ARCH DERMATOL, V111, P726, DOI 10.1001/archderm.111.6.726; *NAT AG MED, 1999, 11999 TLTINFO NAT AG; Palosuo T, 1998, ALLERGY, V53, P59, DOI 10.1111/j.1398-9995.1998.tb03774.x; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; Taylor JS, 1996, ARCH DERMATOL, V132, P265, DOI 10.1001/archderm.132.3.265; TURJANMAA K, 1988, DERMATOL CLIN, V6, P47, DOI 10.1016/S0733-8635(18)30688-0; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; TURJANMAA K, 1988, ACTA U TAMPERENSIS A, V254, P1; WRANGSJO K, 1994, AM J CONTACT DERMAT, V5, P194; YLITALO L, 2000, ACTA U TAMPERENSIS, V719, P1	17	40	45	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S70	S74		10.1067/mai.2002.125332	http://dx.doi.org/10.1067/mai.2002.125332			5	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	586ET	12170246				2022-12-18	WOS:000177572200011
J	Annunziato, F; Cosmi, L; Manetti, R; Brugnolo, F; Parronchi, P; Maggi, E; Nagata, K; Romagnani, S				Annunziato, F; Cosmi, L; Manetti, R; Brugnolo, F; Parronchi, P; Maggi, E; Nagata, K; Romagnani, S			Reversal of human allergen-specific CRTH2(+) T(H)2 cells by IL-12 or the PS-DSP30 oligodeoxynucleotide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; T(H)2; CRTH2; IL-12; IL-12 receptor; IL-4; ODN; CD28	CD4(+) T-CELLS; TH2 CELLS; SELECTIVE EXPRESSION; RECEPTOR EXPRESSION; IN-VITRO; DISEASE; MOLECULE; VIVO	Background: The chemoattractant receptor homologous molecule expressed on T(H)2 cells (CRTH2) is a receptor for prostaglandin D-2, which among human T cells is selectively expressed by T(H)2 and type 2 cytotoxic effectors. Objective: Our purpose was to assess whether the cytokine production profile of T(H)2 effectors could be reversed by exploiting their selective expression of CRTH2. Methods: CRTH2(+) T cells were purified from the blood of allergic subjects, stimulated with the specific allergen in the absence or presence of IL-12, and assessed by flow cytometry at the single-cell level for their ability to produce IL-4 and/or IFN-gamma after antigen or polyclonal stimulation. Results: Both IL-12 and the PS-DSP30 oligodeoxynucleotide enabled CRTH2(+) allergen-stimulated T(H)2 cells to produce IFN-gamma. This change in the profile of cytokine production by TH2 cells from allergic subjects was related to the upregulation of IL-12 receptor beta2 chain and was associated with the loss of CRTH2. Conclusions: These data demonstrate that the cytokine production pattern of fully differentiated T(H)2 effectors can be changed to a less polarized profile, thus providing the physiologic basis for new immunotherapeutic strategies in allergic disorders.	Univ Florence, Dipartimento Med Interna, Sect Clin Immunol Allergy & Resp Dis, I-50134 Florence, Italy; BML Inc, R&D Ctr, Kawagoe, Saitama, Japan	University of Florence; BML, Inc.	Romagnani, S (corresponding author), Univ Florence, Dipartimento Med Interna, Sect Clin Immunol Allergy & Resp Dis, Viale Morgagni 85, I-50134 Florence, Italy.		Annunziato, Francesco/C-1155-2013; Parronchi, Paola/AAE-5422-2022; Maggi, Enrico/AAA-8045-2019	Parronchi, Paola/0000-0002-9184-5089; Maggi, Enrico/0000-0002-1824-3583; Annunziato, Francesco/0000-0001-8798-7589				Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691, DOI 10.1002/jlb.65.5.691; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Carballido JM, 1997, J IMMUNOL, V159, P4316; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; Elloso MM, 2001, EUR J IMMUNOL, V31, P384, DOI 10.1002/1521-4141(200102)31:2<384::AID-IMMU384>3.0.CO;2-9; GARASHI O, 1998, J IMMUNOL, V160, P1638; HEINZEL FP, 1995, J IMMUNOL, V155, P2730; Hilkens CMU, 1996, J IMMUNOL, V157, P4316; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Nagata K, 1999, J IMMUNOL, V162, P1278; Parronchi P, 1999, J IMMUNOL, V163, P5946; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SCHEFFOLD A, 1995, IMMUNOTECHNOLOGY, V1, P127, DOI 10.1016/1380-2933(95)00014-3; Schleimer RP, 1998, CLIN EXP ALLERGY, V28, P15; Smits HH, 2001, EUR J IMMUNOL, V31, P1055, DOI 10.1002/1521-4141(200104)31:4<1055::AID-IMMU1055>3.0.CO;2-7; SOMASSE T, 1996, J EXP MED, V184, P473; Symon FA, 1999, EUR J IMMUNOL, V29, P1324, DOI 10.1002/(SICI)1521-4141(199904)29:04<1324::AID-IMMU1324>3.3.CO;2-U; Yamane H, 2000, EUR J IMMUNOL, V30, P3171; Zingoni A, 1998, J IMMUNOL, V161, P547	23	40	41	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					815	821						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692110				2022-12-18	WOS:000172523800025
J	Branch, DW; Porter, TF; Paidas, MJ; Belfort, MA; Gonik, B				Branch, DW; Porter, TF; Paidas, MJ; Belfort, MA; Gonik, B			Obstetric uses of intravenous immunoglobulin: Successes, failures, and promises	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	IVIG Advisory Meeting	OCT 26-29, 2000	SANTA BARBARA, CALIFORNIA	Bayer Biol		intravenous immune globulin; fetal-neonatal alloimmune thrombocytopenia; fetal-neonatal alloimmune hemolysis; antiphospholipid syndrome; recurrent pregnancy loss	RECURRENT SPONTANEOUS-ABORTION; FETOMATERNAL ALLOIMMUNE THROMBOCYTOPENIA; RANDOMIZED CONTROLLED TRIAL; PLACEBO-CONTROLLED TRIAL; ANTIPHOSPHOLIPID SYNDROME; GAMMA-GLOBULIN; ANTENATAL MANAGEMENT; HEMOLYTIC-DISEASE; PREGNANCY LOSS; IMMUNE GLOBULIN	Intravenous immune globulin (IVIG) is approved for use in a number of conditions that may occur in obstetrical patients, including autoimmune thrombocytopenia and immune deficiency syndromes. IVIG also Is widely used in obstetrics for nonapproved indications, such as fetal-neonatal alloimmune thrombocytopenia, antiphospholipid syndrome, and recurrent miscarriage. This review critically analyzes the use of IVIG for these indications based on the best available information. The authors conclude IVIG is effective in the management of fetal-neonatal alloimmune thrombocytopenia. IVIG appears promising as a treatment for severe fetal-neonatal alloimmune hemolysis due to antierythrocyte antibodies. A prospective multicenter trial should be undertaken. IVIG is no more effective than heparin and low-dose aspirin In the treatment of pregnancies complicated by antiphospholipid syndrome but has not been adequately evaluated in refractory cases. Finally, pending convincing studies, IVIG is not effective and should not be used for the management of recurrent miscarriage.	Univ Utah, Hlth Sci Ctr, Dept Obstet & Gynecol, Salt Lake City, UT 84132 USA; IHC Perinatol Ctr, Salt Lake City, UT USA; NYU, Med Ctr, Dept Obstet & Gynecol, New York, NY 10016 USA; Wayne State Univ, Sch Med, Dept Obstet & Gynecol, Detroit, MI 48201 USA	Utah System of Higher Education; University of Utah; New York University; Wayne State University	Branch, DW (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Obstet & Gynecol, Room 2B200 Med Ctr, Salt Lake City, UT 84132 USA.							*AM COLL OBST GYN, 1999, PRACT B, V4; American College of Obstetricians and Gynecologists, 1999, ACOG PRACT B; BERLIN G, 1985, LANCET, V1, P1153; BLANCHETTE VS, 1990, BRIT J HAEMATOL, V74, P209, DOI 10.1111/j.1365-2141.1990.tb02567.x; BLANK M, 1991, P NATL ACAD SCI USA, V88, P3069, DOI 10.1073/pnas.88.8.3069; BRANCH DW, 1990, AM J OBSTET GYNECOL, V163, P210, DOI 10.1016/S0002-9378(11)90700-5; BRANCH DW, 1992, OBSTET GYNECOL, V80, P614; Branch DW, 2000, AM J OBSTET GYNECOL, V182, P122, DOI 10.1016/S0002-9378(00)70500-X; Bussel J B, 1996, J Matern Fetal Med, V5, P281, DOI 10.3109/14767059609025435; Bussel JB, 1997, NEW ENGL J MED, V337, P22, DOI 10.1056/NEJM199707033370104; Bussel JB, 1996, AM J OBSTET GYNECOL, V174, P1414, DOI 10.1016/S0002-9378(96)70582-3; BUSSEL JB, 1988, PEDIATR RES, V23, P337; Carreras LO, 2000, J AUTOIMMUN, V15, P163, DOI 10.1006/jaut.2000.0401; CHITKARA U, 1990, OBSTET GYNECOL, V76, P703; CHRISTIANSEN OB, 1995, HUM REPROD, V10, P2690, DOI 10.1093/oxfordjournals.humrep.a135769; Clark AL, 1999, OBSTET GYNECOL, V93, P437, DOI 10.1016/S0029-7844(98)00437-2; COULAM CB, 1995, AM J REPROD IMMUNOL, V34, P333, DOI 10.1111/j.1600-0897.1995.tb00960.x; Daya S, 1999, HUM REPROD UPDATE, V5, P475, DOI 10.1093/humupd/5.5.475; DELACAMARA C, 1988, NEW ENGL J MED, V318, P519; DOOREN MC, 1994, VOX SANG, V66, P253, DOI 10.1111/j.1423-0410.1994.tb00324.x; DWYER JM, 1992, NEW ENGL J MED, V326, P107; Gilman-Sachs A, 1999, AM J REPROD IMMUNOL, V41, P99; Gottvall T, 1995, ACTA OBSTET GYN SCAN, V74, P777, DOI 10.3109/00016349509021196; Jablonowska B, 1999, HUM REPROD, V14, P838, DOI 10.1093/humrep/14.3.838; Kaplan C, 1998, BRIT J HAEMATOL, V100, P62; Kutteh WH, 1996, AM J OBSTET GYNECOL, V174, P1584, DOI 10.1016/S0002-9378(96)70610-5; Kwak JYH, 1996, AM J REPROD IMMUNOL, V35, P363; Lima F, 1996, CLIN EXP RHEUMATOL, V14, P131; MARGULIES M, 1991, VOX SANG, V61, P181, DOI 10.1111/j.1423-0410.1991.tb00944.x; MUELLERECKHARDT C, 1989, LANCET, V1, P363; MUELLERECKHARDT G, 1991, LANCET, V337, P424, DOI 10.1016/0140-6736(91)91197-3; MUELLERECKHARDT G, 1989, VOX SANG, V56, P151, DOI 10.1111/j.1423-0410.1989.tb02018.x; MURPHY MF, 1994, TRANSFUSION MED, V4, P281, DOI 10.1111/j.1365-3148.1994.tb00265.x; Pattison NS, 2000, AM J OBSTET GYNECOL, V183, P1008, DOI 10.1067/mob.2000.106754; Perino A, 1997, HUM REPROD, V12, P2388, DOI 10.1093/humrep/12.11.2388; Pierangeli SS, 2000, J AUTOIMMUN, V15, P241, DOI 10.1006/jaut.2000.0420; Porter T F, 1997, Obstet Gynecol Surv, V52, P193, DOI 10.1097/00006254-199703000-00022; Rai R, 1997, BRIT MED J, V314, P253, DOI 10.1136/bmj.314.7076.253; REWALD E, 1985, LANCET, V2, P208; Ruiz JE, 1996, AM J REPROD IMMUNOL, V35, P370; Sacher R A, 1989, Obstet Gynecol Surv, V44, P25; SCOTT JR, 1988, AM J OBSTET GYNECOL, V159, P1055, DOI 10.1016/0002-9378(88)90411-5; Silver RM, 2000, AM J OBSTET GYNECOL, V182, P1233, DOI 10.1067/mob.2000.104841; SPINNATO JA, 1995, AM J OBSTET GYNECOL, V172, P690, DOI 10.1016/0002-9378(95)90595-2; Stephenson MD, 1998, AM J REPROD IMMUNOL, V39, P82; Tannirandorn Y, 1990, Baillieres Clin Haematol, V3, P289, DOI 10.1016/S0950-3536(05)80052-6; Ulm B, 1999, TRANSFUSION, V39, P1235, DOI 10.1046/j.1537-2995.1999.39111235.x; Voto LS, 1997, J PERINAT MED, V25, P85, DOI 10.1515/jpme.1997.25.1.85; Wilson WA, 1999, ARTHRITIS RHEUM, V42, P1309, DOI 10.1002/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F; ZINGSEM J, 1994, BRIT J OBSTET GYNAEC, V101, P1072	50	40	42	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4		S			S133	S138		10.1067/mai.2001.117821	http://dx.doi.org/10.1067/mai.2001.117821			6	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	487KL	11586281				2022-12-18	WOS:000171874200011
J	Annett, RD				Annett, RD			Assessment of health status and quality of life outcomes for children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma management behaviors; health outcomes; quality of life	CHILDHOOD; DISEASE; ILLNESS; QUESTIONNAIRES; ASSOCIATION; ADJUSTMENT; SEVERITY; EVERYDAY; STRESS; ISSUES	Increasing Interest has been directed to understanding health outcomes associated with pediatric disease processes, Including asthma, Salient areas of interest to health outcomes research include the child's and parent's subjective experience with the disease, a concept most often identified as quality of life. Quality of life reports fit within a broader scope of outcome measures embodied in the concept of children's health status. This article provides a description for how a child's health status can be understood theoretically, from a research perspective and in clinical practice, Emphasis is directed to how information obtained from both the child and parent is critical to outcomes research and clinical practice. Unique methodologic problems in assessing child health outcomes such as the challenge of understanding how the child's changing cognitive development may have an impact on responses to outcome measures and the role of contextual variables such as family characteristics are discussed. A variety of subjective and objective outcome measures currently exist that may be used in research on children with asthma, Practical guidelines for implementing outcomes research for children with asthma are presented. Clinical researchers must use multiple outcome measures for assessing asthma characteristics, including psychosocial characteristics which have an impact on adherence and treatment regimens.	Univ New Mexico, Hlth Sci Ctr, Dept Pediat, Pediat Pulm Ctr, Albuquerque, NM 87131 USA	University of New Mexico; University of New Mexico's Health Sciences Center	Annett, RD (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Pediat, Pediat Pulm Ctr, Albuquerque, NM 87131 USA.							Achenbach T.M., 1983, MANUAL CHILD BEHAVIO; Beausoleil JL, 1997, PEDIATRICS, V99, P40, DOI 10.1542/peds.99.1.40; Bender BG, 2000, ARCH PEDIAT ADOL MED, V154, P706, DOI 10.1001/archpedi.154.7.706; BIBACE R, 1980, PEDIATRICS, V66, P912; Bonner MJ, 1996, ADV CLIN CHILD PSYCH, V18, P231; BURBACH DJ, 1986, HEALTH PSYCHOL, V5, P307, DOI 10.1037/0278-6133.5.3.307; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CHRISTIE M, 1994, ASSESSMENT QUALITY L, P157; CHRISTIE MJ, 1993, PSYCHOSOM MED, V55, P541, DOI 10.1097/00006842-199311000-00010; Cicchetti D.V., 1994, PSYCHOL ASSESSMENTS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; COHEN S, 1993, J PERS SOC PSYCHOL, V64, P131, DOI 10.1037/0022-3514.64.1.131; COHEN S, 1991, PSYCHOL BULL, V109, P5, DOI 10.1037/0033-2909.109.1.5; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT, V18; EISEN M, 1980, RAND CORPORATION PUB; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FITZPATRICK R, 1992, BRIT MED J, V305, P1074, DOI 10.1136/bmj.305.6861.1074; FLETCHER JM, 1991, AM PSYCHOL, V46, P1267, DOI 10.1037/0003-066X.46.12.1267; FRANK SH, 1992, TOOLS PRIMARY CARE R, P229; FRENCH DJ, 1994, QUAL LIFE RES, V3, P215, DOI 10.1007/BF00435387; FRITZ G, 1994, J ASTHMA, V31, P473, DOI 10.3109/02770909409089489; Fritz GK, 1996, J PEDIATR PSYCHOL, V21, P153, DOI 10.1093/jpepsy/21.2.153; Fritz GK, 1996, J AM ACAD CHILD PSY, V35, P1033, DOI 10.1097/00004583-199608000-00014; Gavin LA, 1999, J PEDIATR PSYCHOL, V24, P355, DOI 10.1093/jpepsy/24.4.355; GOLDMAN SL, 1991, J PEDIATR PSYCHOL, V16, P747, DOI 10.1093/jpepsy/16.6.747; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; HARBECKWEBER C, 1993, ANN CHILD DEV, V9, P133; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; JUNIPER EF, 1994, PAEDIAT ASTHMA QUALI; Kabacoff RI., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KAZDIN AE, 1990, J CHILD PSYCHOL PSYC, V31, P121, DOI 10.1111/j.1469-7610.1990.tb02276.x; MACLEAN WE, 1992, J PEDIATR PSYCHOL, V17, P159, DOI 10.1093/jpepsy/17.2.159; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; McQuaid EL, 1996, PEDIATR PULM, V22, P357, DOI 10.1002/(SICI)1099-0496(199612)22:6<357::AID-PPUL4>3.0.CO;2-G; Moos RH., 2002, FAMILY ENV SCALE MAN; MRAZEK DA, 1987, J AM ACAD CHILD PSY, V26, P516, DOI 10.1097/00004583-198707000-00009; Mrazek DA, 1998, J CHILD PSYCHOL PSYC, V39, P247, DOI 10.1111/1469-7610.00318; PANTELL RH, 1987, J CHRON DIS, V40, pS99, DOI 10.1016/S0021-9681(87)80039-5; Peterson L, 1999, PSYCHOL ASSESSMENT, V11, P458, DOI 10.1037/1040-3590.11.4.458; Piaget J., 1952, ORIGINS INTELLIGENCE, DOI [10.1037/11494-000, DOI 10.1037/11494-000]; Reynolds C.R., 1985, REVISED CHILDRENS MA; Rietveld S, 1996, J ASTHMA, V33, P221, DOI 10.3109/02770909609055363; Rietveld S, 1998, ADV CLIN CHILD PSYCH, V20, P153; ROGOSA DR, 1985, PSYCHOMETRIKA, V50, P203, DOI 10.1007/BF02294247; Shapiro ES, 1999, PSYCHOL ASSESSMENT, V11, P448, DOI 10.1037/1040-3590.11.4.448; Shasha M., 1999, CHILDRENS SERVICES S, V2, P225; SPIRITO A, 1988, J PEDIATR PSYCHOL, V13, P555, DOI 10.1093/jpepsy/13.4.555; SPIRITO A, 1995, J AM ACAD CHILD PSY, V34, P283, DOI 10.1097/00004583-199503000-00011; Stein REK, 1990, MANUAL PERSONAL ADJU; TOWNSEND M, 1991, ANN ALLERGY, V67, P403; WALKER DK, 1990, J DEV BEHAV PEDIATR, V11, P116; WILSON SR, 1993, J PEDIATR PSYCHOL, V18, P63, DOI 10.1093/jpepsy/18.1.63	52	40	41	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5		S			S473	S481		10.1067/mai.2001.114949	http://dx.doi.org/10.1067/mai.2001.114949			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	435RD	11344377				2022-12-18	WOS:000168894200006
J	Petersen, A; Suck, R; Hagen, S; Cromwell, O; Fiebig, H; Becker, WM				Petersen, A; Suck, R; Hagen, S; Cromwell, O; Fiebig, H; Becker, WM			Group 13 grass allergens: Structural variability between different grass species and analysis of proteolytic stability	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cross-reactivity; grass pollen; group 13 allergens; IgE binding; immunoblotting; polygalacturonase; timothy grass	PHLEUM-PRATENSE POLLEN; JAPANESE CEDAR POLLEN; GROUP-V ALLERGENS; MAJOR ALLERGEN; P-I; MOLECULAR-CLONING; ASPERGILLUS-NIGER; COMPLEMENTARY-DNA; PROTEINS; NITROCELLULOSE	Background: Determination of the allergen composition of an extract is essential for the improvement of hyposensitization therapy. Surprisingly, although grass pollen extracts have been studied intensively for 20 years, a further major allergen, Phl p 13, was detected recently in timothy grass pollen. Objectives: We sought to determine the occurrence and importance of group 13 allergens in various grass species and to investigate their proteolytic stability. Methods: The group 13 allergens were determined by means of 2-dimensional PAGE blotting with patient sera and group 13-specific mAbs. The allergens were isolated chromatographically from several pollen extracts and analyzed by means of microsequencing. Cross-reactivity among various grass species was studied by using Western blots and immunoblot inhibition tests. The stability of the allergens was tested under defined extraction conditions. Results: Group 13 allergens are detectable in all common grasses and show IgE cross-reactivity among them. The allergenic components were identified in the neutral pH range with molecular masses of 50 to 60 kd, and in the case of Phl p 13, maximal binding of the isoforms was observed at 55 kd and at an isoelectric point of 6 to 7.5, Protein sequencing clearly confirms structural identities between different grass species, although individual variations are found. If low-molecular-mass components were depleted by means of gel filtration, a rapid degradation of group 13 allergens was observed. This is in contrast to other pollen allergens described thus far. Conclusion: Group 13 allergens are widespread and are major allergens in the grasses. Predicted from their primary structures, these allergens are polygalacturonases, This class of enzymes is already known from microorganisms, and these enzymes are recognized as potential inducers of asthma, Our studies indicate that the group 13 allergens show a considerable microheterogeneity and degradation, especially after depletion of low-molecular-mass components, One has to be aware of this pivotal fact when soluble grass pollen extracts are prepared for diagnostics and hyposensitization therapy.	Forschungszentrum Borstel, Borstel, Germany; Allergopharma Joachim Ganzer KG, Reinbek, Germany	Forschungszentrum Borstel; Allergopharma	Petersen, A (corresponding author), Res Ctr Borstel, Parkallee 22, D-23845 Borstel, Germany.							Bufe A, 1998, AM J RESP CRIT CARE, V157, P1269, DOI 10.1164/ajrccm.157.4.9709040; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; BUSSINK HJD, 1990, FEBS LETT, V273, P127, DOI 10.1016/0014-5793(90)81066-W; EKRAMODDOULLAH AKM, 1983, MOL IMMUNOL, V20, P465, DOI 10.1016/0161-5890(83)90027-5; Fahlbusch B, 1998, CLIN EXP ALLERGY, V28, P799; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; Hadfield KA, 1998, PLANT PHYSIOL, V117, P337, DOI 10.1104/pp.117.2.337; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P309, DOI 10.1111/j.1365-2222.1991.tb01662.x; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P297, DOI 10.1111/j.1365-2222.1991.tb01661.x; NAMBA M, 1994, FEBS LETT, V353, P124, DOI 10.1016/0014-5793(94)01022-6; NIOGRET MF, 1991, PLANT MOL BIOL, V17, P1155, DOI 10.1007/BF00028732; OHTSUKI T, 1995, ALLERGY, V50, P483, DOI 10.1111/j.1398-9995.1995.tb01183.x; PETERSEN A, 1995, J ALLERGY CLIN IMMUN, V95, P987, DOI 10.1016/S0091-6749(95)70099-4; PETERSEN A, 1992, INT ARCH ALLERGY IMM, V98, P105, DOI 10.1159/000236172; PETERSEN A, 1995, INT ARCH ALLERGY IMM, V108, P49, DOI 10.1159/000237117; PETERSEN A, 1997, PROGR ALLERGY CLIN I, V4, P139; Sander I, 1998, J ALLERGY CLIN IMMUN, V102, P256, DOI 10.1016/S0091-6749(98)70109-5; Sen D, 1998, CLIN EXP ALLERGY, V28, P363, DOI 10.1046/j.1365-2222.1998.00244.x; Soldatova LN, 2000, J ALLERGY CLIN IMMUN, V105, P482, DOI 10.1067/mai.2000.104549; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1111/j.1365-2222.1996.tb00641.x; Suck R, 1999, J IMMUNOL METHODS, V229, P73, DOI 10.1016/S0022-1759(99)00101-5; Suck R, 2000, CLIN EXP ALLERGY, V30, P324, DOI 10.1046/j.1365-2222.2000.00843.x; Suck R, 2000, CLIN EXP ALLERGY, V30, P1395, DOI 10.1046/j.1365-2222.2000.00886.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896	32	40	42	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					856	862						7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	434JX	11344353				2022-12-18	WOS:000168812300014
J	Katoh, S; Matsumoto, N; Fukushima, K; Mukae, H; Kadota, J; Kohno, S; Matsukura, S				Katoh, S; Matsumoto, N; Fukushima, K; Mukae, H; Kadota, J; Kohno, S; Matsukura, S			Elevated chemokine levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophilic pneumonia; eotaxin; RANTES; monocyte chemotactic protein 1; macrophage inflammatory protein 1 beta; IL-8; bronchoalveolar lavage fluid; eosinophil	MONOCYTE CHEMOATTRACTANT PROTEIN-1; IL-1 RECEPTOR ANTAGONIST; GUINEA-PIG MODEL; ALLERGIC INFLAMMATION; TISSUE EOSINOPHILIA; CYTOKINE RANTES; T-LYMPHOCYTES; LUNG-DISEASES; IN-VIVO; EOTAXIN	Background: Allergic lung inflammation is caused by accumulation and activation of different leukocyte subsets, such as eosinophils and T lymphocytes, in the lung, The chemokines are a large group of chemotactic cytokines that regulate leukocyte trafficking and may play an important role in allergic lung inflammation. Objective: The purpose of this study was to evaluate the role of various chemokines, including eotaxin, RANTES, monocyte chemotactic protein (MCP)-1, macrophage inflammatory protein (MIP)-1 beta, and IL-8 in the pathogenesis of eosinophilic pneumonia (EP). Methods: The concentrations of eotaxin, RANTES, MCP-1, MIP-1 beta, and IL-8 in bronchoalveolar lavage fluid (BALF) were measured by using ELISA in 15 patients with EP, 10 with idiopathic pulmonary fibrosis, 10 with sarcoidosis, and 11 healthy volunteers. Results: Eotaxin in BALF was high only in patients with EP, and its level correlated significantly with the number of eosinophils in BALF of patients with EP and healthy volunteers. MCP-1 and MIP-1 beta in BALF were preferentially increased in patients with EP. There was a significant correlation between MCP-1 levels and the number of macrophages in BALF of patients with EP and healthy volunteers. Conclusion: Our findings suggest that these CC chemokines contribute to the pathogenesis of EP through the specific recruitment of leukocyte subsets in the lung.	Miyazaki Med Coll, Dept Internal Med 3, Kiyotake, Miyazaki 8891692, Japan; Nagasaki Perfecture Tarami Hosp, Nagasaki, Japan; Nagasaki Univ, Sch Med, Dept Internal Med 2, Nagasaki 852, Japan	University of Miyazaki; Nagasaki University	Katoh, S (corresponding author), Miyazaki Med Coll, Dept Internal Med 3, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.							Alam R, 1997, J ALLERGY CLIN IMMUN, V99, P273, DOI 10.1016/S0091-6749(97)70042-3; ALBERA C, 1995, EUR RESPIR J, V8, P1281, DOI 10.1183/09031936.95.08081281; ALLEN JN, 1994, AM J RESP CRIT CARE, V150, P1423, DOI 10.1164/ajrccm.150.5.7952571; ALLEN JN, 1989, NEW ENGL J MED, V321, P569, DOI 10.1056/NEJM198908313210903; Allen JN, 1996, J ALLERGY CLIN IMMUN, V97, P1366, DOI 10.1016/S0091-6749(96)70206-3; CARR MW, 1994, P NATL ACAD SCI USA, V91, P3652, DOI 10.1073/pnas.91.9.3652; CARRINGT.CB, 1969, NEW ENGL J MED, V280, P787, DOI 10.1056/NEJM196904102801501; Chensue SW, 1996, J IMMUNOL, V157, P4602; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; GILAT D, 1994, J IMMUNOL, V153, P4899; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gunn MD, 1997, J IMMUNOL, V158, P376; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kadota J, 1996, CLIN EXP IMMUNOL, V103, P461; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; Katoh S, 1999, ALLERGY, V54, P1286, DOI 10.1034/j.1398-9995.1999.00277.x; KeaneMyers A, 1997, J IMMUNOL, V158, P2042; Kita H, 1996, AM J RESP CRIT CARE, V153, P1437, DOI 10.1164/ajrccm.153.4.8616578; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; WALKER C, 1994, AM J RESP CRIT CARE, V150, P1038, DOI 10.1164/ajrccm.150.4.7921434	29	40	40	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2000	106	4					730	736		10.1067/mai.2000.109827	http://dx.doi.org/10.1067/mai.2000.109827			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	365ZP	11031344	Bronze			2022-12-18	WOS:000089980600017
J	Noirey, N; Rougier, N; Andre, C; Schmitt, D; Vincent, C				Noirey, N; Rougier, N; Andre, C; Schmitt, D; Vincent, C			Langerhans-like dendritic cells generated from cord blood progenitors internalize pollen allergens by macropinocytosis, and part of the molecules are processed and can activate autologous naive T lymphocytes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; antigen-presenting cell; dendritic cells; Langerhans' cells; recombinant Bet v 1; recombinant Phl p 1; internalization; macropinocytosis; primary response	SUBLINGUAL-SWALLOW IMMUNOTHERAPY; STANDARDIZED 5-GRASS-POLLEN EXTRACT; PLACEBO-CONTROLLED EVALUATION; DOUBLE-BLIND; CONTROLLED TRIAL; ORAL HYPOSENSITIZATION; GRASS-POLLEN; RECEPTOR; ASTHMA; RHINITIS	Background: The safety and efficacy of sublingual immunotherapy have been demonstrated in moderate allergic asthma and seasonal rhinitis. However, not much is known about the precise mechanism of action of the allergen when it crosses the oral mucosa. Objective: To define this mechanism, we investigated the role of Langerhans' cells in the capture and internalization of allergens. Methods: We generated dendritic cells in vitro with the phenotypic characteristics of Langerhans-like dendritic cells (LLDCs) from cord blood CD34(+) progenitors. We used two recombinant major allergens: Bet v 1 and Phl p 1 labeled with FITC. Results: Internalization of allergens and control proteins was dose- and time-dependent and related to the immature state of the cells. LLDCs internalized allergens with a high efficiency in comparison with control molecules. Allergens were only internalized by macropinocytosis, as demonstrated by the use of various inhibitors. Addition of intracellular pH-modifying molecules indicated that only a part of the allergens was accumulated in acidic vesicles, whereas the majority remained in other cytoplasmic structures. Pulse-chase experiments calculated a half-life of 4 hours, suggesting that part of the molecules were not metabolized in the lysosome. Allergen internalization by LLDCs might be followed by processing in some experiments, as demonstrated by activation of autologous T lymphocytes in 4 of 9 experiments. Conclusion: These elements showed that Langerhans' cells present in mucosa might play an active role in immune responses to allergens.	Hop Edouard Herriot, INSERM, U346, Lab Rech Peau Humaine & Immun, F-69437 Lyon 03, France; Stallergenes SA, Antony, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); Stallergenes Greer	Vincent, C (corresponding author), Hop Edouard Herriot, INSERM, U346, Lab Rech Peau Humaine & Immun, F-69437 Lyon 03, France.							Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Brossart P, 1997, BLOOD, V90, P1594, DOI 10.1182/blood.V90.4.1594.1594_1594_1599; Caux C, 1998, EUR J DERMATOL, V8, P375; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; Gaudriault G, 1997, J BIOL CHEM, V272, P2880, DOI 10.1074/jbc.272.5.2880; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; KASHIHARA M, 1986, J INVEST DERMATOL, V87, P602, DOI 10.1111/1523-1747.ep12455849; Marone G, 1998, IMMUNOL TODAY, V19, P5, DOI 10.1016/S0167-5699(97)01187-0; Matsuno K, 1996, J EXP MED, V183, P1865, DOI 10.1084/jem.183.4.1865; MAURER D, 1995, J IMMUNOL, V154, P6285; MOLL H, 1993, IMMUNOL TODAY, V14, P383, DOI 10.1016/0167-5699(93)90138-B; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Novak N, 1999, ALLERGY, V54, P792, DOI 10.1034/j.1398-9995.1999.00101.x; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; ROUGIER N, 1998, J INVEST DERMATOL, V110, P101; ROUGIER N, 2000, IN PRESS TOXICOLOGY; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Siegel S, 1956, NONPARAMETRIC STAT B; SOUSA CRE, 1993, J EXP MED, V178, P509, DOI 10.1084/jem.178.2.509; Spangfort MD, 1997, INT ARCH ALLERGY IMM, V113, P243, DOI 10.1159/000237559; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; TAUDORF E, 1985, ALLERGY, V40, P321, DOI 10.1111/j.1398-9995.1985.tb00243.x; Valladeau J, 1999, EUR J IMMUNOL, V29, P2695, DOI 10.1002/(SICI)1521-4141(199909)29:09<2695::AID-IMMU2695>3.3.CO;2-H; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WILEMAN T, 1984, BIOCHEM J, V220, P665, DOI 10.1042/bj2200665; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	30	40	43	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1194	1201		10.1067/mai.2000.106545	http://dx.doi.org/10.1067/mai.2000.106545			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	327EX	10856155				2022-12-18	WOS:000087781800022
J	Aghayan-Ugurluoglu, R; Ball, T; Vrtala, S; Schweiger, C; Kraft, D; Valenta, R				Aghayan-Ugurluoglu, R; Ball, T; Vrtala, S; Schweiger, C; Kraft, D; Valenta, R			Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: A study performed with purified recombinant pollen allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant pollen allergens; allergic conjunctivitis; allergen-specific IgA and IgE; mucosal atopy	GRASS PHLEUM-PRATENSE; IMMUNOGLOBULIN-E ANTIBODIES; ORAL IMMUNOTHERAPY; VERNAL CONJUNCTIVITIS; CELIAC-DISEASE; MAJOR ALLERGEN; EYE DISEASE; BIRCH; CELLS; RHINOCONJUNCTIVITIS	Background: Trees and grass pollen allergens represent potent elicitors of allergic rhinoconjunctivitis and asthma. Little is known regarding the presence of allergen-specific IgA antibodies in sera and tears and their association with IgE responses in patients with allergic conjunctivitis. Objective: The purpose of this study was to compare the specificities of IgE and IgA antibodies in sera and tears of pollen-allergic patients with conjunctivitis by using purified recombinant pollen allergens. Methods: Sera and tears collected from 23 pollen-allergic and from 23 nonatopic individuals were analyzed for IgE and IgA reactivity to nitrocellulose-blotted birch and timothy grass pollen extracts. In addition, we determined the specificities of IgE, IgG(1-4), and IgA antibodies with use of a panel of purified recombinant pollen allergens (timothy grass: rPhl p 1, rPhl p 2, rPhl p 5; birch: rBet v 1, rBet v 2) in serum and tear samples by immunoblotting and ELISA. Statistical analyses of data were performed by t test and Mann Whitney U test. Results: Serum and tears of many of the pollen-allergic individuals with conjunctivitis exhibited specificity for the very same pollen allergens. No allergen-specific IgE antibodies were detected in tears of nonatopic individuals. IgA antibodies in sera and tears of patients with allergic conjunctivitis were mainly directed against nonallergenic moieties and showed specificities that were significantly different from those of IgE antibodies. Conclusion: The dissociation of IgE and IgA responses and the lack of allergen-specific IgA antibodies in mucosal secretions leg, tears) may contribute to allergic manifestations in target organs of atopy. Induction of allergen-specific IgA antibodies may hence be considered as a promising strategy for the treatment of mucosal forms of atopy.	Univ Vienna, Dept Pathophysiol, Vienna, Austria; Univ Vienna, Clin Inst Med & Chem Lab Diagnost, Vienna, Austria	University of Vienna; University of Vienna	Aghayan-Ugurluoglu, R (corresponding author), Univ Vienna, Dept Pathophysiol, Waehringer Guertel 18, Vienna, Austria.			Vrtala, Susanne/0000-0003-4250-8243; Valenta, Rudolf/0000-0001-5944-3365				Bagnasco M, 1997, CLIN EXP ALLERGY, V27, P737; BALLOW M, 1984, J ALLERGY CLIN IMMUN, V73, P376, DOI 10.1016/0091-6749(84)90411-1; BALLOW M, 1980, J ALLERGY CLIN IMMUN, V66, P112, DOI 10.1016/0091-6749(80)90057-3; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BUTRUS SI, 1990, OPHTHALMOLOGY, V97, P1678; CIPRANDI G, 1993, J ALLERGY CLIN IMMUN, V91, P783, DOI 10.1016/0091-6749(93)90198-O; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; Fujishima H, 1997, CLIN EXP ALLERGY, V27, P372; GARCIAORTEGA P, 1989, CLIN EXP ALLERGY, V19, P529, DOI 10.1111/j.1365-2222.1989.tb02428.x; Goodman JS, 1998, INT ARCH ALLERGY IMM, V116, P177, DOI 10.1159/000023943; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; HoffmannSommergruber K, 1996, CLIN EXP ALLERGY, V26, P79, DOI 10.1111/j.1365-2222.1996.tb00059.x; Kay A.B., 1997, ALLERGY ALLERGIC DIS; KELLY CP, 1991, DIGEST DIS SCI, V36, P743, DOI 10.1007/BF01311231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Metz DP, 1996, J ALLERGY CLIN IMMUN, V98, P686, DOI 10.1016/S0091-6749(96)70103-3; Metz DP, 1997, J ALLERGY CLIN IMMUN, V100, P817, DOI 10.1016/S0091-6749(97)70279-3; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; Montan PG, 1996, CLIN EXP ALLERGY, V26, P1125, DOI 10.1046/j.1365-2222.1996.d01-263.x; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258, DOI 10.1016/S0091-6749(98)70391-4; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; OMAHONY S, 1991, GUT, V32, P29, DOI 10.1136/gut.32.1.29; SOMPOLINSKY D, 1984, INT ARCH ALLER A IMM, V75, P317, DOI 10.1159/000233640; SULLIVAN DA, 1994, HDB MUCOSAL IMMUNOLO, P569; TAUDORF E, 1994, ALLERGY, V49, P760, DOI 10.1111/j.1398-9995.1994.tb02099.x; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URBANEK R, 1990, EUR J PEDIATR, V149, P545, DOI 10.1007/BF01957689; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; van Ginkel FW, 1999, J IMMUNOL, V163, P1951; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4	40	40	40	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					803	813		10.1067/mai.2000.104782	http://dx.doi.org/10.1067/mai.2000.104782			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756233	Bronze			2022-12-18	WOS:000086604100021
J	Majori, M; Poletti, V; Curti, A; Corradi, M; Falcone, F; Pesci, A				Majori, M; Poletti, V; Curti, A; Corradi, M; Falcone, F; Pesci, A			Bronchoalveolar lavage in bronchiolitis obliterans organizing pneumonia primed by radiation therapy to the breast	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						bronchiolitis; obliterans organizing pneumonia; bronchoalveolar lavage; radiation therapy; breast cancer	GROWTH-FACTOR-BETA; MAST-CELLS; HYPERSENSITIVITY PNEUMONITIS; PULMONARY FIBROSIS; LUNG; RADIOTHERAPY; IRRADIATION; CARCINOMA; DISEASE; INJURY	Background: Growing evidence indicates that unilateral lung irradiation for breast cancer may "prime" the development of migratory lung infiltrates with histologic features of bronchiolitis obliterans organizing pneumonia, Objective: Our purpose was to evaluate the cytologic and immunocytologic features of bronchoalveolar lavage in this condition. Methods: We analyzed the profile bronchoalveolar lavage cell differentials and lymphocyte subpopulations of 11 women with bronchiolitis obliterans organizing pneumonia syndrome after radiation therapy for breast cancer in comparison to 9 healthy women. Results: The bronchoalveolar lavage analysis demonstrated a significant increase in the percentage of lymphocytes (36.7% +/- 5.4% vs 8.6% +/- 1.1%, P =.0002), neutrophils (3.8% +/- 1.2% vs 0.6% +/- 0.2%, P =.005), eosinophils (2.4% +/- 1% vs 0.3% +/- 0.1 %, P =.01), and mast cells (1.4% +/- 0.6% vs 0.1% +/- 0.02%, P =.05) with a significant decrease in the percentage of macrophages (56.1% +/- 6% vs 90.3% +/- 1.4%, P =.0002) in patients with bronchiolitis obliterans organizing pneumonia compared with the control subjects. The percentage of CD3(+) cells was significantly increased in patients with bronchiolitis obliterans organizing pneumonia (93.7% +/- 1.3% vs 70.9% +/- 4%, P =.0004), with a significant decrease in CD4(+) cells (32.7% +/- 4.7% vs 55.4% +/- 2.6%, P =.002) and a significant increase in CD8(+) cells (61.2% +/- 4.8 % vs 37.5 % +/- 2.9%, P =.003) in comparison to control subjects. The CD4/CD8 ratio was significantly reduced in patients with bronchiolitis obliterans organizing pneumonia compared with control subjects (0.6% +/- 0.1% vs 1.5% +/-i 0.1%, P=.001), Conclusion: These data add to the view that unilateral lung irradiation for breast cancer may "prime" the development of a syndrome quite similar to idiopathic bronchiolitis obliterans organizing pneumonia.	Univ Parma, Ist Clin Malattie Apparato Resp, I-43100 Parma, Italy; Osped Maggiore Bologna, Dipartimento Malattie Torace, Bologna, Italy	University of Parma; AUSL di Bologna	Pesci, A (corresponding author), Univ Parma, Ist Clin Malattie Apparato Resp, Via Rasori 10, I-43100 Parma, Italy.		Poletti, Venerino/K-8821-2016	Poletti, Venerino/0000-0002-8634-2284; corradi, massimo/0000-0002-2808-4184; Majori, Maria/0000-0001-7453-7247				ALDENBORG F, 1993, AM J RESP CELL MOL, V8, P112, DOI 10.1165/ajrcmb/8.1.112; Anscher MS, 1997, INT J RADIAT ONCOL, V37, P253, DOI 10.1016/S0360-3016(96)00529-9; ANSCHER MS, 1994, INT J RADIAT ONCOL, V30, P671, DOI 10.1016/0360-3016(92)90954-G; Arbetter KR, 1999, MAYO CLIN PROC, V74, P27, DOI 10.4065/74.1.27; Bai Yun-Hong, 1993, Journal of Environmental Pathology Toxicology and Oncology, V12, P199; BAYLE JY, 1995, EUR RESPIR J, V8, P322, DOI 10.1183/09031936.95.08020322; Bentzen SM, 1996, J NATL CANCER I, V88, P918, DOI 10.1093/jnci/88.13.918; BIENENSTOCK J, 1987, AM REV RESPIR DIS, V135, pS5; CHERNIACK RM, 1994, AM J RESP CRIT CARE, V150, P1169, DOI 10.1164/ajrccm.150.4.7921454; COSTABEL U, 1992, EUR RESPIR J, V5, P791; CRESTANI B, 1995, EUR RESPIR J, V8, P318, DOI 10.1183/09031936.95.08020318; Crestani B, 1998, AM J RESP CRIT CARE, V158, P1929, DOI 10.1164/ajrccm.158.6.9711036; DAVIS SD, 1992, AM J ROENTGENOL, V159, P1157, DOI 10.2214/ajr.159.6.1442375; Enelow RI, 1998, J CLIN INVEST, V102, P1653, DOI 10.1172/JCI4174; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; FINKELSTEIN JN, 1994, INT J RADIAT ONCOL, V28, P621, DOI 10.1016/0360-3016(94)90187-2; GROSS NJ, 1977, ANN INTERN MED, V86, P81, DOI 10.7326/0003-4819-86-1-81; HALLMAN M, 1990, AM REV RESPIR DIS, V141, P998, DOI 10.1164/ajrccm/141.4_Pt_1.998; KAUFMAN J, 1990, CHEST, V97, P1243, DOI 10.1378/chest.97.5.1243; Martin C, 1999, EUR RESPIR J, V13, P727, DOI 10.1034/j.1399-3003.1999.13d05.x; MORGAN GW, 1995, INT J RADIAT ONCOL, V31, P361, DOI 10.1016/0360-3016(94)00477-3; Pesci A, 1996, CHEST, V110, P383, DOI 10.1378/chest.110.2.383; Poletti V, 1996, EUR RESPIR J, V9, P2513, DOI 10.1183/09031936.96.09122513; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; ROBERTS CM, 1993, ANN INTERN MED, V118, P696, DOI 10.7326/0003-4819-118-9-199305010-00006; ROCKWELL S, 1998, PULMONARY DIS DISORD, P1099; ROSIELLO RA, 1990, CLIN CHEST MED, V11, P65; RUBIN P, 1995, INT J RADIAT ONCOL, V33, P99, DOI 10.1016/0360-3016(95)00095-G; Sabbioni MEE, 1999, SUPPORT CARE CANCER, V7, P149, DOI 10.1007/s005200050245; Salinas F V, 1995, Semin Respir Infect, V10, P143; SOLER P, 1987, THORAX, V42, P565, DOI 10.1136/thx.42.8.565; TRENTIN L, 1990, J IMMUNOL, V145, P2147; vanLaar JM, 1997, RESP MED, V91, P241, DOI 10.1016/S0954-6111(97)90046-9; WATANABE S, 1974, LAB INVEST, V31, P555	34	40	40	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				239	244		10.1016/S0091-6749(00)90071-X	http://dx.doi.org/10.1016/S0091-6749(00)90071-X			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	285RQ	10669842				2022-12-18	WOS:000085402200006
J	Cuesta-Herranz, J; Lazaro, M; Martinez, A; Figueredo, E; Palacios, R; de-Las-Heras, M; Martinez, J				Cuesta-Herranz, J; Lazaro, M; Martinez, A; Figueredo, E; Palacios, R; de-Las-Heras, M; Martinez, J			Pollen allergy in peach-allergic patients: Sensitization and cross-reactivity to taxonomically unrelated pollens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fruit allergy; peach; allergy; food pollen; cross-reactivity; profilin; carbohydrate determinants	BIRCH-POLLEN; SUNFLOWER POLLEN; KIWI-FRUIT; IDENTIFICATION; PROFILIN; SENSITIVITY; POLLINOSIS; MELON; APPLE; IGE	Background: Fruit allergy has been attributed to cross-reactive IgE to pollens and has been associated with a particular pollen sensitization. Objective: The aim of the study was to evaluate sensitization to several taxonomically unrelated pollens in peach- and pollen-allergic patients and to study cross-reactivity between them. Methods: One hundred sixty-five patients were evaluated: 70 peach- allergic patients together with 95 pollen-allergic patients (control group). Pollen skin tests in duplicate were performed to 5 grasses, 8 trees, and 7 weeds, Cross-reactivity between peach and taxonomically diverse pollens was determined by radioallergosorbent inhibition and Western blot inhibition tests, Experiments were also carried out after preadsorption of the sera with purified natural profilin. Results: The skin test results revealed that peach-allergic patients frequently reacted to most pollens-grasses, weeds, and trees-even when some of these are not found in our geographic area. There was a statistically significant increase in sensitization frequency to most trees and weeds, with a statistically higher occurrence of asthma (odds ratio 2.98, 95% confidence interval 1.46-6.09). Inhibition test results provided evidence that taxonomically unrelated grasses, weeds, and trees produced various and substantial degrees of inhibition in specific IgE to peach and that the peach extract elicited strong inhibitions to those pollens. Profilin was found to be a relevant cross-reactive antigen in these patients. Conclusion: The results of this study provide evidence that peach allergy is linked to sensitization to several taxonomically unrelated pollens. This is attributable to the ubiquitous nature of the IgE binding determinants-such as profilins-between peach and taxonomically unrelated pollens.	Bial Aristegui, Dept Res & Dev, Bilbao, Spain; Univ Autonoma Madrid, Fundacion Jimenex Diaz, Dept Allergy, Servicio Alergia, Madrid 28040, Spain	Autonomous University of Madrid	Cuesta-Herranz, J (corresponding author), Univ Autonoma Madrid, Fundacion Jimenex Diaz, Dept Allergy, Servicio Alergia, C Reyes Catolicos 2, Madrid 28040, Spain.			MARTINEZ, JORGE/0000-0001-7002-0056				Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Asturias JA, 1998, MOL IMMUNOL, V35, P469, DOI 10.1016/S0161-5890(98)00036-4; Babich M, 1996, BIOCHEM BIOPH RES CO, V218, P125, DOI 10.1006/bbrc.1996.0022; Baldo B. A., 1984, Advances in Cereal Science and Technology, V6, P289; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P102; Cuesta-Herranz J, 1998, ALLERGY, V53, P78, DOI 10.1111/j.1398-9995.1998.tb03777.x; Cuesta-Herranz J, 1998, J ALLERGY CLIN IMMUN, V102, P275, DOI 10.1016/S0091-6749(98)70096-X; DREBORG S, 1983, ALLERGY, V38, P167, DOI 10.1111/j.1398-9995.1983.tb01602.x; *EUR AC ALL CLIN I, 1989, ALLERGY S, V44, P13; HEIIS S, 1996, J ALLERGY CLIN IMMUN, V98, P938; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; JIMENEZ A, 1994, INT ARCH ALLERGY IMM, V105, P297, DOI 10.1159/000236772; Juhlin-Dannfelt C., 1948, ACTA MED SCAND, V26, P563; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARO M, 1994, REV ESP ALERGOL IMMU, V9, P66; Ortiz JCG, 1996, J INVEST ALLERG CLIN, V6, P378; Ortolani C, 1998, ALLERGY, V53, P58, DOI 10.1111/j.1398-9995.1998.tb04963.x; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; Pastorello EA, 1998, ALLERGY, V53, P48, DOI 10.1111/j.1398-9995.1998.tb04960.x; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; SUBIZA J, 1995, J ALLERGY CLIN IMMUN, V96, P15, DOI 10.1016/S0091-6749(95)70028-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; Voitenko V, 1997, ALLERGY, V52, P136, DOI 10.1111/j.1398-9995.1997.tb00967.x; WIDE L, 1967, LANCET, V2, P1105	35	40	41	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				688	694		10.1016/S0091-6749(99)70343-X	http://dx.doi.org/10.1016/S0091-6749(99)70343-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482847	Bronze			2022-12-18	WOS:000082870000035
J	del Pozo, V; Arrieta, I; Tunon, T; Cortegano, I; Gomez, B; Cardaba, B; Gallardo, S; Rojo, M; Renedo, G; Palomino, P; Tabar, AI; Lahoz, C				del Pozo, V; Arrieta, I; Tunon, T; Cortegano, I; Gomez, B; Cardaba, B; Gallardo, S; Rojo, M; Renedo, G; Palomino, P; Tabar, AI; Lahoz, C			Immunopathogenesis of human gastrointestinal infection by Anisakis simplex	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anisakiasis; anisakis simplex allergy; T-H2 response; cytokines; eosinophilic gastroenteritis; eosinophils	ACUTE GASTRIC ANISAKIASIS; ASCARIS-LUMBRICOIDES; EOSINOPHILS; EOTAXIN; FISH; SUUM	Background: Anisakis simplex is a parasite of fish, and in the case of human infestation, it should be considered as a possible cause of gastrointestinal disease, especially in countries where raw or undercooked fish is a frequent food. Clinical features of anisakiasis may simulate acute abdominal pain, such as that found in patients with gastric ulcers, appendicitis, and Crohn's disease. Furthermore, many cases of anisakiasis are diagnosed as eosinophilic gastroenteritis, which is a broad term for a specific disease. Objective: The purpose of this study was to investigate the immunopathogenesis of human gastrointestinal infestation by A simplex. Methods: Thirteen intestinal biopsy specimens from patients with anisakiasis were analyzed for the presence of messenger (m)RNA for different cytokines and inflammatory mediators by RT-PCR. Specific IgE, eosinophil cationic protein, eosinophil protein X, and tryptase levels were measured in each patient's serum. Also, cell cultures were set up with lymphocytes from some patients and stimulated in vitro with Anisakis and Ascaris antigens. Results: We performed immunologic phenotyping in 13 patients. All patients underwent biopsy after emergency surgery caused by episodes of acute abdominal pain. In all cases inflammatory infiltrate composed of eosinophils and lymphocytes was found in the intestinal wall. We demonstrated that after infestation, a T-H2-type immune response occurred. Also, major basic protein, nitric oxide, and eotaxin were found in the tissue, and eosinophil cationic protein and eosinophil protein X levels were elevated in sera. Conclusion: These data and in vitro lymphocyte cultures indicate that a T-H2 mechanism plays an important role in the inflammatory infiltrate produced by the anchorage of parasites in the gastrointestinal wall.	Fdn Jimenez Diaz, Dept Immunol, E-28040 Madrid, Spain; Hosp Navarra, Dept Pathol, Pamplona, Spain; Hosp Virgen Camino, Dept Allergy, Pamplona, Spain; Fdn Jimenez Diaz, Dept Pathol, E-28040 Madrid, Spain	Servicio Navarro de Salud - Osasunbidea; Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea	Lahoz, C (corresponding author), Fdn Jimenez Diaz, Dept Immunol, E-28040 Madrid, Spain.		Tuñón, Teresa/B-2525-2017; Cárdaba, Blanca/S-3772-2019; Cortegano, Isabel/AAE-1500-2020; Tuñón, María Jesús/L-2456-2017	Tuñón, Teresa/0000-0001-6589-1084; Cardaba, Blanca/0000-0003-0142-9901				Adams AM, 1997, REV SCI TECH OIE, V16, P652, DOI 10.20506/rst.16.2.1059; Alonso A, 1997, NEW ENGL J MED, V337, P350, DOI [10.1056/NEJM199707313370518, 10.1056/NEJM199707313370517]; BASTELS J, 1996, BIOCHEM BIOPH RES CO, V225, P1045; CHRISTIE JF, 1990, IMMUNOLOGY, V69, P596; DEANDRES B, 1994, BIOTECHNIQUES, V18, P42; delPozo V, 1997, J IMMUNOL, V158, P859; DELPOZO V, 1997, PROGR ALLERGY CLIN I, P132; Desreumaux P, 1996, CURR OPIN IMMUNOL, V8, P790, DOI 10.1016/S0952-7915(96)80006-9; DOOLEY JR, 1978, PATHOLOGY TROPICAL E, P475; Gomez B, 1998, ALLERGY, V53, P1148, DOI 10.1111/j.1398-9995.1998.tb03834.x; IKEDA K, 1989, GASTROINTEST ENDOSC, V35, P304, DOI 10.1016/S0016-5107(89)72797-8; Ishikura H, 1993, Prog Clin Parasitol, V3, P43; KAKIZOE S, 1995, AM J GASTROENTEROL, V90, P761; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; KENNEDY MW, 1988, MOL BIOCHEM PARASIT, V31, P35, DOI 10.1016/0166-6851(88)90143-0; KLIKS MM, 1983, AM J TROP MED HYG, V32, P526, DOI 10.4269/ajtmh.1983.32.526; LEE CM, 1993, AM J GASTROENTEROL, V88, P70; LI MS, 1995, BIOCHEM J, V305, P921, DOI 10.1042/bj3050921; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; MCKERROW JH, 1988, NEW ENGL J MED, V319, P1228; MUDRY J, 1986, GASTROEN CLIN BIOL, V10, P83; Petras Robert E., 1994, P1311; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; ROSAI J, 1996, ACKERMANS SURG PATHO, P589; SAKANARI JA, 1988, AM J CLIN PATHOL, V90, P107, DOI 10.1093/ajcp/90.1.107; SIMON HU, 1995, INT ARCH ALLERGY IMM, V107, P124, DOI 10.1159/000236950; SMITH JW, 1983, J HELMINTHOL, V57, P205, DOI 10.1017/S0022149X00009512; SUGIMACHI K, 1985, JAMA-J AM MED ASSOC, V253, P1012, DOI 10.1001/jama.253.7.1012; VALDISERRI RO, 1981, AM J CLIN PATHOL, V76, P329	29	40	40	0	14	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				637	643		10.1016/S0091-6749(99)70336-2	http://dx.doi.org/10.1016/S0091-6749(99)70336-2			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482840	Bronze			2022-12-18	WOS:000082870000028
J	Aksoy, MO; Li, XX; Borenstein, M; Yi, Y; Kelsen, SG				Aksoy, MO; Li, XX; Borenstein, M; Yi, Y; Kelsen, SG			Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway epithelium; corticosteroids; fluticasone; budesonide; triamcinolone; eicosanoids; prostaglandins; phospholipase A2; cyclooxygenase	CYTOSOLIC PHOSPHOLIPASE A(2); ARACHIDONIC-ACID; BRONCHOALVEOLAR LAVAGE; TRACHEAL EPITHELIUM; RABBIT UTEROGLOBIN; ALLERGEN CHALLENGE; ATOPIC ASTHMATICS; BRONCHIAL-ASTHMA; ELEVATED LEVELS; GLUCOCORTICOIDS	Background: Airway epithelial cells are among the first cells to come in contact with aerosolized corticosteroids. However, the relative potencies and time course of action of the several commonly used aerosolized corticosteroids on eicosanoid production by airway epithelial cells are unknown. Objectives: This study compared the effects of fluticasone, budesonide, and triamcinolone on eicosanoid output by human airway epithelial cells in vitro. We also determined the spectrum of eicosanoids affected and the mechanism for corticosteroid action. Methods: Cultured BEAS-2B airway epithelial cells (a transformed cell line) were exposed to corticosteroids (1 nmol/L to 1 mu mol/L) for 2 to 48 hours and then assayed for basal- and bradykinin (BK)-stimulated eicosanoid output. The eicosanoid profile was identified by HPLC in tritiated arachidonic acid prelabelled cells, and PGE(2), the major eicosanoid product, was quantitated by RIA. The effect of corticosteroids on the immunoreactivity of key proteins involved in eicosanoid metabolism tie, cyclooxygenase [COX], phospholipase A2 [PLA(2)], and Clara cell protein, a PLA(2) inhibitor) was determined by Western blotting. Results: Eicosanoid output was largely confined to prostaglandins with values of 5 +/- 2 and 82 +/- 35 ng PGE(2)/10(6) cells for basal- and BK stimulation, respectively (n = 8). All 3 corticosteroids inhibited basal- and BK-induced PGE(2) output in a dose- and time-dependent manner. Fluticasone and budesonide completely eliminated PGE(2) output in nanomolar concentrations in contrast to triamcinolone, which required micromolar concentration. The rank order of potency was: fluticasone = budesonide > triamcinolone. The time course of action for PGE(2) inhibition also differed, with budesonide acting more slowly than the other 2 corticosteroids (P = .04). All 3 corticosteroids markedly reduced COX2 with little effect on COX1, cPLA(2) (Type IV), or iPLA(2) (Type VI) immunoreactivity or their relative distribution in cytosol versus membrane fractions. Clara cell protein immunoreactivity was undetectable in control and corticosteroid-treated cell lysates. Conclusion: These results show that in a human airway epithelial cell line, the 3 inhaled corticosteroids commonly used to treat asthma differ in onsets of action as inhibitors of prostaglandin synthesis and vary considerably in potency. All 3 corticosteroids act mechanistically in similar fashion by inhibiting COX2 synthesis.	Temple Univ, Sch Med, Dept Med, Div Pulm, Philadelphia, PA 19122 USA; Temple Univ, Sch Pharm, Drug Res Unit, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Aksoy, MO (corresponding author), Rm 920,Parkinson Pavil,3401 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; AKSOY M, 1994, AM J RESP CRIT CARE, V149, pA988; AKSOY MO, 1995, AM J RESP CELL MOL, V13, P410, DOI 10.1165/ajrcmb.13.4.7546770; Asano K, 1996, AM J PHYSIOL-LUNG C, V271, pL126, DOI 10.1152/ajplung.1996.271.1.L126; BARNES PJ, 1988, PHARMACOL REV, V40, P49; CAMPBELL AM, 1993, AM REV RESPIR DIS, V147, P529, DOI 10.1164/ajrccm/147.3.529; CHOUDRY NB, 1989, AM REV RESPIR DIS, V140, P137, DOI 10.1164/ajrccm/140.1.137; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449, DOI 10.1164/ajrccm/140.2.449; COYNE DW, 1992, AM J PHYSIOL, V263, pF97, DOI 10.1152/ajprenal.1992.263.1.F97; Croxtall JD, 1996, BIOCHEM PHARMACOL, V52, P351, DOI 10.1016/0006-2952(95)02442-5; DECKERS IA, 1989, EUR J PHARMACOL, V167, P415, DOI 10.1016/0014-2999(89)90451-2; DEHARO MSL, 1985, BIOCHEM J, V225, P255; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; FU JY, 1990, J BIOL CHEM, V265, P16737; GOPPELTSTRUEBE M, 1992, BIOCHIM BIOPHYS ACTA, V1127, P163, DOI 10.1016/0005-2760(92)90273-X; HAGEN G, 1990, NUCLEIC ACIDS RES, V18, P2939, DOI 10.1093/nar/18.10.2939; HAMASAKI Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P226, DOI 10.1006/abbi.1993.1343; HOLTZMAN MJ, 1991, AM REV RESPIR DIS, V143, P188, DOI 10.1164/ajrccm/143.1.188; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; LEIKAUF GD, 1988, AM REV RESPIR DIS, V137, P435, DOI 10.1164/ajrccm/137.2.435; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MANTILE G, 1993, J BIOL CHEM, V268, P20343; MAROM Z, 1981, J CLIN INVEST, V67, P1695, DOI 10.1172/JCI110207; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; MONICK M, 1987, AM REV RESPIR DIS, V135, P72; NOAH TL, 1991, AM J RESP CELL MOL, V5, P484, DOI 10.1165/ajrcmb/5.5.484; RAEBURN D, 1990, GEN PHARMACOL, V21, P11, DOI 10.1016/0306-3623(90)90587-C; REDDEL RR, 1988, CANCER RES, V48, P1904; Sambrook J, 1989, MOL CLONING LAB MANU; SCHLEIMER RP, 1983, J CLIN INVEST, V71, P1830, DOI 10.1172/JCI110938; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; TAMAOKI J, 1995, AM J RESP CRIT CARE, V152, P1325, DOI 10.1164/ajrccm.152.4.7551390; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Walenga RW, 1996, PROSTAGLANDINS, V52, P341, DOI 10.1016/S0090-6980(96)00101-3; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450, DOI 10.1164/ajrccm/139.2.450; WIDDICOMBE JH, 1989, AM J PHYSIOL, V256, pL351; Wu KK, 1996, J LAB CLIN MED, V128, P242, DOI 10.1016/S0022-2143(96)90023-2; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; Wu T, 1996, BBA-MOL CELL RES, V1310, P175, DOI 10.1016/0167-4889(95)00143-3; Yao XL, 1998, AM J PHYSIOL-LUNG C, V274, pL864, DOI 10.1152/ajplung.1998.274.5.L864	46	40	43	0	6	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1999	103	6					1081	1091		10.1016/S0091-6749(99)70183-1	http://dx.doi.org/10.1016/S0091-6749(99)70183-1			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207GT	10359890				2022-12-18	WOS:000080929500017
J	Peng, ZK; Simons, FER				Peng, ZK; Simons, FER			A prospective study of naturally acquired sensitization and subsequent desensitization to mosquito bites and concurrent antibody responses	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IGG ANTIBODIES; ANTIGENS		Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada	University of Manitoba; University of Manitoba	Simons, FER (corresponding author), AE101-840 Sherbrook St, Winnipeg, MB R3A 1S1, Canada.							AILUS K, 1985, INT ARCH ALLER A IMM, V78, P375, DOI 10.1159/000233916; Li H., 1996, Journal of Allergy and Clinical Immunology, V97, P337, DOI 10.1016/S0091-6749(96)80838-4; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P238, DOI 10.1016/S1081-1206(10)63262-0; PENG ZK, 1995, ANN ALLERG ASTHMA IM, V74, P259; PENNEYS NS, 1988, J AM ACAD DERMATOL, V18, P87, DOI 10.1016/S0190-9622(88)70013-4	5	40	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				284	286		10.1016/S0091-6749(98)70395-1	http://dx.doi.org/10.1016/S0091-6749(98)70395-1			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500765				2022-12-18	WOS:000072244800021
J	Vailes, LD; Kinter, MT; Arruda, LK; Chapman, MD				Vailes, LD; Kinter, MT; Arruda, LK; Chapman, MD			High-level expression of cockroach allergen, Bla g 4, in Pichia pastoris	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach; asthma; calycin; allergen; recombinant; Pichia pastoris	MAJOR ALLERGEN; RISK-FACTORS; ASTHMA; PROTEINS; CLONING; EXPOSURE; CHILDREN; SENSITIZATION; PURIFICATION; HOMOLOGY	Exposure to cockroach allergens is a risk factor for allergic disease and has been linked to an increase in asthma morbidity among cockroach-sensitive inner-city children. Bla g 4 is a ligand-binding protein (or calycin) that causes IgE antibody responses in 40% to 60% of patients allergic to cockroaches. Recombinant Bla g 4 was expressed in Escherichia coli as an 18 kd protein but provided poor yields (only 0.25 mg/L culture). To improve yields, Bla g 4 was expressed in the Pichia pastoris yeast system as a 23 kd secreted protein at concentrations of 50 mg allergen/L. By cross-inhibition radioimmunoassay, Bla g 4 expressed in E. coli or P. pastoris. provided overlapping inhibition curves. Both allergen preparations bound comparable Levels of serum IgE antibody and showed similar skin test reactivity in individuals allergic to cockroaches (10(-1) to 10(-3) mu g/ml). Deglycosylation of Pichia-expressed Bla g 4 with endoglycosidase F resulted in an 18 to 20 kd doublet, and liquid chromatography-mass spectrometry results suggested that the 20 kd band contained residual sugar residues. Both glycosylated and deglycosylated Pichia Bla g 4 showed comparable inhibition of IgE antibody binding in radioimmunoassay. Pichia-produced Bla g 4 had the same antigenic reactivity as that produced in E. coli, and glycosylation had no effect on IgE antibody binding. The high yield of Bla g 4 obtained in the Pichia system will facilitate studies on the structure and function of calycin allergens and on the immune response of asthma patients to cockroach allergens.	Univ Virginia, Biomol Res Facil, HSC, Charlottesville, VA 22908 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Chapman, MD (corresponding author), Univ Virginia, Biomol Res Facil, HSC, Box 225, Charlottesville, VA 22908 USA.		Arruda, L. Karla/D-5845-2013	Arruda, L. Karla/0000-0002-7505-210X; Chapman, Martin/0000-0002-0845-3632; Kinter, Michael/0000-0001-7409-8918	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032557, U01AI034607, U19AI034607] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34607, AI32557] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARRUDA KA, 1997, J BIOL CHEM, V272, P20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563, DOI 10.1074/jbc.270.33.19563; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHAPMAN MD, 1997, ALLERGY ALLERGIC DIS, P940; CLARE JJ, 1991, BIO-TECHNOL, V9, P455, DOI 10.1038/nbt0591-455; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; DANDEU JP, 1995, J ALLERGY CLIN IMMUN, V95, P348; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385, DOI 10.1159/000237397; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; *INV CORP, 1996, MAN METH EXPR REC PR, P1; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; KOZNIECZNY A, 1995, J ALLERGY CLIN IMMUN, V95, P161; Mantyjarvi R, 1996, J ALLERGY CLIN IMMUN, V97, P1297, DOI 10.1016/S0091-6749(96)70198-7; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sambrook J, 1989, MOL CLONING LAB MANU; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; vantHof W, 1997, J BIOL CHEM, V272, P1837; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; Wu CH, 1996, J BIOL CHEM, V271, P17937, DOI 10.1074/jbc.271.30.17937	30	40	44	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1998	101	2	1				274	280		10.1016/S0091-6749(98)70393-8	http://dx.doi.org/10.1016/S0091-6749(98)70393-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	YZ342	9500762				2022-12-18	WOS:000072244800018
J	Kammerer, R; Chvatchko, Y; Kettner, A; Dufour, N; Corradin, G; Spertini, F				Kammerer, R; Chvatchko, Y; Kettner, A; Dufour, N; Corradin, G; Spertini, F			Modulation of T-cell response to phospholipase A(2) and phospholipase A(2) derived peptides by conventional bee venom immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; desensitization; T cell; phospholipase A(2); peptides	ANTIGEN CONCENTRATION; INTERLEUKIN-4 PRODUCTION; ALLERGIC INDIVIDUALS; IGE SYNTHESIS; IL-4; ANTIBODIES; INDUCTION; CLONES; STOP; HYPERSENSITIVITY	Background: Immunologic mechanisms of desensitization are still incompletely understood, Safer methods of immunotherapy with reduced risks of anaphylaxis need to be developed. Objective: To study the effects of conventional venom immunotherapy (VIT) on phospholipase A(2)(PLA(2))-specific T cells and on T-cell reactivity to short and long synthetic peptides that map the PLA(2) molecule. Method: Proliferation of a CD4(+) cell-enriched peripheral blood mononuclear cell fraction and cytokine secretion by T cell lines from patients hypersensitive to bee venom and undergoing VIT in response to PLA(2) and PLA(2) synthetic peptides were measured. Results: T-cell proliferation in response to three synthetic peptides, 10 to 60 amino acids long and mapping the entire PLA(2) molecule with an overlap of 10 residues (1 to 59, 51 to 99, and 90 to 134) steadily increased during the first 14 weeks of MT corresponding to the treatment period with incremental doses of antigen, These results are in contrast to the low proliferation indices obtained with short (15 amino acid-long) peptides, and the inability to characterize the immunodominant region of the molecule with short peptides. At the end of VIT (after 3 to 5 years), there was correspondingly, a marked decrease in T cell responsiveness to PLA(2) and to its long synthetic peptides, This response was paralleled by a shift in the pattern of cytokine secretion by T cell lines from a T-H0-type to a T-H1-type pattern. Conclusion: After a transient increase in T-cell proliferation, late VIT was characterized by T-cell hyporesponsiveness to allergen and by modulation of cytokine secretion from a T-H0-type to a T-H1-type pattern. Because of their capacity to recruit multiple T-cell epitopes, long peptides mapping the entire PLA(2) molecule appear to be efficient T cell stimulators and may represent potential candidates for peptide immunotherapy.	CHU VAUDOIS,DIV IMMUNOL & ALLERGY,CH-1011 LAUSANNE,SWITZERLAND; UNIV LAUSANNE,INST BIOCHEM,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne								ATHERTON E, 1979, BIOORG CHEM, V8, P351, DOI 10.1016/0045-2068(79)90062-2; BIRNBAUM J, 1993, CLIN EXP ALLERGY, V23, P226, DOI 10.1111/j.1365-2222.1993.tb00886.x; BLAAUW PJ, 1985, J ALLERGY CLIN IMMUN, V75, P556, DOI 10.1016/0091-6749(85)90029-6; BLASER K, 1982, PROG ALLERGY, V32, P203; BOUTIN Y, 1994, J ALLERGY CLIN IMMUN, V93, P1039, DOI 10.1016/S0091-6749(94)70053-2; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P1357, DOI 10.1002/eji.1830220605; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; DEKRUYFF RH, 1989, J EXP MED, V170, P1477, DOI 10.1084/jem.170.5.1477; DEKRUYFF RH, 1992, J IMMUNOL, V149, P3468; DEMOTZ S, 1989, J IMMUNOL, V142, P394; DHILLON M, 1992, J ALLERGY CLIN IMMUN, V90, P42, DOI 10.1016/S0091-6749(06)80009-6; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; FASLER S, 1995, J IMMUNOL, V155, P4199; GOLDBERG A, 1988, ANN ALLERGY, V61, P177; GOLDEN DBK, 1989, ALLERGY PROC, V10, P103, DOI 10.2500/108854189778960964; GRAFT DF, 1991, J ALLERGY CLIN IMMUN, V88, P409, DOI 10.1016/0091-6749(91)90105-W; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; JENKINS MK, 1987, IMMUNOL REV, V95, P113, DOI 10.1111/j.1600-065X.1987.tb00502.x; JENKINS MK, 1990, J IMMUNOL, V144, P1585; JUTEL M, 1995, J IMMUNOL, V154, P4187; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; MAHMOOD T, 1982, J ALLERGY CLIN IMMUN, V70, P445, DOI 10.1016/0091-6749(82)90007-0; MARSHALL JD, 1993, CELL IMMUNOL, V152, P18, DOI 10.1006/cimm.1993.1264; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MULLER HL, 1966, J ASTHMA RES, V3, P331; MULLER U, 1993, ALLERGY, V48, P37; MULLER U, 1991, J ALLERGY CLIN IMMUN, V87, P702, DOI 10.1016/0091-6749(91)90392-2; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Muller UR., 1990, INSECT STING ALLERGY; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; REISMAN RE, 1994, J ALLERGY CLIN IMMUN, V94, P651, DOI 10.1016/0091-6749(94)90167-8; REISMAN RE, 1991, J ALLERGY CLIN IMMUN, V87, P618, DOI 10.1016/0091-6749(91)90378-2; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; UHLIN T, 1987, ALLERGY, V42, P222, DOI 10.1111/j.1398-9995.1987.tb02203.x; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; WALKER C, 1991, J IMMUNOL, V146, P1829	43	40	46	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					96	103						8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257793	Bronze			2022-12-18	WOS:A1997XP42800015
J	Nagata, K; Ishitobi, K; Yamamoto, Y; Ikeda, T; Hori, S; Matsumoto, Y; Sasaki, T				Nagata, K; Ishitobi, K; Yamamoto, Y; Ikeda, T; Hori, S; Matsumoto, Y; Sasaki, T			Increased theophylline metabolism in the menstrual phase of healthy women	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						theophylline; menstrual cycle; estrogen; premenstrual asthma	DRUG-INTERACTIONS; PHARMACOKINETICS; DISPOSITION	Background: We previously reported on a Japanese woman with premenstrual asthma whose serum theophylline concentration was lower before the onset of her menstrual period. We evaluated the clearance of theophylline in each phase of her menstrual cycle and found an increase in clearance in the premenstrual and menstrual phases. Objective: This study was designed to investigate whether changes in theophylline clearance may occur with the menstrual cycle in nonasthmatic women. Methods: Aminophylline, 250 mg, was infused intravenously for 45 minutes, and the clearance of theophylline was calculated in seven healthy, ovulatory women on days 1 or 2, 10, and 20 or 25 of the menstrual cycle. The serum concentration of theophylline was determined with an enzyme immunoassay (homogeneous). Results: Theophylline clearance was significantly higher and its half-life was significantly shorter in the menstrual phase than in the follicular phase. Conclusion: The metabolism of theophylline, and consequently, its clearance were increased in healthy women around the onset of menses. Clinicians must therefore consider the menstrual variation in theophylline metabolism when prescribing this drug to female patients.	TOTTORI UNIV,FAC MED,CTR HLTH SCI,YONAGO,TOTTORI 683,JAPAN	Tottori University	Nagata, K (corresponding author), TOTTORI UNIV,FAC MED,DEPT INTERNAL MED 3,36-1 NISHI MACHI,YONAGO,TOTTORI 683,JAPAN.			Nagata, Keiko/0000-0002-7726-0439				BRUGUEROLLE B, 1990, EUR J CLIN PHARMACOL, V39, P59, DOI 10.1007/BF02657059; BUKOWSKYJ M, 1984, ANN INTERN MED, V101, P63, DOI 10.7326/0003-4819-101-1-63; CARTER BL, 1986, OBSTET GYNECOL, V68, P555; EISALO A, 1968, ACTA OBSTET GYN SCAN, V47, P58, DOI 10.3109/00016346809157466; GARDNER MJ, 1983, BRIT J CLIN PHARMACO, V16, P271, DOI 10.1111/j.1365-2125.1983.tb02161.x; GARDNER MJ, 1986, INT J PHARM, V33, P55, DOI 10.1016/0378-5173(86)90038-4; JONKMAN JHG, 1986, J ALLERGY CLIN IMMUN, V78, P736, DOI 10.1016/0091-6749(86)90054-0; JONKMAN JHG, 1984, CLIN PHARMACOKINET, V9, P309, DOI 10.2165/00003088-198409040-00002; KOREN G, 1985, CLIN INVEST MED, V8, P222; LOHMANN SM, 1976, J PHARMACOL EXP THER, V196, P213; NAGATA K, 1993, KOKYUU, V12, P372; RIELY CA, 1992, MED FETUS MOTHER, P1077; SUTTON PL, 1978, J ALLERGY CLIN IMMUN, V61, P174, DOI 10.1016/0091-6749(78)90392-5; TORNATORE KM, 1982, EUR J CLIN PHARMACOL, V23, P129, DOI 10.1007/BF00545966	14	40	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1997	100	1					39	43		10.1016/S0091-6749(97)70192-1	http://dx.doi.org/10.1016/S0091-6749(97)70192-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XP428	9257785				2022-12-18	WOS:A1997XP42800007
J	Meltzer, EO				Meltzer, EO			The prevalence and medical and economic impact of allergic rhinitis in the United States - Introduction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									UNIV CALIF SAN DIEGO,ALLERGY & ASTHMA MED GRP & RES CTR,SAN DIEGO,CA 92103	University of California System; University of California San Diego								ADAMS PF, 1994, 961521 PHS US DEP 10; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634	2	40	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1997	99	6	2	S			S807	S807		10.1016/S0091-6749(97)80039-5	http://dx.doi.org/10.1016/S0091-6749(97)80039-5			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	XJ363					2022-12-18	WOS:A1997XJ36300001
J	Hill, DJ; Thompson, PJ; Stewart, GA; Carlin, JB; Nolan, TM; Kemp, AS; Hosking, CS				Hill, DJ; Thompson, PJ; Stewart, GA; Carlin, JB; Nolan, TM; Kemp, AS; Hosking, CS			The Melbourne House Dust Mite Study: Eliminating house dust mites in the domestic environment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mites; Der p 1; carpets; mattresses; asthma; mite avoidance	ALLERGEN AVOIDANCE; P-I; DERMATOPHAGOIDES-PTERONYSSINUS; BRONCHIAL HYPERREACTIVITY; CHILDHOOD ASTHMA; CONTROLLED TRIAL; CHILDREN; AUSTRALIA; EXPOSURE; SENSITIZATION	Background: Hypersensitivity to house dust mite allergens is associated with increased asthma morbidity. Asthma severity appears to be related to the degree of mite allergen exposure. Short-term studies suggest that complete avoidance reduces disease severity. Objective: The study was designed to assess the effect of different mattress covers and floor coverings on mite allergen concentrations in the homes of mite-sensitive children with asthma in the city of Melbourne, Australia. Methods: Mite allergen Der p 1 concentration was measured on mattress covers, mattress surfaces, and carpeted and uncarpeted boors in 107 dwellings; and measurement was performed on three occasions over a 5-month period. After the first sampling, all mattress covers and impermeable encasements mere permanently removed. Results: The initial geometric mean concentrations of Der p 1 (micrograms per gram of fine dust) from the surfaces of sheepskin, wool, and cotton mattress coverings were greater than those from the surfaces of impermeable mattress encasements (116, 113, and 19 vs 0.4) (p < 0.001); corresponding concentrations on the underlying mattresses were 142, 38, 20, and 0.6, respectively (p < 0.05 to 0.001). At the end of the study these mattress surface concentrations were 79, 65, 9.7, and 3.1, respectively. In 24 dwellings an uncarpeted room was adjacent to a carpeted room. At each visit the concentration of Der p 1 in uncarpeted rooms was below the reported threshold for sensitization and significantly less than that in the adjacent carpeted room. Conclusion: In homes of children with asthma, ''asthmogenic'' concentrations of Der p 1 were found on nonencased mattresses and carpeted floors, but the use of impermeable mattress encasements and carpet exclusion were associated with concentrations of Der p 1 below the reported threshold for sensitization.	UNIV WESTERN AUSTRALIA, DEPT MED, NEDLANDS, WA 6009, AUSTRALIA; UNIV WESTERN AUSTRALIA, DEPT MICROBIOL, NEDLANDS, WA 6009, AUSTRALIA; ROYAL CHILDRENS HOSP, CLIN EPIDEMIOL & BIOSTAT UNIT, PARKVILLE, VIC 3052, AUSTRALIA; UNIV MELBOURNE, DEPT PAEDIAT, PARKVILLE, VIC 3052, AUSTRALIA	University of Western Australia; University of Western Australia; Royal Children's Hospital Melbourne; University of Melbourne	Hill, DJ (corresponding author), ROYAL CHILDRENS HOSP, DEPT ALLERGY, FLEMINGTON RD, PARKVILLE, VIC 3052, AUSTRALIA.		Nolan, Terry/A-2236-2008; Carlin, John B/B-3492-2012; Carlin, John/AAG-4332-2020	Nolan, Terry/0000-0001-6018-3863; Carlin, John B/0000-0002-2694-9463; Carlin, John/0000-0002-2694-9463				ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; COLLOFF MJ, 1991, CLIN EXP ALLERGY, V21, P225, DOI 10.1111/j.1365-2222.1991.tb00834.x; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; FEATHER IH, 1993, THORAX, V48, P5, DOI 10.1136/thx.48.1.5; FERGUSON P, 1995, AM J RESP CRIT CARE, V151, P71, DOI 10.1164/ajrccm.151.1.7812575; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; HUSS RW, 1994, J ALLERGY CLIN IMMUN, V94, P27, DOI 10.1016/0091-6749(94)90067-1; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; Munir A K, 1993, Pediatr Allergy Immunol, V4, P136, DOI 10.1111/j.1399-3038.1993.tb00082.x; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; Nishima S, 1993, Arerugi, V42, P192; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; PEAT JK, 1992, BMJ-BRIT MED J, V305, P1326, DOI 10.1136/bmj.305.6865.1326; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442, DOI 10.1164/ajrccm.149.6.8004296; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; ROBERTSON CF, 1993, PEDIATR PULM, V16, P219, DOI 10.1002/ppul.1950160403; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; THOMPSON PJ, 1989, MED J AUSTRALIA, V151, P408, DOI 10.5694/j.1326-5377.1989.tb101225.x; TOVEY ER, 1975, MED J AUSTRALIA, V2, P770, DOI 10.5694/j.1326-5377.1975.tb106278.x; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; vanStrien RT, 1995, CLIN EXP ALLERGY, V25, P1184, DOI 10.1111/j.1365-2222.1995.tb03042.x; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103, DOI 10.1093/oxfordjournals.aje.a117398; WAHN U, 1995, PEDIATR ALLERGY IMMU, V6, P42, DOI 10.1111/j.1399-3038.1995.tb00384.x; WALSHAW MJ, 1986, Q J MED, V58, P199; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8	37	40	41	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1997	99	3					323	329		10.1016/S0091-6749(97)70049-6	http://dx.doi.org/10.1016/S0091-6749(97)70049-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WM422	9058687				2022-12-18	WOS:A1997WM42200008
J	Adelroth, E; Inman, MD; Summers, E; Pace, D; Modi, M; OByrne, PM				Adelroth, E; Inman, MD; Summers, E; Pace, D; Modi, M; OByrne, PM			Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D-4-receptor antagonist cinalukast	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; exercise bronchoconstriction; cysteinyl leukotriene	INDUCED ASTHMA; RECEPTOR ANTAGONIST; SALMETEROL	Objectives: The degree and duration of protection against exercise-induced bronchoconstriction afforded by three doses of a specific leukotriene D-4 receptor antagonist, cinalukast, were assessed after an initial dosing and after 1 week of therapy. Methods: A placebo-controlled crossover study was performed in eight made patients who had mild, stable asthma and exercise-induced bronchoconstriction. Treatment consisted of four 7-day periods of placebo and three dose levels of the drug (10, 50, and 200 mg administered orally). Exercise challenge was performed at 2 hours and 8 hours after treatment on the first and seventh treatment days. The response was measured as the area under the Fev(1)-time effect curve (AUEC). Results: On the first day of treatment, the mean (+/- SEM) AUEC at 2 hours was 24.2 +/- 3.3 L . min after placebo and was 5.5 +/- 2.2 L . min, 6.3 +/- 2.7 L . min, 3.3 +/- 3.8 L . min after 10 mg, 50 mg, and 200 mg, respectively (p < 0.05 for all values compared with placebo). The AUEC at 8 hours on the first day was 25.1 +/- 4.4 L . min after placebo and was 6.8 +/- 4.1 L . min, 11.2 +/- 2.5 L . min, and 5.0 +/- 2.8 L . min after 10 mg, 50 mg, and 200 mg, respectively (p < 0.05 for all values compared with placebo). The protection afforded by 10 mg of cinalukast was lost after 7 days of treatment but persisted with 50 mg and 200 mg doses. Conclusion: Orally administered cinalukast provides at least 8 hours of protection against exercise-induced bronchoconstriction. This protection is lost with regular treatment for 1 week for the lowest dose studied.	MCMASTER UNIV,ASTHMA RES GRP,HAMILTON,ON,CANADA; HOFFMANN LA ROCHE INC,DEPT CLIN PHARMACOL,NUTLEY,NJ 07110	McMaster University; Roche Holding				O'Byrne, Paul/0000-0003-0979-281X				ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ANDERSON SD, 1991, CHEST, V100, P1254, DOI 10.1378/chest.100.5.1254; ANDERSON SD, 1984, AUST NZ J MED, V14, P803, DOI 10.1111/j.1445-5994.1984.tb04356.x; ANDERSON SD, 1985, CHEST, V87, P191; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; GILBERT IA, 1987, J APPL PHYSIOL, V63, P1681, DOI 10.1152/jappl.1987.63.4.1681; INMAN MD, 1994, AM REV RESPIR DIS, V149, pA1048; JONES B, 1989, DESIGN ANAL CROSS OV, P197; JONES NL, 1988, CLIN EXERCISE TESTIN, P135; Keppel G., 1982, DESIGN ANAL RES HDB; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; MALO JL, 1992, J ALLERGY CLIN IMMUN, V89, P567, DOI 10.1016/0091-6749(92)90324-U; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MCFADDEN ER, 1987, CHEST S, V91, P151; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; *NAT HEART LUNG AS, 1991, GUID DIAGN MAN ASTHM, V91; ODONNELL M, 1991, J PHARMACOL EXP THER, V259, P751; ROBUSCHI M, 1992, AM REV RESPIR DIS, V145, P1285, DOI 10.1164/ajrccm/145.6.1285; TAYLOR IK, 1992, J APPL PHYSIOL, V73, P743, DOI 10.1152/jappl.1992.73.2.743; WEISS JW, 1983, JAMA-J AM MED ASSOC, V249, P284	22	40	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					210	215		10.1016/S0091-6749(97)70098-8	http://dx.doi.org/10.1016/S0091-6749(97)70098-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042047				2022-12-18	WOS:A1997WH83100010
J	Bender, BG; Ikle, DN; DuHamel, T; Tinkelman, D				Bender, BG; Ikle, DN; DuHamel, T; Tinkelman, D			Retention of asthmatic patients in a longitudinal clinical trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						patient attrition; asthma trial	INHALED CORTICOSTEROID BUDESONIDE; CHILDREN	Background: Prevention of study patient attrition and assessment of its impact on outcome data are problems that receive little attention despite their obvious importance in asthma research. Objective: The medical, demographic, and psychologic characteristics of asthmatic children and adults who dropped out of a yearlong medication trial were assessed to determine whether this group differed from those who completed the study, potentially introducing bias into the data set and interfering with completion of the study's objectives. Methods: Profiles of 362 adult and pediatric asthmatic patient dropouts from the multicenter trial were contrasted with profiles of those who completed the study. Despite a 1-month prerandomization screening, 24% of patients failed to complete the trial for varied reasons, which largely included noncompliance and treatment dissatisfaction. Results: Although attrition rates were equal among adults and children, dropout-completer differentiation was not. Adult completers did not differ from dropouts in any variables. However, pediatric dropouts were more likely than completers to be female (67% and 36%, p = 0.008) and to have more reactive airways (PD20, 2.29 +/- 1.32 and 5.2 +/- 1.23, p = 0.05), to have reduce scores on tests of intelligence (Full Scale IQ, 102.2 +/- 2.6 and 112.5 +/- 1.6, p = 0.002) and problem solving (Wisconsin Card Sorting Test Error Scores, 39.8 +/- 4.1 and 29.1 +/- 2.0, p = 0.01), and to have increased behavioral problems (Child Behavior Checklist Total Problem Score, 60.7 +/- 2.5 and 53.6 +/- 1.1, p = 0.003). Conclusion: These findings demonstrate the potential of patient attrition to bias outcome in clinical trials and underscore the necessity of: (1) preventing its occurrence, (2) correctly assessing its causes, and (3) determining its ultimate impact on study results. Strategies for each of these three tasks should be implemented at the study's initial planning stages.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BIOSTAT,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT PSYCHIAT,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PREVENT MED & BIOMETR,DENVER,CO 80262; UNIV WASHINGTON,SCH MED,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle	Bender, BG (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,1400 JACKSON ST,DENVER,CO 80206, USA.		Ikle, David/AAK-7541-2020	Ikle, David/0000-0003-0091-5246				BELL RL, 1985, CONTROL CLIN TRIALS, V6, P89, DOI 10.1016/0197-2456(85)90114-X; CHERNIACK RM, 1996, ANN M AM THOR SOC NE; CLANCY J, 1983, COMPR PSYCHIAT, V24, P508, DOI 10.1016/0010-440X(83)90017-2; COLLINS JF, 1981, CONTROL CLIN TRIALS, V2, P78, DOI 10.1016/0197-2456(81)90096-9; CRAMER JA, 1988, CONTROL CLIN TRIALS, V9, P47, DOI 10.1016/0197-2456(88)90008-6; GOLDMAN AI, 1982, CONTROL CLIN TRIALS, V3, P75, DOI 10.1016/0197-2456(82)90037-X; Meinert CL, 1986, CLIN TRIALS DESIGN C; ORR PR, 1992, CONTROL CLIN TRIALS, V13, P40, DOI 10.1016/0197-2456(92)90028-X; Probstfield J L, 1989, Arthritis Care Res, V2, pS48; PROBSTFIELD JL, 1986, AM J MED, V80, P777, DOI 10.1016/0002-9343(86)90615-7; ROBINSON A, 1990, BIRTH DEFECTS, V26, P59; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547, DOI 10.1164/ajrccm/146.3.547; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WAALKENS JH, 1993, EUR RESPIR J, V6, P652	15	40	41	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1997	99	2					197	203		10.1016/S0091-6749(97)70096-4	http://dx.doi.org/10.1016/S0091-6749(97)70096-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	WH831	9042045				2022-12-18	WOS:A1997WH83100008
J	Petersen, LJ; Brasso, K; Pryds, M; Skov, PS				Petersen, LJ; Brasso, K; Pryds, M; Skov, PS			Histamine release in intact human skin by monocyte chemoattractant factor-1, RANTES, macrophage inflammatory protein-1 alpha, stem cell factor, anti-IgE, and codeine as determined by an ex vivo skin microdialysis technique	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine release; monocyte chemoattractant factor-1; RANTES; macrophage inflammatory protein-1 alpha; stem cell factor; anti-IgE; codeine; skin microdialysis	LUNG MAST-CELLS; C-KIT RECEPTOR; ACTIVATING FACTOR; MEDIATOR RELEASE; HUMAN BASOPHILS; CYTOKINE FAMILY; IN-VIVO; LIGAND; CHEMOKINES; PURIFICATION	Background: The chemokines monocyte chemoattractant factor-1, RANTES, and macrophage inflammatory protein-1 alpha release histamine from human basophils, as well as rat and mouse mast cells. The purpose of this investigation was to determine whether these chemokines release histamine from human skin mast cells in situ. Methods: A microdialysis technique was used to measure histamine release in skin. First, the model was validated by using anti-IgE, codeine, and stem cell factor (SCF); then the histamine-releasing effects of the chemokines were investigated. A total of 47 skin specimens from 41 donors were investigated. Hollow microdialysis fibers were inserted intradermally, and each fiber was slowly perfused (3 mu l/min). Anti-IgE, codeine, SCF, or chemokines were injected intradermally above individual fibers, and dialysate was collected at 2-minute intervals for 20 minutes. Each series of investigations comprised five to eight single experiments. Results: Anti-IgE (4 to 4000 U/ml), codeine (0.001 to 1 mg/ml), and SCF (5.4 X (10(-11) to 10(-8) mol/L)) released histamine in a dose-dependent manner; maximum histamine release was 97.4, 116.3, and 9.5 pmol/20 min, respectively. Monocyte chemoattractant factor-1, RANTES, and macrophage inflammatory protein-1 alpha in concentrations of 10(-9) to 10(-6) mol/L did not release histamine; histamine release by 10(-6) mol/L chemokine was less than 0.2 pmol/20 min. None of the chemokines modulated anti-IgE-induced histamine release. In contrast, SCF significantly potentiated anti-IgE-induced histamine release by 33%. All chemokines, but not SCF, released histamine from human basophils. Conclusion: We conclude that the chemokines monocyte chemoattractant factor-1 RANTES, and macrophage inflammatory protein-1 alpha do not release histamine from human skin mast cells.	BISPEBJERG HOSP,DEPT SURG GASTROENTEROL,DK-2400 COPENHAGEN,DENMARK; UNIV COPENHAGEN,NATL UNIV HOSP,REFERENCE LAB,COPENHAGEN,DENMARK	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen	Petersen, LJ (corresponding author), BISPEBJERG HOSP,DEPT DERMATOL,DK-2400 COPENHAGEN,DENMARK.							ALAM R, 1992, J CLIN INVEST, V89, P723, DOI 10.1172/JCI115648; ALAM R, 1994, J IMMUNOL, V152, P1298; ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; ALAM R, 1992, AM J RESP CELL MOL, V7, P427, DOI 10.1165/ajrcmb/7.4.427; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BENYON RC, 1987, J IMMUNOL, V138, P861; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; COLUMBO M, 1992, J IMMUNOL, V149, P599; COLUMBO M, 1994, BIOCHEM PHARMACOL, V47, P2137, DOI 10.1016/0006-2952(94)90248-8; DAHINDEN CA, 1993, ADV EXP MED BIOL, V351, P99; FUREDER W, 1995, ANN HEMATOL, V70, P251; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GRUBER B, 1986, ARTHRITIS RHEUM, V29, P944, DOI 10.1002/art.1780290802; KAPLAN AP, 1994, ALLERGY, V49, P495, DOI 10.1111/j.1398-9995.1994.tb01119.x; KUNA P, 1992, J EXP MED, V175, P489, DOI 10.1084/jem.175.2.489; KUNA P, 1992, J IMMUNOL, V149, P636; KUNA P, 1993, J IMMUNOL, V150, P1932; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; LOUIS R, 1994, INT ARCH ALLERGY IMM, V105, P18, DOI 10.1159/000236798; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSBECH H, 1987, ALLERGY, V42, P553, DOI 10.1111/j.1398-9995.1987.tb00382.x; NAKAJIMA K, 1992, BIOCHEM BIOPH RES CO, V183, P1076, DOI 10.1016/S0006-291X(05)80300-6; NITSCHKE M, 1995, ALLERGY S26, V50, P15; OKAYAMA Y, 1995, CLIN EXP ALLERGY, V25, P890, DOI 10.1111/j.1365-2222.1995.tb00032.x; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Petersen LJ, 1996, J ALLERGY CLIN IMMUN, V97, P672, DOI 10.1016/S0091-6749(96)70313-5; PETERSEN LJ, 1995, CLIN EXP ALLERGY, V25, P1045, DOI 10.1111/j.1365-2222.1995.tb03250.x; PETERSEN LJ, 1994, J ALLERGY CLIN IMMUN, V94, P773, DOI 10.1016/0091-6749(94)90186-4; PETERSEN LJ, 1995, J ALLERGY CLIN IMMUN, V95, P225; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SCHULMAN ES, 1985, AM REV RESPIR DIS, V131, P230; SKOV PS, 1984, AGENTS ACTIONS, V14, P414, DOI 10.1007/BF01973840; SPERR WR, 1994, BLOOD, V84, P3876, DOI 10.1182/blood.V84.11.3876.bloodjournal84113876; SPERR WR, 1993, INT ARCH ALLERGY IMM, V102, P170, DOI 10.1159/000236568; TAKAISHI T, 1994, ALLERGY, V49, P837, DOI 10.1111/j.1398-9995.1994.tb00784.x; TAUB D, 1995, J IMMUNOL, V154, P2393; VALENT P, 1994, IMMUNOL TODAY, V15, P111, DOI 10.1016/0167-5699(94)90153-8	38	40	40	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					790	796		10.1016/S0091-6749(96)70128-8	http://dx.doi.org/10.1016/S0091-6749(96)70128-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876555	Bronze			2022-12-18	WOS:A1996VM66500012
J	STROMBERG, LGE; LUDVIGSSON, GJ; BJORKSTEN, B				STROMBERG, LGE; LUDVIGSSON, GJ; BJORKSTEN, B			ATOPIC ALLERGY AND DELAYED-HYPERSENSITIVITY IN CHILDREN WITH DIABETES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGY; TYPE I DIABETES; IMMUNE RESPONSE; CHILDREN; DELAYED HYPERSENSITIVITY	ENVIRONMENTAL-FACTORS; INSULIN; MELLITUS; ASTHMA; AUTOIMMUNITY; ASSOCIATION; RESPONSES; RELATIVES; RHINITIS	The prevalence of atopy was studied in 61 children with type I insulin-dependent diabetes mellitus (IDDM) and 72 age- and sex-matched control subjects. The two groups had a similar prevalence of atopic disease and did not differ significantly with respect to history, clinical findings, skin prick test results, total serum IgE levels or presence of circulating IgE antibodies to allergen. We also studied delayed-type hypersensitivity reactions in 37 of the children with IDDM and 46 of the control subjects. Children with IDDM, as compared with those without IDDM, move often had other autoimmune diseases in their family histories (p < 0.01). They also had significantly stronger delayed hypersensitivity reactions than the control subjects, as determined with tetanus toroid (p < 0.05) and mumps antigen (p < 0.01). The reactivity to purified protein derivate of tuberculin and Candida antigen was similar in the two groups The study does not confirm previous suggestions of an inverse relationship between IDDM and atopic disease brit does confirm that IDDM is associated with other immunologic disturbances. The different genetic and immunologic traits do not prevent allergic manifestations in children with diabetes.	LINKOPING UNIV HOSP,S-58185 LINKOPING,SWEDEN	Linkoping University	STROMBERG, LGE (corresponding author), CTY HOSP,DEPT PAEDIAT,S-60182 NORRKOPING,SWEDEN.							ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BETTERLE C, 1984, DIABETOLOGIA, V26, P431; BJORKSTEN B, 1987, ACTA PAEDIATR SCAND, V76, P935, DOI 10.1111/j.1651-2227.1987.tb17267.x; BJORKSTEN B, 1984, CLIN REV ALLERG, V2, P92; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; CAVAGNI G, 1983, ARCH FR PEDIATR, V40, P319; Charpin J, 1966, Mars Med, V103, P895; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; FRICK OL, 1979, J ALLERGY CLIN IMMUN, V63, P228, DOI 10.1016/0091-6749(79)90106-4; HELANDER E, 1958, ACTA MED SCAND, V162, P165; HERMANSSON B, 1971, HUM HERED, V21, P504, DOI 10.1159/000152443; ISHIZAKA K, 1983, IMMUNOL TODAY, V4, P192, DOI 10.1016/0167-5699(83)90080-4; JOSLIN EP, 1959, TREATMENT DIABETES M, P405; KJELLMAN NIM, 1988, ALLERGY, V4, P277; KONIG F, 1935, MED KLIN, V17, P545; LABOIRE F, 1967, J MED BORDEAUX, V14, P1143; LORINI R, 1986, EUR J PEDIATR, V145, P182, DOI 10.1007/BF00446060; MADACSY L, 1987, Acta Paediatrica Hungarica, V28, P209; MARSHALL MO, 1988, DIABETES RES CLIN EX, V9, P169; MORRISONSMITH J, 1971, CLIN ALLERGY, V1, P57; NELSON HS, 1985, ANN ALLERGY, V55, P441; NERUP J, 1981, AM J MED, V70, P135, DOI 10.1016/0002-9343(81)90420-4; POPP W, 1989, ALLERGY, V44, P572, DOI 10.1111/j.1398-9995.1989.tb04202.x; POZILLI P, 1987, DIABETES RES, V6, P5; POZILLI P, 1985, LANCET, V2, P954; SERN N, 1932, J ALLERGY, V2, P875; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; VANEDEN W, 1983, CLIN EXP IMMUNOL, V52, P287; VILLA MP, 1988, AM J DIS CHILD, V142, P726, DOI 10.1001/archpedi.1988.02150070040021; WILLMER HB, 1936, S MED J, V29, P197; WOLF E, 1983, DIABETOLOGIA, V24, P224; YOON JW, 1991, DIABETES 1991, P395; 1990, DIABETES, V39, P858	36	40	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					188	192		10.1016/S0091-6749(95)70007-2	http://dx.doi.org/10.1016/S0091-6749(95)70007-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636056	Bronze			2022-12-18	WOS:A1995RQ00100007
J	TAN, JQ; REIMERT, CM; DELEURAN, B; ZACHARIAE, C; SIMONSEN, C; THESTRUPPEDERSEN, K				TAN, JQ; REIMERT, CM; DELEURAN, B; ZACHARIAE, C; SIMONSEN, C; THESTRUPPEDERSEN, K			CETIRIZINE INHIBITS THE IN-VITRO AND EX-VIVO CHEMOTACTIC RESPONSE OF T-LYMPHOCYTES AND MONOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CETIRIZINE DIHYDROCHLORIDE; CHEMOTAXIS; EOSINOPHIL CATIONIC PROTEIN; MONOCYTES; T LYMPHOCYTES	EOSINOPHIL CATIONIC PROTEIN; LINKED-IMMUNOSORBENT-ASSAY; ATOPIC-DERMATITIS; ALLERGIC RHINITIS; CHRONIC URTICARIA; HISTAMINE; CELLS; ANTIHISTAMINES; CHALLENGE; ASTHMA	We have studied the effect of a nonsedating antihistamine, cetirizine dihydrochloride, on the in vitro chemotaxis of leukocytes from human peripheral blood. We observed that 0.25 mu g/ml of cetirizine dihydrochloride in vitro significantly inhibited the chemotaxis of monocytes toward N-formyl-methionyl-leucyl-phenylalanine and leukotriene B-4. Higher concentrations of cetirizine, 1.0 and 2.5 mu g/ml, completely inhibited monocyte chemotaxis without affecting cell viability. T-lymphocyte migration was also significantly depressed but not abolished. Pyrilamine (mepyramine) was nor inhibitory in equimolar concentrations. According to these in vitro observations, we extended our studies to measure monocyte and T-lymphocyte. chemotaxis in an open study, where foul healthy volunteers and six patients with atopic dermatitis took 10 and 20 mg/day cetirizine 3 days. We observed a reduction in ex vivo monocyte and T-lymphocyte chemotaxis toward N-formyl-methionyl-leucyl-phenylalanine and leukotriene B-4 without a reduction of the blood cell count. The results were confirmed in an ensuing double-blind, placebo-controlled study of 16 healthy subjects and 14 adult patients with atopic dermatitis, where ex vivo monocyte chemotaxis was reduced or abolished during cetirizine therapy. Serum levels of the two eosinophil-derived granule proteins, eosinophilcationic protein P and eosinophil protein X, were not changed during the treatment I period of 7 days. The results show that cetirizine dihydrochloride has an inhibitory effect on monocytes and T lymphocytes in vitro and ex vivo. Our findings support the clinical observations that cetirizine dihydrochloride has an antiinflammatory effect besides its H-1-blocking activity.	AARHUS UNIV, MARSELISBORG HOSP, DEPT DERMATOL, DK-8000 AARHUS C, DENMARK; NATL UNIV HOSP, MED ALLERGOL LAB, COPENHAGEN, DENMARK	Aarhus University			Zachariae, Claus Otto Carl/G-6144-2018	Zachariae, Claus Otto Carl/0000-0001-5506-1319; Deleuran, Bent/0000-0002-7079-1587				BEHRENDT H, 1990, CLIN EXP ALLERGY, V20, P25, DOI 10.1111/j.1365-2222.1990.tb02473.x; BERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P177, DOI 10.1016/0091-6749(88)90273-4; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; CHARLESWORTH EN, 1992, J PHARMACOL EXP THER, V262, P964; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; CIPRANDI G, 1992, NOV M INT AC BIOM DR; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; JENSEN JR, 1981, CLIN EXP IMMUNOL, V45, P118; JENSEN JR, 1983, J INVEST DERMATOL, V80, P53, DOI 10.1111/1523-1747.ep12531067; JUHLIN L, 1992, ACTA DERM-VENEREOL, V72, P197; JUHLIN L, 1988, BRIT J DERMATOL, V119, P67, DOI 10.1111/j.1365-2133.1988.tb07103.x; JUHLIN L, 1987, J ALLERGY CLIN IMMUN, V80, P599, DOI 10.1016/0091-6749(87)90014-5; KAPP A, 1991, J AM ACAD DERMATOL, V24, P555, DOI 10.1016/0190-9622(91)70081-C; KURZEJA A, 1989, LANCET, V1, P556; KYANAUNG U, 1992, J ALLERGY CLIN IMMUN, V90, P270, DOI 10.1016/0091-6749(92)90083-E; LEPREVOST C, 1988, INT ARCH ALLER A IMM, V87, P9, DOI 10.1159/000234641; MUHLETHALER K, 1990, ALLERGOLOGIE, V13, P265; PLAUT M, 1982, PHARM HISTAMINE RECE, P392; REIMERT CM, 1991, J IMMUNOL METHODS, V141, P97, DOI 10.1016/0022-1759(91)90214-Z; REIMERT CM, 1991, J IMMUNOL METHODS, V138, P285, DOI 10.1016/0022-1759(91)90177-H; REUNALA T, 1991, CLIN EXP ALLERGY, V21, P617, DOI 10.1111/j.1365-2222.1991.tb00855.x; RIHOUX JP, 1985, ANN ALLERGY, V55, P392; Sehmi R, 1993, Pediatr Allergy Immunol, V4, P13; TAN JQ, 1993, J IMMUNOL, V151, P4545; TERNOWITZ T, 1986, ARCH DERMATOL RES, V278, P454, DOI 10.1007/BF00455163; WALSH GM, 1991, INT ARCH ALLER A IMM, V95, P158, DOI 10.1159/000235422; WATSON WTA, 1989, J ALLERGY CLIN IMMUN, V84, P457, DOI 10.1016/0091-6749(89)90358-8	28	40	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1995	95	5	1				979	986		10.1016/S0091-6749(95)70098-6	http://dx.doi.org/10.1016/S0091-6749(95)70098-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QY917	7751519				2022-12-18	WOS:A1995QY91700009
J	SEDER, RA				SEDER, RA			ACQUISITION OF LYMPHOKINE-PRODUCING PHENOTYPE BY CD4+ T-CELLS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							INTERFERON-GAMMA PRODUCTION; STIMULATORY FACTOR; IFN-GAMMA; TRANSGENIC MICE; INTERLEUKIN-4; INVITRO; PRECURSORS; SECRETION; INDUCTION; CYTOKINE				SEDER, RA (corresponding author), NIAID,CLIN INVEST LAB,LYMPHOKINE REGULAT SECT,BETHESDA,MD 20892, USA.							CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HSIEH CS, 1993, INT IMMUNOL, V5, P371; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; MACATONIA SE, 1993, INT IMMUNOL, V5, P1119, DOI 10.1093/intimm/5.9.1119; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; POWERS GD, 1988, J IMMUNOL, V140, P3352; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SEDER RA, 1993, P NATL ACAD SCI USA, V90, P10188, DOI 10.1073/pnas.90.21.10188; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SWAIN SL, 1988, IMMUNOL REV, V102, P77, DOI 10.1111/j.1600-065X.1988.tb00742.x; SWAIN SL, 1990, J IMMUNOL, V144, P1788; SWAIN SL, 1988, J IMMUNOL, V141, P3445; SWAIN SL, 1990, FED PROC, V4, P2020; WEINBERG AD, 1990, J IMMUNOL, V144, P1800; WOLF SF, 1991, J IMMUNOL, V146, P3074	22	40	43	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	2	S			1195	1202		10.1016/0091-6749(94)90332-8	http://dx.doi.org/10.1016/0091-6749(94)90332-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QA020	7798560				2022-12-18	WOS:A1994QA02000012
J	APTER, AJ; ZUWALLACK, RL; CLIVE, J				APTER, AJ; ZUWALLACK, RL; CLIVE, J			COMMON MEASURES OF ASTHMA SEVERITY LACK ASSOCIATION FOR DESCRIBING ITS CLINICAL COURSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ASTHMA; PEAK EXPIRATORY FLOW RATE; INHALED ALBUTEROL; COMPLIANCE; INHALED BECLOMETHASONE	OBSTRUCTION; MANAGEMENT; PERCEPTION; MORTALITY; PATIENT; TRIALS	Background and Objective: To address the problems of increasing asthma morbidity and mortality rates, reliable severity measures must be identified. Accordingly, we compared three measures and their relationship to beclomethasone compliance. Methods: Three clinical measures (symptom scores, morning peak expiratory flow rates, and number of as needed albuterol inhalations with Nebulizer Chronologs [Forefront Technologies, Inc., Lakewood, Colo.]) were assessed daily in 13 adults with asthma for 8.9 +/- 2.1 weeks. The relationships among these three variables were analyzed in terms of Pearson correlation coefficients. These were evaluated for each of the three possible pairs of the three clinical measures for each of the 13 patients. The relationship between inhaled beclomethasone compliance and the pairwise correlations was studied with the use of nonparametric statistical procedures. Results: In four of the 13 patients, no pairwise correlations between any of the three severity measures were observed. The peak expiratory, flow rate-symptom score relationship was observed in eight patients, whereas peak expiratory flow rate-albuterol use and albuterol use-symptom score correlations were each seen in four patients. Mean beclomethasone compliance was 64% and was greatest in those patients whose albuterol use increased concurrently with symptom scores (94% vs 50%, p = 0.02). Conclusions: The commonly used measures of asthma severity symptom scores, peak flow rate, and beta-agonist use may not be interchangeable in describing the clinical course. Patients whose beta-agonist use is driven by symptoms tend to be more compliant with use of inhaled corticosteroids.	UNIV CONNECTICUT,CTR HLTH,CLIN RES CTR,FARMINGTON,CT; ST FRANCIS HOSP & MED CTR,HARTFORD,CT	University of Connecticut; Saint Francis Hospital & Medical Center	APTER, AJ (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV PULM MED,ALLERGY & IMMUNOL SECT,FARMINGTON,CT 06032, USA.							BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; BURROWS B, 1992, NEW ENGL J MED, V326, P560, DOI 10.1056/NEJM199202203260809; CLARK NM, 1992, AM REV RESPIR DIS, V145, P722, DOI 10.1164/ajrccm/145.3.722; CROSS D, 1991, J ALLERGY CLIN IMMUN, V87, P120, DOI 10.1016/0091-6749(91)90223-B; ELLIS ME, 1985, BRIT J DIS CHEST, V79, P43, DOI 10.1016/0007-0971(85)90006-3; GREENBERGER PA, 1988, NEW ENGL REG ALLERGY, V9, P147; JOBANPUTRA P, 1991, BRIT J GEN PRACT, V41, P410; MAWHINNEY H, 1991, ANN ALLERGY, V66, P294; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V77, P1, DOI 10.1016/0091-6749(86)90313-1; PEIFFER C, 1989, CLIN SCI, V77, P237, DOI 10.1042/cs0770237; RUBINFELD AR, 1976, LANCET, V1, P882; SEARS MR, 1988, J ALLERGY CLIN IMMUN, V82, P957, DOI 10.1016/0091-6749(88)90130-3; SHIM CS, 1980, AM J MED, V68, P11, DOI 10.1016/0002-9343(80)90155-2; SHIM CS, 1983, ARCH INTERN MED, V143, P890; SPECTOR SL, 1986, J ALLERGY CLIN IMMUN, V77, P65, DOI 10.1016/0091-6749(86)90325-8; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WILSON SR, 1993, MED CARE, V31, pMS49; 1991, J ALLERGY CLIN IMMUN, V88, P425; 1987, AM REV RESPIR DIS, V136, P225; 1990, MMWR-MORBID MORTAL W, V39, P493	21	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1994	94	4					732	737		10.1016/0091-6749(94)90181-3	http://dx.doi.org/10.1016/0091-6749(94)90181-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PM273	7930307				2022-12-18	WOS:A1994PM27300012
J	ALBERTS, WM				ALBERTS, WM			INDOOR AIR-POLLUTION - NO, NO2, CO, AND CO2	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Symposium on Building-Related and Home-Related Complaints and Illnesses: Sick Building Syndrome	DEC 03-05, 1992	LAKE BUENA VISTA, FL				NITROGEN-DIOXIDE EXPOSURE; OBSTRUCTIVE PULMONARY-DISEASE; CARBON-MONOXIDE; RESPIRATORY SYMPTOMS; HOCKEY PLAYERS; SHORT-TERM; HEALTH; REACTIVITY; VOLUNTEERS; CHILDREN		UNIV S FLORIDA,COLL PUBL HLTH,DEPT ENVIRONM & OCCUPAT HLTH,TAMPA,FL 33620	State University System of Florida; University of South Florida	ALBERTS, WM (corresponding author), UNIV S FLORIDA,COLL MED,DEPT INTERNAL MED,DIV PULM CRIT CARE & OCCUPAT MED,TAMPA,FL 33612, USA.							ALLRED EN, 1989, NEW ENGL J MED, V311, P406; BAKER MD, 1988, J PEDIATR-US, V113, P501, DOI 10.1016/S0022-3476(88)80638-3; BAUER M A, 1984, American Review of Respiratory Disease, V129, pA151; BEARD RR, 1982, PATTYS IND HYGIENE T; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42, DOI 10.1164/ajrccm/145.1.42; BRUNEKREEF B, 1987, 4TH P INT C IND AIR, V1, P304; BUNNELL DE, 1988, AVIAT SPACE ENVIR MD, V59, P1133; BURGESS WA, 1989, VENTILATION CONTROL; BYLIN G, 1988, EUR RESPIR J, V1, P606; BYLIN G, 1985, EUR J RESPIR DIS, V66, P205; CHANG L, 1988, TOXICOL APPL PHARM, V90, P451; DEKONING HW, 1985, B WORLD HEALTH ORGAN, V63, P11; DOUGLAS WW, 1989, MAYO CLIN PROC, V64, P291, DOI 10.1016/S0025-6196(12)65249-5; ELLENBECKER MJ, 1992, CLIN CHEST MED, V13, P193; FAWCETT TA, 1992, J OCCUP ENVIRON MED, V34, P12; FERNANDEZCALDAS E, 1992, MED CLIN N AM, V76, P935, DOI 10.1016/S0025-7125(16)30333-9; FRAMPTON MW, 1989, ENVIRON RES, V48, P179, DOI 10.1016/S0013-9351(89)80033-7; FRAMPTON MW, 1991, AM REV RESPIR DIS, V143, P522, DOI 10.1164/ajrccm/143.3.522; FREEMAN G, 1972, AM REV RESPIR DIS, V106, P563, DOI 10.1164/arrd.1972.106.4.563; GOLD DR, 1992, CLIN CHEST MED, V13, P215; GOLDSTEIN IF, 1988, ARCH ENVIRON HEALTH, V43, P138, DOI 10.1080/00039896.1988.9935842; GONG H, 1992, CLIN CHEST MED, V13, P201; HAZUCHA MJ, 1983, J APPL PHYSIOL, V54, P730, DOI 10.1152/jappl.1983.54.3.730; HEDBERG K, 1989, JAMA-J AM MED ASSOC, V262, P3014; ILANO AL, 1990, CHEST, V97, P165, DOI 10.1378/chest.97.1.165; KLEINMAN MT, 1983, J TOXICOL ENV HEALTH, V12, P815, DOI 10.1080/15287398309530472; LEVESQUE B, 1990, AM J PUBLIC HEALTH, V80, P594, DOI 10.2105/AJPH.80.5.594; LINN WS, 1985, ARCH ENVIRON HEALTH, V40, P313, DOI 10.1080/00039896.1985.10545939; LINN WS, 1986, ARCH ENVIRON HEALTH, V41, P292, DOI 10.1080/00039896.1986.9936699; MAGNUSSEN H, 1992, EUR RESPIR J, V5, P1040; MEREDITH T, 1988, BMJ-BRIT MED J, V296, P77, DOI 10.1136/bmj.296.6615.77; MOHESIN V, 1988, ARCH ENVIRON HEALTH, V43, P242; MORROW PE, 1992, AM REV RESPIR DIS, V145, P291, DOI 10.1164/ajrccm/145.2_Pt_1.291; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204, DOI 10.1093/oxfordjournals.aje.a116073; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; ROGER LJ, 1985, TOXICOLOGIST, V5, P70; ROSENSTOCK L, 1987, OCCUPATIONAL MED STA, P303; SAMET J, 1990, AM REV RESPIR DIS, V142, P915, DOI 10.1164/ajrccm/142.4.915; SAMET JM, 1988, AM REV RESPIR DIS, V137, P221, DOI 10.1164/ajrccm/137.1.221; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486, DOI 10.1164/ajrccm/136.6.1486; SAMET JM, 1990, TOXICOL IND HEALTH, V6, P247, DOI 10.1177/074823379000600204; SHEPS DS, 1990, ANN INTERN MED, V113, P343, DOI 10.7326/0003-4819-113-5-343; TRAYNOR GW, 1987, ENVIRON SCI TECHNOL, V21, P691, DOI 10.1021/es00161a010; WRIGHT G, 1973, ARCH ENVIRON HEALTH, V27, P349, DOI 10.1080/00039896.1973.10666400; 1992, LANCET, V339, P396; 1989, ASHRAE621989 AM SOC	46	40	42	0	15	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				289	295		10.1016/0091-6749(94)90088-4	http://dx.doi.org/10.1016/0091-6749(94)90088-4			7	Allergy; Immunology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077581				2022-12-18	WOS:A1994PG77000003
J	KLEINETEBBE, J; JOSTIES, C; FRANK, G; STALLEICKEN, D; BUSCHAUER, A; SCHUNACK, W; KUNKEL, G; CZARNETZKI, B				KLEINETEBBE, J; JOSTIES, C; FRANK, G; STALLEICKEN, D; BUSCHAUER, A; SCHUNACK, W; KUNKEL, G; CZARNETZKI, B			INHIBITION OF IGE-MEDIATED AND NON-IGE-MEDIATED HISTAMINE-RELEASE FROM HUMAN BASOPHIL LEUKOCYTES IN-VITRO BY A HISTAMINE H-1-ANTAGONIST, DESETHOXYCARBONYL-LORATADINE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ANTIHISTAMINES; BASOPHILS; HISTAMINE RELEASE; LORATADINE	H1-RECEPTOR ANTAGONISTS; ANTIALLERGIC ACTIVITY; PROTEIN-KINASE; ANTIHISTAMINE; ACTIVATION; ANTIGEN; H-2	Loratadine, a new nonsedating histamine H-1-antagonist, has been shown to inhibit immunologic release of inflammatory mediators in addition to its H-1-receptor blocking properties. After oral administration the agent is metabolized primarily to desethoxycarbonyl-loratadine (DCL). The basic piperidine, DCL, is readily soluble in water whereas the nonbasic urethane, loratadine, is insufficiently soluble in water for some in vitro investigations. Therefore we used the metabolite, DCL, to study its influence on in vitro leukocyte histamine release (LHR) in 24 allergic and 22 nonallergic subjects. IgE-mediated and calcium ionophore A23187-induced LHR were inhibited by DCL in a dose-dependent fashion (values of drug concentration to induce 30% inhibition after stimulation with inhalant antigen, anti-IgE, concanavalin A, and calcium ionophore A23187 were 6, 8, 5, and 11 mu mol/L, respectively). Higher concentrations of DCL caused mediator release in all subjects (n = 45, 30 mu mol/L DC: 11% +/- 2% LHR, 100 mu mol/L DCL: 35% +/- 1% LHR), abolishing any inhibitory effect of the drug. Rapid onset of inhibition by 10 mu mol/L DCL was found in kinetic studies (n = 10). The inhibition of anti-IgE-induced histamine secretion was synergistically increased by simultaneous preincubation of DCL with the potent histamine H-2-agonist, FRA-19. Additional data indicate that the inhibition of LHR by DCL might involve biochemical events that occur after cellular Ca++ influx because LHR induced by N-formyl-methionyl-leucyl-phenylalanine or the phorbol ester, 12-O-tetradecanoyl phorbol-12-acetate, was not significantly affected by DCL.	FREE UNIV BERLIN,HOSP RUDOLF VIRCHOW,DERMATOL CLIN,BERLIN,GERMANY; FREE UNIV BERLIN,HOSP RUDOLF VIRCHOW,CLIN IMMUNOL CLIN,BERLIN,GERMANY; FREE UNIV BERLIN,HOSP RUDOLF VIRCHOW,ASTHMA CLIN,BERLIN,GERMANY; ESSEX PHARMA,DEPT PHARMACEUT RES,MUNICH,GERMANY; FREE UNIV BERLIN,INST PHARM,BERLIN,GERMANY	Free University of Berlin; Free University of Berlin; Free University of Berlin; Free University of Berlin			Buschauer, Armin/D-2861-2009	Kleine-Tebbe, Joerg/0000-0002-2862-7353				ANDERSSON M, 1991, ALLERGY, V46, P540, DOI 10.1111/j.1398-9995.1991.tb00618.x; BARENHOLTZ HA, 1989, DICP ANN PHARMAC, V23, P445, DOI 10.1177/106002808902300601; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V81, P211, DOI 10.1016/0091-6749(88)90409-5; BERTHON B, 1992, ALLERGY S, V47, P46; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BUSCHAUER A, 1992, EUR J MED CHEM, V27, P321, DOI 10.1016/0223-5234(92)90145-Q; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DEVOS C, 1989, INT ARCH ALLER A IMM, V83, P862; GALLI SJ, 1988, ALLERGY PRINCIPLES P, P106; HILBERT J, 1987, J CLIN PHARMACOL, V27, P694, DOI 10.1002/j.1552-4604.1987.tb03090.x; KALINER MA, 1992, J ALLERGY CLIN IMMUN, V90, P725; KEMP JP, 1987, AM J RHINOL, V1, P151; KLEINETEBBE J, 1990, AGENTS ACTIONS, V30, P137, DOI 10.1007/BF01969020; KLEINETEBBE J, 1992, AGENTS ACTIONS, V35, P185, DOI 10.1007/BF01997498; KLEINETEBBE J, 1991, NEW TRENDS ALLERGY, V3, P152; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KREUTNER W, 1987, ALLERGY, V42, P57, DOI 10.1111/j.1398-9995.1987.tb02188.x; LETARI O, 1992, ALLERGY S, V47, P237; LICHTENSTEIN LM, 1975, J PHARMACOL EXP THER, V192, P441; LITTLE MM, 1989, J ALLERGY CLIN IMMUN, V83, P862, DOI 10.1016/0091-6749(89)90096-1; NABE M, 1989, CLIN EXP ALLERGY, V19, P512; NACLERIO RM, 1992, J ALLERGY CLIN IMMUN, V90, P715, DOI 10.1016/0091-6749(92)90157-W; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167, DOI 10.1164/ajrccm/142.1.167; NEMETH A, 1988, AGENTS ACTIONS, V23, P194, DOI 10.1007/BF02142538; PAUL D, 1988, ALLERGY S7, V43, P122; SIMONS FER, 1992, J ALLERGY CLIN IMMUN, V90, P705, DOI 10.1016/0091-6749(92)90156-V; SIRAGANIAN RP, 1980, MANUAL CLIN IMMUNOLO, P808; SKASSABROCIEK W, 1988, J ALLERGY CLIN IMMUN, V81, P175, DOI 10.1016/0091-6749(88)90262-X; SKASSABROCIEK W, 1988, J ALLERGY CLIN IMMUN, V81, P725, DOI 10.1016/0091-6749(88)91045-7; TEDESCHI A, 1991, ALLERGY, V46, P626, DOI 10.1111/j.1398-9995.1991.tb00634.x; TEMPLE DM, 1988, PROSTAGLANDINS, V35, P549, DOI 10.1016/0090-6980(88)90030-5; Tomioka H, 1979, Monogr Allergy, V14, P313; TUNG RS, 1981, J PHARMACOL EXP THER, V218, P642; 1992, J ALLERGY CLIN IMMUN, V90, P720	34	40	49	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1994	93	2					494	500		10.1016/0091-6749(94)90359-X	http://dx.doi.org/10.1016/0091-6749(94)90359-X			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	MY581	7509820				2022-12-18	WOS:A1994MY58100011
J	LIN, RY; SHEN, HD; HAN, SH				LIN, RY; SHEN, HD; HAN, SH			IDENTIFICATION AND CHARACTERIZATION OF A 30-KD MAJOR ALLERGEN FROM PARAPENAEUS-FISSURUS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SHRIMP; ALLERGEN; MONOCLONAL ANTIBODY	ANTIBODIES; ANTIGENS; SHRIMP; POLLEN; FOODS; GEL	The allergenic components of the shrimp (Parapenaeus fissurus) were identified by immunoblotting, with sera from 10 allergic patients. Six components, ranging in molecular weight from about 86 to 39 kd, showed IgE-binding activity and were identified as allergens of the shrimp. The component with a molecular weight of about 39 kd showed the highest frequency of IgE binding (70%) and was considered to be one of its major allergens. Two monoclonal antibodies against this 39 kd component were generated, and their antigenic cross-reactivity with five different kinds of seafood, shrimp, crab, cuttlefish, oyster, and pomfret was analyzed. Monoclonal antibody 1-6-10B reacted with the 39 kd component from shrimp only but monoclonal antibody 2-7-1E also reacted with the 39 kd component from crab. By extraction with 0.5% sodium dodecylsulfate and ethanol precipitation, a highly purified shrimp 39 kd component was obtained. In two-dimensional gel electrophoresis six isoforms of this purified 39 kd component, with isoelectric point values from 5 1 to 5 6, were identified No marked difference was observed when the ammo acid composition of this purified 39 kd allergen was compared with those of serum albumin from different animals. They all contain a high proportion of acidic amino acids. There was also a 62% to 83% sequence homology among three different pairs of peptide fragments of purified 39 kd components of shrimp and crab. In conclusion, a 39 kd major allergen from the shrimp has been identified and characterized in the present study. According to the suggestions of the International Union of Immunological Societies, this allergen is designated as Par f L	VET GEN HOSP TAIPEI,DEPT MED RES,TAIPEI 11217,TAIWAN; NATL DEF MED CTR,TRI SERV GEN HOSP,GRAD INST MED SCI,TAIPEI,TAIWAN; NATL DEF MED CTR,TRI SERV GEN HOSP,DEPT DERMATOL,TAIPEI,TAIWAN	National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center; Tri-Service General Hospital								ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; CHANG Z-N, 1988, Proceedings of the National Science Council Republic of China Part B Life Sciences, V12, P140; DAUL C B, 1991, Journal of Allergy and Clinical Immunology, V87, P192, DOI 10.1016/0091-6749(91)91497-H; GINAZZA E, 1980, J CHROMATOGR, V193, P1; Hardy PM., 1985, CHEM BIOCH AMINO ACI, P6; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; HSIEH JC, 1988, ANAL BIOCHEM, V170, P1, DOI 10.1016/0003-2697(88)90082-6; LEMANSKE RF, 1987, CLIN REV ALLERG, V5, P23; MARSH DG, 1987, J ALLERGY CLIN IMMUN, V80, P639, DOI 10.1016/0091-6749(87)90282-X; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; METCALFE DD, 1985, CLIN REV ALLERG, V3, P331, DOI 10.1007/BF02992999; MORGAN J E, 1990, Journal of Allergy and Clinical Immunology, V85, P170; NAGPAL S, 1989, J ALLERGY CLIN IMMUN, V83, P26, DOI 10.1016/0091-6749(89)90474-0; Peters T Jr, 1970, Adv Clin Chem, V13, P37, DOI 10.1016/S0065-2423(08)60385-6; SHEN HD, 1990, ELECTROPHORESIS, V11, P878, DOI 10.1002/elps.1150111018; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; SHEN HD, 1988, INT ARCH ALLER A IMM, V85, P167, DOI 10.1159/000234497	18	40	45	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1993	92	6					837	845		10.1016/0091-6749(93)90061-J	http://dx.doi.org/10.1016/0091-6749(93)90061-J			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ML893	8258618				2022-12-18	WOS:A1993ML89300009
J	IGARASHI, Y; KALINER, MA; HAUSFELD, JN; IRANI, AMA; SCHWARTZ, LB; WHITE, MV				IGARASHI, Y; KALINER, MA; HAUSFELD, JN; IRANI, AMA; SCHWARTZ, LB; WHITE, MV			QUANTIFICATION OF RESIDENT INFLAMMATORY CELLS IN THE HUMAN NASAL-MUCOSA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						INFLAMMATORY CELLS; NASAL MUCOSA; IMMUNOHISTOCHEMISTRY	HUMAN MAST-CELLS; INTERLEUKIN-2 RECEPTOR; MONOCLONAL-ANTIBODIES; INTERFERON-GAMMA; PATHO-PHYSIOLOGY; LYMPHOCYTES-T; HUMAN NOSE; IDENTIFICATION; HETEROGENEITY; SUBSETS	Background: To define the normal resident inflammatory cell population in the nasal mucosa, surgical specimens of human nasal turbinates were immunohistologically stained for various cell markers. Methods: Freeze-dried paraffin-embedded sections were stained for lymphocyte cell-surface markers, and Carnoy's fixed sections were stained for mast cells and immunoglobulins. The numbers of stained cells were microscopically counted. Results: T cells (CD3+ cells) were abundant in the lamina propria, and the number of CD4+ cells and CD8+ cells accounted for two thirds and one third of CD3+ cell number, respectively. Cells that stained for the alpha-chain of the interleukin-2 receptor (activated cells, CD25+) were limited and accounted for only 0.6% of CD3+ cell number. B cells (CD22+ cells) and monocytes and macrophages (CD14+ cells) were observed less frequently than T cells. Many immunoglobulin-producing cells were found in close proximity to the submucosal glands, and those cells were predominantly IgA+. Mast cells were widely distributed in the nasal mucosa, and about one third of these cells were stained for IgE molecules. Nonmast cells bearing IgE were rarely observed Conclusion: Thus the dominant cell in the nasal mucosa is a CD3+, CD4+, CD25-lymphocyte.	NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BLDG 10,ROOM 11C207,9000 ROCKVILLE PIKE,BETHESDA,MD 20892; WASHINGTON HOSP CTR,DEPT FACIAL PLAST & RECONSTRUCT SURG,WASHINGTON,DC 20010; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PEDIAT,RICHMOND,VA 23298	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); MedStar Washington Hospital Center; Virginia Commonwealth University; Virginia Commonwealth University								AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407, DOI 10.1164/ajrccm/142.6_Pt_1.1407; BACHERT C, 1989, AM J RHINOL, V4, P215; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BRANDTZAEG P, 1983, MOL IMMUNOL, V20, P941, DOI 10.1016/0161-5890(83)90036-6; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; CLARK EA, 1984, LEUKOCYTE TYPING 2, V2, P155; CONRAD DH, 1989, CLIN REV ALLERG, V7, P165; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DELPRETE G, 1988, J IMMUNOL, V140, P4193; ERNST PB, 1987, BASIC CLIN IMMUNOL, P159; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66, DOI 10.1159/000235281; FREEDMAN AS, 1984, LEUKOCYTE TYPING 2 H, V2, P443; GANZER U, 1988, ORL J OTO-RHINO-LARY, V50, P257, DOI 10.1159/000276000; GREENE WC, 1986, ANNU REV IMMUNOL, V4, P69, DOI 10.1146/annurev.iy.04.040186.000441; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; IRANI AA, 1986, CLIN RES, V34, pA277; IRANI AMA, 1989, CLIN EXP ALLERGY, V19, P143, DOI 10.1111/j.1365-2222.1989.tb02357.x; IRANI AMA, 1989, J HISTOCHEM CYTOCHEM, V37, P1509, DOI 10.1177/37.10.2674273; JARRY A, 1990, EUR J IMMUNOL, V20, P1097, DOI 10.1002/eji.1830200523; KING CL, 1989, P NATL ACAD SCI USA, V86, P10085, DOI 10.1073/pnas.86.24.10085; KIRSHENBAUM AS, 1989, J IMMUNOL, V142, P2424; KISHIMOTO T, 1988, ANNU REV IMMUNOL, V6, P485, DOI 10.1146/annurev.iy.06.040188.002413; LANIER LL, 1983, J IMMUNOL, V131, P1789; LAWRENCE ID, 1987, J IMMUNOL, V139, P3062; LEONARD WJ, 1982, NATURE, V300, P267, DOI 10.1038/300267a0; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; MEREDITH SD, 1989, J ALLERGY CLIN IMMUN, V84, P920, DOI 10.1016/0091-6749(89)90390-4; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; RAMBALDI A, 1987, EUR J IMMUNOL, V17, P153, DOI 10.1002/eji.1830170127; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; SIEGEL JP, 1987, SCIENCE, V238, P75, DOI 10.1126/science.3116668; STEIN H, 1985, LAB INVEST, V52, P676; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; STOOP AE, 1989, J ALLERGY CLIN IMMUN, V84, P734, DOI 10.1016/0091-6749(89)90302-3; WINTHER B, 1987, ARCH OTOLARYNGOL, V113, P59; WOOD GS, 1983, J IMMUNOL, V131, P212; YAM LT, 1988, ADV IMMUNOHISTOCHEMI, P1	38	40	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					1082	1093		10.1016/0091-6749(93)90223-3	http://dx.doi.org/10.1016/0091-6749(93)90223-3			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491941				2022-12-18	WOS:A1993LC97800017
J	PALMQVIST, M; BALDER, B; LOWHAGEN, O; MELANDER, B; SVEDMYR, N; WAHLANDER, L				PALMQVIST, M; BALDER, B; LOWHAGEN, O; MELANDER, B; SVEDMYR, N; WAHLANDER, L			LATE ASTHMATIC REACTION DECREASED AFTER PRETREATMENT WITH SALBUTAMOL AND FORMOTEROL, A NEW LONG-ACTING BETA-2-AGONIST	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGIC ASTHMA; BRONCHIAL ALLERGEN CHALLENGE; BETA-2-AGONIST; EARLY ASTHMATIC REACTION; LATE ASTHMATIC REACTION	SODIUM CROMOGLYCATE; INHALED SALBUTAMOL; ALLERGEN; RESPONSES; INHALATION; IMMEDIATE; HISTAMINE; RELEASE; TRIAL	The inhibitory effect of salbutamol and formoterol, a new long-acting beta(2)-agonist for inhalation, on the late asthmatic reaction (LAR), was studied in 12 patients with allergic asthma. After a single-blind, placebo-treatment control, equipotent bronchodilating doses of inhaled salbutamol (500-mu-g) and formoterol (30-mu-g) were administered 30 minutes before bronchial allergen challenge in a double-blind randomized design. The early asthmatic reaction was completely inhibited by both drugs (p < 0.01) but not by placebo. The LAR was also significantly inhibited by both drugs (p < 0.01); formoterol was only slightly, but significantly, more effective than salbutamol (p = 0.04). In contrast to some earlier studies, the present study indicates an inhibitory effect of beta(2)-agonists on the LAR.	GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT CLIN PHARMACOL,S-41345 GOTHENBURG,SWEDEN; CIBA GEIGY CORP,DEPT MED,GOTHENBURG,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg	PALMQVIST, M (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,CTR ASTHMA & ALLERGY,S-41345 GOTHENBURG,SWEDEN.							ARVIDSSON P, 1989, EUR RESPIR J, V2, P325; BALDER B, 1989, METODBESKRIVNING DRA, V1, P19; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BUTTCHERS PR, 1979, BRIT J PHARMACOL, V67, P23; CHURCH MK, 1983, BRIT J PHARMACOL, V78, P671, DOI 10.1111/j.1476-5381.1983.tb09419.x; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; DAHL R, 1982, EUR J RESPIR DIS S, V122, P167; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; DURHAM SR, 1984, J ALLERGY CLIN IMMUN, V74, P49, DOI 10.1016/0091-6749(84)90086-1; HARGREAVE FE, 1974, CAN MED ASSOC J, V110, P415; HEGARDT B, 1981, ALLERGY, V36, P115, DOI 10.1111/j.1398-9995.1981.tb04105.x; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323, DOI 10.1159/000227979; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; HOLGATE ST, 1985, INT ARCH ALLER A IMM, V77, P47, DOI 10.1159/000233752; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; LAM S, 1983, J ALLERGY CLIN IMMUN, V72, P134, DOI 10.1016/0091-6749(83)90520-1; LOFDAHL CG, 1989, ALLERGY, V44, P264, DOI 10.1111/j.1398-9995.1989.tb01068.x; LOWHAGEN O, 1990, HYGIEA S1, V1, P85; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; METZGER WJ, 1986, CHEST, V88, P369; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; PALMQVIST M, 1989, J ALLERGY CLIN IMMUN, V83, P244; PEPYS J, 1977, AM REV RESPIR DIS, V116, P573, DOI 10.1164/arrd.1977.116.4.573; PEPYS J, 1968, LANCET, V2, P134; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; SENN SJ, 1989, STAT MED, V8, P1339, DOI 10.1002/sim.4780081106; TWENTYMAN O P, 1990, Clinical and Experimental Allergy, V20, P94; TWENTYMAN OP, 1990, LANCET, V336, P1338, DOI 10.1016/0140-6736(90)92894-N; VANCAMPAGNE JGL, 1969, SCAND J RESPIR DIS, V50, P76; WARNER JO, 1978, LANCET, V2, P912; 1974, ACTA ALLERGOL, V29, P222	34	40	40	0	2	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					844	849		10.1016/0091-6749(92)90440-D	http://dx.doi.org/10.1016/0091-6749(92)90440-D			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1348515	Bronze			2022-12-18	WOS:A1992HN86000010
J	BRUNET, C; BEDARD, PM; LAVOIE, A; JOBIN, M; HEBERT, J				BRUNET, C; BEDARD, PM; LAVOIE, A; JOBIN, M; HEBERT, J			ALLERGIC RHINITIS TO RAGWEED POLLEN .2. MODULATION OF HISTAMINE-RELEASING FACTOR PRODUCTION BY SPECIFIC IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IMMUNOTHERAPY; RHINITIS; HRF; BASOPHIL; RELEASABILITY; HISTAMINE; RAGWEED; SYMPTOMS; IGE; IGG	HUMAN MONONUCLEAR-CELLS; ASTHMATIC-PATIENTS; IGE ANTIBODIES; FACTOR HRF; MAST-CELLS; LYMPHOCYTES; INVITRO; IDENTIFICATION; BASOPHILS	A number of cytokines, including histamine-releasing factors (HRFs), have a role to play in IgE-mediated asthma. However, the influence of HRF in allergic rhinitis without asthma remains to be revealed. This article presents a double-blind, placebo-controlled study on the role of HRF in ragweed-allergic rhinitis and its modulation by natural pollen exposure and specific immunotherapy (IT). Twenty-seven patients allergic to ragweed were randomly assigned to receive either preseasonal alum-precipitated aqueous extracts of ragweed or placebo. Before the onset of therapy and during the ragweed-pollen season, subjects were evaluated for each of the following: clinical scores, ragweed IgE and IgG antibody levels, and spontaneous and allergen-driven HRF production. Thirteen nonatopic volunteers were also studied in the same protocol. First, before the initiation of therapy, more HRF was produced by both unstimulated and ragweed-stimulated mononuclear cells (MNCs) of atopic subjects as compared to MNCs of nonatopic subjects. Second, MNCs of the placebo-treated group produced significantly more spontaneous and ragweed-specific HRF during the pollen season compared to the preseasonal values. Finally, specific IT not only improved the clinical manifestation of allergy but also prevented the seasonal rise of spontaneous and ragweed-driven HRF production, along with a well-known change in other immunologic parameters associated with successful IT.	CHU LAVAL,CTR RECH INFLAMMAT & IMMUNOL RHUMATOL,SUITE 9800,2705 BOUL LAURIER,QUEBEC CITY G1V 4G2,QUEBEC,CANADA	Laval University								ALAM R, 1989, J IMMUNOL, V143, P2280; ALAM R, 1988, CELL IMMUNOL, V115, P447, DOI 10.1016/0008-8749(88)90197-9; ALAM R, 1985, ANN ALLERGY, V55, P825; ALAM R, 1985, ALLERGY, V40, P124, DOI 10.1111/j.1398-9995.1985.tb02671.x; ALAM R, 1987, J ALLERGY CLIN IMMUN, V79, P103, DOI 10.1016/S0091-6749(87)80023-4; ALAM R, 1984, ANN ALLERGY, V53, P66; ALAM R, 1991, Journal of Allergy and Clinical Immunology, V87, P241, DOI 10.1016/0091-6749(91)91690-U; BAEZA ML, 1989, J CLIN INVEST, V83, P1204, DOI 10.1172/JCI114002; BEAULIEU L, 1986, J IMMUNOL METHODS, V86, P131, DOI 10.1016/0022-1759(86)90276-0; BEDARD PM, 1986, J ALLERGY CLIN IMMUN, V78, P1121, DOI 10.1016/0091-6749(86)90260-5; BROIDE DH, 1990, J IMMUNOL, V145, P1838; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P76, DOI 10.1016/S0091-6749(05)80043-0; EZEAMUZIE IC, 1983, AGENTS ACTIONS, V13, P222, DOI 10.1007/BF01967337; EZEAMUZIE IC, 1986, AGENTS ACTIONS, V18, P159, DOI 10.1007/BF01988010; GOETZL EJ, 1984, IMMUNOLOGY, V53, P227; HEBERT J, 1988, ANN ALLERGY, V60, P226; HEBERT J, 1988, AM J RHINOL, V2, P71; IRONS JS, 1977, J ALLERGY CLIN IMMUN, V59, P190, DOI 10.1016/0091-6749(77)90149-X; KAPLAN AP, 1985, J IMMUNOL, V135, P2027; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; MECHERI S, 1988, IMMUNOLOGY, V64, P11; MOURAD W, 1987, CLIN EXP IMMUNOL, V67, P391; PRUZANSKY JJ, 1967, J ALLERGY, V39, P44, DOI 10.1016/0021-8707(67)90126-8; SEDGWICK JD, 1981, CLIN EXP IMMUNOL, V45, P409; THUESON DO, 1979, J IMMUNOL, V123, P626; WHITE MV, 1988, J IMMUNOL, V141, P3575; 1985, SAS USERS GUIDE STAT	29	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				87	94		10.1016/S0091-6749(05)80044-2	http://dx.doi.org/10.1016/S0091-6749(05)80044-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1370511	Bronze			2022-12-18	WOS:A1992GZ90800010
J	JAMES, JM; COOKE, SK; BARNETT, A; SAMPSON, HA				JAMES, JM; COOKE, SK; BARNETT, A; SAMPSON, HA			ANAPHYLACTIC REACTIONS TO A PSYLLIUM-CONTAINING CEREAL	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PSYLLIUM; IMMUNOBLOT; ANAPHYLAXIS	MODERATE HYPERCHOLESTEROLEMIA; OCCUPATIONAL ASTHMA; IGE SENSITIZATION; PRUDENT DIET; NURSES; HYPERSENSITIVITY; INGESTION; MILD	Historical data were obtained by questionnaire and telephone survey on 20 of 24 women with reported allergic reactions to a psyllium-containing cereal, Heartwise. Protein fractions from this new cereal, as well as from psyllium mucilloid and a psyllium-containing laxative, Metamucil, were extracted, quantitated, and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Patients' sera were collected, and specific IgE and IgG antibodies to these psyllium antigens were detected by immunoblotting techniques. Of the 20 women evaluated, all but six were nurses. Eighteen (90%) of the women had historical and/or laboratory evidence of atopy. Exposures included ingestion or dispensing of psyllium-containing products. Only three women denied prior exposure to psyllium. Symptoms developed shortly after small amounts of the cereal were ingested and most commonly included moderate to severe wheezing, throat and chest tightness, and urticaria. All the women required medical therapy, 11 (55%) in an emergency room. Specific IgE and IgG antibodies to various psyllium protein fractions were documented in all the subjects. It was concluded that individuals sensitized by occupational exposure to psyllium dust are at high risk for allergic reactions to ingested psyllium-containing products.	JOHNS HOPKINS UNIV HOSP, SCH MED, CMSC-1103, 600 N WOLFE ST, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine								ASCHER MS, 1941, J ALLERGY, P607; BARDY JD, 1987, AM REV RESPIR DIS, V135, P1033; BELL LP, 1989, JAMA-J AM MED ASSOC, V261, P3419, DOI 10.1001/jama.261.23.3419; BeMiller J. N., 1973, IND GUMS, P339; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSSE WW, 1975, ANN INTERN MED, V83, P361, DOI 10.7326/0003-4819-83-3-361; CARTIER A, 1987, CLIN ALLERGY, V17, P1, DOI 10.1111/j.1365-2222.1987.tb02313.x; CHAN JKC, 1988, CEREAL FOOD WORLD, V33, P919; GORANSSON K, 1979, SCAND J WORK ENV HEA, V5, P251; KAPLAN MJ, 1990, NEW ENGL J MED, V323, P1072; KIRBY J, 1986, J ALLERGY CLIN IMMUN, V77, P134; LANTNER RR, 1990, JAMA-J AM MED ASSOC, V264, P2534, DOI 10.1001/jama.264.19.2534; LEVIN EG, 1990, ARCH INTERN MED, V150, P1822, DOI 10.1001/archinte.150.9.1822; MACHADO L, 1979, ALLERGY, V34, P51, DOI 10.1111/j.1398-9995.1979.tb02000.x; MACHADO L, 1984, ALLERGY, V39, P65, DOI 10.1111/j.1398-9995.1984.tb01934.x; MATRICARDI PM, 1989, ANN ALLERGY, V63, P532; NELSON WL, 1987, J OCCUP ENVIRON MED, V29, P497; SCHOENWETTER WF, 1985, J ALLERGY CLIN IMMUN, V75, P209, DOI 10.1016/0091-6749(85)90555-X; SEGGEV JS, 1984, ANN ALLERGY, V53, P325; SUHONEN R, 1983, ALLERGY, V38, P363, DOI 10.1111/j.1398-9995.1983.tb04132.x; VOLLER A, 1986, MANUAL CLIN IMMUNOLO, P106; VYSZENSKI-MOHER D, 1990, Journal of Allergy and Clinical Immunology, V85, P152; ZALOGA GP, 1984, J ALLERGY CLIN IMMUN, V74, P79, DOI 10.1016/0091-6749(84)90091-5	24	40	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1991	88	3	1				402	408		10.1016/0091-6749(91)90104-V	http://dx.doi.org/10.1016/0091-6749(91)90104-V			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GG126	1890270				2022-12-18	WOS:A1991GG12600036
J	AALBERS, R; KAUFFMAN, HF; GROEN, H; KOETER, GH; DEMONCHY, JGR				AALBERS, R; KAUFFMAN, HF; GROEN, H; KOETER, GH; DEMONCHY, JGR			THE EFFECT OF NEDOCROMIL SODIUM ON THE EARLY AND LATE REACTION AND ALLERGEN-INDUCED BRONCHIAL HYPERRESPONSIVENESS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							LATE ASTHMATIC RESPONSES; INDUCED BRONCHOCONSTRICTION; AIRWAY RESPONSIVENESS; INDUCED BRONCHOSPASM; HISTAMINE; CROMOGLYCATE; HYPERREACTIVITY; CHALLENGE; METHACHOLINE; INDOMETHACIN	Bronchial hyperresponsiveness (BHR) to methacholine was studied in 14 patients with asthma and five healthy control subjects, with and without pretreatment with nedocromil sodium, 3 and 24 hours after allergen challenge. Eleven patients demonstrated a dual asthmatic response. A significant decrease in the provocative concentration causing a 20% fall in FEV1 was found from a geometric mean starting value of 1.18 mg/ml on the control day to 0.24 mg/ml (p < 0.001) and to 0.17 mg/ml (p < 0.001) 3 and 24 hours after allergen challenge. A significant correlation was observed between the increased BHR at 3 hours and the magnitude of the late response (r = -0.57; p < 0.05). Nedocromil sodium (6 mg) significantly inhibited the increase in BHR, 1 mg/ml (p < 0.001) at 3 hours and 0.50 mg/ml (p < 0.001) at 24 hours. Nedocromil sodium shifted the severity of the early allergic reaction (EAR) from mean -34.8% to -6.9% and inhibited the later allergic reaction (LAR) from -30.5% to +0.4% (p < 0.005). From the study can be concluded that nedocromil sodium inhibits the EAR and LAR and the allergen-induced increase in BHR. The inhibitory effect of nedocromil sodium on the LAR may be related to its ability to inhibit the increased BHR before the development of the LAR.	STATE UNIV GRONINGEN HOSP,DEPT PULM,INTERNAL MED CLIN,9713 EZ GRONINGEN,NETHERLANDS	University of Groningen	AALBERS, R (corresponding author), STATE UNIV GRONINGEN HOSP,DEPT ALLERGOL,INTERNAL MED CLIN,DOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.		Groen, Henk/B-2163-2013	Groen, Henk/0000-0002-6629-318X				ABRAHAM WM, 1988, J APPL PHYSIOL, V65, P1062, DOI 10.1152/jappl.1988.65.3.1062; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; BRITTON JR, 1988, AM REV RESPIR DIS, V138, P530, DOI 10.1164/ajrccm/138.3.530; CHANYEUNG M, 1977, AM REV RESPIR DIS, V116, P1023; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; COCKCROFT DW, 1987, THORAX, V42, P302, DOI 10.1136/thx.42.4.302; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1977, AM REV RESPIR DIS, V119, P505; CRIMI E, 1989, J ALLERGY CLIN IMMUN, V83, P985, DOI 10.1016/0091-6749(89)90116-4; CRIMI E, 1987, CLIN ALLERGY, V17, P135, DOI 10.1111/j.1365-2222.1987.tb02331.x; DAHL R, 1986, EUR J RESPIR DIS, V69, P263; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DIAZ P, 1989, AM REV RESPIR DIS, V139, P1383, DOI 10.1164/ajrccm/139.6.1383; DIXON CMS, 1987, THORAX, V42, P462, DOI 10.1136/thx.42.6.462; DIXON CMS, 1990, BRIT J CLIN PHARMACO, V30, P371, DOI 10.1111/j.1365-2125.1990.tb03786.x; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; DURHAM SR, 1987, J ALLERGY CLIN IMMUN, V79, P398, DOI 10.1016/0091-6749(87)90161-8; FABBRI LM, 1985, AM REV RESPIR DIS, V132, P1010; GOKEMEIJER JDM, 1976, HYPERREACTIVITEIT LU; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOLGATE ST, 1986, EUR J RESPIR DIS, V69, P149; HOLTZMAN MJ, 1980, AM REV RESPIR DIS, V122, P17; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; JOOS GF, 1987, B EUR PHYSIOPATH RES, V23, pS312; KIRBY JG, 1989, J APPL PHYSIOL, V66, P578, DOI 10.1152/jappl.1989.66.2.578; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44, DOI 10.1164/ajrccm/137.1.44; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LANES S, 1986, J APPL PHYSIOL, V61, P864, DOI 10.1152/jappl.1986.61.3.864; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P406; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P747, DOI 10.1016/0091-6749(87)90206-5; RAINEY D K, 1989, European Respiratory Journal, V2, p561S; RICHARDS R, 1989, CLIN EXP ALLERGY, V19, P285, DOI 10.1111/j.1365-2222.1989.tb02385.x; ROBUSCHI M, 1987, CLIN ALLERGY, V17, P69, DOI 10.1111/j.1365-2222.1987.tb02321.x; RUGGIERI F, 1989, European Respiratory Journal, V2, p568S; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; THOMPSON NC, 1986, CLIN ALLERGY, V16, P309; WELLS E, 1986, J IMMUNOL, V137, P3941	40	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					993	1001		10.1016/0091-6749(91)90422-K	http://dx.doi.org/10.1016/0091-6749(91)90422-K			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	1851191	Bronze			2022-12-18	WOS:A1991FM09500012
J	MEZZETTI, M; SOLOPERTO, M; FASOLI, A; MATTOLI, S				MEZZETTI, M; SOLOPERTO, M; FASOLI, A; MATTOLI, S			HUMAN BRONCHIAL EPITHELIAL-CELLS MODULATE CD3 AND MITOGEN-INDUCED DNA-SYNTHESIS IN T-CELLS BUT FUNCTION POORLY AS ANTIGEN-PRESENTING CELLS COMPARED TO PULMONARY MACROPHAGES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							IA ANTIGENS; PROLIFERATION; LYMPHOCYTES; EXPRESSION; INTERLEUKIN-2; FIBROBLASTS; INHIBITION; ANTIBODY	This study was undertaken to investigate the ability of bronchial epithelial cells (ECs) to function as accessory cells. Pulmonary monocytes were our reference cells. ECs and pulmonary monocytes were isolated from the bronchial mucosa and pulmonary parenchyma of subjects undergoing lobectomy for standard clinical reasons. Circulating autologous T cells were rigorously depleted of accessory cells to the extent that they lost the capacity to respond to mitogenic lectins alone. ECs restored mitogen-induced DNA synthesis and DNA synthesis triggered by CD3 cross-linking in T cells, as did pulmonary macrophages, and this was unrelated to HLA-DR expression. The ability of promoting T cell proliferation after CD3 cross-linking was, in part, due to the secretory products of ECs, since their supernatants were also effective. Interferon-gamma-treated ECs were capable of presenting antigens to autologous T cells. This was an HLA-DR-restricted phenomenon, but EC efficiency in this system was < 40% of efficiency demonstrated by pulmonary monocytes. However, ECs greatly upregulated antigen-specific responses supported by pulmonary monocytes.	UNIV MILAN,SCH MED,DEPT INTERNAL MED,LUNG CELLULAR & MOLEC BIOL SECT,PADIGLIONE LITTA,I-20122 MILAN,ITALY; UNIV MILAN,SCH MED,DEPT THORAC SURG,I-20122 MILAN,ITALY	University of Milan; University of Milan			Mattoli, Sabrina/H-8211-2014	Mattoli, Sabrina/0000-0002-6866-604X				BAUMGARTEN H, 1986, J IMMUNOL METHODS, V94, P91, DOI 10.1016/0022-1759(86)90219-X; CARRERA AC, 1988, J IMMUNOL, V141, P1919; FRIERS KA, 1984, P NATL ACAD SCI USA, V81, P4917; GASPARI AA, 1988, J IMMUNOL, V140, P2956; GEPPERT TD, 1985, J IMMUNOL, V135, P3750; GEPPERT TD, 1987, J IMMUNOL, V138, P385; GLANVILLE AR, 1989, AM REV RESPIR DIS, V139, P330, DOI 10.1164/ajrccm/139.2.330; GOODWIN JS, 1978, J CLIN INVEST, V62, P753, DOI 10.1172/JCI109186; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HAUSSIAU FA, 1989, J IMMUNOL, V143, P2520; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HOLSTI MA, 1989, J IMMUNOL, V143, P2514; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; LONDEI M, 1984, NATURE, V312, P639, DOI 10.1038/312639a0; MASON DW, 1984, IMMUNOBIOLOGY, V168, P167, DOI 10.1016/S0171-2985(84)80107-2; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; MATTOLI S, 1990, J CELL PHYSIOL, V142, P379, DOI 10.1002/jcp.1041420222; MATTOLI S, 1990, AM J PHYSIOL, V259, pL320, DOI 10.1152/ajplung.1990.259.4.L320; MATTOLI S, 1990, CELLULAR COMMUNICATI, P25; MEUER SC, 1986, J IMMUNOL, V136, P4106; ROSENTHA.AS, 1973, J EXP MED, V138, P1194, DOI 10.1084/jem.138.5.1194; SCHWARTZ RH, 1976, J IMMUNOL, V117, P531; TODD I, 1985, CLIN EXP IMMUNOL, V61, P265; WALKER C, 1983, J IMMUNOL, V130, P1770; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844	25	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1991	87	5					930	938		10.1016/0091-6749(91)90414-J	http://dx.doi.org/10.1016/0091-6749(91)90414-J			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FM095	1827479				2022-12-18	WOS:A1991FM09500004
J	BERDY, SS; BLOCH, KJ				BERDY, SS; BLOCH, KJ			SCHNITZLER SYNDROME - A BROADER CLINICAL SPECTRUM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							CHRONIC URTICARIA; MONOCLONAL IMMUNOGLOBULINS; MACROGLOBULINEMIA; VASCULITIS; IGM; DEFICIENCY; DISEASE; PATIENT	Schnitzler's syndrome is characterized by chronic urticaria, recurrent fever, bone pain, and lymphadenopathy in conjunction with a serum IgM M component in a concentration that is usually < 10,000 mg/L. Complement activation and cryoprecipitation do not appear to be involved. We report two additional patients who share many of the characteristics of this entity. These patients differ from patients previously reported because of the markedly elevated IgM M-component concentration in one patient and the severity of anemia in the second patient. An increased frequency of IgG autoantibodies to interleukin-1-alpha has been reported by other investigators; it has been suggested that an antibody-mediated prolongation of the half-life of interleukin-1-alpha might account for some of the symptoms and signs of this disorder. However, neither the mediators involved in the induction of nonpruritic urticaria nor the role of the IgM M component has been established.	MASSACHUSETTS GEN HOSP,GEN MED SERV,CLIN IMMUNOL UNIT,55 FRUIT ST,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,GEN MED SERV,ALLERGY UNIT,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital								ATKINSON JP, 1977, MEDICINE, V56, P225, DOI 10.1097/00005792-197705000-00004; BARRIERE H, 1976, SEM HOP PARIS, V52, P221; BARRIERE H, 1974, B SOC FR DERMATOL SY, V81, P361; CLAUVEL JP, 1982, CLIN IMMUNOL IMMUNOP, V25, P348, DOI 10.1016/0090-1229(82)90199-4; DIDIERJEAN L, 1990, J INVEST DERMATOL, V94, P575; DOUTRE MS, 1987, ANN ALLERGY, V58, P413; FARHANGI M, 1986, SEMIN ONCOL, V13, P366; GEHA RS, 1985, NEW ENGL J MED, V312, P534, DOI 10.1056/NEJM198502283120902; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; GOREVIC PD, 1988, IMMUNOLOGICAL DISEAS, P1687; HAUSER C, 1986, J IMMUNOL, V136, P3317; JANIER M, 1989, J AM ACAD DERMATOL, V20, P206, DOI 10.1016/S0190-9622(89)70023-2; KAPLAN AP, 1985, ALLERGY, P439; LAMBERT D, 1982, NOUV PRESSE MED, V11, P1948; LARSON EB, 1984, MEDICINE, V63, P82, DOI 10.1097/00005792-198403000-00002; LOUGHLIN S, 1978, ARCH DERMATOL, V114, P879; MCDUFFIE FC, 1973, MAYO CLIN PROC, V48, P340; OLSEN E, 1980, ACTA MED SCAND, V207, P379; SANCHEZ NP, 1982, J AM ACAD DERMATOL, V7, P599, DOI 10.1016/S0190-9622(82)70139-2; SAURAT JH, 1988, DERMATOLOGICA, V177, P259; SCHNITZLER L, 1974, B SOC FR DERMATOL SY, V81, P363; SCHNITZLER L, 1989, ANN DERMATOL VENER, V116, P54; SCHNITZLER L, 1990, MED HYG, V48, P727; SERGENT JS, 1976, MEDICINE, V55, P1, DOI 10.1097/00005792-197601000-00001; SOTER NA, 1974, J INVEST DERMATOL, V63, P485, DOI 10.1111/1523-1747.ep12680443	25	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1991	87	4					849	854		10.1016/0091-6749(91)90132-8	http://dx.doi.org/10.1016/0091-6749(91)90132-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FG059	1826507				2022-12-18	WOS:A1991FG05900015
J	CRIMI, E; VOLTOLINI, S; TROISE, C; GIANIORIO, P; CRIMI, P; BRUSASCO, V; NEGRINI, AC				CRIMI, E; VOLTOLINI, S; TROISE, C; GIANIORIO, P; CRIMI, P; BRUSASCO, V; NEGRINI, AC			LOCAL IMMUNOTHERAPY WITH DERMATOPHAGOIDES EXTRACT IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							PTERONYSSINUS ANTIGEN; CONTROLLED TRIAL; HOUSE DUST; HYPOSENSITIZATION; CHILDREN; BRONCHOPROVOCATION; INVIVO	Local immunotherapy (LIT) with Dermatophagoides extract or placebo were administered to two groups of 11 patients with allergic asthma in a double-blind fashion. All patients received cromolyn sodium (20 mg four times a day) during treatments. Bronchial provocation tests with allergen and methacholine were performed before, 1 week, and 4 weeks after the end of treatments. Symptom score, drug consumption, and peak expiratory flow were monitored daily from 2 weeks before to 4 weeks after treatments. Compared to baseline, early bronchial sensitivity to allergen was significantly reduced both 1 week (p < 0.0005) and 4 weeks (p < 0.01) after LIT but not after placebo administration. Late bronchial reaction to allergen occurred similarly after placebo administration and LIT. However, in the group with LIT, the severity of late reaction was unchanged after treatment in spite of the significantly larger doses of allergen administered to provoke the early asthmatic reaction. Neither symptom score, nor drug consumption, nor peak expiratory flow were significantly different in the two groups before and during the treatment period even though both symptom score and drug consumption tended to be reduced after LIT. We conclude that LIT may be an effective and safe alternative to traditional immunotherapy.	UNIV GENOA, INST HYG & PREVENT MED COMMUNITY MED, I-16132 GENOA, ITALY; SAN MARTINO HOSP, SERV ALLERGY, GENOA, ITALY	University of Genoa; University of Genoa; IRCCS AOU San Martino IST	CRIMI, E (corresponding author), UNIV GENOA, INST SPORTS MED CLIN RESP PHYSIOL, VIALE BENEDETTO XV 10, I-16132 GENOA, ITALY.							ANDERSON HC, 1983, RAST INHIBITION PROC; BONER AL, 1986, ANN ALLERGY, V57, P367; BONER AL, 1986, ANN ALLERGY, V57, P363; BOOIJ-NOORD H, 1972, Clinical Allergy, V2, P43, DOI 10.1111/j.1365-2222.1972.tb01267.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; CRIMI E, 1986, J ALLERGY CLIN IMMUN, V78, P908, DOI 10.1016/0091-6749(86)90239-3; CRIMI E, 1986, ANN ALLERGY, V56, P183; FILIPPO S, 1984, RHINOLOGY, V22, P261; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P40, DOI 10.1159/000227899; LAI CKW, 1989, CLIN EXP ALLERGY, V19, P209, DOI 10.1111/j.1365-2222.1989.tb02366.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MEHTA S B, 1975, Clinical Allergy, V5, P279; MELLILLO G, 1980, RESPIRATORY ALLERGY, P203; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; OHMAN JL, 1989, J ALLERGY CLIN IMMUN, V84, P133, DOI 10.1016/0091-6749(89)90313-8; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; ROHATGI N, 1988, J ALLERGY CLIN IMMUN, V82, P389, DOI 10.1016/0091-6749(88)90010-3; SMITH AP, 1971, BRIT MED J, V4, P204, DOI 10.1136/bmj.4.5781.204; TAYLOR WW, 1984, J ALLERGY CLIN IMMUN, V74, P230; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399, DOI 10.1111/j.1365-2222.1989.tb02405.x; WARNER JO, 1978, LANCET, V2, P912; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1	23	40	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1991	87	3					721	728		10.1016/0091-6749(91)90395-5	http://dx.doi.org/10.1016/0091-6749(91)90395-5			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FB801	2005326	Bronze			2022-12-18	WOS:A1991FB80100019
J	STANKUS, RP; HORNER, WE; LEHRER, SB				STANKUS, RP; HORNER, WE; LEHRER, SB			IDENTIFICATION AND CHARACTERIZATION OF IMPORTANT COCKROACH ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TULANE UNIV, SCH MED, ALLERGY & CLIN IMMUNOL SECT, NEW ORLEANS, LA 70112 USA	Tulane University					NIAID NIH HHS [AI22918] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022918] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1970, ANN ALLERGY, V28, P543; FEINBERG AR, 1956, J ALLERGY, V27, P437, DOI 10.1016/0021-8707(56)90103-4; HORNER WE, UNPUB COMMON GERMAN; KANG B, 1985, CLIN REV ALLERG, V3, P363, DOI 10.1007/BF02993001; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; LEHRER SB, UNPUB COMP COCKROACH; MATHEWS KP, 1989, IMMUNOL ALLERGY CLIN, V9, P321; MENON P, IN PRESS ANN ALLERGY; RICHMAN PG, 1984, J ALLERGY CLIN IMMUN, V73, P590, DOI 10.1016/0091-6749(84)90516-5; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V81, P548, DOI 10.1016/0091-6749(88)90195-9; STEINBERG DR, 1987, J ALLERGY CLIN IMMUN, V80, P586, DOI 10.1016/0091-6749(87)90012-1; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; WU CH, 1988, J ALLERGY CLIN IMMUN, V82, P727, DOI 10.1016/0091-6749(88)90071-1	14	40	42	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1990	86	5					781	786		10.1016/S0091-6749(05)80183-6	http://dx.doi.org/10.1016/S0091-6749(05)80183-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EJ631	2229843				2022-12-18	WOS:A1990EJ63100011
J	PARIS, S; FITTING, C; RAMIREZ, E; LATGE, JP; DAVID, B				PARIS, S; FITTING, C; RAMIREZ, E; LATGE, JP; DAVID, B			COMPARISON OF DIFFERENT EXTRACTION METHODS OF ALTERNARIA ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									INST PASTEUR,IMMUNOALLERGY UNIT,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	PARIS, S (corresponding author), INST PASTEUR,MYCOL UNIT,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Latge, Jean Paul/C-9846-2014; latge, jean paul/F-3581-2011					[Anonymous], 1968, PLANT PATHOLOGISTS P; AUKRUST L, 1985, Allergy (Copenhagen), V40, P43, DOI 10.1111/j.1398-9995.1985.tb02641.x; BENGTSSON A, 1986, INT ARCH ALLER A IMM, V80, P383, DOI 10.1159/000234085; BUSH RK, 1983, J ALLERGY CLIN IMMUN, V71, P239, DOI 10.1016/0091-6749(83)90105-7; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; EVANS HJ, 1972, METHOD ENZYMOL, V24, P473; FADEL R, 1986, J ALLERGY CLIN IMMUN, V77, P242; HELM RM, 1987, INT ARCH ALLER A IMM, V82, P178, DOI 10.1159/000234184; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; HOFFMAN DR, 1984, MOULD ALLERGY, P104; KROUTIL LA, 1987, J ALLERGY CLIN IMMUN, V80, P170, DOI 10.1016/0091-6749(87)90126-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAO J, 1985, INT ARCH ALLER A IMM, V76, P289, DOI 10.1159/000233709; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; NYHOLM L, 1983, J ALLERGY CLIN IMMUN, V71, P461, DOI 10.1016/0091-6749(83)90462-1; PARIS S, UNPUB INT ARCH ALLER; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P229; STERINGER I, 1987, INT ARCH ALLER A IMM, V84, P190, DOI 10.1159/000234422; SWEENEY M, 1985, J ALLERGY CLIN IMMUN, V75, P118, DOI 10.1016/0091-6749(85)90188-5; TEE RD, 1987, J ALLERGY CLIN IMMUN, V79, P627, DOI 10.1016/S0091-6749(87)80159-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIJAY HM, 1987, INT ARCH ALLER A IMM, V83, P325, DOI 10.1159/000234316; VIJAY HM, 1985, INT ARCH ALLER A IMM, V78, P37, DOI 10.1159/000233860; VIJAY HM, 1979, INT ARCH ALLER A IMM, V60, P229, DOI 10.1159/000232347; WEEKE B, 1974, ACTA ALLERGOL, V29, P402, DOI 10.1111/j.1398-9995.1974.tb01661.x; WEEKE B, 1973, MANUAL QUANTITATIVE, P47; WIDE L, 1967, LANCET, V2, P1105	28	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1990	85	5					941	948		10.1016/0091-6749(90)90081-E	http://dx.doi.org/10.1016/0091-6749(90)90081-E			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DD959	2332567				2022-12-18	WOS:A1990DD95900019
J	HAKANSSON, L; CARLSON, M; STALENHEIM, G; VENGE, P				HAKANSSON, L; CARLSON, M; STALENHEIM, G; VENGE, P			MIGRATORY RESPONSES OF EOSINOPHIL AND NEUTROPHIL GRANULOCYTES FROM PATIENTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV HOSP UPPSALA, DEPT LUNG MED, S-75185 UPPSALA, SWEDEN	Uppsala University; Uppsala University Hospital	HAKANSSON, L (corresponding author), UNIV HOSP UPPSALA, DEPT CLIN CHEM, INFLAMMAT RES LAB, S-75185 UPPSALA, SWEDEN.							BASS DA, 1980, J CLIN INVEST, V66, P1265, DOI 10.1172/JCI109978; CAMPBELL HD, 1987, P NATL ACAD SCI USA, V84, P6629, DOI 10.1073/pnas.84.19.6629; CARLSON M, 1989, European Journal of Clinical Investigation, V19, pA59; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DEMONCHY JGR, 1988, PRETREATMENT INHALED, P249; DESIMONE C, 1982, CLIN EXP IMMUNOL, V48, P249; FORSHAM PH, 1948, J CLIN ENDOCRINOL, V8, P15, DOI 10.1210/jcem-8-1-15; FUKUDA T, 1985, AM REV RESPIR DIS, V132, P981; GOSSET P, 1986, CLIN EXP IMMUNOL, V65, P654; GRIFFIN E, UNPUB INCREASED CHEM; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; HAKANSSON L, 1980, SCAND J IMMUNOL, V11, P271, DOI 10.1111/j.1365-3083.1980.tb00235.x; HAKANSSON L, 1983, SCAND J IMMUNOL, V18, P531, DOI 10.1111/j.1365-3083.1983.tb00888.x; HAKANSSON L, 1984, SCAND J IMMUNOL, V19, P63, DOI 10.1111/j.1365-3083.1984.tb00900.x; HAKANSSON L, 1985, J LEUKOCYTE BIOL, V38, P521, DOI 10.1002/jlb.38.4.521; HAKANSSON L, 1987, J LEUKOCYTE BIOL, V42, P689, DOI 10.1002/jlb.42.6.689; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; KELLER HU, 1977, CLIN EXP IMMUNOL, V27, P377; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; METCALF D, 1986, BLOOD, V67, P37; PRIN L, 1983, INT ARCH ALLER A IMM, V72, P336, DOI 10.1159/000234893; PRIN L, 1984, CLIN EXP IMMUNOL, V57, P735; RAK S, UNPUB IMMUNOTHERAPY; RAK S, 1988, BRONCHIAL HYPERRESPO, P161; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; Spry CJ, 1988, EOSINOPHILS COMPREHE; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; TOMONAGA M, 1986, BLOOD, V67, P31; VENGE P, 1981, BURNS, V8, P6, DOI 10.1016/0305-4179(81)90083-8; VENGE P, 1982, ALLERGY, V37, P55, DOI 10.1111/j.1398-9995.1982.tb04117.x; VENGE P, 1987, J ALLERGY CLIN IMMUN, V80, P679, DOI 10.1016/0091-6749(87)90287-9; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; WHITE CJ, 1986, J INFECT DIS, V154, P778, DOI 10.1093/infdis/154.5.778; WINQVIST I, 1982, IMMUNOLOGY, V47, P531; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	37	40	41	3	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1990	85	4					743	750		10.1016/0091-6749(90)90193-8	http://dx.doi.org/10.1016/0091-6749(90)90193-8			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DA437	2324413	Bronze			2022-12-18	WOS:A1990DA43700010
J	ANSELMINO, LM; PERUSSIA, B; THOMAS, LL				ANSELMINO, LM; PERUSSIA, B; THOMAS, LL			HUMAN BASOPHILS SELECTIVELY EXPRESS THE FC-GAMMA-RII (CDW32) SUBTYPE OF IGG RECEPTOR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									RUSH MED COLL,DEPT IMMUNOL MICROBIOL,1653 W CONGRESS PKWY,CHICAGO,IL 60612; WISTAR INST,PHILADELPHIA,PA 19104	Rush University; The Wistar Institute					NATIONAL CANCER INSTITUTE [R01CA037155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017177] Funding Source: NIH RePORTER; NCI NIH HHS [CA37155, CA45884] Funding Source: Medline; NIAID NIH HHS [AI17177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AALBERSE RC, 1983, J IMMUNOL, V130, P722; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; BERMAN JW, 1980, J IMMUNOL METHODS, V36, P335, DOI 10.1016/0022-1759(80)90138-6; EISEN H N, 1964, Methods Med Res, V10, P94; FAGAN DL, 1982, J ALLERGY CLIN IMMUN, V70, P399, DOI 10.1016/0091-6749(82)90031-8; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GILLESPIE E, 1972, J CLIN INVEST, V51, P2941, DOI 10.1172/JCI107118; GRANT JA, 1972, J IMMUNOL, V109, P20; HUBER H, 1971, NATURE, V229, P419, DOI 10.1038/229419a0; ISHIZAKA T, 1979, J IMMUNOL, V123, P578; Ishizaka T, 1988, ALLERGY PRINCIPLES P, P71; LIU FT, 1980, J IMMUNOL, V124, P2728; MERRETT J, 1983, CLIN ALLERGY, V13, P397, DOI 10.1111/j.1365-2222.1983.tb02615.x; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MIEDEMA F, 1984, EUR J IMMUNOL, V14, P518, DOI 10.1002/eji.1830140607; PARISH WE, 1970, LANCET, V2, P591; PENDY LM, 1986, J IMMUNOL METHODS, V91, P59, DOI 10.1016/0022-1759(86)90102-X; PERUSSIA B, 1983, J EXP MED, V158, P1092, DOI 10.1084/jem.158.4.1092; PERUSSIA B, 1983, J IMMUNOL, V130, P2133; PERUSSIA B, 1987, J IMMUNOL, V138, P765; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; POULSEN LK, 1988, INT ARCH ALLER A IMM, V86, P383, DOI 10.1159/000234623; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; SCHMEICHEL CJ, 1987, J IMMUNOL, V138, P1896; SIMMONS D, 1988, NATURE, V333, P568, DOI 10.1038/333568a0; Spiegelberg H L, 1974, Adv Immunol, V19, P259, DOI 10.1016/S0065-2776(08)60254-0; STAIN C, 1987, BLOOD, V70, P1872; STENGELIN S, 1988, EMBO J, V7, P1053, DOI 10.1002/j.1460-2075.1988.tb02913.x; TRINCHIERI G, 1986, J EXP MED, V164, P1206, DOI 10.1084/jem.164.4.1206; UNKELESS JC, 1989, J CLIN INVEST, V83, P355, DOI 10.1172/JCI113891; VALENT P, 1989, BLOOD, V73, P1778; VANTOORENENBERGEN AW, 1982, INT ARCH ALLER A IMM, V67, P117, DOI 10.1159/000233000; VAUGHN M, 1985, J IMMUNOL, V135, P4059; WILLIS HE, 1988, J IMMUNOL, V140, P234	35	40	47	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				907	914		10.1016/0091-6749(89)90388-6	http://dx.doi.org/10.1016/0091-6749(89)90388-6			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2532230				2022-12-18	WOS:A1989CG29300009
J	TOWNLEY, RG; HOPP, RJ; AGRAWAL, DK; BEWTRA, AK				TOWNLEY, RG; HOPP, RJ; AGRAWAL, DK; BEWTRA, AK			PLATELET-ACTIVATING FACTOR AND AIRWAY REACTIVITY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review											TOWNLEY, RG (corresponding author), CREIGHTON UNIV,SCH MED,CTR ALLERG DIS,OMAHA,NE 68178, USA.		Agrawal, Devendra/GLR-3925-2022; Hopp, Russell/K-4578-2019	Agrawal, Devendra/0000-0001-5445-0013; 				AGRAWAL DK, 1987, BIOCHEM BIOPH RES CO, V143, P1, DOI 10.1016/0006-291X(87)90620-6; AGRAWAL DK, 1987, J ALLERGY CLIN IMMUN, V79, P171; AGRAWAL DK, 1987, 10TH INT C PHARM IUP; AGRAWAL DK, 1988, GINKGOLIDES CHEM BIO, V1, P355; AGRAWAL DK, IN PRESS PLATELET AC; ALAM I, 1986, BIOCHIM BIOPHYS ACTA, V884, P67, DOI 10.1016/0304-4165(86)90228-X; ALONSO F, 1982, J BIOL CHEM, V257, P3376; ARNOUX B, 1985, American Review of Respiratory Disease, V131, pA2; ARNOUX B, 1980, EUR J CLIN INVEST, V10, P437, DOI 10.1111/j.1365-2362.1980.tb02082.x; ARNOUX B, 1982, AGENTS ACTIONS, V12, P713, DOI 10.1007/BF01965089; ARNOUX B, 1988, GINKGOLIDES CHEM BIO, P295; ARNOUX B, 1983, INSERM S, V23, P335; BARNES PJ, 1987, BRIT J PHARMACOL, V90, P709, DOI 10.1111/j.1476-5381.1987.tb11224.x; BARNES PJ, 1980, NATURE, V285, P569, DOI 10.1038/285569a0; BARNES PJ, 1988, J ALLERGY CLIN IMMUN, V81, P919, DOI 10.1016/0091-6749(88)90952-9; BARNES PJ, 1986, LANCET, V1, P242; BEER HJ, 1985, ADV INFLAMMAT RES, P323; BENHAMOU M, 1986, J IMMUNOL, V136, P1385; BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BENVENISTE J, 1972, J EXP MED, V136, P1356, DOI 10.1084/jem.136.6.1356; BERGREN D R, 1987, American Review of Respiratory Disease, V135, pA162; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BLANK ML, 1981, J BIOL CHEM, V256, P175; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; BOULET LP, 1987, J ALLERGY CLIN IMMUN, V80, P655, DOI 10.1016/0091-6749(87)90284-3; BOUSHY HA, 1987, AM REV RESPIR DIS, V121, P389; BRAQUET P, 1985, PROSTAGLANDINS, V30, P721, DOI 10.1016/0090-6980(85)90065-6; Braquet P, 1986, Adv Prostaglandin Thromboxane Leukot Res, V16, P179; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1985, LANCET, V1, P1501; BRAQUET P, 1987, PLATELET ACTIVATING, P191; CAMUSSI G, 1983, J IMMUNOL, V131, P2397; CAPRON A, 1986, IMMUNOL TODAY, V7, P15, DOI 10.1016/0167-5699(86)90184-2; CAPRON A, 1985, INT ARCH ALLER A IMM, V77, P107, DOI 10.1159/000233762; CASALSSTENZEL J, 1987, J PHARMACOL EXP THER, V241, P974; CASALSSTENZEL J, 1986, 2ND INT C PLAT ACT F, P108; CHAIGNARD M, 1980, BRIT J HAEMATOL, V46, P455; CHUNG KF, 1986, J PHARMACOL EXP THER, V236, P580; CHUNG KF, 1988, J ALLERGY CLIN IMMUN, V81, P1192, DOI 10.1016/0091-6749(88)90890-1; CHUNG KF, IN PRESS AM REV RESP; CHUNG KF, 1987, AM REV RESPIR DIS, V135, P181; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COYLE A, 1987, CLIN RES, V35, pA254; COYLE AJ, IN PRESS EUR J PHARM; COYLE AJ, 1988, AM REV RESPIR DIS, V137, P5; CUSS FM, 1986, LANCET, V2, P189; DARIUS H, 1986, SCIENCE, V232, P58, DOI 10.1126/science.3082008; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DENJEAN A, 1983, J APPL PHYSIOL, V55, P799, DOI 10.1152/jappl.1983.55.3.799; DEWAR A, 1984, J PATHOL, V144, P25034; DUNHILL MS, 1978, ALLERGY PRINICIPLES, P678; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FINK A, 1988, ALLERGY P, V9, P441; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; GATEAU O, 1984, AM REV RESPIR DIS S, V129, P3; GRANDEL KE, 1983, FED PROC, V42, P1026; Gresele P, 1987, Agents Actions Suppl, V21, P119; GUINOT P, 1987, PROSTAGLANDINS, V34, P723, DOI 10.1016/0090-6980(87)90295-4; HAHN HL, 1986, FED PROC, V45, P3085; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HOPP RJ, 1987, ANN ALLERGY, V60, P129; HWANG SB, 1985, BIOCHEM BIOPH RES CO, V128, P972, DOI 10.1016/0006-291X(85)90142-1; JOSEPH M, 1983, NATURE, V303, P310; JOUVINMARCHE E, 1984, FED PROC, V43, P1924; KARLSSON G, 1984, EUR J CLIN PHARMACOL, V27, P371, DOI 10.1007/BF00542179; KLOPROGGE E, 1984, BIOCHEM J, V223, P901, DOI 10.1042/bj2230901; LAGENTE V, 1987, PROSTAGLANDINS, V33, P265, DOI 10.1016/0090-6980(87)90011-6; LARTIGUEMATTEI C, 1984, AGENTS ACTIONS, V15, P643, DOI 10.1007/BF01966786; LEE TC, 1984, J BIOL CHEM, V259, P5526; LEE TC, 1985, PHOSPHOLIPIDS CELLUL, V2, P1; LEFF AR, 1986, AM REV RESPIR DIS S, V133, pA175; LEFORT J, 1986, British Journal of Pharmacology, V89, p768P; LELLOUCHTUBIANA A, 1987, INT ARCH ALLER A IMM, V83, P198, DOI 10.1159/000234356; LELLOUCHTUBIANA A, 1985, BRIT J EXP PATHOL, V66, P345; LELLOUCHTUBIANA A, IN PRESS J LIPID MED; LICHTENSTEIN LM, 1986, ASTHMA, V3, P1; LOTNER GZ, 1980, J IMMUNOL, V124, P676; Martin J F, 1987, Agents Actions Suppl, V21, P37; MAZZONI L, 1985, British Journal of Pharmacology, V86, p571P; MAZZONI L, 1985, J PHYSIOL-LONDON, V365, pP107; MCMANUS LM, 1980, J IMMUNOL, V125, P1950; MENCIAHUERTA JM, 1986, ASTHMA CLIN PHARM TH, P237; Menz G, 1987, Agents Actions Suppl, V21, P139; Metzger W J, 1987, Agents Actions Suppl, V21, P151; MEURS H, 1982, J ALLERGY CLIN IMMUN, V70, P272, DOI 10.1016/0091-6749(82)90063-X; MORLEY J, 1982, BRONCHIAL HYPERREACT; NAIR N, 1986, ANN ALLERGY, V56, P226; NAKAMURA T, 1987, INT ARCH ALLER A IMM, V82, P57, DOI 10.1159/000234290; NINIO E, 1983, BIOCHIM BIOPHYS ACTA, V751, P298, DOI 10.1016/0005-2760(83)90287-4; OFLAHERTY JT, 1982, LAB INVEST, V47, P314; PAGE CP, 1984, INT ARCH ALLER A IMM, V74, P347, DOI 10.1159/000233571; PAGE CP, 1984, TRENDS PHARMACOL SCI, V5, P239, DOI 10.1016/0165-6147(84)90431-0; PATTERSON R, 1984, J LAB CLIN MED, V104, P340; PINKARD RN, 1984, IMMUNOPHARMACOLOGY L, P73; PRETOLANI M, 1987, INT C PHARM SYDNEY; RAAIJMAKERS JAM, 1987, THESIS U UTRECHT UTR; RIBBES G, 1985, FEBS LETT, V191, P195, DOI 10.1016/0014-5793(85)80007-7; ROBERTSON DN, 1987, BRIT J PHARMACOL, V92, P105, DOI 10.1111/j.1476-5381.1987.tb11301.x; RUBIN AHE, 1987, AM REV RESPIR DIS, V136, P1145, DOI 10.1164/ajrccm/136.5.1145; SANJAR S, 1987, ASTHMA REV, V1, P141; SANO Y, 1983, J ALLERGY CLIN IMMUN, V72, P495, DOI 10.1016/0091-6749(83)90587-0; SCHELLENBERG RR, 1983, J ALLERGY CLIN IMMUN, V71, P145, DOI 10.1016/0091-6749(83)90351-2; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321, DOI 10.1152/jappl.1986.60.4.1321; SLATER DH, 1987, LANCET, V1, P110; SMITH LJ, 1988, AM REV RESPIR DIS, V137, P1015, DOI 10.1164/ajrccm/137.5.1015; SNYDER F, 1985, MED RES REV, V5, P107, DOI 10.1002/med.2610050105; STIMLERGERARD NP, 1986, J PHARMACOL EXP THER, V237, P209; TAKEYAMA H, 1985, J ALLERGY CLIN IMMUN, V75, P140, DOI 10.1016/0091-6749(85)90276-3; TAKI F, 1986, AM REV RESPIR DIS, V133, P362; TAMURA N, 1988, J IMMUNOL, V141, P4291; TAMURA N, 1987, BIOCHEM BIOPH RES CO, V142, P638, DOI 10.1016/0006-291X(87)91462-8; TASHKIN DP, 1982, AM REV RESPIR DIS, V125, P185; TENCE M, 1980, BIOCHIMIE, V62, P251, DOI 10.1016/S0300-9084(80)80399-3; TONNEL AB, 1983, LANCET, V1, P1406; TOUQUI L, 1985, BIOCHEM J, V229, P811, DOI 10.1042/bj2290811; TOUVAY C, 1987, FED PROC, V46, P1202; TOWNLEY R, 1988, American Review of Respiratory Disease, V137, P429; TOWNLEY RG, 1988, CHEST, V94, P452, DOI 10.1378/chest.94.3.452; TOWNLEY RG, 1979, J ALLERGY CLIN IMMUN, V64, P569, DOI 10.1016/0091-6749(79)90014-9; TOWNLEY RG, 1986, 2ND P INT C PAF GATL, P154; VALONE FH, 1982, J IMMUNOL, V129, P1637; VALONE FH, 1983, IMMUNOLOGY, V48, P141; Vargaftig B B, 1981, Ann N Y Acad Sci, V370, P119, DOI 10.1111/j.1749-6632.1981.tb29727.x; VARGAFTIG BB, 1987, BRIT MED BULL, V43, P312, DOI 10.1093/oxfordjournals.bmb.a072185; WARDLAW AJ, 1986, J ALLERGY CLIN IMMUN, V77, P236; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; WIRTZ H, 1986, FED PROC, V45, P418	129	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1989	83	6					997	1010		10.1016/0091-6749(89)90437-5	http://dx.doi.org/10.1016/0091-6749(89)90437-5			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AC235	2659646				2022-12-18	WOS:A1989AC23500001
J	MCCLEAN, SP; ARREAZA, EE; LETTBROWN, MA; GRANT, JA				MCCLEAN, SP; ARREAZA, EE; LETTBROWN, MA; GRANT, JA			REFRACTORY CHOLINERGIC URTICARIA SUCCESSFULLY TREATED WITH KETOTIFEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											MCCLEAN, SP (corresponding author), UNIV TEXAS,MED BRANCH,DEPT MED,DIV ALLERGY,ROUTE G-62,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022940] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-73] Funding Source: Medline; NIAID NIH HHS [AI-22940] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAADSGAARD O, 1984, ACTA DERM-VENEREOL, V64, P344; BLUMBERG MZ, 1978, ANN ALLERGY, V41, P99; BRODDE OE, 1985, J CLIN INVEST, V76, P1096, DOI 10.1172/JCI112063; CASALE TB, 1986, JAMA-J AM MED ASSOC, V255, P2049, DOI 10.1001/jama.255.15.2049; CRAPS LP, 1984, RESPIRATION, V45, P411, DOI 10.1159/000194648; Duke WW, 1924, J AMER MED ASSOC, V83, P3, DOI 10.1001/jama.1924.02660010007002; FARNAM J, 1986, J ALLERGY CLIN IMMUN, V78, P353, DOI 10.1016/S0091-6749(86)80089-6; GRANT JA, 1981, J ALLERGY CLIN IMMUN, V67, P75, DOI 10.1016/0091-6749(81)90049-X; Grant RT, 1936, CLIN SCI, V2, P253; GREENWOOD C, 1982, CHEST, V82, pS45, DOI 10.1378/chest.82.1.45S; HUSTON DP, 1986, ANN INTERN MED, V104, P507, DOI 10.7326/0003-4819-104-4-507; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P319, DOI 10.1016/0091-6749(81)90158-5; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; KAPLAN AP, 1981, J ALLERGY CLIN IMMUN, V68, P438; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; Paver K, 1970, Australas J Dermatol, V11, P97, DOI 10.1111/j.1440-0960.1970.tb00454.x; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1987, J ALLERGY CLIN IMMUN, V80, P850, DOI 10.1016/S0091-6749(87)80276-2; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SOTER NA, 1980, NEW ENGL J MED, V302, P604, DOI 10.1056/NEJM198003133021104; SOTER NA, 1980, J ALLERGY CLIN IMMUN, V66, P358, DOI 10.1016/0091-6749(80)90114-1; SOTER NA, 1977, FED PROC, V36, P1736; VERBURG KM, 1983, LIFE SCI, V32, P2855, DOI 10.1016/0024-3205(83)90322-3	23	40	42	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1989	83	4					738	741		10.1016/0091-6749(89)90008-0	http://dx.doi.org/10.1016/0091-6749(89)90008-0			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	U3420	2651507	Bronze			2022-12-18	WOS:A1989U342000005
J	BRUTTMANN, G; CHARPIN, D; GERMOUTY, J; HORAK, F; KUNKEL, G; WITTMANN, G				BRUTTMANN, G; CHARPIN, D; GERMOUTY, J; HORAK, F; KUNKEL, G; WITTMANN, G			EVALUATION OF THE EFFICACY AND SAFETY OF LORATADINE IN PERENNIAL ALLERGIC RHINITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP ST MARGUERITE,MARSIELLE,FRANCE; HOP CLUZEAU,LIMOGES,FRANCE; VIENNA UNIV,EAR NOSE & THROAT CLIN,A-1090 VIENNA,AUSTRIA; FREE UNIV BERLIN,DEPT CLIN IMMUNOL & ASTHMA OPD,D-1000 BERLIN 33,FED REP GER	UDICE-French Research Universities; Aix-Marseille Universite; CHU Limoges; University of Vienna; Free University of Berlin								AHN HS, 1986, EUR J PHARMACOL, V127, P153, DOI 10.1016/0014-2999(86)90219-0; BARNETT A, 1984, AGENTS ACTIONS, V14, P590, DOI 10.1007/BF01978891; GUTKOWSKI A, 1986, MAY EUR AC ALL CLIN; KEMP JP, 1987, J ALLERGY CLIN IMMUN, V79, P190; OEI HD, 1987, J ALLERGY CLIN IMMUN, V79, P190; SKASSABROCIEK W, 1986, J ALLERGY CLIN IMMUN, V77, P137	6	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	1989	83	2	1				411	416		10.1016/0091-6749(89)90127-9	http://dx.doi.org/10.1016/0091-6749(89)90127-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T4489	2563743				2022-12-18	WOS:A1989T448900008
J	PIEN, LC; GRAMMER, LC; PATTERSON, R				PIEN, LC; GRAMMER, LC; PATTERSON, R			MINIMAL COMPLICATIONS IN A SURGICAL POPULATION WITH SEVERE ASTHMA RECEIVING PROPHYLACTIC CORTICOSTEROIDS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,303 E CHICAGO AVE,CHICAGO,IL 60611	Northwestern University				Grammer, Leslie/0000-0001-6860-2014	NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERNSTEIN IL, 1983, ALLERGY PRINCIPLES P, V2, P901; DUNLAP NE, 1984, CLIN CHEST MED, V5, P669; EICKHOFF TC, 1980, SURG CLIN N AM, V60, P175; GARIBALDI RA, 1981, AM J MED, V70, P677, DOI 10.1016/0002-9343(81)90595-7; GOLD MI, 1963, ANESTH ANALG, V42, P283; OH SH, 1974, J ALLERGY CLIN IMMUN, V53, P345, DOI 10.1016/0091-6749(74)90118-3; PALMER K N, 1955, Postgrad Med J, V31, P25; PARIS J, 1961, P STAFF M MAYO CLIN, V36, P305; POLK HC, 1977, HOSPITAL ACQUIRED IN, P1; PRICKMAN LE, 1944, MED CLIN N AM, V28, P991; REISBERG BE, 1986, INFECTIOUS DISEASE S; STEIN M, 1970, J AMER MED ASSOC, V211, P787, DOI 10.1001/jama.211.5.787; WIGHTMAN JA, 1968, BRIT J SURG, V55, P85, DOI 10.1002/bjs.1800550202; 1962, AM REV RESPIR DIS, V85, P762	14	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1988	82	4					696	700		10.1016/0091-6749(88)90985-2	http://dx.doi.org/10.1016/0091-6749(88)90985-2			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q6399	3171010				2022-12-18	WOS:A1988Q639900025
J	LISS, GM; BERNSTEIN, DI; MOLLER, DR; GALLAGHER, JS; STEPHENSON, RL; BERNSTEIN, IL				LISS, GM; BERNSTEIN, DI; MOLLER, DR; GALLAGHER, JS; STEPHENSON, RL; BERNSTEIN, IL			PULMONARY AND IMMUNOLOGICAL EVALUATION OF FOUNDRY WORKERS EXPOSED TO METHYLENE DIPHENYLDIISOCYANATE (MDI)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,CINCINNATI,OH 45267; MINIST LABOR,HLTH STUDIES SERV,TORONTO,ONTARIO,CANADA; NHLBI,BETHESDA,MD 20205; NIOSH,DIV SURVEILLANCE HAZARD EVALUAT & FIELD STUDIES,CINCINNATI,OH 45226	University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)					PHS HHS [HHE 80-073-1589] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAUR X, 1984, J OCCUP ENVIRON MED, V26, P285; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BERNSTEIN DI, 1982, J ALLERGY CLIN IMMUN, V69, P311, DOI 10.1016/S0091-6749(82)80009-2; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; GLEICH GJ, 1971, J LAB CLIN MED, V77, P690; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; LISS GM, 1984, J ALLERGY CLIN IMMUN, V73, P348, DOI 10.1016/0091-6749(84)90407-X; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MALO JL, 1982, AM REV RESPIR DIS, V125, P113; MUNN A., 1965, ANN OCCUP HYG, V8, P163; OBRIEN IM, 1979, CLIN ALLERGY, V9, P1, DOI 10.1111/j.1365-2222.1979.tb01516.x; TSE CST, 1979, TOXICOL APPL PHARM, V51, P39, DOI 10.1016/0041-008X(79)90006-1; VOLLER A, 1976, B WORLD HEALTH ORGAN, V53, P55; WIDE L, 1967, LANCET, V2, P1105; ZAMMITTABONA M, 1983, AM REV RESPIR DIS, V128, P226; ZEISS CR, 1980, J ALLERGY CLIN IMMUN, V65, P346, DOI 10.1016/0091-6749(80)90211-0	19	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1988	82	1					55	61		10.1016/0091-6749(88)90051-6	http://dx.doi.org/10.1016/0091-6749(88)90051-6			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	P4004	3392370				2022-12-18	WOS:A1988P400400010
J	MOSBECH, H; KORSGAARD, J; LIND, P				MOSBECH, H; KORSGAARD, J; LIND, P			CONTROL OF HOUSE DUST MITES BY ELECTRICAL HEATING BLANKETS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALK RES GRP,COPENHAGEN,DENMARK; AARHUS UNIV HOSP,CHEST CLIN,DK-8000 AARHUS C,DENMARK; UNIV COPENHAGEN,PROT LAB,DK-1168 COPENHAGEN K,DENMARK	Aarhus University; University of Copenhagen	MOSBECH, H (corresponding author), STATE UNIV HOSP COPENHAGEN,DEPT MED TTA,ALLERGY UNIT,TAGENSVEJ 20,DK-2200 COPENHAGEN N,DENMARK.							ARLIAN LG, 1983, J MED ENTOMOL, V20, P99, DOI 10.1093/jmedent/20.1.99; BURR ML, 1980, THORAX, V35, P513, DOI 10.1136/thx.35.7.513; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; BURR ML, 1976, LANCET, V1, P333; CARSWELL F, 1982, CLIN ALLERGY, V12, P533, DOI 10.1111/j.1365-2222.1982.tb02552.x; COLLOFF MJ, 1986, CLIN ALLERGY, V16, P41, DOI 10.1111/j.1365-2222.1986.tb01952.x; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; LEYSEN MT, 1974, ACTA ALLERGOL, V29, P455, DOI 10.1111/j.1398-9995.1974.tb01665.x; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; LIND P, 1979, ALLERGY, V34, P319; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MOSBECH H, 1985, ALLERGY, V40, P81, DOI 10.1111/j.1398-9995.1985.tb02665.x; MOSBECH H, 1986, ALLERGY, V41, P373, DOI 10.1111/j.1398-9995.1986.tb00315.x; MULLA MS, 1975, J MED ENTOMOL, V12, P5, DOI 10.1093/jmedent/12.1.5; MURRAY AB, 1983, PEDIATRICS, V71, P418; PENAUD A, 1975, Clinical Allergy, V5, P109, DOI 10.1111/j.1365-2222.1975.tb01842.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; VANBRONS.JE, 1973, J MED ENTOMOL, V10, P63, DOI 10.1093/jmedent/10.1.63; VANDEMAELE B, 1983, PHARMATHERAPEUTICA, V3, P441; WALSHAW MJ, 1986, Q J MED, V58, P199	22	40	44	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1988	81	4					706	710		10.1016/0091-6749(88)91042-1	http://dx.doi.org/10.1016/0091-6749(88)91042-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	N0650	3356849	Bronze			2022-12-18	WOS:A1988N065000011
J	SLATER, JE; KALINER, M				SLATER, JE; KALINER, M			EFFECTS OF SEX-HORMONES ON BASOPHIL HISTAMINE-RELEASE IN RECURRENT IDIOPATHIC ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,CLIN INVEST LAB,ALLERG DIS SECT,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								COX RP, 1970, J CELL PHYSL, V77, P71; DISORBO DM, 1977, LIFE SCI, V20, P1593, DOI 10.1016/0024-3205(77)90453-2; ELIASSON O, 1986, J ALLERGY CLIN IMMUN, V77, P87, DOI 10.1016/0091-6749(86)90328-3; FARAH FS, 1971, J ALLERGY CLIN IMMUN, V48, P257, DOI 10.1016/0091-6749(71)90025-X; GIBBS CJ, 1984, THORAX, V39, P833, DOI 10.1136/thx.39.11.833; HART R, 1977, ARCH DERMATOL, V113, P426, DOI 10.1001/archderm.113.4.426; ISHIZAKA T, 1969, J IMMUNOL, V102, P884; LEECH SH, 1981, ANN ALLERGY, V46, P201; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; MCGIBBON DH, 1979, BRIT J DERMATOL, V101, P65; MEGGS WJ, 1984, NEW ENGL J MED, V311, P1236, DOI 10.1056/NEJM198411083111907; MIDDLETON E, 1960, J ALLERGY, V31, P448, DOI 10.1016/0021-8707(60)90008-3; MYERS G, 1981, J ALLERGY CLIN IMMUN, V67, P305, DOI 10.1016/0091-6749(81)90026-9; NOAH JW, 1954, J ALLERGY, V25, P210, DOI 10.1016/0021-8707(54)90180-X; RENOIR JM, 1984, MOL CELL ENDOCRINOL, V37, P1, DOI 10.1016/0303-7207(84)90123-0; SALE SR, 1981, JAMA-J AM MED ASSOC, V246, P2336, DOI 10.1001/jama.246.20.2336; SCHLEIMER RP, 1981, NATURE, V292, P454, DOI 10.1038/292454a0; SIRAGANIAN RP, 1974, ANAL BIOCHEM, V57, P383, DOI 10.1016/0003-2697(74)90093-1; SLATER JE, IN PRESS OBSTET GYNE; SONIN L, 1983, ANN INTERN MED, V99, P634, DOI 10.7326/0003-4819-99-5-634; TROMOVITCH TA, 1967, CALIF MED, V106, P211; ZONDEK B, 1945, J ALLERGY, V16, P1, DOI 10.1016/0021-8707(45)90035-9	23	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				285	290		10.1016/0091-6749(87)90033-9	http://dx.doi.org/10.1016/0091-6749(87)90033-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	2442235				2022-12-18	WOS:A1987K103600009
J	ZIMMERMAN, B; STRINGER, D; FEANNY, S; REISMAN, J; HAK, H; RASHED, N; DEBENEDICTIS, F; MCLAUGHLIN, J; LEVISON, H				ZIMMERMAN, B; STRINGER, D; FEANNY, S; REISMAN, J; HAK, H; RASHED, N; DEBENEDICTIS, F; MCLAUGHLIN, J; LEVISON, H			PREVALENCE OF ABNORMALITIES FOUND BY SINUS X-RAYS IN CHILDHOOD ASTHMA - LACK OF RELATION TO SEVERITY OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOSP SICK CHILDREN,DEPT PEDIAT,DIV CHEST,TORONTO M5G 1X8,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	ZIMMERMAN, B (corresponding author), HOSP SICK CHILDREN,DIV ALLERGY,ASTHMA CLIN,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA.		McLaughlin, John R/E-4577-2013					CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; DOLOVICH J, 1983, ASTHMA, P132; FRIEDMAN R, 1984, J ALLERGY CLIN IMMUN, V74, P185, DOI 10.1016/0091-6749(84)90284-7; GODFREY S, 1975, J PEDIATR-US, V87, P465, DOI 10.1016/S0022-3476(75)80663-9; GODFREY S, 1983, ASTHMA, P415; GREGG I, 1983, EUR J RESPIR DIS, V64, P369; GUERIN B, 1977, CLIN ALLERGY, V12, P428; KOVATCH AL, 1984, PEDIATRICS, V73, P306; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; SACHA RF, 1985, ANN ALLERGY, V54, P195; SHAPIRO GG, 1986, J ALLERGY CLIN IMMUN, V77, P59, DOI 10.1016/0091-6749(86)90324-6; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; 1983, CAN MED ASS J, V129, P947	16	40	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1987	80	3	1				268	273		10.1016/0091-6749(87)90029-7	http://dx.doi.org/10.1016/0091-6749(87)90029-7			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	K1036	3624681				2022-12-18	WOS:A1987K103600005
J	CHURCH, MK; FEATHERSTONE, RL; CUSHLEY, MJ; MANN, JS; HOLGATE, ST				CHURCH, MK; FEATHERSTONE, RL; CUSHLEY, MJ; MANN, JS; HOLGATE, ST			RELATIONSHIPS BETWEEN ADENOSINE, CYCLIC-NUCLEOTIDES, AND XANTHINES IN ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											CHURCH, MK (corresponding author), SOUTHAMPTON GEN HOSP, F LEVEL, CTR BLOCK, TREMONA RD, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND.							Arch J R, 1978, Essays Biochem, V14, P82; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; BERGSTRAND H, 1980, EUR J RESPIR DIS, V61, P37; BONTEMPS F, 1983, P NATL ACAD SCI-BIOL, V80, P2829, DOI 10.1073/pnas.80.10.2829; BROWN CM, 1982, BRIT J PHARMACOL, V76, P381, DOI 10.1111/j.1476-5381.1982.tb09231.x; CHURCH MK, 1983, BRIT J PHARMACOL, V80, P719, DOI 10.1111/j.1476-5381.1983.tb10063.x; CHURCH MK, 1985, CLIN ALLERGY, V15, P311, DOI 10.1111/j.1365-2222.1985.tb02998.x; CONTI MA, 1980, FED PROC, V39, P1569; CUSHLEY HJ, 1983, THORAX, V38, P705; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; CUSHLEY MJ, 1984, AM REV RESPIR DIS, V129, P380; CUSHLEY MJ, 1985, J ALLERGY CLIN IMMUN, V75, P272, DOI 10.1016/0091-6749(85)90057-0; CUSHLEY MJ, 1982, BRIT J CLIN PHARMACO, V14, pP607; DAHLEN SE, 1983, P NATL ACAD SCI-BIOL, V80, P1712, DOI 10.1073/pnas.80.6.1712; DALY JW, 1982, J MED CHEM, V25, P197, DOI 10.1021/jm00345a001; FARMER JB, 1967, J PHARM PHARMACOL, V19, P124, DOI 10.1111/j.2042-7158.1967.tb08047.x; FREDHOLM BB, 1980, EUR J RESPIR DIS, V61, P29; FREDHOLM BB, 1982, EUR J PHARMACOL, V81, P673, DOI 10.1016/0014-2999(82)90359-4; FREDHOLM BB, 1981, ACTA PHYSIOL SCAND, V111, P507, DOI 10.1111/j.1748-1716.1981.tb06772.x; FREDHOLM BB, 1980, TRENDS PHARMACOL SCI, V1, P129; FREDHOLM BB, 1979, ACTA PHARMACOL TOX, V45, P336; HANDSLIP PDJ, 1981, THORAX, V36, P741, DOI 10.1136/thx.36.10.741; HIGBEE MD, 1982, J ALLERGY CLIN IMMUN, V70, P377, DOI 10.1016/0091-6749(82)90028-8; HOLGATE S T, 1984, British Journal of Pharmacology, V82, p262P; HORROBIN DF, 1977, PROSTAGLANDINS, V13, P33, DOI 10.1016/0090-6980(77)90040-5; HOWARTH PH, 1985, AM REV RESPIR DIS, V132, P986; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; JAMES GWL, 1967, J PHARM PHARMACOL, V19, P797, DOI 10.1111/j.2042-7158.1967.tb09546.x; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; KARLSSON JA, 1981, BRIT J PHARMACOL, V74, P73, DOI 10.1111/j.1476-5381.1981.tb09956.x; KOLBECK RC, 1979, LUNG, V156, P173, DOI 10.1007/BF02714008; LOHMANN SM, 1977, BIOCHIM BIOPHYS ACTA, V499, P238, DOI 10.1016/0304-4165(77)90006-X; MANN JS, 1984, THORAX, V39, P230; MANN JS, 1983, CLIN SCI, V65, pP22; MANN JS, 1985, BRIT J CLIN PHARMACO, V19, P685, DOI 10.1111/j.1365-2125.1985.tb02696.x; MENTZER RM, 1975, AM J PHYSIOL, V229, P1625; PERSSON CGA, 1982, LIFE SCI, V30, P2181, DOI 10.1016/0024-3205(82)90292-2; PERSSON CGA, 1981, ACTA PHARMACOL TOX, V49, P313; POLSON JB, 1978, CLIN EXP PHARMACOL P, V5, P535; RUFFIN RE, 1981, EUR J RESPIR DIS, V62, P123; SCHLEIMER RP, 1983, CLIN REV ALLERG, V1, P327; STUBBS AD, 1984, CLIN SCI, V66, pP57; SYDBOM A, 1982, ACTA PHYSIOL SCAND, V114, P243, DOI 10.1111/j.1748-1716.1982.tb06978.x; TRINER L, 1977, EUR J PHARMACOL, V41, P37, DOI 10.1016/0014-2999(77)90368-5; WEINBERGER M, 1978, J PEDIATR-US, V92, P1, DOI 10.1016/S0022-3476(78)80058-4; WINSLOW CM, 1984, PROG ALLERGY, V34, P236	46	40	40	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				670	675		10.1016/0091-6749(86)90044-8	http://dx.doi.org/10.1016/0091-6749(86)90044-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3021833				2022-12-18	WOS:A1986E568400002
J	MOTALA, C; POTTER, PC; WEINBERG, EG; MALHERBE, D; HUGHES, J				MOTALA, C; POTTER, PC; WEINBERG, EG; MALHERBE, D; HUGHES, J			ANTI-STAPHYLOCOCCUS-AUREUS-SPECIFIC IGE IN ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CAPE TOWN,DEPT CLIN SCI & IMMUNOL,CAPE TOWN,SOUTH AFRICA	University of Cape Town	MOTALA, C (corresponding author), UNIV CAPE TOWN,RED CROSS WAR MEM CHILDRENS HOSP,INST CHILD HLTH,RONDEBOSCH 7700,SOUTH AFRICA.							ABRAMSON JS, 1982, J AM ACAD DERMATOL, V7, P105, DOI 10.1016/S0190-9622(82)80017-0; ARCHAMBEAULTJON.C, 1975, PROCEDURES NURSING B, P38; DEFILIPPI I, 1981, ANN ALLERGY, V46, P249; FRIEDMAN SJ, 1985, ARCH DERMATOL, V121, P869, DOI 10.1001/archderm.121.7.869; FRIEDMAN SJ, 1984, J IMMUNOL METHODS, V66, P369, DOI 10.1016/0022-1759(84)90350-8; HANIFIN JM, 1977, ARCH DERMATOL, V113, P1383, DOI 10.1001/archderm.113.10.1383; HAUSER C, 1985, ACTA DERM-VENEREOL S, V114, P101; JOHNSON EE, 1974, J ALLERGY CLIN IMMUN, V54, P94, DOI 10.1016/0091-6749(74)90037-2; LUNDKVIST U, 1975, P RAST S PALM SPRING, P85; SCHOPFER K, 1979, NEW ENGL J MED, V300, P835, DOI 10.1056/NEJM197904123001506; SCHOPFER K, 1980, INFECT IMMUN, V2, P563; Siegel S., 1956, NONPARAMETRIC STAT, P96; WALSH GA, 1981, J CLIN MICROBIOL, V13, P1046, DOI 10.1128/JCM.13.6.1046-1048.1981; WILLIAMS RE, 1963, BACTERIOL REV, V27, P56, DOI 10.1128/MMBR.27.1.56-71.1963	14	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	1				583	589		10.1016/0091-6749(86)90075-8	http://dx.doi.org/10.1016/0091-6749(86)90075-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5682	3771950				2022-12-18	WOS:A1986E568200006
J	PERSSON, CGA				PERSSON, CGA			DEVELOPMENT OF SAFER XANTHINE DRUGS FOR TREATMENT OF OBSTRUCTIVE AIRWAYS DISEASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV LUND HOSP,DEPT CLIN PHARMACOL,S-22185 LUND,SWEDEN	Lund University; Skane University Hospital	PERSSON, CGA (corresponding author), AB DRACO,PHARMACOL LAB,POB 34,S-22100 LUND,SWEDEN.							AITKEN M L, 1985, American Review of Respiratory Disease, V131, pA68; Allard E, 1904, ARCH KLIN MED, V80, P510; ANDERSSON KE, 1984, EUR J CLIN PHARMACOL, V26, P33, DOI 10.1007/BF00546705; ANDERSSON KE, 1985, ANTIASTHMA XANTHINES, P1; ANDERSSON P, 1985, ANTIASTHMA XANTHINES, P187; ARLOCK P, 1985, ANTIASTHMA XANTHINES, P424; AUBIER M, 1981, NEW ENGL J MED, V305, P249, DOI 10.1056/NEJM198107303050503; BERGSTRAND H, 1977, MOL PHARMACOL, V13, P38; BORGA O, 1983, CLIN PHARMACOL THER, V34, P799, DOI 10.1038/clpt.1983.252; BRUNS RF, 1983, P NATL ACAD SCI-BIOL, V80, P2077, DOI 10.1073/pnas.80.7.2077; BUCKLEY BM, 1983, LANCET, V2, P618; BURKLE WS, 1981, AM J HOSP PHARM, V38, P1164, DOI 10.1093/ajhp/38.8.1164; CHURCH MK, 1980, BRIT J PHARMACOL, V70, P307, DOI 10.1111/j.1476-5381.1980.tb07937.x; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; CONRADSON TB, 1985, CHEST, V88, P537, DOI 10.1378/chest.88.4.537; EKELUND L, 1985, PEDIATR RES, V19, P1000, DOI 10.1203/00006450-198510000-00007; FINNEY MJB, 1985, BRIT J PHARMACOL, V85, P29, DOI 10.1111/j.1476-5381.1985.tb08827.x; FREDHOLM BB, 1985, ACTA PHYSIOL SCAND, V123, P183, DOI 10.1111/j.1748-1716.1985.tb07576.x; GREENBERG A, 1984, AM J MED, V76, P854, DOI 10.1016/0002-9343(84)90997-5; GUADREAULT P, 1983, J PEDIATR, V102, P474; HOLGATE ST, 1984, J ALLERGY CLIN IMMUN, V74, P302, DOI 10.1016/0091-6749(84)90262-8; JOHANNESSON N, 1985, AM REV RESPIR DIS, V131, P26; KARLSSON JA, 1982, BR J PHARM, V77, pP369; KARLSSON JA, 1984, NEURAL NONNEURAL MEC, P83; Kjellin G., 1985, ANTIASTHMA XANTHINES, P223; KROLL F, 1985, ANTIASTHMA XANTHINES, P193; LAURSEN LC, 1985, ANTIASTHMA XANTHINES, P156; LUNELL E, 1983, ACTA PHARMACOL TOX, V53, P205; LUNELL E, 1983, EUR J RESPIR DIS, V64, P333; LUNELL E, 1984, EUR J RESPIR DIS, V65, P28; MOXHAM J, 1985, THORAX, V40, P288, DOI 10.1136/thx.40.4.288; NAKADA T, 1983, WESTERN J MED, V138, P371; PAUWELS R, 1985, J ALLERGY CLIN IMMUN, V76, P583, DOI 10.1016/0091-6749(85)90779-1; PAUWELS R, 1985, ANTIASTHMA XANTHINES, P97; PERSSON CGA, 1985, THORAX, V40, P881, DOI 10.1136/thx.40.12.881; PERSSON CGA, 1986, J ALLERGY CLIN IMMUN, V78, P780, DOI 10.1016/0091-6749(86)90061-8; PERSSON CGA, 1983, J CARDIOVASC PHARM, V5, P778, DOI 10.1097/00005344-198309000-00012; PERSSON CGA, 1982, LIFE SCI, V30, P2181, DOI 10.1016/0024-3205(82)90292-2; PERSSON CGA, 1986, ACTA PHYSIOL SCAND, V127, P95, DOI 10.1111/j.1748-1716.1986.tb07880.x; PERSSON CGA, 1981, ACTA PHARMACOL TOX, V49, P313; PERSSON CGA, 1980, EUR J RESPIR DIS, V61, P7; PERSSON CGA, 1985, ANTIASTHMA XANTHINES, P23; PERSSON CGA, 1985, LUNG, V164, P33; PERSSON CGA, 1982, PHARM ASTHMA, P115; PERSSON CGA, 1985, ANTIASTHMA XANTHINES, P61; PERSSON CGA, 1983, ARCH INT PHARMACODYN, V258, P261; RYRFELDT A, 1985, ANTIASTHMA XANTHINES, P341; SUPINSKI GS, 1984, AM REV RESPIR DIS, V130, P429; VINGE E, 1984, ACTA PHYSIOL SCAND, V120, P117, DOI 10.1111/j.1748-1716.1984.tb07380.x; WAHL M, 1976, PFLUG ARCH EUR J PHY, V362, P55, DOI 10.1007/BF00588681; WAHLANDER S, 1985, ANTIASTHMA XANTHINES, P477	51	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1986	78	4	2				817	824		10.1016/0091-6749(86)90067-9	http://dx.doi.org/10.1016/0091-6749(86)90067-9			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	E5684	3534062	Bronze			2022-12-18	WOS:A1986E568400025
J	LOSADA, E; HINOJOSA, M; MONEO, I; DOMINGUEZ, J; GOMEZ, MLD; IBANEZ, MD				LOSADA, E; HINOJOSA, M; MONEO, I; DOMINGUEZ, J; GOMEZ, MLD; IBANEZ, MD			OCCUPATIONAL ASTHMA CAUSED BY CELLULASE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											LOSADA, E (corresponding author), CTR RAMON & CAJAL,SERV ALERGIA,CARRETERA COLMENAR KM 91,E-28034 MADRID,SPAIN.		Dominguez, Javier/I-1210-2015	Dominguez, Javier/0000-0001-7256-388X				Beecher W., 1951, ILLINOIS MED J, V59, P343; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V73, P574, DOI 10.1016/0091-6749(84)90513-X; DOMINGUEZ J, 1984, ALLERGY, V39, P529, DOI 10.1111/j.1398-9995.1984.tb00874.x; FLINDT MLH, 1979, LANCET, V1, P1407; FLINDT MLH, 1969, LANCET, V1, P1177; GALLEGUILLOS F, 1978, CLIN ALLERGY, V8, P21, DOI 10.1111/j.1365-2222.1978.tb00443.x; HARTMANN AL, 1983, SCHWEIZ MED WSCHR, V113, P265; HINOJOSA M, 1984, J ALLERGY CLIN IMMUN, V74, P782, DOI 10.1016/0091-6749(84)90179-9; MILNE J, 1975, BRIT J IND MED, V32, P302; MONEO I, 1983, INT ARCH ALLER A IMM, V71, P285, DOI 10.1159/000233406; OOSGOOG H, 1945, J ALLERGY, V16, P245; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; PAUWELS R, 1978, LANCET, V1, P669; PEPYS J, 1969, LANCET, V1, P1181; ZWEIMAN B, 1966, J ALLERGY, V39, P11	15	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1986	77	4					635	639		10.1016/0091-6749(86)90358-1	http://dx.doi.org/10.1016/0091-6749(86)90358-1			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	A9381	3958392				2022-12-18	WOS:A1986A938100018
J	TASHKIN, DP; KROENING, RJ; BRESLER, DE; SIMMONS, M; COULSON, AH; KERSCHNAR, H				TASHKIN, DP; KROENING, RJ; BRESLER, DE; SIMMONS, M; COULSON, AH; KERSCHNAR, H			A CONTROLLED TRIAL OF REAL AND SIMULATED ACUPUNCTURE IN THE MANAGEMENT OF CHRONIC ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF LOS ANGELES,SCH MED,DEPT ANAESTHESIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT EPIDEMIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	TASHKIN, DP (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024, USA.				NIGMS NIH HHS [GM 20821-01-2] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUHUYS A, 1971, J APPL PHYSIOL, V30, P670, DOI 10.1152/jappl.1971.30.5.670; BRESLER DE, 1977, ACUPUNCTURE CONTROL; BURNS RBP, 1983, J ASTHMA, V20, P105, DOI 10.3109/02770908309077073; CALEHR H, 1973, American Journal of Acupuncture, V1, P41; CHENG R, 1980, INT J NEUROSCI, V10, P95, DOI 10.3109/00207458009160487; CHENG R, 1979, LIFE SCI, V24, P1481, DOI 10.1016/0024-3205(79)90031-6; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; DUBOIS AB, 1956, J CLIN INVEST, V35, P322, DOI 10.1172/JCI103281; GAYRARD P, 1975, AM REV RESPIR DIS, V111, P433; GUILLEMIN R, 1977, SCIENCE, V197, P1367, DOI 10.1126/science.197601; Hollander M, 1973, NONPARAMETRIC STAT M, P27; KWON S, ZHUNGGUO JIHYE DACID; LIAO U, 1979, AM J CHINESE MED, V7, P362; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; MAYER DJ, 1977, BRAIN RES, V121, P368, DOI 10.1016/0006-8993(77)90161-5; MORRIS JF, 1976, WESTERN J MED, V125, P110; POLGAR GE, 1971, PULMONARY FUNCTION T, P178; POMERANZ B, 1976, LIFE SCI, V19, P1757, DOI 10.1016/0024-3205(76)90084-9; TAKISHIMA T, 1982, ANN ALLERGY, V48, P44; TASHKIN DP, 1977, ANN ALLERGY, V39, P379; VIRSIK K, 1980, PROG RESPIR RES, V14, P271; WINER BJ, 1971, STATISTICAL PRINCIPL, P518; YU DYC, 1976, CLIN SCI MOL MED, V51, P503, DOI 10.1042/cs0510503	23	40	41	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1985	76	6					855	864		10.1016/0091-6749(85)90760-2	http://dx.doi.org/10.1016/0091-6749(85)90760-2			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AWX93	3905922				2022-12-18	WOS:A1985AWX9300016
J	HARGREAVE, FE; OBYRNE, PM; RAMSDALE, EH				HARGREAVE, FE; OBYRNE, PM; RAMSDALE, EH			MEDIATORS, AIRWAY RESPONSIVENESS, AND ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University	HARGREAVE, FE (corresponding author), ST JOSEPHS HOSP,DEPT MED,FIRESTONE REG CHEST & ALLERGY UNIT,50 CHARLTON AVE,HAMILTON L8N 4A6,ONTARIO,CANADA.			O'Byrne, Paul/0000-0003-0979-281X				ANDERSON SD, 1985, AIRWAY RESPONSIVENES; ANDERSON SD, 1985, CHEST, V87, P191; ASAD SI, 1983, CLIN ALLERGY, V13, P459, DOI 10.1111/j.1365-2222.1983.tb02622.x; BARNES N, 1984, THORAX, V39, P697; COCKCROFT DW, 1983, CHEST, V83, P751, DOI 10.1378/chest.83.5.751; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKCROFT DW, 1977, THORAX, V32, P429, DOI 10.1136/thx.32.4.429; CUSHLEY, 1983, BR J CLIN PHARM, V15, P161; DEJONGSTE JC, 1984, EUR J RESPIR DIS, V65, P196; EISER NM, 1983, B EUR PHYSIOPATH RES, V19, P495; FAIRFAX AJ, 1982, PROSTA LEUKOTR MED, V8, P239, DOI 10.1016/0262-1746(82)90046-4; FULLER RW, 1984, THORAX, V39, P699; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; HARGREAVE FE, 1985, CHEST S, V87, P202; HARGREAVE FE, 1985, AIRWAY RESPONSIVENES; HARGREAVE FE, 1984, ASTHMA PHYSL IMMUNOP, P263; HOLTZMAN MJ, 1983, BIOCHEM BIOPH RES CO, V114, P1071, DOI 10.1016/0006-291X(83)90671-X; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; KALINER MM, 1984, J ALLERGY CLIN IMMUN, V73, P311, DOI 10.1016/0091-6749(84)90401-9; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; NAGY L, 1982, NEW ENGL J MED, V306, P497, DOI 10.1056/NEJM198203043060901; NEIJENS HJ, 1984, AM REV RESPIR DIS, V130, P744; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P220; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PLATTSMILLS TAE, 1982, LANCET, V2, P675; RAK S, 1983, J ALLERGY CLIN IMMUN, V71, P149, DOI 10.1016/0091-6749(83)90367-6; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; RAMSDALE EH, THORAX; RYAN G, 1985, J ALLERGY CLIN IMMUN, V75, P25, DOI 10.1016/0091-6749(85)90007-7; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; STERK PJ, AM REV RESPIR DIS; THOMSON NC, 1981, J ALLERGY CLIN IMMUN, V68, P392, DOI 10.1016/0091-6749(81)90138-X; WALTERS EH, 1981, THORAX, V36, P571, DOI 10.1136/thx.36.8.571; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71	39	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					272	276		10.1016/0091-6749(85)90641-4	http://dx.doi.org/10.1016/0091-6749(85)90641-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	3894483				2022-12-18	WOS:A1985APE8900005
J	LEWIS, RA; ROBIN, JL				LEWIS, RA; ROBIN, JL			ARACHIDONIC-ACID DERIVATIVES AS MEDIATORS OF ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT RHEUMATOL & IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital					NIAID NIH HHS [AI-22563, AI-10356] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022563] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADKINSON NF, 1983, IMMUNOPHARMACOLOGY L, P55; ATLURU D, 1984, J CLIN INVEST, V74, P1444, DOI 10.1172/JCI111556; BACH MK, 1982, PROSTAGLANDINS, V23, P759; BADR KF, 1984, CIRC RES, V54, P492, DOI 10.1161/01.RES.54.5.492; BALLERMANN BJ, 1985, CIRC RES, V56, P324, DOI 10.1161/01.RES.56.3.324; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P2148, DOI 10.1073/pnas.76.5.2148; COLES SJ, 1983, PROSTAGLANDINS, V25, P155, DOI 10.1016/0090-6980(83)90101-6; DAHLEN SE, 1981, P NATL ACAD SCI-BIOL, V78, P3887, DOI 10.1073/pnas.78.6.3887; DRAZEN JM, 1980, P NATL ACAD SCI-BIOL, V77, P4354, DOI 10.1073/pnas.77.7.4354; FELS AOS, 1982, P NATL ACAD SCI-BIOL, V79, P7866, DOI 10.1073/pnas.79.24.7866; GODARD P, 1983, CLIN RES, V31, pA548; GOLDMAN DW, 1982, J IMMUNOL, V129, P1600; HAM EA, 1983, P NATL ACAD SCI-BIOL, V80, P4349, DOI 10.1073/pnas.80.14.4349; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HIRATA F, 1982, BIOCHEM BIOPH RES CO, V109, P223, DOI 10.1016/0006-291X(82)91588-1; HIRATA F, 1983, J IMMUNOL, V130, P1930; HOGABOOM GK, 1983, BIOCHEM BIOPH RES CO, V116, P1136, DOI 10.1016/S0006-291X(83)80261-7; HOOVER RL, 1984, P NATL ACAD SCI-BIOL, V81, P2191, DOI 10.1073/pnas.81.7.2191; KENNERLY DA, 1979, J EXP MED, V150, P1039, DOI 10.1084/jem.150.4.1039; KRILIS S, 1984, P NATL ACAD SCI-BIOL, V81, P4529, DOI 10.1073/pnas.81.14.4529; KRILIS S, 1983, J CLIN INVEST, V71, P909, DOI 10.1172/JCI110845; KRILIS S, 1985, PROSTAGLANDINS MEMBR, P91; LEE TH, 1984, J CLIN INVEST, V74, P1922, DOI 10.1172/JCI111612; LEITCH AG, 1984, J IMMUNOL, V132, P2559; LEWIS RA, 1982, J IMMUNOL, V129, P1627; LEWIS RA, 1980, P NATL ACAD SCI-BIOL, V77, P3710, DOI 10.1073/pnas.77.6.3710; LEWIS RA, 1980, BIOCHEM BIOPH RES CO, V96, P271, DOI 10.1016/0006-291X(80)91210-3; LEWIS RA, 1981, BIOCH ACUTE ALLERGIC, P239; LEWIS RA, 15TH S COLL INT ALL; MACGLASHAN DW, 1982, J CLIN INVEST, V70, P747, DOI 10.1172/JCI110670; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MICHELASSI F, 1982, SCIENCE, V217, P841, DOI 10.1126/science.6808665; MURPHY RC, 1981, PROSTAG OTH LIPID M, V22, P613, DOI 10.1016/0090-6980(81)90070-8; OATES JA, 1983, BIOL RESPONSE MEDIAT, P41; PARKER CW, 1980, BIOCHEM BIOPH RES CO, V97, P1038, DOI 10.1016/0006-291X(80)91480-1; PAYAN DG, 1983, J IMMUNOL, V131, P551; PFEFFER MA, 1983, AM J PHYSIOL, V244, pH628, DOI 10.1152/ajpheart.1983.244.4.H628; PIPER PJ, 1973, BRIT J PHARMACOL, V47, P291, DOI 10.1111/j.1476-5381.1973.tb08327.x; RAZIN E, 1984, J IMMUNOL, V133, P938; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCHELHAMER JH, 1982, CHEST, V81, pS36; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; STENMARK KR, 1983, NEW ENGL J MED, V309, P77, DOI 10.1056/NEJM198307143090204; VICTORIA EJ, 1971, BIOCHIM BIOPHYS ACTA, V239, P443, DOI 10.1016/0005-2760(71)90036-1; Weiss J W, 1982, Trans Assoc Am Physicians, V95, P30; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WILLIAMS JD, 1985, J IMMUNOL, V134, P2624; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034	52	40	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	76	2					259	264		10.1016/0091-6749(85)90639-6	http://dx.doi.org/10.1016/0091-6749(85)90639-6			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	APE89	3926852				2022-12-18	WOS:A1985APE8900003
J	SONIN, L; PATTERSON, R				SONIN, L; PATTERSON, R			METABISULFITE CHALLENGE IN PATIENTS WITH IDIOPATHIC ANAPHYLAXIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University					NIAID NIH HHS [AI 11403] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI011403] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BACAL E, 1978, CLIN ALLERGY, V8, P295, DOI 10.1111/j.1365-2222.1978.tb03227.x; BAKER GJ, 1981, MED J AUSTRALIA, V2, P614, DOI 10.5694/j.1326-5377.1981.tb113018.x; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; FURIA TE, 1972, HDB FOOD ADDITIVES, P142; HABENICHT HA, 1983, IMMUNOL ALLERGY PRAC, V8, P243; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; LIEBERMAN P, 1979, ARCH INTERN MED, V139, P1032, DOI 10.1001/archinte.139.9.1032; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V71, P498, DOI 10.1016/0091-6749(83)90468-2; PATTERSON R, 1975, J ALLERGY CLIN IMMUN, V56, P152, DOI 10.1016/0091-6749(75)90120-7; PRENNER BM, 1976, ANN ALLERGY, V37, P180; SALE SR, 1981, JAMA-J AM MED ASSOC, V246, P2336, DOI 10.1001/jama.246.20.2336; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SONGSIRIDEJ V, 1983, CLIN ALLERGY, V13, P317, DOI 10.1111/j.1365-2222.1983.tb02606.x; SONIN L, 1983, ANN INTERN MED, V99, P634, DOI 10.7326/0003-4819-99-5-634; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; WILLIAMSON RS, 1983, PUBLIUS J FEDERALISM, V13, P11, DOI 10.1093/oxfordjournals.pubjof.a037427; 1980, AM THORAC SOC NE SPR, P11	21	40	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1985	75	1					67	69		10.1016/0091-6749(85)90014-4	http://dx.doi.org/10.1016/0091-6749(85)90014-4			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ABF26	3968330				2022-12-18	WOS:A1985ABF2600010
J	EGGLESTON, PA				EGGLESTON, PA			METHODS OF EXERCISE CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											EGGLESTON, PA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205, USA.							CLOUTIER MM, 1981, PEDIATRICS, V67, P6; DAY G, 1973, ARCH DIS CHILD, V48, P355, DOI 10.1136/adc.48.5.355; DEAL EC, 1979, J APPL PHYSIOL, V46, P476, DOI 10.1152/jappl.1979.46.3.476; EGGLESTON PA, 1981, CLIN PHARMACOL THER, V29, P505, DOI 10.1038/clpt.1981.70; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; FISH JE, 1981, J APPL PHYSIOL, V50, P1079, DOI 10.1152/jappl.1981.50.5.1079; GARDNER RM, 1979, AM REV RESPIR DIS, V119, P831; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; JOHNSON WR, 1980, SCI MED EXERCISE SPO, P125; KAWABORI I, 1976, J ALLERGY CLIN IMMUN, V58, P447, DOI 10.1016/0091-6749(76)90188-3; KONIG P, 1973, ARCH DIS CHILD, V48, P513, DOI 10.1136/adc.48.7.513; MARTIN AJ, 1980, AM REV RESPIR DIS, V122, P609; MCFADDEN ER, 1979, NEW ENGL J MED, V301, P763; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; PHILLIPS YY, 1983, J ALLERGY CLIN IMMUN, V71, P107, DOI 10.1016/0091-6749(83)90198-7; SCHACHTER EN, 1981, ANN ALLERGY, V46, P12; SCHNALL RP, 1980, THORAX, V35, P828, DOI 10.1136/thx.35.11.828; SHEPHARD RJ, 1968, B WORLD HEALTH ORGAN, V38, P765; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882, DOI 10.1136/adc.47.256.882; SKORECKI K, 1976, ACTA PAEDIATR SCAND, V65, P39, DOI 10.1111/j.1651-2227.1976.tb04405.x	21	40	41	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					666	669		10.1016/0091-6749(84)90302-6	http://dx.doi.org/10.1016/0091-6749(84)90302-6			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6715731				2022-12-18	WOS:A1984SS04600009
J	FITCH, KD				FITCH, KD			MANAGEMENT OF ALLERGIC OLYMPIC ATHLETES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											FITCH, KD (corresponding author), UNIV WESTERN AUSTRALIA,DEPT HUMAN MOVEMENT & RECREAT STUDIES,NEDLANDS,WA 6009,AUSTRALIA.							BOUSHEY HA, 1982, J ALLERGY CLIN IMMUN, V69, P335, DOI 10.1016/0091-6749(82)90142-7; CHEN WY, 1977, RESPIRATION, V34, P305, DOI 10.1159/000193842; FITCH KD, 1976, JAMA-J AM MED ASSOC, V236, P152, DOI 10.1001/jama.236.2.152; FRASER D, 1965, GOLD MEDAL GIRL, P10; HANLEY DF, 1976, JAMA-J AM MED ASSOC, V236, P147, DOI 10.1001/jama.236.2.147; MCCAFFERTY WB, 1981, AIR POLLUTION ATHLET, P184; MORTON AR, 1982, ANN ALLERGY, V48, P123; PALAEOLOGOS K, 1981, ETERNAL OLYMPICS, P108; SCHNALL RP, 1980, THORAX, V35, P828, DOI 10.1136/thx.35.11.828; 1984, DOPING CLASSES EXAMP	10	40	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1984	73	5					722	727		10.1016/0091-6749(84)90314-2	http://dx.doi.org/10.1016/0091-6749(84)90314-2			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	SS046	6715736				2022-12-18	WOS:A1984SS04600021
J	CHIU, JT				CHIU, JT			IMPROVEMENT IN ASPIRIN-SENSITIVE ASTHMATIC SUBJECTS AFTER RAPID ASPIRIN DESENSITIZATION AND ASPIRIN MAINTENANCE (ADAM) TREATMENT	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV CALIF IRVINE,COLL MED,DEPT MED,DIV ALLERGY & IMMUNOL,ORANGE,CA 92668	University of California System; University of California Irvine								BUDRYS S, 1979, IMMUNOL ALLERGY PRAC, V1, P35; KORDANSKY D, 1978, ANN INTERN MED, V88, P508, DOI 10.7326/0003-4819-88-4-508; LOCKEY RF, 1973, ANN INTERN MED, V78, P57, DOI 10.7326/0003-4819-78-1-57; PATERSON NAM, 1981, J ALLERGY CLIN IMMUN, V67, P426, DOI 10.1016/0091-6749(81)90095-6; SAMTER M, 1968, ANN INTERN MED, V68, P975, DOI 10.7326/0003-4819-68-5-975; SAMTER M, 1967, J ALLERGY, V40, P281, DOI 10.1016/0021-8707(67)90076-7; SETTIPANE GA, 1981, ARCH INTERN MED, V141, P328, DOI 10.1001/archinte.141.3.328; SMITH LJ, 1976, J ALLERGY CLIN IMMUN, V58, P456, DOI 10.1016/0091-6749(76)90189-5; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1981, N ENGL SOC ALLERGY P, V2, P88; SZEZEKLIK A, 1975, BR MED J, V1, P57; TOOGOOD JH, 1977, CHEST, V72, P135, DOI 10.1378/chest.72.2.135; Widal M, 1922, PRESSE MED, V30, P189; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2; 1981, LANCET, V2, P1266	15	40	42	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1983	71	6					560	567		10.1016/0091-6749(83)90437-2	http://dx.doi.org/10.1016/0091-6749(83)90437-2			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QV139	6853924	Bronze			2022-12-18	WOS:A1983QV13900007
J	KOHLER, PF; COOK, RD; BROWN, WR; MANGUSO, RL				KOHLER, PF; COOK, RD; BROWN, WR; MANGUSO, RL			COMMON VARIABLE HYPOGAMMAGLOBULINEMIA WITH T-CELL NODULAR LYMPHOID INTERSTITIAL PNEUMONITIS AND B-CELL NODULAR LYMPHOID HYPERPLASIA - DIFFERENT LYMPHOCYTE POPULATIONS WITH A SIMILAR RESPONSE TO PREDNISONE THERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV COLORADO,SCH MED,DIV GASTROENTEROL,DENVER,CO 80262; VET ADM MED CTR,DENVER,CO 80220; AURORA PRESBYTERIAN HOSP,DEPT MED,AURORA,CO	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA)	KOHLER, PF (corresponding author), UNIV COLORADO,SCH MED,DEPT MED,DIV CLIN IMMUNOL,DENVER,CO 80262, USA.		Brown, William/GXN-2777-2022		NCRR NIH HHS [RR-51] Funding Source: Medline; NIAID NIH HHS [AI-07166, AI-12028] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHERSON GL, 1980, DIAGNOSIS TREATMENT, P41; CRYSTAL RG, 1981, AM J MED, V70, P542, DOI 10.1016/0002-9343(81)90577-5; DAVIS SD, 1970, ARCH INTERN MED, V126, P668, DOI 10.1001/archinte.126.4.668; DUKES RJ, 1978, THORAX, V33, P603, DOI 10.1136/thx.33.5.603; GREAVES MF, 1979, EUR J IMMUNOL, V9, P356, DOI 10.1002/eji.1830090504; KOHLER PF, 1969, CLIN EXP IMMUNOL, V4, P191; KUNG PC, 1979, SCIENCE, V206, P347, DOI 10.1126/science.314668; LEVINSON AI, 1976, ARCH INTERN MED, V136, P213, DOI 10.1001/archinte.136.2.213; LIEBOW AA, 1973, MED CLIN N AM, V57, P809, DOI 10.1016/S0025-7125(16)32278-7; NAGURA H, 1979, LAB INVEST, V40, P66; NICHOLS PW, 1982, AM J MED, V72, P467, DOI 10.1016/0002-9343(82)90516-2; REINHERZ EL, 1980, NEW ENGL J MED, V303, P370, DOI 10.1056/NEJM198008143030704; STEIN H, 1980, J HISTOCHEM CYTOCHEM, V28, P746, DOI 10.1177/28.8.7003001	13	40	43	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1982	70	4					299	305		10.1016/0091-6749(82)90066-5	http://dx.doi.org/10.1016/0091-6749(82)90066-5			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PL151	6981662				2022-12-18	WOS:A1982PL15100010
J	MALISH, D; GLOVSKY, MM; HOFFMAN, DR; GHEKIERE, L; HAWKINS, JM				MALISH, D; GLOVSKY, MM; HOFFMAN, DR; GHEKIERE, L; HAWKINS, JM			ANAPHYLAXIS AFTER SESAME SEED INGESTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									SO CALIF PERMANENTE MED GRP, DEPT ALLERGY & CLIN IMMUNOL, LOS ANGELES, CA 90027 USA; E CAROLINA UNIV, SCH MED, GREENVILLE, NC 27834 USA	Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of North Carolina; East Carolina University								HOFFMAN DR, 1974, J ALLERGY CLIN IMMUN, V54, P165, DOI 10.1016/0091-6749(74)90053-0; KING TP, 1978, IMMUNOLOGICAL DISEAS, P790; KRAFT D, 1977, CLIN ALLERGY, V7, P21, DOI 10.1111/j.1365-2222.1977.tb01420.x; PARISH W E, 1971, Clinical Allergy, V1, P369, DOI 10.1111/j.1365-2222.1971.tb00788.x; REISMAN RE, 1976, J ALLERGY CLIN IMMUN, V57, P547, DOI 10.1016/0091-6749(76)90005-1; RUBENSTEIN L, 1950, NEW YORK STATE J MED, V50, P343; SPIES JR, 1974, J AGR FOOD CHEM, V22, P30, DOI 10.1021/jf60191a005; TORSNEY PJ, 1964, J ALLERGY, V35, P514, DOI 10.1016/0021-8707(64)90083-8; UVITSKY IH, 1951, J ALLERGY, V22, P377, DOI 10.1016/0021-8707(51)90039-1	9	40	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	67	1					35	38		10.1016/0091-6749(81)90042-7	http://dx.doi.org/10.1016/0091-6749(81)90042-7			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KZ173	7451770				2022-12-18	WOS:A1981KZ17300007
J	NICKELSEN, JA; GOLDSTEIN, S; MUELLER, U; WYPYCH, J; REISMAN, RE; ARBESMAN, CE				NICKELSEN, JA; GOLDSTEIN, S; MUELLER, U; WYPYCH, J; REISMAN, RE; ARBESMAN, CE			LOCAL INTRANASAL IMMUNOTHERAPY FOR RAGWEED ALLERGIC RHINITIS .2. IMMUNOLOGICAL RESPONSE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									BUFFALO GEN HOSP,ALLERGY RES LAB,BUFFALO,NY 14203; SUNY BUFFALO,SCH MED,DEPT MED,DIV ALLERGY & CLIN IMMUNOL,BUFFALO,NY 14214	Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NIAID NIH HHS [AI 01303] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARBESMAN CE, 1977, INT ARCH ALLER A IMM, V53, P310, DOI 10.1159/000231767; JOHANSSON SGO, 1979, INT ARCH ALLER A IMM, V60, P447, DOI 10.1159/000232376; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; OKUDA M, 1977, ARCH OTO-RHINO-LARYN, V214, P241, DOI 10.1007/BF00458318; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; SHIMIZU M, 1978, J IMMUNOL METHODS, V19, P317, DOI 10.1016/0022-1759(78)90016-9; WELSH W, 1980, J ALLERGY CLIN IMMUN, V65, P191	8	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1981	68	1					41	45		10.1016/0091-6749(81)90121-4	http://dx.doi.org/10.1016/0091-6749(81)90121-4			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LY101	6972401				2022-12-18	WOS:A1981LY10100007
J	BLACK, PL; MARSH, DG				BLACK, PL; MARSH, DG			CORRELATION BETWEEN LYMPHOCYTE-RESPONSES AND IMMEDIATE HYPERSENSITIVITY TO PURIFIED ALLERGENS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,HOWARD HUGHES MED INST LAB,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED,DIV CLIN IMMUNOL,BALTIMORE,MD 21239	Johns Hopkins University; Johns Hopkins University					NIAID NIH HHS [AI 13370, AI 00423] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK PL, 1976, IMMUNOGENETICS, V3, P349, DOI 10.1007/BF01576967; BLACK PL, 1977, THESIS J HOPKINS U B; Bloom B R, 1971, Adv Immunol, V13, P101, DOI 10.1016/S0065-2776(08)60184-4; BROSTOFF J, 1969, LANCET, V2, P1269; BUCKLEY RH, 1977, J ALLERGY CLIN IMMUN, V59, P70, DOI 10.1016/0091-6749(77)90180-4; CHESS L, 1974, J IMMUNOL, V113, P1122; DOLOVICH J, 1973, J ALLERGY CLIN IMMUN, V52, P38, DOI 10.1016/0091-6749(73)90119-X; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; GATIEN JG, 1975, CLIN IMMUNOL IMMUNOP, V4, P32, DOI 10.1016/0090-1229(75)90036-7; GERRARD JW, 1978, AM J HUM GENET, V30, P46; GIRARD JP, 1967, J ALLERGY, V39, P65, DOI 10.1016/0021-8707(67)90113-X; GO S, 1970, LANCET, V1, P1115; GREEN GR, 1967, J ALLERGY, V40, P224, DOI 10.1016/0021-8707(67)90085-8; ISHIZAKA K, 1967, J IMMUNOL, V98, P490; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; JOHNSON P, 1965, EUR POLYM J, V1, P63; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; MAINI RN, 1971, CLIN EXP IMMUNOL, V9, P449; MARSH DG, 1974, P NATL ACAD SCI USA, V71, P3588, DOI 10.1073/pnas.71.9.3588; MARSH DG, 1977, IMMUNOGENETICS, V5, P235, DOI 10.1007/BF01570479; MARSH DG, 1977, IMMUNOGENETICS, V5, P217, DOI 10.1007/BF01570478; MARSH DG, 1975, ANTIGENS, V3, P271; MARSH DG, 1979, CLIN IMMUNOLOGY SECT, P81; MASSIE FS, 1972, ANN ALLERGY, V30, P676; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MULLIGAN JJ, 1966, J IMMUNOL, V96, P324; PEPYS J, 1968, EXCERPTA MED INT C S, P221; RICHTER M, 1968, J ALLERGY, V41, P140, DOI 10.1016/0021-8707(68)90054-3; ROCKLIN RE, 1974, J CLIN INVEST, V53, P735, DOI 10.1172/JCI107612; SLAVIN RG, 1963, J ALLERGY, V34, P368, DOI 10.1016/0021-8707(63)90055-8; Snedecor G.W., 1980, STAT METHODS, V7; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; WILLCOX HNA, 1978, IMMUNOGENETICS, V6, P209, DOI 10.1007/BF01563911; YOUNG SH, 1968, PEDIATRICS, V42, P976; ZEITZ SJ, 1966, J ALLERGY, V38, P321, DOI 10.1016/0021-8707(66)90030-X	38	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	5					394	401		10.1016/0091-6749(80)90119-0	http://dx.doi.org/10.1016/0091-6749(80)90119-0			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KQ965	7440857	Bronze			2022-12-18	WOS:A1980KQ96500008
J	SANTILLI, J; POTSUS, RL; GOODFRIEND, L; MARSH, DG				SANTILLI, J; POTSUS, RL; GOODFRIEND, L; MARSH, DG			SKIN REACTIVITY TO PURIFIED POLLEN ALLERGENS IN HIGHLY RAGWEED-SENSITIVE INDIVIDUALS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ALLERGY CLIN MED CTR, SCOTT AFB, BELLEVILLE, IL USA; ROYAL VICTORIA HOSP, DIV IMMUNOCHEM, MONTREAL H3A 1A1, QUEBEC, CANADA; JOHNS HOPKINS UNIV, GOOD SAMARITAN HOSP,SCH MED,DIV CLIN IMMUNOL, HOWARD HUGHES MED INST LAB, BALTIMORE, MD 21239 USA	United States Department of Defense; United States Air Force; McGill University; Royal Victoria Hospital; Johns Hopkins University								BELIN LGA, 1977, CLIN ALLERGY, V7, P55, DOI 10.1111/j.1365-2222.1977.tb01425.x; Goodfriend L, 1977, Monogr Allergy, V11, P80; GRIFFITHS BW, 1971, CAN J BIOCHEM CELL B, V49, P396, DOI 10.1139/o71-058; HENDERSON DA, 1976, SCI AM, V235, P25, DOI 10.1038/scientificamerican1076-25; JOHNSON P, 1966, IMMUNOCHEMISTRY, V3, P91, DOI 10.1016/0019-2791(66)90290-4; JOHNSON P, 1965, EUR POLYM J, V1, P63; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LAPKOFF CB, 1974, INT ARCH ALLER A IMM, V46, P215, DOI 10.1159/000231125; LICHTENSTEIN L, 1973, J ALLERGY CLIN IMMUN, V51, P285, DOI 10.1016/0091-6749(73)90130-9; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LICHTENSTEIN LM, 1969, J ALLERGY, V44, P307, DOI 10.1016/0021-8707(69)90035-5; MALLEY A, 1967, J IMMUNOL, V99, P825; MARSH DG, 1973, SCIENCE, V179, P691, DOI 10.1126/science.179.4074.691; MARSH DG, 1970, J ALLERGY, V46, P107, DOI 10.1016/0021-8707(70)90078-X; MARSH DG, 1975, IMMUNOCHEMISTRY, V12, P539, DOI 10.1016/0019-2791(75)90081-6; MARSH DG, 1975, ANTIGENS, V3, P271; MARSH DG, 1973, 8TH P C INT ASS ALL, P381; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; MOORE PG, 1972, STANDARD STATISTICAL, P52; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P94, DOI 10.1016/0091-6749(73)90081-X; ROEBBER M, 1975, J IMMUNOL, V115, P303; ROEBBER M, 1976, THESIS MCGILL U MONT; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031	24	40	40	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	6					406	412		10.1016/0091-6749(80)90232-8	http://dx.doi.org/10.1016/0091-6749(80)90232-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JV764	7372962				2022-12-18	WOS:A1980JV76400002
J	SAXON, A; KAPLAN, M; STEVENS, RH				SAXON, A; KAPLAN, M; STEVENS, RH			ISOTYPE-SPECIFIC HUMAN LYMPHOCYTES-B THAT PRODUCE IMMUNOGLOBULIN-E INVITRO WHEN STIMULATED BY POKEWEED MITOGEN	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article											SAXON, A (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,CTR INTERDISCIPLINARY RES IMMUNOL DIS,DEPT MED,LOS ANGELES,CA 90024, USA.				NATIONAL CANCER INSTITUTE [P01CA012800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI015332, R21AI015251, R01AI015251] Funding Source: NIH RePORTER; NCI NIH HHS [CA 12800] Funding Source: Medline; NIAID NIH HHS [AI-15251, AI-15332] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON J, 1977, J EXP MED, V145, P1520, DOI 10.1084/jem.145.6.1520; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUCKLEY RH, 1978, IMMUNOL REV, V41, P288, DOI 10.1111/j.1600-065X.1978.tb01469.x; COOPER MD, 1972, CLIN EXP IMMUNOL, V11, P143; DWYER JM, 1976, J EXP MED, V143, P781, DOI 10.1084/jem.143.4.781; FISER PM, 1979, J IMMUNOL, V123, P1788; GODING JW, 1976, J IMMUNOL METHODS, V10, P61, DOI 10.1016/0022-1759(76)90007-7; GONZALEZMOLINA A, 1977, J CLIN INVEST, V59, P616, DOI 10.1172/JCI108679; ISHIZAKA K, 1978, J IMMUNOL, V120, P655; MAGE MG, 1977, J IMMUNOL METHODS, V15, P47, DOI 10.1016/0022-1759(77)90016-3; Makela O, 1970, Transplant Rev, V5, P3; MANNING DD, 1976, J EXP MED, V144, P288, DOI 10.1084/jem.144.1.288; MARCHALONIS J, 1971, BIOCH J, V113, P299; MARRACK P, 1974, J IMMUNOL, V113, P830; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; NEIBURGER RG, 1978, J ALLERGY CLIN IMMUN, V61, P88, DOI 10.1016/0091-6749(78)90230-0; OHARA J, 1978, J IMMUNOL, V121, P2088; QUINTANS J, 1973, EUR J IMMUNOL, V3, P392, DOI 10.1002/eji.1830030704; SAXON A, 1977, J IMMUNOL, V118, P1872; SAXON A, 1980, J CLIN INVEST, V65, P1457, DOI 10.1172/JCI109810; SAXON A, 1977, CANCER RES, V37, P1154; SAXON A, 1976, J IMMUNOL METHODS, V12, P285, DOI 10.1016/0022-1759(76)90050-8; SAXON A, 1979, CLIN IMMUNOL IMMUNOP, V14, P474, DOI 10.1016/0090-1229(79)90100-4; STEVENS RH, 1978, J CLIN INVEST, V62, P1154, DOI 10.1172/JCI109234; STEVENS RH, 1979, CELL IMMUNOL, V45, P142, DOI 10.1016/0008-8749(79)90369-1; STEVENS RH, 1979, J IMMUNOL, V122, P2498; SUEMURA M, 1978, J IMMUNOL, V121, P2413; TJIO AH, 1979, J IMMUNOL, V122, P2131; URBAN JF, 1977, J IMMUNOL, V119, P583; URBAN JF, 1978, J IMMUNOL, V121, P199; WINCHESTER RJ, 1975, J IMMUNOL, V114, P1210; YODOI J, 1979, J IMMUNOL, V122, P2577; ZOLLINGER WD, 1976, J IMMUNOL, V117, P1788	33	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	66	3					233	241		10.1016/0091-6749(80)90045-7	http://dx.doi.org/10.1016/0091-6749(80)90045-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KH358	6967881				2022-12-18	WOS:A1980KH35800011
J	SIGLER, RW; EVANS, R; HORAKOVA, Z; OTTESEN, E; KAPLAN, AP				SIGLER, RW; EVANS, R; HORAKOVA, Z; OTTESEN, E; KAPLAN, AP			THE ROLE OF CYPROHEPTADINE IN THE TREATMENT OF COLD URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									WALTER REED ARMY MED CTR,WASHINGTON,DC 20012; NHLBI,BETHESDA,MD 20014; NIAID,PARASITOL LAB,BETHESDA,MD 20014; NIAID,ALLERG DIS SECT,BETHESDA,MD 20014	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; ROSE BRAM, 1941, JOUR ALLERGY, V12, P327, DOI 10.1016/S0021-8707(41)90260-5; SIGLER RW, 1978, J ALLERGY CLIN IMMUN, V63, P35; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P366, DOI 10.1016/0091-6749(71)90083-2; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	8	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1980	65	4					309	312		10.1016/0091-6749(80)90161-X	http://dx.doi.org/10.1016/0091-6749(80)90161-X			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JN548	6102102				2022-12-18	WOS:A1980JN54800012
J	SCHUSTER, DL; PIERSON, D; BONGIOVANNI, B; LEVINSON, AI				SCHUSTER, DL; PIERSON, D; BONGIOVANNI, B; LEVINSON, AI			SUPPRESSOR CELL-FUNCTION IN ATOPIC-DERMATITIS ASSOCIATED WITH ELEVATED IMMUNOGLOBULIN-E	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV PENN,SCH MED,PHILADELPHIA,PA 19174	University of Pennsylvania	SCHUSTER, DL (corresponding author), WALTER REED ARMY MED CTR,ALLERGY & IMMUNOL SERV,WASHINGTON,DC 20012, USA.							ABDOU NI, 1976, CLIN IMMUNOL IMMUNOP, V6, P192, DOI 10.1016/0090-1229(76)90110-0; ANDERSEN E, 1975, ACTA DERM-VENEREOL, V55, P345; BECKER WG, 1978, J ALLERGY CLIN IMMUN, V61, P177, DOI 10.1016/0091-6749(78)90401-3; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; BRISHNIHAN B, 1977, J CLIN INVEST, V59, P106; CARAPETO FJ, 1976, ARCH DERMATOL, V112, P1095, DOI 10.1001/archderm.112.8.1095; DAHL MV, 1976, ARCH DERMATOL, V112, P1387, DOI 10.1001/archderm.112.10.1387; DALTON R, 1972, J EXP MED, V136, P1445; EVANS EI, 1952, ANN SURG, V135, P804, DOI 10.1097/00000658-195206000-00006; FONTAN G, 1976, ACTA PAEDIATR SCAND, V65, P509, DOI 10.1111/j.1651-2227.1976.tb04922.x; GLICK G, 1971, J LAB CLIN MED, V77, P690; HALLGREN HM, 1977, J IMMUNOL, V118, P2004; HAYNES BF, 1977, J IMMUNOL, V118, P2281; HUBERT C, 1976, CLIN EXP IMMUNOL, V26, P98; JONES HE, 1973, ARCH DERMATOL, V107, P217, DOI 10.1001/archderm.107.2.217; KISHIMOTO T, 1974, J IMMUNOL, V112, P1685; LOBITZ WC, 1972, BRIT J DERMATOL, V86, P317, DOI 10.1111/j.1365-2133.1972.tb05045.x; LUCKASEN JR, 1974, ARCH DERMATOL, V110, P375, DOI 10.1001/archderm.110.3.375; MCCOMBS CC, 1978, J IMMUNOL, V120, P532; MCGEADY SJ, 1975, J ALLERGY CLIN IMMUN, V56, P393, DOI 10.1016/0091-6749(75)90133-5; OKUMURA K, 1973, NATURE-NEW BIOL, V245, P180, DOI 10.1038/newbio245180a0; OKUMURA K, 1974, J IMMUNOL, V112, P783; OKUMURA K, 1971, J IMMUNOL, V107, P1682; OKUMURA K, 1971, J IMMUNOL, V106, P1019; PALACIOS J, 1966, J INVEST DERMATOL, V47, P484, DOI 10.1038/jid.1966.172; PATTERSON R, 1975, CLIN EXP IMMUNOL, V20, P265; PEAVY DL, 1974, J EXP MED, V140, P356, DOI 10.1084/jem.140.2.356; RICH RR, 1975, J IMMUNOL, V114, P1112; RICH RR, 1973, J EXP MED, V137, P649, DOI 10.1084/jem.137.3.649; ROGGE JL, 1976, ARCH DERMATOL, V112, P1391, DOI 10.1001/archderm.112.10.1391; SCHWARTZ SA, 1977, P NATL ACAD SCI USA, V74, P2099, DOI 10.1073/pnas.74.5.2099; SHOU L, 1976, J EXP MED, V143, P1100, DOI 10.1084/jem.143.5.1100; SIEGAL FP, 1976, J CLIN INVEST, V58, P109, DOI 10.1172/JCI108439; TADA T, 1975, PROG ALLERGY, V19, P122, DOI 10.1159/000313387; TADA T, 1972, J IMMUNOL, V108, P1535; TADA T, 1971, J IMMUNOL, V106, P1012; TADA T, 1973, J IMMUNOL, V111, P952; TADA T, 1971, J IMMUNOL, V106, P1022; TAKATSU K, 1976, J IMMUNOL, V116, P1257; Waldmann T A, 1975, Trans Assoc Am Physicians, V88, P120; WALDMANN TA, 1974, LANCET, V2, P609; WATANABE N, 1977, J EXP MED, V145, P1501, DOI 10.1084/jem.145.6.1501	42	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	64	2					139	145		10.1016/0091-6749(79)90048-4	http://dx.doi.org/10.1016/0091-6749(79)90048-4			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HG426	313412				2022-12-18	WOS:A1979HG42600008
J	SIGLER, RW; LEVINSON, AI; HORAKOVA, Z; KAPLAN, AP				SIGLER, RW; LEVINSON, AI; HORAKOVA, Z; KAPLAN, AP			EVALUATION OF A PATIENT WITH COLD AND CHOLINERGIC URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NIAID,ALLERGIC DIS SECT,CLIN INVEST LAB,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	SIGLER, RW (corresponding author), WALTER REED ARMY MED CTR,DEPT ALLERGY & CLIN IMMUNOL,WASHINGTON,DC 20012, USA.							BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; HERXHEIMER A, 1956, CLIN SCI, V15, P194; HOUSER DD, 1970, AM J MED, V49, P23, DOI 10.1016/S0002-9343(70)80110-3; ILLIG L, 1967, ARCH KLIN EXP DERM, V229, P231, DOI 10.1007/BF00502986; ILLIG L, 1967, ARCH KLIN EXP DERM, V229, P360, DOI 10.1007/BF00509213; KAPLAN AP, 1975, J ALLERGY CLIN IMMUN, V55, P394, DOI 10.1016/0091-6749(75)90078-0; MATHEWS K P, 1970, Algerie Medicale, V72, P241; MOOREROBINSON M, 1968, BRIT J DERMATOL, V80, P794, DOI 10.1111/j.1365-2133.1968.tb11948.x; MOROZ A, 1971, CRYOPATHIES IMMUNOLO, V1, P459; SOTER NA, 1976, NEW ENGL J MED, V294, P687, DOI 10.1056/NEJM197603252941302; WANDERER AA, 1977, ARCH DERMATOL, V113, P1375, DOI 10.1001/archderm.113.10.1375; WANDERER AA, 1971, J ALLERGY CLIN IMMUN, V48, P13, DOI 10.1016/0091-6749(71)90050-9; WASSERMAN SI, 1977, J CLIN INVEST, V60, P189, DOI 10.1172/JCI108756	13	40	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	1					35	38		10.1016/0091-6749(79)90159-3	http://dx.doi.org/10.1016/0091-6749(79)90159-3			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GE110	82566				2022-12-18	WOS:A1979GE11000005
J	TREMBATH, PW; GREENACRE, JK; ANDERSON, M; DIMMOCK, S; MANSFIELD, L; WADSWORTH, J; GREEN, M				TREMBATH, PW; GREENACRE, JK; ANDERSON, M; DIMMOCK, S; MANSFIELD, L; WADSWORTH, J; GREEN, M			COMPARISON OF 4 WEEKS TREATMENT WITH FENOTEROL AND TERBUTALINE AEROSOLS IN ADULT ASTHMATICS - DOUBLE-BLIND CROSSOVER STUDY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST BARTHOLOMEWS HOSP,DEPT CHEST,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT CLIN PHARMACOL,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,COMP UNI MED SCI,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London								BHATIA SP, 1975, BRIT J CLIN PHARMACO, V2, P463, DOI 10.1111/j.1365-2125.1975.tb00557.x; CONNOLLY ME, 1971, BRIT J PHARMACOL, V43, P389; COTES JE, 1975, LUNG FUNCTION ASSESS, P374; DACOSTA JL, 1973, MED J AUSTRALIA, V2, P588; HOLGATE ST, 1977, LANCET, V2, P375; JENNE JW, 1977, J ALLERGY CLIN IMMUN, V59, P383, DOI 10.1016/0091-6749(77)90023-9; LARRSN S, 1977, J ALLERGY CLIN IMMUN, V59, P93; LEIFER KN, 1975, ANN ALLERGY, V35, P69; MATTILA MJ, 1967, ARZNEI-FORSCHUNG, V17, P362; NELSON HS, 1975, J ALLERGY CLIN IMMUN, V55, P299, DOI 10.1016/0091-6749(75)90002-0; PATERSON JW, 1968, LANCET, V2, P426; RUBINFIELD AR, 1976, LANCET, V1, P883; SCHULZ V, 1972, INT J CLIN PHARMA S4, P167; SIMI WW, 1977, J ALLERGY CLIN IMMUN, V59, P178, DOI 10.1016/0091-6749(77)90222-6; SPEIZER FE, 1968, BRIT MED J, V1, P335, DOI 10.1136/bmj.1.5588.335; STEEN SN, 1977, CHEST, V72, P291, DOI 10.1378/chest.72.3.291; THIRINGER G, 1976, SCAND J RESPIR DIS, V57, P17; 1976, BRIT MED J, V2, P387	18	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1979	63	6					395	400		10.1016/0091-6749(79)90212-4	http://dx.doi.org/10.1016/0091-6749(79)90212-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GY514	376572				2022-12-18	WOS:A1979GY51400005
J	BACAL, E; ZEISS, CR; SUSZKO, I; LEVITZ, D; PATTERSON, R				BACAL, E; ZEISS, CR; SUSZKO, I; LEVITZ, D; PATTERSON, R			POLYMERIZED WHOLE RAGWEED - AN IMPROVED METHOD OF IMMUNOTHERAPY	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									NORTHWESTERN UNIV,SCH MED,DEPT MED,ALLERGY IMMUNOL SECT,CHICAGO,IL 60611	Northwestern University								GRIFFITHS BW, 1971, CAN J BIOCHEM CELL B, V49, P396, DOI 10.1139/o71-058; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; LEVY DA, 1971, J CLIN INVEST, V50, P360, DOI 10.1172/JCI106503; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LIDD D, 1962, J ALLERGY, V33, P45, DOI 10.1016/0021-8707(62)90062-X; Lieberman P, 1974, Adv Intern Med, V19, P391; METZGER WJ, 1976, NEW ENGL J MED, V295, P1160, DOI 10.1056/NEJM197611182952103; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V61, P28, DOI 10.1016/0091-6749(78)90470-0; PATTERSON R, 1976, J ALLERGY CLIN IMMUN, V57, P168, DOI 10.1016/0091-6749(76)90036-1; PATTERSON R, 1973, J IMMUNOL, V110, P1413; ZEISS CR, 1977, CLIN EXP IMMUNOL, V28, P250; ZEISS CR, 1973, J IMMUNOL, V110, P414; ZEISS CR, UNPUBLISHED	13	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	5					289	294		10.1016/0091-6749(78)90160-4	http://dx.doi.org/10.1016/0091-6749(78)90160-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FW432					2022-12-18	WOS:A1978FW43200006
J	DAMAN, L; LIEBERMAN, P; GANIER, M; HASHIMOTO, K				DAMAN, L; LIEBERMAN, P; GANIER, M; HASHIMOTO, K			LOCALIZED HEAT URTICARIA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV TENNESSEE,DIV ALLERGY & IMMUNOL,MEMPHIS,TN 38163; UNIV TENNESSEE,VET ADM HOSP,DEPT MED,DIV DERMATOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center								BEAVEN MA, 1972, CLIN CHIM ACTA, V37, P91, DOI 10.1016/0009-8981(72)90419-6; DELORME P, 1969, J ALLERGY, V53, P5; DELORME P, 1969, J ALLERGY, V53, P284; FUDENBERG HH, 1976, BASIC CLINICAL IMMUN, P312; GREAVES MW, 1974, BRIT J DERMATOL, V90, P289, DOI 10.1111/j.1365-2133.1974.tb06404.x; Kabat EA, 1961, EXPT IMMUNOHISTOCHEM, P133; KAPLAN AP, 1976, J INVEST DERMATOL, V67, P327, DOI 10.1111/1523-1747.ep12514352; LEIGH IM, 1975, BRIT J DERMATOL, V92, P191, DOI 10.1111/j.1365-2133.1975.tb03057.x; MORAGAS JMD, 1973, ARCH DERMATOL, V108, P684	9	40	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	61	4					273	278		10.1016/0091-6749(78)90203-8	http://dx.doi.org/10.1016/0091-6749(78)90203-8			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EV080	632476	Bronze			2022-12-18	WOS:A1978EV08000028
J	IMBEAU, SA; NICHOLS, D; FLAHERTY, D; VALDIVIA, E; PETERS, ME; DICKIE, H; REED, CE				IMBEAU, SA; NICHOLS, D; FLAHERTY, D; VALDIVIA, E; PETERS, ME; DICKIE, H; REED, CE			ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV WISCONSIN,CTR HLTH SCI,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,CTR HLTH SCI,DEPT PREVENT MED,MADISON,WI 53706; UNIV WISCONSIN,CTR HLTH SCI,DEPT PATHOL,MADISON,WI 53706; UNIV WISCONSIN,CTR HLTH SCI,DEPT RADIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								CHANYEUN.M, 1971, CHEST, V59, P33, DOI 10.1378/chest.59.1.33; FLAHERTY D, 1974, J ALLERGY CLIN IMMUN, V53, P324; FLAHERTY DK, 1978, CLIN ALLERGY, V8, P73, DOI 10.1111/j.1365-2222.1978.tb00451.x; GOODMAN DH, 1974, ANN ALLERGY, V33, P289; HOENE JH, 1973, CHEST, V63, P177; HUSEBYE KO, 1967, DIS CHEST, V51, P327, DOI 10.1378/chest.51.3.327; IMBEAU SA, 1977, AM J DIS CHILD, V131, P1127, DOI 10.1001/archpedi.1977.02120230073013; KATZENSTEIN AL, 1975, AM REV RESPIR DIS, V111, P497; KUMAR UN, 1975, POSTGRAD MED, V58, P141, DOI 10.1080/00325481.1975.11714206; MALO JL, 1977, THORAX, V32, P254, DOI 10.1136/thx.32.3.254; MALO JL, 1977, THORAX, V32, P275, DOI 10.1136/thx.32.3.275; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI DOI 10.1111/J.1365-2222.1971.TB; OWEN GC, 1974, CLIN ALLERGY, V4, P141, DOI 10.1111/j.1365-2222.1974.tb01371.x; PANDE JN, 1971, THORAX, V26, P727, DOI 10.1136/thx.26.6.727; PATTERSON R, 1973, AM J MED, V54, P16, DOI 10.1016/0002-9343(73)90078-8; REED C, 1978, J ALLERGY CLIN IMMUN, V61, P227, DOI 10.1016/0091-6749(78)90189-6; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; TURNERWARWICK M, 1975, CHEST, V68, P346, DOI 10.1378/chest.68.3.346	19	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1978	62	4					243	255		10.1016/0091-6749(78)90214-2	http://dx.doi.org/10.1016/0091-6749(78)90214-2			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FS392	701659				2022-12-18	WOS:A1978FS39200008
J	BURGE, HP; SOLOMON, WR; BOISE, JR				BURGE, HP; SOLOMON, WR; BOISE, JR			COMPARATIVE MERITS OF 8 POPULAR MEDIA IN AEROMETRIC STUDIES OF FUNGI	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV ALLERGY,ALLERGY SECT,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan								de Vries GA., 1952, CONTRIBUTION KNOWLED; KRAMER C. L., 1959, TRANS KANSAS A CAD SCI, V62, P184, DOI 10.2307/3626975; KRAMER C. L., 1961, TRANS KANSAS ACAD SCI, V64, P110, DOI 10.2307/3626929; LUMPKINS ED, 1973, ANN ALLERGY, V31, P361; MORROW MB, 1964, ANN ALLERGY, V22, P575; PADY SM, 1960, MYCOLOGIA, V52, P347, DOI 10.2307/3756022; Raper K.B., 1949, MANUAL PENICILLIA; Raper KB, 1965, GENUS ASPERGILLUS GE; ROGERSON CLARK T., 1958, TRANS KANSAS ACAD SCI, V61, P155, DOI 10.2307/3626644; SHELDON JM, 1967, MANUAL CLINICAL ALLE; SOLOMON WR, 1976, J ALLERGY CLIN IMMUN, V57, P318, DOI 10.1016/0091-6749(76)90088-9; Stevens R.R., 1974, MYCOLOGY GUIDEBOOK; SWAEBLY MA, 1950, J ALLERGY, V21, P404, DOI 10.1016/0021-8707(50)90015-3	13	40	40	0	4	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1977	60	3					199	203		10.1016/0091-6749(77)90124-5	http://dx.doi.org/10.1016/0091-6749(77)90124-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DU852	556550				2022-12-18	WOS:A1977DU85200008
J	ISHIZAKA, T; URBAN, J; TAKATSU, K; ISHIZAKA, K				ISHIZAKA, T; URBAN, J; TAKATSU, K; ISHIZAKA, K			IMMUNOGLOBULIN E SYNTHESIS IN PARASITE INFECTION	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									JOHNS HOPKINS UNIV,GOOD SAMARITAN HOSP,SCH MED,DEPT MED & MICROBIOL,BALTIMORE,MD 21239	Johns Hopkins University				Urban, Joseph/0000-0002-1590-8869				BALL PAJ, 1969, T ROY SOC TROP MED H, V63, P362, DOI 10.1016/0035-9203(69)90011-X; BAZIN H, 1974, EUR J IMMUNOL, V4, P44, DOI 10.1002/eji.1830040112; BLOCH KJ, 1973, J IMMUNOL, V110, P197; CARSON D, 1975, J IMMUNOL, V114, P521; EISEN H N, 1964, Methods Med Res, V10, P94; HAMAOKA T, 1974, J IMMUNOL, V113, P958; HAMAOKA T, 1973, J EXP MED, V138, P538, DOI 10.1084/jem.138.3.538; ISHIZAKA K, 1973, Journal of Immunology, V110, P1067; ISHIZAKA T, 1976, CELL IMMUNOL, V22, P248, DOI 10.1016/0008-8749(76)90027-7; ISHIZAKA T, 1975, J IMMUNOL, V115, P1078; JARRETT E, 1974, NATURE, V251, P613, DOI 10.1038/251613a0; JARRETT E, 1974, NATURE, V250, P420, DOI 10.1038/250420a0; JARRETT EEE, 1972, IMMUNOLOGY, V23, P749; JARRETT EEE, IN PRESS; JOHANSSON SG, 1968, LANCET, V1, P1118; JONES PP, 1974, J EXP MED, V139, P581, DOI 10.1084/jem.139.3.581; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KATZ DH, 1974, J IMMUNOL, V113, P974; KISHIMOTO T, 1973, J IMMUNOL, V111, P720; KISHIMOTO T, 1972, J IMMUNOL, V109, P612; KISHIMOTO T, 1972, J IMMUNOL, V109, P1163; KLINMAN NR, 1969, CLIN EXP IMMUNOL, V4, P473; KOJIMA S, 1975, CELL IMMUNOL, V17, P383, DOI 10.1016/S0008-8749(75)80042-6; KOJIMA S, 1975, CELL IMMUNOL, V15, P274, DOI 10.1016/0008-8749(75)90006-4; MOTA I, 1969, LIFE SCI PT 1 PHYSI, V8, P813, DOI 10.1016/0024-3205(69)90099-X; MOTA I, 1969, IMMUNOLOGY, V16, P71; OGILVIE BM, 1967, IMMUNOLOGY, V12, P113; OGILVIE BM, 1964, NATURE, V204, P91, DOI 10.1038/204091a0; OGILVIE BM, 1973, PROG ALLERGY, V17, P93, DOI 10.1159/000313292; OGILVIE BM, 1966, NATURE, V209, P1221, DOI 10.1038/2091221a0; OKUDAIRA H, 1973, J IMMUNOL, V111, P1420; ORR TSC, 1971, IMMUNOLOGY, V20, P185; REVOLTELLA R, 1973, INT ARCH ALLER A IMM, V36, P283; ROSENBERG EB, 1970, NEW ENGL J MED, V283, P1148, DOI 10.1056/NEJM197011192832107; SADUN EH, 1968, J PARASITOL, V54, P814, DOI 10.2307/3277045; TADA T, 1971, J IMMUNOL, V107, P1137; TAKATSU K, 1976, J IMMUNOL, V116, P1257; WILSON RJM, 1968, J IMMUNOL, V100, P622; ZVAIFLER NJ, 1967, EXP PARASITOL, V20, P278, DOI 10.1016/0014-4894(67)90050-1	39	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1976	58	4					523	538		10.1016/0091-6749(76)90196-2	http://dx.doi.org/10.1016/0091-6749(76)90196-2			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CH210	1085781				2022-12-18	WOS:A1976CH21000009
J	MCFADDEN, ER				MCFADDEN, ER			CHRONICITY OF ACUTE ATTACKS OF ASTHMA - MECHANICAL AND THERAPEUTIC IMPLICATIONS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HARVARD UNIV,MED SCH,DEPT MED,PULM DIS DIV,BOSTON,MA; PETER BENT BRIGHAM HOSP,721 HUNTINGTON AVE,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital								BEALE HD, 1952, J ALLERGY, V23, P1, DOI 10.1016/0021-8707(52)90067-1; BENTIVOGLIO LG, 1963, J CLIN INVEST, V42, P1193, DOI 10.1172/JCI104805; BRISCOE WA, 1952, THORAX, V7, P66, DOI 10.1136/thx.7.1.66; CADE JF, 1973, AUST NZ J MED, V3, P545, DOI 10.1111/j.1445-5994.1973.tb04293.x; FERRIS BG, 1964, J APPL PHYSIOL, V19, P653, DOI 10.1152/jappl.1964.19.4.653; GOLD WM, 1967, J APPL PHYSIOL, V23, P433, DOI 10.1152/jappl.1967.23.4.433; HERSCHFUS JA, 1953, AM J MED, V14, P34, DOI 10.1016/0002-9343(53)90355-6; HERSCHFUS JA, 1953, AM J MED, V14, P23, DOI 10.1016/0002-9343(53)90354-4; KRAEPELIEN S, 1958, Acta Paediatr, V47, P399, DOI 10.1111/j.1651-2227.1958.tb07652.x; LOWELL FC, 1955, J ALLERGY, V26, P113, DOI 10.1016/0021-8707(55)90045-9; LUKAS DS, 1951, J ALLERGY, V22, P411, DOI 10.1016/0021-8707(51)90144-X; MACKLEM PT, 1967, J APPL PHYSIOL, V22, P395, DOI 10.1152/jappl.1967.22.3.395; MCCARTHY D, 1973, AM REV RESPIR DIS, V107, P559, DOI 10.1164/arrd.1973.107.4.559; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; MCFADDEN ER, 1972, AM J MED, V52, P725, DOI 10.1016/0002-9343(72)90078-2; MCFADDEN ER, 1969, J APPL PHYSIOL, V27, P452, DOI 10.1152/jappl.1969.27.4.452; MCFADDEN ER, 1968, J APPL PHYSIOL, V25, P365, DOI 10.1152/jappl.1968.25.4.365; MCFADDEN ER, P ASILOMAR INT S AST; MCFADDEN ER, UNPUBLISHED OBSERVAT; MCFADDEN ER, BRONCHIAL ASTHMA MEC; ORAZALESI MM, 1964, ACTA PAEDIATR, V53, P401; OTIS AB, 1956, J APPL PHYSIOL, V8, P427, DOI 10.1152/jappl.1956.8.4.427; REES HA, 1967, QUART J MED, V38, P541; TOOLEY WH, 1965, J PEDIATR-US, V66, P517, DOI 10.1016/S0022-3476(65)80116-0; Weibel E.R., 1963, MORPHOMETRY HUMAN LU, DOI DOI 10.1007/978-3-642-87553-3; WENG TR, 1969, AM REV RESPIR DIS, V99, P719; WOOLCOCK AJ, 1968, AM REV RESPIR DIS, V98, P788; WOOLCOCK AJ, 1966, AUSTRALAS ANN MED, V15, P196	28	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	56	1					18	26		10.1016/0091-6749(75)90030-5	http://dx.doi.org/10.1016/0091-6749(75)90030-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AH615	1138017				2022-12-18	WOS:A1975AH61500002
J	OREHEK, J; GAYRARD, P; GRIMAUD, C; CHARPIN, J				OREHEK, J; GAYRARD, P; GRIMAUD, C; CHARPIN, J			EFFECT OF BETA-ADRENERGIC-BLOCKADE ON BRONCHIAL SENSITIVITY TO INHALED ACETYLCHOLINE IN NORMAL SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									HOP SALVATOR,LAB EXPLORATIONS FONCTIONNELLES RESP,MARSEILLE,FRANCE; HOP ST MARGUERITE,CLIN PNEUMOPHTISIOL,13274 MARSEILLE,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille								BOUHUYS A, 1971, J CLIN INVEST, V50, pA9; CARA M, 1967, TABLES REFERENCES PO; DOUGLAS JS, 1973, J PHARMACOL EXP THER, V184, P169; DUBOIS AB, 1956, J CLIN INVEST, V35, P327, DOI 10.1172/JCI103282; GAYRARD P, 1973, REV FR ALLERGOL, V13, P31, DOI 10.1016/S0035-2845(73)80030-7; GEORGE CF, 1972, ARCH INTERN MED, V130, P361, DOI 10.1001/archinte.130.3.361; GRIECO MH, 1971, J ALLERGY CLIN IMMUN, V48, P143, DOI 10.1016/0091-6749(71)90009-1; MARCELLE R, 1968, ACTA ALLERGOL, V23, P11, DOI 10.1111/j.1398-9995.1968.tb04043.x; MCDONALD AG, 1967, BRIT J ANAESTH, V39, P919; MCGEADY S, 1968, J ALLERGY, V41, P108; RYO UY, 1972, J ALLERGY CLIN IMMUN, V49, P105; SCHILD HO, 1949, BRIT J PHARM CHEMOTH, V4, P277, DOI 10.1111/j.1476-5381.1949.tb00548.x; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; Tiffeneau R., 1957, EXAMEN PULMONAIRE AS; TURNER P, 1971, ARCH INT PHARMACOD T, V191, P104; ZACEST R, 1972, PHARMACOLOGY, V7, P178, DOI 10.1159/000136287; ZAID G, 1966, N ENGL J MED, V275, P203; 1970, AVLOCARDYL ALDERLEY	18	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1975	55	3					164	169		10.1016/0091-6749(75)90012-3	http://dx.doi.org/10.1016/0091-6749(75)90012-3			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	V8448	1112949				2022-12-18	WOS:A1975V844800003
J	SHERMAN, NA; SMITH, RS; MIDDLETO.E				SHERMAN, NA; SMITH, RS; MIDDLETO.E			EFFECT OF ADRENERGIC COMPOUNDS, AMINOPHYLLINE AND HYDROCORTISONE, ON IN-VITRO IMMUNOGLOBULIN-SYNTHESIS BY NORMAL HUMAN PERIPHERAL LYMPHOCYTES	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									CHILDRENS ASTHMA RES INST & HOSP,DENVER,CO 80204									AHLQUIST RP, 1968, ANNU REV PHARMACOLOG, V8, P259, DOI 10.1146/annurev.pa.08.040168.001355; AMBROSE CT, 1970, 36 CIB F STUD GROUP, P100; BARKA T, 1970, EXP CELL RES, V62, P50, DOI 10.1016/0014-4827(79)90508-1; BENNER MH, 1968, J ALLERGY, V41, P110; BLISS CI, 1967, STATISTICS BIOLOGY; BOURNE HR, 1972, J IMMUNOL, V108, P695; BRODIE BB, 1966, PHARMACOL REV, V18, P273; DUQUESNOY RJ, 1970, P SOC EXP BIOL MED, V133, P201; FABRIS N, 1971, CLIN EXP IMMUNOL, V9, P209; FULLER RW, 1970, BIOCHEM PHARMACOL, V19, P1518, DOI 10.1016/0006-2952(70)90072-9; Gabrielsen A E, 1967, Adv Immunol, V6, P91, DOI 10.1016/S0065-2776(08)60522-2; Hadden J W, 1970, Cell Immunol, V1, P583, DOI 10.1016/0008-8749(70)90024-9; HALLIDAY WJ, 1964, J IMMUNOL, V93, P757; HENNEY CS, 1972, J IMMUNOL, V108, P1526; HENSON EC, 1970, INT ARCH ALLER A IMM, V37, P458, DOI 10.1159/000230236; ISHIZUKA M, 1970, P SOC EXP BIOL MED, V134, P963; KATZ RL, 1968, P SOC EXP BIOL MED, V128, P1140; LICHTENSTEIN LM, 1964, J EXP MED, V120, P507, DOI 10.1084/jem.120.4.507; LOGSDON PJ, 1972, J ALLERGY CLIN IMMUN, V50, P45, DOI 10.1016/0091-6749(72)90078-4; MAKINO S, 1970, Federation Proceedings, V29, P431; MALAMUD D, 1968, EXP CELL RES, V50, P581, DOI 10.1016/0014-4827(68)90420-5; MCMILLAN R, 1970, J LAB CLIN MED, V76, P333; MCMILLAN R, 1971, BLOOD-J HEMATOL, V37, P316, DOI 10.1182/blood.V37.3.316.316; MORAN NC, 1967, ANN NY ACAD SCI, V139, P649, DOI 10.1111/j.1749-6632.1967.tb41235.x; PANDIAN MR, 1971, J EXP MED, V134, P1095, DOI 10.1084/jem.134.5.1095; PEARLMAN DS, 1971, J ALLERGY, V47, P109; PIERPAOLI W, 1968, J IMMUNOL, V101, P1036; ROBISON GA, 1967, ANN NY ACAD SCI, V139, P703, DOI 10.1111/j.1749-6632.1967.tb41239.x; SMITH JW, 1971, J CLIN INVEST, V50, P432, DOI 10.1172/JCI106510; SMITH R S, 1970, Journal of Immunology, V104, P367; SMITH RS, 1973, J ALLERGY CLIN IMMUN, V51, P328, DOI 10.1016/0091-6749(73)90071-7; SMITH RS, 1970, IMMUNOCHEMISTRY, V7, P661, DOI 10.1016/0019-2791(70)90248-X; SMITH RS, 1972, INT ARCH ALLER A IMM, V43, P859, DOI 10.1159/000230903; TUCHINDA M, 1972, INT ARCH ALLER A IMM, V42, P533, DOI 10.1159/000230634; Uhr J W, 1970, Cell Immunol, V1, P228, DOI 10.1016/0008-8749(70)90010-9; 1970, INT ARCH ALLERGY APP, V38, P664	36	40	40	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1973	52	1					13	22		10.1016/0091-6749(73)90116-4	http://dx.doi.org/10.1016/0091-6749(73)90116-4			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	Q1826	4715271				2022-12-18	WOS:A1973Q182600002
J	GRIGGS, RC; CONDEMI, JJ; VAUGHAN, JH				GRIGGS, RC; CONDEMI, JJ; VAUGHAN, JH			EFFECT OF THERAPEUTIC DOSAGES OF PREDNISONE ON HUMAN IMMUNOGLOBULIN-G METABOLISM	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article														Griggs, Robert/0000-0001-7988-4854				ABRAHAM G, 1971, J CLIN INVEST, V50, pA1; ANDERSEN SB, 1964, METABOLISM HUMAN GLO; BERGLUND K, 1965, MOLECULAR CELLULAR B, P405; CLAMAN HN, 1971, J LAB CLIN MED, V78, P499; FISCHEL EE, 1951, P SOC EXP BIOL MED, V77, P111; FISCHEL EE, 1952, P SOC EXP BIOL MED, V81, P344, DOI 10.3181/00379727-81-19872; GRIGGS RC, 1969, ARCH NEUROL-CHICAGO, V21, P303, DOI 10.1001/archneur.1969.00480150093012; HELMKAMP RW, 1960, CANCER RES, V20, P1495; LEVY AL, 1970, J CLIN INVEST, V49, P1679, DOI 10.1172/JCI106385; MATTHEWS CME, 1957, PHYS MED BIOL, V2, P36, DOI 10.1088/0031-9155/2/1/305; MCFARLANE AS, 1970, J CLIN INVEST, V49, P1903, DOI 10.1172/JCI106409; RABELLINO E, 1971, J EXP MED, V133, P156, DOI 10.1084/jem.133.1.156; ROTHSCHILD MA, 1958, J CLIN INVEST, V37, P1229, DOI 10.1172/JCI103711; Schwartz R, 1968, HUMAN TRANSPLANTATIO, P440; STERLING K, 1960, J CLIN INVEST, V39, P1900, DOI 10.1172/JCI104214; SWANSON MA, 1967, NEW ENGL J MED, V277, P163, DOI 10.1056/NEJM196707272770401; WALLIS WA, 1956, STATISTICS NEW APPRO; WOCHNER RD, 1970, J CLIN INVEST, V49, pA104, DOI 10.1172/JCI106254; WOCHNER RD, 1966, J CLIN INVEST, V45, P321, DOI 10.1172/JCI105346	19	40	40	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		1972	49	5					267	+		10.1016/0091-6749(72)90094-2	http://dx.doi.org/10.1016/0091-6749(72)90094-2			1	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	M4215	4623125				2022-12-18	WOS:A1972M421500002
J	Tomayko, MM; Damsky, W; Fathy, R; McMahon, DE; Turner, N; Valentin, MN; Rallis, T; Aivaz, O; Fox, LP; Freeman, EE				Tomayko, Mary M.; Damsky, William; Fathy, Ramie; McMahon, Devon E.; Turner, Noel; Valentin, Monica N.; Rallis, Tena; Aivaz, Ohara; Fox, Lindy P.; Freeman, Esther E.			Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material									[Tomayko, Mary M.; Damsky, William; Turner, Noel] Yale Univ Sch Med, Dept Dermatol, New Haven, CT USA; [Tomayko, Mary M.; Damsky, William] Yale Univ Sch Med, Dept Pathol, New Haven, CT USA; [Fathy, Ramie] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [McMahon, Devon E.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA; [Freeman, Esther E.] Harvard Med Sch, Med Practice Evaluat Ctr, Mongan Inst, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Valentin, Monica N.] Anne Arundel Dermatol, Fairfax, VA USA; [Rallis, Tena] HVMA Atrius Hlth, Peabody, MA USA; [Aivaz, Ohara] Cedars Sinai Med Grp, Dept Dermatol, Beverly Hills, CA USA; [Fox, Lindy P.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA USA; [McMahon, Devon E.] Harvard Med Sch, Boston, MA 02115 USA	Yale University; Yale University; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Cedars Sinai Medical Center; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Tomayko, MM (corresponding author), Yale Univ Sch Med, Dept Dermatol, New Haven, CT USA.; Tomayko, MM (corresponding author), Yale Univ Sch Med, Dept Pathol, New Haven, CT USA.	mary.tomayko@yale.edu			International League of Dermatologic Societies; Dermatology Foundation	International League of Dermatologic Societies; Dermatology Foundation	The American Academy of Dermatology/International League of Dermatological Soci-eties COVID-19 Dermatology Registry is supported by a grant from the International League of Dermatologic Societies to Massachusetts General Hospital and by in-kind support from the American Academy of Dermatology. Dr Damsky is supported by a Career Development Award from the Dermatology Foundation.	de la Fuente S, 2013, PEDIATR DERMATOL, V30, P741, DOI 10.1111/pde.12231; Kasperkiewicz M, 2022, J AM ACAD DERMATOL, V86, P1160, DOI 10.1016/j.jaad.2021.04.061; Kridin K, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00220; McMahon DE, 2021, J AM ACAD DERMATOL, V85, P46, DOI 10.1016/j.jaad.2021.03.092; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243	5	39	39	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2021	148	3					750	751		10.1016/j.jaci.2021.06.026	http://dx.doi.org/10.1016/j.jaci.2021.06.026		SEP 2021	2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	UP2VR	34275656	Bronze, Green Published			2022-12-18	WOS:000695242900023
J	Egami, S; Yamagami, J; Amagai, M				Egami, Shohei; Yamagami, Jun; Amagai, Masayuki			Autoimmune bullous skin diseases, pemphigus and pemphigoid	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Autoimmune bullous diseases; desmoglein; BP180; type XVII collagen BP230; ELISA; rituximab	LINKED-IMMUNOSORBENT-ASSAY; BASEMENT-MEMBRANE SEPARATION; INDUCE SUBEPIDERMAL BLISTERS; DERMAL-EPIDERMAL SEPARATION; FOLIACEUS FOGO SELVAGEM; DOUBLE-BLIND TRIAL; ANTI-DESMOGLEIN 1; IN-VITRO MODEL; CLASS-II GENES; PARANEOPLASTIC PEMPHIGUS	Autoimmune bullous skin diseases, such as pemphigus and pemphigoid, may enable clarification of the mechanisms of immune regulation in the skin. Pemphigus and pemphigoid are mediated by essentially IgG autoantibodies against structural proteins of the desmosomes at cell-cell junctions and hemidesmosomes at epidermal-dermal junctions, respectively, and are characterized by blisters and erosions in the skin and/or mucous membranes. Intensive investigation over the last 3 decades has identified their target antigens and developed serological diagnostic tools as well as mouse models to help us understand their pathophysiology. Based on these advances, several new therapeutic approaches have become available, and more effective and less toxic targeted approaches are under development.	[Egami, Shohei; Yamagami, Jun; Amagai, Masayuki] Keio Univ, Sch Med, Dept Dermatol, Tokyo, Japan; [Egami, Shohei; Amagai, Masayuki] RIKEN Ctr Integrat Med Sci, Lab Skin Homeostasis, Yokohama, Kanagawa, Japan	Keio University; RIKEN	Amagai, M (corresponding author), Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	amagai@keio.jp	Amagai, Masayuki/K-5325-2013	Amagai, Masayuki/0000-0003-3314-7052	Health and Labor Sciences Research Grants for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan [17933604]; Japan Agency for Medical Research and Development [17824562, 19111560]	Health and Labor Sciences Research Grants for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan; Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	M.A. receives research support from Health and Labor Sciences Research Grants for Research on Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan (grant no. 17933604) and Japan Agency for Medical Research and Development (grant no. 17824562). J.Y. receives research support from Grants-Aid for Scientific Research (grant no. 19111560).	Abasq C, 2009, ARCH DERMATOL, V145, P529, DOI 10.1001/archdermatol.2009.9; Abida O, 2009, BRIT J DERMATOL, V161, P522, DOI 10.1111/j.1365-2133.2009.09207.x; Ahmed AR, 2015, NEW ENGL J MED, V373, P2693, DOI 10.1056/NEJMc1508234; AHMED AR, 1991, P NATL ACAD SCI USA, V88, P5056, DOI 10.1073/pnas.88.11.5056; Almugairen N, 2013, J AM ACAD DERMATOL, V69, P583, DOI 10.1016/j.jaad.2013.05.016; Alpsoy E, 2015, ARCH DERMATOL RES, V307, P291, DOI 10.1007/s00403-014-1531-1; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Amagai M, 2000, J CLIN INVEST, V105, P625, DOI 10.1172/JCI8748; Amagai M, 1999, BRIT J DERMATOL, V140, P351; Amagai M, 1999, J DERMATOL SCI, V20, P92, DOI 10.1016/S0923-1811(99)00016-X; Amagai M., 2017, DERMATOLOGY; Amagai M, 2017, J DERMATOL SCI, V85, P77, DOI 10.1016/j.jdermsci.2016.11.003; Amagai M, 2014, J DERMATOL, V41, P471, DOI 10.1111/1346-8138.12486; Amagai M, 2009, J AM ACAD DERMATOL, V60, P595, DOI 10.1016/j.jaad.2008.09.052; Amber KT, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00201; Amber KT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01190; AMERIAN ML, 1984, J AM ACAD DERMATOL, V10, P215, DOI 10.1016/S0190-9622(84)70025-9; Anan T, 2011, J DERMATOL, V38, P1084, DOI 10.1111/j.1346-8138.2010.01192.x; Anhalt GJ, 2004, J INVEST DERM SYMP P, V9, P29, DOI 10.1111/j.1087-0024.2004.00832.x; ANHALT GJ, 1986, J IMMUNOL, V137, P2835; Anstey A, 2015, BRIT J DERMATOL, V173, pE23, DOI 10.1111/bjd.14162; Aoki V, 2015, J DERMATOL, V42, P18, DOI 10.1111/1346-8138.12675; ARBESMAN CE, 1974, ARCH DERMATOL, V110, P378, DOI 10.1001/archderm.110.3.378; Balestri R, 2016, J DERMATOL, V43, P125, DOI 10.1111/1346-8138.13079; Bastuji-Garin S, 2002, AM J EPIDEMIOL, V155, P249, DOI 10.1093/aje/155.3.249; BASTUJIGARIN S, 1995, J INVEST DERMATOL, V104, P302, DOI 10.1111/1523-1747.ep12612836; Bech R, 2013, BRIT J DERMATOL, V169, P469, DOI 10.1111/bjd.12324; Beissert S, 2006, ARCH DERMATOL, V142, P1447, DOI 10.1001/archderm.142.11.1447; Bektas M, 2013, J BIOL CHEM, V288, P9447, DOI 10.1074/jbc.M112.438010; Belloni-Fortina A, 2009, CLIN DEV IMMUNOL, P1, DOI 10.1155/2009/187864; BERNARD P, 1995, ARCH DERMATOL, V131, P48, DOI 10.1001/archderm.131.1.48; Bertram F, 2009, J DTSCH DERMATOL GES, V7, P434, DOI 10.1111/j.1610-0387.2008.06976.x; Bevans SL, 2018, DERMATOL THER, V31, DOI 10.1111/dth.12726; Blocker IM, 2012, BRIT J DERMATOL, V166, P964, DOI 10.1111/j.1365-2133.2012.10820.x; Bolotin D, 2011, J AM ACAD DERMATOL 2, V64, P33; Bolotin D, 2011, J AM ACAD DERMATOL, V64, P1027, DOI 10.1016/j.jaad.2010.09.776; Brenner S, 1998, CLIN DERMATOL, V16, P393, DOI 10.1016/S0738-081X(98)00010-8; Brodin P, 2017, NAT REV IMMUNOL, V17, P21, DOI 10.1038/nri.2016.125; BURGER DR, 1976, J IMMUNOL, V117, P797; Cai SCS, 2015, JAMA DERMATOL, V151, P665, DOI 10.1001/jamadermatol.2014.5263; Calka O, 2006, CLIN EXP DERMATOL, V31, P515, DOI 10.1111/j.1365-2230.2006.02132.x; Campa M, 2016, DERMATOL ONLINE J, V22; Caplan A, 2017, J AM ACAD DERMATOL, V76, P201, DOI 10.1016/j.jaad.2016.02.1241; Caplan A, 2017, J AM ACAD DERMATOL, V76, P191, DOI 10.1016/j.jaad.2016.02.1240; Caplan A, 2017, J AM ACAD DERMATOL, V76, P1, DOI 10.1016/j.jaad.2016.01.062; Caplan A, 2017, J AM ACAD DERMATOL, V76, P11, DOI 10.1016/j.jaad.2016.02.1239; Chakievska L, 2019, J AUTOIMMUN, V96, P104, DOI 10.1016/j.jaut.2018.09.003; Chams-Davatchi C, 2007, J AM ACAD DERMATOL, V57, P622, DOI 10.1016/j.jaad.2007.05.024; Chan LS, 2002, ARCH DERMATOL, V138, P370, DOI 10.1001/archderm.138.3.370; Chan RY, 1999, INVEST OPHTH VIS SCI, V40, P2283; Chen M, 2012, AUTOIMMUNITY, V45, P91, DOI 10.3109/08916934.2011.606450; Chen YJ, 2011, BRIT J DERMATOL, V165, P593, DOI 10.1111/j.1365-2133.2011.10386.x; Cheng SW, 2002, BRIT J DERMATOL, V147, P261, DOI 10.1046/j.1365-2133.2002.04838.x; Chiu YW, 2017, EUR J DERMATOL, V27, P375, DOI 10.1684/ejd.2017.3060; Cho YT, 2016, J DERMATOL SCI, V83, P78, DOI 10.1016/j.jdermsci.2016.03.009; Claudepierre T, 2005, J COMP NEUROL, V487, P190, DOI 10.1002/cne.20549; Cohen S, 2018, J DERMATOL TREAT, V29, P815, DOI 10.1080/09546634.2018.1459034; Cozzani E, 2001, J EUR ACAD DERMATOL, V15, P317, DOI 10.1046/j.1468-3083.2001.00275.x; Cozzani E, 2015, AUTOIMMUN REV, V14, P438, DOI 10.1016/j.autrev.2015.01.006; Culton DA, 2008, J AUTOIMMUN, V31, P311, DOI 10.1016/j.jaut.2008.08.003; Cummins DL, 2007, J AM ACAD DERMATOL, V56, P153, DOI 10.1016/j.jaad.2006.06.007; Dainichi T, 2016, BRIT J DERMATOL, V175, P187, DOI 10.1111/bjd.14411; De D, 2019, BRIT J DERMATOL, V180, P662, DOI 10.1111/bjd.17136; Maehara LDN, 2018, BRIT J DERMATOL, V178, pE212, DOI 10.1111/bjd.16022; Delgado JC, 1996, P NATL ACAD SCI USA, V93, P8569, DOI 10.1073/pnas.93.16.8569; della Torre R, 2012, BRIT J DERMATOL, V167, P1111, DOI 10.1111/j.1365-2133.2012.11108.x; Demidova-Rice TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032146; Di Zenzo G, 2012, J CLIN INVEST, V122, P3781, DOI 10.1172/JCI64413; Dreyer Sean, 2017, JAAD Case Rep, V3, P113, DOI 10.1016/j.jdcr.2017.01.009; Du FH, 2017, AUTOIMMUN HIGHLIGHTS, V8, DOI 10.1007/s13317-017-0100-y; Eberhard Y, 2005, ARCH DERMATOL RES, V296, P309, DOI 10.1007/s00403-004-0528-6; EL-Komy MHM, 2018, ARCH DERMATOL RES, V310, P375, DOI 10.1007/s00403-018-1824-x; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; Ellebrecht CT, 2014, JAMA DERMATOL, V150, P1331, DOI 10.1001/jamadermatol.2014.1939; Empinotti JC, 2006, BRIT J DERMATOL, V155, P446, DOI 10.1111/j.1365-2133.2006.07302.x; Espana A, 2017, J EUR ACAD DERMATOL, V31, P791, DOI 10.1111/jdv.13889; Fairley JA, 2009, J ALLERGY CLIN IMMUN, V123, P704, DOI 10.1016/j.jaci.2008.11.035; Fang H, 2016, J DERMATOL SCI, V83, P116, DOI 10.1016/j.jdermsci.2016.04.009; Feliciani C, 2015, BRIT J DERMATOL, V172, P867, DOI 10.1111/bjd.13717; Flores-Climente V, 2019, PEDIATR DERMATOL, V36, P984, DOI 10.1111/pde.13971; Frew JW, 2011, DERMATOL CLIN, V29, P607, DOI 10.1016/j.det.2011.06.016; Fujio Y, 2017, J DERMATOL SCI, V85, P208, DOI 10.1016/j.jdermsci.2016.12.007; FULLERTON SH, 1992, JAMA-J AM MED ASSOC, V267, P1500; Furue M, 2016, J DERMATOL, V43, P237, DOI 10.1111/1346-8138.13207; Galijasevic S, 2019, BIOORG MED CHEM LETT, V29, P1, DOI 10.1016/j.bmcl.2018.11.031; GAMMON WR, 1982, J INVEST DERMATOL, V78, P285, DOI 10.1111/1523-1747.ep12507222; Gazit E, 2005, AUTOIMMUN REV, V4, P16, DOI 10.1016/j.autrev.2004.05.002; Genovese G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01506; Genovese G, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1089-2; GIUDICE GJ, 1993, J IMMUNOL, V151, P5742; Goletz S, 2014, J AM ACAD DERMATOL, V71, P185, DOI 10.1016/j.jaad.2014.02.036; Gomi H, 1999, LANCET, V354, P1794, DOI 10.1016/S0140-6736(99)04708-X; Gudi VS, 2005, BRIT J DERMATOL, V153, P424, DOI 10.1111/j.1365-2133.2005.06662.x; Haeberle S, 2018, J ALLERGY CLIN IMMUN, V142, P1831, DOI 10.1016/j.jaci.2018.04.006; Hahn-Ristic K, 2002, J EUR ACAD DERMATOL, V16, P68, DOI 10.1046/j.1468-3083.2002.00384.x; Hall RP, 2013, J INVEST DERMATOL, V133, P2786, DOI 10.1038/jid.2013.236; Han L, 2015, FRONT MED-PRC, V9, P10, DOI 10.1007/s11684-015-0388-9; Harman KE, 2001, BRIT J DERMATOL, V144, P775, DOI 10.1046/j.1365-2133.2001.04132.x; Hashimoto T, 2017, BRIT J DERMATOL, V177, P141, DOI 10.1111/bjd.15114; HASHIMOTO T, 1993, J INVEST DERMATOL, V100, P385, DOI 10.1111/1523-1747.ep12471985; Hata T, 2013, J IMMUNOL, V191, P83, DOI 10.4049/jimmunol.1203536; Hayakawa T, 2016, EUR J DERMATOL, V26, P155, DOI 10.1684/ejd.2015.2719; Hayakawa T, 2014, OR SURG OR MED OR PA, V117, P483, DOI 10.1016/j.oooo.2013.12.402; Heelan K, 2015, CLIN EXP DERMATOL, V40, P593, DOI 10.1111/ced.12634; HIETANEN J, 1982, ACTA DERM-VENEREOL, V62, P491; Higashihara T, 2017, THER APHER DIAL, V21, P243, DOI 10.1111/1744-9987.12557; Hiroyasu S, 2013, AM J PATHOL, V182, P828, DOI 10.1016/j.ajpath.2012.11.029; Hohwy T, 2004, EUR J HAEMATOL, V73, P206, DOI 10.1111/j.1600-0609.2004.00280.x; Horikawa H, 2018, BRIT J DERMATOL, V178, P1462, DOI 10.1111/bjd.16479; Hubner F, 2016, J INVEST DERMATOL, V136, P2495, DOI 10.1016/j.jid.2016.07.013; Intong LRA, 2011, DERMATOL CLIN, V29, P447, DOI 10.1016/j.det.2011.03.002; Ishii N, 2015, BRIT J DERMATOL, V173, P59, DOI 10.1111/bjd.13711; Iwata H, 2009, J INVEST DERMATOL, V129, P919, DOI 10.1038/jid.2008.305; Izumi K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00978; Izumi K, 2016, J INVEST DERMATOL, V136, P2201, DOI 10.1016/j.jid.2016.06.622; Jakes AD, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2557; Javor J, 2010, J EUR ACAD DERMATOL, V24, P65, DOI 10.1111/j.1468-3083.2009.03260.x; Jolly PS, 2010, J BIOL CHEM, V285, P8936, DOI 10.1074/jbc.M109.087999; Joly P, 2002, NEW ENGL J MED, V346, P321, DOI 10.1056/NEJMoa011592; Joly P, 2007, NEW ENGL J MED, V357, P545, DOI 10.1056/NEJMoa067752; Joly P, 2017, LANCET, V389, P2031, DOI 10.1016/S0140-6736(17)30070-3; Joly P, 2012, J INVEST DERMATOL, V132, P1998, DOI 10.1038/jid.2012.35; Joly P, 2011, CLIN DERMATOL, V29, P432, DOI 10.1016/j.clindermatol.2011.01.013; Jung M, 1999, J AM ACAD DERMATOL, V41, P266, DOI 10.1016/S0190-9622(99)70061-7; Kalantari-Dehaghi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057587; Kalinska-Bienias A, 2019, INT J DERMATOL, V58, P172, DOI 10.1111/ijd.14270; Kamaguchi M, 2019, LAB INVEST, V99, P48, DOI 10.1038/s41374-018-0113-9; Kamata A, 2020, BRIT J DERMATOL, V182, P1221, DOI 10.1111/bjd.18364; Kaplan I, 2004, ORAL ONCOL, V40, P553, DOI 10.1016/j.oraloncology.2003.09.020; Kasperkiewicz M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.26; Kasperkiewicz M, 2012, J PATHOL, V228, P8, DOI 10.1002/path.4023; Kawaguchi Y, 2019, J DIABETES INVEST, V10, P392, DOI 10.1111/jdi.12877; Kawasaki H, 2006, J INVEST DERMATOL, V126, P2621, DOI 10.1038/sj.jid.5700450; Kim JH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01259; Kim JH, 2012, J DERMATOL, V39, P477, DOI 10.1111/j.1346-8138.2011.01360.x; Kobayashi M, 2002, J DERMATOL SCI, V30, P224, DOI 10.1016/S0923-1811(02)00109-3; Koga H, 2019, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00362; Kokkonen N, 2017, J INVEST DERMATOL, V137, P71, DOI 10.1016/j.jid.2016.09.010; Komasawa N, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006653; Kremer N, 2019, AM J CLIN DERMATOL, V20, P209, DOI 10.1007/s40257-018-0401-6; Kridin K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02466; Kridin K, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00220; Kridin K, 2016, J AM ACAD DERMATOL, V75, P925, DOI 10.1016/j.jaad.2016.06.055; Kwon EJ, 2008, J EUR ACAD DERMATOL, V22, P1070, DOI 10.1111/j.1468-3083.2008.02715.x; Lakshmi MJD, 2017, J AM ACAD DERMATOL, V76, P895, DOI 10.1016/j.jaad.2016.11.039; Lamberts A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00248; Lammer J, 2019, ACTA DERM-VENEREOL, V99, P508, DOI 10.2340/00015555-3154; Langan SM, 2011, J INVEST DERMATOL, V131, P631, DOI 10.1038/jid.2010.357; Lazarova Z, 2000, CLIN IMMUNOL, V95, P26, DOI 10.1006/clim.2000.4845; Lazarova Z, 2000, J INVEST DERMATOL, V114, P178, DOI 10.1046/j.1523-1747.2000.00829.x; Lazarova Z, 1996, J CLIN INVEST, V98, P1509, DOI 10.1172/JCI118942; Le Jan S, 2014, J INVEST DERMATOL, V134, P2908, DOI 10.1038/jid.2014.263; Lee JM, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00306; Lee J, 2015, LUNG, V193, P593, DOI 10.1007/s00408-015-9732-8; Leger S, 2012, ARCH DERMATOL, V148, P1165, DOI 10.1001/archdermatol.2012.1830; LEVER WF, 1953, MEDICINE, V32, P1; Lin L, 2018, J INVEST DERMATOL, V138, P1032, DOI 10.1016/j.jid.2017.11.031; Lin L, 2012, MATRIX BIOL, V31, P38, DOI 10.1016/j.matbio.2011.09.003; LINDELOF B, 1990, ARCH DERMATOL, V126, P66, DOI 10.1001/archderm.126.1.66; Lings K, 2015, ACTA DERM-VENEREOL, V95, P466, DOI 10.2340/00015555-1990; Liu Q, 2008, BRIT J DERMATOL, V158, P587, DOI 10.1111/j.1365-2133.2007.08361.x; Liu Z, 1998, J EXP MED, V188, P475, DOI 10.1084/jem.188.3.475; Lopez-Robles E, 2001, INT J DERMATOL, V40, P185, DOI 10.1046/j.1365-4362.2001.01083.x; Luftl M, 2003, BRIT J DERMATOL, V149, P598, DOI 10.1046/j.1365-2133.2003.05513.x; Mahmoud A, 2012, J LARYNGOL OTOL, V126, P1041, DOI 10.1017/S0022215112001375; Mahoney MG, 1998, J INVEST DERMATOL, V111, P308, DOI 10.1046/j.1523-1747.1998.00279.x; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; Mai Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01224; MAJESKI JA, 1977, J LAB CLIN MED, V90, P259; Mao XM, 2014, J INVEST DERMATOL, V134, P68, DOI 10.1038/jid.2013.224; Mao XM, 2010, AM J PATHOL, V177, P2724, DOI 10.2353/ajpath.2010.100483; Mao XM, 2009, J INVEST DERMATOL, V129, P908, DOI 10.1038/jid.2008.339; Marchenko S, 2010, J BIOL CHEM, V285, P3695, DOI 10.1074/jbc.M109.081570; Martel P, 2003, J AUTOIMMUN, V20, P91, DOI 10.1016/S0896-8411(02)00092-6; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021; McKinley SK, 2014, PEDIATR DERMATOL, V31, P241, DOI 10.1111/pde.12006; Mergler R, 2017, CASE REP DERMATOL, V9, P121, DOI 10.1159/000468919; Meudec L, 2019, BRIT J DERMATOL, V181, P828, DOI 10.1111/bjd.17882; Micali G, 1998, INT J DERMATOL, V37, P197, DOI 10.1046/j.1365-4362.1998.00428.x; Monk E, 2011, PHARMACOL RES, V63, P130, DOI 10.1016/j.phrs.2010.10.007; MORINI JP, 1993, ARCH DERMATOL, V129, P69, DOI 10.1001/archderm.129.1.69; Moriuchi R, 2015, J DERMATOL SCI, V78, P21, DOI 10.1016/j.jdermsci.2015.01.013; Mosaad YM, 2012, HUM IMMUNOL, V73, P560, DOI 10.1016/j.humimm.2012.02.001; Motegi S, 2005, J DERMATOL, V32, P809, DOI 10.1111/j.1346-8138.2005.tb00849.x; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; MUELLER S, 1989, J INVEST DERMATOL, V92, P33, DOI 10.1111/1523-1747.ep13070476; Muramatsu K, 2018, J ALLERGY CLIN IMMUN, V142, P1818, DOI 10.1016/j.jaci.2018.03.014; Murrell DF, 2020, J AM ACAD DERMATOL, V82, P575, DOI 10.1016/j.jaad.2018.02.021; Mutasim DF, 2001, J AM ACAD DERMATOL, V45, P803, DOI 10.1067/mjd.2001.117518; Nanda A, 2004, INT J DERMATOL, V43, P876, DOI 10.1111/j.1365-4632.2004.02292.x; Naseer SY, 2015, AUTOIMMUNITY, V48, P231, DOI 10.3109/08916934.2014.976629; Nelson KC, 2006, J CLIN INVEST, V116, P2892, DOI 10.1172/JCI17891; Nishie W, 2007, NAT MED, V13, P378, DOI 10.1038/nm1496; NISHIHARA H, 2017, ERJ OPEN RES, V3, DOI DOI 10.1212/NXG.0000000000000171; Nousari HC, 1999, NEW ENGL J MED, V340, P1406, DOI 10.1056/NEJM199905063401805; OGAWA H, 1995, J DERMATOL SCI, V9, P136, DOI 10.1016/0923-1811(94)00371-K; Ohata C, 2017, BRIT J DERMATOL, V177, P152, DOI 10.1111/bjd.15232; Okamura A, 2017, BRIT J DERMATOL, V176, P224, DOI 10.1111/bjd.14725; Oktarina DAM, 2011, BRIT J DERMATOL, V165, P552, DOI 10.1111/j.1365-2133.2011.10463.x; Parameswaran A, 2015, BRIT J DERMATOL, V172, P729, DOI 10.1111/bjd.13433; Goncalves GAP, 2011, AN BRAS DERMATOL, V86, P1109, DOI 10.1590/S0365-05962011000600007; PISANTI S, 1974, ORAL SURG ORAL MED O, V38, P382, DOI 10.1016/0030-4220(74)90365-X; Polansky M, 2019, J AM ACAD DERMATOL, V81, P179, DOI 10.1016/j.jaad.2019.03.049; Porro AM, 2014, AN BRAS DERMATOL, V89, P96, DOI 10.1590/abd1806-4841.20142459; Prussmann W, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0278-x; Qian Y, 2016, J IMMUNOL, V196, P2041, DOI 10.4049/jimmunol.1502233; Qian Y, 2015, J INVEST DERMATOL, V135, P913, DOI 10.1038/jid.2014.430; Rafei D, 2011, AM J PATHOL, V178, P718, DOI 10.1016/j.ajpath.2010.10.016; Rapp MB, 2018, J DRUGS DERMATOL, V17, P1338; Rashid KA, 2006, J IMMUNOL, V176, P1968, DOI 10.4049/jimmunol.176.3.1968; Rashid KA, 2013, INVEST OPHTH VIS SCI, V54, P7707, DOI 10.1167/iovs.12-11404; ROCK B, 1990, J CLIN INVEST, V85, P296, DOI 10.1172/JCI114426; ROENIGK HH, 1971, ARCH DERMATOL, V103, P1, DOI 10.1001/archderm.103.1.1; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; Sadik CD, 2018, SEMIN IMMUNOL, V37, P21, DOI 10.1016/j.smim.2018.03.002; Saha M, 2009, CLIN EXP DERMATOL, V34, pE979, DOI 10.1111/j.1365-2230.2009.03608.x; Saito M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050696; Saleh MA, 2011, J DERMATOL SCI, V62, P169, DOI 10.1016/j.jdermsci.2011.03.003; Saruta H, 2013, JAMA DERMATOL, V149, P1209, DOI 10.1001/jamadermatol.2013.5244; Sasai S, 2014, ACTA DERM-VENEREOL, V94, P734, DOI 10.2340/00015555-1848; Sato M, 2000, LAB INVEST, V80, P1583, DOI 10.1038/labinvest.3780168; Schlesinger N, 2002, BRIT J DERMATOL, V146, P836, DOI 10.1046/j.1365-2133.2002.04696.x; Schmidt E, 2000, J INVEST DERMATOL, V115, P842, DOI 10.1046/j.1523-1747.2000.00141.x; Schmidt E, 2007, BRIT J DERMATOL, V156, P352, DOI 10.1111/j.1365-2133.2006.07646.x; Schmidt E, 2019, LANCET, V394, P882, DOI 10.1016/S0140-6736(19)31778-7; Schmidt E, 2013, LANCET, V381, P320, DOI 10.1016/S0140-6736(12)61140-4; Schmidt E, 2011, DERMATOL CLIN, V29, P427, DOI 10.1016/j.det.2011.03.010; Schulze F, 2015, J INVEST DERMATOL, V135, P1445, DOI 10.1038/jid.2014.547; SCOLA F, 1995, J AM ACAD DERMATOL, V32, P516, DOI 10.1016/0190-9622(95)90092-6; Serwin AB, 2007, MED SCI MONITOR, V13, pCR360; Shi Connie R, 2018, JAAD Case Rep, V4, P162, DOI 10.1016/j.jdcr.2017.09.032; Shimanovich I, 2004, J PATHOL, V204, P519, DOI 10.1002/path.1674; Siddiqui Salahuddin, 2017, Hematol Oncol Stem Cell Ther, V10, P155, DOI 10.1016/j.hemonc.2016.05.003; SIMON DG, 1980, ARCH DERMATOL, V116, P1035, DOI 10.1001/archderm.116.9.1035; Sitaru C, 2005, J CLIN INVEST, V115, P870, DOI 10.1172/JCI200521386; Sitaru C, 2006, J IMMUNOL, V177, P3461, DOI 10.4049/jimmunol.177.5.3461; Slomov E, 2005, HUM IMMUNOL, V66, P1213, DOI 10.1016/j.humimm.2005.11.004; Souroujon MC, 2012, ANN NY ACAD SCI, V1274, P120, DOI 10.1111/j.1749-6632.2012.06844.x; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; Takahashi H, 2011, J CLIN INVEST, V121, P3677, DOI 10.1172/JCI57379; Takahashi H, 2009, J IMMUNOL, V182, P1740, DOI 10.4049/jimmunol.182.3.1740; Tallab T, 2001, INT J DERMATOL, V40, P570, DOI 10.1046/j.1365-4362.2001.01247.x; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; TAYLOR G, 1993, J AM ACAD DERMATOL, V29, P181, DOI 10.1016/0190-9622(93)70164-O; Thorne JE, 2004, OPHTHALMOLOGY, V111, P45, DOI 10.1016/j.ophtha.2003.03.001; Toosi S, 2010, MED HYPOTHESES, V74, P727, DOI 10.1016/j.mehy.2009.10.038; Torzecka JD, 2003, MEDIAT INFLAMM, V12, P303, DOI 10.1080/09629350310001619735; Toto P, 2000, J IMMUNOL, V164, P522, DOI 10.4049/jimmunol.164.1.522; Tsuchisaka A, 2014, J INVEST DERMATOL, V134, P2283, DOI 10.1038/jid.2014.151; Tsunoda K, 2003, J IMMUNOL, V170, P2170, DOI 10.4049/jimmunol.170.4.2170; Turner MS, 2000, J AM ACAD DERMATOL, V43, P1058, DOI 10.1067/mjd.2000.109297; Ujiie H, 2019, J DERMATOL, V46, P1102, DOI 10.1111/1346-8138.15111; Ujiie H, 2014, J IMMUNOL, V193, P4415, DOI 10.4049/jimmunol.1400095; Vadasz Z, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-94; van Beek N, 2017, JAMA DERMATOL, V153, P30, DOI 10.1001/jamadermatol.2016.3357; VASSILEVA S, 1994, J AM ACAD DERMATOL, V30, P1027, DOI 10.1016/S0190-9622(09)80149-7; Venning VA, 2012, BRIT J DERMATOL, V167, P1200, DOI 10.1111/bjd.12072; VENNING VA, 1990, BRIT J DERMATOL, V123, P439; Vinay K, 2015, JAMA DERMATOL, V151, P878, DOI 10.1001/jamadermatol.2014.3674; Vorobyev A, 2015, J INVEST DERMATOL, V135, P1565, DOI 10.1038/jid.2015.51; Waisbourd-Zinman O, 2008, J AM ACAD DERMATOL, V58, P41, DOI 10.1016/j.jaad.2007.08.010; Wang HH, 2015, ACTA DERM-VENEREOL, V95, P928, DOI 10.2340/00015555-2116; Warren SJP, 2000, NEW ENGL J MED, V343, P23, DOI 10.1056/NEJM200007063430104; Wong SN, 2002, BRIT J DERMATOL, V147, P476, DOI 10.1046/j.1365-2133.2002.04919.x; Woodley DT, 2005, J INVEST DERMATOL, V124, P958, DOI 10.1111/j.0022-202X.2005.23702.x; Yan L, 2012, BRIT J DERMATOL, V167, P768, DOI 10.1111/j.1365-2133.2012.11040.x; Yayli S, 2011, BRIT J DERMATOL, V165, P1133, DOI 10.1111/j.1365-2133.2011.10481.x; Yokoyama T, 2011, INT IMMUNOL, V23, P365, DOI 10.1093/intimm/dxr020; Yoshida M, 2006, J DERMATOL SCI, V41, P21, DOI 10.1016/j.jdermsci.2005.11.002; Yu KK, 2014, J AM ACAD DERMATOL, V71, P468, DOI 10.1016/j.jaad.2014.04.053; Yuan H, 2017, J INVEST DERMATOL, V137, pS7, DOI 10.1016/j.jid.2017.05.032; Zakka LR, 2011, AUTOIMMUN REV, V11, P40, DOI 10.1016/j.autrev.2011.07.002; Zhang J, 2011, J CANCER RES CLIN, V137, P229, DOI 10.1007/s00432-010-0874-z; Zhang SY, 2019, BRIT J DERMATOL, V180, P828, DOI 10.1111/bjd.17191; Zhou SR, 2020, J INVEST DERMATOL, V140, P309, DOI 10.1016/j.jid.2019.07.717; ZILLIKENS D, 1995, ARCH DERMATOL, V131, P957, DOI 10.1001/archderm.131.8.957	276	39	41	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2020	145	4					1031	1047		10.1016/j.jaci.2020.02.013	http://dx.doi.org/10.1016/j.jaci.2020.02.013			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LA0FR	32272980	Bronze			2022-12-18	WOS:000523633400001
J	Levin, ME; Botha, M; Basera, W; Facey-Thomas, HE; Gaunt, B; Gray, CL; Kiragu, W; Ramjith, J; Watkins, A; Genuneit, J				Levin, Michael E.; Botha, Maresa; Basera, Wisdom; Facey-Thomas, Heidi E.; Gaunt, Ben; Gray, Claudia L.; Kiragu, Wanjiku; Ramjith, Jordache; Watkins, Alexandra; Genuneit, Jon			Environmental factors associated with allergy in urban and rural children from the South African Food Allergy (SAFFA) cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Aeroallergen; aeroallergen sensitization; Africa; allergic rhinitis; asthma; atopic dermatitis; eczema; food allergy; prevalence; food sensitization; environmental exposures; fast foods; advanced glycation end-products; smoking; probiotics; prebiotics; unpasteurized milk; antibiotics; antihelminthics; pets; farm animals; sunlight; delivery mode; cesarean section; cooking fuel; heating fuel; rural; urban; urbanization	XHOSA-SPEAKING PATIENTS; GLYCATION END-PRODUCTS; FARM MILK CONSUMPTION; VERY-LOW PREVALENCE; INVERSE ASSOCIATION; ATOPIC-DERMATITIS; CHILDHOOD ASTHMA; EARLY-LIFE; HAY-FEVER; SENSITIZATION	Background: The prevalence of allergic diseases differs in urban and rural populations. Objective: We sought to assess associations between environmental and dietary factors with allergic diseases in urban and rural South African children. Methods: Toddlers aged 12 to 36 months were assessed for food allergen and aeroallergen sensitization, atopic dermatitis, allergic rhinitis, asthma, and challenge-proved food allergy. Information was collected on family history of allergic diseases, household size, socioeconomic status, delivery mode, antibiotic and probiotic use, exposure to fermented and unpasteurized milk, antihelminth treatment, sunlight exposure, pet and farm animal exposure, cigarette smoke, and household cooking and heating fuels. Antenatal exposures to pets, livestock, and cigarette smoke were assessed. A subsection completed questions on consumption of fruits and vegetables, fast foods, soft drinks/fruit juices, and fried/microwaved meat. Results: Risk and protective factors differed between urban and rural settings. Exposure to farm animals in infants and their mothers during pregnancy was protective against allergic outcomes in the rural population. Consumption of unpasteurized milk is uncommon in this group of rural children and is unlikely to be an important factor in rural protection. In urban children birth by cesarean section is associated with food allergy, and consumption of fermented milk products is associated with reduced asthma and atopic dermatitis. In both cohorts antenatal maternal smoking and environmental smoking exposure were predominantly associated with asthma, and consumption of fast foods and fried meats were associated with allergy. Conclusion: In this rural environment exposure to livestock is the strongest protective factor. In urban communities, where animal contact is rare, risk factors include cesarian section, and protective factors include consumption of fermented milk products. Modifiable risk factors urgently require interventions to prevent increasing allergy rates in countries undergoing rapid urbanization.	[Levin, Michael E.; Botha, Maresa; Facey-Thomas, Heidi E.; Gray, Claudia L.; Watkins, Alexandra] Univ Cape Town, Dept Paediat, Div Paediat Allergy, Cape Town, South Africa; [Basera, Wisdom] Univ Cape Town, Fac Hlth Sci, Sch Publ Hlth & Family Med, Cape Town, South Africa; [Gaunt, Ben] Univ Cape Town, Hlth Sci Fac, Div Primary Hlth Care, Cape Town, South Africa; [Ramjith, Jordache] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Cape Town, South Africa; [Levin, Michael E.] InVIVO Planetary Hlth Grp Worldwide Univ Network, Bisho, South Africa; [Gaunt, Ben] Zithulele Hosp, Eastern Cape Dept Hlth, Bisho, South Africa; [Kiragu, Wanjiku] Aga Khan Univ Hosp, Dept Paediat, Nairobi, Kenya; [Ramjith, Jordache] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Hlth Evidence, Biostat Res Grp,Med Ctr, Nijmegen, Netherlands; [Genuneit, Jon] Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, Germany; [Genuneit, Jon] Univ Leipzig, Med Ctr, Ctr Pediat Res Leipzig, Hosp Children & Adolescents, Leipzig, Germany	University of Cape Town; University of Cape Town; University of Cape Town; University of Cape Town; Radboud University Nijmegen; Ulm University; Leipzig University	Levin, ME (corresponding author), Red Cross Hosp, Room 516,ICH Bldg,Klipfontein Rd, ZA-7700 Rondebosch, South Africa.	michael.levin@uct.ac.za	Ramjith, Jordache/AAB-7339-2019; Levin, Michael/AAT-2370-2020; Genuneit, Jon/I-9323-2012; Ramjith, Jordache/N-7307-2018	Ramjith, Jordache/0000-0003-4431-7395; Levin, Michael/0000-0003-2439-7981; Genuneit, Jon/0000-0001-5764-1528; Ramjith, Jordache/0000-0003-4431-7395	Medical Research Council of South Africa; Nestle; Mylan; Thermo Fisher	Medical Research Council of South Africa(South African Medical Research Council); Nestle(Nestle SA); Mylan; Thermo Fisher	Supported by the Medical Research Council of South Africa, Nestle, Mylan, and Thermo Fisher.	[Anonymous], 2018, SAV MOTH 2014 2016 7; Basera W, 2015, ANN ALLERG ASTHMA IM, V115, P113, DOI 10.1016/j.anai.2015.06.003; Botha M, 2018, J ALLERGY CLIN IMMUN, V143, pe2; Botha M, 2016, CURR ALLERGY CLIN IM, V29, P202; Botha M, 2019, PEDIAT ALLERG IMM-UK, V30, P511, DOI 10.1111/pai.13058; Botha M, 2019, J ALLERGY CLIN IMMUN, V143, P662, DOI 10.1016/j.jaci.2018.07.023; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; DeChristopher LR, 2016, PUBLIC HEALTH NUTR, V19, P123, DOI 10.1017/S1368980015000865; Douwes J, 2007, ALLERGY, V62, P1158, DOI 10.1111/j.1398-9995.2007.01490.x; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ege MJ, 2017, ANN AM THORAC SOC, V14, pS348, DOI 10.1513/AnnalsATS.201702-139AW; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Ellwood P, 2013, THORAX, V68, P351, DOI 10.1136/thoraxjnl-2012-202285; Feng ML, 2016, CHEST, V149, P1030, DOI 10.1016/j.chest.2015.12.028; Gray CL, 2015, PEDIAT ALLERG IMM-UK, V26, P721, DOI 10.1111/pai.12459; Gray CL, 2014, PEDIAT ALLERG IMM-UK, V25, P572, DOI 10.1111/pai.12270; Grimshaw K, 2017, ARCH DIS CHILD, V102, P179, DOI 10.1136/archdischild-2015-309770; Holbreich M, 2012, J ALLERGY CLIN IMMUN, V129, P1671, DOI 10.1016/j.jaci.2012.03.016; Huang YJ, 2017, J ALLERGY CLIN IMMUN, V139, P1099, DOI 10.1016/j.jaci.2017.02.007; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Lampi J, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007350; Laurence C, 2018, PEDIAT ALLERG IMM-UK, V29, P311, DOI 10.1111/pai.12859; Le Souef PN, 2000, LANCET, V356, P242; Levin ME, 2008, PEDIAT ALLERG IMM-UK, V19, P449, DOI 10.1111/j.1399-3038.2007.00663.x; Levin ME, 2006, SAMJ S AFR MED J, V96, P1080; Levin ME, 2011, SAMJ S AFR MED J, V101, P472; Levin ME, 2007, CURR ALLERGY CLIN IM, V20, P74; Levin ME, 2016, CURR PEDIAT REP, V4, P129; Levin ME, 2005, DISCORDANT DEFINITIO; Levin M, 2012, J ALLERGY CLIN IMMUN, V130, P265, DOI 10.1016/j.jaci.2012.03.033; Loss G, 2011, J ALLERGY CLIN IMMUN, V128, P766, DOI 10.1016/j.jaci.2011.07.048; Ma Y, 2009, PEDIATR PULM, V44, P793, DOI 10.1002/ppul.21061; Mahdavinia M, 2018, J ALLERGY CLIN IMMUN, V143; Mahdavinia M, 2017, ANN ALLERG ASTHMA IM, V118, P742, DOI 10.1016/j.anai.2017.04.011; Mathee A, 2018, DEV SO AFR, V35, P283, DOI 10.1080/0376835X.2017.1419857; Obeng BB, 2011, INT ARCH ALLERGY IMM, V155, P63, DOI 10.1159/000318704; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Prescott SL, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-017-0160-5; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rook GAW, 2005, GUT, V54, P317, DOI 10.1136/gut.2004.053785; Ruokolainen L, 2017, CLIN EXP ALLERGY, V47, P665, DOI 10.1111/cea.12895; Smith PK, 2017, CURR OPIN ALLERGY CL, V17, P325, DOI 10.1097/ACI.0000000000000385; Smith PK, 2017, J ALLERGY CLIN IMMUN, V139, P429, DOI 10.1016/j.jaci.2016.05.040; Sozanska B, 2014, J ALLERGY CLIN IMMUN, V133, P1347, DOI 10.1016/j.jaci.2013.10.035; Stein MM, 2016, NEW ENGL J MED, V375, P411, DOI 10.1056/NEJMoa1508749; Steyn K, 1997, S AFR MED J, V87, P460; Steyn K, 2006, PAEDIATR PERINAT EP, V20, P90, DOI 10.1111/j.1365-3016.2006.00707.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Viinanen A, 2007, ALLERGY, V62, P272, DOI 10.1111/j.1398-9995.2007.01279.x; von Mutius E, 2016, J ALLERGY CLIN IMMUN, V137, P680, DOI 10.1016/j.jaci.2015.12.1301; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Wu CH, 2011, FOOD FUNCT, V2, P224, DOI 10.1039/c1fo10026b	55	39	42	3	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2020	145	1					415	426		10.1016/j.jaci.2019.07.048	http://dx.doi.org/10.1016/j.jaci.2019.07.048			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KA1WZ	31606483	Bronze			2022-12-18	WOS:000505590800044
J	Allinne, J; Scott, G; Lim, WK; Birchard, D; Erjefalt, JS; Sanden, C; Ben, LH; Agrawal, A; Kaur, N; Kim, JH; Kamat, V; Fury, W; Huang, T; Stahl, N; Yancopoulos, GD; Murphy, AJ; Sleeman, MA; Orengo, JM				Allinne, Jeanne; Scott, George; Lim, Wei Keat; Birchard, Dylan; Erjefalt, Jonas S.; Sanden, Caroline; Ben, Li-Hong; Agrawal, Amit; Kaur, Navneet; Kim, Jee Hae; Kamat, Vishal; Fury, Wen; Huang, Tammy; Stahl, Neil; Yancopoulos, George D.; Murphy, Andrew J.; Sleeman, Matthew A.; Orengo, Jamie M.			IL-33 blockade affects mediators of persistence and exacerbation in a model of chronic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-33; airway inflammation; asthma; house dust mite; airway remodeling; exacerbation; anti-IL-33	INNATE LYMPHOID-CELLS; LUNG-FUNCTION DECLINE; PULMONARY-FIBROSIS; HUMAN BASOPHILS; MOUSE MODELS; ASTHMA; MUCUS; COPD; INTERLEUKIN-33; MECHANISMS	Background: Severe inflammatory airway diseases are associated with inflammation that does not resolve, leading to structural changes and an overall environment primed for exacerbations. Objective: We sought to identify and inhibit pathways that perpetuate this heightened inflammatory state because this could lead to therapies that allow for a more quiescent lung that is less predisposed to symptoms and exacerbations. Methods: Using prolonged exposure to house dust mite in mice, we developed a mouse model of persistent and exacerbating airway disease characterized by a mixed inflammatory phenotype. Results: We show that lung IL-33 drives inflammation and remodeling beyond the type 2 response classically associated with IL-33 signaling. IL-33 blockade with an IL-33 neutralizing antibody normalized established inflammation and improved remodeling of both the lung epithelium and lung parenchyma. Specifically, IL-33 blockade normalized persisting and exacerbating inflammatory end points, including eosinophilic, neutrophilic, and ST21CD41 T-cell infiltration. Importantly, we identified a key role for IL-33 in driving lung remodeling because anti-IL-33 also re-established the presence of ciliated cells over mucus-producing cells and decreased myofibroblast numbers, even in the context of continuous allergen exposure, resulting in improved lung function. Conclusion: Overall, this study shows that increased IL-33 levels drive a self-perpetuating amplification loop that maintains the lung in a state of lasting inflammation and remodeled tissue primed for exacerbations. Thus IL-33 blockade might ameliorate symptoms and prevent exacerbations by quelling persistent inflammation and airway remodeling.	[Allinne, Jeanne; Scott, George; Lim, Wei Keat; Birchard, Dylan; Ben, Li-Hong; Agrawal, Amit; Kaur, Navneet; Kim, Jee Hae; Kamat, Vishal; Fury, Wen; Huang, Tammy; Stahl, Neil; Yancopoulos, George D.; Murphy, Andrew J.; Sleeman, Matthew A.; Orengo, Jamie M.] Regeneron Pharmaceut, Tarrytown, NY USA; [Erjefalt, Jonas S.] Lund Univ, Unit Airway Inflammat, Lund, Sweden; [Erjefalt, Jonas S.; Sanden, Caroline] Medetect AB, Lund, Sweden	Regeneron; Lund University	Orengo, JM (corresponding author), 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.	jamie.orengo@regeneron.com		Orengo, Jamie/0000-0002-2695-6508; Kamat, Vishal/0000-0002-6299-7024	Regeneron Pharmaceuticals; Sanofi	Regeneron Pharmaceuticals(Regeneron); Sanofi	This study was sponsored by Regeneron Pharmaceuticals and Sanofi.	Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Bafadhel M, 2018, LANCET RESP MED, V6, P117, DOI 10.1016/S2213-2600(18)30006-7; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Beale J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009124; Bergqvist A, 2015, CLIN SCI, V128, P47, DOI 10.1042/CS20140309; Bonini M, 2015, THER ADV RESPIR DIS, V9, P281, DOI 10.1177/1753465815588064; Boser SR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182378; Cardell BS, 1959, THORAX, V14, P341; Cayrol C, 2018, NAT IMMUNOL, V140, P777; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Cohen ES, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9327; Corren J, 2017, NEW ENGL J MED, V377, P936, DOI 10.1056/NEJMoa1704064; Debeuf Nincy, 2016, Curr Protoc Mouse Biol, V6, P169, DOI 10.1002/cpmo.4; Denlinger LC, 2017, AM J RESP CRIT CARE, V195, P302, DOI 10.1164/rccm.201602-0419OC; Dransfield MT, 2017, AM J RESP CRIT CARE, V195, P324, DOI 10.1164/rccm.201605-1014OC; Endo Y, 2015, IMMUNITY, V42, P294, DOI 10.1016/j.immuni.2015.01.016; Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061; Gamble E, 2007, EUR RESPIR J, V30, P467, DOI 10.1183/09031936.00013006; Garth J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113402; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Gregory LG, 2009, CLIN EXP ALLERGY, V39, P1597, DOI 10.1111/j.1365-2222.2009.03302.x; Gross NJ, 2017, AM J RESP CRIT CARE, V195, P159, DOI 10.1164/rccm.201610-2074PP; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hastie AT, 2018, CLIN EXP ALLERGY, V48, P787, DOI 10.1111/cea.13129; Hays SR, 2003, AM J MED, V115, P68, DOI 10.1016/S0002-9343(03)00260-2; Hirota N, 2013, CHEST, V144, P1026, DOI 10.1378/chest.12-3073; Jacobsen EA, 2014, CLIN EXP ALLERGY, V44, P1119, DOI 10.1111/cea.12358; Johnson JR, 2008, AM J PHYSIOL-LUNG C, V295, pL780, DOI 10.1152/ajplung.90229.2008; Johnson JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016175; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Kearley J, 2015, IMMUNITY, V42, P566, DOI 10.1016/j.immuni.2015.02.011; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; KUHN C, 1991, AM J PATHOL, V138, P1257; Lee JU, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0380-z; Li D, 2014, J ALLERGY CLIN IMMUN, V134, P1422, DOI 10.1016/j.jaci.2014.05.011; Li MR, 2016, EXP BIOL MED, V241, P1, DOI 10.1177/1535370215597194; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; Lloyd CM, 2007, CURR ALLERGY ASTHM R, V7, P231, DOI 10.1007/s11882-007-0077-0; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Lunderius-Andersson C, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00082; Luzina IG, 2013, AM J RESP CELL MOL, V49, P999, DOI 10.1165/rcmb.2013-0093OC; Macdonald LE, 2014, P NATL ACAD SCI USA, V111, P5147, DOI 10.1073/pnas.1323896111; Maghni K, 2004, AM J RESP CRIT CARE, V169, P367, DOI 10.1164/rccm.200309-1238OC; Makris D, 2007, RESP MED, V101, P1305, DOI 10.1016/j.rmed.2006.10.012; Manetti M, 2010, ANN RHEUM DIS, V69, P598, DOI 10.1136/ard.2009.119321; Martin NT, 2016, NAT IMMUNOL, V17, P122, DOI 10.1038/ni.3370; Martin RJ, 2002, J ALLERGY CLIN IMMUN, V109, pS447, DOI 10.1067/mai.2002.121409; McKenzie ANJ, 2014, IMMUNITY, V41, P366, DOI 10.1016/j.immuni.2014.09.006; Meijer M, 2013, EXPERT REV CLIN IMMU, V9, P1055, DOI 10.1586/1744666X.2013.851347; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; MOLOFSKY AB, 2015, IMMUNITY, V42, P1005, DOI [DOI 10.1016/j.immuni.2015.06.006, DOI 10.1016/J.IMMUNI.2015.06.006]; Mullane K, 2014, BIOCHEM PHARMACOL, V87, P131, DOI 10.1016/j.bcp.2013.06.026; Murphy AJ, 2014, P NATL ACAD SCI USA, V111, P5153, DOI 10.1073/pnas.1324022111; Nakanishi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078099; Nials AT, 2008, DIS MODEL MECH, V1, P213, DOI 10.1242/dmm.000323; Nihlberg K, 2010, THORAX, V65, P670, DOI 10.1136/thx.2009.129320; Orengo J, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA977; Ortega H, 2018, J ALLER CL IMM-PRACT, V6, P980, DOI 10.1016/j.jaip.2017.12.019; Patel AC, 2011, AM J RESP CELL MOL, V44, P261, DOI 10.1165/rcmb.2010-0468ED; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Postma DS, 2015, NEW ENGL J MED, V373, P1241, DOI 10.1056/NEJMra1411863; Poueymirou WT, 2007, NAT BIOTECHNOL, V25, P91, DOI 10.1038/nbt1263; PRESCOTT E, 1995, EUR RESPIR J, V8, P1333, DOI 10.1183/09031936.95.08081333; Ramos FL, 2014, INT J CHRONIC OBSTR, V9, P139, DOI 10.2147/COPD.S38938; REID LM, 1987, J ALLERGY CLIN IMMUN, V80, P415, DOI 10.1016/0091-6749(87)90064-9; Serapinas D, 2011, MULTIDISCIP RESP MED, V6, P214, DOI 10.1186/2049-6958-6-4-214; Sjoberg LC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03674-0; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Uyttebroek A, 2015, ALLERGY ASTHMA IMMUN, V7, P416, DOI 10.4168/aair.2015.7.4.416; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; Vannella KM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1938; Wambre E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam9171; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551; Zeiger RS, 2018, J ALLER CL IMM-PRACT, V6, P944, DOI 10.1016/j.jaip.2017.10.004; ZHANG K, 1994, AM J PATHOL, V145, P114	83	39	43	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1624	+		10.1016/j.jaci.2019.08.039	http://dx.doi.org/10.1016/j.jaci.2019.08.039			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31562870	hybrid			2022-12-18	WOS:000500694900020
J	Perkin, MR; Logan, K; Bahnson, HT; Marrs, T; Radulovic, S; Craven, J; Flohr, C; Mills, EN; Versteeg, SA; van Ree, R; Lack, G; Young, L; Offord, V; DeSousa, M; Cullen, J; Taylor, K; Tseng, A; Raji, B; Byrom, S; Regis, G; Bigwood, C; Stedman, C; Tonner, S; Banks, E; Kahnum, Y; Babic, R; Stockwell, B; Thompson, E; Wheatley, L; Patkunam, D; Richards, K; Pietraszewicz, E; Stephens, A; Sudra, A; Turcanu, V				Perkin, Michael R.; Logan, Kirsty; Bahnson, Henry T.; Marrs, Tom; Radulovic, Suzana; Craven, Joanna; Flohr, Carsten; Mills, E. N.; Versteeg, Serge A.; van Ree, Ronald; Lack, Gideon; Young, Louise; Offord, Victoria; DeSousa, Mary; Cullen, Jason; Taylor, Katherine; Tseng, Anna; Raji, Bunmi; Byrom, Sarah; Regis, Gillian; Bigwood, Charlie; Stedman, Charlotte; Tonner, Sharon; Banks, Emily; Kahnum, Yasmin; Babic, Rachel; Stockwell, Ben; Thompson, Erin; Wheatley, Lorna; Patkunam, Devi; Richards, Kerry; Pietraszewicz, Ewa; Stephens, Alick; Sudra, Asha; Turcanu, Victor		EAT Study Team	Efficacy of the Enquiring About Tolerance (EAT) study among infants at high risk of developing food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; diet; allergens; infancy; breastfeeding; randomized controlled trial; adherence	PEANUT ALLERGY; PREVENTION; GUIDELINES; CHILDREN; TRIAL	Background: The Enquiring About Tolerance (EAT) study was a randomized trial of the early introduction of allergenic solids into the infant diet from 3 months of age. The intervention effect did not reach statistical significance in the intention-to-treat analysis of the primary outcome. Objective: We sought to determine whether infants at high risk of developing a food allergy benefited from early introduction. Methods: A secondary intention-to-treat analysis was performed of 3 groups: nonwhite infants; infants with visible eczema at enrollment, with severity determined by SCORAD; and infants with enrollment food sensitization (specific IgE >= 0.1 kU/L). Results: Among infants with sensitization to 1 or more foods at enrollment (>= 0.1 kU/L), early introduction group (EIG) infants developed significantly less food allergy to 1 or more foods than standard introduction group (SIG) infants (SIG, 34.2%; EIG, 19.2%; P = .03), and among infants with sensitization to egg at enrollment, EIG infants developed less egg allergy (SIG, 48.6%; EIG, 20.0%; P = .01). Similarly, among infants with moderate SCORAD (15-<40) at enrollment, EIG infants developed significantly less food allergy to 1 or more foods (SIG, 46.7%; EIG, 22.6%; P = .048) and less egg allergy (SIG, 43.3%; EIG, 16.1%; P = .02). Conclusion: Early introduction was effective in preventing the development of food allergy in specific groups of infants at high risk of developing food allergy: those sensitized to egg or to any food at enrollment and those with eczema of increasing severity at enrollment. This efficacy occurred despite low adherence to the early introduction regimen. This has significant implications for the new national infant feeding recommendations that are emerging around the world.	[Perkin, Michael R.] St Georges Univ London, Populat Hlth Res Inst, London, England; [Logan, Kirsty; Marrs, Tom; Radulovic, Suzana; Craven, Joanna; Lack, Gideon] Kings Coll London, Sch Life Course Sci, Dept Women & Childrens Hlth, Paediat Allergy Res Grp, London, England; [Bahnson, Henry T.] Benaroya Res Inst, Seattle, WA USA; [Flohr, Carsten] Kings Coll London, Fac Life Sci & Med, Unit Populat Based Dermatol Res, Sch Basic & Med Biosci,St Johns Inst Dermatol, London, England; [Mills, E. N.] Univ Manchester, Manchester Inst Biotechnol, Manchester Acad Hlth Sci Ctr, Sch Biol Sci,Div Infect Immun & Resp Med, Manchester, Lancs, England; [Versteeg, Serge A.; van Ree, Ronald] Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands; [van Ree, Ronald] Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands	St Georges University London; University of London; King's College London; Benaroya Research Institute; University of London; King's College London; University of Manchester; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Lack, G (corresponding author), Kings Coll London, Guys & St Thomas NHS Fdn Trust, Clin Acad Paediat Allergy Serv,Paediat Allergy, Childrens Allergies Dept,St Thomas Hosp, Westminster Bridge Rd, London SE1 7EH, England.	gideon.lack@kcl.ac.uk	Perkin, Michael/AID-7491-2022	Perkin, Michael/0000-0001-9272-2585; Tonner, Sharon/0000-0002-7775-9926; Lack, Gideon/0000-0001-7350-4021	UK Food Standards Agency (FSA) [T07051]; Medical Research Council (MRC) [MC_G1001205]; UK National Institute for Health Research (NIHR); NIHR Clinician Scientist Award [NIHRCS/01/2008/009]; FSA [FS101178]; European Union (Integrated Approaches to Food Allergen and Allergy Risk Management [iFAAM]) [312147]; MRC [MC_G1001205] Funding Source: UKRI	UK Food Standards Agency (FSA); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Clinician Scientist Award; FSA; European Union (Integrated Approaches to Food Allergen and Allergy Risk Management [iFAAM]); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The main components of the Enquiring About Tolerance (EAT) study were jointly funded by the UK Food Standards Agency (FSA; contract code T07051) and the Medical Research Council (MRC; grant MC_G1001205). Additionally, we would like to thank the Davis Foundation. The skin-related aspects of the EAT study were supported by the UK National Institute for Health Research (NIHR). C.F. held an NIHR Clinician Scientist Award (NIHRCS/01/2008/009). The analyses presented in this article were supported by a subsequent grant from the FSA (contract code FS101178) and the European Union (Integrated Approaches to Food Allergen and Allergy Risk Management [iFAAM], grant agreement no. 312147). The views expressed in this publication are those of the authors and not necessarily those of the FSA, MRC, the NHS, the NIHR, theWellcome Trust, the European Union or the UK Department of Health.	[Anonymous], ETHN CAT 2011 CENS; Du Toit G, 2015, NEW ENGL J MED, V372, P803, DOI 10.1056/NEJMoa1414850; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Hill DJ, 2004, PEDIAT ALLERG IMM-UK, V15, P435, DOI 10.1111/j.1399-3038.2004.00188.x; Ierodiakonou D, 2016, JAMA-J AM MED ASSOC, V316, P1181, DOI 10.1001/jama.2016.12623; Kunz B, 1997, DERMATOLOGY, V195, P10, DOI 10.1159/000245677; Mills C., INTEGRATED APPROACHE; Panjari M, 2016, CLIN EXP ALLERGY, V46, P602, DOI 10.1111/cea.12699; Perkin MR, 2019, J ALLERGY CLIN IMMUN, V144, P1595, DOI 10.1016/j.jaci.2019.06.046; Perkin MR, 2016, J ALLERGY CLIN IMMUN, V137, P1477, DOI 10.1016/j.jaci.2015.12.1322; Perkin MR, 2016, NEW ENGL J MED, V374, P1733, DOI 10.1056/NEJMoa1514210; Perkin MR, EAT STUDY PROTOCOL; Rothwell PM, 2005, LANCET, V365, P176, DOI 10.1016/S0140-6736(05)17709-5; Schnabel E, 2010, CLIN EXP ALLERGY, V40, P450, DOI 10.1111/j.1365-2222.2009.03400.x; Togias A, 2017, PEDIATR DERMATOL, V34, P5, DOI 10.1111/pde.13092; Togias A, 2017, J ALLERGY CLIN IMMUN, V139, P29, DOI 10.1016/j.jaci.2016.10.010; Tsakok T, 2016, J ALLERGY CLIN IMMUN, V137, P1071, DOI 10.1016/j.jaci.2015.10.049; Turner PJ, 2018, CLIN EXP ALLERGY, V48, P912, DOI 10.1111/cea.13218; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303	19	39	39	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2019	144	6					1606	+		10.1016/j.jaci.2019.06.045	http://dx.doi.org/10.1016/j.jaci.2019.06.045			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JT0NR	31812184	Green Accepted, Green Published, hybrid			2022-12-18	WOS:000500694900018
J	Gupta, A; Ikeda, M; Geng, B; Azmi, J; Price, RG; Bradford, ES; Yancey, SW; Steinfeld, J				Gupta, Atul; Ikeda, Masanori; Geng, Bob; Azmi, Jay; Price, Robert G.; Bradford, Eric S.; Yancey, Steven W.; Steinfeld, Jonathan			Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pediatric asthma; eosinophilia; mepolizumab	DOUBLE-BLIND; MULTICENTER; THERAPY; PREVALENCE; EFFICACY	Background: Mepolizumab is approved for patients with severe asthma with an eosinophilic phenotype aged 12 or more (United States) or 6 or more (European Union) years, but its long-term use in children aged 6 to 11 years has not yet been assessed. Objective: We sought to assess the long-term safety, efficacy, and pharmacodynamics of mepolizumab in children aged 6 to 11 years with severe asthma with an eosinophilic phenotype. Methods: In this open-label, uncontrolled, repeat-dose extension study (NCT02377427), children aged 6 to 11 years with severe asthma with an eosinophilic phenotype (blood eosinophil counts >= 150 cells/mu L at screening or >= 300 cells/mu L in the previous year) received a body weight-dependent dose of subcutaneous mepolizumab of 40 mg (<40 kg) or 100 mg (>= 40 kg) over 52 weeks. End points included the incidence of adverse events (AEs) and immunogenicity (primary), absolute blood eosinophil counts (cells per microliter; secondary), and annualized exacerbation rates and asthma control questionnaire/childhood asthma control test scores (exploratory). Results: Over 52 weeks, 30 children received mepolizumab; 27 (90%) and 7 (23%) experienced on-treatment AEs and serious AEs, respectively. No serious AEs were treatment related. There were no fatal AEs. No specific patterns of AEs were evident, and no anti-drug antibody or neutralizing antibody responses were reported. Compared with baseline values, mepolizumab treatment reduced blood eosinophil counts and asthma exacerbations and improved asthma control across all treatment groups. Conclusion: Long-term safety, pharmacodynamic, and efficacy data from this study support a positive benefit-risk profile for mepolizumab in children with severe asthma with an eosinophilic phenotype and were similar to data in studies in adults and adolescents.	[Gupta, Atul] Kings Coll Hosp NHS Fdn Trust, London, England; [Ikeda, Masanori] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pediat Acute Med, Okayama, Japan; [Geng, Bob] Univ Calif San Diego, Dept Pediat, Div Allergy & Immunol, San Diego, CA 92103 USA; [Geng, Bob] Univ Calif San Diego, Dept Med, Div Allergy & Immunol, San Diego, CA 92103 USA; [Azmi, Jay] GlaxoSmithKline, Resp TAU, Stockley Pk, Uxbridge, Middx, England; [Price, Robert G.] GlaxoSmithKline, Biostat, Stevenage, Herts, England; [Bradford, Eric S.; Yancey, Steven W.] GlaxoSmithKline, Resp Therapeut Area, Res Triangle Pk, NC USA; [Steinfeld, Jonathan] GlaxoSmithKline, Resp TAU, Philadelphia, PA USA; [Steinfeld, Jonathan] GlaxoSmithKline, Flexible Discovery Unit, Philadelphia, PA USA	King's College Hospital NHS Foundation Trust; Okayama University; University of California System; University of California San Diego; University of California System; University of California San Diego; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Steinfeld, J (corresponding author), GSK, Resp TAU, Upper Providence UP1210, Collegeville, PA 19426 USA.; Steinfeld, J (corresponding author), GSK, Flexible Discovery Unit, Upper Providence UP1210, Collegeville, PA 19426 USA.	jonathan.x.steinfeld@gsk.com		Price, Robert/0000-0001-6418-6818	GlaxoSmithKline (GSK) [200363]; GlaxoSmithKline	GlaxoSmithKline (GSK)(GlaxoSmithKline); GlaxoSmithKline(GlaxoSmithKline)	This study was funded by GlaxoSmithKline (GSK ID 200363; ClinicalTrials.gov no. NCT02377427). Editorial support (in the form of writing assistance, including development of the initial draft based on author direction, assembling tables and figures, collating authors' comments, grammatical editing, and referencing) was provided by Elizabeth Hutchinson, PhD, CMPP, and Bianca Paris, BSc, Fishawack Indicia and was funded by GlaxoSmithKline.	Aldington S, 2007, THORAX, V62, P447, DOI 10.1136/thx.2005.045203; Baan EJ, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA5439; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Chupp GL, 2017, LANCET RESP MED, V5, P390, DOI 10.1016/S2213-2600(17)30125-X; Costa DD, 2019, J PEDIAT-BRAZIL, V95, P401, DOI [10.1016/j.jped.2018.10.010, 10.1016/j.jped.2019.10.010]; Cousino MK, 2013, J PEDIATR PSYCHOL, V38, P809, DOI 10.1093/jpepsy/jst049; Coverstone A, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-015-0521-5; Gupta A, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA5447; Haldar P, 2014, J ALLERGY CLIN IMMUN, V133, P921, DOI 10.1016/j.jaci.2013.11.026; Khatri S, 2019, J ALLERGY CLIN IMMUN, V143, P1742, DOI 10.1016/j.jaci.2018.09.033; Lugogo N, 2016, CLIN THER, V38, P2058, DOI 10.1016/j.clinthera.2016.07.010; Nordlund B, 2014, RESP MED, V108, P1234, DOI 10.1016/j.rmed.2014.05.015; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Ortiz-Alvarez O, 2012, PAED CHILD HEALT-CAN, V17, P251, DOI 10.1093/pch/17.5.251; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Yancey SW, 2017, J ALLERGY CLIN IMMUN, V140, P1509, DOI 10.1016/j.jaci.2017.10.005	22	39	42	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2019	144	5					1336	+		10.1016/j.jaci.2019.08.005	http://dx.doi.org/10.1016/j.jaci.2019.08.005			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	JK7EU	31425781	Green Published, hybrid			2022-12-18	WOS:000495004700024
J	Tyler, SR; Bunyavanich, S				Tyler, Scott R.; Bunyavanich, Supinda			Leveraging -omics for asthma endotyping	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; endotype; -ome; -omit; transcriptome; epigenome; microbiome; metabolome; proteome; multi-ome; phenotype; cluster; integrate	EPIGENOME-WIDE ASSOCIATION; VOLATILE ORGANIC-COMPOUNDS; GENE-EXPRESSION; ALLERGIC DISEASES; CELLS; INFLAMMATION; PHENOTYPES; METABOLOMICS; BIOMARKERS; SIGNATURE	Asthma is a highly heterogeneous disease, often manifesting with wheeze, dyspnea, chest tightness, and cough as prominent symptoms. The eliciting factors, natural history, underlying molecular biology, and clinical management of asthma vary highly among affected subjects. Because of this variation, many efforts have gone into subtyping asthma. Endotypes are subtypes of disease based on distinct pathophysiologic mechanisms. Endotypes can be clinically useful because they organize our mechanistic understanding of heterogeneous diseases and can direct treatment toward modalities that are likely to be the most effective. Asthma endotyping can be shaped by clinical features, laboratory parameters, and/or-omics approaches. We discuss the application of -omics approaches, including transcriptomics, epigenomics, microbiomics, metabolomics, and proteomics, to asthma endotyping. -Omics approaches have provided supporting evidence for many existing endotyping paradigms and also suggested novel ways to conceptualize asthma endotypes. Although endotypes based on single -omics approaches are relatively common, their integrated multi-omics application to asthma endotyping has been more limited thus far. We discuss paths forward to integrate multi-omics with clinical features and laboratory parameters to achieve the goal of precise asthma endotypes.	[Tyler, Scott R.; Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Bunyavanich, Supinda] Icahn Sch Med Mt Sinai, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Bunyavanich, S (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,1498, New York, NY 10029 USA.	supinda@post.harvard.edu			National Institutes of Health (NIH) [R01 AI118833, U19 AI136053]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118833, U19AI136053] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	S.B. is funded by the National Institutes of Health (NIH) grants R01 AI118833 and U19 AI136053.	Baines KJ, 2014, J ALLERGY CLIN IMMUN, V133, P997, DOI 10.1016/j.jaci.2013.12.1091; Barnes PJ, 2018, NAT REV IMMUNOL, V18, P454, DOI 10.1038/s41577-018-0006-6; Bigler J, 2017, AM J RESP CRIT CARE, V195, P1311, DOI 10.1164/rccm.201604-0866OC; Brinkman P, 2019, J ALLERGY CLIN IMMUN, V143, P1811, DOI 10.1016/j.jaci.2018.10.058; Bunyavanich S, 2015, J ALLERGY CLIN IMMUN, V135, P31, DOI 10.1016/j.jaci.2014.10.015; Casale TB, 2017, J ALLERGY CLIN IMMUN, V139, P1411, DOI 10.1016/j.jaci.2017.03.006; Chen W, 2017, J ALLERGY CLIN IMMUN, V140, P571, DOI 10.1016/j.jaci.2016.11.030; Chipps BE, 2017, J ALLERGY CLIN IMMUN, V139, P1431, DOI 10.1016/j.jaci.2017.03.002; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Chung KF, 2017, J ALLERGY CLIN IMMUN, V139, P1071, DOI 10.1016/j.jaci.2017.02.004; Durack J, 2017, J ALLERGY CLIN IMMUN, V140, P63, DOI 10.1016/j.jaci.2016.08.055; Duvall MG, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam5446; Fazlollahi M, 2018, J ALLERGY CLIN IMMUN, V142, P834, DOI 10.1016/j.jaci.2018.02.020; Fitzpatrick AM, 2017, J ALLER CL IMM-PRACT, V5, P901, DOI 10.1016/j.jaip.2017.05.015; Fricker M, 2019, J ALLERGY CLIN IMMUN, V144, P51, DOI 10.1016/j.jaci.2018.12.1020; Hekking PP, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.02298-2016; Hekking PP, 2018, J ALLERGY CLIN IMMUN, V141, P1280, DOI 10.1016/j.jaci.2017.06.037; Hidru D, ARXIV14094018; Hizawa N, 2006, CLIN EXP ALLERGY, V36, P1109, DOI 10.1111/j.1365-2222.2006.02550.x; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Howrylak JA, 2016, J ALLERGY CLIN IMMUN, V137, P1390, DOI 10.1016/j.jaci.2015.09.058; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V136, P874, DOI 10.1016/j.jaci.2015.05.044; Ibrahim B, 2011, THORAX, V66, P804, DOI 10.1136/thx.2010.156695; Jartti T, 2017, J ALLERGY CLIN IMMUN, V140, P895, DOI 10.1016/j.jaci.2017.08.003; Kelly RS, 2017, CHEST, V151, P262, DOI 10.1016/j.chest.2016.10.008; Kumar D, 2011, 29TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, P1413; Kuo CHS, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02135-2016; Lefaudeux D, 2017, J ALLERGY CLIN IMMUN, V139, P1797, DOI 10.1016/j.jaci.2016.08.048; Liang LM, 2015, NATURE, V520, P670, DOI 10.1038/nature14125; Liu T, 2015, RESP MED, V109, P1391, DOI 10.1016/j.rmed.2015.09.016; Liu WM, 2017, J ALLERGY CLIN IMMUN, V139, P1548, DOI 10.1016/j.jaci.2016.08.032; McGeachie MJ, 2015, IMMUN INFLAMM DIS, V3, P224, DOI 10.1002/iid3.61; Mo QX, 2018, BIOSTATISTICS, V19, P71, DOI 10.1093/biostatistics/kxx017; Muraro A, 2016, J ALLERGY CLIN IMMUN, V137, P1347, DOI 10.1016/j.jaci.2016.03.010; Nagasaki T, 2017, ALLERGOL INT, V66, P404, DOI 10.1016/j.alit.2017.02.003; Neerincx AH, 2017, PEDIATR PULM, V52, P1616, DOI 10.1002/ppul.23785; Nguyen T, 2017, GENOME RES, V27, P2025, DOI 10.1101/gr.215129.116; Nicodemus-Johnson J, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90151; Pandey G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27189-4; Peters MC, 2019, AM J RESP CRIT CARE, V199, P465, DOI 10.1164/rccm.201807-1291OC; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Rappoport N, 2018, NUCLEIC ACIDS RES, V46, P10546, DOI 10.1093/nar/gky889; Rathore JS, 2016, VACCINE, V34, P1504, DOI 10.1016/j.vaccine.2016.02.021; Ray A, 2017, TRENDS IMMUNOL, V38, P942, DOI 10.1016/j.it.2017.07.003; Ricciardolo FLM, 2017, J ALLERGY CLIN IMMUN, V140, P395, DOI 10.1016/j.jaci.2016.10.034; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Rossios C, 2018, J ALLERGY CLIN IMMUN, V141, P560, DOI 10.1016/j.jaci.2017.02.045; Schofield JPR, 2019, J ALLERGY CLIN IMMUN, V144, P70, DOI 10.1016/j.jaci.2019.03.013; Shikotra A, 2017, J IMMUNOL, V198, P3307, DOI 10.4049/jimmunol.1600606; Sinha A, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1365-7; Skloot GS, 2016, CURR OPIN PULM MED, V22, P3, DOI 10.1097/MCP.0000000000000225; Sugita K, 2018, J ALLERGY CLIN IMMUN, V141, P300, DOI 10.1016/j.jaci.2017.02.038; Svenningsen S, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00158; Sverrild A, 2017, J ALLERGY CLIN IMMUN, V140, P407, DOI 10.1016/j.jaci.2016.10.046; Taylor SL, 2018, J ALLERGY CLIN IMMUN, V141, P94, DOI 10.1016/j.jaci.2017.03.044; Tini G., 2017, BRIEF BIOINFORM, DOI [10.1093/bib/bbx167, DOI 10.1093/BIB/BBX167]; Tliba O, 2019, J ALLERGY CLIN IMMUN, V143, P1287, DOI 10.1016/j.jaci.2018.06.008; Turi KN, 2018, J ALLERGY CLIN IMMUN, V141, P1191, DOI 10.1016/j.jaci.2017.04.021; Uppal K, 2018, BIOINFORMATICS, V34, P701, DOI 10.1093/bioinformatics/btx656; van der Schee MP, 2013, CLIN EXP ALLERGY, V43, P1217, DOI 10.1111/cea.12147; Wang B, 2014, NAT METHODS, V11, P333, DOI [10.1038/NMETH.2810, 10.1038/nmeth.2810]; Wisniewski JA, 2018, J ALLERGY CLIN IMMUN, V141, P2048, DOI 10.1016/j.jaci.2017.08.020; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Yan XT, 2016, ANN AM THORAC SOC, V13, pS104, DOI 10.1513/AnnalsATS.201510-681MG; Yang IV, 2017, J ALLERGY CLIN IMMUN, V140, P14, DOI 10.1016/j.jaci.2017.05.011; Yang IV, 2015, J ALLERGY CLIN IMMUN, V136, P69, DOI 10.1016/j.jaci.2015.01.025; Yick CY, 2013, EUR RESPIR J, V42, P662, DOI 10.1183/09031936.00115412; Zhou D., 2007, P 24 INT C MACHINE L, P1159, DOI DOI 10.1145/1273496.1273642	68	39	40	2	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2019	144	1					13	24		10.1016/j.jaci.2019.05.015	http://dx.doi.org/10.1016/j.jaci.2019.05.015			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	IF9SM	31277743	Green Accepted, Bronze			2022-12-18	WOS:000473432800002
J	Toki, S; Goleniewska, K; Reiss, S; Zhang, J; Bloodworth, MH; Stier, MT; Zhou, WS; Newcomb, DC; Ware, LB; Stanwood, GD; Galli, A; Boyd, KL; Niswender, KD; Peebles, RS				Toki, Shinji; Goleniewska, Kasia; Reiss, Sara; Zhang, Jian; Bloodworth, Melissa H.; Stier, Matthew T.; Zhou, Weisong; Newcomb, Dawn C.; Ware, Lorraine B.; Stanwood, Gregg D.; Galli, Aurelio; Boyd, Kelli L.; Niswender, Kevin D.; Peebles, R. Stokes, Jr.			Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Glucagon-like peptide 1 receptor; liraglutide; group 2 innate lymphoid cells; IL-33; Alternaria	NF-KAPPA-B; RECEPTOR AGONIST; TYPE-2 IMMUNITY; INFLAMMATION; ASTHMA; GLP-1; ASSOCIATION; EXPRESSION; MODEL; PHENOTYPES	Background: IL-33 is one of the most consistently associated gene candidates for asthma identified by using a genome-wide association study. Studies in mice and in human cells have confirmed the importance of IL-33 in inducing type 2 cytokine production from both group 2 innate lymphoid cells (ILC2s) and T(H)2 cells. However, there are no pharmacologic agents known to inhibit IL-33 release from airway cells. Objective: We sought to determine the effect of glucagon-like peptide 1 receptor (GLP-1R) signaling on aeroallergen-induced airway IL-33 production and release and on innate type 2 airway inflammation. Methods: BALB/c mice were challenged intranasally with Alternaria extract for 4 consecutive days. GLP-1Ragonist or vehicle was administered starting either 2 days before the first Alternaria extract challenge or 1 day after the first Alternaria extract challenge. Results: GLP-1R agonist treatment starting 2 days before the first Alternaria extract challenge decreased IL-33 release in the bronchoalveolar lavage fluid and dual oxidase 1 (Duox1) mRNA expression 1 hour after the first Alternaria extract challenge and IL-33 expression in lung epithelial cells 24 hours after the last Alternaria extract challenge. Furthermore, GLP-1R agonist significantly decreased the number of ILC2s expressing IL-5 and IL-13, lung protein expression of type 2 cytokines and chemokines, the number of perivascular eosinophils, mucus production, and airway responsiveness compared with vehicle treatment. GLP-1R agonist treatment starting 1 day after the first Alternaria extract challenge also significantly decreased eosinophilia and type 2 cytokine and chemokine expression in the airway after 4 days of Alternaria extract challenge. Conclusion: These results reveal that GLP-1R signaling might be a therapy to reduce IL-33 release and inhibit the ILC2 response to protease-containing aeroallergens, such as Alternaria.	[Toki, Shinji; Goleniewska, Kasia; Reiss, Sara; Zhang, Jian; Zhou, Weisong; Newcomb, Dawn C.; Ware, Lorraine B.; Peebles, R. Stokes, Jr.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37212 USA; [Bloodworth, Melissa H.; Stier, Matthew T.; Newcomb, Dawn C.; Ware, Lorraine B.; Boyd, Kelli L.; Peebles, R. Stokes, Jr.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Galli, Aurelio; Niswender, Kevin D.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37212 USA; [Niswender, Kevin D.] Vanderbilt Univ, Sch Med, Div Diabet Endocrinol & Metab, Nashville, TN 37212 USA; [Galli, Aurelio; Niswender, Kevin D.] Vanderbilt Univ, Sch Med, Vanderbilt Brain Inst, Nashville, TN 37212 USA; [Stanwood, Gregg D.] Florida State Univ, Dept Biomed Sci, Tallahassee, FL 32306 USA; [Stanwood, Gregg D.] Florida State Univ, Ctr Brain Repair, Tallahassee, FL 32306 USA; [Niswender, Kevin D.; Peebles, R. Stokes, Jr.] Tennessee Valley Healthcare Syst, Dept Vet Affairs, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; State University System of Florida; Florida State University; State University System of Florida; Florida State University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Peebles, RS (corresponding author), Vanderbilt Univ, Med Ctr, 1161 21st Ave,T-1218 MCN, Nashville, TN 37232 USA.; Niswender, KD (corresponding author), MRB 4,2213 Garland Ave, Nashville, TN 37232 USA.	kevin.niswender@vanderbilt.edu; stokes.peebles@vanderbilt.edu	Ware, Lorraine/AAJ-9307-2021	Ware, Lorraine/0000-0002-9429-4702; Stanwood, Gregg/0000-0001-6005-1203	National Institutes of Health [AI 095227-02, AI 111820, AI124456, HL 090664-04]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA038058] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported by the National Institutes of Health grants AI 095227-02, AI 111820, AI124456, and HL 090664-04.	Arakawa M, 2010, DIABETES, V59, P1030, DOI 10.2337/db09-1694; Bankova LG, 2016, P NATL ACAD SCI USA, V113, P6242, DOI 10.1073/pnas.1605957113; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Billington CK, 2013, PULM PHARMACOL THER, V26, P112, DOI 10.1016/j.pupt.2012.05.007; Borish L, 2016, ANN ALLERG ASTHMA IM, V117, P108, DOI 10.1016/j.anai.2016.04.022; Cayrol C, 2014, CURR OPIN IMMUNOL, V31, P31, DOI 10.1016/j.coi.2014.09.004; De Marinis YZ, 2010, CELL METAB, V11, P543, DOI 10.1016/j.cmet.2010.04.007; Denzler KL, 2000, J IMMUNOL, V165, P5509, DOI 10.4049/jimmunol.165.10.5509; Divino V, 2014, DIABETES THER, V5, P499, DOI 10.1007/s13300-014-0087-6; Egan AG, 2014, NEW ENGL J MED, V370, P794, DOI 10.1056/NEJMp1314078; Gou S, 2014, INT IMMUNOPHARMACOL, V22, P498, DOI 10.1016/j.intimp.2014.07.010; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hardman CS, 2013, EUR J IMMUNOL, V43, P488, DOI 10.1002/eji.201242863; Herrant M, 2015, ALLERGY ASTHMA CL IM, V11, DOI 10.1186/s13223-015-0090-0; Hogan AE, 2011, DIABETOLOGIA, V54, P2745, DOI 10.1007/s00125-011-2232-3; Hogan AE, 2014, DIABETOLOGIA, V57, P781, DOI 10.1007/s00125-013-3145-0; Holst JJ, 2007, PHYSIOL REV, V87, P1409, DOI 10.1152/physrev.00034.2006; Hristova M, 2016, J ALLERGY CLIN IMMUN, V137, P1545, DOI 10.1016/j.jaci.2015.10.003; Hung LY, 2013, P NATL ACAD SCI USA, V110, P282, DOI 10.1073/pnas.1206587110; Iwai T, 2006, NEUROSCI RES, V55, P352, DOI 10.1016/j.neures.2006.04.008; Kalesnikoff J, 2011, METHODS MOL BIOL, V677, P207, DOI 10.1007/978-1-60761-869-0_15; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kurokawa M, 2011, INT ARCH ALLERGY IMM, V155, P12, DOI 10.1159/000327259; Kurowska-Stolarska M, 2011, J INTERN MED, V269, P29, DOI 10.1111/j.1365-2796.2010.02316.x; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780, DOI 10.4049/jimmunol.181.7.4780; Lee YS, 2012, DIABETOLOGIA, V55, P2456, DOI 10.1007/s00125-012-2592-3; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Lim GE, 2006, DIABETES, V55, pS70, DOI 10.2337/db06-S020; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Nieuwenhuis MA, 2016, ALLERGY, V71, P1712, DOI 10.1111/all.12990; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Parthsarathy V, 2013, EUR J PHARMACOL, V700, P42, DOI 10.1016/j.ejphar.2012.12.012; Peebles RS, 1999, J MED VIROL, V57, P186, DOI 10.1002/(SICI)1096-9071(199902)57:2<186::AID-JMV17>3.0.CO;2-Q; Pyke C, 2014, ENDOCRINOLOGY, V155, P1280, DOI 10.1210/en.2013-1934; Reddy IA, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.86; Savenije OE, 2014, J ALLERGY CLIN IMMUN, V134, P170, DOI 10.1016/j.jaci.2013.12.1080; Shiraki A, 2012, ATHEROSCLEROSIS, V221, P375, DOI 10.1016/j.atherosclerosis.2011.12.039; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Spreckley Eleanor, 2015, Front Nutr, V2, P23, DOI 10.3389/fnut.2015.00023; Toki S, 2016, THORAX, V71, P633, DOI 10.1136/thoraxjnl-2015-207728; Viby NE, 2013, ENDOCRINOLOGY, V154, P4503, DOI 10.1210/en.2013-1666; Vilsboll T, 2000, DIABETES CARE, V23, P807, DOI 10.2337/diacare.23.6.807; Wang Y, 2014, BRIT J PHARMACOL, V171, P723, DOI 10.1111/bph.12490; Yanay O, 2015, J INFLAMM RES, V8, P129, DOI 10.2147/JIR.S84993; Zhou WS, 2007, J LEUKOCYTE BIOL, V81, P809, DOI 10.1189/jlb.0606375; Zhou WS, 2007, J IMMUNOL, V178, P702, DOI 10.4049/jimmunol.178.2.702; Zhou WS, 2016, AM J RESP CRIT CARE, V193, P31, DOI 10.1164/rccm.201410-1793OC; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zhu T, 2015, INT J MOL SCI, V16, P20195, DOI 10.3390/ijms160920195	51	39	41	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2018	142	5					1515	+		10.1016/j.jaci.2017.11.043	http://dx.doi.org/10.1016/j.jaci.2017.11.043			22	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ5BL	29331643	Green Accepted, Bronze			2022-12-18	WOS:000449429800015
J	Jensen, ET; Dellon, ES				Jensen, Elizabeth T.; Dellon, Evan S.			Environmental factors and eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Environment; early life; microbiome; epigenetics; gene-environment interaction	HELICOBACTER-PYLORI INFECTION; ACID-SUPPRESSIVE MEDICATIONS; INFANT GUT MICROBIOTA; GROUP-B STREPTOCOCCUS; ALLERGIC DISEASE; INCREASED RISK; INTESTINAL MICROBIOTA; SEASONAL DISTRIBUTION; HYGIENE HYPOTHESIS; CHILDHOOD ASTHMA	The incidence and prevalence of eosinophilic esophagitis (EoE) have markedly increased over the past 2 decades, outpacing increased detection of the disease. Although genetic susceptibility markers for EoE have begun to be elucidated, the rate at which EoE has increased in incidence suggests environmental factors predominate. Despite many advances in understanding of the pathogenesis of EoE, the cause of EoE is unknown. This article reviews the emerging data related to environmental risk factors for EoE. Many of these environmental factors are rooted in the theoretical framework of the hygiene hypothesis, specifically mediation of disease development through dysbiosis. Other hypotheses are based on associations that have been observed in studies of non-EoE allergic disease. We describe the evidence that early-life exposures, including antibiotic use, acid suppression, and cesarean delivery, can increase the risk of disease. We also describe the evidence that infectious agents, such as Helicobacter pylori, are inversely associated with disease. Current evidence on geographic risk factors, such as population density, climate zone, and seasonality, is reviewed. We also describe behavioral factors that have been evaluated. Limitations of the existing research are discussed, and recommendations for future areas of research, including assessment of gene-environment interaction, are presented.	[Jensen, Elizabeth T.] Wake Forest Baptist Med Ctr, Dept Pediat, Div Gastroenterol Hepatol & Nutr, Winston Salem, NC USA; [Jensen, Elizabeth T.; Dellon, Evan S.] Univ N Carolina, Sch Med, Div Gastroenterol & Hepatol, Ctr Esophageal Dis & Swallowing, Chapel Hill, NC 27515 USA	Wake Forest University; Wake Forest Baptist Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Dellon, ES (corresponding author), UNC CH, CB 7080,Bioinformat Bldg,130 Mason Farm Rd, Chapel Hill, NC 27599 USA.	edellon@med.unc.edu			CEGIR, Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Disease Research (ORDR), National Center for Advancing Translational Sciences (NCATS) [U54AI117804]; National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; NCATS; American Partnership for Eosinophilic Disorders (APFED) CURED; EFC;  [R01DK101856]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI117804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK101856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	CEGIR, Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Disease Research (ORDR), National Center for Advancing Translational Sciences (NCATS); National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); American Partnership for Eosinophilic Disorders (APFED) CURED; EFC; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported in part by U54AI117804 (CEGIR), which is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Disease Research (ORDR), National Center for Advancing Translational Sciences (NCATS), and is funded through collaboration between the National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, and NCATS. CEGIR is also supported by patient advocacy groups including the American Partnership for Eosinophilic Disorders (APFED) CURED and EFC. This work was also supported by R01DK101856 (to E.S.D.).	Abonia JP, 2013, J ALLERGY CLIN IMMUN, V132, P378, DOI 10.1016/j.jaci.2013.02.030; Abonia JP, 2012, ANNU REV MED, V63, P421, DOI 10.1146/annurev-med-041610-134138; Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Aceves SS, 2007, J CLIN GASTROENTEROL, V41, P252, DOI 10.1097/01.mcg.0000212639.52359.f1; Alexander ES, 2014, J ALLERGY CLIN IMMUN, V134, P1084, DOI 10.1016/j.jaci.2014.07.021; Almansa C, 2009, AM J GASTROENTEROL, V104, P828, DOI 10.1038/ajg.2008.169; Amberbir A, 2014, CLIN EXP ALLERGY, V44, P563, DOI 10.1111/cea.12289; Andersen ABT, 2012, ALIMENT PHARM THER, V35, P1190, DOI 10.1111/j.1365-2036.2012.05073.x; Arboleya S, 2015, J PEDIATR-US, V166, P538, DOI 10.1016/j.jpeds.2014.09.041; Assa'ad Amal, 2008, Gastrointest Endosc Clin N Am, V18, P119, DOI 10.1016/j.giec.2007.09.001; ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781; Attwood SE, 2009, GUT, V58, P1041, DOI 10.1136/gut.2008.175612; Azad MB, 2016, BJOG-INT J OBSTET GY, V123, P983, DOI 10.1111/1471-0528.13601; Azad MB, 2015, CLIN EXP ALLERGY, V45, P632, DOI 10.1111/cea.12487; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P51, DOI 10.1067/mai.2003.34; Basavaraju KP, 2008, INT J CLIN PRACT, V62, P1096, DOI 10.1111/j.1742-1241.2008.01782.x; Baxi S, 2006, GASTROINTEST ENDOSC, V64, P473, DOI 10.1016/j.gie.2006.03.931; Bendiks M, 2013, CURR ALLERGY ASTHM R, V13, P487, DOI 10.1007/s11882-013-0382-8; Benitez AJ, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0085-6; Biasucci G, 2010, EARLY HUM DEV, V86, pS13, DOI 10.1016/j.earlhumdev.2010.01.004; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Burk CM, 2016, DIS ESOPHAGUS, V29, P558, DOI 10.1111/dote.12356; Butel MJ, 2018, J DEV ORIG HLTH DIS, V9, P590, DOI 10.1017/S2040174418000119; Byers PH, 2017, AM J MED GENET C, V175, P40, DOI 10.1002/ajmg.c.31553; Cabana MD, 2017, PEDIATRICS, V140; Cassidy-Bushrow AE, 2016, J DEV ORIG HLTH DIS, V7, P45, DOI 10.1017/S2040174415001361; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Chehade Mirna, 2008, Gastrointest Endosc Clin N Am, V18, P33, DOI 10.1016/j.giec.2007.09.002; Chernikova DA, 2016, J MATERN-FETAL NEO M, V29, P99, DOI 10.3109/14767058.2014.987748; Clayton F, 2014, GASTROENTEROLOGY, V147, P602, DOI 10.1053/j.gastro.2014.05.036; Collins MH, 2008, CLIN GASTROENTEROL H, V6, P621, DOI 10.1016/j.cgh.2008.01.004; Corvaglia L, 2016, J PEDIATR GASTR NUTR, V62, P304, DOI 10.1097/MPG.0000000000000928; Dauer EH, 2005, ANN OTO RHINOL LARYN, V114, P827, DOI 10.1177/000348940511401103; Dellon ES, 2014, GASTROENTEROL CLIN N, V43, P201, DOI 10.1016/j.gtc.2014.02.002; Dellon ES, 2014, CLIN GASTROENTEROL H, V12, P589, DOI 10.1016/j.cgh.2013.09.008; Dellon ES, 2011, GASTROENTEROLOGY, V141, P1586, DOI 10.1053/j.gastro.2011.06.081; Dellon ES, 2009, CLIN GASTROENTEROL H, V7, P1305, DOI 10.1016/j.cgh.2009.08.030; DeVries A, 2017, J ALLERGY CLIN IMMUN, V140, P534, DOI 10.1016/j.jaci.2016.10.041; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Elias MK, 2015, DYSPHAGIA, V30, P67, DOI 10.1007/s00455-014-9574-1; Elitsur Y, 2014, HELICOBACTER, V19, P367, DOI 10.1111/hel.12129; Elitsur Y, 2013, J CLIN GASTROENTEROL, V47, P287, DOI 10.1097/MCG.0b013e31826df861; Ellermann M, 2017, MICROBIOTA IN GASTROINTESTINAL PATHOPHYSIOLOGY: IMPLICATIONS FOR HUMAN HEALTH, PREBIOTICS, PROBIOTICS, AND DYSBIOSIS, P15; Fahey L, 2017, J PEDIATR GASTR NUTR, V64, P22, DOI 10.1097/MPG.0000000000001245; Fallani M, 2010, J PEDIATR GASTR NUTR, V51, P77, DOI 10.1097/MPG.0b013e3181d1b11e; Ferreiro A, 2018, CELL, V172, P1216, DOI 10.1016/j.cell.2018.02.015; Franulovic OZ, 2013, PEDIATR INT, V55, pe38, DOI 10.1111/ped.12027; Fritz J, 2018, J PEDIATR GASTR NUTR, V66, P609, DOI [10.1097/MPG.0000000000001748, 10.1097/mpg.0000000000001748]; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Furuta K, 2013, J CLIN BIOCHEM NUTR, V53, P60, DOI 10.3164/jcbn.13-15; Gabello M, 2010, WORLD J GASTROENTERO, V16, P1097, DOI 10.3748/wjg.v16.i9.1097; Georgountzou A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00957; Harris JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128346; Hill DA, 2018, ANN ALLERG ASTHMA IM, V120, P113, DOI 10.1016/j.anai.2017.10.003; Holt PG, 2011, ALLERGY, V66, P13, DOI 10.1111/j.1398-9995.2011.02623.x; Holvoet S, 2016, ALLERGY, V71, P1753, DOI 10.1111/all.12951; Hopkins AM, 2002, J PHARM PHARMACOL, V54, P341, DOI 10.1211/0022357021778583; Hruz P, 2011, J ALLERGY CLIN IMMUN, V128, P1349, DOI 10.1016/j.jaci.2011.09.013; Hruz P, 2011, GASTROENTEROLOGY, V140, pS238; Hurrell JM, 2012, AM J GASTROENTEROL, V107, P698, DOI 10.1038/ajg.2012.6; Iwanczak B, 2011, ADV MED SCI-POLAND, V56, P151, DOI 10.2478/v10039-011-0038-7; Jahreis S, 2018, J ALLERGY CLIN IMMUN, V141, P741, DOI 10.1016/j.jaci.2017.03.017; Jensen ET, 2017, MICROBIOTA IN GASTROINTESTINAL PATHOPHYSIOLOGY: IMPLICATIONS FOR HUMAN HEALTH, PREBIOTICS, PROBIOTICS, AND DYSBIOSIS, P27; Jensen ET, 2015, ALIMENT PHARM THER, V42, P461, DOI 10.1111/apt.13273; Jensen ET, 2018, J ALLERGY CLIN IMMUN, V141, P214, DOI 10.1016/j.jaci.2017.05.018; Jensen ET, 2016, J PEDIATR GASTR NUTR, V62, P36, DOI 10.1097/MPG.0000000000000865; Jensen ET, 2015, CLIN GASTROENTEROL H, V13, P1426, DOI 10.1016/j.cgh.2015.02.018; Jensen ET, 2015, AM J GASTROENTEROL, V110, P626, DOI 10.1038/ajg.2014.316; Jensen ET, 2013, GASTROENTEROLOGY, V144, pS491; Jensen ET, 2013, J PEDIATR GASTR NUTR, V57, P67, DOI 10.1097/MPG.0b013e318290d15a; JENSEN ET, 2017, GASTROENTEROLOGY S1, V152, pS861; Jensen ET, 2018, J ALLERGY CLIN IMMUN, V141; Jensen ET, 2018, GASTROENTEROLOGY; Judge DP, 2005, LANCET, V366, P1965, DOI 10.1016/S0140-6736(05)67789-6; Koutlas NT, 2018, DIS ESOPHAGUS, V31, DOI 10.1093/dote/dox111; Kozyrskyj AL, 2007, CHEST, V131, P1753, DOI 10.1378/chest.06-3008; Lee YJ, 2015, DIS ESOPHAGUS, V28, P19, DOI 10.1111/dote.12164; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras Chris A, 2011, Gastroenterol Hepatol (N Y), V7, P264; Lindberg GM, 2008, NAT CLIN PRACT GASTR, V5, P527, DOI 10.1038/ncpgasthep1225; Liu AH, 2015, J ALLERGY CLIN IMMUN, V136, P860, DOI 10.1016/j.jaci.2015.08.012; Magnus MC, 2016, INT J EPIDEMIOL, V45, P512, DOI 10.1093/ije/dyv366; Masclee GMC, 2015, AM J GASTROENTEROL, V110, P749, DOI 10.1038/ajg.2015.119; Michel S, 2013, ALLERGY, V68, P355, DOI 10.1111/all.12097; Moawad FJ, 2010, ALIMENT PHARM THER, V31, P509, DOI 10.1111/j.1365-2036.2009.04199.x; Moawad FJ, 2010, AM J GASTROENTEROL, V105, P468, DOI 10.1038/ajg.2009.617; Muir AB, 2016, ALLERGY, V71, P1256, DOI 10.1111/all.12943; Mulder IE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028279; Mullin JM, 2008, ALIMENT PHARM THER, V28, P1317, DOI 10.1111/j.1365-2036.2008.03824.x; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Orel R, 2010, AM J GASTROENTEROL, V105, P468, DOI 10.1038/ajg.2009.603; Osborn DA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006474.pub3; Peterson K, 2016, AM J GASTROENTEROL, V111, P926, DOI 10.1038/ajg.2016.185; Prasad GA, 2009, CLIN GASTROENTEROL H, V7, P1055, DOI 10.1016/j.cgh.2009.06.023; Radano MC, 2014, J ALLER CL IMM-PRACT, V2, P475, DOI 10.1016/j.jaip.2014.02.018; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Roy-Ghanta S, 2008, CLIN GASTROENTEROL H, V6, P531, DOI 10.1016/j.cgh.2007.12.045; Sankar SA, 2015, SYST APPL MICROBIOL, V38, P276, DOI 10.1016/j.syapm.2015.03.004; Schwarze J, 2002, EUR RESPIR J, V19, P341, DOI 10.1183/09031936.02.00254302; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Simon D, 2016, ALLERGY, V71, P611, DOI 10.1111/all.12846; Slae M, 2015, DIGEST DIS SCI, V60, P3364, DOI 10.1007/s10620-015-3740-7; Sordillo JE, 2017, J ALLERGY CLIN IMMUN, V139, P482, DOI 10.1016/j.jaci.2016.08.045; Sordillo JE, 2015, J ALLERGY CLIN IMMUN, V135, P441, DOI 10.1016/j.jaci.2014.07.065; Sorser SA, 2013, J GASTROENTEROL, V48, P81, DOI 10.1007/s00535-012-0608-x; Spergel JM, 2011, J PEDIATR GASTR NUTR, V52, P300, DOI 10.1097/MPG.0b013e3181eb5a9f; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Squires KAG, 2009, J PEDIATR GASTR NUTR, V49, P246, DOI 10.1097/MPG.0b013e31817b5b73; Srivastava MD, 2013, J ALLERGY CLIN IMMUN, V131, pAB177, DOI 10.1016/j.jaci.2012.12.1296; Statovci D, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00838; Stewart CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073465; Taye B, 2015, CLIN EXP ALLERGY, V45, P882, DOI 10.1111/cea.12404; Trikha A, 2013, PEDIAT ALLERG IMM-UK, V24, P582, DOI 10.1111/pai.12103; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI [10.1016/S0091-6749(03)01719-6, 10.1016/mai.2003.1681]; van Rhijn BD, 2013, NEUROGASTROENT MOTIL, V25, P47, DOI 10.1111/nmo.12009; van Rhijn BD, 2012, GASTROENTEROLOGY, V142, pS1138; Vercelli D, 2018, J ALLERGY CLIN IMMUN, V141, P525, DOI 10.1016/j.jaci.2017.12.973; von Arnim U, 2016, ALIMENT PHARM THER, V43, P825, DOI 10.1111/apt.13560; Walker A, 2014, J CLIN GASTROENTEROL, V48, pS8, DOI 10.1097/MCG.0000000000000230; Walker WA, 2015, PEDIATR RES, V77, P220, DOI 10.1038/pr.2014.160; Wang FY, 2007, J CLIN GASTROENTEROL, V41, P451, DOI 10.1097/01.mcg.0000248019.16139.67; Weber J, 2015, AM J RESP CRIT CARE, V191, P522, DOI 10.1164/rccm.201410-1899OC; West CE, 2015, CLIN EXP ALLERGY, V45, P43, DOI 10.1111/cea.12332; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; Xu CJ, 2018, LANCET RESP MED, V6, P379, DOI 10.1016/S2213-2600(18)30052-3; Zimmermann D, 2016, ACG CASE REP J, V3, P165, DOI 10.14309/crj.2016.38	131	39	39	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					32	40		10.1016/j.jaci.2018.04.015	http://dx.doi.org/10.1016/j.jaci.2018.04.015			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29729305	Green Accepted, Bronze			2022-12-18	WOS:000437837500004
J	Mallory, ML; Lindesmith, LC; Baric, RS				Mallory, Michael L.; Lindesmith, Lisa C.; Baric, Ralph S.			Vaccination-induced herd immunity: Successes and challenges	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						Herd immunity; vaccination; neutralizing antibodies	MEASLES		[Mallory, Michael L.; Lindesmith, Lisa C.; Baric, Ralph S.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill	Baric, RS (corresponding author), Univ North Carolina Chapel Hill, Gillings Sch Global Publ Hlth, Hooker Res Ctr 3304, 135 Dauer Dr,CB7435, Chapel Hill, NC 27599 USA.	rbaric@email.unc.edu			National Institutes of Health, Allergy, and Infectious Diseases [R56 A15-0756, U19 AI109761 CETR]; Wellcome Trust [A17-0915001]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI109761, R56AI106006] Funding Source: NIH RePORTER	National Institutes of Health, Allergy, and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by grants from the National Institutes of Health, Allergy, and Infectious Diseases (R56 A15-0756 and U19 AI109761 CETR) and the Wellcome Trust (A17-0915001).	de Alwis R, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004386; He HQ, 2013, VACCINE, V31, P533, DOI 10.1016/j.vaccine.2012.11.014; Jones DB, IMMUNIZATION VACCINE; Kang HJ, 2017, VACCINE, V35, P4126, DOI 10.1016/j.vaccine.2017.06.058; Katzelnick LC, 2016, P NATL ACAD SCI USA, V113, P728, DOI 10.1073/pnas.1522136113; Lessler J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002802; Lindesmith LC, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001807; Machalek DA, 2017, J INFECT DIS, V215, P202, DOI 10.1093/infdis/jiw530; WHO, IMMUNIZATION COVERAG; Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682	10	39	39	3	26	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					64	66		10.1016/j.jaci.2018.05.007	http://dx.doi.org/10.1016/j.jaci.2018.05.007			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29803799	Bronze, Green Published, Green Accepted			2022-12-18	WOS:000437837500008
J	Rochman, M; Azouz, NP; Rothenberg, ME				Rochman, Mark; Azouz, Nurit P.; Rothenberg, Marc E.			Epithelial origin of eosinophilic esophagitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophilic esophagitis; eosinophilic oesophagitis; esophageal epithelium; epithelial differentiation; epithelial barrier; proteases; protease inhibitors; serine protease inhibitors; Kazal type	KALLIKREIN-RELATED PEPTIDASES; SERINE-PROTEASE INHIBITOR; STEM-CELLS; GENETIC SUSCEPTIBILITY; INCREASED PREVALENCE; ATOPIC-DERMATITIS; PROVIDES INSIGHT; BARRIER FUNCTION; POTENTIAL ROLE; IL-13	Eosinophilic esophagitis (EoE) is a chronic, allergen-driven inflammatory disease of the esophagus characterized predominantly by eosinophilic inflammation, leading to esophageal dysfunction. Converging data have placed the esophageal epithelium at the center of disease pathogenesis. In particular, the main EoE disease susceptibility loci at 2p23 and 5p22 encode for gene products that are produced by the esophageal epithelium: the intracellular protease calpain 14 and thymic stromal lymphopoietin, respectively. Furthermore, genetic and functional data establish a primary role for impaired epithelial barrier function in disease susceptibility and pathoetiology. Additionally, the EoE transcriptome, a set of genes dysregulated in the esophagi of patients with EoE, is enriched in genes that encode for proteins involved in esophageal epithelial cell differentiation. This transcriptome has a high proportion of esophagus-specific epithelial genes that are notable for the unexpected enrichment in genes encoding for proteases and protease inhibitors, as well as in IL-1 family genes, demonstrating a previously unappreciated role for innate immunity responses in the esophagus under homeostatic conditions. Among these pathways, basal production of the serine protease inhibitor, Kazal-type 7 (SPINK7) has been demonstrated to be part of the normal differentiation program of esophageal epithelium. Profound lost expression of SPINK7 occurs in patients with EoE and is sufficient for unleashing increased proteolytic activity (including urokinase plasminogen activator), impaired barrier function, and production of large quantities of proinflammatory and proallergic cytokines, including thymic stromal lymphopoietin. Collectively, we put forth a model in which the esophagus is normally equipped as an anti-inflammatory sensing organ and that defects in this pathway, mediated by epithelial protease/protease inhibitor imbalances, unleash inflammatory responses resulting in disorders, such as EoE.	[Rochman, Mark; Azouz, Nurit P.; Rothenberg, Marc E.] Univ Cincinnati, Coll Med, Dept Pediat,Div Allergy & Immunol, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Rothenberg, ME (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, 3333 Burnet Ave,MLC7028, Cincinnati, OH 45229 USA.	rothenberg@cchmc.org		Azouz, Nurit/0000-0003-4969-1263	National Institutes of Health (NIH) grant [R01 AI124355, R37 A1045898, U19 AI070235]; Campaign Urging Research for Eosinophilic Disease (CURED) Foundation; Sunshine Charitable Foundation; CEGIR, Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS) - National Institute of Allergy and Infectious Diseases (NIAID) [U54 AI117804]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NCATS; American Partnership for Eosinophilic Disorders (APFED); Campaign Urging Research for Eosinophilic Disease (CURED); Eosinophilic Family Coalition (EFC); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI045898, U19AI070235, U54AI117804, R01AI124355] Funding Source: NIH RePORTER	National Institutes of Health (NIH) grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Campaign Urging Research for Eosinophilic Disease (CURED) Foundation; Sunshine Charitable Foundation; CEGIR, Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS) - National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); American Partnership for Eosinophilic Disorders (APFED); Campaign Urging Research for Eosinophilic Disease (CURED); Eosinophilic Family Coalition (EFC); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by National Institutes of Health (NIH) grant R01 AI124355, NIH grant R37 A1045898, NIH grant U19 AI070235, the Campaign Urging Research for Eosinophilic Disease (CURED) Foundation, the Sunshine Charitable Foundation and its supporters, Denise A. Bunning and David G. Bunning, as well as CEGIR (U54 AI117804) as part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), which is co-funded by National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and NCATS. CEGIR is also supported by patient advocacy groups including the American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC).	Abdulnour-Nakhoul SM, 2013, CLIN IMMUNOL, V148, P265, DOI 10.1016/j.clim.2013.05.004; Abonia JP, 2012, ANNU REV MED, V63, P421, DOI 10.1146/annurev-med-041610-134138; Abonia JP, 2010, J ALLERGY CLIN IMMUN, V126, P140, DOI 10.1016/j.jaci.2010.04.009; Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Afonina IS, 2015, IMMUNITY, V42, P991, DOI 10.1016/j.immuni.2015.06.003; Alexander ES, 2014, J ALLERGY CLIN IMMUN, V134, P1084, DOI 10.1016/j.jaci.2014.07.021; Alexander JA, 2012, CLIN GASTROENTEROL H, V10, P742, DOI 10.1016/j.cgh.2012.03.018; Pavon MA, 2016, ONCOTARGET, V7, P57351, DOI 10.18632/oncotarget.10344; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P1513, DOI 10.1016/j.jaci.2017.10.047; Asai Y, 2018, J ALLERGY CLIN IMMUN, V141, P991, DOI 10.1016/j.jaci.2017.09.015; Azouz NP, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap9736; Benitez AJ, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0085-6; Benninger MS, 2017, INT FORUM ALLERGY RH, V7, P757, DOI 10.1002/alr.21968; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P1292, DOI 10.1016/j.jaci.2007.10.024; Blanchard C, 2010, J IMMUNOL, V184, P4033, DOI 10.4049/jimmunol.0903069; Borgono CA, 2007, J BIOL CHEM, V282, P3640, DOI 10.1074/jbc.M607567200; Butz BK, 2014, GASTROENTEROLOGY, V147, P324, DOI 10.1053/j.gastro.2014.04.019; Caldwell JM, 2017, MUCOSAL IMMUNOL, V10, P1190, DOI 10.1038/mi.2016.120; Caldwell JM, 2017, CURR OPIN IMMUNOL, V48, P114, DOI 10.1016/j.coi.2017.08.006; Caughey GH, 2011, ADV EXP MED BIOL, V716, P212, DOI 10.1007/978-1-4419-9533-9_12; Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cianferoni A, 2015, CURR OPIN ALLERGY CL, V15, P417, DOI 10.1097/ACI.0000000000000200; Corradin O, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0085-3; Cousineau I, 2011, MOL GENET GENOMICS, V285, P325, DOI 10.1007/s00438-011-0612-5; Croagh D, 2008, STEM CELL REV, V4, P261, DOI 10.1007/s12015-008-9031-3; Croagh D, 2007, STEM CELLS, V25, P313, DOI 10.1634/stemcells.2006-0421; Cui N, 2017, PROG MOL BIOL TRANSL, V147, P1, DOI 10.1016/bs.pmbts.2017.02.005; D'Mello RJ, 2016, MUCOSAL IMMUNOL, V9, P744, DOI 10.1038/mi.2015.98; Daniely Y, 2004, AM J PHYSIOL-CELL PH, V287, pC171, DOI 10.1152/ajpcell.00226.2003; Davis BP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86355; Davis BP, 2018, CLIN REV ALLERGY IMM; de Veer SJ, 2014, TRENDS MOL MED, V20, P166, DOI 10.1016/j.molmed.2013.11.005; Dellon ES, 2017, GASTROENTEROLOGY, V152, P776, DOI 10.1053/j.gastro.2016.11.021; Deraison C, 2007, MOL BIOL CELL, V18, P3607, DOI 10.1091/mbc.E07-02-0124; DeWard AD, 2014, CELL REP, V9, P701, DOI 10.1016/j.celrep.2014.09.027; Doupe DP, 2012, SCIENCE, V337, P1091, DOI 10.1126/science.1218835; Emami N, 2010, BIOL CHEM, V391, P85, DOI 10.1515/BC.2010.007; Fahey LM, 2018, CLIN TRANSL GASTROEN, V9, DOI 10.1038/s41424-018-0003-x; Fahey LM, 2018, PEDIAT ALLERGY IMMUN; Fischer J, 2013, THROMB HAEMOSTASIS, V110, P442, DOI 10.1160/TH12-11-0836; Fridrich S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153290; Fukuda M, 2016, TRAFFIC, V17, P709, DOI 10.1111/tra.12406; Furio L, 2014, J EXP MED, V211, P499, DOI 10.1084/jem.20131797; Goettig P, 2010, BIOCHIMIE, V92, P1546, DOI 10.1016/j.biochi.2010.06.022; Gresnigt MS, 2013, SEMIN IMMUNOL, V25, P458, DOI 10.1016/j.smim.2013.11.003; Greuter T, 2017, AM J GASTROENTEROL, V112, P1527, DOI 10.1038/ajg.2017.202; Hannula-Jouppi K, 2014, J ALLERGY CLIN IMMUN, V134, P985, DOI 10.1016/j.jaci.2014.07.008; Harris JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128346; Hartmann M, 2013, TRENDS BIOCHEM SCI, V38, P111, DOI 10.1016/j.tibs.2012.12.002; Heinz S, 2013, NATURE, V503, P487, DOI 10.1038/nature12615; Henderson CJ, 2014, J PEDIATR GASTR NUTR, V58, P553, DOI 10.1097/MPG.0000000000000253; Hentze H, 2003, CELL DEATH DIFFER, V10, P956, DOI 10.1038/sj.cdd.4401264; Hirota T, 2017, J ALLERGY CLIN IMMUN, V140, P1713, DOI 10.1016/j.jaci.2017.05.034; Hong XM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7304; Hou JY, 2017, SEMIN CELL DEV BIOL, V64, P58, DOI 10.1016/j.semcdb.2016.08.034; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Ingerski LM, 2010, J PEDIATR-US, V156, P639, DOI 10.1016/j.jpeds.2009.11.008; Jang H, 2016, J INVEST DERMATOL, V136, P127, DOI 10.1038/JID.2015.363; Jensen ET, 2018, J ALLERGY CLIN IMMUN, V141, P632, DOI 10.1016/j.jaci.2017.07.010; Jensen ET, 2018, J ALLERGY CLIN IMMUN, V141, P214, DOI 10.1016/j.jaci.2017.05.018; Jensen Elizabeth T, 2016, Curr Treat Options Gastroenterol, V14, P39, DOI 10.1007/s11938-016-0083-1; Jensen ET, 2015, AM J GASTROENTEROL, V110, P626, DOI 10.1038/ajg.2014.316; Jeong YT, 2016, GUT, V65, P1077, DOI 10.1136/gutjnl-2014-308491; Jiang M, 2015, J CLIN INVEST, V125, P1557, DOI 10.1172/JCI78850; Kagalwalla AF, 2012, J ALLERGY CLIN IMMUN, V129, P1387, DOI 10.1016/j.jaci.2012.03.005; Khor SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18241-w; Kiran KC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127755; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Kottyan LC, 2017, MUCOSAL IMMUNOL, V10, P580, DOI 10.1038/mi.2017.4; Kottyan LC, 2014, NAT GENET, V46, P895, DOI 10.1038/ng.3033; Kraus MRC, 2012, CURR OPIN GENET DEV, V22, P347, DOI 10.1016/j.gde.2012.05.002; Krunic AL, 2013, PEDIATR DERMATOL, V30, pE87, DOI 10.1111/pde.12092; Krupp NL, 2016, PEDIATR PULM, V51, P478, DOI 10.1002/ppul.23327; Kubo A, 2013, AM J HUM GENET, V93, P945, DOI 10.1016/j.ajhg.2013.09.015; Letner D, 2018, DIS ESOPHAGUS, V31, DOI 10.1093/dote/dox122; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Liew FY, 2016, NAT REV IMMUNOL, V16, P676, DOI 10.1038/nri.2016.95; Lim E, 2014, J IMMUNOL, V192, P466, DOI 10.4049/jimmunol.1302454; Litosh VA, 2017, J ALLERGY CLIN IMMUN, V139, P1762, DOI 10.1016/j.jaci.2016.09.027; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Mansoor E, 2016, DIGEST DIS SCI, V61, P2928, DOI 10.1007/s10620-016-4204-4; Marenholz I, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01220-0; Martin LJ, 2018, J ALLERGY CLIN IMMUN, V141, P1690, DOI 10.1016/j.jaci.2017.09.046; Matoso A, 2013, MODERN PATHOL, V26, P665, DOI 10.1038/modpathol.2013.41; Matsumura Yasuhiro, 2012, J Allergy (Cairo), V2012, P903659, DOI 10.1155/2012/903659; Miehlke S, 2016, GUT, V65, P390, DOI 10.1136/gutjnl-2014-308815; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1016/j.gastro.2003.07.007; Mishra A, 2002, J IMMUNOL, V168, P2464, DOI 10.4049/jimmunol.168.5.2464; Muir AB, 2015, EXP CELL RES, V330, P102, DOI 10.1016/j.yexcr.2014.08.026; Muir AB, 2013, EXP CELL RES, V319, P850, DOI 10.1016/j.yexcr.2012.12.002; Nalivaeva NN, 2014, FRONT AGING NEUROSCI, V6, DOI [10.3389/tnagi.2014.00235, 10.3389/fnagi.2014.00235]; Nguyen N, 2018, MUCOSAL IMMUNOL, V11, P415, DOI 10.1038/mi.2017.72; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; O'Shea KM, 2018, GASTROENTEROLOGY, V154, P333, DOI 10.1053/j.gastro.2017.06.065; Okumura T, 2003, ONCOGENE, V22, P4017, DOI 10.1038/sj.onc.1206525; Ono Y, 2016, NAT REV DRUG DISCOV, V15, P854, DOI 10.1038/nrd.2016.212; Orlando RC, 2010, BEST PRACT RES CL GA, V24, P873, DOI 10.1016/j.bpg.2010.08.008; Palomo J, 2015, CYTOKINE, V76, P25, DOI 10.1016/j.cyto.2015.06.017; Paluel-Marmont C, 2017, J ALLERGY CLIN IMMUN, V139, P2003, DOI 10.1016/j.jaci.2016.10.045; Pan QW, 2013, GASTROENTEROLOGY, V144, P761, DOI 10.1053/j.gastro.2012.12.022; Parfitt JR, 2006, MODERN PATHOL, V19, P90, DOI 10.1038/modpathol.3800498; Perez-Silva JG, 2016, NUCLEIC ACIDS RES, V44, pD351, DOI 10.1093/nar/gkv1201; Polivka L, 2018, J ALLERGY CLIN IMMUN; Que JW, 2006, DIFFERENTIATION, V74, P422, DOI 10.1111/j.1432-0436.2006.00096.x; Radano MC, 2014, J ALLER CL IMM-PRACT, V2, P475, DOI 10.1016/j.jaip.2014.02.018; Ramadas RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045784; Rawlings A V, 2004, Dermatol Ther, V17 Suppl 1, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Rawson R, 2016, J ALLERGY CLIN IMMUN, V138, P791, DOI 10.1016/j.jaci.2016.02.028; Rochman M, 2015, MUCOSAL IMMUNOL, V8, P785, DOI 10.1038/mi.2014.109; Rochman M, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96789; Rochman M, 2017, J ALLERGY CLIN IMMUN, V140, P738, DOI 10.1016/j.jaci.2016.11.042; Rosekrans SL, 2015, AM J PHYSIOL-GASTR L, V309, pG216, DOI 10.1152/ajpgi.00088.2015; Rothenberg ME, 2015, J ALLERGY CLIN IMMUN, V135, P500, DOI 10.1016/j.jaci.2014.07.049; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; RUNGE T, 2016, GASTROENTEROLOGY S1, V150, pS664; Safroneeva E, 2015, ALIMENT PHARM THER, V42, P1000, DOI 10.1111/apt.13370; Samuelov L, 2013, NAT GENET, V45, P1244, DOI 10.1038/ng.2739; Sarlo K, 1997, J ALLERGY CLIN IMMUN, V100, P480, DOI 10.1016/S0091-6749(97)70139-8; Schaefer ET, 2008, CLIN GASTROENTEROL H, V6, P165, DOI 10.1016/j.cgh.2007.11.008; Seery JP, 2002, J CELL SCI, V115, P1783; Seery JP, 2000, CURR BIOL, V10, P1447, DOI 10.1016/S0960-9822(00)00803-4; Sherrill JD, 2014, GENES IMMUN, V15, P361, DOI 10.1038/gene.2014.27; Sherrill JD, 2014, MUCOSAL IMMUNOL, V7, P718, DOI 10.1038/mi.2013.90; Sherrill JD, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99922; Sherrill JD, 2014, GASTROENTEROL CLIN N, V43, P269, DOI 10.1016/j.gtc.2014.02.003; Sherrill JD, 2011, J ALLERGY CLIN IMMUN, V128, P23, DOI 10.1016/j.jaci.2011.03.046; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Simon D, 2018, ALLERGY, V73, P239, DOI 10.1111/all.13244; Simon D, 2015, ALLERGY, V70, P443, DOI 10.1111/all.12570; Slae M, 2015, DIGEST DIS SCI, V60, P3364, DOI 10.1007/s10620-015-3740-7; Sleiman PMA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6593; Squier C A, 2001, J Natl Cancer Inst Monogr, P7; Travers J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17541-5; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; van Ginkel CD, 2018, ALLERGY; Vigne S, 2012, BLOOD, V120, P3478, DOI 10.1182/blood-2012-06-439026; Wang R, 2012, MOL BIOL CELL, V23, P1129, DOI 10.1091/mbc.E11-12-1018; Wu DW, 2018, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00538; Yamamoto Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10380; Zeeuwen PLJM, 2010, FASEB J, V24, P3744, DOI 10.1096/fj.10-155879; Zhang XJ, 2006, J CELL SCI, V119, P1053, DOI 10.1242/jcs.02810; Zheng Y, 2015, SKIN PHARMACOL PHYS, V28, P97, DOI 10.1159/000363248; Zhu YN, 2017, J ALLERGY CLIN IMMUN, V140, P1310, DOI 10.1016/j.jaci.2017.01.025; Zorn AM, 2009, ANNU REV CELL DEV BI, V25, P221, DOI 10.1146/annurev.cellbio.042308.113344; Zuo L, 2010, J IMMUNOL, V185, P660, DOI 10.4049/jimmunol.1000471	148	39	40	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2018	142	1					10	23		10.1016/j.jaci.2018.05.008	http://dx.doi.org/10.1016/j.jaci.2018.05.008			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GM1OC	29980278	Bronze, Green Accepted			2022-12-18	WOS:000437837500002
J	Cook, L; Munier, CML; Seddiki, N; van Bockel, D; Ontiveros, N; Hardy, MY; Gillies, JK; Levings, MK; Reid, HH; Petersen, J; Rossjohn, J; Anderson, RP; Zaunders, JJ; Tye-Din, JA; Kelleher, AD				Cook, Laura; Munier, C. Mee Ling; Seddiki, Nabila; van Bockel, David; Ontiveros, Noe; Hardy, Melinda Y.; Gillies, Jana K.; Levings, Megan K.; Reid, Hugh H.; Petersen, Jan; Rossjohn, Jamie; Anderson, Robert P.; Zaunders, John J.; Tye-Din, Jason A.; Kelleher, Anthony D.			Circulating gluten-specific FOXP3(+)CD39(+) regulatory T cells have impaired suppressive function in patients with celiac disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cells; CD39; forkhead box protein 3; celiac disease; gluten; OX40	PERIPHERAL-BLOOD; ANTIGEN CHALLENGE; GLIADIN PEPTIDES; ASSAY; EXPRESSION; COEXPRESSION; LYMPHOCYTES; RESPONSES; SHAPES; USAGE	Background: Celiac disease is a chronic immune-mediated inflammatory disorder of the gut triggered by dietary gluten. Although the effector T-cell response in patients with celiac disease has been well characterized, the role of regulatory T (Treg) cells in the loss of tolerance to gluten remains poorly understood. Objective: We sought to define whether patients with celiac disease have a dysfunction or lack of gluten-specific forkhead box protein 3 (FOXP3)(+) Treg cells. Methods: Treated patients with celiac disease underwent oral wheat challenge to stimulate recirculation of gluten-specific T cells. Peripheral blood was collected before and after challenge. To comprehensively measure the gluten-specific CD4(+) T-cell response, we paired traditional IFN-gamma ELISpot with an assay to detect antigen-specific CD4(+) T cells that does not rely on tetramers, antigen stimulated cytokine production, or proliferation but rather on antigen-induced coexpression of CD25 and OX40 (CD134). Results: Numbers of circulating gluten-specific Treg cells and effector T cells both increased significantly after oral wheat challenge, peaking at day 6. Surprisingly, we found that approximately 80% of the ex vivo circulating gluten-specific CD4(+) T cells were FOXP3(+) CD39(+) Treg cells, which reside within the pool of memory CD4(+) CD25(+) CD127(low) CD45RO(+) Treg cells. Although we observed normal suppressive function in peripheral polyclonal Treg cells from patients with celiac disease, after a short in vitro expansion, the gluten-specific FOXP3(+) CD39(+) Treg cells exhibited significantly reduced suppressive function compared with polyclonal Treg cells. Conclusion: This study provides the first estimation of FOXP3(+) CD39(+) Treg cell frequency within circulating gluten-specific CD4(+) T cells after oral gluten challenge of patients with celiac disease. FOXP3(+) CD39(+) Treg cells comprised a major proportion of all circulating gluten-specific CD4(+) T cells but had impaired suppressive function, indicating that Treg cell dysfunction might be a key contributor to disease pathogenesis.	[Cook, Laura; Munier, C. Mee Ling; Seddiki, Nabila; van Bockel, David; Zaunders, John J.; Kelleher, Anthony D.] UNSW Sydney, Immunovirol & Pathogenesis Program, Kirby Inst, Sydney, NSW, Australia; [Cook, Laura; Seddiki, Nabila; Zaunders, John J.; Kelleher, Anthony D.] St Vincents Hosp, St Vincents Ctr Appl Med Res, Sydney, NSW, Australia; [Ontiveros, Noe; Hardy, Melinda Y.; Anderson, Robert P.; Tye-Din, Jason A.] Walter & Eliza Hall Inst Med Res, Div Immunol, Parkville, Vic, Australia; [Ontiveros, Noe; Hardy, Melinda Y.; Anderson, Robert P.; Tye-Din, Jason A.] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia; [Gillies, Jana K.; Levings, Megan K.] Univ British Columbia, Dept Surg, Vancouver, BC, Canada; [Reid, Hugh H.; Petersen, Jan; Rossjohn, Jamie] Monash Univ, Infect & Immun Program, Dept Biochem & Mol Biol, Biomed Discovery Inst, Clayton, Vic, Australia; [Reid, Hugh H.; Petersen, Jan; Rossjohn, Jamie] Monash Univ, Australian Res Council, Ctr Excellence Adv Mol Imaging, Clayton, Vic, Australia; [Rossjohn, Jamie] Cardiff Univ, Sch Med, Inst Infect & Immun, Heath Pk, Cardiff, S Glam, Wales; [Anderson, Robert P.] ImmusanT, Cambridge, England; [Tye-Din, Jason A.] Royal Melbourne Hosp, Dept Gastroenterol, Parkville, Vic, Australia; [Cook, Laura] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Seddiki, Nabila] INSERM, U955, Creteil, France; [Seddiki, Nabila] UPEC, Vaccine Res Inst, Creteil, France	University of New South Wales Sydney; Kirby Institute; St Vincents Hospital Sydney; Walter & Eliza Hall Institute; University of Melbourne; University of British Columbia; Monash University; Monash University; Cardiff University; Royal Melbourne Hospital; University of British Columbia; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Cook, L (corresponding author), BC Childrens Hosp Res Inst, Levings Lab, Room A4-102,950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada.	lcook@bcchr.ca	Zaunders, John/J-6553-2012; Tye-Din, Jason A./A-6109-2019; Cook, Laura/X-7707-2019; Munier, C. Mee Ling/AAZ-8837-2021; Rossjohn, Jamie/F-9032-2013	Zaunders, John/0000-0002-5912-5989; Tye-Din, Jason A./0000-0001-7687-9654; Cook, Laura/0000-0003-3153-2045; Munier, C. Mee Ling/0000-0002-6419-142X; Rossjohn, Jamie/0000-0002-2020-7522; Anderson, Robert/0000-0002-0764-7267; Levings, Megan/0000-0002-0305-5790; Ontiveros, Noe/0000-0001-8678-0447; Kelleher, Anthony/0000-0002-0009-3337; Seddiki, Nabila/0000-0002-0379-8527; Hardy, Melinda/0000-0003-4923-0678	Australian Government Department of Health and Ageing; NHMRC [1085875, 510448]; Australian Research Council Australia Laureate Fellowship [FL160100049]; Practitioner Fellowship; Coeliac Research Fund; Australian Postgraduate Award; UNSW Research Excellence Scholarship; National Health and Medical Research Council [1085875]	Australian Government Department of Health and Ageing(Australian GovernmentDepartment of Health & Ageing); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council Australia Laureate Fellowship(Australian Research Council); Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); Coeliac Research Fund; Australian Postgraduate Award(Australian Government); UNSW Research Excellence Scholarship; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Supported by the Australian Government Department of Health and Ageing; the NHMRC through a program (510448) grant, NHMRC project grant (1085875), an Australian Research Council Australia Laureate Fellowship (FL160100049) (to J.R.), and a Practitioner Fellowship (to A. D.K.); a Coeliac Research Fund Grant (to N.S., R.P.A., J.T.-D., and A. D.K.); an Australian Postgraduate Award; and a UNSW Research Excellence Scholarship (to L.C.). H.H.R. has received a grant from the National Health and Medical Research Council (1085875).	Abadie V, 2012, SEMIN IMMUNOPATHOL, V34, P551, DOI 10.1007/s00281-012-0316-x; Ahmed MB, 2009, J IMMUNOL, V182, P6763, DOI 10.4049/jimmunol.0801792; Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Anderson RP, 2005, GUT, V54, P1217, DOI 10.1136/gut.2004.059998; Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Betts RJ, 2012, J VIROL, V86, P2817, DOI 10.1128/JVI.05685-11; Brincks EL, 2013, J IMMUNOL, V190, P3438, DOI 10.4049/jimmunol.1203140; Broughton SE, 2012, IMMUNITY, V37, P611, DOI 10.1016/j.immuni.2012.07.013; Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318; DePaolo RW, 2011, NATURE, V471, P220, DOI 10.1038/nature09849; Frisullo G, 2009, HUM IMMUNOL, V70, P430, DOI 10.1016/j.humimm.2009.04.006; Gianfrani C, 2006, J IMMUNOL, V177, P4178, DOI 10.4049/jimmunol.177.6.4178; Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P695, DOI 10.1101/pdb.prot5633; Granzotto M, 2009, DIGEST DIS SCI, V54, P1513, DOI 10.1007/s10620-008-0501-x; Gregori Silvia, 2007, Methods Mol Biol, V380, P83; He HQ, 2014, IMMUNOLOGY, V141, P362, DOI 10.1111/imm.12198; Hmida NB, 2012, AM J GASTROENTEROL, V107, P604, DOI 10.1038/ajg.2011.397; Hsu Denise C, 2012, Tuberculosis (Edinb), V92, P321, DOI 10.1016/j.tube.2012.03.008; Kelleher AD, 2001, J EXP MED, V193, P375, DOI 10.1084/jem.193.3.375; Keoshkerian E, 2012, J IMMUNOL METHODS, V375, P148, DOI 10.1016/j.jim.2011.10.004; Koskinen L, 2009, IMMUNOGENETICS, V61, P247, DOI 10.1007/s00251-009-0361-3; McMurchy AN, 2012, EUR J IMMUNOL, V42, P27, DOI 10.1002/eji.201141651; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Monsuur AJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002270; Ontiveros N, 2014, CLIN EXP IMMUNOL, V175, P305, DOI 10.1111/cei.12232; Peres RS, 2015, P NATL ACAD SCI USA, V112, P2509, DOI 10.1073/pnas.1424792112; Petersen J, 2014, NAT STRUCT MOL BIOL, V21, P480, DOI 10.1038/nsmb.2817; Qiao SW, 2011, J IMMUNOL, V187, P3064, DOI 10.4049/jimmunol.1101526; Quigley Maire F, 2011, Curr Protoc Immunol, VChapter 10, DOI 10.1002/0471142735.im1033s94; Rissiek A, 2015, J AUTOIMMUN, V58, P12, DOI 10.1016/j.jaut.2014.12.007; Sadler R, 2014, CYTOM PART B-CLIN CY, V86, P350, DOI 10.1002/cyto.b.21165; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Seddiki N, 2014, EUR J IMMUNOL, V44, P1644, DOI 10.1002/eji.201344102; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; Sollid LM, 2012, IMMUNOGENETICS, V64, P455, DOI 10.1007/s00251-012-0599-z; Su LF, 2016, P NATL ACAD SCI USA, V113, pE6192, DOI 10.1073/pnas.1611723113; Tong WWY, 2015, J INFECT DIS, V211, P405, DOI 10.1093/infdis/jiu461; Tye-Din JA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001012; Tye-Din JA, 2010, CLIN IMMUNOL, V134, P289, DOI 10.1016/j.clim.2009.11.001; Vukmanovic-Stejic M, 2015, J INVEST DERMATOL, V135, P1752, DOI 10.1038/jid.2015.63; Vukmanovic-Stejic M, 2013, J IMMUNOL, V190, P977, DOI 10.4049/jimmunol.1201331; WALKERSMITH JA, 1990, ARCH DIS CHILD, V65, P909, DOI 10.1136/adc.65.8.909; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Zanzi D, 2011, AM J GASTROENTEROL, V106, P1308, DOI 10.1038/ajg.2011.80; Zaunders JJ, 2009, J IMMUNOL, V183, P2827, DOI 10.4049/jimmunol.0803548	45	39	39	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2017	140	6					1592	+		10.1016/j.jaci.2017.02.015	http://dx.doi.org/10.1016/j.jaci.2017.02.015			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FO9KI	28283419	hybrid, Green Accepted, Green Published			2022-12-18	WOS:000417206000014
J	Korosec, P; Turner, PJ; Silar, M; Kopac, P; Kosnik, M; Gibbs, BF; Shamji, MH; Custovic, A; Rijavec, M				Korosec, Peter; Turner, Paul J.; Silar, Mira; Kopac, Peter; Kosnik, Mitja; Gibbs, Bernhard F.; Shamji, Mohamed H.; Custovic, Adnan; Rijavec, Matija			Basophils, high-affinity IgE receptors, and CCL2 in human anaphylaxis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; basophils; CD63 activation; Fc epsilon RI expression; CCL2; serum tryptase	PLATELET-ACTIVATING-FACTOR; INSECT-STING CHALLENGE; ALLERGIC REACTIONS; MAST-CELL; ATOPIC-DERMATITIS; FOOD CHALLENGES; TRYPTASE LEVELS; TRANSENDOTHELIAL MIGRATION; VENOM IMMUNOTHERAPY; IMMUNOGLOBULIN-E	Background: The role of basophils in anaphylaxis is unclear. Objective: We sought to investigate whether basophils have an important role in human anaphylaxis. Methods: In an emergency department study we recruited 31 patients with acute anaphylaxis, predominantly to Hymenoptera venom. We measured expression of basophil activation markers (CD63 and CD203c); the absolute number of circulating basophils; whole-blood FCER1A, carboxypeptidase A3 (CPA3), and L-histidine decarboxylase (HDC) gene expression; and serum markers (CCL2, CCL5, CCL11, IL-3, and thymic stromal lymphopoietin) at 3 time points (ie, during the anaphylactic episode and in convalescent samples 7 and 30 days later). We recruited 134 patients with Hymenoptera allergy and 76 healthy control subjects for comparison. We then investigated whether the changes observed during venom-related anaphylaxis also occur during allergic reactions to food in 22 patients with peanut allergy undergoing double-blind, placebo-controlled food challenge to peanut. Results: The number of circulating basophils was significantly lower during anaphylaxis (median, 3.5 cells/mu L) than 7 and 30 days later (17.5 and 24.7 cells/mu L, P < .0001) and compared with those in patients with venom allergy and healthy control subjects (21 and 23.4 cells/mu L, P < .0001). FCER1A expression during anaphylaxis was also significantly lower than in convalescent samples (P <= .002) and control subjects with venom allergy (P < .0001). CCL2 levels (but not those of other serum markers) were significantly higher during anaphylaxis (median, 658 pg/mL) than in convalescent samples (314 and 311 pg/mL at 7 and 30 days, P < .001). Peanut-induced allergic reactions resulted in a significant decrease in circulating basophil counts compared with those in prechallenge samples (P = .016), a decrease in FCER1A expression (P = .007), and an increase in CCL2 levels (P = .003). Conclusions: Our findings imply an important and specific role for basophils in the pathophysiology of human anaphylaxis.	[Korosec, Peter; Silar, Mira; Kopac, Peter; Kosnik, Mitja; Rijavec, Matija] Univ Hosp Resp & Allerg Dis, Golnik, Slovenia; [Turner, Paul J.; Custovic, Adnan] Imperial Coll London, Sect Paediat, London, England; [Turner, Paul J.; Shamji, Mohamed H.; Custovic, Adnan] Imperial Coll London, MRC, London, England; [Turner, Paul J.; Shamji, Mohamed H.; Custovic, Adnan] Imperial Coll London, Asthma UK Ctr Allerg Mech Asthma, London, England; [Gibbs, Bernhard F.] Univ Kent, Medway Sch Pharm, Chatham, Kent, England; [Shamji, Mohamed H.] Imperial Coll London, Natl Heart & Lung Inst, Sect Allergy & Clin Immunol, London, England	Imperial College London; Imperial College London; Imperial College London; University of London; King's College London; University of Greenwich; University of Kent; Imperial College London	Korosec, P (corresponding author), Univ Clin Resp & Allerg Dis, Lab Clin Immunol & Mol Genet, Golnik 36, Golnik 4204, Slovenia.	peter.korosec@klinika-golnik.si	Sumbayev, Vadim/HCH-7696-2022; Košnik, Mitja/AAI-2295-2019; Shamji, Mohamed/AAU-8811-2020; Custovic, Adnan/A-2435-2012; Shamji, Mohamed/AAD-1788-2019	Košnik, Mitja/0000-0002-4701-7374; Shamji, Mohamed/0000-0003-3425-3463; Custovic, Adnan/0000-0001-5218-7071; Rijavec, Matija/0000-0002-2596-4952; Turner, Paul/0000-0001-9862-5161	Slovenian Research Agency [P3-0360]; Clinician Scientist award - UK Medical Research Council [MR/K010468/1]; European Union [312147]; UK Medical Research Council [WM/3306381]; National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust; Imperial College London; MRC [MR/K010468/1] Funding Source: UKRI; Medical Research Council [MR/K010468/1, G1000758B, G1000758] Funding Source: researchfish; Asthma UK [MRC-Asthma UK Centre, MRC-AsthmaUKCentre] Funding Source: researchfish	Slovenian Research Agency(Slovenian Research Agency - Slovenia); Clinician Scientist award - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust; Imperial College London(General Electric); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Asthma UK	P. Korosec, M.S., and M.K. applied for European Patent Application No. 13164630.9. P. Korosec, M.K., and M.R. are supported by the Slovenian Research Agency (reference P3-0360). P.J.T. is in receipt of a Clinician Scientist award funded by the UK Medical Research Council (reference MR/K010468/1). Some of the clinical work in this project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 312147 (Integrated Approaches to Food Allergen and Allergy Risk Management [iFAAM]). B.F.G. is in receipt of an award funded by the UK Medical Research Council (reference WM/3306381). P.J.T. and A.C. are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, NIHR, or the Department of Health.	Beyer K, 1998, INT ARCH ALLERGY IMM, V116, P110, DOI 10.1159/000023933; BOCHNER BS, 1989, J IMMUNOL, V142, P3180; Celesnik N, 2012, ALLERGY, V67, P1594, DOI 10.1111/all.12044; Commins SP, 2014, J ALLERGY CLIN IMMUN, V134, P108, DOI 10.1016/j.jaci.2014.01.024; Didichenko SA, 2008, BLOOD, V112, P3949, DOI 10.1182/blood-2008-04-149419; DUNSKY EH, 1979, J ALLERGY CLIN IMMUN, V63, P426, DOI 10.1016/0091-6749(79)90217-3; EBISAWA M, 1994, J IMMUNOL, V153, P2153; Eckl-Dorna J, 2012, ALLERGY, V67, P601, DOI 10.1111/j.1398-9995.2012.02792.x; Eckman JA, 2010, J ALLERGY CLIN IMMUN, V125, P889, DOI 10.1016/j.jaci.2009.09.012; Erzen R, 2012, ALLERGY, V67, P822, DOI 10.1111/j.1398-9995.2012.02817.x; Iikura M, 2004, J IMMUNOL, V173, P5189, DOI 10.4049/jimmunol.173.8.5189; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354, DOI 10.1016/S0091-6749(98)70248-9; Knol EF, 2012, ALLERGY, V67, P579, DOI 10.1111/j.1398-9995.2012.02816.x; Korosec P, 2009, CLIN EXP ALLERGY, V39, P1730, DOI 10.1111/j.1365-2222.2009.03347.x; Kuramasu A, 1998, J BIOL CHEM, V273, P31607, DOI 10.1074/jbc.273.47.31607; Lilla JN, 2011, BLOOD, V118, P6930, DOI 10.1182/blood-2011-03-343962; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; MacGlashan DW, 2013, J ALLERGY CLIN IMMUN, V132, P777, DOI 10.1016/j.jaci.2013.06.038; McLean-Tooke A, 2014, J CLIN PATHOL, V67, P134, DOI 10.1136/jclinpath-2013-201769; Muller UR., 1990, INSECT STING ALLERGY; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; Nouri-Aria KT, 2001, J ALLERGY CLIN IMMUN, V108, P205, DOI 10.1067/mai.2001.117175; SAAVEDRADELGADO AMP, 1980, J ALLERGY CLIN IMMUN, V66, P464, DOI 10.1016/0091-6749(80)90007-X; Salter BM, 2015, J ALLERGY CLIN IMMUN, V136, P1636, DOI 10.1016/j.jaci.2015.03.039; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SAMPSON HA, 1989, NEW ENGL J MED, V321, P228, DOI 10.1056/NEJM198907273210405; Sampson HA, 2012, J ALLERGY CLIN IMMUN, V130, P1260, DOI 10.1016/j.jaci.2012.10.017; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P179, DOI 10.1016/j.jaci.2014.09.001; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; Shamji MH, 2015, ALLERGY, V70, P171, DOI 10.1111/all.12543; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI [10.1016/j.jaci.2007.05.001, 10.1016/j.jaci.2007.05.016]; Simons FER, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-9; Siracusa MC, 2013, J ALLERGY CLIN IMMUN, V132, P789, DOI 10.1016/j.jaci.2013.07.046; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Stone SF, 2009, J ALLERGY CLIN IMMUN, V124, P786, DOI 10.1016/j.jaci.2009.07.055; Suzukawa M, 2005, INT IMMUNOL, V17, P1249, DOI 10.1093/intimm/dxh301; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Turner PJ, 2016, ALLERGY, V71, P1241, DOI 10.1111/all.12924; Turner PJ, 2015, J ALLERGY CLIN IMMUN, V135, pAB33, DOI 10.1016/j.jaci.2014.12.1037; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Vadas P, 2013, J ALLERGY CLIN IMMUN, V131, P144, DOI 10.1016/j.jaci.2012.08.016; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; VANDERLINDEN PWG, 1993, BLOOD, V82, P1740	49	39	39	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					750	+		10.1016/j.jaci.2016.12.989	http://dx.doi.org/10.1016/j.jaci.2016.12.989			24	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28342911	Green Published, Green Submitted, hybrid			2022-12-18	WOS:000409241500014
J	Silkoff, PE; Laviolette, M; Singh, D; FitzGerald, JM; Kelsen, S; Backer, V; Porsbjerg, CM; Girodet, PO; Berger, P; Kline, JN; Chupp, G; Susulic, VS; Barnathan, ES; Baribaud, F; Loza, MJ				Silkoff, Philip E.; Laviolette, Michel; Singh, Dave; FitzGerald, J. Mark; Kelsen, Steven; Backer, Vibeke; Porsbjerg, Celeste M.; Girodet, Pierre-Olivier; Berger, Patrick; Kline, Joel N.; Chupp, Geoffrey; Susulic, Vedrana S.; Barnathan, Elliot S.; Baribaud, Frederic; Loza, Matthew J.		Airways Dis Endotyping Personalize	Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; type 2 inflammation; phenotypes; airway mucosal gene expression; biomarkers	EXHALED NITRIC-OXIDE; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; EXPRESSION; EOTAXIN; EOSINOPHILS; MEPOLIZUMAB; VALIDATION; PERIOSTIN; CYTOKINES	Background: The Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study profiled patients with mild, moderate, and severe asthma and nonatopic healthy control subjects. Objective: We explored this data set to define type 2 inflammation based on airway mucosal IL-13-driven gene expression and how this related to clinically accessible biomarkers. Methods: IL-13-driven gene expression was evaluated in several human cell lines. We then defined type 2 status in 25 healthy subjects, 28 patients with mild asthma, 29 patients with moderate asthma, and 26 patients with severe asthma based on airway mucosal expression of (1) CCL26 (the most differentially expressed gene), (2) periostin, or (3) a multigene IL-13 in vitro signature (IVS). Clinically accessible biomarkers included fraction of exhaled nitric oxide (FENO) values, blood eosinophil (bEOS) counts, serum CCL26 expression, and serum CCL17 expression. Results: Expression of airway mucosal CCL26, periostin, and IL-13-IVS all facilitated segregation of subjects into type 2-high and type 2-low asthmatic groups, but in the ADEPT study population CCL26 expression was optimal. All subjects with high airway mucosal CCL26 expression and moderate-to-severe asthma had FENO values (>= 35 ppb) and/or high bEOS counts (>= 300 cells/mm(3)) compared with a minority (36%) of subjects with low airway mucosal CCL26 expression. A combination of FENO values, bEOS counts, and serum CCL17 and CCL26 expression had 100% positive predictive value and 87% negative predictive value for airway mucosal CCL26-high status. Clinical variables did not differ between subjects with type 2-high and type 2-low status. Eosinophilic inflammation was associated with but not limited to airway mucosal type 2 gene expression. Conclusion: A panel of clinical biomarkers accurately classified type 2 status based on airway mucosal CCL26, periostin, or IL13-IVS gene expression. Use of FENO values, bEOS counts, and serum marker levels (eg, CCL26 and CCL17) in combination might allow patient selection for novel type 2 therapeutics.	[Silkoff, Philip E.; Susulic, Vedrana S.; Barnathan, Elliot S.; Baribaud, Frederic; Loza, Matthew J.] Janssen Res & Dev LLC, Spring House, PA USA; [Laviolette, Michel] IUCPQ, Quebec City, PQ, Canada; [Singh, Dave] Univ Manchester, Ctr Resp Med & Allergy, Manchester, Lancs, England; [Singh, Dave] Univ Hosp South Manchester NHS Fdn Trust, Med Evaluat Unit, Manchester, Lancs, England; [FitzGerald, J. Mark] Gordon & Leslie Diamond Hlth Care Ctr, Lung Ctr, Inst Heart & Lung Hlth, Vancouver, BC, Canada; [Kelsen, Steven] Temple Univ, Sch Med, Dept Thorac Med & Surg, Philadelphia, PA USA; [Backer, Vibeke; Porsbjerg, Celeste M.] Bispebjerg Hosp, Dept Resp Med, Resp Res Unit, Copenhagen, Denmark; [Girodet, Pierre-Olivier; Berger, Patrick] uniborUniv Bordeaux, Ctr Rech Cardiothorac Bordeaux, Bordeaux, France; [Kline, Joel N.] Univ Iowa, Div Pulm Crit Care & Occupat Med, Iowa City, IA USA; [Chupp, Geoffrey] Yale Sch Med, New Haven, CT USA	Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Laval University; University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Copenhagen; Bispebjerg Hospital; University of Iowa; Yale University	Silkoff, PE (corresponding author), 715 Bryn Mawr Ave, Penn Valley, PA 19072 USA.	philsilkoff@gmail.com	Backer, Vibeke/AAQ-9379-2021; Singh, Dave/AAH-4342-2020; Berger, Patrick/D-8779-2012	Singh, Dave/0000-0001-8918-7075; Berger, Patrick/0000-0003-4702-0343; Porsbjerg, Celeste/0000-0003-4825-9436; chanez, pascal/0000-0003-4059-0917; Calhoun, William/0000-0001-7075-712X; Loza, Matthew/0000-0002-8609-118X; kline, joel/0000-0002-5523-8855; Girodet, Pierre-Olivier/0000-0002-9298-9711	Janssen R&D, Spring House, Pa; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER	Janssen R&D, Spring House, Pa; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by Janssen R&D, Spring House, Pa.	Alving K, 2010, EUR RESPIR MONOGR, P1, DOI 10.1183/1025448x.00028509; [Anonymous], 2000, Am J Respir Crit Care Med, V162, P2341; Barros R, 2008, ALLERGY, V63, P917, DOI 10.1111/j.1398-9995.2008.01665.x; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; Castro M, 2014, LANCET RESP MED, V2, P879, DOI 10.1016/S2213-2600(14)70201-2; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Coleman JM, 2012, THORAX, V67, P1061, DOI 10.1136/thoraxjnl-2012-201634; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cowan DC, 2010, RESPIROLOGY, V15, P683, DOI 10.1111/j.1440-1843.2010.01740.x; Fahy JV, 2015, NAT REV IMMUNOL, V15, P57, DOI 10.1038/nri3786; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Jana AS, 2005, CHEST, V128, P1140; Alvarez-Gutierrez FJ, 2010, ARCH BRONCONEUMOL, V46, P370, DOI 10.1016/j.arbres.2010.04.003; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; Karta MR, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-015-0581-6; Kelly MM, 2001, METH MOLEC MED, V56, P77, DOI 10.1385/1-59259-151-5:77; Komiya A, 2003, CELL IMMUNOL, V225, P91, DOI 10.1016/j.cellimm.2003.10.001; Larose MC, 2015, J ALLERGY CLIN IMMUN, V136, P904, DOI 10.1016/j.jaci.2015.02.039; Li GH, 2006, ATHEROSCLEROSIS, V188, P292, DOI 10.1016/j.atherosclerosis.2005.11.002; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Loza MJ, 2002, J IMMUNOL, V169, P3061, DOI 10.4049/jimmunol.169.6.3061; Loza MJ, 2001, NAT IMMUNOL, V2, P917, DOI 10.1038/ni1001-917; Malinovschi A, 2013, J ALLERGY CLIN IMMUN, V132, P821, DOI 10.1016/j.jaci.2013.06.007; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; Nomura T, 2002, CYTOKINE, V20, P49, DOI 10.1006/cyto.2002.1979; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Peters MC, 2014, J ALLERGY CLIN IMMUN, V133, P388, DOI 10.1016/j.jaci.2013.07.036; Provost V, 2013, J LEUKOCYTE BIOL, V94, P213, DOI 10.1189/jlb.0212074; Silkoff PE, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0299-y; Syed F, 2007, BIOMARKERS, V12, P414, DOI 10.1080/13547500701192652; Teran LM, 1999, AM J RESP CELL MOL, V20, P777, DOI 10.1165/ajrcmb.20.4.3508; van Hartingsveldt B, 2013, BRIT J CLIN PHARMACO, V75, P1289, DOI 10.1111/j.1365-2125.2012.04477.x; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC	42	39	40	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2017	140	3					710	719		10.1016/j.jaci.2016.11.038	http://dx.doi.org/10.1016/j.jaci.2016.11.038			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FF8CA	28089872	Bronze			2022-12-18	WOS:000409241500010
J	Homann, A; Schramm, G; Jappe, U				Homann, Arne; Schramm, Gabriele; Jappe, Uta			Glycans and glycan-specific IgE in clinical and molecular allergology: Sensitization, diagnostics, and clinical symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cross-reactive carbohydrate determinants; galactose-alpha-(1,3)-galactose; anti-glycan IgE; anaphylaxis; clinical allergology; molecular allergology; Schistosoma species; parasite immunomodulation	REACTIVE CARBOHYDRATE DETERMINANTS; C-TYPE LECTIN; SCHISTOSOMA-MANSONI SYNTHESIZES; DENDRITIC CELLS; ANTIBODY-RESPONSES; MASS-SPECTROMETRY; DC-SIGN; STRUCTURAL-CHARACTERIZATION; ANTIINFLAMMATORY ACTIVITY; LINKED OLIGOSACCHARIDES	Glycan-specific IgE antibodies cross-react with highly similar or even identical carbohydrate structures on a variety of different natural allergens, the so-called cross-reactive carbohydrate determinants (CCDs). In clinical practice CCDs often interfere with the specificity of in vitro allergy diagnostics, thus impairing allergy therapy decisions for individual patients. Strikingly, these IgE antibodies directed against CCDs often do not cause clinically relevant allergy symptoms. On the other hand, the IgE-binding glycan allergen galactose-alpha-(1,3)-galactose (alpha-Gal) is associated with IgE-mediated delayed anaphylaxis in meat allergy. The reason for this discrepancy is not known. The discovery of -Gal stimulated new discussions and investigations regarding the relevance of anti-glycan IgE for allergic diseases. In this review the effect of glycans and glycanspecific IgE on sensitization to allergens and allergy diagnosis is described. Because parasite infections elicit a similar immunologic environment as allergic diseases, the association of glycan-specific antibodies against parasite glycoproteins with glycan structures on allergens is discussed	[Homann, Arne; Jappe, Uta] Univ Lubeck, Div Clin & Mol Allergol, Prior Res Area Asthma & Allergy, ARCN,German Ctr Lung Res DZL, Lubeck, Germany; [Schramm, Gabriele] Univ Lubeck, Div Expt Pneumol, Prior Res Area Asthma & Allergy, Res Ctr Borstel, Lubeck, Germany; [Jappe, Uta] Univ Lubeck, Interdisciplinary Allergy Outpatient Clin, Lubeck, Germany	University of Lubeck; University of Lubeck; University of Lubeck	Jappe, U (corresponding author), Res Ctr Borstel, Div Clin & Mol Allergol, Pk Allee 35, D-23845 Borstel, Germany.	ujappe@fz-borstel.de			Aif ZIM (Federal Ministry of Economy and Technology); Federal Ministry of Research and Education (BMBF); German Research Foundation; Fraunhofer-Zukunftsstiftung	Aif ZIM (Federal Ministry of Economy and Technology); Federal Ministry of Research and Education (BMBF)(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG)); Fraunhofer-Zukunftsstiftung	U. Jappe's institution received a grant from Aif ZIM (Federal Ministry of Economy and Technology) for this work and grants from the Federal Ministry of Research and Education (BMBF) and German Research Foundation for other works and fees for lectures from Chiesi and Allergopharma, and U. Jappe personally received consultancy fees from Fraunhofer-Zukunftsstiftung and accommodations from ALK-Abello. The rest of the other authors declare that they have no relevant conflicts of interest.	Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akdis M, 2014, J ALLERGY CLIN IMMUN, V133, P621, DOI 10.1016/j.jaci.2013.12.1088; Al-Ghouleh A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033929; Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Amoah AS, 2013, J ALLERGY CLIN IMMUN, V132, P639, DOI 10.1016/j.jaci.2013.04.023; [Anonymous], 2015, SURFACE EXPRESSION P; Apostolovic D, 2015, ALLERGY, V70, P1497, DOI 10.1111/all.12695; Ayoub D, 2013, MABS-AUSTIN, V5, P699, DOI 10.4161/mabs.25423; Becker Y, 2006, VIRUS GENES, V33, P235, DOI 10.1007/s11262-006-0064-x; Behrendt H, 2014, CHEM IMMUNOL ALLERGY, V100, P268, DOI 10.1159/000359918; Bencurova M, 2004, GLYCOBIOLOGY, V14, P457, DOI 10.1093/glycob/cwh058; Bochner BS, 2015, J ALLERGY CLIN IMMUN, V135, P598, DOI 10.1016/j.jaci.2014.11.031; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Brehler R, 2013, CURR OPIN ALLERGY CL, V13, P360, DOI 10.1097/ACI.0b013e328362c544; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Colley DG, 2014, PARASITE IMMUNOL, V36, P347, DOI 10.1111/pim.12087; Collin M, 2013, EXP DERMATOL, V22, P511, DOI 10.1111/exd.12171; Commins SP, 2015, CURR ALLERGY ASTHM R, V15, DOI 10.1007/s11882-014-0492-y; Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; de Boer AR, 2008, GLYCOCONJUGATE J, V25, P75, DOI 10.1007/s10719-007-9100-x; DEMEURE CE, 1993, J INFECT DIS, V168, P1000, DOI 10.1093/infdis/168.4.1000; der Kleij DV, 2002, J INFECT DIS, V185, P531; Doenhoff MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159542; Dullaers M, 2012, J ALLERGY CLIN IMMUN, V129, P635, DOI 10.1016/j.jaci.2011.10.029; Eberlein B, 2012, J ALLERGY CLIN IMMUN, V130, P155, DOI 10.1016/j.jaci.2012.02.008; Emara M, 2011, J BIOL CHEM, V286, P13033, DOI 10.1074/jbc.M111.220657; Everts B, 2012, J EXP MED, V209, P1753, DOI 10.1084/jem.20111381; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Frank S, 2012, GLYCOBIOLOGY, V22, P676, DOI 10.1093/glycob/cws004; GALILI U, 1988, J BIOL CHEM, V263, P17755; Ganley-Leal LM, 2006, AM J TROP MED HYG, V75, P1053, DOI 10.4269/ajtmh.2006.75.1053; Geijtenbeek TBH, 2002, J LEUKOCYTE BIOL, V71, P921; Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569; Ghaderi D, 2010, NAT BIOTECHNOL, V28, P863, DOI 10.1038/nbt.1651; Gonzalez-Quintela A, 2008, CLIN EXP ALLERGY, V38, P152, DOI 10.1111/j.1365-2222.2007.02863.x; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Gryseels B, 2012, INFECT DIS CLIN N AM, V26, P383, DOI 10.1016/j.idc.2012.03.004; Haas H, 1999, EUR J IMMUNOL, V29, P918, DOI 10.1002/(SICI)1521-4141(199903)29:03&lt;918::AID-IMMU918&gt;3.0.CO;2-T; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; Harn DA, 2009, IMMUNOL REV, V230, P247, DOI 10.1111/j.1600-065X.2009.00799.x; Holzweber F, 2013, ALLERGY, V68, P1269, DOI 10.1111/all.12229; Homann A, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-90; Homann A, 2010, BEILSTEIN J ORG CHEM, V6, DOI 10.3762/bjoc.6.24; Homann A, 2009, NAT PROD REP, V26, P1555, DOI 10.1039/b909990p; Hsu SC, 2007, J ALLERGY CLIN IMMUN, V119, P1522, DOI 10.1016/j.jaci.2007.01.034; James L. K., 2016, POTENTIAL MECH IGG4; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Jappe U, 2012, HAUTARZT, V63, P299, DOI 10.1007/s00105-011-2266-y; Jappe U, 2013, ALLERGO J, V22, P25, DOI 10.1007/s15007-013-0015-5; Jin C, 2008, J ALLERGY CLIN IMMUN, V121, P185, DOI 10.1016/j.jaci.2007.07.047; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862; Kleine-Tebbe J, 2015, ALLERGO J, V24, P33, DOI 10.1007/s40629-015-0067-z; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; Kumar S, 2013, J PROTEOMICS, V93, P50, DOI 10.1016/j.jprot.2013.02.003; Linneberg A, 2010, INT ARCH ALLERGY IMM, V153, P86, DOI 10.1159/000301583; Looney TJ, 2016, J ALLERGY CLIN IMMUN, V137, P579, DOI 10.1016/j.jaci.2015.07.014; Lu MF, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003339; MacDonald AS, 2002, INFECT IMMUN, V70, P427, DOI 10.1128/IAI.70.2.427-433.2002; MacGlashan D, 2016, J ALLERGY CLIN IMMUN, V137, P1256, DOI 10.1016/j.jaci.2015.10.043; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Maizels RM, 2012, ANTICARBOHYDRATE ANT, P161; Malandain H, 2005, Eur Ann Allergy Clin Immunol, V37, P122; Mari A, 2008, ALLERGY, V63, P891, DOI 10.1111/j.1398-9995.2008.01703.x; Martinez-Pomares L, 2012, J LEUKOCYTE BIOL, V92, P1177, DOI 10.1189/jlb.0512231; Medzhitov R, 2012, SCIENCE, V335, P936, DOI 10.1126/science.1214935; Meevissen MHJ, 2012, INT J PARASITOL, V42, P269, DOI 10.1016/j.ijpara.2012.01.004; Meevissen MHJ, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005710; Meevissen MHJ, 2010, J PROTEOME RES, V9, P2630, DOI 10.1021/pr100081c; Meyer NH, 2015, J BIOL CHEM, V290, P22111, DOI 10.1074/jbc.M115.675066; Mullins RJ, 2012, J ALLERGY CLIN IMMUN, V129, P1334, DOI 10.1016/j.jaci.2012.02.038; Mwinzi PNM, 2009, J INFECT DIS, V199, P272, DOI 10.1086/595792; Naus CWA, 2003, INFECT IMMUN, V71, P5676, DOI 10.1128/IAI.71.10.5676-5681.2003; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; Nyame AK, 1999, GLYCOBIOLOGY, V9, P1029, DOI 10.1093/glycob/9.10.1029; Nyame AK, 2003, EXP PARASITOL, V104, P1, DOI 10.1016/S0014-4894(03)00110-3; Nyame AK, 1996, EXP PARASITOL, V82, P191, DOI 10.1006/expr.1996.0024; Nyame AK, 2000, EXP PARASITOL, V96, P202, DOI 10.1006/expr.2000.4573; Oefner CM, 2012, J ALLERGY CLIN IMMUN, V129, P1647, DOI 10.1016/j.jaci.2012.02.037; Okano M, 1999, J IMMUNOL, V163, P6712; Pearce OMT, 2016, GLYCOBIOLOGY, V26, P111, DOI 10.1093/glycob/cwv097; Qian J, 2007, ANAL BIOCHEM, V364, P8, DOI 10.1016/j.ab.2007.01.023; Rispens T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055566; Rispens T, 2009, J IMMUNOL, V182, P4275, DOI 10.4049/jimmunol.0804338; ROMANO C, 1995, CLIN EXP ALLERGY, V25, P643, DOI 10.1111/j.1365-2222.1995.tb01112.x; Roncati L, 2013, FORENSIC SCI INT, V228, pE28, DOI 10.1016/j.forsciint.2013.02.036; Royer PJ, 2010, J IMMUNOL, V185, P1522, DOI 10.4049/jimmunol.1000774; Salazar F, 2013, J ALLERGY CLIN IMMUN, V132, P27, DOI 10.1016/j.jaci.2013.02.001; Samraj AN, 2015, P NATL ACAD SCI USA, V112, P542, DOI 10.1073/pnas.1417508112; Santos AF, 2015, J ALLERGY CLIN IMMUN, V135, P1249, DOI 10.1016/j.jaci.2015.01.012; Schramm G, 2009, MOL BIOCHEM PARASIT, V166, P4, DOI 10.1016/j.molbiopara.2009.02.003; Schramm G, 2010, MICROBES INFECT, V12, P881, DOI 10.1016/j.micinf.2010.06.001; Sharquie IK, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-54; Shreffler WG, 2006, J IMMUNOL, V177, P3677, DOI 10.4049/jimmunol.177.6.3677; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; SRIVATSAN J, 1992, J BIOL CHEM, V267, P20196; Stacey M, 2003, BLOOD, V102, P2916, DOI 10.1182/blood-2002-11-3540; Stadlmann J, 2008, PROTEOMICS, V8, P2858, DOI 10.1002/pmic.200700968; Subbarayal B, 2013, ALLERGY, V68, P1377, DOI 10.1111/all.12236; Sundaram S, 2011, MABS-AUSTIN, V3, P505, DOI 10.4161/mabs.3.6.18090; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tangvoranuntakul P, 2003, P NATL ACAD SCI USA, V100, P12045, DOI 10.1073/pnas.2131556100; Uermosi C, 2014, ALLERGY, V69, P338, DOI 10.1111/all.12327; Van de Vijver KK, 2006, GLYCOBIOLOGY, V16, P237, DOI 10.1093/glycob/cwj058; van den Berg TK, 2004, J IMMUNOL, V173, P1902, DOI 10.4049/jimmunol.173.3.1902; van Die I, 2003, GLYCOBIOLOGY, V13, P471, DOI 10.1093/glycob/cwg052; van Liempt E, 2006, FEBS LETT, V580, P6123, DOI 10.1016/j.febslet.2006.10.009; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; van Remoortere A, 2003, EXP PARASITOL, V105, P219, DOI 10.1016/j.exppara.2003.12.005; van Stijn CMW, 2010, MOL IMMUNOL, V47, P1544, DOI 10.1016/j.molimm.2010.01.014; van Vliet SJ, 2008, IMMUNOL CELL BIOL, V86, P580, DOI 10.1038/icb.2008.55; van Vliet SJ, 2005, INT IMMUNOL, V17, P661, DOI 10.1093/intimm/dxh246; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VELUPILLAI P, 1994, P NATL ACAD SCI USA, V91, P18, DOI 10.1073/pnas.91.1.18; Vidal C, 2009, ALCOHOL CLIN EXP RES, V33, P1322, DOI 10.1111/j.1530-0277.2009.00961.x; Westphal S, 2003, EUR J BIOCHEM, V270, P1327, DOI 10.1046/j.1432-1033.2003.03503.x; Wolfert MA, 2013, NAT CHEM BIOL, V9, P776, DOI [10.1038/NCHEMBIO.1403, 10.1038/nchembio.1403]; Worm M, 2014, ALLERGO J, V23, P16, DOI 10.1007/s15007-014-0483-2; Wuhrer M, 2006, FEBS J, V273, P2276, DOI 10.1111/j.1742-4658.2006.05242.x; Yoshino TP, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001569; Zhang ZS, 1997, T ROY SOC TROP MED H, V91, P606, DOI 10.1016/S0035-9203(97)90047-X	125	39	39	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2017	140	2					356	368		10.1016/j.jaci.2017.04.019	http://dx.doi.org/10.1016/j.jaci.2017.04.019			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	FC5BK	28479330	Bronze			2022-12-18	WOS:000406855500004
J	Dullaers, M; Schuijs, MJ; Willart, M; Fierens, K; Van Moorleghem, J; Hammad, H; Lambrecht, BN				Dullaers, Melissa; Schuijs, Martijn J.; Willart, Monique; Fierens, Kaat; Van Moorleghem, Justine; Hammad, Hamida; Lambrecht, Bart N.			House dust mite-driven asthma and allergen-specific T cells depend on B cells when the amount of inhaled allergen is limiting	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic asthma; B cells; house dust mite; T(H)2 cells; antigen; presentation	ANTIGEN-PRESENTING CELLS; DELTA-CHAIN EXPRESSION; RESIDENT MEMORY CELLS; DENDRITIC CELLS; IN-VIVO; DEFICIENT MICE; AIRWAY HYPERRESPONSIVENESS; MEDIATED-IMMUNITY; EPITHELIAL-CELLS; TYPE-2 IMMUNITY	Background: Allergic asthma is a CD4 T(H)2-lymphocyte driven disease characterized by airway hyperresponsiveness and eosinophilia. B cells can present antigens to CD4 T cells and produce IgE immunoglobulins that arm effector cells; however, mouse models are inconclusive on whether B cells are necessary for asthma development. Objectives: We sought to address the role of B cells in a house dust mite (HDM)-driven T(H)2-high asthma mouse model. Methods: Wild-type and B cell-deficient muMT mice were sensitized and challenged through the airways with HDM extracts. The antigen-presenting capacities of B cells were studied by using new T-cell receptor transgenic 1-DER mice specific for the Der p 1 allergen. Results: In vitro-activated B cells from HDM-exposed mice presented antigen to 1-DER T cells and induced a T(H)2 phenotype. InvivoBcellswere dispensable for activation of naive 1-DERTcells but necessary for full expansion of primed 1-DER T cells. At high HDMchallenge doses, Bcells were not required for development of pulmonary asthmatic features yet contributed to T(H)2 expansion in themediastinal lymph nodes but not in the lungs. When theamount of challenge allergen was decreased, muMT mice had reduced asthma features. Under these limiting conditions, B cells contributed also to expansion of T(H)2 effector cells in the lungs and central memory T cells in the mediastinal lymph nodes. Conclusion: B cells are a major part of the adaptive immune response to inhaled HDM allergen, particularly when the amount of inhaled allergen is low, by expanding allergen-specific T cells.	[Dullaers, Melissa; Schuijs, Martijn J.; Willart, Monique; Fierens, Kaat; Van Moorleghem, Justine; Hammad, Hamida; Lambrecht, Bart N.] Univ Ghent, VIB Inflammat Res Ctr, Lab Immunoregulat & Mucosal Immunol, B-9050 Ghent, Belgium; [Dullaers, Melissa; Schuijs, Martijn J.; Willart, Monique; Fierens, Kaat; Van Moorleghem, Justine; Hammad, Hamida; Lambrecht, Bart N.] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [Lambrecht, Bart N.] ErasmusMC, Dept Pulm Med, Rotterdam, Netherlands	Flanders Institute for Biotechnology (VIB); Ghent University; Ghent University; Ghent University Hospital; Erasmus University Rotterdam; Erasmus MC	Lambrecht, BN (corresponding author), Univ Ghent, Lab Immunoregulat & Mucosal Immunol, VIB Inflammat Res Ctr, VIB, B-9050 Ghent, Belgium.	bart.lambrecht@ugent.be	Lambrecht, Bart N/K-2484-2014; Hammad, Hamida/J-9391-2015	Lambrecht, Bart N/0000-0003-4376-6834; Hammad, Hamida/0000-0003-3762-8603; Dullaers, Melissa/0000-0003-0223-230X	ERC consolidator grant; FP7 grant EUBIOPRED; FP7 grant MedALL; University of Ghent MRP grant (GROUP-ID consortium); FWO; Belspo Return Grant	ERC consolidator grant; FP7 grant EUBIOPRED; FP7 grant MedALL; University of Ghent MRP grant (GROUP-ID consortium); FWO(FWO); Belspo Return Grant	Supported by an ERC consolidator grant, FP7 grants EUBIOPRED and MedALL, a University of Ghent MRP grant (GROUP-ID consortium), and several FWO grants (to B.N.L.) and by a Belspo Return Grant, an FWO Post-Doc Fellowship, and an FWO personal grant (to M.D.).	Angeli V, 2006, IMMUNITY, V24, P203, DOI 10.1016/j.immuni.2006.01.003; Ballesteros-Tato A, 2016, IMMUNITY, V44, P259, DOI 10.1016/j.immuni.2015.11.017; Blackwell NM, 2001, INFECT IMMUN, V69, P3860, DOI 10.1128/IAI.69.6.3860-3868.2001; Bradley LM, 2002, EUR J IMMUNOL, V32, P2338, DOI 10.1002/1521-4141(200208)32:8<2338::AID-IMMU2338>3.0.CO;2-R; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Burrows KE, 2015, EUR J IMMUNOL, V45, P1116, DOI 10.1002/eji.201445163; CONSTANT S, 1995, J IMMUNOL, V155, P3734; Constant SL, 1999, J IMMUNOL, V162, P5695; Coquet JM, 2015, IMMUNITY, V43, P318, DOI 10.1016/j.immuni.2015.07.015; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Crawford A, 2006, J IMMUNOL, V176, P3498, DOI 10.4049/jimmunol.176.6.3498; Dodev TS, 2015, ALLERGY, V70, P720, DOI 10.1111/all.12607; Drake LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121660; Dullaers M, 2012, J ALLERGY CLIN IMMUN, V129, P635, DOI 10.1016/j.jaci.2011.10.029; Dwyer DF, 2014, J IMMUNOL, V193, P529, DOI 10.4049/jimmunol.1303247; FUCHS EJ, 1992, SCIENCE, V258, P1156, DOI 10.1126/science.1439825; Ghosh S, 2012, J IMMUNOL, V189, P1322, DOI 10.4049/jimmunol.1200138; Gloudemans AK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/542091; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Gregory LG, 2011, TRENDS IMMUNOL, V32, P402, DOI 10.1016/j.it.2011.06.006; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; Hamelmann E, 1997, P NATL ACAD SCI USA, V94, P1350, DOI 10.1073/pnas.94.4.1350; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Harris NL, 2002, J EXP MED, V195, P317, DOI 10.1084/jem.20011558; Hasan M, 2002, EUR J IMMUNOL, V32, P3463, DOI 10.1002/1521-4141(200212)32:12<3463::AID-IMMU3463>3.0.CO;2-B; Hernandez HJ, 1997, J IMMUNOL, V158, P4832; Hondowicz BD, 2016, IMMUNITY, V44, P155, DOI 10.1016/j.immuni.2015.11.004; Humbert M, 2014, J ALLER CL IMM-PRACT, V2, P525, DOI 10.1016/j.jaip.2014.03.010; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lambrecht BN, 2014, J ALLERGY CLIN IMMUN, V134, P499, DOI 10.1016/j.jaci.2014.06.036; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Leon B, 2012, NAT IMMUNOL, V13, P681, DOI 10.1038/ni.2309; Lindell DM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003129; Linton PJ, 2003, J EXP MED, V197, P875, DOI 10.1084/jem.20021290; Liu Q, 2007, J IMMUNOL, V179, P3821, DOI 10.4049/jimmunol.179.6.3821; MacLean JA, 1999, AM J RESP CELL MOL, V20, P379, DOI 10.1165/ajrcmb.20.3.3291; Macpherson AJS, 2001, NAT IMMUNOL, V2, P625, DOI 10.1038/89775; Neyt K, 2016, MUCOSAL IMMUNOL, V9, P999, DOI 10.1038/mi.2015.91; Payne R.W., 2009, GENSTAT WINDOWS INTR, V12th ed.; Perona-Wright G, 2008, J IMMUNOL, V181, P6697, DOI 10.4049/jimmunol.181.10.6697; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Rodriguez-Pinto D, 2005, EUR J IMMUNOL, V35, P1097, DOI 10.1002/eji.200425732; Sallmann E, 2011, J IMMUNOL, V187, P164, DOI 10.4049/jimmunol.1003392; Schuijs MJ, 2015, SCIENCE, V349, P1106, DOI 10.1126/science.aac6623; Schwarze J, 1998, AM J RESP CRIT CARE, V158, P519, DOI 10.1164/ajrccm.158.2.9801014; Serreze DV, 1998, J IMMUNOL, V161, P3912; TAYLORROBINSON AW, 1994, INFECT IMMUN, V62, P2490, DOI 10.1128/IAI.62.6.2490-2498.1994; Thomas WR, 2010, TRENDS MOL MED, V16, P321, DOI 10.1016/j.molmed.2010.04.008; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311	54	39	39	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2017	140	1					76	+		10.1016/j.jaci.2016.09.020	http://dx.doi.org/10.1016/j.jaci.2016.09.020			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EZ2LY	27746238	Bronze			2022-12-18	WOS:000404542000008
J	Noguchi, T; Nakagome, K; Kobayashi, T; Uchida, Y; Soma, T; Nakamoto, H; Nagata, M				Noguchi, Toru; Nakagome, Kazuyuki; Kobayashi, Takehito; Uchida, Yoshitaka; Soma, Tomoyuki; Nakamoto, Hidetomo; Nagata, Makoto			Periostin upregulates the effector functions of eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGIC INFLAMMATION; ACTIVATION; BIOMARKER; ASTHMA		[Noguchi, Toru; Nakagome, Kazuyuki; Kobayashi, Takehito; Uchida, Yoshitaka; Soma, Tomoyuki; Nagata, Makoto] Saitama Med Univ, Allergy Ctr, Saitama, Japan; [Noguchi, Toru; Nakagome, Kazuyuki; Kobayashi, Takehito; Uchida, Yoshitaka; Soma, Tomoyuki; Nagata, Makoto] Saitama Med Univ, Dept Resp Med, Saitama, Japan; [Noguchi, Toru; Kobayashi, Takehito; Nakamoto, Hidetomo] Saitama Med Univ, Dept Gen Internal Med, Saitama, Japan	Saitama Medical University; Saitama Medical University; Saitama Medical University	Nakagome, K (corresponding author), Saitama Med Univ, Allergy Ctr, Saitama, Japan.	nakagomek-tky@umin.ac.jp		Kobayashi, Takehito/0000-0001-6466-3434				Izuhara K, 2014, ALLERGOL INT, V63, P143, DOI 10.2332/allergolint.13-RAI-0663; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Johansson MW, 2013, CLIN EXP ALLERGY, V43, P292, DOI 10.1111/j.1365-2222.2012.04065.x; Johansson Mats W, 2013, Front Pharmacol, V4, P33, DOI 10.3389/fphar.2013.00033; Johansson MW, 2013, AM J RESP CELL MOL, V48, P503, DOI 10.1165/rcmb.2012-0150OC; Kanemitsu Y, 2013, J ALLERGY CLIN IMMUN, V132, P305, DOI 10.1016/j.jaci.2013.04.050; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Matsumoto H, 2014, ALLERGOL INT, V63, P153, DOI 10.2332/allergolint.13-RAI-0678; Shoda T, 2013, ALLERGY, V68, P1467, DOI 10.1111/all.12240; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Yang G, 2014, J ALLERGY CLIN IMMUN, V133, P1702, DOI 10.1016/j.jaci.2014.02.019; Yu XF, 2013, SCIENCE, V342, P727, DOI 10.1126/science.1243884; Zheng PY, 2009, GUT, V58, P1473, DOI 10.1136/gut.2009.181701	13	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1449	+		10.1016/j.jaci.2016.05.020	http://dx.doi.org/10.1016/j.jaci.2016.05.020			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27423493	Bronze			2022-12-18	WOS:000389542700029
J	Schwarz, A; Panetta, V; Cappella, A; Hofmaier, S; Hatzler, L; Rohrbach, A; Tsilochristou, O; Bauer, CP; Hoffmann, U; Forster, J; Zepp, F; Schuster, A; D'Amelio, R; Wahn, U; Keil, T; Lau, S; Matricardi, PM				Schwarz, Alina; Panetta, Valentina; Cappella, Antonio; Hofmaier, Stephanie; Hatzler, Laura; Rohrbach, Alexander; Tsilochristou, Olympia; Bauer, Carl-Peter; Hoffmann, Ute; Forster, Johannes; Zepp, Fred; Schuster, Antje; D'Amelio, Raffaele; Wahn, Ulrich; Keil, Thomas; Lau, Susanne; Matricardi, Paolo Maria			IgG and IgG(4) to 91 allergenic molecules in early childhood by route of exposure and current and future IgE sensitization: Results from the Multicentre Allergy Study birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergenic molecules; IgE sensitization; birth cohort; childhood; IgE; IgG; IgG(4); microarray; prediction	IMMUNOGLOBULIN-G ANTIBODIES; INHALANT ALLERGENS; NONATOPIC CHILDREN; HAY-FEVER; SERUM IGG; CAT; RESPONSES; POLLEN; INFANCY; BIRCH	Background: Studies of a limited number of allergens suggested that nonsensitized children produce IgG responses mainly to foodborne allergens, whereas IgE-sensitized children also produce strong IgG responses to the respective airborne molecules. Objective: We sought to systematically test the hypothesis that both the route of exposure and IgE sensitization affect IgG responses to a broad array of allergenic molecules in early childhood. Methods: We examined sera of 148 children participating in the Multicentre Allergy Study, a birth cohort born in 1990. IgG to 91 molecules of 42 sources were tested with the ImmunoCAP Solid-Phase Allergen Chip (ISAC; TFS, Uppsala, Sweden). IgE sensitization at age 2 and 7 years was defined by IgE levels of 0.35 kU(A)/L or greater to 1 or more of 8 or 9 extracts from common allergenic sources, respectively. Results: The prevalence and geometric mean levels of IgG to allergenic molecules in nonsensitized children were lower at age 2 years than in IgE-sensitized children, and they were extremely heterogeneous: highest for animal food (87% +/- 13%; 61 ISAC Standardized Units [ISU], [95% CI, 52.5-71.5 ISU]), intermediate for vegetable food (48% +/- 27%; 13 ISU [95% CI, 11.2-16.1 ISU]), and lowest for airborne allergens (24% +/- 20%; 3 ISU [95% CI, 2.4-3.4 ISU]; P for trend < .001 [for percentages], P for trend < .001 [for levels]). IgG(4) antibodies were infrequent (< 5%) and contributed poorly (< 3%) to overall IgG antibody levels. IgG responses at age 2 years were slightly more frequent and stronger among children with than in those without IgE sensitization at age 7 years. Conclusion: The children's repertoire of IgG antibodies at 2 years of age to a broad array of animal foodborne, vegetable foodborne, and airborne allergenic molecules is profoundly dependent on the route of allergen exposure and the child's IgE sensitization status and only marginally involves the IgG4 isotype.	[Schwarz, Alina; Hofmaier, Stephanie; Hatzler, Laura; Rohrbach, Alexander; Tsilochristou, Olympia; Wahn, Ulrich; Lau, Susanne; Matricardi, Paolo Maria] Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany; [Keil, Thomas] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Panetta, Valentina] Laltrastat Srl, Consultancy & Training, Biostat Off, Rome, Italy; [Cappella, Antonio; D'Amelio, Raffaele] Sapienza Univ Rome, S Andrea Univ Hosp, Dept Clin & Mol Med, Rome, Italy; [Bauer, Carl-Peter; Hoffmann, Ute] Tech Univ Munich, Dept Pediat, Munich, Germany; [Forster, Johannes] St Josefs Hosp, Dept Pediat St Hedwig, Freiburg, Germany; [Zepp, Fred] Univ Med Mainz, Dept Pediat, Mainz, Germany; [Schuster, Antje] Univ Dusseldorf, Dept Pediat, Dusseldorf, Germany; [Keil, Thomas] Univ Wurzburg, Inst Clin Epidemiol & Biometry, Wurzburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Technical University of Munich; Johannes Gutenberg University of Mainz; Heinrich Heine University Dusseldorf; University of Wurzburg	Matricardi, PM (corresponding author), Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	paolo.matricardi@charite.de	Dramburg, Stephanie/AAM-8340-2020	Tsilochristou, Olympia/0000-0002-4540-4602; Dramburg, Stephanie/0000-0002-9303-3260; Hatzler, Laura/0000-0001-8795-6205; Lau, Susanne/0000-0002-5189-4265	Deutsche Forschungsgemeinschaft (DFG) [MA-4740/1-1]; German Federal Ministry of Education and Research [07015633, 07 ALE 27, 01EE9405/5, 01EE9406]; German Research Foundation [KE 1462/2-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Research Foundation(German Research Foundation (DFG))	Supported by Deutsche Forschungsgemeinschaft (DFG) MA-4740/1-1. The Multicentre Allergy Study was funded by grants from the German Federal Ministry of Education and Research (07015633, 07 ALE 27, 01EE9405/5, and 01EE9406) and the German Research Foundation (KE 1462/2-1).	AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; Aalberse RC, 2000, AM J RESP CRIT CAR S, V162; Asarnoj A, 2008, CLIN EXP ALLERGY, V38, P1507, DOI 10.1111/j.1365-2222.2008.03046.x; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Buters J, 2015, J ALLERGY CLIN IMMUN, V136, P87, DOI 10.1016/j.jaci.2015.01.049; CALKHOVEN PG, 1991, CLIN EXP ALLERGY, V21, P99, DOI 10.1111/j.1365-2222.1991.tb00810.x; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; Curin M, 2014, J ALLERGY CLIN IMMUN, V133, P918, DOI 10.1016/j.jaci.2013.10.058; Eysink PED, 1999, CLIN EXP ALLERGY, V29, P604, DOI 10.1046/j.1365-2222.1999.00554.x; Eysink PED, 2002, CLIN EXP ALLERGY, V32, P556, DOI 10.1046/j.0954-7894.2002.01335.x; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Harfast B, 1998, PEDIATR ALLERGY IMMU, V9, P208, DOI 10.1111/j.1399-3038.1998.tb00375.x; Hatzler L, 2012, J ALLERGY CLIN IMMUN, V130, P894, DOI 10.1016/j.jaci.2012.05.053; Hesselmar B, 2003, CLIN EXP ALLERGY, V33, P1681, DOI 10.1111/j.1365-2222.2003.01821.x; Hofmaier S, 2015, J ALLERGY CLIN IMMUN, V135, P1367, DOI 10.1016/j.jaci.2014.09.048; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; HUSBY S, 1986, ALLERGY, V41, P379, DOI 10.1111/j.1398-9995.1986.tb00316.x; Jenmalm MC, 1999, PEDIATR ALLERGY IMMU, V10, P112, DOI 10.1034/j.1399-3038.1999.00015.x; Jonsson F, 2012, BLOOD, V119, P2533, DOI 10.1182/blood-2011-07-367334; JOHANSSON SG, 1969, P ROY SOC MED, V62, P975, DOI 10.1177/003591576906200947; KoloppSarda MN, 1997, CLIN EXP ALLERGY, V27, P1285, DOI [10.1046/j.1365-2222.1997.1490951.x, 10.1111/j.1365-2222.1997.tb01173.x]; Kukkonen AK, 2011, CLIN EXP ALLERGY, V41, P1414, DOI 10.1111/j.1365-2222.2011.03821.x; Lindmark-Mansson H, 2003, INT DAIRY J, V13, P409, DOI 10.1016/S0958-6946(03)00032-3; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Matricardi PM, 2009, CLIN EXP ALLERGY, V39, P1551, DOI 10.1111/j.1365-2222.2009.03348.x; ORGEL HA, 1975, J ALLERGY CLIN IMMUN, V56, P296, DOI 10.1016/0091-6749(75)90104-9; Orivuori L, 2014, PEDIAT ALLERG IMM-UK, V25, P329, DOI 10.1111/pai.12246; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Pomponi D, 2013, BRIT J DERMATOL, V168, P1205, DOI 10.1111/bjd.12161; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727, DOI 10.1136/adc.60.8.727; Shamji MH, 2011, CLIN EXP ALLERGY, V41, P1235, DOI 10.1111/j.1365-2222.2011.03804.x; Sverremark-Ekstrom E, 2012, PEDIAT ALLERG IMM-UK, V23, P224, DOI 10.1111/j.1399-3038.2012.01290.x; Thorisdottir B, 2014, ACTA PAEDIATR, V103, P512, DOI 10.1111/apa.12576; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI 10.1016/S0091-6749(03)02022-0; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x	38	39	39	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2016	138	5					1426	+		10.1016/j.jaci.2016.01.057	http://dx.doi.org/10.1016/j.jaci.2016.01.057			20	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	EE4AA	27264457	Bronze			2022-12-18	WOS:000389542700023
J	Bateman, ED; Goehring, UM; Richard, F; Watz, H				Bateman, Eric D.; Goehring, Udo-Michael; Richard, Frank; Watz, Henrik			Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; roflumilast; montelukast; phosphodiesterase 4 inhibitors	PHOSPHODIESTERASE-4 INHIBITOR ROFLUMILAST; QUESTIONNAIRE; SPUTUM	Background: Roflumilast, a selective phosphodiesterase 4 inhibitor, has been shown to provide modest improvements in lung function in patients with mild-to-moderate asthma, but its efficacy in patients with moderate-to-severe asthma has not been assessed. We hypothesized that this drug might provide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose symptoms are uncontrolled by inhaled corticosteroids and long-acting beta-agonists. Objective: We sought to examine the efficacy, safety, and mode of action of the addition of roflumilast and montelukast versus montelukast alone in patients with moderate-to-severe asthma. Methods: In a phase 2, randomized, double-blind, placebo-controlled, multiple-dose, 2-sequence, crossover study, 64 patients were randomized to receive 500 mu g of roflumilast plus montelukast followed by placebo plus 10 mg of montelukast (sequence AB) or placebo plus 10 mg of montelukast followed by 500 mu g of roflumilast plus 10 mg of montelukast (sequence BA). All patients had a diagnosis of bronchial asthma inadequately controlled by at least a medium-dose inhaled corticosteroid plus a long-acting beta-agonist. Results: The analysis of FEV1 change from baseline to week 4 showed a statistically significant and clinically meaningful treatment difference of 100 mL for roflumilast plus montelukast versus placebo plus montelukast. Also, improvements in patient-reported outcomes and a reduction in urinary leukotriene E-4 levels were observed during roflumilast plus montelukast treatment compared with placebo plus montelukast treatment. Adverse events were consistent with the known safety profile of roflumilast. Conclusion: The combination of roflumilast with montelukast compared with montelukast alone improved lung function and asthma control in patients with moderate-to-severe asthma and deserves further study for this indication.	[Bateman, Eric D.] Univ Cape Town, Dept Med, Div Pulmonol, George St, ZA-7700 Cape Town, South Africa; [Goehring, Udo-Michael] Takeda Pharmaceut Int GmbH, Zurich, Switzerland; [Richard, Frank] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Watz, Henrik] German Ctr Lung Res, Airway Res Ctr North, Pulm Res Inst Lung Clin Grosshansdorf, Grosshansdorf, Germany	University of Cape Town; Boehringer Ingelheim	Bateman, ED (corresponding author), Univ Cape Town, Dept Med, Div Pulmonol, George St, ZA-7700 Cape Town, South Africa.	Eric.Bateman@uct.ac.za		Richard, Frank/0000-0003-1027-3814	Takeda	Takeda(Takeda Pharmaceutical Company Ltd)	Medical writing support was provided by Caroline Loder of Synergy Vision (United Kingdom) and funded by Takeda.	Bateman ED, 2011, EUR RESPIR J, V38, P553, DOI 10.1183/09031936.00178710; Bateman ED, 2006, ANN ALLERG ASTHMA IM, V96, P679, DOI 10.1016/S1081-1206(10)61065-4; Bateman ED, 2015, J ALLERGY CLIN IMMUN, V136, P914, DOI 10.1016/j.jaci.2015.03.023; Bohmer GM, 2009, J CLIN PHARMACOL, V49, P389, DOI 10.1177/0091270008330980; Calverley PMA, 2009, LANCET, V374, P685, DOI 10.1016/S0140-6736(09)61255-1; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Essayan DM, 1999, BIOCHEM PHARMACOL, V57, P965, DOI 10.1016/S0006-2952(98)00331-1; Gauvreau GM, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-140; Grootendorst DC, 2007, THORAX, V62, P1081, DOI 10.1136/thx.2006.075937; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Martinez C, 2015, ARCH BRONCONEUMOL, V51, P105, DOI 10.1016/j.arbres.2014.05.005; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Normansell R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub4; Olin JT, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5517; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pedersen F, 2015, CYTOKINE, V71, P401, DOI 10.1016/j.cyto.2014.10.008; Rabinovitch N, 2014, J ALLERGY CLIN IMMUN, V133, P350, DOI 10.1016/j.jaci.2013.07.039; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; SCHUDT C, 1995, EUR RESPIR J, V8, P1179, DOI 10.1183/09031936.95.08071179; Szefler SJ, 2012, J ALLERGY CLIN IMMUN, V129, pS9, DOI 10.1016/j.jaci.2011.12.979; Theron AJ, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/608930; Timmer W, 2002, J CLIN PHARMACOL, V42, P297, DOI 10.1177/00912700222011328; van Schalkwyk E, 2005, J ALLERGY CLIN IMMUN, V116, P292, DOI 10.1016/j.jaci.2005.04.023; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578	26	39	44	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2016	138	1					142	+		10.1016/j.jaci.2015.11.035	http://dx.doi.org/10.1016/j.jaci.2015.11.035			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DR1IL	26915674	hybrid			2022-12-18	WOS:000379659100016
J	Amaral, AFS; Newson, RB; Abramson, MJ; Anto, JM; Bono, R; Corsico, AG; de Marco, R; Demoly, P; Forsberg, B; Gislason, T; Heinrich, J; Huerta, I; Janson, C; Jogi, R; Kim, JL; Maldonado, J; Rovira, JMM; Neukirch, C; Nowak, D; Pin, I; Probst-Hensch, N; Raherison-Semjen, C; Svanes, C; Landa, IU; van Ree, R; Versteeg, SA; Weyler, J; Zock, JP; Burney, PGJ; Jarvis, DL				Amaral, Andre F. S.; Newson, Roger B.; Abramson, Michael J.; Anto, Josep M.; Bono, Roberto; Corsico, Angelo G.; de Marco, Roberto; Demoly, Pascal; Forsberg, Bertil; Gislason, Thorarinn; Heinrich, Joachim; Huerta, Ismael; Janson, Christer; Jogi, Rain; Kim, Jeong-Lim; Maldonado, Jose; Rovira, Jesus Martinez-Moratalla; Neukirch, Catherine; Nowak, Dennis; Pin, Isabelle; Probst-Hensch, Nicole; Raherison-Semjen, Chantal; Svanes, Cecilie; Landa, Isabel Urrutia; van Ree, Ronald; Versteeg, Serge A.; Weyler, Joost; Zock, Jan-Paul; Burney, Peter G. J.; Jarvis, Deborah L.			Changes in IgE sensitization and total IgE levels over 20 years of follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergens; sensitization; cohort study; epidemiology; IgE; longitudinal analysis; aging; immunosenescence	RESPIRATORY-HEALTH-SURVEY; AEROALLERGEN SENSITIZATION; ALLERGIC SENSITIZATION; TEST REACTIVITY; AGE; PREVALENCE; COHORT; ASSOCIATION; POPULATION; REMISSION	Background: Cross-sectional studies have reported a lower prevalence of sensitization in older adults, but few longitudinal studies have examined whether this is an aging or a year-of-birth cohort effect. Objective: We sought to assess changes in sensitization and total IgE levels in a cohort of European adults as they aged over a 20-year period. Methods: Levels of serum specific IgE to common aeroallergens (house dust mite, cat, and grass) and total IgE levels were measured in 3206 adults from 25 centers in the European Community Respiratory Health Survey on 3 occasions over 20 years. Changes in sensitization and total IgE levels were analyzed by using regression analysis corrected for potential differences in laboratory equipment and by using inverse sampling probability weights to account for nonresponse. Results: Over the 20-year follow-up, the prevalence of sensitization to at least 1 of the 3 allergens decreased from 29.4% to 24.8% (-4.6%; 95% CI, -7.0% to -2.1%). The prevalence of sensitization to house dust mite (-4.3%; 95% CI, -6.0% to -2.6%) and cat (-2.1%; 95% CI, -3.6% to -0.7%) decreased more than sensitization to grass (-0.6%; 95% CI, -2.5% to 1.3%). Age-specific prevalence of sensitization to house dust mite and cat did not differ between year-of-birth cohorts, but sensitization to grass was most prevalent in the most recent ones. Overall, total IgE levels decreased significantly (geometric mean ratio, 0.63; 95% CI, 0.58-0.68) at all ages in all year-of-birth cohorts. Conclusion: Aging was associated with lower levels of sensitization, especially to house dust mite and cat, after the age of 20 years.	[Amaral, Andre F. S.; Newson, Roger B.; Burney, Peter G. J.; Jarvis, Deborah L.] Univ London Imperial Coll Sci Technol & Med, Resp Epidemiol Occupat Med & Publ Hlth, Natl Heart & Lung Inst, Emmanuel Kaye Bldg,1B Manresa Rd, London SW3 6LR, England; [Newson, Roger B.] Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Publ Hlth, Sch Publ Hlth, London, England; [Abramson, Michael J.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia; [Anto, Josep M.; Zock, Jan-Paul] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain; [Anto, Josep M.] IMIM Hosp del Mar, Med Res Inst, Barcelona, Spain; [Anto, Josep M.; Zock, Jan-Paul] UPF, Barcelona, Spain; [Anto, Josep M.; Zock, Jan-Paul] CIBERESP, Madrid, Spain; [Bono, Roberto] Univ Turin, Dept Publ Hlth & Pediat, Turin, Italy; [Corsico, Angelo G.] Univ Pavia, Div Resp Dis, IRCCS Policlin San Matteo Fdn, Via Palestro 3, I-27100 Pavia, Italy; [de Marco, Roberto] Univ Verona, Unit Epidemiol & Med Stat, Dept Publ Hlth & Community Med, I-37100 Verona, Italy; [Demoly, Pascal] CHU Montpellier, Dept Pulmonol, Div Allergy, Arnaud de Villeneuve Hosp, Paris, France; [Demoly, Pascal] INSERM, EPAR Team, UMR S 1136, Paris, France; [Forsberg, Bertil] Umea Univ, Div Occupat & Environm Med, Dept Publ Hlth & Clin Med, Umea, Sweden; [Gislason, Thorarinn] Univ Iceland, Fac Med, Reykjavik, Iceland; [Gislason, Thorarinn] Natl Univ Hosp Iceland, Landspitali, Dept Resp Med & Sleep, Reykjavik, Iceland; [Heinrich, Joachim] Helmholtz Zentrum, Inst Epidemiol 1, Munich, Germany; [Heinrich, Joachim; Nowak, Dennis] Univ Munich, Inst & Outpatient Clin Occupat Social & Environm, Inner City Clin, Univ Hosp Munich, Munich, Germany; [Huerta, Ismael] Dept Hlth Asturias, Directorate Gen Publ Hlth, Epidemiol Surveillance Sect, Oviedo, Spain; [Janson, Christer] Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Uppsala, Sweden; [Jogi, Rain] Tartu Univ Hosp, Lung Clin, Tartu, Estonia; [Kim, Jeong-Lim] Univ Gothenburg, Dept Publich Hlth & Community Med, Sahlgrenska Acad, Gothenburg, Sweden; [Maldonado, Jose] Univ Hosp Huelva, Unit Clin Management Pneumol & Allergy, Huelva, Spain; [Rovira, Jesus Martinez-Moratalla] Univ Hosp Albacete, Unit Pneumol, Albacete, Spain; [Neukirch, Catherine] INSERM, UMR1152, Paris, France; [Neukirch, Catherine] Univ Paris 07, UMR1152, Paris, France; [Nowak, Dennis] German Ctr Lung Res, Munich, Germany; [Pin, Isabelle] CHU Grenoble, Pole Couple Enfants, Pediat, F-38043 Grenoble, France; [Pin, Isabelle] Inst Albert Bonniot, INSERM, U823, Grenoble, France; [Pin, Isabelle] Univ Grenoble 1, Grenoble, France; [Probst-Hensch, Nicole] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Probst-Hensch, Nicole] Univ Basel, Basel, Switzerland; [Raherison-Semjen, Chantal] Bordeaux Univ, Inst Publ Hlth & Epidemiol, INSERM, U897, Bordeaux, France; [Svanes, Cecilie] Univ Bergen, Ctr Int Hlth, Bergen, Norway; [Svanes, Cecilie] Haukeland Hosp, Dept Occupat Med, N-5021 Bergen, Norway; [Landa, Isabel Urrutia] Galdakao Hosp, Dept Pneumol, Bizkaia, Spain; [van Ree, Ronald; Versteeg, Serge A.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Weyler, Joost] Univ Antwerp, Epidemiol & Social Med, B-2020 Antwerp, Belgium; [Weyler, Joost] Univ Antwerp, StatUA Stat Ctr, B-2020 Antwerp, Belgium	Imperial College London; Imperial College London; Monash University; Pompeu Fabra University; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; University of Turin; IRCCS Fondazione San Matteo; University of Pavia; University of Verona; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Umea University; University of Iceland; Landspitali National University Hospital; Helmholtz Association; University of Munich; University of Gothenburg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Basel; Swiss Tropical & Public Health Institute; University of Basel; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Bergen; University of Bergen; Haukeland University Hospital; Galdakao Hospital; University of Amsterdam; University of Amsterdam; University of Antwerp; University of Antwerp	Amaral, AFS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Resp Epidemiol Occupat Med & Publ Hlth, Natl Heart & Lung Inst, Emmanuel Kaye Bldg,1B Manresa Rd, London SW3 6LR, England.	a.amaral@imperial.ac.uk	Heinrich, Joachim/N-1720-2013; PIN, Isabelle/N-3020-2013; Bono, Roberto/J-8954-2012; Abramson, Michael/AAQ-2671-2020; Amaral, Andre FS/A-7662-2008; Anto, J M/H-2676-2014; Zock, Jan-Paul/P-5034-2018; Corsico, Angelo Guido/AAC-8138-2019; Demoly, Pascal/Y-9938-2019; Amaral, Andre F. S./M-4202-2019; Svanes, Cecilie/N-7556-2017; Weyler, Joost JJ/O-8594-2016	Heinrich, Joachim/0000-0002-9620-1629; Bono, Roberto/0000-0002-2471-6594; Abramson, Michael/0000-0002-9954-0538; Amaral, Andre FS/0000-0002-0369-9449; Anto, J M/0000-0002-4736-8529; Zock, Jan-Paul/0000-0002-2941-6259; Corsico, Angelo Guido/0000-0002-8716-4694; Demoly, Pascal/0000-0001-7827-7964; Amaral, Andre F. S./0000-0002-0369-9449; Svanes, Cecilie/0000-0001-8512-5192; Weyler, Joost JJ/0000-0001-7271-5492; Jarvis, Deborah/0000-0002-1753-3896; Burney, Peter/0000-0001-8635-5678	Australia (Melbourne): Allen and Hanbury's; Australia (Melbourne): National Health and Medical Research Council; Belgium (Antwerp City and Antwerp South): Belgian Science Policy Office; Belgium (Antwerp City and Antwerp South): National Fund for Scientific Research [G.0402.00]; Belgium (Antwerp City and Antwerp South): University of Antwerp; Belgium (Antwerp City and Antwerp South): Flemish Health Ministry; Belgium (Antwerp City and Antwerp South): Research Foundation of Flanders [G.0.410.08.N.10]; Estonia (Tartu): Estonian Science Foundation [1088 4350]; Estonia (Tartu): Estonian Ministry of Education [SF0180060s09]; France: Ministere de la Sante; France: Glaxo France; France: Insitut Pneumologique d'Aquitaine; France: Contrat de Plan Etat-Region Languedoc-Rousillon; France: CNMATS; France: CNMRT [90MR/10, 91AF/6]; France: Ministre Delegue de la Sante; France: RNSP; France: GSF; France: Programme Hospitalier de Recherche Clinique National; France (Bordeaux): Institut Pneumologique d'Aquitaine; France (Bordeaux): INSERM -Universite Bordeaux Segalen [U897]; France (Grenoble): Direction de la Recherche Clinique de Grenoble [2610]; France (Grenoble): Ministere de l'Emploi et de la Solidarite; France (Grenoble): Direction Generale de la Sante; France (Grenoble): CHU Grenoble; France (Grenoble): Comity des Maladies Respiratoires de l'Isere; France (Grenoble): Comity Scientifique AGIRadom; France (Montpellier): Aventis; France (Montpellier): Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon; France (Paris): Ministere de l'Emploi et de la Solidarite; France (Paris): Direction Generale de la Sante; France (Paris): Union Chimique Belge-Pharma; France (Paris): Aventis; France (Paris): Glaxo France; France (Paris): Agence Nationale de la Sante; France (Paris): Region Ile de France; France (Paris): Domaine d'interet majeur; Germany: Bundesminister fur Forschung and Technologie; Germany (Erfurt): DFG German Research Foundation [FR1526/1-1, HE 3294/10-1]; Germany (Hamburg): DFG German Research Foundation [MA 711/4-1, NO 262/7-1]; Iceland (Reykjavik): Icelandic Research Council; Iceland (Reykjavik): Icelandic University Hospital Fund; Iceland (Reykjavik): Landspitali University Hospital Research Fund; Iceland (Reykjavik): University of Iceland Research Fund; Iceland (Reykjavik): ResMed Foundation (California); Iceland (Reykjavik): Orkuveita Reykjavikur (geothermal plant); Iceland (Reykjavik): Vegageroin (Icelandic Road Administration [ICERA]); Italy: Ministero dell'Universita e della Ricerca Scientifica e Tecnologica; Italy: CNR; Italy: Regione Veneto [RSF381/05.93]; Italy: National Board of Health; Italy: CHIESI; Italy (Pavia): GlaxoSmithKline Italy; Italy (Pavia): Local University Funding for Research; Italy (Turin): Azienda Sanitaria Locale 4 Regione Piemonte; Italy (Turin): Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico-Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte; Italy (Turin): Department of Public Health and Pediatrics; Italy (Turin): University of Turin, Unit of Respiratory Medicine, National Health Service [ASL TO2]; Italy (Verona): Glaxo Wellcome Spa; Italy (Verona): Fondazione Cariverona; Italy (Verona): Education Ministry (MIUR); Norway (Bergen): Norwegian Research Council [101422/310, 214123]; Norway (Bergen): Norwegian Asthma and Allergy Association; Norway (Bergen): Glaxo Wellcome AS; Norway (Bergen): Norway Research Fund; Norway (Bergen): Western Norway Regional Health Authorities [911631]; Norway (Bergen): Bergen Medical Research Foundation; Spain: Ministerio de Sanidad y Consumo FIS [91/0016060/00E-05E, 93/0393, 97/0035-01, 99/0034-01, 99/0034-02]; Spain (Albacete): Hospital General de Albacete; Spain (Albacete): Hospital Universitario de Albacete; Spain (Albacete): Consejeria de Sanidad; Spain (Albacete): FIS [PS09/02457]; Spain (Barcelona): Sociedad Espanola de Neumologia y Cirugia Toracica; Spain (Barcelona): Public Health Service [R01 HL62633-01]; Spain (Barcelona): Consell Interdepartamental de Recerca i Innovacio Tecnologica [1999SGR-00241]; Spain (Barcelona): Instituto de Salud Carlos III; Spain (Barcelona): Red de Centros de Epidemiologia y Salud Publica [C03/09]; Spain (Barcelona): Red de Bases moleculares y fisiologicas de las Enfermedades Respiratorias [C03/011]; Spain (Barcelona): Red de Grupos Infancia y Medio Ambiente [G03/176]; Spain (Barcelona): FIS [PS09/00716]; Spain (Galdakao): Basque Health Department; Spain (Galdakao): FIS [09/01511]; Spain (Huelva): Hospital General Juan Ramon Jimenez; Spain (Huelva): FIS [PS09/02185]; Spain (Huelva): Servicio Andaluz de Salud; Spain (Oviedo): Consejeria de Sanidad Principado de Asturias; Spain (Oviedo): FIS [PS09/03190]; Sweden (Gothenburg, Umea, and Uppsala): Swedish Medical Research Council; Sweden (Gothenburg, Umea, and Uppsala): Swedish Heart-Lung Foundation; Sweden (Gothenburg, Umea, and Uppsala): Swedish Association against Asthma and Allergy; Sweden (Gothenburg, Umea, and Uppsala): Swedish Cancer and Allergy Foundation; Sweden (Gothenburg, Umea, and Uppsala): Swedish Council for Working Life and Social Research; Sweden (Umea): Vasterbotten Country Council ALF grant; Switzerland (Basel): Swiss National Science Foundation [33CS30-148470/1, 33CSCO-134276/1, 33CSCO-108796, 324730-135673, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099, PMPDP3-129021/1, PMPDP3-141671/1]; Federal Office for the Environment; Federal Office of Public Health; Federal Office of Roads and Transport; canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zurich; Swiss Lung League; canton's Lung League of Basel Stadt/Basel Landschaft, Geneva, Ticino, Valais, Graubunden, and Zurich; Stiftung ehemals Bundner Heilstatten; SUVA; Freiwillige Akademische Gesellschaft; UBS Wealth Foundation; Talecris Biotherapeutics GmbH; Abbott Diagnostics; European Commission [018996-GABRIEL]; Wellcome Trust [WT084703MA]; United Kingdom: Asthma UK; United Kingdom: Department of Health, South Thames Regional Health Authority; United Kingdom: Medical Research Council [G0901214/1]; European Commission; Medical Research Council [G0901214/1]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062633] Funding Source: NIH RePORTER; Medical Research Council [G0901214] Funding Source: researchfish; MRC [G0901214] Funding Source: UKRI	Australia (Melbourne): Allen and Hanbury's; Australia (Melbourne): National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Belgium (Antwerp City and Antwerp South): Belgian Science Policy Office; Belgium (Antwerp City and Antwerp South): National Fund for Scientific Research; Belgium (Antwerp City and Antwerp South): University of Antwerp; Belgium (Antwerp City and Antwerp South): Flemish Health Ministry; Belgium (Antwerp City and Antwerp South): Research Foundation of Flanders; Estonia (Tartu): Estonian Science Foundation; Estonia (Tartu): Estonian Ministry of Education; France: Ministere de la Sante; France: Glaxo France; France: Insitut Pneumologique d'Aquitaine; France: Contrat de Plan Etat-Region Languedoc-Rousillon(Region Occitanie); France: CNMATS; France: CNMRT; France: Ministre Delegue de la Sante; France: RNSP; France: GSF; France: Programme Hospitalier de Recherche Clinique National; France (Bordeaux): Institut Pneumologique d'Aquitaine; France (Bordeaux): INSERM -Universite Bordeaux Segalen; France (Grenoble): Direction de la Recherche Clinique de Grenoble; France (Grenoble): Ministere de l'Emploi et de la Solidarite; France (Grenoble): Direction Generale de la Sante; France (Grenoble): CHU Grenoble; France (Grenoble): Comity des Maladies Respiratoires de l'Isere; France (Grenoble): Comity Scientifique AGIRadom; France (Montpellier): Aventis; France (Montpellier): Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon; France (Paris): Ministere de l'Emploi et de la Solidarite; France (Paris): Direction Generale de la Sante; France (Paris): Union Chimique Belge-Pharma; France (Paris): Aventis; France (Paris): Glaxo France; France (Paris): Agence Nationale de la Sante(French National Research Agency (ANR)); France (Paris): Region Ile de France(Region Ile-de-France); France (Paris): Domaine d'interet majeur; Germany: Bundesminister fur Forschung and Technologie; Germany (Erfurt): DFG German Research Foundation; Germany (Hamburg): DFG German Research Foundation(German Research Foundation (DFG)); Iceland (Reykjavik): Icelandic Research Council; Iceland (Reykjavik): Icelandic University Hospital Fund; Iceland (Reykjavik): Landspitali University Hospital Research Fund; Iceland (Reykjavik): University of Iceland Research Fund; Iceland (Reykjavik): ResMed Foundation (California); Iceland (Reykjavik): Orkuveita Reykjavikur (geothermal plant); Iceland (Reykjavik): Vegageroin (Icelandic Road Administration [ICERA]); Italy: Ministero dell'Universita e della Ricerca Scientifica e Tecnologica; Italy: CNR; Italy: Regione Veneto; Italy: National Board of Health; Italy: CHIESI(Chiesi Pharmaceuticals Inc); Italy (Pavia): GlaxoSmithKline Italy; Italy (Pavia): Local University Funding for Research; Italy (Turin): Azienda Sanitaria Locale 4 Regione Piemonte; Italy (Turin): Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico-Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte; Italy (Turin): Department of Public Health and Pediatrics; Italy (Turin): University of Turin, Unit of Respiratory Medicine, National Health Service; Italy (Verona): Glaxo Wellcome Spa; Italy (Verona): Fondazione Cariverona; Italy (Verona): Education Ministry (MIUR); Norway (Bergen): Norwegian Research Council; Norway (Bergen): Norwegian Asthma and Allergy Association; Norway (Bergen): Glaxo Wellcome AS; Norway (Bergen): Norway Research Fund; Norway (Bergen): Western Norway Regional Health Authorities; Norway (Bergen): Bergen Medical Research Foundation; Spain: Ministerio de Sanidad y Consumo FIS; Spain (Albacete): Hospital General de Albacete; Spain (Albacete): Hospital Universitario de Albacete; Spain (Albacete): Consejeria de Sanidad; Spain (Albacete): FIS; Spain (Barcelona): Sociedad Espanola de Neumologia y Cirugia Toracica; Spain (Barcelona): Public Health Service; Spain (Barcelona): Consell Interdepartamental de Recerca i Innovacio Tecnologica; Spain (Barcelona): Instituto de Salud Carlos III; Spain (Barcelona): Red de Centros de Epidemiologia y Salud Publica; Spain (Barcelona): Red de Bases moleculares y fisiologicas de las Enfermedades Respiratorias; Spain (Barcelona): Red de Grupos Infancia y Medio Ambiente; Spain (Barcelona): FIS; Spain (Galdakao): Basque Health Department; Spain (Galdakao): FIS; Spain (Huelva): Hospital General Juan Ramon Jimenez; Spain (Huelva): FIS; Spain (Huelva): Servicio Andaluz de Salud; Spain (Oviedo): Consejeria de Sanidad Principado de Asturias; Spain (Oviedo): FIS; Sweden (Gothenburg, Umea, and Uppsala): Swedish Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Sweden (Gothenburg, Umea, and Uppsala): Swedish Heart-Lung Foundation; Sweden (Gothenburg, Umea, and Uppsala): Swedish Association against Asthma and Allergy; Sweden (Gothenburg, Umea, and Uppsala): Swedish Cancer and Allergy Foundation; Sweden (Gothenburg, Umea, and Uppsala): Swedish Council for Working Life and Social Research; Sweden (Umea): Vasterbotten Country Council ALF grant; Switzerland (Basel): Swiss National Science Foundation; Federal Office for the Environment; Federal Office of Public Health; Federal Office of Roads and Transport; canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zurich; Swiss Lung League; canton's Lung League of Basel Stadt/Basel Landschaft, Geneva, Ticino, Valais, Graubunden, and Zurich; Stiftung ehemals Bundner Heilstatten; SUVA; Freiwillige Akademische Gesellschaft; UBS Wealth Foundation; Talecris Biotherapeutics GmbH; Abbott Diagnostics(Abbott Laboratories); European Commission(European CommissionEuropean Commission Joint Research Centre); Wellcome Trust(Wellcome Trust); United Kingdom: Asthma UK; United Kingdom: Department of Health, South Thames Regional Health Authority; United Kingdom: Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Commission(European CommissionEuropean Commission Joint Research Centre); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Australia (Melbourne): Allen and Hanbury's and the National Health and Medical Research Council. Belgium (Antwerp City and Antwerp South): the Belgian Science Policy Office, National Fund for Scientific Research (G.0402.00), University of Antwerp, Flemish Health Ministry, and Research Foundation of Flanders (G.0.410.08.N.10). Estonia (Tartu): the Estonian Science Foundation (nos. 1088 4350) and Estonian Ministry of Education (SF0180060s09). France: Ministere de la Sante, Glaxo France, Insitut Pneumologique d'Aquitaine, Contrat de Plan Etat-Region Languedoc-Rousillon, CNMATS, CNMRT (90MR/10, 91AF/6), Ministre Delegue de la Sante, RNSP, GSF, and Programme Hospitalier de Recherche Clinique National 2010. France (Bordeaux): Institut Pneumologique d'Aquitaine and INSERM U897-Universite Bordeaux Segalen. France (Grenoble): Direction de la Recherche Clinique de Grenoble 2000 (no. 2610), Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, CHU Grenoble, Comity des Maladies Respiratoires de l'Isere, and Comity Scientifique AGIRadom 2011. France (Montpellier): Aventis and Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon. France (Paris): Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, Union Chimique Belge-Pharma, Aventis, Glaxo France, Agence Nationale de la Sante, Region Ile de France, and Domaine d'interet majeur. Germany: Bundesminister fur Forschung and Technologie. Germany (Erfurt): DFG German Research Foundation (FR1526/1-1, HE 3294/10-1). Germany (Hamburg): DFG German Research Foundation (MA 711/4-1, NO 262/7-1). Iceland (Reykjavik): Icelandic Research Council, Icelandic University Hospital Fund, Landspitali University Hospital Research Fund, University of Iceland Research Fund, ResMed Foundation (California), Orkuveita Reykjavikur (geothermal plant), and Vegageroin (Icelandic Road Administration [ICERA]). Italy: Ministero dell'Universita e della Ricerca Scientifica e Tecnologica, CNR, Regione Veneto (RSF381/05.93), National Board of Health, and CHIESI. Italy (Pavia): GlaxoSmithKline Italy and Local University Funding for Research, 1998 and 1999. Italy (Turin): Azienda Sanitaria Locale 4 Regione Piemonte, Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico-Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte, Department of Public Health and Pediatrics; University of Turin, Unit of Respiratory Medicine, National Health Service, ASL TO2. Italy (Verona): Glaxo Wellcome Spa, Fondazione Cariverona, and Education Ministry (MIUR); Norway (Bergen): Norwegian Research Council (no. 101422/310, no. 214123), Norwegian Asthma and Allergy Association, Glaxo Wellcome AS, Norway Research Fund, Western Norway Regional Health Authorities (no. 911631), and the Bergen Medical Research Foundation. Spain: Ministerio de Sanidad y Consumo FIS (no. 91/0016060/00E-05E, no. 93/0393, no. 97/0035-01, no. 99/0034-01, no. 99/0034-02). Spain (Albacete): Hospital General de Albacete, Hospital Universitario de Albacete, Consejeria de Sanidad, and FIS (PS09/02457). Spain (Barcelona): Sociedad Espanola de Neumologia y Cirugia Toracica, Public Health Service (R01 HL62633-01), Consell Interdepartamental de Recerca i Innovacio Tecnologica (no. 1999SGR-00241), Instituto de Salud Carlos III, Red de Centros de Epidemiologia y Salud Publica (C03/09), Red de Bases moleculares y fisiologicas de las Enfermedades Respiratorias (C03/011), Red de Grupos Infancia y Medio Ambiente (G03/176), and FIS (PS09/00716).; Spain (Galdakao): Basque Health Department and FIS (no. 09/01511). Spain (Huelva): Hospital General Juan Ramon Jimenez, FIS (PS09/02185), and Servicio Andaluz de Salud. Spain (Oviedo): Consejeria de Sanidad Principado de Asturias, FIS (PS09/03190). Sweden (Gothenburg, Umea, and Uppsala): the Swedish Medical Research Council, Swedish Heart-Lung Foundation, Swedish Association against Asthma and Allergy, Swedish Cancer and Allergy Foundation, and Swedish Council for Working Life and Social Research. Sweden (Umea): Also received funding from a Vasterbotten Country Council ALF grant. Switzerland (Basel): the Swiss National Science Foundation (no. 33CS30-148470/1, no. 33CSCO-134276/1, no. 33CSCO-108796, no. 324730-135673, no. 3247BO-104283, no. 3247BO-104288, no. 3247BO-104284, no. 3247-065896, no. 3100-059302, no. 3200-052720, no. 3200-042532, no. 4026-028099, PMPDP3-129021/1, PMPDP3-141671/1); the Federal Office for the Environment; the Federal Office of Public Health; the Federal Office of Roads and Transport; the canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zurich; the Swiss Lung League; the canton's Lung League of Basel Stadt/Basel Landschaft, Geneva, Ticino, Valais, Graubunden, and Zurich; Stiftung ehemals Bundner Heilstatten; SUVA; Freiwillige Akademische Gesellschaft; UBS Wealth Foundation; Talecris Biotherapeutics GmbH; Abbott Diagnostics; the European Commission (no. 018996-GABRIEL); and the Wellcome Trust (WT084703MA). United Kingdom: Asthma UK (formerly known as National Asthma Campaign), Department of Health, South Thames Regional Health Authority, and the Medical Research Council (G0901214/1). The coordination of the European Community Respiratory Health Survey (ECRHS) I and ECRHS II was supported by the European Commission. The coordination of ECRHS III was supported by the Medical Research Council (G0901214/1).	Ackaert C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104520; Albertine JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111712; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Bousquet J, 2012, ALLERGY, V67, P18, DOI 10.1111/j.1398-9995.2011.02728.x; Broadfield E, 2002, J ALLERGY CLIN IMMUN, V109, P969, DOI 10.1067/mai.2002.124772; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dottorini ML, 2007, CLIN EXP ALLERGY, V37, P188, DOI 10.1111/j.1365-2222.2007.02652.x; Fisher R.A., 1921, METRON, V1, P3, DOI DOI 10.1093/BIOMET/9.1-2.22; Flohrs K, 2012, INT ARCH ALLERGY IMM, V158, P27, DOI 10.1159/000329855; FUJIWARA M, 1979, J IMMUNOL, V123, P263; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Haynes BF, 2000, IMMUNOL RES, V22, P253, DOI 10.1385/IR:22:2-3:253; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Linneberg A, 2007, CLIN EXP ALLERGY, V37, P1137, DOI 10.1111/j.1365-2222.2007.02760.x; Linneberg A, 2002, CLIN EXP ALLERGY, V32, P1702, DOI 10.1046/j.1365-2222.2002.01537.x; Linneberg A, 2010, INT ARCH ALLERGY IMM, V151, P142, DOI 10.1159/000236004; Newson R, 2006, STATA J, V6, P309, DOI 10.1177/1536867X0600600302; Newson RB, 2013, STATA J, V13, P672, DOI 10.1177/1536867X1301300402; Olivier JGJ, 2013, TRENDS GLOBAL CO2 EM; ROBINS JM, 1994, J AM STAT ASSOC, V89, P846, DOI 10.2307/2290910; Rubelt F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049774; Salo PM, 2014, J ALLERGY CLIN IMMUN, V134, P350, DOI 10.1016/j.jaci.2013.12.1071; Sansoni P, 2008, EXP GERONTOL, V43, P61, DOI 10.1016/j.exger.2007.06.008; Smith M, 2014, ALLERGY, V69, P913, DOI 10.1111/all.12419; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Warm K, 2012, J ALLERGY CLIN IMMUN, V129, P136, DOI 10.1016/j.jaci.2011.08.033; Werther RL, 2012, WORLD ALLERGY ORGAN, V5, P200, DOI 10.1097/WOX.0b013e31827e6513; Yagi T, 1997, J ALLERGY CLIN IMMUN, V99, P38, DOI 10.1016/S0091-6749(97)70298-7; Ziello C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034076	36	39	40	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2016	137	6					1788	+		10.1016/j.jaci.2015.09.037	http://dx.doi.org/10.1016/j.jaci.2015.09.037			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DO1GT	26586040	Green Submitted, Green Published, Green Accepted, hybrid			2022-12-18	WOS:000377527200020
J	Yeh, JJ; Wang, YC; Hsu, WH; Kao, CH				Yeh, Jun-Jun; Wang, Yu-Chiao; Hsu, Wu-Huei; Kao, Chia-Hung			Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mycoplasma pneumoniae; asthma; antibiotic; steroid; cohort study	CHLAMYDOPHILA-PNEUMONIAE; REFRACTORY ASTHMA; ALLERGIC DISEASES; INITIAL ONSET; INFECTION; CHILDREN; EXACERBATIONS; PATHOGENESIS; TAIWAN; SURVEILLANCE	Background: Previous studies investigating the relationship between Mycoplasma pneumoniae and incident asthma in the general population have been inconclusive. Objective: We conducted a nationwide cohort study to clarify this relationship. Methods: Using the National Health Insurance Research Database of Taiwan, we identified 1591 patients with M pneumoniae infection (International Classification of Diseases, Ninth Revision, Clinical Modification code 4830) given diagnoses between 2000 and 2008. We then frequency matched 6364 patients without M pneumoniae infection from the general population according to age, sex, and index year. Cox proportional hazards regression analysis was performed to determine the adjusted hazard ratio (aHR) of the occurrence of asthma in the M pneumoniae cohort compared with that in the non-M pneumoniae cohort. Results: Regardless of comorbidities and the use of antibiotic or steroid therapies, patients with M pneumonia infection had a higher risk of incident asthma than those without it. The aHR of asthma was 3.35 (95% CI, 2.71-4.15) for the M pneumoniae cohort, with a significantly higher risk when patients were stratified by age, sex, follow-up time, and comorbidities, including allergic rhinitis, atopic dermatitis, or allergic conjunctivitis. Patients with M pneumoniae infection had a higher risk of having early-onset (age, <12 years; aHR, 2.87) and late-onset (age, >= 12 years; aHR, 3.95) asthma. The aHR was also higher within the less than 2-year follow-up in the M pneumoniae cohort (aHR, 4.41; 95% CI, 3.40-5.74) than in the cohort without the infection. Conclusion: This study found that incident cases of early-onset and late-onset asthma are closely related to M pneumoniae infection, even in nonatopic patients.	[Yeh, Jun-Jun] Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Chest Med & Family Med, Chiayi, Taiwan; [Yeh, Jun-Jun] Chia Nan Univ Pharm & Sci, Tainan, Taiwan; [Yeh, Jun-Jun] Meiho Univ, Pingtung, Taiwan; [Wang, Yu-Chiao] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan; [Wang, Yu-Chiao; Hsu, Wu-Huei] China Med Univ Hosp, Sch Med, Taichung, Taiwan; [Kao, Chia-Hung] China Med Univ Hosp, Grad Inst Clin Med Sci, Taichung, Taiwan; [Kao, Chia-Hung] China Med Univ Hosp, Coll Med, Sch Med, Taichung, Taiwan; [Kao, Chia-Hung] China Med Univ Hosp, Dept Nucl Med, Taichung, Taiwan; [Kao, Chia-Hung] China Med Univ Hosp, PET Ctr, Taichung, Taiwan	Chia Nan University of Pharmacy & Science; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Kao, CH (corresponding author), China Med Univ, Grad Inst Clin Med Sci, 2 Yuh Der Rd, Taichung 404, Taiwan.; Kao, CH (corresponding author), China Med Univ, Sch Med, Coll Med, 2 Yuh Der Rd, Taichung 404, Taiwan.	d10040@mail.cmuh.org.tw			Taiwan Ministry of Health and Welfare Clinical Trial and the Research Center of Excellence [MOHW104-TDU-B-212-113002]; China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project [BM104010092]; NRPB Stroke Clinical Trial Consortium [MOST 103-2325-B-039-006]; Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan; CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan	Taiwan Ministry of Health and Welfare Clinical Trial and the Research Center of Excellence; China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project; NRPB Stroke Clinical Trial Consortium; Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan; CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan	Supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and the Research Center of Excellence (MOHW104-TDU-B-212-113002); the China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project (BM104010092); the NRPB Stroke Clinical Trial Consortium (MOST 103-2325-B-039-006); the Tseng-Lien Lin Foundation, Taichung, Taiwan; the Taiwan Brain Disease Foundation, Taipei, Taiwan; the Katsuzo and Kiyo Aoshima Memorial Funds, Japan; and the CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan.	Bacharier LB, 2012, J ALLERGY CLIN IMMUN, V130, P287, DOI 10.1016/j.jaci.2012.04.025; Bebear CM, 2008, ARCH PEDIATRIE, V15, P1253, DOI 10.1016/j.arcped.2008.02.010; Biscardi S, 2004, CLIN INFECT DIS, V38, P1341, DOI 10.1086/392498; Blanchard E, 2010, REV MAL RESPIR, V27, P890, DOI 10.1016/j.rmr.2010.04.002; Caughey GH, 2001, AM J RESP CRIT CARE, V164, pS26, DOI 10.1164/ajrccm.164.supplement_2.2106071; CHAN ED, 1995, WESTERN J MED, V162, P133; Chiang CH, 2011, STROKE, V42, P2940, DOI 10.1161/STROKEAHA.110.608075; Cho YM, 2014, J ASTHMA, V51, P373, DOI 10.3109/02770903.2013.876648; Cosentini R, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-48; Cunningham AF, 1998, EUR RESPIR J, V11, P345, DOI 10.1183/09031936.98.11020345; Darveaux JI, 2014, J ALLER CL IMM-PRACT, V2, P658, DOI 10.1016/j.jaip.2014.09.011; Esposito S, 2000, EUR RESPIR J, V16, P1142, DOI 10.1034/j.1399-3003.2000.16f21.x; GOLTZ JP, 1986, CAN J VET RES, V50, P59; Grad R, 2012, J ALLERGY CLIN IMMUN, V130, P299, DOI 10.1016/j.jaci.2012.05.022; Hong SJ, 2012, ALLERGY ASTHMA IMMUN, V4, P59, DOI 10.4168/aair.2012.4.2.59; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP; Juhn YJ, 2014, J ALLERGY CLIN IMMUN, V134, P247, DOI 10.1016/j.jaci.2014.04.024; Kawai Y, 2013, ANTIMICROB AGENTS CH, V57, P4046, DOI 10.1128/AAC.00663-13; LAITINEN LA, 1992, EUR RESPIR J, V5, P670; Lim WS, 2009, THORAX, V64, P1, DOI 10.1136/thx.2009.121434; Ma YJ, 2014, J MICROBIOL IMMUNOL; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595, DOI 10.1067/mai.2001.113563; Medina JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102613; Medina JL, 2012, AM J RESP CELL MOL, V46, P815, DOI 10.1165/rcmb.2011-0135OC; Miyashita N, 2007, J MED MICROBIOL, V56, P1625, DOI 10.1099/jmm.0.47119-0; MOK JYQ, 1979, ARCH DIS CHILD, V54, P506, DOI 10.1136/adc.54.7.506; Nisar N, 2007, POSTGRAD MED J, V83, P100, DOI 10.1136/pgmj.2006.049023; Peters J, 2011, CHEST, V140, P401, DOI 10.1378/chest.11-0221; Rakovskaia IV, 2006, ZHURN MIKROBIOL, V4, P78; Rantala A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027912; SABATO AR, 1984, ARCH DIS CHILD, V59, P1034, DOI 10.1136/adc.59.11.1034; Saraya T, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00410; Shin Jeong Eun, 2014, Korean J Pediatr, V57, P271, DOI 10.3345/kjp.2014.57.6.271; Singh AM, 2006, THORAX, V61, P809, DOI 10.1136/thx.2005.045179; Steel HC, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/584262; Sutherland ER, 2007, CHEST, V132, P1962, DOI 10.1378/chest.06-2415; Tagliabue C, 2008, J INFECT DIS, V198, P1180, DOI 10.1086/591915; Tan DJ, 2015, EXPERT REV RESP MED, V9, P109, DOI 10.1586/17476348.2015.1000311; Tseng SH, 2012, J MICROBIOL IMMUNOL, V45, P79, DOI 10.1016/j.jmii.2012.03.007; van Schayck CP, 2000, THORAX, V55, P562, DOI 10.1136/thorax.55.7.562; Watanabe H, 2014, ALLERGY ASTHMA PROC, V35, P204, DOI 10.2500/aap.2014.35.3742; Wood PR, 2013, ANN ALLERG ASTHMA IM, V110, P328, DOI 10.1016/j.anai.2013.01.022; Xepapadaki Paraskevi, 2008, Allergy Asthma Clin Immunol, V4, P111, DOI 10.1186/1710-1492-4-3-111; Xu XA, 2006, J EXP MED, V203, P2907, DOI 10.1084/jem.20061232; YANO T, 1994, AM J RESP CRIT CARE, V149, P1348, DOI 10.1164/ajrccm.149.5.8173777; Ye Q, 2014, SCI WORLD J, DOI 10.1155/2014/986527; Yeh JJ, 2014, EUR RADIOL, V24, P2372, DOI 10.1007/s00330-014-3279-6; Yeh KW, 2006, ASIAN PAC J ALLERGY, V24, P183; Yeh KW, 2008, ASIAN PAC J ALLERGY, V26, P257	50	39	47	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2016	137	4					1017	U566		10.1016/j.jaci.2015.09.032	http://dx.doi.org/10.1016/j.jaci.2015.09.032			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DI2TG	26586037	Bronze			2022-12-18	WOS:000373351200006
J	Koplin, JJ; Suaini, NHA; Vuillermin, P; Ellis, JA; Panjari, M; Ponsonby, AL; Peters, RL; Matheson, MC; Martino, D; Dang, T; Osborne, NJ; Martin, P; Lowe, A; Gurrin, LC; Tang, MLK; Wake, M; Dwyer, T; Hopper, J; Dharmage, SC; Allen, KJ				Koplin, Jennifer J.; Suaini, Noor H. A.; Vuillermin, Peter; Ellis, Justine A.; Panjari, Mary; Ponsonby, Anne-Louise; Peters, Rachel L.; Matheson, Melanie C.; Martino, David; Thanh Dang; Osborne, Nicholas J.; Martin, Pamela; Lowe, Adrian; Gurrin, Lyle C.; Tang, Mimi L. K.; Wake, Melissa; Dwyer, Terry; Hopper, John; Dharmage, Shyamali C.; Allen, Katrina J.		HealthNuts Study	Polymorphisms affecting vitamin D-binding protein modify the relationship between serum vitamin D (25[OH]D-3) and food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food hypersensitivity; vitamin D; food allergy; gene; polymorphism; vitamin D binding protein	D INSUFFICIENCY; RISK-FACTORS; EGG ALLERGY; BIRTH; PREVALENCE; CRITERIA; SEASON	Background: There is evolving evidence that vitamin D insufficiency may contribute to food allergy, but findings vary between populations. Lower vitamin D-binding protein (DBP) levels increase the biological availability of serum vitamin D. Genetic polymorphisms explain almost 80% of the variation in binding protein levels. Objective: We sought to investigate whether polymorphisms that lower the DBP could compensate for adverse effects of low serum vitamin D on food allergy risk. Methods: From a population-based cohort study (n = 5276) we investigated the association between serum 25-hydroxyvitamin D3 (25[OH] D3) levels and food allergy at age 1 year (338 challenge-proven food-allergic and 269 control participants) and age 2 years (55 participants with persistent and 50 participants with resolved food allergy). 25(OH) D3 levels were measured using liquid chromatography-tandem mass spectrometry and adjusted for season of blood draw. Analyses were stratified by genotype at rs7041 as a proxy marker of DBP levels (low, the GT/TT genotype; high, the GG genotype). Results: Low serum 25(OH) D3 level (<= 50 nM/L) at age 1 years was associated with food allergy, particularly among infants with the GG genotype (odds ratio [OR], 6.0; 95% CI, 0.9-38.9) but not in those with GT/TT genotypes (OR, 0.7; 95% CI, 0.2-2.0; P interaction 5.014). Maternal antenatal vitamin D supplementation was associated with less food allergy, particularly in infants with the GT/TT genotype (OR, 0.10; 95% CI, 0.03-0.41). Persistent vitamin D insufficiency increased the likelihood of persistent food allergy (OR, 12.6; 95% CI, 1.5-106.6), particularly in those with the GG genotype. Conclusions: Polymorphisms associated with lower DBP level attenuated the association between low serum 25(OH) D3 level and food allergy, consistent with greater vitamin D bioavailability in those with a lower DBP level. This increases the biological plausibility of a role for vitamin D in the development of food allergy.	[Koplin, Jennifer J.; Suaini, Noor H. A.; Vuillermin, Peter; Ellis, Justine A.; Panjari, Mary; Ponsonby, Anne-Louise; Peters, Rachel L.; Matheson, Melanie C.; Martino, David; Thanh Dang; Martin, Pamela; Lowe, Adrian; Gurrin, Lyle C.; Tang, Mimi L. K.; Wake, Melissa; Dwyer, Terry; Dharmage, Shyamali C.; Allen, Katrina J.] Univ Melbourne, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Koplin, Jennifer J.; Lowe, Adrian; Gurrin, Lyle C.; Hopper, John; Dharmage, Shyamali C.] Univ Melbourne, Sch Populat & Global Hlth, Parkville, Vic 3052, Australia; [Vuillermin, Peter] Barwon Hlth, Child Hlth Res Unit, Geelong, Vic, Australia; [Vuillermin, Peter] Deakin Univ, Geelong, Vic 3217, Australia; [Suaini, Noor H. A.; Ellis, Justine A.; Ponsonby, Anne-Louise; Peters, Rachel L.; Martino, David; Tang, Mimi L. K.; Wake, Melissa; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Osborne, Nicholas J.] Univ Exeter, Sch Med, European Ctr Environm & Human Hlth, Penryn, Cornwall, England; [Tang, Mimi L. K.; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Flemington Rd, Parkville, Vic 3052, Australia; [Wake, Melissa] Royal Childrens Hosp, Ctr Community Child Hlth, Flemington Rd, Parkville, Vic 3052, Australia; [Allen, Katrina J.] Univ Manchester, Sch Inflammat & Repair, Manchester M13 9PL, Lancs, England	Murdoch Children's Research Institute; University of Melbourne; University of Melbourne; Deakin University; University of Melbourne; University of Exeter; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Manchester	Allen, KJ (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Matheson, Melanie C/O-4721-2015; Tang, Mimi/ABD-8350-2020; Allen, Katrina/I-4361-2018; Dang, Thanh/AAK-1608-2021; Wake, Melissa/J-1396-2012; Osborne, Nicholas/D-2086-2011; Ponsonby, Anne-Louise/AAE-4351-2019; Martino, DJ/X-1753-2019	Matheson, Melanie C/0000-0002-5822-3499; Tang, Mimi/0000-0002-3839-5293; Allen, Katrina/0000-0002-1921-4493; Dang, Thanh/0000-0003-2010-5582; Wake, Melissa/0000-0001-7501-9257; Osborne, Nicholas/0000-0002-6700-2284; Martino, DJ/0000-0001-6823-4696; Suaini, Noor H. A./0000-0003-1161-8845; Ponsonby, Anne-Louise/0000-0002-6581-3657; Peters, Rachel/0000-0002-2411-6628; Gurrin, Lyle/0000-0001-7052-1969; Ellis, Justine/0000-0003-4103-4445; Koplin, Jennifer/0000-0002-7576-5142	National Health and Medical Research Council of Australia [491233, 1006215]; Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program	This work was supported by funding from the National Health and Medical Research Council of Australia (grants 491233 and 1006215), Ilhan Food Allergy Foundation, AnaphylaxiStop, Charles and Sylvia Viertel Medical Research Foundation, and the Victorian Government's Operational Infrastructure Support Program. The study sponsors had no involvement in the study design, collection, analysis, and interpretation of data, writing of the report, or decision to submit the paper for publication.	Allen KJ, 2013, J ALLERGY CLIN IMMUN, V131, P1109, DOI 10.1016/j.jaci.2013.01.017; [Anonymous], DAT SINGL NUCL POL D; Bhan I, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/561214; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; He Cheng-Shiun, 2013, ISRN Nutr, V2013, P723139, DOI 10.5402/2013/723139; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, 2011, DIETARY REFERENCE IN; Koplin JJ, 2012, J ALLERGY CLIN IMMUN, V129, P1145, DOI 10.1016/j.jaci.2011.09.044; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Little R. J., 2019, STAT ANAL MISSING DA, V793; Liu X, 2011, ALLERGY, V66, P1442, DOI 10.1111/j.1398-9995.2011.02681.x; Liu X, 2013, PEDIATR RES, V74, P321, DOI 10.1038/pr.2013.110; Lucas RM, 2011, NEUROLOGY, V76, P540, DOI 10.1212/WNL.0b013e31820af93d; Mullins RJ, 2010, PEDIAT ALLERG IMM-UK, V21, pE413, DOI 10.1111/j.1399-3038.2009.00962.x; Mullins RJ, 2011, PEDIAT ALLERG IMM-UK, V22, P583, DOI 10.1111/j.1399-3038.2011.01151.x; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Peters RL, 2014, J ALLERGY CLIN IMMUN, V133, P485, DOI 10.1016/j.jaci.2013.11.032; Powe CE, 2013, NEW ENGL J MED, V369, P1991, DOI 10.1056/NEJMoa1306357; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; van der Mei IAF, 2007, ENVIRON HEALTH PERSP, V115, P1132, DOI 10.1289/ehp.9937; Vassallo MF, 2010, ALLERGY, V65, P1492, DOI 10.1111/j.1398-9995.2010.02384.x; Vassallo MF, 2010, J ALLERGY CLIN IMMUN, V126, P217, DOI 10.1016/j.jaci.2010.06.011; Vimaleswaran KS, 2012, ALLERGY, V67, P1033, DOI 10.1111/j.1398-9995.2012.02856.x; Vuillermin PJ, 2013, CLIN EXP ALLERGY, V43, P599, DOI 10.1111/cea.12048; Weisse K, 2013, ALLERGY, V68, P220, DOI 10.1111/all.12081; Yao TC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099105	29	39	44	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2016	137	2					500	+		10.1016/j.jaci.2015.05.051	http://dx.doi.org/10.1016/j.jaci.2015.05.051			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	DC5BN	26260969	Bronze			2022-12-18	WOS:000369235500019
J	Edwards, MO; Kotecha, SJ; Lowe, J; Richards, L; Watkins, WJ; Kotecha, S				Edwards, Martin O.; Kotecha, Sarah J.; Lowe, John; Richards, Louise; Watkins, W. John; Kotecha, Sailesh			Early-term birth is a risk factor for wheezing in childhood: A cross-sectional population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cesarean section; asthma; wheezing; gestational age; atopy; bronchodilators	ELECTIVE CESAREAN-SECTION; LATE-PRETERM BIRTH; RESPIRATORY MORBIDITY; ANTENATAL BETAMETHASONE; MODERATE PRETERM; ASTHMA; CHILDREN; OUTCOMES; AGE; QUESTIONNAIRE	Background: Early term-born (37-38 weeks' gestation) infants have increased respiratory morbidity during the neonatal period compared with full term-born (39-42 weeks' gestation) infants, but longer-term respiratory morbidity remains unclear. Objective: We assessed whether early term-born children have greater respiratory symptoms and health care use in childhood compared with full term-born children. Methods: We surveyed 1- to 10-year-old term-born children (n = 13,361). Questionnaires assessed respiratory outcomes with additional data gathered from national health databases. Results: Of 2,845 eligible participants, 545 were early term-born and 2,300 were full term-born. Early term-born children had higher rates of admission to the neonatal unit (odds ratio [OR], 1.7; 95% CI, 1.2-2.5) and admission to the hospital during their first year of life (OR, 1.6; 95% CI, 1.2-2.1). Forty-eight percent of early term-born children less than 5 years old reported wheeze ever compared with 39% of full term-born children (OR, 1.5; 95% CI, 1.1-1.9), and 26% versus 17% reported recent wheezing (OR, 1.7; 95% CI, 1.3-2.4). Early term-born children older than 5 years reported higher rates of wheeze ever (OR, 1.4; 95% CI, 1.05-1.8) and recent wheezing over the last 12 months than full-term control subjects (OR, 1.4; 95% CI, 1.02-2.0). Increased rates of respiratory symptoms in early term-born children persisted when family history of atopy and delivery by means of cesarean sections were included in logistic regression models. Conclusion: Early term-born children had significantly increased respiratory morbidity and use of health care services when compared with full term-born children, even when stratified by mode of delivery and family history of atopy.	[Edwards, Martin O.; Kotecha, Sarah J.; Lowe, John; Watkins, W. John; Kotecha, Sailesh] Cardiff Univ, Sch Med, Dept Child Hlth, Cardiff CF14 4XN, S Glam, Wales; [Richards, Louise] NHS Wales Informat Serv, Cardiff, S Glam, Wales	Cardiff University	Kotecha, S (corresponding author), Cardiff Univ, Sch Med, Dept Child Hlth, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	kotechas@cardiff.ac.uk		Kotecha, Sailesh/0000-0003-3535-7627; Watkins, W. John/0000-0003-3262-6588	Mason Medical Research Foundation; CYPRN; MRC [MR/M022552/1] Funding Source: UKRI; Medical Research Council [MR/M022552/1] Funding Source: researchfish	Mason Medical Research Foundation; CYPRN; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported in part by Mason Medical Research Foundation and CYPRN.	Adams M, 2008, CLIN EXP ALLERGY, V38, P554, DOI 10.1111/j.1365-2222.2008.02948.x; Ananth CV, 2013, CLIN PERINATOL, V40, P601, DOI 10.1016/j.clp.2013.07.001; [Anonymous], 2013, Obstet Gynecol, V121, P911, DOI 10.1097/01.AOG.0000428649.57622.a7; [Anonymous], 2013, Obstet Gynecol, V122, P1139, DOI 10.1097/01.AOG.0000437385.88715.4a; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bendiks M, 2013, CURR ALLERGY ASTHM R, V13, P487, DOI 10.1007/s11882-013-0382-8; Boyle EM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e896; Crump C, 2013, EPIDEMIOLOGY, V24, P270, DOI 10.1097/EDE.0b013e318280da0f; De Luca R, 2009, PEDIATRICS, V123, pE1064, DOI 10.1542/peds.2008-2407; Edwards MO, 2013, PAEDIATR RESPIR REV, V14, P29, DOI 10.1016/j.prrv.2012.02.002; Fleischman AR, 2010, OBSTET GYNECOL, V116, P136, DOI 10.1097/AOG.0b013e3181e24f28; Goyal NK, 2011, PEDIATRICS, V128, pE830, DOI 10.1542/peds.2011-0809; Hansen AK, 2008, BMJ-BRIT MED J, V336, P85, DOI 10.1136/bmj.39405.539282.BE; Hansen AK, 2007, ACTA OBSTET GYN SCAN, V86, P389, DOI 10.1080/00016340601159256; Harju M, 2014, J PEDIATR-US, V164, P295, DOI 10.1016/j.jpeds.2013.09.057; Hibbard JU, 2010, JAMA-J AM MED ASSOC, V304, P419, DOI 10.1001/jama.2010.1015; Hospital Episode Statistics Analysis Health and Social Care Information Center, 2013, NHS MAT STAT 2012 13; Huang LS, 2015, J ASTHMA, V52, P16, DOI 10.3109/02770903.2014.952435; Joshi S, 2007, EARLY HUM DEV, V83, P789, DOI 10.1016/j.earlhumdev.2007.09.007; Joshi S, 2013, J PEDIATR-US, V162, P813, DOI 10.1016/j.jpeds.2012.09.040; Kotecha SJ, 2012, SEMIN FETAL NEONAT M, V17, P77, DOI 10.1016/j.siny.2012.01.004; Kotecha SJ, 2012, THORAX, V67, P54, DOI 10.1136/thoraxjnl-2011-200329; Kuzniewicz MW, 2013, CLIN PERINATOL, V40, P753, DOI [10.1016/j.c1p.2013.07.008, 10.1016/j.clp.2013.07.008]; Marlow N, 2012, ARCH DIS CHILD-FETAL, V97, pF158, DOI 10.1136/fetalneonatal-2011-301507; Menezes AMB, 2011, CLIN EXP ALLERGY, V41, P218, DOI 10.1111/j.1365-2222.2010.03611.x; National Institute for Health and Care Excellence, CG132 CAES SECT NICE; Office for National Statistics, 2011, OFF NAT STAT 2012 BI; Pan H, LMSGROWTH MICROSOFT; Paranjothy S, 2013, PEDIATRICS, V132, pE1562, DOI 10.1542/peds.2013-1737; Parikh LI, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.03.021; Powell CVE, 2002, ARCH DIS CHILD, V87, P376, DOI 10.1136/adc.87.5.376; Roduit C, 2009, THORAX, V64, P107, DOI 10.1136/thx.2008.100875; Sengupta S, 2013, JAMA PEDIATR, V167, P1053, DOI 10.1001/jamapediatrics.2013.2581; Stutchfield P, 2005, BMJ-BRIT MED J, V331, P662, DOI 10.1136/bmj.38547.416493.06; Stutchfield PR, 2013, ARCH DIS CHILD-FETAL, V98, pF195, DOI 10.1136/archdischild-2012-303157; Tita ATN, 2009, NEW ENGL J MED, V360, P111, DOI 10.1056/NEJMoa0803267; Trinick R, 2012, EUR RESPIR J, V39, P899, DOI 10.1183/09031936.00070311; Werner A, 2007, ACTA PAEDIATR, V96, P595, DOI 10.1111/j.1651-2227.2006.00150.x; Wilmink FA, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.052	39	39	39	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					581	+		10.1016/j.jaci.2015.05.005	http://dx.doi.org/10.1016/j.jaci.2015.05.005			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26115906				2022-12-18	WOS:000360913300007
J	Fingleton, J; Travers, J; Williams, M; Charles, T; Bowles, D; Strik, R; Shirtcliffe, P; Weatherall, M; Beasley, R				Fingleton, James; Travers, Justin; Williams, Mathew; Charles, Thomas; Bowles, Darren; Strik, Rianne; Shirtcliffe, Philippa; Weatherall, Mark; Beasley, Richard		New Zealand Respiratory Hlth	Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Phenotype; asthma; chronic obstructive pulmonary disease; inhaled corticosteroid; bronchodilator	RANDOMIZED CONTROLLED-TRIALS; ASTHMA PHENOTYPES; CLUSTER-ANALYSIS; EXTERNAL VALIDITY; EXACERBATIONS; MEPOLIZUMAB; FEATURES; DEFINE; COPD	Background: Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous disorders encompassing different phenotypes of airflow obstruction, which might differ in their response to treatment. Objective: The aim of this study was to determine distinct phenotypes comprising the syndromes of asthma and COPD and the treatment responsiveness of these phenotypes to inhaled beta-agonist, antimuscarinic, and corticosteroid therapy. Methods: We undertook a cross-sectional study with 3 phases. In phase 1, 1,264 participants aged 18 to 75 years with self-reported current wheeze and breathlessness were identified from a random population sample of 16,459. In phase 2, 451 participants attended for detailed assessment, including responsiveness to inhaled salbutamol and ipratropium bromide. In phase 3, 168 steroid-naive participants were enrolled in a 12-week trial of inhaled budesonide. Cluster analysis was performed in 389 participants who completed phase 2 with full data. Treatment responsiveness was compared between phenotypes. Results: Cluster analysis identified 5 phenotypes: moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, obese-comorbid, mild childhood-onset atopic asthma, and mild intermittent. Bronchodilation after salbutamol was equal to or greater than that after ipratropium for all phenotypes. The moderate-to-severe childhood-onset atopic asthma, asthma-COPD overlap, and obese-comorbid phenotypes had greater efficacy with inhaled corticosteroid treatment than the mild intermittent group. Conclusion: Cluster analysis of adults with symptomatic airflow obstruction identifies 5 disease phenotypes, including asthma-COPD overlap and obese-comorbid phenotypes, and provides evidence that patients with the asthma-COPD overlap syndrome might benefit from inhaled corticosteroid therapy.	[Fingleton, James; Travers, Justin; Williams, Mathew; Charles, Thomas; Bowles, Darren; Strik, Rianne; Shirtcliffe, Philippa; Beasley, Richard] Med Res Inst New Zealand, Wellington 6242, New Zealand; [Fingleton, James; Bowles, Darren; Shirtcliffe, Philippa; Weatherall, Mark; Beasley, Richard] Capital & Coast Dist Hlth Board, Wellington, New Zealand; [Fingleton, James; Beasley, Richard] Victoria Univ Wellington, Wellington, New Zealand; [Travers, Justin] Hutt Valley Dist Hlth Board, Lower Hutt, New Zealand; [Weatherall, Mark] Univ Otago Wellington, Wellington, New Zealand	Medical Research Institute Of New Zealand; Victoria University Wellington; University of Otago	Beasley, R (corresponding author), Med Res Inst New Zealand, Private Bag 7902, Wellington 6242, New Zealand.	richard.beasley@mrinz.ac.nz	Braithwaite, Irene/G-2045-2014; Beasley, Richard/AAH-3908-2019; Weatherall, Mark/Y-6824-2019; Braithwaite, Irene/L-2811-2019	Braithwaite, Irene/0000-0001-5327-3027; Beasley, Richard/0000-0003-0337-406X; Weatherall, Mark/0000-0002-0051-9107; Braithwaite, Irene/0000-0001-5327-3027; Fingleton, James/0000-0001-9148-196X; Pritchard, Alison/0000-0002-2709-329X; Travers, Justin/0000-0002-5992-7682	Health Research Council of New Zealand [10/174]; AstraZeneca AB, Sweden; AstraZeneca Limited, New Zealand; Genentech	Health Research Council of New Zealand(Health Research Council of New Zealand); AstraZeneca AB, Sweden(AstraZeneca); AstraZeneca Limited, New Zealand; Genentech(Roche HoldingGenentech)	The primary funder of the study was the Health Research Council of New Zealand (grant no. 10/174). Additional research funding was provided by AstraZeneca AB, Sweden; AstraZeneca Limited, New Zealand; and Genentech.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; [Anonymous], 2014, GLOB STRAT ASTHM MAN; Baldacci S, 2001, EUR RESPIR J, V17, P773, DOI 10.1183/09031936.01.17407730; Beasley R, 2009, LANCET, V374, P670, DOI 10.1016/S0140-6736(09)61541-5; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Boudier A, 2013, AM J RESP CRIT CARE, V188, P550, DOI 10.1164/rccm.201301-0156OC; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Desai D, 2013, AM J RESP CRIT CARE, V188, P657, DOI 10.1164/rccm.201208-1470OC; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; Everitt BS, 2011, CLUSTER ANAL, DOI DOI 10.1002/9780470977811; Garcia-Aymerich J, 2011, THORAX, V66, P430, DOI 10.1136/thx.2010.154484; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI 10.1164/rccm.200711-1754OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Han MK, 2010, AM J RESP CRIT CARE, V182, P598, DOI 10.1164/rccm.200912-1843CC; Hanania NA, 2013, AM J RESP CRIT CARE, V187, P804, DOI 10.1164/rccm.201208-1414OC; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Kraft M, 2011, NEW ENGL J MED, V365, P1141, DOI 10.1056/NEJMe1108666; Marsh Suzanne, 2006, N Z Med J, V119, pU2281; Masoli M, 2004, EUR RESPIR J, V23, P552, DOI 10.1183/09031936.04.00076604; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nagasaki T, 2013, CLIN EXP ALLERGY, V43, P608, DOI 10.1111/cea.12073; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Prosperi MCF, 2013, AM J RESP CRIT CARE, V188, P1303, DOI 10.1164/rccm.201304-0694OC; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Sutherland ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036631; Travers J, 2012, EUR RESPIR J, V39, P1033, DOI 10.1183/09031936.00122811; Travers J, 2007, RESP MED, V101, P1313, DOI 10.1016/j.rmed.2006.10.011; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; Vanfleteren LEGW, 2014, THORAX, V69, P72, DOI 10.1136/thoraxjnl-2013-203602; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Weatherall M, 2010, EUR RESPIR J, V36, P472, DOI 10.1183/09031936.00035210; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678	40	39	39	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					601	609		10.1016/j.jaci.2015.01.013	http://dx.doi.org/10.1016/j.jaci.2015.01.013			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	25746966	Bronze			2022-12-18	WOS:000360913300010
J	Reddel, HK				Reddel, Helen K.			Treatment of overlapping asthma-chronic obstructive pulmonary disease: Can guidelines contribute in an evidence-free zone?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; chronic obstructive pulmonary disease; asthma-chronic obstructive pulmonary disease overlap syndrome; guidelines	RANDOMIZED CONTROLLED-TRIALS; CLINICAL-PRACTICE GUIDELINE; INHALED CORTICOSTEROIDS; EXTERNAL VALIDITY; AMERICAN-COLLEGE; THORACIC-SOCIETY; UNITED-STATES; LUNG-DISEASE; SPANISH COPD; DIAGNOSIS	In their most typical forms, asthma and chronic obstructive pulmonary disease (COPD) are clearly distinguishable, but many patients with chronic airflow limitation demonstrate features of both conditions and have worse health outcomes than those with either disease alone. This has been called the asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS), but as yet, it lacks a precise definition. However, given the different pathways by which a patient can come to demonstrate features of both asthma and COPD, ACOS is not thought to represent a single disease but to include several heterogeneous phenotypes with different underlying mechanisms. These issues have important implications for guidelines because some existing treatment recommendations for asthma and COPD are in conflict, and patients with both asthma and COPD have specifically been excluded from major pharmacologic trials. As a result, there is little evidence at present to support specific treatment recommendations for ACOS on the basis of efficacy or effectiveness, yet these patients continue to present for diagnosis and management, mainly in primary care. This article highlights the need for clinical guidance about ACOS, summarizes recommendations about its diagnosis and treatment from a sample of national asthma and COPD guidelines, and proposes a way forward, as suggested in a collaborative Global Initiative for Asthma/Global Initiative for Chronic Obstructive Lung Disease report, to provide health professionals with interim recommendations about syndromic recognition and initial treatment based on both potential effectiveness and potential risk. Additional research in broad populations is urgently needed to develop a precise definition for ACOS, characterize its phenotypes, and identify opportunities for targeted treatment.	Univ Sydney, Woolcock Inst Med Res, Glebe, NSW 2037, Australia	University of Sydney; Woolcock Institute of Medical Research	Reddel, HK (corresponding author), Univ Sydney, Woolcock Inst Med Res, 431 Glebe Point Rd, Glebe, NSW 2037, Australia.	helen.reddel@sydney.edu.au	Reddel, Helen/ABD-6338-2021; Reddel, Helen/AAC-3394-2020	Reddel, Helen/0000-0002-6695-6350	AstraZeneca; GlaxoSmithKline; Aerocrine; Mundipharma; Novartis; Teva	AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Aerocrine; Mundipharma; Novartis(Novartis); Teva(Teva Pharmaceutical Industries)	H. K. Reddel is on advisory boards and a Data and Safety Monitoring Board for AstraZeneca, GlaxoSmithKline, and Novartis; was an advisory board member for Boehringer Ingelheim; is on a Data and Safety Monitoring Board for Merck; has provided consulting for AstraZeneca and GlaxoSmithKline; has received grants from AstraZeneca and GlaxoSmithKline; has received payment for lectures from Aerocrine, AstraZeneca, GlaxoSmithKline, Mundipharma, Novartis, and Teva; and is chair of the Global Initiative for Asthma (GINA) Science Committee.	Aaron SD, 2008, CAN MED ASSOC J, V179, P1121, DOI 10.1503/cmaj.081332; Abramson M, 2014, COPD X PLAN AUSTR NZ; Andersen H, 2013, CLIN RESPIR J, V7, P342, DOI 10.1111/crj.12013; [Anonymous], 2015, AUSTR ASTHM HDB V1 1; Bafadhel M, 2012, AM J RESP CRIT CARE, V186, P48, DOI 10.1164/rccm.201108-1553OC; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Boulet LP, 2012, EUR RESPIR J, V39, P1220, DOI 10.1183/09031936.00184511; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; de Marco R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062985; Excellence NIfHaC, 2010, CHRON OBSTR PULM DIS; Executive Committee GEMA 2009, 2010, J Investig Allergol Clin Immunol, V20 Suppl 1, P1; Gibson PG, 2004, THORAX, V59, P94, DOI 10.1136/thorax.2003.011858; Haahtela Tari, 2013, Duodecim, V129, P994; Hanania NA, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-6; Hardin M, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-127; Israel E, 2014, AM J RESP CRIT CARE, V189, P619, DOI 10.1164/rccm.201402-0205ED; Soler-Cataluna JJ, 2012, ARCH BRONCONEUMOL, V48, P331, DOI 10.1016/j.arbres.2011.12.009; Kankaanranta H, 2015, BASIC CLIN PHARMACOL, V116, P291, DOI 10.1111/bcpt.12366; Kauppi P, 2011, J ASTHMA, V48, P279, DOI 10.3109/02770903.2011.555576; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Levy Mark L, 2006, Prim Care Respir J, V15, P20, DOI 10.1016/j.pcrj.2005.10.004; Lougheed M Diane, 2012, Can Respir J, V19, pe81; Luks VP, 2010, EUR RESPIR J, V36, P255, DOI 10.1183/09031936.00165109; Malerba M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/271918; Mannino DM, 2000, ARCH INTERN MED, V160, P1683, DOI 10.1001/archinte.160.11.1683; Marsh SE, 2008, THORAX, V63, P761, DOI 10.1136/thx.2007.089193; Martinez Fernando D, 2009, Proc Am Thorac Soc, V6, P272, DOI 10.1513/pats.200808-092RM; Masoli M, 2004, EUR RESPIR J, V23, P552, DOI 10.1183/09031936.04.00076604; Miravitlles M, 2013, PRIM CARE RESP J, V22, P117, DOI 10.4104/pcrj.2013.00016; Miravitlles M, 2012, ARCH BRONCONEUMOL, V48, P247, DOI 10.1016/j.arbres.2012.04.001; Montnemery P, 2002, FAM PRACT, V19, P365, DOI 10.1093/fampra/19.4.365; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; O'Donnell DE, 2007, CAN RESPIR J, V14, p5B, DOI 10.1155/2007/830570; Pascoe S, 2015, LANCET RESP MED, V3, P435, DOI 10.1016/S2213-2600(15)00106-X; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511, DOI 10.1164/ajrccm.158.5.9804028; Poulos LM, 2013, PRIM CARE RESP J, V22, P201, DOI 10.4104/pcrj.2013.00036; Qaseem A, 2007, ANN INTERN MED, V147, P633, DOI 10.7326/0003-4819-147-9-200711060-00008; Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008; Roche N, 2013, LANCET RESP MED, V1, pE29, DOI 10.1016/S2213-2600(13)70199-1; Schirnhofer L, 2011, RESPIRATION, V81, P476, DOI 10.1159/000320251; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Suissa S, 2002, THORAX, V57, P880, DOI 10.1136/thorax.57.10.880; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Travers J, 2007, RESP MED, V101, P1313, DOI 10.1016/j.rmed.2006.10.011; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001, DOI 10.1164/ajrccm.160.3.9812110; White P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075221; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Zwerink M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub3	54	39	40	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2015	136	3					546	552		10.1016/j.jaci.2015.06.043	http://dx.doi.org/10.1016/j.jaci.2015.06.043			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CQ9EA	26343938	Bronze			2022-12-18	WOS:000360913300003
J	Lougaris, V; Tabellini, G; Vitali, M; Baronio, M; Patrizi, O; Tampella, G; Biasini, A; Moratto, D; Parolini, S; Plebani, A				Lougaris, Vassilios; Tabellini, Giovanna; Vitali, Massimiliano; Baronio, Manuela; Patrizi, Ornella; Tampella, Giacomo; Biasini, Augusto; Moratto, Daniele; Parolini, Silvia; Plebani, Alessandro			Defective natural killer-cell cytotoxic activity in NFKB2-mutated CVID-like disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COMMON VARIABLE IMMUNODEFICIENCY; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; SEQUENCING DATA; NFKB2 MUTATION; DEFICIENCY		[Lougaris, Vassilios; Vitali, Massimiliano; Baronio, Manuela; Tampella, Giacomo; Moratto, Daniele; Plebani, Alessandro] Univ Brescia, Spedali Civili, Dept Clin & Expt Sci, Pediat Clin, Brescia, Italy; [Lougaris, Vassilios; Vitali, Massimiliano; Baronio, Manuela; Tampella, Giacomo; Moratto, Daniele; Plebani, Alessandro] Univ Brescia, Spedali Civili, Dept Clin & Expt Sci, Inst Mol Med Angelo Nocivelli, Brescia, Italy; [Tabellini, Giovanna; Patrizi, Ornella; Parolini, Silvia] Univ Brescia, Dept Mol & Translat Med, Brescia, Italy; [Biasini, Augusto] Univ Bologna, Maternal Infantile Dept, Pediat Clin, Cesena, Italy	Hospital Spedali Civili Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia; University of Brescia; University of Bologna	Lougaris, V (corresponding author), Univ Brescia, Spedali Civili, Dept Clin & Expt Sci, Pediat Clin, Brescia, Italy.	vlougarisbs@yahoo.com	Patrizi, Ornella/ABC-5102-2020	PAROLINI, Silvia/0000-0003-1968-7765				Bryceson YT, 2007, BLOOD, V110, P1906, DOI 10.1182/blood-2007-02-074468; Chen K, 2013, AM J HUM GENET, V93, P812, DOI 10.1016/j.ajhg.2013.09.009; Chiang SCC, 2013, BLOOD, V121, P1345, DOI 10.1182/blood-2012-07-442558; Cunningham-Rundles C, 2012, IMMUNOL RES, V54, P227, DOI 10.1007/s12026-012-8318-2; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Kogawa K, 2002, BLOOD, V99, P61, DOI 10.1182/blood.V99.1.61; Lee CE, 2014, BLOOD, V124, P2964, DOI 10.1182/blood-2014-06-578542; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Lindsley AW, 2014, J CLIN IMMUNOL, V34, P910, DOI 10.1007/s10875-014-0095-3; Liu YW, 2014, J CLIN IMMUNOL, V34, P686, DOI 10.1007/s10875-014-0064-x; Lougaris V, 2014, J VACCINES VACCIN, V5, P223; Orange JS, 2013, J ALLERGY CLIN IMMUN, V132, P515, DOI 10.1016/j.jaci.2013.07.020; Orange JS, 2002, J CLIN INVEST, V109, P1501, DOI 10.1172/JCI200214858; Plagnol V, 2012, BIOINFORMATICS, V28, P2747, DOI 10.1093/bioinformatics/bts526; Salzer U, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4032; Tucker E, 2007, J IMMUNOL, V179, P7514, DOI 10.4049/jimmunol.179.11.7514; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603	18	39	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1641	1643		10.1016/j.jaci.2014.11.038	http://dx.doi.org/10.1016/j.jaci.2014.11.038			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25605273	Green Submitted, Bronze			2022-12-18	WOS:000355933400029
J	Pino-Yanes, M; Gignoux, CR; Galanter, JM; Levin, AM; Campbell, CD; Eng, C; Huntsman, S; Nishimura, KK; Gourraud, PA; Mohajeri, K; O'Roak, BJ; Hu, DL; Mathias, RA; Nguyen, EA; Roth, LA; Padhukasahasram, B; Moreno-Estrada, A; Sandoval, K; Winkler, CA; Lurmann, F; Davis, A; Farber, HJ; Meade, K; Avila, PC; Serebrisky, D; Chapela, R; Ford, JG; Lenoir, MA; Thyne, SM; Brigino-Buenaventura, E; Borrell, LN; Rodriguez-Cintron, W; Sen, S; Kumar, R; Rodriguez-Santana, JR; Bustamante, CD; Martinez, FD; Raby, BA; Weiss, ST; Nicolae, DL; Ober, C; Meyers, DA; Bleecker, ER; Mack, SJ; Hernandez, RD; Eichler, EE; Barnes, KC; Williams, LK; Torgerson, DG; Burchard, EG				Pino-Yanes, Maria; Gignoux, Christopher R.; Galanter, Joshua M.; Levin, Albert M.; Campbell, Catarina D.; Eng, Celeste; Huntsman, Scott; Nishimura, Katherine K.; Gourraud, Pierre-Antoine; Mohajeri, Kiana; O'Roak, Brian J.; Hu, Donglei; Mathias, Rasika A.; Nguyen, Elizabeth A.; Roth, Lindsey A.; Padhukasahasram, Badri; Moreno-Estrada, Andres; Sandoval, Karla; Winkler, Cheryl A.; Lurmann, Fred; Davis, Adam; Farber, Harold J.; Meade, Kelley; Avila, Pedro C.; Serebrisky, Denise; Chapela, Rocio; Ford, Jean G.; Lenoir, Michael A.; Thyne, Shannon M.; Brigino-Buenaventura, Emerita; Borrell, Luisa N.; Rodriguez-Cintron, William; Sen, Saunak; Kumar, Rajesh; Rodriguez-Santana, Jose R.; Bustamante, Carlos D.; Martinez, Fernando D.; Raby, Benjamin A.; Weiss, Scott T.; Nicolae, Dan L.; Ober, Carole; Meyers, Deborah A.; Bleecker, Eugene R.; Mack, Steven J.; Hernandez, Ryan D.; Eichler, Evan E.; Barnes, Kathleen C.; Williams, L. Keoki; Torgerson, Dara G.; Burchard, Esteban G.			Genome-wide association study and admixture mapping reveal new loci associated with total IgE levels in Latinos	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; genome-wide association study; admixture mapping; allergy; asthma; next-generation sequencing; Latinos; Hispanics; minority populations	ATOPIC-DERMATITIS; AFRICAN-AMERICAN; SUSCEPTIBILITY LOCI; IMMUNOGLOBULIN-E; GENETIC-ANALYSIS; ASTHMA; METAANALYSIS; PHENOTYPES; FRAMEWORK; ANCESTRY	Background: IgE is a key mediator of allergic inflammation, and its levels are frequently increased in patients with allergic disorders. Objective: We sought to identify genetic variants associated with IgE levels in Latinos. Methods: We performed a genome-wide association study and admixture mapping of total IgE levels in 3334 Latinos from the Genes-environments & Admixture in Latino Americans (GALA II) study. Replication was evaluated in 454 Latinos, 1564 European Americans, and 3187 African Americans from independent studies. Results: We confirmed associations of 6 genes identified by means of previous genome-wide association studies and identified a novel genome-wide significant association of a polymorphism in the zinc finger protein 365 gene (ZNF365) with total IgE levels (rs200076616, P = 2.3 x 10(-8)). We next identified 4 admixture mapping peaks (6p21.32-p22.1, 13p22-31, 14q23.2, and 22q13.1) at which local African, European, and/or Native American ancestry was significantly associated with IgE levels. The most significant peak was 6p21.32-p22.1, where Native American ancestry was associated with lower IgE levels (P = 4.95 x 10(-8)). All but 22q13.1 were replicated in an independent sample of Latinos, and 2 of the peaks were replicated in African Americans (6p21.32-p22.1 and 14q23.2). Fine mapping of 6p21.32-p22.1 identified 6 genome-wide significant single nucleotide polymorphisms in Latinos, 2 of which replicated in European Americans. Another single nucleotide polymorphism was peak-wide significant within 14q23.2 in African Americans (rs1741099, P = 3.7 x 10(-6)) and replicated in non-African American samples (P = .011). Conclusion: We confirmed genetic associations at 6 genes and identified novel associations within ZNF365, HLA-DQA1, and 14q23.2. Our results highlight the importance of studying diverse multiethnic populations to uncover novel loci associated with total IgE levels.	[Pino-Yanes, Maria; Gignoux, Christopher R.; Galanter, Joshua M.; Eng, Celeste; Huntsman, Scott; Nishimura, Katherine K.; Hu, Donglei; Nguyen, Elizabeth A.; Roth, Lindsey A.; Torgerson, Dara G.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Gignoux, Christopher R.; Galanter, Joshua M.; Hernandez, Ryan D.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Sen, Saunak] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Pino-Yanes, Maria] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Gignoux, Christopher R.; Moreno-Estrada, Andres; Sandoval, Karla; Bustamante, Carlos D.] Stanford Univ, Dept Genet, Palo Alto, CA 94304 USA; [Levin, Albert M.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA; [Padhukasahasram, Badri; Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Policy & Hlth Serv Res, Detroit, MI USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI USA; [Campbell, Catarina D.; Mohajeri, Kiana; O'Roak, Brian J.; Eichler, Evan E.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; [Gourraud, Pierre-Antoine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [O'Roak, Brian J.] Oregon Hlth & Sci Univ, Mol & Med Genet Dept, Portland, OR 97201 USA; [Mathias, Rasika A.; Barnes, Kathleen C.] Johns Hopkins Univ, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD USA; [Winkler, Cheryl A.] NCI, Basic Res Lab, Ctr Canc Res, Leidos Biomed,Frederick Natl Lab Canc Res, Frederick, MD 21701 USA; [Lurmann, Fred] Sonoma Technol, Petaluma, NC USA; [Davis, Adam; Meade, Kelley] Childrens Hosp & Res Ctr Oakland, Houston, TX USA; [Farber, Harold J.] Baylor Coll Med, Dept Pediat, Sect Pulmonol, Houston, TX 77030 USA; [Farber, Harold J.] Texas Childrens Hosp, Houston, TX 77030 USA; [Avila, Pedro C.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Kumar, Rajesh] Northwestern Univ, Childrens Mem Hosp, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Serebrisky, Denise] Jacobi Med Ctr, Pediat Pulm Div, Bronx, NY USA; [Chapela, Rocio] INER, Mexico City, DF, Mexico; [Ford, Jean G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Lenoir, Michael A.] Bay Area Pediat, Oakland, CA USA; [Thyne, Shannon M.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Pediat, San Francisco, CA 94143 USA; [Brigino-Buenaventura, Emerita] Kaiser Permanente Vallejo Med Ctr, Dept Allergy & Immunol, Vallejo, CA USA; [Borrell, Luisa N.] CUNY, Grad Program Publ Hlth, Dept Hlth Sci, Bronx, NY USA; [Rodriguez-Cintron, William] Vet Caribbean Hlth Care Syst, San Juan, PR USA; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, San Juan, PR USA; [Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Martinez, Fernando D.] Univ Arizona, Inst BIO5, Tucson, AZ USA; [Raby, Benjamin A.; Weiss, Scott T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Charming Div Network Med,Dept Med, Boston, MA 02115 USA; [Nicolae, Dan L.; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Meyers, Deborah A.; Bleecker, Eugene R.] Wake Forest Sch Med, Ctr Genom & Personalized Med Res, Winston Salem, NC USA; [Mack, Steven J.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; [Eichler, Evan E.] Howard Hughes Med Inst, Seattle, WA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III; Stanford University; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; Oregon Health & Science University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Baylor College of Medicine; Baylor College of Medicine; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Northwestern University; Feinberg School of Medicine; Jacobi Medical Center; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Kaiser Permanente; City University of New York (CUNY) System; University of Arizona; University of Arizona; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Chicago; Wake Forest University; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; Howard Hughes Medical Institute	Pino-Yanes, M (corresponding author), Univ Calif San Francisco, Dept Med, 1550 4th St,Rock Hall Rm 582,UCSF Box 2911, San Francisco, CA 94143 USA.	mdelpino@ull.edu.es	Borrell, Luisa N./G-8753-2018; Moreno-Estrada, Andres/AAP-4657-2021; Pino-Yanes, Maria/C-8498-2017; Raby, Benjamin/AAK-3866-2021; Gourraud, Pierre-Antoine FD/O-3024-2015; Moreno-Estrada, Andres/R-3950-2017	Borrell, Luisa N./0000-0002-0560-4853; Moreno-Estrada, Andres/0000-0001-8329-8292; Pino-Yanes, Maria/0000-0003-0332-437X; Moreno-Estrada, Andres/0000-0001-8329-8292; Galanter, Joshua/0000-0002-2561-6384; Bustamante, Carlos D./0000-0002-4187-7920; Kumar, Rajesh/0000-0002-1962-7108; Sandoval, Karla/0000-0002-6175-2463; Nicolae, Dan/0000-0002-0918-4630; Nguyen, Elizabeth/0000-0002-8070-6382; Gourraud, Pierre-Antoine/0000-0003-1131-9554; Ober, Carole/0000-0003-4626-9809; O'Roak, Brian/0000-0002-4141-0095	NCATS NIH HHS [UL1 TR000430, KL2TR000143] Funding Source: Medline; NCRR NIH HHS [M01-RR00188] Funding Source: Medline; NHLBI NIH HHS [HL004464, HL078885, HL083069, HL087680, R01 HL088133, HL101543, K23 HL111636, HL088133, HL075419, HL093023, HL104608, HL066289, HL65899, HL101651, RC2 HL101651, R01 HL117004, HL117004, HL111636] Funding Source: Medline; NIAID NIH HHS [AI079139, AI061774, U19 AI095230] Funding Source: Medline; NIEHS NIH HHS [R01 ES015794, ES015794] Funding Source: Medline; NIGMS NIH HHS [GM007175, GM007546] Funding Source: Medline; NIMHD NIH HHS [P60 MD006902, MD006902] Funding Source: Medline; PHS HHS [HHSN26120080001E] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC010022] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000143, UL1TR000430] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000188] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL093023, RC2HL101543, K23HL004464, R01HL066289, R37HL066289, U01HL075419, P01HL083069, RC2HL101651, R01HL088133, R01HL087680, U01HL065899, K23HL111636, R01HL117004, R01HL104608, R01HL078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI079139, R01AI061774, U19AI095230] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P60MD006902] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Baran Y, 2012, BIOINFORMATICS, V28, P1359, DOI 10.1093/bioinformatics/bts144; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Flohr C, 2009, CLIN EXP ALLERGY, V39, P20, DOI 10.1111/j.1365-2222.2008.03134.x; Galanter JM, 2014, J ALLERGY CLIN IMMUN, V134, P295, DOI 10.1016/j.jaci.2013.08.055; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; Granada M, 2012, J ALLERGY CLIN IMMUN, V129, P840, DOI 10.1016/j.jaci.2011.09.029; Han B, 2011, AM J HUM GENET, V88, P586, DOI 10.1016/j.ajhg.2011.04.014; HANSON B, 1991, AM J HUM GENET, V48, P873; Haritunians T, 2011, GUT, V60, P1060, DOI 10.1136/gut.2010.227256; Hirota T, 2012, NAT GENET, V44, P1222, DOI 10.1038/ng.2438; Hoffmann TJ, 2011, GENOMICS, V98, P422, DOI 10.1016/j.ygeno.2011.08.007; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Kang HM, 2010, NAT GENET, V42, P348, DOI 10.1038/ng.548; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Lappalainen T, 2013, NATURE, V501, P506, DOI 10.1038/nature12531; Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Levin AM, 2013, J ALLERGY CLIN IMMUN, V131, P1176, DOI 10.1016/j.jaci.2012.10.002; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Mansur AH, 2004, THORAX, V59, P876, DOI 10.1136/thx.2003.014092; Mansur AH, 1999, AM J RESP CRIT CARE, V159, P1796, DOI 10.1164/ajrccm.159.6.9804036; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Nagarajan R, 2013, BAYESIAN NETWORKS R; Naqvi M, 2007, J ALLERGY CLIN IMMUN, V120, P137, DOI 10.1016/j.jaci.2007.02.045; O'Roak BJ, 2012, SCIENCE, V338, P1619, DOI 10.1126/science.1227764; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836, DOI 10.1164/ajrccm.161.6.9805104; Potaczek DP, 2012, CLIN EXP ALLERGY, V42, P852, DOI 10.1111/j.1365-2222.2011.03953.x; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; RCore Team, 2022, R LANG ENV STAT COMP; Reiner AP, 2012, AM J HUM GENET, V91, P502, DOI 10.1016/j.ajhg.2012.07.023; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Shriner D, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002325; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Torgerson DG, 2012, J ALLERGY CLIN IMMUN, V130, P76, DOI 10.1016/j.jaci.2012.02.040; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Turner EH, 2009, NAT METHODS, V6, P315, DOI 10.1038/nmeth.f.248; Vergara C, 2013, GENET EPIDEMIOL, V37, P393, DOI 10.1002/gepi.21702; Vergara C, 2009, HUM GENET, V125, P565, DOI 10.1007/s00439-009-0649-2; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Weidinger S, 2013, HUM MOL GENET, V22, P4841, DOI 10.1093/hmg/ddt317; Weidinger S, 2010, CURR OPIN ALLERGY CL, V10, P408, DOI 10.1097/ACI.0b013e32833d7d2d; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044; Yatagai Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080941; Zhang YQ, 2013, CELL CYCLE, V12, P2817, DOI 10.4161/cc.25882	53	39	39	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1502	1510		10.1016/j.jaci.2014.10.033	http://dx.doi.org/10.1016/j.jaci.2014.10.033			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25488688	Bronze, Green Accepted			2022-12-18	WOS:000355933400013
J	Sonnenschein-van der Voort, AMM; Howe, LD; Granell, R; Duijts, L; Sterne, JAC; Tilling, K; Henderson, AJ				Sonnenschein-van der Voort, Agnes M. M.; Howe, Laura D.; Granell, Raquel; Duijts, Liesbeth; Sterne, Jonathan A. C.; Tilling, Kate; Henderson, A. John			Influence of childhood growth on asthma and lung function in adolescence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALSPAC; asthma; cohort study; growth; lung function	POSTNATAL WEIGHT-GAIN; SCHOOL-AGE-CHILDREN; BODY-MASS INDEX; BIRTH-WEIGHT; PRESCHOOL-CHILDREN; PULMONARY-FUNCTION; FETAL-GROWTH; FOLLOW-UP; ASSOCIATIONS; ADIPOKINES	Background: Low birth weight and rapid infant growth in early infancy are associated with increased risk of childhood asthma, but little is known about the role of postinfancy growth in asthmatic children. Objectives: We sought to examine the associations of children's growth patterns with asthma, bronchial responsiveness, and lung function until adolescence. Methods: Individual growth trajectories from birth until 10 years of age were estimated by using linear spline multilevel models for 9723 children participating in a population-based prospective cohort study. Current asthma at 8, 14, and 17 years of age was based on questionnaires. Lung function and bronchial responsiveness or reversibility were measured during clinic visits at 8 and 15 years of age. Results: Rapid weight growth between 0 and 3 months of age was most consistently associated with increased risks of current asthma at the ages of 8 and 17 years, bronchial responsiveness at age 8 years, and bronchial reversibility at age 15 years. Rapid weight growth was associated with lung function values, with the strongest associations for weight gain between 3 and 7 years of age and higher forced vital capacity (FVC) and FEV1 values at age 15 years (0.12 [95% CI, 0.08 to 0.17] and 0.11 [95% CI, 0.07 to 0.15], z score per SD, respectively) and weight growth between 0 and 3 months of age and lower FEV1/FVC ratios at age 8 and 15 years (-0.13 [95% CI, -0.16 to -0.10] and -0.04 [95% CI, -0.07 to -0.01], z score per SD, respectively). Rapid length growth was associated with lower FVC and FVC1 values at age 15 years. Conclusion: Faster weight growth in early childhood is associated with asthma and bronchial hyperresponsiveness, and faster weight growth across childhood is associated with higher FVC and FEV1 values.	[Sonnenschein-van der Voort, Agnes M. M.; Howe, Laura D.; Granell, Raquel; Sterne, Jonathan A. C.; Tilling, Kate; Henderson, A. John] Univ Bristol, Sch Social & Community Med, Bristol BS8 2BN, Avon, England; [Howe, Laura D.] Univ Bristol, Med Res Council Integrat Epidemiol Unit, Bristol BS8 2BN, Avon, England; [Sonnenschein-van der Voort, Agnes M. M.; Duijts, Liesbeth] Erasmus MC, Dept Pediat, Div Resp Med, Rotterdam, Netherlands; [Sonnenschein-van der Voort, Agnes M. M.; Duijts, Liesbeth] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Duijts, Liesbeth] Erasmus MC, Dept Pediat, Div Neonatol, Rotterdam, Netherlands	University of Bristol; University of Bristol; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Henderson, AJ (corresponding author), Univ Bristol, Sch Social & Community Med, Oakfield House, Bristol BS8 2BN, Avon, England.	a.j.henderson@bristol.ac.uk	Sterne, Jonathan/Z-3106-2019; Granell, Raquel/AAY-4846-2020; Granell, Raquel/AAB-5256-2022; Tilling, Kate/AAY-1578-2021	Sterne, Jonathan/0000-0001-8496-6053; Granell, Raquel/0000-0002-4890-4012; Tilling, Kate/0000-0002-1010-8926; Howe, Laura/0000-0003-3357-2796	UK Medical Research Council [102215/2/13/2, G0401540, MC_UU_12013/5]; Wellcome Trust [092731]; University of Bristol; European Respiratory Society Fellowship [STRTF 93-2012]; Ter Meulen Fund; Royal Netherlands Academy of Arts and Sciences [TMF2012/228]; UK Medical Research Council fellowships [G0401540, G1002375]; European Respiratory Society/Marie Curie Joint Research Fellowship [MC 1226-2009, PCOFUND-GA-2008-229571]; Lung Foundation Netherlands [3.2.12.089; 2012]; Medical Research Council [MC_UU_12013/5, G1002375, MC_PC_15018, G0401540] Funding Source: researchfish; National Institute for Health Research [NF-SI-0611-10168] Funding Source: researchfish; MRC [G0401540, MC_UU_12013/5, G1002375] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); University of Bristol; European Respiratory Society Fellowship; Ter Meulen Fund; Royal Netherlands Academy of Arts and Sciences; UK Medical Research Council fellowships(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Respiratory Society/Marie Curie Joint Research Fellowship; Lung Foundation Netherlands; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The Avon Longitudinal Study of Parents and Children (ALSPAC) receives core funding (102215/2/13/2) from the UK Medical Research Council, the Wellcome Trust (grant reference 092731) and the University of Bristol. The lung function measures were supported by a grant from the UK Medical Research council (G0401540). A.M.M.S.-V. is the recipient of a European Respiratory Society Fellowship (STRTF 93-2012) and received a grant from the Ter Meulen Fund, Royal Netherlands Academy of Arts and Sciences (TMF2012/228). L.D.H. and R.G. are funded by UK Medical Research Council fellowships (G1002375 and G0401540). L.D.H. and K.T. work in a unit that receives funding from the UK Medical Research Council (MC_UU_12013/5) and the University of Bristol. L.D. received funding from a European Respiratory Society/Marie Curie Joint Research Fellowship (no. MC 1226-2009, grant agreement RESPIRE, PCOFUND-GA-2008-229571) and the Lung Foundation Netherlands (no 3.2.12.089; 2012).	Anderson EL, 2013, PEDIAT ALLERG IMM-UK, V24, P122, DOI 10.1111/pai.12049; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Arif AA, 2007, RESPIROLOGY, V12, P675, DOI 10.1111/j.1440-1843.2007.01122.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Baek HS, 2011, ANN ALLERG ASTHMA IM, V107, P14, DOI 10.1016/j.anai.2011.03.013; Beuther DA, 2006, AM J RESP CRIT CARE, V174, P112, DOI 10.1164/rccm.200602-231PP; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Canoy D, 2007, THORAX, V62, P396, DOI 10.1136/thx.2006.066241; Caudri D, 2007, AM J RESP CRIT CARE, V175, P1078, DOI 10.1164/rccm.200610-1441OC; CHINN S, 1992, THORAX, V47, P707, DOI 10.1136/thx.47.9.707; Cockcroft DW, 2010, CHEST, V138, p18S, DOI 10.1378/chest.10-0088; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crown S, 1979, MANUAL CROWN CRISP E; Duijts L, 2012, CHEST, V141, P876, DOI 10.1378/chest.11-0112; Duijts L, 2012, EUR J EPIDEMIOL, V27, P5, DOI 10.1007/s10654-012-9657-y; Eising JB, 2014, EUR RESPIR J, V43, P1189, DOI 10.1183/09031936.00149613; Flexeder C, 2012, ALLERGY, V67, P257, DOI 10.1111/j.1398-9995.2011.02748.x; Hancox RJ, 2009, THORAX, V64, P228, DOI 10.1136/thx.2008.103978; Howe L.D., 2013, STAT METHODS MED RES; Howe LD, 2013, EPIDEMIOLOGY, V24, P1, DOI 10.1097/EDE.0b013e31827623b1; Jartti T, 2009, ALLERGY, V64, P770, DOI 10.1111/j.1398-9995.2008.01872.x; Joshi S, 2007, EARLY HUM DEV, V83, P789, DOI 10.1016/j.earlhumdev.2007.09.007; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Kim KW, 2008, PEDIAT ALLERG IMM-UK, V19, P535, DOI 10.1111/j.1399-3038.2007.00690.x; Kindlund K, 2010, THORAX, V65, P146, DOI 10.1136/thx.2009.117101; Kotecha SJ, 2012, THORAX, V67, P54, DOI 10.1136/thoraxjnl-2011-200329; Kotecha SJ, 2010, AM J RESP CRIT CARE, V181, P969, DOI 10.1164/rccm.200906-0897OC; Lim RH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010134; Lucas JS, 2004, AM J RESP CRIT CARE, V170, P534, DOI 10.1164/rccm.200311-1583OC; Maritz GS, 2001, PEDIATR PULM, V32, P201, DOI 10.1002/ppul.1109; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Melen E, 2013, CLIN EXP ALLERGY, V43, P463, DOI 10.1111/cea.12054; Nagel G, 2009, PEDIAT ALLERG IMM-UK, V20, P81, DOI 10.1111/j.1399-3038.2008.00740.x; Narayanan M, 2012, AM J RESP CRIT CARE, V185, P186, DOI 10.1164/rccm.201107-1348OC; Parker AL, 2002, CHEST, V121, P1818, DOI 10.1378/chest.121.6.1818; Paul IM, 2010, PEDIAT ALLERG IMM-UK, V21, P82, DOI 10.1111/j.1399-3038.2009.00926.x; Pike KC, 2010, THORAX, V65, P1099, DOI 10.1136/thx.2010.134742; Rona RJ, 2005, THORAX, V60, P549, DOI 10.1136/thx.2004.032359; Rzehak P, 2013, J ALLERGY CLIN IMMUN, V131, P1528, DOI 10.1016/j.jaci.2013.01.001; Shaheen SO, 1998, THORAX, V53, P549, DOI 10.1136/thx.53.7.549; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Sonnenschein-van der Voort AMM, 2012, EUR RESPIR J, V39, P81, DOI 10.1183/09031936.00178110; Sonnenschein-van der Voort AMM, 2012, AM J RESP CRIT CARE, V185, P731, DOI 10.1164/rccm.201107-1266OC; Spratt M, 2010, AM J EPIDEMIOL, V172, P478, DOI 10.1093/aje/kwq137; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Taveras EM, 2006, PEDIATR PULM, V41, P643, DOI 10.1002/ppul.20427; Turner S, 2008, THORAX, V63, P234, DOI 10.1136/thx.2006.064642; Turner S, 2011, AM J RESP CRIT CARE, V184, P407, DOI 10.1164/rccm.201012-2075OC; van der Gugten AC, 2012, EUR RESPIR J, V39, P403, DOI 10.1183/09031936.00188310; Wignarajah D, 2002, PEDIATR RES, V51, P681, DOI 10.1203/01.PDR.0000017485.64723.0A; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; Yuan W, 2002, INT J EPIDEMIOL, V31, P1240, DOI 10.1093/ije/31.6.1240	53	39	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2015	135	6					1435	+		10.1016/j.jaci.2014.10.046	http://dx.doi.org/10.1016/j.jaci.2014.10.046			16	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CK0ZC	25577593	hybrid, Green Published			2022-12-18	WOS:000355933400004
J	Ming, M; Zhao, BZ; Shea, CR; Shah, P; Qiang, L; White, SR; Sims, DM; He, YY				Ming, Mei; Zhao, Baozhong; Shea, Christopher R.; Shah, Palak; Qiang, Lei; White, Steven R.; Sims, Diane M.; He, Yu-Ying			Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sirtuin 1 (SIRT1); skin barrier; filaggrin	ATOPIC-DERMATITIS; FILAGGRIN MUTATIONS; MAMMALIAN SIRTUINS; CELL-SURVIVAL; ANIMAL-MODEL; DISEASE; RECEPTOR; EXPRESSION; LORICRIN; REPAIR	Background: Skin barrier integrity requires a highly coordinated molecular system involving the structural protein filaggrin (FLG). Mutational loss of the skin barrier protein FLG predisposes subjects to the development of atopic dermatitis (AD). Objective: We sought to determine the role of sirtuin 1 (SIRT1) in skin barrier function, FLG expression, and development of AD. Methods: Skin histology of mice with skin-specific SIRT1 deletion and wild-type control animals was examined by using hematoxylin and eosin staining. Protein and mRNA abundance was analyzed by means of immunoblotting, immunohistochemistry, immunofluorescence, and RT-PCR. Serum antibody levels were assessed by means of ELISA. Results: Here we show that FLG is regulated by the protein deacetylase SIRT1 and that SIRT1 is critical for skin barrier integrity. Epidermis-specific SIRT1 ablation causes AD-like skin lesions in mice, and mice with epidermal SIRT1 deletion are sensitive to percutaneous challenge by the protein allergen ovalbumin. In normal human keratinocytes and mouse skin SIRT1 knockdown or genetic deletion downregulates FLG, and regulation of FLG expression by SIRT1 requires the deacetylase activity of SIRT1. SIRT1 also promotes activation of the aryl hydrocarbon receptor, and the aryl hydrocarbon receptor ligand restores FLG expression in SIRT1-inhibited cells. Compared with normal human skin, SIRT1 is downregulated in both AD and non-AD lesions. Conclusion: Our findings demonstrate a critical role of SIRT1 in skin barrier maintenance, open up new opportunities to use SIRT1 as a pharmacologic target, and might facilitate the development of mechanism-based agents for AD prevention and therapy.	[Ming, Mei; Zhao, Baozhong; Shea, Christopher R.; Shah, Palak; Qiang, Lei; Sims, Diane M.; He, Yu-Ying] Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA; [White, Steven R.] Univ Chicago, Dept Med, Sect Pulm Crit Care, Chicago, IL 60637 USA	University of Chicago; University of Chicago	He, YY (corresponding author), Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Shea, Christopher R./AAJ-7143-2021; Qiang, Lei/B-2763-2012	Qiang, Lei/0000-0002-7164-3164	National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS) [ES016936]; American Cancer Society (ACS) [RSG-13-078-01]; University of Chicago Cancer Research Center [P30 CA014599]; CTSA (NIH) [TR000430]; University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936] Funding Source: NIH RePORTER	National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Cancer Society (ACS)(American Cancer Society); University of Chicago Cancer Research Center; CTSA (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by the National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS) grant ES016936 (to Y.Y.H.), American Cancer Society (ACS) grant RSG-13-078-01 (to Y.Y.H.), the University of Chicago Cancer Research Center (P30 CA014599), the CTSA (NIH TR000430), and the University of Chicago Friends of Dermatology Endowment Fund.	Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Blander G, 2009, J INVEST DERMATOL, V129, P41, DOI 10.1038/jid.2008.179; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; Chan LS, 2001, J INVEST DERMATOL, V117, P977, DOI 10.1046/j.0022-202x.2001.01484.x; Dajee M, 2006, J INVEST DERMATOL, V126, P1792, DOI 10.1038/sj.jid.5700307; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; Elias PM, 2008, CURR ALLERGY ASTHM R, V8, P299, DOI 10.1007/s11882-008-0048-0; Elias PM, 2011, CLIN REV ALLERG IMMU, V41, P282, DOI 10.1007/s12016-010-8231-1; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fan W, 2010, MOL CELL, V39, P247, DOI 10.1016/j.molcel.2010.07.006; Fiset PO, 2006, J ALLERGY CLIN IMMUN, V118, P287, DOI 10.1016/j.jaci.2006.03.046; Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755; Guarente L, 2000, GENE DEV, V14, P1021; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Ichikawa T, 2013, RESPIROLOGY, V18, P332, DOI 10.1111/j.1440-1843.2012.02284.x; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kim BE, 2011, J INVEST DERMATOL, V131, P1272, DOI 10.1038/jid.2011.24; Kim SR, 2010, J ALLERGY CLIN IMMUN, V125, P449, DOI 10.1016/j.jaci.2009.08.009; Kwon HS, 2008, CELL HOST MICROBE, V3, P158, DOI 10.1016/j.chom.2008.02.002; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Li CJ, 2010, P NATL ACAD SCI USA, V107, P4687, DOI 10.1073/pnas.0912807107; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Ming M, 2014, ONCOGENE; Ming M, 2011, CANCER RES, V71, P5287, DOI 10.1158/0008-5472.CAN-10-4614; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Nakai K, 2012, AM J PATHOL, V181, P969, DOI 10.1016/j.ajpath.2012.06.005; Nakamura H, 2002, GENE THER, V9, P1221, DOI 10.1038/sj.gt.3301724; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111; Qiang L, 2013, J BIOL CHEM, V288, P1603, DOI 10.1074/jbc.M112.415224; Robertson ED, 2012, J CELL SCI, V125, P3320, DOI 10.1242/jcs.095125; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schug TT, 2010, MOL CELL BIOL, V30, P4712, DOI 10.1128/MCB.00657-10; STEVEN AC, 1990, J STRUCT BIOL, V104, P150, DOI 10.1016/1047-8477(90)90071-J; Tanaka A, 2007, J INVEST DERMATOL, V127, P855, DOI 10.1038/sj.jid.5700603; van den Bogaard EH, 2013, J CLIN INVEST, V123, P917, DOI 10.1172/JCI65642; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Wu R, 2007, J PHARMACOL EXP THER, V320, P448, DOI 10.1124/jpet.106.111773	52	39	42	4	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2015	135	4					936	+		10.1016/j.jaci.2014.09.035	http://dx.doi.org/10.1016/j.jaci.2014.09.035			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CF0MQ	25445829	Green Accepted			2022-12-18	WOS:000352238600015
J	Reeves, SR; Kolstad, T; Lien, TY; Elliott, M; Ziegler, SF; Wight, TN; Debley, JS				Reeves, Stephen R.; Kolstad, Tessa; Lien, Tin-Yu; Elliott, Molly; Ziegler, Steven F.; Wight, Thomas N.; Debley, Jason S.			Asthmatic airway epithelial cells differentially regulate fibroblast expression of extracellular matrix components	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; children; airway remodeling; epithelial cells; human lung fibroblasts; extracellular matrix; collagen I; collagen III; hyaluronic acid; fibronectin; TGF-beta 2	GROWTH-FACTOR-BETA; HUMAN-LUNG; FUNCTIONAL-CHARACTERIZATION; BASEMENT-MEMBRANE; GENE-EXPRESSION; TGF-BETA; CHILDREN; COLLAGEN; MECHANISMS; PROLIFERATION	Background: Airway remodeling might explain lung function decline among asthmatic children. Extracellular matrix (ECM) deposition by human lung fibroblasts (HLFs) is implicated in airway remodeling. Airway epithelial cell (AEC) signaling might regulate HLF ECM expression. Objectives: We sought to determine whether AECs from asthmatic children differentially regulate HLF expression of ECM constituents. Methods: Primary AECs were obtained from well-characterized atopic asthmatic (n = 10) and healthy (n = 10) children intubated during anesthesia for an elective surgical procedure. AECs were differentiated at an air-liquid interface for 3 weeks and then cocultured with HLFs from a healthy child for 96 hours. Collagen I (COL1A1), collagen III (COL3A1), hyaluronan synthase (HAS) 2, and fibronectin expression by HLFs and prostaglandin E-2 synthase (PGE2S) expression by AECs were assessed by using RT-PCR. TGF-beta 1 and TGF-beta 2 concentrations in media were measured by using ELISA. Results: COL1A1 and COL3A1 expression by HLFs cocultured with AECs from asthmatic patients was greater than that by HLFs cocultured with AECs from healthy subjects (2.2-fold, P < .02; 10.8-fold, P < .02). HAS2 expression by HLFs cocultured with AECs from asthmatic patients was 2.5-fold higher than that by HLFs cocultured with AECs from healthy subjects (P < .002). Fibronectin expression by HLFs cocultured with AECs from asthmatic patients was significantly greater than that by HLFs alone. TGF-beta 2 activity was increased in cocultures of HLFs with AECs from asthmatic patients (P < .05), whereas PGES2 was downregulated in AEC-HLF cocultures (2.2-fold, P < .006). Conclusions: HLFs cocultured with AECs from asthmatic patients showed differential expression of the ECM constituents COL1A1 and COL3A1 and HAS2 compared with HLFs cocultured with AECs from healthy subjects. These findings support a role for altered ECM production in asthmatic airway remodeling, possibly regulated by unbalanced AEC signaling.	[Reeves, Stephen R.; Elliott, Molly; Debley, Jason S.] Univ Washington, Seattle Childrens Hosp, Div Pulm Med, Seattle, WA 98195 USA; [Reeves, Stephen R.; Kolstad, Tessa; Lien, Tin-Yu; Elliott, Molly; Debley, Jason S.] Seattle Childrens Res Inst, Ctr Immun & Immunotherapies, Seattle, WA USA; [Ziegler, Steven F.; Wight, Thomas N.] Benaroya Res Inst, Seattle, WA USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; Seattle Children's Hospital; Benaroya Research Institute	Debley, JS (corresponding author), Seattle Childrens Hosp, Div Pulm, MS OC 7-720,4800 Sand Point Way NE, Seattle, WA 98105 USA.	jason.debley@seattlechildrens.org		Reeves, Stephen/0000-0002-8552-6022	Firland Foundation [201208]; American Lung Association Senior Research Training Fellowship [RT-268263-N]; NIH [R01AI068731, PO1 HL098067]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL098067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068731] Funding Source: NIH RePORTER	Firland Foundation; American Lung Association Senior Research Training Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by the Firland Foundation 201208 (PI: S.R.R.); American Lung Association Senior Research Training Fellowship RT-268263-N (PI: S.R.R.); NIH R01AI068731 (PI: S.F.Z.); NIH PO1 HL098067 (PI: S.F.Z., Subproject T.N.W.).	American Lung Association, 2006, EST PREV INC LUNG DI; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bloom B, 2007, VITAL HLTH STAT, V10, P1; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Broide DH, 2008, J ALLERGY CLIN IMMUN, V121, P560, DOI 10.1016/j.jaci.2008.01.031; Brown SD, 2012, J ALLERGY CLIN IMMUN, V129, P388, DOI 10.1016/j.jaci.2011.11.037; Chakir J, 2003, J ALLERGY CLIN IMMUN, V111, P1293, DOI 10.1067/mai.2003.1557; Cheng G, 2011, MATRIX BIOL, V30, P126, DOI 10.1016/j.matbio.2010.12.003; Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009; Eisma RJ, 1997, AM J OTOLARYNG, V18, P405, DOI 10.1016/S0196-0709(97)90062-4; Goulet S, 2007, J CELL PHYSIOL, V210, P167, DOI 10.1002/jcp.20836; Hackett TL, 2007, CURR OPIN ALLERGY CL, V7, P63, DOI 10.1097/ACI.0b013e328013d61b; Halwani R, 2011, AM J RESP CELL MOL, V44, P127, DOI 10.1165/rcmb.2010-0027TR; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Hostettler KE, 2008, CLIN EXP ALLERGY, V38, P1309, DOI 10.1111/j.1365-2222.2008.03017.x; Huang J, 1999, AM J RESP CRIT CARE, V160, P725, DOI 10.1164/ajrccm.160.2.9809040; Johnson PRA, 2006, AM J RESP CRIT CARE, V173, P32, DOI 10.1164/rccm.200406-703OC; Kelly MM, 2005, AM J RESP CELL MOL, V32, P99, DOI 10.1165/rcmb.2004-0190OC; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P567, DOI 10.1111/j.1365-2222.2004.1917.x; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; Lama V, 2002, AM J RESP CELL MOL, V27, P752, DOI 10.1165/rcmb.4857; Lane C, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-53; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; Liang JR, 2011, J ALLERGY CLIN IMMUN, V128, P403, DOI 10.1016/j.jaci.2011.04.006; Lopez-Guisa JM, 2012, J ALLERGY CLIN IMMUN, V129, P990, DOI 10.1016/j.jaci.2011.11.035; Malmstrom K, 2011, THORAX, V66, P157, DOI 10.1136/thx.2010.139246; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Michalik M, 2009, MED SCI MONITOR, V15, pBR194; Minshall E, 2000, J ALLERGY CLIN IMMUN, V105, P232, DOI 10.1016/S0091-6749(00)90070-8; NAKAMURA Y, 1995, AM J PHYSIOL-LUNG C, V269, pL377, DOI 10.1152/ajplung.1995.269.3.L377; Ohkawara Y, 2000, AM J RESP CELL MOL, V23, P444, DOI 10.1165/ajrcmb.23.4.3875; Ohno I, 1996, AM J RESP CELL MOL, V15, P404, DOI 10.1165/ajrcmb.15.3.8810646; Papadopoulos NG, 2012, ALLERGY, V67, P976, DOI 10.1111/j.1398-9995.2012.02865.x; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Petrov VV, 2002, HYPERTENSION, V39, P258, DOI 10.1161/hy0202.103268; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Phan SH, 2002, CHEST, V122, p286S, DOI 10.1378/chest.122.6_suppl.286S; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2002.120951; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Radaev S, 2010, J BIOL CHEM, V285, P14806, DOI 10.1074/jbc.M109.079921; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; Roberts C R, 1998, Can Respir J, V5, P48; ROBERTS CR, 1995, CHEST, V107, pS111, DOI 10.1378/chest.107.3_Supplement.111S; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Semlali A, 2010, ALLERGY, V65, P1438, DOI 10.1111/j.1398-9995.2010.02376.x; Serpero L, 2006, IMMUNOL LETT, V105, P61, DOI 10.1016/j.imlet.2006.01.003; Skibinski G, 2007, AM J PHYSIOL-LUNG C, V293, pL69, DOI 10.1152/ajplung.00299.2006; Torrego A, 2007, THORAX, V62, P307, DOI 10.1136/thx.2006.063487; Wadsworth SJ, 2012, AM J RESP CRIT CARE, V185, pA6345; Wight TN, 2011, AM J PHYSIOL-GASTR L, V301, pG950, DOI 10.1152/ajpgi.00132.2011; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277; ZHANG K, 1994, AM J PATHOL, V145, P114	58	39	40	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					663	+		10.1016/j.jaci.2014.04.007	http://dx.doi.org/10.1016/j.jaci.2014.04.007			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24875618	Green Accepted, Bronze			2022-12-18	WOS:000341372400020
J	Schmid, JM; Wurtzen, PA; Dahl, R; Hoffmann, HJ				Schmid, Johannes Martin; Wurtzen, Peter Adler; Dahl, Ronald; Hoffmann, Hans Jurgen			Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							WASP VENOM ALLERGY; DESENSITIZATION		[Schmid, Johannes Martin; Dahl, Ronald; Hoffmann, Hans Jurgen] Aarhus Univ, Aarhus Univ Hosp, Dept Pulm Med, Aarhus, Denmark; [Schmid, Johannes Martin; Dahl, Ronald; Hoffmann, Hans Jurgen] Aarhus Univ, Dept Clin Med, Aarhus, Denmark; [Wurtzen, Peter Adler] ALK, Dept Immunol, Horsholm, Denmark	Aarhus University; Aarhus University	Schmid, JM (corresponding author), Aarhus Univ, Aarhus Univ Hosp, Dept Pulm Med, Aarhus, Denmark.	hans.jurgen.hoffmann@ki.au.dk	Hoffman, Hans Jurgen/I-6969-2018	Hoffman, Hans Jurgen/0000-0002-6743-7931; Schmid, Johannes/0000-0002-4558-2943				Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Celesnik N, 2012, ALLERGY, V67, P1594, DOI 10.1111/all.12044; Ebo DG, 2007, CYTOM PART B-CLIN CY, V72B, P196, DOI 10.1002/cyto.b.20142; Erdmann SM, 2004, ALLERGY, V59, P1102, DOI 10.1111/j.1398-9995.2004.00624.x; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Lalek N, 2010, CLIN EXP ALLERGY, V40, P1186, DOI 10.1111/j.1365-2222.2010.03524.x; Nopp A, 2009, ALLERGY, V64, P811, DOI 10.1111/j.1398-9995.2008.01900.x; Shamji MH, 2012, ALLERGY, V67, P217, DOI 10.1111/j.1398-9995.2011.02745.x	9	39	43	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					741	744		10.1016/j.jaci.2014.04.029	http://dx.doi.org/10.1016/j.jaci.2014.04.029			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GR	24934275				2022-12-18	WOS:000341372400034
J	Daham, K; James, A; Balgoma, D; Kupczyk, M; Billing, B; Lindeberg, A; Henriksson, E; FitzGerald, GA; Wheelock, CE; Dahlen, SE; Dahlen, B				Daham, Kameran; James, Anna; Balgoma, David; Kupczyk, Maciej; Billing, Bo; Lindeberg, Agneta; Henriksson, Elisabeth; FitzGerald, Garret A.; Wheelock, Craig E.; Dahlen, Sven-Erik; Dahlen, Barbro			Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; COX; NSAIDs; eicosanoids; prostaglandin; thromboxane; leukotrienes; airway hyperresponsiveness; mass spectrometry; urinary metabolites	ARACHIDONIC-ACID METABOLISM; ASPIRIN-SENSITIVE ASTHMA; INHALED PGE(2); BIOSYNTHESIS; RESPONSES; INDOMETHACIN; THROMBOXANE; CELECOXIB; LEUKOTRIENE-E4; ACTIVATION	Background: Prostaglandins that constrict and relax airways are synthesized in reactions catalyzed by either COX-1 or COX-2. It is not known whether selective inhibition of COX-2 makes asthmatic responses better or worse. Objective: To determine the effects of the selective COX-2 inhibitor, etoricoxib, on allergen-induced bronchoconstriction in asthmatic subjects. Methods: Sixteen subjects with mild atopic asthma underwent rising dose inhalation challenges with allergen or methacholine to determine PD20 FEV1 during a control study period or after 10 to 13 days of treatment with etoricoxib (90 mg once daily). The order of study periods was randomized with at least 2-week washout periods. Induced sputum cells and fractional exhaled nitric oxide levels were used to assess airway inflammation and blood assays for COX-1 and COX-2 activity to assess enzyme inhibition. Urinary excretion of lipids was used to assess prostaglandin biosynthesis. Results: Etoricoxib did not change baseline lung function, nor airway responsiveness to allergen or to methacholine. Neither were the allergen-induced increase in sputum eosinophils and fractional exhaled nitric oxide levels affected by treatment. The biochemical effectiveness of the treatment was established both in the blood assays and by the distinct inhibitory effect of etoricoxib on urinary excretion of tetranor-prostaglandin E-2 (P < .001). Conclusions: This first study of COX-2 inhibition in provoked asthma found no negative effects of etoricoxib on allergeninduced airflow obstruction and sputum eosinophils, basal lung function, or methacholine responsiveness. The study suggests that short-term use of COX-2 inhibitors is safe in subjects with asthma.	[Daham, Kameran; Billing, Bo; Lindeberg, Agneta; Henriksson, Elisabeth; Dahlen, Barbro] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden; [Daham, Kameran; James, Anna; Balgoma, David; Kupczyk, Maciej; Billing, Bo; Lindeberg, Agneta; Henriksson, Elisabeth; Wheelock, Craig E.; Dahlen, Sven-Erik; Dahlen, Barbro] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [James, Anna; Balgoma, David; Kupczyk, Maciej; Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Wheelock, Craig E.] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden; [FitzGerald, Garret A.] Univ Penn, Philadelphia, PA 19104 USA	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; University of Pennsylvania	Daham, K (corresponding author), Karolinska Univ Hosp, Dept Resp Med & Allergy, SE-14185 Stockholm, Sweden.	kameran.daham@ki.se	Balgoma, David/ABG-9548-2020; James, Anna/AAY-9937-2021	Balgoma Hernando, David/0000-0001-6463-4502	Swedish Heart-Lung Foundation; Swedish Medical Research Council, Vinnova (CiDAT); Stockholm County Council Research Funds (ALF); Asthma and Allergy Research Foundation; Centre for Allergy Research; Karolinska Institutet; Bernard Osher Initiative; Unbiased BIOmarkers in PREDiction of respiratory disease outcomes project (Innovative Medicines Initiative)	Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation); Swedish Medical Research Council, Vinnova (CiDAT); Stockholm County Council Research Funds (ALF); Asthma and Allergy Research Foundation; Centre for Allergy Research; Karolinska Institutet(Karolinska Institutet); Bernard Osher Initiative; Unbiased BIOmarkers in PREDiction of respiratory disease outcomes project (Innovative Medicines Initiative)	This study was supported by the Swedish Heart-Lung Foundation, the Swedish Medical Research Council, Vinnova (CiDAT), The Stockholm County Council Research Funds (ALF), the Asthma and Allergy Research Foundation, The Centre for Allergy Research, and Karolinska Institutet. A.J. and M.K. were supported by the Bernard Osher Initiative for research on severe asthma, and D.B. was supported by the Unbiased BIOmarkers in PREDiction of respiratory disease outcomes project (Innovative Medicines Initiative for severe asthma).	Balgoma D, 2013, ANAL CHEM, V85, P7866, DOI 10.1021/ac401461b; BEASLEY RCW, 1989, J APPL PHYSIOL, V66, P1685, DOI 10.1152/jappl.1989.66.4.1685; Brideau C, 1996, INFLAMM RES, V45, P68, DOI 10.1007/BF02265118; Daham K, 2011, CLIN EXP ALLERGY, V41, P36, DOI 10.1111/j.1365-2222.2010.03617.x; Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; Diamant Z, 2013, J ALLERGY CLIN IMMUN, V132, P1045, DOI 10.1016/j.jaci.2013.08.023; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; FAIRFAX AJ, 1983, CLIN EXP IMMUNOL, V52, P393; Fajt ML, 2013, J ALLERGY CLIN IMMUN, V131, P1504, DOI 10.1016/j.jaci.2013.01.035; FISH JE, 1981, AM REV RESPIR DIS, V123, P609; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31, DOI 10.1164/ajrccm.159.1.9804030; Grosser T, 2010, ANNU REV MED, V61, P17, DOI 10.1146/annurev-med-011209-153129; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; Harrington LS, 2008, FASEB J, V22, P4005, DOI 10.1096/fj.08-107979; KIRBY JG, 1989, J APPL PHYSIOL, V66, P578, DOI 10.1152/jappl.1989.66.2.578; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96, DOI 10.1164/ajrccm/146.1.96; LUPINETTI MD, 1989, AM REV RESPIR DIS, V140, P932, DOI 10.1164/ajrccm/140.4.932; MANNING PJ, 1991, EUR RESPIR J, V4, P667; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Norel X, 1999, BRIT J PHARMACOL, V126, P867, DOI 10.1038/sj.bjp.0702392; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; Peebles RS, 2002, AM J RESP CRIT CARE, V165, P1154, DOI 10.1164/rccm.2106025; Pettipher R, 2012, J MED CHEM, V55, P2915, DOI 10.1021/jm2013997; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308, DOI 10.1164/ajrccm.154.2.8756799; Richter M, 2000, EUR J PHARMACOL, V389, P225, DOI 10.1016/S0014-2999(99)00878-X; Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Safholm J, 2013, BRIT J PHARMACOL, V168, P794, DOI 10.1111/j.1476-5381.2012.02189.x; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572, DOI 10.1164/ajrccm.153.2.8564100; Seymour ML, 2001, AM J RESP CRIT CARE, V164, P2051, DOI 10.1164/ajrccm.164.11.2008137; SLADEK K, 1990, AM REV RESPIR DIS, V141, P1441, DOI 10.1164/ajrccm/141.6.1441; Song WL, 2012, J CLIN INVEST, V122, P1459, DOI 10.1172/JCI59262; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Swedin L, 2010, PROSTAG OTH LIPID M, V92, P44, DOI 10.1016/j.prostaglandins.2010.02.004; Szczeklik A, 1996, AM J RESP CRIT CARE, V153, P567, DOI 10.1164/ajrccm.153.2.8564099; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; TAYLOR IK, 1991, AM REV RESPIR DIS, V143, P119, DOI 10.1164/ajrccm/143.1.119; Wechsler ME, 2011, NEW ENGL J MED, V365, P119, DOI 10.1056/NEJMoa1103319; Yu Y, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003787	40	39	40	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2014	134	2					306	313		10.1016/j.jaci.2013.12.002	http://dx.doi.org/10.1016/j.jaci.2013.12.002			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AO5GB	24461582				2022-12-18	WOS:000341370800008
J	Ichihara, A; Wang, ZZ; Jinnin, M; Izuno, Y; Shimozono, N; Yamane, K; Fujisawa, A; Moriya, C; Fukushima, S; Inoue, Y; Ihn, H				Ichihara, Asako; Wang, Zhongzhi; Jinnin, Masatoshi; Izuno, Yuki; Shimozono, Naoki; Yamane, Keitaro; Fujisawa, Akihiko; Moriya, Chikako; Fukushima, Satoshi; Inoue, Yuji; Ihn, Hironobu			Upregulation of miR-18a-5p contributes to epidermal necrolysis in severe drug eruptions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MicroRNA; apoptosis; drug eruption; keratinocyte; serum	STEVENS-JOHNSON-SYNDROME; MICRORNA EXPRESSION; MIR-17-92 CLUSTER; BCL-2 FAMILY; CANCER; ANGIOGENESIS; GRANULYSIN; BIOMARKERS; APOPTOSIS; GENOMICS	Background: Toxic epidermal necrolysis (TEN) is a severe drug-induced cutaneous reaction. Although one of the primary histologic features of TEN is keratinocyte apoptosis, its exact mechanism remains unknown. Objectives: We investigated the role of microRNAs (miRNAs) in the pathogenesis of severe drug eruptions and evaluated the possibility that miRNA can be a disease marker. Methods: miRNAs were extracted from tissues and sera of patients. PCR array analyses were performed to identify pathogenic miRNAs. The results were confirmed with quantitative real-time PCR, in situ hybridization, transient transfection of small interfering RNAs or miRNA mimics into cultured keratinocytes, flow cytometry, immunoblotting, luciferase assay, and immunohistochemistry. Results: PCR array analysis and real-time PCR using tissue miRNAs demonstrated that the miR-18a-5p level was increased in the skin of patients with TEN in vivo. Transfection of the miR-18a5p mimic into keratinocytes in vitro resulted in increased apoptotic cell numbers and caspase-9 activity, which were also increased in the skin of patients with TEN. The miR-18a-5p mimic also downregulated the expression of B-cell lymphoma/leukemia-2-like protein 10 (BCL2L10), an anti-intrinsic apoptotic molecule. A luciferase assay with the BCL2L10 39 untranslated region showed BCL2L10 is directly targeted by miR-18a-5p. The protein and mRNA expressions of BCL2L10 were decreased in the skin of patients with TEN. Transfection with BCL2L10 small interfering RNA induced keratinocyte apoptosis and caspase activity. Furthermore, serum miR-18a-5p levels tended to be increased in patients with TEN and were correlated with areas of skin erythema or erosion in patients with drug eruptions. Conclusions: Our results indicated that downregulated BCL2L10 caused by miR-18a-5p overexpression mediates intrinsic keratinocyte apoptosis in patients with TEN. Serum miR-18a-5p levels can be a useful disease marker for drug eruptions.	[Ichihara, Asako; Wang, Zhongzhi; Jinnin, Masatoshi; Izuno, Yuki; Shimozono, Naoki; Yamane, Keitaro; Fujisawa, Akihiko; Moriya, Chikako; Fukushima, Satoshi; Inoue, Yuji; Ihn, Hironobu] Kumamoto Univ, Dept Dermatol & Plast Surg, Fac Life Sci, Kumamoto 8608556, Japan	Kumamoto University	Jinnin, M (corresponding author), Kumamoto Univ, Dept Dermatol & Plast Surg, Fac Life Sci, 1-1-1 Honjo, Kumamoto 8608556, Japan.	mjin@kumamoto-u.ac.jp	Wang, Zhongzhi/AAA-6868-2020	Wang, Zhongzhi/0000-0002-4533-8414; Fukushima, Satoshi/0000-0002-0622-7682				Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bostjancic E, 2008, ACTA DERMATOVEN ALP, V17, P95; Brock M, 2011, J BIOL CHEM, V286, P40142, DOI 10.1074/jbc.M111.251793; Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133; Cheng YH, 2010, J CARDIOVASC TRANSL, V3, P251, DOI 10.1007/s12265-010-9169-7; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Davidson-Moncada J, 2010, ANN NY ACAD SCI, V1183, P183, DOI 10.1111/j.1749-6632.2009.05121.x; Edlich F, 2011, CELL, V145, P104, DOI 10.1016/j.cell.2011.02.034; Filipowicz W, 2005, CURR OPIN STRUC BIOL, V15, P331, DOI 10.1016/j.sbi.2005.05.006; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fujita Y, 2011, J AM ACAD DERMATOL, V65, P65, DOI 10.1016/j.jaad.2010.04.042; Furer V, 2010, CLIN IMMUNOL, V136, P1, DOI 10.1016/j.clim.2010.02.005; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Herrera BM, 2010, DIABETOLOGIA, V53, P1099, DOI 10.1007/s00125-010-1667-2; Jimeno A, 2005, CANCER RES, V65, P3003, DOI 10.1158/0008-5472.CAN-04-3586; Kanemaru H, 2011, J DERMATOL SCI, V61, P187, DOI 10.1016/j.jdermsci.2010.12.010; Kroh EM, 2010, METHODS, V50, P298, DOI 10.1016/j.ymeth.2010.01.032; Kuehbacher A, 2008, TRENDS PHARMACOL SCI, V29, P12, DOI 10.1016/j.tips.2007.10.014; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Long JM, 2011, BIOCHEM BIOPH RES CO, V404, P889, DOI 10.1016/j.bbrc.2010.12.053; Lu Z, 2011, EXP CELL RES, V317, P1935, DOI 10.1016/j.yexcr.2011.05.019; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Morimura R, 2011, BRIT J CANCER, V105, P1733, DOI 10.1038/bjc.2011.453; Nakashima T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014334; Provost P, 2010, BRAIN RES, V1338, P58, DOI 10.1016/j.brainres.2010.03.069; Sand M, 2012, BRIT J DERMATOL, V167, P847, DOI 10.1111/j.1365-2133.2012.11022.x; Sand M, 2009, J DERMATOL SCI, V53, P169, DOI 10.1016/j.jdermsci.2008.10.004; Song LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025454; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Takakura S, 2008, CANCER SCI, V99, P1147, DOI 10.1111/j.1349-7006.2008.00800.x; Tsuchida A, 2011, CANCER SCI, V102, P2264, DOI 10.1111/j.1349-7006.2011.02081.x; Tvrdik D, 2012, MED SCI MONITOR, V18, pBR60, DOI 10.12659/MSM.882205; Voso MT, 2011, LEUKEMIA, V25, P1910, DOI 10.1038/leu.2011.170; Wei CY, 2012, DRUG METAB PHARMACOK, V27, P132, DOI 10.2133/dmpk.DMPK-11-RV-116; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Xu JD, 2011, J PATHOL, V223, P400, DOI 10.1002/path.2811; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhu Weizhu, 2009, BMC Res Notes, V2, P89, DOI 10.1186/1756-0500-2-89	40	39	40	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2014	133	4					1065	1074		10.1016/j.jaci.2013.09.019	http://dx.doi.org/10.1016/j.jaci.2013.09.019			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	AD8QW	24184144				2022-12-18	WOS:000333531700017
J	Izawa, K; Isobe, M; Matsukawa, T; Ito, S; Maehara, A; Takahashi, M; Yamanishi, Y; Kaitani, A; Oki, T; Okumura, K; Kitamura, T; Kitaura, J				Izawa, Kumi; Isobe, Masamichi; Matsukawa, Toshihiro; Ito, Shinichi; Maehara, Akie; Takahashi, Mariko; Yamanishi, Yoshinori; Kaitani, Ayako; Oki, Toshihiko; Okumura, Ko; Kitamura, Toshio; Kitaura, Jiro			Sphingomyelin and ceramide are physiological ligands for human LMIR3/CD300f, inhibiting Fc epsilon RI-mediated mast cell activation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							RECEPTOR; RESPONSES; BINDING		[Izawa, Kumi; Isobe, Masamichi; Matsukawa, Toshihiro; Ito, Shinichi; Maehara, Akie; Takahashi, Mariko; Yamanishi, Yoshinori; Kaitani, Ayako; Oki, Toshihiko; Kitamura, Toshio; Kitaura, Jiro] Univ Tokyo, Inst Med Sci, Div Cellular Therapy, Tokyo, Japan; [Oki, Toshihiko; Kitamura, Toshio] Univ Tokyo, Inst Med Sci, Div Stem Cell Signaling, Tokyo, Japan; [Izawa, Kumi; Okumura, Ko] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; [Okumura, Ko] Juntendo Univ, Sch Med, Atopy Res Ctr, Tokyo 113, Japan	University of Tokyo; University of Tokyo; Juntendo University; Juntendo University	Izawa, K (corresponding author), Univ Tokyo, Inst Med Sci, Div Cellular Therapy, Tokyo, Japan.	kitamura@ims.u-tokyo.ac.jp; kitaura-tky@umin.ac.jp	Matsukawa, Toshihiro/A-4194-2016; Kitamura, Toshio/AAA-2071-2021	Matsukawa, Toshihiro/0000-0003-2371-3778				Alvarez-Errico D, 2007, J IMMUNOL, V178, P808, DOI 10.4049/jimmunol.178.2.808; Cannon JP, 2012, IMMUNOGENETICS, V64, P39, DOI 10.1007/s00251-011-0562-4; Chung DH, 2003, J IMMUNOL, V171, P6541, DOI 10.4049/jimmunol.171.12.6541; Izawa K, 2012, IMMUNITY, V37, P827, DOI 10.1016/j.immuni.2012.08.018; Izawa K, 2009, J IMMUNOL, V183, P925, DOI 10.4049/jimmunol.0900552; Nakahashi-Oda C, 2012, J EXP MED, V209, P1493, DOI 10.1084/jem.20120096; Simhadri VR, 2012, BLOOD, V119, P2799, DOI 10.1182/blood-2011-08-372425; Yamaji A, 1998, J BIOL CHEM, V273, P5300, DOI 10.1074/jbc.273.9.5300; Yamanishi Y, 2010, J EXP MED, V207, P1501, DOI 10.1084/jem.20090581	9	39	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					270	273		10.1016/j.jaci.2013.08.008	http://dx.doi.org/10.1016/j.jaci.2013.08.008			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	24035150	Bronze			2022-12-18	WOS:000329105700040
J	Kiwamoto, T; Brummet, ME; Wu, F; Motari, MG; Smith, DF; Schnaar, RL; Zhu, Z; Bochner, BS				Kiwamoto, Takumi; Brummet, Mary E.; Wu, Fan; Motari, Mary G.; Smith, David F.; Schnaar, Ronald L.; Zhu, Zhou; Bochner, Bruce S.			Mice deficient in the St3gal3 gene product alpha 2,3 sialyltransferase (ST3Gal-III) exhibit enhanced allergic eosinophilic airway inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Eosinophils; asthma; Siglec-F; 6 '-sulfated sialyl Lewis X; 6 '-sulfated sialyl N-acetyl-D-lactosamine; apoptosis; glycan ligands; lung; St3gal3	SIGLEC-F; MAST-CELLS; APOPTOSIS; LIGANDS; EXPRESSION; MECHANISM	Background: Sialic acid-binding immunoglobulin-like lectin (Siglec)-F is a proapoptotic receptor on mouse eosinophils, but little is known about its natural tissue ligand. Objective: We previously reported that the St3gal3 gene product alpha 2,3 sialyltransferase (ST3Gal-III) is required for constitutive Siglec-F lung ligand synthesis. We therefore hypothesized that attenuation of ST3Gal-III will decrease Siglec-F ligand levels and enhance allergic eosinophilic airway inflammation. Methods: C57BL/6 wild-type mice and St3gal3 heterozygous or homozygous deficient (St3gal3(+/-) and St3gal3(-/-)) mice were used. Eosinophilic airway inflammation was induced through sensitization to ovalbumin (OVA) and repeated airway OVA challenge. Siglec-F human IgG(1) fusion protein (Siglec-F-Fc) was used to detect Siglec-F ligands. Lung tissue and bronchoalveolar lavage fluid (BALF) were analyzed for inflammation, as well as various cytokines and chemokines. Serum was analyzed for allergen-specific immunoglobulin levels. Results: Western blotting with Siglec-F-Fc detected approximately 500-kDa and approximately 200-kDa candidate Siglec-F ligands that were less abundant in St3gal3(+/-) lung extracts and nearly absent in St3gal3(-/-) lung extracts. After OVA sensitization and challenge, Siglec-F ligands were increased in wild-type mouse lungs but less so in St3gal3 mutants, whereas peribronchial and BALF eosinophil numbers were greater in the mutants, with the following rank order: St3gal3(-/-) >= St3gal3(+/-) > wild-type mice. Levels of various cytokines and chemokines in BALF were not significantly different among these 3 types of mice, although OVA-specific serum IgG(1) levels were increased in St3gal3(-/-) mice. Conclusions: After OVA sensitization and challenge, St3gal3(+/-) and St3gal3(-/-) mice have more intense allergic eosinophilic airway inflammation and less sialylated Siglec-F ligands in their airways. One possible explanation for these findings is that levels of sialylated airway ligands for Siglec-F might be diminished in mice with attenuated levels of ST3Gal-III, resulting in a reduction in a natural proapoptotic pathway for controlling airway eosinophilia.	[Kiwamoto, Takumi; Brummet, Mary E.; Wu, Fan; Zhu, Zhou; Bochner, Bruce S.] Johns Hopkins Univ, Sch Med, Dept Med, Div Allergy & Clin Immunol, Baltimore, MD 21205 USA; [Motari, Mary G.; Schnaar, Ronald L.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Smith, David F.] Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	Johns Hopkins University; Johns Hopkins University; Emory University	Bochner, BS (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	bbochner@jhmi.edu	Kiwamoto, Takumi/AAX-8140-2021; Schnaar, Ronald L/S-8967-2016	Kiwamoto, Takumi/0000-0003-3918-9878; Schnaar, Ronald L/0000-0002-7701-5484	National Institutes of Health [AI72265, HL107151]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL107151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072265, R56AI072265] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM098791] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants AI72265 and HL107151 from the National Institutes of Health.	Bochner BS, 2009, CLIN EXP ALLERGY, V39, P317, DOI 10.1111/j.1365-2222.2008.03173.x; Bochner BS, 2012, J ALLERGY CLIN IMMUN, V130, P587, DOI 10.1016/j.jaci.2012.07.024; Bochner BS, 2010, J ALLERGY CLIN IMMUN, V126, P16, DOI 10.1016/j.jaci.2010.02.026; Bochner BS, 2005, J BIOL CHEM, V280, P4307, DOI 10.1074/jbc.M412378200; Cho JY, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-154; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Ellies LG, 2002, BLOOD, V100, P3618, DOI 10.1182/blood-2002-04-1007; Feng YH, 2012, J ZHEJIANG UNIV-SC B, V13, P386, DOI 10.1631/jzus.B1100218; Guo JP, 2011, AM J RESP CELL MOL, V44, P238, DOI 10.1165/rcmb.2010-0007OC; Kikly KK, 2000, J ALLERGY CLIN IMMUN, V105, P1093, DOI 10.1067/mai.2000.107127; Kiwamoto T, 2013, CURR OPIN ALLERGY CL, V13, P106, DOI 10.1097/ACI.0b013e32835b594a; Kiwamoto T, 2012, PHARMACOL THERAPEUT, V135, P327, DOI 10.1016/j.pharmthera.2012.06.005; Na HJ, 2012, CYTOKINE, V57, P169, DOI 10.1016/j.cyto.2011.10.007; Nutku E, 2005, BIOCHEM BIOPH RES CO, V336, P918, DOI 10.1016/j.bbrc.2005.08.202; Nutku E, 2003, BLOOD, V101, P5014, DOI 10.1182/blood-2002-10-3058; Nutku-Bilir E, 2008, AM J RESP CELL MOL, V38, P121, DOI 10.1165/rcmb.2007-0154OC; Rubinstein E, 2011, J PEDIATR GASTR NUTR, V53, P409, DOI 10.1097/MPG.0b013e3182182ff8; Shin MK, 2013, EOSINOPHILS IN HEALTH AND DISEASE, P592; Song DJ, 2009, J IMMUNOL, V183, P5333, DOI 10.4049/jimmunol.0801421; Song DJ, 2009, CLIN IMMUNOL, V131, P157, DOI 10.1016/j.clim.2008.11.009; Stevens WW, 2007, J IMMUNOL METHODS, V327, P63, DOI 10.1016/j.jim.2007.07.011; Tateno H, 2005, GLYCOBIOLOGY, V15, P1125, DOI 10.1093/glycob/cwi097; Varki A, 2006, GLYCOBIOLOGY, V16, p1R, DOI 10.1093/glycob/cwj008; von Gunten S, 2008, ANN NY ACAD SCI, V1143, P61, DOI 10.1196/annals.1443.011; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255; Zimmermann N, 2008, ALLERGY, V63, P1156, DOI 10.1111/j.1398-9995.2008.01709.x	26	39	39	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					240	+		10.1016/j.jaci.2013.05.018	http://dx.doi.org/10.1016/j.jaci.2013.05.018			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23830412	Green Accepted, Bronze			2022-12-18	WOS:000329105700032
J	Mendola, P; Mannisto, TI; Leishear, K; Reddy, UM; Chen, Z; Laughon, SK				Mendola, Pauline; Maennistoe, Tuija I.; Leishear, Kira; Reddy, Uma M.; Chen, Zhen; Laughon, S. Katherine			Neonatal health of infants born to mothers with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Neonatal health; maternal asthma; respiratory distress syndrome; transient tachypnea of the newborn; neonatal jaundice; preterm birth	MATERNAL ASTHMA; PERINATAL OUTCOMES; TRANSIENT TACHYPNEA; PREGNANT-WOMEN; RISK; DELIVERY; HOSPITALIZATION; ASSOCIATION	Background: Maternal asthma is associated with serious pregnancy complications, but newborn morbidity is understudied. Objective: We wanted to determine whether infants of asthmatic mothers have more neonatal complications. Methods: The Consortium on Safe Labor (2002-2008), a retrospective cohort, included 223,512 singleton deliveries at >= 23 weeks' gestation. Newborns of mothers with asthma (n = 17,044) were compared with newborns of women without asthma by using logistic regression models with generalized estimating equations to calculate adjusted odds ratios (ORs) and 95% CIs. Electronic medical record data included gestational week at delivery, birth weight, resuscitation, neonatal intensive care unit (NICU) admission, NICU length of stay, hyperbilirubinemia, respiratory distress syndrome, apnea, sepsis, anemia, transient tachypnea of the newborn, infective pneumonia, asphyxia, intracerebral hemorrhage, seizure, cardiomyopathy, periventricular or intraventricular hemorrhage, necrotizing enterocolitis, aspiration, retinopathy of prematurity, and perinatal mortality. Results: Preterm delivery was associated with maternal asthma for each week after 33 completed weeks of gestation and not earlier. Maternal asthma also increased the adjusted odds of small for gestational age (OR 5 1.10; 95% CI, 1.05-1.16), NICU admission (OR 5 1.12; 95% CI, 1.07-1.17), hyperbilirubinemia (OR 5 1.09; 95% CI, 1.04-1.14), respiratory distress syndrome (OR 5 1.09; 95% CI, 1.01-1.19), transient tachypnea of the newborn (OR 5 1.10; 95% CI, 1.02-1.19), and asphyxia (OR 5 1.34; 95% CI, 1.03-1.75). Findings persisted for term infants (>= 37 weeks) who had additional increased odds of intracerebral hemorrhage (OR 5 1.84; 95% CI, 1.11-3.03) and anemia (OR 5 1.30; 95% CI, 1.04-1.62). Conclusions: Maternal asthma was associated with prematurity and small for gestational age. Adverse neonatal outcomes, including respiratory complications, hyperbilirubinemia, and NICU admission, were increased in association with maternal asthma even among term deliveries.	[Mendola, Pauline; Maennistoe, Tuija I.; Laughon, S. Katherine] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Epidemiol Branch, Rockville, MD USA; [Leishear, Kira] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Epidemiol Stat & Prevent Res, Rockville, MD USA; [Reddy, Uma M.] NICHD, Pregnancy & Perinatol Branch, Rockville, MD USA; [Chen, Zhen] NICHD, DESPR, Bioinformat & Biostat Branch, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mendola, P (corresponding author), NICHHD, 6100 Execut Blvd,Rm 7B03F, Rockville, MD 20852 USA.	pauline.mendola@nih.gov	Chen, Zhen/M-3936-2017	Chen, Zhen/0000-0002-9946-1362; Mendola, Pauline/0000-0001-5330-2844; Grantz, Katherine/0000-0003-0276-8534; Mannisto, Tuija/0000-0002-6382-9153	National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health [HHSN267200603425C]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008923, ZIAHD008794] Funding Source: NIH RePORTER	National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Supported by the Intramural Research Program of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development. The Consortium on Safe Labor was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, through contract no. HHSN267200603425C.	Alexander S, 1998, OBSTET GYNECOL, V92, P435, DOI 10.1016/S0029-7844(98)00191-4; Aspberg S, 2010, PEDIAT ALLERG IMM-UK, V21, pE733, DOI 10.1111/j.1399-3038.2010.01038.x; Bakhireva LN, 2008, ANN ALLERG ASTHMA IM, V101, P137, DOI 10.1016/S1081-1206(10)60201-3; BARNES PJ, 1986, J ALLERGY CLIN IMMUN, V77, P791, DOI 10.1016/0091-6749(86)90375-1; Berg CJ, 2009, OBSTET GYNECOL, V113, P1075, DOI 10.1097/AOG.0b013e3181a09fc0; Clark JM, 2007, PAEDIATR PERINAT EP, V21, P154, DOI 10.1111/j.1365-3016.2007.00784.x; Clifton VL, 2012, J PREGNANCY, V2012, DOI 10.1155/2012/741613; Clifton VL, 2005, CELL TISSUE RES, V322, P63, DOI 10.1007/s00441-005-1117-5; Demissie K, 1998, PEDIATRICS, V102, P84, DOI 10.1542/peds.102.1.84; Dodds L, 1999, BRIT MED J, V318, P1011, DOI 10.1136/bmj.318.7189.1011; Dombrowski Mitchell P, 2008, Obstet Gynecol, V111, P457, DOI 10.1097/AOG.0b013e3181665ff4; Dombrowski MP, 2010, CLIN OBSTET GYNECOL, V53, P301, DOI 10.1097/GRF.0b013e3181de8906; Enriquez R, 2007, J ALLERGY CLIN IMMUN, V120, P625, DOI 10.1016/j.jaci.2007.05.044; Enriquez R, 2006, AM J OBSTET GYNECOL, V195, P149, DOI 10.1016/j.ajog.2006.01.065; Ku MS, 2012, PEDIAT ALLERG IMM-UK, V23, P623, DOI 10.1111/j.1399-3038.2012.01345.x; Kwon HL, 2006, IMMUNOL ALLERGY CLIN, V26, P29, DOI 10.1016/j.iac.2005.11.002; Lim A, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1094; Mannisto T, 2013, AM J EPIDEMIOL, V178, P731, DOI 10.1093/aje/kwt031; Martinez FD, 1997, CIBA F SYMP, V206, P233; Mendola P, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2012.11.007; Murphy VE, 2013, BJOG-INT J OBSTET GY, V120, P812, DOI 10.1111/1471-0528.12224; Murphy VE, 2011, BJOG-INT J OBSTET GY, V118, P1314, DOI 10.1111/j.1471-0528.2011.03055.x; *NAT ASTHM ED PREV, 2005, WORK GROUP REP MAN A; Pettigrew MM, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-15; SCHATZ M, 1991, AM J DIS CHILD, V145, P156, DOI 10.1001/archpedi.1991.02160020046013; Schatz M, 2006, AM J OBSTET GYNECOL, V194, P120, DOI 10.1016/j.ajog.2005.06.028; VanderWeele TJ, 2012, EPIDEMIOLOGY, V23, P1, DOI 10.1097/EDE.0b013e31823aca5d; Wilcox AJ, 2011, AM J EPIDEMIOL, V174, P1062, DOI 10.1093/aje/kwr230; WYSZOGRODSKI I, 1974, AM J OBSTET GYNECOL, V119, P1107, DOI 10.1016/0002-9378(74)90267-1; YUDKIN PL, 1987, LANCET, V1, P1192; Zetstra-van der Woude PA, 2013, J ALLERGY CLIN IMMUN, V131, P711, DOI 10.1016/j.jaci.2012.08.027; Zhang J, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.06.058	32	39	41	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2014	133	1					85	+		10.1016/j.jaci.2013.06.012	http://dx.doi.org/10.1016/j.jaci.2013.06.012			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	281MM	23916153	Green Accepted			2022-12-18	WOS:000329105700011
J	Brunner, PM; Koszik, F; Reininger, B; Kalb, ML; Bauer, W; Stingl, G				Brunner, Patrick M.; Koszik, Frieder; Reininger, Baerbel; Kalb, Madeleine L.; Bauer, Wolfgang; Stingl, Georg			Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)(+) dendritic cells and macrophages	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Psoriasis; myeloid dendritic cells; 6-sulfo-LacNac; IL-12p40; TNF-alpha	NECROSIS-FACTOR-ALPHA; TNF-ALPHA; IN-VITRO; PSORIATIC SKIN; T(H)17 CELLS; HUMAN BLOOD; MECHANISMS; LACNAC; EXPRESSION; DIFFERENTIATION	Background: The spectrum of TNF-alpha-producing cells in patients with psoriasis, as well as their fate during treatment with TNF-alpha antagonists, is not clearly defined. Objective: We sought to analyze the effects of anti-TNF-alpha treatment on TNF-alpha 1 cells in the skin and blood of patients with psoriasis. Methods: Lesional psoriatic skin was analyzed by means of immunohistologic staining and quantitative RT-PCR, and peripheral blood cells were phenotypically characterized by means of multicolor immunofluorescence labeling. Results: By using a tyramide-based signal amplification system, TNF-alpha was detected in dermal CD45(+)HLA-DR+ leukocytes consisting of CD11c(+) dendritic cells and CD163(+) macrophages. In peripheral blood we observed an increase in the TNF-alpha-producing myeloid subsets of CD14(-) 6-sulfo-LacNac(+) dendritic cells and CD14(+)CD16(+) "intermediate" monocytes compared with healthy control subjects. Strikingly, we did not find detectable levels of TNF-alpha in other cells, including keratinocytes or T cells, making these cell types unlikely targets of TNF-alpha blockers. Up to 48 hours after the intravenous administration of the TNF-alpha antagonist infliximab, we encountered no overt changes in numbers of TNF-alpha 1 cells or signs of apoptosis in lesional psoriatic skin. Yet we observed a rapid decrease in IL-12p40, IL-1 beta, CCL20, and IL12RB1 mRNA levels. Consistently, TNF-alpha blockade during in vitro stimulation of 6-sulfo-LacNac DCs resulted in decreased production of IL-12 and IL-23 but not IL-6. In a mixed leukocyte reaction infliximab led to significantly decreased proliferation rates of T cells independent of the Fc antibody fragment. Conclusion: The decrease in tissue inflammation during anti-TNF-alpha therapy is not due to immediate killing of TNF-alpha-producing cells but rather results from a rapid downregulation of the pathogenic IL-12/IL-23-driven immune response.	[Brunner, Patrick M.; Koszik, Frieder; Reininger, Baerbel; Kalb, Madeleine L.; Bauer, Wolfgang; Stingl, Georg] Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis, A-1090 Vienna, Austria	Medical University of Vienna	Stingl, G (corresponding author), Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	georg.stingl@meduniwien.ac.at		Brunner, Patrick/0000-0002-3488-3345; Bauer, Wolfgang/0000-0002-0155-1176	Austrian Science Fund, Vienna, Austria [DK-W1212-B13]	Austrian Science Fund, Vienna, Austria(Austrian Science Fund (FWF))	Supported by a research grant from the Austrian Science Fund, Vienna, Austria (DK-W1212-B13).	Ackermann L, 1998, ARCH DERMATOL RES, V290, P353, DOI 10.1007/s004030050317; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Amatschek S, 2007, BLOOD, V109, P4777, DOI 10.1182/blood-2006-10-053280; Armstrong EJ, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000062; Arora T, 2009, CYTOKINE, V45, P124, DOI 10.1016/j.cyto.2008.11.008; Austin LM, 1999, J INVEST DERMATOL, V113, P752, DOI 10.1046/j.1523-1747.1999.00749.x; Bangert C, 2011, DERMATOLOGY, V222, P36, DOI 10.1159/000321711; Christophers E, 2001, CLIN EXP DERMATOL, V26, P314, DOI 10.1046/j.1365-2230.2001.00832.x; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Davidovici BB, 2010, J INVEST DERMATOL, V130, P1785, DOI 10.1038/jid.2010.103; Dobel T, 2013, BLOOD, V121, P3609, DOI 10.1182/blood-2012-08-447045; Feldman SR, 2005, ANN RHEUM DIS, V64, P65, DOI 10.1136/ard.2004.031237; Fuentes-Duculan J, 2010, J INVEST DERMATOL, V130, P2412, DOI 10.1038/jid.2010.165; Gerspach J, 2000, MICROSC RES TECHNIQ, V50, P243, DOI 10.1002/1097-0029(20000801)50:3<243::AID-JEMT8>3.0.CO;2-B; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Gunther C, 2012, CLIN EXP DERMATOL, V37, P169, DOI 10.1111/j.1365-2230.2011.04213.x; Hansel A, 2011, J ALLERGY CLIN IMMUN, V127, P787, DOI 10.1016/j.jaci.2010.12.009; Harper EG, 2009, J INVEST DERMATOL, V129, P2175, DOI 10.1038/jid.2009.65; Horiuchi T, 2010, RHEUMATOLOGY, V49, P1215, DOI 10.1093/rheumatology/keq031; Hunyady B, 1996, J HISTOCHEM CYTOCHEM, V44, P1353, DOI 10.1177/44.12.8985127; Johansen C, 2006, J IMMUNOL, V176, P1431, DOI 10.4049/jimmunol.176.3.1431; Kalb ML, 2012, J IMMUNOL, V188, P1583, DOI 10.4049/jimmunol.1102437; Kaymakcalan Z, 2009, CLIN IMMUNOL, V131, P308, DOI 10.1016/j.clim.2009.01.002; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KRISTENSEN M, 1993, CLIN EXP IMMUNOL, V94, P354; Lowes MA, 2005, P NATL ACAD SCI USA, V102, P19057, DOI 10.1073/pnas.0509736102; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Mitoma H, 2008, ARTHRITIS RHEUM-US, V58, P1248, DOI 10.1002/art.23447; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; NICKOLOFF BJ, 1991, AM J PATHOL, V138, P129; Reich K, 2012, J EUR ACAD DERMATOL, V26, P3, DOI 10.1111/j.1468-3083.2011.04410.x; Reich K, 2012, BRIT J DERMATOL, V166, P179, DOI 10.1111/j.1365-2133.2011.10583.x; Rossol M, 2012, ARTHRITIS RHEUM-US, V64, P671, DOI 10.1002/art.33418; Schakel K, 2006, IMMUNITY, V24, P767, DOI 10.1016/j.immuni.2006.03.020; Schakel K, 1998, EUR J IMMUNOL, V28, P4084, DOI 10.1002/(SICI)1521-4141(199812)28:12<4084::AID-IMMU4084>3.0.CO;2-4; Schakel K, 2002, IMMUNITY, V17, P289, DOI 10.1016/S1074-7613(02)00393-X; Stary G, 2010, AM J PATHOL, V177, P2421, DOI 10.2353/ajpath.2010.100277; Terajima S, 1998, ARCH DERMATOL RES, V290, P246, DOI 10.1007/s004030050299; Tracey D, 2008, PHARMACOL THERAPEUT, V117, P244, DOI 10.1016/j.pharmthera.2007.10.001; van der Laan N, 2001, ARCH DERMATOL RES, V293, P226, DOI 10.1007/s004030100214; Wong KL, 2012, IMMUNOL RES, V53, P41, DOI 10.1007/s12026-012-8297-3; Wong KL, 2011, BLOOD, V118, pE15, DOI 10.1182/blood-2010-12-326355; Zaba LC, 2007, J CLIN INVEST, V117, P2517, DOI 10.1172/JCI32282; Zaba LC, 2009, J INVEST DERMATOL, V129, P79, DOI 10.1038/jid.2008.194; Zawada AM, 2011, BLOOD, V118, pE50, DOI 10.1182/blood-2011-01-326827; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957	49	39	42	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1184	+		10.1016/j.jaci.2013.05.036	http://dx.doi.org/10.1016/j.jaci.2013.05.036			18	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23890755	Bronze			2022-12-18	WOS:000326235600021
J	Cui, H; Okamoto, Y; Yoshioka, K; Du, W; Takuwa, N; Zhang, W; Asano, M; Shibamoto, T; Takuwa, Y				Cui, Hong; Okamoto, Yasuo; Yoshioka, Kazuaki; Du, Wa; Takuwa, Noriko; Zhang, Wei; Asano, Masahide; Shibamoto, Toshishige; Takuwa, Yoh			Sphingosine-1-phosphate receptor 2 protects against anaphylactic shock through suppression of endothelial nitric oxide synthase in mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sphingosine-1-phosphate; S1P(2); vascular permeability; anaphylaxis; endothelial nitric oxide synthase; nitric oxide; nitrosylation; beta-catenin; VE-cadherin; adherens junction	SPHINGOSINE 1-PHOSPHATE; LYMPHOCYTE EGRESS; S-NITROSYLATION; BETA-CATENIN; IN-VIVO; ANGIOGENESIS; ACTIVATION; S1P(2); HYPOTENSION; INTEGRITY	Background: Sphingosine-1-phosphate receptor 2 (S1P(2)) is expressed in vascular endothelial cells (ECs). However, the role of S1P(2) in vascular barrier integrity and anaphylaxis is not well understood. Endothelial nitric oxide synthase (eNOS) generates nitric oxide to mediate vascular leakage, compromising survival in patients with anaphylaxis. We recently observed that endothelial S1P(2) inhibits Akt, an activating kinase of eNOS. Objective: We tested the hypothesis that endothelial S1P(2) might suppress eNOS, exerting a protective effect against endothelial barrier disruption and anaphylaxis. Methods: Mice deficient in S1P(2) and eNOS underwent antigen challenge or platelet-activating factor (PAF) injection. Analyses were performed to examine vascular permeability and the underlying mechanisms. Results: S1pr2 deletion augmented vascular leakage and lethality after either antigen challenge or PAF injection. PAF injection induced activation of Akt and eNOS in the aortas and lungs of S1pr2-null mice, which were augmented compared with values seen in wild-type mice. Consistently, PAF-induced increase in cyclic guanosine monophosphate levels in the aorta was enhanced in S1pr-null mice. Genetic Nos3 deletion or pharmacologic eNOS blockade protected S1pr2-null mice from aggravation of barrier disruption after antigen challenge and PAF injection. ECs isolated from S1pr2-null mice exhibited greater stimulation of Akt and eNOS, with enhanced nitric oxide production in response to sphingosine-1-phosphate or PAF, compared with that seen in wild-type ECs. Moreover, S1pr2-deficient ECs showed more severe disassembly of adherens junctions with augmented S-nitrosylation of beta-catenin in response to PAF, which was restored by pharmacologic eNOS blockade. Conclusion: S1P(2) diminishes harmful robust eNOS stimulation and thereby attenuates vascular barrier disruption, suggesting potential usefulness of S1P(2) agonists as novel therapeutic agents for anaphylaxis.	[Cui, Hong; Okamoto, Yasuo; Yoshioka, Kazuaki; Du, Wa; Takuwa, Noriko; Takuwa, Yoh] Kanazawa Univ, Sch Med, Dept Physiol, Kanazawa, Ishikawa 9208640, Japan; [Asano, Masahide] Kanazawa Univ, Div Transgen Anim Sci, Adv Sci Res Ctr, Kanazawa, Ishikawa 9208640, Japan; [Takuwa, Noriko] Ishikawa Prefectural Nursing Univ, Kahoku, Ishikawa, Japan; [Zhang, Wei; Shibamoto, Toshishige] Kanazawa Med Univ, Dept Physiol 2, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University; Kanazawa Medical University	Takuwa, Y (corresponding author), Kanazawa Univ, Sch Med, Dept Physiol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.	ytakuwa@med.kanazawa-u.ac.jp	Du, Wa/I-8453-2019; Yoshioka, Kazuaki/G-1038-2013; OKAMOTO, Yasuo/J-8438-2015	Du, Wa/0000-0002-1518-7301; Yoshioka, Kazuaki/0000-0002-8631-3846; TAKUWA, Noriko/0000-0002-4278-2704; Zhang, Wei/0000-0001-6937-5562	Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology in Japan; Takeda Science Foundation; Kanazawa University Strategic Research Development Program; IPNU Research Promotion Program; Grants-in-Aid for Scientific Research [23590257] Funding Source: KAKEN	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Kanazawa University Strategic Research Development Program; IPNU Research Promotion Program; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science; a Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology in Japan; funds from the Takeda Science Foundation; funds from the Kanazawa University Strategic Research Development Program; and the IPNU Research Promotion Program.	Camerer E, 2009, J CLIN INVEST, V119, P1871, DOI 10.1172/JCI38575; Cauwels A, 2006, J CLIN INVEST, V116, P2244, DOI 10.1172/JCI25426; Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004; Du W, 2010, CANCER RES, V70, P772, DOI 10.1158/0008-5472.CAN-09-2722; Duran WN, 2010, CARDIOVASC RES, V87, P254, DOI 10.1093/cvr/cvq139; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Fleming I, 2010, PFLUG ARCH EUR J PHY, V459, P793, DOI 10.1007/s00424-009-0767-7; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Hatakeyama T, 2006, J PHYSIOL-LONDON, V574, P275, DOI 10.1113/jphysiol.2006.108175; Hess DT, 2012, J BIOL CHEM, V287, P4411, DOI 10.1074/jbc.R111.285742; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2008, CIRC RES, V102, P630, DOI 10.1161/CIRCRESAHA.108.173799; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Jaffrey S R, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.86.pl1; Korhonen H, 2009, J EXP MED, V206, P411, DOI 10.1084/jem.20082150; Lee JF, 2009, AM J PHYSIOL-HEART C, V296, pH33, DOI 10.1152/ajpheart.00097.2008; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Liu W, 2007, AM J PHYSIOL-REG I, V293, pR1947, DOI 10.1152/ajpregu.00904.2006; Lorenz JN, 2007, AM J PHYSIOL-REG I, V292, pR440, DOI 10.1152/ajpregu.00085.2006; Lucas KA, 2000, PHARMACOL REV, V52, P375; Marin N, 2012, CIRC RES, V111, P553, DOI 10.1161/CIRCRESAHA.112.274548; Marsolais D, 2009, NAT REV DRUG DISCOV, V8, P297, DOI 10.1038/nrd2356; Olivera A, 2013, IMMUNOL LETT, V150, P89, DOI 10.1016/j.imlet.2013.01.005; Olivera A, 2010, J CLIN INVEST, V120, P1429, DOI 10.1172/JCI40659; Oo ML, 2011, J CLIN INVEST, V121, P2290, DOI 10.1172/JCI45403; Oskeritzian CA, 2010, J EXP MED, V207, P465, DOI 10.1084/jem.20091513; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Rosen H, 2008, IMMUNOL REV, V223, P221, DOI 10.1111/j.1600-065X.2008.00645.x; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sanchez T, 2005, P NATL ACAD SCI USA, V102, P4312, DOI 10.1073/pnas.0409784102; Sanna MG, 2006, NAT CHEM BIOL, V2, P434, DOI 10.1038/nchembio804; Seok YM, 2010, HYPERTENSION, V56, P934, DOI 10.1161/HYPERTENSIONAHA.110.160853; Skoura A, 2009, J LIPID RES, V50, pS293, DOI 10.1194/jlr.R800047-JLR200; Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Takano H, 2007, J PHARMACOL SCI, V104, P212, DOI 10.1254/jphs.FP0070169; Takuwa Y, 2012, BIOFACTORS, V38, P329, DOI 10.1002/biof.1030; Thibeault S, 2010, MOL CELL, V39, P468, DOI 10.1016/j.molcel.2010.07.013; Venkataraman K, 2008, CIRC RES, V102, P669, DOI 10.1161/CIRCRESAHA.107.165845; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yoshioka K, 2012, NAT MED, V18, P1560, DOI 10.1038/nm.2928	44	39	42	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1205	+		10.1016/j.jaci.2013.07.026	http://dx.doi.org/10.1016/j.jaci.2013.07.026			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	24021572	Green Submitted			2022-12-18	WOS:000326235600023
J	Rabenhorst, A; Christopeit, B; Leja, S; Gerbaulet, A; Kleiner, S; Forster, A; Raap, U; Wickenhauser, C; Hartmann, K				Rabenhorst, Anja; Christopeit, Bastian; Leja, Silke; Gerbaulet, Alexander; Kleiner, Svea; Foerster, Anja; Raap, Ulrike; Wickenhauser, Claudia; Hartmann, Karin			Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FRACTURES; DENSITY; COHORT		[Rabenhorst, Anja; Christopeit, Bastian; Leja, Silke; Foerster, Anja; Hartmann, Karin] Univ Cologne, Dept Dermatol, Cologne, Germany; [Gerbaulet, Alexander] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Immunol, Dresden, Germany; [Kleiner, Svea; Raap, Ulrike] Hannover Med Sch, Dept Dermatol & Allergy, Hannover, Germany; [Wickenhauser, Claudia] Univ Leipzig, Inst Pathol, D-04109 Leipzig, Germany	University of Cologne; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Hannover Medical School; Leipzig University	Rabenhorst, A (corresponding author), Univ Cologne, Dept Dermatol, Cologne, Germany.	karin.hartmann@uni-koeln.de	Rabenhorst, Anja/J-3217-2016; Hartmann, Karin/N-4865-2015	Hartmann, Karin/0000-0002-4595-8226				Barete S, 2010, ANN RHEUM DIS, V69, P1838, DOI 10.1136/ard.2009.124511; Escribano L, 2009, J ALLERGY CLIN IMMUN, V124, P514, DOI 10.1016/j.jaci.2009.05.003; Guillaume N, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2012.07.018; Hartmann K, 2013, J ALLERGY CLIN IMMUN, V132, P232, DOI 10.1016/j.jaci.2012.11.008; Horny HP AC, 2008, WHO CLASSIFICATION T, P54; Kushnir-Sukhov NM, 2006, INT ARCH ALLERGY IMM, V139, P265, DOI 10.1159/000091172; Rossini M, 2011, BONE, V49, P880, DOI 10.1016/j.bone.2011.07.004; Takayanagi H, 2012, NAT REV RHEUMATOL, V8, P684, DOI 10.1038/nrrheum.2012.167; van der Veer E, 2012, ALLERGY, V67, P431, DOI 10.1111/j.1398-9995.2011.02780.x	9	39	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2013	132	5					1234	1237		10.1016/j.jaci.2013.06.019	http://dx.doi.org/10.1016/j.jaci.2013.06.019			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	242JH	23910691				2022-12-18	WOS:000326235600033
J	Flohr, C; Irvine, AD				Flohr, Carsten; Irvine, Alan D.			Systemic therapies for severe atopic dermatitis in children and adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							ECZEMA; MANAGEMENT; AZATHIOPRINE; METHOTREXATE; CYCLOSPORINE; MULTICENTER; DIAGNOSIS		[Flohr, Carsten] Guys & St Thomas Hosp NHS Fdn Trust, St Johns Inst Dermatol, Dept Paediat Dermatol, London, England; [Flohr, Carsten] Kings Coll London, London, England; [Irvine, Alan D.] Natl Childrens Res Ctr, Dublin, Ireland; [Irvine, Alan D.] Our Ladys Childrens Hosp, Dept Pediat Dermatol, Dublin D12, Ireland; [Irvine, Alan D.] Univ Dublin Trinity Coll, Dept Clin Med, Dublin 2, Ireland	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; National Children's Research Centre (NCRC); Trinity College Dublin; National Children's Research Centre (NCRC); Trinity College Dublin	Irvine, AD (corresponding author), Our Ladys Childrens Hosp, Dept Pediat Dermatol, Dublin D12, Ireland.	irvinea@tcd.ie	Irvine, Alan D/A-3982-2008	Irvine, Alan D/0000-0002-9048-2044	Wellcome Trust; National Children's Research Centre; Janssen	Wellcome Trust(Wellcome TrustEuropean Commission); National Children's Research Centre; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc)	A. D. Irvine has consultant arrangements with Janssen and Galderma, receives grants from the Wellcome Trust and the National Children's Research Centre, receives payment for lectures from Janssen, and receives royalties from Wiley. J. T. Li has consulted for Abbott. C. Flohr declares that he has no relevant conflicts of interest.	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Bath-Hextall FJ, 2010, BRIT J DERMATOL, V163, P12, DOI 10.1111/j.1365-2133.2010.09743.x; Braham SJ, 2010, J DERMATOL TREAT, V21, P62, DOI [10.3109/09546630902911854, 10.1080/09546630902911854]; Darsow U, 2010, J EUR ACAD DERMATOL, V24, P317, DOI 10.1111/j.1468-3083.2009.03415.x; El-Khalawany MA, 2013, EUR J PEDIATR, V172, P351, DOI 10.1007/s00431-012-1893-3; Masunaga Y, 2007, ANN PHARMACOTHER, V41, P21, DOI 10.1345/aph.1H219; McAleer MA, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4770; Meggitt SJ, 2006, LANCET, V367, P839, DOI 10.1016/S0140-6736(06)68340-2; Mitchell C, 2010, LEUKEMIA, V24, P406, DOI 10.1038/leu.2009.256; National Institute for Clinical Excellence (NICE), AT ECZ CHILDR GUID C; Proudfoot L, 2012, J INVEST DERMATOL, V132, pS70; Schmedt N, 2012, PHARMACOEPIDEM DR S, V21, P1216, DOI 10.1002/pds.3320; Schmitt J, 2007, J EUR ACAD DERMATOL, V21, P606, DOI 10.1111/j.1468-3083.2006.02023.x; Schmitt J, 2007, ACTA DERM-VENEREOL, V87, P100, DOI 10.2340/00015555-0207; Schram ME, 2011, J ALLERGY CLIN IMMUN, V128, P353, DOI 10.1016/j.jaci.2011.03.024; Staab D, 2006, BMJ-BRIT MED J, V332, P933, DOI 10.1136/bmj.332.7547.933; Taieb A, 2012, J DTSCH DERMATOL GES, V10, P174, DOI 10.1111/j.1610-0387.2011.07760.x	17	39	41	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2013	132	3					774	+		10.1016/j.jaci.2013.03.016	http://dx.doi.org/10.1016/j.jaci.2013.03.016			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	207OS	23993356	Bronze			2022-12-18	WOS:000323612000045
J	Depner, M; Ege, MJ; Genuneit, J; Pekkanen, J; Roponen, M; Hirvonen, MR; Dalphin, JC; Kaulek, V; Krauss-Etschmann, S; Riedler, J; Braun-Fahrlander, C; Roduit, C; Lauener, R; Pfefferle, PI; Weber, J; von Mutius, E				Depner, Martin; Ege, Markus J.; Genuneit, Jon; Pekkanen, Juha; Roponen, Marjut; Hirvonen, Maija-Riitta; Dalphin, Jean-Charles; Kaulek, Vincent; Krauss-Etschmann, Susanne; Riedler, Josef; Braun-Fahrlaender, Charlotte; Roduit, Caroline; Lauener, Roger; Pfefferle, Petra I.; Weber, Juliane; von Mutius, Erika		PASTURE Study Grp	Atopic sensitization in the first year of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic sensitization; early life; environmental exposures	ASTHMA; EXPOSURE; ALLERGEN; RISK; IGE; CONSUMPTION; DISEASES; CHILDREN	Background: There is conflicting evidence on whether allergen-specific memory is primed prenatally, whether this priming affects persistent immunologic effects, and whether it is modulated by the first environmental exposures in infancy. Objective: We sought to explore the course of atopic sensitization between birth and 12 months of age. Methods: Specific IgE levels for 6 food and 13 common inhalant allergens were assessed in cord blood and 1-year blood samples in the Protection against Allergy-Study in Rural Environments (PASTURE) birth cohort including 793 children from rural regions of 5 European countries. Detailed information on children's health, nutrition, and farm-related exposures was gathered by using a pregnancy questionnaire, 2 questionnaires at 2 and 12 months of age, and a diary covering the time in between. Results: Sensitization was more common at 12 months of age than at birth for almost all specificities. On an individual level, persistent sensitization to the same allergens was rare (1%), whereas transient (only at birth, 11%) and incident (only at 12 months, 34%) sensitization was seen in substantial proportions of children. Associations of transient sensitization with maternal sensitization differed with the allergen specificities, with the strongest associations for food allergens (odds ratio [OR], 10.6; 95% CI, 6.0-18.6) and the weakest associations for seasonal allergens (OR, 1.64; 95% CI, 0.94-2.86). Associations of maternal sensitization with incident sensitization were also seen. Incident sensitization was related to distinct prenatal and postnatal environmental exposures of mother and child, such as consumption of cereals for incident sensitization to seasonal allergens (OR, 0.66; 95% CI, 0.50-0.88). Conclusion: IgE sensitization patterns change between birth and 12 months and are related to maternal and environmental influences. (J Allergy Clin Immunol 2013;131:781-8.)	[Depner, Martin; Ege, Markus J.; Krauss-Etschmann, Susanne; Weber, Juliane; von Mutius, Erika] Univ Childrens Hosp, Munich, Germany; [Genuneit, Jon] Univ Ulm, Inst Epidemiol, D-89069 Ulm, Germany; [Pekkanen, Juha; Hirvonen, Maija-Riitta] Natl Inst Hlth & Welf, Dept Environm Hlth, Kuopio, Finland; [Pekkanen, Juha] Univ Eastern Finland, Kuopio, Finland; [Roponen, Marjut; Hirvonen, Maija-Riitta] Univ Eastern Finland, Dept Environm Sci, Kuopio, Finland; [Roponen, Marjut; Hirvonen, Maija-Riitta] Univ Hosp Besancon, Dept Resp Dis, CNRS, UMR Chronoenvironm 6249, Besancon, France; [Krauss-Etschmann, Susanne] Helmholtz Ctr Munich, Comprehens Pneumol Ctr, Munich, Germany; [Riedler, Josef] Childrens Hosp, Schwarzach, Austria; [Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Braun-Fahrlaender, Charlotte] Univ Basel, CH-4003 Basel, Switzerland; [Roduit, Caroline; Lauener, Roger] Univ Zurich, Childrens Hosp, Davos, Switzerland; [Roduit, Caroline; Lauener, Roger] Christine Kuhne Ctr Allergy Res & Educ, Davos, Switzerland; [Pfefferle, Petra I.] Univ Philippines, Inst Lab Med & Pathobiochem, Quezon City 1101, Philippines	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Ulm University; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; Centre National de la Recherche Scientifique (CNRS); Universite de Franche-Comte; CHU Besancon; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Basel; Swiss Tropical & Public Health Institute; University of Basel; University of Zurich; University of the Philippines System; University of the Philippines Diliman	Depner, M (corresponding author), Dr von Haunersche Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.	martin.depner@med.uni-muenchen.de	Genuneit, Jon/I-9323-2012; Roduit, Caroline/S-4928-2017; riedler, josef/AAQ-4666-2020; Loss, Georg/F-1557-2013; Lauener, Roger P/O-8612-2016; Krauss-Etschmann, Susanne/H-5198-2018; Roponen, Marjut/C-2086-2017; Schaub, Bianca/B-9935-2019; Ege, Markus/C-1962-2012	Genuneit, Jon/0000-0001-5764-1528; Lauener, Roger P/0000-0002-8412-606X; Krauss-Etschmann, Susanne/0000-0001-5945-5702; Roponen, Marjut/0000-0002-4442-9090; Schaub, Bianca/0000-0003-1652-8873; Ege, Markus/0000-0001-6643-3923; Roduit, Caroline/0000-0002-5988-0570; von Mutius, Erika/0000-0002-8893-4515; Loss, Georg/0000-0003-1090-812X	European Commission [QLK4-CT-2001-00250, FOOD-CT-2006-31708, KBBE-2007-2-2-06]; European Research Council; European Union; French Ministry of Health; GlaxoSmithKline; Novartis; AstraZeneca; Chiesi; French Society of Respiratory Diseases; European Community; Kuhne Foundation; German Research Foundation; German Federal Ministry of Education and Research	European Commission(European CommissionEuropean Commission Joint Research Centre); European Research Council(European Research Council (ERC)European Commission); European Union(European Commission); French Ministry of Health; GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis); AstraZeneca(AstraZeneca); Chiesi(Chiesi Pharmaceuticals Inc); French Society of Respiratory Diseases; European Community(European Commission); Kuhne Foundation; German Research Foundation(German Research Foundation (DFG)); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	Supported by the European Commission (research grants QLK4-CT-2001-00250, FOOD-CT-2006-31708, and KBBE-2007-2-2-06).; Disclosure of potential conflict of interest: M. Depner has received grants from the European Research Council. M. J. Ege has received grants from the European Commission. M. Roponen and M.-R. Hirvonen have received grants from the European Union. J.-C. Dalphin has received grants and travel support from the French Ministry of Health and the European Community; has received writing assistance, medicine, equipment, or administrative support from the French Society of Respiratory Diseases; is a board member for Novartis; has received grants from GlaxoSmithKline; has received payment for lectures from Novartis, GlaxoSmithKline, AstraZeneca, and Chiesi; has received payment for development of educational presentations from Novartis; and has received travel support from GlaxoSmithKline, Novartis, AstraZeneca, and Chiesi. R. Lauener has received grants, travel support, and fees for participation in review activities from the European Union and the Kuhne Foundation and has received payment for lectures from Phadia-Thermo Fisher. J. Weber has received grants from the European Commission. E. von Mutius has received grants from the European Commission, the European Research Council, the German Research Foundation, and the German Federal Ministry of Education and Research. M. Kabesch has received a grant from the European Union and has received payment for lectures from the European Respiratory Society, the European Academy of Allergy and Clinical Immunology, the American Thoracic Society, Novartis, and GlaxoSmithKline. G. Doekes has received grants and travel support from the European Union Commission. B. Schaub has received grants from the German Research Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Basagana X, 2002, PEDIAT ALLERG IMM-UK, V13, P412, DOI 10.1034/j.1399-3038.2002.02081.x; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; Bonnelykke K, 2010, J ALLERGY CLIN IMMUN, V126, P657, DOI 10.1016/j.jaci.2010.06.027; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; Herzum I, 2005, CLIN CHEM LAB MED, V43, P963, DOI 10.1515/CCLM.2005.165; Holt PG, 2008, J ALLERGY CLIN IMMUN, V122, P717, DOI 10.1016/j.jaci.2008.08.019; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jacobs DR, 2007, AM J CLIN NUTR, V85, P1606, DOI 10.1093/ajcn/85.6.1606; Kamemura N, 2012, J ALLERGY CLIN IMMUN, V130, P113, DOI 10.1016/j.jaci.2012.02.023; Kjaer HF, 2009, PEDIAT ALLERG IMM-UK, V20, P726, DOI 10.1111/j.1399-3038.2009.00862.x; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rindsjo E, 2010, ALLERGY, V65, P554, DOI 10.1111/j.1398-9995.2010.02345.x; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Szepfalusi Z, 2006, CLIN EXP ALLERGY, V36, P1130, DOI 10.1111/j.1365-2222.2006.02559.x; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x	27	39	39	0	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2013	131	3					781	+		10.1016/j.jaci.2012.11.048	http://dx.doi.org/10.1016/j.jaci.2012.11.048			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	098ZM	23333112	Bronze			2022-12-18	WOS:000315587800020
J	Caillaud, DM; Martin, S; Segala, C; Besancenot, JP; Clot, B; Thibaudon, M				Caillaud, Denis M.; Martin, Sylvie; Segala, Claire; Besancenot, Jean-Pierre; Clot, Bernard; Thibaudon, Michel		French Aerobiol Network	Nonlinear short-term effects of airborne Poaceae levels on hay fever symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							ALLERGEN CHALLENGE; POLLEN; ADMISSIONS		[Caillaud, Denis M.] Gabriel Montpied Hosp, Pulm & Allergol Dept, Clermont Ferrand, France; [Besancenot, Jean-Pierre; Thibaudon, Michel] RNSA, French Network Aerobiol Monitoring, Brussieu, France; [Clot, Bernard] Fed Off Meteorol & Climatol MeteoSwiss, Payerne, Switzerland	CHU Clermont Ferrand; Federal Office of Meteorology & Climatology (MeteoSwiss)	Caillaud, DM (corresponding author), Gabriel Montpied Hosp, Pulm & Allergol Dept, Clermont Ferrand, France.	dcaillaud@chu-clermontferrand.fr		Clot, Bernard Alain/0000-0003-3935-6509				Bell ML, 2004, ANNU REV PUBL HEALTH, V25, P247, DOI 10.1146/annurev.publhealth.25.102802.124329; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; DAVIES RR, 1973, CLIN ALLERGY, V3, P477, DOI 10.1111/j.1365-2222.1973.tb01332.x; de Bruin-Weller MS, 1999, CLIN EXP ALLERGY, V29, P159; Ellis AK, 2010, ANN ALLERG ASTHMA IM, V104, P293, DOI 10.1016/j.anai.2010.01.012; Erbas B, 2007, CLIN EXP ALLERGY, V37, P1641, DOI 10.1111/j.1365-2222.2007.02818.x; Brito FF, 2011, ANN ALLERG ASTHMA IM, V106, P146, DOI 10.1016/j.anai.2010.11.003; Reinartz SM, 2009, RHINOLOGY, V47, P192; Tobias A, 2004, CLIN EXP ALLERGY, V34, P871, DOI 10.1111/j.1365-2222.2004.01983.x	9	39	41	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					812	814		10.1016/j.jaci.2012.04.034	http://dx.doi.org/10.1016/j.jaci.2012.04.034			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	001LZ	22704534				2022-12-18	WOS:000308463500035
J	Schumock, GT; Stayner, LT; Valuck, RJ; Joo, MJ; Gibbons, RD; Lee, TA				Schumock, Glen T.; Stayner, Leslie T.; Valuck, Robert J.; Joo, Min J.; Gibbons, Robert D.; Lee, Todd A.			Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: A nested case-control study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; suicide; leukotriene-modifying agents; montelukast; drug safety	ADOLESCENT SUICIDE; PHYSICAL ILLNESS; PHARMACY RECORDS; BEHAVIOR; IDEATION; DISORDERS; LIFE; ASSOCIATION; PREVALENCE; VALIDATION	Background: The US Food and Drug Administration has issued safety alerts about leukotriene receptor-modifying agents and suicidality/suicide, but because these were based on case reports, there is controversy about the association. Objective: We conducted a nested case-control study to determine the association between leukotriene-modifying agents (LTMAs) and attempted suicide among asthmatic children and young adults. Methods: Cases and control subjects were from a cohort of asthmatic patients aged 5 to 24 years who were new users of LTMAs or other asthma medications. Data were from an insurance claims database. Cases were defined as those with a suicide attempt (SA) occurring after exposure to asthma medication. Control subjects were persons at risk and were selected by using incidence density sampling in a 10:1 match. Conditional logistic regression was used to determine the association between LTMA exposure and the risk of attempted suicide adjusted for important covariates. Results: We identified 344 cases and 3438 matched control subjects. Cases were more likely than control subjects to have risk factors for suicide. We found that current use of any LTMA was not associated with increased risk of an SA; in fact, the direction of effect was the opposite (adjusted odd ratio, 0.70; 95% CI, 0.36-1.39). Conclusion: In this analysis we found that use of LTMAs was not associated with an increased risk of SAs in children, adolescents, and young adults with asthma. Further research needs to be conducted to more fully understand the association between LTMAs and suicide, particularly in subpopulations. (J Allergy Clin Immunol 2012;130:368-75.)	[Schumock, Glen T.; Lee, Todd A.] Univ Illinois, Coll Pharm, Ctr Pharmacoecon Res, Chicago, IL USA; [Schumock, Glen T.; Lee, Todd A.] Univ Illinois, Coll Pharm, Dept Pharm Practice, Chicago, IL USA; [Stayner, Leslie T.] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL USA; [Valuck, Robert J.] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Aurora, CO USA; [Joo, Min J.] Univ Illinois, Coll Med, Dept Med, Sect Pulm Crit Care Sleep & Allergy, Chicago, IL USA; [Gibbons, Robert D.] Univ Chicago, Pritzker Sch Med, Ctr Hlth Stat, Chicago, IL 60637 USA; [Gibbons, Robert D.] Univ Chicago, Pritzker Sch Med, Dept Med, Chicago, IL 60637 USA; [Gibbons, Robert D.] Univ Chicago, Pritzker Sch Med, Dept Hlth Studies, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Chicago; University of Chicago	Schumock, GT (corresponding author), 833 S Wood St,MC 886, Chicago, IL 60612 USA.	schumock@uic.edu		Lee, Todd/0000-0003-3619-5367	Novartis	Novartis(Novartis)	T. A. Lee is a consultant for Merck and Forest Pharmaceuticals and has received research support from Novartis. The rest of the authors declare they have no relevant conflicts of interest.	[Anonymous], 2008, EUR ANN ALLERGY CLIN, V40, P64; Beautrais AL, 2000, AUST NZ J PSYCHIAT, V34, P420, DOI 10.1080/j.1440-1614.2000.00691.x; BRENT DA, 1995, SUICIDE LIFE-THREAT, V25, P52, DOI 10.1111/j.1943-278X.1995.tb00490.x; Bridge JA, 2006, J CHILD PSYCHOL PSYC, V47, P372, DOI 10.1111/j.1469-7610.2006.01615.x; Bronnum-Hansen H, 2005, J NEUROL NEUROSUR PS, V76, P1457, DOI 10.1136/jnnp.2004.056747; Centers for Disease Control and Prevention, 2010, ASTHM GLANC; Coryell W, 2005, J CLIN PSYCHIAT, V66, P412, DOI 10.4088/JCP.v66n0401; Druss B, 2000, ARCH INTERN MED, V160, P1522, DOI 10.1001/archinte.160.10.1522; Goodwin RD, 2005, AM J PUBLIC HEALTH, V95, P717, DOI 10.2105/AJPH.2003.019109; Goodwin RD, 2003, ARCH GEN PSYCHIAT, V60, P1125, DOI 10.1001/archpsyc.60.11.1125; Goodwin RD, 2003, PSYCHOSOM MED, V65, P501, DOI 10.1097/01.PSY.0000041544.14277.EC; Goodwin Renee D, 2004, Crisis, V25, P99, DOI 10.1027/0227-5910.25.3.99; Greenland KJ, 2008, MODERN EPIDEMIOLOGY; Harwood DMJ, 2006, PSYCHOL MED, V36, P1265, DOI 10.1017/S0033291706007872; Haw C, 2009, INT PSYCHOGERIATR, V21, P440, DOI 10.1017/S1041610209009065; Heaton PC, 2006, J MANAGE CARE PHARM, V12, P33, DOI 10.18553/jmcp.2006.12.1.33; Iribarren C, 2000, SOC PSYCH PSYCH EPID, V35, P288, DOI 10.1007/s001270050241; Jewell N., 2004, STAT EPIDEMIOLOGY, P69; Jick H, 2009, PHARMACOTHERAPY, V29, P165, DOI 10.1592/phco.29.2.165; Jolin Edith M, 2007, Curr Psychiatry Rep, V9, P122; Karassa FB, 2003, ANN RHEUM DIS, V62, P58, DOI 10.1136/ard.62.1.58; Khan A, 2002, J AFFECT DISORDERS, V68, P183, DOI 10.1016/S0165-0327(01)00354-8; Komiti A, 2001, AUST NZ J PSYCHIAT, V35, P747, DOI 10.1046/j.1440-1614.2001.00943.x; Lang M, 2011, HLTH EC; Lau HS, 1997, J CLIN EPIDEMIOL, V50, P619, DOI 10.1016/S0895-4356(97)00040-1; Melonie Heron Ph.D, 2009, NATL VITAL STAT REPO, V57; *NAT HEART LUNG BL, 2007, GUID DIAGN MAN ASTHM; Nikolas H, 2007, EPILEPSY BEHAV, V10, P363, DOI 10.1016/j.yebeh.2007.01.005; Palmer BA, 2005, ARCH GEN PSYCHIAT, V62, P247, DOI 10.1001/archpsyc.62.3.247; Pang D, 1999, OCCUP ENVIRON MED, V56, P67, DOI 10.1136/oem.56.1.67; Paris J, 2005, DEV PSYCHOPATHOL, V17, P1091, DOI 10.1017/S0954579405050510; Philip G, 2004, CURR MED RES OPIN, V20, P1549, DOI 10.1185/030079904X3348; Riccioni G, 2007, CURR MED CHEM, V14, P1966; Robinson D, 2009, BRIT J CANCER, V101, P198, DOI 10.1038/sj.bjc.6605110; Schatz M, 2004, AM J MANAG CARE, V10, P25; Schatz M, 2010, AM J MANAG CARE, V16, P327; Schumock GT, 2012, DRUG INF J, V46, P99, DOI 10.1177/0092861511427856; Schumock GT, 2011, DRUG HEALTHC PATIENT, V3, P47, DOI 10.2147/DHPS.S23665; Schumock GT, 2011, DRUG SAFETY, V34, P533, DOI 10.2165/11587260-000000000-00000; Soykan A, 2003, TRANSPLANT P, V35, P1290, DOI 10.1016/S0041-1345(03)00522-0; Spiegel B, 2007, ALIMENT PHARM THER, V26, P183, DOI 10.1111/j.1365-2036.2007.03357.x; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; Tang NKY, 2006, PSYCHOL MED, V36, P575, DOI 10.1017/S0033291705006859; US Food and Drug Administration, 2009, FOLL UP MARCH 27 200; US Food and Drug Administration, 2008, SUIC THOUGHTS BEH AN; US Food and Drug Administration, 2008, EARL COMM ONG SAF RE; US Food and Drug Administration, 2009, UP INF LEUK INH MONT; US Food and Drug Administration, 2004, SUIC CHILDR AD BEING; Wahlin TBR, 2007, PATIENT EDUC COUNS, V65, P279, DOI 10.1016/j.pec.2006.08.009; Wang Shuu-Jiun, 2007, Expert Rev Neurother, V7, P1069, DOI 10.1586/14737175.7.9.1069	50	39	41	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					368	375		10.1016/j.jaci.2012.04.035	http://dx.doi.org/10.1016/j.jaci.2012.04.035			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22698520				2022-12-18	WOS:000307002200015
J	Skytt, N; Bonnelykke, K; Bisgaard, H				Skytt, Nanna; Bonnelykke, Klaus; Bisgaard, Hans			"To wheeze or not to wheeze": That is not the question	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Wheeze; troublesome lung symptoms; asthma; young child	LUNG-FUNCTION; ASTHMA	Background: The diagnosis of asthma in young children is difficult and based on clinical assessment of symptoms and results of physical examination. Respiratory wheeze has traditionally been used to define asthma in young children. Objective: We sought to compare the qualitative diagnosis of wheeze with a quantitative global assessment of significant troublesome lung symptoms during the first 3 years of life as a predictor of asthma by age 7 years. Methods: Children born to asthmatic mothers (n = 411) were followed prospectively to age 7 years. Parents were instructed to visit the research clinic during the first 3 years of life each time the child had significant troublesome lung symptoms for 3 days. At the clinic, a research physician performed a physical examination, including auscultation for wheeze and excluding differential diagnoses. We tested whether wheeze was independently associated with asthma at age 7 years after adjusting for the total number of episodes. Results: Three hundred thirteen children had full follow-up by age 7 years. In a multivariable analysis the total number of acute clinic visits for asthma symptom was significantly associated with later asthma (P < .0001), whereas the presence of wheeze at these visits was not (P = .5). The total number of acute clinic visits for significant troublesome lung symptoms was also significantly associated with later asthma in children who had never presented with any wheeze (P = .03). Conclusion: A quantitative global assessment of significant troublesome lung symptoms in the first 3 years of life is a better predictor of asthma than assessment of wheeze. Doctor-diagnosed wheeze is not a prerequisite for the diagnosis of asthma, and relying on the symptom of wheeze will likely be an important cause of undertreatment. (J Allergy Clin Immunol 2012;130:403-7.)	[Bisgaard, Hans] Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark; [Bisgaard, Hans] Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Gentofte, Denmark	University of Copenhagen; University of Copenhagen	Bisgaard, H (corresponding author), Univ Copenhagen, Copenhagen Prospect Studies Asthma Childhood, Copenhagen, Denmark.	Bisgaard@copsac.com	Bisgaard, Hans/N-4761-2016; Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592; Bonnelykke, Klaus/0000-0003-2003-1018	Lundbeck Foundation; Pharmacy Foundation; Danish Medical Research Council; Danish Pediatric Asthma Center; Danish Lung Association; Copenhagen Prospective Study of Asthma in Childhood research unit	Lundbeck Foundation(Lundbeckfonden); Pharmacy Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Danish Pediatric Asthma Center; Danish Lung Association; Copenhagen Prospective Study of Asthma in Childhood research unit	The Lundbeck Foundation, the Pharmacy Foundation of 1991, the Danish Medical Research Council, the Danish Pediatric Asthma Center, and the Danish Lung Association provided the core funding of the Copenhagen Prospective Study of Asthma in Childhood research unit.	Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381, DOI 10.1016/S1081-1206(10)61398-1; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; Bisgaard H, 2012, J ALLERGY CLIN IMMUN; Bisgaard H, 2010, BMJ-BRIT MED J, V341; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Bush A, 2009, NEW ENGL J MED, V360, P409, DOI 10.1056/NEJMe0808951; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Elphick HE, 2001, ARCH DIS CHILD, V84, P35, DOI 10.1136/adc.84.1.35; Kocevar VS, 2004, CHEST, V125, P1680, DOI 10.1378/chest.125.5.1680; Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539; PASTERKAMP H, 1987, CHEST, V91, P376, DOI 10.1378/chest.91.3.376; Turner SW, 2008, ARCH DIS CHILD, V93, P701, DOI 10.1136/adc.2007.134569	14	39	39	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2012	130	2					403	+		10.1016/j.jaci.2012.04.043	http://dx.doi.org/10.1016/j.jaci.2012.04.043			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	981WC	22766098				2022-12-18	WOS:000307002200020
J	Forno, E; Lasky-Su, J; Himes, B; Howrylak, J; Ramsey, C; Brehm, J; Klanderman, B; Ziniti, J; Melen, E; Pershagen, G; Wickman, M; Martinez, F; Mauger, D; Sorkness, C; Tantisira, K; Raby, BA; Weiss, ST; Celedon, JC				Forno, Erick; Lasky-Su, Jessica; Himes, Blanca; Howrylak, Judie; Ramsey, Clare; Brehm, John; Klanderman, Barbara; Ziniti, John; Melen, Erik; Pershagen, Goran; Wickman, Magnus; Martinez, Fernando; Mauger, Dave; Sorkness, Christine; Tantisira, Kelan; Raby, Benjamin A.; Weiss, Scott T.; Celedon, Juan C.			Genome-wide association study of the age of onset of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; pediatrics; age of onset; asthma genetics; C1orf100; genome-wide association study; pediatric asthma	1ST 6 YEARS; AIRWAY RESPONSIVENESS; SEVERITY; VARIANTS; CHILDREN; RISK; MEPOLIZUMAB; EXPOSURE; 17Q21; LONG	Background: Childhood asthma is a complex disease with known heritability and phenotypic diversity. Although an earlier onset has been associated with more severe disease, there has been no genome-wide association study of the age of onset of asthma in children. Objective: We sought to identify genetic variants associated with earlier onset of childhood asthma. Methods: We conducted the first genome-wide association study of the age of onset of childhood asthma among participants in the Childhood Asthma Management Program (CAMP) and used 3 independent cohorts from North America, Costa Rica, and Sweden for replication. Results: Two single nucleotide polymorphisms (SNPs) were associated with earlier onset of asthma in the combined analysis of CAMP and the replication cohorts: rs9815663 (Fisher P = 2.31 x 10(-8)) and rs7927044 (P = 6.54 x 10(-9)). Of these 2 SNPs, rs9815663 was also significantly associated with earlier asthma onset in an analysis including only the replication cohorts. Ten SNPs in linkage disequilibrium with rs9815663 were also associated with earlier asthma onset (2.24 x 10(-7) < P < 8.22 x 10(-6)). Having 1 or more risk alleles of the 2 SNPs of interest (rs9815663 and rs7927044) was associated with lower lung function and higher asthma medication use during 4 years of follow-up in CAMP. Conclusions: We have identified 2 SNPs associated with earlier onset of childhood asthma in 4 independent cohorts. (J Allergy Clin Immunol 2012;130:83-90.)	[Forno, Erick] Univ Miami, Dept Pediat, Div Pediat Pulmonol, Miami, FL 33136 USA; [Forno, Erick; Lasky-Su, Jessica; Himes, Blanca; Howrylak, Judie; Brehm, John; Klanderman, Barbara; Ziniti, John; Melen, Erik; Tantisira, Kelan; Raby, Benjamin A.; Weiss, Scott T.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Brehm, John; Tantisira, Kelan; Raby, Benjamin A.] Brigham & Womens Hosp, Dept Med, Div Pulm Crit Care Med, Boston, MA 02115 USA; [Forno, Erick; Lasky-Su, Jessica; Himes, Blanca; Brehm, John; Tantisira, Kelan; Raby, Benjamin A.; Weiss, Scott T.] Harvard Univ, Sch Med, Boston, MA USA; [Ramsey, Clare] Univ Manitoba, Dept Med, Winnipeg, MB, Canada; [Melen, Erik; Pershagen, Goran; Wickman, Magnus] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Wickman, Magnus] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; [Martinez, Fernando] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA; [Mauger, Dave] Penn State Hershey Coll Med, Hershey, PA USA; [Sorkness, Christine] Univ Wisconsin, Madison, WI USA; [Celedon, Juan C.] Univ Pittsburgh, Sch Med, Div Pediat Pulm Med Allergy & Immunol, Childrens Hosp Pittsburgh,UPMC,Dept Pediat, Pittsburgh, PA 15260 USA	University of Miami; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Manitoba; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Forno, E (corresponding author), Univ Miami, Dept Pediat, Div Pediat Pulmonol, 1580 NW 10th Ave 125, Miami, FL 33136 USA.	eforno@med.miami.edu	Forno, Erick/I-1476-2019; Raby, Benjamin/AAK-3866-2021	Forno, Erick/0000-0001-6497-9885; Lasky-Su, Jessica/0000-0001-6236-4705; Pershagen, Goran/0000-0002-9701-1130	US National Institutes of Health [HL04370, HL66289]; National Heart, Lung, and Blood Institute and General Clinical Research Center from the National Center for Research Resources [M01RR00051, M01RR0099718-24, M01RR02719-14, RR00036]; European Commission as part of GA-BRIEL [018996, LSH-2004-1.2.5-1]; Wellcome Trust [WT084703MA]; US Federal Government from the National Heart, Lung, and Blood Institute [N02-HL-6 4278]; Swedish Research Council; Stockholm County Council; Centre for Allergy Research, Karolinska Institutet; Swedish Heart Lung Foundation; Swedish Fulbright Commission; Riksbankens Jubileumsfond; Erik Ronnberg's scholarship; National Heart, Lung, and Blood Institute; Childhood Asthma Management Program (CAMP); Childhood Asthma Research and Education (CARE) network; Abbott; National Institutes of Health; National Heart Lung and Blood Institute;  [NO1-HR-16044];  [16045];  [16046];  [16047];  [16048];  [16049];  [16050];  [16051];  [16052]; DIVISION OF LUNG DISEASES [N01HR016047, N01HR016048, N01HR016051, N01HR016050, N01HR016052, N01HR016049, N01HR016044, N01HR016046, N01HR016045] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR002719, M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066289, K01HL004370, R00HL096840, R37HL066289, R01HL064278] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart, Lung, and Blood Institute and General Clinical Research Center from the National Center for Research Resources; European Commission as part of GA-BRIEL; Wellcome Trust(Wellcome TrustEuropean Commission); US Federal Government from the National Heart, Lung, and Blood Institute; Swedish Research Council(Swedish Research CouncilEuropean Commission); Stockholm County Council(Stockholm County Council); Centre for Allergy Research, Karolinska Institutet(Karolinska Institutet); Swedish Heart Lung Foundation(Swedish Heart-Lung Foundation); Swedish Fulbright Commission; Riksbankens Jubileumsfond; Erik Ronnberg's scholarship; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Childhood Asthma Management Program (CAMP); Childhood Asthma Research and Education (CARE) network; Abbott(Abbott Laboratories); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); ; ; ; ; ; ; ; ; ; DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Genetics of Asthma in Costa Rica Study is supported by grants HL04370 and HL66289 from the US National Institutes of Health. The Childhood Asthma Management Program is supported by contracts NO1-HR-16044, 16045, 16046, 16047, 16048, 16049, 16050, 16051, and 16052 with the National Heart, Lung, and Blood Institute and General Clinical Research Center grants M01RR00051, M01RR0099718-24, M01RR02719-14, and RR00036 from the National Center for Research Resources. The genome-wide association study in BAMSE (Children, Allergy, Milieu, Stockholm, Epidemiological Survey) is supported by the European Commission as part of GA-BRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community), contract no. 018996 under the Integrated Program LSH-2004-1.2.5-1, and the Wellcome Trust under WT084703MA: "A second-generation genome-wide association study for asthma.'' Single-nucleotide Polymorphism Health Association Asthma Resource Project (SHARP) genotyping was performed by Affymetrix, Inc, under US Federal Government contract no. N02-HL-6 4278 from the National Heart, Lung, and Blood Institute. The BAMSE study was supported by the Swedish Research Council, Stockholm County Council, Centre for Allergy Research, Karolinska Institutet and the Swedish Heart Lung Foundation. E. M. is supported by a post doc grant from the Swedish Heart Lung Foundation, the Swedish Fulbright Commission and Riksbankens Jubileumsfond, and Erik Ronnberg's scholarship for research on early childhood diseases. SHARP was funded by the National Heart, Lung, and Blood Institute and was composed of researchers from the Asthma Clinical Research Network (ACRN), the Childhood Asthma Management Program (CAMP), and the Childhood Asthma Research and Education (CARE) network.; Disclosure of potential conflict of interest: F. Martinez is a consultant for MedImmune and has received lecture fees from Abbott. D. Mauger is a consultant for GlaxoSmithKline. K. Tantisira has received research support from the National Institutes of Health. J. C. Celedon is on the advisory board for Genentech; has received research support from the National Institutes of Health; and is author of a chapter in Up To Date. The rest of the authors declare that they have no relevant conflicts of interest.; The single-nucleotide polymorphism health association-asthma resource project (SHARP) was funded by the National Heart Lung and Blood Institute, and was composed of researchers from the Asthma Clinical Research Network (ACRN), the Childhood Asthma Management Program (CAMP), and the Childhood Asthma Research and Education (CARE) network.	Akhabir L, 2011, RESPIROLOGY, V16, P396, DOI 10.1111/j.1440-1843.2011.01939.x; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; [Anonymous], 1999, Control Clin Trials, V20, P91; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403, DOI 10.1164/ajrccm.162.4.9912111; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Foster PS, 2002, LAB INVEST, V82, P455, DOI 10.1038/labinvest.3780438; Gonzalez P, 1999, BIOTECHNIQUES, V26, P884, DOI 10.2144/99265st01; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Henderson J, 2009, ARCH DIS CHILD, V94, P333, DOI 10.1136/adc.2008.143636; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051; Ly NP, 2008, CHEST, V133, P107, DOI 10.1378/chest.07-2130; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Melen E, 2008, ENVIRON HEALTH PERSP, V116, P1077, DOI 10.1289/ehp.11117; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Rizzo CA, 2002, J ALLERGY CLIN IMMUN, V109, P404, DOI 10.1067/mai.2002.122459; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; Syed F, 1998, QJM-MON J ASSOC PHYS, V91, P567, DOI 10.1093/qjmed/91.8.567; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Takatsu K, 2009, ADV IMMUNOL, V101, P191, DOI 10.1016/S0065-2776(08)01006-7; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Van Steen Kristel, 2005, Hum Genomics, V2, P67; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001; Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	42	39	40	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					83	+		10.1016/j.jaci.2012.03.020	http://dx.doi.org/10.1016/j.jaci.2012.03.020			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22560479	Green Accepted, Green Published			2022-12-18	WOS:000306644800011
J	Torgerson, DG; Gignoux, CR; Galanter, JM; Drake, KA; Roth, LA; Eng, C; Huntsman, S; Torres, R; Avila, PC; Chapela, R; Ford, JG; Rodriguez-Santana, JR; Rodriguez-Cintron, W; Hernandez, RD; Burchard, EG				Torgerson, Dara G.; Gignoux, Christopher R.; Galanter, Joshua M.; Drake, Katherine A.; Roth, Lindsey A.; Eng, Celeste; Huntsman, Scott; Torres, Raul; Avila, Pedro C.; Chapela, Rocio; Ford, Jean G.; Rodriguez-Santana, Jose R.; Rodriguez-Cintron, William; Hernandez, Ryan D.; Burchard, Esteban G.			Case-control admixture mapping in Latino populations enriches for known asthma-associated genes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Admixture mapping; genome-wide association study; asthma; Latino populations; population-specific risk factors	GENOME-WIDE ASSOCIATION; DATABASE; RISK; HERITABILITY; VARIANTS; ANCESTRY; BROWSER; LOCUS; UCSC	Background: Polymorphisms in more than 100 genes have been associated with asthma susceptibility, yet much of the heritability remains to be explained. Asthma disproportionately affects different racial and ethnic groups in the United States, suggesting that admixture mapping is a useful strategy to identify novel asthma-associated loci. Objective: We sought to identify novel asthma-associated loci in Latino populations using case-control admixture mapping. Methods: We performed genome-wide admixture mapping by comparing levels of local Native American, European, and African ancestry between children with asthma and nonasthmatic control subjects in Puerto Rican and Mexican populations. Within candidate peaks, we performed allelic tests of association, controlling for differences in local ancestry. Results: Between the 2 populations, we identified a total of 62 admixture mapping peaks at a P value of less than 10(-3) that were significantly enriched for previously identified asthma-associated genes (P = .0051). One of the peaks was statistically significant based on 100 permutations in the Mexican sample (6q15); however, it was not significant in Puerto Rican subjects. Another peak was identified at nominal significance in both populations (8q12); however, the association was observed with different ancestries. Conclusion: Case-control admixture mapping is a promising strategy for identifying novel asthma-associated loci in Latino populations and implicates genetic variation at 6q15 and 8q12 regions with asthma susceptibility. This approach might be useful for identifying regions that contribute to both shared and population-specific differences in asthma susceptibility. (J Allergy Clin Immunol 2012;130:76-82.)	[Torgerson, Dara G.; Gignoux, Christopher R.; Galanter, Joshua M.; Drake, Katherine A.; Roth, Lindsey A.; Eng, Celeste; Huntsman, Scott; Torres, Raul; Burchard, Esteban G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA; [Avila, Pedro C.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA; [Chapela, Rocio] INER, Mexico City, DF, Mexico; [Ford, Jean G.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, New York, NY USA; [Rodriguez-Santana, Jose R.] Ctr Neumol Pediat, Caguas, PR USA; [Rodriguez-Cintron, William] VA Med Ctr, San Juan, PR USA; [Hernandez, Ryan D.; Burchard, Esteban G.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; Northwestern University; Johns Hopkins University; University of California System; University of California San Francisco	Torgerson, DG (corresponding author), Univ Calif San Francisco, Dept Med, 1550 4th St, San Francisco, CA 94158 USA.	dara.torgerson@ucsf.edu		Galanter, Joshua/0000-0002-2561-6384	National Institute of Health [HL088133, HL078885]; National Institutes of Environmental Health Sciences [ES015794]; Flight Attendant Medical Research Institute; Sandler Foundation; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078885, R01HL088133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015794] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007546] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Flight Attendant Medical Research Institute; Sandler Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the National Institute of Health (HL088133 and HL078885 to E. G. B.), the National Institutes of Environmental Health Sciences (ES015794 to E. G. B.), the Flight Attendant Medical Research Institute, and the Sandler Foundation.; C. R. Gignoux owns stock in 23 and Me, Inc. P. C. Avila has received research support from the National Institutes of Health. The rest of the authors declare that they have no relevant conflicts of interest.	Alexander DH, 2009, GENOME RES, V19, P1655, DOI 10.1101/gr.094052.109; Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Beavitt SJE, 2005, J IMMUNOL, V175, P1867, DOI 10.4049/jimmunol.175.3.1867; Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Cheng CY, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000908; Cheng CY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000490; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; Fijal BA, 2011, J CLIN PSYCHIAT; Freedman ML, 2006, P NATL ACAD SCI USA, V103, P14068, DOI 10.1073/pnas.0605832103; Galanter JM, 2011, J ALLERGY CLIN IMMUN, V128, P37, DOI 10.1016/j.jaci.2011.03.050; Gravel S, 2011, P NATL ACAD SCI USA, V108, P11983, DOI 10.1073/pnas.1019276108; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lantieri F, 2010, AM J MED GENET B, V153B, P1127, DOI 10.1002/ajmg.b.31110; Lavedan C, 2009, MOL PSYCHIATR, V14, P804, DOI 10.1038/mp.2008.56; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Mathias RA, 2010, J ALLERGY CLIN IMMUN, V125, P336, DOI 10.1016/j.jaci.2009.08.031; McKeigue PM, 2005, AM J HUM GENET, V76, P1, DOI 10.1086/426949; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Price AL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000519; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Reich D, 2005, NAT GENET, V37, P1113, DOI 10.1038/ng1646; Sankararaman S, 2008, AM J HUM GENET, V82, P290, DOI 10.1016/j.ajhg.2007.09.022; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Thomsen SF, 2010, CLIN EXP ALLERGY, V40, P1054, DOI 10.1111/j.1365-2222.2010.03525.x; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tzetis M, 2001, HUM GENET, V108, P216, DOI 10.1007/s004390100467; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132	36	39	40	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					76	+		10.1016/j.jaci.2012.02.040	http://dx.doi.org/10.1016/j.jaci.2012.02.040			19	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	977GN	22502797	Bronze, Green Accepted			2022-12-18	WOS:000306644800010
J	Wells, KE; Peterson, EL; Ahmedani, BK; Severson, RK; Gleason-Comstock, J; Williams, LK				Wells, Karen E.; Peterson, Edward L.; Ahmedani, Brian K.; Severson, Richard K.; Gleason-Comstock, Julie; Williams, L. Keoki			The relationship between combination inhaled corticosteroid and long-acting beta-agonist use and severe asthma exacerbations in a diverse population	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Long-acting beta-agonist; inhaled corticosteroid; severe asthma exacerbation; safety; racially and ethnically diverse population; observational study	PERSISTENT ASTHMA; SALMETEROL; FORMOTEROL; BUDESONIDE; ADHERENCE; SAFETY; RACE	Background: Safety concerns surround the use of long-acting beta-agonists (LABAs) for the treatment of asthma, even in combination with inhaled corticosteroids (ICSs) and particularly in high-risk subgroups. Objective: To estimate the effect of ICS therapy and fixed-dose ICS/LABA combination therapy on severe asthma exacerbations in a racially diverse population. Methods: ICS and ICS/LABA exposure was estimated from pharmacy data for patients with asthma aged 12 to 56 years who were members of a large health maintenance organization. ICS and ICS/LABA use was estimated for each day of follow-up to create a moving window of exposure. Proportional hazard models were used to assess the relationship between ICS and ICS/LABA combination therapy and severe asthma exacerbations (ie, use of oral corticosteroids, asthma-related emergency department visit, or asthma-related hospitalization). Results: Among the 1828 patients who met the inclusion criteria, 37% were African American, 46% were treated with ICS therapy alone, and 54% were treated with an ICS/LABA combination. Models assessing the risk of severe asthma exacerbations among individuals using ICS treatment alone and ICS/LABA combination therapy suggested that the overall protective effect was as good or better for ICS/LABA combination therapy when compared with ICS treatment alone (hazard ratio, 0.65 vs 0.72, respectively). Analyses in several subgroups, including African American patients, showed a similar statistically significant protective association for combination therapy. Conclusion: Treatment with ICS/LABA fixed-dose combination therapy appeared to perform as well as or better than ICS treatment alone in reducing severe asthma exacerbations; this included multiple high-risk subgroups. (J Allergy Clin Immunol 2012;129:1274-9.)	[Wells, Karen E.] Henry Ford Hlth Syst, Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA; [Ahmedani, Brian K.; Williams, L. Keoki] Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI 48202 USA; [Williams, L. Keoki] Henry Ford Hlth Syst, Dept Internal Med, Detroit, MI 48202 USA; [Wells, Karen E.; Severson, Richard K.] Wayne State Univ, Off Provost, Dept Family Med & Publ Hlth Sci, Detroit, MI 48202 USA; [Gleason-Comstock, Julie] Wayne State Univ, Off Provost, Ctr Urban Studies, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Wayne State University; Wayne State University	Wells, KE (corresponding author), Henry Ford Hlth Syst, Henry Ford Hosp, Dept Publ Hlth Sci, 1 Ford Pl,5C, Detroit, MI 48202 USA.	kwells1@hfhs.org			Fund for Henry Ford Hospital; American Asthma Foundation; National Institute of Allergy and Infectious Diseases [R01AI079139, R01AI061774]; National Heart, Lung, and Blood Institute [R01HL079055]; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health [R01DK064695]; National Institutes of Health (National Institute of Allergy and Infectious Diseases); National Institutes of Health (National Heart, Lung, and Blood Institute); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061774, R01AI079139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064695] Funding Source: NIH RePORTER	Fund for Henry Ford Hospital; American Asthma Foundation; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health (National Institute of Allergy and Infectious Diseases)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health (National Heart, Lung, and Blood Institute)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the Fund for Henry Ford Hospital, the American Asthma Foundation, the National Institute of Allergy and Infectious Diseases (grant nos. R01AI079139 and R01AI061774), the National Heart, Lung, and Blood Institute (grant no. R01HL079055), and the National Institute of Diabetes and Digestive and Kidney Diseases (grant no. R01DK064695), National Institutes of Health. This work represents a partial requirement for a Masters of Public Health degree at the Department of Family Medicine and Public Health Sciences, Wayne State University for Karen E. Wells.; Disclosure of potential conflict of interest: L. K. Williams has received research support from the National Institutes of Health (National Institute of Allergy and Infectious Diseases, National Heart, Lung, and Blood Institute, and National Institute of Diabetes and Digestive and Kidney Diseases) and the American Asthma Foundation. The rest of the authors declare that they have no relevant conflicts of interest.	Allen-Ramey FC, 2006, J MANAGE CARE PHARM, V12, P310, DOI 10.18553/jmcp.2006.12.4.310; Bailey W, 2008, CURR MED RES OPIN, V24, P1669, DOI 10.1185/03007990802119111; Bateman ED, 2008, ALLERGY, V63, P932, DOI 10.1111/j.1398-9995.2008.01724.x; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Busse WW, 1996, ARCH INTERN MED, V156, P1514, DOI 10.1001/archinte.156.14.1514; Chan J, 2007, J MANAG CARE PHARM, V13, P21, DOI 10.18553/jmcp.2007.13.1.21; Chowdhury BA, 2010, NEW ENGL J MED, V362, P1169, DOI 10.1056/NEJMp1002074; FDA Drug Safety Communication, 2011, FDA DRUG SAF COMM FD; Friedman H, 2008, CLIN THER, V30, P1908, DOI 10.1016/j.clinthera.2008.10.002; Gamble J, 2009, AM J RESP CRIT CARE, V180, P817, DOI 10.1164/rccm.200902-0166OC; INMAN WHW, 1993, BRIT MED J, V306, P1610, DOI 10.1136/bmj.306.6892.1610; Jaeschke R, 2008, AM J RESP CRIT CARE, V178, P1009, DOI 10.1164/rccm.200804-494OC; Kramer JM, 2009, NEW ENGL J MED, V360, P1592, DOI 10.1056/NEJMp0810561; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70; Masoli M, 2005, THORAX, V60, P730, DOI 10.1136/thx.2004.039180; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Paris J, 2008, ANN ALLERG ASTHMA IM, V101, P482, DOI 10.1016/S1081-1206(10)60286-4; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Salpeter SR, 2006, ANN INTERN MED, V144, P904, DOI 10.7326/0003-4819-144-12-200606200-00126; Salpeter SR, 2010, AM J MED, V123, P322, DOI 10.1016/j.amjmed.2009.07.035; SAS Institute Inc, 2009, SAS STAT 9 2 US GUID; Sears MR, 2009, EUR RESPIR J, V33, P21, DOI 10.1183/09031936.00145006; Thomas M, 2009, J ALLERGY CLIN IMMUN, V123, P116, DOI 10.1016/j.jaci.2008.09.035; U.S. Food and Drug Administration, 2008, 4398B101 US FDA; Wang J, 2009, PHARM IND SAS US GRO; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2007, J ALLERGY CLIN IMMUN, V119, P168, DOI 10.1016/j.jaci.2006.09.029; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Williams LK, 2010, J ALLERGY CLIN IMMUN, V126, P225, DOI 10.1016/j.jaci.2010.03.034; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; Yang JJ, 2008, J ALLERGY CLIN IMMUN, V122, P820, DOI 10.1016/j.jaci.2008.07.044	35	39	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1274	U388		10.1016/j.jaci.2011.12.974	http://dx.doi.org/10.1016/j.jaci.2011.12.974			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	934CG	22281166	Green Accepted			2022-12-18	WOS:000303418000014
J	Kesserwan, C; Sokolic, R; Cowen, EW; Garabedian, E; Heselmeyer-Haddad, K; Lee, CCR; Pittaluga, S; Ortiz, C; Baird, K; Lopez-Terrada, D; Bridge, J; Wayne, AS; Candotti, F				Kesserwan, Chimene; Sokolic, Robert; Cowen, Edward W.; Garabedian, Elizabeth; Heselmeyer-Haddad, Kerstin; Lee, Chyi-Chia Richard; Pittaluga, Stefania; Ortiz, Clarymar; Baird, Kristin; Lopez-Terrada, Dolores; Bridge, Julia; Wayne, Alan S.; Candotti, Fabio			Multicentric dermatofibrosarcoma protuberans in patients with adenosine deaminase-deficient severe combined immune deficiency	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Severe combined immunodeficiency; adenosine deaminase; dermatofibrosarcoma; adenosine; fibrosis	GIANT-CELL FIBROBLASTOMA; BONE-MARROW TRANSPLANTATION; MICE; CHILDHOOD; GENETICS; FIBROSIS; CHILDREN; FUSION; TUMORS	Background: Dermatofibrosarcoma protuberans (DFSP) is a rare malignant skin tumor associated with a characteristic chromosomal translocation (t[17; 22][q22;q13]) resulting in the COL1A1-platelet-derived growth factor beta (PDGFB) fusion gene. This malignancy is rarely diagnosed in childhood. Objective: We observed an unexpected high incidence of this DFSP in children affected with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) and set out to evaluate the association of these 2 clinical entities. Methods: Twelve patients with ADA-SCID were evaluated with a complete dermatologic examination and skin biopsy when indicated. Conventional cytogenetic and molecular analyses (fluorescence in situ hybridization, RT-PCR, or both) were performed when possible. Results: Eight patients were found to have DFSP. Six patients had multicentric involvement (4-15 lesions), primarily of the trunk and extremities. Most lesions presented as 2- to 15-mm, round atrophic plaques. Nodular lesions were present in 3 patients. In all cases CD34 expression was diffusely positive, and diagnosis was confirmed either by means of cytogenetic analysis, molecular testing, or both. The characteristic DFSP-associated translocation, t(17; 22)(q22; q13), was identified in 6 patients; results of fluorescence in situ hybridization were positive for fusion of the COL1A1 and PDGFB loci in 7 patients; and RTPCR showed the COL1A1-PDGFB fusion transcript in 6 patients. Conclusions: We describe a previously unrecognized association between ADA-SCID and DFSP with unique features, such as multicentricity and occurrence in early age. We hypothesize that the t(17; 22)(q22; q13) translocation that results in dermal overexpression of PDGFB and favors the development of fibrotic tumors might arise because of the known DNA repair defect in patients with ADA-SCID. Although the natural course of DFSP in the setting of ADA-SCID is unknown, this observation should prompt regular screening for DFSP in patients with ADA-SCID. (J Allergy Clin Immunol 2012; 129: 762-9.)	[Candotti, Fabio] NHGRI, Disorders Immun Sect, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; [Kesserwan, Chimene; Sokolic, Robert; Garabedian, Elizabeth; Candotti, Fabio] NHGRI, Med Genet Branch, Bethesda, MD 20892 USA; [Cowen, Edward W.] NCI, Dermatol Branch, NIH, Bethesda, MD 20892 USA; [Heselmeyer-Haddad, Kerstin; Ortiz, Clarymar] NCI, Sect Canc Genom, NIH, Bethesda, MD 20892 USA; [Lee, Chyi-Chia Richard; Pittaluga, Stefania] NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; [Baird, Kristin; Wayne, Alan S.] NCI, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA; [Lopez-Terrada, Dolores] Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA; [Bridge, Julia] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Baylor College of Medicine; University of Nebraska System; University of Nebraska Medical Center	Candotti, F (corresponding author), NHGRI, Disorders Immun Sect, Genet & Mol Biol Branch, NIH, 49 Convent Dr,Bldg 49,Rm 3A04,MSC 4442, Bethesda, MD 20892 USA.	fabio@nhgri.nih.gov	Sokolic, Robert/I-6072-2012; Lee, Chyi-Chia R/I-1938-2013; Sokolic, Robert/E-6224-2017; Lee, Chyi-Chia Richard/AAO-1149-2020; kesserwan, chimene/N-2106-2018	Lee, Chyi-Chia R/0000-0002-5306-7781; Sokolic, Robert/0000-0002-3399-7893; kesserwan, chimene/0000-0001-6043-2065; Baird, Kristin/0000-0002-1650-8269; Candotti, Fabio/0000-0001-6399-6042	National Institutes of Health, National Human Genome Research Institute; National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIDBC011317] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIAHG000122, ZIAHG000121, Z01HG000122] Funding Source: NIH RePORTER	National Institutes of Health, National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	Supported by the Intramural Research Program of the National Institutes of Health, National Human Genome Research Institute and National Cancer Institute.	Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Bowne WB, 2000, CANCER, V88, P2711; Carroll D, 2003, PEDIATR SURG INT, V19, P495, DOI 10.1007/s00383-002-0827-y; Checketts SR, 2000, J AM ACAD DERMATOL, V42, P907, DOI 10.1016/S0190-9622(00)90270-6; Chunn JL, 2005, J IMMUNOL, V175, P1937, DOI 10.4049/jimmunol.175.3.1937; Criscione VD, 2007, J AM ACAD DERMATOL, V56, P968, DOI 10.1016/j.jaad.2006.09.006; DuBay D, 2004, CANCER-AM CANCER SOC, V100, P1008, DOI 10.1002/cncr.20051; Fernandez P, 2008, AM J PATHOL, V172, P1675, DOI 10.2353/ajpath.2008.070952; Gaspar HB, 2009, BLOOD, V114, P3524, DOI 10.1182/blood-2009-06-189209; HIRSCHHORN R, 1981, J CLIN INVEST, V68, P1387, DOI 10.1172/JCI110389; Hirschorn R, 2006, PRIMARY IMMUNODEFICI, P169; Huang DL, 2010, GENE CHROMOSOME CANC, V49, P810, DOI 10.1002/gcc.20788; Jafarian F, 2008, PEDIATR DERMATOL, V25, P317, DOI 10.1111/j.1525-1470.2008.00674.x; JOHNSTONE AP, 1982, NATURE, V300, P368, DOI 10.1038/300368a0; Kimmel Z, 2007, ANN SURG ONCOL, V14, P2113, DOI 10.1245/s10434-006-9233-3; LeBoit PE, 2006, WHO CLASSIFICATION T; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; Mitchell BS, 2001, METABOLIC MOL BASES; Monnier D, 2006, J EUR ACAD DERMATOL, V20, P1237, DOI 10.1111/j.1468-3083.2006.01780.x; Nelson R, 2006, CLIN IMMUNOL, V119, pS138, DOI 10.1016/j.clim.2006.04.327; Patel KU, 2008, HUM PATHOL, V39, P184, DOI 10.1016/j.humpath.2007.06.009; Reddy C, 2009, J PLAST RECONSTR AES, V62, P819, DOI 10.1016/j.bjps.2007.11.009; Rubocki RJ, 2001, BLOOD, V97, P809, DOI 10.1182/blood.V97.3.809; Sandberg AA, 2003, CANCER GENET CYTOGEN, V140, P1, DOI 10.1016/S0165-4608(02)00848-8; Sirvent N, 2003, GENE CHROMOSOME CANC, V37, P1, DOI 10.1002/gcc.10202; Terrier-Lacombe MJ, 2003, AM J SURG PATHOL, V27, P27, DOI 10.1097/00000478-200301000-00004; Topar G, 2008, CLIN EXP DERMATOL, V33, P373, DOI 10.1111/j.1365-2230.2007.02501.x; Weinstein JM, 2003, ARCH DERMATOL, V139, P207, DOI 10.1001/archderm.139.2.207	28	39	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					762	U240		10.1016/j.jaci.2011.10.028	http://dx.doi.org/10.1016/j.jaci.2011.10.028			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	904IW	22153773	Green Accepted			2022-12-18	WOS:000301189300023
J	Lowe, A; Braback, L; Ekeus, C; Hjern, A; Forsberg, B				Lowe, Adrian; Braback, Lennart; Ekeus, Cecilia; Hjern, Anders; Forsberg, Bertil			Maternal obesity during pregnancy as a risk for early-life asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Lowe, Adrian; Braback, Lennart; Forsberg, Bertil] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden; [Lowe, Adrian] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Lowe, Adrian] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Sch Populat Hlth, Melbourne, Vic, Australia; [Braback, Lennart] Vasternorrland Cty Council, Dept Res & Dev, Sundsvall, Sweden; [Ekeus, Cecilia] Karolinska Inst, Dept Woman & Child, Stockholm, Sweden; [Hjern, Anders] Stockholm Univ, Ctr Hlth Equ Studies CHESS, Karolinska Inst, S-10691 Stockholm, Sweden; [Hjern, Anders] Natl Board Hlth & Welf, Ctr Epidemiol, Stockholm, Sweden	Umea University; Murdoch Children's Research Institute; University of Melbourne; Karolinska Institutet; Karolinska Institutet; Stockholm University; National Board of Health & Welfare	Lowe, A (corresponding author), Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden.	Lowe.adrian@gmail.com	; Braback, Lennart/A-3793-2015	Lowe, Adrian/0000-0002-4691-8162; Hjern, Anders/0000-0002-1645-2058; Ekeus, Cecilia/0000-0002-5861-4692; Braback, Lennart/0000-0001-9930-7755				Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; Catalano PM, 2010, REPRODUCTION, V140, P365, DOI 10.1530/REP-10-0088; Haberg SE, 2009, PAEDIATR PERINAT EP, V23, P352, DOI 10.1111/j.1365-3016.2009.01034.x; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Poston L, 2011, PEDIATR RES, V69, P175, DOI 10.1203/PDR.0b013e3182055ede; Reichman NE, 2008, MATERN CHILD HLTH J, V12, P725, DOI 10.1007/s10995-007-0292-2; Rokholm B, 2010, OBES REV, V11, P835, DOI 10.1111/j.1467-789X.2010.00810.x; Scholtens S, 2010, INT J OBESITY, V34, P606, DOI 10.1038/ijo.2009.194; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537	9	39	40	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1107	1109		10.1016/j.jaci.2011.08.025	http://dx.doi.org/10.1016/j.jaci.2011.08.025			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21958587	Bronze			2022-12-18	WOS:000296578200026
J	Zeiger, RS; Mellon, M; Chipps, B; Murphy, KR; Schatz, M; Kosinski, M; Lampl, K; Ramachandran, S				Zeiger, Robert S.; Mellon, Michael; Chipps, Bradley; Murphy, Kevin R.; Schatz, Michael; Kosinski, Mark; Lampl, Kathy; Ramachandran, Sulabha			Test for Respiratory and Asthma Control in Kids (TRACK): Clinically meaningful changes in score	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma control; epidemiologic measurements; questionnaire; pediatric; preschool children; risk; validation studies; wheezing	MINIMALLY IMPORTANT DIFFERENCES; CHILDHOOD ASTHMA; HEALTH-STATUS; QUESTIONNAIRE; VALIDATION	Background: The Test for Respiratory and Asthma Control in Kids (TRACK) is the first validated questionnaire to assess respiratory and asthma control exclusively in young children. Objective: We sought to determine the minimally important difference (MID) for interpreting meaningful changes in individual patients' TRACK scores. Methods: In this prospective, nonrandomized, longitudinal study conducted at 20 US pediatric sites, TRACK was administered at 2 separate clinic visits (4-6 weeks apart) to caregivers of children aged less than 5 years with symptoms consistent with asthma. Anchor-based methods were used to determine the MID from mean score differences between patients based on multiple criteria measures: physician guidelines-based respiratory control rating, physician-recommended changes to therapy, episodes of symptoms lasting more than 24 hours in the past 3 months, oral corticosteroid use for respiratory tract illnesses in the past year, physician-assessed change in control status at follow-up, and caregiver-reported change in respiratory status. The MID also was determined from distribution-based methods. Results: TRACK scores were assessed at baseline (426 caregivers) and follow-up (396 caregivers). Mean differences in TRACK scores between patients differing on criteria measures ranged from 3.4 to 16.4 points (mean, 11.1 points). Distribution-based techniques confirmed these findings. Based on logistic regression analyses, scoring 10 or more points less than 80 on TRACK was associated with an approximately 2-fold increased odds of having uncontrolled asthma or respiratory symptoms. Conclusion: Changes in TRACK scores of 10 or more points represent clinically meaningful changes in respiratory control status in individual young children with respiratory symptoms consistent with asthma and should alert health care providers to re-evaluate asthma management. (J Allergy Clin Immunol 2011;128:983-8.)	[Zeiger, Robert S.; Mellon, Michael; Schatz, Michael] Kaiser Permanente, Dept Allergy, San Diego, CA USA; [Chipps, Bradley] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA; [Murphy, Kevin R.] Boys Town Natl Res Hosp, Omaha, NE 68131 USA; [Kosinski, Mark] QualityMetric Inc, Outcomes Insight Consulting Div, Lincoln, NE USA; [Ramachandran, Sulabha] AstraZeneca LP, Hlth Econ & Outcomes Res, Wilmington, DE USA; [Lampl, Kathy] AstraZeneca LP, Clin Res Resp & Inflammat Therapeut Area, Wilmington, DE USA	Kaiser Permanente; Boys Town National Research Hospital; AstraZeneca; AstraZeneca	Zeiger, RS (corresponding author), Kaiser Permanente San Diego, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	Robert.S.Zeiger@kp.org		Zeiger, Robert/0000-0001-5788-5063	AstraZeneca LP; Aerocrine; Genentech; Merck and Co; GlaxoSmithKline; Alcon; AstraZeneca; Novartis; Sunovion; Merck/Schering-Plough; Dey	AstraZeneca LP(AstraZeneca); Aerocrine; Genentech(Roche HoldingGenentech); Merck and Co(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); Alcon(Novartis); AstraZeneca(AstraZeneca); Novartis(Novartis); Sunovion; Merck/Schering-Plough(Merck & CompanySchering Plough Corporation); Dey	Supported by AstraZeneca LP.; Disclosure of potential conflict of interest: R. S. Zeiger has consultant arrangements with AstraZeneca, Aerocrine, Genentech, Merck and Co, Schering-Plough, MedImmune, and Sunovion and receives research support from Aerocrine, Genentech, Merck and Co, and GlaxoSmithKline. M. Mellon has consultant arrangements with AstraZeneca. B. Chipps has consultant arrangements with Alcon, Genentech, AstraZeneca, GlaxoSmithKline, Meda, Novartis, Sunovion, Merck/Schering-Plough, ISTA, Quintiles, and Dey; is on the speakers' bureau for Alcon, Genentech, AstraZeneca, GlaxoSmithKline, Meda, Novartis, Sunovion, Merck/Schering-Plough, ISTA, and Dey; and receives grant support from Alcon, Genentech, AstraZeneca, GlaxoSmithKline, Novartis, Sunovion, and Merck/Schering-Plough. K. R. Murphy has consultant arrangements with AstraZeneca, Merck and Co, Schering-Plough, ISTA, and Dey; is on the speakers' bureau for AstraZeneca, Novartis, Merck and Co, Schering-Plough, Aerocrine, ISTA, and Dey; and receives research support from AstraZeneca, Merck, Novartis, GlaxoSmithKline, Sunovion, Dey, and Boehringer Ingelheim. M. Schatz has consultant arrangements with Merck, Amgen, and GlaxoSmithKline and receives research support from Aerocrine, Merck, GlaxoSmithKline, and Genentech. K. Lampl and S. Ramachandran are employed by AstraZeneca. M. Kosinski has declared that he has no conflict of interest.	Akinbami Lara, 2006, Adv Data, P1; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; American Academy of Pediatrics, QUIIN QUAL IMPR INN; Chipps B, 2011, PEDIATRICS, V127, pE737, DOI 10.1542/peds.2010-1465; Cohen J., 1988, STAT POWER ANAL BEHA; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; Guyatt GH, 2002, MAYO CLIN PROC, V77, P371, DOI 10.4065/77.4.371; Hays Ron D, 2005, COPD, V2, P63; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Murphy KR, 2009, J ALLERGY CLIN IMMUN, V123, P833, DOI 10.1016/j.jaci.2009.01.058; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Revicki D, 2008, J CLIN EPIDEMIOL, V61, P102, DOI 10.1016/j.jclinepi.2007.03.012; Schatz M, 2009, J ALLERGY CLIN IMMUN, V124, P719, DOI 10.1016/j.jaci.2009.06.053; Skinner Elizabeth A, 2004, Dis Manag, V7, P305, DOI 10.1089/dis.2004.7.305; US Department of Health and Human Services Food and Drug Administration, 2009, CLIN MED GUID IND PA; Wyrwich KW, 1999, J CLIN EPIDEMIOL, V52, P861, DOI 10.1016/S0895-4356(99)00071-2; Yost KJ, 2005, EVAL HEALTH PROF, V28, P172, DOI 10.1177/0163278705275340	21	39	46	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					983	988		10.1016/j.jaci.2011.08.010	http://dx.doi.org/10.1016/j.jaci.2011.08.010			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	842FJ	21906790				2022-12-18	WOS:000296578200010
J	Matheson, MC; Dharmage, SC; Abramson, MJ; Walters, EH; Sunyer, J; de Marco, R; Leynaert, B; Heinrich, J; Jarvis, D; Norback, D; Raherison, C; Wjst, M; Svanes, C				Matheson, Melanie Claire; Dharmage, Shyamali Chandrika; Abramson, Michael John; Walters, Eugene Haydn; Sunyer, Jordi; de Marco, Roberto; Leynaert, Benedicte; Heinrich, Joachim; Jarvis, Deborah; Norback, Dan; Raherison, Chantal; Wjst, Matthias; Svanes, Cecilie			Early-life risk factors and incidence of rhinitis: Results from the European Community Respiratory Health Study-an international population-based cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Rhinitis; atopy; gender; pet exposure; siblings; farming lifestyle	ALLERGIC RHINITIS; HAY-FEVER; GENERAL-PRACTICE; NATURAL-HISTORY; CHILDHOOD PETS; ASTHMA; EXPOSURE; CHILDREN; SENSITIZATION; ATOPY	Background: Rhinitis is an increasingly common condition with a heavy health care burden, but relatively little is known about its risk factors. Objective: To examine the association between early-life factors and the development of rhinitis in the European Community Respiratory Health Study (ECRHS). Methods: In 1992-1994, community-based samples of 20-44-year-old people were recruited from 48 centers in 22 countries. On average, 8.9 years later, 28 centers reinvestigated their samples. Onset of rhinitis was reported by 8486 participants in interviewer-led questionnaires. Cox regression was used to assess independent predictors of rhinitis at ages <= 5, 6-10, 11-20, and >= 21 years. Results: The crude lifelong incidence of rhinitis was 7.00/1000/year (men) and 7.95/1000/year (women) (P = .002). Women developed less rhinitis in later childhood (hazard ratios [HR], 0.63; 95% CI, 0.47-0.85) and more rhinitis in adulthood (HR, 1.36; 95% CI, 1.11-1.66) than did men. In atopic subjects, siblings were associated with lower risk of rhinitis throughout life (pooled HR, 0.94; 95% CI, 0.91-0.98 per 1 sibling). Early contact with children in the family or day care was associated with less incidence of rhinitis, predominantly before age 5 years (HR, 0.84; 95% CI, 0.72-0.99). Early childhood pets or growing up on a farm was associated with less incidence of rhinitis in adolescence (HR, 0.50; 95% CI, 0.37-0.68). Combining these factors showed evidence of a dose-response relationship (trend P = .0001). Conclusions: Gender is a strong risk factor for rhinitis, with age patterns varying according to atopic status. Protective effects of early contact with children and animals were suggested for incident rhinitis, with risk patterns varying by age window and atopic status. (J Allergy Clin Immunol 2011;128:816-23.)	[Matheson, Melanie Claire; Dharmage, Shyamali Chandrika] Univ Melbourne, MEGA Epidemiol, Melbourne, Vic 3010, Australia; [Abramson, Michael John] Monash Univ, Melbourne, Vic, Australia; [Walters, Eugene Haydn] Univ Tasmania, Menzies Res Inst, Hobart, Tas, Australia; [Sunyer, Jordi] Ctr Recerca Epidemiol Ambiental, Barcelona, Spain; [de Marco, Roberto] Univ Verona, Dept Med & Publ Hlth, I-37100 Verona, Italy; [Leynaert, Benedicte] Univ Paris Diderot Paris 7, INSERM, Epidemiol U700, Paris, France; [Heinrich, Joachim; Wjst, Matthias] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Jarvis, Deborah] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Norback, Dan] Uppsala Univ, Uppsala, Sweden; [Raherison, Chantal] Univ Bordeaux, Dept Resp Dis, Haut Leveque CHU Bordeaux, Bordeaux, France; [Wjst, Matthias] EURAC Res, Inst Med Genet, Bozen Bolzano, Italy; [Svanes, Cecilie] Univ Bergen, Bergen Resp Res Grp, Inst Med, Bergen, Norway; [Svanes, Cecilie] Haukeland Hosp, Dept Occupat Med, N-5021 Bergen, Norway	University of Melbourne; Monash University; University of Tasmania; Menzies Institute for Medical Research; University of Verona; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Imperial College London; Uppsala University; CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; European Academy of Bozen-Bolzano; University of Bergen; University of Bergen; Haukeland University Hospital	Matheson, MC (corresponding author), Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Dept Publ Hlth, Sch Populat Hlth, Level 1-723 Swanston St, Carlton, Vic 3053, Australia.	mcmat@unimelb.edu.au	Heinrich, Joachim/N-1720-2013; Abramson, Michael/AAQ-2671-2020; Sunyer, Jordi/G-6909-2014; Leynaert, Benedicte/N-5251-2018; Matheson, Melanie C/O-4721-2015; Svanes, Cecilie/N-7556-2017; Raherison, Chantal/T-3556-2019; WALTERS, Eugene/AAL-2264-2021; de Marco, Roberto/A-5470-2008	Heinrich, Joachim/0000-0002-9620-1629; Abramson, Michael/0000-0002-9954-0538; Sunyer, Jordi/0000-0002-2602-4110; Matheson, Melanie C/0000-0002-5822-3499; Svanes, Cecilie/0000-0001-8512-5192; Walters, Eugene/0000-0002-0993-4374; Norback, Dan/0000-0002-5174-6668; Leynaert, Benedicte/0000-0001-5045-2492; Jarvis, Deborah/0000-0002-1753-3896	National Health and Medical Research Council of Australia; Clifford Craig Medical Trust; GlaxoSmithKline; Belgian Science Policy Office; Ministere de la Sante, Glaxo France; Insitut Pneumologique d'Aquitaine; Contrat de Plan Etat-Region Languedoc-Rousillon; CNMATS; CNMRT [90MR/10, 91AF/6]; Ministre delegue de la sante; RNSP, France; GSF; Bundesminister fur Forschung und Technologie, Bonn, Germany; Ministero dell'Universita e della Ricerca Scientifica e Tecnologica; CNR, Regione Veneto [381/05.93]; Norwegian Research Council [101422/310]; Dutch Ministry of Wellbeing, Public Health and Culture, Netherlands; Ministero Sanidad y Consumo FIS [91/0016060/00E-05E, 93/0393]; Hospital General de Albacete; Hospital General Juan Ramon Jimenenz; Consejeria de Sanidad Principado de Asturias, Spain; Swedish Medical Research Council; Swedish Heart Lung Foundation; Swedish Association against Asthma and Allergy; Swiss National Science Foundation [402628099]; National Asthma Campaign; British Lung Foundation; Department of Health; South Thames Regional Health Authority, United Kingdom; United States Department of Health, Education and Welfare Public Health Service [2 S07 RR05521-28]; Victorian Health Promotion Foundation and Allen Hanburys; European Commission; Albacete: Fondo de Investigaciones Santarias (FIS) [97/0035-01, 99/0034-01, 99/0034-02]; Hospital Universitario de Albacete, Consejeria de Sanidad; Antwerp: FWO (Fund for Scientific Research)-Flanders Belgium [G.0402.00]; University of Antwerp, Flemish Health Ministry; Barcelona: SEPAR, Public Health Service [R01 HL62633-01]; Fondo de Investigaciones Santarias (FIS) [97/0035-01, 99/0034-01, 99/0034-02]; CIRIT [1999SGR 00241]; Red Respira ISCII; Basel: Swiss National Science Foundation; Swiss Federal Office for Education Science; USC NIEHS Center [5P30 ES07048]; Bergen: Norwegian Research Council,Norwegian Asthma & Allergy Association (NAAF); Glaxo Wellcome AS; Norway Research Fund; Bordeaux: Institut Pneumologique d'Aquitaine; Erfurt: GSF-National Research Centre for Environment Health; Deutsche Forschungsgemeinschaft (DFG) [FR 1526/1-1]; Galdakao: Basque Health Department; Goteborg: Swedish Heart Lung Foundation; Swedish Foundation for Health Care Sciences & Allergy Research; Swedish Asthma & Allergy Foundation; Swedish Cancer& Allergy Foundation; Grenoble: Programme Hospitalier de Recherche Clinique-DRC de Grenoble [2610]; Ministry of Health, Direction de la Recherche Clinique; Ministere de l'Emploi et de la Solidarite; Direction Generale de la Sante; CHU de Grenoble; Comite des Maladies Respiratoires de l'Isere; Hamburg: GSF-National Research Centre for Environment Health; Ipswich; Norwich: AsthmaUK(formerly known as National Asthma Campaign); Huelva: Fondo de Investigaciones Santarias (FIS) [97/0035-01, 99/0034-01, 99/0034-02]; Montpellier: Programme Hospitalier de Recherche Clinique-DRC de Grenoble [2610]; Direction Generale de la Sante, Aventis (France); Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon; Oviedo: Fondo de Investigaciones Santarias (FIS) [97/0035-01, 99/0034-01, 99/0034-02]; Paris: Ministere de l'Emploi et de la Solidarite; UCB-Pharma (France); Aventis (France); Glaxo France; Programme Hospitalier de Recherche Clinique-DRC de Grenoble [2610]; Pavia: Glaxo-SmithKline Italy; Italian Ministry of University and Scientific and Technological Research (MURST); Local University; Portland: American Lung Association of Oregon; Northwest Health Foundation; Collins Foundation; Merck Pharmaceutical; Reykjavik: Icelandic Research Council; Icelandic University Hospital; Tartu: Estonian Science Foundation; Turin: ASL 4 Regione Piemonte (Italy); AO CTO/ICORMA Regione Piemonte (Italy); Ministero dell'Universita e della Ricerca Scientifica (Italy); Glaxo Wellcome spa (Verona, Italy); Umea: Swedish Heart Lung Foundation; Swedish Cancer & Allergy Foundation; Uppsala: Swedish Heart Lung Foundation; Verona: University of Verona; Glaxo-SmithKline Italy; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005521] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007048] Funding Source: NIH RePORTER	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Clifford Craig Medical Trust; GlaxoSmithKline(GlaxoSmithKline); Belgian Science Policy Office(Belgian Federal Science Policy Office); Ministere de la Sante, Glaxo France; Insitut Pneumologique d'Aquitaine; Contrat de Plan Etat-Region Languedoc-Rousillon(Region Occitanie); CNMATS; CNMRT; Ministre delegue de la sante; RNSP, France; GSF; Bundesminister fur Forschung und Technologie, Bonn, Germany; Ministero dell'Universita e della Ricerca Scientifica e Tecnologica(Ministry of Education, Universities and Research (MIUR)); CNR, Regione Veneto(Consiglio Nazionale delle Ricerche (CNR)); Norwegian Research Council(Research Council of NorwayEuropean Commission); Dutch Ministry of Wellbeing, Public Health and Culture, Netherlands; Ministero Sanidad y Consumo FIS; Hospital General de Albacete; Hospital General Juan Ramon Jimenenz; Consejeria de Sanidad Principado de Asturias, Spain; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Heart Lung Foundation(Swedish Heart-Lung Foundation); Swedish Association against Asthma and Allergy; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); National Asthma Campaign; British Lung Foundation; Department of Health; South Thames Regional Health Authority, United Kingdom; United States Department of Health, Education and Welfare Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Victorian Health Promotion Foundation and Allen Hanburys; European Commission(European CommissionEuropean Commission Joint Research Centre); Albacete: Fondo de Investigaciones Santarias (FIS)(Instituto de Salud Carlos III); Hospital Universitario de Albacete, Consejeria de Sanidad; Antwerp: FWO (Fund for Scientific Research)-Flanders Belgium; University of Antwerp, Flemish Health Ministry; Barcelona: SEPAR, Public Health Service; Fondo de Investigaciones Santarias (FIS)(Instituto de Salud Carlos III); CIRIT; Red Respira ISCII; Basel: Swiss National Science Foundation; Swiss Federal Office for Education Science; USC NIEHS Center; Bergen: Norwegian Research Council,Norwegian Asthma & Allergy Association (NAAF); Glaxo Wellcome AS; Norway Research Fund; Bordeaux: Institut Pneumologique d'Aquitaine; Erfurt: GSF-National Research Centre for Environment Health; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Galdakao: Basque Health Department; Goteborg: Swedish Heart Lung Foundation; Swedish Foundation for Health Care Sciences & Allergy Research; Swedish Asthma & Allergy Foundation; Swedish Cancer& Allergy Foundation; Grenoble: Programme Hospitalier de Recherche Clinique-DRC de Grenoble; Ministry of Health, Direction de la Recherche Clinique; Ministere de l'Emploi et de la Solidarite; Direction Generale de la Sante(General Electric); CHU de Grenoble; Comite des Maladies Respiratoires de l'Isere; Hamburg: GSF-National Research Centre for Environment Health; Ipswich; Norwich: AsthmaUK(formerly known as National Asthma Campaign); Huelva: Fondo de Investigaciones Santarias (FIS)(Instituto de Salud Carlos III); Montpellier: Programme Hospitalier de Recherche Clinique-DRC de Grenoble; Direction Generale de la Sante, Aventis (France)(Sanofi-Aventis); Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon; Oviedo: Fondo de Investigaciones Santarias (FIS)(Instituto de Salud Carlos III); Paris: Ministere de l'Emploi et de la Solidarite; UCB-Pharma (France)(UCB Pharma SA); Aventis (France)(Sanofi-Aventis); Glaxo France; Programme Hospitalier de Recherche Clinique-DRC de Grenoble; Pavia: Glaxo-SmithKline Italy; Italian Ministry of University and Scientific and Technological Research (MURST)(Ministry of Education, Universities and Research (MIUR)); Local University; Portland: American Lung Association of Oregon; Northwest Health Foundation; Collins Foundation; Merck Pharmaceutical(Merck & Company); Reykjavik: Icelandic Research Council; Icelandic University Hospital; Tartu: Estonian Science Foundation; Turin: ASL 4 Regione Piemonte (Italy); AO CTO/ICORMA Regione Piemonte (Italy); Ministero dell'Universita e della Ricerca Scientifica (Italy)(Ministry of Education, Universities and Research (MIUR)); Glaxo Wellcome spa (Verona, Italy); Umea: Swedish Heart Lung Foundation; Swedish Cancer & Allergy Foundation; Uppsala: Swedish Heart Lung Foundation; Verona: University of Verona; Glaxo-SmithKline Italy(GlaxoSmithKline); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	M.C. Matheson and S. C. Dharmage are supported by the National Health and Medical Research Council of Australia. The ECRHS study is a joint project by many participants and funded by many sources. See the Acknowledgments section for complete funding and study information.; S.C. Dharmage has received research support from the National Health and Medical Research Council (Australia) and the Clifford Craig Medical Trust. M.J. Abramson is the chair of the Australian Lung Foundation's guidelines committee. E. H. Walters has received research support from GlaxoSmithKline. M. Wjst is married to an employee of Bencard. The rest of the authors have declared that they have no conflict of interest.; Financial support for ECRHS I centers: Belgian Science Policy Office, National Fund for Scientific Research; Ministere de la Sante, Glaxo France, Insitut Pneumologique d'Aquitaine, Contrat de Plan Etat-Region Languedoc-Rousillon, CNMATS, CNMRT (90MR/10, 91AF/6), Ministre delegue de la sante, RNSP, France; GSF, and the Bundesminister fur Forschung und Technologie, Bonn, Germany; Ministero dell'Universita e della Ricerca Scientifica e Tecnologica, CNR, Regione Veneto grant RSF no. 381/05.93, Italy; Norwegian Research Council project no. 101422/310; Dutch Ministry of Wellbeing, Public Health and Culture, Netherlands; Ministero Sanidad y Consumo FIS (grants #91/0016060/00E-05E and #93/0393), and grants from Hospital General de Albacete, Hospital General Juan Ramon Jimenenz, Consejeria de Sanidad Principado de Asturias, Spain; The Swedish Medical Research Council, the Swedish Heart Lung Foundation, the Swedish Association against Asthma and Allergy; Swiss National Science Foundation grant 402628099; National Asthma Campaign, British Lung Foundation, Department of Health, South Thames Regional Health Authority, United Kingdom; United States Department of Health, Education and Welfare Public Health Service (grant #2 S07 RR05521-28). Australia: Victorian Health Promotion Foundation and Allen & Hanburys.; Financial support for ECRHS II: The coordination of ECRHS II was supported by the European Commission, as part of its Quality of Life program. The following bodies funded the local studies in ECRHS II included in this article: Albacete: Fondo de Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01, and 99/0034-02), Hospital Universitario de Albacete, Consejeria de Sanidad; Antwerp: FWO (Fund for Scientific Research)-Flanders Belgium (grant code: G.0402.00), University of Antwerp, Flemish Health Ministry; Barcelona: SEPAR, Public Health Service (grant code: R01 HL62633-01), Fondo de Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01, and 99/0034-02), CIRIT (grant code: 1999SGR 00241) Red Respira ISCII; Basel: Swiss National Science Foundation, Swiss Federal Office for Education & Science, Swiss National Accident Insurance Fund (SUVA), USC NIEHS Center grant 5P30 ES07048; Bergen: Norwegian Research Council,Norwegian Asthma & Allergy Association (NAAF), Glaxo Wellcome AS, Norway Research Fund; Bordeaux: Institut Pneumologique d'Aquitaine; Erfurt: GSF-National Research Centre for Environment& Health, Deutsche Forschungsgemeinschaft (DFG) (grant code FR 1526/1-1); Galdakao: Basque Health Department; Goteborg: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences & Allergy Research, Swedish Asthma & Allergy Foundation, Swedish Cancer& Allergy Foundation; Grenoble: Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 no. 2610, Ministry of Health, Direction de la Recherche Clinique, Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, CHU de Grenoble, Comite des Maladies Respiratoires de l'Isere; Hamburg: GSF-National Research Centre for Environment & Health, Deutsche Forschungsgemeinschaft (DFG) (grant codeMA711/4-1); Ipswich and Norwich: AsthmaUK(formerly known as National Asthma Campaign); Huelva: Fondo de Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01, and 99/0034-02); Montpellier: Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 no. 2610, Ministry of Health, Direction de la Recherche Clinique, CHU de Grenoble, Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, Aventis (France), Direction Regionale des Affaires Sanitaires et Sociales Languedoc-Roussillon; Oviedo: Fondo de Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01, and 99/0034-02); Paris: Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, UCB-Pharma (France), Aventis (France), Glaxo France, Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 no.; 2610, Ministry of Health, Direction de la Recherche Clinique, CHU de Grenoble; Pavia: Glaxo-SmithKline Italy, Italian Ministry of University and Scientific and Technological Research (MURST), Local University Funding for research 1998 & 1999 (Pavia, Italy); Portland: American Lung Association of Oregon, Northwest Health Foundation, Collins Foundation, Merck Pharmaceutical; Reykjavik: Icelandic Research Council, Icelandic University Hospital Fund; Tartu: Estonian Science Foundation; Turin: ASL 4 Regione Piemonte (Italy), AO CTO/ICORMA Regione Piemonte (Italy), Ministero dell'Universita e della Ricerca Scientifica (Italy), Glaxo Wellcome spa (Verona, Italy); Umea: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences & Allergy Research, Swedish Asthma & Allergy Foundation, Swedish Cancer & Allergy Foundation; Uppsala: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences & Allergy Research, Swedish Astma & Allergy Foundation, Swedish Cancer & Allergy Foundation; Verona: University of Verona; Italian Ministry of University and Scientific and Technological Research (MURST); Glaxo-SmithKline Italy.	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Biagini JM, 2006, PEDIAT ALLERG IMM-UK, V17, P278, DOI 10.1111/j.1399-3038.2006.00386.x; Blaiss MS, 2007, ALLERGY ASTHMA PROC, V28, P393, DOI 10.2500/aap.2007.28.3013; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet PJ, 2008, ALLERGY, V63, P1301, DOI 10.1111/j.1398-9995.2008.01824.x; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Chen CM, 2008, EUR RESPIR J, V31, P963, DOI 10.1183/09031936.00092807; de Bot CMA, 2009, PEDIAT ALLERG IMM-UK, V20, P571, DOI 10.1111/j.1399-3038.2008.00829.x; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; Fasce L, 2005, ANN ALLERG ASTHMA IM, V94, P561, DOI 10.1016/S1081-1206(10)61134-9; Goldstein IF, 2005, INT ARCH ALLERGY IMM, V137, P249, DOI 10.1159/000086338; Govaere E, 2007, PEDIAT ALLERG IMM-UK, V18, P671, DOI 10.1111/j.1399-3038.2007.00570.x; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Huurre TM, 2004, J ASTHMA, V41, P311, DOI 10.1081/JAS-120026088; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Keil T, 2010, PEDIAT ALLERG IMM-UK, V21, P962, DOI 10.1111/j.1399-3038.2010.01046.x; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829, DOI 10.1164/ajrccm.164.10.2103137; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Lowe AJ, 2008, J ALLERGY CLIN IMMUN, V121, P1190, DOI 10.1016/j.jaci.2008.01.034; Matheson MC, 2009, CLIN EXP ALLERGY, V39, P370, DOI 10.1111/j.1365-2222.2008.03175.x; Matheson MC, 2011, J ALLERGY CLIN IMMUN, V128, P816, DOI 10.1016/j.jaci.2011.05.039; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Nicholas C, 2009, AM J EPIDEMIOL, V170, P388, DOI 10.1093/aje/kwp139; Osman Mustafa, 2007, Prim Care Respir J, V16, P28, DOI 10.3132/pcrj.2007.00006; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Perzanowski MS, 2008, CLIN EXP ALLERGY, V38, P968, DOI 10.1111/j.1365-2222.2008.02967.x; Prescott SL, 2010, P NUTR SOC, V69, P366, DOI 10.1017/S0029665110001874; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Svanes C, 2008, INDOOR AIR, V18, P84, DOI 10.1111/j.1600-0668.2008.00523.x; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Svanes C, 2002, THORAX, V57, P945, DOI 10.1136/thorax.57.11.945; Svanes C, 2006, J ALLERGY CLIN IMMUN, V118, P691, DOI 10.1016/j.jaci.2006.06.017; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; WRIGHT AL, 1994, PEDIATRICS, V94, P895	41	39	41	1	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					816	+		10.1016/j.jaci.2011.05.039	http://dx.doi.org/10.1016/j.jaci.2011.05.039			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	841UA	21752439				2022-12-18	WOS:000296538100018
J	An, P; Barron-Casella, EA; Strunk, RC; Hamilton, RG; Casella, JF; DeBaun, MR				An, Ping; Barron-Casella, Emily A.; Strunk, Robert C.; Hamilton, Robert G.; Casella, James F.; DeBaun, Michael R.			Elevation of IgE in children with sickle cell disease is associated with doctor diagnosis of asthma and increased morbidity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Total IgE; allergen-specific IgE; asthma risk indicator; acute chest syndrome; pain; sickle cell disease; hemoglobinopathies	ACUTE CHEST SYNDROME; SKIN-TEST REACTIVITY; PARENTAL SMOKING; RISK-FACTORS; SERUM IGE; EXPOSURE; ANEMIA; POPULATION; PREVALENCE; PAIN	Background: A doctor's diagnosis of asthma is associated with increased morbidity (pain and acute chest syndrome [ACS]) among children with sickle cell disease (SCD). An association between IgE levels and asthma and morbidity has not been investigated in children with SCD. Objective: We tested the hypothesis that elevated total and allergen-specific IgE levels are associated with asthma and SCD morbidity in children with SCD. Methods: A cross-sectional study of children with SCD who participated in the Silent Cerebral Infarct Trial was conducted. Logistic regression and negative binomial regression were used to investigate potential associations of total and allergen-specific IgE levels with asthma diagnosis and SCD morbidity, both confirmed by medical record review. Elevation of total IgE level was defined as age-adjusted and sex-adjusted IgE level exceeding the 90th percentile compared with a nonatopic reference population. IgE antibody positivity to Alternaria alternata (mold), Blattella germanica (cockroach), and Dermatophagoides pteronyssinus (dust mite) was assessed by ImmunoCAP analysis. Results: Children with SCD (140 with asthma; 381 without asthma) were evaluated. Elevations in total IgE level (P = .04) and IgE antibody specific for Alternaria alternata (P = .0003), Blattella germanica (P = .008), and Dermatophagoides pteronyssinus (P = .01) were associated with asthma. ACS (P = .048) but not pain (P = .20) was associated with total IgE level, but neither was associated with specific IgE levels. Conclusion: Significantly increased levels of total and allergen-specific IgE levels are associated with asthma in SCD. High IgE levels are a risk factor for ACS but not pain rates. (J Allergy Clin Immunol 2011;127:1440-6.)	[DeBaun, Michael R.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA; [DeBaun, Michael R.] Monroe Carell Jr Childrens Hosp Vanderbilt, Nashville, TN 37232 USA; [An, Ping] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; [Strunk, Robert C.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Strunk, Robert C.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Barron-Casella, Emily A.; Casella, James F.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Hematol, Baltimore, MD 21205 USA; [Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Hamilton, Robert G.] Johns Hopkins Univ, Sch Med, Dept Clin Immunol & Pathol, Baltimore, MD USA	Vanderbilt University; Vanderbilt University; Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	DeBaun, MR (corresponding author), Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA.	m.debaun@vanderbilt.edu			National Institute of Neurological Disorders and Stroke [U01 NS042804]; National Heart, Lung, and Blood Institute [RO1-HL079937]; National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS042804] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by the National Institute of Neurological Disorders and Stroke (U01 NS042804) and the National Heart, Lung, and Blood Institute (RO1-HL079937).; Disclosure of potential conflict of interest: J. Casella receives research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; Bernaudin F, 2008, HAEMATOL-HEMATOL J, V93, P1917, DOI 10.3324/haematol.13090; Boyd JH, 2006, BLOOD, V108, P2923, DOI 10.1182/blood-2006-01-011072; Boyd JH, 2004, PEDIATR PULM, V38, P229, DOI 10.1002/ppul.20066; Bryant Rosalind, 2005, J Pediatr Health Care, V19, P157, DOI 10.1016/j.pedhc.2004.12.003; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Casella JF, 2010, PEDIATR HEMAT ONCOL, V27, P69, DOI 10.3109/08880010903360367; Duckworth L, 2007, PEDIATR PULM, V42, P332, DOI 10.1002/ppul.20582; Hebbel RP, 2004, MICROCIRCULATION, V11, P129, DOI 10.1080/10739680490278402; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Knight-Madden JM, 2005, THORAX, V60, P206, DOI 10.1136/thx.2004.029165; Matsui EC, 2010, ALLERGY, V65, P1414, DOI 10.1111/j.1398-9995.2010.02412.x; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; National Heart Lung and Blood Institute, NAT HEART LUNG BLOOD; Nelson KA, 2009, J PEDIATR-US, V154, P111, DOI 10.1016/j.jpeds.2008.07.017; Nordness Mark E, 2005, Clin Mol Allergy, V3, P2, DOI 10.1186/1476-7961-3-2; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Palma-Carlos A G, 2005, Eur Ann Allergy Clin Immunol, V37, P177; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; Powars DR, 2005, MEDICINE, V84, P363, DOI 10.1097/01.md.0000189089.45003.52; SAARINEN UM, 1982, ACTA PAEDIATR SCAND, V71, P489, DOI 10.1111/j.1651-2227.1982.tb09457.x; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Strunk RC, 2008, PEDIATR PULM, V43, P924, DOI 10.1002/ppul.20884; Sylvester KP, 2007, PEDIATR PULM, V42, P103, DOI 10.1002/ppul.20430; Vichinsky EP, 2000, NEW ENGL J MED, V342, P1855, DOI 10.1056/NEJM200006223422502; Wahn U, 2004, CHEM IMMUNOL, V84, P128; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420, DOI 10.1164/ajrccm.149.6.8004293; Webber MP, 2002, PEDIATR PULM, V34, P105, DOI 10.1002/ppul.10146; Wuthrich B, 1996, INT ARCH ALLERGY IMM, V111, P396, DOI 10.1159/000237398	29	39	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1440	1446		10.1016/j.jaci.2010.12.1114	http://dx.doi.org/10.1016/j.jaci.2010.12.1114			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21388662	Green Accepted, Bronze			2022-12-18	WOS:000291048500020
J	Custovic, A; Soderstrom, L; Ahlstedt, S; Sly, PD; Simpson, A; Holt, PG				Custovic, Adnan; Soderstrom, Lars; Ahlstedt, Staffan; Sly, Peter D.; Simpson, Angela; Holt, Patrick G.			Allergen-specific IgG antibody levels modify the relationship between allergen-specific IgE and wheezing in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; IgE; IgG; IgG4; birth cohorts	HOUSE-DUST MITE; LUNG-FUNCTION; MANCHESTER ASTHMA; CAT ALLERGEN; SENSITIZATION; EXPOSURE; RESPONSES; CHILDREN; QUANTIFICATION; IMMUNOTHERAPY	Background: An increase in IgE antibody levels to inhalant allergens is associated with an increased likelihood of wheezing. The role of allergen-specific IgG and IgG4 in relation to wheezing is yet to be determined. Objective: We sought to investigate whether Fel d 1-specific IgG and IgG4 antibodies modify the association between cat allergen-specific IgE and childhood wheezing. Methods: We used data from 2 population-based birth cohorts (United Kingdom [UK], n = 473; Australia, n = 1336). Current wheeze was defined as wheezing in the previous 12 months at age 5 (UK) and 14 (Australia) years. We determined cat allergen-specific IgE (whole extract) and IgG and IgG4 antibody (purified rFel d 1) levels and used logistic regression to estimate the relationship between wheeze and the quantitative allergen antibody levels. Results: In the univariate analysis risk of wheezing increased significantly with increasing cat-specific IgE levels (UK: odds ratio [OR], 1.56; 95% CI, 1.28-1.90; Australia: OR, 1.29; 95% CI, 1.19-1.40). rFel d 1-specific IgG or IgG4 had no significant effect on wheeze in either population. However, a different pattern of the relationship between antibody levels and wheezing emerged in the multivariate analysis. In the UK cat-specific IgE increased the risk of wheeze (OR, 2.01; 95% CI, 1.29-3.12; P = .002), whereas rFel d 1-specific IgG decreased the risk (OR, 0.46; 95% CI, 0.21-0.99; P = .05). This finding was replicated in Australia (IgE: OR, 1.46; 95% CI, 1.28-1.68; P < .001; IgG: OR, 0.66; 95% CI, 0.44-0.99; P = .049). There was no significant association between IgG4 antibody levels and wheezing in either population. Conclusions: rFel d 1-specific IgG but not IgG4 antibody levels significantly modify the association between cat-specific IgE and childhood wheezing, with the risk of symptoms decreasing with increasing IgG levels. (J Allergy Clin Immunol 2011;127:1480-5.)	[Custovic, Adnan; Simpson, Angela] Univ Manchester, Univ Hosp S Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Manchester M23 9LT, Lancs, England; [Soderstrom, Lars] LS Biometr AB, Uppsala, Sweden; [Ahlstedt, Staffan] Karolinska Inst, Inst Environm Med, Ctr Allergy Res, S-10401 Stockholm, Sweden; [Sly, Peter D.; Holt, Patrick G.] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Karolinska Institutet; Telethon Kids Institute; University of Western Australia	Custovic, A (corresponding author), Univ Manchester, Univ Hosp S Manchester NHS Fdn Trust, Educ & Res Ctr, 2nd Floor, Manchester M23 9LT, Lancs, England.	adnan.custovic@manchester.ac.uk	Study, Raine/G-9547-2015; Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010; Custovic, Adnan/A-2435-2012	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201; Custovic, Adnan/0000-0001-5218-7071; Simpson, Angela/0000-0003-2733-6666; Soderstrom, Lars/0000-0002-6474-6501	Asthma UK [04/014]; Moulton Charitable Foundation; MRC [G0601361]; National Health and Medical Research Council of Australia; RAINE Foundation; Medical Research Council (UK); Medical Research Council [G0601361] Funding Source: researchfish; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI078511] Funding Source: NIH RePORTER	Asthma UK; Moulton Charitable Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); RAINE Foundation; Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Manchester Asthma and Allergy Study (MAAS) was supported by Asthma UK Grant no. 04/014 and the Moulton Charitable Foundation and is currently supported by MRC Grant G0601361. The Western Australia Pregnancy Cohort (RAINE) study is funded by the National Health and Medical Research Council of Australia and the RAINE Foundation.; Disclosure of potential conflict of interest: A. Custovic and A. Simpson have received research support from the Medical Research Council (UK) and the Moulton Charitable Foundation. S. Ahlstedt is a retired employee of Phadia AB. The rest of the authors have declared that they have no conflict of interest.	Aalberse RC, 2009, CLIN EXP ALLERGY, V39, P469, DOI 10.1111/j.1365-2222.2009.03207.x; AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 2002, PEDIAT ALLERG IMM-UK, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; DEVEY M E, 1975, Clinical Allergy, V5, P353, DOI 10.1111/j.1365-2222.1975.tb01874.x; Francis JN, 2004, J IMMUNOL, V172, P268, DOI 10.4049/jimmunol.172.1.268; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; ISKANDER R, 1981, INT ARCH ALLER A IMM, V66, P200, DOI 10.1159/000232819; Jarvis D, 2007, J ALLERGY CLIN IMMUN, V119, P697, DOI 10.1016/j.jaci.2006.10.042; Jeal H, 2006, AM J RESP CRIT CARE, V174, P21, DOI 10.1164/rccm.200506-964OC; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Marinho S, 2007, ALLERGY, V62, P1379, DOI 10.1111/j.1398-9995.2007.01502.x; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252, DOI 10.4049/jimmunol.172.5.3252; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; OTTESEN EA, 1981, J IMMUNOL, V127, P2014; PARISH WE, 1981, BRIT J DERMATOL, V105, P223, DOI 10.1111/j.1365-2133.1981.tb01210.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Simpson A, 2003, CLIN EXP ALLERGY, V33, P1183, DOI 10.1046/j.1365-2745.2003.01679.x; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Wachholz PA, 2004, CURR OPIN ALLERGY CL, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Wang J, 2008, J ALLERGY CLIN IMMUN, V121, P1219, DOI 10.1016/j.jaci.2007.12.1150; Williams PB, 2000, J ALLERGY CLIN IMMUN, V105, P1221, DOI 10.1067/mai.2000.105219; Witteman AM, 1996, INT ARCH ALLERGY IMM, V109, P369, DOI 10.1159/000237265; Wood RA, 2007, ANN ALLERG ASTHMA IM, V99, P34, DOI 10.1016/S1081-1206(10)60618-7	37	39	40	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1480	1485		10.1016/j.jaci.2011.03.014	http://dx.doi.org/10.1016/j.jaci.2011.03.014			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21492924	Green Accepted			2022-12-18	WOS:000291048500025
J	Wallner, M; Hauser, M; Himly, M; Zaborsky, N; Mutschlechner, S; Harrer, A; Asam, C; Pichler, U; van Ree, R; Briza, P; Thalhamer, J; Bohle, B; Achatz, G; Ferreira, F				Wallner, Michael; Hauser, Michael; Himly, Martin; Zaborsky, Nadja; Mutschlechner, Sonja; Harrer, Andrea; Asam, Claudia; Pichler, Ulrike; van Ree, Ronald; Briza, Peter; Thalhamer, Josef; Bohle, Barbara; Achatz, Gernot; Ferreira, Fatima			Reshaping the Bet v 1 fold modulates T-H polarization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Protein remodeling; tree pollen allergens; Bet v 1 family; TH-cell polarization; IgE reactivity; allergenicity; antigen uptake; lysosomal degradation	BIRCH POLLEN ALLERGEN; EPITOPE ANALYSIS; IGE REACTIVITY; POTENTIAL USE; ISOFORMS; BET-V-1; STANDARDIZATION; IMMUNOTHERAPY; INDIVIDUALS; PRODUCTS	Background: Several alternative mechanisms have been proposed to explain why some proteins are able to induce a TH2-biased and IgE-mediated immune response. These include specific interactions with receptors of the innate immune system, proteolytic activities, allergen-associated carbohydrate structures, and intrinsic structural determinants. Objectives: Available data suggest that a fold-dependent allergy-promoting mechanism could be a driving force for the TH2-polarization activity of Bet v 1, the major birch pollen allergen. Methods: Computer-aided sequence and fold analysis of the Bet v 1 family identified a short stretch susceptible for mutations inducing an altered fold of the entire molecule. With this knowledge, 7 consecutive amino acids of Bet v 1 were replaced with the homologous Mal d 1 sequence, creating the derivative BM4. Results: The minimal changes of the sequence led to a loss of the Bet v 1-like fold and influenced the immunologic behavior. Compared to wild-type Bet v 1, BM4 induced elevated T-cell proliferation of human PBMCs. In the mouse model, immunization with Bet v 1 absorbed to aluminum hydroxide triggered strong T(H)2 polarization, whereas BM4 immunization additionally recruited T(H)1 cells. Furthermore, the fold variant BM4 showed enhanced uptake by dendritic cells and a decreased susceptibility to endo-/lysosomal proteolysis. Conclusion: Modifications in the 3-dimensional structure of Bet v 1.0101 resulted in a change of its immunologic properties. We observed that the fold alteration led to a modified crosstalk with dendritic cells and a shift of the immune response polarization toward a mixed T(H)1/T(H)2 cytokine production. (J Allergy Clin Immunol 2011;127:1571-8.)	[Wallner, Michael] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, Dept Mol Biol, A-5020 Salzburg, Austria; [Mutschlechner, Sonja; Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol & Allergy Res, Christian Doppler Lab Immunomodulat, Vienna, Austria; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1012 WX Amsterdam, Netherlands; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1012 WX Amsterdam, Netherlands	Salzburg University; Medical University of Vienna; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Wallner, M (corresponding author), Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, Dept Mol Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.	michael.wallner@sbg.ac.at	Hauser, Michael/P-6148-2017; Wallner, Michael/L-5437-2015; Ferreira, Fatima/E-4889-2011; Ferreira, Fatima/AAB-4321-2019; Briza, Peter/D-7309-2012; Achatz, Gernot/E-5073-2011; Thalhamer, Josef/E-5787-2011; Himly, Martin/D-1568-2015	Hauser, Michael/0000-0001-6558-755X; Wallner, Michael/0000-0001-6568-7892; Ferreira, Fatima/0000-0003-0989-2335; Ferreira, Fatima/0000-0003-0989-2335; Briza, Peter/0000-0002-4941-6782; Thalhamer, Josef/0000-0003-2285-6400; Harrer, Andrea/0000-0001-7717-6125; Zaborsky, Nadja/0000-0002-9775-185X; Himly, Martin/0000-0001-5416-085X; Bohle, Barbara/0000-0002-5105-7985	Christian Doppler Research Association, Austria; Biomay AG, Vienna, Austria; Austrian Science Fund (FWF) [L688]; Austrian National Bank, Austria [12533]; CK-Care AG, Switzerland; Biomay AG; Austrian Research Promotion Agency; HAL Allergy BV; Christian Doppler Forschungsgesellschaft; Christian Doppler Research Association; European Union; Austrian Science Fund (FWF) [L 688] Funding Source: researchfish	Christian Doppler Research Association, Austria; Biomay AG, Vienna, Austria; Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Austrian National Bank, Austria; CK-Care AG, Switzerland; Biomay AG; Austrian Research Promotion Agency; HAL Allergy BV(HAL Allergy Group); Christian Doppler Forschungsgesellschaft; Christian Doppler Research Association; European Union(European Commission); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Supported by the Christian Doppler Research Association, Austria; Biomay AG, Vienna, Austria; Austrian Science Fund (FWF) Project L688; and Jubilaumsfondsproject 12533 of the Austrian National Bank, Austria.; M. Hauser receives research support from CK-Care AG, Switzerland. M. Himly receives research support from the Austrian Science Fund, Biomay AG, and the Austrian Research Promotion Agency. R. van Ree is a consultant for and receives research support from HAL Allergy BV. J. Thalhamer has consultant arrangements with Biomay AG and receives research support from Biomay AG, Christian Doppler Forschungsgesellschaft, and the Austrian Science Fund. B. Bohle receives research support from the Austrian Science Fund and Christian Doppler Forschungsgesellschaft. F. Ferreira receives research support from Biomay AG, the Austrian Science Fund, the Christian Doppler Research Association, and the European Union and has provided consultation for the AllergenOnline Database. The rest of the authors have declared that they have no conflict of interest.	Bauer R, 2006, J ALLERGY CLIN IMMUN, V118, P269, DOI 10.1016/j.jaci.2006.03.033; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Egger Matthias, 2009, Front Biosci (Elite Ed), V1, P77; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Gamboa PM, 2003, ALLERGY, V58, P312, DOI 10.1034/j.1398-9995.2003.00096.x; Himly M, 2009, ALLERGY, V64, P1038, DOI 10.1111/j.1398-9995.2009.01957.x; MARTONEN TB, 1991, GRANA, V30, P82, DOI 10.1080/00173139109427776; Mogensen JE, 2002, J BIOL CHEM, V277, P23684, DOI 10.1074/jbc.M202065200; Mothes N, 2004, INT ARCH ALLERGY IMM, V135, P357, DOI 10.1159/000082332; Mutschlechner S, 2010, J ALLERGY CLIN IMMUN, V125, P711, DOI 10.1016/j.jaci.2009.10.052; Neudecker P, 2003, BIOCHEM J, V376, P97, DOI 10.1042/BJ20031057; Oberg KA, 2004, EUR J BIOCHEM, V271, P2937, DOI 10.1111/j.1432-1033.2004.04220.x; Reese G, 2007, J ALLERGY CLIN IMMUN, V119, P944, DOI 10.1016/j.jaci.2006.11.699; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Smole U, 2010, ALLERGY, V65, P1388, DOI 10.1111/j.1398-9995.2010.02407.x; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Thalhamer T, 2010, J ALLERGY CLIN IMMUN, V125, P926, DOI 10.1016/j.jaci.2010.01.031; Van Ree R, 2008, ALLERGY, V63, P310, DOI 10.1111/j.1398-9995.2007.01612.x; Vaz DC, 2006, PROTEIN SCI, V15, P33, DOI 10.1110/ps.051593306; Vogel L, 2005, ALLERGY, V60, P1021, DOI 10.1111/j.1398-9995.2005.00803.x; Wagner S, 2008, J ALLERGY CLIN IMMUN, V121, P246, DOI 10.1016/j.jaci.2007.08.006; Wallner M, 2007, J ALLERGY CLIN IMMUN, V120, P374, DOI 10.1016/j.jaci.2007.05.021; Wallner M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008457; Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138; Zaborsky N, 2010, J IMMUNOL, V184, P725, DOI 10.4049/jimmunol.0902080	29	39	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2011	127	6					1571	U392		10.1016/j.jaci.2011.01.064	http://dx.doi.org/10.1016/j.jaci.2011.01.064			17	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	769WH	21420160	Green Accepted			2022-12-18	WOS:000291048500039
J	Sordillo, JE; Webb, T; Kwan, D; Kamel, J; Hoffman, E; Milton, DK; Gold, DR				Sordillo, Joanne E.; Webb, Tara; Kwan, Doris; Kamel, Jimmy; Hoffman, Elaine; Milton, Donald K.; Gold, Diane R.			Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; dust mite; cat; allergens; exhaled nitric oxide; allergic sensitization; home environment	PHYSICAL-ACTIVITY; MOUSE ALLERGEN; POPULATION; TELEVISION; ATOPY; CHILDHOOD; WEIGHT; WHEEZE; SAMPLE; PREDICTORS	Background: Studies on airway inflammation, measured as fraction of exhaled nitric oxide (FENO), have focused on its relation to control of asthma, but the contribution of allergen exposure to the increase in FENO levels is unknown. Objective: We evaluated (1) whether FENO levels were increased in children with allergic sensitization or asthma; (2) whether specific allergen exposure increased FENO levels in sensitized, but not unsensitized, children; and (3) whether sedentary behavior increased FENO levels independent of allergen exposures. Methods: At age 12 years, in a birth cohort of children with a parental history of allergy or asthma, we measured bed dust allergen (dust mite, cat, and cockroach) by means of ELISA, specific allergic sensitization primarily based on specific IgE levels, and respiratory disease (current asthma, rhinitis, and wheeze) and hours of television viewing/video game playing by means of questionnaire. Children performed spirometric maneuvers before and after bronchodilator responses and had FENO levels measured by using electrochemical detection methods (NIOX MINO). Results: FENO levels were increased in children with current asthma (32.2 ppb), wheeze (27.0 ppb), or rhinitis (23.2 ppb) compared with subjects without these respective symptoms/diagnoses (16.4-16.6 ppb, P <.005 for all comparisons). Allergic sensitization to indoor allergens (cat, dog, and dust mite) predicted higher FENO levels and explained one third of the variability in FENO levels. FENO levels were highest in children both sensitized and exposed to dust mite. Greater than 10 hours of weekday television viewing was associated with a 0.64-log increase in FENO levels after controlling for indoor allergen exposure, body mass index, and allergic sensitization. Conclusion: Allergen exposures and sedentary behavior (television viewing/video game playing) might increase airway inflammation, which was measured as the FENO. (J Allergy Clin Immunol 2011;127:1165-72.)	[Sordillo, Joanne E.; Webb, Tara; Kwan, Doris; Kamel, Jimmy; Gold, Diane R.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Sordillo, Joanne E.; Gold, Diane R.] Harvard Univ, Sch Med, Boston, MA USA; [Hoffman, Elaine] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Milton, Donald K.] Univ Maryland, College Pk, MD 20742 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; University System of Maryland; University of Maryland College Park	Sordillo, JE (corresponding author), 181 Longwood Ave, Boston, MA 02215 USA.	rejoa@channing.harvard.edu	Milton, Donald K/G-3286-2010	Milton, Donald K/0000-0002-0550-7834	National Institutes of Health [AI35786, ES07036]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035786, R56AI035786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007036, R56ES007036] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Supported by National Institutes of Health grants AI35786 and ES07036.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; Barreto M, 2001, PEDIATR ALLERGY IMMU, V12, P247, DOI 10.1034/j.1399-3038.2001.00041.x; Bodini A, 2007, CHEST, V132, P1520, DOI 10.1378/chest.07-1025; Byrnes CA, 1997, PEDIATR PULM, V24, P312; Cardinale F, 2005, PEDIAT ALLERG IMM-UK, V16, P236, DOI 10.1111/j.1399-3038.2005.00265.x; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Corbo GM, 2008, EPIDEMIOLOGY, V19, P747, DOI 10.1097/EDE.0b013e3181776213; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Davies Donna E, 2009, Proc Am Thorac Soc, V6, P678, DOI 10.1513/pats.200907-067DP; Eisenmann JC, 2002, OBES RES, V10, P379, DOI 10.1038/oby.2002.52; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227, DOI 10.1164/ajrccm.160.1.9807104; Grund A, 2001, PUBLIC HEALTH NUTR, V4, P1245, DOI 10.1079/PHN2001178; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hark WT, 2005, ANN ALLERG ASTHMA IM, V94, P247, DOI 10.1016/S1081-1206(10)61303-8; Ihre E, 2006, EUR RESPIR J, V27, P1152, DOI 10.1183/09031936.06.00142905; Jackson DJ, 2009, J ALLERGY CLIN IMMUN, V124, P949, DOI 10.1016/j.jaci.2009.07.024; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738, DOI 10.1164/ajrccm.164.5.2012125; Jouaville LF, 2003, CLIN EXP ALLERGY, V33, P1506, DOI 10.1046/j.1365-2222.2003.01800.x; Lex C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/rccm.200603-352OC; Lopuhaa CE, 2003, ALLERGY, V58, P300, DOI 10.1034/j.1398-9995.2003.00075.x; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nordvall SL, 2005, ALLERGY, V60, P469, DOI 10.1111/j.1398-9995.2005.00735.x; Olin AC, 2010, AM J RESP CRIT CARE, V181, P324, DOI 10.1164/rccm.200907-1079OC; Perez de Llano LA, 2010, EUR RESPIR J, V35, P1200; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Phipatanakul W, 2008, ALLERGY, V63, P1512, DOI 10.1111/j.1398-9995.2008.01679.x; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075, DOI 10.1067/mai.2000.110795; Puckett JL, 2010, PEDIATR PULM, V45, P174, DOI 10.1002/ppul.21172; Salmon J, 2006, MED J AUSTRALIA, V184, P64, DOI 10.5694/j.1326-5377.2006.tb00117.x; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911, DOI 10.1164/ajrccm.159.3.9802108; Sherriff A, 2009, THORAX, V64, P321, DOI 10.1136/thx.2008.104406; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45, DOI 10.1164/ajrccm.160.1.9809091; Spanier AJ, 2008, PEDIATR PULM, V43, P576, DOI 10.1002/ppul.20816; van Amsterdam JGC, 2003, CLIN EXP ALLERGY, V33, P187, DOI 10.1046/j.1365-2222.2003.01597.x; van Asch CJJ, 2008, ANN ALLERG ASTHMA IM, V100, P59, DOI 10.1016/S1081-1206(10)60406-1; Warke TJ, 2004, J ASTHMA, V41, P751, DOI 10.1081/JAS-200027838; Wiecha JL, 2006, ARCH PEDIAT ADOL MED, V160, P436, DOI 10.1001/archpedi.160.4.436	39	39	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1165	U441		10.1016/j.jaci.2011.01.066	http://dx.doi.org/10.1016/j.jaci.2011.01.066			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	756NG	21463890	Green Accepted			2022-12-18	WOS:000290018600010
J	Owens, G; MacGinnitie, A				Owens, Gregory; MacGinnitie, Andrew			Higher-ovalbumin-content influenza vaccines are well tolerated in children with egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							VACCINATION		[Owens, Gregory; MacGinnitie, Andrew] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Pulm Med Allergy & Immunol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Owens, G (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Pulm Med Allergy & Immunol, Pittsburgh, PA 15213 USA.	gregory.owens@chp.edu						*CDCP, VACC INF STAT INT IN; Chung EY, 2010, PEDIATRICS, V125, pE1024, DOI 10.1542/peds.2009-2512; Esposito S, 2008, VACCINE, V26, P4664, DOI 10.1016/j.vaccine.2008.06.095; Fiore Anthony E., 2008, Morbidity and Mortality Weekly Report, V57, P1; Gagnon R, 2010, J ALLERGY CLIN IMMUN, V126, P317, DOI 10.1016/j.jaci.2010.05.037; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; King JC, 2006, NEW ENGL J MED, V355, P2523, DOI 10.1056/NEJMoa055414; Kramarz P, 2001, J PEDIATR-US, V138, P306, DOI 10.1067/mpd.2001.112168; Li JT, 2010, J ALLERGY CLIN IMMUN, V125, P1412, DOI 10.1016/j.jaci.2010.03.009; PICKERING LK, 2009, RED BOOK 2009 REPORT, P400; WAIBEL KH, 2010, J ALLERGY CLIN IMMUN, V125, pE1; Waibel KH, 2010, J ALLERGY CLIN IMMUN, V125, P749, DOI 10.1016/j.jaci.2009.12.015	12	39	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					264	265		10.1016/j.jaci.2010.10.005	http://dx.doi.org/10.1016/j.jaci.2010.10.005			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	702SY	21094520				2022-12-18	WOS:000285917300038
J	Hale, JE; Bonilla, FA; Pai, SY; Gerstel-Thompson, JL; Notarangelo, LD; Eaton, RB; Comeau, AM				Hale, Jaime E.; Bonilla, Francisco A.; Pai, Sung-Yun; Gerstel-Thompson, Jacalyn L.; Notarangelo, Luigi D.; Eaton, Roger B.; Comeau, Anne Marie			Identification of an infant with severe combined-immunodeficiency bynewborn screening	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									[Hale, Jaime E.; Gerstel-Thompson, Jacalyn L.; Eaton, Roger B.; Comeau, Anne Marie] Univ Massachusetts, Sch Med, New England Newborn Screening Program, Boston, MA 02125 USA; [Bonilla, Francisco A.; Notarangelo, Luigi D.] Childrens Hosp Boston, Div Immunol, Boston, MA USA; [Pai, Sung-Yun] Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA; [Pai, Sung-Yun] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA; [Eaton, Roger B.; Comeau, Anne Marie] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Boston; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Worcester	Hale, JE (corresponding author), Univ Massachusetts, Sch Med, New England Newborn Screening Program, Boston, MA 02125 USA.	anne.comeau@umassmed.edu	Notarangelo, Luigi D/F-9718-2016; Pai, Sung-Yun/AAH-7762-2019	Notarangelo, Luigi D/0000-0002-8335-0262; Pai, Sung-Yun/0000-0002-0158-8147	NCEH CDC HHS [IV01-EH000362-01] Funding Source: Medline; NATIONAL CENTER FOR ENVIRONMENTAL HEALTH [U01EH000362] Funding Source: NIH RePORTER	NCEH CDC HHS; NATIONAL CENTER FOR ENVIRONMENTAL HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)		*ADV COMM HER DIS, 2010, 20 M WASH DC ADV COM; Buckley RH, 2004, ANNU REV IMMUNOL, V22, P625, DOI 10.1146/annurev.immunol.22.012703.104614; COMEAU AM, 2010, J INHERIT M IN PRESS; Shearer WT, 2003, J ALLERGY CLIN IMMUN, V112, P973, DOI 10.1016/j.jaci.2003.07.003; Thompson J.G., 2010, CLIN CHEM, V56, P1466, DOI 10.1373/clinchem.2010.144915	5	39	41	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					1073	1074		10.1016/j.jaci.2010.08.043	http://dx.doi.org/10.1016/j.jaci.2010.08.043			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	674HB	20933257				2022-12-18	WOS:000283727100027
J	DeWan, AT; Triche, EW; Xu, XM; Hsu, LI; Zhao, C; Belanger, K; Hellenbrand, K; Willis-Owen, SAG; Moffatt, M; Cookson, WOC; Himes, BE; Weiss, ST; Gauderman, WJ; Baurley, JW; Gilliland, F; Wilk, JB; O'Connor, GT; Strachan, DP; Hoh, J; Bracken, MB				DeWan, Andrew T.; Triche, Elizabeth W.; Xu, Xuming; Hsu, Ling-I; Zhao, Connie; Belanger, Kathleen; Hellenbrand, Karen; Willis-Owen, Saffron A. G.; Moffatt, Miriam; Cookson, William O. C.; Himes, Blanca E.; Weiss, Scott T.; Gauderman, W. James; Baurley, James W.; Gilliland, Frank; Wilk, Jemma B.; O'Connor, George T.; Strachan, David P.; Hoh, Josephine; Bracken, Michael B.			PDE11A associations with asthma: Results of a genome-wide association scan	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							CHILDHOOD ASTHMA; REPLICATION; VARIANTS; RISK		[DeWan, Andrew T.; Xu, Xuming; Hsu, Ling-I; Hoh, Josephine] Yale Univ, Sch Publ Hlth, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Belanger, Kathleen; Hellenbrand, Karen; Bracken, Michael B.] Yale Univ, Sch Publ Hlth, Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT USA; [Belanger, Kathleen; Hellenbrand, Karen; Bracken, Michael B.] Yale Univ, Sch Med, Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT USA; [Triche, Elizabeth W.] Brown Univ, Sch Med, Dept Community Hlth & Epidemiol, Providence, RI 02912 USA; [Zhao, Connie] Rockefeller Univ, Genom Resource Ctr, New York, NY 10021 USA; [Willis-Owen, Saffron A. G.; Moffatt, Miriam; Cookson, William O. C.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Himes, Blanca E.; Weiss, Scott T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab,Partners Ctr Personalized Genet Med, Boston, MA 02115 USA; [Gauderman, W. James; Baurley, James W.; Gilliland, Frank] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA; [Wilk, Jemma B.; O'Connor, George T.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Strachan, David P.] Univ London, London WC1E 7HU, England	Yale University; Yale University; Yale University; Brown University; Rockefeller University; Imperial College London; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Southern California; Boston University; University of London	DeWan, AT (corresponding author), Yale Univ, Sch Publ Hlth, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA.	andrew.dewan@yale.edu	Triche, Elizabeth/I-4986-2014; Cookson, William/HHC-1790-2022	O'Connor, George/0000-0002-6476-3926; Willis-Owen, Saffron/0000-0003-2633-1150; DeWan, Andrew/0000-0002-7679-8704	MRC [G0000934] Funding Source: UKRI; Medical Research Council [G0000934] Funding Source: Medline; NCRR NIH HHS [S10 RR019895, S10 RR019895-01, RR19895] Funding Source: Medline; NHLBI NIH HHS [K12 HL089990, R01 HL087680, R01 HL087680-03] Funding Source: Medline; NIAID NIH HHS [R01 AI041040, R01 AI041040-09, AI41040] Funding Source: Medline; NIDA NIH HHS [R01 DA005484] Funding Source: Medline; NIEHS NIH HHS [P01 ES011627, P01 ES011627-09, P30 ES007048, P30 ES007048-05] Funding Source: Medline; Wellcome Trust [068545/Z/02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019895] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K12HL089990, R01HL087680] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011627, P30ES007048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005484] Funding Source: NIH RePORTER; National Institute for Health Research [NF-SI-0508-10212] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Wellcome Trust(Wellcome Trust); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))		Armitage P., 1987, STAT METHODS MED RES; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Boswell-Smith V, 2006, BRIT J PHARMACOL, V147, pS252, DOI 10.1038/sj.bjp.0706495; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; Butland BK, 2007, ANN ALLERG ASTHMA IM, V98, P337, DOI 10.1016/S1081-1206(10)60879-4; Clarke GM, 2007, AM J HUM GENET, V81, P995, DOI 10.1086/521952; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768, DOI 10.1164/ajrccm.159.3.9804144; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pritchard JK, 2000, GENETICS, V155, P945; RUDD RM, 1983, BRIT J DIS CHEST, V77, P78, DOI 10.1016/S0007-0971(83)80061-8; Skol AD, 2006, NAT GENET, V38, P209, DOI 10.1038/ng1706; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; 1999, CONTROL CLIN TRIALS, V20, P91	19	39	44	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					871	U321		10.1016/j.jaci.2010.06.051	http://dx.doi.org/10.1016/j.jaci.2010.06.051			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	658SP	20920776	Green Accepted			2022-12-18	WOS:000282510000029
J	Thomsen, SF; Duffy, DL; Kyvik, KO; Backer, V				Thomsen, Simon Francis; Duffy, David Lorenzo; Kyvik, Kirsten Ohm; Backer, Vibeke			Genetic influence on the age at onset of asthma: A twin study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; genetics; twin study; age at onset; heritability; epidemiology	TOBACCO-SMOKE EXPOSURE; FRENCH EGEA FAMILIES; SURVIVAL MODELS; RISK-FACTORS; OF-ONSET; ADULTS; VACCINATION; PERSISTENT; PHENOTYPES; HISTORY	Background: Although the genetics of asthma susceptibility have been frequently explored, little is known about genetic factors that influence the age at onset of asthma. Objective: To study the variation in the age at onset of asthma attributable to genetic and environmental factors. Methods: Data on the age at onset and predictors of asthma were collected in 2002 via a multidisciplinary questionnaire study of 34,782 Danish twins 20 to 71 years of age. Survival analytic methods were applied to partition variation in the age at onset of asthma into genetic and environmental components. Results: Sex, hay fever, atopic dermatitis, smoking, and exposure to passive smoking in childhood were significant risk factors, whereas BCG vaccination was protective for asthma. The risk of asthma in the co-twin of an affected twin was higher in monozygotic than in dizygotic twins (hazard ratio, 2.59; 95% CI, 1.83-3.68; P < .001). The risk of asthma in the co-twin decreased with increasing age at onset of asthma in the index twin (hazard ratio per ten years, 0.86; 95% CI, 0.76-0.98; P = .019). The effect was attenuated in dizygotic twins relative to monozygotic twins (P = .005). Genetic factors explained 34% of the variation in the age at onset of asthma, and environmental factors accounted for 66%. Conclusion: Host-related differences in genetic makeup cause different individuals to develop asthma at different ages. Better understanding of the causes for variation in the age at onset of disease may ultimately lead the way to targeted treatments. (J Allergy Clin Immunol 2010;126:626-30.)	[Thomsen, Simon Francis; Backer, Vibeke] Bispebjerg Hosp, Dept Resp Med, DK-2400 Copenhagen, NV, Denmark; [Duffy, David Lorenzo] Queensland Inst Med Res, Brisbane, Qld 4006, Australia; [Kyvik, Kirsten Ohm] Univ So Denmark, Danish Twin Registry, Odense, Denmark; [Kyvik, Kirsten Ohm] Univ So Denmark, Inst Reg Hlth Serv Res, Odense, Denmark	University of Copenhagen; Bispebjerg Hospital; QIMR Berghofer Medical Research Institute; University of Southern Denmark; University of Southern Denmark	Thomsen, SF (corresponding author), Bispebjerg Hosp, Dept Resp Med, DK-2400 Copenhagen, NV, Denmark.	sft@city.dk	Backer, Vibeke/AAQ-9379-2021; Duffy, David L/B-7392-2013; Kyvik, Kirsten O/K-5680-2016; Backer, Vibeke/I-9573-2014	Duffy, David L/0000-0001-7227-632X; Kyvik, Kirsten O/0000-0003-2981-0245; Backer, Vibeke/0000-0002-7806-7219	Danish Medical Research Council	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	S. F. T. is sponsored by the Danish Medical Research Council grant.	Alcais A, 2001, GENET EPIDEMIOL, V21, pS168, DOI 10.1002/gepi.2001.21.s1.s168; Bager P, 2003, CLIN EXP ALLERGY, V33, P1512, DOI 10.1046/j.1365-2222.2003.01796.x; Balicer RD, 2007, PEDIATRICS, V120, pE1269, DOI 10.1542/peds.2006-3569; Bouzigon E, 2007, HUM GENET, V121, P711, DOI 10.1007/s00439-007-0363-x; Christiansen L, 2003, TWIN RES, V6, P275, DOI 10.1375/136905203322296610; Dizier MH, 2001, EUR J HUM GENET, V9, P867, DOI 10.1038/sj.ejhg.5200732; Eisner MD, 2002, ENVIRON HEALTH PERSP, V110, P765, DOI 10.1289/ehp.02110765; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Hizawa N, 2002, AM J RESP CRIT CARE, V166, P686, DOI 10.1164/rccm.200202-090OC; Hsu JY, 2004, RESPIROLOGY, V9, P369, DOI 10.1111/j.1440-1843.2004.00572.x; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; Jamrozik E, 2009, RESPIROLOGY, V14, P814, DOI 10.1111/j.1440-1843.2009.01562.x; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Pankratz VS, 2005, GENET EPIDEMIOL, V28, P97, DOI 10.1002/gepi.20043; Reed CE, 2006, J ALLERGY CLIN IMMUN, V118, P543, DOI 10.1016/j.jaci.2006.06.020; Romanet-Manent S, 2002, ALLERGY, V57, P607, DOI 10.1034/j.1398-9995.2002.23504.x; Segala C, 2000, ALLERGY, V55, P634, DOI 10.1034/j.1398-9995.2000.00488.x; Shen H, 2008, ALLERGY, V63, P555, DOI 10.1111/j.1398-9995.2008.01637.x; Skytthe A, 2002, TWIN RES, V5, P352; ten Brinke A, 2008, CURR OPIN ALLERGY CL, V8, P63, DOI 10.1097/ACI.0b013e3282f3b5b5; THOMAS DC, 1990, GENET EPIDEMIOL, V7, P121, DOI 10.1002/gepi.1370070203; Thomsen SF, 2006, CLIN EXP ALLERGY, V36, P1382, DOI 10.1111/j.1365-2222.2006.02512.x; THOMSEN SF, 2006, THESIS U COPENHAGEN; Thomsen SF, 2008, CLIN RESPIR  J, V2, P63; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Yoo B, 2001, GENET EPIDEMIOL, V21, pS811, DOI 10.1002/gepi.2001.21.s1.s811	28	39	40	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					626	630		10.1016/j.jaci.2010.06.017	http://dx.doi.org/10.1016/j.jaci.2010.06.017			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	646CF	20673982				2022-12-18	WOS:000281512500032
J	Nair, P; Kjarsgaard, M; Armstrong, S; Efthimiadis, A; O'Byrne, PM; Hargreave, FE				Nair, Parameswaran; Kjarsgaard, Melanie; Armstrong, Susan; Efthimiadis, Ann; O'Byrne, Paul M.; Hargreave, Frederick E.			Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							MEPOLIZUMAB; GUIDE		[Nair, Parameswaran; Kjarsgaard, Melanie; Armstrong, Susan; Efthimiadis, Ann; O'Byrne, Paul M.; Hargreave, Frederick E.] McMaster Univ, Dept Med, Firestone Inst Resp Hlth, St Josephs Healthcare, Hamilton, ON, Canada	McMaster University	Nair, P (corresponding author), McMaster Univ, Dept Med, Firestone Inst Resp Hlth, St Josephs Healthcare, Hamilton, ON, Canada.	parames@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X				Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454, DOI 10.1164/ajrccm.153.1.8542158; Lane C, 2004, THORAX, V59, P757, DOI 10.1136/thx.2003.014894; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800, DOI 10.1164/ajrccm.152.2.7633745; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Puckett JL, 2008, RESP PHYSIOL NEUROBI, V163, P166, DOI 10.1016/j.resp.2008.07.020; Que LG, 2009, AM J RESP CRIT CARE, V180, P226, DOI 10.1164/rccm.200901-0158OC; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Stirling RG, 1998, THORAX, V53, P1030, DOI 10.1136/thx.53.12.1030; Taylor DR, 2006, J ALLERGY CLIN IMMUN, V117, P259, DOI 10.1016/j.jaci.2005.11.010; 1999, AM J RESP CRIT CARE, V160, P2104	15	39	40	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2								10.1016/j.jaci.2010.05.032	http://dx.doi.org/10.1016/j.jaci.2010.05.032			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	642IL	20621343				2022-12-18	WOS:000281203800035
J	Munthe-Kaas, MC; Torjussen, TM; Gervin, K; Carlsen, KCL; Carlsen, KH; Granum, B; Hjorthaug, HS; Undlien, D; Lyle, R				Munthe-Kaas, Monica Cheng; Torjussen, Tale Maehre; Gervin, Kristina; Carlsen, Karin C. Lodrup; Carlsen, Kai Hakon; Granum, Berit; Hjorthaug, Hanne Sagsveen; Undlien, Dag; Lyle, Robert			CD14 polymorphisms and serum CD14 levels through childhood: A role for gene methylation?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; association study; asthma; CD14; child; cohort study; epigenetics; genetic analysis; methylation patterns	SOLUBLE CD14; FUNCTIONAL-SIGNIFICANCE; PROMOTER POLYMORPHISMS; ATOPIC PHENOTYPES; CHILDREN; ASTHMA; EPIGENETICS; EXPRESSION; FARMERS; AGE	Background: CD14 is a pattern-recognition receptor for environmental LPS, and engagement of the CD14-LPS complex activates innate host defense mechanisms. Single nucleotide polymorphisms (SNPs) in the CD14 gene have been associated with soluble CD14 (sCD14) levels, but inconsistencies between studies suggest the presence of regulatory mechanisms hitherto not well understood. Objective: We sought to investigate possible associations between CD14 SNPs and sCD14 levels at different time points in childhood (at birth [cord blood] and 2 and 10 years) and to explore whether these associations were related to CD14 gene methylation. Methods: Four SNPs, rs2569191 (-1145GA), rs5744455 (-550CT or 651CT), rs2569.190 (-159CT or -260CT), and rs4914 in CD14 were genotyped in 762 children from the Environmental and Childhood Asthma study. Genotype frequencies were analyzed for association with sCD14 levels in 660 babies, 346 children at age 2 years, and 360 children at age 10 years. In a subgroup of 157 children with DNA available at both 2 and 10 years of age, CD14 methylation patterns were determined and analyzed against detected CD14 gene sCD14 associations. Results: rs2569191, rs5744455, and rs2569190 were associated with sCD14 levels at birth and 2 years, but only rs5744455 was associated with sCD14 levels at 10 years. CD14 methylation increased significantly from age 2 to 10 years, and the level of methylation was inversely correlated with sCD14 levels at 10 years. Conclusion: The reduced effect of CD14 polymorphisms on sCD14 levels from early to late childhood paralleled a small but significant increase in CD14 methylation during the same period. (J Allergy Clin Immunol 2010;125:1361-8.)	[Munthe-Kaas, Monica Cheng; Gervin, Kristina; Undlien, Dag] Univ Oslo, Oslo Univ Hosp, Fac Div, Inst Med Genet, N-0316 Oslo, Norway; [Munthe-Kaas, Monica Cheng; Torjussen, Tale Maehre; Carlsen, Karin C. Lodrup] Oslo Univ Hosp, Dept Pediat, Oslo, Norway; [Carlsen, Karin C. Lodrup; Carlsen, Kai Hakon] Univ Oslo, Fac Med, N-0316 Oslo, Norway; [Carlsen, Kai Hakon] Oslo Univ Hosp, Voksentoppen BKL, Oslo, Norway; [Granum, Berit] Norwegian Inst Publ Hlth, Oslo, Norway; [Hjorthaug, Hanne Sagsveen; Undlien, Dag; Lyle, Robert] Oslo Univ Hosp, Dept Med Genet, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; Norwegian Institute of Public Health (NIPH); University of Oslo	Munthe-Kaas, MC (corresponding author), Ullevaal Univ Hosp, Dept Pediat, N-0407 Oslo, Norway.	m.c.munthe-kaas@medisin.uio.no	Granum, Berit/AAA-7823-2022	Gervin, Kristina/0000-0002-9851-1890; Granum, Berit/0000-0002-3401-8132	Norwegian Research Council; University of Oslo; Eastern Norway Regional Health Authority; Norwegian Foundation for Health and Rehabilitation; Norwegian Association for Asthma and Allergy; Kloster foundation; Voksentoppen BKL; AstraZeneca; Ulleval University Hospital, Phadia; Hakon group	Norwegian Research Council(Research Council of NorwayEuropean Commission); University of Oslo; Eastern Norway Regional Health Authority; Norwegian Foundation for Health and Rehabilitation; Norwegian Association for Asthma and Allergy; Kloster foundation; Voksentoppen BKL; AstraZeneca(AstraZeneca); Ulleval University Hospital, Phadia; Hakon group	The Environment and Childhood Asthma study was financially supported by the Norwegian Research Council, the University of Oslo, the Eastern Norway Regional Health Authority, the Norwegian Foundation for Health and Rehabilitation, the Norwegian Association for Asthma and Allergy, the Kloster foundation, Voksentoppen BKL, AstraZeneca, Ulleval University Hospital, Phadia, and the Hakon group. The genetic analysis was financially supported by the University of Oslo, Norway; Research Council Norway through the National Programme for Research in Functional Genomics in Norway (FUGE); and the Southeastern Norway Regional Health Authority.	Arroyo-Espliguero R, 2004, HEART, V90, P983, DOI 10.1136/hrt.2002.001297; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Buckova D, 2006, J HUM GENET, V51, P977, DOI 10.1007/s10038-006-0050-0; Carlsen KCL, 2006, PEDIAT ALLERG IMM-UK, V17, P304, DOI 10.1111/j.1399-3038.2006.00412.x; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; Dahmer Mary K, 2005, Pediatr Crit Care Med, V6, pS61, DOI 10.1097/01.PCC.0000161970.44470.C7; Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Feinberg AP, 2008, JAMA-J AM MED ASSOC, V299, P1345, DOI 10.1001/jama.299.11.1345; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Gu W, 2008, CRIT CARE MED, V36, P2274, DOI 10.1097/CCM.0b013e318180b1ed; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; LeVan TD, 2005, AM J RESP CRIT CARE, V171, P773, DOI 10.1164/rccm.200404-530OC; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Levan TD, 2008, J ALLERGY CLIN IMMUN, V121, P434, DOI 10.1016/j.jaci.2007.08.050; LeVan TT, 2006, GENES IMMUN, V7, P77, DOI 10.1038/sj.gene.6364276; Lewin J, 2004, BIOINFORMATICS, V20, P3005, DOI 10.1093/bioinformatics/bth346; Liang XH, 2006, PHARMACOGENET GENOM, V16, P229; Martin AC, 2006, AM J RESP CRIT CARE, V173, P617, DOI 10.1164/rccm.200509-1367OC; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; Schauber J, 2008, J INVEST DERMATOL, V128, P816, DOI 10.1038/sj.jid.5701102; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; Smit LAM, 2007, CLIN EXP ALLERGY, V37, P1602, DOI 10.1111/j.1365-2222.2007.02831.x; The International HapMap Consortium, 2005, NATURE, V437, P1299, DOI DOI 10.1038/NATURE04226; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Zdolsek HA, 2004, CLIN EXP ALLERGY, V34, P532, DOI 10.1111/j.1365-2222.2004.1921.x	33	39	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2010	125	6					1361	1368		10.1016/j.jaci.2010.02.010	http://dx.doi.org/10.1016/j.jaci.2010.02.010			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	611PH	20398919				2022-12-18	WOS:000278831000026
J	Di Capite, J; Nelson, C; Bates, G; Parekh, AB				Di Capite, Joseph; Nelson, Charmaine; Bates, Grant; Parekh, Anant B.			Targeting Ca2+ release-activated Ca2+ channel channels and leukotriene receptors provides a novel combination strategy for treating nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Calcium channel; calcium signal; leukotrienes; cysteinyl leukotriene type I receptor; 5-lipoxygenase; nasal polyposis	HUMAN MAST-CELLS; CYSTEINYL-LEUKOTRIENES; ALLERGIC RHINITIS; CRAC CHANNELS; 5-LIPOXYGENASE INHIBITOR; CALCIUM-CHANNELS; HUMAN BASOPHILS; C-4 SECRETION; HUMAN BRONCHI; MICE LACKING	Background: Nasal polyposis is a chronic inflammatory disease of the upper respiratory tract that affects around 2% of the population and almost 67% of patients with aspirin-intolerant asthma. Polyps are rich in mast cells and eosinophils, resulting in high levels of the proinflammatory cysteinyl leukotrienes. Objectives: To better understand the role of the proinflammatory leukotrienes in nasal polyposis, we asked the following questions: (1) How do nasal polyps produce leukotriene C-4 (LTC4)? (2) Can LTC4 feed back in a paracrine way to maintain mast cell activation? (3) Could a combination therapy targeting the elements of this feed-forward loop provide a novel therapy for allergic disease? Methods: We have used immunohistochemistry, enzyme immunoassay, and cytoplasmic calcium ion (Ca2+) imaging to address these questions on cultured and acutely isolated human mast cells from patients with polyposis. Results: Ca2+ entry through store-operated Ca2+ release-activated Ca2+ (CRAC) channels in polyps produced LTC4 in a manner dependent on protein kinase C. LTC4 thus generated activated mast cells through cysteinyl leukotriene type I receptors. Hence Ca2+ influx into mast cells stimulates LTC4 production, which then acts as a paracrine signal to activate further Ca2+ influx. A combination of a low concentration of both a CRAC channel blocker and a leukotriene receptor antagonist was as effective at suppressing mast cell activation as a high concentration of either antagonist alone. Conclusion: A drug combination directed against CRAC channels and leukotriene receptor antagonist suppresses the feed-forward loop that leads to aberrant mast cell activation. Hence our results identify a new potential strategy for combating polyposis and mast cell-dependent allergies. (J Allergy Clin Immunol 2009;124:1014-21.)	[Di Capite, Joseph; Nelson, Charmaine; Parekh, Anant B.] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3PT, England; [Bates, Grant] John Radcliffe Hosp, Dept Ear Nose & Throat Surg, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Parekh, AB (corresponding author), Univ Oxford, Dept Physiol Anat & Genet, Parks Rd, Oxford OX1 3PT, England.	anant.parekh@dpag.ox.ac.uk			Medical Research Council; Christopher Welch; Medical Research Council [G0601485] Funding Source: researchfish; MRC [G0601485] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Christopher Welch; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by the Medical Research Council. Disclosure of potential conflict of interest: J. Di Capile received research support from the Christopher Welch Scholarship. C. Nelson receives research support from the Medical Research Council. A. B. Parekh receives research support from the Medical Research Council, United Kingdom. G. Bates has declared that he has no conflict of interest.	Adamjee J, 2006, J PATHOL, V209, P392, DOI 10.1002/path.1979; Baba Y, 2008, NAT IMMUNOL, V9, P81, DOI 10.1038/ni1546; Bandeira-Melo C, 2002, J ALLERGY CLIN IMMUN, V109, P975, DOI 10.1067/mai.2002.124269; Bateman ND, 2003, J LARYNGOL OTOL, V117, P1, DOI 10.1258/002221503321046577; BJORCK T, 1993, PULM PHARMACOL, V6, P87, DOI 10.1006/pulp.1993.1012; Chang WC, 2004, J BIOL CHEM, V279, P29994, DOI 10.1074/jbc.M403969200; Chang WC, 2008, J BIOL CHEM, V283, P4622, DOI 10.1074/jbc.M705002200; Chang WC, 2006, FASEB J, V20, P2381, DOI 10.1096/fj.06-6016fje; Chao SS, 2006, ANN OTO RHINOL LARYN, V115, P394, DOI 10.1177/000348940611500513; COHAN V, 1989, BIOCHEM PHARMACOL, V38, P4455, DOI 10.1016/0006-2952(89)90656-4; Di Capite J, 2009, CURR BIOL, V19, P853, DOI 10.1016/j.cub.2009.03.063; Di Capite J, 2009, FASEB J, V23, P894, DOI 10.1096/fj.08-118935; DrakeLee A, 1997, J LARYNGOL OTOL, V111, P340, DOI 10.1017/S0022215100137260; DRAKELEE AB, 1982, INT ARCH ALLER A IMM, V69, P268, DOI 10.1159/000233182; ELLIS JL, 1994, AM J RESP CRIT CARE, V149, P118, DOI 10.1164/ajrccm.149.1.8111568; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; FLOWERS BK, 1990, OTOLARYNG HEAD NECK, V102, P219; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Glitsch MD, 2002, J PHYSIOL-LONDON, V539, P93, DOI 10.1113/jphysiol.2001.012826; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; KUSNER EJ, 1994, EUR J PHARMACOL, V257, P285, DOI 10.1016/0014-2999(94)90140-6; Lee YN, 2004, J IMMUNOL, V173, P2571, DOI 10.4049/jimmunol.173.4.2571; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; MARONE G, 1979, J IMMUNOL, V123, P1664; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Ng SW, 2008, J BIOL CHEM, V283, P31348, DOI 10.1074/jbc.M804942200; Ozen Z, 2007, ORL-J OTO-RHIN-LARYN, V69, P176, DOI 10.1159/000099228; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Paruchuri S, 2008, J BIOL CHEM, V283, P16477, DOI 10.1074/jbc.M705822200; Pawankar R, 2003, CURR OPIN ALLERGY CL, V3, P1, DOI 10.1097/01.all.0000053260.61007.d6; PETERS SP, 1981, NATURE, V292, P455, DOI 10.1038/292455a0; Philip G, 2007, ALLERGY ASTHMA PROC, V28, P296, DOI 10.2500/aap.2007.28.3000; Radenne F, 1999, J ALLERGY CLIN IMMUN, V104, P79, DOI 10.1016/S0091-6749(99)70117-X; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; Van Hoecke H, 2007, DRUGS, V67, P2717, DOI 10.2165/00003495-200767180-00006; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2008, NAT IMMUNOL, V9, P89, DOI 10.1038/ni1550; WARNER JA, 1988, J PHARMACOL EXP THER, V247, P218; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103	43	39	39	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2009	124	5					1014	1021		10.1016/j.jaci.2009.08.030	http://dx.doi.org/10.1016/j.jaci.2009.08.030			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	523XI	19895990				2022-12-18	WOS:000272108000022
J	Clerisme-Beaty, EM; Karam, S; Rand, C; Patino, CM; Bilderback, A; Riekert, KA; Okelo, SO; Diette, GB				Clerisme-Beaty, Emmanuelle M.; Karam, Sabine; Rand, Cynthia; Patino, Cecilia M.; Bilderback, Andrew; Riekert, Kristin A.; Okelo, Sande O.; Diette, Gregory B.			Does higher body mass index contribute to worse asthma control in an urban population?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma control; obesity; overweight; body mass index; inner city; asthma communication control instrument; ACCI; African American	HEALTH-CARE UTILIZATION; QUALITY-OF-LIFE; UNITED-STATES; OBESITY; SEVERITY; ADULTS; ASSOCIATION; PREVALENCE; OVERWEIGHT; QUESTIONNAIRE	Background: Epidemiologic findings support a positive association between asthma and obesity. Objective: Determine whether obesity or increasing level of body mass index (BMI) are associated with worse asthma control in an ethnically diverse urban population. Methods: C ross-sectional assessment of asthma control was performed in patients with asthma recruited from primary care offices by using 4 different validated asthma control questionnaires: the Asthma Control and Communication Instrument (ACCI), the Asthma Control Test (ACT), the Asthma Control Questionnaire (ACQ), and the Asthma Therapy Assessment Questionnaire (ATAQ). Multiple linear regression analysis was performed to evaluate the association between obesity and increasing BMI level and asthma control. Results: Of 292 subjects with a mean age of 47 years, the majority were women (82%) and African American (67%). There was a high prevalence of obesity with 63%, with only 15% normal weight. The mean score from all 4 questionnaires showed an average suboptimal asthma control (mean score/maximum possible score): ACCI (8.3/19), ACT (15.4/25), ACQ (2.1/6), and ATAQ (1.3/4). Regression analysis showed no association between obesity or increasing BMI level and asthma control using all 4 questionnaires. This finding persisted even after adjusting for FEV1, smoking status, race, sex, selected comorbid illnesses, and long-term asthma controller use. Conclusion: Using 4 validated asthma control questionnaires, we failed to find an association between obesity and asthma control in an urban population with asthma. Weight loss may not be an appropriate strategy to improve asthma control in this population. (J Allergy Clin Immunol 2009;124:207-12.)	[Clerisme-Beaty, Emmanuelle M.; Rand, Cynthia; Bilderback, Andrew; Riekert, Kristin A.; Diette, Gregory B.] Johns Hopkins Univ, Dept Med, Baltimore, MD USA; [Okelo, Sande O.] Johns Hopkins Univ, Dept Pediat, Baltimore, MD USA; [Karam, Sabine] Albert Einstein Coll Med, Dept Med, New York, NY USA; [Patino, Cecilia M.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA	Johns Hopkins University; Johns Hopkins University; Yeshiva University; University of Southern California	Diette, GB (corresponding author), Div Pulm Crit Care Med, 1830 E Monument St,5th Floor, Baltimore, MD 21205 USA.	gdiette@jhmi.edu		Patino, Cecilia M./0000-0001-5742-2157	National Heart, Lung, and Blood Institute [5UO1HL072455]; National Institutes of Health [K12 RR017627]; NATIONAL CENTER FOR RESEARCH RESOURCES [K12RR017627] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072455] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Heart, Lung, and Blood Institute grant 5UO1HL072455 and National Institutes of Health grant K12 RR017627.	Akerman MJH, 2004, J ASTHMA, V41, P521, DOI 10.1081/JAS-120037651; Arif AA, 2003, EUR RESPIR J, V21, P827, DOI 10.1183/09031936.03.00054103a; *ARRD, 1991, AM REV RESPIR DIS, V144, P1202; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Ford ES, 2005, J ASTHMA, V42, P91, DOI 10.1081/JAS-51328; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179, DOI 10.1164/ajrccm.159.1.9712108; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Jones RL, 2006, CHEST, V130, P827, DOI 10.1378/chest.130.3.827; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kuczmarski MF, 2001, J AM DIET ASSOC, V101, P28, DOI 10.1016/S0002-8223(01)00008-6; Lavoie KL, 2006, RESP MED, V100, P648, DOI 10.1016/j.rmed.2005.08.001; Leung TF, 2004, PEDIAT ALLERG IMM-UK, V15, P344, DOI 10.1111/j.1399-3038.2004.00164.x; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Mancuso CA, 2008, CHEST, V133, P1142, DOI 10.1378/chest.07-2243; McLachlan CR, 2007, J ALLERGY CLIN IMMUN, V119, P634, DOI 10.1016/j.jaci.2006.10.029; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; *NAT HEART LUNG BL, 2002, EXP PAN REP GUID DIA; *NAT HEART LUNG BL, 2007, 3 NAT HEART LUNG BLO, P36; *NHLBI, CLASS RISKS OV OB; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Patino CM, 2008, J ALLERGY CLIN IMMUN, V122, P936, DOI 10.1016/j.jaci.2008.08.027; Pelegrino Nilva Regina Gelamo, 2007, J. bras. pneumol., V33, P641, DOI 10.1590/S1806-37132007000600006; Peters D, 2006, CHEST, V129, P918, DOI 10.1378/chest.129.4.918; RHODES L, 2004, ASTHMA PREVALENCE CO, P145; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schatz M, 2007, J ASTHMA, V44, P391, DOI 10.1080/02770900701364296; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Sin DD, 2002, ARCH INTERN MED, V162, P1477, DOI 10.1001/archinte.162.13.1477; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Taylor B, 2008, THORAX, V63, P14, DOI 10.1136/thx.2007.082784; Thomson CC, 2003, CHEST, V124, P795, DOI 10.1378/chest.124.3.795; Todd DC, 2007, CLIN EXP ALLERGY, V37, P1049, DOI 10.1111/j.1365-2222.2007.02748.x; Trochtenberg DS, 2008, J ASTHMA, V45, P165, DOI 10.1080/02770900701847076; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647, DOI 10.1164/ajrccm.160.5.9902098; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028	41	39	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					207	212		10.1016/j.jaci.2009.05.034	http://dx.doi.org/10.1016/j.jaci.2009.05.034			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	482CD	19615731	Green Accepted, Bronze			2022-12-18	WOS:000268860400005
J	Soyer, OU; Aytac, S; Tuncer, A; Cetin, M; Yetgin, S; Sekerel, BE				Soyer, Ozge Uysal; Aytac, Selin; Tuncer, Ayfer; Cetin, Mualla; Yetgin, Sevgi; Sekerel, Bulent Enis			Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Acute lymphoblastic leukemia; L-asparaginase; child; allergy; premedication; desensitization	ESCHERICHIA-COLI ASPARAGINASE; CHILDHOOD; ANTIBODIES; HYPERSENSITIVITY; ANAPHYLAXIS; ADULTS; IMPACT	Background: L-asparaginase is a crucial chemotherapeutic agent for the treatment of acute lymphoblastic leukemia. The alternatives to L-asparaginase are not available in many parts of the world, including Turkey. Objective: We sought to evaluate the utility of premedication with or without a desensitization protocol in children with acute lymphoblastic leukemia and systemic hypersensitivity reactions to Escherichia coli-asparaginase. Methods: In this prospective study patients with systemic hypersensitivity reactions to E coli-asparaginase for whom we were unable to ascertain/provide other alternatives to asparaginase were either premedicated, desensitized, or both to receive their chemotherapy as E coli-asparaginase according to the severity of the hypersensitivity reaction. Results: Nineteen patients (13 male patients) with a mean age of 7.4 +/- 4.7 years experienced a systemic hypersensitivity reaction to E coli-asparaginase during a 4-year period. Polyethylene glycol-asparaginase could be used for 3 patients. Eight of the remaining 16 children, who had experienced anaphylaxis, were premedicated and desensitized with E coli-asparaginase, and in 7 patients treatment was tolerated. The other 8 patients, with acute allergic reactions to E coli-asparaginase, were premedicated first, and 5 of them showed no reaction subsequently. Three of them demonstrated systemic hypersensitivity reactions again (anaphylaxis, n = 3), and premedication and desensitization with E coli-asparaginase resulted in anaphylaxis. Polyethylene glycol-asparaginase was administered uneventfully to the patients who could be provided it. Conclusion: E coli-asparaginase could be administered to more than half of the patients who had a hypersensitivity reaction, and all of these patients were able to receive their planned doses of asparaginase. In countries with shortages of alternative asparaginase preparations, our approach might be a suitable option. (J Allergy Clin Immunol 2009;123:895-9.)	[Soyer, Ozge Uysal; Sekerel, Bulent Enis] Hacettepe Univ, Fac Med, Pediat Allergy & Asthma Unit, TR-06100 Ankara, Turkey; [Aytac, Selin; Tuncer, Ayfer; Cetin, Mualla; Yetgin, Sevgi] Hacettepe Univ, Fac Med, Pediat Hematol Unit, TR-06100 Ankara, Turkey	Hacettepe University; Ankara University; Hacettepe University	Sekerel, BE (corresponding author), Hacettepe Univ, Fac Med, Pediat Allergy & Asthma Unit, TR-06100 Ankara, Turkey.	b_sekerel@yahoo.com	Sekerel, Bulent Enis/I-9309-2013	Sekerel, Bulent Enis/0000-0001-7402-6850				ASSELIN BL, 1993, J CLIN ONCOL, V11, P1780, DOI 10.1200/JCO.1993.11.9.1780; BILLETT AL, 1992, CANCER, V70, P201, DOI 10.1002/1097-0142(19920701)70:1<201::AID-CNCR2820700131>3.0.CO;2-M; Bonno M, 1998, J ALLERGY CLIN IMMUN, V101, P571; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; CHEUNG NKV, 1986, AM J PEDIAT HEMATOL, V8, P99; CLARKSON B, 1970, Cancer, V25, P279, DOI 10.1002/1097-0142(197002)25:2<279::AID-CNCR2820250205>3.0.CO;2-7; FABRY U, 1985, PEDIATR RES, V19, P400, DOI 10.1203/00006450-198519040-00017; Fu CH, 2007, EXPERT OPIN PHARMACO, V8, P1977, DOI 10.1517/14656566.8.12.1977; Graham ML, 2003, ADV DRUG DELIVER REV, V55, P1293, DOI 10.1016/S0169-409X(03)00110-8; Hak LJ, 2004, LEUKEMIA, V18, P1072, DOI 10.1038/sj.leu.2403351; HASKELL CM, 1969, BIOCHEM PHARMACOL, V18, P2578, DOI 10.1016/0006-2952(69)90375-X; JAFFE N, 1971, CANCER RES, V31, P942; KILLANDER D, 1976, CANCER, V37, P220, DOI 10.1002/1097-0142(197601)37:1<220::AID-CNCR2820370132>3.0.CO;2-W; KORHOLZ D, 1990, MONATSSCHR KINDERH, V138, P23; Larson RA, 1998, LEUKEMIA, V12, P660, DOI 10.1038/sj.leu.2401007; Muller HJ, 1998, CRIT REV ONCOL HEMAT, V28, P97, DOI 10.1016/S1040-8428(98)00015-8; Narta UK, 2007, CRIT REV ONCOL HEMAT, V61, P208, DOI 10.1016/j.critrevonc.2006.07.009; NESBIT M, 1979, American Journal of Pediatric Hematology Oncology, V1, P9; PRATT CB, 1970, J PEDIATR-US, V77, P474, DOI 10.1016/S0022-3476(70)80023-3; PRATT CB, 1971, AM J DIS CHILD, V121, P406, DOI 10.1001/archpedi.1971.02100160076008; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; TALLAL L, 1970, Cancer, V25, P306, DOI 10.1002/1097-0142(197002)25:2<306::AID-CNCR2820250206>3.0.CO;2-H; Unal S, 2004, PEDIATR HEMAT ONCOL, V21, P279, DOI 10.1080/08880010490277097; *US FDA, 2006, FDA APPR ONC NEWL DI; Wang B, 2003, LEUKEMIA, V17, P1583, DOI 10.1038/sj.leu.2403011; Woo MH, 1998, LEUKEMIA, V12, P1527, DOI 10.1038/sj.leu.2401162; Woo MH, 2000, J CLIN ONCOL, V18, P1525, DOI 10.1200/JCO.2000.18.7.1525; Zalewska-Szewczyk B, 2004, PEDIATR BLOOD CANCER, V43, P600, DOI 10.1002/pbc.20064; Zalewska-Szewczyk B, 2007, LEUKEMIA LYMPHOMA, V48, P931, DOI 10.1080/10428190701292049	29	39	40	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					895	899		10.1016/j.jaci.2008.10.034	http://dx.doi.org/10.1016/j.jaci.2008.10.034			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	431JW	19081614				2022-12-18	WOS:000265058600017
J	Kumar, R; Curtis, LM; Khiani, S; Moy, J; Shalowitz, MU; Sharp, L; Durazo-Arvizu, RA; Shannon, JJ; Weiss, KB				Kumar, Rajesh; Curtis, Laura Marie; Khiani, Sanjay; Moy, James; Shalowitz, Madeleine U.; Sharp, Lisa; Durazo-Arvizu, Ramon A.; Shannon, John Jay; Weiss, Kevin B.			A community-based study of tobacco smoke exposure among inner-city children with asthma in Chicago	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						inner-city asthma; child; tobacco smoke exposure; continine	CIGARETTE-SMOKING; COTININE LEVELS; ELEMENTARY SCHOOLCHILDREN; GENDER-DIFFERENCES; SUBSTANCE USE; ALCOHOL-USE; HEALTH; DISORDERS; SAMPLE; LIFE	Background: Little is known about the level of tobacco exposure and the factors that influence exposure in children with persistent asthma. Objective: We sought to measure tobacco smoke exposure and determine factors associated with exposure in a large urban sample of asthmatic children. Methods: This cross-sectional study is based on a community-based cohort of 482 children (8-14 years old) with persistent asthma. Caregiver and household tobacco use were reported by the caregiver. Child tobacco smoke exposure was assessed by using salivary cotinine level. Multivariate linear regression of log-transformed salivary cotinine levels were used to characterize the relationship between smoke exposure and caregiver, household, and demographic characteristics. We used a multivariate logistic model to characterize associations with caregiver smoking. Results: Overall, 68.5% of children had tobacco smoke exposure. Compared with nonexposed children, those exposed to smoking by a caregiver or another household member had cotinine levels that were 1.68 (95% CI, 1.45-1.94) or 1.40 (95% CI, 1.22-1.62) times higher, respectively. Compared with Hispanic children, African American and white/other children had 1.55 (95% CI, 1.16-2.06) and 1.59 (95% CI 1.18-2.14) times higher cotinine levels, respectively. Child exposure was also associated with caregiver depression symptoms (odds ratio, 1.01; 95% CI 1.01-1.02), and higher household income was protective (odds ratio, 0.73; 95% CI, 0.56-0.95). Independent predictors of caregiver smoking included a protective effect of higher education (odds ratio, 0.35; 95% CI, 0.15-0.83) and a positive association with potential problematic drug/alcohol use (odds ratio, 2.30; 95% CI, 1.39-3.83). Conclusions: Tobacco smoke exposure was high in this urban sample of asthmatic children. Caregiver smoking was strongly associated with child exposure and also was associated with lower socioeconomic status, non-Hispanic ethnicity, and depression symptoms.	[Kumar, Rajesh] Childrens Mem Hosp, Div Allergy, Chicago, IL 60614 USA; [Curtis, Laura Marie; Weiss, Kevin B.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; [Khiani, Sanjay; Moy, James] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; [Shalowitz, Madeleine U.] Univ Illinois, Rush Med Sch, Div Allergy, Chicago, IL USA; [Sharp, Lisa] Univ Illinois, Dept Family Med, Chicago, IL USA; [Durazo-Arvizu, Ramon A.] Loyola Univ, Med Ctr, Chicago, IL 60611 USA; [Shannon, John Jay] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA; [Weiss, Kevin B.] Hines VA Hosp, Chicago, IL USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Loyola University Chicago; John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Kumar, R (corresponding author), Childrens Mem Hosp, Div Clin Immunol & Allergy, 2300 Childrens Plaza,Box 60, Chicago, IL 60614 USA.	rkumar@childrensmemorial.org		Curtis, Laura/0000-0003-2380-2201; Kumar, Rajesh/0000-0002-1962-7108; Sharp, Lisa/0000-0002-7809-9042	National Heart, Lung, and Blood Institute grant [1UO1 HL072496-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL072496] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by National Heart, Lung, and Blood Institute grant 1UO1 HL072496-01.	[Anonymous], 2002, MMWR Recomm Rep, V51, P1; [Anonymous], 2002, MMWR RECOMM REP, V51, p[i, 1]; Austin JB, 2005, ARCH DIS CHILD, V90, P253, DOI 10.1136/adc.2004.049346; Binnie V, 2004, ORAL DIS, V10, P287, DOI 10.1111/j.1601-0825.2004.01018.x; Brown C, 2000, INT J PSYCHIAT MED, V30, P15, DOI 10.2190/NY79-CJ0H-VBAY-5M1U; Brown ES, 2006, PEDIATRICS, V118, pE1715, DOI 10.1542/peds.2006-1119; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Chowdhury PP, 2006, ETHNIC DIS, V16, P534; Dawson DA, 2000, DRUG ALCOHOL DEPEN, V59, P235, DOI 10.1016/S0376-8716(99)00130-1; Delva J, 2005, AM J PREV MED, V29, P218, DOI 10.1016/j.amepre.2005.05.004; Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439, DOI 10.1289/ehp.99107s3439; Epstein JA, 1999, TOB CONTROL, V8, P45, DOI 10.1136/tc.8.1.45; Epstein JA, 1998, J ADOLESCENT HEALTH, V23, P160, DOI 10.1016/S1054-139X(98)00027-5; Falk DE, 2006, ALCOHOL RES HEALTH, V29, P162; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429, DOI 10.1164/ajrccm.163.2.2006009; Goodwin RD, 2007, ANN ALLERG ASTHMA IM, V98, P447, DOI 10.1016/S1081-1206(10)60759-4; Griffin KW, 2003, ADDICT BEHAV, V28, P1141, DOI 10.1016/S0306-4603(02)00225-3; Grucza RA, 2006, ALCOHOL CLIN EXP RES, V30, P2046, DOI 10.1111/j.1530-0277.2006.00255.x; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; Jorm AF, 1999, MED J AUSTRALIA, V170, P74, DOI 10.5694/j.1326-5377.1999.tb126887.x; Kurukulaaratchy RJ, 2005, ACTA PAEDIATR, V94, P553, DOI 10.1080/08035250510027282; Lewis SJ, 2003, BIOMARKERS, V8, P218, DOI 10.1080/1354750031000120125; Martinez ME, 2004, PREV MED, V38, P492, DOI 10.1016/j.ypmed.2003.12.006; Needham BL, 2007, SOC SCI MED, V65, P1166, DOI 10.1016/j.socscimed.2007.04.037; O'Loughlin J, 1998, ANN EPIDEMIOL, V8, P308, DOI 10.1016/S1047-2797(97)00209-3; Pattenden S, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015065; PEREZSTABLE EJ, 1995, PREV MED, V24, P171, DOI 10.1006/pmed.1995.1031; PEREZSTABLE EJ, 1992, AM REV RESPIR DIS, V145, P53, DOI 10.1164/ajrccm/145.1.53; Radloff LS, 1997, APPL PSYCH MEAS, V1, P384; RONCHETTI R, 1994, EUR RESPIR J, V7, P472, DOI 10.1183/09031936.94.07030472; Scherer G, 1999, HUM EXP TOXICOL, V18, P297, DOI 10.1191/096032799678840075; Shalowitz MU, 2007, AMBUL PEDIATR, V7, P271, DOI 10.1016/j.ambp.2007.03.004; Shalowitz MU, 1998, HEALTH SERV RES, V33, P1381; Siegel D, 1996, J Cardiovasc Risk, V3, P295, DOI 10.1097/00043798-199606000-00006; Urban R, 2006, NICOTINE TOB RES, V8, P565, DOI 10.1080/14622200600789940; Vargas PA, 2007, PEDIATR PULM, V42, P646, DOI 10.1002/ppul.20637; Webb MS, 2007, J BEHAV MED, V30, P371, DOI 10.1007/s10865-007-9112-9; Weil CM, 1999, PEDIATRICS, V104, P1274, DOI 10.1542/peds.104.6.1274; Yamamoto Y, 2005, J CLIN PERIODONTOL, V32, P1041, DOI 10.1111/j.1600-051X.2005.00819.x; Yarnell JWG, 2003, CLIN EXP ALLERGY, V33, P96, DOI 10.1046/j.1365-2222.2003.01572.x	40	39	39	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					754	759		10.1016/j.jaci.2008.08.006	http://dx.doi.org/10.1016/j.jaci.2008.08.006			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Allergy; Immunology	359LU	19014767				2022-12-18	WOS:000259989000020
J	Maneechotesuwan, K; Supawita, S; Kasetsinsombat, K; Wongkajornsilp, A; Barnes, PJ				Maneechotesuwan, Kittipong; Supawita, Sirinya; Kasetsinsombat, Kanda; Wongkajornsilp, Adisak; Barnes, Peter J.			Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; indoleamine-2; 3-dioxyenase; kynurenine; inhaled corticosteroid; IL-10	CYTOKINE GENE-EXPRESSION; T-CELL PROLIFERATION; TRYPTOPHAN CATABOLISM; DENDRITIC CELLS; PREDNISOLONE TREATMENT; COMPLEMENT ACTIVATION; COMBINATION THERAPY; 2,3-DIOXYGENASE; INHIBITION; INTERLEUKIN-10	Background: Indoleamine-2, 3-dioxygenase (IDO), a tryptophan-degrading enzyme, plays a key role in the regulation of T-lymphocyte function. IDO inhibits eosinophilic inflammation in a murine asthma model, but little is known about its role in asthmatic patients or the effects of corticosteroids on this key regulatory enzyme. Objective: We studied IDO activity and the effect of inhaled corticosteroids (ICSs) in patients with asthma and how this correlated with eosinophilic inflammation. Methods: After a 1-week run-in period on no therapy, 34 asthmatic patients were treated with only short-acting beta(2)-agonists as required or an ICS or an ICS in combination with a long-acting beta(2)-agonist, which were required for asthma control, and the treatment was continued for a further 4 weeks. Each patient underwent sputum induction at the end of the run-in and treatment periods. Sputum supernatant specimens were analyzed for IDO activity and kynurenine concentrations by using HPLC. Results: All patients with mild intermittent and mild-to-moderate persistent asthma had low baseline IDO activity in induced sputum compared with that seen in age-matched nonasthmatic subjects. The IDO activity was markedly enhanced by either ICS (P =.03) or ICS/long-acting beta(2)-agonist (P <.0001) treatment, and this increase negatively correlated with sputum eosinophils but was positively associated with an increase in IL-10-positive macrophages. Conclusion: ICSs might exert their anti-inflammatory activity in asthmatic airways, at least in part, through the upregulation of IDO activity associated with increased IL-10 secretion from macrophages.	[Maneechotesuwan, Kittipong; Supawita, Sirinya] Mahidol Univ, Siriraj Hosp, Fac Med, Div Resp Dis & Tuderculosis, Bangkok 10700, Thailand; [Kasetsinsombat, Kanda; Wongkajornsilp, Adisak] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Pharmacol, Bangkok 10700, Thailand; [Barnes, Peter J.] Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, London, England	Mahidol University; Mahidol University; Imperial College London	Maneechotesuwan, K (corresponding author), Mahidol Univ, Siriraj Hosp, Fac Med, Div Resp Dis & Tuderculosis, 2 Prannok St, Bangkok 10700, Thailand.	sikmn@mahidol.ac.th	Wongkajornsilp, Adisak/AAH-7668-2019	Wongkajornsilp, Adisak/0000-0002-3965-0997; Barnes, Peter/0000-0002-5122-4018				Barnes PJ, 2002, EUR RESPIR J, V19, P182, DOI 10.1183/09031936.02.00283202; Barnes PJ, 2001, PULM PHARMACOL THER, V14, P329, DOI 10.1006/pupt.2000.0318; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Bentley AM, 1996, AM J RESP CRIT CARE, V153, P551, DOI 10.1164/ajrccm.153.2.8564096; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Caucheteux SM, 2003, IMMUNITY, V18, P169, DOI 10.1016/S1074-7613(03)00028-1; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; *GLOB IN ASTHM AST, 2006, GLOB STRAT ASTHM MAN; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Magnan A, 1998, ALLERGY, V53, P1092, DOI 10.1111/j.1398-9995.1998.tb03821.x; Maneechotesuwan K, 2005, CHEST, V128, P1936, DOI 10.1378/chest.128.4.1936; Mellor A, 2005, BIOCHEM BIOPH RES CO, V338, P20, DOI 10.1016/j.bbrc.2005.08.232; Mellor AL, 2001, NAT IMMUNOL, V2, P64, DOI 10.1038/83183; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909, DOI 10.4049/jimmunol.173.10.5909; Raitala A, 2006, MOL IMMUNOL, V43, P1054, DOI 10.1016/j.molimm.2005.06.022; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401, DOI 10.1164/ajrccm/148.2.401; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P704, DOI 10.1164/rccm.200408-1041OC; von Bubnoff D, 2004, CLIN EXP ALLERGY, V34, P1056, DOI 10.1111/j.1365-2222.2004.01984.x; YONG S, 1979, J CHROMATOGR, V175, P343, DOI 10.1016/S0021-9673(00)89443-1	26	39	46	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2008	121	1					43	50		10.1016/j.jaci.2007.10.011	http://dx.doi.org/10.1016/j.jaci.2007.10.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	251KM	18036645				2022-12-18	WOS:000252372000007
J	Mai, XM; Becker, AB; Sellers, EAC; Liem, JJ; Kozyrskyj, AL				Mai, Xiao-Mei; Becker, Allan B.; Sellers, Elizabeth A. C.; Liem, Joel J.; Kozyrskyj, Anita L.			The relationship of breast-feeding, overweight, and asthma in preadolescents	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; breast-feeding. case-control studies; sex; herediry; leptin; overweight; preadolescent	FORMULA-FED INFANTS; BODY-MASS INDEX; ALLERGIC DISEASE; BIRTH COHORT; CHILDHOOD ASTHMA; YOUNG-CHILDREN; OBESITY; RISK; LEPTIN; LIFE	Background: Breast-feeding is suggested to be associated with overweight or asthma in children. Overweight and asthma may share common environmental influences of which breast-feeding may be one. Objective: We evaluated whether short duration of exclusive breast-feeding and subsequent overweight were associated with asthma. Methods: A nested case-control study included 246 children with pediatric allergist-diagnosed asthma and 477 controls without asthma at age 8 to 10 years. Information on exclusive breast-feeding was obtained from questionnaire data. Overweight at 8 to 10 years of age was defined as body mass index >=85th percentile of age and sex-specific growth charts. The association between asthma and exclusive breast-feeding <12 weeks plus overweight, adjusted for sex, parental asthma, aboriginal origin, passive smoking at birth, residence location, and family income, was determined in logistic regression analyses. Results: Exclusive breast-feeding <12 weeks was closely associated with overweight at age 8 to 10 years (P <.001). Exclusive breast-feeding <12 weeks plus overweight was significantly. associated with asthma (adjusted OR, 1.81; 95% CI. 1.11-2.95, P =.018). This association appeared to be strong in children whose mothers had asthma (adjusted OR, 3.93; 95% Cl. 1.17-13.2) and also in boys (adjusted OR, 2.22; 95% Cl. 1.14-4.34). Asthma was not associated with either exclusive breast-feeding <12 weeks or overweight in the absence of the other. Conclusion: Short duration of exclusive breast-feeding and subsequent overweight are associated with asthma in susceptible children, suggesting a common pathway.	Univ Manitoba, Manitoba Inst Ch, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Manitoba Inst Child Hlth, Fac Pharm, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Manitoba Inst Child Hlth, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba	Kozyrskyj, AL (corresponding author), Univ Manitoba, 210 Pharm Bldg, Winnipeg, MB R3T 2N2, Canada.	kozvrsk@cc.utnanitoba.ca						Almqvist C, 2005, CLIN EXP ALLERGY, V35, P612, DOI 10.1111/j.1365-2222.2005.02243.x; [Anonymous], CDC GROWTH CHARTS; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Becker A, 2005, CAN MED ASSOC J, V173, pS3; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P159, DOI 10.1046/j.1365-2222.2002.01343.x; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344, DOI 10.1164/ajrccm.163.6.2006140; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chulada PC, 2003, J ALLERGY CLIN IMMUN, V111, P328, DOI 10.1067/mai.2003.127; Dell S, 2001, ARCH PEDIAT ADOL MED, V155, P1261, DOI 10.1001/archpedi.155.11.1261; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gillman MW, 2001, JAMA-J AM MED ASSOC, V285, P2461, DOI 10.1001/jama.285.19.2461; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hanson LA, 2000, ADV EXP MED BIOL, V478, P65; Heinig MJ, 2001, PEDIATR CLIN N AM, V48, P105, DOI 10.1016/S0031-3955(05)70288-1; Hilson JA, 1997, AM J CLIN NUTR, V66, P1371, DOI 10.1093/ajcn/66.6.1371; Holt Patrick G, 2004, Paediatr Respir Rev, V5 Suppl A, pS27, DOI 10.1016/S1526-0542(04)90006-1; Juniper E, 1994, HISTAMINE METHACHOLI; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Lewis SA, 2005, AM J EPIDEMIOL, V161, P406, DOI 10.1093/aje/kwi059; Liese AD, 2001, INT J OBESITY, V25, P1644, DOI 10.1038/sj.ijo.0801800; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Matarese G, 2002, TRENDS IMMUNOL, V23, P182, DOI 10.1016/S1471-4906(02)02188-9; Melen E, 2004, CLIN EXP ALLERGY, V34, P839, DOI 10.1111/j.1365-2222.2004.01957.x; Obihara CC, 2005, EUR RESPIR J, V25, P970, DOI 10.1183/09031936.05.00116504; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Oddy WH, 2004, AM J PUBLIC HEALTH, V94, P1531, DOI 10.2105/AJPH.94.9.1531; Ong KKL, 1999, J CLIN ENDOCR METAB, V84, P1145, DOI 10.1210/jc.84.3.1145; Rothenbacher D, 2005, CLIN EXP ALLERGY, V35, P1014, DOI 10.1111/j.1365-2222.2005.02298.x; Savino F, 2005, ACTA PAEDIATR, V94, P531, DOI 10.1080/08035250510027642; Savino F, 2004, J PEDIATR ENDOCR MET, V17, P1527; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Takemura Y, 2001, AM J EPIDEMIOL, V154, P115, DOI 10.1093/aje/154.2.115; Tantisira KG, 2001, THORAX, V56, P64; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; von Kries R, 1999, BRIT MED J, V319, P147, DOI 10.1136/bmj.319.7203.147; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Wickens K, 2005, THORAX, V60, P7, DOI 10.1136/thx.2002.001529; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	42	39	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					551	556		10.1016/j.jaci.2007.05.004	http://dx.doi.org/10.1016/j.jaci.2007.05.004			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	211DV	17586035				2022-12-18	WOS:000249505400012
J	Gao, YF; Wang, DY; Ong, TC; Tay, SL; Yap, KH; Chew, FT				Gao, Yun Feng; Wang, De Yun; Ong, Tan Ching; Tay, Su Ling; Yap, Kwong Hsia; Chew, Fook Tim			Identification and characterization of a novel allergen from Blomia tropicalis: Blo t 21	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dust mite; Blomia tropicalis; allergen; IgE binding; cross-reactivity; immunolocalization; genomic organization	IGE CROSS-REACTIVITY; DUST-MITE FAUNA; DERMATOPHAGOIDES-PTERONYSSINUS; ASTHMATIC-PATIENTS; CLONING; SENSITIZATION; EXPRESSION; SINGAPORE; PROTEASES; PROTEINS	Background: Allergenic components from Blomia tropicalis are important triggers of allergies in the tropics. Objective: We sought to identify and characterize a novel allergen, Bin t 21, from B tropicalis. Methods: Blo t 21 was initially identified from an expressed sequence tag database generated from a B tropicalis cDNA library. Allergenicity of this antigen was examined by means of skin prick testing, ELISA, and IgE immuno-dot blotting. We evaluated whether Blo t 21 and Bin t 5 were cross-reactive by using IgE inhibition ELISAs. Results: Blo t 21, a 129-amino-acid protein sharing 39% identity with Blo t 5, is a product of a single-copy gene. It has an oz-helical secondary structure and localizes to midgut and hindgut contents of B tropicalis, as well as fecal particles. Positive responses to Blo t 21 were shown in 93 % (40/43) by means of ELISA and 95 % (41/43) by means of skin prick testing when assayed in 43 adult patients with ongoing persistent allergic rhinitis. However, sera of 494 consecutive individuals attending outpatient allergy clinics over 1 1/2 years showed 57.9% (286/494) had positive responses to Blo t 21. Although the majority (>75%) of sensitized individuals were cosensitized to both Blo t 5 and Blo t 21, these 2 allergens had a low-to-moderate degree of cross- reactivity. Conclusion: Blo t 21 is a major allergen in B tropicalis that is not highly cross-reactive to Blo t 5, despite sharing some sequence and structural identity. Clinical implications: Blo t 21, representing a new group of allergens, is an important B tropicalis allergen.	Natl Univ Singapore, Allergy & Mol Immunol Lab, Lee Hiok Kwee Funct Genom Labs, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Otolaryngol, Singapore 117543, Singapore	National University of Singapore; National University of Singapore	Chew, FT (corresponding author), Natl Univ Singapore, Allergy & Mol Immunol Lab, Lee Hiok Kwee Funct Genom Labs, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.	dbscft@nus.edu.sg	Chew, Fook Tim/E-7259-2010	Chew, Fook Tim/0000-0003-1337-5146				Angus Aaron Chen, 2004, Am J Pharmacogenomics, V4, P357, DOI 10.2165/00129785-200404060-00003; Arruda LK, 1997, AM J RESP CRIT CARE, V155, P343, DOI 10.1164/ajrccm.155.1.9001334; BAQUEIRA T, 2006, J ASTHMA, V43, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Caraballo L, 1997, INT ARCH ALLERGY IMM, V112, P341, DOI 10.1159/000237478; CARABALLO L, 1994, CLIN EXP ALLERGY, V24, P1056, DOI 10.1111/j.1365-2222.1994.tb02743.x; Chan SL, 2006, J IMMUNOL, V176, P4852, DOI 10.4049/jimmunol.176.8.4852; Cheong N, 2003, ALLERGY, V58, P912, DOI 10.1034/j.1398-9995.2003.00215.x; Chew FT, 1999, CLIN EXP ALLERGY, V29, P201, DOI 10.1046/j.1365-2222.1999.00493.x; Chew FT, 1999, ALLERGY, V54, P1150, DOI 10.1034/j.1398-9995.1999.00050.x; Chew FT, 1998, J ALLERGY CLIN IMMUN, V101, pS28; Chew FT, 1999, CLIN EXP ALLERGY, V29, P982, DOI 10.1046/j.1365-2222.1999.00543.x; DAMERVAL C, 1986, ELECTROPHORESIS, V7, P52, DOI 10.1002/elps.1150070108; Dixit A, 1998, PLANT MOL BIOL REP, V16, P91, DOI 10.1023/A:1007414505189; FERNANDEZCALDAS E, 1993, CLIN EXP ALLERGY, V23, P292, DOI 10.1111/j.1365-2222.1993.tb00325.x; FERNANDEZCALDAS E, 1993, J INVEST ALLERG CLIN, V3, P245; Finkelman MA, 2006, J ENDOTOXIN RES, V12, P241, DOI 10.1179/096805106X102237; Flores I, 2003, INT ARCH ALLERGY IMM, V130, P12, DOI 10.1159/000068375; Johansson E, 1997, CLIN EXP ALLERGY, V27, P691, DOI 10.1111/j.1365-2222.1997.tb01198.x; Kidon MI, 2007, J ALLERGY CLIN IMMUN, V119, pS211, DOI 10.1016/j.jaci.2006.12.197; Kuo IC, 2003, J ALLERGY CLIN IMMUN, V111, P603, DOI 10.1067/mai.2003.167; Mariana A, 2000, Southeast Asian J Trop Med Public Health, V31, P712; Montealegre F, 1997, P R Health Sci J, V16, P109; Mora C, 2003, CLIN EXP ALLERGY, V33, P28, DOI 10.1046/j.1365-2222.2003.01480.x; Morgan MS, 1996, ANN ALLERG ASTHMA IM, V77, P386, DOI 10.1016/S1081-1206(10)63337-6; Ong S. T., 2004, Journal of Allergy and Clinical Immunology, V113, pS228, DOI 10.1016/j.jaci.2004.01.277; ONG ST, 2004, ABSTR BOOK 23 EUR AC, P185; POTTER P, 2006, ABSTR BOOK 25 EUR AC, P18; Puerta L, 1996, J ALLERGY CLIN IMMUN, V98, P932, DOI 10.1016/S0091-6749(96)80009-1; Ramos JDA, 2001, INT ARCH ALLERGY IMM, V126, P286, DOI 10.1159/000049525; STANALAND BE, 1994, J ALLERGY CLIN IMMUN, V94, P452, DOI 10.1016/0091-6749(94)90200-3; Tan CL, 2006, J ALLERGY CLIN IMMUN, V117, pS120, DOI 10.1016/j.jaci.2005.12.480; Trivedi L, 2003, J ALLERGY CLIN IMMUN, V111, P777, DOI 10.1067/mai.2003.1338; Tsai JJ, 2003, ANN ALLERG ASTHMA IM, V91, P485, DOI 10.1016/S1081-1206(10)61518-9; Wang DY, 2003, ALLERGY, V58, P78, DOI 10.1034/j.1398-9995.2003.23746.x; Yi FC, 2004, CLIN EXP ALLERGY, V34, P1762, DOI 10.1111/j.1365-2222.2004.02107.x; Yi FC, 2002, CLIN EXP ALLERGY, V32, P1203, DOI 10.1046/j.1365-2745.2002.01449.x	37	39	43	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					105	112		10.1016/j.jaci.2007.02.032	http://dx.doi.org/10.1016/j.jaci.2007.02.032			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	190NS	17445876				2022-12-18	WOS:000248066400015
J	Kawaguchi, M; Kokubu, F; Huang, SK; Homma, T; Odaka, M; Watanabe, S; Suzuki, S; Ieki, K; Matsukura, S; Kurokawa, M; Adachi, M				Kawaguchi, Mio; Kokubu, Fumio; Huang, Shau-Ku; Homma, Tetsuya; Odaka, Miho; Watanabe, Shin; Suzuki, Shintaro; Ieki, Koushi; Matsukura, Satoshi; Kurokawa, Masatsugu; Adachi, Mitsuru			The IL-17F signaling pathway is involved in the induction of IFN-gamma-inducible protein 10 in bronchial epithelial cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						extracellular signal-regulated kinase 1/2; IL-17F; interferon-gamma-inducible protein 10; p90 ribosomal S6 kinase; cyclic AMP response element-binding protein	COLONY-STIMULATING FACTOR; T-CELLS; AIRWAY INFLAMMATION; IN-VIVO; EXPRESSION; CYTOKINE; CHEMOKINES; KINASE; ML-1; ACTIVATION	Background: IL-17F is involved in airway inflammation, but its biologic activity and signaling pathway remain incompletely defined. Interferon-gamma-inducible protein 10 (IP-10) is widely expressed and plays a role in airway inflammatory diseases. Objective: We sought to investigate the functional linkage between IL-17F and IP-10 expression in bronchial epithelial cells. Methods: Bronchial epithelial cells were cultured in the presence or absence of IL-17F, and/or a T(H)1 cytokine, T(H)2 cytokines, proinflammatory cytokines, various kinase inhibitors, or a Raf1 dominant-negative mutant to analyze the expression of IP-10. Moreover, the involvement of p90 ribosomal S6 kinase (p90RSK) and cyclic AMP response element-binding protein (CREB) in IL-17F-induced IP-10 expression were investigated. Results: IL-17F induces the gene and protein expression of IP-10. The addition of IFN-gamma, IL-1 beta, and TNF-alpha augmented IL-17F-induced IP-10 expression. The mitogen-activated protein kinase kinase (MEK) inhibitors PD98059, U0126, and Raf1 kinase inhibitor I significantly inhibited its production. In contrast, a p38 inhibitor, a JNK inhibitor, protein kinase C inhibitors, and a phosphatidylinositol 3-kinase inhibitor, showed no inhibitory effect. Furthermore, overexpression of a Raf1 dominant-negative mutant inhibited its expression. Of interest, IL-17F phosphorylated p90RSK and CREB, and transfection of the cells with a short interfering RNA for p90RSK or CREB inhibited its expression, suggesting p90RSK and CREB as novel signaling molecules of IL-17F. Conclusion: IL-17F is a potent inducer of IP-10 in bronchial epithelial cells through the activation of the Raf1-MEK1/2-extracellular signal-regulated kinase 1/2-p90RSK-CREB pathway, supporting its regulatory role in airway inflammation. Clinical implications: The IL-17F-IP-10 axis might be a novel and critical therapeutic target for airway inflammatory diseases.	Showa Univ, Sch Med, Dept Internal Med 1, Shinagawa Ku, Tokyo 1428666, Japan; Showa Univ, Fujigaoka Hosp, Dept Resp Med, Yokohama, Kanagawa 227, Japan; Johns Hopkins Univ, Ctr Asthma & Allergy, Baltimore, MD 21224 USA	Showa University; Showa University; Johns Hopkins University	Kawaguchi, M (corresponding author), Showa Univ, Sch Med, Dept Internal Med 1, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan.	miokawguchi@aol.com	Huang, Shau-Ku/F-5509-2010					Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1016/j.jaci.2003.08.012; Boorsma DM, 1998, ARCH DERMATOL RES, V290, P335, DOI 10.1007/s004030050314; Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Fukakusa M, 2005, J ALLERGY CLIN IMMUN, V115, P280, DOI 10.1016/j.jaci.2004.10.036; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Hurst SD, 2002, J IMMUNOL, V169, P443, DOI 10.4049/jimmunol.169.1.443; Hwang SY, 2004, BIOCHEM BIOPH RES CO, V318, P691, DOI 10.1016/j.bbrc.2004.04.082; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Kawaguchi J, 2003, ACTA ASTRONAUT, V52, P117, DOI 10.1016/S0094-5765(02)00146-7; Kawaguchi M, 2006, J ALLERGY CLIN IMMUN, V117, P795, DOI 10.1016/j.jaci.2005.12.1346; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P1265, DOI 10.1016/j.jaci.2004.10.019; Kawaguchi M, 2004, J ALLERGY CLIN IMMUN, V114, P444, DOI 10.1016/j.jaci.2004.03.047; Kawaguchi M, 2003, J PHARMACOL EXP THER, V307, P1213, DOI 10.1124/jpet.103.056341; Kawaguchi M, 2002, J BIOL CHEM, V277, P15229, DOI 10.1074/jbc.C100641200; Kawaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P804, DOI 10.1067/mai.2001.119027; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; Matsukura S, 2006, CLIN EXP ALLERGY, V36, P1049, DOI 10.1111/j.1365-2222.2006.02530.x; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; Medoff BD, 2002, J IMMUNOL, V168, P5278, DOI 10.4049/jimmunol.168.10.5278; Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524; Oda N, 2005, AM J RESP CRIT CARE, V171, P12, DOI 10.1164/rccm.200406-778OC; Panzner P, 2003, CHEST, V124, P1909, DOI 10.1378/chest.124.5.1909; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Sauty A, 1999, J IMMUNOL, V162, P3549; Spurrell JCL, 2005, AM J PHYSIOL-LUNG C, V289, pL85, DOI 10.1152/ajplung.00397.2004; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Tan JQ, 2000, J IMMUNOL, V165, P1548, DOI 10.4049/jimmunol.165.3.1548; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Ying S, 2005, J IMMUNOL, V174, P8183, DOI 10.4049/jimmunol.174.12.8183	33	39	43	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1408	1414		10.1016/j.jaci.2007.02.036	http://dx.doi.org/10.1016/j.jaci.2007.02.036			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	178PO	17418381				2022-12-18	WOS:000247232800016
J	Hamilton, RG				Hamilton, RG			Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						human; IgE; IgE antibody; omalizumab (Xolair); human IgG(1) anti-IgE; human IgG antihuman IgE autoantibodies; College of American Pathologists proficiency survey; immunoenzymetric assay; alpha-Fc epsilon R1	HUMANIZED MONOCLONAL-ANTIBODY; SEVERE ALLERGIC-ASTHMA; FC-EPSILON-RI; ALPHA-CHAIN; IN-VITRO; SERUM; AUTOANTIBODIES; SPECIFICITY; COMPLEXES; RECEPTOR	Background: Although serological IgE measurements can aid in efficacy assessment of patients with asthma on omalizumab (Xolair [Genentech, Inc., South San Francisco, Calif]; humanized IgG(1) antihuman IgE Fc), its effect on clinically used IgE assay performance is unknown. Objective: This study investigated the hypothesis that IgE:IgG-anti-IgE immune complex formation after omalizumab administration diminishes accuracy and increases variability of IgE assays performed in diagnostic immunology laboratories. Methods: Plasma from 4 atopic adults was incubated with omalizumab (50 or 200 molar excess to IgE) or buffer. Paired specimens were sent masked to 159 clinical laboratories in the College of American Pathologists Diagnostic Allergy Proficiency Survey (cycles SE-C-2003, SE-A-2005). Inhibitory effects produced by omalizumab on accuracy and reproducibility of US Food and Drug Administration (FDA)cleared total and allergen-specific IgE assays were computed by using national proficiency survey data. Results: Total serum IgE levels measured in the 2 ImmunoCAP assays were minimally reduced (2.4-9.0%) by the presence of omalizumab, whereas 5 other assays showed marked reductions from 12.5% to 67.2% (P <.001) that increased in proportion to total serum IgE levels. The degree of interference was not large enough to produce detectable misclassification of IgE antibody results (positive to negative) in 4 multiallergen screening assays. or 11 FDA-cleared IgE antibody assays, only 3 (ImmunoCAP, UniCAP, Immulite-2000) generated quantitative IU/mL results that could be assessed for interference. Omalizumab produced 0.8% to 27.8% reduction in allergen-specific IgE levels across 8 allergen specificities. Conclusion: Although as much as 62% loss in accuracy was observed in FDA-cleared human IgE assays, the ImmunoCAP system was sufficiently robust to provide accurate and reproducible total and allergen-specific IgE antibody results in a clinical setting where therapeutic levels of omalizumab are present in serum. Clinical implications: Accurate monitoring of total and allergen-specific IgE, together with free IgE levels, in serum from patients on omalizumab may help optimize dosing and maximize the efficacy of Xolair therapy.	Johns Hopkins Univ, Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Div Clin Immunol & Allergy, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Hamilton, RG (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Room 1A20,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	rhamilto@jhmi.edu						Bochner B, 2005, CLIN REV ALLERG IMMU, V29, P1, DOI 10.1385/CRIAI:29:1:001; Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; CARINI C, 1983, ANN ALLERGY, V51, P251; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110, DOI 10.1016/S0091-6749(97)70202-1; CHANG TW, 1990, BIO-TECHNOL, V8, P122, DOI 10.1038/nbt0290-122; Davis LA, 2004, ANN PHARMACOTHER, V38, P1236, DOI 10.1345/aph.1D626; HAAKFRENDSCHO M, 1993, J IMMUNOL, V151, P351; Hamilton R. G., 2004, Journal of Allergy and Clinical Immunology, V113, pS289, DOI 10.1016/j.jaci.2004.01.518; Hamilton RG, 2005, J IMMUNOL METHODS, V303, P81, DOI 10.1016/j.jim.2005.06.008; Hamilton RG, 2004, J ALLERGY CLIN IMMUN, V114, P213, DOI 10.1016/j.jaci.2004.06.046; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; INGANAS M, 1981, INT ARCH ALLER A IMM, V65, P51, DOI 10.1159/000232737; LICHTENSTEIN LM, 1992, J IMMUNOL, V148, P3929; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; MATSON P, 1997, 1LA20A CLIN LAB STAN; PAGANELLI R, 1988, J CLIN LAB IMMUNOL, V26, P153; QUINTI I, 1986, J ALLERGY CLIN IMMUN, V77, P586, DOI 10.1016/0091-6749(86)90350-7; REIMER CB, 1986, MONOCLONAL ANTIBODY, V4, P2; RITTER C, 1991, J ALLERGY CLIN IMMUN, V88, P793, DOI 10.1016/0091-6749(91)90187-S; Saini SS, 1999, J IMMUNOL, V162, P5624; STADLER BM, 1989, INT ARCH ALLER A IMM, V88, P206, DOI 10.1159/000234787; Stedman K, 2001, VET IMMUNOL IMMUNOP, V78, P349, DOI 10.1016/S0165-2427(01)00242-2	23	39	41	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					759	766		10.1016/j.jaci.2006.01.012	http://dx.doi.org/10.1016/j.jaci.2006.01.012			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	033QB	16630931				2022-12-18	WOS:000236862800006
J	Caballero, T; Lopez-Serrano, C				Caballero, T; Lopez-Serrano, C			Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter									Univ Madrid, Hosp La Paz, Serv Alergia, E-28046 Madrid, Spain	Hospital Universitario La Paz	Caballero, T (corresponding author), Univ Madrid, Hosp La Paz, Serv Alergia, P Castellana 261, E-28046 Madrid, Spain.		Caballero, Teresa/H-6454-2014; Caballero, Teresa/AAU-3982-2020	Caballero, Teresa/0000-0003-3005-9858; Caballero, Teresa/0000-0003-3005-9858				Cicardi M, 2003, MOL IMMUNOL, V40, P197; Williams A, 2003, TRANSFUS APHER SCI, V29, P255, DOI 10.1016/S1473-0502(03)00170-8; WILLIAMS T, 2005, J ALLERGY CLIN IMMUN, V115, pS181	3	39	40	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					476	477		10.1016/j.jaci.2005.10.045	http://dx.doi.org/10.1016/j.jaci.2005.10.045			2	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IM	16461161				2022-12-18	WOS:000235687300042
J	Koch, S; Kohl, K; Klein, E; von Bubnoff, D; Bieber, T				Koch, S; Kohl, K; Klein, E; von Bubnoff, D; Bieber, T			Skin homing of Langerhans cell precursors: Adhesion, chemotaxis, and migration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Langerhans cell; adhesion; migration; chemotaxis; matrix metalloproteinases	DENDRITIC CELLS; MATRIX METALLOPROTEINASES; CRITICAL STEP; IN-VITRO; CHEMOKINES; TRAFFICKING; INVOLVEMENT; ACTIVATION; MECHANISMS; EXPRESSION	Langerhans cells (LCs) are epidermal antigen-presenting dendritic cells. They contain unique granules, known as Birbeck granules, which are substructures of the endosornal recycling compartment. LCs migrate from the epidermis to the regional lymph nodes for presentation of antigenic peptides to T cells. There LCs either initiate a primary immune response or induce antigen-specific tolerance. The replenishment of the LC pool in the epidermis is the topic of this review. Chemokines produced by epidermal keratinocytes and by dermal fibroblasts guide the arrest of LC precursors on endothelial cells of dermal venules, followed by their transmigration through endothelium and dermis toward the epidermis. One necessary prerequisite for this is the coordinated expression of adhesion receptors and counterreceptors on LC precursors and on endothelial and dermal cells. LC precursors attach to and degrade basement membrane proteins to penetrate the dermal matrix and the basement membrane of the dermal-epidermal junction. LC migration depends on the activity of matrix metalloproteinases, which are proteolytic endopeptidases cleaving matrix components. Matrix metalloproteinases also execute an important role in modulating inflammatory and immune responses by processing chemokines, which turns then) into dual players for the immigration of LC precursors into the epidermis.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany	University of Bonn	Koch, S (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Susanne.koch@ukb.uni-bonn.de						Bazzoni G, 2003, CURR OPIN CELL BIOL, V15, P525, DOI 10.1016/S0955-0674(03)00104-2; Chen Z, 2002, BIOCHEM BIOPH RES CO, V290, P66, DOI 10.1006/bbrc.2001.6147; Ferrero E, 2003, BLOOD, V101, P186, DOI 10.1182/blood-2002-03-0768; Fritsche J, 2003, IMMUNOLOGY, V110, P450, DOI 10.1111/j.1365-2567.2003.01754.x; Imhof BA, 2004, NAT REV IMMUNOL, V4, P432, DOI 10.1038/nri1375; Kanitakis J, 2004, NEW ENGL J MED, V351, P2661, DOI 10.1056/NEJM200412163512523; Kobayashi Y, 1999, J IMMUNOL, V163, P5989; Koh K, 2004, EUR J CELL BIOL, V83, P805, DOI 10.1078/0171-9335-00426; Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310; Ley K, 2003, MICROCIRCULATION, V10, P289, DOI 10.1038/sj.mn.7800194; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47; Muller WA, 2003, TRENDS IMMUNOL, V24, P327, DOI 10.1016/S1471-4906(03)00117-0; Noirey N, 2002, EUR J CELL BIOL, V81, P383, DOI 10.1078/0171-9335-00252; Nomura L, 2003, J ALLERGY CLIN IMMUN, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Ono SJ, 2003, J ALLERGY CLIN IMMUN, V111, P1185, DOI 10.1067/mai.2003.1594; Opdenakker G, 2001, TRENDS IMMUNOL, V22, P571, DOI 10.1016/S1471-4906(01)02023-3; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Partida-Sanchez S, 2004, IMMUNITY, V20, P279, DOI 10.1016/S1074-7613(04)00048-2; Ratzinger G, 2002, J IMMUNOL, V168, P4361, DOI 10.4049/jimmunol.168.9.4361; Reymond N, 2004, J EXP MED, V199, P1331, DOI 10.1084/jem.20032206; Rosenzwajg M, 2000, BLOOD, V95, P453, DOI 10.1182/blood.V95.2.453; Schenkel AR, 2004, NAT IMMUNOL, V5, P393, DOI 10.1038/ni1051; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Sebastiani S, 2002, J INVEST DERMATOL, V118, P1052, DOI 10.1046/j.1523-1747.2002.01771.x; Sharp LL, 2005, CRIT REV IMMUNOL, V25, P1, DOI 10.1615/CritRevImmunol.v25.i1.10; Sozzani S, 2000, J CLIN IMMUNOL, V20, P151, DOI 10.1023/A:1006659211340; van Gisbergen KPJM, 2005, J EXP MED, V201, P1281, DOI 10.1084/jem.20041276; Vermaelen KY, 2003, J IMMUNOL, V171, P1016, DOI 10.4049/jimmunol.171.2.1016; Weis M, 2002, ARTERIOSCL THROM VAS, V22, P1817, DOI 10.1161/01.ATV.0000036418.04998.D5; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zen K, 2004, MOL BIOL CELL, V15, P3926, DOI 10.1091/mbc.E04-04-0317	33	39	42	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2006	117	1					163	168		10.1016/j.jaci.2005.10.003	http://dx.doi.org/10.1016/j.jaci.2005.10.003			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IK	16387601				2022-12-18	WOS:000235687100026
J	Sturm, GJ; Schuligoi, R; Sturm, EM; Royer, JF; Lang-Loidolt, D; Stammberger, H; Amann, R; Peskar, BA; Heinemann, A				Sturm, GJ; Schuligoi, R; Sturm, EM; Royer, JF; Lang-Loidolt, D; Stammberger, H; Amann, R; Peskar, BA; Heinemann, A			5-oxo-6,8,11,14-eicosatetraenoic acid is a potent chemoattractant for human basophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; chemoattractants; eicosanoids; allergy; chemotaxis; Ca2+ flux	PROSTAGLANDIN D-2; HUMAN EOSINOPHILS; BLOOD BASOPHILS; HUMAN MONOCYTES; GROWTH-FACTOR; RESPONSES; CHEMOKINES; EXPRESSION; EOTAXIN; CALCIUM	Background: 5-Oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) is a chemoattractant for eosinophils and neutrophils, and the messenger RNA for its receptor, the oxo-eicosatetraenoic acid receptor (OXE), has been detected in several tissues. Objectives: This study aimed at clarifying the role of 5-oxo-ETE in the regulation of basophil function. Methods: Basophil responses were determined in assays of flow-cytometric shape change, Ca2+ flux, chemotaxis, and histamine release. Messenger RNA for OXE was detected by real-time PCR. Results: We observed that human eosinophils were 3 to 10 times more sensitive to 5-oxo-ETE than neutrophils in flow-cytometric shape change and Ca2+ flux assays, as estimated from the half-maximal responses of the cells. Basophils responded to 5-oxo-ETE in the shape change assay with a sensitivity similar to that of eosinophils. 5-Oxo-ETE was a weak inducer of Ca2+ flux in basophils and did not cause histamine release but was a highly effective chemoattractant for basophils in the low nanomolar concentration range in a pertussis toxin-sensitive manner. In agreement with these functional studies, the messenger RNA for the 5-oxo-ETE receptor, OXE, was detectable in basophils as in monocytes, eosinophils, and neutrophils, but not in fibroblasts. Specimens from sinus mucosa, tonsils, and adenoids also contained detectable levels of messenger RNA for OXE. Conclusion: Our data suggest that 5-oxo-ETE is potentially involved in the regulation of basophil recruitment and might hence be a useful therapeutic target in atopic disease.	Med Univ Graz, Dept Expt & Clin Pharmacol, A-8010 Graz, Austria; Med Univ Graz, Dept Environm Dermatol & Allergy, A-8010 Graz, Austria; Med Univ Graz, Dept Otorhinolaryngol, A-8010 Graz, Austria	Medical University of Graz; Medical University of Graz; Medical University of Graz	Heinemann, A (corresponding author), Med Univ Graz, Dept Expt & Clin Pharmacol, Univ Pl 4, A-8010 Graz, Austria.	akos.heinemann@meduni-graz.at	lang-loidolt, doris/AAS-5236-2020	Sturm, Eva/0000-0003-4898-884X; Heinemann, Akos/0000-0002-8554-2372	Austrian Science Fund FWF [P 16668] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Bryan SA, 2002, AM J RESP CRIT CARE, V165, P1602, DOI 10.1164/rccm.200111-059OC; CHARLESWORTH EN, 1989, J CLIN INVEST, V83, P1519, DOI 10.1172/JCI114047; COLUMBO M, 1995, J ALLERGY CLIN IMMUN, V95, P565, DOI 10.1016/S0091-6749(95)70319-5; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; Hartnell A, 2004, J IMMUNOL, V173, P6448, DOI 10.4049/jimmunol.173.10.6448; Heinemann A, 2000, J IMMUNOL, V165, P7224, DOI 10.4049/jimmunol.165.12.7224; Heinemann A, 2003, J IMMUNOL, V170, P4752, DOI 10.4049/jimmunol.170.9.4752; Heinemann A, 2003, PHARMACOLOGY, V67, P49, DOI 10.1159/000066786; Hevko JM, 2001, J PHARMACOL EXP THER, V296, P293; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Jones CE, 2003, MOL PHARMACOL, V63, P471, DOI 10.1124/mol.63.3.471; LIU MC, 1991, AM REV RESPIR DIS, V144, P51, DOI 10.1164/ajrccm/144.1.51; MACGLASHAN D, 1993, J IMMUNOL, V150, P980; Mercier F, 2004, AM J PHYSIOL-LUNG C, V287, pL631, DOI 10.1152/ajplung.00005.2004; Mochizuki M, 1998, J IMMUNOL, V160, P60; Monneret G, 2005, J PHARMACOL EXP THER, V312, P627, DOI 10.1124/jpet.104.074823; Muro S, 2003, J ALLERGY CLIN IMMUN, V112, P768, DOI 10.1016/S0091-6749(03)01888-8; OFlaherty JT, 1996, J BIOL CHEM, V271, P17821, DOI 10.1074/jbc.271.30.17821; OFLaherty JT, 1996, J IMMUNOL, V157, P336; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; PEREZ HD, 1989, J CLIN INVEST, V83, P1963, DOI 10.1172/JCI114105; Powell WS, 2005, PROG LIPID RES, V44, P154, DOI 10.1016/j.plipres.2005.04.002; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; SCHWENK U, 1995, J BIOL CHEM, V270, P15029, DOI 10.1074/jbc.270.25.15029; SKOFITSCH G, 1981, J CHROMATOGR, V226, P53, DOI 10.1016/S0378-4347(00)84205-X; Sozzani S, 1996, J IMMUNOL, V157, P4664; Stamatiou P, 1998, J CLIN INVEST, V102, P2165, DOI 10.1172/JCI1995; Stubbs VEL, 2002, J BIOL CHEM, V277, P26012, DOI 10.1074/jbc.M201803200; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Ulcar R, 2004, EUR J PHARMACOL, V501, P9, DOI 10.1016/j.ejphar.2004.08.003; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; Ying S, 1999, J IMMUNOL, V163, P3976; Zimpfer U, 2000, INFLAMM RES, V49, P633, DOI 10.1007/s000110050641	34	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1014	1019		10.1016/j.jaci.2005.08.001	http://dx.doi.org/10.1016/j.jaci.2005.08.001			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	017IG	16275369				2022-12-18	WOS:000235686700010
J	Faffe, DS; Flynt, L; Mellema, M; Moore, PE; Silverman, ES; Subramaniam, V; Jones, MR; Mizgerd, JP; Whitehead, T; Imrich, A; Panettieri, RA; Shore, SA				Faffe, DS; Flynt, L; Mellema, M; Moore, PE; Silverman, ES; Subramaniam, V; Jones, MR; Mizgerd, JP; Whitehead, T; Imrich, A; Panettieri, RA; Shore, SA			Oncostatin M causes eotaxin-1 release from airway smooth muscle: Synergy with IL-4 and IL-13	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						signal transducer and activator of transcription 3; extracellular signal-regulated kinase; c-Jun N-terminal kinase; IL-4R alpha; monocyte chemoattractant protein 1; vascular endothelial growth factor	LEUKEMIA INHIBITORY FACTOR; MYELOID PROGENITOR CELLS; FIBROBLASTS IN-VITRO; SIGNALING PATHWAYS; EPITHELIAL-CELLS; EOSINOPHILIC INFLAMMATION; CHEMOKINE RELEASE; INTERFERON-GAMMA; M RECEPTOR; EXPRESSION	Background: Eotaxin is implicated in asthmatic eosinophilia. Oncostatin M (OSM) causes eotaxin release from fibroblasts. Objective: We sought to examine the effects and mechanism of action of OSM and other IL-6 family cytokines on eotaxin release from human airway smooth muscle cells. Methods: Eotaxin 1 release was measured by means of ELISA. Western blotting was used to examine mitogen-activated protein kinase and signal transducer and activator of transcription 3 (STAT-3) phosphorylation. Eotaxin promoter activity was analyzed in cells transfected with wild-type STAT-3, a mutant form of STAT-3 that cannot be phosphorylated, and a constitutively active form of STAT-3. The mRNA and protein expression of IL-4R alpha, the signaling receptor for IL-4 and IL-13, was evaluated by means of real-time PCR and flow cytometry, respectively. Results: OSM increased eotaxin I release and augmented IL-4-or IL-13-induced eotaxin release, whereas other IL-6 family cytokines did not. OSM caused a greater increase in STAT-3 phosphorylation and STAT-3-mediated gene transcription than other IL-6 family cytokines. OSM increased eotaxin promoter activity and augmented IL-13- and IL-4-induced increases in promoter activity. The constitutively active form of STAT-3 increased eotaxin promoter activity, whereas the mutant form of STAT-3 that cannot be phosphorylated significantly reduced eotaxin promoter activity induced by OSM or IL-4 plus OSM. OSM increased IL-4R alpha mRNA and protein levels. Conclusions: OSM induces eotaxin 1 expression in human airway smooth muscle cells by a mechanism involving STAT-3. OSM synergizes with IL-13 and 11-4 to increase eotaxin I expression, possibly as a result of effects on IL-4Ra expression.	Harvard Univ, Sch Publ Hlth, Physiol Program, Boston, MA 02115 USA; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Respirat Physiol, BR-21941 Rio De Janeiro, Brazil; Vanderbilt Univ, Dept Pediat, Nashville, TN USA; Univ Penn, Dept Med, Div Pulm & Crit Care, Philadelphia, PA 19104 USA	Harvard University; Harvard T.H. Chan School of Public Health; Universidade Federal do Rio de Janeiro; Vanderbilt University; University of Pennsylvania	Shore, SA (corresponding author), Harvard Univ, Sch Publ Hlth, Physiol Program, 665 Huntington Ave, Boston, MA 02115 USA.	sshore@hsph.harvard.edu	panettieri, reynold/AAG-9485-2019; Mizgerd, Joseph/GRY-6369-2022	Jones, Matthew/0000-0003-4647-2962; Mizgerd, Joseph/0000-0002-4042-3169	NHLBI NIH HHS [K08 HL004395, R01 HL068153, HL67664, P01 HL067664, P50 HL067664, P01 HL033009, HL04395, HL33009, HL68153] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068153, P01HL033009, K08HL004395, P50HL067664, P01HL067664] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMARAL MC, 1993, J CLIN INVEST, V92, P848, DOI 10.1172/JCI116659; Baraldo S, 2003, AM J PHYSIOL-LUNG C, V284, pL1093, DOI 10.1152/ajplung.00300.2002; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BROWN TJ, 1987, J IMMUNOL, V139, P2977; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FELDMAN GM, 1991, BLOOD, V78, P1678; Fujii T, 2002, AM J RESP CELL MOL, V27, P34, DOI 10.1165/ajrcmb.27.1.4787; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; Grenier A, 1999, BLOOD, V93, P1413, DOI 10.1182/blood.V93.4.1413.404k06_1413_1421; Grenier A, 2001, LAB INVEST, V81, P133, DOI 10.1038/labinvest.3780220; Hallsworth MP, 2001, AM J RESP CRIT CARE, V164, P688, DOI 10.1164/ajrccm.164.4.2011004; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44, DOI 10.1016/S0091-6749(97)70193-3; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hermanns HM, 1999, J IMMUNOL, V163, P6651; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/ajrccm.165.8.2107158; Knight DA, 1999, AM J RESP CELL MOL, V20, P834, DOI 10.1165/ajrcmb.20.4.3429; Lahiri T, 2002, AM J PHYSIOL-LUNG C, V283, pL1239, DOI 10.1152/ajplung.00231.2001; Lahiri T, 2001, AM J PHYSIOL-LUNG C, V280, pL1225, DOI 10.1152/ajplung.2001.280.6.L1225; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Langdon C, 1997, ARTHRITIS RHEUM-US, V40, P2139, DOI 10.1002/art.1780401207; Langdon C, 2000, AM J PATHOL, V157, P1187, DOI 10.1016/S0002-9440(10)64634-2; Langdon C, 2003, J IMMUNOL, V170, P548, DOI 10.4049/jimmunol.170.1.548; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141, DOI 10.1164/ajrccm.164.1.2008060; Laporte JD, 2000, AM J PHYSIOL-LUNG C, V279, pL932, DOI 10.1152/ajplung.2000.279.5.L932; Laporte JD, 1999, AM J PHYSIOL-LUNG C, V277, pL943, DOI 10.1152/ajplung.1999.277.5.L943; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669, DOI 10.1164/ajrccm.163.7.9812044; Lin SK, 2004, ARTHRITIS RHEUM-US, V50, P785, DOI 10.1002/art.20058; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; Matsukura S, 2001, AM J RESP CELL MOL, V24, P755, DOI 10.1165/ajrcmb.24.6.4351; Matsukura S, 1999, J IMMUNOL, V163, P6876; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; Moore PE, 2002, AM J PHYSIOL-LUNG C, V282, pL847, DOI 10.1152/ajplung.00245.2001; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; O'Hara KA, 2003, CLIN EXP ALLERGY, V33, P1026, DOI 10.1046/j.1365-2222.2003.01714.x; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; Peng Q, 2004, AM J RESP CRIT CARE, V169, P596, DOI 10.1164/rccm.200307-888OC; Repovic P, 2002, J NEUROSCI, V22, P5334; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; RUHL S, 1993, CYTOKINE, V5, P144, DOI 10.1016/1043-4666(93)90053-8; Ruprecht K, 2001, J NEUROPATH EXP NEUR, V60, P1087, DOI 10.1093/jnen/60.11.1087; Suda T, 2002, CYTOKINE, V17, P335, DOI 10.1006/cyto.2002.1023; Tamura S, 2002, DEV DYNAM, V225, P327, DOI 10.1002/dvdy.10156; Wang YP, 2000, J BIOL CHEM, V275, P25273, DOI 10.1074/jbc.M002296200; Weiss TW, 2003, CARDIOVASC RES, V59, P628, DOI 10.1016/S0008-6363(03)00463-2	49	39	40	2	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					514	520		10.1016/j.jaci.2004.11.033	http://dx.doi.org/10.1016/j.jaci.2004.11.033			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	907AN	15753898				2022-12-18	WOS:000227687000013
J	Singh, J; Schwartz, DA				Singh, J; Schwartz, DA			Endotoxin and the lung: Insight into the host-environment interaction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; LPS; asthma; allergy; COPD; hygiene; T(H)1; T(H)2; genetics; genomics; polymorphisms; innate immunity; TLR	HOUSE-DUST ENDOTOXIN; LIPOPOLYSACCHARIDE EXPOSURE; ASTHMA; CHILDREN; ATOPY; POLYMORPHISM; RESPONSES; SEVERITY; INJURY; RISK	Understanding the pathophysiology and basic mechanisms of asthma and chronic obstructive pulmonary disease (COPD) has been an intense source of investigation over the years. For decades, research in these fields has focused on the control of inflammation. However, new evidence has emerged demonstrating that airway inflammation is just the surface of a more complex pathobiological relationship between the disease and its host. Specifically, the relationship is a unique interaction of one's genetic background and the environment. The airway response to inhaled endotoxin serves as an effective model for studying the pathobiology of asthma as well as the importance of host genetic susceptibility. In this review, we provide a brief overview on the role of endotoxin in asthma and COPD, highlighting a few of the major discoveries, but also discussing future directions.	Duke Univ, Ctr Med, Dept Med, Durham, NC 27710 USA; Durham Dept Vet Affairs, Ctr Med, Durham, NC USA	Duke University	Singh, J (corresponding author), Duke Univ, Ctr Med, Dept Med, Durham, NC 27710 USA.	Jaspal.Singh@duke.edu			NIEHS NIH HHS [ES07498, ES012496, ES011961, ES11375] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES011961, R01ES007498, U19ES011375] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Boehlecke B, 1999, AM J RESP CRIT CARE, V159, pA699; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Calvani M, 2002, EUR RESPIR J, V20, P391, DOI 10.1183/09031936.02.00274502; Cardoso MRA, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-19; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Cochran JR, 2002, PEDIATR PULM, V34, P267, DOI 10.1002/ppul.10161; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Domenici L, 2004, PATHOBIOLOGY, V71, P59, DOI 10.1159/000074418; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965, DOI 10.1164/ajrccm.163.4.2004164; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 2003, J ENDOTOXIN RES, V9, P293, DOI 10.1179/096805103225002539; Montealegre F, 2004, J ASTHMA, V41, P485, DOI 10.1081/JAS-120033993; Mueller-Anneling L, 2004, ENVIRON HEALTH PERSP, V112, P583, DOI 10.1289/ehp.6552; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591, DOI 10.1164/ajrccm.163.7.2009111; Park JH, 2001, AM J RESP CRIT CARE, V163, P322, DOI 10.1164/ajrccm.163.2.2002088; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rccm.200207-634OC; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981, DOI 10.1164/ajrccm/140.4.981; SCHWARTZ DA, 1992, ANN INTERN MED, V116, P630, DOI 10.7326/0003-4819-116-8-630; SIGSGAARD T, 1992, AM J IND MED, V22, P163, DOI 10.1002/ajim.4700220204; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152, DOI 10.1165/ajrcmb.26.1.4652; Yang IA, 2004, GENES IMMUN, V5, P41, DOI 10.1038/sj.gene.6364037; Zaas D, 2003, SEMIN RESP CRIT CARE, V24, P185, DOI 10.1055/s-2003-39017	33	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					330	333		10.1016/j.jaci.2004.11.021	http://dx.doi.org/10.1016/j.jaci.2004.11.021			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696090				2022-12-18	WOS:000227043600019
J	Sutherland, ER; Make, BJ; Vedal, S; Zhang, LN; Dutton, SJ; Murphy, JR; Silkoff, PE				Sutherland, ER; Make, BJ; Vedal, S; Zhang, LN; Dutton, SJ; Murphy, JR; Silkoff, PE			Wildfire smoke and respiratory symptoms in patients with chronic obstructive pulmonary disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							AIR-POLLUTION; MEXICO-CITY; EXPOSURE; ADMISSIONS; MORTALITY		Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80202 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80202 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sutherland, ER (corresponding author), 1400 Jackson St,J217, Denver, CO 80206 USA.		Sutherland, Everett Rand/B-7666-2008; Dutton, Steven J/C-5912-2011; silkoff, philip/S-9037-2016	silkoff, philip/0000-0001-6018-5199				Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; Bravo AH, 2002, ENVIRON POLLUT, V117, P243, DOI 10.1016/S0269-7491(01)00277-9; Ebelt ST, 2000, J AIR WASTE MANAGE, V50, P1081, DOI 10.1080/10473289.2000.10464166; Johnston FH, 2002, MED J AUSTRALIA, V176, P535, DOI 10.5694/j.1326-5377.2002.tb04551.x; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701, DOI 10.1164/ajrccm.154.3.8810608; Pope CA, 1996, ENVIRON HEALTH PERSP, V104, P414, DOI 10.2307/3432686; SUNYER J, 1993, AM J EPIDEMIOL, V137, P701, DOI 10.1093/oxfordjournals.aje.a116730; Tellez-Rojo MM, 2000, EUR RESPIR J, V16, P391, DOI 10.1034/j.1399-3003.2000.016003391.x	9	39	40	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					420	422		10.1016/j.jaci.2004.11.030	http://dx.doi.org/10.1016/j.jaci.2004.11.030			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	897YU	15696107				2022-12-18	WOS:000227043600035
J	Barnes, N; Thomas, M; Price, D; Tate, H				Barnes, N; Thomas, M; Price, D; Tate, H			The national montelukast survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						montelukast; survey; retrospective	INHALED BECLOMETHASONE; ORAL MONTELUKAST; CONTROLLED-TRIAL; ASTHMA; THERAPY; CHILDREN; ANTAGONISTS; BUDESONIDE; ADULTS	Background: Randomized controlled trials have demonstrated the efficacy of montelukast for treating asthma; whether this can be extrapolated to clinical effectiveness in routine practice has yet to be established. Objective: To examine the use, effectiveness, and tolerability of montelukast in clinical practice for treating asthma and to explore prognostic factors that could predict a favorable response to the drug. Methods: This was a retrospective, cross-sectional, observational study of clinical outcomes seen in patients prescribed montelukast for asthma that used routinely collected clinical information. Data were collected on all consenting patients who had been prescribed montelukast for asthma irrespective of the continuation or duration of treatment. Independent observers, treating physicians, and patients assessed certain outcomes after the initiation of montelukast, including the general asthma response and changes in activity-related symptoms. Results: Fifty-six centers in the United Kingdom (20 primary care and 36 secondary care) participated. The analysis was based on 1351 eligible patients for whom essential data were available. Eight hundred thirty patients (66.4%; 95% CI, 63.8% to 69.0%) were recorded as having shown an improvement in their asthma control, and 103 (8.2%; 95% CI, 6.8% to 9.9%) experienced a dramatic improvement. The greatest proportion of patients responding was seen in those with mild to moderate asthma. Montelukast was well tolerated; no new adverse events were recorded. Conclusions: Montelukast is an effective, well-tolerated treatment for asthma in routine practice. The overall response rate and tolerability seen in this survey are similar to those reported in randomized clinical trials.	London Chest Hosp, London E2 9JX, England; Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB9 1FX, Scotland; Univ Aberdeen, Gen Practice Airways Grp, Dept Gen Practice & Primary Care, Aberdeen AB9 1FX, Scotland; New House Farm, Debden, Essex, England	University of London; Queen Mary University London; University of Aberdeen; University of Aberdeen	Tate, H (corresponding author), Merck Sharp & Dohme Ltd, Hertford Rd, Hoddesdon EN11 9BU, Herts, England.	helen_tate@merck.com	Price, David/H-2837-2019	Price, David/0000-0002-9728-9992; Thomas, Mike/0000-0001-5939-1155				BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Helms PJ, 2002, PEDIAT ALLERG IMM-UK, V13, P4, DOI 10.1034/j.1399-3038.2002.00194.x; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; LINDGREN S, 1987, EUR J RESPIR DIS, V70, P93; Maspero JF, 2001, CURR MED RES OPIN, V17, P96, DOI 10.1185/0300799039117037; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Pearson M, 2004, J EVAL CLIN PRACT, V10, P297, DOI 10.1111/j.1365-2753.2003.00434.x; Price DB, 2003, THORAX, V58, P211, DOI 10.1136/thorax.58.3.211; Radford MJ, 2001, JAMA-J AM MED ASSOC, V286, P1228, DOI 10.1001/jama.286.10.1228; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Sampson A, 1998, BRIT MED J, V316, P1257, DOI 10.1136/bmj.316.7140.1257; Thomas M, 2003, EXPERT OPIN PHARMACO, V4, P351, DOI 10.1517/14656566.4.3.351; Thomson NC, 2003, THORAX, V58, P190, DOI 10.1136/thorax.58.3.190; Vaquerizo MJ, 2003, THORAX, V58, P204, DOI 10.1136/thorax.58.3.204; Williams B, 2001, CLIN EXP ALLERGY, V31, P845, DOI 10.1046/j.1365-2222.2001.01085.x; 2004, PREVALENCE ASTHMA TR	19	39	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					47	54		10.1016/j.jaci.2004.10.011	http://dx.doi.org/10.1016/j.jaci.2004.10.011			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	886XS	15637546	Bronze			2022-12-18	WOS:000226267000006
J	MacGlashan, D				MacGlashan, D			Loss of receptors and IgE in vivo during treatment with anti-IgE antibody	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							FC-EPSILON-RI; HUMAN BASOPHILS; EXPRESSION		Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	MacGlashan, D (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol & Allergy, Baltimore, MD 21224 USA.							Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Ong Y., 2004, Journal of Allergy and Clinical Immunology, V113, pS84, DOI 10.1016/j.jaci.2003.12.280; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003	7	39	41	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1472	1474		10.1016/j.jaci.2004.07.064	http://dx.doi.org/10.1016/j.jaci.2004.07.064			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	877NN	15577855				2022-12-18	WOS:000225577400034
J	Feistritzer, C; Mosheimer, BA; Sturn, DH; Bijuklic, K; Patsch, JR; Wiedermann, CJ				Feistritzer, C; Mosheimer, BA; Sturn, DH; Bijuklic, K; Patsch, JR; Wiedermann, CJ			Expression and function of the angiopoietin receptor Tie-2 in human eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophils; vascular endothelial growth factor; angiopoietin; asthma	ENDOTHELIAL GROWTH-FACTOR; BLOOD-VESSEL FORMATION; TYROSINE KINASE; OVEREXPRESSING ANGIOPOIETIN-1; G(BETA-GAMMA) SUBUNITS; ASTHMATIC-PATIENTS; TRANSGENIC MICE; GENE-EXPRESSION; INDUCED SPUTUM; CELLS	Background: Increased vascularity of bronchial mucosa is closely related to the expression of angiogenic factors, which contribute to the pathogenesis of diseases such as asthma bronchiale. Objective: Here we examine the effects of the angiogenic growth factors angiopoietin 1 and angiopoietin 2 on eosinophil function in vitro and possible involvement of the angiopoietin receptor Tie-2. Methods: Eosinophil migration was studied by micropore filter assays. Signaling mechanisms required for angiopoietin-dependent migration were tested by using signaling enzyme blockers. Tie-2 mRNA and receptor expression on the cell surface of eosinophils was demonstrated in RT-PCR and by fluorescence-activated cell sorting analysis. Results: Angiopoietin I significantly stimulated eosinophil chemotaxis via activation of phosphodiesterase, phosphatidylinositol 3'-kinase, and tyrosine kinases. The effect on eosinophil migration of angiopoietin I was reversed by an antibody against the Tie-2 receptor and by angiopoietin 2. Incubation of eosinophils with angiopoietin 1 abolished the chemotactic effects of vascular endothelial growth factor on human eosinophils via the Tie-2 receptor. Finally, Tie-2 expression by human eosinophils was demonstrated on the transcriptional and protein level. Conclusions: Data suggest that angiopoietin I stimulates directed migration and possibly inhibits vascular endothelial growth factor-induced eosinophil chemotaxis via its Tie-2 receptor, which is expressed by eosinophils. Thus, angiopoietin 1 may play an important role in the modulation of eosinophilic inflammation.	Med Univ Innsbruck, Dept Internal Med, Div Gen Internal Med, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Wiedermann, CJ (corresponding author), Med Univ Innsbruck, Dept Internal Med, Div Gen Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.	christian.wiedermann@uibk.ac.at	Wiedermann, Christian J./ABG-9521-2020					ABOOD ME, 1982, J BIOL CHEM, V257, P540; Asai K, 2003, CLIN EXP ALLERGY, V33, P595, DOI 10.1046/j.1365-2222.2003.01576.x; Asai K, 2002, J ALLERGY CLIN IMMUN, V110, P571, DOI 10.1067/mai.2002.127797; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Boulay ME, 2003, CHEST, V123, p430S, DOI 10.1378/chest.123.3_suppl.430S; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chong AY, 2004, J AM COLL CARDIOL, V43, P423, DOI 10.1016/j.jacc.2003.08.042; Daly C, 2004, GENE DEV, V18, P1060, DOI 10.1101/gad.1189704; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; Dunzendorfer S, 2000, IMMUNOL LETT, V71, P5, DOI 10.1016/S0165-2478(99)00161-3; Dunzendorfer S, 1998, BLOOD, V91, P1527, DOI 10.1182/blood.V91.5.1527.1527_1527_1532; Feistritzer C, 2004, AM J RESP CELL MOL, V30, P729, DOI 10.1165/rcmb.2003-0314OC; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Hallak H, 2000, J BIOL CHEM, V275, P2255, DOI 10.1074/jbc.275.4.2255; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; Kaser A, 1999, J IMMUNOL, V163, P3232; Kim I, 2001, CIRC RES, V89, P477, DOI 10.1161/hh1801.097034; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39, DOI 10.1164/ajrccm.164.supplement_2.2106065; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Sato A, 1998, INT IMMUNOL, V10, P1217, DOI 10.1093/intimm/10.8.1217; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schratzberger P, 1998, CARDIOVASC RES, V38, P516, DOI 10.1016/S0008-6363(98)00014-5; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Wang YH, 2004, J CELL PHYSIOL, V198, P53, DOI 10.1002/jcp.10386; Wardlaw AJ, 1995, ADV IMMUNOL, V60, P151, DOI 10.1016/S0065-2776(08)60586-6; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	42	39	41	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1077	1084		10.1016/j.jaci.2004.06.045	http://dx.doi.org/10.1016/j.jaci.2004.06.045			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	870HI	15536413	Bronze			2022-12-18	WOS:000225047800013
J	Szema, AM; Khedkar, M; Maloney, PF; Takach, PA; Nickels, MS; Patel, H; Modugno, F; Tso, AY; Lin, DH				Szema, AM; Khedkar, M; Maloney, PF; Takach, PA; Nickels, MS; Patel, H; Modugno, F; Tso, AY; Lin, DH			Clinical deterioration in pediatric asthmatic patients after September 11, 2001	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pediatric; world trade center; September 11, 2001; peakflow	OUTDOOR AIR-POLLUTION; FINE PARTICULATE MATTER; RESPIRATORY HEALTH; CLIMATIC CHANGES; CHILDREN; FIREFIGHTERS	Background: New York City residents were exposed to a variety of inhaled substances after the collapse of the World Trade Center. Exposure to these substances might lead to an increase in asthma severity, with residential distance from Ground Zero predictive of the degree of change. Objective: We sought to assess the effect of the World Trade Center collapse on local pediatric asthmatic patients. Methods: We retrospectively reviewed the charts of 205 pediatric patients with established asthma from a clinic in lower Manhattan's Chinatown. Clinical data were obtained for the year before and the year after September 11, 2001. Measurements included numbers of visits, asthma medication prescriptions, oral corticosteroid prescriptions, weekly doses of rescue inhaler, and peak expiratory flow rates. Residential zip codes were used to compare the asthma severity of patients living within and beyond a 5-mile radius of Ground Zero. Results: After September 11, 2001, these children had more asthma-related clinic visits (P = .002) and received more prescriptions for asthma medications (P = .018). No significant differences in oral steroid or rescue inhaler use were noted. Those living within 5 miles had more clinic visits after September 11, 2001 (P = .013); the increase in clinic visits for patients living more than 5 miles from Ground Zero was not significant. Mean percent predicted peak expiratory flow rates decreased solely for those patients living within 5 miles of Ground Zero during the 3 months after September 11, 2001. Conclusions: Asthma severity worsened after September 11, 2001, in pediatric asthmatic patients living near Ground Zero. Residential proximity to Ground Zero was predictive of the degree of decrease in asthma health.	SUNY Stony Brook, Sch Med, Ctr Asthma & Allergy, Dept Med, Stony Brook, NY 11794 USA; Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; Charles B Wang Community Hlth Ctr, New York, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Szema, AM (corresponding author), SUNY Stony Brook, Sch Med, Ctr Asthma & Allergy, Dept Med, T16,Room 041, Stony Brook, NY 11794 USA.							Banauch GI, 2003, AM J RESP CRIT CARE, V168, P54, DOI 10.1164/rccm.200211-1329OC; BEHRMAN RE, 2000, NELSON TXB PEDIAT, P666; Busse WW, 2002, J ALLERGY CLIN IMMUN, V110, P703, DOI 10.1067/mai.2002.129368; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P781; Chen H, 2003, COMMUNITY MENT HLT J, V39, P157, DOI 10.1023/A:1022614821300; Chen JP, 2002, WESTERN J MED, V176, P239; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; D'Amato G, 2002, EUR RESPIR J, V20, P763, DOI 10.1183/09031936.02.00401402; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587, DOI 10.1164/ajrccm/139.3.587; Galea S, 2002, NEW ENGL J MED, V346, P982, DOI 10.1056/NEJMsa013404; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P981, DOI 10.1289/ehp.5931; Goldsmith Carroll-Ann W., 1999, Reviews on Environmental Health, V14, P121; Higgins BG, 2000, EUR RESPIR J, V16, P61, DOI 10.1034/j.1399-3003.2000.16a11.x; Just J, 2002, EUR RESPIR J, V20, P899, DOI 10.1183/09031936.02.00236902; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703, DOI 10.1289/ehp.02110703; McGee JK, 2003, ENVIRON HEALTH PERSP, V111, P972, DOI 10.1289/ehp.5930; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; *NIH, 1997, NIH PUBL; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12, DOI 10.1016/S1081-1206(10)62334-4; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Teague WG, 2001, PEDIATR CLIN N AM, V48, P1167, DOI 10.1016/S0031-3955(05)70367-9; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802, DOI 10.1136/oem.56.12.802; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Voter K Z, 1996, Pediatr Rev, V17, P53, DOI 10.1542/pir.17-2-53; Yeung A, 2002, WESTERN J MED, V176, P253; 1999, ENV HLTH PERSPECT, V107, pA617	28	39	39	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					420	426		10.1016/j.jaci.2003.12.015	http://dx.doi.org/10.1016/j.jaci.2003.12.015			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007340				2022-12-18	WOS:000220144200011
J	Tsicopoulos, A; Shimbara, A; de Nadai, P; Aldewachi, O; Lamblin, C; Lassalle, P; Walls, AF; Senechal, S; Levitt, RC; Darras, J; Hamid, Q; Wallaert, B				Tsicopoulos, A; Shimbara, A; de Nadai, P; Aldewachi, O; Lamblin, C; Lassalle, P; Walls, AF; Senechal, S; Levitt, RC; Darras, J; Hamid, Q; Wallaert, B			Involvement of IL-9 in the bronchial phenotype of patients with nasal polyposis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nasal polyposis; bronchial hyperresponsiveness; asthma; interleukin-9; bronchial biopsy	EOTAXIN RECEPTOR CCR3; AIRWAY HYPERRESPONSIVENESS; PULMONARY INFLAMMATION; EPITHELIAL-CELLS; MESSENGER-RNA; INTERLEUKIN 9; MAST-CELLS; EXPRESSION; ALLERGEN; BASOPHILS	Background: Nasal polyposis (NP) is frequently associated with asthma. In this disease, asymptomatic bronchial hyperresponsiveness (BHR) is thought to precede the development of asthma. IL-9 and its receptor have been reported as candidate genes for asthma and to be associated with BHR. Objective: The objective of this study was to assess the contribution of IL-9 to the pathogenesis of BHR in NP by comparing the expression of IL-9 and its receptor in bronchial biopsy specimens from three groups of patients with NP : NP without BHR, NP with asymptomatic BHR, and NP and BHR and asthma. Methods: Bronchial biopsy specimens were examined in terms of cellular infiltration and in terms of expression of IL-9 protein and mRNA as well as its receptor by using immunohistochemistry and in situ hybridization. Results: Patients with NP with asthma as compared with two other groups exhibited and an increased bronchial infiltration of basophils, eosinophils, and T cells that correlated with the asthma score. The two groups of patients with NP with BHR showed an increase in the expression of IL-9 mRNA at the epithelial level. These modifications were inversely correlated with the airway responsiveness to methacholine, producing a 20% fall in FEV1. There was a close association between IL-9(+) cells , IL-5 mRNA expression, and eosinophil infiltration that correlated with each other. Conclusions: These results suggest an important role for IL-9 in the pathogenesis of BHR and a causal relation between IL-9 and the development of bronchial eosinphilia in asthma.	Inst Pasteur, INSERM U416, F-59019 Lille, France; CHRU, Clin Malad Resp, Lille, France; CHRU, Serv Otorhinolaryngol, Lille, France; Genaera Corp, Plymouth Meeting, PA USA; Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO9 4XY, Hants, England; McGill Univ, Meakins Christie Labs, Montreal, PQ H3A 2T5, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; CHU Lille; University of Southampton; McGill University	Tsicopoulos, A (corresponding author), Inst Pasteur, INSERM U416, BP245, F-59019 Lille, France.		Lassalle, Philippe/L-6705-2018; Tsicopoulos, Anne/C-2260-2019	Tsicopoulos, Anne/0000-0002-1579-2763; lassalle, philippe/0000-0001-6434-0344; de NADAI, Patricia/0000-0001-6084-7447				*AM THOR SOC, 1987, AM REV RESPIR DIS, V1365, P225; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; Cheng G, 2002, AM J RESP CRIT CARE, V166, P409, DOI 10.1164/rccm.2105079; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dong Q, 1999, EUR J IMMUNOL, V29, P2130, DOI 10.1002/(SICI)1521-4141(199907)29:07<2130::AID-IMMU2130>3.0.CO;2-S; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280, DOI 10.1164/ajrccm.153.4.8616554; DRUEZ C, 1990, J IMMUNOL, V145, P2494; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; Godfraind C, 1998, J IMMUNOL, V160, P3989; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Holroyd KJ, 1998, GENOMICS, V52, P233, DOI 10.1006/geno.1998.5445; HOPP RJ, 1990, AM REV RESPIR DIS, V141, P2, DOI 10.1164/ajrccm/141.1.2; HURD S, 1992, EUR RESPIR J, V5, P115; Jansen DF, 1997, RESP MED, V91, P121, DOI 10.1016/S0954-6111(97)90048-2; Kung TT, 2001, AM J RESP CELL MOL, V25, P600, DOI 10.1165/ajrcmb.25.5.4533; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lamblin C, 2000, AM J RESP CRIT CARE, V161, P406, DOI 10.1164/ajrccm.161.2.9905075; Lamblin C, 2001, AM J RESP CRIT CARE, V163, P1226, DOI 10.1164/ajrccm.163.5.2004197; Larsen K, 1996, ALLERGY ASTHMA PROC, V17, P243, DOI 10.2500/108854196778662255; Little FF, 2001, AM J RESP CELL MOL, V25, P347, DOI 10.1165/ajrcmb.25.3.4349; Louahed J, 2001, BLOOD, V97, P1035, DOI 10.1182/blood.V97.4.1035; McEuen AR, 1999, LAB INVEST, V79, P27; McLane MP, 1998, AM J RESP CELL MOL, V19, P713, DOI 10.1165/ajrcmb.19.5.3457; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; Perdow-Hickman S, 2000, J INTERF CYTOK RES, V20, P603, DOI 10.1089/10799900050044804; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; QUANJER PH, 1993, EUR RESPIR J, V6, P5, DOI 10.1183/09041950.005s1693; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353, DOI 10.1002/jlb.57.3.353; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Shimbara A, 2000, J ALLERGY CLIN IMMUN, V105, P108, DOI 10.1016/S0091-6749(00)90185-4; SODERBERG M, 1993, ALLERGY, V48, P173, DOI 10.1111/j.1398-9995.1993.tb00709.x; SOUSSIGOUNNI A, 2001, J IMMUNOL, V166, P2768; SOUSSIGOUNNI A, 2000, BLOOD, V96, P2163; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Ying S, 1999, J IMMUNOL, V163, P3976	45	39	42	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					462	469		10.1016/j.jaci.2003.12.009	http://dx.doi.org/10.1016/j.jaci.2003.12.009			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	802DM	15007348	Bronze			2022-12-18	WOS:000220144200018
J	Kao, SH; Hsu, CH; Su, SN; Hor, WT; Chang, WHT; Chow, LP				Kao, SH; Hsu, CH; Su, SN; Hor, WT; Chang, WHT; Chow, LP			Identification and immunologic characterization of an allergen, alliin lyase, from garlic (Allium sativum)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						proteomics; allergen; lectin-binding reactivity; cross-reactivity; alliin lyase; garlic; Allium sativum	OCCUPATIONAL ASTHMA; CDNA CLONING; BIOCHEMICAL-CHARACTERIZATION; DERMATITIS; ONION; STANDARDIZATION; EXPRESSION; ASPARAGUS; INGESTION; URTICARIA	Background: Garlic (Allium sativum) is one of the most common relishes used in cooking worldwide. Very few garlic allergens have been reported, and garlic allergy has been rarely studied. Objective: The aim of the study was to identify allergenic proteins in garlic and to investigate their importance in allergies to other Allium species (leek, shallot, and onion). Methods: A crude extract of garlic proteins was separated by SDS-PAGE and 2-dimensional electrophoresis; immunoblotting was then performed with the use of individual and pooled sera from patients with garlic allergy, and the major IgE-binding proteins were analyzed by amino acid sequencing and mass spectrometry. The putative allergens were further purified by chromatography; the antigenicity, allergenicity, and IgE-binding cross-reactivity of the purified protein were then studied by immunoblotting, periodate oxidation, skin tests, and IgE-binding inhibition assays. Results: A major allergen, alliin lyase, was identified by mass spectrometry and Edman sequencing and purified to homogeneity through the use of a simple 2-step chromatographic method. Skin tests showed that the purified protein elicited IgE-mediated hypersensitive responses in patients with garlic allergy. Periodate oxidation showed that carbohydrate groups were involved in the antigenicity, allergenicity, and cross-reactivity. Garlic alliin lyase showed strong cross-reactivity with alliin lyases from other Allium species, namely leek, shallot, and onion. Conclusions: Alliin lyase was found to be a major garlic allergen in a garlic-allergic group of patients in Taiwan. The wide distribution of alliin lyase in Allium suggests it may be a new cross-reactive allergen.	Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 100, Taiwan; China Med Coll, Dept Pediat, Taichung, Taiwan; Vet Gen Hosp Taipei, Dept Med Res & Educ, Taipei, Taiwan; Gods Help Hosp, Dept Pediat, Chiayi, Taiwan; Natl Taiwan Univ Hosp, Dept Med Genet, Taipei, Taiwan	National Taiwan University; China Medical University Taiwan; National Taiwan University; National Taiwan University Hospital	Chow, LP (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, 1,Sec 1 Jen Ai Rd, Taipei 100, Taiwan.		Kao, Shao-Hsuan/I-3875-2019	CHOW, LU-PING/0000-0002-4420-211X				ADETUMBI MA, 1983, MED HYPOTHESES, V12, P227, DOI 10.1016/0306-9877(83)90040-3; Anibarro B, 1997, J ALLERGY CLIN IMMUN, V100, P734, DOI 10.1016/S0091-6749(97)70266-5; Asero R, 2001, J ALLERGY CLIN IMMUN, V108, P309, DOI 10.1067/mai.2001.116983; Asero R, 1998, J ALLERGY CLIN IMMUN, V101, P427, DOI 10.1016/S0091-6749(98)70261-1; Burks W, 2002, ANN NY ACAD SCI, V964, P1; Cadot P, 2001, ALLERGY, V56, P192, DOI 10.1034/j.1398-9995.2001.056002192.x; Chow LP, 1999, BIOCHEM J, V341, P51, DOI 10.1042/0264-6021:3410051; CRONIN E, 1987, CONTACT DERMATITIS, V17, P265, DOI 10.1111/j.1600-0536.1987.tb01475.x; Escribano MM, 1998, ALLERGY, V53, P622, DOI 10.1111/j.1398-9995.1998.tb03942.x; EWAN PW, 1990, ALLERGY, V45, P22, DOI 10.1111/j.1398-9995.1990.tb01080.x; FALLERONI AE, 1981, J ALLERGY CLIN IMMUN, V68, P159; Hiemori M, 2000, INT ARCH ALLERGY IMM, V122, P238, DOI 10.1159/000024404; Iacovacci P, 2001, CLIN EXP ALLERGY, V31, P458, DOI 10.1046/j.1365-2222.2001.01019.x; Kanerva L, 1996, CONTACT DERMATITIS, V35, P157, DOI 10.1111/j.1600-0536.1996.tb02334.x; KAWANE H, 1995, J ALLERGY CLIN IMMUN, V96, P568, DOI 10.1016/S0091-6749(95)70307-1; Krest I, 1999, PLANTA MED, V65, P139, DOI 10.1055/s-1999-13975; Lancaster JE, 2000, PLANT PHYSIOL, V122, P1269, DOI 10.1104/pp.122.4.1269; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; Lopez-Rubio A, 1998, ALLERGY, V53, P1216, DOI 10.1111/j.1398-9995.1998.tb03845.x; LYBARGER JA, 1982, J ALLERGY CLIN IMMUN, V69, P448, DOI 10.1016/0091-6749(82)90120-8; Manabe T, 1998, EUR J BIOCHEM, V257, P21, DOI 10.1046/j.1432-1327.1998.2570021.x; MIRELMAN D, 1987, J INFECT DIS, V156, P243, DOI 10.1093/infdis/156.1.243; Moritz RL, 1996, ELECTROPHORESIS, V17, P907, DOI 10.1002/elps.1150170512; Munno G, 2001, ALLERGY, V56, P921, DOI 10.1034/j.1398-9995.2001.00266.x; NAVARRO JA, 1995, J ALLERGY CLIN IMMUN, V96, P690, DOI 10.1016/S0091-6749(95)70269-5; NELSON HS, 1996, J ALLERGY CLIN IMMUN, V97, P193; Perez-Pimiento AJ, 1999, ALLERGY, V54, P626, DOI 10.1034/j.1398-9995.1999.00806.x; Peumans WJ, 1997, PLANTA, V201, P298, DOI 10.1007/s004250050070; Piirila P, 1999, ALLERGY, V54, P273, DOI 10.1034/j.1398-9995.1999.00947.x; PLATTSMILLS TAE, 1991, J ALLERGY CLIN IMMUN, V87, P621, DOI 10.1016/0091-6749(91)90379-3; RABINKOV A, 1994, APPL BIOCHEM BIOTECH, V48, P149, DOI 10.1007/BF02788739; RABINKOV A, 1995, GLYCOCONJUGATE J, V12, P690, DOI 10.1007/BF00731266; Rafaat M, 2000, PEDIATR DERMATOL, V17, P475, DOI 10.1046/j.1525-1470.2000.01828.x; SEURI M, 1993, CLIN EXP ALLERGY, V23, P1011, DOI 10.1111/j.1365-2222.1993.tb00292.x; Su SN, 1996, J ALLERGY CLIN IMMUN, V98, P486, DOI 10.1016/S0091-6749(96)70080-5; VANDAMME EJM, 1992, EUR J BIOCHEM, V209, P751; vanRee R, 1997, ALLERGY, V52, P795; Vieths S, 1998, ALLERGY, V53, P65, DOI 10.1111/j.1398-9995.1998.tb04965.x; Wilkins MR, 1998, J MOL BIOL, V278, P599, DOI 10.1006/jmbi.1998.1726; Yates JR, 1998, ELECTROPHORESIS, V19, P893, DOI 10.1002/elps.1150190604; Yu CJ, 2003, J IMMUNOL, V170, P445, DOI 10.4049/jimmunol.170.1.445	41	39	40	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					161	168		10.1016/j.jaci.2003.10.040	http://dx.doi.org/10.1016/j.jaci.2003.10.040			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	760MP	14713923	Bronze			2022-12-18	WOS:000187837900022
J	Garabrant, DH; Schweitzer, S				Garabrant, DH; Schweitzer, S			Epidemiology of latex sensitization and allergies in health care workers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Meeting on Natural Rubber Latex Sensitivity	FEB 09-10, 2001	SAN FRANCISCO, CA	Malaysian Rubber Res Inst		allergy; sensitization; latex rubber; occupation; health care industry; epidemiologic	NATURAL-RUBBER LATEX; IGE ANTIBODIES; OCCUPATIONAL ASTHMA; OPERATING-THEATER; UNIT PERSONNEL; GLOVE ALLERGY; SKIN SYMPTOMS; PREVALENCE; EXPOSURE; HYPERSENSITIVITY	Although it is often claimed that health care workers are at increased risk of latex sensitization and type I allergies, there has been no systematic analysis of the epidemiologic studies that are relevant to this conclusion. A systematic analysis of the epidemiologic literature found that, in the past 14 years, there have been 48 epidemiologic studies of type I latex allergy among health care workers. Of these, 2 cohort studies estimated the incidence of latex sensitization by skin prick testing at between 1% and 2.5% per year. Neither compared the risk to that in the general population. The prevalence of sensitization in health care workers varied between 0% and 30%, yet this large variation was unexplained. Increased risk of sensitization was not clearly associated with the duration of work in health care, the time spent wearing latex gloves, the frequency of exposure, the specific job categories, the use of powdered versus nonpowdered latex gloves, the use of latex versus nonlatex gloves, or any measurements of ambient exposure to latex proteins. The epidemiologic studies do not support a conclusion that health care workers are at clearly increased risk of latex sensitization or type I allergies compared to other occupations in the United States. The role of latex gloves in causing latex sensitization and type I allergic symptoms remains poorly defined because of the inconsistent results across studies. Future epidemiologic studies are needed that include measured exposures to latex antigens, that compare health care workers to appropriate referent groups, and that address confounding by atopy, age, sex, and race.	Univ Michigan, Sch Publ Hlth, Dept Med, Ann Arbor, MI 48104 USA; Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Garabrant, DH (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Med, 1420 Washington Hts, Ann Arbor, MI 48104 USA.	dhg@umich.edu						Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; Amin A, 1998, INT DENT J, V48, P77, DOI 10.1111/j.1875-595X.1998.tb00464.x; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; BERKY ZT, 1992, JAMA-J AM MED ASSOC, V268, P2695; Brehler R, 1997, EUR J SURG, V163, P23; Brown RH, 1998, ANESTHESIOLOGY, V89, P292, DOI 10.1097/00000542-199808000-00004; BUBAK ME, 1992, MAYO CLIN PROC, V67, P1075, DOI 10.1016/S0025-6196(12)61122-7; CHAROUS BL, 1994, J ALLERGY CLIN IMMUN, V94, P12, DOI 10.1016/0091-6749(94)90065-5; Cherry N, 2000, BRIT J DERMATOL, V142, P1128, DOI 10.1046/j.1365-2133.2000.03537.x; de Groot H, 1998, CONTACT DERMATITIS, V38, P159; Douglas R, 1997, AUST NZ J MED, V27, P165, DOI 10.1111/j.1445-5994.1997.tb00933.x; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301, DOI 10.1136/oem.54.5.301; Garabrant DH, 2001, AM J EPIDEMIOL, V153, P515, DOI 10.1093/aje/153.6.515; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222, DOI 10.1164/ajrccm.162.4.2001023; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841, DOI 10.1164/ajrccm.155.6.9196084; Geller M, 1998, J ALLERGY CLIN IMMUN, V101, pS204; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; Hamann CP, 1998, J AM DENT ASSOC, V129, P43, DOI 10.14219/jada.archive.1998.0021; HUNT LW, 1995, J OCCUP ENVIRON MED, V37, P1204, DOI 10.1097/00043764-199510000-00011; IACOBELLI AM, 1993, J ALLERGY CLIN IMMUN, V91, P216; Jolanki R, 1999, CONTACT DERMATITIS, V40, P329, DOI 10.1111/j.1600-0536.1999.tb06088.x; Kaczmarek RG, 1996, ANN ALLERG ASTHMA IM, V76, P51, DOI 10.1016/S1081-1206(10)63406-0; Katelaris CH, 1996, MED J AUSTRALIA, V164, P711, DOI 10.5694/j.1326-5377.1996.tb122267.x; Kibby T, 1997, ANN ALLERG ASTHMA IM, V78, P41, DOI 10.1016/S1081-1206(10)63370-4; Konrad C, 1997, ANESTH ANALG, V84, P629, DOI 10.1097/00000539-199703000-00031; KUJALA VM, 1995, AM J IND MED, V28, P89, DOI 10.1002/ajim.4700280108; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Leung R, 1997, CLIN EXP ALLERGY, V27, P167; Levy DA, 1998, J ALLERGY CLIN IMMUN, V101, pS160; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; Mace SR, 1998, ANN ALLERG ASTHMA IM, V80, P252, DOI 10.1016/S1081-1206(10)62966-3; Mason JO, 1987, MMWR MORB MORTAL WKL, V36; Michelsen S, 1998, J ALLERGY CLIN IMMUN, V101, pS141; Miller W, 1998, J ALLERGY CLIN IMMUN, V101, pS204; Page EH, 2000, J OCCUP ENVIRON MED, V42, P613, DOI 10.1097/00043764-200006000-00010; PAGE EH, 1998, 9800962737 NIOSH HET, P1; Palczynski C, 1999, AM J IND MED, V35, P413; Safadi GS, 1996, ANN ALLERG ASTHMA IM, V77, P39, DOI 10.1016/S1081-1206(10)63477-1; Safadi GS, 1996, J AM DENT ASSOC, V127, P83, DOI 10.14219/jada.archive.1996.0034; Sinha A, 1998, OCCUP MED-OXFORD, V48, P405, DOI 10.1093/occmed/48.6.405; Smedley J, 1999, OCCUP ENVIRON MED, V56, P833, DOI 10.1136/oem.56.12.833; SUSSMAN GL, 1995, ANN ALLERG ASTHMA IM, V74, P415; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171, DOI 10.1016/S0091-6749(98)70381-1; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54, DOI 10.1164/ajrccm.151.1.7812572; Watts DN, 1998, AM J IND MED, V34, P359, DOI 10.1002/(SICI)1097-0274(199810)34:4<359::AID-AJIM9>3.0.CO;2-N; WRANGSJO K, 1994, CONTACT DERMATITIS, V30, P102, DOI 10.1111/j.1600-0536.1994.tb00572.x; WRANGSJO K, 1994, CONTACT DERMATITIS, V30, P139, DOI 10.1111/j.1600-0536.1994.tb00694.x; YASSIN MS, 1994, ANN ALLERGY, V72, P245	51	39	44	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2		S			S82	S95		10.1067/mai.2002.124967	http://dx.doi.org/10.1067/mai.2002.124967			14	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Allergy; Immunology	586ET	12170248				2022-12-18	WOS:000177572200013
J	Sobol, SE; Taha, R; Schloss, MD; Mazer, BD; Manoukian, JJ; Tewfik, TL; Hamid, Q				Sobol, SE; Taha, R; Schloss, MD; Mazer, BD; Manoukian, JJ; Tewfik, TL; Hamid, Q			T(H)2 cytokine expression in atopic children with otitis media with effusion	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						otitis media; cytokines; allergies; atopy; children; effusion	MAJOR BASIC-PROTEIN; MIDDLE-EAR EFFUSIONS; ANTIGEN CHALLENGE; CHRONIC SINUSITIS; MESSENGER-RNA; RISK-FACTORS; EOSINOPHIL; ASTHMA; IL-5; INFLAMMATION	Background: Otitis media with effusion (OME) is more common in atopic children. Few studies have looked for the presence of inflammatory mediators in the middle-ear effusions of this population. Objective: We hypothesize that atopic children with OME have a different inflammatory cell and cytokine profile than nonatopic patients with the disease. Methods: Twenty-six patients with OME undergoing myringotomy and ventilation tube placement were recruited at the McGill University Hospital Center. The atopic status was determined for each patient by using standard skin testing. By means of immunocytochemistry, fluid specimens were assessed for T lymphocytes (CD3), eosinophils (major basic protein), neutrophils (elastase), mast cells (tryptase), and basophils (BB1). By using in situ hybridization, the expression of IL-4, IL-5, and IFN-gamma was assessed. Results: There is a higher percentage of eosinophils and T lymphocytes in atopic patients with OME (n = 8) compared with that seen in nonatopic patients (n = 18, P <<01). There is a higher percentage of neutrophils in nonatopic patients with OME compared with that seen in atopic patients (P <.01). In examining cytokine profiles, there is a higher percentage of cells expressing IL-4 and IL-5 in atopic patients with OME compared with that seen in nonatopic patients (P <.01). Conclusion: The predominance of eosinophils, T lymphocytes, and T(H)2 mediators in the middle-ear effusions of atopic children provides evidence that allergy might play a role in the pathogenesis of OME.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Dept Otolaryngol, Montreal, PQ H2X 2P2, Canada; McGill Univ, Dept Allergy & Immunol, Montreal, PQ H2X 2P2, Canada	McGill University; McGill University; McGill University	Hamid, Q (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.							ACKERMAN MN, 1984, J ALLERGY CLIN IMMUN, V73, P604, DOI 10.1016/0091-6749(84)90519-0; ALHO OP, 1995, ARCH OTOLARYNGOL, V121, P432; BASCOM R, 1988, J ALLERGY CLIN IMMUN, V81, P570, DOI 10.1016/0091-6749(88)90198-4; BERNSTEIN JM, 1993, OTOLARYNG HEAD NECK, V109, P611; BIKHAZI P, 1995, LARYNGOSCOPE, V105, P629, DOI 10.1288/00005537-199506000-00013; Caffarelli C, 1998, CLIN EXP ALLERGY, V28, P591; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V105, P211, DOI 10.1016/S0091-6749(00)90068-X; Cypress B K, 1983, Vital Health Stat 13, V75, P1; DURHAM SR, 1992, J IMMUNOL, V148, P2390; FIREMAN P, 1988, J ALLERGY CLIN IMMUN, V81, P953, DOI 10.1016/0091-6749(88)90159-5; FREW AJ, 1988, J IMMUNOL, V141, P4158; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; Hurst DS, 2000, ALLERGY, V55, P435, DOI 10.1034/j.1398-9995.2000.00289.x; HURST DS, 1993, OTOLARYNG HEAD NECK, V108, P711, DOI 10.1177/019459989310800614; Hurst DS, 1999, LARYNGOSCOPE, V109, P471, DOI 10.1097/00005537-199903000-00024; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Kotsimbos ATC, 1997, MEM I OSWALDO CRUZ, V92, P75, DOI 10.1590/S0074-02761997000800012; KRAEMER MJ, 1983, JAMA-J AM MED ASSOC, V249, P1022, DOI 10.1001/jama.249.8.1022; Kvaerner KJ, 1996, INT J PEDIATR OTORHI, V35, P127, DOI 10.1016/0165-5876(95)01299-0; MCMAHAN JT, 1981, OTOLARYNG HEAD NECK, V89, P427, DOI 10.1177/019459988108900315; MOGI G, 1992, ACTA OTO-LARYNGOL, P155; Mogi G, 1997, ANN NY ACAD SCI, V830, P61, DOI 10.1111/j.1749-6632.1997.tb51879.x; MOY JN, 1990, J IMMUNOL, V145, P2626; NACLERIO RM, 1994, J ALLERGY CLIN IMMUN, V94, P1303, DOI 10.1016/0091-6749(94)90346-8; Nassif PS, 1998, OTOLARYNG HEAD NECK, V119, P564, DOI 10.1016/S0194-5998(98)70012-9; Oddera S, 1996, ALLERGY, V51, P100, DOI 10.1111/j.1398-9995.1996.tb04565.x; OJALA K, 1982, ACTA OTO-LARYNGOL, V93, P55, DOI 10.3109/00016488209130852; Ondrey FG, 1998, OTOLARYNG HEAD NECK, V119, P342, DOI 10.1016/S0194-5998(98)70075-0; Paradise JL, 2001, NEW ENGL J MED, V344, P1179, DOI 10.1056/NEJM200104193441601; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SHAW CB, 1995, OTOLARYNG HEAD NECK, V113, P234, DOI 10.1016/S0194-5998(95)70111-7; SIPILA M, 1988, ACTA OTO-LARYNGOL, V106, P94, DOI 10.3109/00016488809107375; TAINIO VM, 1988, PEDIATR RES, V23, P509, DOI 10.1203/00006450-198805000-00015; TEELE DW, 1984, PEDIATRICS, V74, P282; TEELE DW, 1981, J PEDIATR-US, V98, P537, DOI 10.1016/S0022-3476(81)80755-X; Watson P, 1996, NEW ZEAL MED J, V109, P182; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737, DOI 10.1164/ajrccm.156.3.9610046; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344; Wright ED, 2000, OTOLARYNG HEAD NECK, V123, P533, DOI 10.1067/mhn.2000.109472; Zielhuis G A, 1988, Adv Otorhinolaryngol, V40, P65	44	39	46	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					125	130		10.1067/mai.2002.125697	http://dx.doi.org/10.1067/mai.2002.125697			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	574CF	12110831	Green Submitted			2022-12-18	WOS:000176870300023
J	Dahlen, B; Roquet, A; Inman, MD; Karlsson, O; Naya, I; Anstren, G; O'Byrne, PM; Dahlen, SE				Dahlen, B; Roquet, A; Inman, MD; Karlsson, O; Naya, I; Anstren, G; O'Byrne, PM; Dahlen, SE			Influence of zafirlukast and loratadine on exercise-induced bronchoconstriction	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						histamine; leukotrienes; exercise-induced asthma; leukotriene receptor antagonists	MAST-CELL ACTIVATION; INDUCED ASTHMA; RECEPTOR ANTAGONIST; HISTAMINE-RELEASE; URINARY-EXCRETION; ALLERGEN; INHIBITION; AIRWAY; LEUKOTRIENES; MEDIATORS	Background: Airway obstruction induced by physical exercise is a common feature in asthma, and conventional treatments do not offer optimal protection. There is thus a need for additional therapies for optimal control of exercise-induced bronchoconstriction (EIB). Objective: The influence of treatment with the antihistamine loratadine and the antileukotriene zafirlukast alone and in combination on EIB was investigated. This combination has previously shown beneficial additive effects in allergen-induced bronchoconstriction. Methods: In a double-blind cross-over study loratadine (10 mg twice daily) and zafirlukast (80 mg twice daily) were evaluated alone and in combination in 16 nonsmoking patients with mild asthma, previously documented EIB, and airways hyperresponsiveness to histamine. Results: The mean SE maximum decrease in FEV1 after a standardized exercise provocation was 21.6% +/- 3% after placebo, 22.8% +/- 3% after loratadine, 13.9% +/- 2% after zafirlukast (P < .05 vs placebo), and 10.3% +/- 2% after the combination of loratadine and zafirlukast (P < .05 vs placebo). Expressed as the area under the FEV1 percentage change versus time curve, the mean protection produced by zafirlukast and the combination of zafirlukast and loratadine was 57% and 65%, respectively, whereas loratadine alone had no significant protective effect. There was also no significant difference between the effect of zafirlukast alone or in combination with loratadine. Conclusion: The study confirmed the beneficial effect of a leukotriene receptor antagonist in EIB but failed to obtain evidence that H-1-receptor antagonism alone or together with the cysteinyl-leukotriene 1 receptor antagonist zafirlukast offers a protective effect.	Karolinska Hosp, Thorac Clin, Dept Med, Div Resp Med, SE-17176 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; McMaster Univ, Asthma Res Grp, Hamilton, ON, Canada; Firestone Hosp, Hamilton, ON, Canada; AstraZeneca, Molndal, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; McMaster University; AstraZeneca	Dahlen, B (corresponding author), Karolinska Hosp, Thorac Clin, Dept Med, Div Resp Med, SE-17176 Stockholm, Sweden.			O'Byrne, Paul/0000-0003-0979-281X				Adelroth E, 1997, J ALLERGY CLIN IMMUN, V99, P210, DOI 10.1016/S0091-6749(97)70098-8; ANDERSON SD, 1999, LUNG BIOL HEALTH DIS, V130, P77; BARNES NC, 1984, PROSTAGLANDINS, V28, P629, DOI 10.1016/0090-6980(84)90137-0; BROIDE DH, 1990, AM REV RESPIR DIS, V141, P563, DOI 10.1164/ajrccm/141.3.563; CLISSOLD SP, 1989, DRUGS, V37, P42, DOI 10.2165/00003495-198937010-00003; Crampette L, 1996, ALLERGY, V51, P346, DOI 10.1111/j.1398-9995.1996.tb00098.x; Dahlen B, 2001, EUR RESPIR J, V17, P581, DOI 10.1183/09031936.01.17405810; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; FINNERTY JP, 1993, EUR RESPIR J, V6, P1132; GONG H, 1990, J ALLERGY CLIN IMMUN, V85, P632, DOI 10.1016/0091-6749(90)90104-C; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65, DOI 10.1164/ajrccm.153.1.8542164; JARJOUR NN, 1992, J ALLERGY CLIN IMMUN, V89, P60, DOI 10.1016/S0091-6749(05)80041-7; Kumlin M, 2000, CLIN EXP ALLERGY, V30, P585; Larsson L, 1999, INFLAMM RES, V48, pS9; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; MAKKER HK, 1993, AM REV RESPIR DIS, V147, P1413, DOI 10.1164/ajrccm/147.6_Pt_1.1413; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931, DOI 10.1164/ajrccm.153.3.8630575; O'Sullivan S, 1998, CLIN EXP ALLERGY, V28, P1332; O'Sullivan S, 1998, EUR RESPIR J, V12, P345, DOI 10.1183/09031936.98.12020345; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; PATEL KR, 1984, BRIT MED J, V288, P1496, DOI 10.1136/bmj.288.6429.1496; PETERS SP, 1995, ASTHMA RHINITIS, P221; POPPIUS H, 1986, EUR J RESPIR DIS, V68, P319; ROBUSCHI M, 1992, AM REV RESPIR DIS, V145, P1285, DOI 10.1164/ajrccm/145.6.1285; ROQUET A, 1995, ALLERGY, V50, P414, DOI 10.1111/j.1398-9995.1995.tb01171.x; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856, DOI 10.1164/ajrccm.155.6.9196086; SCHOOR JV, 1997, AM J RESP CRIT CARE, V155, P875; SMITH CM, 1991, AM REV RESPIR DIS, V144, P1411, DOI 10.1164/ajrccm/144.6.1411; TOWN GI, 1990, J ALLERGY CLIN IMMUN, V86, P886, DOI 10.1016/S0091-6749(05)80151-4; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; WOODBAKER R, 1993, J ALLERGY CLIN IMMUN, V91, P1005, DOI 10.1016/0091-6749(93)90213-Y	33	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					789	793		10.1067/mai.2002.123306	http://dx.doi.org/10.1067/mai.2002.123306			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	553QW	11994701				2022-12-18	WOS:000175687800007
J	Karjalainen, J; Nieminen, MM; Aromaa, A; Klaukka, T; Hurme, M				Karjalainen, J; Nieminen, MM; Aromaa, A; Klaukka, T; Hurme, M			The IL-1 beta genotype carries asthma susceptibility only in men	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inflammation; IL-1 beta; sex difference	INTERLEUKIN-1; POLYMORPHISM; DISEASE	One proinflammatory cytokine possibly implicated in the pathogenesis of asthma is IL-1beta. We analyzed the polymorphism of the IL-1beta gene (single nucleotide exchange at position -511) in a cohort of 245 patients with asthma (mean age, 58 years; age range, 31-84 years) and 405 controls. There were no differences in the allele frequencies. However, in men the genotype distribution differed significantly between asthmatic and control subjects (P = .03). The number of 1.2 heterozygotes was decreased in the patient group (P = .01). In subgroup analysis, the genotype distributions between cases and controls proved significantly different only. in men with lower serum IgE (<100 IU/mL, P = .009). The odds ratio of the 1.2 heterozygote men was 0.37 (95% CI, 0.19-0.71). Thus in the case of men the effect of the IL-1beta locus is clear, whereas in women there is no effect. In men this might make a significant contribution to the total asthma prevalence because of the high number of functional genotypes (ie, 50/50 IL-1beta homozygote/heterozygote ratio).	Univ Tampere, Sch Med, Dept Immunol & Microbiol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland; Natl Publ Hlth Inst, Helsinki, Finland; Social Insurance Inst, Helsinki, Finland; Tampere Univ Hosp, Ctr Lab Med, Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital; Finland National Institute for Health & Welfare; Tampere University; Tampere University Hospital	Karjalainen, J (corresponding author), Univ Tampere, Sch Med, Dept Immunol & Microbiol, FIN-33014 Tampere, Finland.			Hurme, Mikko/0000-0002-8614-1044				Bidwell J, 1999, GENES IMMUN, V1, P3, DOI 10.1038/sj.gene.6363645; Busse WW, 2001, NEW ENGL J MED, V344, P350, DOI 10.1056/NEJM200102013440507; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68, DOI 10.1164/ajrccm.162.1.9907008; Di Giovine F. S., 1992, Human Molecular Genetics, V1, P450; Hakonarson H, 2001, CURR OPIN PEDIATR, V13, P267, DOI 10.1097/00008480-200106000-00010; Hurme M, 1998, ANN MED, V30, P469, DOI 10.3109/07853899809002488; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565, DOI 10.1164/ajrccm.164.4.2012146; Lahita R G, 2000, J Gend Specif Med, V3, P19; Postma DS, 2000, AM J RESP CRIT CARE, V162, pS118, DOI 10.1164/ajrccm.162.supplement_2.ras-13; Read RC, 2000, J INFECT DIS, V182, P1557, DOI 10.1086/315889	10	39	42	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					514	516		10.1067/mai.2002.121948	http://dx.doi.org/10.1067/mai.2002.121948			3	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	534KW	11898000				2022-12-18	WOS:000174586400020
J	Nakamura, H; Luster, AD; Nakamura, T; In, KH; Sonna, LA; Deykin, A; Israel, E; Drazen, JM; Lilly, CM				Nakamura, H; Luster, AD; Nakamura, T; In, KH; Sonna, LA; Deykin, A; Israel, E; Drazen, JM; Lilly, CM			Variant eotaxin: Its effects on the asthma phenotype	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eotaxin; single-nucleotide polymorphism; chemokines; human genetics; asthma	MESSENGER-RNA; BRONCHOALVEOLAR LAVAGE; MOLECULAR-CLONING; RECEPTOR CCR3; EXPRESSION; IDENTIFICATION; HYPERRESPONSIVENESS; ASSOCIATION; ACTIVATION; CHEMOKINE	Background: Eotaxin, a CC chemokine expressed in the asthmatic lung, has been associated with impaired lung function. The role of its variant form is unknown. Objective: The purpose of this study was to detect the population frequency and effects of a known single-nucleotide polymorphism in the eotaxin gene in which a threonine residue (THR23) is substituted for the wild-type alanine (ALA(23)) at the 23rd amino acid at the terminus of the peptide leader sequence. Methods: We measured eotaxin protein secretion in 293 cells transfected with expression vectors and in PBMCs obtained from individuals bearing the alternative forms of the gene. A case-control study of plasma eotaxin levels and eosinophil counts, a comparison of baseline lung function by genotype in a population of 806 subjects with asthma, and a comparison of the allele frequency with a nonasthmatic population were performed. Results: Human 293 cells and PBMCs with THR23 variant eotaxin secreted significantly less eotaxin protein than did ALA(23)-bearing cells. In the case-control study, THR23-THR23 individuals had lower plasma levels of eotaxin (310 [240-350] vs 420 [270-700] pg/mL; P < .05) and eosinophil counts (120 [5-220] vs 190 [110-470] cells/<mu>L; P < .05) than ALA(23)-ALA(23) subjects; heterozygous subjects had intermediate levels. Higher levels of lung function were associated with THR23 eotaxin (percent of predicted FEV1, 65% 3.5% [THR23-THR23] VS 58% <plus/minus> 0.9% [THR23-ALA(23)] and 56% +/- 0.5% [ALA(23)-ALA(23)]; P < .05). Conclusion: The THR23 variant is associated with both decreased eosinophil counts and higher levels of lung function in subjects with asthma.	Brigham & Womens Hosp, Dept Med, Div Resp, Combined Program Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; Harvard Med Sch, Charlestown, MA USA; USA, Environm Med Res Inst, Natick, MA 01760 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Lilly, CM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Resp, Combined Program Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.		Luster, Andrew/ABE-6504-2020; Drazen, Jeffrey M/E-5841-2012	Luster, Andrew/0000-0001-9679-7912; 	NHLBI NIH HHS [HL/AI-64104] Funding Source: Medline; NIAID NIH HHS [AI 40618] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI040618, R01AI040618] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Bartels J, 1996, BIOCHEM BIOPH RES CO, V225, P1045, DOI 10.1006/bbrc.1996.1292; BEIER DR, 1993, MAMM GENOME, V4, P627, DOI 10.1007/BF00360898; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; FOLZ RJ, 1988, J BIOL CHEM, V263, P2070; GarciaZepeda EA, 1997, GENOMICS, V41, P471, DOI 10.1006/geno.1997.4656; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Kauffmann F, 1999, CLIN EXP ALLERGY, V29, P17; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; Lilly CM, 1999, J ALLERGY CLIN IMMUN, V104, P786, DOI 10.1016/S0091-6749(99)70288-5; Marsh DG, 1997, NAT GENET, V15, P389; Nakamura H, 1999, AM J RESP CRIT CARE, V160, P1952, DOI 10.1164/ajrccm.160.6.9811089; Nakamura H, 1998, AM J PHYSIOL-LUNG C, V275, pL601, DOI 10.1152/ajplung.1998.275.3.L601; National Institutes of Health National Heart Lung and Blood Institue National Asthma Education and Prevention Program, 1997, 974051 NIH NAT HEART; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Peled A, 1998, BLOOD, V91, P1909, DOI 10.1182/blood.V91.6.1909.1909_1909_1916; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291, DOI 10.1165/ajrcmb.21.3.f160; ROTHENBERG ME, 1995, J EXP MED, V181, P1211, DOI 10.1084/jem.181.3.1211; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	27	39	41	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					946	953		10.1067/mai.2001.120135	http://dx.doi.org/10.1067/mai.2001.120135			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	505WK	11742272				2022-12-18	WOS:000172938400010
J	Shaida, A; Kenyon, G; Devalia, J; Davies, RJ; MacDonald, TT; Pender, SLF				Shaida, A; Kenyon, G; Devalia, J; Davies, RJ; MacDonald, TT; Pender, SLF			Matrix metalloproteinases and their inhibitors in the nasal mucosa of patients with perennial allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinitic; nasal; matrix metalloproteinases; TIMPs; tissue inflammation; tissue remodeling	ASTHMATIC AIRWAY INFLAMMATION; BRONCHOALVEOLAR LAVAGE FLUID; TUMOR NECROSIS FACTOR; TISSUE INHIBITOR; SUBEPITHELIAL FIBROSIS; COLLAGENASE; FIBROBLASTS; EXPRESSION; DISEASE; INJURY	Background: Allergic rhinitis and asthma show many similarities in their epithelial and inflammatory responses to allergens. However, one notable difference is that disruption and desquamation of the epithelium is a characteristic feature of asthma, whereas in perennial allergic rhinitis the epithelium is intact and thickened. One reason for this might be differing expression of matrix metalloproteinases (MMPs) or their inhibitors (TIMPs). There are few published data on the presence of MMPs or TIMPs in the nasal mucosa in rhinitis. Objective: The purpose of this study was to investigate MMP and TIMP mRNA and protein in nasal mucosa from subjects with perennial allergic rhinitis and from nonrhinitic control subjects. Methods: Biopsy specimens of nasal mucosa were taken from 10 well-characterized subjects with perennial allergic rhinitis and 10 nonrhinitic control subjects. MMP and TIMP mRNA was quantified through use of competitive RT-PCR, and protein was detected by means of Western blotting and ELISA. Results: TIMP-1 mRNA and TIMP-2 mRNA were present in nasal samples, but there was no significant difference between the 2 groups. Only small amounts of MMP-1, -2, -3, and -9 mRNA were detected in the same samples. The corresponding proteins were detected by means of Western blotting. TIMP-1 protein and TIMP-2 protein were quantified in tissue homogenates; there was no significant difference between the 2 groups. Conclusion: Our studies have demonstrated the presence of large amounts of TIMP-1 and TIMP-2 mRNA and protein in nasal mucosa. There is no upregulation of MMPs or changes in TIMP expression in the nasal mucosa of patients with allergic rhinitis.	Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Southampton, Hants, England; St Bartholomews & Royal London Sch Med & Dent, Dept Otolaryngol, London, England; St Bartholomews & Royal London Sch Med & Dent, Dept Acad Resp Med, London, England	University of Southampton; University of London; Queen Mary University London; University of London; Queen Mary University London	Pender, SLF (corresponding author), Southampton Gen Hosp, Div Infect Inflammat & Repair, Tissue Remodeling & Repair Grp, Mailpoint 813,Level E,S Acad Block, Southampton SO16 6YD, Hants, England.				NEI NIH HHS [EY-05587] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Busse WW, 1995, ASTHMA RHINITIS, P12; CALDERON MA, 1994, J ALLERGY CLIN IMMUN, V93, P635, DOI 10.1016/S0091-6749(94)70075-3; Chakir J, 1996, LAB INVEST, V75, P735; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; Djukanovic R, 1996, CLIN EXP ALLERGY, V26, P44, DOI 10.1111/j.1365-2222.1996.tb00659.x; DREBORG S, 1989, J AM ACAD DERMATOL, V21, P820, DOI 10.1016/S0190-9622(89)70256-5; Ferry G, 1997, FEBS LETT, V402, P111, DOI 10.1016/S0014-5793(96)01508-6; FRIGAS E, 1991, EUR RESPIR J, V4, pS123; GARBISA S, 1986, J BIOL CHEM, V261, P2369; Hayashi T, 1996, AM J PATHOL, V149, P1241; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Kanbe N, 1999, EUR J IMMUNOL, V29, P2645; Lechapt-Zalcman E, 2001, J PATHOL, V193, P233, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH771>3.0.CO;2-W; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; LEPPERT D, 1995, J IMMUNOL, V154, P4379; Magnan A, 1997, CLIN EXP ALLERGY, V27, P389; Mautino G, 1999, AM J RESP CRIT CARE, V160, P324, DOI 10.1164/ajrccm.160.1.9808087; MEIKLE MC, 1989, J PERIODONTAL RES, V24, P207, DOI 10.1111/j.1600-0765.1989.tb02007.x; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120, DOI 10.1165/ajrcmb/7.2.120; MYGIND N, 1990, RHINITIS ASTHMA SIMI, P21; Naclerio RM, 1997, ALLERGY, V52, P7, DOI 10.1111/j.1398-9995.1997.tb04816.x; Ohno I, 1997, AM J RESP CELL MOL, V16, P212, DOI 10.1165/ajrcmb.16.3.9070604; Pender SLF, 1998, J IMMUNOL, V160, P4098; Pender SLF, 1997, J IMMUNOL, V158, P1582; Rajah R, 1996, AM J PHYSIOL-LUNG C, V271, pL1014, DOI 10.1152/ajplung.1996.271.6.L1014; ROCHE WR, 1989, LANCET, V1, P520; RoweJones JM, 1997, ALLERGY, V52, P20, DOI 10.1111/j.1398-9995.1997.tb04818.x; SEPPER R, 1995, CHEST, V107, P1641, DOI 10.1378/chest.107.6.1641; SEPPER R, 1994, CHEST, V106, P1129, DOI 10.1378/chest.106.4.1129; Tarnuzzer RW, 1996, BIOTECHNIQUES, V20, P670; Torii K, 1997, AM J RESP CRIT CARE, V155, P43, DOI 10.1164/ajrccm.155.1.9001287; VanCauwenberge PB, 1997, ALLERGY, V52, P7; Vignola A M, 1997, Monaldi Arch Chest Dis, V52, P159; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945, DOI 10.1164/ajrccm.158.6.9803014; WELGUS HG, 1985, J CLIN INVEST, V76, P219, DOI 10.1172/JCI111949; WILHELM SM, 1989, J BIOL CHEM, V264, P17213	40	39	40	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					791	796		10.1067/mai.2001.119024	http://dx.doi.org/10.1067/mai.2001.119024			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	498RG	11692106	Bronze			2022-12-18	WOS:000172523800021
J	Santanello, NC; DeMuro-Mercon, C; Davies, G; Ostrom, N; Noonan, M; Rooklin, A; Knorr, B				Santanello, NC; DeMuro-Mercon, C; Davies, G; Ostrom, N; Noonan, M; Rooklin, A; Knorr, B			Validation of a pediatric asthma caregiver diary	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; pediatric; outcomes research; diary; symptom assessment; validation	TIDAL BREATHING ANALYSIS; RESPIRATORY RESISTANCE; EMERGENCY-DEPARTMENT; SODIUM CROMOGLYCATE; PRESCHOOL-CHILDREN; YOUNG-CHILDREN; SYMPTOM DIARY; HEALTH-STATUS; PARENTS; SCORES	Background: Young children are generally not able to consistently and reliably perform tests of airway function, and normative values are not available, Reliable and valid measures of parental reporting of asthma symptoms and functioning are needed to determine the efficacy of asthma interventions. Objective: A pediatric asthma caregiver diary was developed and validated for use in interventional asthma studies. Methods: A 3-week prospective study of 125 caregiver parents and their children, aged 2 to 5 years, with persistent asthma was conducted, At baseline, children were classified as either stable (no change to anti-inflammatory therapy) or unstable (anti-inflammatory therapy added or increased). Results: A symptom scale and day without asthma symptoms (DWAS) were defined from pediatric asthma caregiver diary questions. The scale and DWAS statistically differentiated between the stable and unstable groups at week 1 and detected change between the 2 groups (P <.01). On average, caregivers reported low symptom scores. However, the frequency of DWAS was only 43% of days in the stable group and 22% in the unstable group. Conclusion: The pediatric asthma caregiver diary scale and DWAS have acceptable measurement characteristics for use in clinical trials of children with asthma symptoms. The DWAS indicates an opportunity for improvement in asthma control in this population.	Chester Crozer Ctr, Upland, PA USA; Allergy Associates, Res Ctr, Portland, OR USA; Allergy & Asthma Med Grp, San Diego, CA USA; Res Ctr, San Diego, CA USA; Merck Res Labs, West Point, PA USA	Merck & Company	Santanello, NC (corresponding author), Dept Epidemiol, POB 4,BL 1-7, West Point, PA 19486 USA.							ARCHER LNJ, 1985, ARCH DIS CHILD, V60, P473, DOI 10.1136/adc.60.5.473; Beimer P., 1991, MEASUREMENT ERRORS S; CARLSEN KH, 1994, EUR RESPIR J, V7, P2154, DOI 10.1183/09031936.94.07122154; COGSWELL JJ, 1985, ARCH DIS CHILD, V60, P736, DOI 10.1136/adc.60.8.736; CONNOLLY N, 1970, Journal of Asthma Research, V8, P31, DOI 10.3109/02770907009105028; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DEYO RA, 1991, CONTROL CLIN TRIALS, V12, pS142, DOI 10.1016/S0197-2456(05)80019-4; Ducharme FM, 1997, CHEST, V111, P1519, DOI 10.1378/chest.111.6.1519; Ducharme FM, 1998, CHEST, V113, P1566, DOI 10.1378/chest.113.6.1566; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9, DOI 10.1164/ajrccm/149.2_Pt_2.S9; FERGUSON AE, 1995, BRIT MED J, V310, P1161, DOI 10.1136/bmj.310.6988.1161; FISH L, 1992, J ALLERGY CLIN IMMUN, V89, P188; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Klug B, 1996, PEDIATR PULM, V21, P290; KOCH GG, 1982, BIOMETRICS, V38, P563, DOI 10.2307/2530041; *NIH, 1995, GLOB IN ASTH; OCONNOR GT, 1994, AM J RESP CRIT CARE, V149, pS21, DOI 10.1164/ajrccm/149.2_Pt_2.S21; ROTHMAN ML, 1993, MED CARE, V31, pMS82; Santanello NC, 1997, EUR RESPIR J, V10, P646; Santanello NC, 1996, J ALLERGY CLIN IMMUN, V97, P298; Santanello NC, 1999, ARCH DIS CHILD, V80, P414, DOI 10.1136/adc.80.5.414; STREINER DL, 1995, HLTH MEASUREMENTS SC; Tasche MJA, 1997, LANCET, V350, P1060, DOI 10.1016/S0140-6736(97)05333-6; Tepper R, 1996, EUR RESPIR J, V9, pS12; USHERWOOD TP, 1990, ARCH DIS CHILD, V65, P779, DOI 10.1136/adc.65.7.779; vanderEnt CK, 1996, AM J RESP CRIT CARE, V153, P1253, DOI 10.1164/ajrccm.153.4.8616550; VANDERWINDT DAWM, 1994, J CLIN EPIDEMIOL, V47, P635, DOI 10.1016/0895-4356(94)90211-9	27	39	39	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					861	866		10.1067/mai.2000.110478	http://dx.doi.org/10.1067/mai.2000.110478			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	417ZK	11080707				2022-12-18	WOS:000167865200009
J	Profita, M; Sala, A; Riccobono, L; Paterno, A; Mirabella, A; Bonanno, A; Guerrera, D; Pace, E; Bonsignore, G; Bousquet, J; Vignola, AM				Profita, M; Sala, A; Riccobono, L; Paterno, A; Mirabella, A; Bonanno, A; Guerrera, D; Pace, E; Bonsignore, G; Bousquet, J; Vignola, AM			15-lipoxygenase expression and 15(S)-hydroxyeicoisatetraenoic acid release and reincorporation in induced sputum of asthmatic subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						15(S)-HETE; asthma; airway macrophages; induced sputum	HUMAN ALVEOLAR MACROPHAGES; ARACHIDONIC-ACID; EPITHELIAL-CELLS; 15-HYDROXYEICOSATETRAENOIC ACID; HEALTHY-SUBJECTS; SELECTIVE INCORPORATION; FUNCTIONAL ASSESSMENT; GENERATION; PHOSPHATIDYLINOSITOL; LEUKOTRIENES	Background: Recent evidence shows that 15(S)-hydroly-eicoisatetraenoic acid (15[S]-HETE) can be released and rapidly reincorporated into cellular lipids. These mechanisms exert several immunoregulatory functions that may be relevant in airway inflammation. Objective: Our purpose was to evaluate the levels of both soluble and cell-associated 15(S)-HETE and to examine 15-lipoxygenase (15-LO) messenger RNA (mRNA) expression in sputum samples obtained from 10 control and 18 asthmatic subjects. Methods: Levels of 15(S)-HETE were measured by reverse-phase HPLC separation followed by RIA in supernatants and in cell membrane-extracted phospholipids after acid hydrolysis. 15-LO mRNA was evaluated by primed in situ hybridization (PRINS), Combined immunocytochemistry and PRINS was used to identify the phenotype of cells bearing 15-LO transcripts. Results: Levels of both soluble and cell-associated 15(S)-HETE were higher in asthmatic than in control subjects (P < .0001). The percentage of cells expressing 15-LO mRNA was higher in asthmatic than in control subjects (P < .01). On double staining for specific cell-type markers and 15-LO mRNA, macrophages were the major source for 15-LO. Conclusion: This study shows that the induced sputum technique allows the evaluation of 15-LO activity and that soluble, cell-associated 15(S)-HETE and 15-LO levels are higher in asthmatic than in control subjects. In addition, this study indicates that, in induced sputum, airway macrophages are the major source of 15(S)-HETE in asthma.	CNR, Ist Fisiopatol Resp, I-90146 Palermo, Italy; Univ Palermo, Ist Med Gen & Pneumol, Palermo, Italy; Univ Milan, Ctr Cardiopulm Pharmacol, Milan, Italy; INSERM, U454, Montpellier, France	Consiglio Nazionale delle Ricerche (CNR); University of Palermo; University of Milan; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Vignola, AM (corresponding author), CNR, Ist Fisiopatol Resp, Via Trabucco 180, I-90146 Palermo, Italy.		Riccobono, Loredana/F-7950-2015; Profita, Mirella/D-8957-2018; bonanno, anna/F-7613-2015; Bonanno, Anna/AAV-9474-2020; Profita, Mirella/AAY-3165-2020; Sala, Angelo/H-5478-2019; Profita, Mirella/AFU-7423-2022; Pace, Elisabetta/AAL-2537-2020	Riccobono, Loredana/0000-0002-0012-3591; Profita, Mirella/0000-0002-7821-8283; bonanno, anna/0000-0003-3448-283X; Pace, Elisabetta/0000-0003-1141-9010; Sala, Angelo/0000-0001-9290-0257				ALPERT SE, 1993, AM J RESP CELL MOL, V8, P273, DOI 10.1165/ajrcmb/8.3.273; ALPERT SE, 1995, LUNG CELL MOL PHYSL, V269, pL734; BALTER MS, 1988, AM REV RESPIR DIS, V138, P1134, DOI 10.1164/ajrccm/138.5.1134; BRADY HR, 1995, AM J PHYSIOL-RENAL, V268, pF1, DOI 10.1152/ajprenal.1995.268.1.F1; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CAMPBELL A, 1992, CHEST, V101, pS25, DOI 10.1378/chest.101.3_Supplement.25S-a; Catena E, 1993, Monaldi Arch Chest Dis, V48, P6; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; CHAVIS C, 1992, EICOSANOIDS, V5, P203; CHAVIS C, 1991, PROSTAG LEUKOTR ESS, V42, P95, DOI 10.1016/0952-3278(91)90074-F; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COSTELLO PB, 1991, INFLAMMATION, V15, P269, DOI 10.1007/BF00917312; DAMON M, 1986, EUR J RESPIR DIS, V69, P206; DAMON M, 1987, PROSTAG OTH LIPID M, V34, P291, DOI 10.1016/0090-6980(87)90251-6; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53, DOI 10.1164/ajrccm.152.1.7599862; Fuller R W, 1988, Pulm Pharmacol, V1, P101, DOI 10.1016/S0952-0600(88)80006-1; GIRTON RA, 1994, KIDNEY INT, V45, P972, DOI 10.1038/ki.1994.131; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; HAMBERG M, 1980, ACTA PHYSIOL SCAND, V110, P219, DOI 10.1111/j.1748-1716.1980.tb06656.x; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; JOHNSON HG, 1985, AM REV RESPIR DIS, V131, P917; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; KOCH J, 1992, CYTOGENET CELL GENET, V60, P1, DOI 10.1159/000133281; KUMLIN M, 1990, ARCH BIOCHEM BIOPHYS, V282, P254, DOI 10.1016/0003-9861(90)90114-E; LAI CKW, 1990, AM REV RESPIR DIS, V141, P1423; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; LEVY BD, 1993, J CLIN INVEST, V92, P1572, DOI 10.1172/JCI116738; Maestrelli P, 1996, AM J RESP CRIT CARE, V154, P1296, DOI 10.1164/ajrccm.154.5.8912739; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MENEELY GR, 1962, AM REV RESPIR DIS, V85, P762; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; Profita M, 1999, AM J RESP CELL MOL, V20, P61, DOI 10.1165/ajrcmb.20.1.3151; RANKIN JA, 1989, J ALLERGY CLIN IMMUN, V83, P722, DOI 10.1016/0091-6749(89)90005-5; SALARI H, 1989, AM J RESP CELL MOL, V1, P245, DOI 10.1165/ajrcmb/1.3.245; SAMUELSSON B, 1987, DRUGS, V33, P2, DOI 10.2165/00003495-198700331-00003; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940, DOI 10.1164/ajrccm.149.4.8143059; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; TURK J, 1982, J BIOL CHEM, V257, P7068; VANDERHOEK JY, 1988, ANN NY ACAD SCI, V524, P240, DOI 10.1111/j.1749-6632.1988.tb38547.x; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P505, DOI 10.1164/ajrccm.157.2.9703070; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111	43	39	44	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					711	716		10.1067/mai.2000.105122	http://dx.doi.org/10.1067/mai.2000.105122			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756220				2022-12-18	WOS:000086604100008
J	Schmidt, D; Rabe, KF				Schmidt, D; Rabe, KF			Immune mechanisms of smooth muscle hyperreactivity in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immune mechanisms; bronchial smooth muscle; hyperreactivity; asthma; sensitization; IgE; cytokines; airway inflammation	OBSTRUCTIVE PULMONARY-DISEASE; BRONCHIAL BIOPSY SPECIMENS; SERUM IGE LEVELS; AIRWAY HYPERRESPONSIVENESS; PASSIVE SENSITIZATION; T-LYMPHOCYTES; IMMUNOGLOBULIN-E; ALTERED RESPONSIVENESS; CONTRACTILE RESPONSES; CIGARETTE SMOKERS	Asthma is characterized by bronchial hyperresponsiveness to a variety of bronchospasmogenic stimuli. To study the pathophysiologic mechanisms underlying the increased sensitivity and degree of maximal airway narrowing, various in vivo and in vitro models have been developed with methods of active and passive sensitization. These studies indicated a major role for alterations in the smooth muscle itself rather than neural dysfunction or airway inflammation as the underlying cause for the development of bronchial hyperresponsiveness. During the last years smooth muscle cells were found to exhibit not only the "classical" contractile phenotype hut also a proliferative-synthetic phenotype, which is capable of producing proinflammatory cytokines, chemotaxins, and growth factors. Allergic sensitization can alter both contractile and secretory functions, thereby indicating that the smooth muscle cell could contribute directly to the persistence of airway inflammation in asthma, ri better understanding of the changes within the smooth muscle cells and of the mechanisms that lead to their induction could contribute to the development of novel therapeutic approaches for the treatment of asthma.	Leiden Univ, Med Ctr, Dept Pulmonol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Rabe, KF (corresponding author), Leiden Univ, Med Ctr, Dept Pulmonol, C3-P,POB 9600, NL-2300 RC Leiden, Netherlands.		Rabe, Klaus F./AAW-6296-2021	Rabe, Klaus F./0000-0002-7020-1401				ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; AKASAKA K, 1975, TOHOKU J EXP MED, V117, P55, DOI 10.1620/tjem.117.55; Amrani Y, 1998, THORAX, V53, P713, DOI 10.1136/thx.53.8.713; ANTICEVICH SZ, 1995, EUR J PHARMACOL, V284, P221, DOI 10.1016/0014-2999(95)00463-U; ANTONISSEN LA, 1979, J APPL PHYSIOL, V46, P681, DOI 10.1152/jappl.1979.46.4.681; ARMOUR CL, 1984, RESP PHYSIOL, V58, P223, DOI 10.1016/0034-5687(84)90150-6; AVITAL A, 1995, THORAX, V50, P511, DOI 10.1136/thx.50.5.511; BAHNA SL, 1983, ALLERGY, V38, P57, DOI 10.1111/j.1398-9995.1983.tb00857.x; BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; BENJEBRIA A, 1993, BRIT J PHARMACOL, V109, P131, DOI 10.1111/j.1476-5381.1993.tb13542.x; BLACK JL, 1989, J ALLERGY CLIN IMMUN, V84, P440, DOI 10.1016/0091-6749(89)90356-4; BONNEFOY JY, 1993, CURR OPIN IMMUNOL, V5, P944, DOI 10.1016/0952-7915(93)90110-E; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835, DOI 10.1164/ajrccm.155.6.9196083; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BYRON KA, 1994, CLIN EXP IMMUNOL, V95, P333, DOI 10.1111/j.1365-2249.1994.tb06533.x; CERRINA J, 1986, AM REV RESPIR DIS, V134, P57; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4, DOI 10.1164/ajrccm.157.1.9703002; DAVIS C, 1983, CAN J PHYSIOL PHARM, V61, P705, DOI 10.1139/y83-109; DEJONGSTE JC, 1987, EUR J RESPIR DIS, V71, P23; DEJONGSTE JC, 1988, AM REV RESPIR DIS, V138, P321, DOI 10.1164/ajrccm/138.2.321; DeSanctis GT, 1997, NAT MED, V3, P460, DOI 10.1038/nm0497-460; DOW L, 1992, AM REV RESPIR DIS, V146, P402, DOI 10.1164/ajrccm/146.2.402; DUNLOP LS, 1977, BRIT J PHARMACOL, V59, pP475; EBINA M, 1993, AM REV RESPIR DIS, V148, P720, DOI 10.1164/ajrccm/148.3.720; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648, DOI 10.1152/ajplung.1997.273.3.L648; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Gelfand EW, 1997, NAT MED, V3, P382, DOI 10.1038/nm0497-382; Grunberg K, 1999, CLIN EXP ALLERGY, V29, P65; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; Hakonarson H, 1998, P NATL ACAD SCI USA, V95, P5257, DOI 10.1073/pnas.95.9.5257; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hakonarson H, 1997, J CLIN INVEST, V99, P117, DOI 10.1172/JCI119122; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040, DOI 10.1152/ajplung.1996.270.6.L1040; Halayko AJ, 1999, AM J PHYSIOL-LUNG C, V276, pL197, DOI 10.1152/ajplung.1999.276.1.L197; Hirst SJ, 1996, EUR RESPIR J, V9, P808, DOI 10.1183/09031936.96.09040808; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; JENSEN EJ, 1992, J ALLERGY CLIN IMMUN, V90, P224, DOI 10.1016/0091-6749(92)90075-D; JIANG H, 1992, AM J RESP CELL MOL, V7, P567, DOI 10.1165/ajrcmb/7.6.567; Johnson SR, 1997, TRENDS PHARMACOL SCI, V18, P288, DOI 10.1016/S0165-6147(97)01092-4; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; Kumagai K, 1999, J IMMUNOL, V162, P4212; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771, DOI 10.1152/jappl.1993.74.6.2771; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Leckie MJ, 1999, AM J RESP CRIT CARE, V159, pA624; LEVY DA, 1967, J IMMUNOL, V99, P1062; MARTHAN R, 1992, RESP PHYSIOL, V90, P239, DOI 10.1016/0034-5687(92)90084-A; Mitchell RW, 1997, J APPL PHYSIOL, V83, P1276, DOI 10.1152/jappl.1997.83.4.1276; MITCHELL RW, 1994, AM J PHYSIOL, V267, pL218, DOI 10.1152/ajplung.1994.267.2.L218; Moller GM, 1999, J APPL PHYSIOL, V86, P1352, DOI 10.1152/jappl.1999.86.4.1352; OHICKEY SP, 1988, EUR RESPIR J, V1, P913; Peat JK, 1996, ALLERGY, V51, P804, DOI 10.1111/j.1398-9995.1996.tb00026.x; PERPINA M, 1989, RESPIRATION, V55, P105; PLATTSMILLS TAE, 1992, AM REV RESPIR DIS, V145, pS44, DOI 10.1164/ajrccm/145.2_Pt_2.S44; PRAUSNITZ C, 1921, ZBL BAKT           1, V86, P160; PUNNONEN J, 1994, ALLERGY, V49, P576, DOI 10.1111/j.1398-9995.1994.tb00122.x; QUAST U, 1992, FUND CLIN PHARMACOL, V6, P279, DOI 10.1111/j.1472-8206.1992.tb00122.x; Rabe KF, 1998, AM J RESP CRIT CARE, V158, pS161, DOI 10.1164/ajrccm.158.supplement_2.13tac130; Rieber EP, 1996, ALLERGOLOGIE, V19, P180; ROBERTS JA, 1984, THORAX, V39, P837, DOI 10.1136/thx.39.11.837; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Roux E, 1999, AM J RESP CRIT CARE, V160, P439, DOI 10.1164/ajrccm.160.2.9811007; SCHILD HO, 1951, LANCET, V261, P376; Schmidt D, 1999, EUR RESPIR J, V14, P315, DOI 10.1034/j.1399-3003.1999.14b13.x; Schmidt D, 2000, CLIN EXP ALLERGY, V30, P233; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P1818, DOI 10.1164/ajrccm.157.6.9710023; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204, DOI 10.1164/ajrccm.157.1.9703027; Solway J, 1997, AM J RESP CELL MOL, V17, P144, DOI 10.1165/ajrcmb.17.2.f137; SOUHRADA M, 1984, SCIENCE, V225, P723, DOI 10.1126/science.6087455; STERK PJ, 1986, AM REV RESPIR DIS, V134, P714; Sunyer J, 1997, THORAX, V52, P235, DOI 10.1136/thx.52.3.235; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TAYLOR SM, 1985, AM REV RESPIR DIS, V132, P30; VINCENC KS, 1983, AM REV RESPIR DIS, V128, P875; Watson N, 1998, CLIN EXP ALLERGY, V28, P679, DOI 10.1046/j.1365-2222.1998.00269.x; Watson N, 1997, AM J RESP CRIT CARE, V155, P839, DOI 10.1164/ajrccm.155.3.9117014; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YING S, 1995, AM J RESP CELL MOL, V12, P477, DOI 10.1165/ajrcmb.12.5.7742012	86	39	40	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2000	105	4					673	682		10.1067/mai.2000.105705	http://dx.doi.org/10.1067/mai.2000.105705			10	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	306PB	10756215				2022-12-18	WOS:000086604100003
J	Geiger, E; Magerstaedt, R; Wessendorf, JHM; Kraft, S; Hanau, D; Bieber, T				Geiger, E; Magerstaedt, R; Wessendorf, JHM; Kraft, S; Hanau, D; Bieber, T			IL-4 induces the intracellular expression of the alpha chain of the high-affinity receptor for IgE in in vitro-generated dendritic cells	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; Langerhans cells; Fc receptors; allergy; stem cells; IL-4; homing receptors	FC-EPSILON-RI; EPIDERMAL LANGERHANS CELLS; HUMAN PERIPHERAL-BLOOD; PROGENITOR CELLS; TNF-ALPHA; IN-VITRO; GM-CSF; ANTIGEN; GAMMA; SKIN	Background: Recent findings have shown that the surface expression of the high-affinity receptor for IgE (Fc epsilon RI) on human CD1a(+) Langerhans cells (LC) and related dendritic cells (DC) in the skin, despite a constant intracellular expression of its alpha chain (Fc epsilon RI alpha), is highly up-regulated in atopic dermatitis. Moreover, this surface expression correlates with the IgE serum level, strongly suggesting yet-to-be-defined common signals in the regulation of Fc epsilon RI display on LC/DC and IgE synthesis. Objectives: In this study me examined the influence of different cytokines on the expression of Fc epsilon RI on in vitro-generated CD1a(+) LC/DC; Methods: CD34(+) precursor cells were isolated from cord blood with use of high-gradient magnetic cell sorting, cultured with GM-CSF; TNF-alpha, IL-4, or IFN-gamma, and surface and cytoplasmic staining for flow cytometry were performed. Results: IL-4 strongly enhanced the generation of CD1a(+) LC/DC and also up-regulated the expression of the skin-homing structures E-cadherin and cutaneous lymphocyte antigen, In contrast, IFN-gamma was found to suppress the E-cadherin expression and to be a strong antagonist of IL-4 by inhibiting the production of CD1a(+) cells. Most important, IL-4 induced the cytoplasmic expression of Fc epsilon RI alpha in CD1a(+) LC/DC but not its surface expression. This up-regulation was antagonized by IFN-gamma. Conclusion: IL-4 is not only a key cytokine in the regulation of IgE hut also induces the expression of its receptor binding chain as well as up-regulation of skin homing molecules on LC/DC. Expression of these structures during generation of LC/DC reflects the in vivo situation encountered in LC.	Univ Bonn, Dept Dermatol, D-53105 Bonn, Germany; Univ Munich, Dept Haematol Oncol, Munich, Germany; Etab Transfus Sanguine, CJF Inst Natl Sante & Rech Med 94 03, Strasbourg, France	University of Bonn; University of Munich; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bieber, T (corresponding author), Univ Bonn, Dept Dermatol, Sigmund Freud Str 25, D-53105 Bonn, Germany.							BABI LFS, 1995, J IMMUNOL, V154, P1543; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Bieber T, 1996, CURR OPIN IMMUNOL, V8, P773, DOI 10.1016/S0952-7915(96)80003-3; Bieber T, 1997, INT ARCH ALLERGY IMM, V113, P30, DOI 10.1159/000237500; BIRBECK MS, 1961, J INVEST DERMATOL, V37, P51, DOI 10.1038/jid.1961.80; Bonnefoy JY, 1996, IMMUNOL TODAY, V17, P418, DOI 10.1016/0167-5699(96)10054-2; BORKOWSKI TA, 1994, EUR J IMMUNOL, V24, P2767, DOI 10.1002/eji.1830241129; Caux C, 1996, J EXP MED, V184, P695, DOI 10.1084/jem.184.2.695; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Cumberbatch M, 1996, ARCH DERMATOL RES, V288, P739, DOI 10.1007/s004030050134; Ebner S, 1998, IMMUNOBIOLOGY, V198, P568, DOI 10.1016/S0171-2985(98)80079-X; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; JURGENS M, 1995, J IMMUNOL, V155, P5184; KOHLER I, 1995, IMMUNOBIOLOGY, V193, P273; Kraft S, 1998, J IMMUNOL, V161, P1000; Lardon F, 1997, IMMUNOLOGY, V91, P553, DOI 10.1046/j.1365-2567.1997.00295.x; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MACKENSEN A, 1995, BLOOD, V86, P2699; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; PICKER LJ, 1990, J IMMUNOL, V145, P3247; RISKE F, 1991, J BIOL CHEM, V266, P11245; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; ROSS EL, 1994, IMMUNOLOGY, V81, P303; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SCHONEICH JT, 1992, J IMMUNOL, V148, P2181; Strunk D, 1996, BLOOD, V87, P1292, DOI 10.1182/blood.V87.4.1292.bloodjournal8741292; Strunk D, 1997, J EXP MED, V185, P1131, DOI 10.1084/jem.185.6.1131; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; Toru H, 1996, INT IMMUNOL, V8, P1367; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WOLLENBERG A, 1995, LANCET, V346, P1626, DOI 10.1016/S0140-6736(95)91958-9; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yasaka N, 1996, J DERMATOL SCI, V11, P19, DOI 10.1016/0923-1811(95)00411-4	39	39	42	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				150	156		10.1016/S0091-6749(00)90190-8	http://dx.doi.org/10.1016/S0091-6749(00)90190-8			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	278LW	10629465				2022-12-18	WOS:000084992100020
J	Nakasato, H; Ohrui, T; Sekizawa, K; Matsui, T; Yamaya, M; Tamura, G; Sasaki, H				Nakasato, H; Ohrui, T; Sekizawa, K; Matsui, T; Yamaya, M; Tamura, G; Sasaki, H			Prevention of severe premenstrual asthma attacks by leukotriene receptor antagonist	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						menstruation; asthma; leukotrienes; glucocorticoids; female sex steroids; inflammatory cells	MENSTRUAL-CYCLE; MAST-CELL; INDUCED BRONCHOCONSTRICTION; 5-LIPOXYGENASE INHIBITION; RADIOIMMUNOASSAY; HISTAMINE; CHROMATOGRAPHY; PROGESTERONE; EXACERBATION; ACTIVATION	Background: The etiology and treatment of premenstrual exacerbations of asthma (PMA) remain uncertain. Objective: We investigated the role of cellular mediators released from inflammatory cells in the airflow limitation during PMA. Methods: Serum levels of leukotriene (LT) B-4, LTC4, platelet-activating factor, histamine, IL-1 beta, IL-4, IL-5, IL-6, and GMCSF were measured at different time points, first just before or during menstruation when the peak expiratory flow rate (PEFR) began to decrease precipitously and second during the menstrual midcycle meek (days 10-16) when the PEFR returned to baseline values in patients with PMA and in age-matched asthma patients without PMA at the same intervals. Results: Serum levels of LTC4 were significantly higher during exacerbations of asthma than after recovery (69.0 +/- 16.0 pg/mL vs 24.0 +/- 9.5 pg/mL, P < .05), whereas those of IL-1 beta, IL-4, n-5, IL-6, GM-CSF, histamine, LTB4, and platelet-activating factor did not differ between 2 periods in 5 patients with PMA, In contrast, in 5 asthmatic patients without PMA serum levels of cellular mediators did not differ between corresponding periods. Oral administration of pranlukast, an LT receptor antagonist (225 mg twice daily), significantly reduced decreases in PEFR from the baseline values (110 +/- 21 L/min with pranlukast vs 233 +/- 20 L/min without pranlukast, P < .01) in association with an improvement of asthma symptom scores (6.5 +/-. 1.1 with pranlukast vs 9.8 +/- 0.7 without pranlukast, P < 0.05) in 5 patients with PMA. Conclusion: LTs are partly involved in the pathogenesis of PMA, and LT receptor antagonists may be useful for preventing airflow obstruction in patients with PMA.	Tohoku Univ, Sch Med, Dept Geriatr Med, Aoba Ku, Sendai, Miyagi 980, Japan; Tohoku Univ, Sch Med, Dept Internal Med 1, Aoba Ku, Sendai, Miyagi 980, Japan	Tohoku University; Tohoku University	Sasaki, H (corresponding author), Tohoku Univ, Sch Med, Dept Geriatr Med, Aoba Ku, Seiryo Machi 1-1, Sendai, Miyagi 980, Japan.			Matsui, Toshifumi/0000-0002-8478-2809				BEYNON HLC, 1988, LANCET, V2, P370; CANTRELL MA, 1985, P NATL ACAD SCI USA, V82, P6250, DOI 10.1073/pnas.82.18.6250; CHIRAY M, 1940, PRESSE MED, V48, P201; Claude F., 1938, PRESSE MED, V38, P755; COONEY SJ, 1992, J IMMUNOL METHODS, V151, P131, DOI 10.1016/0022-1759(92)90111-6; Derimanov GS, 1998, ANN ALLERG ASTHMA IM, V81, P243, DOI 10.1016/S1081-1206(10)62820-7; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; ELIASSON O, 1987, J ALLERGY CLIN IMMUN, V79, P909, DOI 10.1016/0091-6749(87)90240-5; FISCHER AR, 1995, AM J RESP CRIT CARE, V152, P1203, DOI 10.1164/ajrccm.152.4.7551371; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GIBBS CJ, 1984, THORAX, V39, P833, DOI 10.1136/thx.39.11.833; HANLEY SP, 1981, BRIT J DIS CHEST, V75, P306, DOI 10.1016/0007-0971(81)90010-3; HAYES EC, 1983, J IMMUNOL, V131, P429; Horwitz RJ, 1998, AM J RESP CRIT CARE, V157, P1363, DOI 10.1164/ajrccm.157.5.9706059; JEZIORSKA M, 1995, BIOL REPROD, V53, P312, DOI 10.1095/biolreprod53.2.312; Kajitani H, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000252; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; MITTMAN RJ, 1989, J ALLERGY CLIN IMMUN, V84, P304, DOI 10.1016/0091-6749(89)90412-0; Ohrui T, 1997, LANCET, V350, P1178, DOI 10.1016/S0140-6736(05)63825-1; OZKARAGOZ K, 1970, Journal of Asthma Research, V7, P171, DOI 10.3109/02770907009104290; PADILLA L, 1990, CELL MOL BIOL, V36, P93; PAULI BD, 1989, AM REV RESPIR DIS, V140, P358, DOI 10.1164/ajrccm/140.2.358; POUBELLE PE, 1987, J IMMUNOL, V139, P1273; REES L, 1963, J PSYCHOSOM RES, V7, P191, DOI 10.1016/0022-3999(63)90003-5; SEKIZAWA K, 1993, AM REV RESPIR DIS, V147, P92, DOI 10.1164/ajrccm/147.1.92; Skobeloff EM, 1996, ARCH INTERN MED, V156, P1837, DOI 10.1001/archinte.156.16.1837; STEEL C, 1993, J IMMUNOL, V150, P5511; TANIGUCHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P507, DOI 10.1016/0091-6749(93)90074-P; VLIAGOFTIS H, 1992, INT ARCH ALLERGY IMM, V98, P398, DOI 10.1159/000236217; WENZEL SE, 1995, AM J RESP CRIT CARE, V152, P897, DOI 10.1164/ajrccm.152.3.7663802; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86, DOI 10.1164/ajrccm.149.1.8111605; YAMATODANI A, 1985, J CHROMATOGR, V344, P115, DOI 10.1016/S0378-4347(00)82012-5; YOKOYAMA A, 1995, AM J RESP CRIT CARE, V151, P1354, DOI 10.1164/ajrccm.151.5.7735584	34	39	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	1999	104	3	1				585	588		10.1016/S0091-6749(99)70327-1	http://dx.doi.org/10.1016/S0091-6749(99)70327-1			4	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	241EP	10482831				2022-12-18	WOS:000082870000019
J	Woessner, KM; Simon, RA; Stevenson, DD				Woessner, KM; Simon, RA; Stevenson, DD			Monosodium glutamate sensitivity in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						monosodium glutamate; asthma; aspirin-sensitive asthma; single-blind; placebo-controlled oral challenges	ADVERSE REACTIONS; ASPIRIN	Background: Questions have been raised since the early 1980s about monosodium glutamate (MSG) and provocation of asthma. Because MSG is widely available as a chemical in both natural foods and as an additive in many prepared foods, the need to define the relationship of MSG to asthma is of great importance. Objective: The purpose of this study was to determine whether MSG ingestion induces asthma attacks in asthmatic subjects. Methods: With single-blind, placebo-controlled screening challenges, 100 subjects with asthma (30 subjects with a history of Oriental restaurant asthma attacks; 70 subjects with a negative history) were challenged with 2.5 g of MSG. A total of 78 patients were proved to have aspirin-sensitive asthma, Results: No-patient had a significant fall in FEV1 value or the development of asthma symptoms during the MSG challenge. The mean change in FEV1 with MSG challenge was no different from that of placebo challenge. Subjects with an MSG-positive history showed no significant percent decrease in FEV1 values after placebo challenges compared with MSG 2.5 g oral challenge (P = .28), In the group with an MSG-negative history, there was no statistical difference in the change in lowest FEV1 values between the placebo and MSG challenges (P = .44). The exact 1-sided 95% confidence interval (CI) for the probability of MSG,sensitivity in individuals with aspirin-sensitive asthma (negative history) is 0% to 0.04%. When combined with previous studies that did not demonstrate MSG-provoked asthma, the 95% CI is 0% to 0.03%, For patients with an MSG-positive history, the exact 1-sided 95% CI for the probability of MSG sensitivity in this study was 0% to 0.07%, which is somewhat wider because of the smaller sample size. Conclusions: MSG challenges in subjects with and without a perceived sensitivity to MSG failed to induce signs or symptoms of asthma, Therefore in view of the poorly conducted studies that proposed that MSG induced asthma and the subsequent studies that failed to confirm those findings, it is important to maintain a healthy skepticism about the existence of MSG sensitivity in individuals with asthma.	Scripps Clin, Div Asthma Allergy & Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA	Scripps Research Institute; Scripps Research Institute	Stevenson, DD (corresponding author), Scripps Clin, Div Asthma Allergy & Immunol, W-205,10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR00833] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLEN D, 1981, NEW ENGL J MED, V278, P1154; ALLEN DH, 1987, J ALLERGY CLIN IMMUN, V80, P530, DOI 10.1016/0091-6749(87)90003-0; FILER LJ, 1994, CRIT REV FOOD SCI, V34, P159, DOI 10.1080/10408399409527655; GERMANO P, 1991, Journal of Allergy and Clinical Immunology, V87, P177, DOI 10.1016/0091-6749(91)91438-Y; GIACOMETTI T, 1979, GLUTAMIC ACID ADV BI, P25; Lehmann E RJ, 2005, TESTING STAT HYPOTHE, V3; MONERET-VAUTRIN D A, 1987, Allergie et Immunologie (Paris), V19, P29; PLESKOW WW, 1983, J ALLERGY CLIN IMMUN, V71, P574, DOI 10.1016/0091-6749(83)90439-6; PLESKOW WW, 1982, J ALLERGY CLIN IMMUN, V69, P11, DOI 10.1016/0091-6749(82)90081-1; SCHWARTZSTEIN RM, 1987, J ASTHMA, V24, P167, DOI 10.3109/02770908709070933; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1986, J ALLERGY CLIN IMMUN, V78, P182, DOI 10.1016/0091-6749(86)90011-4; Woods RK, 1998, J ALLERGY CLIN IMMUN, V101, P762, DOI 10.1016/S0091-6749(98)70305-7	13	39	40	0	10	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1999	104	2	1				305	310		10.1016/S0091-6749(99)70371-4	http://dx.doi.org/10.1016/S0091-6749(99)70371-4			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	232HH	10452749				2022-12-18	WOS:000082364800020
J	De Boeck, K; Alifier, M; Warnier, G				De Boeck, K; Alifier, M; Warnier, G			Is the correct use of a dry powder inhaler (Turbohaler) age dependent?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; dry powder inhaler; children; Turbohaler	METERED-DOSE INHALER; INSPIRATORY FLOW-THROUGH; ASTHMATIC-PATIENTS; INHALATION TECHNIQUE; BRICANYL TURBUHALER; CHILDREN; TERBUTALINE; DEVICE; PERFORMANCE; BUDESONIDE	Background: The metered-dose inhalers are the most commonly used devices in the treatment of asthma, but dry powder inhalers (eg, Turbohaler) are being increasingly used. Studies evaluating how well children can use a Turbohaler are lacking. Objective: We assessed whether the correct use of Turbohaler could be easily taught to unselected stable asthmatic children, Methods: One hundred sixty-one asthmatic children aged 5 to 17 years (mean, 9.8 years) consecutively attending the outpatient clinic were included in study. After a demonstration and 10 minutes of training, the inhalation technique was checked in a standardized way (yes/no response). Keeping the device upright, proper preparation of the drug dose and inspiratory flow on inhalation were measured by the Turbohaler trainer. Results: One hundred thirty-three children (83%) performed every step correctly (ie, 96% of children older than 8 years but only 55% of children between 5 and 8 years; P < .001). Of 28 children incorrectly using the Turbuhaler-trainer, 20 generated insufficient inspiratory flow through the device. There was no significant difference in airway obstruction (expressed as percent of predicted forced vital capacity, FEV1, and Tiffeneau index) between correct and incorrect users, but when measured through the pneumotachograph, mean peak inspiratory flow (expressed as percent predicted) was significantly lower in those children incorrectly using the device. Turbohaler use was reevaluated after 4.7 +/- 2.0 months in a subset of 64 patients. Fifty-three of 64 (83%) children again used the device correctly. Only 3 of 13 who used the device incorrectly at the first evaluation used it correctly at the second evaluation. Conclusions: We conclude that the correct use of the Turbohaler can be easily taught to asthmatic children older than 8 years. Those who use the device correctly after initial instructions continue to do so afterwards.	Univ Hosp Gasthuisberg, Dept Pediat, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven	De Boeck, K (corresponding author), Univ Hosp Gasthuisberg, Dept Pediat, Herestr 49, B-3000 Louvain, Belgium.							AGERTOFT L, 1993, ARCH DIS CHILD, V69, P130, DOI 10.1136/adc.69.1.130; AHLSTROM H, 1989, ALLERGY, V44, P515, DOI 10.1111/j.1398-9995.1989.tb04191.x; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792; BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069; FUGLSANG G, 1989, PEDIATR PULM, V7, P112, DOI 10.1002/ppul.1950070211; GOLDMAN DE, 1994, AM J RESP CRIT CARE, V150, P1256; GOREN A, 1994, PEDIATR PULM, V18, P77, DOI 10.1002/ppul.1950180204; HANSEN OR, 1989, EUR RESPIR J, V2, P637; HARVEY J, 1992, BRIT J CLIN PRACT, V46, P249; Hill LS, 1998, RESP MED, V92, P105, DOI 10.1016/S0954-6111(98)90040-3; Hirsch T, 1997, RESP MED, V91, P341, DOI 10.1016/S0954-6111(97)90060-3; HULTQUIST C, 1989, ALLERGY, V44, P467, DOI 10.1111/j.1398-9995.1989.tb04184.x; JACKSON L, 1994, EUR RESPIR J, V7, P1598, DOI 10.1183/09031936.94.07091598; LABERGE S, 1994, J PEDIATR-US, V124, P815, DOI 10.1016/S0022-3476(05)81381-2; LARSEN JS, 1994, J ASTHMA, V31, P193, DOI 10.3109/02770909409044826; LIARD R, 1995, REV EPIDEMIOL SANTE, V43, P242; MEAKIN BJ, 1995, INT J PHARMACEUT, V116, P169; Meijer RJ, 1996, THORAX, V51, P433, DOI 10.1136/thx.51.4.433; OLDAEUS G, 1995, ANN ALLERG ASTHMA IM, V74, P34; PEDERSEN S, 1990, ARCH DIS CHILD, V65, P308, DOI 10.1136/adc.65.3.308; QUANJER PH, 1989, EUR RESPIR J S4, V2, pS148; RIBEIRO LB, 1990, ALLERGY, V45, P382, DOI 10.1111/j.1398-9995.1990.tb00515.x; RICHARDS R, 1993, THORAX, V48, P1186, DOI 10.1136/thx.48.11.1186; SLY PD, 1991, J PAEDIATR CHILD H, V27, P7, DOI 10.1111/j.1440-1754.1991.tb00337.x; Stahl E, 1996, PEDIATR PULM, V22, P106, DOI 10.1002/(SICI)1099-0496(199608)22:2<106::AID-PPUL5>3.0.CO;2-O; van Beerendonk I, 1998, J ASTHMA, V35, P273, DOI 10.3109/02770909809068218; van der Palen J, 1994, Ned Tijdschr Geneeskd, V138, P1417; WARNER JO, 1987, NEW CONCEPT INHALATI, P166	28	39	39	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1999	103	5	1				763	767		10.1016/S0091-6749(99)70417-3	http://dx.doi.org/10.1016/S0091-6749(99)70417-3			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	199FP	10329807				2022-12-18	WOS:000080470200008
J	Mozo, L; Gayo, A; Suarez, A; Rivas, D; Zamorano, J; Gutierrez, C				Mozo, L; Gayo, A; Suarez, A; Rivas, D; Zamorano, J; Gutierrez, C			Glucocorticoids inhibit IL-4 and mitogen-induced IL-4R alpha chain expression by different posttranscriptional mechanisms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						glucocorticoids; dexamethasone; IL-4R alpha; phorbol myristate acetate; gene transcription; mRNA half-life; posttranscriptional regulation	MESSENGER-RNA STABILIZATION; HUMAN T-CELLS; RECEPTOR GENE-EXPRESSION; PROTEIN-KINASE-C; INTERLEUKIN-4 RECEPTOR; INTERFERON-GAMMA; FUNCTIONAL ANTAGONISM; TRANSCRIPTION FACTOR; B-LYMPHOCYTES; IFN-GAMMA	Background: A high level of expression of IL-4R alpha chain on the surface of lymphocytes has been described in certain allergic and inflammatory autoimmune diseases. Progression of these diseases are usually controlled by steroid treatment. One mechanism by which these drugs exert their antiinflammatory and immunosuppressive effects is by widely repressing or enhancing the production of cytokines and their receptors. Objectives: The effect of glucocorticoids on IL-4R alpha chain expression has not been previously studied, and this is the aim of the present report. For this purpose, human lymphocytes were induced to express IL-4R alpha chain by means of protein kinase C (PKC) activation with phorbol myristate acetate (PMA) or by triggering the Janus kinase-Stat pathway with IL-4 in the presence or absence of pharmacologic doses of dexamethasone. Methods: IL-4R alpha cell surface expression was studied by flow cytofluorometry. The levels and stability of mRNA were assessed by Northern blot analysis. The effect of dexamethasone on the IL-4R alpha rate of transcription was determined by nuclear run-on experiments. Results: Dexamethasone significantly downregulated PMA-induced IL-4R alpha mRNA and protein levels in total peripheral blood mononuclear cells and in isolated T cells. The mechanism involved a posttranscriptional regulation of IL-4R alpha expression because dexamethasone decreased the PMA-induced IL-4R alpha mRNA half-life. However, we found that PMA did not influence the transcription rate of IL-4R alpha gene, irrespective of the presence or absence of dexamethasone. This immunosuppressor also diminished the IL-4induced IL-4R alpha expression on the surface of isolated T and B lymphocytes but, interestingly, without modifying mRNA levels that indicates that dexamethasone downregulated IL-4-dependent IL-4R alpha expression by acting at a translational or posttranslational level. In fact, we observed that the drug did not affect IL-4-induced IL-4R alpha gene transcription rate nor did it shorten mRNA half-life. The effect of dexamethasone on the IL-4R alpha was steroid specific because it was totally reversed by the glucocorticoid receptor antagonist RU486. Conclusion: Our results support that dexamethasone may influence the course of allergic and inflammatory diseases by downregulating the expression of IL-4R alpha.	Ctr Univ Oviedo, Hosp Cent Asturias, Serv Inmunol, Dept Immunol, Oviedo 33006, Spain; Univ Oviedo, Oviedo, Spain	Central University Hospital Asturias; University of Oviedo	Gutierrez, C (corresponding author), Ctr Univ Oviedo, Hosp Cent Asturias, Serv Inmunol, Dept Immunol, Julian Claveria S-N, Oviedo 33006, Spain.		Zamorano, Jose/Q-2514-2017; Suarez, Ana/F-4492-2015	Zamorano, Jose/0000-0002-4271-3741; Suarez, Ana/0000-0002-4452-7539				AKAHOSHI T, 1988, J EXP MED, V167, P924, DOI 10.1084/jem.167.3.924; ALMAWI WY, 1991, J IMMUNOL, V146, P3523; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BOUMPAS DT, 1991, J CLIN INVEST, V87, P1739, DOI 10.1172/JCI115192; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEBETS JMH, 1989, CLIN EXP IMMUNOL, V78, P224; DOKTER WHA, 1993, BLOOD, V81, P35; DOKTER WHA, 1992, BLOOD, V80, P2721; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IKIZAWA K, 1995, CLIN EXP IMMUNOL, V100, P383; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KALDY P, 1995, EUR J IMMUNOL, V25, P889, DOI 10.1002/eji.1830250405; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KERN JA, 1988, J CLIN INVEST, V81, P237, DOI 10.1172/JCI113301; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LAMAS M, 1993, CELL IMMUNOL, V151, P437, DOI 10.1006/cimm.1993.1252; LEE SW, 1988, P NATL ACAD SCI USA, V85, P1204, DOI 10.1073/pnas.85.4.1204; MORRIS L, 1992, J IMMUNOL, V149, P2715; MOZO L, 1993, J IMMUNOL, V150, P4261; OHH M, 1994, BLOOD, V84, P2632; PALIOGIANNI F, 1993, J IMMUNOL, V151, P4081; PATERSON RLK, 1994, J IMMUNOL, V152, P2139; PAUL WE, 1991, BLOOD, V77, P1859; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; POYET P, 1989, MOL ENDOCRINOL, V3, P1961, DOI 10.1210/mend-3-12-1961; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; REED JC, 1986, J IMMUNOL, V137, P150; RENZ H, 1992, J INVEST DERMATOL, V99, P403, DOI 10.1111/1523-1747.ep12616114; RIVAS D, 1995, J AUTOIMMUN, V8, P587, DOI 10.1016/0896-8411(95)90010-1; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHIEH JH, 1993, BLOOD, V81, P1745; SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838; STRICKLAND RW, 1986, J IMMUNOL, V137, P1577; Suarez A, 1997, EUR J IMMUNOL, V27, P2822, DOI 10.1002/eji.1830271112; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TOBLER A, 1992, BLOOD, V79, P45; WANG HH, 1992, INSECT MOL BIOL, V1, P1; ZUBIAGA AM, 1992, J IMMUNOL, V149, P107	45	39	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1998	102	6	1				968	976		10.1016/S0091-6749(98)70335-5	http://dx.doi.org/10.1016/S0091-6749(98)70335-5			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	150XE	9847438				2022-12-18	WOS:000077690700015
J	McDyer, JF; Wu, CY; Seder, RA				McDyer, JF; Wu, CY; Seder, RA			The regulation of IL-12: Its role in infectious, autoimmune, and allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTERLEUKIN-12 PRODUCTION; INTERFERON-GAMMA; T-CELLS; IFN-GAMMA; AIRWAY HYPERRESPONSIVENESS; TOXOPLASMA-GONDII; IMMUNE-RESPONSE; HUMAN MONOCYTES; TNF-ALPHA		NIAID, Clin Immunol Sect, Clin Invest Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Seder, RA (corresponding author), NIAID, Clin Immunol Sect, Clin Invest Lab, NIH, Bldg 10,Room 11C215,9000 Rockville Pike, Bethesda, MD 20892 USA.							AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; Carrera L, 1996, J EXP MED, V183, P515, DOI 10.1084/jem.183.2.515; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; CHEHIMI J, 1994, J EXP MED, V179, P1361, DOI 10.1084/jem.179.4.1361; Chougnet C, 1996, J INFECT DIS, V174, P46, DOI 10.1093/infdis/174.1.46; Compos-Neto A, 1998, J IMMUNOL, V160, P2037; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; DeKruyff RH, 1997, J IMMUNOL, V158, P359; FLESCH IEA, 1995, J EXP MED, V181, P1615, DOI 10.1084/jem.181.5.1615; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gazzinelli RT, 1996, J IMMUNOL, V157, P798; Gerosa F, 1996, J EXP MED, V183, P2559, DOI 10.1084/jem.183.6.2559; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; Grewal IS, 1996, IMMUNOL REV, V153, P85, DOI 10.1111/j.1600-065X.1996.tb00921.x; Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137; HAYES MP, 1995, BLOOD, V86, P646, DOI 10.1182/blood.V86.2.646.bloodjournal862646; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Jeannin P, 1996, J IMMUNOL, V156, P3159; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kennedy MK, 1996, EUR J IMMUNOL, V26, P370, DOI 10.1002/eji.1830260216; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Marth T, 1997, J EXP MED, V185, P1987, DOI 10.1084/jem.185.11.1987; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; SchartonKersten TM, 1996, J IMMUNOL, V157, P4045; Seder RA, 1996, J IMMUNOL, V157, P2745; SHU U, 1995, EUR J IMMUNOL, V25, P1125, DOI 10.1002/eji.1830250442; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; Szalay G, 1996, J IMMUNOL, V157, P4746; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; ZHOU P, 1998, IN PRESS J EXP MED	34	39	40	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	1998	102	1					11	15						5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	102DX	9679841				2022-12-18	WOS:000074909500002
J	Tinghino, R; Barletta, B; Palumbo, S; Afferni, C; Iacovacci, P; Mari, A; Di Felice, G; Pini, C				Tinghino, R; Barletta, B; Palumbo, S; Afferni, C; Iacovacci, P; Mari, A; Di Felice, G; Pini, C			Molecular characterization of a cross-reactive Juniperus oxycedrus pollen allergen, Jun o 2: A novel calcium-binding allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Cupressaceae; Juniperus oxycedrus; cDNA cloning; IgE; calcium-binding protein; cross reactivity	MAJOR ALLERGEN; CUPRESSUS-SEMPERVIRENS; CHAMAECYPARIS-OBTUSA; BIRCH POLLEN; IGE-BINDING; PROTEINS; IDENTIFICATION; PURIFICATION; ARIZONICA; PROFILIN	Background: Species belonging to the Cupressaceae family are a relevant source of allergens that are present in a wide number of countries. Objective:We sought to identify, purify, and characterize recombinant allergens from Juniperus oxycedrus, a species belonging to the Cupressaceae family. Methods: Double-stranded cDNA was synthesized from mRNA and cloned into the lambda-ZAP expression vector. IgE screening of the Library was performed with a pool of sera from subjects allergic to Cupressaceae. A recombinant 6 x His-tagged Juniperus oxycedrus allergen, Jun o 2, was expressed in Escherichia coli and purified by Ni(2+) affinity chromatography. It was studied further by immunoblotting inhibition with pollen extracts from other Cupressaceae, Oleaceae, Urticaceae, and Graminaceae. The role of protein-bound calcium on the allergen's IgE-binding capacity was tested in a plaque assay in the presence or absence of EGTA. Results: A cDNA coding for a newly identified Juniperus oxycedrus pollen allergen, dun o 2, was isolated. The deduced amino acid sequence contained four typical Ca(2+) binding sites and showed a significant sequence similarity to calmodulins. Depletion of Ca(2+) in the plaque assay led to a loss of IgE-binding capacity of dun o 2. Immunoblotting inhibition revealed that J. oxycedrus, J. ashei, Cupressus arizonica, C. sempervirens, Parietaria judaica, Olea europaea, and Lolium perenne pollen extracts were able to inhibit IgE binding to blotted rJun o 2 at different concentrations. Conclusion: rJun o 2 contains IgE-binding epitopes shared by taxonomically unrelated species, and therefore it can be regarded as a new panallergen. These findings could contribute to an explanation for the phenomenon of multiple positive test results in polysensitized patients and the potential symptom-eliciting role of allergenic sources previously not encountered.	Ist Super Sanita, Dept Immunol, Immunol Lab, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Pini, C (corresponding author), Ist Super Sanita, Dept Immunol, Immunol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Di Felice, Gabriella/B-9985-2016; AFFERNI, CLAUDIA/B-9978-2016; BARLETTA, BIANCA/B-9980-2016	Di Felice, Gabriella/0000-0001-7387-9683; AFFERNI, CLAUDIA/0000-0002-8567-7365; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; APPLE RD, 1994, TRENDS BIOCHEM SCI, V19, P258; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHOLTZ GA, 1985, ANN ALLERGY, V55, P805; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CHEUNG WY, 1982, SCI AM, V246, P48; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; DAYAN YB, 1995, CLIN EXP ALLERGY, V25, P456, DOI 10.1111/j.1365-2222.1995.tb01077.x; DE CESARE F, 1993, ALLERGY, V48, P248; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFELICE G, 1994, J ALLERGY CLIN IMMUN, V94, P547, DOI 10.1016/0091-6749(94)90212-7; ELSAYED S, 1981, SCAND J IMMUNOL, V14, P207, DOI 10.1111/j.1365-3083.1981.tb00201.x; GOETZ DW, 1995, ANN ALLERG ASTHMA IM, V75, P256; Guerin B, 1996, INT ARCH ALLERGY IMM, V110, P91, DOI 10.1159/000237317; Hepler PK, 1994, CUR TOP PL, V12, P111; IACOVACCI P, 1998, IN PRESS J ALLERGY C; ITO H, 1995, ANN ALLERG ASTHMA IM, V74, P299; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; Larsen JN, 1996, J ALLERGY CLIN IMMUN, V97, P577; Lindstrom CDV, 1996, SCAND J IMMUNOL, V44, P335, DOI 10.1046/j.1365-3083.1996.d01-314.x; Mari A, 1996, J ALLERGY CLIN IMMUN, V98, P21, DOI 10.1016/S0091-6749(96)70222-1; Mari A, 1997, ALLERGY, V52, P355, DOI 10.1111/j.1398-9995.1997.tb01008.x; Midoro-Horiuti T, 1992, Acta Paediatr Jpn, V34, P501; MUCCI B, 1993, CLIN RADIOL, V47, P424, DOI 10.1016/S0009-9260(05)81065-7; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PHAM NH, 1995, CLIN EXP ALLERGY, V25, P599, DOI 10.1111/j.1365-2222.1995.tb01107.x; PIGNATTI S, 1982, FLORA ITALIA, P81; REID MJ, 1992, J ALLERGY CLIN IMMUN, V89, P593, DOI 10.1016/0091-6749(92)90327-X; Sambrook J, 1989, MOL CLONING LAB MANU; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; SEIBERLER S, 1994, EMBO J, V13, P3481, DOI 10.1002/j.1460-2075.1994.tb06654.x; Suphioglu C, 1997, FEBS LETT, V402, P167, DOI 10.1016/S0014-5793(96)01520-7; Suzuki M, 1996, MOL IMMUNOL, V33, P451, DOI 10.1016/0161-5890(95)00147-6; Toriyama K, 1995, PLANT MOL BIOL, V29, P1157, DOI 10.1007/BF00020459; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97, DOI 10.1159/000236171	41	39	45	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1998	101	6	1				772	777		10.1016/S0091-6749(98)70306-9	http://dx.doi.org/10.1016/S0091-6749(98)70306-9			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZW470	9648704				2022-12-18	WOS:000074414200010
J	Nakajima-Adachi, H; Hachimura, S; Ise, W; Honma, K; Nishiwaki, S; Hirota, M; Shimojo, N; Katsuki, T; Ametani, A; Kohno, Y; Kaminogawa, S				Nakajima-Adachi, H; Hachimura, S; Ise, W; Honma, K; Nishiwaki, S; Hirota, M; Shimojo, N; Katsuki, T; Ametani, A; Kohno, Y; Kaminogawa, S			Determinant analysis of IgE and IgG4 antibodies and T cells specific for bovine alpha(s1)-casein from the same patients allergic to cow's milk: Existence of alpha(s1)-casein-specific B cells and T cells characteristic in cow's-milk allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alpha(s1)-casein; cow's-milk allergy; IgE; IgG4; T-cell line; determinant; peptide	OVERLAPPING SYNTHETIC PEPTIDES; ALPHA-S1-CASEIN CROSS-REACT; BIRCH POLLEN ALLERGEN; GROUP-II ANTIGEN; DER-P-II; MAJOR ALLERGEN; DERMATOPHAGOIDES-PTERONYSSINUS; ATOPIC-DERMATITIS; EPITOPE-SPECIFICITY; HISTAMINE-RELEASE	In an effort to clarify the etiology of milk allergy from the standpoint of allergen-specific immune reactions, me investigated the determinants of IgE, IgG4, and T cells specific for bovine alpha(s1)-casein from the same individual patients by using its synthetic peptides and cyanogen bromide-digested fragments. alpha(s1)-Casein is a major allergen in cow's milk, and its unique conformation enabled us to investigate the determinants of antibodies without consideration about missing the reactivities because of conformational changes. Nine patients were selected as subjects from among 129 milk-sensitive infants screened by ELISA to assess the anti-alpha(s1)-casein IgE levels in their sera. By using ELISA for epitope mapping, a C-terminal region of alpha(s1)-casein was identified as a common binding site for IgE from all of these patients, whereas those for anti-alpha(s1)-casein IgG4 were located in multiple regions of alpha(s1)-casein. We determined the specificities of seven alpha(s1)-casein-specific T-cell lines established from peripheral blood mononuclear cells of two of the patients. These T cells have been shown to secrete IL-4. All of the T-cell lines had different specificities to alpha(s1)-casein. However, a common amino acid residue use was found among the determinants of various T-cell lines from each patient. The results suggest that patients allergic to cow's milk have characteristic B cells recognizing a limited region of alpha(s1)-casein and secreting alpha(s1)-casein-specific IgE. These B cells may interact particularly with T cells recognizing determinants with a common structure.	Juntendo Univ, Sch Med, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 113, Japan; Chiba Univ, Sch Med, Dept Pediat, Chiba, Japan	Juntendo University; Chiba University	Nakajima-Adachi, H (corresponding author), Juntendo Univ, Sch Med, Dept Appl Biol Chem, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 113, Japan.							Akdis CA, 1997, J ALLERGY CLIN IMMUN, V99, P345, DOI 10.1016/S0091-6749(97)70052-6; AMETANI A, 1988, BIOCHEM BIOPH RES CO, V154, P876, DOI 10.1016/0006-291X(88)90221-5; AMETANI A, 1987, J BIOCHEM, V102, P421, DOI 10.1093/oxfordjournals.jbchem.a122069; ATASSI H, 1986, EUR J IMMUNOL, V16, P229, DOI 10.1002/eji.1830160304; Baba M, 1989, ACI NEWS, V1, P71; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; BALL T, 1994, J BIOL CHEM, V269, P28323; Blaher B, 1996, J ALLERGY CLIN IMMUN, V98, P124, DOI 10.1016/S0091-6749(96)70234-8; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; COLLOFF MJ, 1992, INT ARCH ALLERGY IMM, V97, P44, DOI 10.1159/000236094; DHILLON M, 1992, J ALLERGY CLIN IMMUN, V90, P42, DOI 10.1016/S0091-6749(06)80009-6; DONOVAN GR, 1994, BBA-PROTEIN STRUCT M, V1204, P48, DOI 10.1016/0167-4838(94)90031-0; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; ENOMOTO A, 1990, MOL IMMUNOL, V27, P581, DOI 10.1016/0161-5890(90)90077-D; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Gros E., 1967, METHOD ENZYMOL, V11, P238; HACHIMURA S, 1993, BIOSCI BIOTECH BIOCH, V57, P1674, DOI 10.1271/bbb.57.1674; HACHIMURA S, 1994, INT IMMUNOL, V6, P1791, DOI 10.1093/intimm/6.11.1791; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HONMA K, 1994, INT ARCH ALLERGY IMM, V103, P28, DOI 10.1159/000236602; Honma K, 1996, CLIN EXP IMMUNOL, V103, P446; HUANG SK, 1995, J IMMUNOL, V154, P6157; JABARA HH, 1993, J IMMUNOL, V151, P4528; JEANNIN P, 1992, MOL IMMUNOL, V29, P739, DOI 10.1016/0161-5890(92)90184-Y; KAMINOGAWA S, 1996, STRUCTURE ANTIGEN, V3, P387; Katsuki T, 1996, INT ARCH ALLERGY IMM, V109, P344, DOI 10.1159/000237261; KIM SM, 1993, INT ARCH ALLERGY IMM, V101, P260, DOI 10.1159/000236455; Kobayashi I, 1996, J ALLERGY CLIN IMMUN, V97, P638, DOI 10.1016/S0091-6749(96)70309-3; KUMOSINSKI TF, 1991, J DAIRY SCI, V74, P2889, DOI 10.3168/jds.S0022-0302(91)78470-1; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; MOHAPATRA SS, 1994, IMMUNOL TODAY, V15, P596, DOI 10.1016/0167-5699(94)90226-7; Nakajima H, 1996, J ALLERGY CLIN IMMUN, V97, P1342, DOI 10.1016/S0091-6749(96)70203-8; ONG EK, 1995, MOL IMMUNOL, V32, P295, DOI 10.1016/0161-5890(94)00127-M; OSHIKA E, 1992, ANN ALLERGY, V69, P427; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RENTZ H, 1993, J EXP MED, V177, P1175; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SHON DH, 1991, EUR J IMMUNOL, V21, P1475, DOI 10.1002/eji.1830210622; SNOW RE, 1995, J IMMUNOL, V154, P5576; SPIEGELBERG HL, 1994, J IMMUNOL, V152, P4706; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; VANDERSTOEP N, 1994, EUR J IMMUNOL, V24, P1307, DOI 10.1002/eji.1830240610; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5; VANMILLIGEN FJ, 1994, INT ARCH ALLERGY IMM, V103, P274, DOI 10.1159/000236639; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; YSSEL H, 1992, J IMMUNOL, V148, P738; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0; Zhang L, 1996, IMMUNOLOGY, V87, P283, DOI 10.1046/j.1365-2567.1996.467533.x; ZITTLE CA, 1963, J DAIRY SCI, V46, P1183, DOI 10.3168/jds.S0022-0302(63)89242-5; ZWEIMAN B, 1993, CURR OPIN IMMUNOL, V5, P950, DOI 10.1016/0952-7915(93)90111-5	59	39	47	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1998	101	5					660	671		10.1016/S0091-6749(98)70175-7	http://dx.doi.org/10.1016/S0091-6749(98)70175-7			12	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	ZN926	9600504				2022-12-18	WOS:000073697400015
J	Benlounes, N; Dupont, C; Candalh, C; Blaton, MA; Darmon, N; Desjeux, JF; Heyman, M				Benlounes, N; Dupont, C; Candalh, C; Blaton, MA; Darmon, N; Desjeux, JF; Heyman, M			The threshold for immune cell reactivity to milk antigens decreases in cow's milk allergy with intestinal symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; mononuclear cells; TNF-alpha; intestinal barrier; Ussing chambers	RAT SMALL-INTESTINE; EPITHELIAL-CELLS; SENSITIVE ENTEROPATHY; BETA-LACTOGLOBULIN; TRANSPORT; LINE; ABSORPTION; EXPRESSION; EMERGENCE; INFANTS	Background: In cow's milk allergy (CMA) with intestinal symptoms, peripheral blood mononuclear cells (PBMCs) secrete tumor necrosis factor-alpha (TNF-alpha), altering intestinal function. However, the type of cow's milk protein (CMP) that triggers symptoms (intact or intestinally processed) is not known, and neither is the minimal amount required. Methods: PBMCs were isolated from infants with active CMA or cured infants just before a new challenge and stimulated with intact or intestinally processed CMP. Supernatants were tested for cytokine content and for their ability to perturb intestinal barrier capacity, measured in Ussing chambers in HT29-19A intestinal cells. Results: PBMCs from infants with active CMA secreted more TNF-alpha, when they were stimulated with intact rather than intestinally processed CMPs, and more TNF-alpha than PBMCs from cured infants. Accordingly, supernatants from PBMCs stimulated with intact but not intestinally processed CMPs significantly increased intestinal permeability. The CMP concentration required to trigger TNF-alpha secretion capable of altering intestinal function was very small in infants with active CMA (congruent to 2 mu g/ml), but about 300 times higher in cured infants. Conclusion: Intact rather than intestinally processed proteins stimulate PBMCs to release TNF-alpha and either intestinal barrier capacity. The threshold for PBMC reactivity of milk antigens drops considerably during active CMA with intestinal symptoms.	HOP ST LAZARE,INSERM,U290,F-75010 PARIS,FRANCE; HOP ST VINCENT DE PAUL,F-75674 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			Darmon, Nicole/AAC-4255-2019	Darmon, Nicole/0000-0001-6625-4466				AUGERON C, 1984, CANCER RES, V44, P3961; BLAND PW, 1986, IMMUNOLOGY, V58, P1; BOCK SA, 1994, PEDIATR CLIN N AM, V41, P1047; CHUNG YC, 1979, GASTROENTEROLOGY, V76, P1415; DAVIDSON M, 1965, J PEDIATR-US, V66, P545, DOI 10.1016/S0022-3476(65)80119-6; Diagnostic criteria for food allergy with predominantly intestinal symptoms, 1992, J PEDIAT GASTROENTER, V14, P108; DUPONT C, 1989, J PEDIATR GASTR NUTR, V8, P459, DOI 10.1097/00005176-198905000-00007; GOTTELAND M, 1989, PEDIATR RES, V26, P237, DOI 10.1203/00006450-198909000-00016; HASHIMOTO Y, 1988, CELL TISSUE RES, V254, P41; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514, DOI 10.1016/0016-5085(94)90405-7; HEYMAN M, 1992, J PEDIATR GASTR NUTR, V15, P48, DOI 10.1097/00005176-199207000-00008; HEYMAN M, 1990, J CELL PHYSIOL, V143, P391, DOI 10.1002/jcp.1041430225; HEYMAN M, 1982, AM J PHYSIOL, V242, pG558, DOI 10.1152/ajpgi.1982.242.6.G558; HILL DJ, 1988, CLIN ALLERGY, V18, P469, DOI 10.1111/j.1365-2222.1988.tb02897.x; KAISERLIAN D, 1989, EUR J IMMUNOL, V19, P1513, DOI 10.1002/eji.1830190827; MAEHLY AC, 1954, METHOD BIOCHEM ANAL, V1, P357; MAYER L, 1991, GASTROENTEROLOGY, V100, P3, DOI 10.1016/0016-5085(91)90575-6; MIKOGAMI T, 1994, AM J PHYSIOL, V267, pG308, DOI 10.1152/ajpgi.1994.267.2.G308; NATALI PG, 1981, TRANSPLANTATION, V31, P75, DOI 10.1097/00007890-198101000-00017; NATH SK, 1989, AM J PHYSIOL, V256, pG335, DOI 10.1152/ajpgi.1989.256.2.G335; PHILLIPS AD, 1979, GUT, V20, P509, DOI 10.1136/gut.20.6.509; SAIDI D, 1995, CR ACAD SCI III-VIE, V318, P683; *SAS I INC, 1985, SAS US GUID BAS; WALKERSMITH J, 1978, ARCH DIS CHILD, V53, P375, DOI 10.1136/adc.53.5.375	24	39	41	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	1996	98	4					781	789		10.1016/S0091-6749(96)70127-6	http://dx.doi.org/10.1016/S0091-6749(96)70127-6			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VM665	8876554				2022-12-18	WOS:A1996VM66500011
J	Harvey, RP; Comer, C; Sanders, B; Westley, R; Marsh, W; Shapiro, H; Wiener, M				Harvey, RP; Comer, C; Sanders, B; Westley, R; Marsh, W; Shapiro, H; Wiener, M			Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinoconjunctivitis; quality of life; cetirizine; terfenadine; chlorpheniramine; cost; managed care; multiattribute; efficacy	DAYTIME SLEEPINESS; CLINICAL-TRIALS; PERFORMANCE; DIPHENHYDRAMINE; CETIRIZINE; QUALITY; LIFE; CARE	Background: Drug selection for optimal treatment of common medical conditions may be difficult and involve may diverse factors. Objective: The efficacy, safety, quality of life, and cost of treatment of seasonal allergic rhinitis with cetirizine, chlorpheniramine, or terfenadine were compared in a prospective, two-phase, randomized, single-blind clinical trial conducted in a managed care setting. Methods: In phase I, which lasted 2 weeks, patients were randomized to receive one of the study drugs. In phase II, which lasted 4 weeks, the initial treatment was continued unless patients were dissatisfied, in which case they could be randomly assigned to receive another study drug. In both phases pseudoephedrine could be taken as needed. Patients kept daily diaries of symptoms and costs, and study drugs were evaluated at the end of each phase for efficacy, safety, and effect on quality of life by means of validated questionnaire. A multiattribute outcomes assessment model for formulary decision making was used to rank the antihistamines. Results: Physicians' and patients' assessments in phase I and II indicated that cetirizine and chlorpheniramine were significantly more effective than terfenadine (p < 0.05). Incidence of sedation in phase I and phase II was 40.5% and 16.7% for chlorpheniramine, 11.6% and 9.8% for cetirizine, and 6.7% and 5.1% for terfenadine, respectively. At the end of phase I, 28.9% of the patients treated with chlorpheniramine, 50% of the patients treated with terfenadine, and 69.4% of the patients treated with cetirizine were satisfied with their therapy and chose not to switch their medication. Quality of life scores improved most after treatment with cetirizine and least after treatment with terfenadine. Conclusion: The results of this trial indicate that antihistamine selection is best made with the use of a multiattribute evaluation that includes quality of life. In this study cetirizine was favored by patients and physicians most often, followed by chlorpheniramine and then terfenadine.	PRESBYTERIAN ST LUKES,OFF RES & DEV,DENVER,CO; PHARMATEC INC,DENVER,CO		Harvey, RP (corresponding author), KAISER PERMANENTE SYST,DEPT ALLERGY,10400 E ALAMEDA AVE,DENVER,CO 80231, USA.							BETTS T, 1984, BRIT MED J, V288, P281, DOI 10.1136/bmj.288.6413.281; DEYO RA, 1991, ANN INTERN MED, V114, P695, DOI 10.7326/0003-4819-114-8-695; FOX RW, 1992, J RESP DIS S, V13, pS34; GENGO FM, 1990, ANN ALLERGY, V64, P520; GUYATT GH, 1989, CAN MED ASSOC J, V140, P1441; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P900, DOI 10.1016/0091-6749(88)90032-2; MOSER L, 1978, EUR J CLIN PHARMACOL, V14, P417, DOI 10.1007/BF00716383; MOSKOWITZ H, 1988, CUTIS, V42, P14; NICHOLSON AN, 1985, AVIAT SPACE ENVIR MD, V56, P293; OHANLON JF, 1988, CUTIS, V42, P10; ROEHRS TA, 1984, SLEEP, V7, P137, DOI 10.1093/sleep/7.2.137; *SAS I INC, 1985, SAS US GUID STAT VER; SCHUMACHER GE, 1991, AM J HOSP PHARM, V48, P301, DOI 10.1093/ajhp/48.2.301; SEIDEL WF, 1987, ANN ALLERGY, V59, P58; SIMONS FER, 1991, RESP DIGEST, P1; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925	17	39	41	1	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	1996	97	6					1233	1241		10.1016/S0091-6749(96)70190-2	http://dx.doi.org/10.1016/S0091-6749(96)70190-2			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	VD607	8648018				2022-12-18	WOS:A1996VD60700010
J	Lagier, B; Pons, N; Rivier, A; Chanal, I; Chanez, P; Bousquet, J; Pene, J				Lagier, B; Pons, N; Rivier, A; Chanal, I; Chanez, P; Bousquet, J; Pene, J			Seasonal variations of interleukin-4 and interferon-gamma release by peripheral blood mononuclear cells from atopic subjects stimulated by polyclonal activators	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						interleukin-4; IgE; atopy; pollen; season	HUMAN B-CELLS; CD4+ T-CELLS; IGE SYNTHESIS INVITRO; POLLEN SEASON; IMMUNOLOGICAL CHARACTERISTICS; GRASS POLLENS; IFN-GAMMA; HUMAN TH1; IL-4; IMMUNOTHERAPY	IgE synthesis is controlled by interleukin (IL)-4 and interferon (IFN)-gamma, but there is heterogeneity in the IL-4 response depending on the sensitization of patients and natural allergen exposure. In patients sensitized to various allergens, we studied the synthesis of IL-4 IFN-gamma, and IgE to determine to what extent their in vitro immune response may be influenced by pollen season, depending on their sensitization. We studied 12 nonallergic individuals, seven patients sensitized to cypress pollen, 12 sensitized to grass pollen, 14 sensitized to several pollens, and 42 patients with polysensitization. The release of IL-4 and IFN-gamma from peripheral blood mononuclear cells stimulated by polyclonal agents (calcium ionophore A23187 and phorbol myristate acetate) was measured by ELISA. The spontaneous and IL-4-induced release of IgE was measured by ELISA. In patients with cypress pollen allergy, IL-4 and IgE release were significantly lower than in patients with other allergies. In the pollen-sensitized group, IL-4 and IgE release were significantly higher during the pollen season than out of it. No variation in IL-4 ol IgE release was observed in the polysensitized group. IFN-gamma production was not affected by the pollen season. These data show that the seasonal variations of IL-4 and IgE synthesis differ according to the sensitization of patients.	HOP ARNAUD VILLENEUVE,INSERM,CJF 9210,F-34295 MONTPELLIER 5,FRANCE; CHU MONTPELLIER,MALAD RESP CLIN,MONTPELLIER,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier			Bousquet, Jean/O-4221-2019	chanez, pascal/0000-0003-4059-0917				BJORKSTEN B, 1990, ALLERGY, V45, P572, DOI 10.1111/j.1398-9995.1990.tb00942.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; BOUSQUET J, 1993, ALLERGY PRINCIPLES P, P573; CHRETIEN I, 1990, EUR J IMMUNOL, V20, P243, DOI 10.1002/eji.1830200203; COUR P, 1973, POLLEN SPORES, V16, P103; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DELPRETE G, 1988, J IMMUNOL, V140, P4193; GAGNON R, 1993, J ALLERGY CLIN IMMUN, V91, P950, DOI 10.1016/0091-6749(93)90353-H; GAGNON R, 1993, CLIN EXP ALLERGY, V23, P498, DOI 10.1111/j.1365-2222.1993.tb03237.x; GASCAN H, 1991, J IMMUNOL, V147, P8; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; ISHIZAKA A, 1990, CLIN EXP IMMUNOL, V79, P392; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; Malling HJ., 2003, ALLERGY, V48, P55; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSH DG, 1981, NEW ENGL J MED, V9, P60; MOSMANN TR, 1991, IMMUNOL REV, V123, P209, DOI 10.1111/j.1600-065X.1991.tb00612.x; PENE J, 1994, IMMUNOLOGY, V81, P58; PENE J, 1988, J IMMUNOL, V141, P1218; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PRIETO L, 1993, CLIN EXP ALLERGY, V23, P172, DOI 10.1111/j.1365-2222.1993.tb00878.x; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; PUNNONEN J, 1994, J IMMUNOL, V152, P1094; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; REID M, 1989, N ENGL REGIONAL ALLE, V9, P225; ROCKEN M, 1991, J IMMUNOL, V146, P577; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SPIEGELBERG HL, 1981, J CLIN INVEST, V68, P845, DOI 10.1172/JCI110339; VANDERPOUWKRAAN T, 1993, EUR J IMMUNOL, V23, P1, DOI 10.1002/eji.1830230102; VANDERPOUWKRAAN T, 1992, EUR J IMMUNOL, V22, P1237, DOI 10.1002/eji.1830220519; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WEYER A, 1978, CLIN ALLERGY, V8, P187, DOI 10.1111/j.1365-2222.1978.tb00463.x; WILHELM D, 1994, EXP CLIN IMMUNOGENET, V10, P208; YSSEL H, 1993, ANN FR ANESTH, V12, P109, DOI 10.1016/S0750-7658(05)81018-4	39	39	40	0	3	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1995	96	6	1				932	940		10.1016/S0091-6749(95)70231-8	http://dx.doi.org/10.1016/S0091-6749(95)70231-8			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	TN124	8543752				2022-12-18	WOS:A1995TN12400011
J	OOSTERHOFF, Y; KAUFFMAN, HF; RUTGERS, B; ZIJLSTRA, FJ; KOETER, GH; POSTMA, DS				OOSTERHOFF, Y; KAUFFMAN, HF; RUTGERS, B; ZIJLSTRA, FJ; KOETER, GH; POSTMA, DS			INFLAMMATORY CELL NUMBER AND MEDIATORS IN BRONCHOALVEOLAR LAVAGE FLUID AND PERIPHERAL-BLOOD IN SUBJECTS WITH ASTHMA WITH INCREASED NOCTURNAL AIRWAYS NARROWING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						NOCTURNAL ASTHMA; CIRCADIAN PEAK EXPIRATORY FLOW VARIATION; BRONCHOALVEOLAR LAVAGE; PERIPHERAL BLOOD LEUKOCYTES; EOSINOPHILS; EG(2)(+) CELLS; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL-DERIVED NEUROTOXIN; HISTAMINE PROSTAGLANDIN D-2; THROMBOXANE B-2; EICOSANOIDS	EOSINOPHIL CATIONIC PROTEIN; CIRCADIAN VARIATION; SYMPTOMATIC ASTHMA; MAST-CELL; HISTAMINE; RESPONSIVENESS; PROSTAGLANDIN-D2; METHACHOLINE; BUDESONIDE; BAMBUTEROL	Background: Increased nocturnal airways narrowing (NAN) in asthma is thought to occur as the result of intensification of inflammatory processes in the airways. In this study we investigated the presence of inflammatory cells and mediators in bronchoalveolar lavage (BAL) fluid and peripheral blood (PB) and assessed their relationship with the occurrence of increased NAN. Methods: BAL fluid and PB samples were assessed at 16:00 and 04:00 hours, separated by 7 days or more, in eight nonatopic healthy subjects (group 1) and 17 atopic subjects with asthma who were using inhaled bronchodilators only. The fatter subjects were prospectively assigned to groups with and without NAN, as defined by a mean circadian peak expiratory flow variation of less than 15% (group 2) and 15% or more (group 3), respectively. Results: Significantly higher eosinophil numbers and inflammatory activation products (eosinophil cationic protein, eosinophil-derived neurotoxin, histamine) were found in BAL fluid and PB from subjects with asthma in comparison with control subjects. However; increased NAN was not generally associated with a circadian fluctuation in cell number and inflammatory mediators in BAL fluid and PB. No differences in inflammatory cell numbers existed that distinguished between groups 2 and 3. However, in group 3 significantly higher BAL prostaglandin D-2 levels (70 vs 24 pg/ml; range 28 to 102 vs 11 to 90 pg/ml; p = 0.04) and serum eosinophil cationic protein levels (17.6 vs 16.1 ng/ml; range, 6.3 to 17.5 vs 6.3 to 60.3 ng/ml; p = 0.03) at 16:00 hours were detected compared with group 2. Conclusions: Our findings suggest that increased NAN is more likely to occur in subjects with asthma with ongoing increased cellular activation during the day.	UNIV GRONINGEN HOSP,DEPT PULMONOL,9713 EZ GRONINGEN,NETHERLANDS; UNIV GRONINGEN HOSP,DEPT ALLERGOL,GRONINGEN,NETHERLANDS; ERASMUS UNIV ROTTERDAM,FAC MED,DEPT PHARMACOL,3000 DR ROTTERDAM,NETHERLANDS	University of Groningen; University of Groningen; Erasmus University Rotterdam								ARM JP, 1992, ADV IMMUNOL, V51, P323, DOI 10.1016/S0065-2776(08)60491-5; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRAAT MCP, 1992, CLIN PHARMACOKINET, V22, P231, DOI 10.2165/00003088-199222030-00005; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P577, DOI 10.1164/ajrccm/145.3.577; CARLSON M, 1991, J ALLERGY CLIN IMMUN, V87, P27, DOI 10.1016/0091-6749(91)90209-7; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; FITZPATRICK MF, 1992, CLIN SCI, V83, P227, DOI 10.1042/cs0830227; FULLER RW, 1986, AM REV RESPIR DIS, V133, P252; HAUS E, 1983, AM J ANAT, V168, P467, DOI 10.1002/aja.1001680406; HOLGATE ST, 1986, J ALLERGY CLIN IMMUN, V77, P274, DOI 10.1016/S0091-6749(86)80104-X; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905, DOI 10.1164/ajrccm/146.4.905; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83, DOI 10.1164/ajrccm/144.1.83; LIU MC, 1990, AM REV RESPIR DIS, V142, P126, DOI 10.1164/ajrccm/142.1.126; MARINI M, 1992, CHEST, V102, P661, DOI 10.1378/chest.102.3.661; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351, DOI 10.1164/ajrccm/143.2.351; OOSTERHOFF Y, 1993, AM REV RESPIR DIS, V147, P512, DOI 10.1164/ajrccm/147.3.512; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62, DOI 10.1164/ajrccm/136.1.62; SZEFLER SJ, 1991, CLIN PHARMACOL THER, V49, P59, DOI 10.1038/clpt.1991.11; TAI PC, 1984, NATURE, V309, P182, DOI 10.1038/309182a0; WARDLAW AJ, 1988, AM REV RESPIR DIS, V136, P379; WEMPE JB, 1992, J ALLERGY CLIN IMMUN, V90, P349, DOI 10.1016/S0091-6749(05)80014-4; WEMPE JB, 1992, J ALLERGY CLIN IMMUN, V90, P757, DOI 10.1016/0091-6749(92)90099-N; ZIJLSTRA FJ, 1992, EUR J CLIN INVEST, V22, P301, DOI 10.1111/j.1365-2362.1992.tb01466.x; 1987, AM REV RESPIR DIS, V136, P225; 1985, AM REV RESPIR DIS, V132, P180	28	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1995	96	2					219	229		10.1016/S0091-6749(95)70011-0	http://dx.doi.org/10.1016/S0091-6749(95)70011-0			11	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	RQ001	7636059	Green Published			2022-12-18	WOS:A1995RQ00100011
J	BORRES, MP; ODELRAM, H; IRANDER, K; KJELLMAN, NIM; BJORKSTEN, B				BORRES, MP; ODELRAM, H; IRANDER, K; KJELLMAN, NIM; BJORKSTEN, B			PERIPHERAL-BLOOD EOSINOPHILIA IN INFANTS AT 3 MONTHS OF AGE IS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF ATOPIC DISEASE IN EARLY-CHILDHOOD	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPY; ATOPIC HEREDITY; EOSINOPHILS; SKIN PRICK TEST; IGE	METACHROMATIC CELLS; IGE; ALLERGY; CHILDREN; SKIN	Background: We tested the hypothesis that eosinophilia in peripheral blood and nasal mucosa of infants is an early sign of allergic disease. Methods. The appearance of eosinophilic leukocytes in peripheral blood and nasal mucosa was studied prospectively in 67 infants up to 18 months of age, with or without a family history of atopy. Results: eosinophilia was associated with simultaneous presence or subsequent development of atopic disease at 3, 9, and 18 months of age, but not significantly so at 6 months. At 3 months children in whom atopic disease developed later during the observation period had significantly higher numbers of blood eosinophils than children without atopy (p < 0.01). Thus pronounced eosinophilia (> 7 x 10(8) cells/L) at that age was associated with moderate or severe allergic disease during the 18-month observation period. These children continued to have eosinophilia throughout the follow-up period. Blood eosinophilia at 3 months of age also correlated significantly to cord blood IgE levels and to skin prick test reactivity later during the follow-up period. Nasal eosinophilia was a common finding and therefore had little diagnostic or predictive value. Conclusions: Elevated eosinophil counts in peripheral blood of apparently healthy infants at 3 months of age is associated with a subsequent diagnosis of atopic disease.	LINKOPING UNIV HOSP,FAC HLTH SCI,DEPT OTORHINOLARYNGOL,S-58185 LINKOPING,SWEDEN	Linkoping University	BORRES, MP (corresponding author), LINKOPING UNIV HOSP,FAC HLTH SCI,DEPT PEDIAT,S-58185 LINKOPING,SWEDEN.							BORRES MP, 1990, ALLERGY, V45, P98, DOI 10.1111/j.1398-9995.1990.tb00465.x; BORRES MP, 1991, INT ARCH ALLER A IMM, V95, P289, DOI 10.1159/000235463; BORRES MP, 1991, PEDIATR ALLERGY IMMU, V4, P184; CALBI M, 1992, ALLERGY          S12, V47, P5; CHRISTENSEN RD, 1987, AM J PEDIAT HEMATOL, V9, P140; COHEN GA, 1985, ANN ALLERGY, V54, P112; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DEVOS C, 1989, INT ARCH ALLER A IMM, V88, P212, DOI 10.1159/000234789; FOUCARD T, 1974, ACTA PAEDIATR SCAND, V63, P129, DOI 10.1111/j.1651-2227.1974.tb04361.x; FREW AJ, 1990, J ALLERGY CLIN IMMUN, V85, P533, DOI 10.1016/0091-6749(90)90090-Q; GERRITSEN J, 1990, J ALLERGY CLIN IMMUN, V85, P116, DOI 10.1016/0091-6749(90)90232-S; HALONEN M, 1982, J ALLERGY CLIN IMMUN, V69, P221, DOI 10.1016/0091-6749(82)90103-8; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HARRIS JR, 1956, AMA J DIS CHILD, V92, P27, DOI 10.1001/archpedi.1956.02060030029008; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; KEMP AS, 1982, INT J PEDIATR OTORHI, V4, P293, DOI 10.1016/0165-5876(82)90041-6; KERR RC, 1956, Q J EXP PHYSL, V47, P18; KOCHWESE.J, 1968, ARCH INTERN MED, V121, P255, DOI 10.1001/archinte.121.3.255; LOWELL FC, 1967, J AMER MED ASSOC, V202, P875, DOI 10.1001/jama.202.9.875; MATHESON A, 1957, J PEDIATR, V57, P502; ORFANAKIS NG, 1970, AM J CLIN PATHOL, V53, P647; ORGEL HA, 1977, ANN ALLERGY, V39, P161; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; SPRY CJF, 1988, EOSINOPHILS COMPREHE, P24; VISSCHER MB, 1954, ANN NY ACAD SCI, V59, P834; WATANABE G, 1956, J APPL PHYSIOL, V9, P461, DOI 10.1152/jappl.1956.9.3.461; 1960, DOCUMENTA GEIGY, P550	28	39	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	1995	95	3					694	698		10.1016/S0091-6749(95)70174-5	http://dx.doi.org/10.1016/S0091-6749(95)70174-5			5	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	QM017	7897152				2022-12-18	WOS:A1995QM01700009
J	NIGGEMANN, B; BEYER, K; WAHN, U				NIGGEMANN, B; BEYER, K; WAHN, U			THE ROLE OF EOSINOPHILS AND EOSINOPHIL CATIONIC PROTEIN IN MONITORING ORAL CHALLENGE TESTS IN CHILDREN WITH FOOD-SENSITIVE ATOPIC-DERMATITIS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ATOPIC DERMATITIS; CHALLENGE; CHILDREN; ECP; EOSINOPHIL; FOOD; PROVOCATION	PERIPHERAL-BLOOD; DISEASE-ACTIVITY; MILK ALLERGY; HYPERSENSITIVITY; SERUM; PATHOGENESIS; ECZEMA; RADIOIMMUNOASSAY; ADOLESCENTS; IMMEDIATE	To investigate the role of peripheral blood eosinophils and eosinophil cationic protein as parameters in monitoring oral food challenges, we monitored 25 infants and children with atopic dermatitis for up to 48 hours after 47 placebo-controlled oral food challenges with cow's milk hen's egg, cow's milk and hen's egg, or placebo for up to 48 hours. Sir healthy young nonatopic adult volunteers sewed as control subjects. Compared with baseline values, peripheral blood eosinophils decreased significantly immediately after clinical reaction in positive challenges (p < 0.0004), independent of the kind of reaction. Eosinophil cationic protein increased significantly 8 hours after provocation, with a maximum at 24 hours (p < 0.03). This increase was predominantly related to eczematous reactions (p < 0.005). Blood sampling immediately after clinical reaction (for eosinophils) and at 24 hours (for eosinophil cationic protein) seems to be useful in monitoring oral food challenges in children with atopic dermatitis.			NIGGEMANN, B (corresponding author), FREE UNIV BERLIN,CHILDRENS HOSP,KAVH,DIV PEDIAT PNEUMOL & IMMUNOL,HEUBNERWEG 6,D-14059 BERLIN,GERMANY.							ALLEN R, 1988, BRIT MED J, V297, P1459, DOI 10.1136/bmj.297.6661.1459; ATHERTON DJ, 1978, LANCET, V1, P401; AXEN RE, 1988, NEW ENG REG ALLERGY, V9, P503; BURKS AW, 1992, J PEDIATR-US, V121, pS64, DOI 10.1016/S0022-3476(05)81409-X; BURKS AW, 1988, J PEDIATR-US, V113, P447, DOI 10.1016/S0022-3476(88)80626-7; Businco L, 1993, Pediatr Allergy Immunol, V4, P33; CHARLESWORTH EN, 1993, CLIN EXP ALLERGY, V23, P391, DOI 10.1111/j.1365-2222.1993.tb00344.x; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; CZECH W, 1992, BRIT J DERMATOL, V126, P351, DOI 10.1111/j.1365-2133.1992.tb00677.x; FORD RPK, 1983, ARCH DIS CHILD, V58, P856, DOI 10.1136/adc.58.11.856; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; JACOB T, 1991, ARCH DERMATOL RES, V283, P5; KAGI MK, 1992, DERMATOLOGY, V185, P88, DOI 10.1159/000247419; KAPP A, 1991, J AM ACAD DERMATOL, V24, P555, DOI 10.1016/0190-9622(91)70081-C; KAPP A, 1993, ALLERGY, V48, P1, DOI 10.1111/j.1398-9995.1993.tb02167.x; PAGANELLI R, 1991, INT ARCH ALLER A IMM, V96, P175, DOI 10.1159/000235490; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SAMPSON HA, 1988, J ALLERGY CLIN IMMUN, V81, P635, DOI 10.1016/0091-6749(88)91033-0; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; SUGAI T, 1992, CLIN EXP ALLERGY, V22, P275, DOI 10.1111/j.1365-2222.1992.tb03083.x; SUR S, 1991, FASEB J, V5, pA641; TSUDA S, 1992, Journal of Dermatology (Tokyo), V19, P208; VENGE P, 1977, BRIT J HAEMATOL, V37, P331, DOI 10.1111/j.1365-2141.1977.tb01003.x; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x; WINQVIST I, 1981, ALLERGY, V36, P419, DOI 10.1111/j.1398-9995.1981.tb01848.x	32	39	39	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1994	94	6	1				963	971		10.1016/0091-6749(94)90114-7	http://dx.doi.org/10.1016/0091-6749(94)90114-7			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PY230	7798544				2022-12-18	WOS:A1994PY23000004
J	HODGSON, M; LEVIN, H; WOLKOFF, P				HODGSON, M; LEVIN, H; WOLKOFF, P			VOLATILE ORGANIC-COMPOUNDS AND INDOOR AIR	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						OCCUPATIONAL HEALTH; VOLATILE ORGANIC COMPOUNDS; SICK BUILDING SYNDROME	SICK-BUILDING SYNDROME; SENSORY IRRITATION; MIXTURE	Volatile organic compounds represent one of the two major pollutant categories implicated in the sick-building syndrome. This article reviews measurement and analytic methods, presents a summary of the etiologic considerations, and presents newer nonregulatory intervention strategies that can be used to prevent complaints resulting from this pollutant category.	HAL LEVIN ASSOCIATES, SANTA CRUZ, CA USA; INST OCCUPAT SAFETY & HLTH, COPENHAGEN, DENMARK		HODGSON, M (corresponding author), UNIV CONNECTICUT, CTR HLTH, ENVIRONM & OCCUPAT MED SECT, FARMINGTON, CT USA.			Wolkoff, Peder/0000-0003-1933-7351				BAKER EL, 1986, J OCCUP ENVIRON MED, V28, P126; Berglund B., 1982, ENVIRON INT, V8, P327; BOLLA KI, 1991, ENVIRON HEALTH PERSP, V95, P93, DOI 10.2307/3431113; BREYSSE PA, 1993, INDOOR AIR QUALITY 9, P13; COLOMBO A, 1990, SCI TOTAL ENVIRON, V91, P237, DOI 10.1016/0048-9697(90)90301-A; COMETTOMUNIZ JE, 1992, ANN NY ACAD SCI, V641, P137, DOI 10.1111/j.1749-6632.1992.tb16539.x; GUSTAFSSON H, 1992, D10 SWED COUNC BUILD; HANSEN LF, 1991, INDOOR AIR, V2, P95; HODGSON AT, 1989, ASTM STP, V1002, P244; HODGSON MJ, 1991, J OCCUP ENVIRON MED, V33, P527; HODGSON MJ, 1989, OCCUP MED, V4, P593; HODGSON MJ, 1986, 1986 P IND AIR QUALA, P1; HODGSON MJ, 1993, IN PRESS INDOOR QUAL; HOFFMAN RE, 1993, AM J PUBLIC HEALTH, V83, P89, DOI 10.2105/AJPH.83.1.89; KJAERGAARD SK, 1991, ATMOS ENVIRON A-GEN, V25, P1417; KNOEPPEL H, 1993, CHEM MICROBIOLOGICAL, P37; KNOPPEL H, 1992, EURO CH ENV, V4, P37; Kreiss K., 1982, ENVIRON INT, V8, P337; LEVIN H, 1992, EURO CH ENV, V4, P321; MIDDAUGH DA, 1992, J OCCUP ENVIRON MED, V34, P1197; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; NIELSEN GD, 1991, CRIT REV TOXICOL, V21, P183, DOI 10.3109/10408449109089879; NORBACK D, 1990, SCAND J WORK ENV HEA, V16, P121, DOI 10.5271/sjweh.1808; NORBACK D, 1990, BRIT J IND MED, V47, P733; OTTO DA, 1992, ARCH ENVIRON HEALTH, V47, P23, DOI 10.1080/00039896.1992.9935940; RAFFERTY E, 1993, INDOOR AIR QUALITY 9, P23; SAARELA K, 1991, INDOOR AIR QUALITY 9, P262; Wallace L., 1991, INDOOR AIR, V1, P465; WECHSLER C, 1992, INDOOR AIR QUALITY 9, P137; WOLKOFF P, 1990, ENVIRON TECHNOL, V11, P327, DOI 10.1080/09593339009384869; WOLKOFF P, 1988, ENVIRON INT, V14, P43, DOI 10.1016/0160-4120(88)90376-5; WOLKOFF P, 1991, IAQ 91 HLTH BUILDING, P160; WOLKOFF P, 1991, FLECIAQ91 HLTH BUILD, P161; Wolkoff P., 1991, INDOOR AIR, V1, P389; E9814 AM SOC TEST MA; 1994, IN PRESS AM IND HYG; 1991, EPA560291002 PUBL; D511690 AM SOC TEST	38	39	40	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1994	94	2	2				296	303		10.1053/ai.1994.v94.a56008	http://dx.doi.org/10.1053/ai.1994.v94.a56008			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	PG770	8077582				2022-12-18	WOS:A1994PG77000004
J	GORDON, S; TEE, RD; TAYLOR, AJN				GORDON, S; TEE, RD; TAYLOR, AJN			ANALYSIS OF RAT URINE PROTEINS AND ALLERGENS BY SODIUM DODECYL-SULFATE POLYACRYLAMIDE-GEL ELECTROPHORESIS AND IMMUNOBLOTTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						LABORATORY ANIMAL ALLERGY; RAT URINE; PROTEINS; ALLERGENS; AGE; SEX	LABORATORY-ANIMAL ALLERGY	Background: In rats, urine has been identified as a major source of the allergens that cause laboratory animal allergy, an important occupational health problem. Methods and Results: Urinary proteins and allergens of Wistar rats were studied by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting. Proteins excreted by male and female rats during puberty were similar and of low molecular weight. In adulthood, moderate increases in diffuse staining of 26 and 21 kd occurred in female urine. In males the 1 7 kd protein increased dramatically and the 23 and 21 kd proteins moderately. The urine excretion of high-molecular-weight proteins (75 to 63 kd) increased with age in males (females not studied). Immunoblot studies with six sera showed allergens in urine of male and female rats of all ages, three of which were present in all urine (75, 68, and 21 kd). Three allergens (I 7, 16, and 15 kd) in female urine may be allergenically similar to the 1 7 kd allergen in adult male urine. Adult male urine allergens were studied further with sera from 83 rat-hypersensitive subjects. Major allergens were identified at 23, 21, and 17 kd, and all sera had IgE to one or more of these proteins. Twenty-seven percent had IgE to 68 and 63 kd allergens. Minor allergens were identified at 75, 51, and 44 kd. Conclusions: Rat urine is an important source of the major allergens associated with rat hypersensitivity. Age and sex markedly influence the protein and allergenic constituents of rat urine.			GORDON, S (corresponding author), NATL HEART & LUNG INST, DEPT OCCUPAT & ENVIRONM MED, MANRESA RD, LONDON SW3 6LR, ENGLAND.							AGRUP G, 1986, BRIT J IND MED, V43, P192; ALT JM, 1980, LAB ANIM, V14, P95, DOI 10.1258/002367780780942809; AOYAMA K, 1992, BRIT J IND MED, V49, P41; BEESON MF, 1983, CLIN ALLERGY, V13, P433, DOI 10.1111/j.1365-2222.1983.tb02619.x; BIRD CR, 1988, J IMMUNOL METHODS, V106, P175, DOI 10.1016/0022-1759(88)90194-9; BOTHAM PA, 1987, BRIT J IND MED, V44, P627; BUREK JD, 1988, INT REV EXP PATHOL, V30, P231; CESKA M, 1972, J ALLERGY CLIN IMMUN, V49, P1, DOI 10.1016/0091-6749(72)90117-0; CHEN CLC, 1978, J BIOL CHEM, V253, P7880; DAVIES GE, 1981, INT ARCH ALLER A IMM, V64, P302, DOI 10.1159/000232707; DINH BAO-LMH, 1965, J IMMUNOL, V95, P574; EDWARDS RG, 1983, INT ARCH ALLER A IMM, V71, P53, DOI 10.1159/000233362; HAARS LJ, 1979, J BIOL CHEM, V254, P9401; HAARS LJ, 1980, EUR J BIOCHEM, V107, P539; HAARS LJ, 1980, ARCH BIOCHEM BIOPHYS, V201, P556, DOI 10.1016/0003-9861(80)90545-7; IPSEN H, 1988, HDB IMMUNOBLOTTING P, V2, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LONGBOTTOM JL, 1983, 11 P INT C ALL CLIN, P525; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; ROY AK, 1966, P SOC EXP BIOL MED, V121, P894; ROY AK, 1967, NATURE, V214, P618, DOI 10.1038/214618b0; SELLERS AL, 1952, J EXP MED, V95, P465, DOI 10.1084/jem.95.5.465; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; TAYLOR AN, 1977, LANCET, V2, P847; TOVEY ER, 1987, ELECTROPHORESIS, V8, P452, DOI 10.1002/elps.1150080915; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDOREN G, 1983, EUR J BIOCHEM, V134, P175, DOI 10.1111/j.1432-1033.1983.tb07548.x; VENABLES KM, 1988, BRIT J IND MED, V45, P660; WALLS AF, 1983, ALLERGY, V38, P501, DOI 10.1111/j.1398-9995.1983.tb02359.x	30	39	39	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	1993	92	2					298	305		10.1016/0091-6749(93)90173-D	http://dx.doi.org/10.1016/0091-6749(93)90173-D			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LT469	8349940				2022-12-18	WOS:A1993LT46900010
J	DESJARDINS, A; BENOIT, C; GHEZZO, H; LARCHEVEQUE, J; LEBLANC, C; PAQUETTE, L; CARTIER, A; MALO, JL				DESJARDINS, A; BENOIT, C; GHEZZO, H; LARCHEVEQUE, J; LEBLANC, C; PAQUETTE, L; CARTIER, A; MALO, JL			EXPOSURE TO DOMESTIC-ANIMALS AND RISK OF IMMUNOLOGICAL SENSITIZATION IN SUBJECTS WITH ASTHMA	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ALLERGENS; HYPERSENSITIVITY; RESPIRATORY HYPERSENSITIVITY	ENVIRONMENTAL-CONTROL; INDOOR ALLERGENS; CLINICAL SURVEY; FURRED PETS; DUST MITES; POPULATION; PREVALENCE; REACTIVITY; CHILDHOOD; HISTAMINE	Background: The objective of the study was to determine whether exposure to domestic animals plays a significant role, beyond atopy, in the development of immediate sensitization to animal-derived antigens. . Methods: To test this hypothesis, 200 subjects with asthma (85 male subjects and 115 female subjects; mean age, 37 +/- 16 years) seen consecutively in an asthma clinic were enrolled in a cross-sectional survey. Each subject answered a questionnaire about allergy symptoms and past and current exposure to domestic animals. Skin prick testing with extracts of common inhalant allergens including antigens from eight species of animal (cat, dog, horse, rabbit, rat, mouse, guinea pig, and hamster) were also carried out. Results: Seventy-nine percent of subjects were atopic, and 91% had kept animals at home at some point (figures were 80% for dogs, 68% for cats, 23% for rabbits, and 20% for rodents). Using two-by-two tables, we showed that skin reactivity to at least one animal antigen was strongly linked to atopy (86% of atopic subjects had skin reactions as compared with 34% of nonatopic subjects; p < 0.001) but not to previous and current exposure to domestic animals (78% of both exposed and never exposed subjects). However, with the use of logistic regression, the determinants of skin reactivity to animals were atopy (p < 0.001), followed by cumulative duration of exposure to domestic animals (p < 0.01). The number of animals times the number of species times the duration of exposure was also a significant determinant of skin reactivity (p = 0.05). Conclusions: We conclude that beyond the predominant role of atopy, cumulative duration of exposure to domestic animals is a significant determinant for immediate sensitization to animal-derived antigens in subjects with asthma.	HOP SACRE COEUR, DEPT CHEST MED, 5400 W GOUIN, MONTREAL H4J 1C5, QUEBEC, CANADA	Universite de Montreal								ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; BEESON MF, 1983, CLIN ALLERGY, V13, P433, DOI 10.1111/j.1365-2222.1983.tb02619.x; BLUMENTHAL MN, 1986, J ALLERGY CLIN IMMUN, V78, P962, DOI 10.1016/0091-6749(86)90286-1; BOUSQUET J, 1986, REV MAL RESPIR, V3, P25; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; COCKCROFT A, 1981, LANCET, V1, P827; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334, DOI 10.1164/ajrccm/143.6.1334; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; HANSON B, 1985, J ALLERGY CLIN IMMUN, V75, P155, DOI 10.1016/0091-6749(85)90337-9; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; KAHN HA, 1983, INTRO EPIDEMIOLOGIC, P100; KJELLMAN B, 1983, ALLERGY, V38, P65, DOI 10.1111/j.1398-9995.1983.tb00858.x; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; MALO JL, 1983, AM REV RESPIR DIS, V128, P8, DOI 10.1164/arrd.1983.128.1.8; MOIRA CY, 1986, AM REV RESPIR DIS, V133, P686; MUSK AW, 1989, BRIT J IND MED, V46, P636; PAULI G, 1979, J ALLERGY CLIN IMMUN, V63, P245, DOI 10.1016/0091-6749(79)90108-8; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339, DOI 10.1159/000235398; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POPP W, 1990, ALLERGY, V45, P75, DOI 10.1111/j.1398-9995.1990.tb01087.x; REED CE, 1985, CHEST, V87, pS40; SCHWARTZ B, 1987, INT ARCH ALLER A IMM, V82, P447, DOI 10.1159/000234250; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; SLOVAK AJM, 1987, BRIT J IND MED, V44, P129; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; VENABLES KM, 1988, BRIT J IND MED, V45, P660; WHITE NW, 1992, AM REV RESPIR DIS, V143, pA273	35	39	40	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	1993	91	5					979	986		10.1016/0091-6749(93)90210-7	http://dx.doi.org/10.1016/0091-6749(93)90210-7			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	LC978	8491948				2022-12-18	WOS:A1993LC97800004
J	BERKOWITZ, RB; TINKELMAN, DG; LUTZ, C; CRUMMIE, A; SMITH, K				BERKOWITZ, RB; TINKELMAN, DG; LUTZ, C; CRUMMIE, A; SMITH, K			EVALUATION OF THE MULTITEST DEVICE FOR IMMEDIATE HYPERSENSITIVITY SKIN TESTING	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						MULTITEST; SKIN TESTING; VARIABILITY; REPRODUCIBILITY; STANDARDIZATION; HISTAMINE; ALLERGENS; SITE SPACING	PRICK TEST; TEST RESPONSES; HISTAMINE; STANDARDIZATION; EXTRACTS; INFANCY	Test-to-test reproducibility, user variability, and the effect of positive reactions on adjacent negative sites were evaluated for the Multi-Test skin testing device. Twenty-five subjects had skin tests with 24 histamine (1 mg/ml), four glycerosaline controls, and four ''dry'' controls on two testings 7 days apart. To assess reproducibility from large and smaller histamine reactions and/or their effect on adjacent negative controls, 10 of the 25 subjects were retested once with the same testing format, but histamine at 10 mg/ml was substituted. To determine whether large allergen reactions affect adjacent negative controls differently than histamine reactions, 24 additional patients were retested on arms and back with negative controls adjacent to allergens to which they had prior 3+ to 4+ skin test reactions. Conclusions from 2688 skin tests on 49 patients are as follows: large (mean >10 mm) histamine reactions reproduced better than smaller (mean <7 mm) responses-coefficients of variation were 12.3 and 21.4 respectively. A 14% user variability occurred when comparing mean wheal sizes from histamine produced by each nurse and 1.2% when comparing their coefficients of variation. Neither small histamine reactions nor large reactions from histamine and allergens affected adjacent negative controls. We conclude that Multi-Test is a highly reliable skin testing technique that provides good reproducibility of results and low user variability.	ATLANTA ALLERGY & IMMUNOL RES FDN,ATLANTA,GA		BERKOWITZ, RB (corresponding author), ATLANTA ALLERGY CLIN,6667 VERNON WOODS DR NE,SUITE A12,ATLANTA,GA 30328, USA.							AAS K, 1980, ALLERGY, V35, P250, DOI 10.1111/j.1398-9995.1980.tb01763.x; AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; BASARAN M, 1988, J ALLERGY CLIN IMMUN, V81, P171, DOI 10.1016/0091-6749(88)90247-3; ENGLER DB, 1991, J ALLERGY CLIN IMMUN, V87, P329; GARIBALDI E, 1990, ANN ALLERGY, V65, P481; GRATER WC, 1982, ANN ALLERGY, V49, P49; HAMBURGER RN, 1991, ANN ALLERGY, V67, P133; LIN RY, 1990, ANN ALLERGY, V65, P222; MAHAN A, 1990, 47TH ANN M AM COLL A; MENARDO JL, 1982, ANN ALLERGY, V48, P235; MURPHREE JT, 1979, ANN ALLERGY, V43, P279; RAO KS, 1988, J ALLERGY CLIN IMMUN, V82, P752, DOI 10.1016/0091-6749(88)90075-9; SULLIVAN TJ, 1982, J ALLERGY CLIN IMMUN, V69, P260, DOI 10.1016/S0091-6749(82)80002-X; TAUDORF E, 1985, ALLERGY, V40, P344, DOI 10.1111/j.1398-9995.1985.tb00245.x; ZEIGER RS, 1983, J ASTHMA, V20, P341, DOI 10.3109/02770908309077377; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	17	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1992	90	6	1				979	985		10.1016/0091-6749(92)90471-D	http://dx.doi.org/10.1016/0091-6749(92)90471-D			7	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	KD190	1460201				2022-12-18	WOS:A1992KD19000015
J	DUPUIS, R; COLLINS, DS; KOH, YY; POLLICE, M; ALBERTINE, KH; FISH, JE; PETERS, SP				DUPUIS, R; COLLINS, DS; KOH, YY; POLLICE, M; ALBERTINE, KH; FISH, JE; PETERS, SP			EFFECT OF ANTIGEN DOSE ON THE RECRUITMENT OF INFLAMMATORY CELLS TO THE LUNG BY SEGMENTAL ANTIGEN CHALLENGE	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SEGMENTAL ANTIGEN CHALLENGE; BRONCHOALVEOLAR LAVAGE; MACROPHAGES; LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; LUNG INFLAMMATION	ALLERGEN CHALLENGE; BRONCHOALVEOLAR LAVAGE; ALVEOLAR MACROPHAGES; AIRWAY INFLAMMATION; MEDIATOR RELEASE; MAST-CELLS; INVIVO; ASTHMA	Bronchoscopic antigen challenge of atopic volunteers results in an immediate release of inflammatory mediators and, after a number of hours, the recruitment of inflammatory cells to the lung. The purpose of this work was to investigate the effect of antigen dose on the subsequent recruitment of inflammatory cells to the lung. Twenty-two volunteers without asthma, eight nonatopic control subjects, and 14 ragweed-allergic subjects underwent 25 local antigen-challenge procedures that consisted of a baseline lavage of a control segment, antigen challenge of another segment in the contralateral lung, and lavage of the challenged segment 24 hours later. A 25,000-fold range of antigen doses was used from 0.004 to 100 PNU/ml (0.02 to 500 ng/ml of ragweed antigen E [Amb a I]). Challenge of nonatopic control subjects resulted in the recruitment of only a small number of inflammatory cells, less than a twofold increase in comparison with the cells of control lavage; this increase was primarily due to an increase in neutrophils. Challenge of atopic subjects, in contrast, resulted in approximately a threefold to ninefold increase in inflammatory cells with more cells recruited at larger doses of antigen. Only subjects challenged with a "high" dose of antigen (greater-than-or-equal-to 1 PNU/ml) recruited significant quantities of eosinophils to the lung. In these subjects, a twofold increase in macrophages, a fourfold increase in lymphocytes, a 90-fold increase in neutrophils, and an 800-fold increase in eosinophils were observed; the number of neutrophils and eosinophils recruited averaged between 30 and 60 million. There was a direct relationship between the log of the dose of antigen used for challenge and the log of the number of eosinophils recruited (r = 0.75; p < 0.001). We conclude that the dose of antigen used for local antigen challenge is an important factor that affects both the number and type of inflammatory cells recruited to the lung.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV PULM MED & CRIT CARE,PHILADELPHIA,PA 19107	Jefferson University			Koh, Young Yull/D-6059-2012	Albertine, Kurt/0000-0001-8497-0861	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024509] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 24509] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASCOM R, 1988, AM REV RESPIR DIS, V138, P406, DOI 10.1164/ajrccm/138.2.406; BERTHIAUME Y, 1989, J APPL PHYSIOL, V67, P1887, DOI 10.1152/jappl.1989.67.5.1887; CALHOUN WJ, 1990, AM REV RESPIR DIS, V141, P878; CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671; Colton T., 1974, STAT MED, V1; FISH JE, 1980, J ALLERGY CLIN IMMUN, V65, P154, DOI 10.1016/0091-6749(80)90201-8; FREELAND HS, 1988, AM REV RESPIR DIS, V138, P389, DOI 10.1164/ajrccm/138.2.389; KOH YY, 1991, AM REV RESPIR DIS, V143, P38; LIU M, 1990, Journal of Allergy and Clinical Immunology, V85, P263; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; MIADONNA A, 1990, J ALLERGY CLIN IMMUN, V85, P906, DOI 10.1016/0091-6749(90)90076-G; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527, DOI 10.1164/ajrccm/140.6.1527; TONNEL AB, 1983, LANCET, V1, P1406; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002; YOSS EB, 1990, AM J RESP CELL MOL, V2, P69, DOI 10.1165/ajrcmb/2.1.69	17	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	1992	89	4					850	857		10.1016/0091-6749(92)90441-4	http://dx.doi.org/10.1016/0091-6749(92)90441-4			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	HN860	1560168				2022-12-18	WOS:A1992HN86000011
J	JENSENJAROLIM, E; VOGEL, M; DEWECK, AL; STADLER, BM				JENSENJAROLIM, E; VOGEL, M; DEWECK, AL; STADLER, BM			ANTI-IGE AUTOANTIBODIES MISTAKEN FOR SPECIFIC IGG	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						SPECIFIC IGE; SPECIFIC IGG; ALLERGEN; ANTI-IGE AUTOANTIBODY; RAST; IMMUNOASSAY	GRASS-POLLEN; ATOPIC-DERMATITIS; DUST MITE; ANTIBODIES; IMMUNOTHERAPY; SUBCLASS; HYPOSENSITIZATION; EXPRESSION; PROTEINS; ELISA	During isolation of specific IgE by affinity chromatography, we obtained IgG acting as "specific IgG" in dot immunoassay and RAST. Further analysis of this fraction revealed that this specific IgG was indeed an immune complex consisting of IgG anti-IgE autoantibodies and specific IgE that falsely appeared as specific IgG in the immunoassay. After disruption of complexes, more IgE became accessible, resulting in increased counts per minute in the RAST. Thus, anti-IgE autoantibodies may hinder determination of specific IgE in in vitro immunoassays, since they hide specific IgE immunologically. To demonstrate the isotope specificity of such immune complex-derived IgG, the purified anti-IgE autoantibodies were radiolabeled and used as detection antibodies in immunoblotting. These autoantibodies recognized different IgE preparations, including a recombinant IgE peptide.	INSELSPITAL BERN,INST CLIN IMMUNOL,CH-3010 BERN,SWITZERLAND	University of Bern; University Hospital of Bern			Jensen-Jarolim, Erika/C-5120-2018	Jensen-Jarolim, Erika/0000-0003-4019-5765				AALBERSE RC, 1983, J IMMUNOL, V130, P722; AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; BOSCO MC, 1987, EUR J IMMUNOL, V17, P673; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; DJURUP R, 1985, J ALLERGY CLIN IMMUN, V76, P46, DOI 10.1016/0091-6749(85)90803-6; GANG Q, 1990, EUR J IMMUNOL, V20, P2191; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HELFMAN DM, 1983, P NATL ACAD SCI-BIOL, V80, P31, DOI 10.1073/pnas.80.1.31; HONG CS, 1986, J IMMUNOL METHODS, V95, P195; INGENAS M, 1981, INT ARCH ALLER A IMM, V65, P51; ISERSKY C, 1983, J IMMUNOL, V131, P388; JAROLIM E, 1990, J ALLERGY CLIN IMMUN, V85, P996, DOI 10.1016/0091-6749(90)90043-4; KEMENY DM, 1990, CLIN EXP ALLERGY, V20, P67, DOI 10.1111/j.1365-2222.1990.tb02777.x; KEMENY DM, 1989, CLIN EXP ALLERGY, V19, P545, DOI 10.1111/j.1365-2222.1989.tb02431.x; KNUTTIMULLER JM, 1986, ALLERGY, V41, P457, DOI 10.1111/j.1398-9995.1986.tb00327.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE D, 1986, INT ARCH ALLER A IMM, V79, P344, DOI 10.1159/000234000; LEE HB, 1988, J ALLERGY CLIN IMMUN, V82, P11, DOI 10.1016/0091-6749(88)90044-9; LOEWENSTEIN H, 1986, J ALLERGY CLIN IMMUN, V77, P497; MALLING HJ, 1988, ALLERGY, V43, P60, DOI 10.1111/j.1398-9995.1988.tb02045.x; MARONE G, 1989, J INVEST DERMATOL, V93, P246, DOI 10.1111/1523-1747.ep12277582; MCCONAHEY PJ, 1966, INT ARCH ALLER A IMM, V29, P185, DOI 10.1159/000229699; MIYAZAWA H, 1988, J ALLERGY CLIN IMMUN, V82, P407, DOI 10.1016/0091-6749(88)90013-9; MOSBECH H, 1990, ALLERGY, V45, P130, DOI 10.1111/j.1398-9995.1990.tb00471.x; NAWATA Y, 1985, J IMMUNOL, V135, P478; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; OESTERBALLE O, 1982, ALLERGY, V37, P209; QUINTI I, 1986, J ALLERGY CLIN IMMUN, V77, P586, DOI 10.1016/0091-6749(86)90350-7; RITTER C, 1991, J ALLERGY CLIN IMMUN, V88, P793, DOI 10.1016/0091-6749(91)90187-S; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; STEVENS WJ, 1984, J ALLERGY CLIN IMMUN, V73, P276, DOI 10.1016/S0091-6749(84)80020-2; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625, DOI 10.1159/000231566; VASSELLA CC, 1990, CLIN EXP ALLERGY, V20, P295, DOI 10.1111/j.1365-2222.1990.tb02687.x; WILLIAMS RC, 1972, J CLIN INVEST, V51, P955, DOI 10.1172/JCI106890	35	39	39	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1992	89	1	1				31	43		10.1016/S0091-6749(05)80038-7	http://dx.doi.org/10.1016/S0091-6749(05)80038-7			13	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	GZ908	1730838				2022-12-18	WOS:A1992GZ90800004
J	BERNSTEIN, DI; MITTMAN, RJ; KAGEN, SL; KORBEE, L; ENRIONE, M; BERNSTEIN, IL				BERNSTEIN, DI; MITTMAN, RJ; KAGEN, SL; KORBEE, L; ENRIONE, M; BERNSTEIN, IL			CLINICAL AND IMMUNOLOGICAL STUDIES OF RAPID VENOM IMMUNOTHERAPY IN HYMENOPTERA-SENSITIVE PATIENTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									ST ELIZABETH HOSP,APPLETON,WI		BERNSTEIN, DI (corresponding author), UNIV CINCINNATI,MED CTR,DEPT MED,DIV IMMUNOL,231 BETHESDA AVE,ML 563,CINCINNATI,OH 45267, USA.							BARNARD JH, 1973, J ALLERGY CLIN IMMUN, V52, P259, DOI 10.1016/0091-6749(73)90044-4; CLAYTON WF, 1983, CLIN ALLERGY, V13, P123, DOI 10.1111/j.1365-2222.1983.tb02579.x; GOLDEN DBK, 1980, ANN INTERN MED, V92, P620, DOI 10.7326/0003-4819-92-5-620; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P727, DOI 10.1016/0091-6749(86)90418-5; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; LICHTENSTEIN LM, 1974, NEW ENGL J MED, V290, P1223, DOI 10.1056/NEJM197405302902204; MAY CD, 1970, J ALLERGY, V46, P12, DOI 10.1016/0021-8707(70)90056-0; NATAF P, 1984, CLIN ALLERGY, V14, P269, DOI 10.1111/j.1365-2222.1984.tb02206.x; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P171, DOI 10.1016/0091-6749(88)90996-7; REISMAN RE, 1988, ALLERGY PRINCIPLES P, V2, P1345; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; URBANEK R, 1978, DEUT MED WOCHENSCHR, V103, P1656, DOI 10.1055/s-0028-1129317; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329, DOI 10.1136/bmj.287.6402.1329; YUNGINGER JW, 1979, J ALLERGY CLIN IMMUN, V63, P340, DOI 10.1016/0091-6749(79)90129-5	16	39	41	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	1989	84	6	1				951	959		10.1016/0091-6749(89)90394-1	http://dx.doi.org/10.1016/0091-6749(89)90394-1			9	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CG293	2480972	Bronze			2022-12-18	WOS:A1989CG29300015
J	STOOP, AE; HAMELEERS, DMH; VONRUN, PEM; BIEWENGA, J; VANDERBAAN, S				STOOP, AE; HAMELEERS, DMH; VONRUN, PEM; BIEWENGA, J; VANDERBAAN, S			LYMPHOCYTES AND NONLYMPHOID CELLS IN THE NASAL-MUCOSA OF PATIENTS WITH NASAL POLYPS AND OF HEALTHY-SUBJECTS	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									FREE UNIV AMSTERDAM,FAC MED,DEPT CELL BIOL,1007 MC AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam	STOOP, AE (corresponding author), FREE UNIV AMSTERDAM HOSP,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS.							Brandtzaeg P., 1984, IMMUNOLOGY LUNG UPPE, P28; ERNST PB, 1987, BASIC CLIN IMMUNOL, P159; GREEN DR, 1982, P NATL ACAD SCI-BIOL, V79, P889, DOI 10.1073/pnas.79.3.889; HAMELEERS DMH, 1989, INT ARCH ALLER A IMM, V88, P317, DOI 10.1159/000234818; HIRSCHBERG H, 1976, NATURE, V263, P63, DOI 10.1038/263063a0; HUME DA, 1987, J LEUKOCYTE BIOL, V42, P474, DOI 10.1002/jlb.42.5.474; KORSRUD FR, 1981, SCAND J IMMUNOL, V13, P271, DOI 10.1111/j.1365-3083.1981.tb00135.x; LEE A, 1988, EUR J IMMUNOL, V18, P21, DOI 10.1002/eji.1830180105; LEHNER T, 1985, IMMUNOLOGY, V54, P713; LINDAHL G, 1985, CLIN EXP IMMUNOL, V61, P475; MAYER L, 1987, J EXP MED, V166, P1471, DOI 10.1084/jem.166.5.1471; METZGAR RS, 1979, J IMMUNOL, V122, P949; NISHIMOTO K, 1988, ACTA OTO-LARYNGOL, V106, P291, DOI 10.3109/00016488809106439; ROTTEVEEL FTM, 1988, J EXP MED, V168, P1659, DOI 10.1084/jem.168.5.1659; SCHREZENMEIER H, 1988, J IMMUNOL, V141, P398; SELBY WS, 1983, CLIN EXP IMMUNOL, V53, P614; SHAW S, 1987, IMMUNOL TODAY, V8, P1, DOI 10.1016/0167-5699(87)90816-4; TAKADA S, 1987, J IMMUNOL, V139, P3231; WINTHER B, 1987, ARCH OTOLARYNGOL, V113, P59; ZOLA H, 1987, IMMUNOL TODAY, V8, P308, DOI 10.1016/0167-5699(87)90018-1	20	39	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	1989	84	5	1				734	741		10.1016/0091-6749(89)90302-3	http://dx.doi.org/10.1016/0091-6749(89)90302-3			8	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	CA314	2530264				2022-12-18	WOS:A1989CA31400011
J	GORIN, LJ; JEHA, SC; SULLIVAN, MP; ROSENBLATT, HM; SHEARER, WT				GORIN, LJ; JEHA, SC; SULLIVAN, MP; ROSENBLATT, HM; SHEARER, WT			BURKITTS-LYMPHOMA DEVELOPING IN A 7-YEAR-OLD BOY WITH HYPER-IGE SYNDROME	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article									TEXAS CHILDRENS HOSP,BAYLOR COLL MED,DEPT PEDIAT,ALLERGY & IMMUNOL SERV,HOUSTON,TX 77030; TEXAS CHILDRENS HOSP,BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,ALLERGY & IMMUNOL SERV,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DIV PEDIAT ONCOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center				Shearer, William/0000-0002-2483-2130				BALE JF, 1977, CANCER, V39, P2386, DOI 10.1002/1097-0142(197706)39:6<2386::AID-CNCR2820390612>3.0.CO;2-X; BEARD J, 1980, J IMMUNOL, V124, P1943; BOYUM A, 1986, SCAND J CLIN LAB I S, V97, P31; BRESTEL EP, 1982, AM J DIS CHILD, V136, P774, DOI 10.1001/archpedi.1982.03970450016003; BUCKLEY RH, 1972, PEDIATRICS, V49, P59; BUCKLEY RH, 1981, CLIN IMMUNOLOGY UPDA, P147; CEDERBAUM SD, 1976, J PEDIATR-US, V89, P737, DOI 10.1016/S0022-3476(76)80793-7; EISEN SA, 1972, IMMUNOL COMMUN, V1, P571, DOI 10.3109/08820137209022965; GATTI RA, 1971, CANCER-AM CANCER SOC, V28, P89, DOI 10.1002/1097-0142(197107)28:1<89::AID-CNCR2820280117>3.0.CO;2-Q; Greaves M F, 1970, Transplant Rev, V5, P45; HONG R, 1972, CLIN IMMUNOL IMMUNOP, V1, P15; HONTO DW, 1983, ANN SURG, V198, P356; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; LIND SE, 1985, ANN INTERN MED, V102, P338, DOI 10.7326/0003-4819-102-3-338; PURTILO D, 1984, PATHOGENESIS LEUKEMI, P235; ROSENBLATT HM, 1986, MAJOR PROBLEMS PATHO, V18, P31; SCHWARTZ RS, 1975, NEW ENGL J MED, V293, P181, DOI 10.1056/NEJM197507242930406; SHEARER WT, 1985, NEW ENGL J MED, V312, P1151, DOI 10.1056/NEJM198505023121804; SPECTOR BD, 1978, CLIN IMMUNOL IMMUNOP, V11, P12, DOI 10.1016/0090-1229(78)90200-3; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WYBRAN J, 1972, J CLIN INVEST, V51, P2537, DOI 10.1172/JCI107069; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7	22	39	40	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	1989	83	1					5	10		10.1016/0091-6749(89)90471-5	http://dx.doi.org/10.1016/0091-6749(89)90471-5			6	Allergy; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Allergy; Immunology	T0419	2783597				2022-12-18	WOS:A1989T041900002
